Part II

Department of Health and Human Services

Centers for Medicare & Medicaid Services

42 CFR Parts 405, 412, 413, et al.

Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2017 Rates; Quality Reporting Requirements for Specific Providers; Graduate Medical Education; Hospital Notification Procedures Applicable to Beneficiaries Receiving Observation Services; Technical Changes Relating to Costs to Organizations and Medicare Cost Reports; Finalization of Interim Final Rules With Comment Period on LTCH PPS Payments for Severe Wounds, Modifications of Limitations on Redesignation by the Medicare Geographic Classification Review Board, and Extensions of Payments to MDHs and Low-Volume Hospitals; Final Rule
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 405, 412, 413, and 489

[CMS–1655–F; CMS–16644–F; CMS–1632–F2]

RIN 0938–AS77; 0938–AS88; 0938–AS41

Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2017 Rates; Quality Reporting Requirements for Specific Providers; Graduate Medical Education; Hospital Notification Procedures Applicable to Beneficiaries Receiving Observation Services; Technical Changes Relating to Costs to Organizations and Medicare Cost Reports; Finalization of Interim Final Rules With Comment Period on LTCH PPS Payments for Severe Wounds, Modifications of Limitations on Redesignation by the Medicare Geographic Classification Review Board, and Extensions of Payments to MDHs and Low-Volume Hospitals

AGENCY: Centers for Medicare and Medicaid Services (CMS), HHS.

ACTION: Final rule.

SUMMARY: We are revising the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals to implement changes arising from our continuing experience with these systems for FY 2017. Some of these changes will implement certain statutory provisions contained in the Pathway for Sustainable Growth Reform Act of 2013, the Improving Medicare Post-Acute Care Transformation Act of 2014, the Notice of Observation Treatment and Implications for Care Eligibility Act of 2015, and other legislation. We also are providing the estimated market basket update to apply to the rate-of-increase limits for certain hospitals excluded from the IPPS that are paid on a reasonable cost basis subject to these limits for FY 2017.

We are updating the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs) for FY 2017.

In addition, we are making changes relating to direct graduate medical education (GME) and indirect medical education payments; establishing new requirements or revising existing requirements for quality reporting by specific Medicare providers (acute care hospitals, PPS-exempt cancer hospitals, LTCHs, and inpatient psychiatric facilities), including related provisions for eligible hospitals and critical access hospitals (CAHs) participating in the Electronic Health Record Incentive Program; updating policies relating to the Hospital Value-Based Purchasing Program, the Hospital Readmissions Reduction Program, and the Hospital-Acquired Condition Reduction Program; implementing statutory provisions that require hospitals and CAHs to furnish notification to Medicare beneficiaries, including Medicare Advantage enrollees, when the beneficiaries receive outpatient observation services for more than 24 hours; announcing the implementation of the Frontier Community Health Integration Project Demonstration; and making technical corrections and changes to regulations relating to costs to related organizations and Medicare cost reports; we are providing notice of the closure of three teaching hospitals and the opportunity to apply for available GME resident slots under section 5506 of the Affordable Care Act.

We are finalizing the provisions of interim final rules with comment period that relate to a temporary exception for certain wound care discharges from the application of the site neutral payment rate under the LTCH PPS for certain LTCHs; application of two judicial decisions relating to modifications of limitations on redesignation by the Medicare Geographic Classification Review Board; and legislative extensions of the Medicare-dependent, small rural hospital program and changes to the payment adjustment for low-volume hospitals.

DATES: Effective Date: These final rules are effective on October 1, 2016.

FOR FURTHER INFORMATION CONTACT: Inong Jye Cheng, (410) 786–4543, and Donald Thompson, (410) 786–4487, Operating Prospective Payment, MS–DRGs, Wage Index, New Medical Service and Technology Add-On Payments, Hospital Geographic Reclassifications, Graduate Medical Education, Capital Prospective Payment, Excluded Hospitals, Medicare Disproportionate Share Hospital (DSH) Issues, Medicare-Dependent Small Rural Hospital (MDH) Program, and Low-Volume Hospital Payment Adjustment Issues.

Michele Hudson, (410) 786–4487, and Emily Lipkin, (410) 786–3633, Long-Term Care Hospital Prospective Payment System and MS–LTC–DRG Relative Weights Issues.

Mollie Knight (410) 786–7948, and Bridget Dickensheets, (410) 786–8670, Rebasin and Revising the LTCH Market Basket Issues.

Siddhartha Mazumdar, (410) 786–6673, Rural Community Hospital Demonstration Program Issues.


Kathryn McCann Smith, (410) 786–7623, Hospital Notification Procedures for Beneficiaries Receiving Outpatient Observation Services Issues; or Stephanie Simons, (206) 615–2420, only for Related Medicare Health Plans Issues.

Lein Han, (617) 879–0129, Hospital Readmissions Reduction Program—Readmission Measures for Hospitals Issues.

Delia Houseal, (410) 786–2724, Hospital-Acquired Condition Reduction Program and Hospital Readmissions Reduction Program—Administration Issues.


James Poyer, (410) 786–2261, Hospital Inpatient Quality Reporting and Hospital Value-Based Purchasing—Program Administration, Validation, and Reconsideration Issues.


Kim Spaulding Bush, (410) 786–3232, Hospital Value-Based Purchasing Efficiency Measures Issues.

Elizabeth Goldstein, (410) 786–6665, Hospital Inpatient Quality Reporting—Hospital Consumer Assessment of Healthcare Providers and Systems Measures Issues.

James Poyer, (410) 786–2261, PPS-Exempt Cancer Hospital Quality Reporting Issues.

Mary Pratt, (410) 786–6867, Long-Term Care Hospital Quality Data Reporting Issues.


Elizabeth Myers, (410) 786–4751, EHR Incentive Program Nonclinical Quality Measure Related Issues.

Lauren Wu, (202) 690–7151, Certified EHR Technology Related Issues.
Kollie Shannon, (410) 786–0416.

Technical Changes Relating to Costs to Organizations and Medicare Cost Reports Issues.

SUPPLEMENTARY INFORMATION:

Electronic Access

This Federal Register document is available from the Federal Register online database through Federal Digital System (FDsys), a service of the U.S. Government Printing Office. This database can be accessed via the Internet at: http://www.gpo.gov/fdsys.

Tables Available Only Through the Internet on the CMS Web Site

In the past, a majority of the tables referred to throughout this preamble and in the Addendum to the proposed rule and the final rule were published in the Federal Register as part of the annual proposed and final rules. However, beginning in FY 2012, some of the IPPS tables and LTCH PPS tables are no longer published in the Federal Register. Instead, these tables generally will be available only through the Internet. The IPPS tables for this final rule are available through the Internet on the CMS Web site at: http://www.cms.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled, “FY 2017 IPPS Final Rule Home Page” or “Acute Inpatient—Files for Download.” The LTCH PPS tables for this FY 2017 final rule are available through the Internet on the CMS Web site at: http://www.cms.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html under the list item for Regulation Number CMS–1655–F. For further details on the contents of the tables referenced in this final rule, we refer readers to section VI. of the Addendum to this final rule.

Readers who experience any problems accessing any of the tables that are posted on the CMS Web sites identified above should contact Michael Treitel at (410) 786–4552.

Acronyms

3M 3M Health Information System
AAMC Association of American Medical Colleges
ACGME Accreditation Council for Graduate Medical Education
ACoS American Joint Committee on Cancer
AHIMA American Health Information Management Association
AHIP American Hospital Information
AHRQ Agency for Healthcare Research and Quality
AJCC American Joint Committee on Cancer
ALOS Average length of stay
ALTSA American Long-Term Hospital Association
AMA American Medical Association
AMGA American Medical Group Association
AMI Acute myocardial infarction
AOA American Osteopathic Association
APR DRG All Patient Refined Diagnosis Related Group System
APRN Advanced practice registered nurse
ASNT American Society of Interventional and Therapeutic Neuroradiology
ASPE Assistant Secretary for Planning and Evaluation (DHHS)
ATRA American Taxpayer Relief Act of 2012, Public Law 112–240
BBRA Medicare, Medicaid, and SCHIP [State Children’s Health Insurance Program] Balanced Budget Refinement Act of 1999, Public Law 106–113
BLS Bureau of Labor Statistics
CADB Coronary artery bypass graft surgery
CAH Critical access hospital
CARE [Medicare] Continuity Assessment Record & Evaluation [Instrument]
CARP CMS Abstraction & Reporting Tool
CATHU Catheter-associated urinary tract infection
CBSAs Core-based statistical areas
CC Complication or comorbidity
CCN CMS Certification Number
CCR Cost-to-charge ratio
CDAC [Medicare] Clinical Data Abstraction Center
CDAD Clostridium difficile-associated disease
CDC Centers for Disease Control and Prevention
CERT Comprehensive error rate testing
CDI Clostridium difficile [C. difficile] infection
CFR Code of Federal Regulations
CLABSI Central line-associated bloodstream infection
CPI Capital input price index
CM Case-mix index
CMS Centers for Medicare & Medicaid Services
CMSA Consolidated Metropolitan Statistical Area
COBRA Consolidated Omnibus Reconciliation Act of 1985, Public Law 99–272
COLA Cost-of-living adjustment
CoP [Hospital] condition of participation
COPID Chronic obstructive pulmonary disease
CPI Consumer price index
CQL Clinical quality language
CQM Clinical quality measure
CY Calendar year
DACA Data Accuracy and Completeness Acknowledgement
DPP Disproportionate patient percentage
DRC Diagnosis-related group
DSH Disproportionate share hospital
EBRT External beam radiotherapy
ECE Extraordinary circumstances exemption
ECI Employment cost index
eCQM Electronic clinical quality measure
EDB [Medicare] Enrollment Database
EHR Electronic health record
EML Electronic medical record
EP Eligible professional
FAH Federation of American Hospitals
FDA Food and Drug Administration
FFY Federal fiscal year
FPL Federal poverty line
FQHC Federally qualified health center
FR Federal Register
FTE Full-time equivalent
FY Fiscal year
GAF Geographic Adjustment Factor
GME Graduate medical education
HAC Hospital-acquired condition
HAI Healthcare-associated infection
HCACPS Hospital Consumer Assessment of Healthcare Providers and Systems
HCFA Health Care Financing Administration
HCO High-cost outlier
HCP Healthcare personnel
HCRIS Hospital Cost Report Information System
HCRS Hospital Reimbursement System
HF Heart failure
HHA Home health agency
HHS Department of Health and Human Services
HICAN Health Insurance Claims Account Number
HIPAA Health Insurance Portability and Accountability Act of 1996, Public Law 104–191
HIPC Health Information Policy Council
HIS Health information system
HIT Health information technology
HMO Health maintenance organization
HPMP Hospital Payment Monitoring Program
HSA Health savings account
HSCRC [Maryland] Health Services Cost Review Commission
HSRV Hospital-specific relative value
HSLR Hospital-specific relative value cost center
HQA Hospital Quality Alliance
HQI Hospital Quality Initiative
HwH Hospital-within-hospital
ICD–9–CM International Classification of Diseases, Ninth Revision, Clinical Modification
ICD–10–CM International Classification of Diseases, Tenth Revision, Clinical Modification
ICD–10–PCS International Classification of Diseases, Tenth Revision, Procedure Coding System
ICRF Information collection requirement
ICU Intensive care unit
IGI IHS Global Insight, Inc.
IHS Indian Health Service
IME Indirect medical education
IMPACT Act Improving Medicare Post–Acute Care Transformation Act of 2014, Public Law 113–183

Federal Register / Vol. 81, No. 162 / Monday, August 22, 2016 / Rules and Regulations 56763
6. The Notice of Observation Treatment and Implication for Care Eligibility Act (the NOTICE Act) of 2015 (Public Law 114–42)
D. Issuance of Notice of Proposed Rulemaking
E. Finalization of Interim Final Rule With Comment Period on the Temporary Exception to the Site Neutral Payment Rate Under the LTCH PPS for Certain Severe Wound Discharges From Certain LTCHs as Required by the Consolidated Appropriations Act, 2016; and Modification of Limitation on Redesignation by the Medicare Geographic Classification Review Board
G. Finalization of Interim Final Rule With Comment Period on Medicare Dependent Small Rural Hospital Program and Payment to Low-Volume Hospitals
II. Changes to Medicare Severity Diagnosis-Related Group (MS–DRG) Classifications and Relative Weights
A. Background
B. MS–DRG Reclassifications
C. Adoption of the MS–DRGs in FY 2008
D. FY 2017 MS–DRG Documentation and Coding Adjustment
1. Background on the Prospective MS–DRG Documentation and Coding Adjustments for FY 2008 and FY 2009 Authorized by Public Law 110–90
2. Adjustment to the Average Standardized Amounts Required by Public Law 110–90
a. Prospective Adjustment Required by Section 7(b)(1)(A) of Public Law 110–90
b. Recoupment or Repayment Adjustments in FYs 2010 Through 2012 Required by Section 7(b)(1)(B) of Public Law 110–90
3. Retrospective Evaluation of FY 2008 and FY 2009 Claims Data
4. Prospective Adjustments for FY 2008 and FY 2009 Authorized by Section 7(b)(1)(A) of Public Law 110–90
5. Recoupment or Repayment Adjustment Authorized by Section 7(b)(1)(B) of Public Law 110–90
6. Recoupment or Repayment Adjustment Authorized by Section 631 of the American Taxpayer Relief Act of 2012 (ATRA)
E. Refinement of the MS–DRG Relative Weight Calculation
1. Background
2. Discussion of Policy for FY 2017
F. Changes to Specific MS–DRG Classifications
1. Discussion of Changes to Coding System and Basis for MS–DRG Updates
a. Conversion of MS–DRGs to the International Classification of Diseases, 10th Revision (ICD–10)
1. Basis for FY 2017 MS–DRG Updates
2. Pre-Major Diagnostic Category (Pre-MDC): Total Artificial Heart Replacement
3. MDC 1 (Diseases and Disorders of the Nervous System)
   a. Endovascular Embolization (Coiling) or Occlusion of Head and Neck Procedures
   b. Mechanical Complication Codes
4. MDC 4 (Diseases and Disorders of the Ear, Nose, Mouth and Throat)
   a. Reassignment of Diagnosis Code R22.2 (Localized Swelling, Mass and Lump, Trunk)
   b. Pulmonary Embolism With tPA or Other Thrombolytic Therapy
5. MDC 5 (Diseases and Disorders of the Circulatory System)
   a. Implant of Loop Recorder
   b. Endovascular Thrombectomy of the Lower Limbs
c. Pacemaker Procedures Code Combinations
d. Transcatheter Mitral Valve Repair With Implant
e. MS–DRG 245 (AICD Generator Procedures)
6. MDC 6 (Diseases and Disorders of the Digestive System): Excision of Ileum
7. MDC 7 (Diseases and Disorders of the Hepatobiliary System and Pancreas): Bypass Procedures of the Veins
8. MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue)
   a. Updates to MS–DRGs 469 and 470 (Major Joint Replacement or Reattachment of Lower Extremity With and Without MCC, Respectively)
   (1) Total Ankle Replacement (TAR) Procedures
   (2) Hip Replacements Procedures With Principal Diagnosis of Hip Fracture
   b. Revision of Total Ankle Replacement Procedures
   (1) Revision of Total Ankle Replacement Procedures
   (2) Combination Codes for Removal and Replacement of Knee Joints
c. Decompression Laminectomy
d. Lordosis
9. MDC 13 (Diseases and Disorders of the Female Reproductive System): Vaginal Evisceration
10. MDC 19 (Mental Diseases and Disorders): Modification of Title of MS–DRG 884 (Organic Disturbances and Mental Retardation)
11. MDC 23 (Factors Influencing Health Status and Other Contacts With Health Services): Logic of MS–DRGs 945 and 946 (Rehabilitation With and Without CC/MCC, Respectively)
12. Medicare Code Editor (MCE) Changes
   a. Age Conflict Edit
   (1) Newborn Diagnosis Category
   (2) Pediatric Diagnosis Category
   b. Sex Conflict Edit
c. Non-Covered Procedure Edit
   (1) Endovascular Mechanical Thrombectomy
   (2) Radical Prostatectomy
   d. Unacceptable Principal Diagnosis Edit
   (1) Liveborn Infant
   (2) Multiple Gestation
   (3) Supervision of High Risk Pregnancy
e. Other MCE Issues
   (1) Procedure Inconsistent With Length of Stay Edit
   (2) Maternity Diagnoses
   (3) Manifestation Codes Not Allowed as Principal Diagnosis Edit
   (4) Questionable Admission Edit
   (5) Removal of Edits and Future Enhancement
13. Changes to Surgical Hierarchies
14. Changes to the MS–DRG Diagnosis Codes for FY 2017
15. Complications or Comorbidity (CC) Exclusions List
a. Background of the CC List and the CC Exclusions List
b. CC Exclusions List for FY 2017
16. Review of Procedure Codes in MS–DRGs 981 Through 983; 984 Through 986; and 987 Through 989
b. Moving Procedure Codes From MS–DRGs 981 Through 983 or MS–DRGs 987 Through 989 Into MDCs
b. Reassignment of Procedures Among MS–DRGs 981 Through 983, 984 Through 986, and 987 Through 989
c. Adding Diagnosis or Procedure Codes to MDCs
(1) Angioplasty of Extracranial Vessel
(2) Excision of Abdominal Arteries
(3) Excision of Retropertitoneal Tissue
(4) Occlusion of Vessels: Esophageal Varies
(5) Excision of Vulva
(6) Lymph Node Biopsy
(7) Obstetrical Laceration Repair
17. Changes to the ICD–10–CM and ICD–10–PCS Coding Systems
a. ICD–10 Coordination and Maintenance Committee
b. Code Freeze
18. Replaced Devices Offered Without Cost or With a Credit
a. Background
b. Changes for FY 2017
19. Other Policy Changes
a. MS–DRG GROUPER Logic
(1) Operations on Products of Conception
(2) Other Heart Revascularization
(3) Procedures on Vascular Bodies: Chemoreceptors
(4) Repair of the Intestine
(5) Insertion of Infusion Pump
(6) Procedures on the Bursa
(7) Procedures on the Breast
(8) Excision of Subcutaneous Tissue and Fascia
(9) Shoulder Replacement
(10) Reposition
(11) Insertion of Infusion Device
(12) Bladder Neck Repair
(13) Future Consideration
b. Issues Relating to MS–DRG 999 (Ungroupable)
c. Other Operating Room (O.R.) and Non-O.R. Issues
(1) O.R. Procedures to Non-O.R. Procedures
   (a) Endoscopic/Transorifice Insertion
   (b) Endoscopic/Transorifice Removal
   (c) Tracheostomy Device Removal
   (d) Endoscopic/Percutaneous Insertion
   (e) Percutaneous Removal
   (f) Percutaneous Drainage
   (g) Percutaneous Inspection
   (h) Inspection Without Incision
   (i) Dilation of Stomach
   (j) Endoscopic/Percutaneous Occlusion
   (k) Infusion Device
   (l) Non-O.R. Procedures to O.R. Procedures
      (a) Drainage of Pleural Cavity
      (b) Drainage of Cerebral Ventricle
20. Out of Scope Public Comments
G. Recalibration of the FY 2017 MS–DRG Relative Weights
1. Data Sources for Developing the Relative Weights
2. Methodology for Calculation of the Relative Weights
3. Development of National Average CCRs
III. Changes to the Hospital Wage Index for

FY 2017 Status of Technologies
Approved for FY 2016 Add-On Payments
a. Kcentra®
b. Argus® II Retinal Prosthesis System
c. CardioMEMSTM HF (Heart Failure) Monitoring System
d. MitraClip® System
e. Responsive Neurostimulator (RNS®) System
f. Bliinatumomab (BLINCYTO® Trade Brand)
g. Lutonix® Drug Coated Balloon PTA Catheter and In.PACTSTM Admiral®
Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter
5. FY 2017 Applications for New Technology Add-On Payments
a. MAGEC® Spinal Bracing and Distraction System (MAGEC® Spine)
b. MIRODERM® Biologic Wound Matrix (MIRODERM)
c. Idarucizumab
d. Titan Spine (Titan Spine Endoskeleton® nanoLOCK™ Interbody Device)
e. Difetilo® (Defibride)
f. GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE)
g. Vistogard® (Uridine Triacetate)

III. Changes to the Hospital Wage Index for
Acute Care Hospitals

A. Background
1. Legislative Authority
2. Core-Based Statistical Areas (CBSAs)
Revisions for the FY 2017 Hospital Wage Index
B. Worksheet S–3 Wage Data for the FY 2017 Wage Index
1. Included Categories of Costs
2. Excluded Categories of Costs
3. Use of Wage Index Data by Suppliers and Providers Other Than Acute Care Hospitals Under the IPPS
C. Verification of Worksheet S–3 Wage Data

IV. Other Decisions and Changes to the IPPS

A. Occupational Mix Adjustment to the FY 2017 Wage Index
1. Use of 2013 Occupational Mix Survey for the FY 2017 Wage Index
2. Development of the 2016 Medicare Wage Index Occupational Mix Survey for the FY 2019 Wage Index
3. Calculation of the Occupational Mix Adjustment for FY 2017
F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2017 Occupational Mix Adjusted Wage Index
C. Verification of Wage Indexes
1. Background
2. Transition for Hospitals in Urban Areas That Became Rural
3. Transition for Hospitals Deemed Urban Under Section 1886(d)(8)(B) of the Act Where the Urban Area Became Rural Under the New OMB Delineations
4. Budget Neutrality
H. Application of the Rural, Imputed, and Frontier Floors
1. Rural Floor
2. Imputed Floor for FY 2017
3. State Frontier Floor for FY 2017
4. FY 2017 Wage Index
J. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications
1. General Policies and Effects of Reclassification and Redesignation
2. Finalization of Interim Final Rule With Comment Period on Provisions Related to Modification on Limitations on Redesignations by the Medicare Geographic Classification Review Board (MGCRB)
3. Other Policy Regarding Reclassifications for Terminated Hospitals
4. Redesignation of Hospitals Under Section 1886(d)(8)(B) of the Act
5. Waiving Lugar Redesignation for the Out-Migrant Adjustment
K. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees for FY 2017
L. Notification Regarding CMS “Lock-In” Date for Urban to Rural Reclassifications Under § 412.103
M. Process for Requests for Wage Index Data Corrections
N. Labor Market Share for the FY 2017 Wage Index
O. Public Comments on Treatment of Overhead and Home Office Costs in the Wage Index Calculation as a Result of Our Solicitation

IV. Other Decisions and Changes to the IPPS

A. Operational Mix Adjustment to the FY 2017 Wage Index
1. Use of 2013 Occupational Mix Survey for the FY 2017 Wage Index
2. Development of the 2016 Medicare Wage Index Occupational Mix Survey for the FY 2019 Wage Index
3. Calculation of the Occupational Mix Adjustment for FY 2017
F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2017 Occupational Mix Adjusted Wage Index
C. Verification of Wage Indexes
1. Background
2. Transition for Hospitals in Urban Areas That Became Rural
3. Transition for Hospitals Deemed Urban Under Section 1886(d)(8)(B) of the Act Where the Urban Area Became Rural Under the New OMB Delineations
4. Budget Neutrality
H. Application of the Rural, Imputed, and Frontier Floors
1. Rural Floor
2. Imputed Floor for FY 2017
3. State Frontier Floor for FY 2017
4. FY 2017 Wage Index
J. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications
1. General Policies and Effects of Reclassification and Redesignation
2. Finalization of Interim Final Rule With Comment Period on Provisions Related to Modification on Limitations on Redesignations by the Medicare Geographic Classification Review Board (MGCRB)
3. Other Policy Regarding Reclassifications for Terminated Hospitals
4. Redesignation of Hospitals Under Section 1886(d)(8)(B) of the Act
5. Waiving Lugar Redesignation for the Out-Migrant Adjustment
K. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees for FY 2017
L. Notification Regarding CMS “Lock-In” Date for Urban to Rural Reclassifications Under § 412.103
M. Process for Requests for Wage Index Data Corrections
N. Labor Market Share for the FY 2017 Wage Index
O. Public Comments on Treatment of Overhead and Home Office Costs in the Wage Index Calculation as a Result of Our Solicitation

IV. Other Decisions and Changes to the IPPS

A. Operational Mix Adjustment to the FY 2017 Wage Index
1. Use of 2013 Occupational Mix Survey for the FY 2017 Wage Index
2. Development of the 2016 Medicare Wage Index Occupational Mix Survey for the FY 2019 Wage Index
3. Calculation of the Occupational Mix Adjustment for FY 2017
F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2017 Occupational Mix Adjusted Wage Index
C. Verification of Wage Indexes
1. Background
2. Transition for Hospitals in Urban Areas That Became Rural
3. Transition for Hospitals Deemed Urban Under Section 1886(d)(8)(B) of the Act Where the Urban Area Became Rural Under the New OMB Delineations
a. Condition-Specific Hospital Level, Risk-Standardized Payment Measures
b. Finalized Update to an Existing Measure for the FY 2021 Program Year; Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Percutaneous Coronary Intervention (PCI) Hospitalization (NQF #0466) (Updated Cohort)

5. New Measure for the FY 2022 Program Year: Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery (NQF #2558)

6. Previously Adopted and Newly Finalized Baseline and Performance Periods
   a. Background
   b. Patient- and Caregiver-Centered Experience of Care/Care Coordination Domain (Person and Community Engagement Domain Beginning With the FY 2019 Program Year)
   c. Efficiency and Cost Reduction Domain
   d. Safety Domain
   e. Clinical Care Domain
   f. Summary of Previously Adopted and Newly Finalized Baseline and Performance Periods for the FY 2018, FY 2019, FY 2020, FY 2021, and FY 2022 Program Years

7. Immediate Jeopardy Policy Changes
   a. Background
   b. Increase of Immediate Jeopardy Citations From Two to Three Surveys
   c. EMRA-Related Immediate Jeopardy Citations

8. Performance Standards for the Hospital VBP Program
   a. Background
   b. Previously Adopted and Newly Finalized Performance Standards for the FY 2019 Program Year
   c. Previously Adopted Performance Standards for Certain Measures for the FY 2020 Program Year
   d. Previously Adopted and Newly Finalized Performance Standards for Certain Measures for the FY 2021 Program Year
   e. Performance Standards for Certain Measures for the FY 2022 Program Year

9. FY 2019 Program Year Scoring Methodology
   a. Domain Weighting for the FY 2019 Program Year for Hospitals That Receive a Score on All Domains
   b. Domain Weighting for the FY 2019 Program Year for Hospitals Receiving Scores on Fewer Than Four Domains
   i. Changes to the Hospital-Acquired Condition (HAC) Reduction Program
   1. Background
   2. Implementation of the HAC Reduction Program for FY 2017
      a. Clarification of Complete Data Requirements for Domain 1
      b. Clarification of NHSN CDC HAI Data Submission Requirements for Newly Opened Hospitals
   3. Finalization of the HAC Reduction Program for FY 2018
      a. Adoption of Modified PSI 90: Patient Safety and Adverse Events Composite (NQF #0531)
      b. Applicable Time Periods for the FY 2018 HAC Reduction Program and the FY 2019 HAC Reduction Program
   c. Changes to the HAC Reduction Program Scoring Methodology
   d. Comments on Additional Measures for Potential Future Adoption
   e. Maintenance of Technical Specifications for Quality Measures
   f. Extraordinary Circumstance Exception Policy for the HAC Reduction Program Beginning in FY 2016 and for Subsequent Years
   g. Payment for Graduate Medical Education (GME) and Indirect Medical Education (IME) Costs (§§ 412.105, 413.05 Through 413.83)
   h. Background
   i. Change in New Program Growth From 3 Years to 5 Years
      a. Urban and Rural Hospitals
      b. Policy Changes Relating to Rural Training Tracks at Urban Hospitals
      c. Effective Date
   j. Section 5506 Closed Hospitals
   k. Rural Community Hospital Demonstration Program
   1. Background
   a. Fiscal Years 2005 Through 2013
   b. Fiscal Years 2014 and 2015
   c. Fiscal Year 2016
   a. Budget Neutrality Methodology for FY 2017
   i. Hospital and CAH Notification Procedures for Outpatients Receiving Observation Services
      a. Background
      b. Statutory Authority
      c. Effective Date
      a. Notice Process
      b. Notification Recipients
      c. Timing of Notice Delivery
      d. Requirements for Written Notice
   iii. Outpatient Observation Services and Beneficiary Financial Liability
      a. Delivery of the Medicare Outpatient Observation Notice
      b. Oral Notice
      c. Signature Requirements
   iv. No Appeal Rights Under the NOTICE Act
   vi. Technical Correction to 42 CFR 413.200(c)(1)(ii) Relating to Medicare Cost Report Due Dates for Organ Procurement Organizations and Histocompatibility Laboratories
   vii. Finalization of Interim Final Rule With Comment Period Implementing Legislative Extensions Relating to the Payment Adjustments for Low-Volume Hospitals and the Medicare-Dependent, Small Rural Hospital (MDH) Program
   viii. Clarification Regarding the Medicare Utilization Requirement for Medicare-Dependent, Small Rural Hospitals (MDHs) (§ 412.108)
   ix. Adjustment to IPPS Rates Resulting From 2-Midnight Policy

V. Changes to the IPPS for Capital-Related Costs
   a. Overview
   b. Additional Provisions
      1. Exception Payments
      2. New Hospitals
      3. Changes in Payments for Hospitals Located in Puerto Rico
   c. Annual Update for FY 2017

VI. Changes for Hospitals Excluded From the IPPS
   a. Rate-of-Increase in Payments to Excluded Hospitals for FY 2017
   b. Report of Adjustment (Exceptions) Payments
   c. Critical Care Hospitals (CAHs)
      1. Background
      2. Frontier Community Health Integration Project (FCHIP) Demonstration

VII. Changes to the Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY 2017
   a. Background of the LTCH PPS
   b. Legislative and Regulatory Authority
   c. Criteria for Classification as a LTCH
   d. Hospitals Excluded From the LTCH PPS
   e. Limitation on Charges to Beneficiaries
   f. Administrative Simplification
   g. Compliance Act (ASCA) and Health Insurance Portability and Accountability Act (HIPAA) Compliance
   h. Modifications to the Application of the Site Neutral Payment Rate (§ 412.522)
      1. Background
      2. Technical Correction of Definition of “Subsection (d) Hospital” for the Site Neutral Payment Rate (§ 412.563)
   i. Finalization of Interim Final Rule With Comment Period: Temporary Exception to the Site Neutral Payment Rate Under the LTCH PPS For Certain Severe Wound Discharges From Certain LTCHs
   j. Medicare Severity Long-Term Care Diagnosis-Related Group (MS–LT–DRG) Classifications and Relative Weights for FY 2017
      1. Background
      2. Patient Classifications Into MS–LT–DRGs
      a. Background
      b. Changes to the MS–LT–DRGs for FY 2017
   3. Development of the FY 2017 MS–LT–DRG Relative Weights
      a. General Overview of the Development of the MS–LT–DRG Relative Weights
      b. Development of the MS–LT–DRG Relative Weights for FY 2017
c. Data
 d. Hospital-Specific Relative Value (HSRV) Methodology
e. Treatment of Severity Levels in Developing the MS–LTC–DRG Relative Weights
f. Low-Volume MS–LTC–DRGs
g. Steps for Determining the FY 2017 MS–LTC–DRG Relative Weights

D. Rebasing of the LTCH Market Basket
 1. Background
 2. Overview of the 2013-Based LTCH Market Basket
 3. Development of the 2013-Based LTCH Market Basket Cost Categories and Weights

a. Use of Medicare Cost Report Data
   (1) Wages and Salaries Costs
   (2) Employee Benefit Costs
   (3) Contract Labor Costs
   (4) Pharmaceutical Costs
   (5) Professional Liability Insurance Costs
   (6) Capital Costs
   b. Final Major Cost Category Computation
      c. Derivation of the Detailed Operating Cost Weights
   d. Derivation of the Detailed Capital Cost Weights

E. 2013-Based LTCH Market Basket Cost Categories and Weights

4. Selection of Price Proxies
   a. Use of Medicare Cost Report Data
      (1) Wages and Salaries
      (2) Employee Benefits
      (3) Contract Labor
      (4) Pharmaceuticals
      (5) Professional Liability Insurance
      (6) Capital Costs
   b. Final Major Cost Category Computation
      c. Derivation of the Detailed Operating Cost Weights
   d. Derivation of the Detailed Capital Cost Weights

F. 2013-Based LTCH Market Basket Cost Categories and Weights

4. Selection of Price Proxies
   a. Price Proxies for the Operating Portion of the 2013-Based LTCH Market Basket
      (1) Wages and Salaries
      (2) Employee Benefits
      (3) Electricity
      (4) Fuel, Oil, and Gasoline
      (5) Water and Sewage
      (6) Professional Liability Insurance
      (7) Pharmaceuticals
      (8) Food: Direct Purchases
      (9) Food: Contract Services
      (10) Chemicals
      (11) Medical Instruments
      (12) Rubber and Plastics
      (13) Paper and Printing Products
      (14) Miscellaneous Products
      (15) Professional Fees: Labor-Related
      (16) Administrative and Facilities Support Services
      (17) Installation, Maintenance, and Repair Services
      (18) All Other: Labor-Related Services
      (19) Professional Fees: Non-labor-Related
      (20) Financial Services
      (21) Telephone Services
      (22) All Other: Non-labor-Related Services
   b. Price Proxies for the Capital Portion of the 2013-Based LTCH Market Basket
      (1) Capital Price Proxies Prior to Vintage Weighting
      (2) Vintage Weights for Price Proxies
         a. Summary of Price Proxies of the 2013-Based LTCH Market Basket
      d. FY 2017 Market Basket Update for LTCHs
      e. FY 2017 Labor-Related Share
      f. Changes to the LTCH PPS Payment Rates for FY 2017 and Other Changes to the LTCH PPS for FY 2017
         1. Overview of Development of the LTCH PPS Standard Federal Payment Rates
         2. FY 2017 LTCH PPS Standard Federal Payment Rate Annual Market Basket Update
         a. Overview

3. Retention and Update to Previously Finalized Quality Measures for PCHs Beginning With the FY 2019 Program Year
   a. Background
   b. Update of Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382) Measure for FY 2019 Program Year and Subsequent Years
4. New Quality Measure Beginning With the FY 2019 Program Year
   a. Considerations in the Selection of Quality Measures
   b. Adoption of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy Measure
5. Possible New Quality Measure Topics for Future Years
7. Public Display Requirements
   a. Background
   b. Additional Public Display Requirements
   c. Public Display of Additional PCHQR Measure
   d. Public Display of Updated Measure
   e. Postponement of Public Display of Two Measures
8. Form, Manner, and Timing of Data Submission
9. Exceptions From PCHQR Program Requirements
C. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)
1. Background and Statutory Authority
2. General Considerations Used for Selection of Quality, Resource Use, and Other Measures for the LTCH QRP
3. Policy for Retention of LTCH QRP Measures Adopted for Previous Payment Determinations
4. Policy for Adopting Changes to LTCH QRP Measures
5. Quality Measures Previously Finalized for and Currently Used in the LTCH QRP
6. LTCH QRP Quality, Resource Use and Other Measures for the FY 2018 Payment Determination and Subsequent Years
   a. Measure To Address the IMPACT Act Domain of Resource Use and Other Measures: Total Estimated MSPB—PAC LTCH QRP
   b. Measure To Address the IMPACT Act Domain of Resource Use and Other Measures: Potentially Preventable 30-Day Post-Discharge Readmission Measure for the LTCH QRP
7. LTCH QRP Quality Measure Finalized for the FY 2020 Payment Determination and Subsequent Years
   a. Background
   b. Measure To Address the IMPACT Act Domain of Medication Reconciliation: Drug Regimen Review Conducted With Follow-Up For Identified Issues-Post Acute Care LTCH QRP
8. LTCH QRP Quality Measures and Measure Concepts Under Consideration for Future Years
9. Form, Manner, and Timing of Quality Data Submission for the FY 2018 Payment Determination and Subsequent Years
   a. Background
   b. Timeline for Data Submission Under the LTCH QRP for the FY 2018 Payment Determination and Subsequent Years
   c. Timeline for Data Submission Mechanisms for the FY 2018 Payment Determination and Subsequent Years for the LTCH QRP Resource Use and Other Measures—Claims-Based Measures
   d. Revisions to the Previously Adopted Data Collection Period and Submission Deadlines for Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) for the FY 2019 Payment Determination and Subsequent Years
   e. Timeline and Data Submission Mechanisms for the Newly Finalized LTCH QRP Quality Measure for the FY 2020 Payment Determination and Subsequent Years
10. LTCH QRP Data Completion Thresholds for the FY 2016 Payment Determination and Subsequent Years
11. LTCH QRP Data Validation Process for the FY 2016 Payment Determination and Subsequent Years
12. Change to Previously Codified LTCH QRP Submission Exception and Extension Policies
13. Previously Finalized LTCH QRP Reconsideration and Appeals Procedures
14. Policies Regarding Public Display of Measure Data for the LTCH QRP and Procedures for the Opportunity To Review and Correct Data and Information
   a. Public Display of Measures
   b. Procedures for the Opportunity To Review and Correct Data and Information
15. Mechanism for Providing Feedback Reports to LTCHs
D. Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program
1. Background
   a. Statutory Authority
   b. Covered Entities
   c. Considerations in Selecting Quality Measures
2. Retention of IPFQR Program Measures Adopted in Previous Payment Determinations
3. Update to Previously Finalized Measure: Screening for Metabolic Disorders
4. New Quality Measures for the FY 2019 Payment Determination and Subsequent Years
   a. SUB–3—Alcohol and Other Drug Use Disorder Treatment Provided or Offered at Discharge and the Subset Measure
   b. Thirty-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF
5. Summary of Measures for the FY 2019 Payment Determination and Subsequent Years
6. Possible IPFQR Program Measures and Topics for Future Consideration
7. Public Display and Review Requirements
8. Form, Manner, and Timing of Quality Data Submission
   a. Procedural and Submission Requirements
   b. Change to the Reporting Periods and Submission Timeframes
   c. Population and Sampling
   d. Data Accuracy and Completeness Acknowledgement (DACA) Requirements
9. Reconsideration and Appeals Procedures
10. Exceptions to Quality Reporting Requirements
E. Clinical Quality Measurement for Eligible Hospitals and Critical Access Hospitals (CAHs) Participating in the EHR Incentive Programs in 2017
   1. Background
   2. CQM Reporting for the Medicare and Medicaid EHR Incentive Programs in 2016
   a. Background
   b. CQM Reporting Period for the Medicare and Medicaid EHR Incentive Programs in CY 2017
   c. CQM Reporting Form and Method for the Medicare EHR Incentive Program in 2017
IX. MedPAC Recommendations
X. Other Required Information
   1. Requests for Data From the Public
   2. Collection of Information Requirements
      a. Statutory Requirement for Solicitation of Comments
      b. ICRs for Add-On Payments for New Services and Technologies
      c. ICRs for the Occupational Mix Adjustment to the FY 2017 Wage Index (Hospital Wage Index Occupational Mix Survey)
      d. Hospital Applications for Geographic Reclassifications by the MGCGRB
      e. ICRs for Applications for GEEL MTAC Resident Slots
      f. ICRs for the Notice of Observation Treatment by Hospitals and CAHs
      g. ICRs for the Hospital Inpatient Quality Reporting (IQR) Program
      h. ICRs for PFS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
      i. ICRs for Hospital Value-Based Purchasing (VBP) Program
      j. ICRs for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)
      k. ICRs for the Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program
      l. ICRs for the Electronic Health Record (EHR) Incentive Programs and Meaningful Use
Regulation Text
Addendum—Schedule of Standardized Amounts, Update Factors, and Rate-of-Increase Percentages Effective With Cost Reporting Periods Beginning on or after October 1, 2016 and Payment Rates for LTCHs Effective With Discharges Occurring on or After October 1, 2016
I. Summary and Background
II. Changes to the Prospective Payment Rates for Hospital Inpatient Operating Costs for Acute Care Hospitals for FY 2017
   A. Calculation of the Adjusted Standardized Amount
Appendix A—Economic Analyses

I. Regulatory Impact Analysis
   A. Introduction
   B. Need
   C. Objectives of the IPPS
   D. Limitations of Our Analysis
   E. Hospitals Included in and Excluded From the IPPS
   F. Effects on Hospitals and Hospital Units Excluded from the IPPS
   G. Quantitative Effects of the Policy Changes Under the IPPS for Operating Costs
      1. Basis and Methodology of Estimates
      2. Analysis of Table I
      3. Impact Analysis of Table II
   H. Effects of Other Policy Changes
      1. Effects of Policy Relating to New Medical Service and Technology Add-On Payments
      2. Effect of Changes Relating to Payment Adjustment for Medicare Disproportionate Share Hospitals
      3. Effects of Reduction Under the Hospital Readmissions Reduction Program
      4. Effects of Changes Under the FY 2017 Hospital Value-Based Purchasing (VBP) Program
      5. Effects of the Changes to the HAC Reduction Program for FY 2017
      6. Effects of Policy Changes Relating to Direct GME and IME Payments for Rural Training Tracks at Urban Hospitals
      7. Effects of Implementation of Rural Community Hospital Demonstration Program
      8. Effects of Implementation of the Notice of Observation Treatment and Implications for Care Eligibility Act (NOTICE Act)
      9. Effects of Technical Changes and Correction of Typographical Errors in Certain Regulations Under 42 CFR part 413 Relating to Costs to Related Organizations and Medicare Cost Reports
      10. Effects of Implementation of the Frontier Community Health Integration Project (FCHIP) Demonstration
   I. Effects of Changes in the Capital IPPS
      1. General Considerations
      2. Results
   J. Effects of Payment Rate Changes and Policy Changes Under the LTCH PPS
      1. Introduction and General Considerations
      2. Impact on Rural Hospitals
      3. Anticipated Effects of LTCH PPS Payment Rate Changes and Policy Changes
      4. Effect on the Medicare Program
      5. Effect on Medicare Beneficiaries
      K. Effects of Requirements for Hospital Inpatient Quality Reporting (IQR) Program
      L. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
      M. Effects of Requirements for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) for the FY 2016 Payment Determination and Subsequent Years
      N. Effects of Updates to the Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program
      O. Effects of Requirements Regarding the Electronic Health Record (EHR) Incentive Programs and Meaningful Use
      P. Alternatives Considered
      Q. Overall Conclusion
         1. Acute Care Hospitals
         2. LTCHs
   II. Accounting Statements and Tables
      A. Acute Care Hospitals
      B. LTCHs
   III. Regulatory Flexibility Act (RFA) Analysis
      IV. Impact on Small Rural Hospitals
      V. Unfunded Mandate Reform Act (UMRA) Analysis
      VI. Executive Order 12866

Appendix B: Recommendation of Update Factors for Operating Cost Rates of Payment for Inpatient Hospital Services

I. Background
   II. Inpatient Hospital Update for FY 2017
      A. FY 2017 Inpatient Hospital Update
      B. Update for SCHs and MDHs for FY 2017
      C. FY 2017 Puerto Rico Hospital Update
      D. Update for Hospitals Excluded From the IPPS
      E. Update for LTCHs for FY 2017
Section 1886(d) of the Social Security Act (the Act), which sets forth a system of payment for the operating costs of acute care hospital inpatient stays under Medicare Part A (Hospital Insurance) based on prospectively set rates. Section 1886(g) of the Act requires that, instead of paying for capital-related costs of inpatient hospital services on a reasonable cost basis, the Secretary use a prospective payment system (PPS).

Section 1886(d)(1)(B) of the Act, which specifies that certain hospitals and hospital units are excluded from the IPPS. These hospitals and units are: Rehabilitation hospitals and units; LTCHs; psychiatric hospitals and units; children’s hospitals; cancer hospitals; and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa). Religious nonprofit health care institutions (RHHIs) are also excluded from the IPPS.

Sections 123(a) and (c) of the BBRA (Pub. L. 106–113) and section 307(b)(1) of the BIPA (Pub. L. 106–554) (as codified under section 1886(m)(1) of the Act), which provide for the development and implementation of a prospective payment system for payment for inpatient hospital services of long-term care hospitals (LTCHs) described in section 1886(d)(1)(B)(iv) of the Act.

Sections 1814(l), 1820, and 1834(g) of the Act, which specify that payments are made to critical access hospitals (CAHs) (that is, rural hospitals or facilities that meet certain statutory requirements) for inpatient and outpatient services and that these payments are generally based on 101 percent of reasonable cost.

Section 1866(k) of the Act, as added by section 3005 of the Affordable Care Act, which establishes a quality reporting program for hospitals described in section 1886(d)(1)(B)(v) of the Act, referred to as “PPS-exempt cancer hospitals.”

Section 1886(a)(4) of the Act, which specifies that costs of approved educational activities are excluded from the operating costs of inpatient hospital services. Hospitals with approved graduate medical education (GME) programs are paid for the direct costs of GME in accordance with section 1886(h) of the Act.

Section 1886(b)(3)(B)(viii) of the Act, which requires the Secretary to reduce the applicable percentage increase in payments to a subsection (d) hospital for a fiscal year if the hospital does not submit data on measures in a form and manner, and at a time, specified by the Secretary.

Section 1886(o) of the Act, which requires the Secretary to establish a Hospital Value-Based Purchasing (VBP) Program under which value-based incentive payments are made in a fiscal year to hospitals meeting performance standards established for a performance period for such fiscal year.

Section 1886(p) of the Act, as added by section 3008 of the Affordable Care Act, which establishes a Hospital-Acquired Condition (HAC) Reduction Program, under which payments to applicable hospitals are adjusted to provide an incentive to reduce hospital-acquired conditions.

Section 1886(q) of the Act, as added by section 3025 of the Affordable Care Act and amended by section 10309 of the Affordable Care Act, which establishes the “Hospital Readmissions Reduction Program” effective for discharges from an “applicable hospital” beginning on or after October 1, 2012, under which payments to those hospitals under section 1886(d) of the Act will be reduced to account for certain excess readmissions.

Section 1886(r) of the Act, as added by section 3133 of the Affordable Care Act, which provides for a reduction to disproportionate share hospital (DSH) payments under section 1886(d)(5)(F) of the Act and for a new uncompensated care payment to eligible hospitals. Specifically, section 1886(r) of the Act requires that, for fiscal year 2014 and each subsequent fiscal year, subsection (d) hospitals that would otherwise receive a DSH payment made under section 1886(d)(5)(F) of the Act will receive two separate payments: (1) 25 percent of the amount they previously would have received under section 1886(d)(5)[F] of the Act for DSH (“the empirically justified amount”), and (2) an additional payment for the DSH hospital’s proportion of uncompensated care, determined as the product of three factors. These three factors are: (1) 75 percent of the payments that would otherwise be made under section 1886(d)(5)[F] of the Act; (2) 1 minus the percent change in the percent of individuals under the age of 65 who are uninsured (minus 0.1 percentage points for FY 2014, and minus 0.2 percentage points for FY 2015 through FY 2017); and (3) a hospital’s uncompensated care amount relative to the uncompensated care amount of all DSH hospitals expressed as a percentage.

Section 1886(m)(6) of the Act, as added by section 1206(a)(1) of the Pathway to Sustainable Growth Rate (SGR) Reform Act of 2013 (Pub. L. 113–67), which provided for the establishment of site neutral payment rate criteria under the LTCH PPS with implementation beginning in FY 2016.

Section 1886(m)(5)(D)(iv) of the Act, as added by section 1206(c) of the Pathway for Sustainable Growth Rate (SGR) Reform Act of 2013 (Pub. L. 113–67), which provides for the establishment of a functional status quality measure under the LTCH QRP for change in mobility among inpatients requiring ventilator support.

Section 1899B of the Act, as added by the Improving Medicare Post-Acute Care Transformation Act of 2014 (the IMPACT Act, Pub. L. 113–185), which imposes data reporting requirements for certain post-acute care providers, including LTCHs.

Section 1886(d)(12) of the Act, as amended by section 204 of the Medicare Access and CHIP Reauthorization Act of 2015, which extends, through FY 2017, changes to the inpatient hospital payment adjustment for certain low-volume hospitals; and section 1886(d)(5)(G) of the Act, as amended by section 205 of the Medicare Access and CHIP Reauthorization Act of 2015, which extends, through FY 2017, the Medicare-dependent, small rural hospital (MDH) program.

Section 1886(m)(6)(A)(i) and (E) of the Act, as amended and added by section 231 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113), which established a temporary exception to the site neutral payment rate under the LTCH PPS for certain severe wound discharges from certain LTCHs occurring prior to January 1, 2017.


a. MS–DRG Documentation and Coding Adjustment

Section 631 of the American Taxpayer Relief Act (ATRA, Pub. L. 112–240) amended section 7(b)(1)(B) of Pub. L. 110–90 to require the Secretary to make a recoupment adjustment to the standardized amount of Medicare payments to acute care hospitals to account for changes in MS–DRG documentation and coding that do not reflect real changes in case-mix, totaling $11 billion over a 4-year period of FYs 2014, 2015, 2016, and 2017. This adjustment represents the amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Pub. L. 110–90 until FY 2013. Prior to the ATRA, this amount could not have been recovered under Pub. L. 110–90.

While our actuaries estimated that a –9.3 percent adjustment to the...
standardized amount would be necessary if CMS were to fully recover the $11 billion recoupment required by section 631 of the ATRA in one year, it is often our practice to delay or phase in rate adjustments over more than one year, in order to moderate the effects on rates in any one year. Therefore, consistent with the policies that we have adopted in many similar cases, we made a −0.8 percent recoupment adjustment to the standardized amount in FY 2014, FY 2015, and FY 2016. For FY 2017, we are making an additional −1.5 percent recoupment adjustment to the standardized amount.

b. Adjustment to IPPS Rates Resulting From 2-Midnight Policy

In this final rule, we are making a permanent adjustment of (1/0.998) to the standardized amount, the hospital-specific payment rates, and the national capital Federal rate using our authority under sections 1886(d)(5)(l)(i) and 1886(g) of the Act to prospectively remove the 0.2 percent reduction to the rate put in place in FY 2014 to offset the estimated increase in IPPS expenditures as a result of the 2-midnight policy. In addition, we are making a temporary one-time prospective increase to the FY 2017 standardized amount, the hospital-specific payment rates, and the national capital Federal rate of 0.6 percent by including a temporary one-time factor of 1.006 in the calculation of the standardized amount, the hospital-specific payment rates, and the national capital Federal rate of 0.6 percent by including a temporary one-time factor of 1.006 in the calculation of the

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which value-based incentive payments are made in a fiscal year to hospitals based on their performance on measures established for a performance period during such fiscal year. In this final rule, we are updating one previously adopted measure beginning with the FY 2019 program year; indicating our intent to propose to remove one measure beginning with the FY 2019 program year and our intent to propose to adopt one measure in future rulemaking; adopting two new measures beginning with the FY 2021 program year; updating one previously adopted measure beginning with the FY 2021 program year; and adopting one new measure beginning with the FY 2022 program year. We also are changing the performance period for one previously adopted measure for the FY 2018 program year and changing the name of the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain to the Person and Community Engagement domain beginning with the FY 2019 program year. In addition, we are making changes to the immediate jeopardy citation policy.

d. Hospital Value-Based Purchasing (VBP) Program

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which value-based incentive payments are made in a fiscal year to hospitals based on their performance on measures established for a performance period during such fiscal year. In this final rule, we are updating one previously adopted measure beginning with the FY 2019 program year; indicating our intent to propose to remove one measure beginning with the FY 2019 program year and our intent to propose to adopt one measure in future rulemaking; adopting two new measures beginning with the FY 2021 program year; updating one previously adopted measure beginning with the FY 2021 program year; and adopting one new measure beginning with the FY 2022 program year. We also are changing the performance period for one previously adopted measure for the FY 2018 program year and changing the name of the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain to the Person and Community Engagement domain beginning with the FY 2019 program year. In addition, we are making changes to the immediate jeopardy citation policy.

e. Hospital-Acquired Condition (HAC) Reduction Program

Section 1886(p) of the Act, as added under section 3008(a) of the Affordable Care Act, establishes an incentive to hospitals to reduce the incidence of hospital-acquired conditions by requiring the Secretary to make an adjustment to payments to applicable hospitals effective for discharges beginning on October 1, 2014. This 1-percent payment reduction applies to a hospital whose ranking is in the top quartile (25 percent) of all applicable hospitals, relative to the national average, of conditions acquired during the applicable period and on all of the hospital’s discharges for the specified fiscal year. In this final rule, we are proposing the following HAC Reduction Program policies: (1) Establishing NHSN CDC HAI data submission requirements for newly opened hospitals; (2) clarifying data requirements for Domain 1 scoring; (3) establishing performance periods for the FY 2018 and FY 2019 HAC Reduction Programs, including revising our regulations to accommodate variable timeframes; (4) adopting the refined PSI 90: Patient Safety and Adverse Events Composite (NQF #0531); and (5) changing the program scoring methodology from the current decile-based scoring to a continuous scoring methodology.

f. DSH Payment Adjustment and Additional Payment for Uncompensated Care

Section 3133 of the Affordable Care Act modified the Medicare disproportionate share hospital (DSH) payment methodology beginning in FY 2014. Under section 1886(r) of the Act, which was added by section 3133 of the Affordable Care Act, starting in FY 2014, DSHs will receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The remaining amount, equal to 75 percent of what otherwise would have been paid as Medicare DSH payments, will be paid as additional payments after the amount is reduced for changes in the percentage of individuals that are uninsured. Each Medicare DSH will receive an additional payment based on its share of the total amount of uncompensated care for all Medicare DSHs for a given time period.

In this final rule, we are updating our estimates of the three factors used to determine uncompensated care payments for FY 2017 and continuing our methodology of using a hospital’s share of insured low-income days for purposes of determining Factor 3. For Puerto Rico hospitals, we are using 14 percent of Medicaid days as a proxy for SSI days in the calculation of Factor 3. We are continuing to use the methodology we established in FY 2015 to calculate the uncompensated care payment amounts for merged hospitals such that we combine uncompensated care data for the hospitals that have undergone a merger in order to calculate their relative share of uncompensated care. We are expanding the time period of the data used to calculate the uncompensated care payment amounts to be distributed, from one cost reporting period to three cost reporting periods. At this time, we are not finalizing a future transition to using Worksheet 5–10 data to determine the amounts and distribution of uncompensated care payments.

We are continuing to use the methodology to accommodate variable timeframes; (4) adopting the refined PSI 90: Patient Safety and Adverse Events Composite (NQF #0531); and (5) changing the program scoring methodology from the current decile-based scoring to a continuous scoring methodology.

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which value-based incentive payments are made in a fiscal year to hospitals based on their performance on measures established for a performance period during such fiscal year. In this final rule, we are updating one previously adopted measure beginning with the FY 2019 program year; indicating our intent to propose to remove one measure beginning with the FY 2019 program year and our intent to propose to adopt one measure in future rulemaking; adopting two new measures beginning with the FY 2021 program year; updating one previously adopted measure beginning with the FY 2021 program year; and adopting one new measure beginning with the FY 2022 program year. We also are changing the performance period for one previously adopted measure for the FY 2018 program year and changing the name of the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain to the Person and Community Engagement domain beginning with the FY 2019 program year. In addition, we are making changes to the immediate jeopardy citation policy.

d. Hospital-Acquired Condition (HAC) Reduction Program

Section 1886(o) of the Act, as added under section 3008(a) of the Affordable Care Act, establishes an incentive to hospitals to reduce the incidence of hospital-acquired conditions by requiring the Secretary to make an adjustment to payments to applicable hospitals effective for discharges beginning on October 1, 2014. This 1-percent payment reduction applies to a hospital whose ranking is in the top quartile (25 percent) of all applicable hospitals, relative to the national average, of conditions acquired during the applicable period and on all of the hospital’s discharges for the specified fiscal year. In this final rule, we are proposing the following HAC Reduction Program policies: (1) Establishing NHSN CDC HAI data

f. DSH Payment Adjustment and Additional Payment for Uncompensated Care

Section 3133 of the Affordable Care Act modified the Medicare disproportionate share hospital (DSH) payment methodology beginning in FY 2014. Under section 1886(r) of the Act, which was added by section 3133 of the Affordable Care Act, starting in FY 2014, DSHs will receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The remaining amount, equal to 75 percent of what otherwise would have been paid as Medicare DSH payments, will be paid as additional payments after the amount is reduced for changes in the percentage of individuals that are uninsured. Each Medicare DSH will receive an additional payment based on its share of the total amount of uncompensated care for all Medicare DSHs for a given time period.

In this final rule, we are updating our estimates of the three factors used to determine uncompensated care payments for FY 2017 and continuing our methodology of using a hospital’s share of insured low-income days for purposes of determining Factor 3. For Puerto Rico hospitals, we are using 14 percent of Medicaid days as a proxy for SSI days in the calculation of Factor 3. We are continuing to use the methodology we established in FY 2015 to calculate the uncompensated care payment amounts for merged hospitals such that we combine uncompensated care data for the hospitals that have undergone a merger in order to calculate their relative share of uncompensated care. We are expanding the time period of the data used to calculate the uncompensated care payment amounts to be distributed, from one cost reporting period to three cost reporting periods. At this time, we are not finalizing a future transition to using Worksheet 5–10 data to determine the amounts and distribution of uncompensated care payments.

We are continuing to use the methodology to accommodate variable timeframes; (4) adopting the refined PSI 90: Patient Safety and Adverse Events Composite (NQF #0531); and (5) changing the program scoring methodology from the current decile-based scoring to a continuous scoring methodology.

Section 1886(o) of the Act requires the Secretary to establish a Hospital VBP Program under which value-based incentive payments are made in a fiscal year to hospitals based on their performance on measures established for a performance period during such fiscal year. In this final rule, we are updating one previously adopted measure beginning with the FY 2019 program year; indicating our intent to propose to remove one measure beginning with the FY 2019 program year and our intent to propose to adopt one measure in future rulemaking; adopting two new measures beginning with the FY 2021 program year; updating one previously adopted measure beginning with the FY 2021 program year; and adopting one new measure beginning with the FY 2022 program year. We also are changing the performance period for one previously adopted measure for the FY 2018 program year and changing the name of the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain to the Person and Community Engagement domain beginning with the FY 2019 program year. In addition, we are making changes to the immediate jeopardy citation policy.

d. Hospital-Acquired Condition (HAC) Reduction Program

Section 1886(o) of the Act, as added under section 3008(a) of the Affordable Care Act, establishes an incentive to hospitals to reduce the incidence of hospital-acquired conditions by requiring the Secretary to make an adjustment to payments to applicable hospitals effective for discharges beginning on October 1, 2014. This 1-percent payment reduction applies to a hospital whose ranking is in the top quartile (25 percent) of all applicable hospitals, relative to the national average, of conditions acquired during the applicable period and on all of the hospital’s discharges for the specified fiscal year. In this final rule, we are proposing the following HAC Reduction Program policies: (1) Establishing NHSN CDC HAI data
Specifically, we had proposed to use a 3-year transition beginning in FY 2018 where we use a combination of Worksheet S–10 and proxy data until FY 2020 when all data used in computing the uncompensated care payment amounts to be distributed would come from Worksheet S–10. In light of public comments, we believe it would be appropriate to institute certain additional quality control and data improvement measures to the Worksheet S–10 instructions and data prior to moving forward with incorporation of Worksheet S–10 data into the calculation of Factor 3. Consequently, we are not finalizing our proposal to begin to incorporate Worksheet S–10 data into the computation of Factor 3 for FY 2018. In light of the significant concerns expressed by commenters regarding the Worksheet S–10 data, we are postponing the decision regarding when to begin incorporating data from Worksheet S–10 and proceeding with revisions to the cost report instructions for Worksheet S–10. We expect data from the revised Worksheet S–10 to be available to use in the calculation of Factor 3 in the near future, and no later than FY 2021. With regard to how Factor 3 will be computed in FY 2018 and subsequent years, we intend to explore whether there is an appropriate proxy for uncompensated care that could be used to calculate Factor 3 until we determine that data from the revised Worksheet S–10 can be used for this purpose. We will undertake further notice-and-comment rulemaking to address the issue of the appropriateness of a use to determine Factor 3 for FY 2018 and subsequent fiscal years.

g. Payments for Capital-Related Costs for Hospitals Located in Puerto Rico

Capital IPPS payments to hospitals located in Puerto Rico are currently computed based on a blend of 25 percent of the capital IPPS Puerto Rico rate and 75 percent of the capital IPPS Federal rate. Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) increased the applicable Federal percentage of the operating IPPS payment for hospitals located in Puerto Rico from 75 percent to 100 percent and decreased the applicable Puerto Rico percentage of the operating IPPS payments for hospitals located in Puerto Rico from 25 percent to zero percent, applicable to discharges occurring on or after January 1, 2016. In this final rule, we are revising the calculation of capital IPPS payments to hospitals located in Puerto Rico to parallel the change in the statutory calculation of operating IPPS payments to hospitals located in Puerto Rico, beginning in FY 2017.

h. Changes to the LTCH PPS

In this final rule, we are revising and rebasing the market basket used under the LTCH PPS (currently the 2009-based LTCH-specific market basket) to reflect a 2013 base year. In addition, in this final rule, we are changing our 25-percent threshold policy by sunsetting our existing regulations at 42 CFR 412.534 and 412.536 and replacing them with a single consolidated 25-percent threshold policy at §412.538. We also are amending our existing regulations limiting allowable charges to beneficiaries for “subclause (II)” LTCHs and making technical corrections to §412.503. In addition, in this document, we are finalizing an April 21, 2016 interim final rule with comment period relating to a temporary exception from the site neutral payment rate under the LTCH PPS for certain severe wound care discharges from certain LTCHs.

i. Hospital Inpatient Quality Reporting (IQR) Program

Under section 1886(b)(3)(B)(viii) of the Act, hospitals are required to report data on measures selected by the Secretary for the Hospital IQR Program in order to receive the full annual percentage increase in payments. In past years, we have established measures for reporting data and the process for submittal and validation of the data.

In this final rule, we are making several changes. First, we are removing 15 measures for the FY 2019 payment determination and subsequent years. Thirteen of these measures are electronic clinical quality measures (eCQMs), two of which we are also removing in their chart-abstracted form, because they are “topped-out,” and two others are structural measures.

Second, we are refining two previously adopted measures beginning with the FY 2018 payment determination: (1) The Hospital-level, Risk-standardized Payment Associated with a 30-day Episode-of-Care for Pneumonia (NQF # 2579); and (2) the Patient Safety and Adverse Events Composite (NQF #0531).

Third, we are adding four new claims-based measures: (1) Aortic Aneurysm Procedure Clinical Episode-Based Payment Measure; (2) Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment Measure; (3) Spinal Fusion Clinical Episode-Based Payment Measure; and (4) Excess Days in Acute Care after Hospitalization for Pneumonia for the FY 2019 payment determination and subsequent years.

Fourth, we summarize public comment we received on potential new quality measures under consideration for future inclusion in the Hospital IQR Program: (1) A refined version of the NIH Stroke Scale for the Hospital 30-Day Mortality Following Acute Ischemic Stroke Hospitalization Measure beginning as early as the FY 2022 payment determination; (2) the National Healthcare Safety Network (NHSN) Antimicrobial Use Measure (NQF #2720); and (3) one or more measures of behavioral health for the inpatient hospital setting, including measures previously adopted for the IPFQR Program (80 FR 46417). Also, we summarize public comment we received on the possibility of future stratification of Hospital IQR Program data by race, ethnicity, sex, and disability on Hospital Compare, as well as on potential future hospital quality measures that incorporate health equity.

Fifth, we are modifying our proposal and requiring hospitals to select and submit 8 of the available eCQMs included in the Hospital IQR Program measure set for four quarters of data, on an annual basis, for the CY 2017 reporting period/FY 2019 payment determination and the CY 2018 reporting period/FY 2020 payment determination, in order to align the Hospital IQR Program with the Medicare and Medicaid EHR Incentive Programs. Also, we are establishing related eCQM submission requirements beginning with the FY 2019 payment determination.

Sixth, we are modifying the existing validation process for Hospital IQR Program data to include validation of eCQMs beginning with the FY 2020 payment determination.

Seventh, we are updating our Extraordinary Circumstances Extensions or Exemptions (ECE) policy by: (1) Extending the ECE request deadline for non-eCQM circumstances from 30 to 90 calendar days following an extraordinary circumstance, beginning in FY 2017 as related to extraordinary circumstances events that occur on or after October 1, 2016; and (2) establishing a separate submission deadline of April 1 following the end of the reporting calendar year for ECEs related to eCQMs beginning with an April 1, 2017 deadline and applying for subsequent eCQM reporting years.

j. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

Section 3004(a) of the Affordable Care Act amended section 1886(m)(5) of the Act to require the Secretary to establish the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). This
program applies to all hospitals certified by Medicare as LTCHs. Beginning with the FY 2014 payment determination and subsequent years, the Secretary is required to reduce any annual update to the LTCH PPS standard Federal rate for discharges occurring during such fiscal year by 2 percentage points for any LTCH that does not comply with the requirements established by the Secretary.

The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) amended the Act in ways that affect the LTCH QRP. Specifically, section 2(a) of the IMPACT Act amended title XVIII of the Act by adding section 1899B, titled Standardized Post-Acute Care (PAC) Assessment Data for Quality, Payment, and Discharge Planning. The Act requires that each LTCH submit, for FYs beginning on or after the specified application date (as defined in section 1899B(a)(2)(E) of the Act), data on quality measures specified under section 1899B(c)(1) of the Act and data on resource use and other measures specified under section 1899B(d)(1) of the Act in a manner and within the timeframes specified by the Secretary. In addition, each LTCH is required to submit standardized patient assessment data required under section 1899B(b)(1) of the Act in a manner and within the timeframes specified by the Secretary. Sections 1899B(c)(1) and 1899B(d)(1) of the Act require the Secretary to specify quality measures and resource use and other measures with respect to certain domains no later than the specified application date in section 1899B(a)(2)(E) of the Act that applies to each measure domain and PAC provider setting.

In this final rule, we are specifying three new measures for the FY 2018 payment determination and subsequent years to meet the requirements as set forth by the IMPACT Act. These measures are: (1) MSPB–PAC LTCH QRP; (2) Discharge to Community–PAC LTCH QRP; and (3) Potentially Preventable 30-Day Post-Discharge Readmission Measure for the PAC LTCH QRP. We also are establishing one new quality measure to meet the requirements of the IMPACT Act for the FY 2020 determination and subsequent years. That measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues–PAC LTCH QRP, addresses the IMPACT Act domain of Medication Reconciliation.

In addition, we will publicly report LTCH quality data beginning in fall 2016, on a CMS Web site, such as Hospital Compare. Initially, we will publicly reported quality data on four quality measures. In this final rule, we are providing that we will publicly report data in 2017 on four additional measures. We are promulgating additional details regarding procedures that will allow individual LTCHs to review and correct their data and information on measures that are to be made public before those measure data are made public. We also will provide confidential feedback reports to LTCHs on their performance on the specified measures, beginning 1 year after the specified application date that applies to such measures and LTCHs. Finally, we are changing the timing for submission of exception and extension requests from 30 days to 90 days from the date of the qualifying event which is preventing an LTCH from submitting their quality data for the LTCH QRP.

k. Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program

Section 1886(s)(4) of the Act, as added and amended by sections 3401(f) and 10322(a) of the Affordable Care Act, requires the Secretary to implement a quality reporting program for inpatient psychiatric hospitals and psychiatric units. Section 1886(s)(4)(C) of the Act requires that, for FY 2014 (October 1, 2013 through September 30, 2014) and each subsequent year, each psychiatric hospital and psychiatric unit must submit to the Secretary data on quality measures as specified by the Secretary. The data must be submitted in a form and manner and at a time specified by the Secretary. In this final rule, for the IPFQR Program, we are making several changes. We are making a technical update to the previously finalized measure, “Screening for Metabolic Disorders.” We are finalizing two new measures beginning with the FY 2019 payment determination:

• SUB–3 Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and SUB–3a Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664); and
• Thirty-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF.

In addition, we are finalizing our proposal to include SUB–3: Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and SUB–3a: Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664) in the list of measures covered by the global sample for the FY 2019 payment determination and subsequent years as proposed. Also, we are finalizing that we will make the data for these measures available as soon as possible and announce both the date of the public display of the program’s data and the 30-day preview period, which will be approximately 12 weeks before the public display date, via subregulatory methods, as opposed to rulemaking. For the FY 2017 payment determination only, we also are finalizing our proposal that, if it is technically feasible to display the data in December 2016, we would provide data to IPFs for a 2-week preview period that would start on October 1, 2016, as proposed. Moreover, we are finalizing as proposed that as a courtesy, for the FY 2017 payment determination only, if we are able to display the data in December 2016, we would ensure that IPFs have approximately 30 days for review if they so choose by providing IPFs with their data as early as mid-September.

3. Summary of Costs and Benefits

• Adjustment for MS–DRG Documentation and Coding Changes.

We are making a –1.5 percent recoupment adjustment to the standardized amount for FY 2017 to implement, in part, the requirement of section 631 of the ATRA that the Secretary make an adjustment totaling $11 billion over a 4-year period of FYs 2014, 2015, 2016, and 2017. This recoupment adjustment represents the amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Public Law 110–90 until FY 2013. Prior to the ATRA, this amount could not have been recovered under Pub. L. 110–90.

While our actuaries estimated that a –9.3 percent recoupment adjustment to the standardized amount would be necessary if CMS were to fully recover the $11 billion recoupment required by section 631 of the ATRA in FY 2014, it is often our practice to delay or phase in rate adjustments over more than one year, in order to moderate the effects on rates in any one year. Taking into account the cumulative effects of this adjustment and the adjustments made in FYs 2014, 2015, and 2016, we estimate that we will recover the full $11 billion required under section 631 of the ATRA by the end of FY 2017. We note that section 414 of the MACRA (Pub. L. 114–10), enacted on April 16, 2015, requires us to not make the single positive adjustment we intended to make in FY 2018, but instead make a 0.5 percent positive adjustment for each of FYs 2018 through 2023. The provision under section 414 of the MACRA does not impact our FY 2017 recoupment adjustment, and we will address this MACRA provision in future rulemaking.
from the 2-midnight policy will increase IPPS payment rates by (1/0.998) * 1.006 for FY 2017. The 1.006 is a one-time factor that will be applied to the standardized amount, the hospital-specific rates, and the national capital Federal rate for FY 2017 only. Therefore, for FY 2018, we will apply a one-time factor of (1/1.006) in the calculation of the rates to remove this one-time prospective increase.

- Changes to the Hospital Readmissions Reduction Program. For FY 2017 and subsequent years, the reduction is based on a hospital’s risk-adjusted readmission rate during a 3-year period for acute myocardial infarction (AMI), heart failure (HF), pneumonia, chronic obstructive pulmonary disease (COPD), total hip arthroplasty/total knee arthroplasty (THA/TKA), and coronary artery bypass graft (CABG). Overall, in this final rule, we estimate that 2,588 hospitals will have their base operating DRG payments reduced by their determined proxy FY 2017 hospital-specific readmission adjustment. As a result, we estimate that the Hospital Readmissions Reduction Program will save approximately $528 million in FY 2017, an increase of approximately $108 million over the estimated FY 2016 savings. This increase in the estimated savings for the Hospital Readmissions Reduction Program in FY 2017 as compared to FY 2016 is primarily due to the inclusion of the refinement of the pneumonia readmissions measure, which expanded the measure cohort, along with the addition of the CABG readmission measure, in the calculation of the payment adjustment.

- Value-Based Incentive Payments under the Hospital VBP Program. We estimate that there will be no net financial impact to the Hospital VBP Program for the FY 2017 program year in the aggregate because, by law, the amount available for value-based incentive payments under the program in a given year must be equal to the total amount of base operating MS–DRG payment amount reductions for the year, as estimated by the Secretary. The estimated amount of base operating MS–DRG payment amount reductions for the FY 2017 program year and, therefore, the estimated amount available for value-based incentive payments for FY 2017 discharges is approximately $1.8 billion.

- Changes to the HAC Reduction Program. In regard to the five changes to existing HAC Reduction Program policies described earlier, because a hospital’s Total HAC score and its ranking in comparison to other hospitals in any given year depends on several different factors, any significant impact due to the HAC Reduction Program changes for FY 2017, including which hospitals will receive the adjustment, will depend on actual experience.

- Medicare DSH Payment Adjustment and Additional Payment for Uncompensated Care. Under section 1886(r) of the Act (as added by section 3133 of the Affordable Care Act), DSH payments to hospitals under section 1886(d)(5)(F) of the Act are reduced and an additional payment for uncompensated care is made to eligible hospitals beginning in FY 2014. Hospitals that receive Medicare DSH payments will receive 25 percent of the amount they previously would have received under the current statutory formula for Medicare DSH payments in section 1886(d)(5)(F) of the Act. The remainder, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, will be the basis for determining the additional payments for uncompensated care after the amount is reduced for changes in the percentage of individuals that are uninsured and additional statutory adjustments. Each hospital that receives Medicare DSH payments will receive an additional payment for uncompensated care based on its share of the total uncompensated care amount reported by Medicare DSHs. The reduction to Medicare DSH payments is not budget neutral.

For FY 2017, we are providing that the 75 percent of what otherwise would have been paid for Medicare DSH is adjusted to approximately 55.36 percent of the amount to reflect changes in the percentage of individuals that are uninsured and additional statutory adjustments. In other words, approximately 41.52 percent (the product of 75 percent and 55.36 percent) of our estimate of Medicare DSH payments, prior to the application of section 3133 of the Affordable Care Act, is available to make additional payments to hospitals for their relative share of the total amount of uncompensated care. We project that estimated Medicare DSH payments, and additional payments for uncompensated care made for FY 2017, will reduce payments overall by approximately 0.4 percent as compared to overall payments with the estimate of Medicare DSH payments and uncompensated care payments that will be distributed in FY 2016. The additional payments have redistributive effects based on a hospital’s uncompensated care amount relative to the uncompensated care amount for all hospitals that are estimated to receive Medicare DSH payments, and the calculated payment amount is not directly tied to a hospital’s number of discharges.

- Update to the LTCH PPS Payment Rates and Other Payment Factors. Based on the best available data for the 420 LTCHs in our data base, we estimate that the changes to the payment rates and factors that we are presenting in the preamble and Addendum of this final rule, which includes the second year under the transition of the statutory application of the new site neutral payment rate required by section 1886(n)(6)(A) of the Act, the update to the LTCH PPS standard Federal payment rate for FY 2017, the update to the LTCH PPS adjustment for differences in area wage levels (which includes the update to the labor-related share based on the revised and rebased LTCH PPS market basket) and estimated changes to the site neutral payment rate and short-stay outlier (SSO) and high-cost outlier (HCO) payments will result in an estimated decrease in payments from FY 2016 of approximately $376 million.

- Hospital Inpatient Quality Reporting Program (IQR) Program. In this final rule, we are removing 15 measures for the FY 2019 payment determination and subsequent years. We are adding 4 new claims-based measures to the Hospital IQR Program for the FY 2019 payment determination and subsequent years. We also are modifying our proposal and requiring hospitals to report on 8 of the available Hospital IQR Program electronic clinical quality measures that align with the Medicare and Medicaid EHR Incentive Programs for four quarters of data on an annual basis for the FY 2019 and FY 2020 payment determination. In addition, we are modifying the existing validation process for the Hospital IQR Program data to include a random sample of up to 200 hospitals for validation of eCQMs. We estimate that our policies for the adoption and removal of measures will result in a total hospital cost decrease of $50.4 million across 3,300 IPPS hospitals.

- Changes Related to the LTCH QRP. In this final rule, we are specifying four quality measures for the LTCH QRP. We estimate that the total cost related to one of these proposed measures, the Drug Regimen Review Conducted with Follow-up for Identified Issues-PAC measure, would be $3,080 per LTCH annually, or $1,330,721 for all LTCHs annually. We also estimate that while there will be some additional burden associated with our expansion of data collection for the measure NQF #0680 Percent of Residents Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (77 FR
located in Alaska or Hawaii, the hospital is located. If the hospital is related share is adjusted by the wage into a labor-related share and a standardized amount that is divided list of diagnosis-related groups (DRGs). Discharges are classified according to a rates for each hospital discharge.

Prospective Payment System (IPPS) policies will result in total costs of Psychiatric Hospitalization in an IPF Unplanned Readmission Following Psychiatric Hospitalization in an IPF. For discharges occurring on or after October 1, 2007, but before October 1, 2017, an MDH receives the higher of the Federal rate or the Federal rate plus 50 percent of the amount by which the Federal rate is exceeded by the highest of its FY 1982, FY 1987, or FY 2002 hospital-specific rate. MDHs are a major source of care for Medicare beneficiaries in their areas. Section 1886(d)(5)(G)(iv) of the Act defines an MDH as a hospital that is located in a rural area, has not more than 100 beds, is not an SCH, and has a high percentage of Medicare discharges (not less than 60 percent of its inpatient days or discharges in its cost reporting year beginning in FY 1987 or in two of its three most recently settled Medicare cost reporting years).

Section 1886(g) of the Act requires the Secretary to pay for the capital-related costs of inpatient hospital services in accordance with a prospective payment system established by the Secretary. The basic methodology for determining capital prospective payments is set forth in our regulations at 42 CFR 412.308 and 412.312. Under the capital IPPS, payments are adjusted by the same DRG for the case as they are under the operating IPPS. Capital IPPS payments are also adjusted for IME and DSH, similar to the adjustments made under the operating IPPS. In addition, hospitals may receive outlier payments for those cases that have unusually high costs.

The current regulations governing payments to hospitals under the IPPS are located in 42 CFR part 412, subparts A through M.

1. Hospitals and Hospital Units Excluded From the IPPS

Under section 1886(d)(1)(B) of the Act, as amended, certain hospitals and hospital units are excluded from the
IPPS. These hospitals and units are: inpatient rehabilitation facility (IRF) hospitals and units; long-term care hospitals (LTCHs); psychiatric hospitals and units; children’s hospitals; cancer hospitals; and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa). Religious nonmedical health care institutions (RNHCIs) are also excluded from the IPPS. Various sections of the Balanced Budget Act of 1997 (BBRA, Pub. L. 105–33), the Medicare, Medicaid and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA, Pub. L. 106–554), and the Medicare, Medicaid, and SCHIP Benefits Improvement and Protection Act of 2000 (BIPA, Pub. L. 106–554) provide for the implementation of PPSs for IRF hospitals and units, LTCHs, and psychiatric hospitals and units (referred to as inpatient psychiatric facilities (IPFs)). (We note that the annual updates to the LTCH PPS are now included as part of the IPPS annual update document. Updates to the IRF PPS and IPF PPS are issued as separate documents.) Children’s hospitals, cancer hospitals, hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa), and RNHCIs continue to be paid solely under a reasonable cost-based system subject to a rate-of-increase ceiling on inpatient operating costs.

The existing regulations governing payments to excluded hospitals and hospital units are located in 42 CFR parts 412 and 413.

3. Long-Term Care Hospital Prospective Payment System (LTCH PPS)

The Medicare prospective payment system (PPS) for LTCHs applies to hospitals described in section 1886(d)(1)(B)(iv) of the Act effective for cost reporting periods beginning on or after October 1, 2002. The LTCH PPS was established under the authority of sections 123 of the BBRA and section 307(b) of the BIPA (as codified under section 1886(m)(1) of the Act). During the 5-year (optional) transition period, a LTCH’s payment under the PPS was based on an increasing proportion of the LTCH Federal rate with a corresponding decreasing proportion based on reasonable cost principles. Effective for cost reporting periods beginning on or after October 1, 2006, all LTCHs are paid 100 percent of the Federal rate. Section 1206(a) of the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) established the site neutral payment rate under the LTCH PPS, which made the LTCH PPS a dual rate payment system beginning in FY 2016. Under this statute, based on a rolling effective date that is linked to the date on which a given LTCH’s Federal FY 2016 cost reporting period begins, LTCHs are paid for LTCH discharges at the site neutral payment rate unless the discharge meets the patient criteria for payment at the LTCH PPS standard Federal payment rate. The existing regulations governing payment under the LTCH PPS are located in 42 CFR Part 412, subpart O. Beginning October 1, 2009, we issue the annual updates to the LTCH PPS in the same documents that update the IPPS (73 FR 26797 through 26798).

4. Critical Access Hospitals (CAHs)

Under sections 1814(l), 1820, and 1834(g) of the Act, payments made to critical access hospitals (CAHs) (that is, rural hospitals or facilities that meet certain statutory requirements) for inpatient and outpatient services are generally based on 101 percent of reasonable cost. Reasonable cost is determined under the provisions of section 1861(v)(1)(A) of the Act and existing regulations under 42 CFR parts 413 and 415.

5. Payments for Graduate Medical Education (GME)

Under section 1886(a)(4) of the Act, costs of approved educational activities are excluded from the operating costs of inpatient hospital services. Hospitals with approved graduate medical education (GME) programs are paid for the direct costs of GME in accordance with section 1886(b) of the Act. The amount of payment for direct GME costs for a cost reporting period is based on the hospital’s number of residents in that period and the hospital’s costs per resident in a base year. The existing regulations governing payments to the various types of hospitals are located in 42 CFR part 413.

C. Summary of Provisions of Recent Legislation Implemented in This Final Rule


The American Taxpayer Relief Act of 2012 (ATRA) (Pub. L. 112–240), enacted on January 2, 2013, made a number of changes that affect the IPPS. In this final rule, we are making policy changes to implement section 631 of the ATRA, which amended section 7(b)(1)(B) of Public Law 110–90 and requires a recoupment adjustment to the standardized amounts under section 1886(d) of the Act based upon the Secretary’s estimates for discharges occurring in FY 2014 through FY 2017 to fully offset $11 billion (which represents the amount of the increase in aggregate payments from FYs 2008 through 2013 for which an adjustment was not previously applied).


The Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) introduced new payment rules in the LTCH PPS. Under section 1206 of this law, discharges in cost reporting periods beginning on or after October 1, 2015 under the LTCH PPS will receive payment under a site neutral rate unless the discharge meets certain patient-specific criteria. In this final rule, we are providing clarifications to prior policy changes that implemented provisions under section 1206 of the Pathway for SGR Reform Act.


The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act (Pub. L. 113–185), enacted on October 6, 2014, made a number of changes that affect the Long-Term Care Quality Reporting Program (LTCH QRP). In this final rule, we are continuing to implement portions of section 1899B of the Act, as added by section 2 of the IMPACT Act, which, in part, requires LTCHs, among other postacute care providers, to report standardized patient assessment data, data on quality measures, and data on resource use and other measures.


The Medicare Access and CHIP Reauthorization Act of 2015 (Pub. L. 114–10) extended the MDH program and changes to the payment adjustment for low-volume hospitals through FY 2017. In this final rule, we are updating the low-volume hospital payment adjustment for FY 2017 under the extension of the temporary changes to the low-volume hospital payment adjustment provided for by section 204 of Public Law 114–10. We also are finalizing in this FY 2017 IPPS/LTCH PPS final rule the provisions of the FY 2016 IPPS/LTCH PPS interim final rule with comment period (80 FR 49594 through 49597) that implemented sections 204 and 205 of Public Law 114–10.
5. The Consolidated Appropriations Act, 2016 (Pub. L. 114–113)

The Consolidated Appropriations Act, 2016 (Pub. L. 114–113), enacted on December 18, 2015, made changes that affect the IPPS and the LTCH PPS. Section 231 of Public Law 114–113 amended section 1886(m)(6) of the Act to provide for a temporary exception to the site neutral payment rate under the LTCH PPS for certain severe wound discharges from certain LTCHs occurring prior to January 1, 2017. This provision was implemented in an interim final rule with comment period that appeared in the Federal Register on April 21, 2016 (81 FR 23428 through 23438). We are finalizing that interim final rule with comment period in section VII.B.3. of this FY 2017 IPPS/LTCH PPS final rule. Section 601 of Public Law 114–113 made changes to the payment calculation for operating IPPS payments for hospitals located in Puerto Rico. Section 602 of Public Law 114–113 specifies that Puerto Rico hospitals are eligible for incentive payments for the meaningful use of certified EHR technology, effective beginning FY 2016, and also applies the adjustments to the applicable percentage increase under the statute for Puerto Rico hospitals that are not meaningful EHR users, effective FY 2022. In this final rule, we are making conforming changes to our regulations to reflect the provisions of section 601 of Public Law 114–113, which increased the applicable Federal percentage of the operating IPPS payment for hospitals located in Puerto Rico from 75 percent to 100 percent and decreased the applicable Puerto Rico percentage of the operating IPPS payments for hospitals located in Puerto Rico from 25 percent to zero percent, applicable to discharges occurring on or after January 1, 2016.

6. The Notice of Observation Treatment and Implication for Care Eligibility Act (the NOTICE Act) (Pub. L. 114–42)

The Notice of Observation Treatment and Implication for Care Eligibility Act (the NOTICE Act) (Pub. L. 114–42) enacted on August 6, 2015, amended section 1866(a)(1) of the Act by adding new subparagraph (Y) that requires hospitals and CAHs to provide to patients receiving observation services as outpatients for more than 24 hours at the hospitals or CAHs. In this final rule, we are implementing the provisions of Public Law 114–42.

D. Issuance of a Notice of Proposed Rulemaking

In the proposed rule that appeared in the Federal Register on April 27, 2016 (81 FR 24946), we set forth proposed payment and policy changes to the Medicare IPPS for FY 2017 operating costs and for capital-related costs of acute care hospitals and certain hospitals and hospital units that are excluded from IPPS, including proposed changes relating to payments for IME and direct GME to certain hospitals that continue to be excluded from the IPPS and paid on a reasonable cost basis. In addition, we set forth proposed changes to the payment rates, factors, and other payment and policy-related changes to programs associated with payment rate policies under the LTCH PPS for FY 2017. Below is a summary of the major changes that we proposed to make:

1. Proposed Changes to MS–DRG Classifications and Recalibrations of Relative Weights

In section II. of the preamble of the proposed rule, we included—

- Proposed changes to MS–DRG classifications based on our yearly review for FY 2017.
- Proposed application of the documentation and coding adjustment for FY 2017 resulting from implementation of the MS–DRG system.
- Proposed recalibrations of the MS–DRG relative weights.
- A discussion of the FY 2017 status of new technologies approved for add-on payments for FY 2016 and a presentation of our evaluation and analysis of the FY 2017 applicants for add-on payments for high-cost new medical services and technologies (including public input, as directed by Pub. L. 108–173, obtained in a town hall meeting).

2. Proposed Changes to the Hospital Wage Index for Acute Care Hospitals

In section III. of the preamble to the proposed rule, we proposed to make revisions to the wage index for acute care hospitals and the annual update of the wage data. Specific issues addressed included, but were not limited to, the following:

- The proposed FY 2017 wage index update using wage data from cost reporting periods beginning in FY 2013.
- Calculation of the proposed occupational mix adjustment for FY 2017 based on the 2013 Occupational Mix Survey.
- Analysis and implementation of the proposed FY 2017 occupational mix adjustment to the wage index for acute care hospitals.
- Proposed application of the rural floor, the proposed imputed floor, and the proposed frontier State floor.
- Transitional wage indexes relating to the continued use of the revised OMB labor market area delineations based on 2010 Decennial Census data.
- Proposed revisions to the wage index for acute care hospitals based on hospital redesignations and recategorizations under sections 1886(d)(6)(B), (d)(6)(E), and (d)(10) of the Act.
- Notification regarding the proposed CMS “lock-in” date for urban to rural recategorizations under § 412.103.
- The proposed adjustment to the wage index for acute care hospitals for FY 2017 based on commuting patterns of hospital employees who reside in a county and work in a different area with a higher wage index.
- Determination of the labor-related share for the proposed FY 2017 wage index.
- Solicitation of Comments on Treatment of Overhead and Home Office Costs in the Wage Index Calculation

3. Other Decisions and Proposed Changes to the IPPS for Operating Costs and GME Costs

In section IV. of the preamble of the proposed rule, we discussed proposed changes or clarifications of a number of the provisions of the regulations in 42 CFR parts 412 and 413, including the following:

- Proposed conforming changes to our regulations to reflect the changes to operating payments for subsection (d) Puerto Rico hospitals in accordance with the provisions of section 601 of Public Law 114–113.
- Proposed changes to the inpatient hospital update for FY 2017.
- Proposed updated national and regional case-mix values and discharges for purposes of determining RRC status.
- The statutorily required IME adjustment factor for FY 2017.
- Proposed changes to the methodologies for determining Medicare DSH payments and the additional payments for uncompensated care.
- Proposed changes to the rules for payment adjustments under the Hospital Readmissions Reduction Program based on hospital readmission measures and the process for hospital review and correction of those rates for FY 2017.
- Proposed changes to the requirements and provision of value-based incentive payments under the Hospital Value-Based Purchasing Program.
• Proposed requirements for payment adjustments to hospitals under the HAC Reduction Program for FY 2017.
• Proposed changes relating to direct GME and IME payments to urban hospitals with rural track training programs.
• Discussion of the Rural Community Hospital Demonstration Program and a proposal for making a budget neutrality adjustment for the demonstration program.
• Proposed implementation of the Notice of Observation Treatment and Implications for Care Eligibility Act (the NOTICE Act) for hospitals and CAHs.
• Proposed technical changes and corrections to regulations relating to cost to related organizations and Medicare cost reports.

4. Proposed FY 2017 Policy Governing the IPPS for Capital-Related Costs

In section V. of the preamble to the proposed rule, we discussed the proposed payment policy requirements for capital-related costs and capital payments to hospitals for FY 2017. In addition, we discussed proposed changes to the calculation of capital IPPS payments to hospitals located in Puerto Rico to parallel the change in the statutory calculation of operating IPPS payments to hospitals located in Puerto Rico, beginning in FY 2017.

5. Proposed Changes to the Payment Rates for Certain Excluded Hospitals: Rate-of-Increase Percentages

In section VI. of the preamble to the proposed rule, we discussed—
• Proposed changes to payments to certain excluded hospitals for FY 2017.
• Proposed implementation of the Frontier Community Health Integration Project (FCHIP) Demonstration.

6. Proposed Changes to the LTCH PPS

In section VII. of the preamble to the proposed rule, we set forth—
• Proposed changes to the LTCH PPS Federal payment rates, factors, and other payment rate policies under the LTCH PPS for FY 2017.
• Proposals to sunset our existing 25-percent threshold policy regulations, and replace them with single consolidated 25 percent threshold policy regulation.
• Proposed changes to the limitation on charges to beneficiaries and related billing requirements for “subclause (II)” LTCHs to align those LTCH PPS payment adjustment policies with the limitation on charges policies applied in the TEFRA payment context.
• Proposed technical corrections to certain definitions to correct and clarify their use under the application of the site neutral payment rate and proposed additional definitions in accordance with our proposed modifications to the 25-percent policy.
• Proposed rebasing and revising of the LTCH market basket to update the LTCH PPS, effective for FY 2017.

7. Proposed Changes Relating to Quality Data Reporting for Specific Providers and Suppliers

In section VIII. of the preamble to the proposed rule, we addressed—
• Proposed requirements for the Hospital Inpatient Quality Reporting (IQR) Program as a condition for receiving the full applicable percentage increase.
• Proposed changes to the requirements for the quality reporting program for PPS-exempt cancer hospitals (PCHQR Program).
• Proposed changes to the requirements under the LTCH Quality Reporting Program (LTCH QRP).
• Proposed changes to the requirements under the Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program.
• Proposed changes relating to clinical quality measures for the Medicare Electronic Health Record (EHR) Incentive Program and eligible hospitals and CAHs.

8. Determining Prospective Payment Operating and Capital Rates and Rate-of-Increase Limits for Acute Care Hospitals

In section VIII. of the Addendum to the proposed rule, we set forth proposed changes to the amounts and factors for determining the proposed FY 2017 prospective payment rates for operating costs and capital-related costs for acute care hospitals. We proposed to establish the threshold amounts for outlier cases. In addition, we addressed the update factors for determining the rate-of-increase limits for cost reporting periods beginning in FY 2017 for certain hospitals excluded from the IPPS.

9. Determining Prospective Payment Rates for LTCHs

In the Addendum to the proposed rule, we set forth proposed changes to the amounts and factors for determining the proposed FY 2017 LTCH PPS standard Federal payment rate and other factors used to determine LTCH PPS payments under both the LTCH PPS standard Federal payment rate and the site neutral payment rate in FY 2017. We proposed to establish the adjustments for wage levels, the labor-related share, the cost-of-living adjustment, and high-cost outliers, including the applicable fixed-loss amounts and the LTCH cost-to-charge ratios (CCRs) for both payment rates. We also provided the estimated market basket update to apply to the ceiling used to determine payments under the existing payment adjustment for “subclause (II)” LTCHs for cost reporting periods beginning in FY 2017.

10. Impact Analysis

In Appendix A of the proposed rule, we set forth an analysis of the impact that the proposed changes would have on affected acute care hospitals, CAHs, LTCHs, PCHs, and IPFs.

11. Recommendation of Update Factors for Operating Cost Rates of Payment for Hospital Inpatient Services

In Appendix B of the proposed rule, as required by sections 1886(e)(4) and (e)(5) of the Act, we provided our recommendations of the appropriate percentage changes for FY 2017 for the following:
• A single average standardized amount for all areas for hospital inpatient services paid under the IPPS for operating costs of acute care hospitals (and hospital-specific rates applicable to SCHs and MDHs).
• Target rate-of-increase limits to the allowable operating costs of hospital inpatient services furnished by certain hospitals excluded from the IPPS.
• The LTCH PPS standard Federal payment rate and the site neutral payment rate for hospital inpatient services provided for LTCH PPS discharges.

12. Discussion of Medicare Payment Advisory Commission Recommendations

Under section 1805(b) of the Act, MedPAC is required to submit a report to Congress, no later than March 15 of each year, in which MedPAC reviews and makes recommendations on Medicare payment policies. MedPAC’s March 2016 recommendations concerning hospital inpatient payment policies address the update factor for hospital inpatient operating costs and capital-related costs for hospitals under the IPPS. We addressed these recommendations in Appendix B of the proposed rule. For further information relating specifically to the MedPAC March 2016 report or to obtain a copy of the report, contact MedPAC at (202) 220–3700 or visit MedPAC’s Web site at: http://www.medpac.gov.
E. Finalization of Interim Final Rule With Comment Period on the Temporary Exception to the Site Neutral Payment Rate Under the LTCH PPS for Certain Severe Wound Discharges From Certain LTCHs Required by the Consolidated Appropriations Act, 2016 and Modification of Limitations on Redesignation by the Medicare Geographic Classification Review Board

In the interim final rule with comment period that appeared in the Federal Register on April 21, 2016 (CMS–1664–IFC; 81 FR 23428 through 23438), we addressed provisions relating to (1) a temporary exception to the site neutral payment rate under the LTCH PPS for certain severe wound discharges from certain LTCHs; and (2) the application of two judicial decisions relating to modifications of the limitations on redesignation by the Medicare Geographic Classification Review Board.

In response to the section of the interim final rule with comment period on the temporary exception to the site neutral payment rate under the LTCH PPS for certain severe wound discharges from certain LTCHs, we received 7 timely pieces of correspondence. In section VII.B.3. of the preamble of this final rule, we summarize our policies and those public comments, present our responses, and finalize our policies regarding this temporary exception.

In response to the section of the interim final rule with comment period on modifications of limitations on redesignation by the MGCRB, we received 7 timely pieces of correspondence. In section III.J.2. of the preamble of this final rule, we summarize these public comments, present our responses, and finalize these provisions.

F. Finalization of Interim Final Rule With Comment Period Implementing Legislative Extensions Relating to the Payment Adjustment for Low-Volume Hospitals and the Medicare-Dependent, Small Rural Hospital (MDH) Program

In the interim final rule with comment period that appeared in the Federal Register on August 17, 2015, as part of the FY 2017 IPPS/LTCH PPS final rule, we addressed the legislative extensions relating to the payment adjustment for low-volume hospitals and the MDH program (CMS–1632–IFC; 80 FR 49594). In response to this interim final rule with comment period, we received 14 timely pieces of correspondence. However, all of the correspondence included public comments that were outside the scope of the provisions of the interim final rule with comment period. We are finalizing this interim final rule with comment in section IV.N. of the preamble of this final rule.

II. Changes to Medicare Severity Diagnosis-Related Group (MS–DRG) Classifications and Relative Weights

A. Background

Section 1886(d) of the Act specifies that the Secretary shall establish a classification system (referred to as diagnosis-related groups (DRGs)) for inpatient discharges and adjust payments under the IPPS based on appropriate weighting factors assigned to each DRG. Therefore, under the IPPS, Medicare pays for inpatient hospital services on a rate per discharge basis that varies according to the DRG to which a beneficiary’s stay is assigned. Each DRG weight represents the average resources required to care for cases in that particular DRG, relative to the average resources used to treat cases in all DRGs.

Congress recognized that it would be necessary to recalculate the DRG relative weights periodically to account for changes in resource consumption. Accordingly, section 1886(d)(4)(C) of the Act requires that the Secretary adjust the DRG classifications and relative weights at least annually. These adjustments are made to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources.

B. MS–DRG Reclassifications

For general information about the MS–DRG system, including yearly reviews and changes to the MS–DRGs, we refer readers to the previous discussions in the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43764 through 43766) and the FYs 2011, 2012, 2013, 2014, 2015, and 2016 LTCH PPS final rules (75 FR 50053 through 50055; 76 FR 51485 through 51487; 77 FR 53273; 78 FR 50512; 79 FR 49871; and 80 FR 49342, respectively).

C. Adoption of the MS–DRGs in FY 2008

For information on the adoption of the MS–DRGs in FY 2008, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47140 through 47189).

D. FY 2017 MS–DRG Documentation and Coding Adjustment

1. Background on the Prospective MS–DRG Documentation and Coding Adjustments for FY 2008 and FY 2009

In the FY 2008 IPPS final rule with comment period (72 FR 47140 through 47189), we adopted the MS–DRG patient classification system for the IPPS, effective October 1, 2007, to better recognize severity of illness in Medicare payment rates for acute care hospitals. The adoption of the MS–DRG system resulted in the expansion of the number of DRGs from 536 in FY 2007 to 745 in FY 2008. (As a result of this final rule, for FY 2017, there are 757 MS–DRGs.) By increasing the number of MS–DRGs and more fully taking into account patient severity of illness in Medicare payment rates for acute care hospitals, MS–DRGs encourage hospitals to improve their documentation and coding of patient diagnoses.

In the FY 2008 IPPS final rule with comment period (72 FR 47175 through 47186), we indicated that the adoption of the MS–DRGs had the potential to lead to increases in aggregate payments without a corresponding increase in actual patient severity of illness due to the incentives for additional documentation and coding. In that final rule with comment period, we exercised our authority under section 1886(d)(3)(A)(vi) of the Act, which authorizes us to maintain budget neutrality by adjusting the national standardized amount, to eliminate the estimated effect of changes in coding or classification that do not reflect real changes in case-mix. Our actuaries estimated that maintaining budget neutrality required an adjustment of −4.8 percent to the national standardized amount. We provided for phasing in this −4.8 percent adjustment over 3 years. Specifically, we established prospective documentation and coding adjustments of −1.2 percent for FY 2008, −1.8 percent for FY 2009, and −1.8 percent for FY 2010.

On September 29, 2007, Congress enacted the TMA [Transitional Medical Assistance], Abstinence Education, and QI [Qualifying Individuals] Programs Extension Act of 2007 (Public Law 110–90). Section 7(a) of Public Law 110–90 reduced the documentation and coding adjustment made as a result of the MS–DRG system that we adopted in the FY 2008 IPPS final rule with comment period to −0.6 percent for FY 2008 and −0.9 percent for FY 2009, and we finalized the FY 2008 adjustment through rulemaking, effective October 1, 2007 (72 FR 66886).
For FY 2009, section 7(a) of Public Law 110–90 required a documentation and coding adjustment of −0.9 percent, and we finalized that adjustment through rulemaking effective October 1, 2008 (73 FR 48447). The documentation and coding adjustments established in the FY 2008 IPPS final rule with comment period, which reflected the amendments made by section 7(a) of Public Law 110–90, are cumulative. As a result, the −0.9 percent documentation and coding adjustment for FY 2009 was in addition to the −0.6 percent adjustment for FY 2008, yielding a combined effect of −1.5 percent.

2. Adjustment to the Average Standardized Amounts Required by Public Law 110–90

a. Prospective Adjustment Required by Section 7(b)(1)(A) of Public Law 110–90

Section 7(b)(1)(A) of Public Law 110–90 requires that, if the Secretary determines that implementation of the MS–DRG system resulted in changes in documentation and coding that did not reflect real changes in case-mix for discharges occurring during FY 2008 or FY 2009 that are different than the prospective documentation and coding adjustments applied under section 7(a) of Public Law 110–90, the Secretary shall make an appropriate adjustment under section 1886(d)(3)(A)(vi) of the Act (including interest) resulting from the difference between the estimated actual documentation and coding effect and the documentation and coding adjustment applied under section 7(a) of Public Law 110–90. This adjustment is in addition to making an appropriate adjustment to the standardized amounts under section 1886(d)(3)(A)(vi) of the Act as required by section 7(b)(1)(A) of Public Law 110–90. That is, these adjustments are intended to recoup (or repay, in the case of underpayments) spending in excess of (or less than) spending that would have occurred had the prospective adjustments for changes in documentation and coding applied in FY 2008 and FY 2009 matched the changes that occurred in those years. Public Law 110–90 requires that the Secretary only make these recoupment or repayment adjustments for discharges occurring during FYs 2010, 2011, and 2012.

b. Recoupment or Repayment Adjustments in FYs 2010 Through 2012 Required by Section 7(b)(1)(B) Public Law 110–90

If, based on a retroactive evaluation of claims data, the Secretary determines that implementation of the MS–DRG system resulted in changes in documentation and coding that did not reflect real changes in case-mix for discharges occurring during FY 2008 or FY 2009 that are different from the prospective documentation and coding adjustments applied under section 7(a) of Public Law 110–90, section 7(b)(1)(B) of Public Law 110–90 requires the Secretary to make an additional adjustment to the standardized amounts under section 1886(d) of the Act. This adjustment must offset the estimated increase or decrease in aggregate payments for FYs 2008 and 2009 (including interest) resulting from the difference between the estimated actual documentation and coding effect and the documentation and coding adjustment applied under section 7(a) of Public Law 110–90. This adjustment is in addition to making an appropriate adjustment to the standardized amounts under section 1886(d)(3)(A)(vi) of the Act as required by section 7(b)(1)(A) of Public Law 110–90. This adjustment is intended to recoup (or repay, in the case of underpayments) spending in excess of (or less than) spending that would have occurred had the prospective adjustments for changes in documentation and coding applied in FY 2008 and FY 2009 matched the changes that occurred in those years. Public Law 110–90 requires that the Secretary only make these recoupment or repayment adjustments for discharges occurring during FYs 2010, 2011, and 2012.

3. Retrospective Evaluation of FY 2008 and FY 2009 Claims Data

In order to implement the requirements of section 7 of Public Law 110–90, we performed a retrospective evaluation of the FY 2008 data for claims paid through December 2008 using the methodology first described in the FY 2009 IPPS/LTCH PPS final rule (73 FR 43768 and 43775) and later discussed in the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43768 through 43772). We performed the same analysis for FY 2009 claims data using the same methodology as we did for FY 2008 claims (75 FR 50057 through 50068). The results of the analysis for the FY 2011 IPPS/LTCH PPS proposed and final rules, and subsequent evaluations in FY 2012, supported that the 5.4 percent estimate accurately reflected the FY 2009 increases in documentation and coding under the MS–DRG system. We were persuaded by both MedPAC’s analysis (as discussed in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50064 through 50065)) and our own review of the methodologies proposed by various commenters that the methodology we employed to determine the required documentation and coding adjustments was sound. As in prior years, the FY 2008, FY 2009, and FY 2010 MedPAR files are available to the public to allow independent evaluations of FY 2008 and FY 2009 documentation and coding effects. Interested individuals may still order these files through the CMS Web site at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/ by clicking on MedPAR Limited Data Set (LDS) - Hospital (National). This CMS Web page describes the file and provides directions and further detailed instructions for how to order.

Persons placing an order must send the following: a Letter of Request, the LDS Data Use Agreement and Research Protocol (refer to the Web site for further instructions), the LDS Form, and a check (refer to the Web site for the required payment amount) to:

Mailing address if using the U.S. Postal Service: Centers for Medicare & Medicaid Services, RDDC Account, Accounting Division, P.O. Box 7520, Baltimore, MD 21207–0520.

Mailing address if using express mail: Centers for Medicare & Medicaid Services, OFM/Division of Accounting—RDDC, 7500 Security Boulevard, G–07–11, Baltimore, MD 21244–1850.

4. Prospective Adjustments for FY 2008 and FY 2009 Authorized by Section 7(b)(1)(A) of Public Law 110–90

In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43767 through 43777), we opted to delay the implementation of any documentation and coding adjustment until a full analysis of case-mix changes based on FY 2009 claims data could be completed. We refer readers to the FY 2010 IPPS/RY LTCH PPS final rule for a detailed description of our proposal, responses to comments, and finalized policy. After analysis of the FY 2009 claims data for the FY 2011 IPPS/LTCH PPS final rule (75 FR 50057 through 50073), we found a total prospective documentation and coding effect of 5.4 percent. After accounting for the −0.6 percent and the −0.9 percent documentation and coding adjustments in FYs 2008 and 2009, we found a remaining documentation and coding effect of 3.9 percent. As we have discussed, an additional cumulative adjustment of −3.9 percent would be necessary to meet the requirements of section 7(b)(1)(A) of Public Law 110–90 to make an adjustment to the average standardized amounts in order to eliminate the full effect of the documentation and coding changes that do not reflect real changes in case-mix on future payments. Unlike section 7(b)(1)(B) of Public Law 110–90, section 7(b)(1)(A) does not specify when we must apply the prospective adjustment, but merely requires us to make an “appropriate” adjustment. Therefore, as we stated in the FY 2011 IPPS/LTCH
PPS final rule (75 FR 50061), we believed the law provided some discretion as to the manner in which we applied the prospective adjustment of −3.9 percent. As we discussed extensively in the FY 2011 IPPS/LTCH PPS final rule, it has been our practice to moderate payment adjustments when necessary to mitigate the effects of significant downward adjustments on hospitals, to avoid what could be widespread, disruptive effects of such adjustments on hospitals. Therefore, we stated that we believed it was appropriate to not implement the −3.9 percent prospective adjustment in FY 2011 because we finalized a −2.9 percent recoupment adjustment for that fiscal year. Accordingly, we did not propose a prospective adjustment under section 7(b)(1)(A) of Public Law 110–90 for FY 2011 (75 FR 23868 through 23870). We noted that, as a result, payments in FY 2011 (and in each future fiscal year until we implemented the requisite adjustment) would be higher than they would have been if we had implemented an adjustment under section 7(b)(1)(A) of Public Law 110–90.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51489 and 51497), we indicated that, because further delay of this prospective adjustment would result in a continued accrual of unrecoverable overpayments, it was imperative that we implement a prospective adjustment for FY 2012, while recognizing CMS’ continued desire to mitigate the effects of any significant downward adjustments on hospitals. Therefore, we implemented a −2.0 percent prospective adjustment to the standardized amount instead of the full −3.9 percent.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53274 through 53276), we completed the prospective portion of the adjustment required under section 7(b)(1)(A) of Public Law 110–90 by finalizing a −1.9 percent adjustment to the standardized amount for FY 2013. We stated that this adjustment would remove the remaining effect of the documentation and coding changes that do not reflect real changes in case-mix that occurred in FY 2008 and FY 2009. We believed that it was imperative to implement the full remaining adjustment, as any further delay would result in an overstated standardized amount in FY 2013 and any future fiscal years until a full adjustment was made.

We noted again that delaying full implementation of the prospective portion of the adjustment required under section 7(b)(1)(A) of Public Law 110–90 until FY 2013 resulted in overpayment being overstated. These overpayments could not be recovered by CMS, as section 7(b)(1)(B) of Public Law 110–90 limited recoupments to overpayments made in FY 2008 and FY 2009.

5. Recoupment or Repayment Adjustment Authorized by Section 7(b)(1)(B) of Public Law 110–90

Section 7(b)(1)(B) of Public Law 110–90 requires the Secretary to make an adjustment to the standardized amounts under section 1886(d) of the Act to offset the estimated increase in aggregate payments for FY 2008 and FY 2009 (including interest) resulting from the difference between the estimated actual documentation and coding effect and the documentation and coding adjustments applied under section 7(a) of Public Law 110–90. This determination must be based on a retrospective evaluation of claims data. Our actuaries estimated that there was a 5.8 percentage point difference resulting in an increase in aggregate payments of approximately $6.9 billion. Therefore, we finalized a −2.9 percent adjustment to the standardized amount, representing approximately half of the aggregate adjustment required under section 7(b)(1)(B) of Public Law 110–90 to adjust the standardized amounts for discharges occurring in FYs 2010, 2011, and/or 2012 to offset the estimated amount of the increase in aggregate payments (including interest) in FYs 2008 and 2009.

It is often our practice to phase in payment rate adjustments over more than one year in order to moderate the effect on payment rates in any one year. Therefore, consistent with the policies that we have adopted in many similar cases, in the FY 2011 IPPS/LTCH PPS final rule, we made an adjustment to the standardized amount of −2.9 percent, representing approximately half of the aggregate adjustment required under section 7(b)(1)(B) of Public Law 110–90, for FY 2011. An adjustment of this magnitude allowed us to moderate the effect on hospitals in one year while simultaneously making it possible to implement the entire adjustment within the timeframe required under section 7(b)(1)(B) of Public Law 110–90 (that is, no later than FY 2012). For FY 2012, in accordance with the timeframes set forth by section 7(b)(1)(B) of Public Law 110–90, and consistent with the discussion in the FY 2011 IPPS/LTCH PPS final rule, we completed the recoupment adjustment by implementing the remaining −2.9 percent adjustment in one year, in addition to removing the effect of the −2.9 percent adjustment to the standardized amount finalized for FY 2011 (76 FR 51489 and 51498). Because these adjustments, in effect, balanced out, there was no year-to-year change in the standardized amount due to this recoupment adjustment for FY 2012. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53276), we made a final +2.9 percent adjustment to the standardized amount, completing the recoupment portion of section 7(b)(1)(B) of Public Law 110–90. We note that with this positive adjustment, according to our estimates, all overpayments made in FY 2008 and FY 2009 have been fully recaptured with appropriate interest, and the standardized amount has been returned to the appropriate baseline.

6. Recoupment or Repayment Adjustment Authorized by Section 631 of the American Taxpayer Relief Act of 2012 (ATRA)

Section 631 of the ATRA amended section 7(b)(1)(B) of Public Law 110–90 to require the Secretary to make a recoupment adjustment in the standardized amounts totaling $11 billion by FY 2017. This adjustment represents the amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Public Law 110–90 until FY 2013. As discussed earlier, this delay in implementation resulted in overstated payment rates in FYs 2010, 2011, and 2012. The resulting overpayments could not have been recovered under Public Law 110–90. Similar to the adjustments authorized under section 7(b)(1)(B) of Public Law 110–90, the adjustment required under section 631 of the ATRA is a one-time recoupment of a prior overpayment, not a permanent reduction to payment rates. Therefore, we anticipated that any adjustment made to reduce payment rates in one year would eventually be offset by a positive adjustment in 2018, once the necessary amount of overpayment was recovered. However, section 414 of the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, Public Law 114–10, enacted on April 16, 2015, replaced the single positive adjustment we intended to make in FY 2018 with a 0.5 percent positive adjustment for each of FYs 2018 through 2023. We stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49345) that we will address this MACRA provision in future rulemaking.

As we stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50515 through 50517), our actuaries estimated that a −9.3 percent adjustment to the standardized amount would be necessary if CMS were to fully recover the $11 billion recoupment required by
section 631 of the ATRA in FY 2014. It is often our practice to phase in payment rate adjustments over more than one year, in order to moderate the effect on payment rates in any one year. Therefore, consistent with the policies we have adopted in many similar cases, and after consideration of the public comments we received, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50515 through 50517), we implemented a -0.8 percent recoupment adjustment to the standardized amount in FY 2014. We stated that if adjustments of approximately -0.8 percent are implemented in FYs 2014, 2015, 2016, and 2017, using standard inflation factors, we estimate that the entire $11 billion will be accounted for by the end of the statutory 4-year timeline. As estimates of any future adjustments are subject to slight variations in total savings, we did not provide for specific adjustments for FYs 2015, 2016, or 2017 at that time. We stated that we believed that this level of adjustment for FY 2014 was a reasonable and fair approach that satisfies the requirements of the statute while mitigating extreme annual fluctuations in payment rates.

Consistent with the approach discussed in the FY 2014 rulemaking for recouping the $11 billion required by section 631 of the ATRA, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49874) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49345), we implemented additional -0.8 percent recoupment adjustments to the standardized amount in FY 2015 and FY 2016, respectively. We estimated that these adjustments, combined with leaving the prior -0.8 percent adjustments in place, would recover up to $2 billion in FY 2015 and another $3 billion in FY 2016. When combined with the approximately $1 billion adjustment made in FY 2014, we estimated that approximately $5 to $6 billion would be left to recover under section 631 of the ATRA by the end of FY 2016.

However, as indicated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24966), due to lower than previously estimated inpatient spending, we determined that an adjustment of -0.8 percent in FY 2017 would not recoup the $11 billion under section 631 of the ATRA. Based on the FY 2017 President’s Budget, our actuaries estimated for the proposed rule that FY 2014 through FY 2016 spending subject to the documentation and coding recoupment adjustment in the absence of the -0.8 percent adjustments made in FYs 2014 through 2016 would have been $123.783 billion in FY 2014, $124.361 billion in FY 2015, and $127.060 billion in FY 2016. As shown in the following table, the amount recouped in each of those fiscal years is therefore calculated as the difference between those amounts and the amounts determined to have been spent in those years with the -0.8 percent adjustment applied, namely $122.801 billion in FY 2014, $122.395 billion in FY 2015, and $124.059 billion in FY 2016. This yields an estimated total recoupment through the end of FY 2016 of $5.950 billion.

### RECoupMENT MADE UNDER SECTION 631 OF THE AMERICAN TAXPAYER RELIEF ACT OF 2012 [ATRA]

<table>
<thead>
<tr>
<th></th>
<th>IPPS Spending* (billions)</th>
<th>Recoupment amount (billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2014</td>
<td>$122,801</td>
<td>$0.98</td>
</tr>
<tr>
<td>FY 2015</td>
<td>122,395</td>
<td>1.97</td>
</tr>
<tr>
<td>FY 2016</td>
<td>124,059</td>
<td>3.00</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>5.95</td>
</tr>
</tbody>
</table>

*Based on FY 2017 President’s Budget, including capital, IME, and DSH payments.

These estimates and the estimate of FY 2017 spending subject to the documentation and coding recoupment adjustment also are included in a memorandum from the Office of the Actuary that we made publicly available on the CMS Web site at: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS) on the FY 2017 IPPS Proposed Rule Home Page. A description of the President’s Budget for FY 2017 is currently available on the OMB Web site at: [https://www.whitehouse.gov/omb/budget/](https://www.whitehouse.gov/omb/budget/).

For the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24967), our actuaries estimated that the FY 2017 spending subject to the documentation and coding recoupment adjustment (including capital, IME, and DSH payment) would be $129.625 billion in the absence of any documentation and recoupment adjustments from FY 2014 through FY 2017. Therefore, at the time of issuance of the FY 2017 proposed rule, our actuaries estimated that, to the nearest tenth of a percent, the FY 2017 documentation and coding adjustment factor that will recoup as closely as possible $11 billion from FY 2014 through FY 2017 without exceeding this amount is -1.5 percent. This adjustment factor yields an estimated spending amount in FY 2017 of $124.693 billion, calculated as $129.625/(1.008*1.008*1.008*1.015). We indicated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24967) that this estimated proposed -1.5 percent adjustment factor would be updated for the final rule based on the FY 2017 President’s Budget Midsession Review. We noted that, based on updated estimates, the necessary adjustment factor to the nearest tenth of a percent could be different than our actuaries’ estimate of -1.5 percent.

**Comment:** MedPAC reiterated its previous support for the recovery of past overpayments due to documentation and coding. MedPAC stated that the law stipulates the amount of the recovery and the timing of the recovery. MedPAC also stated that CMS has little discretion and is proceeding as required by law.

**Response:** We appreciate MedPAC’s support for our proposal.

**Comment:** The vast majority of commenters urged CMS to use its older estimate of the required adjustment for FY 2017 of -0.8 percentage point, rather than its updated proposed estimate of -1.5 percentage points. Commenters argued that the ATRA does not require CMS to update the initial FY 2017 estimate discussed in the FY 2014 final rule with more recent data, that the law allows CMS to continue using the older analysis, and that revisiting the actual recoupments for the preceding fiscal years is not consistent with the ATRA. The commenters’ bases for this argument included that it would be a better interpretation of the statute and it is more consistent with CMS’ approach regarding its use of estimates for outlier payments. The commenters also stated...
that CMS should take into account any savings in Medicare Advantage (MA) payments when determining the $11 billion recoupment or otherwise adjust the $11 billion for policies that have been implemented since the passage of the ATRA. Many commenters also believed that the proposed −1.5 percent adjustment was inconsistent with Congressional intent in the ATRA and the MACRA, which they asserted reflected Congress’ expectation that the final reduction would be 0.8 percentage points or at least statutorily limited the difference between the negative recoupment adjustments under the ATRA and the positive adjustments under the MACRA. Commenters further stated that if CMS does finalize its proposed adjustment under the ATRA for FY 2017, it should make an offsetting adjustment in FY 2018 to for FY 2017, it should make an offsetting adjustment under the ATRA.

Adjustment: One commenter objected to CMS’ use of actuarial assumptions as the basis for determining the level of adjustment required under ATRA. The commenter questioned the variance in the figures for OACT’s 2013 and 2016 estimates and stated that OACT’s most recent estimate could not be externally replicated. The commenter stated that there should be much greater certainty in the estimate before imposing the higher adjustment proposed for FY 2017. Other commenters requested that CMS reexamine the assumption and estimates made by OACT.

Response: While the OACT memorandum containing the estimates acknowledges the uncertainty in the estimates, it also states that the results shown are OACT’s latest and best estimates for Medicare payments for FYs 2014–2017, and CMS believes that the spending estimates presented, as well as the assumptions used to develop the estimates, are reasonable.

We also note that, as explained in OACT’s memorandum and the proposed rule, the estimate from the proposed rule was based on the FY 2017 President’s Budget, subject to certain adjustments. As discussed in the memorandum, the major changes in the projections were due to lower updates to hospital payments than were assumed in 2013, mostly due to the lower than expected market basket adjustments and a lower number of discharges than assumed in 2013. These changes caused the spending levels to be lower than the 2013 projections.

However, in 2013, when CMS made the original projections, everything that was included for 2014 through 2017 was a projection (except for the 2014 update). Now when we make the current projection, we have actual updates for the whole period through 2017, and we have complete data for the number of discharges for 2014 and 2015 and for part of 2016. For that reason, the current projections of spending for 2014 through 2017 are calculated with greater precision than the projections that were done in 2013. For additional information on the specific economic assumptions used in the President's FY 2017 Budget, we refer readers to the OMB Web site at: https://www.whitehouse.gov/omb/budget. The estimates for this final rule are similarly based on the Midsession Review of the President’s FY 2017 Budget. For additional information on the specific economic assumptions used in the

As we did with the proposed adjustment, we are making available on the CMS Web site a memorandum containing our actuaries’ estimates relating to our finalized adjustment (https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS on the FY 2017 IPPS Final Rule Home Page).

After consideration of the public comments we received, we are finalizing our proposal without modification. For this final rule, based on updated estimates by the Office of the Actuary using the Midsession Review of the President’s FY 2017 Budget, we are making an –1.5 percent adjustment as the final adjustment required under section 631 of the ATRA, and when combined with the effects of previous adjustments made in FY 2014, FY 2015, and FY 2016, we estimate will satisfy the recoupment under section 631 of the ATRA. In other words, our actuaries currently estimate that, to the nearest tenth of a percent, the FY 2017 documentation and coding adjustment factor that will recoup as closely as possible $11 billion from FY 2014 through FY 2017 without exceeding this amount is –1.5 percent.

As we stated earlier, the estimates by our actuaries related to this finalized adjustment are included in a memorandum that we are making publicly available on the CMS Web site.

The updated table from our actuaries based on the Midsession Review of the President’s FY 2017 Budget is below.

The interpretation of the table and the calculations are the same as those described in the proposed rule (81 FR 24966 through 24967), except for the update from the FY 2017 President’s Budget to the FY 2017 President’s Budget Midsession Review.

### Recoupment Made Under Section 631 of the American Taxpayer Relief Act of 2012 (ATRA)

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>IPPS Spending* (billions)</th>
<th>Cumulative adjustment factor</th>
<th>Adjusted IPPS spending (billions)</th>
<th>Recoupment amount (billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2014</td>
<td>$122.84</td>
<td>1.00800</td>
<td>$123.82</td>
<td>$0.98</td>
</tr>
<tr>
<td>FY 2015</td>
<td>122.48</td>
<td>1.01606</td>
<td>124.45</td>
<td>1.97</td>
</tr>
<tr>
<td>FY 2016</td>
<td>124.02</td>
<td>1.02419</td>
<td>127.02</td>
<td>3.00</td>
</tr>
<tr>
<td>FY 2017</td>
<td>126.40</td>
<td>1.03956</td>
<td>131.40</td>
<td>5.00</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>10.95</td>
</tr>
</tbody>
</table>

*Based on FY 2017 President’s Budget Midsession Review, including capital, IME, and DSH payments.

For this FY 2017 IPPS/LTCH PPS final rule, our actuaries estimate that the FY 2017 spending subject to the documentation and coding recoupment adjustment (including capital, IME, and DSH payment) would be $131.40 billion in the absence of any documentation and recoupment adjustments from FY 2014 through FY 2017 based on the FY 2017 President’s Budget Midsession Review. Therefore our actuaries estimated that, to the nearest tenth of a percent, the FY 2017 documentation and coding adjustment factor that will recoup as closely as possible $11 billion from FY 2014 through FY 2017 without exceeding this amount is –1.5 percent.

This adjustment factor yields an estimated spending amount in FY 2017 of $126.4 billion, calculated as $131.4/ (1.008*1.008*1.008*1.015).

As stated in the proposed rule, once the recoupment was complete, we had anticipated making a single positive adjustment in FY 2018 to offset the reductions required to recoup the $11 billion under section 631 of the ATRA. However, section 414 of the MACRA replaced the single positive adjustment we intended to make in 2018 with a 0.5 percent positive adjustment for each of FYs 2018 through 2023. The provision under section 414 of the MACRA does not impact our FY 2017 adjustment, as discussed above. As noted previously, while we received public comments on adjustments for FY 2018 and later fiscal years, we will address these adjustments in future rulemaking as we indicated in the proposed rule.

E. Refinement of the MS–DRG Relative Weight Calculation

1. Background

Beginning in FY 2007, we implemented relative weights for DRGs based on cost report data instead of charge information. We refer readers to the FY 2007 IPPS final rule (71 FR 47882) for a detailed discussion of our final policy for calculating the cost-based DRG relative weights and to the FY 2008 IPPS final rule with comment period (72 FR 47199) for information on how we blended relative weights based on the CMS DRGs and MS–DRGs.

As we implemented cost-based relative weights, some public commenters raised concerns about potential bias in the weights due to “charge compression,” which is the practice of applying a higher percentage charge markup over costs to lower cost items and services, and a lower percentage charge markup over costs to higher cost items and services. As a result, the cost-based weights would undervalue high-cost items and overvalue low-cost items if a single cost-to-charge ratio (CCR) is applied to items of widely varying costs in the same cost center. To address this concern, in August 2006, we awarded a contract to the Research Triangle Institute, International (RTI) to study the effects of charge compression in calculating the relative weights and to consider methods to reduce the variation in the CCRs across services within cost centers. For a detailed summary of RTI’s findings, recommendations, and public comments that we received on the report, we refer readers to the FY 2009 IPPS/LTCH PPS final rule (73 FR 48452 through 48453). In addition, we refer readers to RTI’s July 2008 final report titled “Refining Cost to Charge Ratios for Calculating APC and MS–DRG Relative Payment Weights” (available at: http://www.rti.org/reports/cms/HHSM-
In the FY 2009 IPPS final rule (73 FR 48458 through 48467), in response to the RTI's recommendations concerning cost report refinements, we discussed our decision to pursue changes to the cost report to split the cost center for Medical Supplies Charged to Patients into one line for "Medical Supplies Charged to Patients" and another line for "Implantable Devices Charged to Patients." We acknowledged, as RTI had found, that charge compression occurs in several cost centers that exist on the Medicare cost report. However, as we stated in the FY 2009 IPPS final rule, we focused on the CCR for Medical Supplies and Equipment because RTI found that the largest impact on the MS–DRG relative weights could result from correcting charge compression for devices and implants. In determining the items that should be reported in these respective cost centers, we adopted the commentators' recommendations that hospitals use revenue codes established by the AHA's National Uniform Billing Committee to determine the items that should be reported in the "Medical Supplies Charged to Patients" and the "Implantable Devices Charged to Patients" cost centers. Accordingly, a new subscripted line for "Implantable Devices Charged to Patients" was created in July 2009. This new subscripted cost center has been available for use for cost reporting periods beginning on or after May 1, 2009.

As we discussed in the FY 2009 IPPS final rule (73 FR 48458) and in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68519 through 68527), in addition to the findings regarding implantable devices, RTI found that the costs and charges of computed tomography (CT) scans, magnetic resonance imaging (MRI), and cardiac catheterization differ significantly from the costs and charges of other services included in the standard associated cost center. RTI also concluded that both the IPPS and the OPPS relative weights would better estimate the costs of those services if CMS were to add standard cost centers for CT scans, MRIs, and cardiac catheterization in order for hospitals to report separately the costs and charges for those services and in order for CMS to calculate unique CCRs to estimate the costs from charges on claims data. In the FY 2011 IPPS/LTCH PPS final rule (75 FR 50075 through 50080), we finalized our proposal to create standard cost centers for CT scans, MRIs, and cardiac catheterization, and to require that hospitals report the costs and charges for these services under new cost centers on the revised Medicare cost report Form CMS–2552–10. (We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50075 through 50080) for a detailed discussion of the reasons for the creation of standard cost centers for CT scans, MRIs, and cardiac catheterization.) The new standard cost centers for CT scans, MRIs, and cardiac catheterization are effective for cost reporting periods beginning on or after May 1, 2010, on the revised cost report Form CMS–2552–10.

In the FY 2009 IPPS final rule (73 FR 48468), we stated that, due to what is typically a 3-year lag between the reporting of cost report data and the availability for use in ratsetting, we anticipated that we might be able to use data from the new "Implantable Devices Charged to Patients" cost center to develop a CCR for "Implantable Devices Charged to Patients" in the FY 2012 or FY 2013 IPPS rulemaking cycle. However, as noted in the FY 2010 IPPS/LTCH PPS final rule (74 FR 43782), due to delays in the issuance of the revised cost report Form CMS 2552–10, we determined that a new CCR for "Implantable Devices Charged to Patients" might not be available before FY 2013. Similarly, when we finalized the decision in the FY 2011 IPPS/LTCH PPS final rule to add new cost centers for CT scans, MRIs, and cardiac catheterization, we explained that data from any new cost centers that may be created will not be available until at least 3 years after the year they are first used (75 FR 50077). In preparation for the FY 2012 IPPS/LTCH PPS rulemaking, we checked the availability of data in the "Implantable Devices Charged to Patients" cost center on the FY 2009 cost reports, but we did not believe that there was a sufficient amount of data from which to generate a meaningful analysis in this particular situation. Therefore, we did not propose to use data from the "Implantable Devices Charged to Patients" cost center to create a distinct CCR for "Implantable Devices Charged to Patients" in FY 2012.

At the time of the development of the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27506 through 27507), we had a substantial number of hospitals completing all, or some, of these new cost centers on the FY 2011 Medicare cost reports, compared to prior years. We stated that we believed that the analytic findings described using the FY 2011 cost report data and FY 2012 claims data supported our original decision to break out and create new cost centers for implantable devices, MRIs, CT scans, and cardiac catheterization, and we saw no reason to further delay proposing to implement the CCRs of each of these cost centers. Therefore, beginning in FY 2014, we proposed a policy to calculate the MS–DRG relative weights using 19 CCRs,
creating distinct CCRs from cost report data for implantable devices, MRIs, CT scans, and cardiac catheterization.

We refer readers to the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27507 through 27509) and final rule (78 FR 50518 through 50523) in which we presented data analyses using distinct CCRs for implantable devices, MRIs, CT scans, and cardiac catheterization. The FY 2014 IPPS/LTCH PPS final rule also set forth our responses to public comments we received on our proposal to implement these CCRs. As explained in more detail in the FY 2014 IPPS/LTCH PPS final rule, we finalized our proposal to use 19 CCRs to calculate MS–DRG relative weights beginning in FY 2014—the then existing 15 cost centers and the 4 new CCRs for implantable devices, MRIs, CT scans, and cardiac catheterization. Therefore, beginning in FY 2014, we calculate the IPPS MS–DRG relative weights using 19 CCRs, creating distinct CCRs for implantable devices, MRIs, CT scans, and cardiac catheterization.

2. Discussion of Policy for FY 2017

Consistent with our established policy, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24968), we stated that we calculated the proposed MS–DRG relative weights for FY 2017 using two data sources: the MedPAR file as the claims data source and the HCRIS as the cost report data source. We adjusted the charges from the claims to costs by applying the 19 national average CCRs developed from the cost reports. The description of the calculation of the 19 CCRs and the MS–DRG relative weights for FY 2017 is included in section II.G. of the preamble of this final rule.

Comment: One commenter recommended that CMS work with stakeholders to update cost reporting instructions and improve the accuracy and validity of the national average CCRs. The commenter expressed concern that the differences between hospitals’ use of nonstandard cost center codes and CMS’ procedures for mapping and rolling up nonstandard codes to the standard cost centers does not specifically apply to the standard CT scan and MRI cost centers. Although these centers were previously nonstandard cost centers, they were implemented as standard cost centers in Form CMS–2552–10. Therefore, many of the issues relating to inconsistent coding and issues with information “rollup” would not be specifically relevant for the CT scan and MRI standard cost centers. We have previously addressed stakeholder concerns related to the flexibility of cost reporting and accuracy of the CT scan and MRI standard cost centers, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50520 through 50523), and the FY 2011 IPPS/LTCH PPS final rule (7 FR 50077 through 50079).

Consistent with our established policy, we calculated the final MS–DRG relative weights for FY 2017 using two data sources: the MedPAR file as the claims data source and the HCRIS as the cost report data source. We adjusted the charges from the claims to costs by applying the 19 national average CCRs developed from the cost reports. As we did with the FY 2016 IPPS/LTCH PPS final rule, we are providing the version of the HCRIS from which we calculated these 19 CCRs on the CMS Web site at: http://www.cms.gov/Medicare/ Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled, “FY 2017 IPPS Final Rule Home Page” or “Acute Inpatient Files for Download.”

F. Changes to Specific MS–DRG Classifications

1. Discussion of Changes to Coding System and Basis for MS–DRG Updates

a. Conversion of MS–DRGs to the International Classification of Diseases, 10th Revision (ICD–10)

As of October 1, 2015, providers use the International Classification of Diseases, 10th Revision (ICD–10) coding system to report diagnoses and procedures for Medicare hospital inpatient services under the MS–DRG system instead of the ICD–9–CM coding system, which was used through September 30, 2015. The ICD–10 coding system includes the International Classification of Diseases, 10th Revision, Clinical Modification (ICD–10–CM) for diagnostic coding and the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD–10–PCS) for inpatient hospital procedure coding, as well as the Official ICD–10–CM and ICD–10–PCS Guidelines for Coding and Reporting. The ICD–10 coding system was initially adopted for transactions conducted on or after October 1, 2013, as described in the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Administrative Simplification: Modifications to Medical Data Code Set Standards to Adopt ICD–10–CM and ICD–10–PCS Final Rule published in the Federal Register on January 16, 2009 (74 FR 3328 through 3362) (hereinafter referred to as the “ICD–10–CM and ICD–10–PCS final rule”). However, the Secretary of Health and Human Services (the Secretary) issued a final rule that delayed the compliance date for ICD–10 from October 1, 2013, to October 1, 2014. That final rule, entitled “Administrative Simplification: Adoption of a Standard for a Unique Health Plan Identifier; Addition to the National Provider Identifier Requirements; and a Change to the Compliance Date for ICD–10–CM and ICD–10–PCS Medical Data Code Sets,” CMS–0040–F, was published in the Federal Register on September 5, 2012 (77 FR 54664) and is available for viewing on the Internet at: http://www.gpo.gov/fdsys/pkg/FR-2012-09-05/pdf/2012-21238.pdf. On April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113–93) was enacted, which specified that the Secretary may not adopt ICD–10 prior to October 1, 2015. Accordingly, the U.S. Department of Health and Human
Services released a final rule in the Federal Register on August 4, 2014 (79 FR 45128 through 45134) that included a new compliance date that required the use of ICD–10 beginning October 1, 2015. The rule also required HIPAA-covered entities to continue to use ICD–9–CM through September 30, 2015.

The anticipated move to ICD–10 necessitated the development of an ICD–10–CM/ICD–10–PCS version of the MS–DRGs. CMS began a project to convert the ICD–9–CM-based MS–DRGs to ICD–10 MS–DRGs. In response to the FY 2011 IPPS/LTCH PPS proposed rule, we received public comments on the creation of the ICD–10 version of the MS–DRGs to be implemented at the same time as ICD–10 (75 FR 50127 and 50128). While we did not propose an ICD–10 version of the MS–DRGs in the FY 2011 IPPS/LTCH PPS proposed rule, we noted that we have been actively involved in converting current MS–DRGs from ICD–9–CM codes to ICD–10 codes and sharing this information through the ICD–10 (previously ICD–9–CM Coordination and Maintenance Committee. We undertook this early conversion project to assist other payers and providers in understanding how to implement their own conversion projects. We posted ICD–10 MS–DRGs based on Version 26.0 (FY 2009) of the MS–DRGs. We also posted a paper that describes how CMS went about completing this project and suggestions for other payers and providers to follow.

Information on the ICD–10 MS–DRG conversion project can be found on the ICD–10 MS–DRG Conversion Project Web site at: http://www.cms.gov/Medicare/Coding/ICD10-MS-DRG-Conversion-Project.html. We have continued to keep the public updated on our maintenance efforts for ICD–10–CM and ICD–10–PCS coding systems, as well as the General Equivalence Mappings that assist in conversion through the ICD–10 (previously ICD–9–CM) Coordination and Maintenance Committee. Information on these committee meetings can be found on the CMS Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html.

During FY 2011, we developed and posted Version 28.0 of the ICD–10 MS–DRGs based on the FY 2011 MS–DRGs (Version 28.0) that we finalized in the FY 2011 IPPS/LTCH PPS final rule on the CMS Web site. This ICD–10 MS–DRGs Version 28.0 also included the CC Exclusion List and the ICD–10 version of the hospital-acquired conditions (HACs), which was not posted with Version 26. We also discussed this update at the September 15–16, 2010 and the March 9–10, 2011 meetings of the ICD–9–CM Coordination and Maintenance Committee. The minutes of these two meetings are posted on the CMS Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html.

We reviewed comments on the ICD–10 MS–DRGs Version 28 and made updates as a result of these comments. We called the updated version the ICD–10 MS–DRGs Version 28–R1. We posted a Definitions Manual of ICD–10 MS–DRGs Version 28–R1 on our ICD–10 MS–DRG Conversion Project Web site. To make the review of Version 28–R1 updates easier for the public, we also made available pilot software on a CD–ROM that could be ordered through the National Technical Information Service (NTIS). A link to the NTIS ordering page was provided on the CMS ICD–10 MS–DRGs Web site. We stated that we believed that, by providing the ICD–10 MS–DRGs Version 28–R1 Pilot Software (distributed on CD–ROM), the public would be able to more easily review and provide feedback on updates to the ICD–10 MS–DRGs. We discussed the updated ICD–10 MS–DRGs Version 28–R1 at the September 14, 2011 ICD–9–CM Coordination and Maintenance Committee meeting. We encouraged the public to continue to review and provide comments on the ICD–10 MS–DRGs so that CMS could continue to update the system.

In FY 2012, we prepared the ICD–10 MS–DRGs Version 29, based on the FY 2012 MS–DRGs (Version 29.0) that we finalized in the FY 2012 IPPS/LTCH PPS final rule. We posted a Definitions Manual of ICD–10 MS–DRGs Version 29 on our ICD–10 MS–DRG Conversion Project Web site. We also prepared a document that describes changes made from Version 28 to Version 29 to facilitate a review. The ICD–10 MS–DRGs Version 29 was discussed at the ICD–9–CM Coordination and Maintenance Committee meeting on March 5, 2012. Information was provided on the types of updates made. Once again the public was encouraged to review and comment on the most recent update to the ICD–10 MS–DRGs.

CMS prepared the ICD–10 MS–DRGs Version 30 based on the FY 2013 MS–DRGs (Version 30) that we finalized in the FY 2013 IPPS/LTCH PPS final rule. We posted a Definitions Manual of the ICD–10 MS–DRGs Version 30 on our ICD–10 MS–DRG Conversion Project Web site. We also prepared a document that describes changes made from Version 29 to Version 30 to facilitate a review. We produced mainframe and computer software for Version 30, which was made available to the public in February 2013. Information on ordering the mainframe and computer software through NTIS was posted on the ICD–10 MS–DRG Conversion Project Web site. The ICD–10 MS–DRGs Version 30.0 computer software facilitated additional review of the ICD–10 MS–DRGs conversion.

We provided information on a study conducted on the impact of converting the MS–DRGs to ICD–10. Information on this study is summarized in a paper entitled “Impact of the Transition to ICD–10 on Medicare Inpatient Hospital Payments.” This paper was posted on the CMS ICD–10 MS–DRGs Conversion Project Web site and was distributed and discussed at the September 15, 2010 ICD–9–CM Coordination and Maintenance Committee meeting. The paper described CMS’ approach to the conversion of the MS–DRGs from ICD–9–CM to ICD–10 codes. The study was undertaken using the ICD–9–CM MS–DRGs Version 27.0 (FY 2010), which was converted to the ICD–10 MS–DRGs Version 27.0 (FY 2011). The study estimated the impact on aggregate payment to hospitals and the distribution of payments across hospitals. The impact of the conversion from ICD–9–CM to ICD–10 on Medicare MS–DRG hospital payments was estimated using FY 2009 Medicare claims data. The study found a hospital payment increase of 0.05 percent using the ICD–10 MS–DRGs Version 27.

CMS provided an overview of this hospital payment impact study at the March 5, 2012 ICD–9–CM Coordination and Maintenance Committee meeting. This presentation followed presentations on the creation of ICD–10 MS–DRGs Version 29.0. A summary report of this meeting can be found on the CMS Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html. At this March 2012 meeting, CMS announced that it would produce an update on this impact study based on an updated version of the ICD–10 MS–DRGs. This update on the impact study was presented at the March 5, 2013 ICD–9–CM Coordination and Maintenance Committee meeting. The study found that moving from an ICD–9–CM-based system to an ICD–10 MS–DRG replicated system would lead to DRG reassignments on only 1 percent of the 10 million MedPAR sample records used in the study. Ninety-nine percent of the records did not shift to another MS–DRG when using an ICD–10 MS–DRG system. For the 1 percent of the records that shifted, 45 percent of the shifts were to a higher-weighted MS–DRG, while 55 percent of the shifts were...

Version 26. We also discussed this
to lower-weighted MS–DRGs. The net impact across all MS–DRGs was a reduction by 4,10000 or minus 4 pennies per $100. The updated paper is posted on the CMS Web site at: http://
cms.hhs.gov/Medicare/Coding/ICD10/
ICD-10-MS-DRG-Conversion-Project.html under the “Downloads” section. Information on the March 5, 2013 ICD–9–CM Coordination and
Maintenance Committee meeting can be found on the CMS Web site at: http://
cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-
CM-G-and-M-Meeting-Materials.html. This update of the impact paper and the
ICD–10 MS–DRG Version 32 software provided additional information to
the public who were evaluating the conversion of the MS–DRGs to ICD–10
MS–DRGs.

CMS prepared the ICD–10 MS–DRGs Version 31 based on the FY 2014 MS–
DRGs (Version 31) that we finalized in the FY 2014 IPPS/LTCH PPS final rule. In November 2013, we posted a
Definitions Manual of the ICD–10 MS–
DRGs Version 31 on the ICD–10 MS–
DRG Conversion Project Web site at:
http://www.cms.hhs.gov/Medicare/Coding/
ICD10/ICD-10-MS-DRG-Conversion-Project.html. We also prepared a
document that described changes made from Version 31–R to Version 32 to
facilitate a review. We produced mainframe and computer software for
Version 32, which was made available to the public in January 2015.

Information on ordering the mainframe and computer software through NTIS
was made available on the CMS Web site at:
http://www.cms.gov/Medicare/Coding/
ICD10/ICD-10-MS-DRG-Conversion-Project.html under the
“Related Links” section. This ICD–10
MS–DRGs Version 32 computer
software facilitated additional review of the
ICD–10 MS–DRGs conversion. We
encouraged the public to submit to CMS
any comments on areas where they
believed the ICD–10 MS–DRGs did not
accurately reflect grouping logic found in the ICD–9–CM MS–DRGs Version 32.

We discussed five requests from the
public to update the ICD–10 MS–DRGs Version 32 to better replicate the ICD–
9–CM MS–DRGs in section II.G.3., 4.,
and 5. of the preamble of the FY 2016 IPPS/LTCH PPS final rule. In the FY
2016 IPPS/LTCH PPS proposed rule (80 FR 24351), we proposed to implement the MS–DRG code logic in the ICD–10
MS–DRGs Version 32 with any final updates to the ICD–10 MS–
DRGs Version 32 for the final ICD–10
MS–DRGs Version 33. In the proposed rule, we proposed the ICD–10 MS–DRGs Version 33 as the replacement logic for
the ICD–9–CM based MS–DRGs Version 32 as part of the proposed MS–DRG
updates for FY 2016. We invited public comments on how well the ICD–10 MS–
DRGs Version 32 replicated the logic of the MS–DRGs Version 32 based on ICD–
9–CM codes.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49356 through 49357 and
49363 through 49407), we addressed the
public comments we received on the replication in the ICD–10 MS–DRGs
Version 32 of the logic of the MS–DRGs Version 32 based on ICD–9–CM codes.
We refer readers to that final rule for a
discussion of the changes we made in
response to public comments.

b. Basis for FY 2017 MS–DRG Updates
CMS encourages input from our stakeholders concerning the annual
IPPS updates when that input is made
available to us by December 7 of the
year prior to the next annual proposed
rule update. For example, to be
considered for any updates or changes in FY 2017, comments and suggestions
should have been submitted by
December 7, 2015. The comments that
were submitted in a timely manner for
FY 2017 are discussed in this section of the
final rule. Interested parties should
submit any comments and suggestions
for FY 2018 by December 7, 2016, via the
new CMS MS–DRG Classification
Change Requests Mailbox located at:
MSDRGClassification
Change@cms.hhs.gov.

Following are the changes we
proposed to the MS–DRGs for FY 2017
in the FY 2017 IPPS/LTCH PPS
proposed rule (81 FR 24971 through
25016). We invited public comment on
each of the MS–DRG classification
proposed changes as well as our
proposals to maintain certain existing
MS–DRG classifications discussed in
the proposed rule. In some cases, we
proposed changes to the MS–DRG
classifications based on our analysis of claims data. In other cases, we
proposed to maintain the existing MS–DRG
classification based on our analysis of
claims data. For the FY 2017 proposed rule, our MS–DRG analysis was based
on claims data from the December 2015
update of the FY 2015 MedPAR file,
which contains hospital bills received through September 30, 2015, for
discharges occurring through September
30, 2015. In our discussion of the
proposed MS–DRG reclassification
changes, we referred to our analysis of
claims data from the “December 2015
update of the FY 2015 MedPAR file.”

In this FY 2017 IPPS/LTCH PPS final
rule, we summarize the public
comments we received on our
proposals, present our responses, and
state our final policies. For this FY 2017
rule, we did not perform any
further MS–DRG analysis of claims data.
Therefore, all of the data analysis is
based on claims data from the December
2015 update of the FY 2015 MedPAR file,
which contains hospital bills received through September 30, 2015, for
discharges occurring through September
30, 2015.

As explained in previous rulemaking
(76 FR 51487), in deciding whether to
propose to make further modification to
the MS–DRGs for particular
circumstances brought to our attention,
we consider whether the resource
consumption and clinical characteristics
of the patients with a given set of
conditions are significantly different than
the remaining patients at the MS–
DRG. We evaluate patient care costs
using average costs and lengths of stay.
and rely on the judgment of our clinical advisors to decide whether patients are clinically distinct or similar to other patients in the MS–DRG. In evaluating resource costs, we consider both the absolute and percentage differences in average costs between the cases we select for review and the remainder of cases in the MS–DRG. We also consider variation in costs within these groups; that is, whether observed average differences are consistent across patients or attributable to cases that are extreme in terms of costs or length of stay, or both. Further, we consider the number of patients who will have a given set of characteristics and generally prefer not to create a new MS–DRG unless it would include a substantial number of cases.

In our examination of the claims data, we apply the following criteria established in FY 2008 (72 FR 47169) to determine if the creation of a new complication or comorbidity (CC) or major complication or comorbidity (MCC) subgroup within a base MS–DRG is warranted:
- A reduction in variance of costs of at least 3 percent.
- At least 5 percent of the patients in the MS–DRG fall within the CC or MCC subgroup.
- At least 500 cases are in the CC or MCC subgroup.
- There is at least a 20 percent difference in average costs between subgroups.
- There is a $2,000 difference in average costs between subgroups.

In order to warrant creation of a CC or MCC subgroup within a base MS–DRG, the subgroup must meet all five of the criteria.

We note that some of the issues evaluated for the FY 2017 MS–DRGs update continue to relate to the need for the ICD–10 MS–DRGs to accurately replicate the logic of the ICD–9–CM based version of the MS–DRGs. Replication is important because both the logic for the MS–DRGs and the data source used to calculate and develop proposed relative payment weights are based on the same MedPAR claims data. In other words, as the logic for the proposed and final FY 2017 ICD–10 MS–DRGs is based upon the FY 2015 ICD–9–CM MedPAR data, the data source used to calculate and develop the proposed and final FY 2017 relative payment weights is also based on the FY 2015 ICD–9–CM MedPAR claims data, including any MS–DRG classification changes discussed in the proposed rule and this final rule. This is consistent with how the current FY 2016 relative payment weights are based on the ICD–9–CM diagnosis and procedure codes from the FY 2014 MedPAR claims data that were grouped through the ICD–9–CM version of the FY 2016 GROUPER Version 33. We note that we made the MS–DRG GROUPER and Medicare Code Editor (MCE) ICD–9–CM Software Version 33 available to the public for use in analyzing ICD–9–CM data to create relative payment weights using ICD–9–CM data on our CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DRG/ICD-9-DRG-Final-Rule-Home-Page.html?DLSort=0&DLEntries=10 &DLPage=1&DLSortDir=ascending. Therefore, as discussed in section II.G. of the preamble of this final rule, ICD–9–CM data were used for computing the proposed and final FY 2017 MS–DRG relative payment weights.

As we did for FY 2016, we note that, for FY 2017, we have made the MS–DRG GROUPER and Medicare Code Editor (MCE) ICD–9–CM Software Version 34 available to the public for use in analyzing ICD–9–CM data to create relative payment weights using ICD–9–CM data on our CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2017-IPPS-Final-Rule-Home-Page.html?DLSort=0&DLEntries=10 &DLPage=1&DLSortDir=ascending.

With regard to the ability of private payers to adjust claims affected by replication issues, as noted in the FY 2008 IPPS final rule (72 FR 47152), we have stated many times in the past that we encourage private insurers and other non-Medicare payers to make refinements to Medicare’s DRG system to better suit the needs of the patients they serve. Consistent with our general approach for implementing updates to the MS–DRGs, the proposals adopted as final policy in this FY 2017 IPPS/LTCH PPS final rule will apply beginning with the MS–DRGs Version 33 were subject to review and comment by the public as part of the FY 2016 IPPS/LTCH PPS proposed rule, we proposed further updates to the MS–DRG GROUPER logic, to be effective October 1, 2016.

Comment: Some commenters requested that CMS make the FY 2017 finalized MS–DRG GROUPER logic proposals retroactive to October 1, 2015 for current FY 2016 claims. One commenter stated that if the corrected replication issues were retroactive to October 1, 2015, private payers would be able to appropriately adjust claims that had an inappropriate MS–DRG assignment.

Response: We acknowledge the commenters’ request. However, we note that in accordance with section 1886(d)(4)(C) of the Act, we adjust the DRG classifications and relative weights at least annually. The FY 2016 ICD–10 MS–DRGs Version 33 were subject to rule and comment by the public as part of the FY 2016 IPPS/LTCH PPS proposed and final rulemaking process. We encouraged the public to submit any comments on areas where they believed the ICD–10 MS–DRGs did not accurately reflect the GROUPER logic found in the ICD–9–CM MS–DRGs (80 FR 49356), and discussed in the FY 2017 rulemaking the requests we received to update the ICD–10 MS–DRGs to better replicate the ICD–9 MS–DRGs. In the FY 2017 IPPS/LTCH PPS proposed rule, we proposed further updates to the MS–DRG GROUPER logic, to be effective October 1, 2016.

The findings of our data analyses and the recommendations of our clinical advisors supported modifications to the current ICD–10 MS–DRG structure, prior to proposing any changes, we first evaluated whether the requested change could be replicated in the ICD–9–CM MS–DRGs. If the answer was “yes,” from a replication perspective, the change was considered feasible. If the answer was “no,” we examined whether the change in the ICD–10 MS–DRGs was likely to cause a significant number of patient cases to change or “shift” ICD–10 MS–DRGs. If relatively few patient cases would be impacted, we evaluated if it would be feasible to propose the change even though it could not be replicated by the ICD–9–CM MS–DRGs because it would not cause a material payment redistribution. For the ICD–10 MS–DRG classification change requests that could not be replicated in ICD–9–CM and that would cause a significant number of patient cases to shift MS–DRG assignment, we considered other alternatives.
of total internal biventricular heart replacement system) and grouped to MS–DRGs 001 and 002 (Heart Transplant or Implant of Heart Assist System with and without MCC, respectively).

As discussed in section II.F.1.a. of the preamble of the proposed rule and this final rule, to assist in the conversion from the ICD–9–CM based MS–DRGs to ICD–10, beginning in FY 2011, draft versions of the ICD–10 based MS–DRGs were developed and made available for public comment. The two ICD–10–PCS procedure codes 02RKOJZ and 02RL0JZ were assigned as a “cluster” to the draft ICD–10 based MS–DRGs 001 and 002 in prior draft versions of the ICD–10 MS–DRGs. In ICD–10–PCS, a cluster is the term used to describe when a combination of ICD–10–PCS procedure codes are needed to fully satisfy the equivalent meaning of an ICD–9–CM procedure code for it to be considered a plausible translation. Upon review of prior draft versions of the ICD–10 MS–DRGs, it was determined that Version 30 was the last version to include ICD–10–PCS procedure codes 02RKOJZ and 02RL0JZ as a code cluster (from ICD–9–CM procedure code 37.52) that grouped to the draft ICD–10 based MS–DRGs 001 and 002. Subsequent draft versions of the ICD–10 MS–DRGs inadvertently omitted this code cluster from those MS–DRGs.

Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24971 through 24972), for FY 2017, we proposed to assign ICD–10–PCS procedure codes 02RKOJZ and 02RL0JZ as a code cluster to ICD–10 Version 34 MS–DRGs 001 and 002 (Heart Transplant or Implant of Heart Assist System with and without MCC, respectively) to accurately replicate the version 32 ICD–9–CM based MS–DRG logic of procedure code 37.52. We invited public comments on our proposal.

**Comment:** Commenters supported the proposal to assign ICD–10–PCS procedure codes 02RKOJZ and 02RL0JZ as a code cluster to ICD–10 Version 34 MS–DRGs 001 and 002. The commenters noted that this code cluster assignment is crucial to assure that all consumers who require a heart replacement with a total artificial heart will have access to care, regardless of whether they are a Medicare beneficiary, a Medicaid recipient, or a privately insured individual. Other commenters noted the proposal was reasonable, given the data, the ICD–10–PCS codes, and the information provided.

**Response:** We appreciate the commenters’ support. After consideration of the public comments we received, we are finalizing our proposal to assign ICD–10–PCS procedure codes 02RKOJZ (Replacement of right ventricle with synthetic substitute, open approach) and 02RL0JZ (Replacement of left ventricle with synthetic substitute, open approach) as a code cluster to MS–DRGs 001 and 002 (Heart Transplant or Implant of Heart Assist System with and without MCC, respectively) effective October 1, 2016 for ICD–10 MS–DRGs Version 34.

**ICD–10–PCS Codes for Endovascular Embolization or Occlusion of the Head and Neck Procedures Assigned to MS–DRGs 020 Through 027 in ICD–10 MS–DRGs Version 33**

<table>
<thead>
<tr>
<th>ICD–10–PCS code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03L03BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L03DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L04BZ</td>
<td>Occlusion of intracranial artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L04DZ</td>
<td>Occlusion of intracranial artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L03BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L03DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L04BZ</td>
<td>Occlusion of right common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L04DZ</td>
<td>Occlusion of right common carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L03BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L03DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L04BZ</td>
<td>Occlusion of left common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L04DZ</td>
<td>Occlusion of left common carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L03BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L03DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L04BZ</td>
<td>Occlusion of right internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L04DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>ICD–10–PCS code</td>
<td>Code description</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>03LK4DZ</td>
<td>Occlusion of right internal carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LL3BZ</td>
<td>Occlusion of left internal carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03L14BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03L14DZ</td>
<td>Occlusion of left internal carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LM3BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LM3DZ</td>
<td>Occlusion of right external carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LM4BZ</td>
<td>Occlusion of right external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LN3BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LN3DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LN4BZ</td>
<td>Occlusion of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LN4DZ</td>
<td>Occlusion of left external carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LP3BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LP3DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LP4BZ</td>
<td>Occlusion of right vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LP4DZ</td>
<td>Occlusion of right vertebral artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LQ3BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LQ3DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LR3BZ</td>
<td>Occlusion of left vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LR3DZ</td>
<td>Occlusion of left vertebral artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LR4DZ</td>
<td>Occlusion of face artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LS3DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LS4DZ</td>
<td>Occlusion of right temporal artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LT3DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03LT4DZ</td>
<td>Occlusion of left temporal artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03LG4BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VG3BZ</td>
<td>Restriction of intracranial artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VG4BZ</td>
<td>Restriction of intracranial artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VG4DZ</td>
<td>Restriction of intracranial artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VH3BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VH3DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VH4BZ</td>
<td>Restriction of right common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VH4DZ</td>
<td>Restriction of right common carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VJ3BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VJ3DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VJ4BZ</td>
<td>Restriction of left common carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VJ4DZ</td>
<td>Restriction of left common carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VK3BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VK3DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VK4BZ</td>
<td>Restriction of right internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VK4DZ</td>
<td>Restriction of right internal carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VL3BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VL3DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VL4BZ</td>
<td>Restriction of left internal carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VL4DZ</td>
<td>Restriction of left internal carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VM3BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VM3DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VM4BZ</td>
<td>Restriction of right external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VM4DZ</td>
<td>Restriction of right external carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VN3BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VN3DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VN4BZ</td>
<td>Restriction of left external carotid artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VN4DZ</td>
<td>Restriction of left external carotid artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VP3BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VP3DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VP4BZ</td>
<td>Restriction of right vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VP4DZ</td>
<td>Restriction of right vertebral artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VQ3BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VQ3DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VQ4BZ</td>
<td>Restriction of left vertebral artery with bioactive intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VQ4DZ</td>
<td>Restriction of left vertebral artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VR3DZ</td>
<td>Restriction of face artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VR4DZ</td>
<td>Restriction of face artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VS3DZ</td>
<td>Restriction of right temporal artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03VS4DZ</td>
<td>Restriction of right temporal artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>03VT3DZ</td>
<td>Restriction of left temporal artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>03UV3DZ</td>
<td>Restriction of right thyroid artery with intraluminal device, percutaneous approach.</td>
</tr>
</tbody>
</table>
Cases reporting any of the ICD–10–PCS procedure codes listed in the table above that are assigned to MS–DRGs 020, 021, and 022 under MDC 1 require a principal diagnosis of hemorrhage. Cases reporting any of the ICD–10–PCS procedure codes listed in the table above that are assigned to MS–DRGs 023 and 024 require the insertion of a major implant or an acute complex central nervous system (CNS) principal diagnosis. Cases reporting any of the ICD–10–PCS procedure codes listed in the table above that are assigned to MS–DRGs 025, 026, and 027 do not have a principal diagnosis of hemorrhage, an acute complex CNS principal diagnosis, or a major device implant.

The requestor expressed concerns about the appropriateness of the MS–DRG assignment for the endovascular embolization or occlusion of head and neck procedures. The requestor stated that past data demonstrated that the cost of cases involving endovascular coils exceeds the average cost of all cases within each of the MS–DRGs to which these procedures are assigned. The requestor pointed out that these procedures were formerly captured by the following ICD–9–CM codes that were assigned to MS–DRGs 020 through 027:

- 39.72 (Endovascular (total) embolization or occlusion of head and neck vessels); and
- 39.75 (Endovascular embolization or occlusion of vessel(s) of head or neck using bare coils); and
- 39.76 (Endovascular embolization or occlusion of vessel(s) of head or neck using bioactive coils).

The commenter also expressed concern about the appropriateness of the current ICD–10 MS–DRG assignment of the following ICD–9–CM codes that describe other endovascular procedures of head and neck that were previously assigned to MS–DRGs 023 through 027 in the ICD–9–CM MS–DRGs Version 32. The commenter stated that these procedures are more clinically complex than other procedures assigned to these MS–DRGs:

- 00.62 (Percutaneous angioplasty of intracranial vessels(s));
- 39.74 (Endovascular removal of obstruction from head and neck vessel(s)); and
- 39.79 (Other endovascular procedures on other vessels).

As discussed in the FY 2017 IPPS/LTCN PPS proposed rule (81 FR 24972 through 24976), we examined claims data from the December 2015 update of the FY 2015 MedPAR file for the endovascular embolization or occlusion of the head and neck procedures or other endovascular procedures reported under ICD–9–CM procedure codes 00.62, 39.72, 39.74, 39.75, 39.76, and 39.79 in MS–DRGs 020 through 027. The table below shows our findings.

### Table: Endovascular Embolization or Occlusion of the Head and Neck Procedures and Other Endovascular Procedures

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 020—All cases</td>
<td>1,213</td>
<td>16.44</td>
<td>$70,716</td>
</tr>
<tr>
<td>MS–DRG 020—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>895</td>
<td>16.15</td>
<td>72,357</td>
</tr>
<tr>
<td>MS–DRG 021—All cases</td>
<td>350</td>
<td>13.74</td>
<td>53,289</td>
</tr>
<tr>
<td>MS–DRG 021—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>272</td>
<td>13.21</td>
<td>53,478</td>
</tr>
<tr>
<td>MS–DRG 022—All cases</td>
<td>63</td>
<td>7.27</td>
<td>33,606</td>
</tr>
<tr>
<td>MS–DRG 023—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>6,360</td>
<td>10.63</td>
<td>38,204</td>
</tr>
<tr>
<td>MS–DRG 023—All cases</td>
<td>2,183</td>
<td>8.57</td>
<td>38,935</td>
</tr>
<tr>
<td>MS–DRG 024—All cases</td>
<td>2,376</td>
<td>5.52</td>
<td>28,270</td>
</tr>
<tr>
<td>MS–DRG 024—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>1,402</td>
<td>5.46</td>
<td>28,543</td>
</tr>
<tr>
<td>MS–DRG 025—All cases</td>
<td>17,756</td>
<td>9.19</td>
<td>29,657</td>
</tr>
<tr>
<td>MS–DRG 025—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>671</td>
<td>9.20</td>
<td>47,579</td>
</tr>
<tr>
<td>MS–DRG 026—All cases</td>
<td>7,630</td>
<td>5.80</td>
<td>21,441</td>
</tr>
<tr>
<td>MS–DRG 026—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>825</td>
<td>3.11</td>
<td>27,429</td>
</tr>
<tr>
<td>MS–DRG 027—All cases</td>
<td>9,628</td>
<td>2.99</td>
<td>17,158</td>
</tr>
<tr>
<td>MS–DRG 027—Cases with procedure code 00.62, 39.72, 39.74, 39.75, 39.76, or 39.79</td>
<td>1,847</td>
<td>1.62</td>
<td>22,845</td>
</tr>
</tbody>
</table>

As can be seen from the table, most of the cases of endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures reported with procedure codes 00.62, 39.72, 39.74, 39.75, 39.76, and 39.79 occur in MS–DRGs 023, 024, and 027. There were 2,183 of these procedure cases reported in MS–DRG 023 with an average length of stay of 8.57 days and average costs of $38,935, compared to an average length of stay of 10.63 days and average costs of $38,204 for all 6,360 cases reported in MS–DRG 023. There were 1,402 of these cases reported in MS–DRG 024 with an average length of stay of 5.46 days and average costs of $28,543, compared to an average length of stay of 5.52 days and average costs of $28,270 for all 2,376 cases reported in MS–DRG 024. There were 1,847 of these cases reported in MS–DRG 027 with an average length of stay of 1.62 days and average costs of $22,845, compared to an average length of stay of 2.99 days and average costs of $17,158 for all.
9,628 cases reported in MS–DRG 027. The average costs for endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRGs 023 and 024 are not significantly different from the average costs for all cases reported in MS–DRGs 023 and 024. The average costs for endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRG 027 are higher ($22,845) than the average costs of all cases reported in MS–DRG 027 ($17,156). However, average costs are not significantly different for the endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRG 020 ($72,357) compared to the average costs for all cases ($70,716) reported in MS–DRG 020; for the endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRG 021 ($53,478) compared to the average costs for all cases ($53,289) reported in MS–DRG 021; and for the endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRG 022 ($33,606) compared to the average costs for all cases ($33,598) reported in MS–DRG 022.

Average costs were higher for the 671 endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRG 025 ($47,579) compared to the average costs for all 17,756 cases ($29,657) reported in MS–DRG 025. The average costs also were higher for the 825 endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRG 026 ($27,429) compared to the average costs for all 7,630 cases ($21,441) reported in MS–DRG 026. Given that average costs are similar for most endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases reported in MS–DRGs 020, 021, 022, 023, 024, 025, 026, and 027, we stated in the proposed rule that we did not believe that all endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures should be reassigned from these eight MS–DRGs.

We also examined the average costs for each specific ICD–9–CM code compared to the average costs of all cases within each of the eight MS–DRGs. The following table shows our findings.
As can be seen from the table above, there were a large number of cases reporting procedure code 39.74 in MS-DRGs 023 and 024. There were 2,916 cases that reported procedure code 39.74 in MS-DRG 023 compared to 6,360 total cases reported in the MS-DRG. The cases that reported procedure code 39.74 in MS-DRG 023 had an average length of stay of 8.30 days and average costs of $38,047, compared to an average length of stay of 10.63 days and average costs of $38,204 for all cases reported in MS-DRG 023. There were 1,284 cases that reported procedure code 39.74 in MS-DRG 024 compared to 2,576 total cases reported in MS-DRG 024. The cases that reported procedure code 39.74 in MS-DRG 024 had an average length of stay of 5.35 days and average costs of $28,268, compared to an average length of stay of 5.52 days and average costs of $28,270 for all cases reported in MS-DRG 024. The average length of stay and average costs for cases that reported procedure code 39.74 are very similar to the average length of stay and average costs for all cases reported in MS-DRGs 023 and 024. The only other group of endovascular embolization or occlusion of the head and neck procedures and other endovascular procedures cases that exceeded 1,000 in number was reported in MS-DRG 027. There were 1,159 cases that reported procedure code 39.72 in MS-DRG 027, compared to 9,628 total cases reported in MS-DRG 027. The cases that reported procedure code 39.72 in MS-DRG 027 had an average length of stay of 1.58 days and average costs of $22,893, compared to an average length of stay of 2.99 days and average costs of $17,158 for all cases reported in MS-DRG 027. In other words, the cases that reported procedure code 39.72 in MS-DRG 027 had a shorter average length of stay and average costs that were $5,735 higher than the average costs for all cases reported in MS-DRG 027. The cases that reported procedure code 39.72 in MS-DRG 027 had a shorter average length of stay and average costs that were $4,235 higher than the average costs for all cases reported in MS-DRG 020. However, the average costs for the cases that reported procedure code 39.72 in MS-DRGs 021, 022, and 024 were close to the average costs for all cases reported in the three MS-DRGs ($54,715 compared to $53,289 in MS-DRG 021; $32,598 compared to $33,598 in MS-DRG 022; and $29,997 compared to $28,270 in MS-DRG 024).

Our clinical advisors reviewed this issue and advised us that the endovascular embolization or occlusion of head and neck procedures and other endovascular procedures currently are appropriately assigned to MS-DRGs 020 through 027. They did not support reassigning these procedures from MS-DRGs 020 through 027 to another MS-DRG or creating a new MS-DRG for these procedures. Our clinical advisors stated that these procedures are all clinically similar to other procedures in these MS-DRGs. In addition, they stated that the surgical techniques are all designed to correct the same clinical problem and advised us against reassigning the procedures from MS-DRGs 020 through 027.

Based on the findings from our data analyses and the recommendations from our clinical advisors, in the FY 2017 IPPS/LTCH PPS proposed rule, we did not propose to reassign the cited endovascular embolization or occlusion of head and neck procedures and other endovascular procedures from MS-DRGs 020 through 027 to another MS-DRG or to create a new MS-DRG for these procedures for FY 2017. We invited public comments on our proposal to maintain the current MS-DRG assignments of these procedures in MS-DRGs 020 through 027.

Comment: Commenters supported the proposal to maintain the current MS-DRG assignments of endovascular embolization or occlusion of head and neck procedures and other endovascular procedures in MS-DRGs 020 through 027. The commenters did not support reassigning these procedures from MS-DRGs 020 through 027 to another MS-DRG or creating a new MS-DRG for these procedures. The commenters stated that the proposal was reasonable, given the data, the ICD-10-PCS codes, and the information provided. One commenter believed that the cost data and clinical profile of endovascular embolization procedures support MS-DRG refinements. This commenter requested that CMS reexamine the issue when ICD-10 claims data become available.

Response: We appreciate the commenters’ support. We will review this and other related MS-DRG assignments once ICD-10 claims data become available.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS-DRG assignments for endovascular embolization or occlusion of head and neck procedures and other endovascular procedures in MS-DRGs 020 through 027.

b. Mechanical Complication Codes

We received a request to reassign the following four ICD-10-CM diagnosis codes from MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs) under MS-DRGs 919, 920, and 921 (Complications of Treatment with MCC, with CC, and without CC/MCC, respectively) to MDC 1 (Diseases and Disorders of the Nervous System) under MS-DRGs 091, 092, and 093 (Other Disorders of the Nervous System with MCC, with CC, and without CC/MCC, respectively): T85.610A (Breakdown (mechanical) of epidural and subdural infusion catheter, initial encounter); T85.620A (Displacement of epidural and subdural infusion catheter, initial encounter); T85.630A (Leakage of epidural and subdural infusion catheter, initial encounter); and T85.690A (Other mechanical complication of epidural and subdural infusion catheter, initial encounter).
The requestor stated that these ICD–10–CM diagnosis code titles clearly describe mechanical complications of nervous system devices, implants, or grafts and are unquestionably nervous system codes. Therefore, the requestor recommended that these diagnosis codes be reassigned to MDC 1 under MS–DRGs 091, 092, and 093.

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24976), we examined ICD–10–CM diagnosis codes T85.610A, T85.620A, T85.630A, and T85.690A that are currently assigned to MDC 21 under MS–DRGs 919, 920, and 921. We noted that the predecessor ICD–9–CM diagnosis code for these four ICD–10–CM diagnosis codes was diagnosis code 996.59 (Mechanical complication due to other implant and internal device, not elsewhere classified), which also was assigned to MDC 21 under MS–DRGs 919, 920, and 921. ICD–9–CM diagnosis code 996.59 did not describe the location of the device. However, ICD–10–CM diagnosis codes T85.610A, T85.620A, T85.630A, and T85.690A provide additional detail that describes the location of the mechanical complication as being within the nervous system.

Based on the results of our examination, we agreed with the requestor that ICD–10–CM diagnosis codes T85.610A, T85.620A, T85.630A, and T85.690A describe conditions occurring within the nervous system. Within the ICD–9–CM MS–DRGs, codes describing nervous system disorders were assigned to MDC 1. The prior ICD–9–CM codes for mechanical complications did not indicate the type of complication and therefore could not be assigned to a specific MDC.

Therefore, the nonspecific complication codes were assigned to MDC 21. These new ICD–10–CM diagnosis codes describe concepts not previously captured by the ICD–9–CM codes and capture nervous system conditions. Therefore, ICD–10–CM diagnosis codes T85.610A, T85.620A, T85.630A, and T85.690A should be reassigned from MDC 21 under MS–DRGs 919, 920, and 921 to MDC 1 under MS–DRGs 091, 092, and 093. Our clinical advisors reviewed this issue and also agree that the four ICD–10–CM diagnosis codes describe conditions occurring within the nervous system and therefore should be reassigned from MDC 21 to MDC 1.

Response: We appreciate the commenters’ support of our proposal. We also appreciate the commenter’s recommendation to reassign the additional 18 ICD–10–CM diagnosis codes describing procedures performed on the nervous system from MDC 21 under MS–DRGs 919, 920, and 921 to MDC 1 under MS DRGs 091, 092, and 093. Our clinical advisors agree that these 18 diagnosis codes also should be reassigned from MDC 21 under MS–DRGs 919, 920 and 921 to MDC1 under MS–DRGs 091, 092 and 093.

After consideration of the public comments we received, we are finalizing our proposal to reassign ICD–10–CM diagnosis codes T85.610A, T85.620A, T85.630A, and T85.690A from MDC 21 under MS–DRGs 919, 920, and 921 to MDC 1 under MS–DRGs 091, 092, and 093. The official code titles for these four codes were revised after publication of the proposed rule. Effective October 1, 2016, the revised code titles are as follows (and are reflected in Table 6E associated with this final rule, which is available via the Internet on the CMS Web site):

- T85.610A (Breakdown (mechanical) of other nervous system device, implant or graft, initial encounter);
- T85.620A (Displacement of other nervous system device, implant or graft, initial encounter);
- T85.630A (Leakage of other nervous system device, implant or graft, initial encounter);
- T85.690A (Other mechanical complication of other nervous system device, implant or graft, initial encounter); and
- T85.690A (Other specified complication of nervous system prosthetic devices, implants and grafts, initial encounter).

ICD–10–CM DIAGNOSIS CODES RECOMMENDED BY COMMENTER FOR REASSIGNMENT FROM MDC 21 TO MDC 1

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T85.610A</td>
<td>Breakdown (mechanical) of other nervous system device, implant or graft, initial encounter.</td>
</tr>
<tr>
<td>T85.620A</td>
<td>Displacement of other nervous system device, implant or graft, initial encounter.</td>
</tr>
<tr>
<td>T85.630A</td>
<td>Leakage of other nervous system device, implant or graft, initial encounter.</td>
</tr>
<tr>
<td>T85.690A</td>
<td>Other mechanical complication of other nervous system device, implant or graft, initial encounter.</td>
</tr>
<tr>
<td>T85.730A</td>
<td>Infection and inflammatory reaction due to ventricular intracranial (communicating) shunt, initial encounter.</td>
</tr>
<tr>
<td>T85.731A</td>
<td>Infection and inflammatory reaction due to implanted electronic neurostimulator of brain, electrode (lead), initial encounter.</td>
</tr>
<tr>
<td>T85.732A</td>
<td>Infection and inflammatory reaction due to implanted electronic neurostimulator of peripheral nerve, electrode (lead), initial encounter.</td>
</tr>
<tr>
<td>T85.733A</td>
<td>Infection and inflammatory reaction due to implanted electronic neurostimulator of spinal cord, electrode (lead), initial encounter.</td>
</tr>
<tr>
<td>T85.734A</td>
<td>Infection and inflammatory reaction due to implanted electronic neurostimulator, generator, initial encounter.</td>
</tr>
<tr>
<td>T85.735A</td>
<td>Infection and inflammatory reaction due to cranial or spinal infusion catheter, initial encounter.</td>
</tr>
<tr>
<td>T85.738A</td>
<td>Infection and inflammatory reaction due to other nervous system device, implant or graft, initial encounter.</td>
</tr>
<tr>
<td>T85.810A</td>
<td>Embolism due to nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
<tr>
<td>T85.820A</td>
<td>Fibrosis due to nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
<tr>
<td>T85.830A</td>
<td>Hemorrhage due to nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
<tr>
<td>T85.840A</td>
<td>Pain due to nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
<tr>
<td>T85.850A</td>
<td>Stenosis due to nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
<tr>
<td>T85.860A</td>
<td>Thrombosis due to nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
<tr>
<td>T85.890A</td>
<td>Other specified complication of nervous system prosthetic devices, implants and grafts, initial encounter.</td>
</tr>
</tbody>
</table>
We also are reassigning the 18 ICD–10–CM diagnosis codes listed in the table above that were recommended by the commenter from MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs) under MS–DRGs 919, 920, and 921 (Complications of Treatment with MCC, with CC, and without CC/MCC, respectively) to MDC 1 (Diseases and Disorders of the Nervous System) under MS–DRGs 091, 092, and 093 (Other Disorders of the Nervous System with MCC, with CC, and without CC/MCC, respectively) effective October 1, 2016. These 18 codes also are reflected in Table 6E associated with this final rule, which is available via the Internet on the CMS Web site.

4. MDC 4 (Diseases and Disorders of the Ear, Nose, Mouth and Throat)
   a. Reassignment of Diagnosis Code R22.2 (Localized Swelling, Mass and Lump, Trunk)

   We received a request to reassign ICD–10–CM diagnosis code R22.2 (Localized swelling, mass and lump, trunk) from MDC 4 (Diseases and Disorders of the Respiratory System) to MDC 9 (Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast). The requester stated that this code is used to capture a buttock mass. The requestor pointed out that the ICD–10–CM index for localized swelling and localized mass directs the coder to diagnosis code R22.2 for both the chest and the trunk as sites.

   We reviewed this issue and note that diagnosis code R22.2 is included in a category of ICD–10–CM codes describing symptoms and signs involving the skin and subcutaneous tissue (categories R20 through R23). Diagnosis code R22.2 is clearly designated within the ICD–10 coding system as a code that describes a condition of the skin and subcutaneous tissue. Therefore, we agree with the requester that ICD–10–CM diagnosis code R22.2 should be reassigned from MDC 4 to MDC 9. One of the predecessor ICD–9–CM codes for ICD–10–CM diagnosis code R22.2 was diagnosis code 782.2 (Localized superficial swelling, mass, or lump), which is assigned to MS–DRG 606 and 607 (Minor Skin Disorders with and without MCC, respectively). Our clinical advisors reviewed this issue and agree that ICD–10–CM diagnosis code R22.2 captures a skin condition. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24976), for FY 2017, we proposed to reassign ICD–10–CM diagnosis code R22.2 from MDC 4 to MDC 9 under MS–DRGs 606 and 607 (Minor Skin Disorders with and without MCC, respectively). We invited public comments on our proposal to reassign ICD–10–CM diagnosis code R22.2 from MDC 4 to MDC 9 under MS–DRGs 606 and 607.

   Comment: Commenters supported the proposal to reassign ICD–10–CM diagnosis code R22.2 from MDC 4 to MDC 9 under MS–DRGs 606 and 607.

   Response: We appreciate the commenters’ support of our proposal. After consideration of the public comments we received, we are finalizing our proposal to reassign ICD–10–CM diagnosis code R22.2 from MDC 4 to MDC 9 under MS–DRGs 606 and 607 (Minor Skin Disorders with and without MCC, respectively).

b. Pulmonary Embolism With tPA or Other Thrombolytic Therapy

   We received a request to create a new MS–DRG or to reassign cases with a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy was administered from MS–DRGs 175 and 176 (Pulmonary Embolism with and without MCC, respectively) to a higher paying MS–DRG. The requestor suggested that CMS review cases reporting the following ICD–9–CM diagnosis codes describing pulmonary embolism: 415.11 (Iatrogenic pulmonary embolism and infarction), 415.12 (Septic pulmonary embolism), 415.13 (Saddle embolus of pulmonary artery), and 415.19 (Other pulmonary embolism and infarction), when reported in combination with ICD–9–CM procedure code 99.10 (Injection or infusion of thrombolytic agent), to identify that thrombolytic therapy was administered.

   The comparable ICD–10–CM diagnosis code translations for the ICD–9–CM pulmonary embolism diagnosis codes to which the requestor cited consist of the following:

<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I26.01 ..................</td>
<td>Septic pulmonary embolism with acute cor pulmonale.</td>
</tr>
<tr>
<td>I26.02 ..................</td>
<td>Saddle embolus of pulmonary artery with acute cor pulmonale.</td>
</tr>
<tr>
<td>I26.09 ..................</td>
<td>Other pulmonary embolism with acute cor pulmonale.</td>
</tr>
<tr>
<td>I26.90 ..................</td>
<td>Septic pulmonary embolism without acute cor pulmonale.</td>
</tr>
<tr>
<td>I26.99 ..................</td>
<td>Other pulmonary embolism without acute cor pulmonale.</td>
</tr>
</tbody>
</table>

Thrombolytic therapy is identified with the following ICD–10–PCS procedure codes:

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3E03017 ..................</td>
<td>Introduction of other thrombolytic into peripheral vein, open approach.</td>
</tr>
<tr>
<td>3E03317 ..................</td>
<td>Introduction of other thrombolytic into peripheral vein, percutaneous approach.</td>
</tr>
<tr>
<td>3E04017 ..................</td>
<td>Introduction of other thrombolytic into central vein, open approach.</td>
</tr>
<tr>
<td>3E04317 ..................</td>
<td>Introduction of other thrombolytic into central vein, percutaneous approach.</td>
</tr>
<tr>
<td>3E05017 ..................</td>
<td>Introduction of other thrombolytic into peripheral artery, open approach.</td>
</tr>
<tr>
<td>3E05317 ..................</td>
<td>Introduction of other thrombolytic into peripheral artery, percutaneous approach.</td>
</tr>
<tr>
<td>3E06017 ..................</td>
<td>Introduction of other thrombolytic into central artery, open approach.</td>
</tr>
<tr>
<td>3E06317 ..................</td>
<td>Introduction of other thrombolytic into central artery, percutaneous approach.</td>
</tr>
</tbody>
</table>
A pulmonary embolism is an obstruction of pulmonary vasculature most commonly caused by a venous thrombus, and less commonly by fat or tumor tissue or air bubbles or both. Risk factors for a pulmonary embolism include prolonged immobilization from any cause, obesity, cancer, fractured hip or leg, use of certain medications such as oral contraceptives, presence of certain medical conditions such as heart failure, sickle cell anemia, or certain congenital heart defects. Common symptoms of pulmonary embolism include shortness of breath with or without chest pain, tachycardia, hemoptysis, low grade fever, pleural effusion, and depending on the etiology of the embolus, might include lower extremity pain or swelling, syncope, jugular venous distention, and finally a pulmonary embolus could be asymptomatic.

As we discussed in the FY 2017 IPPS/ LTCH PPS proposed rule (81 FR 24977 through 24979), we examined the claims data from the December 2015 update of the FY 2015 MedPAR file for ICD–9–CM MS–DRGs 175 and 176 for cases with a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy (procedure code 99.10) was administered and cases of a principal diagnosis of pulmonary embolism where no tPA or other thrombolytic therapy was administered. Our findings are shown in the table below.

### Principal Diagnosis of Pulmonary Embolism With and Without tPA or Other Thrombolytic Therapy Administered

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 175—All MCC cases</td>
<td>19,274</td>
<td>5.76</td>
<td>$10,479</td>
</tr>
<tr>
<td>MS–DRG 175—MCC cases with principal diagnosis of pulmonary embolism with tPA or other thrombolytic therapy administered</td>
<td>630</td>
<td>6.31</td>
<td>$19,419</td>
</tr>
<tr>
<td>MS–DRG 175—MCC cases with principal diagnosis of pulmonary embolism without tPA or other thrombolytic therapy administered</td>
<td>18,529</td>
<td>5.74</td>
<td>$10,181</td>
</tr>
<tr>
<td>MS–DRG 175—with MCC cases without principal diagnosis of pulmonary embolism with tPA or other thrombolytic therapy administered</td>
<td>33,565</td>
<td>3.81</td>
<td>$6,645</td>
</tr>
<tr>
<td>MS–DRG 176—Without MCC cases principal diagnosis of pulmonary embolism without tPA or other thrombolytic therapy administered</td>
<td>544</td>
<td>5.07</td>
<td>$16,345</td>
</tr>
<tr>
<td>MS–DRG 176—Without MCC cases with principal diagnosis of pulmonary embolism without tPA or other thrombolytic therapy administered</td>
<td>32,789</td>
<td>3.79</td>
<td>$6,483</td>
</tr>
</tbody>
</table>

As shown in the table above, for MS–DRG 175, there were a total of 19,274 cases with an average length of stay of 5.76 days and average costs of $10,479. Of the 19,274 cases in MS–DRG 175, there were 630 cases that reported a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy was also reported with an average length of stay of 6.31 days and average costs of $19,419. For MS–DRG 176, there were a total of 33,565 cases with an average length of stay of 3.81 days and average costs of $6,645. Of the 33,565 cases reported in MS–DRG 176, there were 544 cases that reported a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy also was reported with an average length of stay of 5.07 days and average costs of $16,345.

To address the request we received to create a new MS–DRG, we reviewed the data for the 1,174 total cases (630 and 544, respectively) that reported a principal diagnosis of pulmonary embolism that received tPA or other thrombolytic therapy in MS–DRGs 175 and 176. As shown in the table above, our data analysis demonstrates the average costs for these cases are higher ($19,419 compared to $10,479 for MS–DRG 175, and $16,345 compared to $6,645 for MS–DRG 176) and the length of stay is slightly longer (6.31 days compared to 5.76 days for MS–DRG 175, and 5.07 days compared to 3.81 days for MS–DRG 176) compared to all cases reported in MS–DRGs 175 and 176. Out of a total of 52,492 cases (630 + 18,529 +544 + 32,789) in MS–DRGs 175 and 176 reporting a principal diagnosis of pulmonary embolism, 1,174 (2.24 percent) of these cases also received tPA or other thrombolytic therapy. While we recognize the differences in average costs and length of stay for these cases, the volume of these cases as well as the potential creation of a new MS–DRG for this subset of patients raised some concerns with our clinical advisors. We present our clinical advisors’ concerns following the additional data analysis discussions below.

As shown in the data findings in the tables below, we explored reassigning cases with a principal diagnosis of pulmonary embolism that received tPA or other thrombolytic therapy from MS–DRG 176 to the higher severity level MS–DRG 175. The data do not adequately support this reassignment, as the cases with a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy was administered would continue to be underpaid.

### Principal Diagnosis of Pulmonary Embolism With tPA or Other Thrombolytic Therapy Administered

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 175—All MCC cases</td>
<td>19,274</td>
<td>5.76</td>
<td>$10,479</td>
</tr>
</tbody>
</table>

We then conducted additional data analyses to determine if reassignment of cases with a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy was administered to a higher paying MS–DRG was supported. As displayed in the data findings in the tables below, we explored reassigning cases with a principal diagnosis of pulmonary embolism that received tPA or other thrombolytic therapy from MS–DRG 176 to the higher severity level MS–DRG 175. The data do not adequately support this reassignment, as the cases with a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy was administered would continue to be underpaid.

As shown in the data findings in the table below, the initial data analysis for MS–DRG 175 found the average costs for cases that reported a principal diagnosis of pulmonary embolism that received tPA or other thrombolytic therapy were $19,419, and for MS–DRG 176, the average costs for these cases were $16,345.
As displayed in the table below, if we reassigned the 544 cases with a principal diagnosis of pulmonary embolism where tPA or other thrombolytic therapy is administered from the “without MCC” level, MS–DRG 176, to the “with MCC” severity level, MS–DRG 175, the average costs for all cases in MS–DRG 175 would be approximately $10,640. This figure continues to result in a difference of approximately $9,000 for the MCC cases and $6,000 for the without MCC cases when compared to findings for the average costs of these cases from the initial data analysis ($19,419 – $10,640 = $8,779 and $16,345 – $10,640 = $5,705, respectively). In addition, our clinical advisors had concerns about the prospect of moving the subset of 544 patients from the “without MCC” level to the “with MCC” level. We present these concerns following the additional data analysis discussion below.

### OPTION OF REASSIGNMENT OF CASES OF PRINCIPAL DIAGNOSIS OF PULMONARY EMBOLISM WITH AND WITHOUT tPA

| MS–DRG 175—Cases with pulmonary embolism with MCC or tPA or other thrombolytic therapy | 19,818 | 5.74 | $10,640 |
| MS–DRG 176—Cases with pulmonary embolism without MCC | 33,021 | 3.79 | $6,486 |

We also reviewed claims data in considering the option of adding another severity level to the current structure of MS–DRGs 175 and 176 and assigning the cases with a principal diagnosis of pulmonary embolism that receive tPA or other thrombolytic therapy to the highest level. This option would involve modifying the current 2-way severity level split of “with MCC” and “without MCC” to a 3-way severity level split of “with MCC or tPA, with CC, and without CC/MCC.” Therefore, it would include proposing new MS–DRGs if the data and our clinical advisors supported creation of new MS–DRGs. However, as displayed in the data findings in the table below, the data did not support this option. In addition to similar results from the previous option’s discussion regarding continued differences in average costs for these cases, the data failed to meet the criterion that there be at least a $2,000 difference between the “with CC” and “without CC/MCC” subgroups. Our data analysis shows the average costs in the hypothetical “with CC” subgroup of $6,932 and the average costs in the hypothetical “without CC/MCC” subgroup of $5,309. The difference only amounts to $1,623 ($6,932 minus $5,309 = $1,623).

### PRINCIPAL DIAGNOSIS OF PULMONARY EMBOLISM WITH AND WITHOUT tPA OR OTHER THROMBOLYTIC THERAPY

<table>
<thead>
<tr>
<th>Optional new MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG XXX—Pulmonary embolism with MCC or tPA or other thrombolytic therapy</td>
<td>19,819</td>
<td>5.74</td>
<td>$10,641</td>
</tr>
<tr>
<td>MS–DRG XXX—Pulmonary embolism with CC</td>
<td>23,929</td>
<td>4.04</td>
<td>$6,932</td>
</tr>
<tr>
<td>MS–DRG XXX—Pulmonary embolism without CC/MCC</td>
<td>9,091</td>
<td>3.13</td>
<td>$5,309</td>
</tr>
</tbody>
</table>

Lastly, we explored reassigning cases with a principal diagnosis of pulmonary embolism that receive tPA or other thrombolytic therapy to other MS–DRGs within MDC 4. However, our review did not support reassignment of these cases to any other medical MS–DRGs as these cases would not be clinically coherent with the cases assigned to those other MS–DRGs.

In addition to the results of the various data analyses we performed for creating a new MS–DRG or for reassigning cases of pulmonary embolism with tPA or other thrombolytic therapy to another higher paying MS–DRG, our clinical advisors also expressed a number of concerns. They pointed out that all patients with a diagnosis of pulmonary embolism are considered high risk and the small subset of patients receiving thrombolytic therapy does not necessarily warrant a separate MS–DRG or reassignment at this time. Our clinical advisors noted that it is unclear if: (1) The higher costs associated with receiving tPA or other thrombolytic therapy are due to a different subset of patients or complications; (2) if those patients treated with tPA or other thrombolytic therapy for pulmonary embolism are indeed sicker patients; (3) if the cost of tPA or other thrombolytic therapy for patients with pulmonary embolism is the reason for the higher costs seen with these cases; or (4) if the increased average costs for cases of pulmonary embolism with tPA or other thrombolytic therapy is a combination of numbers (1) through (3). They recommended maintaining the current structure of MS–DRGs 175 and 176.

As a result of the data analysis and the concerns expressed by our clinical advisors, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24977 through 24979), we did not propose to create a new MS–DRG or to reassign cases with a principal diagnosis of pulmonary embolism with tPA or other
thrombolytic therapy for FY 2017. We invited public comment on our proposal.

Comment: Commenters supported the proposal to not create a new MS–DRG or to reassign cases with a principal diagnosis of pulmonary embolism with tPA or other thrombolytic therapy. The commenters stated that the proposal was reasonable, given the data, the ICD–10–CM/PCS codes, and information provided.

Response: We appreciate the commenters’ support of our proposal. After consideration of the public comments we received, we are finalizing our proposal to not create a new MS–DRG or to reassign cases with a principal diagnosis of pulmonary embolism with tPA or other thrombolytic therapy for FY 2017. The current structure of MS–DRGs 175 and 176 (Pulmonary Embolism with and without MCC, respectively) is maintained in the ICD–10 MS–DRGs Version 34 effective October 1, 2016.

5. MDC 5 (Diseases and Disorders of the Circulatory System)

a. Implant of Loop Recorder

We received a request to examine a potential ICD–9 to ICD–10 replication issue for procedures describing implantation or relocation of loop recorder that were reported using ICD–9–CM procedure code 37.79 (Revision or relocation of cardiac device pocket). A loop recorder is also known as an implantable cardiac monitor. It is indicated for patients who experience episodes of unexplained syncope (fainting), heart palpitations, or patients at risk for various types of cardiac arrhythmias, such as atrial fibrillation or ventricular tachyarrhythmia. Loop recorders function by detecting and monitoring potential episodes of these kinds of conditions. The requestor acknowledged that these implantation procedures are often performed in the inpatient setting and suggested that they be recognized under the ICD–10 MS–DRGs as they had been under the ICD–9–CM based MS–DRG logic.

The requestor stated that, under the ICD–9–CM based MS–DRGs, procedure code 37.79 was designated as an operating room (O.R.) procedure in the Definitions Manual under Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index and grouped to MS–DRGs 040, 041, and 042 (Peripheral, Cranial Nerve and Other Nervous System Procedures with MCC, with CC or peripheral neurostimulator, and without CC/MCC, respectively); MS–DRGs 260, 261, and 262 (Cardiac Pacemaker Revision Except Device Replacement with MCC, with CC, and without CC/MCC, respectively); MS–DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC and without CC/MCC, respectively); MS–DRGs 907, 908, and 909 (Other O.R. Procedures for Injuries with MCC, with CC, and without CC/MCC, respectively); and MS–DRGs 957, 958, and 959 (Other O.R. Procedures for Multiple Significant Trauma with MCC, with CC, and without CC/MCC, respectively).

Under the current Version 33 ICD–10 MS–DRGs, there are two comparable ICD–10–PCS code translations for ICD–9–CM code 37.79. They are procedure codes 0JWT0PZ (Revision of cardiac rhythm related device in trunk subcutaneous tissue and fascia, open approach) and 0JWT3PZ (Revision of cardiac rhythm related device in trunk subcutaneous tissue and fascia, percutaneous approach), which are designated as O.R. procedures and group to the above listed MS–DRGs.

According to the requestor, the following six ICD–10–PCS procedure codes identify the implantation or revision of a loop recorder and were not replicated appropriately because they are currently designated as nonoperating room (non-O.R.) procedures under the ICD–10 MS–DRGs. The requestor suggested that these codes be designated as O.R. procedures and assigned to the same MS–DRGs as the former ICD–9–CM procedure code 37.79:

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0JH602Z .............</td>
<td>Insertion of monitoring device into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH632Z .............</td>
<td>Insertion of monitoring device into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH802Z .............</td>
<td>Insertion of monitoring device into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH832Z .............</td>
<td>Insertion of monitoring device into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JWT02Z .............</td>
<td>Revision of monitoring device into trunk subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JWT32Z .............</td>
<td>Revision of monitoring device into trunk subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
</tbody>
</table>

We examined the six ICD–10–PCS procedure codes that the commenter recommended be designated as O.R. procedures and assigned to the same MS–DRGs as ICD–9–CM procedure code 37.79. As discussed in section II.F.1.b. of the preamble of the proposed rule and this final rule, in evaluating requested MS–DRG changes, we determined if they could be replicated in the ICD–9–CM MS–DRGs so as not to affect the FY 2017 relative payment weights. If the answer was “no,” we examined whether the change in the ICD–10 MS–DRGs was likely to cause a significant number of patient cases to change or “shift” ICD–10 MS–DRGs. If relatively few patient cases would be impacted, we evaluated if it would be feasible to propose the change even though it could not be replicated by the ICD–9 MS–DRGs logic because it would not cause a material payment redistribution.

Under our review, we recognized that the six ICD–10–PCS procedure codes are currently identified as comparable translations of ICD–9–CM procedure code 86.09 (Other incision of skin and subcutaneous tissue), which was designated as a non-O.R. procedure code under the ICD–9–CM based MS–DRGs. Therefore, changing the designation of the six ICD–10–PCS procedure codes from non-O.R. to O.R. for the ICD–10 MS–DRGs cannot be replicated in the ICD–9–CM based MS–DRGs. In other words, we cannot designate ICD–9–CM procedure code 86.09 as an O.R. code. However, we stated in the proposed rule that we believe that if we limit the change in designation to four of the six identified ICD–10–PCS procedure codes from non-O.R. to O.R., the change would not have any impact. We did not include the two ICD–10–PCS procedure codes that describe the insertion of a monitoring device into the abdomen in our proposal because a loop recorder is not inserted into that location and it would not be clinically appropriate.

Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24979 through 24980), for FY 2017, we proposed to designate the following four ICD–10–PCS codes as O.R. procedures:
within Appendix E of the Version 34 ICD–10 MS–DRG Definitions Manual:
- 0JH602Z (Insertion of monitoring device into chest subcutaneous tissue and fascia, open approach);
- 0JH632Z (Insertion of monitoring device into chest subcutaneous tissue and fascia, percutaneous approach);
- 0JWT02Z (Revision of monitoring device in trunk subcutaneous tissue and fascia, open approach); and
- 0JWT32Z (Revision of monitoring device in trunk subcutaneous tissue and fascia, percutaneous approach).

We also proposed that the ICD–10 MS–DRG assignment for these four ICD–10–PCS codes replicate the ICD–9–CM based MS–DRG assignment for procedure code 37.79; that is, MS–DRGs 040, 041, 042, 260, 261, and 262 under the ICD–10 MS–DRGs Version 33, all six ICD–10–PCS codes replicate the ICD–9–CM based MS–DRG assignment for these procedures. The commenters also agreed with the proposed MS–DRG assignments for these procedure codes under the ICD–10 MS–DRGs, stating that the proposal was reasonable, given the data, the ICD–10–PCS codes and information provided. One commenter specifically expressed appreciation with CMS’ review of this replication issue and agreed that the codes that were proposed to be changed from non-O.R. to O.R. are accurate and that this change will result in better data on claims. This commenter also commended CMS for the proposed MS–DRG assignments under the ICD–10 MS–DRGs.

Alternatively, another commenter noted that while it agreed with the proposal to change the designation of the four ICD–10–PCS procedure codes from non-O.R. to O.R. and supported the proposed MS–DRG assignments, the commenter believed that the two other ICD–10–PCS procedure codes describing insertion of a monitoring device into the abdomen subcutaneous tissue and fascia (ICD–10–PCS procedure codes 0JH802Z and 0JH832Z) also merit redesignation from non-O.R. to O.R. and assignment to the same corresponding surgical MS–DRGs in order to fully address the ICD–9 to ICD–10 replication issue. According to the commenter, the anatomical location of implants involving loop recorders does not affect the level of effort involved in performing such procedures. The commenter recommended that CMS consider ICD–9–CM procedure code 37.79 (Revision or relocation of cardiac device pocket) and its attributes versus ICD–9–CM procedure code 86.09 (Other incision of skin and subcutaneous tissue) as more appropriate for examining all the comparable ICD–10 code translations and MS–DRG assignments.

Response: We appreciate the commenters’ support of our proposals. We agree with the commenters that this modification will better address the resources involved with these procedures.

With regard to the commenter who recommended that we include the two ICD–10–PCS codes describing insertion of a monitoring device into the abdomen subcutaneous tissue and fascia, we are not clear with respect to the commenter’s statement that the anatomical location of implants involving loop recorders does not affect the level of effort involved in performing such procedures because loop recorders are not inserted in that area of the abdomen. As we noted in the FY 2017 IPPS/LTCH PPS proposed rule, when we were unable to fully replicate the ICD–9 to ICD–10 MS–DRG logic for a specific request, we sought and proposed an alternative option that would not cause MS–DRG shifts or a material payment distribution. For this particular issue, the request was to change the designation of the six ICD–10–PCS procedure codes from non-O.R. to O.R. and, as described above, we were not able to finalize that specific request. Rather, we finalized an alternative option, which was to change the designation for four of the six codes requested. We also point out that, currently, under the ICD–10 MS–DRGs Version 33, all six ICD–10–PCS procedure codes that were subject of our specific proposal are designated as non-O.R. procedures affecting the MS–DRG assignment for MS–DRGs 579, 580, and 581. Therefore, while we are not finalizing the proposal to change the two ICD–10–PCS procedure codes describing insertion of a monitoring device into the abdomen (0JH802Z and 0JH832Z) from non-OR to O.R., we note that these two procedure codes will continue to be recognized as non-O.R. procedures affecting MS–DRGs 579, 580, and 581 under the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

After consideration of the public comments we received, we are finalizing our proposal to designate the following four ICD–10–PCS codes as O.R. procedures within Appendix E of the Version 34 ICD–10 MS–DRG Definitions Manual:
- 0JH602Z (Insertion of monitoring device into chest subcutaneous tissue and fascia, open approach);
- 0JH632Z (Insertion of monitoring device into chest subcutaneous tissue and fascia, percutaneous approach);
- 0JWT02Z (Revision of monitoring device in trunk subcutaneous tissue and fascia, open approach); and
- 0JWT32Z (Revision of monitoring device in trunk subcutaneous tissue and fascia, percutaneous approach).

We are also finalizing our proposal that the ICD–10 MS–DRG assignment for the above four ICD–10–PCS procedure codes replicate the ICD–9–CM based MS–DRG assignment for procedure code 37.79; that is, MS–DRGs 040, 041, 042, and 043 (Peripheral, Cranial Nerve and Other Nervous System Procedures with MCC, with CC or peripheral neurostimulator, and without CC/MCC, respectively); MS–DRGs 260, 261, and 262 (Cardiac Pacemaker Revision Except Device Replacement with MCC, with CC, and without CC/MCC, respectively); MS–DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC and without CC/MCC, respectively); MS–DRGs 907, 908, and 909 (Other O.R. Procedures for Injuries with MCC, with CC and without CC/MCC, respectively); and MS–DRGs 957, 958, and 959 (Other O.R. Procedures for Multiple Significant Trauma with MCC, with CC, and without CC/MCC, respectively), effective October 1, 2016.

b. Endovascular Thrombectomy of the Lower Limbs

We received a comment stating that the logic for ICD–10 MS–DRGs Version 33 is not compatible with the ICD–9–CM MS–DRGs Version 32 for the assignment of procedures describing endovascular thrombectomy of the lower limbs. The commenter asked CMS to reconfigure the MS–DRG structure within the ICD–10 MS–DRGs for endovascular thrombectomy of the lower limbs, specifically MS–DRGs 270, 271, and 272 (Other Major Cardiovascular Procedures with MCC, with CC, and without CC/MCC, respectively)). (We note that in the FY 2017 IPPS/LTCH PPS proposed rule, we incorrectly cited the titles for MS–DRGs 270, 271, and 272 as “(Endovascular Thrombectomy of the Lower Limbs with MCC, with CC, and without CC/MCC, respectively)” The commenter believed that this requested restructuring would be consistent with the MS–DRG assignments for the other procedures describing lower extremity...
thrombectomy, and would accurately replicate the logic of the ICD–9–CM MS–DRGs Version 32. Under the ICD–9–CM, endovascular thrombectomy of the lower limbs is described by procedure code 39.79 (Other endovascular procedures on other vessels). The commenter stated that, with deep vein thrombosis (DVT) or any other circulatory system disorders as the principal diagnosis, cases involving procedures described by procedure code 39.79 grouped to ICD–9–CM MS–DRGs 237 and 238 (Major Cardiovascular Procedures with and without MCC, respectively). However, the commenter pointed out that, for FY 2016, ICD–9–CM MS–DRGs 237 and 238 were deleted and replaced with ICD–10 Version 33 MS–DRGs 268 and 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon with and without MCC, respectively), for the higher complexity procedures, and MS–DRGs 270, 271, and 272 for the lower complexity procedures (80 FR 49389).

The commenter stated that ICD–9–CM procedure code 39.79 describes the lower complexity procedures assigned to ICD–10–PCS MS–DRGs 270, 271, and 272. The commenter believed that the comparable ICD–10–PCS procedure codes also should have been assigned to MS–DRGs 270, 271, and 272.

We agreed with the requestor that procedures describing endovascular thrombectomy of the lower limbs should be assigned to ICD–10 MS–DRGs 270, 271, and 272. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24980 through 24981), for implementation October 1, 2016, we proposed to restructure the ICD–10–PCS MS–DRG configuration and add the ICD–10–PCS code translations listed in the following chart (which would capture procedures describing endovascular thrombectomy of the lower limbs) to ICD–10 Version 34 MS–DRGs 270, 271, and 272.

### ICD–10–PCS Endovascular Thrombectomy Procedure Codes Proposed To Be Assigned to MS–DRGs 270, 271, and 272 For FY 2017

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03C3ZZ</td>
<td>Extirpation of matter from right axillary artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C6ZZ</td>
<td>Extirpation of matter from left axillary artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C7ZZ</td>
<td>Extirpation of matter from right brachial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C8ZZ</td>
<td>Extirpation of matter from left brachial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C9ZZ</td>
<td>Extirpation of matter from right ulnar artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CAZZ</td>
<td>Extirpation of matter from left ulnar artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CBZZ</td>
<td>Extirpation of matter from right radial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CCZZ</td>
<td>Extirpation of matter from left radial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CDZZ</td>
<td>Extirpation of matter from right hand artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CFZZ</td>
<td>Extirpation of matter from left hand artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CYZZ</td>
<td>Extirpation of matter from upper artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CKZZ</td>
<td>Extirpation of matter from right femoral artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CLZZ</td>
<td>Extirpation of matter from left femoral artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CMZZ</td>
<td>Extirpation of matter from right popliteal artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CNZZ</td>
<td>Extirpation of matter from left popliteal artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CPZZ</td>
<td>Extirpation of matter from right anterior tibial artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CQZZ</td>
<td>Extirpation of matter from left anterior tibial artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CRZZ</td>
<td>Extirpation of matter from right posterior tibial artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CSZZ</td>
<td>Extirpation of matter from left posterior tibial artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CTZZ</td>
<td>Extirpation of matter from right peroneal artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CUZZ</td>
<td>Extirpation of matter from left peroneal artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CVZZ</td>
<td>Extirpation of matter from right foot artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CWZZ</td>
<td>Extirpation of matter from left foot artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CYZZ</td>
<td>Extirpation of matter from lower artery, percutaneous approach.</td>
</tr>
<tr>
<td>05C7ZZ</td>
<td>Extirpation of matter from right axillary vein, percutaneous approach.</td>
</tr>
<tr>
<td>05C8ZZ</td>
<td>Extirpation of matter from left axillary vein, percutaneous approach.</td>
</tr>
<tr>
<td>05C9ZZ</td>
<td>Extirpation of matter from right brachial vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CAZZ</td>
<td>Extirpation of matter from left brachial vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CBZZ</td>
<td>Extirpation of matter from right basilic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CCZZ</td>
<td>Extirpation of matter from left basilic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CDZZ</td>
<td>Extirpation of matter from right cephalic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CFZZ</td>
<td>Extirpation of matter from left cephalic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CGZZ</td>
<td>Extirpation of matter from right hand vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CHZZ</td>
<td>Extirpation of matter from left hand vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CLZZ</td>
<td>Extirpation of matter from intracranial vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CMZZ</td>
<td>Extirpation of matter from right internal jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CNZZ</td>
<td>Extirpation of matter from left internal jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CPZZ</td>
<td>Extirpation of matter from right external jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CQZZ</td>
<td>Extirpation of matter from left external jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CRZZ</td>
<td>Extirpation of matter from right vertebral vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CSZZ</td>
<td>Extirpation of matter from left vertebral vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CTZZ</td>
<td>Extirpation of matter from right face vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CVZZ</td>
<td>Extirpation of matter from left face vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CYZZ</td>
<td>Extirpation of matter from upper vein, percutaneous approach.</td>
</tr>
<tr>
<td>06C3ZZ</td>
<td>Extirpation of matter from esophageal vein, percutaneous approach.</td>
</tr>
<tr>
<td>06C6ZZ</td>
<td>Extirpation of matter from right femoral vein, percutaneous approach.</td>
</tr>
<tr>
<td>06CNZZ</td>
<td>Extirpation of matter from left femoral vein, percutaneous approach.</td>
</tr>
<tr>
<td>06CPZZ</td>
<td>Extirpation of matter from right greater saphenous vein, percutaneous approach.</td>
</tr>
<tr>
<td>06CQZZ</td>
<td>Extirpation of matter from left greater saphenous vein, percutaneous approach.</td>
</tr>
<tr>
<td>06CRZZ</td>
<td>Extirpation of matter from right lesser saphenous vein, percutaneous approach.</td>
</tr>
<tr>
<td>06CSZZ</td>
<td>Extirpation of matter from left lesser saphenous vein, percutaneous approach.</td>
</tr>
<tr>
<td>06CTZZ</td>
<td>Extirpation of matter from right foot vein, percutaneous approach.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal to assign the ICD–10–PCS procedures describing the endovascular thrombectomy of the lower limbs listed in the table above to ICD–10 Version 34 MS–DRGs 270, 271, and 272 for FY 2017. The commenters noted it is important that endovascular thrombectomy procedures be assigned to the same MS–DRGs as other procedures describing lower extremity thrombectomy. However, some commenters also noted that a subset of the codes listed in the table in the proposed rule describe non-lower limb procedures. The commenters were concerned that moving the 34 non-lower limb procedure codes displayed in the following table would not support clinical and resource use homogeneity in the MS–DRG.

ICD–10–PCS ENDOVASCULAR THROMBECTOMY NON-LOWER LIMB PROCEDURE CODES IDENTIFIED BY COMMENTERS

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03C3ZZ</td>
<td>Extirpation of matter from right axillary artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C6ZZ</td>
<td>Extirpation of matter from left axillary artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C7ZZ</td>
<td>Extirpation of matter from right brachial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C8ZZ</td>
<td>Extirpation of matter from left brachial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03C9ZZ</td>
<td>Extirpation of matter from right ulnar artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CAZZ</td>
<td>Extirpation of matter from left ulnar artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CBZZ</td>
<td>Extirpation of matter from right radial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CCZZ</td>
<td>Extirpation of matter from left radial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CDZZ</td>
<td>Extirpation of matter from right hand artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CFZZ</td>
<td>Extirpation of matter from left hand artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CYZZ</td>
<td>Extirpation of matter from upper artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CTZZ</td>
<td>Extirpation of matter from right peroneal artery, percutaneous approach.</td>
</tr>
<tr>
<td>04CUZZ</td>
<td>Extirpation of matter from left peroneal artery, percutaneous approach.</td>
</tr>
<tr>
<td>05C7ZZ</td>
<td>Extirpation of matter from right axillary vein, percutaneous approach.</td>
</tr>
<tr>
<td>05C8ZZ</td>
<td>Extirpation of matter from left axillary vein, percutaneous approach.</td>
</tr>
<tr>
<td>05C9ZZ</td>
<td>Extirpation of matter from right brachial vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CAZZ</td>
<td>Extirpation of matter from left brachial vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CBZZ</td>
<td>Extirpation of matter from right basilic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CCZZ</td>
<td>Extirpation of matter from left basilic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CDZZ</td>
<td>Extirpation of matter from right cephalic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CFZZ</td>
<td>Extirpation of matter from left cephalic vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CGZZ</td>
<td>Extirpation of matter from right hand vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CHZZ</td>
<td>Extirpation of matter from left hand vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CLZZ</td>
<td>Extirpation of matter from intracranial vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CMZZ</td>
<td>Extirpation of matter from right internal jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CNZZ</td>
<td>Extirpation of matter from left internal jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CPZZ</td>
<td>Extirpation of matter from right external jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CQZZ</td>
<td>Extirpation of matter from left external jugular vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CRZZ</td>
<td>Extirpation of matter from right vertebral vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CSZZ</td>
<td>Extirpation of matter from left vertebral vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CTZZ</td>
<td>Extirpation of matter from right face vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CVZZ</td>
<td>Extirpation of matter from left face vein, percutaneous approach.</td>
</tr>
<tr>
<td>05CYZZ</td>
<td>Extirpation of matter from upper vein, percutaneous approach.</td>
</tr>
<tr>
<td>06C3ZZ</td>
<td>Extirpation of matter from esophageal vein, percutaneous approach.</td>
</tr>
</tbody>
</table>

One commenter suggested adding two additional procedure codes describing endovascular thrombectomy of the lower limbs [ICD–10–PCS codes 06CV3Z (Extirpation of matter from left foot vein, percutaneous approach) and 06CY3Z (Extirpation of matter from lower vein, percutaneous approach)] to the list of procedure codes to be moved to MS–DRGs 270, 271 and 272. Our clinical advisors reviewed and also agree with removing these 34 non-lower limb procedure codes from the proposed list of codes to be reassigned to MS–DRGs 270, 271 and 272. These 34 non-lower limb procedure codes will remain assigned to MS–DRGs 252, 253, and 254 (Other vascular procedures with MCC, with CC, and without CC/MCC, respectively) for FY 2017.

After consideration of the public comments we received, we are finalizing our proposal with these modifications. We are finalizing the assignment of the ICD–10–PCS procedure codes describing endovascular thrombectomy of the lower limbs listed in the following table to ICD–10 Version 34 MS–DRGs 270, 271 and 272 for FY 2017 (which reflects the removal of the 34 proposed procedure codes and the addition of the 2 procedure codes discussed in our response above).
ICD–10–PCS Procedure Codes Describing Procedures Involving Pacemakers

<table>
<thead>
<tr>
<th>Procedure code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0H604Z ......</td>
<td>Insertion of pacemaker, single chamber into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>J0H605Z ......</td>
<td>Insertion of pacemaker, single chamber rate responsive into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>J0H606Z ......</td>
<td>Insertion of pacemaker, dual chamber into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
</tbody>
</table>

ICD–10–PCS Procedure Codes Describing Procedures Involving ICDs

<table>
<thead>
<tr>
<th>Procedure code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02H40JZ ......</td>
<td>Insertion of pacemaker lead into coronary vein, open approach.</td>
</tr>
<tr>
<td>02H40MZ ......</td>
<td>Insertion of cardiac lead into coronary vein, open approach.</td>
</tr>
<tr>
<td>02H43JZ ......</td>
<td>Insertion of pacemaker lead into coronary vein, percutaneous approach.</td>
</tr>
</tbody>
</table>
ICD–10–PCS procedure codes describing procedures involving cardiac pacemaker devices
(any one code reported from this column list)

<table>
<thead>
<tr>
<th>Code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0JH607Z</td>
<td>Insertion of cardiac resynchronization pacemaker pulse generator into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH60PZ</td>
<td>Insertion of cardiac rhythm related device into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH634Z</td>
<td>Insertion of pacemaker, single chamber into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH635Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH636Z</td>
<td>Insertion of pacemaker, dual chamber into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH637Z</td>
<td>Insertion of cardiac resynchronization pacemaker pulse generator into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH63PZ</td>
<td>Insertion of cardiac rhythm related device into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH804Z</td>
<td>Insertion of pacemaker, single chamber into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH805Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH806Z</td>
<td>Insertion of pacemaker, dual chamber into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH807Z</td>
<td>Insertion of cardiac resynchronization pacemaker pulse generator into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH80PZ</td>
<td>Insertion of cardiac rhythm related device into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH834Z</td>
<td>Insertion of pacemaker, single chamber into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH835Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH836Z</td>
<td>Insertion of pacemaker, dual chamber into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH837Z</td>
<td>Insertion of cardiac resynchronization pacemaker pulse generator into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH83PZ</td>
<td>Insertion of cardiac rhythm related device into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
</tbody>
</table>

ICD–10–PCS procedure codes describing procedures involving cardiac pacemaker leads
(any one code reported from this column list)

<table>
<thead>
<tr>
<th>Code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02H43MZ</td>
<td>Insertion of pacemaker lead into coronary vein, percutaneous approach.</td>
</tr>
<tr>
<td>02H44JZ</td>
<td>Insertion of pacemaker lead into coronary vein, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H44MZ</td>
<td>Insertion of pacemaker lead into coronary vein, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H60JZ</td>
<td>Insertion of pacemaker lead into right atrium, open approach.</td>
</tr>
<tr>
<td>02H60MZ</td>
<td>Insertion of pacemaker lead into right atrium, open approach.</td>
</tr>
<tr>
<td>02H63JZ</td>
<td>Insertion of pacemaker lead into right atrium, percutaneous approach.</td>
</tr>
<tr>
<td>02H63MZ</td>
<td>Insertion of pacemaker lead into right atrium, percutaneous approach.</td>
</tr>
<tr>
<td>02H64JZ</td>
<td>Insertion of pacemaker lead into right atrium, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H64MZ</td>
<td>Insertion of pacemaker lead into right atrium, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H70JZ</td>
<td>Insertion of pacemaker lead into left atrium, open approach.</td>
</tr>
<tr>
<td>02H70MZ</td>
<td>Insertion of pacemaker lead into left atrium, open approach.</td>
</tr>
<tr>
<td>02H73JZ</td>
<td>Insertion of pacemaker lead into left atrium, percutaneous approach.</td>
</tr>
<tr>
<td>02H73MZ</td>
<td>Insertion of pacemaker lead into left atrium, percutaneous approach.</td>
</tr>
<tr>
<td>02H74JZ</td>
<td>Insertion of pacemaker lead into left atrium, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H74MZ</td>
<td>Insertion of pacemaker lead into left atrium, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02HK0JZ</td>
<td>Insertion of pacemaker lead into right ventricle, open approach.</td>
</tr>
<tr>
<td>02HK0MZ</td>
<td>Insertion of cardiac lead into right ventricle, open approach.</td>
</tr>
<tr>
<td>02HK3JZ</td>
<td>Insertion of cardiac lead into right ventricle, percutaneous approach.</td>
</tr>
<tr>
<td>02HK3MZ</td>
<td>Insertion of cardiac lead into right ventricle, percutaneous approach.</td>
</tr>
<tr>
<td>02HK4JZ</td>
<td>Insertion of pacemaker lead into right ventricle, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02HK4MZ</td>
<td>Insertion of cardiac lead into right ventricle, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02HL0JZ</td>
<td>Insertion of pacemaker lead into left ventricle, open approach.</td>
</tr>
<tr>
<td>02HL0MZ</td>
<td>Insertion of cardiac lead into left ventricle, open approach.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal to modify the MS–DRG logic for MS–DRGs 242, 243, and 244 to establish that cases reporting one ICD–10–PCS code from the list of procedure codes describing procedures involving pacemaker devices and one ICD–10–PCS code from the list of procedure codes describing procedures involving pacemaker leads in combination with one another would qualify the case for assignment to MS–DRGs 242, 243, and 244.

Comment: Commenters supported the proposed updates for MS–DRGs 242, 243, and 244. The commenters stated that the proposed logic is simpler than the prior logic. One commenter stated that the proposal was logical and less complicated and appeared to be able to correctly capture procedures involving pacemaker devices. Several commenters recommended that CMS continue to monitor the impact of this change in future years to determine whether further modifications will be necessary.

Response: We appreciate the commenters’ support for our proposed updates to MS–DRGs 242, 243, and 244. We agree that this is a simpler approach to the MS–DRG GROUPER logic. We will continue to monitor this and other related MS–DRGs as we receive ICD–10 claims data.

After consideration of the public comments we received, we are finalizing our proposal to modify the MS–DRG logic for MS–DRGs 242, 243, and 244 to establish that cases reporting one ICD–10–PCS code from the list of procedure codes describing procedures involving pacemaker devices and one ICD–10–PCS code from the list of procedure codes describing procedures involving pacemaker leads in combination with one another will qualify the case for assignment to MS–DRGs 242, 243, and 244.

We also examined our GROUPER logic for MS–DRGs 258 and 259 (Cardiac Pacemaker Device Replacement with and without MCC, respectively). Assignments of cases to these MS–DRGs also include qualifying ICD–10–PCS procedure code combinations describing procedures that involve the removal of pacemaker devices and the insertion of new devices. We believe that this logic may also be overly complex. Moreover, we believe that a more simplified approach would be to compile a list of all ICD–10–PCS procedure codes describing procedures involving cardiac pacemaker device insertions. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24983 through 24984), we proposed this approach for FY 2017. Under the proposed approach, if one of the procedure codes describing procedures involving pacemaker device insertions is reported, and there are no other procedure codes describing procedures involving the insertion of a pacemaker lead reported in combination with one of these procedures, the case would be assigned to MS–DRG 258 and 259. We included in the proposed rule the following listing of ICD–10–PCS procedure codes describing procedures involving pacemaker device insertions that would be assigned to MS–DRG 258 and 259.

PROFILES CODES DESCRIBING PROCEDURES INVOLVING CARDIAC PACEMAKER DEVICE INSERTIONS REPORTED WITHOUT ANY OTHER PACEMAKER DEVICE PROCEDURE CODE PROPOSED TO BE ASSIGNED TO ICD–10 MS–DRGS 258 AND 259 FOR FY 2017

<table>
<thead>
<tr>
<th>Procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0JH604Z ..........</td>
<td>Insertion of pacemaker, single chamber into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH605Z ..........</td>
<td>Insertion of pacemaker, single chamber rate responsive into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH606Z ..........</td>
<td>Insertion of pacemaker, dual chamber into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH607Z ..........</td>
<td>Insertion of cardiac resynchronization pacemaker pulse generator into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH60PZ ..........</td>
<td>Insertion of cardiac rhythm related device into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal to modify the GROUPER logic for MS–DRGs 258 and 259 to establish that a case reporting one procedure code from the proposed rule list of ICD–10–PCS procedure codes describing procedures involving pacemaker device insertions without any other procedure codes describing procedures involving pacemaker leads reported would be assigned to MS–DRGs 258 and 259. The commenters stated that the proposed updates appeared to be logical and less complicated.

Response: We appreciate the commenters’ support for our proposed updates to MS–DRGs 258 and 259. We agree this approach is logical and less complicated.

After consideration of the public comments we received, we are finalizing our proposal to modify the MS–DRG logic for MS–DRGs 258 and 259 (Cardiac Pacemaker Device Replacement with and without MCC, respectively) to establish that a case reporting one ICD–10–PCS procedure code describing procedures involving pacemaker device insertions without any other procedure codes describing procedures involving pacemaker leads reported is assigned to MS–DRGs 258 and 259 for FY 2017. We are finalizing the table above (which was included in the proposed rule) that lists the ICD–10–PCS procedure codes describing procedures involving pacemaker device insertions without any other procedure codes describing procedures involving pacemaker leads reported that are assigned to MS–DRGs 258 and 259 for FY 2017.

We also point out that the ICD–10–PCS pacemaker codes listed in the following table are classified as non-operating room (non-O.R.) codes within the MS–DRGs. The GROUPER logic will continue to classify these codes as non-O.R. codes. However, a case reporting one of these non-O.R. procedure codes describing procedures involving pacemaker device insertions within MS–DRGs 258 and 259 in our final policy.

<table>
<thead>
<tr>
<th>ICD–10–PCS code (non–O.R.)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0JH604Z</td>
<td>Insertion of pacemaker, single chamber into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH605Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH606Z</td>
<td>Insertion of pacemaker, dual chamber into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH634Z</td>
<td>Insertion of pacemaker, single chamber into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH635Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH636Z</td>
<td>Insertion of pacemaker, dual chamber into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH637Z</td>
<td>Insertion of cardiac resynchronization pacemaker pulse generator into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH804Z</td>
<td>Insertion of pacemaker, single chamber into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH805Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH806Z</td>
<td>Insertion of pacemaker, dual chamber into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH834Z</td>
<td>Insertion of pacemaker, single chamber into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH835Z</td>
<td>Insertion of pacemaker, single chamber rate responsive into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH836Z</td>
<td>Insertion of pacemaker, dual chamber into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
</tbody>
</table>
We also examined our GROUPER logic for MS–DRGs 260, 261, and 262 (Cardiac Pacemaker Revision Except Device with MCC, with CC, and without CC/MCC, respectively). Cases assigned to MS–DRGs 260, 261, and 262 also include lists of procedure code combinations describing procedures involving the removal of pacemaker leads and the insertion of new leads, in addition to lists of single procedure codes describing procedures involving the insertion of pacemaker leads, removal of devices, and revision of devices. We stated in the proposed rule that we believe that this logic may also be overly complex. Moreover, we believe that a more simplified approach would be to provide a single list of procedure codes describing procedures involving cardiac pacemaker lead insertions and related procedures involving device insertions that would be assigned to MS–DRGs 260, 261, and 262. If one of these procedure codes describing procedures involving the insertion of pacemaker leads is reported, and there are no other procedure codes describing procedures involving the insertion of a device reported, the case would be assigned to MS–DRGs 260, 261, and 262. In the FY 2017 IPPS/LTCIP rule (81 FR 24984 through 24985), we proposed that the list of ICD–10–PCS procedure codes describing procedures involving pacemaker lead insertion, removal, or revisions and insertion of hemodynamic devices in a table included in the proposed rule (81 FR 24984 through 24985) would be assigned to MS–DRGs 260, 261, and 262. We simply proposed to use a single list of ICD–10–PCS procedure codes to determine the MS–DRG assignment.

We invited public comments on our proposal to modify the GROUPER logic for MS–DRGs 260, 261, and 262 so that cases reporting any one of the ICD–10–PCS procedure codes describing procedures involving pacemakers and related procedures and associated devices listed in the table in the proposed rule would be assigned to MS–DRGs 260, 261, and 262.

**Comment:** Commenters supported the proposal to modify the GROUPER logic for MS–DRGs 260, 261, and 262 so that cases reporting any one of the ICD–10–PCS procedure codes describing procedures involving pacemakers and related procedures and associated devices listed in the table in the proposed rule would be assigned to MS–DRGs 260, 261, and 262. The commenters stated that the proposed updates were logical and less complicated and appeared to be able to correctly capture cardiac pacemaker revisions. However, several of the commenters supporting the proposal pointed out that there were errors in the code titles for codes included in the table labeled “List of Procedure Codes Proposed to be Assigned to MS–DRGs 260, 261, and 262” in the FY 2017 IPPS/LTCIP proposed rule (81 FR 24984 through 24985). The commenters stated that the table included errors such as referring to a “pacemaker” lead instead of a “cardiac” lead in code 02H60MZ (Insertion of Cardiac Lead into Right Atrium, Percutaneous Approach). The commenters recommended that CMS correct the code titles to align with the official ICD–10–PCS code titles.

Response: We appreciate the commenter’s support for our proposal. In addition, we reviewed the list of codes in the table included in the proposed rule and agree that there were errors in some of the code titles (ICD–10–PCS codes 02H60MZ through 02HN4MZ) in that table. We have corrected these title errors and are finalizing a corrected table below. After consideration of the public comments we received, we are finalizing our proposal to modify the GROUPER logic for MS–DRGs 260, 261, and 262 so that cases reporting any one of the ICD–10–PCS procedure codes describing procedures involving pacemakers and related procedures and associated devices listed in the corrected table below are assigned to MS DRGs 260, 261, and 262.

**LIST OF PROCEDURE CODES ASSIGNED TO MS–DRGs 260, 261, AND 262**

<table>
<thead>
<tr>
<th>Procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02H40JZ ..........</td>
<td>Insertion of pacemaker lead into coronary vein, open approach.</td>
</tr>
<tr>
<td>02H40MZ ..........</td>
<td>Insertion of cardiac lead into coronary vein, open approach.</td>
</tr>
<tr>
<td>02H43JZ ..........</td>
<td>Insertion of pacemaker lead into coronary vein, percutaneous approach.</td>
</tr>
<tr>
<td>02H43MZ ..........</td>
<td>Insertion of cardiac lead into coronary vein, percutaneous approach.</td>
</tr>
<tr>
<td>02H44JZ ..........</td>
<td>Insertion of pacemaker lead into coronary vein, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H44MZ ..........</td>
<td>Insertion of cardiac lead into coronary vein, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02H60JZ ..........</td>
<td>Insertion of Cardiac Lead into Right Atrium, Open Approach.</td>
</tr>
<tr>
<td>02H60MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Atrium, Percutaneous Approach.</td>
</tr>
<tr>
<td>02H63JZ ..........</td>
<td>Insertion of Cardiac Lead into Right Atrium, Percutaneous Approach.</td>
</tr>
<tr>
<td>02H63MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Atrium, Percutaneous Approach.</td>
</tr>
<tr>
<td>02H64JZ ..........</td>
<td>Insertion of Cardiac Lead into Right Atrium, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H64MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Atrium, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H70JZ ..........</td>
<td>Insertion of Pacemaker Lead into Left Atrium, Open Approach.</td>
</tr>
<tr>
<td>02H70MZ ..........</td>
<td>Insertion of Cardiac Lead into Left Atrium, Open Approach.</td>
</tr>
<tr>
<td>02H73JZ ..........</td>
<td>Insertion of Pacemaker Lead into Left Atrium, Percutaneous Approach.</td>
</tr>
<tr>
<td>02H73MZ ..........</td>
<td>Insertion of Cardiac Lead into Left Atrium, Percutaneous Approach.</td>
</tr>
<tr>
<td>02H74JZ ..........</td>
<td>Insertion of Pacemaker Lead into Left Atrium, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H74MZ ..........</td>
<td>Insertion of Cardiac Lead into Left Atrium, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H00JZ ..........</td>
<td>Insertion of Pressure Sensor Monitoring Device into Right Ventricle, Open Approach.</td>
</tr>
<tr>
<td>02H00KZ ..........</td>
<td>Insertion of Monitoring Device into Right Ventricle, Open Approach.</td>
</tr>
<tr>
<td>02H02JZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Ventricle, Open Approach.</td>
</tr>
<tr>
<td>02H02KZ ..........</td>
<td>Insertion of Cardiac Lead into Right Ventricle, Percutaneous Approach.</td>
</tr>
<tr>
<td>02H02MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H04JZ ..........</td>
<td>Insertion of Pressure Sensor Monitoring Device into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H04KZ ..........</td>
<td>Insertion of Monitoring Device into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H04MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H06JZ ..........</td>
<td>Insertion of Pressure Sensor Monitoring Device into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H06KZ ..........</td>
<td>Insertion of Monitoring Device into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H06MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H08JZ ..........</td>
<td>Insertion of Pressure Sensor Monitoring Device into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H08KZ ..........</td>
<td>Insertion of Monitoring Device into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02H08MZ ..........</td>
<td>Insertion of Pacemaker Lead into Right Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
</tbody>
</table>
create a new MS–DRG or to reassign the July 1, 2013 deadline. Further due to lack of FDA approval by the MitraClip valve repair with implant procedures. We refer readers to detailed discussions of the MitraClip® System (hereafter referred to as MitraClip®) for transcatheter mitral valve repair with implant procedures. We refer readers to detailed discussions of the MitraClip® System (hereafter referred to as MitraClip®) for transcatheter mitral valve repair in previous rulemakings, including the FY 2012 IPPS/LTCH PPS proposed rule (76 FR 25822) and final rule (76 FR 51528 through 51529) and the FY 2013 IPPS/LTCH PPS proposed rule (77 FR 27902 through 27903) and final rule (77 FR 53308 through 53310), in response to requests for MS–DRG reclassification, as well as the FY 2014 IPPS/LTCH PPS proposed rule (78 FR 27547 through 27552), under the new technology add-on payment policy. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50575), the application for a new technology add-on payment for MitraClip® was unable to be considered further due to lack of FDA approval by the July 1, 2013 deadline. In the FY 2015 IPPS/LTCH PPS final rule, we finalized our proposal to not create a new MS–DRG or to reassign cases reporting procedures involving the MitraClip® to another MS–DRG (79 FR 49890 through 49892). Under a separate process, the request for a new technology add-on payment for the MitraClip® System was approved (79 FR 49941 through 49946). As discussed in section II.1.4.e. of the preamble of the proposed rule and this final rule, we proposed to discontinue the new technology add-on payment for MitraClip® for FY 2017 and are finalizing our proposal in this final rule.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49371), we finalized a modification to the MS–DRGs to which the procedure involving the MitraClip® System was assigned. For the ICD–10 based MS–DRGs to fully replicate the ICD–9–CM based MS–DRGs, ICD–10–PCS code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach), which identifies the use of the MitraClip® technology and is the ICD–10–PCS code translation for ICD–9–CM procedure code 35.97 (Percutaneous mitral valve repair with implant), was assigned to new MS–DRGs 273 and 274 (Percutaneous Intracardiac Procedures with and without MCC, respectively) and continued to be assigned to MS–DRGs 231 and 232 (Coronary Bypass with PTCA with MCC and without MCC, respectively). According to the requestor, there are substantial clinical and resource differences between the transcatheter mitral valve repair procedure and other procedures currently grouping to MS–DRGs 273 and 274, which are the focus of the request.

The requestor submitted three options for CMS to consider for FY 2017. The first option was to create a new MS–DRG for endovascular cardiac valve repair with implant; the second option was to reassign cases for the MitraClip® implant from MS–DRGs 273 and 274 to MS–DRGs 266 and 267 (Endovascular Cardiac Valve Replacement with and without MCC, respectively); and the third option was to reassign cases involving the MitraClip® system to another higher paying MS–DRG.

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule, we analyzed claims data from the December 2015 update of the FY 2015 MedPAR file on reported cases of percutaneous mitral valve repair with implant (ICD–9–CM procedure code 35.97) in MS–DRGs 273 and 274. Our findings are shown in the table below.

<table>
<thead>
<tr>
<th>Procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02HL0MZ</td>
<td>Insertion of Cardiac Lead into Left Ventricle, Open Approach.</td>
</tr>
<tr>
<td>02HL3JZ</td>
<td>Insertion of Pacemaker Lead into Left Ventricle, Percutaneous Approach.</td>
</tr>
<tr>
<td>02HL3MZ</td>
<td>Insertion of Cardiac Lead into Left Ventricle, Percutaneous Approach.</td>
</tr>
<tr>
<td>02HL4JZ</td>
<td>Insertion of Pacemaker Lead into Left Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02HL4MZ</td>
<td>Insertion of Cardiac Lead into Left Ventricle, Percutaneous Endoscopic Approach.</td>
</tr>
<tr>
<td>02HN0JZ</td>
<td>Insertion of pacemaker lead into pericardium, open approach.</td>
</tr>
<tr>
<td>02HN3JZ</td>
<td>Insertion of cardiac lead into pericardium, open approach.</td>
</tr>
<tr>
<td>02HN3MZ</td>
<td>Insertion of pacemaker lead into pericardium, percutaneous approach.</td>
</tr>
<tr>
<td>02HN4JZ</td>
<td>Insertion of cardiac lead into pericardium, percutaneous approach.</td>
</tr>
<tr>
<td>02HN4MZ</td>
<td>Insertion of pacemaker lead into pericardium, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02PA0MZ</td>
<td>Insertion of cardiac lead into pericardium, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02PA3MZ</td>
<td>Removal of cardiac lead from heart, open approach.</td>
</tr>
<tr>
<td>02PA4MZ</td>
<td>Removal of cardiac lead from heart, percutaneous approach.</td>
</tr>
<tr>
<td>02PA4MZ</td>
<td>Removal of cardiac lead from heart, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02WA0MZ</td>
<td>Revision of cardiac lead in heart, open approach.</td>
</tr>
<tr>
<td>02WA3MZ</td>
<td>Revision of cardiac lead in heart, percutaneous approach.</td>
</tr>
<tr>
<td>02WA4MZ</td>
<td>Revision of cardiac lead in heart, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0JH602Z</td>
<td>Insertion of hemodynamic monitoring device into chest subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH630Z</td>
<td>Insertion of hemodynamic monitoring device into chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JH802Z</td>
<td>Insertion of hemodynamic monitoring device into abdomen subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JH830Z</td>
<td>Insertion of hemodynamic monitoring device into abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JPT0PZ</td>
<td>Removal of cardiac rhythm related device from trunk subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JPT3PZ</td>
<td>Removal of cardiac rhythm related device from trunk subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JW0PZ</td>
<td>Revision of cardiac rhythm related device in trunk subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JW3PZ</td>
<td>Revision of cardiac rhythm related device in trunk subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
</tbody>
</table>
As shown in the table, the total number of cases reported in MS–DRG 273 was 6,620 and had an average length of stay of 8.01 days and average costs of $27,625. The number of cases reporting the ICD–9–CM procedure code 35.97 in MS–DRG 273 totaled 457 and had an average length of stay of 7.57 days and average costs of $50,560. For MS–DRG 274, there were a total of 14,220 cases with an average length of stay of 3.46 days and average costs of $19,316. There were a total of 693 cases in MS–DRG 274 that reported procedure code 35.97; these cases had an average length of stay of 2.67 days and average costs of $37,686. We recognize that the cases reporting procedure code 35.97 had a shorter length of stay and higher average costs in comparison to all the cases within MS–DRGs 273 and 274.

As stated above, the first option of the requestor was that we create a new MS–DRG for endovascular cardiac valve repair with implant procedures for all cardiac valve repairs. We reviewed the following list of ICD–10–PCS procedure codes that the requester submitted to comprise this proposed new MS–DRG.

<table>
<thead>
<tr>
<th>ICD–10–PCS code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02UF37Z</td>
<td>Supplement aortic valve with autologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UF38Z</td>
<td>Supplement aortic valve with zooplastic tissue, percutaneous approach.</td>
</tr>
<tr>
<td>02UF3JZ</td>
<td>Supplement aortic valve with synthetic substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UG3KZ</td>
<td>Supplement mitral valve with nonautologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UG37Z</td>
<td>Supplement mitral valve with autologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UG38Z</td>
<td>Supplement mitral valve with zooplastic tissue, percutaneous approach.</td>
</tr>
<tr>
<td>02UG3JZ</td>
<td>Supplement mitral valve with synthetic substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UG3KZ</td>
<td>Supplement mitral valve with nonautologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UH37Z</td>
<td>Supplement pulmonary valve with autologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UH38Z</td>
<td>Supplement pulmonary valve with zooplastic tissue, percutaneous approach.</td>
</tr>
<tr>
<td>02UH3JZ</td>
<td>Supplement pulmonary valve with synthetic substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UH3KZ</td>
<td>Supplement pulmonary valve with nonautologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UJ37Z</td>
<td>Supplement tricuspid valve with autologous tissue substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UJ38Z</td>
<td>Supplement tricuspid valve with zooplastic tissue, percutaneous approach.</td>
</tr>
<tr>
<td>02UJ3JZ</td>
<td>Supplement tricuspid valve with synthetic substitute, percutaneous approach.</td>
</tr>
<tr>
<td>02UJ3KZ</td>
<td>Supplement tricuspid valve with nonautologous tissue substitute, percutaneous approach.</td>
</tr>
</tbody>
</table>

The above list of ICD–10–PCS procedure codes are currently assigned to MS–DRGs 216 through 221 (Cardiac Valve and Other Major Cardiovascular Procedures with and without Cardiac Catheterization with and without CC/MCC, respectively), with the exception of procedure code 02UG3JZ, which is assigned to MS–DRGs 273 and 274, as noted earlier in this section.

All 16 of the ICD–10–PCS procedure codes submitted by the requestor are comparable translations of ICD–9–CM procedure code 35.33 (Annuloplasty), which also grouped to MS–DRGs 216 through 221. However, ICD–10–PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach) is the comparable translation for both ICD–9–CM procedure code 35.33 and ICD–9–CM procedure code 35.97 (Percutaneous mitral valve repair with implant), which group to MS–DRGs 273 and 274 as mentioned previously.

Upon review of the 16 ICD–10–PCS procedure codes submitted for consideration by the requestor, we determined that we could not propose the suggestion of a new MS–DRG because the resulting ICD–10 MS–DRG logic would not be an accurate replication of the ICD–9–CM based MS–DRG logic. Specifically, it is not possible to replicate reassigning the percutaneous annuloplasty codes from ICD–9–CM based MS–DRGs 216 through 221 to a new MS–DRG because we cannot isolate those cases from procedure code 35.33. Under ICD–9–CM, procedure code 35.33 does not differentiate the specific type of approach used to perform the procedure. This is in contrast to the 60 comparable ICD–10 code translations that do differentiate among various approaches (open, percutaneous, and percutaneous endoscopic).

As stated previously, if the ICD–9–CM and ICD–10 versions of the MS–DRGs cease to be replications of each other, the relative payment weights (computed using the ICD–9–CM based MS–DRGs) would be inconsistent with the ICD–10 MS–DRG assignment, which may cause unintended payment redistribution. Therefore, we did not propose to create a new MS–DRG for transcatheter mitral valve repair with implant procedures for FY 2017.

The second option in the request was to evaluate reassigning cases involving the MitraClip® technology to MS–DRGs 266 and 267. This option is not supported for the same reasons provided in previous rulemaking regarding differences between valve replacements and valve repairs. Our clinical advisors did not believe that these procedures are clinically coherent or similar in terms of resource consumption because the MitraClip® technology is utilized for a percutaneous mitral valve repair, while the other technologies assigned to MS–DRGs 266 and 267 are utilized for transcatheter/endovascular cardiac valve replacements. In addition, if cases involving the MitraClip® were
reassigned to MS–DRGs 266 and 267, they would be overpaid by approximately $10,000 as shown in the table below. Our clinical advisors agreed that we should not propose to reassign endovascular cardiac valve repair procedures to the endovascular cardiac valve replacement MS–DRGs.

**ENDOVASCULAR CARDIAC VALVE REPLACEMENT WITH AND WITHOUT MCC**

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 266—All cases</td>
<td>7,436</td>
<td>8.54</td>
<td>$59,675</td>
</tr>
<tr>
<td>MS–DRG 267—All cases</td>
<td>8,480</td>
<td>4.45</td>
<td>47,013</td>
</tr>
</tbody>
</table>

Next, for the proposed rule, we analyzed claims data from the December 2015 update of the FY 2015 MedPAR file relating to the possible reassignment of cases involving the MitraClip® (identified by ICD–9–CM procedure code 35.97) to MS–DRGs 228, 229, and 230 (Other Cardiothoracic Procedures with MCC, with CC, and without CC/MCC, respectively). However, as shown in the findings in the table below, the claims data did not support this option under the current 3-way severity level split. That is, the data findings based on reassignment of MitraClip® cases (ICD–9–CM procedure code 35.97) to MS–DRGs 228, 229, and 230 did not support the required criterion that there be at least a $2,000 difference between subgroups. A reassignment would not meet the requirement for the “with CC” and “without CC/MCC” subgroups ($34,461 minus $33,216 = $1,245).

**OTHER CARDIOTHORACIC PROCEDURES (WITH PROCEDURE CODE 35.97)**

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 228—with MCC</td>
<td>1,966</td>
<td>11.53</td>
<td>$51,634</td>
</tr>
<tr>
<td>MS–DRG 229—with CC</td>
<td>2,318</td>
<td>6.28</td>
<td>34,461</td>
</tr>
<tr>
<td>MS–DRG 230—without CC/MCC</td>
<td>709</td>
<td>3.76</td>
<td>33,216</td>
</tr>
</tbody>
</table>

We then performed additional analysis consisting of the base DRG report for MS–DRGs 228, 229 and 230. As shown in the table below, the average costs between the “with CC” and the “without CC/MCC” subgroups no longer meet the criterion that there be at least a 20-percent difference in average costs between subgroups. These data findings support collapsing MS–DRGs 228, 229, and 230 from a 3-way severity level split into a 2-way severity level split (with MCC and without MCC) based on 2 years (FY 2014 and FY 2015) of MedPAR data. This option would involve the deletion of an MS–DRG.

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases FY 2015</th>
<th>Average length of stay FY 2015</th>
<th>Average costs FY 2015</th>
<th>Number of cases FY 2014</th>
<th>Average length of stay FY 2014</th>
<th>Average costs FY 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 228—with MCC</td>
<td>1,509</td>
<td>12.73</td>
<td>$51,960</td>
<td>1,486</td>
<td>12.75</td>
<td>$50,688</td>
</tr>
<tr>
<td>MS–DRG 229—with CC</td>
<td>1,835</td>
<td>7.16</td>
<td>33,786</td>
<td>1,900</td>
<td>7.46</td>
<td>33,277</td>
</tr>
<tr>
<td>MS–DRG 230—without CC/MCC</td>
<td>499</td>
<td>4.52</td>
<td>30,697</td>
<td>443</td>
<td>4.84</td>
<td>31,053</td>
</tr>
</tbody>
</table>

In the additional analysis, we evaluated if reassignment of cases reporting ICD–9–CM procedure code 35.97 to this proposed 2-way severity split was supported. We confirmed that the reassignment of ICD–9–CM procedure code 35.97 could be replicated under the ICD–9 MS–DRGs. We believe that deleting MS–DRG 230, revising MS–DRG 229, and reassigning cases with procedure code 35.97 from MS–DRGs 273 and 274 to this new structure would reflect these procedures more accurately in the ICD–10 MS–DRGs. Our clinical advisors agreed with a proposal to delete MS–DRG 230 and reassign cases involving percutaneous mitral valve repair with implant (MitraClip®) to MS–DRG 228 and revised MS–DRG 229. We believe that this approach would maintain clinical coherence for these MS–DRGs and reflect more appropriate payment for procedures involving percutaneous mitral valve repair. The proposed revisions to the MS–DRGs, which include the MitraClip® cases, are shown in the table below.

<table>
<thead>
<tr>
<th>Proposed revised MS–DRGs</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 228—with MCC</td>
<td>1,966</td>
<td>11.53</td>
<td>$51,634</td>
</tr>
<tr>
<td>MS–DRG 229—with CC</td>
<td>3,027</td>
<td>5.69</td>
<td>34,169</td>
</tr>
</tbody>
</table>

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24987 through 24988), for FY 2017, we proposed to collapse MS–DRGs 228, 229, and 230 from three severity levels to two severity levels by deleting MS–DRG 230 and revising MS–DRG 229. We also proposed to reassign ICD–9–CM procedure code 35.97 and the cases...
reporting ICD–10–PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach) from MS–DRGs 273 and 274 to MS–DRG 228 and proposed revised MS–DRG 229. The title of MS–DRG 229 would be modified as follows to reflect the “without MCC” designation. The title of proposed revised MS–DRG 229 would be “Other Cardiothoracic Procedures without MCC”. The title for MS–DRG 228 would remain the same: MS–DRG 228 (Other Cardiothoracic Procedures with MCC). We invited public comments on our proposals.

We also noted that, as discussed earlier in this section of the proposed rule and this final rule, in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49371), ICD–10–PCS code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach) was assigned to MS–DRGs 231 and 232 (Coronary Bypass with PTCA with MCC and without MCC, respectively), in addition to new MS–DRGs 273 and 274, to fully replicate the ICD–9–CM based MS–DRG logic for ICD–9–CM procedure code 35.97. We stated that if our proposal in the FY 2017 proposed rule to reassign ICD–9–CM procedure code 02UG3JZ to MS–DRG 228 and proposed revised MS–DRG 229 was finalized in this FY 2017 IPPS/LTCH PPS final rule, it would eliminate the need to continue having ICD–10–PCS code 02UG3JZ and ICD–9–CM code 35.97 group to MS–DRGs 231 and 232. This is due to the fact that, currently, MS–DRGs 228, 229, and 230 are listed higher than MS–DRGs 231 and 232 in the surgical hierarchy, as shown in the ICD–9 and ICD–10 MS–DRGs Definitions Manual Files in Appendix D—MS–DRG Surgical Hierarchy by MDC and MS–DRG, which is available via the Internet on the CMS Web site at:


Therefore, we stated in the proposed rule that if the proposal is finalized for FY 2017, cases reporting ICD–10–PCS procedure code 02UG3JZ will group to MS–DRG 228 and revised MS–DRG 229 versus MS–DRGs 231 and 232 because of the surgical hierarchy GROUPER logic.

As a result, in the FY 2017 IPPS/LTCH PPS proposed rule, we proposed to remove ICD–10–PCS procedure code 02UG3JZ and ICD–9–CM procedure code 35.97 from the PTCA list in MS–DRGs 231 and 232 (Coronary Bypass with PTCA with MCC and without MCC, respectively) for FY 2017 if the proposal to reassign ICD–9–CM procedure code 35.97 and the cases reporting ICD–10–PCS procedure codes 02UG3JZ from MS–DRGs 273 and 274 to MS–DRG 228 and proposed revised MS–DRG 229 is finalized. We invited public comments on our proposals.

Comment: A large number of commenters supported the proposal to reassign ICD–9–CM procedure code 35.97 and ICD–10–PCS procedure code 02UG3JZ, which describe a mitral valve repair procedure involving the MitraClip®, from MS–DRGs 273 and 274 to MS–DRG 228 and proposed revised MS–DRG 229. Commenters stated that patient access to the procedure has been very restricted at their institutions due to the financial hardship that results from the current payment inadequacies. Several commenters noted that mitral valve interventions are an integral part of their organizations structural heart disease programs and stated that, with the expiration of the new technology add-on payment effective September 30, 2016, the insufficient payment amount and ICD–9–CM with patient access would only increase.

Other commenters reported that these high-risk degenerative mitral valve patients have no alternative options, are not surgical candidates for open procedures, are generally older, more complex to treat and require greater resources by a multidisciplinary heart team; therefore, the commenters urged CMS to finalize the proposal. According to the commenters, the procedure is labor and time intensive with a higher complexity than the surgical percutaneous procedures. Commenters also stated the proposed modifications to the MS–DRG structure will enable more patients to have an improved quality of life. These commenters stated that, for the patients who actually receive a mitral valve repair procedure with the MitraClip®, they have witnessed improved clinical outcomes, such as improvements in their NYHA class designation and walk distances. Other commenters described how patients’ families shared the impact of what it meant for their family member to have a new outlook on life after having undergone the procedure. A number of commenters also pointed out the cost savings to Medicare with the procedure, which they stated were evidenced by reduced lengths of stay and decreased heart failure readmissions.

Conversely, a few commenters opposed the proposal to modify the structure of MS–DRGs 228, 229, and 230. These commenters recommended that the only changes made should be for replication of the ICD–9–CM MS–DRG logic. These commenters suggested that, because FY 2016 is the first year of implementation in which CMS will have ICD–10 claims data, CMS allow the data to stabilize prior to evaluating for any proposed changes. The commenters stated that replication is important because both the logic for the proposed MS–DRGs and the data source used to calculate and develop the proposed relative payment weights are based on the same ICD–9–CM MedPAR claims data.

Response: We appreciate the commenters’ support of our proposal. With regard to the commenters who opposed the proposal to modify the structure of MS–DRGs 228, 229, and 230 and recommended that the only changes made should be for replication of the ICD–9–CM MS–DRG logic as noted and illustrated in the tables above, the proposal to revise the structure of MS–DRGs 228, 229, and 230 was based on the analysis of claims data from the December 2015 update of the FY 2015 MedPAR file on reported cases of percutaneous mitral valve repair with implant (ICD–9–CM procedure code 35.97) in the ICD–9 based MS–DRGs 273 and 274. The ICD–9–CM data and our clinical advisors supported the reassignment of ICD–9–CM procedure code 35.97 from ICD–9–CM MS–DRGs 273 and 274 to restructured ICD–9–CM MS–DRGs 228 and 229. Therefore, the proposal for restructuring the ICD–10 MS–DRGs is in fact replicating the ICD–9–CM MS–DRG logic that was finalized. Consistent with how the current FY 2016 relative payment weights are based on the ICD–9–CM diagnosis and procedure codes from the FY 2014 MedPAR data, CMS allow the public for use in analyzing ICD–9–CM data to create relative payment weights using ICD–9–CM data on our CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=ascending.

After consideration of the public comments we received, we are finalizing our proposal to collapse MS–DRGs 228, 229, and 230 from three severity levels to two severity levels by...
deleting MS–DRG 230 and revising MS–DRG 229. We also are finalizing our proposal to reassign ICD–9–CM procedure code 35.97 and the cases reporting ICD–10–PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach) from MS–DRGs 273 and 274 to MS–DRG 228 and revised MS–DRG 229. The title of revised MS–DRG 229 is finalized as follows to reflect the “without MCC” designation, “Other Cardiothoracic Procedures without MCC”. The title for MS–DRG 228 is finalized as “MS–DRG 228 (Other Cardiothoracic Procedures with MCC)”. In addition, we are finalizing our proposal to remove ICD–10–PCS procedure code 02UG3JZ and ICD–9–CM procedure code 35.97 from the PTCA list in MS–DRGs 231 and 232 (Coronary Bypass with PTCA with MCC and without MCC, respectively) for FY 2017. All of these finalized modifications are effective October 1, 2016.

### AICD Generator Procedures

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 245</td>
<td>1,464</td>
<td>5.5</td>
<td>$34,564</td>
</tr>
</tbody>
</table>

We applied the five criteria established in the FY 2008 IPPS final rule (72 FR 47169), as described in section II.F.1.b. of the preamble of the proposed rule and this final rule to determine if it was appropriate to subdivide MS–DRG 245 into severity levels. The table below illustrates our findings.

### AICD Generator Procedures

<table>
<thead>
<tr>
<th>MS–DRG by suggested severity level</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 245—with MCC</td>
<td>449</td>
<td>8.37</td>
<td>$40,175</td>
</tr>
<tr>
<td>MS–DRG 245—with CC</td>
<td>861</td>
<td>4.59</td>
<td>32,518</td>
</tr>
<tr>
<td>MS–DRG 245—without CC/MCC</td>
<td>154</td>
<td>2.86</td>
<td>29,646</td>
</tr>
</tbody>
</table>

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24988 through 24989), based on our analysis of claims data from the December 2015 update of the FY 2015 MedPAR file, the data findings did not support creating new severity levels. The findings showed that the data do not meet the criteria for a 3-way severity level split as the criterion that there be at least a 20-percent difference in average costs between subgroups is not met for the “with CC” and “without CC/MCC” severity levels. We also looked at the prospect of a 2-way severity level split.

### AICD Generator Procedures

<table>
<thead>
<tr>
<th>MS–DRG by suggested severity level</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 245—with MCC</td>
<td>449</td>
<td>8.37</td>
<td>$40,175</td>
</tr>
<tr>
<td>MS–DRG 245—without MCC</td>
<td>1,015</td>
<td>4.33</td>
<td>32,081</td>
</tr>
</tbody>
</table>

The findings did show that the data are close to meeting the criteria for a 2-way severity level split of “with MCC and without MCC.” However, the required criterion that there must be at least 500 cases in the MCC group is not met.

Therefore, for FY 2017, we did not propose to subdivide MS–DRG 245 into severity levels. We invited public comments on our proposal to maintain the current structure for MS–DRG 245.

**Comment:** Commenters supported the proposal not to subdivide MS–DRG 245 into severity levels. One commenter agreed that volumes were not sufficient to justify a three-way split in the AICD generator procedures, but near ed meeting the levels required for a two-way split (with MCC and without MCC). The commenter requested that we examine the issue for a two-way split again next year.

**Response:** We appreciate the commenters’ support. We agree that the criteria were not met to support the subdivision of MS–DRG 245 into severity levels for FY 2017. We will continue to monitor MS–DRG 245 claim data as we analyze issues for the FY 2018 IPPS/LTCH PPS proposed rule.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current structure of MS–DRG 245 (AICD Generator Procedures) for FY 2017.

6. MDC 6 (Diseases and Disorders of the Digestive System): Excision of Ileum

We received a request to analyze an MS–DRG replication issue from the ICD–9–CM based MS–DRGs to the ICD–10 based MS–DRGs for excision procedures performed on the ileum. Under ICD–9–CM, procedure code 45.62 (Other partial resection of small intestine) was assigned to MS–DRGs 329, 330 and 331 (Major Small and Large Bowel Procedures with MCC, with CC, and without CC/MCC, respectively). Under the current ICD–10 MS–DRGs...
Version 33, ICD–10–PCS procedure code 0DBBO2ZZ (Excision of ileum, open approach) is assigned to MS–DRGs 347, 348, and 349 (Anal and Stomal Procedures with MCC, with CC, and without CC/MCC, respectively). The requestor indicated that, despite the variation in terms for “excision” and “resection” between the two code sets, the surgical procedure to remove a portion of the small intestine, whether it is the ileum, duodenum, or jejunum, has not changed and should not result in different MS–DRG assignments when translated from ICD–9–CM to ICD–10.

We agree that this is a replication error. In addition to ICD–10–PCS code 0DBBO2ZZ, we also reviewed the MS–DRG assignments for ICD–10–PCS code 0DBA0ZZ (Excision of jejunum, open approach) and determined the MS–DRG assignment for this code resulted in the same replication error. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24989), we proposed to reassign ICD–10–PCS codes 0DBB0ZZ (Excision of ileum, open approach) and 0DBA0ZZ (Excision of jejunum, open approach) from MS–DRGs 347, 348, and 349 to MS–DRGs 329, 330, and 331 (Major Small and Large Bowel Procedures with MCC, with CC, and without CC/MCC, respectively) effective with the ICD–10 MS–DRGs Version 34 on October 1, 2016.

We invited public comments on our proposal.

Comment: Many commenters supported our proposal to reassign two ICD–10–PCS procedure codes that identify excision procedures performed on the ileum and jejunum. The commenters believed that the proposal was reasonable, given the data, the ICD–10–PCS codes, and the information provided. One commenter recommended that CMS reassign ICD–10–PCS procedure code 0DB90ZZ (Excision of duodenum, open approach) to ICD–10 MS–DRGs 329, 330, and 331, noting that, as stated in the proposed rule, the requester indicated the surgical procedure to remove a portion of the small intestine, whether it is the ileum, duodenum, or jejunum, has not changed and should not result in different MS–DRG assignments when translated from ICD–9–CM to ICD–10.

Response: We appreciate the commenters’ support of our proposal. In response to the commenter’s recommendation that we also reassign ICD–10–PCS procedure code 0DB90ZZ to ICD–10 MS–DRGs 329, 330, and 331, we note that, under ICD–9–CM, procedure code 45.31 (Other local excision of lesion of duodenum) is the comparable translation and was assigned to ICD–9 based MS–DRGs 326, 327, and 328 (Stomach, Esophageal and Duodenal Procedures with MCC, with CC and without CC/MCC, respectively). We did not include ICD–10–PCS procedure code 0DB90ZZ in our proposal because, upon review, we determined that this code is currently assigned to ICD–10 MS–DRGs 326, 327, and 328 (Stomach, Esophageal and Duodenal Procedures with MCC, with CC and without CC/MCC, respectively), and therefore, is accurately replicating the ICD–9 based MS–DRG logic.

After consideration of the public comments we received, we are finalizing our proposal to reassign ICD–10–PCS procedure codes 0DBBO2ZZ (Excision of ileum, open approach) and 0DBA0ZZ (Excision of jejunum, open approach) from MS–DRGs 347, 348, and 349 (Anal and Stomal Procedures with MCC, with CC, and without CC/MCC, respectively) to MS–DRGs 329, 330, and 331 (Major Small and Large Bowel Procedures with MCC, with CC, and without CC/MCC, respectively) effective with the ICD–10 MS–DRGs Version 34 on October 1, 2016.

7. MDC 7 (Diseases and Disorders of the Hepatobiliary System and Pancreas): Bypass Procedures of the Veins

We received a request to assign ICD–10–PCS code 06183DY (Bypass portal vein to lower vein with intraluminal device, percutaneous approach) to MDC 7 (Diseases and Disorders of the Hepatobiliary System and Pancreas) under MS–DRGs 405, 406, and 407 (Pancreas Liver and Shunt Procedures with MCC, with CC, and without CC/MCC, respectively). The requestor described this code as capturing a transjugular intrahepatic portosystem shunt procedure. The requestor stated that, under ICD–9–CM, when a procedure for cirrhosis of the liver was performed, the procedure was assigned to ICD–9–CM code 39.1 (Intra-abdominal venous shunt). The requestor noted that when ICD–9–CM procedure code 39.1 is reported with a principal diagnosis of cirrhosis of the liver, the procedure was assigned to MS–DRG 405, 406, or 407 in the ICD–9–CM MS–DRGs.

Currently, ICD–10–PCS procedure code 06183DY is assigned to only MDC 5 (Diseases and Disorders of the Circulatory System) and MS–DRGs 270, 271, and 272 (Other Major Cardiovascular Procedures with MCC, with CC, and without CC/MCC, respectively) under ICD–10 MS–DRGs Version 33. The requestor stated that ICD–10–PCS procedure code 06183DY should also be assigned to MDC 7 and MS–DRGs 405, 406, and 407 to be consistent with the ICD–9–CM MS–DRGs Version 32.

We analyzed this issue and agreed that the ICD–10 MS–DRGs do not fully replicate the ICD–9–CM MS–DRGs. We agree that ICD–10–PCS procedure code 06183DY should be assigned to MDC 7 and MS–DRGs 405, 406, and 407 to replicate the ICD–9–CM MS–DRGs. Our clinical advisors reviewed this issue and also agreed that ICD–10–PCS procedure code 06183DY should be assigned to MDC 7 and MS–DRGs 405, 406, and 407. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24989), we proposed to assign ICD–10–PCS procedure code 06183DY to MDC 7 and MS–DRGs 405, 406, and 407 for FY 2017.

We invited public comments on our proposal.

Comment: Commenters supported the proposal to assign ICD–10–PCS procedure code 06183DY to MDC 7 under MS–DRGs 405, 406, and 407. One commenter stated that the proposed change to MDC 7 and MS–DRGs 405, 406, and 407 is a more appropriate fit for ICD–10–PCS procedure code 06183DY.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to assign ICD–10–PCS code 06183DY (Bypass portal vein to lower vein with intraluminal device, percutaneous approach) to MDC 7 (Diseases and Disorders of the Hepatobiliary System and Pancreas) under MS–DRGs 405, 406, and 407 (Pancreas Liver and Shunt Procedures with MCC, with CC, and without CC/MCC, respectively). The requestor described this code as capturing a transjugular intrahepatic portosystem shunt procedure. The requestor stated that, under ICD–9–CM, when a procedure for cirrhosis of the liver was performed, the procedure was assigned to ICD–9–CM code 39.1 (Intra-abdominal venous shunt). The requestor noted that when ICD–9–CM procedure code 39.1 is reported with a principal diagnosis of cirrhosis of the liver, the procedure was assigned to MS–DRG 405, 406, or 407 in the ICD–9–CM MS–DRGs.

MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue)

a. Updates to MS–DRGs 469 and 470 (Major Joint Replacement or Reattachment of Lower Extremity With and Without MCC, Respectively)

(1) Total Ankle Replacement (TAR) Procedures

We received a request to create a new MS–DRG for total ankle replacement (TAR) procedures, which are currently assigned to MS–DRGs 469 and 470 (Major Joint Replacement or Reattachment of Lower Extremity With and Without MCC, Respectively). We previously discussed requested changes to the MS–DRG assignment for TAR procedures in the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28013 through 28015) and in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49896 through 49899). For FY 2015, we did not change the MS–DRG assignment for total ankle replacements. The requestor stated that reassigning total ankle replacement procedures from MS–DRGs 469 and 470 to a new MS–DRG would have an important benefit for the new
As the total ankle replacement claims data analysis showed, these procedures represent a small fraction of the total number of cases reported in MS–DRGs 469 and 470. There were 30 total ankle replacement cases reported in MS–DRG 469 and 1,626 total ankle replacement cases in MS–DRG 470, compared to 25,729 total cases reported in MS–DRG 469 and 421,149 total cases reported in MS–DRG 470. The average length of stay for total ankle replacement cases was 5.40 days and average costs for total ankle replacement cases were $34,889 reported in MS–DRG 469, compared to an average length of stay of 6.92 days and average costs of $22,358 for all cases reported in MS–DRG 469. The average length of stay for total ankle replacement cases was 1.94 days and average costs of total ankle replacement cases were $20,019 reported in MS–DRG 470, compared to an average length of stay of 2.92 days and average costs of $14,834 for all cases reported in MS–DRG 470.

Given the low volume of cases, we stated in the proposed rule that we believe these cost data may not be a complete measure of actual differences in inpatient resource utilization for beneficiaries receiving total ankle replacements. In addition, total ankle replacement cases may have been impacted by other factors such as complication or comorbidities. Several expensive cases could impact the average costs for a very small number of patients. The average cost of total ankle replacement cases reported in MS–DRG 469 was $12,531 higher than all cases reported in MS–DRG 469 ($34,889 compared to $22,358 for all reported cases), but there were only 30 cases compared to a total of 25,729 cases reported in MS–DRG 469. The average cost of total ankle replacement cases reported in MS–DRG 470 was $5,185 higher than all cases reported in MS–DRG 470. There were 1,626 total ankle replacement cases out of a total of 421,149 cases reported in MS–DRG 470. The average costs of the total ankle replacement cases were higher than those for all cases reported in MS–DRG 469 and 470. However, some cases have higher and some cases have lower average costs within any MS–DRG. MS–DRGs are groups of clinically similar cases that have similar overall costs. Within a group of cases, one would expect that some cases have costs that are higher than the overall average and some cases have costs that are lower than the overall average.

The data did not support creating a new total ankle replacement MS–DRG for this small number of cases. Also, our clinical advisors pointed out that creating a new MS–DRG for total ankle replacements would result in combining cases reporting an MCC with an average length of stay of 5.40 days and cases not reporting an MCC with an average length of stay of 1.94 days. Our clinical advisors did not recommend the creation of a new MS–DRG for this single procedure with such a small number of cases. They also stated that patients undergoing total ankle replacement have similar clinical features compared to other patients undergoing procedures included in MS–DRGs 469 and 470. Furthermore, we believe that the volume of total ankle replacement procedures performed relative to hip and knee replacement procedures minimizes the benefit that a new MS–DRG would have on the Medicare CJR model. Our clinical advisors determined that the cases involving total ankle replacements are more appropriately assigned to MS–DRGs 469 and 470 with the two severity levels.

Based on the findings from our data analysis and the recommendations from our clinical advisors, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24989 through 24990), we did not propose to create a new MS–DRG for total ankle replacement procedures. We proposed to maintain the current MS–DRG structure for MS–DRGs 469 and 470.

We invited public comments on this proposal.

Comment: Some commenters supported the proposal to maintain the current MS–DRG structure for revision of total ankle replacement procedures within MS–DRGs 469 and 470 and not create a new MS–DRG for total ankle replacements. Several of the commenters stated that the proposal was reasonable, given the data, the ICD–10–PCS codes, and the information provided.

Response: We appreciate the commenters’ support for our proposal.

Comment: Several commenters disagreed with the proposal not to create a new MS–DRG for total ankle replacement procedures and to maintain the current MS–DRG structure for MS–DRGs 469 and 470 for total ankle replacement procedures. The commenters stated that the current MS–DRG assignment for TAR procedures was inadequate to reflect the actual cost and complexity of these procedures. The commenters stated that the combined total ankle replacement cases in MS–DRGs 469 and 470 exceed the minimum number of cases (500) in the criterion which CMS established for consideration of a distinct MS–DRG group. Therefore, the commenters believed that CMS should create a new MS–DRG for total ankle replacements.

The commenters stated that the MS–DRG assignment was impacting Medicare beneficiary access to total ankle replacement as an alternative to an arthrodesis (fusion) of the ankle joint. The commenters further stated that there were significant dissimilarities in the inpatient hospital costs and length of stay, and different postoperative and postdischarge care and rehabilitation protocols for total ankle replacement procedures.
One commenter objected to CMS’ comparison of the volume of total ankle replacement cases to total hip and knee cases within MS–DRG 469 and 470 and the statement that, within the inpatient prospective payment system framework, some cases have higher and some cases have lower average costs within any MS–DRG. The commenter stated that CMS’ statements about possible explanations for the higher costs of total ankle replacement cases within MS–DRGs 469 and 470 does not change the fact that the total ankle replacement cases have higher costs than all cases within MS–DRGs 469 and 470. The commenter stated that total ankle replacement cases have a greater clinical complexity compared to other procedures within MS–DRGs 469 and 470. The commenter stated that a total ankle replacement procedure was a complicated surgery that involved the replacement of the damaged parts of the three bones that make up the ankle joint, as compared to two bones in hip and knee replacement procedures. Furthermore, as the smallest weight-bearing joint in the body, the commenter stated that total ankle replacement demanded a complexity of implant device design, engineering, and manufacture to exacting functional specifications that is vastly different from that of total hip and total knee replacement devices. In addition, the commenter stated that the unique anatomical characteristics and function of the ankle joint requires a specialized surgical skill set, operative technique, and level of operating room resource utilization vastly dissimilar from that of total hip and total ankle replacement procedures.

Another commenter stated that accurate representation of patients within each MS–DRG is an important step for fair payment and analysis. The commenter believed that reassigning fractures and ankle procedures from MS–DRGs 469 and 470 would help to accomplish that purpose. Another commenter asked that CMS reevaluate the appropriate MS–DRG assignment for total ankle replacement procedures once ICD–10 claims data are available.

Response: We disagree with the commenters’ statement that the number of total ankle replacement cases in MS–DRGs 469 and 470 justifies the creation of a new MS–DRG based on the criterion of there being more than 500 cases. The criterion the commenters mentioned is part of criteria established in FY 2008 (72 FR 47169) to determine if the creation of a new CC or MCC subgroup within a base MS–DRG was warranted (which was discussed in the FY 2017 IPPS/LTCH PPS proposed rule [81 FR 24971]), but is not determinative of whether a new MS–DRG should be created.

As stated earlier, the data showed that the average costs of total ankle replacement cases were higher than the average costs for all cases reported in MS–DRG 469 and 470. We found that the average costs of total ankle replacement procedures were higher in MS–DRG 469 ($34,889 compared to $22,358 for all cases) and in MS–DRG 470 ($20,019 compared to $14,834 for all cases). However, there were only 30 total ankle replacement cases in MS–DRG 469 out of 25,729 total cases. There were only 1,626 cases in MS–DRG 470 out of 421,149 cases.

As we explained in the proposed rule, given the low volume of cases, we believe that these cost data may not be a complete measure of actual differences in inpatient resource utilization for beneficiaries receiving total ankle replacements. Several expensive cases could impact the average costs for a very small number of patients. MS–DRGs are groupings of clinically similar cases that have similar overall costs. Within a group of cases, one would expect that some cases have costs that are higher than the overall average and some cases have costs that are lower than the overall average. While the commenters disagreed with this approach to classifying similar procedures within a set of MS–DRGs, our clinical advisors reviewed the procedures assigned within MS–DRGs 469 and 470 and determined that patients undergoing total ankle replacement have similar clinical features compared to other patients undergoing procedures included in MS–DRGs 469 and 470. The clinical differences are not great enough to justify the creation of a new MS–DRG. While the ankle may be the smallest weight-bearing joint in the body and the devices used may be more costly, the joint repairs of the lower extremity are clinically similar. The clinical expertise used by surgeons performing ankle procedures versus the clinical expertise required to perform other lower joint procedures does not justify creating a new MS–DRG. Our clinical advisors determined that the cases involving total ankle replacements are appropriately assigned to MS–DRGs 469 and 470 with the two severity levels.

In response to the commenter’s request that CMS reexamine the appropriate MS–DRG assignment for total ankle replacement procedures once ICD–10 claims data are available, we encourage the public to submit updates to be submitted by December 7 of each year via the new CMS MS–DRG Classification Change Requests Mailbox located at: MSDRGCclassification Change@cms.hhs.gov. Once ICD–10 claims data are received, we will use these data to evaluate MS–DRG assignments.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS–DRG assignment for total ankle replacements in MS–DRGs 469 and 470 and not create a new MS–DRG for total ankle replacements.

(2) Hip Replacement Procedures With Principal Diagnosis of Hip Fracture

We received several requests to remove hip replacement procedures with a principal diagnosis of hip fracture from MS–DRGs 469 and 470 (Major Joint Replacement or Reattachment of Lower Extremity with and without MCC, respectively) and to create a new MS–DRG for assignment of these hip replacement procedures. One requestor suggested that if such a new MS–DRG could not be created, CMS consider reassigning all hip replacement procedures with a principal diagnosis of hip fracture only to MS–DRG 469, even if there were no reported MCC. The requestors stated that hip replacement procedures performed on patients with hip fractures involve a more fragile population of patients than the typical patient population who undergo elective hip or knee replacement and that these more fragile patient cases also are assigned to MS–DRGs 469 and 470. The requestors stated that cases of patients who have hip replacements with hip fractures may have significant comorbidities not present in patients who undergo elective hip replacements. One requestor stated that the absolute number of hospitalizations for hip fractures in the United States is currently more than 350,000 and the number is rising. The requestor stated that 90 percent of hip fractures result from a simple fall and that hip fracture rates increase with age. According to the requestor, the 1-year mortality rate for patients who undergo hip replacement procedures after a hip fracture was approximately 20 percent, and the 3-year mortality rate was up to 50 percent. The requestor also stated that one out of three adults who lived independently before their hip fracture remains in a nursing home for at least a year after the hip fracture. In contrast, the requestor noted that patients under elective hip replacement procedures for arthritis have fewer comorbidities, improved health after the procedure, lower rates of readmission, and less postacute needs. The requestor believed that there are
Many factors that impact the outcome of hip replacements for hip fractures, including patient factors, fracture type, surgeon and hospital factors, treatment decisions, complication rates, and rehabilitation factors/access. The requestor added that, despite the commitment to standardization, the use of protocol-driven care, early surgery (< 24 hours) after surgical optimization, prevention of recurrent fractures, and comanagement with medical/surgical teams, many patients who undergo hip replacement procedures for hip fractures have serious renal, cardiovascular, and liver disease, as well as multiple medical comorbidities. The rates of postoperative infections, readmissions, and postacute care for the patients who undergo hip replacements for hip fractures are higher than for patients who undergo elective hip replacement. Some requestors referenced the Bundled Payments for Care Improvement Initiative (BPCI) and believed that their requested changes to MS–DRGs 469 and 470 would support this effort. The requestors stated that the MS–DRG assignment for the hip replacement procedures with hip fractures has tremendous implications for successful participation in the BPCI because the BPCI’s clinical episodes track to MS–DRG assignment, and the Major Joint Replacement of the Lower Extremity Clinical Episode encompasses procedures assigned to MS–DRGs 469 and 470. Alternatively, the requestors suggested that CMS reassign all cases of hip replacement procedures with a principal diagnosis of hip fracture to MS–DRG 469 to recognize the more significant adverse health profile of these types of cases.

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24990 through 24992), we examined claims data for cases reporting hip replacement procedures for patients admitted with hip fractures under MS–DRGs 469 and 470 in the December 2015 update of the FY 2015 MedPAR file. We used the following list of ICD–9–CM diagnosis codes to identify cases representing hip replacements for hip fractures:

### ICD–9–CM Diagnosis Codes Reviewed for Cases Representing Hip Replacement for Hip Fractures

<table>
<thead>
<tr>
<th>ICD–9–CM Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>733.14</td>
<td>Pathological fracture of neck of femur.</td>
</tr>
<tr>
<td>733.15</td>
<td>Pathological fracture of other specified part of femur.</td>
</tr>
<tr>
<td>733.81</td>
<td>Malunion of fracture.</td>
</tr>
<tr>
<td>733.82</td>
<td>Nonunion of fracture.</td>
</tr>
<tr>
<td>733.96</td>
<td>Stress fracture of femoral neck.</td>
</tr>
<tr>
<td>808.0</td>
<td>Closed fracture of acetabulum.</td>
</tr>
<tr>
<td>808.1</td>
<td>Open fracture of acetabulum.</td>
</tr>
<tr>
<td>820.8</td>
<td>Fracture of unspecified part of neck of femur closed.</td>
</tr>
<tr>
<td>820.9</td>
<td>Fracture of unspecified part of neck of femur open.</td>
</tr>
<tr>
<td>820.00</td>
<td>Fracture of unspecified intracapsular section of neck of femur closed.</td>
</tr>
<tr>
<td>820.01</td>
<td>Fracture of epiphysis (separation) (upper) of neck of femur closed.</td>
</tr>
<tr>
<td>820.02</td>
<td>Fracture of midcervical section of femur closed.</td>
</tr>
<tr>
<td>820.03</td>
<td>Fracture of base of neck of femur closed.</td>
</tr>
<tr>
<td>820.09</td>
<td>Other transcervical fracture of femur closed.</td>
</tr>
<tr>
<td>820.10</td>
<td>Fracture of unspecified intracapsular section of neck of femur open.</td>
</tr>
<tr>
<td>820.11</td>
<td>Fracture of epiphysis (separation) (upper) of neck of femur open.</td>
</tr>
<tr>
<td>820.12</td>
<td>Fracture of midcervical section of femur open.</td>
</tr>
<tr>
<td>820.13</td>
<td>Fracture of base of neck of femur open.</td>
</tr>
<tr>
<td>820.19</td>
<td>Other transcervical fracture of femur open.</td>
</tr>
<tr>
<td>820.20</td>
<td>Fracture of unspecified trochanteric section of femur closed.</td>
</tr>
<tr>
<td>820.21</td>
<td>Fracture of intertrochanteric section of femur closed.</td>
</tr>
<tr>
<td>820.22</td>
<td>Fracture of subtrochanteric section of femur closed.</td>
</tr>
<tr>
<td>820.30</td>
<td>Fracture of unspecified trochanteric section of femur open.</td>
</tr>
<tr>
<td>820.31</td>
<td>Fracture of intertrochanteric section of femur open.</td>
</tr>
<tr>
<td>820.32</td>
<td>Fracture of subtrochanteric section of femur open.</td>
</tr>
</tbody>
</table>

Our findings from our examination of the data are shown in the table below.

### Cases of Hip Replacements With and Without Principal Diagnosis of Hip Fracture

<table>
<thead>
<tr>
<th>MS–DRG</th>
<th>Number of Cases</th>
<th>Average Length of Stay</th>
<th>Average Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 469—All cases</td>
<td>25,729</td>
<td>6.9</td>
<td>$22,358</td>
</tr>
<tr>
<td>MS–DRG 469—Hip replacement cases with hip fractures</td>
<td>14,459</td>
<td>7.9</td>
<td>$22,852</td>
</tr>
<tr>
<td>MS–DRG 469—Hip replacement cases without hip fractures</td>
<td>4,714</td>
<td>5.7</td>
<td>$22,430</td>
</tr>
<tr>
<td>MS–DRG 470—All cases</td>
<td>421,149</td>
<td>2.9</td>
<td>$14,834</td>
</tr>
<tr>
<td>MS–DRG 470—Hip replacement cases with hip fractures</td>
<td>125,607</td>
<td>2.6</td>
<td>$14,870</td>
</tr>
<tr>
<td>MS–DRG 470—Hip replacement cases without hip fractures</td>
<td>14,459</td>
<td>7.9</td>
<td>$22,852</td>
</tr>
</tbody>
</table>

For MS–DRG 469, the average costs of all 25,729 reported cases were $22,358 and the average length of stay was 6.9 days. Within MS–DRG 469, there were 14,459 cases of hip replacements with hip fractures reported, with average costs of $22,852 and an average length of stay of 7.9 days. Within MS–DRG 469, there were 4,714 cases of hip replacements without hip fractures reported, with average costs of $22,430 and an average length of stay of 5.7 days.
days. The average costs of reported cases of hip replacements with hip fractures are similar to the average costs of all cases reported within MS–DRG 469 ($22,852 compared to $22,358), and to the average costs of reported cases of hip replacements without hip fractures ($22,852 compared to $22,430). However, the average length of stay for cases of hip replacements with hip fractures reported in MS–DRG 469 is higher than the average length of stay for all cases reported in MS–DRG 469 and for cases of hip replacements without hip fractures reported in MS–DRG 469 (7.9 days compared to 6.9 days and 5.7 days, respectively.)

For MS–DRG 470, the average costs of all 421,149 cases reported were $14,834 and the average length of stay was 2.9 days. Within MS–DRG 470, there were 49,703 reported cases of hip replacements with hip fractures, with average costs $15,795 and an average length of stay of 4.7 days. Within MS–DRG 470, there were 125,607 cases of hip replacements without hip fractures reported, with average costs of $14,870 and an average length of stay of 2.6 days. However, the average length of stay for cases of hip replacements with hip fractures reported in MS–DRG 470 was higher than the average length of stay for all cases and for cases of hip replacements without hip fractures reported in MS–DRG 470 (4.7 days compared to 2.9 days and 2.6 days, respectively). Therefore, the average costs of cases of hip replacements with hip fractures were similar for both MS–DRG 469 and MS–DRG 470 ($22,852 compared to $22,358 and $15,795 compared to $14,834, respectively). However, the average lengths of stay are longer for cases of hip replacements with hip fractures compared to all cases reported in both MS–DRGs 469 and 470 (7.9 days compared to 6.9 days and 4.7 days compared to 2.9 days, respectively).

The claims data did not support creating a new MS–DRG for the assignment of cases of hip replacements with hip fractures. As discussed earlier, the average costs for cases of hip replacements with hip fractures reported in MS–DRG 469 and MS–DRG 470 are similar to the average costs for all cases reported in MS–DRG 469 and MS–DRG 470. While the average length of stay is longer for cases of hip replacements with hip fractures than for cases of hip replacements without hip fractures reported within MS–DRGs 469 and 470, the increased length of stay did not impact the average costs of reported cases in either MS–DRG 469 or 470. The data showed that cases of hip replacement procedures are clearly influenced by the presence of an MCC. The average costs of all cases reported in MS–DRG 469, which identifies an MCC, were $22,358, compared to average costs of $14,834 for all cases reported in MS–DRG 470, which did not identify an MCC. The data showed that the presence of a principal diagnosis of a hip fracture did not impact the average costs of cases reported in either MS–DRG 469 or MS–DRG 470.

We also examined the data in relation to the request to reassign all procedures of hip replacement with hip fractures from MS–DRG 470 to MS–DRG 469, even if there is no MCC present. The data showed that the 49,703 cases of hip replacements with hip fractures reported in MS–DRG 470 have average costs of $15,795 and an average length of stay of 4.7 days. The 25,729 total cases of hip replacements reported in MS–DRG 469 have average costs of $22,358 and an average length of stay of 4.7 days. Therefore, the data for average costs and average length of stay for all cases involving hip replacement procedures with hip fractures reported in MS–DRG 470 do not support reassigning all cases of hip replacement procedures with hip fractures to MS–DRG 469, even if there is no MCC present.

Our clinical advisors reviewed this issue and agreed that the hip replacement procedures performed for patients with hip fractures are appropriately assigned to MS–DRGs 469 and 470. They did not support reassigning these procedures from MS–DRGs 469 and 470 to a new MS–DRG or reassigning all cases of hip replacement procedures with hip fractures to MS–DRG 469, even if the case does not have an MCC. Our clinical advisors stated that the surgical techniques used for hip replacements are similar for all patients. They advised that the fact that some patients also had a hip fracture would not justify creating a new MS–DRG or reassigning all cases of hip replacement procedures with hip fractures to MS–DRG 469 even if there is no MCC present.

Some commenters have expressed concern with the current MS–DRG assignment for hip replacement procedures with a principal diagnosis of hip fractures. Several commenters stated that the average length of stay and the patient profile are different for hip replacement procedures with a principal diagnosis of hip fractures. One commenter recommended that CMS consider creating an MS–DRG or reassigning all hip replacement procedures with a principal diagnosis of hip fracture only to MS–DRG 469, even if there were no reported MCC. The commenter recognized that the claims data presented in the proposed rule did not show significantly different average costs for hip replacement procedures with a principal diagnosis of hip fractures. However, the commenter stated that the average costs for hip replacement procedures with a principal diagnosis of hip fractures. As discussed in the proposed rule and earlier in this final rule, the average costs for cases of hip replacements with hip fractures reported in MS–DRG 469 and MS–DRG 470 are similar to the average costs for all cases reported in MS–DRG 469 and MS–DRG 470. While the average length of stay is longer for cases of hip replacements with hip fractures than for cases of hip replacements without hip fractures reported within MS–DRGs 469 and 470, the increased length of stay did not impact the average costs of reported cases in either MS–DRG 469 or 470. In response to the commenter’s recommendation that CMS consider

Response: We appreciate the commenters’ support for the proposal. Comment: Several commenters expressed concern with the current MS–DRG assignment for hip replacement procedures with a principal diagnosis of hip fractures. One commenter recommended that CMS consider creating an MS–DRG or reassigning all hip replacement procedures with a principal diagnosis of hip fractures only to MS–DRG 469, even if there were no reported MCC. The commenter recognized that the claims data presented in the proposed rule did not show significantly different average costs for hip replacement procedures with a principal diagnosis of hip fractures. However, the commenter stated that the average length of stay and the patient profile are different for hip replacement procedures with a principal diagnosis of hip fractures. As discussed in the proposed rule and earlier in this final rule, the average costs for cases of hip replacements with hip fractures reported in MS–DRG 469 and MS–DRG 470 are similar to the average costs for all cases reported in MS–DRG 469 and MS–DRG 470. While the average length of stay is longer for cases of hip replacements with hip fractures than for cases of hip replacements without hip fractures reported within MS–DRGs 469 and 470, the increased length of stay did not impact the average costs of reported cases in either MS–DRG 469 or 470. In response to the commenter’s recommendation that CMS consider
reassigning all hip replacement procedures with a principal diagnosis of hip fracture only to MS–DRG 469, even if there is no reported MCC, we also examined the data in relation to the request to reassign all procedures of hip replacement with hip fracture to MS–DRG 469, even if there is no reported MCC. As discussed in the proposed rule and earlier in this final rule, the data for average costs and average length of stay for all cases involving hip replacement procedures with hip fractures reported in MS–DRG 470 do not support reassigning all cases of hip replacement procedures with hip fractures to MS–DRG 469, even if there is no MCC present.

After consideration of the public comments we received, we are finalizing our proposal to maintain the MS–DRG assignment for hip replacements with a principal diagnosis of hip fractures in MS–DRGs 469 and 470 and not create a new MS–DRG for hip replacements with a principal diagnosis of hip fractures.

We agree with the requestor that the previous code used to identify revisions of total ankle replacement procedures, ICD–9–CM procedure code 81.59 (Revision of joint replacement of lower extremity, not elsewhere classified), is not as precise as the new ICD–10–PCS procedure codes that were implemented on October 1, 2015. As discussed in the FY 2015 IPPS/LTCH PPS proposed rule and final rule, ICD–9–CM procedure code 81.59 included procedures involving revisions of joint replacements of a variety of lower extremity joints, including the ankle, foot, and toe. Therefore, the ICD–9–CM procedure code does not provide precise information on the number of revisions of total ankle replacement procedures as do the ICD–10–PCS procedure codes listed above. We also agree that the ICD–10–PCS procedure codes will provide more precise data on revisions of ankle replacements.

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24992 through 24993), we examined claims data from the December 2015 update of the FY 2015 MedPAR file on cases reporting procedure code 81.59 in MS–DRGs 515, 516, and 517. The table below shows our findings.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SWF0JZ ..................</td>
<td>Revision of synthetic substitute in right ankle joint, open approach.</td>
</tr>
<tr>
<td>0SWF3JZ ..................</td>
<td>Revision of synthetic substitute in right ankle joint, percutaneous approach.</td>
</tr>
<tr>
<td>0SWF4JZ ..................</td>
<td>Revision of synthetic substitute in right ankle joint, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0SWFXJZ ..................</td>
<td>Revision of synthetic substitute in right ankle joint, external approach.</td>
</tr>
<tr>
<td>0SWG0JZ ..................</td>
<td>Revision of synthetic substitute in left ankle joint, open approach.</td>
</tr>
<tr>
<td>0SWG3JZ ..................</td>
<td>Revision of synthetic substitute in left ankle joint, percutaneous approach.</td>
</tr>
<tr>
<td>0SWG4JZ ..................</td>
<td>Revision of synthetic substitute in left ankle joint, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0SWGXJZ ..................</td>
<td>Revision of synthetic substitute in left ankle joint, external approach.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Revisions of Joint Replacements Procedures</th>
<th>Number of cases</th>
<th>Average length of stay</th>
<th>Average costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG 515—All cases ..................................</td>
<td>3,852</td>
<td>8.54</td>
<td>$21,900</td>
</tr>
<tr>
<td>MS–DRG 515—Cases reporting procedure code 81.59</td>
<td>2</td>
<td>7.00</td>
<td>36,983</td>
</tr>
<tr>
<td>MS–DRG 516—All cases ..................................</td>
<td>8,567</td>
<td>5.24</td>
<td>14,839</td>
</tr>
<tr>
<td>MS–DRG 516—Cases reporting procedure code 81.59</td>
<td>19</td>
<td>3.74</td>
<td>14,957</td>
</tr>
<tr>
<td>MS–DRG 517—All cases ..................................</td>
<td>5,664</td>
<td>3.20</td>
<td>12,979</td>
</tr>
<tr>
<td>MS–DRG 517—Cases reporting procedure code 81.59</td>
<td>47</td>
<td>1.89</td>
<td>16,524</td>
</tr>
</tbody>
</table>
As can be seen from the data in the above table, there were only 68 total cases reported with procedure code 81.59 among MS–DRGs 515, 516, and 517: 2 cases in MS–DRG 515; 19 cases in MS–DRG 516; and 47 in MS–DRG 517. We point out that while there were 68 total cases reported with procedure code 81.59 in MS–DRGs 515, 516, and 517, we are unable to determine how many of these cases were actually revisions of ankle replacements versus other revisions of joint replacement of lower extremities such as those of the foot or toe. This small number of cases does not justify creating a new MS–DRG as suggested by the requestor in its first option.

While the average costs of cases reporting procedure code 81.59 in MS–DRG 515 were $36,983, compared to $21,900 for all cases reported in MS–DRG 515, there were only 2 cases reporting procedure code 81.59 in MS–DRG 515, of the 3,852 total cases reported in MS–DRG 515. In MS–DRG 516, the average costs of the 19 cases reporting procedure code 81.59 were $14,957, which is very close to the average costs of $14,839 for all 8,567 cases reported in MS–DRG 516. The average costs for cases reporting procedure code 81.59 in MS–DRG 517 were higher than the average costs for all cases reported in MS–DRG 517 ($16,524 for cases reporting procedure code 81.59 compared to $12,979 for all cases reported in MS–DRG 517). While the average costs for cases reporting procedure code 81.59 were $3,343 higher than cases reported in MS–DRG 517, we point out that there were only 47 cases that reported procedure code 81.59 out of the 5,664 total cases reported in MS–DRG 517. The relatively small number of cases may have been impacted by other factors. Several expensive cases could impact the average costs for a very small number of patients.

As stated by the requestor, we do not yet have data using the more precise ICD–10–PCS revisions of total ankle replacement procedure codes that were implemented on October 1, 2015. These new codes will more precisely identify the number of patients who had a revision of total ankle replacement procedure and the number of patients who had revisions of lower joint replacement procedures such as the foot or toe. The available clinical data from the December 2015 update of the FY 2015 MedPAR file do not support the creation of a new MS–DRG for the assignment of revisions of total ankle replacement procedures or the reassignment of these cases to other MS–DRGs, such as MS–DRGs 466, 467, and 468, because there were so few cases and because we could not determine how many of these cases were revisions of ankle replacements. Claims data on the ICD–10–PCS codes will not be available until 2 years after the implementation of the codes, which was October 1, 2015.

Our clinical advisors reviewed this issue and determined that the revision of total ankle replacement procedures are appropriately classified within MS–DRGs 515, 516, and 517 along with other orthopedic procedures captured by nonspecific codes. They did not support reassignment of the procedures to MS–DRGs 466, 467, and 468 until such time as detailed data for ICD–10–PCS claims are available to evaluate revision of total ankle replacement procedures. Therefore, based on the findings of our analysis of claims data and the advice of our clinical advisors, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24992 through 24993), we proposed to maintain the current MS–DRG assignment for revision of total ankle replacement procedures for FY 2017.

We invited public comments on our proposal.

Comment: Commenters supported the proposal to maintain the current MS–DRG structure for revision of total ankle replacement procedures within MS–DRGs 515, 516, and 517. While the average costs for cases reporting procedure code 81.59 were $3,343 higher than cases reported in MS–DRG 517, we point out that there were only 47 cases that reported procedure code 81.59 out of the 5,664 total cases reported in MS–DRG 517. The relatively small number of cases may have been impacted by other factors. Several expensive cases could impact the average costs for a very small number of patients.

Response: We agree with the commenter that ICD–10–PCS claims data will provide more detail to evaluate the MS–DRG assignment for revision of total ankle replacement procedures. Once ICD–10 claims data become available, we will use these claims data to evaluate this and other MS–DRG updates.

Another commenter also recommended that CMS review this MS–DRG assignment again once ICD–10 claims data are available.

Response: We agree with the commenter that ICD–10–PCS claims data will provide more detail to evaluate the MS–DRG assignment for revision of total ankle replacement procedures. Once ICD–10 claims data become available, we will use these claims data to evaluate this and other MS–DRG updates.

After consideration of the public comments we received, we are finalizing our proposal to maintain the current MS–DRG assignment for revision of total ankle replacement procedures.

(2) Combination Codes for Removal and Replacement of Knee Joints

We received several requests asking CMS to examine whether additional combinations of procedure codes for the removal and replacements of knee joints should be added to MS–DRGs 466, 467, and 468 (Revision of Hip or Knee Replacement with MCC, with CC, and without CC/MCC, respectively). This topic was discussed in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24379 through 24395) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49390 through 49406). One requestor stated that the procedure codes in the following table were not included in the code pairs that group to MS–DRGs 466, 467, and 468 in the ICD–10 MS–DRGs Version 33.
<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPD08Z</td>
<td>Removal of spacer from left knee joint, open approach.</td>
</tr>
<tr>
<td>0SPD38Z</td>
<td>Removal of spacer from left knee joint, percutaneous approach.</td>
</tr>
<tr>
<td>0SPD48Z</td>
<td>Removal of spacer from right knee joint, open approach.</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of spacer from right knee joint, open approach.</td>
</tr>
<tr>
<td>0SPC38Z</td>
<td>Removal of spacer from right knee joint, percutaneous approach.</td>
</tr>
<tr>
<td>0SPC48Z</td>
<td>Removal of spacer from right knee joint, percutaneous approach.</td>
</tr>
</tbody>
</table>

Other requestors stated that the procedure codes in the following table are not included in the list of combinations that group to MS–DRGs 466, 467, and 468 when reported in conjunction with an ICD–10–PCS code for the removal of synthetic substitute from the joint in the ICD–10 MS–DRGs Version 33.

<table>
<thead>
<tr>
<th>ICD–10–PCS Procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SRC0J9</td>
<td>Replacement of right knee joint with synthetic substitute, cemented, open approach.</td>
</tr>
<tr>
<td>0SRC0JA</td>
<td>Replacement of right knee joint with synthetic substitute, uncemented, open approach.</td>
</tr>
<tr>
<td>0SRC0JZ</td>
<td>Replacement of right knee joint with autologous tissue substitute, open approach.</td>
</tr>
<tr>
<td>0SRC07Z</td>
<td>Replacement of right knee joint with nonautologous tissue substitute, open approach.</td>
</tr>
</tbody>
</table>

We agree that the joint revision cases involving the removal of a spacer and subsequent insertion of a new knee joint prosthesis should be assigned to MS–DRGs 466, 467, and 468. We examined knee joint revision combination codes that are not currently assigned to MS–DRGs 466, 467, and 468 in ICD–10 MS–DRGs Version 33 and identified 58 additional combinations that should be included so that the same logic is used in the ICD–10 version of the MS–DRGs as is used in the ICD–9–CM version. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24993 through 24996), we proposed to add the following 58 new code combinations that capture the joint revisions to the MS DRG structure for MS–DRGs 466, 467, and 468, effective October 1, 2016.

**ICD–10–PCS Code Pairs Proposed To Be Added To Version 34 ICD–10 MS–DRGs 466, 467, and 468: Proposed New Knee Revision ICD–10–PCS Combinations**

<table>
<thead>
<tr>
<th>Code</th>
<th>Code description</th>
<th>Code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRC0J9</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRC0JA</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRT0J9</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRT0JA</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRV0JZ</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRV0JA</td>
</tr>
<tr>
<td>0SPC08Z</td>
<td>Removal of Spacer from Right Knee Joint, Open Approach.</td>
<td>and</td>
<td>0SRV0JZ</td>
</tr>
<tr>
<td>0SPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>0SRC0J9</td>
</tr>
<tr>
<td>0SPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>0SRC0JA</td>
</tr>
<tr>
<td>0SPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>0SRT0J9</td>
</tr>
<tr>
<td>Code</td>
<td>Code description</td>
<td>Code</td>
<td>Code description</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------</td>
<td>----------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>OSPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>OSTR0JA Replacement of Right Knee Joint, Femoral Surface with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>OSTR0JZ Replacement of Right Knee Joint, Femoral Surface with Synthetic Substitute, Open Approach.</td>
</tr>
<tr>
<td>OSPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>OSRV0J9 Replacement of Right Knee Joint, Tibial Surface with Synthetic Substitute, Cemented, Open Approach.</td>
</tr>
<tr>
<td>OSPC38Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Approach.</td>
<td>and</td>
<td>OSRV0JA Replacement of Right Knee Joint, Tibial Surface with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPC48Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Endoscopic Approach.</td>
<td>and</td>
<td>OSRC0JZ Replacement of Right Knee Joint with Synthetic Substitute, Cemented, Open Approach.</td>
</tr>
<tr>
<td>OSPC48Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Endoscopic Approach.</td>
<td>and</td>
<td>OSRC0J9 Replacement of Right Knee Joint with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPC48Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Endoscopic Approach.</td>
<td>and</td>
<td>OSRV0J9 Replacement of Right Knee Joint, Femoral Surface with Synthetic Substitute, Open Approach.</td>
</tr>
<tr>
<td>OSPC48Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Endoscopic Approach.</td>
<td>and</td>
<td>OSRV0JA Replacement of Right Knee Joint, Tibial Surface with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPC48Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Endoscopic Approach.</td>
<td>and</td>
<td>OSRV0J9 Replacement of Right Knee Joint, Femoral Surface with Synthetic Substitute, Open Approach.</td>
</tr>
<tr>
<td>OSPC48Z</td>
<td>Removal of Spacer from Right Knee Joint, Percutaneous Endoscopic Approach.</td>
<td>and</td>
<td>OSRU0JA Replacement of Left Knee Joint, Femoral Surface with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSRU0JZ Replacement of Left Knee Joint, Femoral Surface with Synthetic Substitute, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0J9 Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0JA Replacement of Left Knee Joint, Tibial Surface with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0J9 Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0JA Replacement of Left Knee Joint with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0J9 Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0JA Replacement of Left Knee Joint with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0J9 Replacement of Left Knee Joint with Synthetic Substitute, Cemented, Open Approach.</td>
</tr>
<tr>
<td>OSPD08Z</td>
<td>Removal of Spacer from Left Knee Joint, Open Approach.</td>
<td>and</td>
<td>OSPR0JA Replacement of Left Knee Joint with Synthetic Substitute, Uncemented, Open Approach.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal to add the joint revision code combinations listed above to the ICD–10 Version 34 MS–DRGs 466, 467, and 468.

**Comment:** A number of commenters supported the proposal to add the joint revision code combinations listed in the table in the proposed rule to the ICD–10 Version 34 MS–DRGs 466, 467, and 468. Several commenters stated that these proposed updates better replicate the logic of the prior ICD–9–CM version of the MS–DRGs. Another commenter stated that adding the 58 new combinations of procedure codes for the removal and replacement of knee joints to MS–DRGs 466, 467, and 468 improves the alignment of these cases under the ICD–10 MS–DRGs. One commenter stated that it appreciated CMS’ proposed updates to MS–DRGs 466, 467, and 468. Several of the commenters requested that the update be made retroactive to FY 2016 because this was a replication error of the ICD–9–CM MS–DRGs.

**Response:** We appreciate the commenters’ support for our proposal. We agree that this addition better replicates the prior ICD–9–CM MS–DRGs. The FY 2016 MS–DRGs were subject to review and comment by the public as part of the FY 2016 IPPS/LTCH PPS rulemaking. As stated earlier, this topic was discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49390 through 49406). We proposed to add the 58 new combinations of procedure codes for the removal and replacement of knee joints to MS–DRGs 466, 467, and 468 in the FY 2017 IPPS/LTCH PPS proposed rule for the FY 2017 MS–DRGs, effective October 1, 2016. Therefore, consistent with our general approach for implementing updates to the MS–DRGs, these updates apply beginning with the FY 2017 MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add the 58 new code combinations listed above that capture the joint revisions to the Version 34 MS DRG structure for MS–DRGs 466, 467, and 468, effective October 1, 2016.

c. **Decompression Laminectomy**

Currently, under ICD–10–PCS, the procedure describing a decompression laminectomy is coded for the “release” of a specified area of the spinal cord. These decompression codes are assigned to MS–DRGs 518, 519, and 520 (Back and Neck Procedures Except Spinal Fusion with MCC, or Disc Device or Neurostimulator, with CC, or without CC/MCC, respectively) in the ICD–10 MS–DRGs Version 33. A commenter brought to our attention that codes describing release of specific peripheral nerve are assigned to MS–DRGs 515, 516, and 517 (Other Musculoskeletal System and Connective Tissue O.R. Procedures with MCC, with CC, and without CC/MCC, respectively). The commenter suggested that a subset of these codes also be assigned to MS–DRGs 518 through 520 and MS–DRGs 518 through 520 for clinical coherence purposes. The commenter stated, for example, that ICD–10–PCS procedure code 00NY0ZZ (Release lumbar spinal...
We invited public comments on our proposal.

Comment: Several commenters supported the proposal to reassign the ICD–10–PCS procedure codes listed in the table in the proposed rule from MS–DRGs 515, 516 and 517 to MS–DRGs 028, 029, and 030. In addition, it is not clear if the commenter was suggesting that we reassign the entire list of ICD–10–PCS codes listed in the following table from MS–DRGs 515 through 517 to MS–DRGs 028 through 030 and MS–DRGs 518 through 520 under the ICD–10 MS–DRGs Version 34.

We stated in the FY 2017 IPPS/LTCH PPS proposed rule that we agreed with the commenter’s suggestion. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24996), for FY 2017, we proposed to reassign the ICD–10–PCS procedure codes listed in the following table from MS–DRGs 515 through 517 to MS–DRGs 028 through 030 and MS–DRGs 518 through 520 under the ICD–10 MS–DRGs Version 34.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01N00ZZ ..................</td>
<td>Release cervical plexus, open approach.</td>
</tr>
<tr>
<td>01N03ZZ ..................</td>
<td>Release cervical plexus, percutaneous approach.</td>
</tr>
<tr>
<td>01N04ZZ ..................</td>
<td>Release cervical plexus, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>01N80ZZ ..................</td>
<td>Release thoracic nerve, open approach.</td>
</tr>
<tr>
<td>01N83ZZ ..................</td>
<td>Release thoracic nerve, percutaneous approach.</td>
</tr>
<tr>
<td>01N84ZZ ..................</td>
<td>Release thoracic nerve, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>01N90ZZ ..................</td>
<td>Release lumbar plexus, open approach.</td>
</tr>
<tr>
<td>01N93ZZ ..................</td>
<td>Release lumbar plexus, percutaneous approach.</td>
</tr>
<tr>
<td>01N94ZZ ..................</td>
<td>Release lumbar plexus, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>01N95ZZ ..................</td>
<td>Release lumbar nerve, percutaneous approach.</td>
</tr>
<tr>
<td>01NA4ZZ ..................</td>
<td>Release lumbar nerve, percutaneous approach.</td>
</tr>
<tr>
<td>01NA5ZZ ..................</td>
<td>Release lumbar nerve, percutaneous endoscopic approach.</td>
</tr>
</tbody>
</table>

The commenter did not make any recommendation for reassignment of the listed ICD–10–PCS procedure codes to MS–DRGs 518, 519, and 520. Response: We appreciate the commenters’ support of our proposal. We note that the commenter who did not support the proposal and recommended we not finalize it in the absence of ICD–10 claims data, we acknowledge that it can be somewhat challenging to fully assess the impact of a proposal without the coded data to analyze. We note that the proposal was based on clinical coherence of the listed ICD–10–PCS codes with other codes describing procedures on the neck and spine currently assigned to MS–DRGs 028, 029, 030 in MDC 1 (Diseases and Disorders of the Nervous System) and MS–DRGs 518, 519, and 520 in MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue). We also note that the ICD–9–CM code 04.49 lacks the detail and specificity of the corresponding ICD–10–PCS codes proposed for reassignment. For example, the ICD–9–CM code does not specify which peripheral nerve is being treated or what approach was utilized. Therefore, we cannot fully evaluate and rely upon the commenter’s analysis results for the ICD–9–CM data to accurately determine the impact of reassigning all the cited ICD–10–PCS codes, which do specify the nerve being treated, and the approach that was used to MS–DRGs 028, 029, and 030. In addition, it is not clear which list of ICD–10–PCS codes the commenter was requesting us to consider for reassignment to MS–DRGs 028, 029, and 030 based on its submitted comment. It is unclear if the commenter was suggesting that we reassign the entire list of ICD–10–PCS codes that appeared in the proposed rule or if the commenter was suggesting that we reassign the entire list of available code options in Table 01N (Release/Peripheral Nervous System) of the ICD–10–PCS classification because the commenter’s language referred to the 01N “category” and that is not a standard term used in ICD–10–PCS.

Therefore, we agree that we should delay this proposed change until the ICD–10 claims data are available, because we will have the ability to better analyze the impact of reassigning the specified codes according to their anatomic location, as well as receive clarification regarding which specific codes should be taken under consideration for reassignment. Our clinical advisors reviewed this issue and recommended maintaining the current structure of MS–DRGs 515, 516, and 517 for FY 2017. They agreed that we should not finalize our proposal to reassign the ICD–10–PCS codes discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24996 through 24997) to MS–DRGs 028, 029, and 030 and MS–DRGs 518, 519, and 520 until ICD–10–PCS data are available for analysis because we will have the opportunity to examine the detailed ICD–10–PCS codes and assess their impact on MS–DRGs 028, 029, and 030 and determine the specific codes.
that were suggested for reassignment (the list of ICD–10–PCS codes displayed in the proposed rule and this final rule above or the entire list of codes available from Table 01N of the ICD–10–PCS classification). We also will have the coded claims data to assess the impact for MS–DRGs 518, 519, and 520 to better evaluate if that reassignment is supported.

After consideration of the public comments we received and based on the recommendations from our clinical advisors, we are not finalizing our proposal to reassign the ICD–10–PCS procedure codes listed in the table in the proposed rule and above from MS–DRGs 515, 516, and 517 (Other Musculoskeletal System and Connective Tissue O.R. Procedures with MCC, with CC and without CC/MCC) to MS–DRGs 028, 029, 030 (Spinal Procedures with MCC, with CC or Spinal Neurostimulators and without CC/MCC, respectively) and MS–DRGs 518, 519, and 520 (Back and Neck Procedures Except Spinal Fusion with MCC or Disc Device or Neurostimulator, with CC and without CC/MCC, respectively) under the ICD–10–MS–DRGs Version 34. The ICD–10–PCS codes that were listed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24996 through 24997) will remain in their current assignment to MS–DRGs 515, 516, and 517.

d. Lordosis

An ICD–10 replication issue involving four diagnosis codes related to lordosis (excessive curvature of the lower spine) was discovered in MS–DRGs 456, 457, and 458 (Spinal Fusion Except Cervical with Spinal Curvature or Malignancy or Infection or Extensive Fusions with MCC, with CC, and without CC/MCC, respectively) and MS–DRGs 518, 519, and 520 (Back and Neck Procedures Except Spinal Fusion with MCC or Disc Device or Neurostimulator, with CC and without CC/MCC, respectively) under the ICD–10–MS–DRGs Version 34. The ICD–10–PCS codes that were listed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24996 through 24997) were proposed to remove the above four diagnosis codes from the secondary diagnosis list. We also proposed to maintain these same four codes in the logic for the principal diagnosis list. We proposed that this proposed change for MS–DRGs 456, 457, and 458 would be effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

We invited public comments on our proposals.

Comment: Commenters supported the proposal to remove diagnoses codes M40.50, M40.55, M40.56, and M40.57 from the secondary diagnosis list for MS DRGs 456, 457, and 458. Commenters also supported the proposal to maintain these same four codes in the logic for the principal diagnosis list for MS–DRGs 456, 457, and 458.

Response: We appreciate the commenters’ support of our proposal to remove the above four diagnosis codes from the secondary diagnosis list and to maintain these same four codes in the logic for the principal diagnosis list for MS DRGs 456, 457, and 458. After consideration of the public comments we received, we are finalizing our proposal to remove diagnoses codes M40.50 (Lordosis, unspecified, site unspecified); M40.55 (Lordosis, unspecified, thoracolumbar region); M40.56 (Lordosis, unspecified, lumbar region); and M40.57 (Lordosis, unspecified, lumbosacral region) from the secondary diagnosis list for MS DRGs 456, 457, and 458. These four codes are retained in the logic for the principal diagnosis list. This change for MS–DRGs 456, 457, and 458 (Spinal fusion except cervical with spinal curvature or malignancy or infection or extensive fusions with MCC, with CC and without CC/MCC) is effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

9. MDC 13 (Diseases and Disorders of the Female Reproductive System): Pelvic Evisceration

In the ICD–10 MS–DRG Definitions Manual Version 33, the GROUPER logic for ICD–10 MS–DRGs 332, 333, and 334 (Rectal Resection with MCC, with CC and without CC/MCC, respectively) under MDC 6 (Diseases and Disorders of the Digestive System) and the GROUPER logic for MS–DRGs 734 and 735 (Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC and without CC/MCC, respectively) under MDC 13 (Diseases and Disorders of the Female Reproductive System) include a “cluster” of ICD–10–PCS procedure codes that describe pelvic evisceration. A “cluster” is the term used to describe a combination of codes that work in tandem to identify a procedure. Inclusion of an ICD–9–CM procedure code for it to be considered a plausible code translation. The code cluster in MS–DRGs 332, 333, and 334 and MS–DRGs 734 and 735 is shown in the table below.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code in cluster</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0TTB0ZZ</td>
<td>Resection of bladder, open approach.</td>
</tr>
<tr>
<td>0TTD0ZZ</td>
<td>Resection of urethra, open approach.</td>
</tr>
<tr>
<td>0UT20ZZ</td>
<td>Resection of bilateral ovaries, open approach.</td>
</tr>
<tr>
<td>0UT70ZZ</td>
<td>Resection of bilateral fallopian tubes, open approach.</td>
</tr>
<tr>
<td>0UT90ZZ</td>
<td>Resection of uterus, open approach.</td>
</tr>
<tr>
<td>0UTC0ZZ</td>
<td>Resection of cervix, open approach.</td>
</tr>
<tr>
<td>0UTG0ZZ</td>
<td>Resection of vagina, open approach.</td>
</tr>
</tbody>
</table>

Pelvic evisceration (or exenteration) is a procedure performed to treat gynecologic cancers (cervical, uterine, vulvar, and vaginal, among others) and involves resection of pelvic structures such as the procedures described by the cluster of procedure codes listed above. Under the ICD–9–CM MS–DRGs Version 32, procedure code 68.8 (Pelvic evisceration) was used to report pelvic evisceration. ICD–9–CM procedure code 68.8 also was assigned to ICD–9–CM MS–DRGs 332, 333, and 334 and MS–DRGs 734 and 735 in MDCs 6 and 13, respectively. The inclusion term in the ICD–9–CM Tabular List of Diseases for pelvic evisceration (procedure code 68.8) was “Removal of ovaries, tubes, uterus, vagina, bladder, and urethra (with removal of sigmoid colon and rectum).” In the ICD–9–CM Tabular List, the terms shown in parentheses are called a “non-essential modifier”. A “non-essential modifier” is used in the classification to identify a supplementary word that may, or may not, be present in the statement of a disease or procedure. In other words, the terms in parentheses do not have to be documented to report the code.

Because the removal of sigmoid colon and the removal of rectum were classified as non-essential modifiers under ICD–9–CM, documentation that identified that removal of those body sites occurred was not required to report the procedure code describing pelvic evisceration (procedure code 68.8). In other words, when a pelvic evisceration procedure was performed and included removal of other body sites (ovaries and tubes, among others) in the inclusion term, absent the terms in parentheses, procedure code 68.8 could
be reported and grouped appropriately to MDC 13 under MS–DRGs 734 and 735. When a pelvic evisceration procedure was performed and removal of the body sites listed in the inclusion term occurred, including the terms in parentheses, procedure code 68.8 could be reported and grouped appropriately to MDC 6 under MS–DRGs 332 through 334.

Under ICD–10–PCS, users are instructed to code separately the organs or structures that are actually removed and for which there is a distinctly defined body part. Therefore, the case of a patient who undergoes a pelvic evisceration (exenteration) that involves the removal of the sigmoid colon and rectum would have each of those procedure sites (sigmoid colon and rectum) coded and reported separately (in addition to the procedure codes displayed in the cluster). In this scenario, if the principal diagnosis is a condition from the MDC 6 diagnosis list, the case would group to MS–DRGs 332, 333, and 334, regardless of the code cluster. In other words, it would not be necessary to retain the code cluster describing procedures performed on female pelvic organs in MDC 6.

Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24997 through 24998), for FY 2017, we proposed to remove the procedure code cluster for pelvic evisceration procedures from MDC 6 under the ICD–10 MS–DRGs Version 34. The cluster would remain in ICD–10 MDC 13 under MS–DRGs 734 and 735 only. We invited public comments on our proposal.

Comment: Commenters supported the proposal to remove the procedure code cluster for pelvic evisceration procedures currently under MDC 6 in ICD–10 MS–DRGs 332, 333, and 334 for the ICD–10 MS–DRGs Version 34. The commenters stated the proposal was reasonable, given the data, the ICD–10–PCS codes, and the information provided.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to remove the following procedure codes currently listed as a “cluster” in MDC 6 under MS–DRGs 332, 333, and 334 effective October 1, 2016 under the ICD–10 MS–DRGs Version 34. The codes will remain as a cluster in MDC 13 under MS–DRGs 734 and 735 (Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC and without CC/MCC, respectively). The codes will remain as a “cluster” in MDC 13 under MS–DRGs 734 and 735 (Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC and without CC/MCC, respectively).

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code in cluster</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0TTB0ZZ ............</td>
<td>Resection of bladder, open approach.</td>
</tr>
<tr>
<td>0TTD0ZZ ............</td>
<td>Resection of urethra, open approach.</td>
</tr>
<tr>
<td>0UT20ZZ ............</td>
<td>Resection of bilateral ovaries, open approach.</td>
</tr>
<tr>
<td>0UT70ZZ ............</td>
<td>Resection of bilateral fallopian tubes, open approach.</td>
</tr>
<tr>
<td>0UT90ZZ ............</td>
<td>Resection of uterus, open approach.</td>
</tr>
<tr>
<td>0UTC0ZZ ............</td>
<td>Resection of cervix, open approach.</td>
</tr>
<tr>
<td>0UTG0ZZ ............</td>
<td>Resection of vagina, open approach.</td>
</tr>
</tbody>
</table>

10. MDC 19 (Mental Diseases and Disorders): Proposed Modification of Title of MS–DRG 884 (Organic Disturbances and Mental Retardation)

We received a request to change the title of MS–DRG 884 (Organic Disturbances and Mental Retardation) under MDC 19 (Mental Diseases and Disorders) to “MS–DRG 884 (Organic Disturbances and Intellectual Disability)” to reflect more recent terminology used to appropriately describe the latter medical condition in the MDC.

We agree with the requestor that the reference to the phrase “Mental Retardation” should be changed to “Intellectual Disability”, to reflect the current terminology used to describe the condition. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24998), we proposed to change the title of MS–DRG 884 as requested by the requestor.

We invited public comments on our proposal to change the title of MS–DRG 884 from “Organic Disturbances and Mental Retardation” to “Organic Disturbances and Intellectual Disability”, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

Comment: Commenters supported the proposal to modify the title for ICD–10 MS–DRG 884. The commenters stated that the proposal was reasonable, given the data and information provided.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to modify the title for ICD–10 MS–DRG 884. The finalized title for MS–DRG 884 for the FY 2017 ICD–10 MS–DRGs Version 34 is “MS–DRG 884 (Organic Disturbances and Intellectual Disability),” effective October 1, 2016.
recommended that CMS review diagnosis codes in ICD–10–CM category I69 for possible addition to MS–DRGs 945 and 946. The requester stated that, upon further review, it believed that a great number of diagnosis codes beyond sequelae of stroke (ICD–10–CM category I69) would need to be added in order to replicate the logic of the ICD–9–CM MS–DRGs. Therefore, the requester modified its recommendation as follows:

- Designate MS–DRGs 945 and 946 as pre-major diagnostic categories (Pre-MDC) MS–DRGs so that cases are grouped to these MS–DRGs on the basis of the procedure code rather than the principal diagnosis. The requester stated that the ICD–10–PCS rehabilitation codes (Section F, Physical Rehabilitation and Diagnostic Audiology, Body system 0, Rehabilitation) should be used to group cases to MS–DRGs 945 and 946 similar to how the MS–DRG GROUPER logic currently treats lung transplants and tracheostomies. This would ensure that rehabilitation procedure codes drive the MS–DRG assignment.

- Revise ICD–10–PCS Official Guidelines for Coding and Reporting and designate that the ICD–10–PCS rehabilitation codes be used only for admissions for rehabilitation therapy.

We acknowledge that ICD–10–CM does not have clear diagnosis codes that indicate the reason for the encounter was for rehabilitation services. For that reason, CMS had to modify the MS–DRG logic using ICD–10–PCS procedure codes to assign these cases to MS–DRGs 945 and 946. The logic used in MS–DRGs 945 and 946 is shown in the Definitions Manual Version 33, which is posted on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Final-Rule-Data-Files.html. Look under the Related Links section and select the ICD–10–CMPCS MS–DRG v33 Definitions Manual Table of Contents Full Titles HTML Version file. Open this file and the Table of Contents page will appear. Click on the link for MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services). On the next page that opens (MDC 23), click on the link titled “MDC 23 Assignment of Diagnosis Codes” on the upper left side of the screen. By using the navigation arrows at the top right hand side of the page, users can review the 23rd listing of all the principal diagnosis codes assigned to MDC 23, including many injury codes for subsequent encounters.

Under the GROUPER Logic, cases are assigned to MS–DRGs 945 and 946 in one of two ways as described in the Definitions Manual as follows:

- The encounter has a principal diagnosis code Z44.8 (Encounter for fitting and adjustment of other external prosthetic devices) or Z44.9 (Encounter for fitting and adjustment of unspecified external prosthetic device). Both of these codes are included in the list of principal diagnosis codes assigned to MDC 23.

- The encounter has an MDC 23 principal diagnosis code and one of the rehabilitation procedure codes listed under MS–DRGs 945 and 946. If the case does not have a principal diagnosis code from the MDC 23 list, but does have a procedure code from the list included under the Rehabilitation Procedures for MS–DRGs 945 and 946, the case will instead be assigned to a MS–DRG within the MDC where the principal diagnosis code is found.

Example: The encounter has a principal diagnosis code of S02119D (Unspecified fracture of occiput, subsequent encounter for fracture with routine healing). This code is included in MDC 8. Therefore, diagnosis code S02119D and a procedure code from the MS–DRG 945 and 946 Rehabilitation Procedure list, such as procedure code F0706GZ (Therapeutic Exercise Treatment of Neurological System—Head and Neck using Aerobic Endurance and Conditioning Equipment) would not lead to assignment of the case to MS–DRGs 945 and 946 because the principal diagnosis code is not included in MDC 23.

Diagnosis code S02119D is included in MDC 8 as was the ICD–9–CM predecessor code, V54.19 (Aftercare for healing traumatic fracture of other bone). Therefore, these cases would be assigned to MS–DRGs 559, 560, and 561 (Aftercare, Musculoskeletal System and Connective Tissue with MCC, with CC, and without MCC/CC, respectively) within MDC 8.

At the time of development of the proposed rule, we did not have any claims data that indicate how well this MS–DRG logic is working. We stated in the proposed rule that we were hesitant to simply add more codes from category I69 without evaluating the impact of doing so using claims data. We also did not have claims data to indicate whether or not there have been changes in the types or numbers of cases assigned to MS–DRGs 945 and 946. We welcomed specific suggestions of codes to be added to MS–DRGs 945 and 946 based on hospitals’ experience in coding these cases. We stated that we would evaluate these suggestions once we have claims data to study the impact. Based on the lack of ICD–10 claims data, we proposed to maintain the current logic of MS–DRGs 945 and 946 and not make updates until these claims data become available.

Comment: A number of commenters supported the proposal to maintain the current structure of MS–DRGs 945 and 946 and reconsider the issue when ICD–10 claims data become available and prior to proposing any updates. Several commenters who agreed with this proposal stated that additional analysis should be undertaken in order to fully understand the industry impact of the current logic of MS–DRGs 945 and 946. The commenters stated that it was not clear to what extent the current logic for these MS–DRGs has created actual payment issues or what the nature of any identified problems might be.
One commenter suggested that an analysis of ICD–10 claims data indicate that the current logic of MS–DRGs 945 and 946 is creating significant payment issues, CMS consider reclassifying MS–DRGs 945 and 946 as pre-MDC MS–DRGs as a possible solution.

Response: We agree with the commenters that, without ICD–10 claims data, it is not possible to evaluate the impact of the logic using ICD–10 codes within MS–DRGs 945 and 946. We agree that it is appropriate to wait for the claims data prior to proposing any MS–DRG updates.

We stated in the proposed rule that we have major concerns about the recommendation to revise the ICD–10–PCS Official Guidelines for Coding and Reporting and designate that the ICD–10–PCS rehabilitation codes be assigned and reported only for admissions for rehabilitation therapy. This would be a major and new process for developing coding and reporting guidelines based on one specific payer’s payment policies, in this case the current acute care prospective payment system policies. Hospitals would need to know who the payer was prior to knowing whether or not they could assign a code for a rehabilitation service that they provided. If those payment policies change, the hospital coder would need to be aware of those changes in order to determine whether or not they could submit a code that captures the fact that a rehabilitation service was provided.

CMS has worked with the Centers for Disease Control and Prevention (CDC), the American Hospital Association (AHA), and the American Health Information Management Association (AHIMA) to make ICD–10–PCS guidelines generic and applicable to all types of inpatient facilities and for all payer types. The current ICD–10–PCS Guidelines for Coding and Reporting do not support this recommendation that rehabilitation services could only be coded and reported if the admission was specifically for rehabilitation therapy. The ICD–10–PCS codes were created to accurately capture services provided. We also have concerns about designating MS–DRGs 945 and 946 as pre-MDCs so that cases are grouped to these MS–DRGs on the basis of a rehabilitation procedure code rather than a principal diagnosis. Pre-MDCs were an addition to Version 8 of the Diagnosis Related Groups. This was the first departure from the use of principal diagnosis as the initial variable in DRG and subsequently MS–DRG assignment. For Pre-MDC DRGs, the initial step in DRG assignment was not the principal diagnosis, but was instead certain surgical procedures with extremely high costs such as heart transplant, liver transplant, bone marrow transplant, and tracheostomies performed on patients on long-term ventilation. These types of services were viewed as being very resource intensive. Recognizing these resource intensive services and assigning them to one of the high-cost MS–DRGs assures appropriate payment even if the patient is admitted for a variety of principal diagnoses.

We believe it is inappropriate to consider rehabilitation services in the same group as high-cost procedures such as heart transplants. There is the significant potential of patients being classified out of higher paying surgical MS–DRGs in other MDCs and into the lower paying MS–DRGs 945 and 946 based on the reporting of a rehabilitation procedure code if these MS–DRGs are moved to the Pre-MDCs. We examined claims data for cases reporting a rehabilitation therapy code and found cases assigned to a wide variety of both medical and surgical MS–DRGs. The current coding and reporting of rehabilitation procedure codes for services provided suggest the potential of significant payment problems if MS–DRGs 945 and 946 were assigned to the Pre-MDC section and the reporting of cases with a rehabilitation code led to an inappropriate reassignment to the lower paying medical MS–DRGs 945 and 946.

The following are only a few examples of current claims data that showed the hospital reported a rehabilitation therapy procedure code for services provided which did not impact the MS–DRG assignment. Under the suggested approach of making MS–DRGs 945 and 946 a Pre-MDC, these cases would move from the appropriately assigned MS–DRGs which may have significantly higher average costs, to MS–DRGs 945 and 946, which have much lower average costs. Based on claims data from the December 2015 update of the FY 2015 MedPAR file, the average costs for cases reported in MS–DRGs 945 and 946 were $8,531 and $8,411, respectively.

Examples of cases reporting a rehabilitation therapy code that would move to MS–DRGs 945 and 946 based on the suggested logic change are as follows:
- An MS–DRG 460 (Spinal Fusion Except Cervical with MCC) case with average costs of $42,390; 
- An MS–DRG 464 (Wound Debridement and Skin Graft Excluding Hand, for Musculoskeletal Tissue Disease with CC) case with average costs of $55,633; 
- An MS–DRG 579 (Other Skin, Subcutaneous Tissue and Breast Procedure with MCC) case with average costs of $63,834; 
- An MS–DRG 854 (Infectious and Parasitic Diseases with O.R. procedure with MCC) case with average costs of $62,455; and 
- An MS–DRG 021 (Intracranial Vascular Procedures with Principal Diagnosis of Hemorrhage with CC) case with average costs of $90,522.

Our clinical advisors reviewed this issue and agreed that we should wait for ICD–10 claims data to become available prior to proposing updates to MS–DRGs 945 and 946. They did not support adding MS–DRGs 945 and 946 to the Pre-MDCs because the rehabilitation services are not as resource intensive as are the other MS–DRGs in the Pre-MDC section.

Considering these ICD–10–PCS guideline concerns, the structure of the pre-MDC section, and the lack of any ICD–10 claims data for MS–DRGs 945 and 946, in the FY 2017 IPPS/ETCH PPS proposed rule (81 FR 24998 through 25000), we proposed to maintain the current structure of MS–DRGs 945 and 946 and reconsider the issue when ICD–10 claims data become available and prior to proposing any updates.

We invited public comments on our proposal to maintain the current structure of MS–DRGs 945 and 946.

Comment: One commenter agreed with CMS that, given there is no ICD–10–CM code describing encounters for rehabilitation, it was reasonable that identification of admissions for rehabilitation had to rely on ICD–10–PCS procedure codes. One commenter believed that it was not appropriate for the MS–DRG logic to require a principal diagnosis from MDC 23 to be assigned to MS–DRGs 945 and 946 because most admissions for rehabilitation would appropriately have any number of diagnosis codes sequenced as the principal diagnosis rather than a diagnosis code from MDC 23. The commenter did not believe it was feasible to identify all of the ICD–10–CM codes for which rehabilitation services might be provided, due to the range and number of diagnoses that could potentially be involved.

Response: We agree with the commenter that there is no ICD–10–CM code describing encounters for rehabilitation. Given this lack of an ICD–10–CM code describing encounters for rehabilitation, we used ICD–10–PCS procedure codes as a means of identifying these cases. Therefore, the ICD–10 MS–DRG logic cannot be the same as the ICD–10–CM code logic. We also agree with the commenter that it is not feasible to identify all of the ICD–10–CM codes for which rehabilitation
services might be provided, due to the range and number of diagnoses that could potentially be involved. Therefore, it is necessary to wait for ICD–10 claims data in order to evaluate and propose MS–DRG updates.

Comment: One commenter disagreed with CMS’ proposal to maintain the current structure of MS–DRGs 945 and 946 and to only reconsider the issue when ICD–10 claims data become available. The commenter stated that further research of claims data was not necessary as there was enough evidence and clinical knowledge to identify the majority of appropriate principal diagnoses that frequently require an inpatient admission for rehabilitation. The commenter advised adding the codes and code categories in the following table to MDC 23.

<table>
<thead>
<tr>
<th>CODE/CODE CATEGORY AND DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>G20    Parkinson’s disease.</td>
</tr>
<tr>
<td>G21.0  Malignant neuroleptic syndrome.</td>
</tr>
<tr>
<td>G21.11 Neuroleptic induced parkinsonism.</td>
</tr>
<tr>
<td>G21.19 Other drug induced secondary parkinsonism.</td>
</tr>
<tr>
<td>G21.2 Secondary parkinsonism due to other external agents.</td>
</tr>
<tr>
<td>G21.3 Postencephalitic parkinsonism.</td>
</tr>
<tr>
<td>G21.4 Vascular parkinsonism.</td>
</tr>
<tr>
<td>G21.8 Other secondary parkinsonism.</td>
</tr>
<tr>
<td>G21.9 Secondary parkinsonism, unspecified.</td>
</tr>
<tr>
<td>G31.84 Mild cognitive impairment, so stated.</td>
</tr>
<tr>
<td>G35    Multiple sclerosis.</td>
</tr>
<tr>
<td>G37.3  Acute transverse myelitis in demyelinating disease of central nervous system.</td>
</tr>
<tr>
<td>G61.0  Guillain-Barre syndrome.</td>
</tr>
<tr>
<td>G61.81 Chronic inflammatory demyelinating polyneuritis.</td>
</tr>
<tr>
<td>G62.81 Critical illness polyneuropathy.</td>
</tr>
<tr>
<td>G62.9  Polyneuropathy, unspecified.</td>
</tr>
<tr>
<td>G65.0  Sequelae of Guillain-Barré syndrome.</td>
</tr>
<tr>
<td>G70.00 Myasthenia gravis without (acute) exacerbation.</td>
</tr>
<tr>
<td>G70.01 Myasthenia gravis with (acute) exacerbation.</td>
</tr>
<tr>
<td>G72.81 Critical illness myopathy.</td>
</tr>
<tr>
<td>G91.0  Communicating hydrocephalus.</td>
</tr>
<tr>
<td>G91.1  Obstructive hydrocephalus.</td>
</tr>
<tr>
<td>G91.2  (Idiopathic) normal pressure hydrocephalus.</td>
</tr>
<tr>
<td>G91.3  Post-traumatic hydrocephalus, unspecified.</td>
</tr>
<tr>
<td>G91.4  Hydrocephalus in diseases classified elsewhere.</td>
</tr>
<tr>
<td>G91.8  Other hydrocephalus.</td>
</tr>
<tr>
<td>G91.9  Hydrocephalus, unspecified.</td>
</tr>
<tr>
<td>G92    Toxic encephalopathy.</td>
</tr>
<tr>
<td>G93.1  Anoxic brain damage, not elsewhere classified.</td>
</tr>
<tr>
<td>G93.40 Encephalopathy, unspecified.</td>
</tr>
<tr>
<td>G93.41 Metabolic encephalopathy.</td>
</tr>
<tr>
<td>G93.49 Other encephalopathy.</td>
</tr>
<tr>
<td>I50.22 Chronic systolic (congestive) heart failure.</td>
</tr>
<tr>
<td>I50.23 Acute on chronic systolic (congestive) heart failure.</td>
</tr>
<tr>
<td>I50.32 Chronic diastolic (congestive) heart failure.</td>
</tr>
<tr>
<td>I50.33 Acute on chronic diastolic (congestive) heart failure.</td>
</tr>
<tr>
<td>I50.42 Chronic combined systolic (congestive) and diastolic (congestive) heart failure.</td>
</tr>
<tr>
<td>I50.43 Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure.</td>
</tr>
<tr>
<td>I50.9  Heart failure, unspecified.</td>
</tr>
<tr>
<td>M62.81 Muscle weakness (generalized).</td>
</tr>
<tr>
<td>M62.82 Rhabdomyolysis.</td>
</tr>
<tr>
<td>R26.0  Ataxic gait.</td>
</tr>
<tr>
<td>R26.1  Paralytic gait.</td>
</tr>
<tr>
<td>R26.2  Difficulty in walking, not elsewhere classified.</td>
</tr>
<tr>
<td>R26.81 Unsteadiness on feet.</td>
</tr>
<tr>
<td>R26.89 Other abnormalities of gait and mobility.</td>
</tr>
<tr>
<td>R26.9  Unspecified abnormalities of gait and mobility.</td>
</tr>
<tr>
<td>R27.0  Ataxia, unspecified.</td>
</tr>
<tr>
<td>R27.8  Other lack of coordination.</td>
</tr>
<tr>
<td>R27.9  Unspecified lack of coordination.</td>
</tr>
<tr>
<td>R41.84 Cognitive communication deficit.</td>
</tr>
<tr>
<td>R41.842 Visuospatial deficit.</td>
</tr>
<tr>
<td>R41.843 Psychomotor deficit.</td>
</tr>
<tr>
<td>R41.844 Frontal lobe and executive function deficit.</td>
</tr>
<tr>
<td>R41.89 Other symptoms and signs involving cognitive functions and awareness.</td>
</tr>
<tr>
<td>Z47.1  Aftercare following joint replacement surgery.</td>
</tr>
<tr>
<td>Z47.81 Encounter for orthopedic aftercare following surgical amputation.</td>
</tr>
<tr>
<td>Z47.89 Encounter for other orthopedic aftercare.</td>
</tr>
<tr>
<td>Z48.21 Encounter for aftercare following heart transplant.</td>
</tr>
<tr>
<td>Z48.22 Encounter for aftercare following kidney transplant.</td>
</tr>
<tr>
<td>Z48.23 Encounter for aftercare following liver transplant.</td>
</tr>
<tr>
<td>Z48.24 Encounter for aftercare following lung transplant.</td>
</tr>
<tr>
<td>Z48.280 Encounter for aftercare following heart-lung transplant.</td>
</tr>
<tr>
<td>Z48.288 Encounter for aftercare following multiple organ transplant.</td>
</tr>
</tbody>
</table>
Response: We disagree with the recommendation to add the list of ICD–10–CM codes shown in the table above to MS–DRGs 945 and 946. As stated previously, we do not have claims data to evaluate how this suggested update would impact MS–DRG assignments. We agree with the other commenters who recommended that CMS wait for claims data in order to evaluate updates to MS–DRGs 945 and 946. While this commenter took the position that further research of claims data was not necessary because there is enough evidence and clinical knowledge to identify the majority of principal diagnoses that frequently require an inpatient admission for rehabilitation, and, as noted, submitted the above list of ICD–10–CM codes and code categories to add to MDC 23, we believe that ICD–10 claims data are necessary to evaluate this recommended change; without claims data, we cannot determine the number of cases that might be reassigned and if this reassignment was appropriate.

Comment: Commenters who agreed with waiting until claims data become available to evaluate MS–DRG updates stated that they understood that the current pre-MDC structure is limited to resource-intensive surgical procedures. However, they believed that there are some similarities between the existing pre-MDCs and MS–DRGs 945 and 946. The commenters stated that, similar to the existing pre-MDCs, the driver for the rehabilitation MS–DRGs is a specific type of service, and this service may be provided for a wide variety of principal diagnoses. Therefore, the commenters suggested the creation of a guideline that limits the use of the ICD–10–PCS rehabilitation codes to rehabilitation admissions would address the potential for patient cases to be reassigned from higher paying surgical MS–DRGs in other MDCs to the lower paying MS–DRGs 945 and 946 based on the reporting of a rehabilitation procedure code if these MS–DRGs were reassigned to the pre-MDCs. One commenter stated that, after the establishment of a new ICD–10–PCS coding guideline, the reporting of ICD–10–PCS rehabilitation codes for nonrehabilitation hospitalizations would be considered coding errors and, as with any coding error, could lead to inappropriate MS–DRG assignment. However, the commenter recommended that edits and reminders would likely be needed to minimize this type of coding error.

Response: We agree with the commenters that the issue of any updates to ICD–10–PCS guidelines should be considered along with any proposed MS–DRG updates because updated guidelines may impact code reporting. We welcome any suggestions on how to update the ICD–10–PCS guidelines. These suggestions should be sent to ICDProcedureCodeRequest@cms.hhs.gov. We plan to take any proposed ICD–10–PCS rehabilitation guideline updates to a future meeting of the ICD–10 Coordination and Maintenance Committee so that the public can provide input on any new rehabilitation guideline. We continue to be concerned about creating a new ICD–10–PCS guideline whose purpose is to restrict assignment to certain MS–DRGs. Over time, the MS–DRGs are updated as part of the annual IPPS rulemaking. To create a guideline on a current MS–DRG structure as opposed to a means of capturing national data for all payers is not consistent with past guideline development. However, we look forward to working with the public on examining the need to improve the ICD–10–PCS guidelines for rehabilitation services reporting.

Comment: Other commenters who agreed with CMS’ proposal to maintain the current structure of MS–DRGs 945 and 946 until such time as ICD–10 claims data become available recommended that the ICD–10 Coordination and Maintenance Committee address the creation of a single, new ICD–10–CM diagnosis code in Section Z of ICD–10–CM to replicate the ICD–9–CM code category V57 (Care involving use of rehabilitation procedures). The commenters recommended that if the CDC created this new code, the new ICD–10–CM code be added to MS–DRGs 945 and 946 when reported as a secondary diagnosis. The commenters urged CMS to obtain industry input from experts in rehabilitation on possible coding and MS–DRG updates.

Several commenters recommended that the existing ICD–10–CM Official Guidelines for Coding and Reporting be maintained to allow the sequencing of the diagnosis code for the condition for which the service is being performed as the principal diagnosis when the purpose for the admission/encounter is rehabilitation. Several commenters recommended a revision of the ICD–10–CM Official Guidelines for Coding and Reporting if a new ICD–10–CM code for care involving use of rehabilitation procedures were created. Some of the commenters recommended that the new diagnosis code be reported as a secondary diagnosis when the purpose for the admission/encounter was rehabilitation while others recommended that the new code be reported as the principal diagnosis. One commenter objected to the development of coding guidelines based on Medicare payment policies. However, the commenter stated that any such guideline should be applied to all payers. The commenter stated that creating such a guideline that would restrict the use of these procedure codes such that they could only be used to identify rehabilitation admissions for the purpose of appropriately assigning MS–DRGs 945 and 946 merited serious consideration.

Response: We have referred the requests for a new ICD–10–CM code for care involving the use of rehabilitation procedures to the CDC for consideration at a future ICD–10 Coordination and Maintenance Committee meeting. Requests for ICD–10–CM code updates should be sent to the CDC at nchscid10CM@cdc.gov. Information on submitting proposals for new diagnosis codes can be found on CDC’s Web site at http://www.cdc.gov/nchs/icd/icd10维持 maintenance.htm. Should such a new diagnosis code be created, CMS would examine the possibility of using this new diagnosis code in the MS–DRGs 945 and 946 logic, as was the case in the ICD–9–CM version of the MS–DRGs. The public is also encouraged to send any specific recommendations for
requests to review the MCE relating specifically to the Age conflict edit, the Sex conflict edit, the Non-covered procedure edit, and the Unacceptable principal diagnosis code edit. We discuss these code edit issues below. In addition, as a result of new and modified code updates approved after the annual spring ICD–10 Coordination and Maintenance Committee meeting, we routinely make changes to the MCE. In the past, in both the IPPS proposed and final rules, we only provided the list of changes to the MCE that were brought to our attention after the prior year’s final rule. We historically have not listed the changes we have made to the MCE as a result of the new and modified codes approved after the annual spring ICD–10 Coordination and Maintenance Committee meeting. These changes are approved too late in the rulemaking schedule for inclusion in the proposed rule. Furthermore, although our MCE policies have been described in our proposed and final rules, we have not provided the detail of each new or modified diagnosis and procedure code edit in the final rule. However, we make available the finalized Definitions of Medicare Code Edits (MCE) file. Therefore, we have made available the FY 2017 ICD–10 MCE Version 34 manual file and an ICD–9–CM MCE Version 34.0A manual file (for analysis purposes only). The links to these MCE manual files, along with the links to purchase the mainframe and computer software for the MCE Version 34 (and ICD–10 MS–DRGs) are posted on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html through the FY 2017 IPPS Final Rule Home Page.

a. Age Conflict Edit

In the MCE, the Age conflict edit exists to detect inconsistencies between a patient’s age and any diagnosis on the patient’s record; for example, a 5-year-old patient with benign prosthetic hypertrophy or a 78-year-old patient coded with a delivery. In these cases, the diagnosis is clinically and virtually impossible for a patient of the stated age. Therefore, either the diagnosis or the age is presumed to be incorrect. Currently, in the MCE, the following four age diagnosis categories appear under the Age conflict edit and are listed in the manual and written in the software program:

- Newborn—Age of 0 years: a subset of diagnoses intended only for newborns and neonates (for example, fetal distress, perinatal jaundice).
- Pediatric—Age is 0–17 years inclusive (for example, Rey’s syndrome, routine child health exam).
- Maternity—Age range is 12–55 years inclusive (for example, diabetes in pregnancy, antepartum pulmonary complication).
- Adult—Age range is 15–124 years inclusive (for example, senile delirium, mature cataract).

(1) Newborn Diagnosis Category

Under the ICD–10–CM Official Guidelines for Coding and Reporting (available on the Web site at: https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-CM-and-GEMS.html), there are general guidelines and chapter-specific coding guidelines. The chapter-specific guidelines state that diagnosis codes from Chapter 16 (Certain Conditions Originating in the Perinatal Period) may be reported throughout the life of the patient if the condition is still present. The requestors noted that several codes from this Chapter 16 appear on the ICD–10 MCE Version 33 Age conflict edit for the newborn diagnosis category. Codes from this chapter are included in the P00 through P96 code range. Therefore, the requestors believed that because the chapter-specific guidelines state that codes within this chapter may be reported throughout the life of a patient, all codes within this range (P00 through P96) should be removed from the newborn diagnosis category on the Age conflict edit code list.

As we discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25000 through 25001), we examined the newborn diagnosis category on the age conflict edit list in the ICD–9–CM MCE Version 32 in comparison to the ICD–9–CM chapter-specific guidelines. Under ICD–9–CM, Chapter 15 (Certain Conditions Originating in the Perinatal Period) includes codes within the 760 through 779 range. We found that the same chapter-specific guideline under ICD–10 exists under ICD–9–CM: Diagnosis codes from Chapter 15 may be reported throughout the life of the patient if the condition is still present. Similar to the ICD–10 MCE Version 33 newborn diagnosis category in the Age conflict edit code list, we noted that several codes from this Chapter 15 appear on the ICD–9–CM MCE Version 32 Age conflict edit for the newborn diagnosis category.

Because the full definition of the chapter-specific guideline for “Certain Conditions Originating in the Perinatal Period” clearly states the codes within this chapter may be reported throughout the life of the patient if the condition is still present, we believe that,
historically, under ICD–9–CM, this was the rationale for inclusion of the diagnosis codes that were finalized for the newborn diagnosis category under the Age conflict edit (in code range 760 through 779). For example, under ICD–9–CM, there are four diagnosis codes in the 760.6x series that specifically include the term “newborn” in the title. These diagnosis codes are:

- 760.61 (Newborn affected by amniocentesis);
- 760.62 (Newborn affected by other in utero procedure);
- 760.63 (Newborn affected by other surgical operations on mother during pregnancy); and
- 760.64 (Newborn affected by previous surgical procedure on mother not associated with pregnancy).

Under the ICD–9–CM classification, the chapter-specific guidelines in Chapter 15 (Certain Conditions Originating in the Perinatal Period) state that, for coding and reporting purposes, the perinatal period is defined as before birth through the 28th day following birth. As such, for coding and reporting purposes, a patient that is beyond the 28th day of life is no longer considered a newborn. Therefore, we believe that the diagnosis codes listed on the newborn diagnosis category in the Age conflict edit code list are, in fact, appropriate because they identify what the title of Chapter 15 describes (certain conditions specific to beginning in the perinatal period); that is, a newborn.

The intent of the diagnosis codes included on the Age conflict edit code list is to identify claims where any one of the listed diagnoses is reported for a patient who is beyond the 28th day of life. If that definition is met according to the patient’s date of birth, the edit is correctly triggered in those cases.

Transitioning to the ICD–10 MCE was based on replication of the ICD–9–CM based MCE (in parallel with the transition to the ICD–10 MS–DRGs, which was based on replication of the ICD–9–CM MS–DRGs). Therefore, the diagnosis codes included in the newborn diagnosis category on the Age conflict edit code list in the ICD–10 MCE are a replication of the diagnosis code descriptions included on the newborn diagnosis category on the Age conflict edit code list under the ICD–9–CM MCE. However, the chapter-specific guideline in ICD–10–CM Chapter 16, section C.16.e. (Low birth weight and immaturity status), specifies that codes within category P07 (Disorders of newborn related to short gestation and low birth weight, not elsewhere classified) are for use for a child or adult who was premature or had a low birth weight as a newborn and this condition is affecting the patient’s current health status. Therefore, we agree that codes within the range of P07.00 through P07.39 should not be listed under newborn diagnosis category on the Age conflict edit code list in the ICD–10 MCE. It is unclear why this range of codes within category P07 is distinguished separately when under the General Perinatal Rules for Chapter 16 (Certain Conditions Originating in the Perinatal Period), section I.C.16.a.1. states that diagnosis codes from Chapter 16 may be reported throughout the life of the patient if the condition is still present. In addition, the guideline at section I.C.16.a.4. states that “should a condition originate in the perinatal period, and continue throughout the life of the patient, the perinatal code should continue to be used regardless of the patient’s age.” According to these general guidelines, we could assume that potentially all codes within Chapter 16 in the code range of P00 through P96 should be considered for removal from the newborn diagnosis category on the Age conflict edit code list. However, a subsequent section of Chapter 16, section I.C.16.e.2. (Codes for conditions specified as having implication for future health care needs), instructs users to assign codes for conditions that have been specified by the provider as having implications for future health care needs. Immediately below that instruction is a note which states: “This guideline should not be used for adult patients.”

The ICD–10–CM Official Guidelines for Coding and Reporting are updated separately from the IPPS rulemaking process. Due to the confusion with the chapter-specific guidelines for codes in Chapter 16 and how they impact the newborn diagnosis category on the Age conflict edit code list, we believe it would be beneficial to fully evaluate the intent of these guidelines with the Centers for Disease Control’s (CDC’s) National Center for Health Statistics (NCHS) because NCHS has the lead responsibility for the ICD–10–CM diagnosis codes.

In the meantime, to address claims processing concerns related to the newborn diagnosis category on the Age conflict edit code list, in the FY 2017 IPPS/LTCPPS proposed rule (81 FR 25001), we proposed to remove all the ICD–10–CM diagnoses in the code range of P00 through P96 from the newborn diagnosis category in the Age conflict code edit list for the ICD–10 MCE for FY 2017. We invited public comments on our proposal. We also solicited public comments on the appropriateness of the other diagnosis codes currently listed under the newborn diagnosis category in the Age conflict edit in the ICD–10 MCE Version 33. We refer readers to Table 6P.1a. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPFS/index.html) for review of the diagnosis codes we proposed to remove.

In addition, for FY 2017, we indicated that we were examining the need to revise the description for the newborn diagnosis category in the Age conflict edit under the MCE. The current description as written, Newborn—Age of 0 years; a subset of diagnoses intended only for newborns and neonates (e.g., fetal distress, perinatal jaundice), is not consistent with the instructions for reporting the diagnosis codes in Chapter 16. We invited public comments on our proposal to revise the description of the newborn diagnosis category in the Age conflict edit under the MCE.

**Comment:** Several commenters supported the proposal to remove all the ICD–10–CM diagnoses in the code range of P00 through P96 from the newborn diagnosis category in the Age conflict code edit list. The commenters did not believe the newborn guidelines were in conflict with each other or required any modifications, as the specific references noted in the proposed rule address unrelated reporting issues. However, the commenters indicated that they planned to submit recommendations directly to the CDC to revise an instructional note that appears at the beginning of Chapter 16 which they believe may be a contributing factor to confusion surrounding the proper application of codes within the chapter.

**Response:** We appreciate the commenters’ support. We also appreciate the commenters’ review of the newborn guidelines and their plan to submit a recommendation to the CDC regarding the instructional note that appears at the beginning of Chapter 16.

We wish to clarify for the commenters that the focus of our proposal was on the removal of codes from the newborn diagnosis category in the Age conflict code edit list. Our discussion involving the references to the guidelines was to simply note the confusion with the guidelines and how those guidelines impact the codes listed under newborn diagnosis category in the Age conflict code edit list. Following that discussion, we stated our belief that it would be beneficial to discuss the intent of the guidelines with CDC.

**Comment:** Many commenters supported the proposal for the MCE
changes related to the Age conflict edit description.

Response: We appreciate the commenters’ support and believe a revised description of the newbornedit better defines the diagnoses that are subject to it.

After consideration of the public comments we received, we are finalizing our proposal to remove all the ICD–10–CM diagnoses in the code range of P00 through P96 from the newborn diagnosis category in the Age conflict code edit list for the ICD–10 MCE for FY 2017. The procedure codes listed in Table 6P.1a. associated with this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) are the finalized list of procedure codes that will be removed from the newborn diagnosis category in the Age conflict code edit list in the ICD–10 MCE Version 34 effective October 1, 2016.

We also are finalizing our proposal to revise the description of the newborn diagnosis category under the ICD–10 MCE from “Newborn. Age of 0 years; a subset of diagnoses intended only for newborns and neonates (e.g., fetal distress, perinatal jaundice)” to “Perinatal/Newborn. Age 0 years only; a subset of diagnoses which will only occur during the perinatal or newborn period of age 0 (e.g., tetanus neonatorum, health examination for newborn under 8 days old)” in the ICD–10 MCE Version 34, effective October 1, 2016.

<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F93.0 ..................</td>
<td>Separation anxiety disorder of childhood.</td>
</tr>
<tr>
<td>F93.8 ..................</td>
<td>Other childhood emotional disorders.</td>
</tr>
<tr>
<td>F93.9 ..................</td>
<td>Childhood emotional disorder, unspecified.</td>
</tr>
<tr>
<td>F94.1 ..................</td>
<td>Reactive attachment disorder of childhood.</td>
</tr>
<tr>
<td>F94.2 ..................</td>
<td>Disinhibited attachment disorder of childhood.</td>
</tr>
<tr>
<td>F94.3 ..................</td>
<td>Other childhood disorders of social functioning.</td>
</tr>
<tr>
<td>F94.9 ..................</td>
<td>Childhood disorder of social functioning, unspecified.</td>
</tr>
<tr>
<td>F98.21 ................</td>
<td>Rumination disorder of infancy.</td>
</tr>
<tr>
<td>F98.29 ................</td>
<td>Other feeding disorders of infancy and early childhood.</td>
</tr>
<tr>
<td>F98.3 ..................</td>
<td>Pica of infancy and childhood.</td>
</tr>
<tr>
<td>F98.8 ..................</td>
<td>Other specified behavioral and emotional disorders with onset usually occurring in childhood and adolescence.</td>
</tr>
<tr>
<td>F98.9 ..................</td>
<td>Unspecified behavioral and emotional disorders with onset usually occurring in childhood and adolescence.</td>
</tr>
</tbody>
</table>

Under the ICD–10–CM Tabular List of Diseases and Injuries, Chapter 5 (Mental, Behavioral and Neurodevelopmental Disorders) contains a section titled “Behavioral and emotional disorders with onset usually occurring in childhood and adolescence” which includes codes for the F90 to F98 code range. At the beginning of this tabular section is an instructional “note” that states: “Codes within categories F90–F98 may be used regardless of the age of a patient. These disorders generally have onset within the childhood or adolescent years, but may continue throughout life or not be diagnosed until adulthood.”

Because the note specifically states that these codes may be used regardless of the age of a patient, we believe they should not be included on the pediatric diagnosis category on the Age conflict edit code list. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25001 through 25002), we proposed to remove the 12 codes that fall within the F90 through F98 code range currently listed for the pediatric diagnosis category on the ICD–10 MCE age conflict edit code list, effective October 1, 2016, for FY 2017. We invited public comments on our proposal.

Comment: Several commenters supported the proposal to address the replication issue for the pediatric diagnosis category on the ICD–10 MCE Age conflict edit list by removing the 12 ICD–10–CM diagnosis codes in the F90 through F98 code range currently listed.

Response: We appreciate the commenters’ support of our proposal. We also agree that removal of the specified ICD–10–CM diagnosis codes from the edit code list will resolve the replication issue and enable proper recording of the conditions regardless of the patient’s age.

After consideration of the public comments we received, we are finalizing our proposal to remove the 12 ICD–10–CM diagnosis codes in the F90 through F98 code range displayed earlier in this section from the pediatric diagnosis category Age conflict edit code list in the ICD–10 MCE Version 34, effective October 1, 2016.
<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H26.001</td>
<td>Unspecified infantile and juvenile cataract, right eye.</td>
</tr>
<tr>
<td>H26.002</td>
<td>Unspecified infantile and juvenile cataract, left eye.</td>
</tr>
<tr>
<td>H26.003</td>
<td>Unspecified infantile and juvenile cataract, bilateral.</td>
</tr>
<tr>
<td>H26.009</td>
<td>Unspecified infantile and juvenile cataract, unspecified eye.</td>
</tr>
<tr>
<td>H26.011</td>
<td>Infantile and juvenile cortical, lamellar, or zonular cataract, right eye.</td>
</tr>
<tr>
<td>H26.012</td>
<td>Infantile and juvenile cortical, lamellar, or zonular cataract, left eye.</td>
</tr>
<tr>
<td>H26.013</td>
<td>Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral.</td>
</tr>
<tr>
<td>H26.019</td>
<td>Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye.</td>
</tr>
<tr>
<td>H26.031</td>
<td>Infantile and juvenile nuclear cataract, right eye.</td>
</tr>
<tr>
<td>H26.032</td>
<td>Infantile and juvenile nuclear cataract, left eye.</td>
</tr>
<tr>
<td>H26.033</td>
<td>Infantile and juvenile nuclear cataract, bilateral.</td>
</tr>
<tr>
<td>H26.039</td>
<td>Infantile and juvenile nuclear cataract, unspecified eye.</td>
</tr>
<tr>
<td>H26.041</td>
<td>Anterior subcapsular polar infantile and juvenile cataract, right eye.</td>
</tr>
<tr>
<td>H26.042</td>
<td>Anterior subcapsular polar infantile and juvenile cataract, left eye.</td>
</tr>
<tr>
<td>H26.043</td>
<td>Anterior subcapsular polar infantile and juvenile cataract, bilateral.</td>
</tr>
<tr>
<td>H26.049</td>
<td>Anterior subcapsular polar infantile and juvenile cataract, unspecified eye.</td>
</tr>
<tr>
<td>H26.051</td>
<td>Posterior subcapsular polar infantile and juvenile cataract, right eye.</td>
</tr>
<tr>
<td>H26.052</td>
<td>Posterior subcapsular polar infantile and juvenile cataract, left eye.</td>
</tr>
<tr>
<td>H26.053</td>
<td>Posterior subcapsular polar infantile and juvenile cataract, bilateral.</td>
</tr>
<tr>
<td>H26.059</td>
<td>Posterior subcapsular polar infantile and juvenile cataract, unspecified eye.</td>
</tr>
<tr>
<td>H26.061</td>
<td>Combined forms of infantile and juvenile cataract, right eye.</td>
</tr>
<tr>
<td>H26.062</td>
<td>Combined forms of infantile and juvenile cataract, left eye.</td>
</tr>
<tr>
<td>H26.063</td>
<td>Combined forms of infantile and juvenile cataract, bilateral.</td>
</tr>
<tr>
<td>H26.069</td>
<td>Combined forms of infantile and juvenile cataract, unspecified eye.</td>
</tr>
<tr>
<td>H26.09</td>
<td>Other infantile and juvenile cataract.</td>
</tr>
</tbody>
</table>

Our clinical advisors reviewed the list of diagnoses presented above and confirmed that these diagnosis codes are appropriate to include in the ICD–10 MCE for the pediatric diagnosis category in the Age conflict edit because the diseases described by these codes are typically diagnosed in early childhood and treated very rapidly to prevent amblyopia. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25002), for FY 2017, we did not propose to remove these codes under the pediatric diagnosis category in the Age conflict edit. We proposed to maintain this list in the ICD–10 MCE Version 34, effective October 1, 2016. We invited public comments on our proposal.

Comment: Commenters supported the proposal to retain the list of ICD–10–CM diagnosis codes describing infantile and juvenile cataracts in the pediatric diagnosis category for the Age conflict edit.

Response: We appreciate the commenters’ support.

As stated earlier, for the pediatric diagnosis category in the Age conflict edit, the MCE considers the age range of 0 through 17 years inclusive. In the ICD–10 MCE Version 33, there are four diagnosis codes describing the body mass index (BMI) for pediatric patients in the pediatric diagnosis category on the Age conflict edit code list. The four ICD–10–CM diagnosis codes describing the BMI percentiles for pediatric patients are as follows:

<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z68.51</td>
<td>Body mass index (BMI) pediatric, less than 5th percentile for age.</td>
</tr>
<tr>
<td>Z68.52</td>
<td>Body mass index (BMI) pediatric, 5th percentile to less than 85th percentile for age.</td>
</tr>
<tr>
<td>Z68.53</td>
<td>Body mass index (BMI) pediatric, 85th percentile to less than 95th percentile for age.</td>
</tr>
<tr>
<td>Z68.54</td>
<td>Body mass index (BMI) pediatric, greater than or equal to 95th percentile for age.</td>
</tr>
</tbody>
</table>

Under the ICD–10–CM Tabular List of Diseases and Injuries, the BMI pediatric diagnosis codes are designated for use in persons 2 through 20 years of age. The percentiles are based on the growth charts published by the CDC. As a result of the age discrepancy between the MCE pediatric diagnosis category in the Age conflict edit (ages 0 through 17) and the Tabular reference for the BMI pediatric codes (ages 2 through 20), in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25002), we proposed to remove ICD–10–CM diagnosis codes Z68.51, Z68.52, Z68.53, and Z68.54 from the ICD–10 MCE pediatric diagnosis category on the Age conflict edit code list for Version 34, effective FY 2017. We invited public comments on our proposal.

Comment: Commenters supported the proposal to remove the four ICD–10–CM diagnosis codes describing body mass index (BMI) for pediatric patients from the pediatric diagnosis category on the Age conflict edit code list. The commenters stated that this proposal would enable proper reporting of these codes.

Response: We appreciate the commenters’ support. We agree that removal of the specified ICD–10–CM diagnosis codes discussed previously from the edit code list will resolve any age discrepancy issues in the reporting of the conditions regardless of the patient’s age.

As a result of the public comments we received, we are finalizing our proposal to remove the four ICD–10–CM diagnosis codes described above from the ICD–10–CM pediatric diagnosis category on the Age conflict edit code list.
We received a request to review ICD–10–CM diagnosis code Z79.890 (Hormone replacement therapy (postmenopausal)). This code is listed on the Diagnoses for females only edit code list. Therefore, when the diagnosis is reported for a male patient, the edit will be triggered. However, the requestor noted that the term “postmenopausal” is enclosed in parentheses and is a “non-essential modifier.” A “non-essential modifier” is used in the ICD–10–CM classification to identify a supplementary word that may, or may not be present in the statement of a diagnosis or procedure. In other words, the term in parentheses does not have to be documented to report the code. If the medical record documentation states a female patient is undergoing hormone replacement therapy, the documentation supports assignment of the case to ICD–10–CM diagnosis code Z79.890 (Hormone replacement therapy (postmenopausal)). There does not need to be a diagnostic statement that the patient is postmenopausal to assign the code. The requester asked that CMS review why this diagnosis code is being classified as applicable to females only because, in the absence of the non-essential modifier (postmenopausal), the code could also apply to males.

We note that the ICD–9–CM equivalent code, V07.4 Hormone replacement therapy (postmenopausal) has been on the female only edit since October 1, 1992 in the ICD–9–CM MCE. We consulted with the ICD–10–CM classification staff at the NCHS to determine the intended use and reporting of this diagnosis code. The staff at NCHS acknowledged that, historically, the intent of the ICD–9–CM diagnosis code was for females only. However, they agreed that, under ICD–10–CM, the diagnosis code Z79.890 can be reported for both men and women. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25003), we proposed to remove this diagnosis code from the Diagnoses for females only edit code list effective October 1, 2016. We invited public comments on our proposal.

Response: We appreciate the commenters’ support for our proposal. We agree it is appropriate to allow the reporting of this diagnosis code for both male and female patients.
These codes describe encounters for breast implants or prostheses. Our clinical advisors and the NCHS staff agree that diagnosis codes Z44.30, Z44.31, Z44.32, Z45.811, Z45.812, and Z45.819 are clinically appropriate to report for male patients and should not be limited to females. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25004), we proposed to remove these diagnosis codes from the Diagnoses for females only edit code list in the ICD–10 MCE, effective October 1, 2016. We invited public comments on our proposal.

Comment: Commenters agreed that the ICD–10–CM diagnosis codes describing encounters for breast implants or prostheses are appropriate to report for male patients and should not be limited to females.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to remove the six ICD–10–CM diagnosis codes displayed earlier in this section that identify an encounter for fitting or adjustment of a breast implant or prosthesis from the Diagnoses for females only edit code list in the ICD–10 MCE Version 34, effective October 1, 2016.

c. Non-Covered Procedure Edit

In the MCE, the Non-covered procedure edit identifies procedures for which Medicare does not provide payment. Payment is not provided due to specific criteria that are established in the National Coverage Determination (NCD) process. We refer readers to the Web site at: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/howtorequestanNCD.html for additional information on this process. In addition, there are procedures that would normally not be paid by Medicare but, due to the presence of certain diagnoses, are paid.

(1) Endovascular Mechanical Thrombectomy

We received several requests to review ICD–10–PCS procedure code 03CG3ZZ (Exirpation of matter from intracranial artery, percutaneous approach) which is currently listed as a non-covered procedure in the ICD–10 MCE Non-covered procedure edit code list. The comparable ICD–9–CM code translations for ICD–10–PCS code 03CG3ZZ are ICD–9–CM codes 17.54 (Percutaneous anherectomy of intracranial vessel(s)) and 39.74 (Endovascular removal of obstruction from head and neck vessel(s)).

The requestors noted, that, under ICD–9–CM, endovascular mechanical thrombectomy of a cerebral artery to remove a clot that is causing an ischemic stroke was reported with procedure code 39.74 (Endovascular removal of obstruction from head and neck vessel(s)) and is a well-recognized procedure that has been covered by Medicare. After implementation of ICD–10 on October 1, 2015, claims that were correctly submitted for endovascular mechanical thrombectomy procedures with ICD–10–PCS procedure code 03CG3ZZ were triggering the Non-covered procedure edit. The requestors sought clarification as to whether there was a change in coverage or if there was a replication issue.

Under the ICD–9–CM MCE Version 32, procedure code 00.62 is listed on the Non-covered procedure edit code list. Percutaneous angioplasty of an intracranial vessel procedure (with and without stent) may be reported under ICD–10 with the ICD–10–PCS procedure codes listed in the following table:

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>037G34Z ................</td>
<td>Dilation of intracranial artery with drug-eluting intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>037G3DZ ................</td>
<td>Dilation of intracranial artery with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>037G3ZZ ................</td>
<td>Dilation of intracranial artery, percutaneous approach.</td>
</tr>
<tr>
<td>037G44Z ................</td>
<td>Dilation of intracranial artery with drug-eluting intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>037G4DZ ................</td>
<td>Dilation of intracranial artery with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>037G4ZZ ................</td>
<td>Dilation of intracranial artery, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>057L3DZ ................</td>
<td>Dilation of intracranial vein with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>057L4DZ ................</td>
<td>Dilation of intracranial vein with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
</tbody>
</table>

We discovered that a replication error occurred due to an outdated ICD–9–CM entry for procedure code 00.62. This error led to ICD–10–PCS procedure codes 03CG3ZZ (Exirpation of matter from intracranial artery, percutaneous approach) and 05CL3ZZ (Exirpation of matter from intracranial vein, percutaneous approach) being listed as comparable translations for ICD–9–CM code 00.62. As a result, ICD–10–PCS procedure code 03CG3ZZ was included on the ICD–10 MCE Version 33 Non-covered procedure edit code list.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25004), for FY 2017, we proposed to remove the ICD–10–PCS procedure codes listed in the following table from the ICD–10 MCE Version 34.0 Non-covered procedure edit code list.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03CG3ZZ ................</td>
<td>Exirpation of matter from intracranial artery, percutaneous approach.</td>
</tr>
<tr>
<td>03CG4ZZ ................</td>
<td>Exirpation of matter from intracranial artery, percutaneous endoscopic approach.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal.

Comment: Many commenters supported the proposal to remove the four ICD–10–PCS procedure codes describing mechanical thrombectomy from the Non-covered procedure edit code list in the ICD–10 MCE to prevent further claims processing issues. Some commenters also recommended that CMS instruct the MACs to reprocess claims that were denied as a result of the codes being listed in the MCE. Other commenters suggested changes to the National Coverage Determination (NCD) for Intracranial Percutaneous Transluminal Angioplasty (PTA) with Stenting (20.7).

Response: We appreciate the commenters’ support for our proposal. We agree that removal of the four ICD–10–PCS procedure codes that describe mechanical thrombectomy procedures from the non-covered procedure edit code list in the ICD–10 MCE will help resolve future claims processing and denial issues associated with the reporting of these codes.

In response to the comment that we instruct the MACs to reprocess any affected claims, we note that contractors began reprocessing affected claims at providers’ request in March 2016. We recommend that providers who have experienced claims processing issues work with their local MACs to resolve any outstanding claims.

With regard to the commenters who suggested that changes be made to the NCD for Intracranial PTA with Stenting, we note that we issued instructions with One-Time Notification, Pub. No. 100–20, Transmittal 1672, Change Request 9631, effective October 1, 2016.

After consideration of the public comments we received, we are finalizing our proposal to remove the four ICD–10–PCS procedure codes displayed earlier in this section from the non-covered procedure edit code list in the ICD–10 MCE Version 34, effective October 1, 2016.

(2) Radical Prostatectomy

We received a request to review ICD–10–PCS procedure codes related to a radical prostatectomy. Specifically, the requestor noted that when coding cases where the removal of the vas deferens is also performed, a Non-covered procedure edit is triggered. The requestor suggested that the edit for this procedure may be intended for cases where the removal of the vas deferens is being performed for sterilization (vasectomy) purposes. According to the requestor, removal of the vas deferens also may be involved with removing the prostate in the radical prostatectomy procedure. The requestor suggested that CMS address this issue by revising the ICD–10 MCE Non-covered procedure edit code list to reflect noncoverage of the procedure codes when the removal of vas deferens procedure is being performed solely for sterilization (vasectomy) purposes.

Because radical procedures can have different meanings, depending on the procedure, the term “radical” is not always reliable information for coding and reporting the procedure. Under ICD–10–PCS, users are instructed to code separately the organs or structures that were actually removed and for which there is a distinctly defined body part. A radical prostatectomy is coded as a “cluster” under ICD–10–PCS. A “cluster” is the term used to describe the circumstance when a combination of ICD–10–PCS procedure codes are needed to fully satisfy the equivalent meaning of an ICD–9–CM procedure code for it to be considered a plausible translation.

The cluster definition for a radical prostatectomy in ICD–10–PCS currently consists of one of the following codes:

- 0VT00ZZ (Resection of prostate, open approach);
- 0VT04ZZ (Resection of prostate, percutaneous endoscopic approach);
- 0VT07ZZ (Resection of prostate, via natural or artificial opening); or
- 0VT08ZZ Resection of prostate, via natural or artificial opening endoscopic; in combination with one of the following codes:
  - 0VT30ZZ (Resection of bilateral seminal vesicles, open approach);
  - 0VT34ZZ (Resection of bilateral seminal vesicles, percutaneous endoscopic approach).

As stated earlier, under ICD–10–PCS, users are instructed to code separately the organs or structures that were actually removed and for which there is a distinctly defined body part. Therefore, a patient who undergoes a radical prostatectomy that involves removal of the vas deferens would have this procedure reported separately, in addition to the options displayed in the “cluster.”

The ICD–10–PCS procedure codes that may be reported for sterilization and involve the bilateral vas deferens include the following:

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0VS500ZZ</td>
<td>Destruction of bilateral vas deferens, open approach.</td>
</tr>
<tr>
<td>0VS503ZZ</td>
<td>Destruction of bilateral vas deferens, percutaneous approach.</td>
</tr>
<tr>
<td>0VS504ZZ</td>
<td>Destruction of bilateral vas deferens, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0VBQ0ZZ</td>
<td>Excision of bilateral vas deferens, open approach.</td>
</tr>
<tr>
<td>0VBQ03ZZ</td>
<td>Excision of bilateral vas deferens, percutaneous approach.</td>
</tr>
<tr>
<td>0VBQ04ZZ</td>
<td>Excision of bilateral vas deferens, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0VTQ0ZZ</td>
<td>Resection of bilateral vas deferens, open approach.</td>
</tr>
<tr>
<td>0VTQ4ZZ</td>
<td>Resection of bilateral vas deferens, percutaneous endoscopic approach.</td>
</tr>
</tbody>
</table>

The eight procedure codes listed above describing various methods to remove the bilateral vas deferens are currently listed on the ICD–10 MCE Version 33 Non-covered procedure edit code list.

The requester is correct in stating that the codes related to removal of the bilateral vas deferens are included on the ICD–10 MCE Version 33 Non-covered procedure edit code list to reflect a sterilization procedure. While the vast majority of sterilization procedures will involve reporting the
bilateral procedure codes, there are instances where one vas deferens may have been previously removed for other reasons and the remaining vas deferens requires sterilization. Therefore, the procedure codes describing removal of a unilateral vas deferens are also included on the ICD–10 MCE Version 33 Non-covered procedure edit code list to reflect a sterilization procedure. We agree that revising the language in the edit will resolve the issue of covered procedures being inappropriately subject to the edit.

In addition, while reviewing the Non-covered procedure edit list of codes that may be reported to identify sterilization procedures for males, we considered the procedure codes that may be reported to identify sterilization procedures for females. We examined the list of ICD–10–PCS procedure codes included on the ICD–10 MCE Version 33 Non-covered procedure edit code list that could reflect female sterilization (removal of fallopian tubes) and determined those codes also could be reported for other conditions and could be inappropriately subject to the current edit as well.

Therefore, in the FY 2017 IPPS/LTC Paymentogh proposes rule (81 FR 25005), for FY 2017, we proposed to create a new ICD–10 MCE Version 34 Non-covered procedure edit to reflect that procedures performed on males involving the unilateral or bilateral vas deferens and procedures performed on females involving the fallopian tubes are not covered procedures for sterilization purposes. The proposed new ICD–10 MCE Version 34 Non-covered procedure edit would be displayed as follows: “G. Non-covered procedure. The procedure codes shown below are identified as non-covered procedures only when ICD–10–CM diagnosis code Z30.2 (Encounter for sterilization) is listed as the principal diagnosis.”

We referred readers to Table 6P.1b associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) to review the proposed list of noncovered procedure codes describing sterilization procedures for males and females for this proposed Non-covered procedure edit. We invited public comments on our proposal to create this new Non-covered procedure edit and also invited public comments on the proposed list of codes to describe sterilization procedures for the proposed edit.

Comment: Commenters supported the proposal to create a new ICD–10 MCE Version 34 Non-covered procedure edit to reflect that procedures performed on males involving the unilateral or bilateral vas deferens and procedures performed on females involving the fallopian tubes are not covered procedures for sterilization purposes. One commenter noted that there could be situations in which a patient is admitted for another condition and a sterilization procedure is performed during that episode of care. For example, the commenter stated a female may be admitted for a cesarean section and have a tubal ligation procedure during that same hospitalization. The commenter suggested that the proposed list of procedure codes be considered as non-covered when ICD–10–CM diagnosis code Z30.2 is reported as a principal or secondary diagnosis on the claim.

Response: We appreciate the commenters’ support for our proposal. We also agree with the commenter that it is appropriate to list ICD–10–CM diagnosis code Z30.2 (Encounter for sterilization) as a principal or secondary diagnosis for purposes of the non-covered procedure edit.

After consideration of the public comments we received, we are finalizing our proposal to create a new ICD–10 MCE Version 34 Non-covered procedure edit. The new edit will be defined as follows: “G. Non-covered procedure. The procedure codes shown below are identified as non-covered procedures only when ICD–10–CM diagnosis code Z30.2 (Encounter for sterilization) is listed as the principal diagnosis or secondary diagnosis.” The procedure codes listed in Table 6P.1b associated with this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) are the finalized list of non-covered procedure codes describing sterilization procedures for males and females for this finalized Non-covered procedure edit in the ICD–10 MCE Version 34, effective October 1, 2016.

d. Unacceptable Principal Diagnosis Edit

In the MCE, there are select codes that describe a circumstance which influences an individual’s health status but does not actually describe a current illness or injury. There also are codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis. In limited situations, there are a few codes on the MCE Unacceptable principal diagnosis edit code list that are considered “acceptable” when a specified secondary diagnosis is also coded and reported on the claim.

(1) Liveborn Infant

We received a request to examine ICD–10–CM diagnosis codes Z38.1 (Single liveborn infant, born outside hospital), Z38.4 (Twin liveborn infant, born outside hospital), and Z38.7 (Other multiple liveborn infant, born outside hospital), all of which are currently listed on the Unacceptable principal diagnosis edit code list for the ICD–10 MCE Version 33. The requestor believed that these codes are listed in error and suggested their removal.

The ICD–10–CM diagnosis code descriptions for liveborn infants differ from the ICD–9–CM diagnosis code descriptions for liveborn infants. The ICD–9–CM codes differentiate between a liveborn infant that was born prior to admission and hospitalized versus a liveborn infant that was born prior to admission and not hospitalized. The following codes in the ICD–9–CM MCE Version 32 included on the Unacceptable principal diagnosis edit code list are those that describe a liveborn infant that was born outside the hospital and not hospitalized:

<table>
<thead>
<tr>
<th>ICD–9–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>V30.2 ..................</td>
<td>Single liveborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V31.2 ..................</td>
<td>Twin birth, mate liveborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V32.2 ..................</td>
<td>Twin birth, mate stillborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V33.2 ..................</td>
<td>Twin birth, unspecified whether mate liveborn or stillborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V34.2 ..................</td>
<td>Other multiple birth (three or more), mates all liveborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V35.2 ..................</td>
<td>Other multiple birth (three or more), mates all stillborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V36.2 ..................</td>
<td>Other multiple birth (three or more), mates liveborn and stillborn, born outside hospital and not hospitalized.</td>
</tr>
<tr>
<td>V37.2 ..................</td>
<td>Other multiple birth (three or more), unspecified whether mates liveborn or stillborn, born outside hospital.</td>
</tr>
<tr>
<td>V39.1 ..................</td>
<td>Liveborn, unspecified whether single, twin or multiple, born before admission to hospital.</td>
</tr>
</tbody>
</table>
Acute Inpatient PPS  \( \text{Description} 
\begin{array}{|c|l|}
\hline
\text{ICD-9-CM diagnosis code} & \text{Description} \\
\hline
V39.2 & \text{Liveborn, unspecified whether single, twin or multiple, born outside hospital and not hospitalized.} \\
\hline
\end{array} 
\)

For replication purposes, the comparable ICD–10–CM diagnosis codes for the above listed codes are: Z38.1 (Single liveborn infant, born outside hospital); Z38.4 (Twin liveborn infant, born outside hospital); and Z38.7 (Other multiple liveborn infant, born outside hospital). There are no other ICD–10–CM diagnosis codes that describe a liveborn infant born outside a hospital.

The liveborn infant codes are an example of where a particular concept involving the place of birth is not the same between the ICD–9–CM and ICD–10–CM classification systems. Because the ICD–10–CM diagnosis codes do not include the same concept as the ICD–9–CM diagnosis codes regarding whether the liveborn infant was hospitalized or not, we agree it would not be appropriate to continue to include the ICD–10–CM diagnosis codes on the Unacceptable principal diagnosis list.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25006), for FY 2017, we proposed to remove ICD–10–CM diagnosis codes Z38.1, Z38.4, and Z38.7 from the Unacceptable principal diagnosis edit in the ICD–10 MCE Version 34. We invited public comments on our proposal.

**Comment:** Several commenters supported the proposal to remove the three ICD–10–CM diagnosis codes describing a liveborn infant born outside of the hospital from the Unacceptable principal diagnosis edit code list in the ICD–10 MCE.

**Response:** We appreciate the commenters’ support of our proposal. After consideration of the public comments we received, we are finalizing our proposal to remove codes Z38.1 (Single liveborn infant, born outside hospital); Z38.4 (Twin liveborn infant, born outside hospital); and Z38.7 (Other multiple liveborn infant, born outside hospital) from the Unacceptable principal diagnosis edit code list in the ICD–10 MCE, effective October 1, 2016.

(2) Multiple Gestation

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25006 through 25007), we received a request to review the ICD–10–CM diagnosis codes related to multiple gestation that are currently listed on the ICD–10 MCE Version 33 Unacceptable principal diagnosis edit code list. The requestor expressed concern that these codes were included in the edit and suggested that CMS evaluate further to determine if they were appropriate.

In the ICD–10–CM classification, a single diagnosis code describes a multiple gestation and contains information pertaining to the placenta. This differs from the ICD–9–CM classification, where two diagnosis codes are required to separately report (1) multiple gestation with a delivery or complication and (2) multiple gestation with the status of the placenta.

In the ICD–9–CM MCE Version 32, only the ICD–9–CM diagnosis codes describing the status of the placenta are listed on the Unacceptable principal diagnosis edit code list. These ICD–9–CM diagnosis codes are:

There are 68 ICD–10–CM diagnosis codes included on the ICD–10 MCE Version 33 Unacceptable principal diagnosis edit code list as comparable translations that describe multiple gestation and status of the placenta. The list of these codes was included in Table 6P.1c. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcutelnpatientPPS/index.html).

Because only one, and not both, concepts from the ICD–9–CM classification was considered to be an unacceptable principal diagnosis (status of placenta) in the ICD–9–CM MCE, we agree this was a replication error that incorrectly included the ICD–10–CM diagnosis codes that identify both concepts (multiple gestation and status of placenta) in a single code on the ICD–10 MCE. The edit cannot isolate the status of placenta for the ICD–10 MCE because it is reported in combination with the multiple gestation as a single code. Therefore, it is inappropriate to include these codes on the Unacceptable principal diagnosis edit code list.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25007), for FY 2017, we proposed to remove the ICD–10–CM diagnosis codes listed in Table 6P.1c. associated with the proposed rule (which is available via Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcutelnpatientPPS/index.html) from the ICD–10 MCE.
Version 34 Unacceptable principal diagnosis list. We invited public comments on our proposal.

Comment: Commenters supported the proposal to remove the ICD–10–CM diagnosis codes listed describing multiple gestation from the Unacceptable principal diagnosis edit code list in the ICD–10 MCE.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to remove the ICD–10–CM diagnosis codes listed in Table 6P.1c. associated with this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) from the ICD–10 MCE Version 34 Unacceptable principal diagnosis list, effective October 1, 2016.

(3) Supervision of High Risk Pregnancy

We received a request to review the ICD–10–CM diagnosis codes related to supervision of high risk pregnancy (elderly primigravida and multigravida) that are currently listed on the ICD–10 MCE Version 33 Unacceptable principal diagnosis edit code list. The requestor stated that these codes were not included in the edit under the ICD–9–CM MCE. According to the requester, the codes describing these conditions should be allowed for reporting as a principal diagnosis based on the ICD–10–CM Tabular List of Diseases instructions for Chapter 15 (Certain Conditions Originating in the Perinatal Period). The chapter-specific guidelines for ICD–10–CM state that “diagnosis code O80 (Encounter for full-term uncomplicated delivery) should be assigned when a woman is admitted for a full-term normal delivery and delivers a single, healthy infant without any complications antepartum, during the delivery, or postpartum during the delivery episode. Code O80 is always a principal diagnosis. It is not to be used if any other code from Chapter 15 is needed to describe a current complication of the antenatal, delivery, or perinatal period.” The requestor stated that obstetric patients admitted as inpatients often meet the definition of an elderly primigravida or elderly multigravida, which is the appropriate condition to be reported as the principal diagnosis. However, because the codes describing this condition are listed on the Unacceptable principal diagnosis edit code list, they are unable to be reported.

The diagnosis codes describing high-risk patients admitted for delivery differ between the ICD–10–CM and ICD–9–CM classifications. Under ICD–9–CM, two diagnosis codes are required to separately report concept 1 of elderly primigravida or elderly multigravida and whether a delivery occurred and concept 2 of supervision of high-risk pregnancy with elderly primigravida or elderly multigravida. We display the codes that correspond to these concepts below and titled them as Code List 1 and Code List 2. A code from each list would be reported to fully describe the circumstances of the admission and the patient.

Code List 1—We note that the following codes are listed on the ICD–9–CM MCE Version 32 Unacceptable principal diagnosis edit code list:

<table>
<thead>
<tr>
<th>ICD–9–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>V23.81</td>
<td>Supervision of high-risk pregnancy with elderly primigravida.</td>
</tr>
<tr>
<td>V23.82</td>
<td>Supervision of high-risk pregnancy with elderly multigravida.</td>
</tr>
</tbody>
</table>

Code List 2—We note that the following codes are not listed on the ICD–9–CM MCE Version 32 Unacceptable principal diagnosis edit code list. However, we display them here for the benefit of the reader in the discussion that follows.

<table>
<thead>
<tr>
<th>ICD–9–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>659.50</td>
<td>Elderly primigravida, unspecified as to episode of care or not applicable.</td>
</tr>
<tr>
<td>659.51</td>
<td>Elderly primigravida, delivered, with or without mention of antepartum condition.</td>
</tr>
<tr>
<td>659.53</td>
<td>Elderly primigravida, antepartum condition or complication.</td>
</tr>
<tr>
<td>659.60</td>
<td>Elderly multigravida, unspecified as to episode of care or not applicable.</td>
</tr>
<tr>
<td>659.61</td>
<td>Elderly multigravida, delivered with or without mention of antepartum condition.</td>
</tr>
<tr>
<td>659.63</td>
<td>Elderly multigravida, antepartum condition or complication.</td>
</tr>
</tbody>
</table>

As noted above, in the ICD–9–CM MCE Version 32, only the ICD–9–CM diagnosis codes describing the supervision of high-risk pregnancy are listed on the Unacceptable principal diagnosis edit code list. There are eight ICD–10–CM diagnosis codes included on the ICD–10 MCE Version 33 Unacceptable principal diagnosis edit code list that describe the concept of elderly primigravida or elderly multigravida and supervision of high-risk pregnancy, in a single code. As shown below, the concept of whether a delivery occurred is not included in the code description for the eight codes.

<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>O09.511</td>
<td>Supervision of elderly primigravida, first trimester.</td>
</tr>
<tr>
<td>O09.512</td>
<td>Supervision of elderly primigravida, second trimester.</td>
</tr>
<tr>
<td>O09.513</td>
<td>Supervision of elderly primigravida, third trimester.</td>
</tr>
<tr>
<td>O09.519</td>
<td>Supervision of elderly primigravida, unspecified trimester.</td>
</tr>
</tbody>
</table>

1 The ICD–10–CM classification defines an elderly primigravida or elderly multigravida as a complication of the pregnancy since the management and care of the expectant mother is affected by the fact they are an older patient.
Because the concepts and coding guidelines between the ICD–9–CM and ICD–10–CM classifications differ greatly in how they define this subset of patients, in the FY 2017 IPPS/LTC PPS proposed rule, we acknowledged that the eight ICD–10–CM diagnosis codes listed above should be removed from the ICD–10 MCE Unacceptable principal diagnosis edit code list to permit the reporting of these codes as principal diagnosis when the documentation supports such assignment. We also note that during our analysis of the eight diagnosis codes describing elderly primigravida and elderly multigravida high-risk pregnancy patients, we found additional codes on the ICD–10 MCE Version 33 Unacceptable principal diagnosis edit code list related to high-risk pregnancy that we believe should also be removed so as to permit the reporting of these codes as principal diagnosis when the documentation supports such assignment.

In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25008 through 25008), for FY 2017, we proposed to remove all the ICD–10–CM diagnosis codes related to high-risk pregnancy currently listed in Table 6P.1d associated with the proposed rule (which is available via Internet on the CMS Web site at: http://www.cdc.gov/nchs/icd/icd10cm.htm) from the ICD–10 MCE Version 34 Unacceptable principal diagnosis edit code list. We invited public comment on our proposal.

\textbf{Comment:} Many commenters supported the proposal to remove the ICD–10–CM diagnosis codes related to high-risk pregnancy from the ICD–10 MCE Unacceptable principal diagnosis edit code list. However, some commenters did not support the proposal. The commenters stated their understanding that the codes from category O09, Supervision of high-risk pregnancy, should only be used for routine prenatal outpatient visits.

\textbf{Response:} We appreciated the commenters’ support of our proposal. With regard to the commenters who did not support the proposal to remove the diagnosis codes related to high-risk pregnancy from the ICD–10 MCE Unacceptable principal diagnosis edit code list, we note that there is confusion with the correct reporting of these diagnosis codes. For example, in the ICD–10–CM Guidelines, the following entry is displayed:

- Pregnancy (childbirth) (labor) (puerperium) \textit{(see also Delivery and Puerperal)}

\begin{itemize}
  \item complicated by (care of) (management affected by)
    \begin{itemize}
      \item elderly primigravida O09.51-
    \end{itemize}
  \end{itemize}

Therefore, the classification is defining an elderly multigravida or elderly primigravida as a complication of the pregnancy. This entry could relate to Chapter 15, Section I.C.15.b.3 of the guidelines for episodes when no delivery occurs, which instructs users that the principal diagnosis should correspond to the principal complication of the pregnancy which necessitated the encounter for care. In other words, if an elderly primigravida is admitted to the hospital with no other complications and does not deliver during that admission, the classification appears to allow the reporting of a code from category O09, Supervision of high-risk pregnancy, as a principal diagnosis based on the Index entry. However, in Chapter 15, Section I.C.15.b.2 of the guidelines, the language instructs users that a code from category O90, Supervision of high-risk pregnancy, should be used as the first-listed diagnosis to report prenatal outpatient visits for high-risk patients.

We consulted with the staff at the CDC’s NCHS to clarify the intent of the ICD–10–CM Alphabetic Index to Diseases entry and the Chapter 15 guidelines related to these codes. According to the CDC NCHS staff, the ICD–10–CM Guidelines have been updated for FY 2017 to explain the appropriate reporting of category O90 codes. The FY 2017 ICD–10–CM Official Guidelines for Coding and Reporting are available via the Internet on the CDC Web site at: http://www.cdc.gov/nchs/ict/icd10cm.htm. We note that, historically, we have not provided coding advice in rulemaking with respect to policy. We collaborate with the American Hospital Association (AHA) through the Coding Clinic for ICD–10–CM and ICD–10–PCS to promote proper coding. In addition, a proposal to revise the ICD–10–CM Alphabetic Index to Diseases will be discussed at the September 13–14, 2016 ICD–10 Coordination and Maintenance Committee meeting.

After consideration of the public comments we received and the updated FY 2017 ICD–10–CM Official Guidelines for Coding and Reporting, we are not finalizing our proposal to remove all the ICD–10–CM diagnosis codes related to high-risk pregnancy currently listed in Table 6P.1d. associated with the proposed rule and this final rule (which is available via Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) from the ICD–10 MCE Version 34 Unacceptable principal diagnosis edit code list. The ICD–10–CM diagnosis codes listed in Table 6P.1d will continue to be subject to the Unacceptable principal diagnosis edit in the ICD–10 MCE Version 34, effective October 1, 2016.

e. Other MCE Issues

The following MCE discussion, proposals, and final policies are the result of internal review of other MCE issues.

1. Procedure Inconsistent With Length of Stay Edit

In the FY 2016 IPPS/LTC PPS final rule (80 FR 49411), we finalized a revision for the language of the ICD–10 MCE Version 33 edit for “Procedure inconsistent with length of stay” with regard to ICD–10–PCS procedure code 5A1955Z (Respiratory ventilation, greater than 96 consecutive hours). The current description of the code edit reads as follows: “The following procedure code should only be coded on claims with a length of stay greater than four days.”

As we strive to assist providers with correct coding and reporting of this service, we proposed to further revise the description of this code edit. In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25008), for FY 2017, we proposed to modify the edit description to read as follows: “The following procedure code should only be coded on claims when the respiratory ventilation is provided for greater than..."
four consecutive days during the length of stay.’

We stated that we believe this proposed modification would further clarify the appropriate circumstances in which ICD–10–PCS code 5A1955Z may be reported. We invited public comments on our proposal.

Comment: Commenters supported the proposal to modify the description for the “Procedure inconsistent with length of stay” edit for ICD–10–PCS code 5A1955Z in the ICD–10 MCE.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to revise the title of MS–DRG 208 by adding an “equal” sign (=) after the “less than” (<) sign to better reflect the GROUPER logic. The finalized title for MS–DRG 208 (Respiratory System Diagnosis with Ventilator Support <=96 Hours) is included in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(2) Maternity Diagnoses

We identified three ICD–10–CM diagnosis codes that describe conditions related to pregnancy or the puerperium that are not currently listed on the ICD–10 MCE Version 33 Age conflict edit code list for maternity diagnoses. The diagnosis codes include:

- C58 (Malignant neoplasm of placenta);
- D39.2 (Neoplasm of uncertain behavior of placenta); and
- F53 (Puerperal psychosis).

To be consistent with other related conditions currently included in the Age conflict edit code list for maternity diagnoses, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25008), we proposed to add ICD–10–CM diagnosis codes C58 (Malignant neoplasm of placenta), D39.2 (Neoplasm of uncertain behavior of placenta), and F53 (Puerperal psychosis) to the Age conflict edit code list for maternity diagnoses.

We invited public comments on our proposals for changes to the ICD–10 MCE Version 34.

Comment: Many commenters supported the proposal to revise the title for ICD–10 MS–DRG 208.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–CM diagnosis codes C58 (Malignant neoplasm of placenta), D39.2 (Neoplasm of uncertain behavior of placenta), and F53 (Puerperal psychosis) to the Age conflict edit code list for maternity diagnosis in the ICD–10 MCE Version 34, effective October 1, 2016.

(3) Manifestation Codes Not Allowed as Principal Diagnosis Edit

Section I.A.13. of the FY 2016 ICD–10–CM Official Guidelines for Coding and Reporting states that certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the classification has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists, there is a “use additional code” note at the etiology code, and a “code first” note at the manifestation code. These instructional notes indicate proper sequencing order of the codes, etiology followed by manifestation.

We found that in the ICD–10–CM Tabular List of Diseases at category M02 (Postinfective and reactive arthropathies), a “Code first underlying disease” note exists. This would indicate that there are codes in that category that are manifestations of an underlying etiology. We then examined the ICD–10 MCE Version 33 to determine if diagnosis codes from that category were included on the Manifestation codes not allowed as principal diagnosis edit code list. Only three ICD–10–CM diagnosis codes from that category were listed:

- M02.88 (Other reactive arthropathies, vertebrae);
- M02.89 (Other reactive arthropathies, multiple sites); and
- M02.9 (Reactive arthropathy, unspecified).

Based on the instructional note at the M02 category level, the title at subcategory M02.8 (Other reactive arthropathies), and the three diagnosis codes listed above on the current ICD–10 MCE Version 33 Manifestation codes not allowed as principal diagnosis edit code list, it seems appropriate that all of the diagnosis codes in subcategory M02.8 should be identified as manifestation codes.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25008 through 25009), we proposed to add the ICD–10–CM diagnosis codes listed in the following table to the ICD–10 MCE Version 34 Manifestation codes not allowed as principal diagnosis edit code list.

<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M02.80 ..................</td>
<td>Other reactive arthropathies, unspecified site.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal.

Comment: Commenters supported the proposal to add the ICD–10–CM codes in the table included in the proposed rule describing other reactive arthropathies to the Manifestation codes not allowed as principal diagnosis edit code list in the ICD–10 MCE.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to add the diagnosis codes in subcategory M02.8 as displayed in the table in the proposed rule and above to the Manifestation codes not allowed as principal diagnosis edit code list in the ICD–10 MCE Version 34, effective October 1, 2016.

(4) Questionable Admission Edit

In the MCE, some diagnoses are not usually sufficient justification for admission to an acute care hospital. For example, if a patient is assigned ICD–10–CM diagnosis code R03.0 (Elevated blood pressure reading, without diagnosis of hypertension), the patient would have a questionable admission because an elevated blood pressure reading is not normally sufficient justification for admission to a hospital.

Upon review of the ICD–10–CM diagnosis codes listed under the ICD–10 MCE Version 33 Questionable Admission edit, our clinical advisors determined that certain diagnoses clinically warrant hospital admission. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25009), we proposed to remove the following diagnosis codes from the ICD–10 MCE Version 34.0 Questionable admission edit.

<table>
<thead>
<tr>
<th>ICD–10–CM diagnosis code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M02.811</td>
<td>Other reactive arthropathies, right shoulder.</td>
</tr>
<tr>
<td>M02.812</td>
<td>Other reactive arthropathies, left shoulder.</td>
</tr>
<tr>
<td>M02.819</td>
<td>Other reactive arthropathies, unspecified shoulder.</td>
</tr>
<tr>
<td>M02.821</td>
<td>Other reactive arthropathies, right elbow.</td>
</tr>
<tr>
<td>M02.822</td>
<td>Other reactive arthropathies, left elbow.</td>
</tr>
<tr>
<td>M02.829</td>
<td>Other reactive arthropathies, unspecified elbow.</td>
</tr>
<tr>
<td>M02.831</td>
<td>Other reactive arthropathies, right wrist.</td>
</tr>
<tr>
<td>M02.832</td>
<td>Other reactive arthropathies, left wrist.</td>
</tr>
<tr>
<td>M02.839</td>
<td>Other reactive arthropathies, unspecified wrist.</td>
</tr>
<tr>
<td>M02.841</td>
<td>Other reactive arthropathies, right hand.</td>
</tr>
<tr>
<td>M02.842</td>
<td>Other reactive arthropathies, left hand.</td>
</tr>
<tr>
<td>M02.849</td>
<td>Other reactive arthropathies, unspecified hand.</td>
</tr>
<tr>
<td>M02.851</td>
<td>Other reactive arthropathies, right hip.</td>
</tr>
<tr>
<td>M02.852</td>
<td>Other reactive arthropathies, left hip.</td>
</tr>
<tr>
<td>M02.859</td>
<td>Other reactive arthropathies, unspecified hip.</td>
</tr>
<tr>
<td>M02.861</td>
<td>Other reactive arthropathies, right knee.</td>
</tr>
<tr>
<td>M02.862</td>
<td>Other reactive arthropathies, left knee.</td>
</tr>
<tr>
<td>M02.869</td>
<td>Other reactive arthropathies, unspecified knee.</td>
</tr>
<tr>
<td>M02.871</td>
<td>Other reactive arthropathies, right ankle and foot.</td>
</tr>
<tr>
<td>M02.872</td>
<td>Other reactive arthropathies, left ankle and foot.</td>
</tr>
<tr>
<td>M02.879</td>
<td>Other reactive arthropathies, unspecified ankle and foot.</td>
</tr>
</tbody>
</table>

• T81.81XA (Complication of inhalation therapy, initial encounter);
• T88.4XXA (Failed or difficult intubation, initial encounter);
• T88.7XXA (Unspecified adverse effect of drug or medicament, initial encounter);
• T88.8XXA (Other specified complications of surgical and medical care, not elsewhere classified, initial encounter); and
• T88.9XXA (Complication of surgical and medical care, unspecified, initial encounter).

We invited public comments on our proposal.

Comment: A number of commenters supported the proposal to remove the ICD–10–CM diagnosis codes listed in the proposed rule from the Questionable admission edit in the ICD–10 MCE.

Response: We appreciate the commenters’ support for our proposal.

After consideration of the public comments we received, we are finalizing our proposal to remove the five ICD–10–CM diagnosis codes listed in the proposed rule and above (T81.81XA, T88.4XXA, T88.7XXA, T88.8XXA, and T88.9XXA) from the ICD–10 MCE Questionable admission edit for the ICD–10 MCE Version 34, effective October 1, 2016.

(5) Removal of Edits and Future Enhancement

With the implementation of ICD–10, it is clear that there are several concepts that differ from the ICD–9–CM classification. These differences are evident in the MCE as discussed earlier in this section. Looking ahead to the needs and uses of coded data as the data continue to evolve from the reporting, collection, processing, coverage, payment and analysis aspect, we believe the need to ensure the accuracy of the coded data becomes increasingly significant.

The purpose of the MCE is to ensure that errors and inconsistencies in the coded data are recognized during Medicare claims processing. As shown in the FY 2016 ICD–10 MCE Version 33 manual file and an ICD–9–CM MCE Version 33.0A manual file (developed for analysis only), an edit code list exists according to the definition or criteria set forth for each specified type of edit. Over time, certain edits under the ICD–9–CM MCE became discontinued as they were no longer needed. However, the MCE manual has continued to make reference to these discontinued edits, including through the replication process with transitioning to ICD–10.

Currently, the FY 2016 ICD–10 MCE Version 33 manual file displays the following edits:

• 12. Open biopsy check. Effective October 1, 2010, the Open biopsy check edit was discontinued and will appear for claims processed using MCE Version 2.0–26.0 only.
• 13. Bilateral procedure. Effective with the ICD–10 implementation, the bilateral procedure edit will be discontinued.

Because these edits are no longer valid, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25009), we proposed to remove the reference to them, effective with the ICD–10 MCE manual and software Version 34, for FY 2017. We invited public comments on our proposal.

Comment: Commenters supported the proposal to remove the language referencing discontinued edits for the
open biopsy check and the bilateral procedure edit from the ICD–10 MCE.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to remove the references to the open biopsy check and the bilateral procedure edit from the ICD–10 MCE Version 34, effective October 1, 2016.

As we continue to evaluate the purpose and function of the MCE with respect to the transition to ICD–10, we encourage public input for future discussion. For instance, we recognize a need to further examine the current list of edits and the definitions of those edits. We encourage public comments on whether there are additional concerns with the current edits, including specific edits or language that should be removed or revised, edits that should be combined, or new edits that should be added to assist in detecting errors or inaccuracies in the coded data.

13. Changes to Surgical Hierarchies

Some inpatient stays entail multiple surgical procedures, each one of which, occurring by itself, could result in assignment of the case to a different MS–DRG within the MDC to which the principal diagnosis is assigned. Therefore, it is necessary to have a decision rule within the GROPER by which these cases are assigned to a single MS–DRG. The surgical hierarchy, an ordering of surgical classes from most resource-intensive to least resource-intensive, performs that function. Application of this hierarchy ensures that cases involving multiple surgical procedures are assigned to the MS–DRG associated with the most resource-intensive surgical class.

Because the relative resource intensity of surgical classes can shift as a function of MS–DRG reclassification and recalibrations, for FY 2017, we reviewed the surgical hierarchy of each MDC, as we have for previous reclassifications and recalibrations, to determine if the ordering of classes coincides with the intensity of resource utilization.

A surgical class can be composed of one or more MS–DRGs. For example, in MDC 11, the surgical class “kidney transplant” consists of a single MS–DRG (MS–DRGs 652) and the class “major bladder procedures” consists of three MS–DRGs (MS–DRGs 653, 654, and 655). Consequently, in many cases, the surgical hierarchy has an impact on more than one MS–DRG. The methodology for determining the most resource-intensive surgical class involves weighting the average resources for each MS–DRG by frequency to determine the weighted average resources for each surgical class. For example, assume surgical class A includes MS–DRGs 001 and 002 and surgical class B includes MS–DRGs 003, 004, and 005. Assume also that the average costs of MS–DRG 001 are higher than that of MS–DRG 003, but the average costs of MS–DRGs 004 and 005 are higher than the average costs of MS–DRG 002. To determine whether surgical class A should be higher or lower than surgical class B in the surgical hierarchy, we would weigh the average costs of each MS–DRG in the class by frequency (that is, by the number of cases in the MS–DRG) to determine average resource consumption for the surgical class. The surgical classes would then be ordered from the class with the highest average resource utilization to that with the lowest, with the exception of “other O.R. procedures” as discussed in this rule.

This methodology may occasionally result in assignment of a case involving multiple procedures to the lower-weighted MS–DRG (in the highest, most resource-intensive surgical class) of the available alternatives. However, given that the logic underlying the surgical hierarchy provides that the GROPER search for the procedure in the most resource-intensive surgical class, in cases involving multiple procedures, this result is sometimes unavoidable.

We note that, notwithstanding the foregoing discussion, there are a few instances when a surgical class with a lower average cost is ordered above a surgical class with a higher average cost. For example, the “other O.R. procedures” surgical class is uniformly ordered last in the surgical hierarchy of each MDC in which it occurs, regardless of the fact that the average costs for the MS–DRG or MS–DRGs in that surgical class may be higher than those for other surgical classes in the MDC. The “other O.R. procedures” class is a group of procedures that are only infrequently related to the diagnoses in the MDC, but are still occasionally performed on patients with cases assigned to the MDC with these diagnoses. Therefore, assignment to these surgical classes should only occur if no other surgical class more closely related to the diagnoses in the MDC is appropriate.

A second example occurs when the difference between the average costs for two surgical classes is very small. We did not receive any public comments on the proposed additions or deletions to the MCC, severity level lists and the proposed additions and deletions to the CC severity level lists for FY 2017 were made available via the Internet on the CMS Web site at: http://cmm.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html as follows:

• Table 61.1—Proposed Additions to the MCC List—FY 2017;
• Table 61.2—Proposed Deletions to the MCC List—FY 2017;
• Table 61.3—Proposed Additions to the CC List—FY 2017; and
• Table 61.2—Proposed Deletions to the CC List—FY 2017.

We did not receive any public comments on the proposed additions or deletions to the MCC and CC lists and, therefore, are adopting them as final, effective October 1, 2016. The final version of these four tables for FY 2017 are available via the Internet on the same CMS Web site cited above.

As we stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49414), certain ICD–10–CM diagnosis codes express conditions that, when coded in
ICD–9–CM, use two or more ICD–9–CM diagnosis codes. In the interest of ensuring that the ICD–10 MS–DRGs place a patient in the same MS–DRG, regardless of whether the patient claim was to be coded in ICD–9–CM or ICD–10, whenever one of these ICD–10–CM combination codes is used as principal diagnosis, the cluster of ICD–9–CM codes that would be coded on an ICD–9–CM claim is considered. If one of the ICD–9–CM codes in the cluster is a CC or an MCC, the single ICD–10–CM combination code used as a principal diagnosis must also imply that the CC or MCC is present. Appendix J of the ICD–10 MS–DRG Definitions Manual Version 33 includes two lists. Part 1 is the list of principal diagnosis codes where the ICD–10–CM code is its own MCC. Part 2 is the list of principal diagnosis codes where the ICD–10–CM code is its own CC. Appendix J of the ICD–10 MS–DRG Definitions Manual Version 33 is available via the internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

For FY 2017, the ICD–10–CM diagnoses for which this implication must be made were listed in Table 6L (Proposed Principal Diagnosis Is Its Own MCC List—FY 2017), Table 6M (Proposed Principal Diagnosis Is Its Own CC List—FY 2017), and Table 6M.1 (Proposed Additions to the Principal Diagnosis Is Its Own CC List—FY 2017) associated with the proposed rule, which were made available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html, as described in section VI. of the Addendum to the proposed rule. We note that there were no proposed changes to Table 6L for FY 2017 and the list of ICD–10–CM diagnoses that will act as its own MCC when reported as a principal diagnosis remains unchanged from the FY 2016 list. Therefore, we did not develop Table 6L.1 (Additions to the Principal Diagnosis Is Its Own MCC List) or Table 6L.2 (Deletions to the Principal Diagnosis Is Its Own MCC List) for FY 2017.

As discussed in the FY 2016 IPPS/LTC PPS final rule (80 FR 49414), ICD–9–CM diagnosis code 591 (Hydronephrosis) is classified as a CC. Under ICD–10–CM, hydronephrosis is reported with a combination code if the hydronephrosis is due to another condition, such as with new ICD–10–CM code N13.0 (Hydronephrosis with ureteral stricture, not elsewhere classified) and N13.2 (Hydronephrosis with renal and ureteral calculous obstruction), should be recognized as a principal diagnosis that acts as its own CC. Accordingly, ICD–10–CM code N13.0 (Hydronephrosis with ureteropelvic junction obstruction) was included in Table 6M (Proposed Principal Diagnosis Is Its Own CC List—FY 2017) and Table 6M.1 (Proposed Additions to the Principal Diagnosis Is Its Own CC List—FY 2017), which were made available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. We did not receive any public comments regarding this specific proposal and, therefore, are adopting it as final, effective October 1, 2016.

15. Complications or Comorbidity (CC) Exclusions List

a. Background of the CC List and the CC Exclusions List

Under the IPPS MS–DRG classification system, we have developed a standard list of diagnoses that are considered CCs. Historically, we developed this list using physician panels that classified each diagnosis code based on whether the diagnosis, when present as a secondary condition, would be considered a substantial complication or comorbidity. A substantial complication or comorbidity was defined as a condition that, because of its presence with a specific principal diagnosis, would cause an increase in the length of stay by at least 1 day in at least 75 percent of the patients. However, depending on the principal diagnosis of the patient, some diagnoses on the basic list of complications and comorbidities may be excluded if they are closely related to the principal diagnosis. In FY 2008, we evaluated each diagnosis code to determine its impact on resource use and to determine the most appropriate CC subclassification (non-CC, CC, or MCC) assignment. We refer readers to sections ILD.2 and 3. of the preamble of the FY 2008 IPPS final rule with comment period for a discussion of the refinement of CCs in relation to the MS–DRGs we adopted for FY 2008 (72 FR 47152 through 47171).

b. CC Exclusions List for FY 2017

In the September 1, 1987 final notice (52 FR 33143) concerning changes to the DRG classification system, we modified the GROUPER logic so that certain diagnoses included on the standard list of CCs would not be considered valid CCs in combination with a particular principal diagnosis. We created the CC Exclusions List for the following reasons: (1) To preclude coding of CCs for closely related conditions; (2) to preclude duplicative or inconsistent coding from being treated as CCs; and (3) to ensure that cases are appropriately classified between the complicated and uncomplicated DRGs in a pair. As previously indicated, we developed a list of diagnoses, using physician panels, to include those diagnoses that, when present as a secondary condition, would be considered a substantial complication or comorbidity. In previous years, we made changes to the list of CCs, either by adding new CCs or deleting CCs already on the list.

In the May 19, 1987 proposed notice (52 FR 18877) and the September 1, 1987 final notice (52 FR 33154), we explained that the excluded secondary diagnoses were established using the following five principles:

• Chronic and acute manifestations of the same condition should not be considered CCs for one another;
• Specific and nonspecific (that is, not otherwise specified (NOS)) diagnosis codes for the same condition should not be considered CCs for one another;
• Codes for the same condition that cannot coexist, such as partial/total, unilateral/bilateral, obstructed/unobstructed, and benign/malignant, should not be considered CCs for one another;
• Codes for the same condition in anatomically proximal sites should not be considered CCs for one another; and
• Closely related conditions should not be considered CCs for one another.

The creation of the CC Exclusions List was a major project involving hundreds of codes. We have continued to review the remaining CCs to identify additional exclusions and to remove diagnoses from the master list that have been shown not to meet the definition of a CC. We refer readers to the FY 2014 IPPS/LTC PPS final rule (78 FR 50541) for detailed information regarding revisions that were made to the CC Exclusion Lists under the ICD–9–CM MS–DRGs.

The ICD–10 MS–DRGs Version 33 CC Exclusion List is included as Appendix C in the ICD–10 MS–DRG Definitions Manual, which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html, and includes two lists identified as Part 1 and Part 2. Part 1 is the list of all diagnosis codes that are defined as a CC or an MCC when
reported as a secondary diagnosis. If the code designated as a CC or an MCC is allowed with all principal diagnoses, the phrase “NoExcl” (for no exclusions) follows the CC or MCC designation. For example, ICD–10–CM diagnosis code A17.83 (Tuberculous neuritis) has this “NoExcl” entry. For all other diagnosis codes on the list, a link is provided to a collection of diagnosis codes which, when used as the principal diagnosis, would cause the CC or MCC diagnosis to be considered as a non-CC. Part 2 is the list of diagnosis codes designated as an MCC only for patients discharged alive; otherwise, they are assigned as a non-CC.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25011), for FY 2017, we proposed changes to the ICD–10 MS–DRGs Version 34 CC Exclusion List. Therefore, we developed Table 6G.1.—Proposed Secondary Diagnosis Order Additions to the CC Exclusions List—FY 2017; Table 6G.2.—Proposed Principal Diagnosis Order Additions to the CC Exclusions List—FY 2017; Table 6H.1.—Proposed Secondary Diagnosis Order Deletions to the CC Exclusions List—FY 2017; and Table 6H.2.— Proposed Principal Diagnosis Order Deletions to the CC Exclusions List—FY 2017. Each of these principal diagnosis codes for which there is a CC exclusion was shown in Table 6G.2. with an asterisk and the conditions that will not count as a CC are provided in an indented column immediately following the affected principal diagnosis. Beginning with discharges on or after October 1 of each year, the indented diagnoses are not recognized by the GROUPER as valid CCs for the asterisked principal diagnoses. Tables 6G and 6H associated with the proposed rule are available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

Comment: Several commenters supported the proposed changes to the CC Exclusion List as displayed in Table 6G.1., Table 6G.2., Table 6H.1., and Table 6H.2. that were associated with the proposed rule and made available via the Internet on the CMS Web site.

Response: We appreciate the commenters’ support of our proposals.

We note that for this FY 2017 IPPS/LTCH PPS final rule, we have developed Table 6K.—Complete List of CC Exclusions, which is available via the Internet on the CMS Web site as Tables 6G and 6H. Table 6K corresponds to the Part 1 list of Appendix C in the ICD–10 MS–DRG Definitions Manual as described above. The complete documentation of the ICD–10 MS–DRGs Version 34 GROUPER logic, including the current CC Exclusions List, is available via the Internet on the CMS Acute Inpatient PPS Web page at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

To capture new and deleted diagnosis and procedure codes, for FY 2017, we developed Table 6A.—New Diagnosis Codes, Table 6B.—New Procedure Codes, and Table 6C.—Invalid Diagnosis Codes to the proposed rule. However, they were not published in the Addendum to the proposed rule but were available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html, as described in section VI. of the Addendum to the proposed rule.

For this final rule, we have developed Table 6D.—Invalid Procedure Codes, to reflect the deletion of 12 ICD–10–PCS procedure codes, effective October 1, 2016, as a result of public comments received after the March 9–10, 2016 ICD–10 Coordination and Maintenance Committee meeting.

We note that while we did not specifically develop a Table 6E.—Revised Diagnosis Code Titles for the proposed rule, a document containing the FY 2017 revised diagnosis code titles, as well as new diagnosis codes that have been finalized to date since implementation of the partial code freeze, was made available in advance in response to requests from the health care industry. During the March 9–10, 2016 ICD–10 Coordination and Maintenance Committee meeting, a discussion regarding this document was presented. Participants were informed that the document titled “FY 2017 New Revised ICD–10–PCS Codes” would contain the information that would otherwise be included for this table. This document has been posted along with the other March 9–10, 2016 ICD–10 Coordination and Maintenance Committee meeting materials on the CDC Web site at: http://www.cdc.gov/nchs/icd/icd9cm_maintenance.htm.

In addition, we did not specifically develop a Table 6F.—Revised Procedure Code Titles for the proposed rule. However, a document containing the FY 2017 revised procedure code titles, as well as new procedure codes that have been finalized to date since implementation of the partial code freeze, was made available in advance in response to requests from the health care industry. During the March 9–10, 2016 ICD–10 Coordination and Maintenance Committee meeting, a discussion regarding this document was presented. Participants were informed that the document titled “FY 2017 New Revised ICD–10–CM Codes” would contain the information that would otherwise be included for this table. This document is posted on the CMS Web site at: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-CM-C-and-M-Meeting-Materials-Items/2016-03-09-MeetingMaterials.html?DLMPage=1&DLEntries=10&DLSort=0&DLSortDir=descending.

After consideration of the public comments we received, we are making available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html the following final tables associated with this final rule:

- Table 6A.—New Diagnosis Codes—FY 2017
- Table 6B.—New Procedure Codes—FY 2017
- Table 6C.—Invalid Diagnosis Codes—FY 2017
- Table 6D.—Invalid Procedure Codes—FY 2017
- Table 6E.—Revised Diagnosis Code Titles—FY 2017
- Table 6F.—Revised Procedure Code Titles—FY 2017
- Table 6G.1.—Secondary Diagnosis Order Additions to the CC Exclusions List—FY 2017
- Table 6G.2.—Principal Diagnosis Order Additions to the CC Exclusions List—FY 2017
- Table 6H.1.—Secondary Diagnosis Order Deletions to the CC Exclusions List—FY 2017
- Table 6H.2.—Principal Diagnosis Order Deletions to the CC Exclusions List—FY 2017
- Table 6I.1.—Additions to the MCC List—FY 2017
- Table 6I.2.—Deletions to the MCC List—FY 2017
- Table 6J.1.—Additions to the MCC List—FY 2017
- Table 6J.2.—Deletions to the CC List—FY 2017
- Table 6K.—Complete List of CC Exclusions—FY 2017
- Table 6L.—Principal Diagnosis Is Its Own MCC List—FY 2017
- Table 6M.—Principal Diagnosis Is Its Own CC List—FY 2017
- Table 6N.—Additions to the Principal Diagnosis Is Its Own CC List—FY 2017
16. Review of Procedure Codes in MS DRGs 981 Through 983: 984 Through 986; and 987 Through 989

Each year, we review cases assigned to MS–DRGs 981, 982, and 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively); MS–DRGs 984, 985, and 986 (Prostatic O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively); and MS–DRGs 987, 988, and 989 (Nonextensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) to determine whether it would be appropriate to change the procedures assigned among these MS–DRGs. MS–DRGs 981 through 983, 984 through 986, and 987 through 989 are reserved for those cases in which none of the O.R. procedures performed are related to the principal diagnosis. These MS–DRGs are intended to capture atypical cases, that is, those cases not occurring with sufficient frequency to represent a distinct, recognizable clinical group. Under ICD–9–CM, MS–DRGs 984 through 986 are assigned to those discharges in which one or more of the following prostatic procedures are performed and are unrelated to the principal diagnosis:

- 60.0 (Incision of prostate);
- 60.12 (Open biopsy of prostate);
- 60.15 (Biopsy of prostatic tissue);
- 60.18 (Other diagnostic procedures on prostate and periprostatic tissue);
- 60.21 (Transurethral prostatectomy);
- 60.29 (Other transurethral prostatectomy);
- 60.61 (Local excision of lesion of prostate);
- 60.69 (Prostatectomy, not elsewhere classified);
- 60.81 (Incision of prostatic tissue);
- 60.82 (Excision of prostatic tissue);
- 60.93 (Repair of prostate);
- 60.94 (Control of (postoperative) hemorrhage of prostate);
- 60.95 (Transurethral balloon dilation of the prostatic urethra);
- 60.96 (Transurethral destruction of prostate tissue by microwave thermotherapy);
- 60.97 (Other transurethral destruction of prostate tissue by other thermotherapy); and
- 60.99 (Other operations on prostate).

Under the ICD–10 MS–DRGs Version 33, the comparable ICD–10–PCS code translations for the above list of codes are available in Table 6P.2. associated with the FY 2017 proposed rule and this final rule (which is available via the Internet on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). All remaining O.R. procedures are assigned to MS–DRGs 981 through 983 and 987 through 989, with MS–DRGs 987 through 989 assigned to those discharges in which the only procedures performed are nonextensive procedures that are unrelated to the principal diagnosis.

We refer the reader to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50544 through 50545) for detailed information regarding modifications that were made to the former ICD–9–CM CMS DRG 468 (MS–DRGs 981 through 983), CMS DRG 476 (MS–DRGs 984 through 986), and CMS DRG 477 (MS–DRGs 987 through 989) with regard to the movement of procedure codes. We note that no procedure codes were moved from these DRGs from FY 2008 through FY 2016. Our review of MedPAR claims data showed that there are no cases that merited movement or should logically be reassigned from ICD–10 MS–DRGs 984 through 986 to any of the other MDCs. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25012), for FY 2017, we did not propose to change the procedures assigned among these MS–DRGs. We invited public comments on our proposal to maintain the current structure of these MS–DRGs.

Response: We appreciate the commenters' support of our proposal. We note that while the comparable ICD–10–PCS code translations for the above list of ICD–9–CM codes were made available in Table 6P.2. associated with the FY 2017 proposed rule (which is available via the Internet on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html), we wish to clarify that the table was not intended to be a representation of the current ICD–10 MS–DRG GROUPER Version 33 logic. Rather, it was to simply demonstrate what the ICD–9–CM to ICD–10–PCS code translations were for purposes of review and comment. For example, the translations that were listed in Table 6P.2 of the FY 2017 proposed rule included six ICD–10–PCS procedure codes that are not included in the current ICD–10 MS–DRG GROUPER Version 33 logic for MS–DRGs 984, 985, and 986. Although these six ICD–10–PCS procedure codes are considered comparable translations of the corresponding ICD–9–CM procedure codes, these ICD–10–PCS procedure codes are currently designated as non-O.R. codes and, therefore, are not defined as prostatic O.R. codes for purposes of MS–DRG assignment under the ICD–10 MS–DRG Version 33 Definitions Manual under Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index.

In addition, as discussed in section II.F.19.c.1.b. of the FY 2017 proposed rule (81 FR 25025), we proposed to change the status of a number of ICD–10–PCS procedure codes from O.R. to non-O.R. Among the list in Table 6P.4b. associated with the proposed rule were procedures describing the endoscopic/ transorifice removal of drainage, infusion, intraluminal or monitoring devices. Four of these codes (which were proposed to change from an O.R. to non-O.R. status) identify procedures performed on the prostate and seminal vesicles and are currently included in the ICD–10 MS–DRG GROUPER Version 33 logic for MS–DRGs 984, 985, and 986. These four procedure codes were also listed in Table 6P.2.—List of ICD–10–PCS code translations for prostatic procedures in MS–DRGs 984, 985, and 986 (Prostatic O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively), are currently designated as O.R. codes, and were proposed to change to a non-O.R. status. As discussed in section II.F.19.c.1(b) of the preamble of this final rule, we received public support for changing the status of the codes listed in Table 6P.4b. and are finalizing our proposal.

To reflect our finalized policy to designate these four codes as non-O.R. codes, as discussed in section II.F.19.c.1(b) of the preamble of this final rule, and also to remove the six ICD–10–PCS procedure codes that are not included in the current ICD–10 MS–DRG GROUPER Version 33 logic for MS–DRGs 984, 985 and 986, we are removing the following 10 ICD–10–PCS procedure codes from Table 6P.2 (which was associated with the FY 2017 proposed rule and available via the Internet on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-FeeforServicePayment/AcuteInpatientPPS/index.html):

- 0T7D7ZZ (Dilation of urethra, via natural or artificial opening);
- 0T7D8ZZ (Dilation of urethra, via natural or artificial opening endoscopic);
- 0VB63ZX (Excision of prostate, percutaneous approach, diagnostic);
We identify those procedures occurring in conjunction with certain principal diagnoses with sufficient frequency to justify adding them to one of the surgical MS–DRGs for the MDC in which the diagnosis falls. As we discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25012), upon review of the claims data from the December 2015 update of the FY 2015 MedPAR file, we did not find any cases that merited movement or that should logically be assigned to any of the other MDCs. Therefore, in the proposed rule for FY 2017, we did not propose to move any procedures from MS–DRGs 981 through 983 or MS–DRGs 987 through 989 into one of the surgical MS–DRGs for the MDC into which the principal diagnosis is assigned. We invited public comments on our proposal to maintain the current structure of these MS–DRGs.

Comment: Several commenters supported our proposal to not move any procedure codes from MS–DRGs 981, 982, 983, 984, 985, 986, 987, 988, or 989.

Response: We appreciate the commenters’ support of our proposal.

After consideration of the public comments we received, we are finalizing our proposal to not move any procedure codes from MS–DRGs 981, 982, 983, 984, 985, 986, and 988 (Prostatic O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively); MS–DRGs 984, 985, and 986 (Prostatic O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively); MS–DRGs 987, 988, and 989 (Nonextensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) with regard to not reassigning any procedure codes among these MS–DRGs for FY 2017.

As discussed in section II.F.16. of the preamble of this final rule, we are removing four procedure codes from MS–DRGs 984, 985, and 986, as they were included in the codes listed in Table 6P.4b that were finalized to change from being designated as O.R. codes to non-O.R. status in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

We annually conduct a review of procedures producing assignment to MS–DRGs 981 through 983 or MS–DRGs 987 Through 989 Into MDCs

We also reviewed the list of ICD–10–PCS procedures that, when in combination with their principal diagnosis code, result in assignment to MS–DRGs 981 through 983, 984 through 986, or 987 through 989, to ascertain whether any of those procedures should be reassigned from one of those three groups of MS–DRGs to another of the three groups of MS–DRGs based on average costs and the length of stay. We look at the data for trends such as shifts in treatment practice or reporting practice that would make the resulting MS–DRG assignment illogical. If we find these shifts, we would propose to move cases to keep the MS–DRGs clinically similar or to provide payment for the cases in a similar manner. Generally, we move only those procedures for which we have an adequate number of discharges to analyze the data.

As we discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25012), based on the review of cases in the MDCs, we proposed to add multiple diagnosis and procedure codes to MDCs for FY 2017 to address replication issues. We discuss each of these proposals below.

(1) Angioplasty of Extracranial Vessel

In the ICD–9–CM MS–DRGs Version 32, procedures describing angioplasty of an extracranial vessel were assigned to MDC 1 (Diseases and Disorders of the Nervous System) under MS–DRGs 037, 038, and 039 (Extracranial Procedures with MCC, with CC, or without CC/MCC, respectively). Under ICD–9–CM, more than one ICD–9–CM code could be reported for these procedures, depending on the approach that was documented. For example, ICD–9–CM procedure code 09.61 (Percutaneous angioplasty of extracranial vessel(s)) would have been appropriately reported...
if the percutaneous approach was documented, and procedure code 39.50 (angioplasty of other non-coronary vessel(s)) would have been appropriately reported if a specified approach was not documented.

A replication issue for 41 ICD–10–PCS procedure codes describing angioplasty with the open approach was identified after implementation of the ICD–10 MS–DRGs Version 33. In the code translation, these 41 ICD–10–PCS procedure codes were grouped and assigned to ICD–10 MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively). However, these procedure codes should have been grouped to ICD–10 MS–DRGs 037 through 039 when a principal diagnosis was reported under MDC 1.

To resolve this replication issue, in the 2017 IPPS/LTCF PPS proposed rule (81 FR 25012 through 25013), we proposed to add the 41 ICD–10–PCS procedure codes listed in the following table to ICD–10 MS–DRGs 037 through 039 under MDC 1.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>037H0DZZ ..................</td>
<td>Dilation of right common carotid artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037H0DDZ ..................</td>
<td>Dilation of right common carotid artery with drug-eluting intraluminal device, open approach.</td>
</tr>
<tr>
<td>037H04DZ ..................</td>
<td>Dilation of right common carotid artery with drug-eluting intraluminal device, open approach.</td>
</tr>
<tr>
<td>037H0ZZ ..................</td>
<td>Dilation of right common carotid artery, open approach.</td>
</tr>
<tr>
<td>037J0DZ ..................</td>
<td>Dilation of right vertebral artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037J0ZZ ..................</td>
<td>Dilation of right vertebral artery, open approach.</td>
</tr>
<tr>
<td>037K0DZ ..................</td>
<td>Dilation of right internal carotid artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037K0ZZ ..................</td>
<td>Dilation of right internal carotid artery, open approach.</td>
</tr>
<tr>
<td>037L0DZ ..................</td>
<td>Dilation of left vertebral artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037L0ZZ ..................</td>
<td>Dilation of left vertebral artery, open approach.</td>
</tr>
<tr>
<td>037M0DZ ..................</td>
<td>Dilation of right external carotid artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037M0ZZ ..................</td>
<td>Dilation of right external carotid artery, open approach.</td>
</tr>
<tr>
<td>037N0DZ ..................</td>
<td>Dilation of left vertebral artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037N0ZZ ..................</td>
<td>Dilation of left vertebral artery, open approach.</td>
</tr>
<tr>
<td>037P0DZ ..................</td>
<td>Dilation of right vertebral artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037P0ZZ ..................</td>
<td>Dilation of right vertebral artery, open approach.</td>
</tr>
<tr>
<td>037Q0DZ ..................</td>
<td>Dilation of right internal jugular vein with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037Q0ZZ ..................</td>
<td>Dilation of right internal jugular vein, open approach.</td>
</tr>
<tr>
<td>037Q4DZ ..................</td>
<td>Dilation of right internal jugular vein with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037R0DZ ..................</td>
<td>Dilation of right external jugular vein with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037R0ZZ ..................</td>
<td>Dilation of right external jugular vein, open approach.</td>
</tr>
<tr>
<td>037S0DZ ..................</td>
<td>Dilation of left vertebral artery with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037S0ZZ ..................</td>
<td>Dilation of left vertebral artery, open approach.</td>
</tr>
<tr>
<td>037T0DZ ..................</td>
<td>Dilation of right face vein with intraluminal device, open approach.</td>
</tr>
<tr>
<td>037T0ZZ ..................</td>
<td>Dilation of right face vein, open approach.</td>
</tr>
</tbody>
</table>

We invited public comments on our proposal to add the above listed codes to ICD–10 MS–DRGs 037, 038, and 039 (Extracranial Procedures with MCC, with CC, or without CC/MCC, respectively) under MDC 1, effective October 1, 2016, for the ICD–10 MS–DRGs Version 34.

Comment: Several commenters supported the proposal to add the codes listed in the table in the proposed rule to ICD–10 MS–DRGs 037, 038, and 039. The commenters also acknowledged CMS’ continued efforts for accurate replication.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.

After consideration of the public comments we received, we are finalizing our proposal to add the above listed codes to ICD–10 MS–DRGs 037, 038, and 039 (Extracranial Procedures with MCC, with CC, or without CC/MCC, respectively) under MDC 1 for the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(2) Excision of Abdominal Arteries

In the ICD–9–CM MS–DRGs Version 32, procedures involving excision of a vessel and anastomosis, such as those performed for the treatment of an abdominal artery aneurysm (aneurysmectomy), are identified with procedure code 38.36 (Resection of vessel with Anastomosis, Abdominal arteries) and are assigned to the following MDCs and MS–DRGs:

- MDC 5 (Diseases and Disorders of the Circulatory System): MS–DRGs 270 through 272 (Other Major Cardiovascular Procedures with MCC,
with CC and without CC/MCC, respectively);

- MDC 6 (Diseases and Disorders of the Digestive System): MS–DRGs 356 through 358 (Other Digestive System O.R. Procedures with MCC, with CC and without CC/MCC, respectively);

- MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract): MS–DRGs 627 through 673 (Other Kidney and Urinary Tract Procedures with MCC, with CC and without CC/MCC, respectively);

- MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs): MS–DRGs 907 through 909 (Other O.R. Procedures for Injuries with MCC, with CC, and without CC/MCC, respectively); and

- MDC 24 (Multiple Significant Trauma): MS–DRG 957 through 959 (Other O.R. Procedures for Multiple Significant Trauma with MCC, with CC and without CC/MCC, respectively).

A replication issue for 34 ICD–10–PCS procedure codes describing aneurysmectomy procedures with the open and percutaneous endoscopic approach was identified after implementation of the ICD–10 MS–DRGs Version 33. For example, cases with a principal diagnosis of I72.2 (Aneurysm of renal artery) and procedure code 04BA0ZZ (Excision of left renal artery, open approach) are resulting in assignment to ICD–10 MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) instead of to MDC 11 in MS–DRGs 673 through 675 (Other Kidney and Urinary Tract Procedures with MCC, with CC, and without CC/MCC, respectively).

To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25013 through 25014), we proposed to add the 34 ICD–10–PCS procedure codes listed in the following table that are comparable translations of ICD–9–CM procedure code 38.36 to ICD–10 MDCs 6, 11, 21, and 24. We noted that there is no replication issue related to MDC 5 as the ICD–10–PCS procedure codes listed in the table below group there appropriately.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04BA0ZZ .......... Excision of left renal artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BA4ZZ .......... Excision of left renal artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BA8ZZ .......... Excision of right renal artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BA9ZZ .......... Excision of right renal artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BB0ZZ .......... Excision of inferior mesenteric artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BB4ZZ .......... Excision of inferior mesenteric artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BC0ZZ .......... Excision of right common iliac artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BC4ZZ .......... Excision of right common iliac artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BD0ZZ .......... Excision of left common iliac artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BD4ZZ .......... Excision of left common iliac artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BE0ZZ .......... Excision of right internal iliac artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BE4ZZ .......... Excision of right internal iliac artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BF0ZZ .......... Excision of left internal iliac artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BF4ZZ .......... Excision of left internal iliac artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BH0ZZ .......... Excision of right external iliac artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BH4ZZ .......... Excision of right external iliac artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
<tr>
<td>04BJ0ZZ .......... Excision of left external iliac artery, open approach.</td>
<td></td>
</tr>
<tr>
<td>04BJ4ZZ .......... Excision of left external iliac artery, percutaneous endoscopic approach.</td>
<td></td>
</tr>
</tbody>
</table>

We stated that adding these procedures to those MDCs in the ICD–10 MS–DRGs Version 34 will result in a more accurate replication for the same procedure under the ICD–9–CM MS–DRGs Version 32. We also proposed that these procedure codes be assigned to the corresponding MS–DRGs in each respective MDC as listed above. We stated that the proposed changes would eliminate erroneous assignment to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) for these procedures.

We invited public comments on our proposal to add the above listed codes to MDCs 6, 11, 21, and 24 in the corresponding MS–DRGs, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

Comment: Several commenters supported the proposal to add the codes listed in the table in the proposed rule to MDCs 6, 11, 21 and 24 in the corresponding ICD–10 MS–DRGs. The commenters also acknowledged CMS’ continued efforts for accurate replication.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.

After consideration of the public comments we received, we are finalizing our proposal to add the codes...
listed in the table in the proposed rule and above to the following MDCs and MS–DRGs for the ICD–10 MS–DRGs Version 34, effective October 1, 2016.  
- **MDC 6 (Diseases and Disorders of the Digestive System):** MS–DRGs 356 through 358 (Other Digestive System O.R. Procedures with MCC, with CC and without CC/MCC, respectively);  
- **MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract):** MS–DRGs 673 through 675 (Other Kidney and Urinary Tract Procedures with MCC, with CC and without CC/MCC, respectively);  
- **MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs):** MS–DRGs 907 through 909 (Other O.R. Procedures for Injuries with MCC, with CC, and without CC/MCC, respectively); and  
- **MDC 24 [Multiple Significant Trauma]:** MS–DRG 957 through 959 (Other O.R. Procedures for Multiple Significant Trauma with MCC, with CC and without CC/MCC, respectively).  

(3) Excision of Retroperitoneal Tissue  
In the ICD–9–CM MS–DRGs Version 32, procedures involving excision of a retroperitoneal lesion (or tissue), such as those performed for the treatment of a neoplasm, are identified with procedure code 54.4 (Excision or destruction of peritoneal tissue) and are assigned to a number of MDCs and MS–DRGs across a variety of body systems, some of which include the following:  
- **MDC 6 (Diseases and Disorders of the Digestive System):** MS–DRGs 356 through 358 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively);  
- **MDC 7 (Diseases and Disorders of the Hepatobiliary System and Pancreas):** MS–DRGs 423 through 425 (Other Hepatobiliary or Pancreas O.R. Procedures with MCC, with CC, and without CC/MCC, respectively); and  
- **MDC 10 (Endocrine, Nutritional and Metabolic Diseases and Disorders):** MS–DRGs 628 through 630 (Other Endocrine, Nutritional and Metabolic O.R. Procedures with MCC, with CC, and without CC/MCC, respectively).  

A replication issue for the ICD–10–PCS procedure codes describing excision of retroperitoneum that involves MDC 6 was identified after implementation of the ICD–10 MS–DRGs Version 33. These procedure codes are ICD–10–PCS codes 0WBH0ZZ (Excision of retroperitoneum, open approach), 0WBH3ZZ (Excision of retroperitoneum, percutaneous approach), and 0WBH4ZZ (Excision of retroperitoneum, percutaneous endoscopic approach). For example, when an ICD–10–CM diagnosis code such as D20.0 (Benign neoplasm of soft tissue of retroperitoneum) is reported with any one of these three ICD–10–PCS procedure codes, the case is assigned to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively).  

To resolve this replication issue, in the FY 2017 IPPS/LTCF PPS proposed rule (81 FR 25014), we proposed to add the three ICD–10–PCS procedure codes to MDC 6 in MS–DRGs 356 through 358 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively). We stated that this would result in a more accurate replication of the comparable procedure under the ICD–9–CM MS–DRGs Version 32. The proposed changes also would eliminate erroneous assignment to MS–DRGs 981 through 983 for these procedures.  

We invited public comments on our proposal to add the three ICD–10–PCS codes describing excision of retroperitoneum to MDC 6 in MS–DRGs 356 through 358, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.  

**Comment:** Several commenters supported the proposal to add ICD–10–PCS code 0WBH0ZZ, 0WBH3ZZ, and 0WBH4ZZ describing excision of retroperitoneum to MDC 6 in MS–DRGs 356 through 358. The commenters also acknowledged CMS' continued efforts for accurate replication.  

**Response:** We appreciate the commenters' support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.  

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS codes 0WBH0ZZ, 0WBH3ZZ (Excision of retroperitoneum, open approach), 0WBH4ZZ (Excision of retroperitoneum, percutaneous approach), and 0WBH4ZZ (Excision of retroperitoneum, percutaneous endoscopic approach) to MDC 6 in MS–DRGs 356 through 358 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) for the ICD–10 MS–DRGs Version 34, effective October 1, 2016.  

(4) Occlusion of Vessels: Esophageal Varices  
In the ICD–9–CM MS–DRGs Version 32, procedures including ligation or surgical occlusion of esophageal varices are identified with procedure code 42.91 (Ligation of esophageal varices) and are assigned to MDC 6 (Diseases and Disorders of the Digestive System) under MS–DRGs 326 through 328 (Stomach, Esophageal and Duodenal Procedures with MCC, with CC, and without CC/MCC, respectively) and MDC 7 (Diseases and Disorders of the Hepatobiliary System and Pancreas) under MS–DRGs 423 through 425 (Other Hepatobiliary or Pancreas O.R. procedures with MCC, with CC, and without CC/MCC, respectively).  

A replication issue for MDC 7 involving ICD–10–PCS procedure codes 06L30CZ (Occlusion of esophageal vein with extraluminal device, open approach) and 06L30DZ (Occlusion of esophageal vein with intraluminal device, open approach) was identified in the ICD–10 MS–DRGs Version 33 after implementation on October 1, 2015. For instance, when an ICD–10–CM diagnosis code such as K70.30 (Alcoholic cirrhosis of liver without ascites) is reported with either one of the ICD–10–PCS procedure codes, it results in assignment to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively).  

To resolve this replication issue, in the FY 2017 IPPS/LTCF PPS proposed rule (81 FR 25015), we proposed to add the two ICD–10–PCS procedure codes describing occlusion of esophageal vein to MDC 7 under MS–DRGs 423 through 425. We stated that this would result in a more accurate replication of the comparable procedure under the ICD–9–CM MS–DRGs Version 32. We stated that the proposed changes also would eliminate erroneous assignment to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively) for these procedures.  

We invited public comments on our proposal to add ICD–10–PCS procedure codes 06L30CZ and 06L30DZ to MDC 7 under MS–DRGs 423 through 425, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.  

**Comment:** Several commenters supported the proposal to add ICD–10–PCS procedure codes 06L30CZ and 06L30DZ to MDC 7 under MS–DRGs 423 through 425 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively).  

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS procedure codes 06L30CZ and 06L30DZ to MDC 7 under MS–DRGs 423 through 425 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) for these procedures.  

We appreciate the commenters' support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.  

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS procedure codes 06L30CZ and 06L30DZ to MDC 7 under MS–DRGs 423 through 425 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively).  

**Response:** We appreciate the commenters' support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.  

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS procedure codes 06L30CZ and 06L30DZ to MDC 7 under MS–DRGs 423 through 425 (Other Digestive System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively).
We invited public comment on our proposal to add ICD–10–PCS procedure code 0UBMZXZ to MDC 13 in MS–DRGs 746 and 747, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

Comment: Several commenters supported the proposal to add ICD–10–PCS procedure code 0UBMZXZ to MDC 13 under MS–DRGs 746 and 747. The commenters also acknowledged CMS’ continued efforts for accurate replication.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS procedure code 0UBMZXZ (Excision of vulva, external approach) to MDC 13 in MS–DRGs 746 and 747. We stated that adding ICD–10–PCS procedure codes considered to be comparable translations that describe diagnostic drainage or excision of specified lymphatic structures and also warrant assignment to the same MDCs across various body systems.

A replication issue involving ICD–10–PCS procedure code 0UBMXZZ (Excision of vulva, external approach) was identified after implementation of the ICD–10 MS–DRGs Version 33. For example, when cases with an ICD–10–CM principal diagnosis of code D07.1 (Carcinoma in situ of vulva) are reported with ICD–10–PCS procedure code 0UBMXZZ (Excision of vulva, external approach), they are resulting in assignment to MS–DRGs 981 through 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC/MCC, respectively).

To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25015), we proposed to add ICD–10–PCS procedure code 0UBMXZZ to MDC 13 under MS–DRGs 746 and 747. We stated that adding procedure code 0UBMXZZ to MDC 13 in MS–DRGs 746 and 747 would result in a more accurate replication of the comparable procedure under the ICD–9–CM MS–DRGs Version 32. The proposed changes also would eliminate erroneous assignment to MS–DRGs 981 through 983 for these procedures. In addition, the proposed changes would be consistent with the assignment of other clinically similar procedures, such as ICD–10–PCS procedure code 0WBNXZZ (Excision of female perineum, external approach). Finally, we noted that there is no replication issue for MDC 9 regarding this procedure code.

We stated that adding procedure code 0UBMXZZ to MDC 13 under MS–DRGs 746 and 747, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

Comment: Several commenters acknowledged CMS’ continued efforts for accurate replication.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS procedure code 0UBMZXZ (Excision of vulva, external approach) to MDC 13 in MS–DRGs 746 and 747. We stated that adding ICD–10–PCS procedure code 0WBNXZZ to MDC 13 in MS–DRGs 746 and 747, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.
We discovered that the ICD–10 MDC and MS–DRG assignment are not consistent with other ICD–10–PCS procedure codes that identify and describe clinically similar procedures for the repair of obstetrical lacerations which are coded and reported based on the extent of the tear. For example, ICD–10–PCS procedure code 0DQP0ZZ (Repair rectum, open approach) is appropriately assigned to MDC 14 (Pregnancy, Childbirth and the Puerperium) under MS–DRG 774 (Vaginal Delivery with Complicating Diagnoses). This procedure may be performed in the treatment of a fourth-degree perineal laceration involving the rectal mucosa. In contrast, ICD–10–PCS procedure code 0DQR0ZZ (Repair anal sphincter, open approach), when reported for repair of a perineal laceration, currently results in assignment to MS–DRGs 987 through 989 (Non-Extensive O.R. Procedure Unrelated to Principal Diagnosis).

To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25016), we proposed to add these eight ICD–10–PCS procedure codes to MDC 14 in MS–DRG 774. We stated that the proposed changes would eliminate erroneous assignment to MS–DRGs 987 through 989 for these procedures.

We invited public comments on our proposal to add the eight listed codes to MDC 14 under MS–DRG 774, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

Comment: Several commenters supported the proposal to add the eight ICD–10–PCS procedure codes listed in the proposed rule to MDC 14 under MS–DRG 774. The commenters also acknowledged CMS’ continued efforts for accurate replication.

One commenter who agreed with the proposal to add the eight ICD–10–PCS procedure codes to MDC 14 under MS–DRG 774 also recommended that CMS consider adding the following six ICD–10–PCS procedure codes to MDC 14 in MS–DRG 774:
- 0UQJ0ZZ (Repair clitoris, open approach);
- 0UQJXZZ (Repair clitoris, external approach);
- 0TQDXZZ (Repair urethra, external approach);
- 0KQM0ZZ (Repair perineum muscle, open approach);
- 0KQM3ZZ (Repair perineum muscle, percutaneous approach); and
- 0KQM4ZZ (Repair perineum muscle, percutaneous endoscopic approach).

The commenter acknowledged that, although procedures involving repair of clitoral and urethral lacerations during delivery are rare, they do occur and require intervention. The commenter noted that its organization observed cases grouping to the Unrelated MS–DRG when reporting any one of these six procedure codes.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.

With regard to the recommendation that we consider the addition of ICD–10–PCS procedure codes describing repair of the clitoris, urethra, and perineum muscle to MDC 14 in MS–DRG 774, we note that the code describing repair of the urethra (0TQDXZZ) is currently listed under MDC 14 in MS–DRG 774 as displayed in the two above-mentioned locations. The three codes describing repair of the perineum muscle (0KQM0ZZ, 0KQM3ZZ, and 0KQM4ZZ) are currently assigned to the following MDCs and MS–DRGs:

- MDC 1 (Diseases and Disorders of the Nervous System): MS–DRGs 404 through 406 (Peripheral, Cranial Nerve and Other Nervous System Procedures with MCC, with CC or Peripheral Neurostimulator, and without CC/MCC, respectively);
- MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue): MS–DRG 500 through 502 (Soft Tissue Procedures with MCC, with CC and without CC/MCC, respectively);
- MDC 9 (Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast): MS–DRGs 579 through 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC, and without CC/MCC, respectively);
- MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs): MS–DRGs 907 through 909 (Other O.R. Procedures for Injuries with MCC, with CC, and without CC/MCC, respectively); and
- MDC 24 (Multiple Significant Trauma): MS–DRG 957 through 959 (Other O.R. Procedures for Multiple Significant Trauma with MCC, with CC and without CC/MCC, respectively).

The two ICD–10–PCS procedure codes describing repair of the clitoris (0UQJ0ZZ and 0UQJXZZ) are currently assigned to MDC 13 (Diseases and Disorders of the Female Reproductive System) in MS–DRGs 746 and 747 (Vagina, Cervix and Vulva Procedures with CC/MCC and without CC/MCC, respectively).

The codes describing repair of the perineum muscle and repair of the clitoris are not currently listed in the Definitions Manual under MDC 14 in MS–DRG 774, it is understandable that, depending on what ICD–10–CM

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0DQQ0ZZ</td>
<td>Repair anus, open approach.</td>
</tr>
<tr>
<td>0DQQ3ZZ</td>
<td>Repair anus, percutaneous approach.</td>
</tr>
<tr>
<td>0DQQ4ZZ</td>
<td>Repair anus, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0DQQ7ZZ</td>
<td>Repair anus, via natural or artificial opening.</td>
</tr>
<tr>
<td>0DQQ8ZZ</td>
<td>Repair anus, via natural or artificial opening endoscopic.</td>
</tr>
<tr>
<td>0DQR0ZZ</td>
<td>Repair anal sphincter, open approach.</td>
</tr>
<tr>
<td>0DQR3ZZ</td>
<td>Repair anal sphincter, percutaneous approach.</td>
</tr>
<tr>
<td>0DQR4ZZ</td>
<td>Repair anal sphincter, percutaneous endoscopic approach.</td>
</tr>
</tbody>
</table>

We appreciate the commenter’s support of our proposal and of our efforts to analyze the replication issues between the ICD–9 and ICD–10 based MS–DRGs brought to our attention.

With regard to the recommendation that we consider the addition of ICD–10–PCS procedure codes describing repair of the clitoris, urethra, and perineum muscle to MDC 14 in MS–DRG 774, we note that the code describing repair of the urethra (0TQDXZZ) is currently listed under MDC 14 in MS–DRG 774 as displayed in the following three codes describing repair of the perineum muscle (0KQM0ZZ, 0KQM3ZZ, and 0KQM4ZZ) are currently assigned to the following MDCs and MS–DRGs:

- MDC 1 (Diseases and Disorders of the Nervous System): MS–DRGs 404 through 406 (Peripheral, Cranial Nerve and Other Nervous System Procedures with MCC, with CC or Peripheral Neurostimulator, and without CC/MCC, respectively);
- MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue): MS–DRG 500 through 502 (Soft Tissue Procedures with MCC, with CC and without CC/MCC, respectively);
- MDC 9 (Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast): MS–DRGs 579 through 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC, and without CC/MCC, respectively);
- MDC 21 (Injuries, Poisonings and Toxic Effects of Drugs): MS–DRGs 907 through 909 (Other O.R. Procedures for Injuries with MCC, with CC, and without CC/MCC, respectively); and
- MDC 24 (Multiple Significant Trauma): MS–DRG 957 through 959 (Other O.R. Procedures for Multiple Significant Trauma with MCC, with CC and without CC/MCC, respectively).

The two ICD–10–PCS procedure codes describing repair of the clitoris (0UQJ0ZZ and 0UQJXZZ) are currently assigned to MDC 13 (Diseases and Disorders of the Female Reproductive System) in MS–DRGs 746 and 747 (Vagina, Cervix and Vulva Procedures with CC/MCC and without CC/MCC, respectively).

The codes describing repair of the perineum muscle and repair of the clitoris are not currently listed in the Definitions Manual under MDC 14 in MS–DRG 774, it is understandable that, depending on what ICD–10–CM
diagnosis code was entered, a case could accurately result in assignment to one of the Unrelated MS–DRGs based on the current GROUPPER logic. Because it is unclear what ICD–10–CM diagnosis codes the commenter entered into the ICD–10 MS–DRG GROUPPER along with the specified ICD–10–PCS procedure codes describing repair of the clitoris, urethra, or perineum, we were not able to fully duplicate the commenter’s exact issue with respect to the Unrelated MS–DRG assignment. We ran test cases through the ICD–10 MS–DRG Version 33 GROUPPER software which resulted in an Unrelated MS–DRG assignment for repair of the urethra, while repair of the perineum muscle codes resulted in appropriate assignment to MS–DRG 774 (Vaginal Delivery with Complicating Diagnoses) when a listed diagnosis code from that specific MS–DRG (which is defined as a complicating diagnosis) was entered. Thus, it appears that there may be a discrepancy between the code list in the ICD–10 MS–DRG Version 33 Definitions Manual and the GROUPPER software for those specific codes describing repair of the urethra and repair of the perineum muscle.

However, we agree that the codes describing repair of urethra and repair of perineum muscle could be performed during an episode of care involving a vaginal delivery and merit assignment to MS–DRG 774.

In our review of the commenter’s recommendations to add the two codes describing repair of the clitoris (0UQJ0ZZ and 0UQJXZZ), we examined whether or not these procedures could be performed during the course of an admission involving a delivery. Our medical advisors agreed that, clinically, a tear involving the clitoris may occur during a vaginal delivery and, therefore, it is appropriate to add these procedures to MS–DRG 774.

We note that the code lists currently displayed in the ICD–10 MS–DRG Version 33 Definitions Manual for MS–DRG 774 require further analysis to clarify what constitutes a vaginal delivery to satisfy the ICD–10 MS–DRG logic. For example, the Definitions Manual currently states that three conditions must be met, the first of which is a vaginal delivery. To satisfy this first condition, codes that describe conditions or circumstances from among three lists of codes must be reported. The first list is comprised of ICD–10–CM diagnosis codes that may be reported as a principal or secondary diagnosis. These diagnosis codes describe conditions in which it is assumed that a vaginal delivery has occurred. The second list of codes are a list of ICD–10–PCS procedure codes that also describe circumstances in which it is assumed that a vaginal delivery occurred. The third list identifies diagnoses describing the outcome of the delivery. Therefore, if any code from one of those three lists is reported, the first condition (vaginal delivery) is considered to be met for assignment to MS–DRG 774.

Our concern with the first list of ICD–10–CM diagnosis codes as currently displayed in the Definitions Manual under the first condition is that not all of the conditions necessarily reflect that a vaginal delivery occurred. Several of the diagnosis codes listed could also reflect that a cesarean delivery occurred. For example, ICD–10–CM diagnosis code O10.02 (Pre-existing essential hypertension complicating childbirth) does not specify that a vaginal delivery took place; yet it is included in the list of conditions that may be reported as a principal or secondary diagnosis in the GROUPPER logic for a vaginal delivery. The reporting of this code could also be appropriate for a delivery that occurred by cesarean section. Therefore, we plan to conduct further analysis of the diagnosis code lists in MS–DRG 774 for FY 2018.

As noted above, the second list of codes for the first condition are comprised of ICD–10–PCS procedure codes. We acknowledge that the current list of procedure codes in MS–DRG 774 appropriately describe that a vaginal delivery occurred. In addition, there are unique procedure codes in ICD–10–PCS that distinguish a vaginal delivery from a cesarean delivery.

After consideration of the public comments we received, we are finalizing our proposal and the comments’ recommendation to add the list of ICD–10–PCS procedure codes in the following table to MS–DRG 774 effective October 1, 2016, for the ICD–10 MS–DRGs Version 34. We also are clarifying that the procedure codes describing repair of perineum muscle currently group to MS–DRG 774 and will continue this assignment for FY 2017.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0DQQ0ZZ</td>
<td>Repair anus, open approach.</td>
</tr>
<tr>
<td>0DQQ3ZZ</td>
<td>Repair anus, percutaneous approach.</td>
</tr>
<tr>
<td>0DQQ4ZZ</td>
<td>Repair anus, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0DQQ7ZZ</td>
<td>Repair anus, via natural or artificial opening.</td>
</tr>
<tr>
<td>0DQQ8ZZ</td>
<td>Repair anal, via natural or artificial opening endoscopic.</td>
</tr>
<tr>
<td>0QRO0ZZ</td>
<td>Repair anal sphincter, open approach.</td>
</tr>
<tr>
<td>0QRO3ZZ</td>
<td>Repair anal sphincter, percutaneous approach.</td>
</tr>
<tr>
<td>0QRO4ZZ</td>
<td>Repair anal sphincter, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>0TDQXZZ</td>
<td>Repair urethra, external approach.</td>
</tr>
<tr>
<td>0UQJ0ZZ</td>
<td>Repair clitoris, open approach.</td>
</tr>
<tr>
<td>0UQJXZZ</td>
<td>Repair clitoris, external approach.</td>
</tr>
</tbody>
</table>

17. Changes to the ICD–10–CM and ICD–10–PCS Coding Systems

a. ICD–10 Coordination and Maintenance Committee

In September 1985, the ICD–9–CM Coordination and Maintenance Committee was formed. This is a Federal interdepartmental committee, co-chaired by the National Center for Health Statistics (NCHS), the Centers for Disease Control and Prevention, and CMS, charged with maintaining and updating the ICD–9–CM system. The final update to ICD–9–CM codes was to be made on October 1, 2013. Thereafter, the name of the Committee was changed to the ICD–10 Coordination and Maintenance Committee, effective with the March 19–20, 2014 meeting. The ICD–10 Coordination and Maintenance Committee addresses updates to the ICD–10–CM and ICD–10–PCS coding systems. The Committee is jointly responsible for approving coding changes, and developing errata, addenda, and other modifications to the coding systems to reflect newly developed procedures and technologies and newly identified diseases. The Committee is also responsible for promoting the use of Federal and non-Federal educational programs and other...
communication techniques with a view toward standardizing coding applications and upgrading the quality of the classification system.


The NCHS has lead responsibility for the ICD–10–CM and ICD–9–CM diagnosis codes included in the Tabular List and Alphabetic Index for Diseases, while CMS has lead responsibility for the ICD–10–PCS and ICD–9–CM procedure codes included in the Tabular List and Alphabetic Index for Procedures.

The Committee encourages participation in the previously mentioned process by health-related organizations. In this regard, the Committee holds public meetings for discussion of educational issues and proposed coding changes. These meetings provide an opportunity for representatives of recognized organizations in the coding field, such as the American Health Information Management Association (AHIMA), the American Hospital Association (AHA), and various physician specialty groups, as well as individual physicians, health information management professionals, and other members of the public, to contribute ideas on coding matters.

After considering the opinions expressed at the public meetings and in writing, the Committee formulates recommendations, which then must be approved by the agencies.

The Committee presented proposals for coding changes for implementation in FY 2017 at a public meeting held on September 22–23, 2015, and finalized the coding changes after consideration of comments received at the meetings and in writing by November 13, 2015.

The Committee held its 2016 meeting on March 9–10, 2016. It was announced at this meeting that any new ICD–10–CM/PCS codes for which there was consensus of public support and for which consensus tabular and indexing changes would be made by May 2016 would be included in the October 1, 2016 update to ICD–10–CM/ICD–10–PCS. As discussed in earlier sections of this preamble, there are new and deleted ICD–10–CM diagnosis codes and ICD–10–PCS procedure codes that are captured in ICD–9–CM/PCS Codes, Table 6B.—New Procedure Codes, and Table 6C.—Invalid Diagnosis Codes for the proposed rule and this final rule, which are available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Because of the length of these tables, they were not published in the Addendum to the proposed rule or this final rule. Rather, they are available via the Internet as discussed in section VI of the Addendum to the proposed rule and this final rule.

Live Webcast recordings of the discussions of procedure codes at the Committee’s September 22–23, 2015 meeting and March 9–10, 2016 meeting can be obtained from the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/index.html?redirect=/icd9ProviderDiagnosticCodes/03_meetings.asp. The minutes of the discussions of diagnosis codes at the September 23–24, 2015 meeting and March 9–10, 2016 meeting are found at: http://www.cdc.gov/nchs/icd/icd9cm_maintenance.html. These Web sites also provide detailed information about the Committee, including information on requesting a new code, attending a Committee meeting, and timeline requirements and meeting dates.

We encourage commenters to address suggestions on coding issues involving diagnosis codes to: Donna Pickett, Co-Chairperson, ICD–10 Coordination and Maintenance Committee, NCHS, Room 2402, 3311 Toledo Road, Hyattsville, MD 20782. Comments may be sent by Email to: nchc@cdc.gov.

Questions and comments concerning the procedure codes should be addressed to: Patricia Brooks, Co-Chairperson, ICD–10 Coordination and Maintenance Committee, CMS, Center for Medicare Management, Hospital and Ambulatory Policy Group, Division of Acute Care, C4–08–06, 7500 Security Boulevard, Baltimore, MD 21244–1850. Comments may be sent by Email to: ICDD ProcedureCodeRequest@cms.hhs.gov.

In the September 7, 2001 final rule implementing the IPPS new technology add-on payments (66 FR 46906), we indicated we would attempt to include proposals for procedure codes that would describe new technology discussed and approved at the Spring meeting as part of the code revisions effective the following October.

Section 503(a) of Public Law 108–173 included a requirement for updating diagnosis and procedure codes twice a year instead of a single update on October 1 by 6A.—New Diagnosis Codes, Table 6B.—New Procedure Codes, and Table 6C.—
December 4–5, 2005 ICD–9–CM Coordination and Maintenance Committee Meeting minutes. The public agreed that there was a need to hold the fall meetings earlier, in September or October, in order to meet the new implementation dates. The public provided comment that additional time would be needed to update hospital systems and obtain new code books and coding software. There was considerable concern expressed about the impact this new April update would have on providers.

In the FY 2005 IPPS final rule, we implemented section 1886(d)(5)(K)(vii) of the Act, as added by section 503(a) of Public Law 108–173, by developing a mechanism for approving, in time for the April update, diagnosis and procedure code revisions needed to describe new technologies and medical services for purposes of the new technology add-on payment process. We also established the following process for making these determinations. Topics considered during the Fall ICD–10 (previously ICD–9–CM) Coordination and Maintenance Committee meeting are considered for an April 1 update if a strong and convincing case is made by the requester at the Committee’s public meeting. The request must identify the reason why a new code is needed in April for purposes of the new technology process. The participants at the meeting and those reviewing the Committee meeting summary report are provided the opportunity to comment on this expedited request. All other topics are considered for the October 1 update. Participants at the Committee meeting are encouraged to comment on all such requests. There were no requests approved for an expedited April 1, 2016 implementation of a code at the September 22–23, 2015 Committee meeting. Therefore, there were no new codes implemented on April 1, 2016.


CMS also sends copies of all ICD–10–CM and ICD–10–PCS coding changes to its Medicare contractors for use in updating their systems and providing education to providers.

The code titles are adopted as part of the ICD–10 (previously ICD–9–CM) Coordination and Maintenance Committee process. Therefore, although we publish the code titles in the IPPS proposed and final rules, they are not subject to comment in the proposed or final rules.

b. Code Freeze

In the January 16, 2009 ICD–10–CM and ICD–10–PCS final rule (74 FR 3340), there was a discussion of the need for a partial or total freeze in the annual updates to both ICD–9–CM and ICD–10–CM and ICD–10–PCS codes. The public comment addressed in that final rule stated that the annual code set updates should cease 1 year prior to the implementation of ICD–10. The commenters noted that this freeze of code updates would allow for instructional and/or coding software programs to be designed and purchased early, without concern that an upgrade would take place immediately before the compliance date, necessitating additional updates and purchases.

HHS responded to comments in the ICD–10 final rule that the ICD–9–CM Coordination and Maintenance Committee has jurisdiction over any action impacting the ICD–9–CM and ICD–10 code sets. Therefore, HHS indicated that the issue of consideration of a moratorium on updates to the ICD–9–CM, ICD–10–CM, and ICD–10–PCS code sets in anticipation of the adoption of ICD–10–CM and ICD–10–PCS would be addressed through the Committee at a future public meeting.

The code freeze was discussed at multiple meetings of the ICD–9–CM Coordination and Maintenance Committee and public comment was actively solicited. The Committee evaluated all comments from participants attending the Committee meetings as well as written comments that were received. The Committee also considered the delay in implementation of ICD–10 until October 1, 2014. There was an announcement at the September 19, 2012 ICD–9–CM Coordination and Maintenance Committee meeting that a partial freeze of both ICD–9–CM and ICD–10 codes would be implemented as follows:

- The last regular annual update to both ICD–9–CM and ICD–10 code sets was made on October 1, 2011.
- On October 1, 2012 and October 1, 2013, there were only limited code updates to both ICD–9–CM and ICD–10 code sets to capture new technology and new diseases.
- On October 1, 2014, there were to be only limited code updates to ICD–10 code sets to capture new technology and diagnoses as required by section 503(a) of Public Law 108–173. There were to be no updates to ICD–9–CM on October 1, 2014.
- On October 1, 2015, 1 year after the originally scheduled implementation of ICD–10, regular updates to ICD–10 were to begin.
- On May 15, 2014, CMS posted an updated Partial Code Freeze schedule on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/ICD-9-CM-Coordination-and-Maintenance-Committee-Meetings.html. This updated schedule provided information on the extension of the partial code freeze until 1 year after the implementation of ICD–10. As stated earlier, on April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113–93) was enacted, which specified that the Secretary may not adopt ICD–10 prior to October 1, 2015.
- On August 4, 2014, the Department published a final rule with a compliance date to require the use of ICD–10 beginning October 1, 2015. The final rule also required HIPAA-covered entities to continue to use ICD–9–CM through September 30, 2015.

Accordingly, the updated schedule for the partial code freeze was as follows:

- The last regular annual updates to both ICD–9–CM and ICD–10 code sets were made on October 1, 2011.
- On October 1, 2012, October 1, 2013, and October 1, 2014, there were only limited code updates to both the ICD–9–CM and ICD–10 code sets to capture new technologies and diseases as required by section 1886(d)(5)(K) of the Act.
- On October 1, 2015, there were only limited code updates to ICD–10 code sets to capture new technologies and diagnoses as required by section 1886(d)(5)(K) of the Act. There were no updates to ICD–9–CM, as it will no longer be used for reporting.
- On October 1, 2016 (1 year after implementation of ICD–10), regular updates to ICD–10 will begin.

The ICD–10 (previously ICD–9–CM) Coordination and Maintenance Committee announced that it would continue to meet twice a year during the freeze. At these meetings, the public was encouraged to comment on whether
or not requests for new diagnosis and procedure codes should be based on the need to capture new technology and new diseases. Any code requests that do not meet the criteria will be evaluated for implementation within ICD–10 1 year after the implementation of ICD–10, once the partial freeze is ended.

Complete information on the partial code freeze and discussions of the issues at the Committee meetings can be found on the ICD–10 Coordination and Maintenance Committee Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.html. A summary of the September 19, 2016 Committee meeting, along with both written and audio transcripts of this meeting, is posted on the Web site at: http://www.cms.hhs.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-CM-C-and-M-Meeting-Materials-Items/2012-09-19-MeetingMaterials.html.

This partial code freeze dramatically decreased the number of codes created each year as shown by the following information.

### TOTAL NUMBER OF CODES AND CHANGES IN TOTAL NUMBER OF CODES PER FISCAL YEAR

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>ICD–9–CM</th>
<th>Change</th>
<th>ICD–10–CM and ICD–10–PCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2009: October 1, 2008</td>
<td>14,025</td>
<td>348</td>
<td>FY 2009:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,025</td>
<td>348</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,824</td>
<td>56</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2010: October 1, 2009</td>
<td>14,315</td>
<td>290</td>
<td>FY 2010:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,315</td>
<td>290</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,838</td>
<td>14</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2011: October 1, 2010</td>
<td>14,922</td>
<td>117</td>
<td>FY 2011:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,922</td>
<td>117</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,859</td>
<td>21</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2012: October 1, 2011</td>
<td>14,567</td>
<td>135</td>
<td>FY 2012:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,877</td>
<td>18</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2013: October 1, 2012</td>
<td>14,567</td>
<td>135</td>
<td>FY 2013:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,877</td>
<td>18</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2014: October 1, 2013</td>
<td>14,567</td>
<td>135</td>
<td>FY 2014:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,882</td>
<td>4</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2015: October 1, 2014</td>
<td>14,567</td>
<td>135</td>
<td>FY 2015:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,882</td>
<td>4</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2016: October 1, 2015</td>
<td>14,567</td>
<td>135</td>
<td>FY 2016:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,882</td>
<td>4</td>
<td>ICD–10–PCS</td>
</tr>
<tr>
<td>FY 2017: October 1, 2016</td>
<td>14,567</td>
<td>135</td>
<td>FY 2017:</td>
</tr>
<tr>
<td>Diagnoses</td>
<td>14,567</td>
<td>135</td>
<td>ICD–10–CM</td>
</tr>
<tr>
<td>Procedures</td>
<td>3,882</td>
<td>4</td>
<td>ICD–10–PCS</td>
</tr>
</tbody>
</table>

As mentioned previously, the public is provided the opportunity to comment on any requests for new diagnosis or procedure codes discussed at the ICD–10 Coordination and Maintenance Committee meeting. The public has supported only a limited number of new codes during the partial code freeze, as can be seen by previously shown data. We have gone from creating several hundred new codes each year to creating only a limited number of new ICD–9–CM and ICD–10 codes.

At the September 22–23, 2015 and March 9–10, 2016 Committee meetings, we discussed any requests we had received for new ICD–10–CM diagnosis codes and ICD–10–PCS procedure codes that were to be implemented on October 1, 2016. We did not discuss ICD–9–CM codes. Because the partial code freeze will end on October 1, 2016, the public no longer had to comment on whether or not new ICD–10–CM and ICD–10–PCS codes should be created based on the partial code freeze criteria. We invited public comments on any code requests discussed at the September 22–23, 2015 and March 9–10, 2016 Committee meetings for implementation as part of the October 1, 2016 update. The deadline for commenting on code proposals discussed at the September 22–23, 2015 Committee meeting was November 13, 2015. The deadline for commenting on code proposals discussed at the March 9–10, 2016 Committee meeting was April 8, 2016.

18. Replaced Devices Offered Without Cost or With a Credit

a. Background

In the FY 2008 IPPS final rule with comment period (72 FR 47246 through 47251), we discussed the topic of Medicare payment for devices that are replaced without cost or where credit for a replaced device is furnished to the hospital. We implemented a policy to reduce a hospital’s IPPS payment for certain MS–DRGs where the implantation of a device that has been recalled determined the base MS–DRG assignment. At that time, we specified that we will reduce a hospital’s IPPS payment for those MS–DRGs where the hospital received a credit for a replaced device equal to 50 percent or more of the cost of the device.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51556 through 51557), we clarified this policy to state that the policy applies if the hospital received a credit equal to 50 percent or more of the cost of the replacement device and issued instructions to hospitals accordingly.

b. Changes for FY 2017

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25019), for FY 2017, we proposed not to add any MS–DRGs to the policy for replaced devices offered without cost or with a credit. We proposed to continue to include the
We solicited public comments on our proposal to continue to include the existing MS-DRGs currently subject to the policy and to not add any additional MS-DRGs to the policy. We indicated that the final list of MS-DRGs subject to the policy for FY 2017 would be listed in this FY 2017 IPPS/LTCH PPS final rule, as well as issued to providers in the form of a Change Request (CR).

We did not receive any public comments opposing our proposal to continue to include the existing MS-DRGs currently subject to the policy and to not add any additional MS-DRGs. Therefore, we are finalizing the list of MS-DRGs in the table included in the proposed rule and above that will be subject to the replaced devices offered without cost or with a credit policy effective October 1, 2016.

<table>
<thead>
<tr>
<th>MDC</th>
<th>MS-DRG</th>
<th>MS-DRG Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-MDC</td>
<td>001</td>
<td>Heart Transplant or Implant of Heart Assist System with MCC</td>
</tr>
<tr>
<td>Pre-MDC</td>
<td>002</td>
<td>Heart Transplant or Implant of Heart Assist System without MCC</td>
</tr>
<tr>
<td>1</td>
<td>023</td>
<td>Craniotomy with Major Device Implant/Acute Complex CNS Principal Diagnosis with MCC or Chemo Implant.</td>
</tr>
<tr>
<td>1</td>
<td>024</td>
<td>Craniotomy with Major Device Implant/Acute Complex CNS Principal Diagnosis without MCC.</td>
</tr>
<tr>
<td>1</td>
<td>025</td>
<td>Craniotomy &amp; Endovascular Intracranial Procedures with MCC.</td>
</tr>
<tr>
<td>1</td>
<td>026</td>
<td>Craniotomy &amp; Endovascular Intracranial Procedures with CC.</td>
</tr>
<tr>
<td>1</td>
<td>027</td>
<td>Craniotomy &amp; Endovascular Intracranial Procedures without CC/MCC.</td>
</tr>
<tr>
<td>1</td>
<td>040</td>
<td>Peripheral/Cranial Nerve &amp; Other Nervous System Procedure with MC.</td>
</tr>
<tr>
<td>1</td>
<td>041</td>
<td>Peripheral/Cranial Nerve &amp; Other Nervous System Procedure with CC or Peripheral Neurostimulator.</td>
</tr>
<tr>
<td>1</td>
<td>042</td>
<td>Peripheral/Cranial Nerve &amp; Other Nervous System Procedure without CC/MCC.</td>
</tr>
<tr>
<td>3</td>
<td>129</td>
<td>Major Head &amp; Neck Procedures with CC/MCC or Major Device.</td>
</tr>
<tr>
<td>5</td>
<td>215</td>
<td>Other Heart Assist System Implant.</td>
</tr>
<tr>
<td>5</td>
<td>216</td>
<td>Cardiac Valve &amp; Other Major Cardiovascular Procedures with Cardiac Catheter with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>217</td>
<td>Cardiac Valve &amp; Other Major Cardiovascular Procedures with Cardiac Catheter without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>218</td>
<td>Cardiac Valve &amp; Other Major Cardiovascular Procedure with Cardiac Catheter without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>219</td>
<td>Cardiac Valve &amp; Other Major Cardiovascular Procedure without Cardiac Catheter with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>220</td>
<td>Cardiac Valve &amp; Other Major Cardiovascular Procedure without Cardiac Catheter without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>221</td>
<td>Cardiac Valve &amp; Other Major Cardiovascular Procedure without Cardiac Catheter with CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>222</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheter with AMI/Heart Failure/Shock with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>223</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheter with AMI/Heart Failure/Shock without MCC.</td>
</tr>
<tr>
<td>5</td>
<td>224</td>
<td>Cardiac Defibrillator Implant with Cardiac Catheter without AMI/Heart Failure/Shock with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>225</td>
<td>Cardiac Defibrillator Implant without Cardiac Catheter without AMI/Heart Failure/Shock with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>226</td>
<td>Cardiac Defibrillator Implant without Cardiac Catheter with CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>227</td>
<td>Cardiac Defibrillator Implant without Cardiac Catheter without MC.</td>
</tr>
<tr>
<td>5</td>
<td>242</td>
<td>Permanent Cardiac Pacemaker Implant with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>243</td>
<td>Permanent Cardiac Pacemaker Implant without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>244</td>
<td>Permanent Cardiac Pacemaker Implant without MCC.</td>
</tr>
<tr>
<td>5</td>
<td>245</td>
<td>AICD Generator Procedures.</td>
</tr>
<tr>
<td>5</td>
<td>258</td>
<td>Cardiac Pacemaker Device Replacement with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>259</td>
<td>Cardiac Pacemaker Device Replacement with CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>260</td>
<td>Cardiac Pacemaker Revision Except Device Replacement without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>261</td>
<td>Cardiac Pacemaker Revision Except Device Replacement with CC.</td>
</tr>
<tr>
<td>5</td>
<td>262</td>
<td>Cardiac Pacemaker Revision Except Device Replacement without MCC.</td>
</tr>
<tr>
<td>5</td>
<td>266</td>
<td>Endovascular Cardiac Valve Replacement with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>267</td>
<td>Endovascular Cardiac Valve Replacement without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>268</td>
<td>Aortic and Heart Assist Procedures except Pulsation Balloon with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>269</td>
<td>Aortic and Heart Assist Procedures except Pulsation Balloon without MCC.</td>
</tr>
<tr>
<td>5</td>
<td>270</td>
<td>Other Major Cardiovascular Procedures with MCC.</td>
</tr>
<tr>
<td>5</td>
<td>271</td>
<td>Other Major Cardiovascular Procedures without CC/MCC.</td>
</tr>
<tr>
<td>5</td>
<td>272</td>
<td>Other Major Cardiovascular Procedures without MCC.</td>
</tr>
<tr>
<td>8</td>
<td>461</td>
<td>Bilateral or Multiple Major Joint Procedures of Lower Extremity without CC/MCC.</td>
</tr>
<tr>
<td>8</td>
<td>462</td>
<td>Bilateral or Multiple Major Joint Procedures of Lower Extremity with CC/MCC.</td>
</tr>
<tr>
<td>8</td>
<td>466</td>
<td>Revision of Hip or Knee Replacement with MCC.</td>
</tr>
<tr>
<td>8</td>
<td>467</td>
<td>Revision of Hip or Knee Replacement without CC/MCC.</td>
</tr>
<tr>
<td>8</td>
<td>468</td>
<td>Revision of Hip or Knee Replacement with CC.</td>
</tr>
<tr>
<td>8</td>
<td>469</td>
<td>Major Joint Replacement or Reattachment of Lower Extremity with MCC.</td>
</tr>
<tr>
<td>8</td>
<td>470</td>
<td>Major Joint Replacement or Reattachment of Lower Extremity without CC/MCC.</td>
</tr>
</tbody>
</table>

We did not receive any public comments opposing our proposal to continue to include the existing MS-DRGs currently subject to the policy and to not add any additional MS-DRGs. Therefore, we are finalizing the list of MS-DRGs in the table included in the proposed rule and above that will be subject to the replaced devices offered without cost or with a credit policy effective October 1, 2016.

19. Other Policy Changes

a. MS-DRG GROUPER Logic

(1) Operations on Products of Conception

In the ICD-9-CM MS-DRGs Version 32, intruterine operations that may be performed in an attempt to correct a fetal abnormality are identified by ICD-9-CM procedure code 75.36 (Correction of fetal defect). This procedure code is designated as an O.R. procedure and is assigned to MDC 14 (Pregnancy, Childbirth and the Puerperium) in MS-DRG 768 (Vaginal Delivery with O.R. Procedure Except Sterilization and/or Dilation and Curettage).

A replication issue for 208 ICD-10-PCS comparable code translations that describe operations on the products of conception (fetus) to correct fetal defects was identified during an internal review. These 208 procedure codes were inadvertently omitted from the MDC 14 GROUPER logic for ICD-10 MS-DRG 768. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25020), we proposed to add the 208 ICD-10-PCS procedure codes shown in Table 6P.3a, associated with the proposed rule (which is available via the Internet on the CMS Web site at:
performed. However, this scenario may during the same episode of care in
requires that a vaginal delivery occur
GROUPER logic for MS–DRG 768 (listed in Table 6P.3a.). For example, the
intrauterine procedures under ICD–10
review, we also concluded that the
described above, during our internal
2016.
DRGs Version 34, effective October 1,
MDC 14 in MS–DRG 768 in ICD–10 MS–
replication issues.
MS–DRG 768. The commenters also
procedure codes describing operations
proposal to add the 208 ICD–10–PCS
intrauterine procedures that describe fetal
diagnosis codes and ICD–10–PCS
DRGs Version 35: (1) The ICD–10–CM
consideration for a possible future
FR 25020), we solicited public
that, as discussed in section II.F.5.d. of
230. In the FY 2017 IPPS/LTCH PPS
omitted from the MDC 5 GROUPER
32, revascularization procedures that are
32, revascularization procedures that are
heart are identified with procedure code
This procedure code is designated as an
heart are identified with procedure code
may undergo a fetoscopic endoluminal
congenital diaphragmatic hernia (CDH)
surgery. For example, a pregnant patient
undergo fetal surgery may be performed with a
subsequent delivery during the same
care to maintain the DRGs in clinical areas
that have very low volume in the
Medicare population, including for
conditions associated with and/or
occurring in the maternal-fetal patient
population. Additional information is
needed to fully and accurately evaluate all the possible fetal conditions that may fall under similar scenarios to the one
described above before making a
specific proposal. Therefore, in the FY
2017 IPPS/LTCH PPS proposed rule (81 FR 25020), we solicited public
comments on two clinical concepts for
consideration for a possible future
proposal for the FY 2018 ICD–10 MS–
DRGs Version 35: (1) The ICD–10–CM
diagnosis codes and ICD–10–PCS
procedure codes that describe fetal
abnormalities for which fetal surgery may be performed in the absence of a
delivery during the same hospital stay; and (2) the ICD–10–CM diagnosis codes
and ICD–10–PCS procedure codes that
describe fetal abnormalities for which
fetal surgery may be performed with a
subsequent delivery during the same
hospital stay. This second concept is the
structure of current MS–DRG 768. We
indicated that commenters should
submit their code recommendations for
these concepts to the following email
address MSDRGCclassificationChange@
cms.hhs.gov by December 7, 2016. We
encouraged public comments as we
consider these enhancements for the FY

(2) Other Heart Revascularization

In the ICD–9–CM MS–DRGs Version 32, revascularization procedures that are performed to restore blood flow to the heart are identified with procedure code 36.39 (Other heart revascularization). This procedure code is designated as an O.R. procedure and is assigned to MDC 5 (Diseases and Disorders of the Circulatory System) in MS–DRGs 228 through 230 (Other Cardiothoracic Procedures with MCC, with CC, and without CC/MCC, respectively).

A replication issue for 16 ICD–10–PCS comparable code translations that describe revascularization procedures was identified after implementation of the ICD–10 MS–DRGs Version 33. These 16 procedure codes were inadvertently omitted from the MDC 5 GROUPER logic for ICD–10 MS–DRGs 228 through 230. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25021), we noted that, as discussed in section II.F.5.d. of the preamble of the proposed rule, we proposed to delete MS–DRG 230 and revise MS–DRG 229. Accordingly, to resolve this replication issue, we proposed to add the 16 ICD–10–PCS procedure codes listed in the table below to MDC 5 in MS–DRGs 228 and proposed revised MS–DRG 229.

<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02103D4</td>
<td>Bypass coronary artery, one site from coronary vein with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02103D4</td>
<td>Bypass coronary artery, one site from coronary vein with drug-eluting intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02104D4</td>
<td>Bypass coronary artery, one site from coronary vein with drug-eluting intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02113D4</td>
<td>Bypass coronary artery, two sites from coronary vein with drug-eluting intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02113D4</td>
<td>Bypass coronary artery, two sites from coronary vein with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02114D4</td>
<td>Bypass coronary artery, two sites from coronary vein with drug-eluting intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02114D4</td>
<td>Bypass coronary artery, two sites from coronary vein with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02123D4</td>
<td>Bypass coronary artery, three sites from coronary vein with drug-eluting intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02123D4</td>
<td>Bypass coronary artery, three sites from coronary vein with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02124D4</td>
<td>Bypass coronary artery, three sites from coronary vein with drug-eluting intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02124D4</td>
<td>Bypass coronary artery, three sites from coronary vein with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02133D4</td>
<td>Bypass coronary artery, four or more sites from coronary vein with drug-eluting intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02133D4</td>
<td>Bypass coronary artery, four or more sites from coronary vein with intraluminal device, percutaneous approach.</td>
</tr>
<tr>
<td>02134D4</td>
<td>Bypass coronary artery, four or more sites from coronary vein with drug-eluting intraluminal device, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>02134D4</td>
<td>Bypass coronary artery, four or more sites from coronary vein with intraluminal device, percutaneous endoscopic approach.</td>
</tr>
</tbody>
</table>
We invited public comments on our proposal to add the above listed ICD–10–PCS procedure codes to MDC 5 in MS–DRGs 228 and proposed revised MS–DRGs 229 (Other Cardiothoracic Procedures with and without MCC, respectively), effective October 1, 2016, in ICD–10 MS–DRGs Version 34. Comments were also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Comment: Commenters supported the proposal to add the 16 ICD–10–PCS procedure codes describing revascularization procedures to MDC 5 in MS–DRGs 228 and proposed revised MS–DRGs 229. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs. We note that, as discussed in section II.F.15.b. of the proposed rule, we made a document consisting of procedure code updates publicly available. This document included the above list of codes that were revised in response to public comments received during the partial code freeze. The revised code titles reflect the term “artery” where the current term “site” is displayed and reflect the term “arteries” where the current term “site” is displayed in the table above. A complete list of all the revised ICD–10–PCS procedure code titles is shown in Table 6F.—Revised Procedure Code Titles associated with this final rule (which is available via the Internet on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index).

After consideration of the public comments we received, we are finalizing our proposal to add the ICD–10–PCS procedure codes in the proposed rule and above in this final rule, with their revised code titles as shown in Table 6F.—Revised Procedure Code Titles, to MDC 5 in MS–DRGs 228 and 229 (Other Cardiothoracic Procedures with and without MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016. We also note that, as discussed in section II.F.5.d. of this final rule, the proposal to collapse MS–DRGs 228, 229, and 230 from three severity levels into two severity levels was finalized.

(3) Procedures on Vascular Bodies: Chemoreceptors

In the ICD–9–CM MS–DRGs Version 32, procedures performed on the sensory receptors are identified with ICD–9–CM procedure code 39.89 (Other operations on carotid body, carotid sinus and other vascular bodies). This procedure code is designated as an O.R. procedure and is assigned to MDC 5 (Diseases and Disorders of the Circulatory System) in MS–DRGs 252, 253, and 254 (Other Vascular Procedures with MCC, with CC, and without CC/MCC, respectively). A replication issue for 234 ICD–10–PCS comparable code translations that describe these procedures was identified after implementation of the ICD–10 MS–DRGs Version 33. These 234 procedure codes were inadvertently omitted from the MDC 5 GROUPER logic for ICD–10–MS–DRGs 252 through 254. To resolve this replication issue, in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25021), we proposed to add the 234 ICD–10–PCS procedure codes listed in Table 6P.3b. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ICD10PCS/index). To resolve this replication issue, in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25021), we proposed to add the 234 ICD–10–PCS procedure codes listed in Table 6P.3b. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ICD10PCS/index). To resolve this replication issue, in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25021), we proposed to add the 234 ICD–10–PCS procedure codes listed in Table 6P.3b. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ICD10PCS/index).

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add the four ICD–10–PCS procedure codes describing repair of the intestine to MDC 6 in MS–DRGs 329, 330, and 331. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add the four ICD–10–PCS procedure codes, 0DQF0ZZ, 0DQG0ZZ, 0DQL0ZZ, and 0DQM0ZZ listed in the proposed rule and above in this final rule, to MDC 6 in MS–DRGs 329, 330, and 331 (Major Small and Large Bowel Procedures with MCC, with CC, and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(5) Insertion of Infusion Pump

In the ICD–9–CM MS–DRGs Version 32, the procedure for insertion of an infusion pump is identified with procedure code 86.06 (Insertion of totally implantable infusion pump), which is designated as an O.R. procedure and assigned to a number of MDCs and MS–DRGs across various body systems. We refer readers to the ICD–9–CM MS–DRG Definitions Manual Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index, which is available on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.
<table>
<thead>
<tr>
<th>ICD–10–PCS procedure code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0JHD0VZ ..................</td>
<td>Insertion of infusion pump into right upper arm subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHD3VZ ..................</td>
<td>Insertion of infusion pump into right upper arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHF0VZ ..................</td>
<td>Insertion of infusion pump into left upper arm subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHF3VZ ..................</td>
<td>Insertion of infusion pump into left upper arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHG0VZ ..................</td>
<td>Insertion of infusion pump into right lower arm subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHG3VZ ..................</td>
<td>Insertion of infusion pump into right lower arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHH0VZ ..................</td>
<td>Insertion of infusion pump into left lower arm subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHH3VZ ..................</td>
<td>Insertion of infusion pump into left lower arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHL0VZ ..................</td>
<td>Insertion of infusion pump into right upper leg subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHL3VZ ..................</td>
<td>Insertion of infusion pump into right upper leg subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHM0VZ ..................</td>
<td>Insertion of infusion pump into left upper leg subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHM3VZ ..................</td>
<td>Insertion of infusion pump into left upper leg subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHN0VZ ..................</td>
<td>Insertion of infusion pump into right lower leg subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHN3VZ ..................</td>
<td>Insertion of infusion pump into right lower leg subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JHP0VZ ..................</td>
<td>Insertion of infusion pump into left lower leg subcutaneous tissue and fascia, open approach.</td>
</tr>
<tr>
<td>0JHP3VZ ..................</td>
<td>Insertion of infusion pump into left lower leg subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
</tbody>
</table>

These codes were inadvertently omitted from the MDCs and MS–DRGs to which they should be assigned (consistent with the assignment of ICD–9–CM procedure code 86.06) to accurately replicate the ICD–9–CM MS–DRG logic. To resolve this replication issue, in the FY 2017 IPPS/LTCPPPS proposed rule (81 FR 25021 through 25022), we proposed to add the 16 ICD–10–PCS procedure codes listed in the table above to the corresponding MDCs and MS–DRGs, as set forth in the ICD–9–CM MS–DRGs Version 33. These six ICD–10–PCS procedure codes were added to the ICD–10–PCS comparable code translations identified after implementation of the ICD–9 MS–DRG Definitions Manual—Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index which is available on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Rule-Data-Files.html in ICD–10 MS–DRGs Version 34, effective October 1, 2016. (6) Procedures on the Bursa

In the ICD–9–CM MS–DRGs Version 32, procedures that involve cutting into the bursa are identified with procedure code 83.03 (Bursotomy). This procedure code is designated as an O.R. procedure and is assigned to MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue) in MS–DRGs 500, 501, and 502 (Soft Tissue Procedures with MCC, with CC, and without CC/MCC, respectively). A replication issue for six ICD–10–PCS comparable code translations was identified after implementation of the ICD–10 MS–DRGs Version 33. These six procedure codes are:

- O8550ZZ (Division of right wrist bursa and ligament, open approach);
- O8553ZZ (Division of right wrist bursa and ligament, percutaneous approach);
- O8554ZZ (Division of right wrist bursa and ligament, percutaneous endoscopic approach);
- O8660ZZ (Division of left wrist bursa and ligament, open approach);
- O8663ZZ (Division of left wrist bursa and ligament, percutaneous approach); and
- O8664ZZ (Division of left wrist bursa and ligament, percutaneous endoscopic approach).

These codes were inadvertently omitted from the MDC 8 GROUPER logic for ICD–10 MS–DRGs 500, 501, and 502. To resolve this replication issue, in the FY 2017 IPPS/LTCPPPS proposed rule (81 FR 25022), we proposed to add the six ICD–10–PCS procedure codes listed above to MDC 8 in MS–DRGs 500, 501, and 502, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Comment: Commenters supported the proposal to add the six ICD–10–PCS procedure codes describing procedures that involve cutting into the bursa listed in the proposed rule to MDC 8 in MS–DRGs 500, 501, and 502. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add the six ICD–10–PCS procedure codes listing the proposed rule and above in this final rule to the corresponding final MDCs and MS–DRGs for ICD–9–CM code 86.06, as set forth in the ICD–9–CM MS–DRG Definitions Manual—Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index which is available on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Rule-Data-Files.html in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(7) Procedures on the Breast

In the ICD–9–CM MS–DRGs Version 32, procedures performed for a simple repair to the skin of the breast may be identified with procedure code 86.59 (Closure of skin and subcutaneous tissue of other sites). This procedure
code is designated as a non-O.R. procedure. Therefore, this procedure code does not have an impact on MS–DRG assignment.

A replication issue for two ICD–10–PCS comparable code translations was identified after implementation of the ICD–10 MS–DRGs Version 33. These two procedure codes are: 0HQVXZZZ (Repair bilateral breast, external approach) and 0HQVYZZZ (Repair supernumerary breast, external approach). These ICD–10–PCS procedures codes were inadvertently assigned to ICD–10 MS–DRGs 981, 982, and 983 (Extensive O.R. Procedure Unrelated to Principal Diagnosis with MCC, with CC, and without CC, respectively) in the ICD–10 MS–DRG GROUPER logic. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25022), we proposed to remove these two ICD–10–PCS procedure codes from MS–DRGs 981, 982, and 983, to designate them as non-O.R. procedures, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Comment: Commenters supported the proposal to designate the two ICD–10–PCS codes (0HQVXZZZ and 0HQVYZZZ) as non-O.R. procedures. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

One commenter expressed concern with the proposal, noting that the proposed change may result in unintended consequences for other procedures because these ICD–10–PCS codes can also be considered comparable translations of ICD–9–CM procedure code 85.89 (Other mammoplasty), which is designated as an O.R. procedure.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs. We also acknowledge the concerns of the commenter who stated that our proposal could result in unintended consequences. We note that a large number of ICD–9–CM procedure codes that have a fourth digit of 9 (XX.X9) and include the term “other” as part of the code title are designated as O.R. procedures under the ICD–9–CM MS–DRGs Version 32. The intent of these codes is to capture procedures that are not able to be identified elsewhere in the classification system with another procedure code. These codes are often very vague and generally do not distinguish what approach is used for a specific anatomic site according to the body system in which it was assigned. Therefore, when these “other” ICD–9–CM procedure codes went through the process of the ICD–10 MS–DRG conversion, they understandably satisfied almost every available option (root operation, body part, approach, among others) within the structure of the specified ICD–10–PCS section, respective of the body system.

As such, while we recognize that ICD–10–PCS procedure codes 0HQVXZZZ (Repair bilateral breast, external approach) and 0HQVYZZZ (Repair supernumerary breast, external approach) can be considered comparable translations of ICD–9–CM procedure code 85.89 (Other mammoplasty), which is designated as an O.R. procedure, we note that, under ICD–10–PCS, there also are more appropriate root operations that could logically be reported to identify that a mammoplasty was performed. For example, a mammoplasty may involve breast augmentation to enhance the appearance, size, or contour of the breast, in which case the ICD–10–PCS root operation “Alteration” could be reported. We believe that, from a clinical perspective, a mammoplasty would not necessarily be coded using the root of Repair with an external approach under ICD–10–PCS.

In addition, we note that the ICD–10–PCS procedure codes describing unilateral repair of the breast with an external approach are currently designated as non-O.R. procedures under the ICD–10 MS–DRGs Version 33. Therefore, the proposal to make bilateral repair of the breast with an external approach non-O.R. would be consistent with those codes.

After consideration of the public comments we received, we are finalizing our proposal to designate ICD–10–PCS procedure codes 0HQVXZZZ (Repair bilateral breast, external approach) and 0HQVYZZZ (Repair supernumerary breast, external approach) as non-O.R. codes in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(8) Excision of Subcutaneous Tissue and Fascia

In the ICD–9–CM MS–DRGs Version 32, procedures involving excision of the skin and subcutaneous tissue are identified with procedure code 86.3 (Other local excision of lesion or tissue of skin and subcutaneous tissue). This procedure code is designated as a non-O.R. procedure that affects MS–DRG assignment for MS–DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC and without CC/MCC, respectively) in MDC 9 (Diseases and Disorders of the Skin, Subcutaneous Tissue and Breast).

A replication issue for 19 ICD–10–PCS comparable code translations was identified after implementation of the ICD–10 MS–DRGs Version 33. These 19 procedure codes are listed in the table below.

<table>
<thead>
<tr>
<th>ICD–10–PCS code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0JB03ZZ</td>
<td>Excision of scalp subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JB43ZZ</td>
<td>Excision of anterior neck subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JB53ZZ</td>
<td>Excision of posterior neck subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JB63ZZ</td>
<td>Excision of chest subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JB73ZZ</td>
<td>Excision of back subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JB83ZZ</td>
<td>Excision of abdomen subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JB93ZZ</td>
<td>Excision of buttock subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBB3ZZ</td>
<td>Excision of periumbilical subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBC3ZZ</td>
<td>Excision of pelvic region subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JD3ZZ</td>
<td>Excision of right upper arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBF3ZZ</td>
<td>Excision of left upper arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBG3ZZ</td>
<td>Excision of right lower arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBH3ZZ</td>
<td>Excision of left lower arm subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBL3ZZ</td>
<td>Excision of right upper leg subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
<tr>
<td>0JBM3ZZ</td>
<td>Excision of left upper leg subcutaneous tissue and fascia, percutaneous approach.</td>
</tr>
</tbody>
</table>
These codes were inadvertently omitted from the ICD–10 MS–DRG GROUPER logic for MDC 9 in MS–DRGs 579, 580, and 581. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25022 through 25023), we proposed to add the 19 ICD–10–PCS procedure codes listed in the table above to MDC 9 in MS–DRGs 579, 580, and 581, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Comment: Commenters supported the proposal to add the 19 ICD–10–PCS procedure codes describing procedures that involve cutting the subcutaneous tissue and fascia listed in the table in the proposed rule to MDC 9 in MS–DRGs 579, 580, and 581. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add the 19 ICD–10–PCS procedure codes listed in the table in the proposed rule and above in this final rule to MDC 9 in MS–DRGs 579, 580, and 581 (Other Skin, Subcutaneous Tissue and Breast Procedures with MCC, with CC and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(9) Shoulder Replacement

In the ICD–9–CM MS–DRGs Version 32, procedures that involve replacing a component of bone from the upper arm are identified with procedure code 78.42 (Other repair or plastic operations on bone, humerus). This procedure code is designated as an O.R. procedure and is assigned to MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue) in MS–DRGs 492, 493, and 494 (Lower Extremity and Humerus Procedures Except Hip, Foot and Femur with MCC, with CC, and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(10) Reposition

In the ICD–9–CM MS–DRGs Version 32, procedures that involve the percutaneous repositioning of an area in the vertebral column are identified with procedure code 81.66 (Percutaneous vertebral augmentation). This procedure code is designated as an O.R. procedure and is assigned to MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue) in MS–DRGs 515, 516, and 517 (Other Musculoskeletal System and Connective Tissue Procedures with MCC, with CC, and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

A replication issue for four ICD–10–PCS procedure codes describing repositioning of vertebra listed in the proposed rule to MDC 8 in MS–DRGs 515, 516, and 517. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25023) we proposed to add these four ICD–10–PCS procedure codes to MDC 8 in MS–DRGs 515, 516, and 517, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Comment: Commenters supported the proposal to add the two ICD–10–PCS procedure codes describing procedures that involve shoulder replacement listed in the proposed rule to MDC 9 in MS–DRGs 492, 493, and 494, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS codes 0PRC0JZ (Replacement of right humeral head with synthetic substitute, open approach) and 0PRD0JZ (Replacement of left humeral head with synthetic substitute, open approach). These two codes were inadvertently omitted from the ICD–10 MS–DRG GROUPER logic for MDC 8 in MS–DRGs 492, 493, and 494. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25023), we proposed to add these two ICD–10–PCS procedure codes to MDC 8 in MS–DRGs 492, 493, and 494, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–PCS codes 0PRC0JZ (Replacement of right humeral head with synthetic substitute, open approach) and 0PRD0JZ (Replacement of left humeral head with synthetic substitute, open approach) to MDC 8 in MS–DRGs 492, 493, and 494 (Lower Extremity and Humerus Procedures Except Hip, Foot and Femur with MCC, with CC, and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(10) Reposition

In the ICD–9–CM MS–DRGs Version 32, procedures that involve the percutaneous repositioning of an area in the vertebral column are identified with procedure code 81.66 (Percutaneous vertebral augmentation). This procedure code is designated as an O.R. procedure and is assigned to MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue) in MS–DRGs 515, 516, and 517 (Other Musculoskeletal System and Connective Tissue Procedures with MCC, with CC, and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.
(11) Insertion of Infusion Device

In the ICD–9–CM MS–DRGs Version 32, the procedure for insertion of an infusion pump is identified with procedure code 86.06 (Insertion of totally implantable infusion pump) which is designated as an O.R. procedure and assigned to a number of MDCs and MS–DRGs, one of which is MDC 8 (Diseases and Disorders of the Musculoskeletal System and Connective Tissue) in MS–DRGs 515, 516, and 517 (Other Musculoskeletal System and Connective Tissue O.R. Procedures with MCC, with CC, and without CC/MCC, respectively).

A replication issue for 49 ICD–10–PCS comparable code translations that describe insertion of an infusion device into a joint or disc was identified after implementation of the ICD–10 MS–DRGs Version 33. These 49 procedure codes appear to describe procedures that utilize a specific type of infusion device known as an infusion pump and were inadvertently omitted from the ICD–10 MS–DRG GROUPER logic for MDC 8. To resolve this replication issue, in the FY 2017 IPPS/LTCF PPS proposed rule (81 FR 25023), we proposed to add the 49 ICD–10–PCS procedure codes shown in Table 6P.3c. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index) to MDC 8 in MS–DRGs 515, 516, and 517, effective October 1, 2016, in ICD–10 MS–DRGs Version 34. We invited public comments on our proposal.

Comment: Several commenters supported the proposal to add the 49 ICD–10–PCS procedure codes describing open insertion of an infusion device into a joint or disc to MDC 8 in MS–DRGs 515, 516, and 517. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

One commenter reported that standard surgical practice does not support procedures involving infusion devices (as well as removal of tracheostomy and occlusion of esophageal vein which are discussed in sections II.F.19.c.1.c. and section II.F.19.c.1.j. of the preamble of this final rule) being performed outside of an operating room setting. This commenter asserted that because these types of procedures are complex, necessitate a sterile environment and general anesthesia support, physicians would rarely perform them in a setting other than the operating room.

However, other commenters did not agree that procedures describing the insertion of an infusion device into a joint or disc should be classified the same as ICD–9–CM code 86.06 (Insertion of totally implantable infusion pump). One commenter noted that the 49 ICD–10–PCS procedure codes describe an infusion device which the ICD–10–PCS classification categorizes as an infusion catheter, and there are separate ICD–10–PCS device values that specifically describe an infusion device, pump. This commenter disagreed with the proposal to assign the 49 ICD–10–PCS procedure codes into MS–DRGs 515, 516, and 517, stating that an infusion pump cannot be inserted into a joint, while a catheter can. The commenter noted that, similar to our discussion in section II.F.19.c.1.k. of the preamble of the proposed rule, these ICD–10–PCS procedures codes reasonably correlate to the insertion of a common infusion catheter versus the insertion of a totally implantable infusion pump.

Another commenter expressed concern with the potential coding and payment impacts as a result of the proposal and noted that while an infusion catheter and an infusion pump may be inserted together, they are separate devices with different levels of resource utilization. The commenter stated that implantable infusion pumps are resource-intensive for hospitals and designated appropriately as O.R. procedures in contrast to infusion catheters.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs. It is not clear if the commenter who stated that standard surgical practice does not support procedures involving infusion devices being performed outside of an operating room was referring to procedures involving an infusion pump versus procedures involving an infusion device as classified under ICD–10–PCS. We note that, as stated above, under ICD–9–CM, procedure code 86.06 describes the insertion of a totally implantable infusion pump. Under ICD–10–PCS, the term “implantable” is not utilized with the infusion device, pump, or infusion codes.

In response to the commenters who disagreed with our proposal, we acknowledge that the ICD–10–PCS classification categorizes the device values for an infusion device (catheter) separately from the device values that describe an infusion device, pump. In addition, our clinical advisors support the commenters’ observation that an infusion device, pump is not inserted into a joint space, but rather the infusion device, catheter would be inserted into the joint space.

It is understandable that the term “infusion device” can be interpreted in different ways because the type of infusion device used is sometimes dependent on whether the prescribed treatment will be administered intermittently (for example, for chemotherapy) or continuously (for example, insulin therapy) and the mechanism used to pump in the drug may vary (for example, battery, electricity, or pressure). Taking these characteristics into account, an “infusion device” could be literally implanted in the body or parts of the device could be found outside of the body. For example, a subcutaneously implanted reservoir may function as an infusion device when it is accessed via a needle attached to another catheter that transports the intended drug to the reservoir. Transport of the drug is via an external mechanical pump. In comparison to the aforementioned example of a subcutaneous reservoir with catheter as an “infusion device” are the elastomeric pumps which rely on the pressure generated by the elastic constriction created when the pump is filled with the drug to be administered. Elastomeric pumps do not rely upon any electronics or additional sources of energy to maintain the flow rate. Elastomeric pumps are typically single-use and disposable. In view of the different types of pumps used for short-term and long-term treatment purposes and the different interpretations of the infusion device codes, we will continue to analyze if further revisions to these codes are needed in ICD–10–PCS to ensure accurate assignment under the ICD–10 MS–DRGs. We also will continue to work with the AHA through the Coding Clinic for ICD–10–CM and ICD–10–PCS to promote proper coding.

After consideration of the public comments we received, we are not finalizing our proposal to assign the 49 ICD–10–PCS procedure codes describing insertion of an infusion device to MDC 8 in MS–DRGs 515, 516, and 517 (Other Musculoskeletal System and Connective Tissue O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) for FY 2017.

Consistent with the discussion in section II.F.19.c.1)(k) of the preamble of the proposed rule and the same section of this final rule, the 49 ICD–10–PCS procedure codes shown in Table 6P.3c. associated with the proposed rule and updated for this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/
bladder repair is identified with procedure code 57.89 (Other repair of bladder) which is designated as an O.R. procedure and assigned to MDC 11 (Diseases and Disorders of the Kidney and Urinary Tract) in MS–DRGs 653, 654, and 655 (Major Bladder Procedures with MCC, with CC, and without CC/MCC, respectively) and MDC 13 (Diseases and Disorders of the Female Reproductive System) in MS–DRGs 749 and 750 (Other Female Reproductive System O.R. Procedures with CC/MCC and without CC/MCC, respectively).

A replication issue for five ICD–10–PCS comparable code translations that describe a bladder neck repair was identified after implementation of the ICD–10 MS–DRGs Version 33. These five procedure codes are:

- **0TQC0ZZ (Repair Bladder Neck, Open Approach)**
- **0TQC3ZZ (Repair Bladder Neck, Percutaneous Approach)**
- **0TQC4ZZ (Repair Bladder Neck, Percutaneous Endoscopic Approach)**
- **0TQC7ZZ (Repair Bladder Neck, Via Natural or Artificial Opening)**
- **0TQC8ZZ (Repair Bladder Neck, Via Natural or Artificial Opening Endoscopic)**

These five ICD–10–PCS procedure codes were inadvertently omitted from the ICD–10 MS–DRG GROUPER logic for MDC 11 in MS–DRGs 653, 654, and 655 and MDC 13 in MS–DRGs 749 and 750. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25023 through 25024), we proposed to add these five ICD–10–PCS procedure codes to MDC 11 in MS–DRGs 653, 654, and 655 (Major Bladder Procedures with MCC, with CC, and without CC/MCC, respectively) and MDC 13 in MS–DRGs 749 and 750 (Other Female Reproductive System O.R. Procedures with CC/MCC and without CC/MCC, respectively) in ICD–10 MS–DRGs Version 34, effective October 1, 2016.

We note that commenters have suggested that there are a number of procedure codes that may not appear to be clinically feasible due to a specific approach or device value in relation to a unique body part in a given body system. These commenters have not identified a comprehensive list of codes to be deleted. However, they have suggested that CMS examine these codes further. Due to the multiaxial structure of ICD–10–PCS, the current system allows for multiple possibilities for a given procedure, some of which may not currently be used. As our focus to refine the ICD–10 MS–DRGs continues, for FY 2018, we will begin to conduct an analysis of where such ICD–10–PCS codes may exist. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25023 through 25024), we welcomed suggestions from the public of code refinements that could address the issue of current ICD–10–PCS codes that capture procedures that would not reasonably be performed. We indicated that commenters should submit their recommendations for these code refinements to the following email address: MSDRGCClassificationChanges@cms.hhs.gov by December 7, 2016.

We also noted in the proposed rule that any suggestions that are received by December 7, 2016 to update ICD–10–PCS, including creating new codes or deleting/omitting codes that would not be addressed by the ICD–10 Coordination and Maintenance Committee. Proposals to address the modification of any ICD–10–PCS codes are discussed at the ICD–10 Coordination and Maintenance Committee meetings held in March and September of each year. We refer the reader to section II.F.17. of the preamble of the proposed rule and this final rule for information related to this process to request updates to ICD–10–PCS.

b. Issues Relating to MS–DRG 999 (Ungroupable)

Under the ICD–9–CM MS–DRGs Version 32, a diagnosis of complications of an obstetric surgical wound after delivery is identified with diagnosis code 674.32 (Other complications of obstetrical surgical wounds, delivered, with mention of postpartum complication) and is assigned to MDC 14 (Pregnancy, Childbirth and the Puerperium) under MS–DRG 769 (Postpartum and Post Abortion Diagnoses with O.R. Procedure) or MS–DRG 776 (Postpartum and Post Abortion Diagnoses without O.R. Procedure). A replication issue under the ICD–10 MS–DRGs Version 33 for this condition was identified after implementation on October 1, 2015. Under ICD–10–CM, diagnosis code O90.2 (Hematoma of obstetric wound) is the comparable translation for ICD–9–CM diagnosis code 674.32. We discovered that cases where a patient has been readmitted to the hospital after a delivery and ICD–10–CM diagnosis code O90.2 is reported as the principal diagnosis are resulting in assignment to MS–DRG 999 (Ungroupable).

In the ICD–9–CM diagnosis code description, the concept of “delivery” is included in the code title. This concept is not present in the ICD–10–CM classification and has led to a replication issue for patients who delivered during a previous stay and are subsequently readmitted for the complication. To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25024), we proposed to add ICD–10–CM diagnosis code O90.2 to MDC 14 under MS–DRG 769 and 776. This proposal will be consistent with the ICD–9–CM diagnosis code assignment and result in a more accurate replication of the ICD–9–CM MS–DRGs Version 32.

We invited public comments on our proposal to add ICD–10–CM diagnosis code O90.2 to MS–DRG 769 and MS–DRG 776 in MDC 14, effective October 1, 2016, in the ICD–10 MS–DRGs Version 34.

Comment: Commenters supported the proposal to add ICD–10–CM diagnosis code O90.2 (Hematoma of obstetric wound) to MDC 14 in MS–DRGs 769 and 776. The commenters also
expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to add ICD–10–CM diagnosis code O90.2 (Hematoma of obstetric wound) to MDC 14 in MS–DRG 769 (Postpartum and Post Abortion Diagnoses with O.R. Procedure) or MS–DRG 776 (Postpartum and Post Abortion Diagnoses without O.R. Procedure) in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(1) O.R. Procedures to Non-O.R. Procedures

For the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25024 through 25026), we continued our efforts to address the MS–DRG replication issues between ICD–9–CM logic and ICD–10 that were brought to our attention. As a result of analyzing those specific requests, we identified areas in the ICD–10–PCS classification where additional refinements could further support our replication efforts. We discuss these below.

We evaluated specific groups of ICD–10–PCS procedure codes with respect to their current operating room (O.R.) designation that were determined to be inconsistent with the ICD–9–CM procedure codes from which the designation was initially derived. Our review demonstrated that these ICD–10–PCS procedure codes should instead have the attributes of a more logical ICD–9–CM procedure code translation for MS–DRG replication purposes. As specified below, we proposed to change the status of ICD–10–PCS procedure codes from being designated as O.R. to non-O.R. for the ICD–10 MS–DRGs Version 34. For each group summarized below, the detailed code lists are shown in Tables 6P.4a through 6P.4k (ICD–10–CM and ICD–10–PCS Codes for Proposed MCE and MS–DRG Changes—FY 2017) associated with the proposed rule, which are available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

(a) Endoscopic/Transorifice Removal

We found 155 ICD–10–PCS procedure codes describing an endoscopic/ transorifice (via natural or artificial opening) removal of common devices such as a drainage device, infusion device, intraluminal device, or monitoring device from various tubular body parts that, when coded under ICD–9–CM, would reasonably correlate to other nonoperative removal of a wide range of devices/appliances procedure codes versus an “incision of [body part]” or “other operation on a [body part]” procedure code. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25025), we proposed that the 155 ICD–10–PCS procedure codes in Table 6P.4b, associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html), be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(b) Endoscopic/Transorifice Insertion

We found 72 ICD–10–PCS procedure codes describing an endoscopic/ transorifice (via natural or artificial opening) insertion of infusion and monitoring devices into various tubular body parts that, when coded under ICD–9–CM, would reasonably correlate to other noninvasive catheterization and monitoring types of procedure codes versus an “incision of [body part]” or “other operation on a [body part]” procedure code. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25024 through 25025), we proposed that the 72 ICD–10–PCS procedure codes in Table 6P.4a, associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html), be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.
appreciation for CMS’ continued efforts towards addressing replication issues.

**Response:** We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to change the designation of the 155 ICD–10–PCS procedure codes in Table 6P.4b. associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). These 155 ICD–10–PCS procedure codes will be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(c) Tracheostomy Device Removal

We found five ICD–10–PCS procedure codes describing removal of a tracheostomy device with various approaches such that, when coded under ICD–9–CM, would reasonably correlate to the nonoperative removal of a tracheostomy device procedure code versus an “incision of [body part]” or “other operation on a [body part]” procedure code. We acknowledge that, under ICD–10–PCS, an “open” approach is defined as “cutting through.” However, this procedure was designated as non-O.R. under ICD–9–CM. For replication purposes, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25025), we proposed that the five ICD–10–PCS procedure codes in Table 6P.4c. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D, which are considered less accurate correlations. We invited public comments on this proposal.

**Comment:** Several commenters supported the proposal to change the designation of five ICD–10–PCS procedure codes describing the removal of a tracheostomy device with various approaches. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

**Response:** We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We note that removal of a tracheostomy frequently occurs at the bedside and is performed by nonoperative, manual removal of the tracheostomy tube. As discussed in the FY 2017 IPPS/LTCH PPS proposed rule and above in this final rule, under ICD–9–CM, removal of tracheostomy was designated as a non-O.R. procedure. After consideration of the public comments we received, we are finalizing our proposal to change the designation of the five ICD–10–PCS procedure codes in Table 6P.4c. associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). These five ICD–10–PCS procedure codes are associated the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(d) Endoscopic/Percutaneous Insertion

We found 124 ICD–10–PCS procedure codes describing the endoscopic/percutaneous insertion of infusion and monitoring devices into vascular and musculoskeletal body parts. We invited public comments on this proposal.

**Comment:** Several commenters supported the proposal to change the designation of five ICD–10–PCS procedure codes describing the removal of a tracheostomy device with various approaches. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

**Response:** We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to change the designation of 117 ICD–10–PCS procedure codes describing the endoscopic/percutaneous insertion of infusion and monitoring devices into vascular and musculoskeletal body parts. We invited public comments on this proposal.

**Comment:** Commenters supported the proposal to change the designation of 117 ICD–10–PCS procedure codes describing the endoscopic/percutaneous insertion of infusion and monitoring devices into vascular and musculoskeletal body parts. We invited public comments on this proposal.

**Response:** After consideration of the public comments we received, we are finalizing our proposal to change the designation of 117 ICD–10–PCS procedure codes in Table 6P.4d. associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). These 117 ICD–10–PCS procedure codes are assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(e) Percutaneous Removal

We found 124 ICD–10–PCS procedure codes describing the percutaneous removal of drainage, infusion and monitoring devices from vascular and musculoskeletal body parts that, when coded under ICD–9–CM, would reasonably correlate to the nonoperative removal of a wide range of devices/appliances procedure codes versus an “incision of [body part]” or “other operation on a [body part]” procedure code. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25025), we proposed that the 124 ICD–10–PCS procedure codes in Table 6P.4e. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and...
descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D, which are considered less accurate correlations. We invited public comments on this proposal.

Comment: Commenters supported the proposal to change the designation of 124 ICD–10–PCS procedure codes describing the percutaneous removal of drainage, infusion and monitoring devices from vascular and musculoskeletal body parts. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to change the designation of the 124 ICD–10–PCS procedure codes associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). These 124 ICD–10–PCS procedure codes are assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D, which are considered less accurate correlations. We invited public comments on this proposal.

Comment: Several commenters supported the proposal to change the designation of 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of all body sites that do not have specific percutaneous drainage codes. The list includes procedure codes for drainage with or without placement of a drainage device. Exceptions to this are cranial, intracranial and the eye where small incisions are the norm and appropriately classified as O.R. These 518 ICD–10–PCS procedures codes, when coded under ICD–9–CM, would reasonably correlate to the nonoperative puncture or drainage of various body sites and other miscellaneous procedures versus an “incision of [body part]” procedure code. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25025), we proposed that the 518 ICD–10–PCS procedure codes in Table 6P.4f, associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D, which are considered less accurate correlations. We invited public comments on this proposal.

Comment: Commenters supported the proposal to change the designation of 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of all body sites that do not have specific percutaneous drainage codes. The list includes procedure codes for drainage with or without placement of a drainage device. Exceptions to this are cranial, intracranial and the eye where small incisions are the norm and appropriately classified as O.R. These 518 ICD–10–PCS procedures codes, when coded under ICD–9–CM, would reasonably correlate to the nonoperative puncture or drainage of various body sites and other miscellaneous procedures versus an “incision of [body part]” procedure code. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25025), we proposed that the 518 ICD–10–PCS procedure codes in Table 6P.4f, associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) be assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure codes and descriptions reflected in column D, which are considered less accurate correlations. We invited public comments on this proposal.

Comment: Commenters supported the proposal to change the designation of 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

We found 518 ICD–10–PCS procedure codes describing the percutaneous therapeutic drainage of various body sites with or without placement of a drainage device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.
assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C would replace the ICD–9–CM procedure code specified in column D, which are considered less accurate correlations. We invited public comments on this proposal.

Comment: Commenters supported the proposal to change the designation of 40 ICD–10–PCS procedure codes describing the dilation of stomach and pylorus body sites with various approaches. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.

After consideration of the public comments we received, we are finalizing our proposal to change the designation of the six ICD–10–PCS procedure codes in Table 6P.4i. associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html). These six ICD–10–PCS procedure codes are assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(j) Endoscopic/Percutaneous Occlusion

We found six ICD–10–PCS codes describing percutaneous occlusion of esophageal vein with and without a device that, when coded under ICD–9–CM would reasonably correlate to the endoscopic excision or destruction of the vessel versus an open surgical procedure. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25026), we proposed that the six ICD–10–PCS procedure codes in Table 6P.4j. associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) be assigned the attributes of the ICD–9–CM code specified in column C. The ICD–9–CM codes and descriptions in column C would replace the ICD–9–CM codes and descriptions reflected in column D, which are considered less accurate correlations. We invited public comments on this proposal.

Comment: Several commenters supported the proposal to change the designation of six ICD–10–PCS procedure codes describing the percutaneous occlusion of esophageal vein with and without a device. The commenters also expressed appreciation for CMS’ continued efforts towards addressing replication issues.

Response: We appreciate the commenters’ support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs.
replication issues between the ICD–9 and ICD–10 based MS–DRGs.

Comment: One commenter stated that standard surgical practice does not support procedures involving occlusion of the esophageal vein being performed outside of an operating room setting. This commenter also stated that these procedure codes were considered valid O.R. procedures under ICD–9–CM.

Response: We disagree with the commenter's statement. We note that percutaneous occlusion of the esophageal vein does not utilize the resources to be designated as an O.R. procedure. In addition, under ICD–9–CM, the endoscopic excision or destruction of lesion or tissue of esophagus for occlusion of esophageal vein was designated as a non-O.R. procedure.

After consideration of the public comments we received, we are finalizing our proposal to change the designation of the six ICD–10–PCS procedure codes in Table 6P.4j, associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcutetInpatientPPS/index.html). These six ICD–10–PCS procedure codes are assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(k) Infusion Device

We found 82 ICD–10–PCS codes describing the insertion of an infusion device to various body parts that, when coded under ICD–9–CM, would reasonably correlate to the insertion of a common infusion catheter versus the insertion of a totally implantable infusion pump. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25026), we proposed that the 82 ICD–10–PCS procedure codes in Table 6P.4k, associated with the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcutetInpatientPPS/index.html) be assigned the attributes of the ICD–9–CM code specified in column C. The ICD–9–CM codes and descriptions in column C would replace the ICD–9–CM codes and descriptions reflected in column D, which were considered less accurate correlations. We invited public comments on this proposal.

Comment: Commenters supported the proposal to change the designation of 82 ICD–10–PCS procedure codes describing the insertion of an infusion device to various parts. The commenters also expressed appreciation for CMS' continued efforts towards addressing replication issues.

Response: We appreciate the commenters' support of our proposal and of our efforts to analyze potential replication issues between the ICD–9 and ICD–10 based MS–DRGs. After consideration of the public comments we received, we are finalizing our proposal to change the designation of the 82 ICD–10–PCS procedure codes in Table 6P.4k associated with the proposed rule and this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcutetInpatientPPS/index.html). These 82 ICD–10–PCS procedure codes are assigned the attributes of the ICD–9–CM procedure code specified in column C. The ICD–9–CM procedure codes and descriptions in column C replace the ICD–9–CM procedure codes and descriptions reflected in column D in the ICD–10 MS–DRGs Version 34, effective October 1, 2016.

(2) Non-O.R. Procedures to O.R. Procedures

(a) Drainage of Pleural Cavity

In the ICD–9–CM MS–DRGs Version 32 Definitions Manual under Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index, procedure code 34.06 (Thoracoscopic drainage of pleural cavity) is designated as an O.R. procedure code and is assigned to MS–DRGs 166 through 168 (Other Respiratory System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively) in MDC 4 (Diseases and Disorders of the Respiratory System).

A replication issue regarding the procedure code designation and MS–DRG assignment for the comparable code translations under the ICD–10 MS–DRGs Version 33 was brought to our attention after implementation on October 1, 2015. The replication issue involves the following four ICD–10–PCS procedure codes:

- **0W9B40Z** (Drainage of right pleural cavity with drainage device, percutaneous endoscopic approach);
- **0W9B44ZZ** (Drainage of right pleural cavity, percutaneous endoscopic approach);
- **0W9B42ZZ** (Drainage of left pleural cavity with drainage device, percutaneous endoscopic approach);
- **0W9B4ZZ** (Drainage of left pleural cavity, percutaneous endoscopic approach).

In the ICD–10 MS–DRGs Version 33, these four ICD–10–PCS procedure codes are not recognized as O.R. procedures for purposes of MS–DRG assignment. We agree that this was a replication error and the designation and MS–DRG assignment should be consistent with the designation and MS–DRG assignment of ICD–9–CM procedure code 34.06.

To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25026), we proposed to add ICD–10–PCS procedure codes **0W9940Z, 0W994ZZ, 0W9B40Z, and 0W9B4ZZ** to the FY 2017 ICD–10 MS–DRGs Version 34 Definitions Manual in Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index as O.R. procedures assigned to MS–DRGs 166 through 168 in MDC 4. We invited public comments on our proposal.

Comment: Commenters supported the proposal to change the designation of four ICD–10–PCS procedure codes describing percutaneous endoscopic drainage of the pleural cavity with or without a drainage device (0W9940Z, 0W994ZZ, 0W9B40Z, and 0W9B4ZZ) from non-O.R. to O.R. These procedure codes are added to the ICD–10 MS–DRGs Version 34 Definitions Manual in Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index and assigned to MS–DRGs 166, 167, and 168 (Other Respiratory System O.R. Procedures with MCC, with CC, and without CC/MCC, respectively), effective October 1, 2016.

(b) Drainage of Cerebral Ventricle

In the ICD–9–CM MS–DRGs Version 32 Definitions Manual under Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index, procedure code 02.22 (Intracranial ventricular shunt or anastomosis) is designated as an O.R. procedure code and is assigned to MS–DRGs 023 through 027, collectively referred to as
In the ICD–10 MS–DRGs Version 33, these ICD–10–PCS procedure codes are not recognized as O.R. procedures for purposes of MS–DRG assignment. We agree that this was a replication error and their translation should be consistent with the designation and MS–DRG assignment of ICD–9–CM procedure code 02.22.

To resolve this replication issue, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25026 through 25027), we proposed to add the ICD–10–PCS procedure codes listed above to the FY 2017 ICD–10 MS–DRGs Version 34 Definitions Manual in Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index as O.R. procedures assigned to MS–DRGs 023 through 027 in MDC 1. We invited public comments on our proposal.

Comment: Commenters supported the proposal to change the designation of 18 ICD–10–PCS procedure codes describing endoscopic/percutaneous drainage of intracranial sites with or without a drainage device from non-O.R. to O.R. The procedure codes are added to the ICD–10 MS–DRGs Version 34 Definitions Manual in Appendix E—Operating Room Procedures and Procedure Code/MS–DRG Index and assigned to MS–DRGs 023 and 024 (Craniotomy with Major Device Implant or Acute Complex Central Nervous System Principal Diagnosis with MCC or Chemotherapy Implant and without MCC, respectively) and to MS–DRGs 025, 026 and 027 (Craniotomy and Endovascular Intracranial Procedures with MCC, with CC, and without CC/ MCC, respectively), effective October 1, 2016.

(3) FY 2018 Refinements

As discussed earlier in this section, for FY 2017, we continued our efforts to address the MS–DRG replication issues between the ICD–9–CM logic and ICD–10 that were brought to our attention. As a result of analyzing specific requests, additional areas in the ICD–10 classification were identified where we proposed modifications to more accurately replicate the logic of ICD–9–CM and to reassign ICD–10 codes based on the different clinical concepts and definitions of the codes under the ICD–10 classification.

In response to some of the proposals set forth in the FY 2017 IPPS/LTCH PPS proposed rule pertaining to changing the designation of an ICD–10–PCS procedure code from O.R. to non-O.R., we received detailed comments and recommendations for consideration that we were not able to fully evaluate for FY 2017. We appreciate the extensive and thorough analysis that the commenters performed and their suggestions for further refinements. As the commenters' recommendations included analysis of over 800 procedure codes for redesignation, we plan to conduct a comprehensive review and analyze these codes for our FY 2018 refinement efforts.

20. Out of Scope Public Comments Received

We received public comments regarding five MS–DRG issues that were outside of the scope of the proposals included in the FY 2017 IPPS/LTCH PPS proposed rule. These comments were as follows:

- Several commenters requested the inclusion of ICD–10–PCS code 02L73ZK (Occlusion of left atrial appendage, percutaneous approach) that describes what is known as the LARIAT procedure in the FY 2017 MS–DRG proposal for the transcatheter mitral valve repair procedure.
- Commenters provided comments on ICD–10–CM diagnosis codes that were not approved at the time of issuance of the proposed rule.
- One commenter requested the creation of new MS–DRGs for the treatment of orphan diseases.
- Comments were submitted regarding the complexity, time commitment, and payment for transesophageal echocardiography services performed for a MitraClip procedure.
We consider these public comments to be outside of the scope of the proposed rule and, therefore, we are not addressing them in this final rule. As stated in section II.F.1.b. of the preamble of this final rule, we encourage individuals with comments about MS–DRG classification to submit these comments no later than December 7 of each year so that they can be considered for possible inclusion in the annual proposed rule and, if included, may be subjected to public review and comment. We will consider these public comments for possible proposals in future rulemaking as part of our annual review process.

G. Recalibration of the FY 2017 MS–DRG Relative Weights

1. Data Sources for Developing the Relative Weights

As we discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25027), in developing the FY 2017 system of weights, we used two data sources: claims data and cost report data. As in previous years, the claims data source is the MedPAR file. This file is based on fully coded diagnostic and procedure data for all Medicare inpatient hospital bills. The FY 2015 MedPAR data used in this final rule include discharges occurring on October 1, 2014, through September 30, 2015, based on bills received by CMS through March 31, 2016, from all hospitals subject to the IPPS and short-term, acute care hospitals in Maryland (which at that time were under a waiver from the IPPS). The FY 2015 MedPAR file used in calculating the relative weights includes data for approximately 9,770,558 Medicare discharges from IPPS providers. Discharges for Medicare beneficiaries enrolled in a Medicare Advantage managed care plan are excluded from this analysis. These discharges are excluded when the MedPAR “GHO Paid” indicator field on the claim record is equal to “1” or when the MedPAR DRG payment field, which represents the total payment for the claim, is equal to the MedPAR “Indirect Medical Education (IME)” payment field, indicating that the claim was an “IME only” claim submitted by a teaching hospital on behalf of a beneficiary enrolled in a Medicare Advantage managed care plan. In addition, the March 31, 2016 update of the FY 2015 MedPAR file complies with version 5010 of the X12 HIPAA Transaction and Code Set Standards, and includes a variable called “claim type.” Claim type “60” indicates that the claim was an inpatient claim paid as fee-for-service. Claim types “61,” “62,” “63,” and “64” relate to encounter claims, Medicare Advantage IME claims, and HMO no-pay claims. Therefore, the calculation of the relative weights for FY 2017 also excludes claims with claim type values not equal to “60.” The data exclude CAHs, including hospitals that subsequently became CAHs after the period from which the data were taken. We note that the FY 2017 relative weights are based on the ICD–9–CM diagnoses and procedures codes from the FY 2015 MedPAR claims data, grouped through the ICD–9–CM version of the FY 2017 GROUPER (Version 34).

The second data source used in the cost-based relative weighting methodology is the Medicare cost report data files from the HCRIS. Normally, we use the HCRIS dataset that is 3 years prior to the IPPS fiscal year. Specifically, we used cost report data from the March 31, 2016 update of the FY 2014 HCRIS for calculating the FY 2017 cost-based relative weights.

2. Methodology for Calculation of the Final Relative Weights

As we explain in section II.E.2. of the preamble of this final rule, we calculated the FY 2017 relative weights based on 19 CCRs, as we did for FY 2016. The methodology we used to calculate the FY 2017 MS–DRG cost-based relative weights based on claims data in the FY 2015 MedPAR file and data from the FY 2014 Medicare cost reports is as follows:

- To the extent possible, all the claims were regrouped using the FY 2017 MS–DRG classifications discussed in sections II.B. and II.F. of the preamble of this final rule.
- The transplant cases that were used to establish the relative weights for heart and heart-lung, liver and/or intestinal, and lung transplants (MS–DRGs 001, 002, 005, 006, and 007, respectively) were limited to those Medicare-approved transplant centers that have cases in the FY 2015 MedPAR file. (Medicare coverage for heart, heart-lung, liver and/or intestinal, and lung transplants is limited to those facilities that have received approval from CMS as transplant centers.)
- Organ acquisition costs for kidney, heart, heart-lung, liver, lung, pancreas, and intestinal (or multivisceral organs) transplants continue to be paid on a reasonable cost basis. Because these acquisition costs are paid separately from the prospective payment rate, it is necessary to subtract the acquisition charges from the total charges on each transplant bill that showed acquisition charges before computing the average cost for each MS–DRG and before eliminating statistical outliers.
  - Claims with total charges or total lengths of stay less than or equal to zero were deleted. Claims that had an amount in the total charge field that differed by more than $10.00 from the sum of the routine day charges, intensive care charges, pharmacy charges, special equipment charges, therapy services charges, operating room charges, cardiology charges, laboratory charges, radiology charges, other service charges, labor and delivery charges, inhalation therapy charges, emergency room charges, blood charges, and anesthesia charges were also deleted.
  - At least 92.1 percent of the providers in the MedPAR file had charges for 14 of the 19 cost centers. All claims for providers that did not have charges greater than zero for at least 14 of the 19 cost centers were deleted. In other words, a provider must have no more than five blank cost centers. If a provider did not have charges greater than zero in more than five cost centers, the claims for the provider were deleted.

- Statistical outliers were eliminated by removing all cases that were beyond 3.0 standard deviations from the geometric mean of the log distribution of both the total charges per case and the total charges per day for each MS–DRG.

- Effective October 1, 2008, because hospital inpatient claims include a POA indicator field for each diagnosis present on the claim, only for purposes of relative weight-setting, the POA indicator field was reset to “Y” for “Yes” for all claims that otherwise have an “N” (No) or a “U” (documentation insufficient to determine if the condition was present at the time of inpatient admission) in the POA field. Under current payment policy, the presence of specific HAC codes, as indicated by the POA field values, can generate a lower payment for the claim. Specifically, if the particular condition is present on admission (that is, a “Y” indicator is associated with the diagnosis on the claim), it is not a HAC, and the hospital is paid for the higher severity (and, therefore, the higher weighted MS–DRG). If the particular condition is not present on admission (that is, an “N” indicator is associated with the diagnosis on the claim) and there are no other complicating conditions, the DRG GROUPER assigns the claim to a lower severity (and, therefore, the lower weighted MS–DRG) as a penalty for allowing a Medicare inpatient to contract a HAC. While the POA reporting meets policy goals of encouraging quality care and generates...
program savings, it presents an issue for the relative weight-setting process. Because cases identified as HACs are likely to be more complex than similar cases that are not identified as HACs, the charges associated with HAC cases are likely to be higher as well. Therefore, if the higher charges of these HAC claims are grouped into lower severity MS–DRGs prior to the relative weight-setting process, the relative weights of these particular MS–DRGs would become artificially inflated, potentially skewing the relative weights. In addition, we want to protect the integrity of the budget neutrality process by ensuring that, in estimating payments, no increase to the standardized amount occurs as a result of lower overall payments in a previous year that stem from using weights and case-mix that are based on lower severity MS–DRG assignments. If this would occur, the anticipated cost savings from the HAC policy would be lost.

To avoid these problems, we reset the POA indicator field to “Y” only for relative weight-setting purposes for all claims that otherwise have an “N” or a “U” in the POA field. This resetting “forced” the more costly HAC claims into the higher severity MS–DRGs as appropriate, and the relative weights calculated for each MS–DRG more closely reflect the true costs of those cases.

In addition, in the FY 2013 IPPS/LTCH PPS final rule, for FY 2013 and subsequent fiscal years, we finalized a policy to treat hospitals that participate in the Bundled Payments for Care Improvement (BPCI) initiative the same as prior fiscal years for the IPPS payment modeling and ratesetting process without regard to hospitals’ participation within these bundled payment models (that is, as if hospitals were not participating in these models under the BPCI initiative). The BPCI initiative, developed under the authority of section 3021 of the Affordable Care Act (codified at section 1115A of the Act), is comprised of four broadly defined models of care, which link payments for multiple services beneficiaries receive during an episode of care. Under the BPCI initiative, organizations enter into payment arrangements that include financial and performance accountability for episodes of care. For FY 2017, as we proposed, we are continuing to include all applicable data from subsection (d) hospitals participating in BPCI Models 1, 2, and 4 in our IPPS payment modeling and ratesetting calculations. We refer readers to the FY 2013 IPPS/LTCH PPS final rule for a complete discussion on our final policy for the treatment of hospitals participating in the BPCI initiative in our ratesetting process. For additional information on the BPCI initiative, we refer readers to the CMS’ Center for Medicare and Medicaid Innovation’s Web site at: http://innovation.cms.gov/initiatives/Bundled-Payments/index.html and to section IV.H.4. of the preamble of the FY 2013 IPPS/LTCH PPS final rule (77 FR 53341 through 53343).

Once the MedPAR data were trimmed and the statistical outliers were removed, the charges for each of the 19 cost groups for each claim were standardized to remove the effects of differences in area wage levels, IME and DSH payments, and for hospitals located in Alaska and Hawaii, the applicable cost-of-living adjustment. Because hospital charges include charges for both operating and capital costs, we standardized total charges to remove the effects of differences in geographic adjustment factors, cost-of-living adjustments, and DSH payments under the capital IPPS as well. Charges were then summed by MS–DRG for each of the 19 cost groups so that each MS–DRG had 19 standardized charge totals. These charges were then adjusted to cost by applying the national average CCRs developed from the FY 2014 cost report data.

The 19 cost centers that we used in the relative weight calculation are shown in the following table. The table shows the lines on the cost report and the corresponding revenue codes that we used to create the proposed 19 national cost center CCRs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25028), we stated that if stakeholders have comments about the groupings in this table, we may consider those comments as we finalize our policy. However, we did not receive any comments on the groupings in this table, and therefore, we are finalizing the groupings as proposed.

<table>
<thead>
<tr>
<th>Cost center group name (19 total)</th>
<th>MedPAR charge field</th>
<th>Revenue codes contained in MedPAR charge field</th>
<th>Cost report line description</th>
<th>Cost from HCRIS (Worksheet C, Part 1, Column 5 and line number)</th>
<th>Charges from HCRIS (Worksheet C, Part 1, Column 6 &amp; 7 and line number)</th>
<th>Medicare Charges from HCRIS (Worksheet D-3, Column &amp; line number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Days</td>
<td>Private Room Charges.</td>
<td>011X and 014X ......</td>
<td>Adults &amp; Pediatrics (General Routine Care).</td>
<td>C_1_C5_30</td>
<td>C_1_C6_30</td>
<td>D3_HOS_C2_30</td>
</tr>
<tr>
<td>Semi-Private Room Charges.</td>
<td>012X, 013X and 016X.</td>
<td>Intensive Care Unit</td>
<td>C_1_C5_31</td>
<td>C_1_C6_31</td>
<td>D3_HOS_C2_31</td>
<td></td>
</tr>
<tr>
<td>Ward Charges.</td>
<td>015X.</td>
<td>Coronary Care Unit</td>
<td>C_1_C5_32</td>
<td>C_1_C6_32</td>
<td>D3_HOS_C2_32</td>
<td></td>
</tr>
<tr>
<td>Intensive Care Charges.</td>
<td>020X .................</td>
<td>Burn Intensive Care Unit</td>
<td>C_1_C5_33</td>
<td>C_1_C6_33</td>
<td>D3_HOS_C2_33</td>
<td></td>
</tr>
<tr>
<td>Coronary Care Charges.</td>
<td>021X .................</td>
<td>Surgical Intensive Care Unit.</td>
<td>C_1_C5_34</td>
<td>C_1_C6_34</td>
<td>D3_HOS_C2_34</td>
<td></td>
</tr>
<tr>
<td>Drugs</td>
<td>Pharmacy Charges.</td>
<td>025X, 026X and 063X.</td>
<td>Drugs Charged To Patient.</td>
<td>C_1_C5_73</td>
<td>C_1_C6_73</td>
<td>D3_HOS_C2_73</td>
</tr>
<tr>
<td>Cost center group name (19 total)</td>
<td>MedPAR charge field</td>
<td>Revenue codes contained in MedPAR charge field</td>
<td>Cost report line description</td>
<td>Cost from HCRIS (Worksheet C, Part 1, Column 5 and line number) Form CMS–2552–10</td>
<td>Charges from HCRIS (Worksheet C, Part 1, Column 6 &amp; 7 and line number) Form CMS–2552–10</td>
<td>Medicare Charges from HCRIS (Worksheet D–3, Column &amp; line number) Form CMS–2552–10</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Supplies and Equipment.</td>
<td>Medical/Surgical Supply Charges.</td>
<td>0270, 0271, 0272, 0273, 0274, 0277, 0279, and 0621, 0622, 0623.</td>
<td>Medical Supplies Charged to Patients.</td>
<td>C_1_C5 71</td>
<td>C_1_C6 71</td>
<td>D3_HOS_C2 71</td>
</tr>
<tr>
<td></td>
<td>Durable Medical Equipment Charges.</td>
<td>0290, 0291, 0292 and 0294–0299.</td>
<td>DME–Rented</td>
<td>C_1_C5 96</td>
<td>C_1_C6 96</td>
<td>D3_HOS_C2 96</td>
</tr>
<tr>
<td></td>
<td>Used Durable Medical Charges.</td>
<td>0293 .......................</td>
<td>DME–Sold</td>
<td>C_1_C5 97</td>
<td>C_1_C6 97</td>
<td>D3_HOS_C2 97</td>
</tr>
<tr>
<td></td>
<td>Implantable Devices</td>
<td>0275, 0276, 0278, and 0624.</td>
<td>Implantable Devices Charged to Patients.</td>
<td>C_1_C5 72</td>
<td>C_1_C6 72</td>
<td>D3_HOS_C2 72</td>
</tr>
<tr>
<td>Therapy Services ...</td>
<td>Physical Therapy Charges.</td>
<td>042X ................................</td>
<td>Physical Therapy</td>
<td>C_1_C5 66</td>
<td>C_1_C6 66</td>
<td>D3_HOS_C2 66</td>
</tr>
<tr>
<td></td>
<td>Occupational Therapy Charges.</td>
<td>043X ................................</td>
<td>Occupational Therapy.</td>
<td>C_1_C5 67</td>
<td>C_1_C6 67</td>
<td>D3_HOS_C2 67</td>
</tr>
<tr>
<td></td>
<td>Speech Pathology Charges.</td>
<td>044X and 047X ..........</td>
<td>Speech Pathology</td>
<td>C_1_C5 68</td>
<td>C_1_C6 68</td>
<td>D3_HOS_C2 68</td>
</tr>
<tr>
<td></td>
<td>Inhalation Therapy ...</td>
<td>041X and 046X ..........</td>
<td>Respiratory Therapy</td>
<td>C_1_C5 65</td>
<td>C_1_C6 65</td>
<td>D3_HOS_C2 65</td>
</tr>
<tr>
<td></td>
<td>Operating Room Charges.</td>
<td>036X ................................</td>
<td>Operating Room</td>
<td>C_1_C5 50</td>
<td>C_1_C6 50</td>
<td>D3_HOS_C2 50</td>
</tr>
<tr>
<td>Labor &amp; Delivery ...</td>
<td>Operating Room Charges.</td>
<td>071X ................................</td>
<td>Recovery Room</td>
<td>C_1_C5 51</td>
<td>C_1_C6 51</td>
<td>D3_HOS_C2 51</td>
</tr>
<tr>
<td></td>
<td>Operating Room Charges.</td>
<td>072X ................................</td>
<td>Delivery Room and Labor Room</td>
<td>C_1_C5 52</td>
<td>C_1_C6 52</td>
<td>D3_HOS_C2 52</td>
</tr>
<tr>
<td>Anesthesia .......................</td>
<td>Anesthesia Charges</td>
<td>037X ................................</td>
<td>Anesthesiology</td>
<td>C_1_C5 53</td>
<td>C_1_C6 53</td>
<td>D3_HOS_C2 53</td>
</tr>
<tr>
<td>Cardiology .......................</td>
<td>Cardiology Charges</td>
<td>048X and 073X ..........</td>
<td>Electrocardiography</td>
<td>C_1_C5 69</td>
<td>C_1_C6 69</td>
<td>D3_HOS_C2 69</td>
</tr>
<tr>
<td>Cardiac Catheterization.</td>
<td>Cardiac Catheterization.</td>
<td>0481 ........................</td>
<td></td>
<td>C_1_C5 59</td>
<td>C_1_C6 59</td>
<td>D3_HOS_C2 59</td>
</tr>
<tr>
<td>Laboratory ........................</td>
<td>Laboratory Charges</td>
<td>030X, 031X, and 075X.</td>
<td>Laboratory</td>
<td>C_1_C5 60</td>
<td>C_1_C6 60</td>
<td>D3_HOS_C2 60</td>
</tr>
<tr>
<td></td>
<td>Laboratory Charges</td>
<td>074X, 086X ..........</td>
<td>PBP Clinic Laboratory Services.</td>
<td>C_1_C5 61</td>
<td>C_1_C6 61</td>
<td>D3_HOS_C2 61</td>
</tr>
<tr>
<td>Radiology ........................</td>
<td>Radiology Charges</td>
<td>032X, 040X ..........</td>
<td>Radiology–Diagnostic.</td>
<td>C_1_C5 70</td>
<td>C_1_C6 70</td>
<td>D3_HOS_C2 70</td>
</tr>
<tr>
<td></td>
<td>Radiology Charges</td>
<td>028x, 0331, 0332, 0333, 0335, 0339, 0342, 0343 and 344 ..........</td>
<td>Radiology–Therapeutic.</td>
<td>C_1_C5 55</td>
<td>C_1_C6 55</td>
<td>D3_HOS_C2 55</td>
</tr>
<tr>
<td></td>
<td>Radiology Charges</td>
<td>035X ........................</td>
<td>Computed Tomography (CT) Scan.</td>
<td>C_1_C5 57</td>
<td>C_1_C6 57</td>
<td>D3_HOS_C2 57</td>
</tr>
<tr>
<td>Computed Tomography (CT) Scan.</td>
<td>CT Scan Charges ...</td>
<td>061X ........................</td>
<td>Magnetic Resonance Imaging (MRI).</td>
<td>C_1_C5 58</td>
<td>C_1_C6 58</td>
<td>D3_HOS_C2 58</td>
</tr>
</tbody>
</table>
3. Development of National Average CCRs

We developed the national average CCRs as follows:

Using the FY 2014 cost report data, we removed CAHs, Indian Health Service hospitals, all-inclusive rate hospitals, and cost reports that represented time periods of less than 1 year (365 days). We included hospitals located in Maryland because we include their charges in our claims database. We then created CCRs for each provider for each cost center (see prior table for line items used in the calculations) and removed any CCRs that were greater than 10 or less than 0.01. We normalized the departmental CCRs by dividing the CCR for each department by the total CCR for the hospital for the purpose of trimming the data. We then took the logs of the normalized cost center CCRs and removed any cost center CCRs where the log of the cost center CCR was greater or less than the mean log plus/minus 3 times the standard deviation for the log of that cost center CCR. Once the cost report data were trimmed, we calculated a Medicare-specific CCR. The Medicare-specific CCR was determined by taking the Medicare charges for each line item from Worksheet D–3 and deriving the Medicare-specific costs by applying the hospital-specific departmental CCRs to the Medicare-specific charges for each line item from Worksheet D–3. Once each hospital’s Medicare-specific costs were established, we summed the total Medicare-specific costs and divided by the sum of the total Medicare-specific charges to produce national average, charge-weighted CCRs.

After we multiplied the total charges for each MS–DRG in each of the 19 cost centers by the corresponding national average CCR, we summed the 19 “costs” across each MS–DRG to produce a total standardized cost for the MS–DRG. The average standardized cost for each MS–DRG was then computed as the total standardized cost for the MS–DRG divided by the transfer-adjusted case count for the MS–DRG. The average cost for each MS–DRG was then divided by the national average standardized cost.
The FY 2017 cost-based relative weights were then normalized by an adjustment factor of 1.691521 so that the average case weight after recalibration was equal to the average case weight before recalibration. The normalization adjustment is intended to ensure that recalibration by itself neither increases nor decreases total payments under the IPPS, as required by section 1886(d)(4)(C)(iii) of the Act.

The 19 national average CCRs for FY 2017 are as follows:

<table>
<thead>
<tr>
<th>Group</th>
<th>CCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine Days</td>
<td>0.457</td>
</tr>
<tr>
<td>Intensive Days</td>
<td>0.375</td>
</tr>
<tr>
<td>Drugs</td>
<td>0.194</td>
</tr>
<tr>
<td>Supplies &amp; Equipment</td>
<td>0.297</td>
</tr>
<tr>
<td>Implantable Devices</td>
<td>0.331</td>
</tr>
<tr>
<td>Therapy Services</td>
<td>0.321</td>
</tr>
<tr>
<td>Laboratory</td>
<td>0.120</td>
</tr>
<tr>
<td>Operating Room</td>
<td>0.191</td>
</tr>
<tr>
<td>Cardiology</td>
<td>0.112</td>
</tr>
<tr>
<td>Cardiac Catheterization</td>
<td>0.118</td>
</tr>
<tr>
<td>Radiology</td>
<td>0.153</td>
</tr>
<tr>
<td>MRIs</td>
<td>0.079</td>
</tr>
<tr>
<td>CT Scans</td>
<td>0.038</td>
</tr>
<tr>
<td>Emergency Room</td>
<td>0.171</td>
</tr>
<tr>
<td>Blood and Blood Products</td>
<td>0.323</td>
</tr>
<tr>
<td>Other Services</td>
<td>0.365</td>
</tr>
<tr>
<td>Other Services</td>
<td>0.194</td>
</tr>
<tr>
<td>Anesthesia</td>
<td>0.089</td>
</tr>
<tr>
<td>Inhalation Therapy</td>
<td>0.170</td>
</tr>
<tr>
<td>Labor &amp; Delivery</td>
<td>0.410</td>
</tr>
</tbody>
</table>

Since FY 2009, the relative weights have been based on 100 percent cost weights based on our MS–DRG grouping system. When we recalibrated the DRG weights for previous years, we set a threshold of 10 cases as the minimum number of cases required to compute a reasonable weight. As we proposed, we use that same case threshold in recalibrating the MS–DRG relative weights for FY 2017. Using data from the FY 2015 MedPAR file, there were 8 MS–DRGs that contain fewer than 10 cases. Under the MS–DRGs, we have fewer low-volume DRGs than under the CMS DRGs because we no longer have separate DRGs for patients aged 0 to 17 years. With the exception of newborns, we previously separated some DRGs based on whether the patient was age 0 to 17 years or age 17 years and older. Other than the age split, cases grouping to these DRGs are identical. The DRGs for patients aged 0 to 17 years generally have very low volumes because children are typically ineligible for Medicare. In the past, we have found that the low volume of cases for the pediatric DRGs could lead to significant year-to-year instability in their relative weights. Although we have always encouraged non-Medicare payers to develop weights applicable to their own patient populations, we have received frequent complaints from providers about the use of the Medicare relative weights in the pediatric population. We believe that eliminating this age split in the MS–DRGs will provide more stable payment for pediatric cases by determining their payment using adult cases that are much higher in total volume. Newborns are unique and require separate MS–DRGs that are not mirrored in the adult population. Therefore, it remains necessary to retain separate MS–DRGs for newborns. All of the low-volume MS–DRGs listed are for newborns. For FY 2017, because we do not have sufficient MedPAR data to set accurate and stable cost relative weights for these low-volume MS–DRGs, as we proposed, we compute relative weights for the low-volume MS–DRGs by adjusting their final FY 2016 relative weights by the percentage change in the average weight of the cases in other MS–DRGs. The crosswalk table is shown:

<table>
<thead>
<tr>
<th>Low-volume MS–DRG</th>
<th>MS–DRG Title</th>
<th>Crosswalk to MS–DRG</th>
</tr>
</thead>
<tbody>
<tr>
<td>768</td>
<td>Vaginal Delivery with O.R. Procedure Except Sterilization and/or D&amp;C.</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>789</td>
<td>Neonates, Died or Transferred to Another Acute Care Facility.</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>790</td>
<td>Extreme Immaturity or Respiratory Distress Syndrome, Neonate.</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>791</td>
<td>Prematurity with Major Problems</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>792</td>
<td>Prematurity without Major Problems</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>793</td>
<td>Full-Term Neonate with Major Problems</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>794</td>
<td>Neonate with Other Significant Problems</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
<tr>
<td>795</td>
<td>Normal Newborn</td>
<td>Final FY 2016 relative weight (adjusted by percent change in average weight of the cases in other MS–DRGs).</td>
</tr>
</tbody>
</table>

We did not receive any public comments on our proposals for establishing the relative weights for FY 2017 and are finalizing them as proposed.

H. Add-On Payments for New Services and Technologies for FY 2017

1. Background

Sections 1886(d)(5)(K) and (L) of the Act establish a process of identifying and ensuring adequate payment for new medical services and technologies (sometimes collectively referred to in this section as “new technologies”) under the IPPS. Section 1886(d)(5)(K)(vi) of the Act specifies that a medical service or technology will be considered new if it meets criteria established by the Secretary after notice and opportunity for public comment. Section 1886(d)(5)(K)(ii)(I) of the Act specifies that a new medical service or technology may be considered for new technology add-on payment if, based on the estimated costs incurred with respect to discharges involving such service or technology, the DRG prospective payment rate otherwise applicable to such discharges under this subsection is inadequate. We note that, beginning with discharges occurring in FY 2008, CMS transitioned from CMS–DRGs to MS–DRGs.

The regulations at 42 CFR 412.87 implement these provisions and specify three criteria for a new medical service or technology to receive the additional payment: (1) The medical service or technology must be new; (2) the medical service or technology must be costly such that the DRG rate otherwise applicable to discharges involving the medical service or technology is determined to be inadequate; and (3) the
service or technology must demonstrate a substantial clinical improvement over existing services or technologies. Below we highlight some of the major statutory and regulatory provisions relevant to the new technology add-on payment criteria, as well as other information. For a complete discussion on the new technology add-on payment criteria, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51572 through 51574).

Under the first criterion, as reflected in § 412.87(b)(2), a specific medical service or technology will be considered “new” for purposes of new medical service or technology add-on payments until such time as Medicare data are available to fully reflect the cost of the technology in the MS–DRG weights through recalibration. We note that we do not consider a service or technology to be new if it is substantially similar to one or more existing technologies. That is, even if a technology receives a new FDA approval or clearance, it may not necessarily be considered “new” for purposes of new technology add-on payments if it is “substantially similar” to a technology that was approved or cleared by FDA and has been on the market for more than 2 to 3 years. In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 through 43814), we established criteria for evaluating whether a new technology is substantially similar to an existing technology, specifically: (1) Whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome; (2) whether a product is assigned to the same or a different MS–DRG; and (3) whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of these criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments. For a detailed discussion of the criteria for substantial similarity, we refer readers to the FY 2006 IPPS final rule (70 FR 47351 through 47352), and the FY 2010 IPPS/LTCH PPS final rule (74 FR 43813 through 43814).

Under the second criterion, § 412.87(b)(3) further provides that, to be eligible for the add-on payment for new medical services or technologies, the MS–DRG prospective payment rate otherwise applicable to the discharge involving the new medical services or technologies must be assessed for adequacy. Under the cost criterion, consistent with the formula specified in section 1886(d)(5)(K)(iii)(I) of the Act, to assess the adequacy of payment for a new technology paid under the applicable MS–DRG prospective payment rate, we evaluate whether the charges for cases involving the new technology exceed certain threshold amounts. Table 10 that was released with the FY 2016 IPPS/LTCH PPS final rule contains the final thresholds that we used to evaluate applications for new medical service and new technology add-on payments for FY 2017. We refer readers to the CMS Web site at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Final-Rule-Tables.html to download and view Table 10.

In the September 7, 2001 final rule that established the new technology add-on payment regulations (66 FR 46917), we discussed the issue of whether the Health Insurance Portability and Accountability Act (HIPPA) Privacy Rule at 45 CFR parts 160 and 164 applies to claims information that providers submit with applications for new medical service and new technology add-on payments. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51573) for complete information on this issue.

Under the third criterion, § 412.87(b)(1) of our existing regulations provides that a new technology is an appropriate candidate for an additional payment when it represents an advance that substantially improves, relative to technologies previously available, the diagnosis or treatment of Medicare beneficiaries. For example, a new technology represents a substantial clinical improvement when it reduces mortality, decreases the number of hospitalizations or physician visits, or reduces recovery time compared to the technologies previously available. (We refer readers to the September 7, 2001 final rule for a more detailed discussion of this criterion (66 FR 46902).)

The new medical service or technology add-on payment policy under the IPPS provides additional payments for cases with relatively high costs involving eligible new medical services or technologies while preserving some of the incentives inherent under an average-based prospective payment system. The payment mechanism is based on the cost to hospitals for the new medical service or technology. Under § 412.88, if the costs of the discharge (determined by applying cost-to-charge ratios (CCRs) as described in § 412.84(b)) exceed the full DRG payment; or (2) 50 percent of the difference between the full DRG payment and the hospital’s estimated cost for the case. Unless the discharge qualifies for an outlier payment, the additional Medicare payment is limited to the full MS–DRG payment plus 50 percent of the estimated costs of the new technology or new medical service.

Section 503(d)(2) of Public Law 108–173 provides that there shall be no reduction or adjustment in aggregate payments under the IPPS due to add-on payments for new medical services and technologies. Therefore, in accordance with section 503(d)(2) of Public Law 108–173, add-on payments for new medical services or technologies for FY 2005 and later years have not been subjected to budget neutrality.

In the FY 2009 IPPS final rule (73 FR 48561 through 48563), we modified our regulations at § 412.87 to codify our longstanding practice of how CMS evaluates the eligibility criteria for new medical service or technology add-on payment applications. That is, we first determine whether a medical service or technology meets the newness criterion, and only if so, do we then make a determination as to whether the technology meets the cost threshold and represents a substantial clinical improvement over existing medical services or technologies. We amended § 412.87(c) to specify that all applicants for new technology add-on payments must have FDA approval or clearance for their new medical service or technology by July 1 of each year prior to the beginning of the fiscal year that the application is being considered.

The Council on Technology and Innovation (CTI) at CMS oversees the agency’s cross-cutting priority on coordinating coverage, coding and payment processes for Medicare with respect to new technologies and procedures, including new drug therapies, as well as promoting the exchange of information on new technologies and medical services between CMS and other entities. The CTI, composed of senior CMS staff and clinicians, was established under section 942(a) of Public Law 108–173. The Council is co-chaired by the Director of the Center for Clinical Standards and Quality (CCSQ) and the Director of the Center for Medicare (CM), who is also designated as the CTI’s Executive Coordinator.
The specific processes for coverage, coding, and payment are implemented by CMS, CCSQ, and the local claims-payment contractors (in the case of local coverage and payment decisions). The CTI supplements, rather than replaces, these processes by working to assure that all of these activities reflect the agency-wide priority to promote high-quality, innovative care. At the same time, the CTI also works to streamline, accelerate, and improve coordination of these processes to ensure that they remain up to date as new issues arise. To achieve its goals, the CTI works to streamline and create more transparent coding and payment processes, improve the quality of medical decisions, and speed patient access to effective new treatments. It is also dedicated to supporting better decisions by patients and doctors in using Medicare-covered services through the promotion of better evidence development, which is critical for improving the quality of care for Medicare beneficiaries. To improve the understanding of CMS’ processes for coverage, coding, and payment and how to access them, the CTI has developed an “Innovator’s Guide” to these processes. The intent is to consolidate this information, much of which is already available in a variety of CMS documents and in various places on the CMS Web site, in a user-friendly format. This guide was published in 2010 and is available on the CMS Web site at: http://www.cms.gov/CouncilonTechInnov/Downloads/InnovatorsGuide5_10.pdf.

As we indicated in the FY 2009 IPPS final rule (73 FR 48554), we invite any product developers or manufacturers of new medical services or technologies to contact the agency early in the process of product development if they have questions or concerns about the evidence that would be needed later in the development process for the agency’s coverage decisions for Medicare.

The CTI aims to provide useful information on its activities and initiatives to stakeholders, including Medicare beneficiaries, advocates, medical product manufacturers, providers, and health policy experts. Stakeholders with further questions about Medicare’s coverage, coding, and payment processes, or who want further guidance about how they can navigate these processes, can contact the CTI at CTI@cms.hhs.gov.

We note that applicants for add-on payments for new medical services and technologies for FY 2018 must submit a formal request, including a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement, along with a significant sample of data to demonstrate that the medical service or technology meets the high-cost threshold. Complete application information, along with final deadlines for submitting a full application, will be posted as it becomes available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html. To allow interested parties to identify the new medical services or technologies under review before the publication of the proposed rule for FY 2018, the CMS Web site also will post the tracking forms completed by each applicant.

2. Public Input Before Publication of a Notice of Proposed Rulemaking on Add-On Payments

Section 1886(d)(5)(K)(viii) of the Act, as amended by section 503(b)(2) of Public Law 108–173, provides for a mechanism for public input before publication of a notice of proposed rulemaking regarding whether a medical service or technology represents a substantial clinical improvement or advancement. The process for evaluating new medical service and technology applications requires the Secretary to—

• Provide, before publication of a proposed rule, for public input regarding whether a new service or technology represents an advance in medical technology that substantially improves the diagnosis or treatment of Medicare beneficiaries;
• Make public and periodically update a list of the services and technologies for which applications for add-on payments are pending;
• Accept comments, recommendations, and data from the public regarding whether a service or technology represents a substantial clinical improvement; and
• Provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS.

As indicated earlier in this section, CMS is required to provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS. In recent years, CMS has live-streamed the town hall meeting through the CMS YouTube Web page and later posted the recorded version of the town hall meeting, as well as written comments submitted on the applications that were received by the due date of February 26, 2016, in our evaluation of the new technology add-on payment applications for FY 2017 presented in the FY 2017 IPPS/LTCH PPS proposed rule.

As indicated earlier in this section, CMS is required to provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS. In recent years, CMS has live-streamed the town hall meeting through the CMS YouTube Web page and later posted the recorded version of the town hall meeting, as well as written comments submitted on the applications that were received by the due date of February 26, 2016, in our evaluation of the new technology add-on payment applications for FY 2017 presented in the FY 2017 IPPS/LTCH PPS proposed rule.

As indicated earlier in this section, CMS is required to provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS. In recent years, CMS has live-streamed the town hall meeting through the CMS YouTube Web page and later posted the recorded version of the town hall meeting, as well as written comments submitted on the applications that were received by the due date of February 26, 2016, in our evaluation of the new technology add-on payment applications for FY 2017 presented in the FY 2017 IPPS/LTCH PPS proposed rule.

As indicated earlier in this section, CMS is required to provide, before publication of a proposed rule, for a meeting at which organizations representing hospitals, physicians, manufacturers, and any other interested party may present comments, recommendations, and data regarding whether a new medical service or technology represents a substantial clinical improvement to the clinical staff of CMS. In recent years, CMS has live-streamed the town hall meeting through the CMS YouTube Web page and later posted the recorded version of the town hall meeting, as well as written comments submitted on the applications that were received by the due date of February 26, 2016, in our evaluation of the new technology add-on payment applications for FY 2017 presented in the FY 2017 IPPS/LTCH PPS proposed rule.
Web site following the meeting. This recording would include closed captioning of all presentations and comments. In addition to submitting materials for discussion at the town hall meeting, individuals would continue to be able to submit other written comments after the town hall meeting on whether the service or technology represents a substantial clinical improvement. We invited public comments on this proposal in the proposed rule.

Comment: One commenter expressed appreciation for CMS’ efforts to organize and host the new technology town hall meetings entirely via teleconference and Webcast, while continuing to maintain an open telephone line with an option for participation through the Webcast and making the recording of the town hall meeting available on the CMS YouTube Web page or other CMS Web site following the meeting. However, the commenter requested that the option for an open face-to-face meeting be maintained in addition to the teleconference and Webcast participation options. The commenter noted that the opportunity to be able to present in an actual face-to-face forum allows attendees and presenters to gauge reaction and foster added awareness of the use of new technologies.

Several commenters disagreed with the proposal to conduct the new technology town hall meetings via phone and video conference only, and instead requested that the option for an open face-to-face meeting be maintained in addition to the teleconference and Webcast participation options. The commenter noted that the opportunity to be able to present in an actual face-to-face forum allows attendees and presenters to gauge reaction and foster added awareness of the use of new technologies.

Response: We appreciate the commenter’s support and have taken into consideration the commenters’ concerns. Therefore, in the interim, we will continue to host the new technology town hall meetings in person. However, we encourage the public to utilize the teleconference and Webcast participation options in order to become familiar with the advancing technological options. We will continue to gauge the public’s interest in CMS hosting the new technology town hall meetings entirely via teleconference and Webcast in subsequent fiscal years.

In response to the published notice and the February 16, 2016 New Technology Town Hall meeting, we received written comments regarding the applications for FY 2017 new technology add-on payments. We summarized in the proposed rule a general comment that did not relate to a specific application, and we summarized comments regarding individual applications, or, if applicable, indicated that there were no comments received in section II.H.5. of the preamble of the proposed rule at the end of each applicable discussion of the individual applications. We note that we did receive public comments unrelated to the substantial clinical improvement criterion. As stated earlier, the purpose of the new technology town hall meeting is specifically to discuss the substantial clinical improvement criterion in regard to pending new technology add-on payment applications for FY 2017. Therefore, we did not summarize these additional comments in the proposed rule.

Comment: Commenters provided additional comments during the 60-day comment period for the proposed rule with regard to the newness, cost, and substantial clinical improvement criteria. Some commenters reiterated comments presented at the town hall meeting, including a recommendation that CMS broaden the criteria applied in making substantial clinical improvement determinations to require, in addition to existing criteria, consideration of whether the new technology or medical service meets one or more of the following additional suggested criteria: (1) Results in a reduction of the length of a hospital stay; (2) improves patient quality of life; (3) creates long-term clinical efficiencies in treatment; (4) addresses patient-centered objectives as defined by the Secretary; or (5) meets such other criteria as the Secretary may specify; and a suggestion that an entity submitting an application for new technology add-on payments be entitled to administrative review of an adverse determination made by the Secretary.

Response: We did not propose any policy changes to the criteria applied to new technology applications in the FY 2016 IPPS/LTCH PPS proposed rule. Therefore, we are not addressing these additional comments in this final rule. Similar to our response in the proposed rule, we will take the commenters’ recommendation and suggestion into consideration in future rulemaking.

3. ICD–10–PCS Section “X” Codes for Certain New Medical Services and Technologies

As discussed in the FY 2016 IPPS/LTCH final rule (80 FR 49434), the ICD–10–PCS includes a new section containing the new Section “X” codes, which began being used with discharges occurring on or after October 1, 2015. Decisions regarding changes to ICD–10–PCS Section “X” codes will be handled in the same manner as the decisions for all of the other ICD–10–PCS code changes. That is, proposals to create, delete, or revise Section “X” codes under the ICD–10–PCS structure will be referred to the ICD–10 Coordination and Maintenance Committee. In addition, several of the new medical services and technologies that have been, or may be, approved for new technology add-on payments may now, and in the future, be assigned a Section “X” code within the structure of the ICD–10–PCS. We posted ICD–10–PCS Guidelines on the CMS Web site at: http://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-PCS-and-GEMs.html, including guidelines for ICD–10–PCS “X” codes. We encourage providers to view the material provided on ICD–10–PCS Section “X” codes.

Comment: One commenter supported the implementation of Section “X” codes, but recommended that CMS, in order to avoid confusion, make it mandatory that requestors of these new Section “X” codes also request the creation of new procedure codes in the body of ICD–10–PCS to accommodate the new medical service or technology. Other commenters also supported the creation and implementation of the Section “X” codes, but noted the need to gain better understanding of how the new section “X” codes will be used and applied. These commenters encouraged CMS to continue to remain transparent in how the agency develops and applies these new codes.

Response: We appreciate the commenters’ support of the new ICD–10–PCS codes. These Section “X” codes are included in Table 6B associated with this final rule (which is available via the Internet on the CMS Web site). Section “X” codes are standalone codes. They are not supplemental codes. Section “X” codes fully represent the specific procedure described in the code title and do not require any additional codes from other sections of ICD–10–PCS. When a section “X” code contains a code title that describes a specific new technology procedure, only that section “X” code is reported for the procedure. There is no need to report a broader, nonspecific code in another section of ICD–10–PCS. Section X of the ICD–10–PCS structure does not introduce any new coding concepts or unusual guidelines for correct coding. We encourage individuals interested in the creation of ICD–10–PCS codes (including Section “X” codes) and any questions related to whether or not there should be a mandatory requirement that new code requests...
include both codes in Section X as well as in other sections of ICD–10–PCS to make this suggestion at future meetings of the ICD–10 Coordination and Maintenance Committee. We encourage participation at these future meetings as well as the presentation of comments during the comment period regarding proposals and approvals for creating and implementing new codes. We refer commenters to the CMS Web site at: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.html for complete details.

4. FY 2017 Status of Technologies Approved for FY 2016 Add-On Payments

a. Kcentra™

CSL Behring submitted an application for new technology add-on payments for Kcentra™ for FY 2014. Kcentra™ is a replacement therapy for fresh frozen plasma (FFP) for patients with an acquired coagulation factor deficiency due to warfarin and who are experiencing a severe bleed. Kcentra™ contains the Vitamin K dependent coagulation factors II, VII, IX and X, together known as the prothrombin complex, and antithrombotic proteins C and S. Factor IX is the lead factor for the potency of the preparation. The product is a heat-treated, non-activated, virus filtered and lyophilized plasma protein concentrate made from pooled human plasma. Kcentra™ is available as a lyophilized powder that needs to be reconstituted with sterile water prior to administration via intravenous infusion. The product is dosed based on Factor IX units. Concurrent Vitamin K treatment is recommended to maintain blood clotting factor levels once the effects of Kcentra™ have diminished.

Kcentra™ was approved by the FDA on April 29, 2013. Under the ICD–10 coding system, Kcentra™ is uniquely identified by ICD–10–CM procedure code 30283B1 (Transfusion of nonautologous 4-factor prothrombin complex concentrate into vein, percutaneous approach).

After evaluation of the newness, cost, and substantial clinical improvement criteria for new technology add-on payments for Kcentra™ and consideration of the public comments we received in response to the FY 2014 IPPS/LTCH PPS proposed rule, we approved Kcentra™ for new technology add-on payments for FY 2014 (78 FR 50575 through 50580). In the application, the applicant estimated that the average Medicare beneficiary would require an average dosage of 2500 International Units (IU). Vials contain 500 IU at a cost of $635 per vial.

Therefore, cases of Kcentra™ would incur an average cost per case of $3,175 ($635 × 5). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum add-on payment for a case of Kcentra™ was $1,587.50 for FY 2014. We refer the reader to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50579) for complete details on the new technology add-on payments for Kcentra™.

As stated above, the new technology add-on payment regulations provide that a medical service or technology may be considered new within 2 or 3 years after the point at which data begin to become available reflecting the ICD–9–CM code assigned to the new service or technology ($412.87(b)(2)). Our practice has been to begin and end new technology add-on payments on the basis of a fiscal year, and we have generally followed a guideline that uses a 6-month window before and after the start of the fiscal year to determine whether to extend the new technology add-on payment for an additional fiscal year. In general, we extend add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on the market occurs in the latter half of the fiscal year (70 FR 47362).

With regard to the newness criterion for Kcentra™, we considered the beginning of the newness period to commence when Kcentra™ was approved by the FDA on April 29, 2013. Because the 3-year anniversary date for Kcentra™ would occur in the latter half of FY 2016 (April 29, 2016), in the FY 2016 IPPS/LTCH PPS final rule, we continued new technology add-on payments for this technology for FY 2016 (80 FR 49437). However, for FY 2017, the 3-year anniversary date of the entry of Kcentra™ on the U.S. market (April 29, 2016) occurred prior to the beginning of FY 2017. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25034), we proposed to discontinue new technology add-on payments for this technology for FY 2017. We invited public comments on this proposal in the proposed rule. We did not receive any public comments on our proposal. Therefore, as we proposed, we are discontinuing new technology add-on payments for Kcentra™ for FY 2017. The 3-year anniversary date of the product’s entry onto the U.S. market occurred prior to the beginning of FY 2020. Therefore, the product is not eligible for new technology add-on payments for FY 2017 because the technology will no longer meet the “newness” criterion.

b. Argus® II Retinal Prosthesis System

Second Sight Medical Products, Inc. submitted an application for new technology add-on payments for the Argus® II Retinal Prosthesis System (Argus® II System) for FY 2014. The Argus® II System is a functional implantable medical device that is intended to provide electrical stimulation of the retina to induce visual perception in patients who are profoundly blind due to retinitis pigmentosa (RP). These patients have bare or no light perception in both eyes. The system employs electrical signals to bypass dead photo-receptor cells and stimulate the underlying neurons according to a real-time video signal that is wirelessly transmitted from an externally worn video camera. The Argus® II implant is intended to be implanted in a single eye, typically the worse-seeing eye. Currently, bilateral implants are not intended for this technology. According to the applicant, the surgical implant procedure takes approximately 4 hours and is performed under general anesthesia.

With regard to the newness criterion, the applicant received a Humanitarian Device Exemption (HDE) approval from the FDA on February 13, 2013. However, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49924 through 49925), we discussed comments we had received informing CMS that the Argus® II System was not available on the U.S. market until December 20, 2013. The applicant explained that, as part of the lengthy approval process, it was required to submit a request to the Federal Communications Commission (FCC) for a waiver of section 15.209(a) of the FCC rules that would allow the applicant to apply for FCC authorization to utilize this specific RF band. The FCC approved the applicant’s waiver request on November 30, 2011. After receiving the FCC waiver of the section 15.209(a) rules, the applicant requested and obtained a required Grant of Equipment Authorization to utilize the specific RF band, which the FCC issued on December 20, 2013. Therefore, the applicant stated that the date the Argus® II System first became available for commercial sale in the United States was December 20, 2013. We agreed with the applicant that, due to the delay, the date of newness for the Argus® II System was December 20, 2013, instead of February 13, 2013.

After evaluation of the new technology add-on payment application and consideration of public comments received, we concluded that the Argus®
II System met all of the new technology add-on payment policy criteria. Therefore, we approved the Argus® II System for new technology add-on payments in FY 2014 (78 FR 50580 through 50583). Cases involving the Argus® II System that are eligible for new technology add-on payments currently are identified when one of the following ICD–10–PCS procedure codes is reported: 08H005Z (Insertion of epiretinal visual prosthesis into right eye, open approach); or 08H105Z (Insertion of epiretinal visual prosthesis into left eye, open approach). In the application, the applicant provided a breakdown of the costs of the Argus® II System. The total operating cost of the Argus® II System is $144,057.50. Under §412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum add-on payment for a case involving the Argus® II System for FY 2014 was $72,028.75.

With regard to the newness criterion for the Argus® II System, we considered the beginning of the newness period to commence when the Argus® II System became available on the U.S. market on December 20, 2013. Because the 3-year anniversary date for the Argus® II System will occur after FY 2016 (December 20, 2016), in the FY 2016 IPPS/LTCH PPS final rule, we continued new technology add-on payments for this technology for FY 2016 (80 FR 49439). However, for FY 2017, the 3-year anniversary date of the entry of the Argus® II System on the U.S. market (December 20, 2016) will occur in the first half of FY 2017. As discussed previously in this section, in general, we extend new technology add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on to the U.S. market occurs in the latter half of the fiscal year. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25034 and 25035), we proposed to discontinue new technology add-on payments for this technology for FY 2017. We invited public comments on this proposal in the proposed rule.

We did not receive any public comments on our proposal. Therefore, as we proposed, we are discontinuing new technology add-on payments for the Argus® II System for FY 2017. The 3-year anniversary date of the product’s entry onto the U.S. market occurs in the first half of FY 2017. Therefore, the technology is not eligible for new technology add-on payments for FY 2017 because the technology will no longer meet the “newness” criterion.

c. CardioMEMSTM HF (Heart Failure) Monitoring System

CardioMEMS, Inc. submitted an application for new technology add-on payment for FY 2015 for the CardioMEMSTM HF (Heart Failure) Monitoring System, which is an implantable hemodynamic monitoring system comprised of an implantable sensor/monitor placed in the distal pulmonary artery. Pulmonary artery hemodynamic monitoring is used in the management of heart failure. The CardioMEMSTM HF Monitoring System measures multiple pulmonary artery pressure parameters for an ambulatory patient to measure and transmit data via a wireless sensor to a secure Web site. The CardioMEMSTM HF Monitoring System utilizes radiofrequency (RF) energy to power the sensor and to measure pulmonary artery (PA) pressure and consists of three components: An Implantable Sensor with Delivery Catheter, an External Electronics Unit, and a Pulmonary Artery Pressure Database. The system provides the physician with the patient’s PA pressure waveform (including systolic, diastolic, and mean pressures) as well as heart rate. The sensor is permanently implanted in the distal pulmonary artery using transcatheter techniques in the catheterization laboratory where it is calibrated using a Swan-Ganz catheter. PA pressures are transmitted by the patient at home in a supine position on a padded antenna, pushing one button which records an 18-second continuous waveform. The data also can be recorded from the hospital, physician’s office or clinic.

The hemodynamic data, including a detailed waveform, are transmitted to a secure Web site that serves as the Pulmonary Artery Pressure Database, so that information regarding PA pressure is available to the physician or nurse at any time via the Internet. Interpretation of trend data allows the clinician to make adjustments to therapy and can be used along with heart failure signs and symptoms to adjust medications.

The applicant received FDA approval on May 28, 2014. After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for the CardioMEMSTM HF Monitoring System and consideration of the public comments we received in response to the FY 2015 IPPS/LTCH PPS proposed rule, we approved the CardioMEMSTM HF Monitoring System for new technology add-on payments for FY 2015 (78 FR 17570). Cases involving the CardioMEMSTM HF Monitoring System that are eligible for new technology add-on payments are identified by either ICD–10–PCS procedure code 02HQ30Z (Insertion of pressure sensor monitoring device into right pulmonary artery, percutaneous approach) or ICD–10–PCS procedure code 02HR30Z (Insertion of pressure sensor monitoring device into left pulmonary artery, percutaneous approach). With the new technology add-on payment application, the applicant stated that the total operating cost of the CardioMEMSTM HF Monitoring System is $17,750. Under §412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the CardioMEMSTM HF Monitoring System is $8,875.

With regard to the newness criterion for the CardioMEMSTM HF Monitoring System, we considered the beginning of the newness period to commence when the CardioMEMSTM HF Monitoring System was approved by the FDA on May 28, 2014. Because the 3-year anniversary date of the entry of the CardioMEMSTM HF Monitoring System on the U.S. market will occur in the latter half of FY 2017 (May 28, 2017), in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25035 and 25036), we proposed to continue new technology add-on payments for this technology for FY 2017. We proposed that the maximum payment for a case involving the CardioMEMSTM HF Monitoring System would remain $8,875 in FY 2017. We invited public comments on our proposal in the proposed rule.

Comment: One commenter, the manufacturer, supported the continuation of new technology add-on payments for the CardioMEMSTM HF Monitoring System in FY 2017. The commenter requested that CMS provide further and more detailed guidance to the various stakeholders, including hospitals, physicians, MACs, and other manufacturers, on the purpose for the additional payment and how the new technology add-on payment is calculated thereafter. The commenter added that when new technology add-on payments are approved, it is ultimately the responsibility of the applicable provider to charge and bill appropriately. The commenter further explained that it is most often the manufacturer that developed the new technology that researches and provides guidance and expertise to the adopting facilities regarding the technology’s use. However, the commenter believed that, given the few new medical services or technologies approved for new
technology add-on payments, hospitals often lack the resources or experience to research and understand the payment calculations. The commenter recommended that CMS provide examples or sample calculations of the new technology add-on payment in a similar fashion that CMS has published examples of other payment methodologies, for example, DSH payments.

Response: We appreciate the commenter’s support. We note that after the development and publication of each final rule, CMS issues instructions to the MACs informing them of important changes for the upcoming fiscal year. In addition, CMS issues a Medicare Learning Matters (MLN) article for the public in order to provide information regarding changes for the upcoming fiscal year. The instructions for the MACs and the MLN article for the public always include which new technologies are eligible for new technology add-on payments for the upcoming fiscal year. We refer readers to the CMS Web site at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2015-Transmittals-Items/R3431CP.html to view the MAC instructions and MLN article issued in conjunction with the FY 2016 IPPS/LTCH final rule.

For information regarding how to receive MLN articles, we refer readers to the CMS Web site at: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/What_Is_MLN_Matters.pdf. Also, the regulations at 42 CFR 412.88 explains how the new technology add-on payment is made. Further, on December 13, 2002, we issued Change Request 2301, which provides examples of how the new technology add-on payment is made. Change Request 2301 is available for download via the Internet from the CMS Web site at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/A02124.pdf. We also educate the public through our conference calls via open door forums.

After consideration of the public comments we received, we are finalizing our proposal to continue new technology add-on payments for the CardioMEMSTM HF Monitoring System for FY 2017. The maximum new technology add-on payment for a case involving the CardioMEMSTM HF Monitoring System will remain at $8,875 for FY 2017.

d. MitraClip® System

Abbott Vascular submitted an application for new technology add-on payments for the MitraClip® System for FY 2015. The MitraClip® System is a transcatheter mitral valve repair system that includes a MitraClip® device implant, a Steerable Guide Catheter, and a Clip Delivery System. It is designed to perform reconstruction of the insufficient mitral valve for high-risk patients who are not candidates for conventional open mitral valve repair surgery.

With regard to the newness criterion, the MitraClip® System received a premarket approval from the FDA on October 24, 2013. The MitraClip® System is indicated “for the percutaneous reduction of significant symptomatic mitral regurgitation (MR >= 3+) due to primary abnormality of the mitral apparatus (degenerative MR) in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.”

The MitraClip® System became immediately available on the U.S. market following FDA approval. The MitraClip® System is a Class III device, and has an investigational device exemption (IDE) for the EVEREST study (Endovascular Valve Edge-to-Edge Repair Study)—IDE G030061, and for the COAPT study (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation)—IDE G120024. Cases involving the MitraClip® System are identified using ICD–10–PCS procedure code 02UG3JZ (Supplement mitral valve with synthetic substitute, percutaneous approach).


After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for the MitraClip® System and consideration of the public comments we received in response to the FY 2015 IPPS/LTCH PPS proposed rule, we approved the MitraClip® System for new technology add-on payments for FY 2015 (79 FR 49946). As discussed in the FY 2015 IPPS/LTCH PPS final rule, this approval is on the basis of using the MitraClip® consistent with the NCD. The average cost of the MitraClip® System is reported as $30,000. Under section 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the MitraClip® System is $15,000 for FY 2015.

With regard to the newness criterion for the MitraClip® System, we considered the beginning of the newness period to commence when the MitraClip® System was approved by the FDA on October 24, 2013. Because the 3-year anniversary date of the entry of the MitraClip® System on the U.S. market (October 24, 2016) will occur after FY 2016, in the FY 2016 IPPS/LTCH PPS final rule, we continued new technology add-on payments for this technology for FY 2016 (80 FR 49442). However, for FY 2017, the 3-year anniversary date of the entry of MitraClip® System on the U.S. market (October 24, 2016) will occur in the first half of FY 2017. As discussed previously in this section, in general, we extend new technology add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on to the U.S. market occurs in the latter half of the fiscal year. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (80 FR 25036), we proposed to discontinue new technology add-on payments for this technology for FY 2017. We invited public comments on this proposal in the proposed rule.

We did not receive any public comments on our proposal. Therefore, as we proposed, we are discontinuing new technology add-on payments for the MitraClip® System for FY 2017. The 3-year anniversary of the product’s entry on to the U.S. market occurs in the first half of FY 2017. Therefore, the technology is not eligible for new technology add-on payments for FY 2017 because the technology will no longer meet the “newness” criterion.

e. Responsive Neurostimulator (RNS®) System

NeuroPace, Inc. submitted an application for new technology add-on payments for FY 2015 for the use of the RNS® System. (We note that the applicant submitted an application for new technology add-on payments for FY 2014, but failed to receive FDA approval prior to the July 1 deadline.) Seizures
The typical patient is treated when electrocorticographic activity is delivered only when abnormal electrographic patterns previously were interrupted. Stimulation is delivered directly to the seizure focus in the brain when abnormal brain activity is detected. A cranially implanted programmable neurostimulator senses and records brain activity through one or two electrode-containing leads that are placed at the patient’s seizure focus/loci. The neurostimulator detects electrographic patterns previously identified by the physician as abnormal, and then provides brief pulses of electrical stimulation through the leads to interrupt those patterns. Stimulation is delivered only when abnormal electrocorticographic activity is detected. The typical patient is treated with a total of 5 minutes of stimulation a day. The RNS® System incorporates remote monitoring, which allows patients to share information with their physicians remotely.

With regard to the newness criterion for the RNS® System, we considered the beginning of the newness period to commence when the RNS® System was approved by the FDA on November 14, 2013. Because the 3-year anniversary date of the entry of the RNS® System on the U.S. market (November 14, 2016) will occur after FY 2016, in the FY 2016 IPPS/LTCPPS final rule, we continued new technology add-on payments for this technology for FY 2016 (80 FR 49443). However, for FY 2017, the 3-year anniversary date of the entry of RNS® System on the U.S. market (November 14, 2016) will occur in the first half of FY 2017. As discussed previously in this section, in general, we extend new technology add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on to the U.S. market occurs in the latter half of the fiscal year. Therefore, in the FY 2017 IPPS/LTCPPS proposed rule (81 FR 25036 and 25037), we proposed to discontinue new technology add-on payments for this technology for FY 2017. We invited public comments on this proposal in the proposed rule.

Comment: One commenter, the manufacturer, submitted a comment and requested that CMS continue to make new technology add-on payments for the RNS® System in FY 2017. The commenter stated that it recognized that the 3-year anniversary date of the RNS® System’s entry onto the U.S. market technically occurs in the first half of FY 2017. However, the commenter believed that CMS should continue to consider the device “new” in FY 2017 for purposes of new technology add-on payments because numerous obstacles were encountered before the product was first sold, resulting in a significant delay in the product’s availability on the U.S. market. As a result of these obstacles, the commenter believed that the data used to analyze and compare cost for the limited number of cases reported in the first half of FY 2014 were also hindering and skewed the comparisons. The commenter provided the following reasons why it believed CMS should continue new technology add-on payments for the RNS® System for FY 2017:

- Because of delays encountered during the FDA approval process for the RNS® System, FDA approval for the use of the new technology was not received by July 1, 2013, which disqualified the approval of the FY 2014 new technology add-on payment application for the RNS® System in FY 2014. Although the RNS® System received FDA approval on November 14, 2013, a 30-day notice to replace a component supplier was required to be submitted to FDA following the approval. According to the manufacturer, the delays significantly impacted the product’s availability on the U.S. market; prohibiting the ability to market or make the product available on the U.S. market until December 18, 2013.

- As a condition of approval by the FDA, the RNS® System can only be sold to Comprehensive Epilepsy Centers (CECs) that meet specific requirements related to physician expertise and center experience. The FDA does not grant approval for the CECs to purchase and implant the RNS® System. Rather, the manufacturer (NeuroPace) has to verify that the CEC meets certain requirements before it allows the CEC to procure the device. After that verification is completed, the CEC then has to comply with its own internal approval processes, which are quite extensive, before the actual acquisition or purchase of the device and commencing use of the device. The approval process typically involves several different groups within the CEC and occurs in a series of sequential steps. According to the manufacturer, as a result, many CECs were unwilling to adopt the use of the technology initially because they would incur a significant financial loss for each Medicare patient treated in FY 2014 because new technology add-on payments for the RNS® System were not available. In addition, the manufacturer stated that further complications and delays were presented and encountered because a number of CECs were unwilling to proceed with acquisition and use of the new technology until CMS announced approval of new technology add-on payments for the RNS® System in the FY 2015 IPPS/LTCPS final rule.

- According to the manufacturer, because the RNS® System can only be sold to CECs, by March 30, 2014 (that
is, during the first half of FY 2014), only six RNS® System commercial implant procedures were performed (which occurred at previous clinical trial sites that allowed the internal approval process to proceed more quickly). Of these cases, only two represented the treatment of Medicare beneficiaries. As a result, the market activity was extremely limited in the first half of that fiscal year. In addition, the manufacturer stated that hospitals incorrectly reported cases involving ICD–9–CM procedure codes 01.20 and 02.93 for non-RNS® System procedures. The manufacturer asserted that, as a result, CMS may have reviewed MedPAR data and may have believed that there were many more RNS® System cases than what actually occurred (including during the first 6 months of FY 2014), which may have negatively impacted how CMS views and applies the criteria regarding new technology add-on payments for the RNS® System for a third year because the MedPAR data does not accurately reflect cases involving treatment using the RNS® System.

• Without the approval for new technology add-on payments in FY 2017, CECs currently offering treatment involving the RNS® System would face the difficult challenge of continuing to provide treatment using the device to Medicare beneficiaries in the face of substantial losses because of an inadequate applicable MS–DRG payment rate.

Response: With regard to the technology’s newness, the timeframe that a new technology can be eligible to receive new technology add-on payments ends when data documenting the use and cost of the procedures become available. Section 412.87(b)(2) states that, a medical service or technology may be considered new within 2 or 3 years after the point at which data begin to become available reflecting the ICD–9–CM code assigned to the new service or technology (depending on when a new code is assigned and data on the new service or technology become available for DRG recalibration). Section 412.87(b)(2) also states, after CMS has recalibrated the DRGs, based on available data, to reflect the costs of an otherwise new medical service or technology, the medical service or technology will no longer be considered “new” under the applicable criteria. Therefore, as discussed in the FY 2005 IPPS final rule (69 FR 49003), if the costs of the technology are included in the change data, and the MS–DRGs have been recalibrated using that data, the technology can no longer be considered “new” for the purposes of this provision. We further stated in the FY 2005 IPPS final rule that the period of newness does not necessarily start with the FDA approval date for the medical service or technology or the issuance of a distinct procedure code. Instead, the newness period begins with the date of availability of the product on the U.S. market, which is when data become available. We have consistently applied this standard, and believe that it is most consistent with the purpose of new technology add-on payments.

With regard to the RNS® System, while there may have been issues with some CECs meeting specific requirements and delays prohibiting the use of the device, as the commenter noted, the RNS® System was available for acquisition on the U.S. market on or after December 18, 2013. We agree that the newness period for the RNS® System should begin on December 18, 2013. However, because the 3-year anniversary date of the entry of the RNS® System on the U.S. market (December 18, 2016) will still occur in the first half of FY 2017, the RNS® System continues to be ineligible for new technology add-on payments in FY 2017. As noted previously, in general, we extend new technology add-on payments for an additional year only if the 3-year anniversary date of the product’s entry on to the U.S. market occurs in the latter half of the fiscal year.

In addition, similar to our discussion in the FY 2006 IPPS final rule (70 FR 47349), we do not believe that case volume is a relevant consideration for making the determination as to whether a product is “new.” Consistent with the statute and our implementing regulations, a technology no longer qualifies as “new” once it is more than 2 to 3 years old, irrespective of how frequently it has been used in the Medicare population. Therefore, if a product is more than 2 to 3 years old, we consider its costs to be included in the MS–DRG relative weights, whether its use in the Medicare population has been frequent or infrequent.

Therefore, based on all of the reasons stated above, the RNS® System is no longer considered “new” for purposes of new technology add-on payments for FY 2017. We are finalizing our proposal to discontinue making new technology add-on payments for the RNS® System for FY 2017.

Comment: Several commenters that had experienced the effects of the correlation placed on the clinical effectiveness of the device and requested the continuation of new technology add-on payments for the RNS® System for FY 2017.

Response: We thank the commenters for their input. However, as stated above, the RNS® System is no longer considered “new” for FY 2017 and, therefore, is no longer eligible for new technology add-on payments.

f. Blinatumomab (BLINCYTO® Trade Brand)

Amgen, Inc. submitted an application for new technology add-on payments for FY 2016 for Blinatumomab (BLINCYTO®), a bi-specific T-cell engager (BiTE) used for the treatment of Philadelphia chromosome-negative (Ph-) relapsed or refractory (R/R) B-cell precursor acute-lymphoblastic leukemia (ALL), which is a rare aggressive cancer of the blood and bone marrow. Approximately 6,050 individuals are diagnosed with Ph- R/R B-cell precursor ALL in the United States each year, and approximately 2,400 individuals, representing 30 percent of new cases, are adults. Ph- R/R B-cell precursor ALL occurs when there are malignant transformations of B-cell or T-cell progenitor cells, causing an accumulation of lymphoblasts in the blood, bone marrow, and occasionally throughout the body. As a bi-specific T-cell engager, the BLINCYTO® technology attaches to a molecule on the surface of the tumor cell, as well as to a molecule on the surface of normal T-cells, bringing the two into closer proximity and allowing the normal T-cell to destroy the tumor cell.

Specifically, the BLINCYTO® technology attaches to a cell identified as CD19, which is present on all of the cells of the malignant transformations that cause Ph- R/R B-cell precursor ALL and helps attract the cell into close proximity of the T-cell CD3 with the intent of getting close enough to allow the T-cell to inject toxins that destroy the cancerous cell. According to the applicant, the BLINCYTO® technology is the first, and the only, bi-specific CD19-directed CD3 T-cell engager single-agent immunotherapy approved by the FDA.

BLINCYTO® is administered as a continuous IV infusion delivered at a constant flow rate using an infusion pump. A single cycle of treatment consists of 28 days of continuous infusion, and each treatment cycle is followed by 2 weeks without treatment prior to administering any further treatments. A course of treatment would consist of two phases. Phase 1 consists of initial inductions or treatments intended to achieve remission followed by additional inductions and treatments to maintain consolidation; or treatments...
given after remission has been achieved to prolong the duration. During phase 1 of a single treatment course, up to two cycles of BLINCYTO® are administered, and up to three additional cycles are administered during consolidation. The recommended dosage of BLINCYTO® administered during the first cycle of treatment is 9 mcg per day for the first 7 days of treatment. The dosage is then increased to 28 mcg per day for 3 weeks until completion. During phase 2 of the treatment course, all subsequent doses are administered as 28 mcg per day throughout the entire duration of the 28-day treatment period.

With regard to the newness criterion, the BLINCYTO® technology received FDA approval on December 3, 2014, for the treatment of patients diagnosed with Ph- R/R B-cell precursor ALL, and the product gained entry onto the U.S. market on December 17, 2014.

After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for BLINCYTO® in consideration of the public comments we received in response to the FY 2016 IPPS/LTCH PPS proposed rule, we approved BLINCYTO® for new technology add-on payments for FY 2016 (80 FR 49449).

Cases involving BLINCYTO® that are eligible for new technology add-on payments are identified using one of the following ICD–10–PCS procedure codes: WX03351 (Introduction of Blinatumomab antineoplastic immunotherapy into peripheral vein, percutaneous approach, new technology group 1), WX03352 (Introduction of Blinatumomab antineoplastic immunotherapy into central vein, percutaneous approach, new technology group 1).

As discussed in the FY 2016 IPPS/LTCH final rule (80 FR 49449), the applicant recommended that CMS consider and use the cost of the full 28-day inpatient treatment cycle as the expected length of treatment when determining the maximum new technology add-on payment for cases involving the BLINCYTO® rather than the average cost of lesser number of days used as other variables. For the reasons discussed, we disagreed with the applicant and established the maximum new technology add-on payment amount for a case involving the BLINCYTO® technology for FY 2016 using the weighted average of the cycle 1 and cycle 2 observed treatment length. Specifically, in the Phase II trial, the most recent data available, 92 patients received cycle 1 for an average length of 21.2 days, 90 patients received cycle 2 for an average length of 10.2 days. The weighted average of cycle 1 and 2 treatment length is 17 days. We noted that a small number of patients also received 3 to 5 treatment cycles. However, based on the data provided, these cases do not appear to be typical at this point and we excluded them from this calculation. We noted that, if we included all treatment cycles in this calculation, the weighted average number of days of treatment is much lower, 10 days. Using the clinical data provided by the applicant, we stated that we believe that setting the maximum new technology add-on payment amount for a case involving the BLINCYTO® technology for FY 2016 based on a 17-day length of treatment cycle is representative of historical and current practice. We also stated that, for FY 2017, if new data on length of treatment are available, we would consider any such data in evaluating the maximum new technology add-on payment amount. However, we did not receive any new data from the applicant to evaluate for FY 2017.

In the application, the applicant estimated that the average Medicare beneficiary would require a dosage of 9mcg/day for the first 7 days under the first treatment cycle, followed by a dosage of 28mcg/day for the duration of the treatment cycle, as well as all days included in subsequent cycles. All vials contain 35mcg at a cost of $3,178.57 per vial. The applicant noted that all vials are single-use. Therefore, we determined that cases involving the use of the BLINCYTO® technology would incur an average cost per case of $34,039.69 (41.0 days × 17 days × $3,178.57/vial). Under 42 CFR 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment amount for a case involving the use of BLINCYTO® is $27,017.85 for FY 2016. With regard to the newness criterion for BLINCYTO®, we considered the beginning of the newness period to commence when the product gained entry onto the U.S. market on December 17, 2014. Because the 3-year anniversary date of the entry of the BLINCYTO® on the U.S. market will occur after FY 2017 (December 17, 2017), in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25038), we proposed to continue new technology add-on payments for this technology for FY 2017. We proposed that the maximum payment for a case involving BLINCYTO® would remain at $27,017.85 for FY 2017. We invited public comments on this proposal in the proposed rule.

Comment: Commenters supported CMS’ proposal to continue new technology add-on payments for BLINCYTO® for FY 2017. The manufacturer submitted a comment with regard to the substantial clinical improvement of the BLINCYTO® and stated that recently released results from a randomized, open-label, Phase 3 confirmatory study (the TOWER study) show significant improvements in overall survival (primary endpoint), complete remission, and event-free survival with BLINCYTO® compared to standard of care chemotherapy in adult patients diagnosed with Ph- R/R B-cell precursor ALL. According to the manufacturer, in this study, 405 patients were randomized in a 2:1 ratio to receive BLINCYTO® or one of four standard of care chemotherapeutic regimens chosen by the investigator. The manufacturer noted that the study was ended early based on a prespecified interim analysis from an independent data monitoring committee (DMC), which found a significant overall survival improvement in the BLINCYTO® arm over standard of care chemotherapy. According to the manufacturer, results from the DMC analysis demonstrated a median overall survival (OS) of 7.8 months.

Response: We appreciate the commenters’ support for our proposal. After consideration of the public comments we received, we are finalizing our proposal to continue new technology add-on payments for BLINCYTO® for FY 2017. The maximum new technology add-on payment for a case involving BLINCYTO® will remain at $27,017.85 for FY 2017.

g. Lutonix® Drug Coated Balloon PTA Catheter and In.PACT™ Admiral™ Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter

Two manufacturers, CR Bard Inc. and Medtronic, submitted applications for new technology add-on payments for FY 2016 for LUTONIX® Drug-Coated Balloon (DCB) Percutaneous Transluminal Angioplasty (PTA) Catheter (LUTONIX®) and In.PACT™ Admiral™ Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (In.PACT™ Admiral™), respectively. Both of these technologies are drug-coated balloon angioplasty treatments for patients diagnosed with peripheral artery disease (PAD). Typical treatments for patients with PAD include angioplasty, stenting, atherectomy and vascular bypass surgery. PAD most commonly occurs in the femoropopliteal segment of the
peripheral arteries, is associated with significant levels of morbidity and impairment in quality of life, and requires treatment to reduce symptoms and prevent or treat ischemic events. Treatment options for symptomatic PAD include noninvasive treatment such as medication and lifestyle modification (for example, exercise programs, diet, and smoking cessation) and invasive options which include endovascular treatment and surgical bypass. The 2013 American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the management of PAD recommend endovascular therapy as the first-line treatment for femoropopliteal artery lesions in patients suffering from claudication (Class I, Level A recommendation).3

According to both applicants, LUTONIX® and IN.PACT™ Admiral™ are the first drug coated balloons that can be used for treatment of patients who are diagnosed with PAD. In the FY 2016 IPPS/LTCH final rule, we stated that because cases eligible for the two devices would group to the same MS–DRGs and we believe that these devices are substantially similar to each other (that is, they are intended to treat the same or similar disease in the same or similar patient population and are purposed to achieve the same therapeutic outcome using the same or similar mechanism of action), we evaluated both technologies as one application for new technology add-on payment under the IPPS. The applicants submitted separate cost and clinical data, and we reviewed and discussed each set of data separately. However, we made one determination regarding new technology add-on payments that applied to both devices. We believe that this is consistent with our policy statements in the past regarding substantial similarity. Specifically, we have noted that approval of new technology add-on payments would extend to all technologies that are substantially similar (66 FR 46915), and that we believe that continuing our current practice of extending a new technology add-on payment without a further application from the manufacturer of the competing product or a specific finding on cost and clinical improvement if we make a finding of substantial similarity among two products is the better policy because we avoid—

- Creating manufacturer-specific codes for substantially similar products;
- Requiring different manufacturers of substantially similar products from having to submit separate new technology applications;
- Having to compare the merits of competing technologies on the basis of substantial clinical improvement; and
- Bestowing an advantage to the first applicant representing a particular new technology to receive approval (70 FR 47351).


In accordance with our policy, we stated in the FY 2016 IPPS/LTCH final rule (80 FR 49463) that we believe it is appropriate to use the earliest market availability date submitted as the beginning of the newness period. Accordingly, for both devices, we stated that the beginning of the newness period will be October 10, 2014.

After evaluation of the newness, costs, and substantial clinical improvement criteria for new technology payments for the LUTONIX® and IN.PACT™ Admiral™ technologies and consideration of the public comments we received in response to the FY 2016 IPPS/LTCH PPS proposed rule, we approved the LUTONIX® and IN.PACT™ Admiral™ technologies for new technology add-on payments for FY 2016 (80 FR 49469). Cases involving the LUTONIX® and IN.PACT™ Admiral™ technologies that are eligible for new technology add-on payments are identified using one of the ICD–10–PCS procedure codes in the following table:

<table>
<thead>
<tr>
<th>ICD–10–PCS code</th>
<th>Code description</th>
</tr>
</thead>
<tbody>
<tr>
<td>047K041 ..........</td>
<td>Dilation of right femoral artery with drug-eluting intraluminal device using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047K021 ..........</td>
<td>Dilation of right femoral artery using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047K3D1 ..........</td>
<td>Dilation of right femoral artery with intraluminal device using drug-coated balloon, percutaneous approach.</td>
</tr>
<tr>
<td>047K2Z1 ..........</td>
<td>Dilation of right femoral artery using drug-coated balloon, percutaneous approach.</td>
</tr>
<tr>
<td>047K441 ..........</td>
<td>Dilation of right femoral artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>047K4Z1 ..........</td>
<td>Dilation of right femoral artery using drug-coated balloon, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>047L041 ..........</td>
<td>Dilation of left femoral artery with drug-eluting intraluminal device using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047L0D1 ..........</td>
<td>Dilation of left femoral artery with intraluminal device using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047L2Z1 ..........</td>
<td>Dilation of left femoral artery using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047L3D1 ..........</td>
<td>Dilation of left femoral artery with intraluminal device using drug-coated balloon, percutaneous approach.</td>
</tr>
<tr>
<td>047L3Z1 ..........</td>
<td>Dilation of left femoral artery using drug-coated balloon, percutaneous approach.</td>
</tr>
<tr>
<td>047L441 ..........</td>
<td>Dilation of left femoral artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>047L4Z1 ..........</td>
<td>Dilation of left femoral artery using drug-coated balloon, percutaneous endoscopic approach.</td>
</tr>
<tr>
<td>047M041 ..........</td>
<td>Dilation of right popliteal artery with drug-eluting intraluminal device using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047M0D1 ..........</td>
<td>Dilation of right popliteal artery with intraluminal device using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047M0Z1 ..........</td>
<td>Dilation of right popliteal artery using drug-coated balloon, open approach.</td>
</tr>
<tr>
<td>047M341 ..........</td>
<td>Dilation of right popliteal artery with drug-eluting intraluminal device using drug-coated balloon, percutaneous approach.</td>
</tr>
<tr>
<td>047M3D1 ..........</td>
<td>Dilation of right popliteal artery with intraluminal device using drug-coated balloon, percutaneous approach.</td>
</tr>
</tbody>
</table>

---


As discussed in the FY 2016 IPPS/LTCH final rule (80 FR 49469), each of the applicants submitted operating costs for its DCB. The manufacturer of the LUTONIX® stated that a mean of 1.37 drug-coated balloons was used during the LEVANT 2 clinical trial. The acquisition price of the hospital will be $1,900 per drug-coated balloon, or $2,603 per case (1.37 × $1,900). The applicant projected that approximately 8,875 cases will involve use of the LUTONIX® for FY 2016. The manufacturer for the IN.PACT™ Admiral™ stated that a mean of 1.4 drug-coated balloons was used during the IN.PACT™ Admiral™ DCB arm. The acquisition price for the hospital will be $1,350 per drug-coated balloon, or $1,890 per case (1.4 × $1,350). The applicant projected that approximately 26,000 cases will involve use of the IN.PACT™ Admiral™ for FY 2016.

For FY 2016, we based the new technology add-on payment for cases involving these technologies on the weighted average cost of the two DCBs described by the ICD–10–PCS procedure codes listed above (which are not manufacturer specific). Because ICD–10 codes are not manufacturer specific, we cannot set one new technology add-on payment amount for IN.PACT™ Admiral™ and a different new technology add-on payment amount for LUTONIX®, both technologies will be captured by using the same ICD–10–PCS procedure code. As such, we stated that we believe that the use of a weighted average of the cost of the standard DCBs based on the projected number of cases involving each technology to determine the maximum new technology add-on payment would be most appropriate. To compute the weighted cost average, we summed the total number of projected cases for each of the applicants, which equaled 34,000 cases (26,000 plus 8,875). We then divided the number of projected cases for each of the applicants by the total number of cases, which resulted in the following case-weighted percentages: 25 percent for the LUTONIX® and 75 percent for the IN.PACT™ Admiral™. We then multiplied the cost per case for the manufacturer specific DCB by the case-weighted percentage (0.25 * $2,603 = $662.41 for LUTONIX® and 0.75 * $1,890 = $1,409.03 for the IN.PACT™ Admiral™). This resulted in a case-weighted average cost of $2,071.45 for DCBs. Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum payment for a case involving the LUTONIX® or IN.PACT™ Admiral™ DCBs is $1,035.72.

With regard to the newness criterion for LUTONIX® and IN.PACT™ Admiral™ technologies, we considered the beginning of the newness period to commence when LUTONIX® gained entry onto the U.S. market on October 10, 2014. Because the 3-year anniversary date of the entry of LUTONIX® on the U.S. market will occur after FY 2017 (October 10, 2017), in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25039 and 25040), we proposed to continue new technology add-on payments for both the LUTONIX® and IN.PACT™ Admiral™ technologies for FY 2017. We proposed that the maximum add-on payment for a case involving LUTONIX® and IN.PACT™ Admiral™ would remain at $1,035.72 for FY 2017. We invited public comments on this proposal in the proposed rule. Comment: Commenters supported CMS’ proposal to continue new technology add-on payments for the LUTONIX® and IN.PACT™ Admiral™ for FY 2017.

Response: We appreciate the commenters’ support for our proposal.

As a result of the public comments received, we are finalizing our proposal and continuing new technology add-on payments for both the LUTONIX® and IN PACT™ Admiral™ for FY 2017. The maximum add-on payment for a case involving LUTONIX® and IN.PACT™ Admiral™ remains at $1,035.72 for FY 2017.

5. FY 2017 Applications for New Technology Add-On Payments

We received nine applications for new technology add-on payments for FY 2017. One applicant withdrew its application prior to the issuance of the FY 2017 IPPS/LTCH PPS proposed rule. Another applicant, Andexanet Alfa, withdrew its application prior to the issuance of the FY 2017 IPPS/LTCH PPS final rule.

In addition, in accordance with the regulations under § 412.87(c), applicants for new technology add-on payments must have FDA approval or clearance by July 1 of each year prior to the beginning of the fiscal year that the application is being considered. One applicant, the EDWARDS INTUITY Elite™ Valve System, did not receive FDA approval for their technology by July 1, 2016, and, therefore, is ineligible for consideration for new technology add-on payments for FY 2017. We are not including the discussions and descriptions of these two applications that were included in the FY 2017 proposed rule in this final rule. We note that we did receive public comments on these two applications. However, because Andexanet Alfa withdrew its application and the EDWARDS INTUITY Elite™ Value System is ineligible for new technology add-on payments for FY 2017 because it did not receive FDA approval by July 1, 2016, we are not summarizing or responding to public comments on these applications in this final rule. A
discussion of the seven remaining applications is presented below.

a. MAGEC® Spinal Bracing and Distraction System (MAGEC® Spine)

Ellipse Technologies, Inc. submitted an application for new technology add-on payments for FY 2017 for the MAGEC® Spine. According to the applicant, the MAGEC® Spine has been developed for use in the treatment of children diagnosed with severe spinal deformities, such as scoliosis. The system can be used in the treatment of skeletally immature patients less than 10 years of age who have been diagnosed with severe progressive spinal deformities associated with or at risk of Thoracic Insufficiency Syndrome (TIS). The MAGEC® Spine consists of a (spinal growth) rod that can be lengthened through the use of magnets that are controlled by an external remote controller (ERC). The rod(s) can be implanted into children as young as 2 years of age. According to the applicant, use of the MAGEC® Spine has proven to be successfully used in the treatment of patients diagnosed with scoliosis who have not been responsive to other treatments.

The MAGEC® Spine initially received FDA clearance for use of the predicate device, which used a Harrington Rod on February 27, 2014. The applicant verified that, due to manufacturing delays, the MAGEC® Spine was not available for implant until April 1, 2014. Specifically, the complete MAGEC® Spine system was produced and available for shipment for the first implant on April 1, 2014. Therefore, the newness period for the MAGEC® Spine begins on April 1, 2014. Subsequent FDA clearance was granted for use of the modified device, which uses a shorter 70 mm rod on September 18, 2014. After minor modification of the product, the MAGEC® Spine received FDA clearances on March 24, 2015, and May 29, 2015, respectively.

The applicant submitted a request for a unique ICD–10–PCS procedure code and was granted approval for the following procedure codes under New Technology Group 2: XNS0032 (Reposition of lumbar vertebra using magnetically controlled growth rod(s), open approach); XNS0432 (Reposition of lumbar vertebra using magnetically controlled growth rod(s), percutaneous endoscopic approach); XNS3032 (Reposition of cervical vertebra using magnetically controlled growth rod(s), open approach); XNS3432 (Reposition of cervical vertebra using magnetically controlled growth rod(s), percutaneous endoscopic approach); XNS4032 (Reposition of thoracic vertebra using magnetically controlled growth rod(s), open approach); and XNS4432 (Reposition of thoracic vertebra using magnetically controlled growth rod(s), percutaneous endoscopic approach).

These new ICD–10–PCS procedure codes are effective on October 1, 2016. In the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43813 through 43814), we established criteria for evaluating whether a new technology is substantially similar to an existing technology, specifically: (1) Whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome; (2) whether a product is assigned to the same or a different MS–DRG; and (3) whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population. If a technology meets all three of these criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments. For a detailed discussion of the criteria for substantial similarity, we refer readers to the FY 2006 IPPS final rule (70 FR 47351 through 47352), and the FY 2010 IPPS/LTCH PPS final rule (74 FR 43813 through 43814).

With regard to the first criterion, the applicant stated that the MAGEC® Spine’s mechanism of action is dependent upon growing rods used for the treatment of patients diagnosed with early onset scoliosis (EOS), and is unique because the technique uses magnetic distraction (lengthening), which does not require the patients to be subjected to the potential and adverse effects of additional surgeries.

The applicant explained that treatment of patients diagnosed with EOS involves the implantation of traditional growth rods (TGRs) followed by surgery every 6 months to distract the rods to accommodate the growing spine. The rods are surgically and permanently affixed to the immature spine in order to correct spinal deformities. As a child grows, the TGRs must be distracted to accommodate spinal growth. The common denominator between TGRs and the MAGEC® Spine is that they both are devices (rods) that use the same mechanism of action to perform and achieve spinal distraction, the implantation of rods that are later lengthened. While we acknowledged that the applicant noted that the MAGEC® Spine does not require the patient to endure the potential and adverse effects of additional surgeries, we stated that this assertion seems to be a component of substantial clinical improvement rather than a basis to distinguish the mechanism of action.

In consideration of the applicant’s statements that the mechanism of action of the MAGEC® Spine, which uses growing rods in the treatment of patients diagnosed with EOS, is unique because the technique of using magnetic distraction (lengthening) does not require patients to endure the potential and adverse effects of additional surgeries, in the proposed rule, we stated that there are other technologies and products currently available that achieve spinal growth without the need to subject patients to potential and adverse effects of additional surgeries. For example, the Shilla growth guidance system, which received FDA clearance in 2014, uses a non-locking set screw at the proximal and distal portions of the construct’s rods. This specific feature is designed to allow the rod to slide through the screw heads as a child’s spine grows, while still providing correction of the spinal deformity. The Shilla technique also eliminates the
need for scheduled distraction surgeries, as the applicant pointed out are needed with the use of TGRs. Therefore, in the proposed rule, we stated that we believe that the MAGEC® Spine's mechanism of action may be similar to the mechanism of action employed by the Shilla growth guidance system because both technologies achieve the same therapeutic outcome and do not require the patient to endure the potential and adverse effects of additional surgeries.

With regard to the second criterion, cases that may be eligible for treatment involving the MAGEC™ Spine map to the following MS–DRGs: 456 (Spinal Fusion Except Cervical With Spinal Curvature or Malignancy or Infection or Extensive Fusions with MCC); 457 (Spinal Fusion Except Cervical with Spinal Curvature or Malignancy or Infection or Extensive Fusions with CC); and 458 (Spinal Fusion Except Cervical with Spinal Curvature or Malignancy or Infection or Extensive Fusions without CC/MCC). All cases involving procedures describing spinal distraction devices and technologies, including those that use TGRs and the Shilla growth guidance system, currently map to the same MS–DRGs.

With regard to the third criterion, we believe that the MAGEC® Spine technology involves the treatment of the same or similar type of disease and the same or similar patient population. Although the applicant stated that the MAGEC® Spine was developed for the use in the treatment of children diagnosed with severe spinal deformities, the MAGEC® Spine treats the same patient population as other currently available spinal distraction devices and technologies, including those that use TGRs and the Shilla growth guidance system. Because it appears that the MAGEC® Spine is substantially similar to these other currently available devices used to treat the same or similar types of diseases and the same or similar patient populations, in the proposed rule we stated that we were concerned that the technology may not be considered “new” for the purposes of new technology add-on payments (81 FR 25041). We also invited public comments on whether the MAGEC® Spine meets the newness criterion.

Comment: The applicant submitted public comments that responded to CMS’ concerns presented in the proposed rule with regard to newness. The applicant provided a working definition of “mechanism of action” of spinal distraction systems as: The combined device-technique interaction with tissues that produces a therapeutic effect. The combined device-technique interaction includes the following elements: Initial fusion; device mechanism; spinal growth control; and spinal curvature control.

The applicant distinguished MAGEC® Spine’s mechanism of action as distinct from the Shilla system’s tissue interaction because the Shilla system provides passive growth guidance and the MAGEC® Spine provides active distraction by noninvasive magnetically controlled lengthening. Furthermore, MAGEC® Spine enables a surgeon to customize or adjust a patient’s therapy with more frequent, noninvasive, magnetic external remote controlled sessions. The applicant described the MAGEC® Spine’s device mechanism as distinct from the Shilla system in that the MAGEC® Spine system’s initial fusion is the cephalad and caudad ends of the spine whereas the Shilla system’s initial fusion is at the apex of the spinal curve. The MAGEC® Spine system drives growth with active noninvasive rod distractions whereas the Shilla system provides passive growth guidance with sliding anchors and limited rigidity.

The applicant further described the MAGEC® Spine’s device mechanism as distinct from TGRs in that the MAGEC® Spine system consists of magnetically controlled growing rods and actuators and an external remote, whereas, TGRs device mechanism consists of growing rods and tandem connectors which must be surgically removed and replaced with longer rods to achieve the desired lengthening. The applicant further compared the MAGEC® Spine system to TGRs and the Shilla growth guidance system, noting that the MAGEC® Spine allows for more frequent noninvasive lengthening in an awake patient to control and adapt spine growth to a child’s development, with low complication rates and few repeated surgeries. TGRs tissue interactions include manual surgical lengthening under general anesthesia at 6-month intervals.

Response: We appreciate the details and input provided by the applicant in response to our concerns. As the commenter has described above, we agree that the MAGEC® Spine’s mechanism of action is distinct from the TGR and the Shilla system. Specifically, the MAGEC® Spine’s noninvasive method of distraction is distinct from TGRs surgical distraction and the MAGEC® Spine’s active distraction is distinct from the Shilla system’s passive distraction. After considering the additional information submitted by the applicant in response to our concern, which supported the technology’s uniqueness in achieving spinal rod distraction, we agree with the applicant that the MAGEC® Spine meets the newness criterion, and we consider the technology to be “new” as of April 1, 2014.

With regard to the cost criterion, the applicant maintained that there is an insufficient number of cases in the Medicare claims data to evaluate because of the small number of potential cases and cases reflecting patients who were actually diagnosed with or who experience early onset scoliosis (EOS) requiring the implantation of growing rods. Specifically, the applicant stated that the majority of the Medicare population is 65 years of age and older, while individuals who may be eligible for the MAGEC® Spine are typically less than 10 years of age. Therefore, the applicant estimated the number of EOS cases using internal estimates for de novo cases (<10 year of age), as well as cases that could potentially convert to using the MAGEC® Spine without searching the MedPAR data file or any other data source. The applicant estimated that a total of 2,500 EOS cases may be eligible for treatment using the MAGEC® Spine in FY 2016. According to the applicant, 580 cases would map to MS–DRG 456, 870 cases would map to MS–DRG 457, and 1,050 cases would map to MS–DRG 458. The applicant based the distribution of cases on data from its medical advisors, customers, and reimbursement support team.

The applicant used Medicare and non-Medicare data for six providers that used the MAGEC® Spine during CY 2016. This resulted in an average unstandardized case-weighted charge per case of $243,999. The applicant then removed charges relative to the indicated technology. Using the Impact File published with the FY 2016 IPPS/LTCH PPS final rule, the applicant standardized the charges and applied an inflation factor of 10 percent. The applicant computed an average CCR of the six hospitals based on the overall hospitals CCRs in the FY 2016 IPPS/LTCH final rule Impact File. The applicant then computed the charges for the device by dividing the costs of the device by the average CCR and added these charges to determine the inflated average standard case-weighted charge per case. The applicant noted that the cost of the technology was proprietary information. Based on the FY 2016 IPPS/LTCH PPS Table 10 thresholds, the average case-weighted threshold amount was $105,909. The applicant computed an inflated average standardized case-weighted charge per case of $248,037. Because the inflated average standardized case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion.
In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25041), we stated that we have the following concerns regarding the applicant’s cost analysis:

- The applicant did not specify how many cases were the basis for the average standardized case-weighted charges per case. Therefore, we cannot determine if the charges per case represent a statistical sample relative to the projected cases eligible for the MAGEC® Spine for the upcoming fiscal year.

- The applicant did not explain why they did not specify how many cases were included in the analysis. We typically rely on Medicare data and understand the limitations of this patient population in the Medicare data (as the applicant explained above). However, CMS would still like the details regarding the numerical representation of Medicare and non-Medicare cases the applicant used in its analysis.

- The applicant did not explain the methodology it used to remove the charges for the predicate technology, as well as the type of technology that the charges replaced. Therefore, in the proposed rule, we stated that we were unable to validate the accuracy of the applicant’s methodology.

- The applicant did not explain the basis of using a 10-percent inflation factor. Specifically, the applicant used cases from CY 2016 and inflated the costs to FY 2017 using a 10-percent inflation factor. However, the 1-year inflation factor in the FY 2016 IPPS/LTCH final rule (80 FR 49784) is 3.7 percent. Therefore, we do not believe that a 10-percent inflation factor is appropriate.

The applicant used the average overall CCR of the six hospitals to convert the costs of the MAGEC® Spine to charges. However, rather than using an average CCR, to increase the precision of determining the charges of the MAGEC® Spine, the applicant could have instead used each hospital’s individual CCR or the implantable device CCR of 0.337 as reported in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49784). We invited public comments on whether the MAGEC® Spine meets the cost criterion, particularly with regard to the concerns we raised in the proposed rule.

Comment: In response to our concerns, the applicant reported that it had conducted a new cost analysis using the FY 2015 MedPAR data set. Specifically, the applicant searched for cases using the following ICD–9–CM diagnosis codes (737.30, 737.32, 737.34, 737.39, 737.43 or 754.2) that map to MS–DRGs 456, 457, and 458. This resulted in fewer than 11 cases in each of the applicable MS–DRGs (456, 457 and 458); therefore, the applicant suppressed the exact number of cases to protect patient privacy. The applicant stated that the total number of cases across all three MS–DRGs was between 11 and 20. This resulted in average case weighted charge per case of $329,370. The applicant then removed charges for the prior technology (traditional growth rods) and standardized the charges which resulted in a case-weighted standardized charge per case of $228,627. Using the FY 2016 IPPS Table 10 thresholds, the average case-weighted threshold amount was $170,061 (all calculations above were performed using unrounded numbers). Without inflating the charges and adding charges for the device to the standardized case-weighted charge per case, the applicant determined that the standardized case-weighted charge per case exceeds the average case-weighted threshold amount.

Because the MedPAR analysis identified only a few cases, the applicant provided additional charge data to demonstrate it would meet the cost criterion. The applicant explained that patients who receive the MAGEC® Spine technology have an average length of stay of 5 days in the hospital. To compute the average implantation procedure costs for the MAGEC® Spine, the applicant used FY 2015 MedPAR data and determined average implantation procedure costs for MS–DRGs 456, 457, and 458 of $40,932. The applicant noted that 20 percent of cases use a single rod while 80 percent of cases use a dual rod. The applicant then computed an average weighted cost of $43,949 for single and dual rod construct of the device (which includes costs for pedicle and rod screws and hooks as well as some connectors). This resulted in a subtotal of total costs of $83,981 ($40,932 + $43,049). The applicant then deducted $13,845 for the additional distraction system (MCGR) system had 57 fewer surgeries as a whole than those patients receiving treatment options using TGRs. According to the applicant, the results further projected decreased rates of infection and attendant costs because the need for additional distraction (lengthening) surgeries is eliminated. In addition, the applicant stated that 1,500 patients located around the world have been successfully treated with the use of this technology. The applicant indicated that the results from another study5 cited the following qualitative outcomes: minimal surgical scarring, decreased psychological distress and improved quality of life, improved pulmonary function tests (PFTs), and capabilities to continuously monitor neurological behaviors because the patient is not exposed to anesthesia during follow-up distractions.

We stated in the proposed rule (81 FR 25042) that we were concerned that the applicant’s assertions that the MAGEC® Spine technology leads to significantly better clinical outcomes; specifically, decreased rates of infection, when compared to treatment options that use TGRs has not been shown by the results of the studies provided. The results of the studies provided did not compare rates of infection for patients receiving treatment using the MAGEC® Spine versus patients receiving treatment using TGRs or other spinal growth rods. Also, as previously mentioned, there are

---

other currently available technologies and devices such as the Shilla growth guidance system that also achieve the same therapeutic outcome and do not require the patient to be subjected to the potential and adverse effects of additional surgery. Therefore, we stated that we were concerned that the MAGEC® Spine may not represent a substantial clinical improvement over existing technologies. We also invited public comments on whether the MAGEC® Spine meets the substantial clinical improvement criterion.

Comment: The applicant submitted public comments that responded to our concerns presented in the proposed rule with regard to substantial clinical improvement. The applicant provided studies which showed frequency of spinal lengthening improves thoracic-sacral spinal growth. The applicant also provided studies which showed improved spinal curve correction, increased spinal height, and decreased complications with the MAGEC® Spine when compared to traditional growth rods.

The applicant maintained that treatment goals for Early Onset Scoliosis (EOS) are not limited to controlling curvature and increasing height, but also include the avoidance of surgical and nonsurgical complications. Specifically, these additional goals include minimizing complications, procedures, hospitalizations, and family burden. The applicant asserted that the use of the MAGEC® Spine system achieves curve correction, increases patient height, results in fewer surgeries/hospitalizations (as compared to TGRs) which leads to fewer complications and better outcomes in a fragile and vulnerable patient population through reduced exposure to anesthesia, reduced exposure to radiation, reduced negative psychosocial outcomes, reduced infections risk due to fewer surgeries, and improved lung development and weight gain.

Several commenters indicated improvements in clinical outcomes and decreased morbidity in this patient population. Other commenters who were parents with children who have converted to the MAGEC® rods from traditional growth rods and body casts considered the MAGEC® rods the best option to eliminate pain and hospitalization. Several other commenters supported approval of new technology add-on payment for the MAGEC® Spine System.

Response: We appreciate the commenters’ support and comments addressing our concerns. We agree that the MAGEC® Spine represents a substantial clinical improvement over existing technologies because it avoids surgical complications. Specifically, the MAGEC® Spine rods can be nonsurgically lengthened, eliminating the need for subsequent surgical intervention for revision.

After consideration of the public comments we received, we have determined that the MAGEC® Spinal Bracing Distraction system meets all of the criteria for approval of new technology add-on payments for FY 2017. Cases involving the MAGEC® Spinal Bracing Distraction system that are eligible for new technology add-on payments will be identified by the ICD–10–PCS procedure codes XNS0032, XNS0432, XNS3032, XNS3432, XNS4032, and XNS4432. With the new technology add-on payment application, the applicant stated that the total operating cost of the MAGEC® Spine is $17,500 for a single rod and $35,000 for a dual rod. It is historical practice for CMS to make the new technology add-on payment based on the average cost of the technology and not the maximum. Therefore, we determined that the MAGEC® Spine is $31,500 ((0.2 * $17,500) + (0.8 * $35,000)). We note that the costs for pedicle and rod screws and hooks as well as some connectors are not unique to the MAGEC® Spine as these components are generic to TGR.

Therefore, they are not considered new and are not included in the costs above. Under $412.88(a)(2), new technology add-on payments are limited to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–DRG payment for the case, whichever is the maximum new technology add-on payment for a case involving the use of the MAGEC® Spinal Bracing Distraction system is $15,750 for FY 2017.

b. MIRODERM Biologic Wound Matrix (MIRODERM)

Miromatrix Medical, Inc. submitted an application for an new technology add-on payments for FY 2017 for MIRODERM. MIRODERM is a non-crosslinked acellular wound matrix that is derived from the porcine liver and is processed and stored in a phosphate buffered aqueous solution. MIRODERM is clinically indicated for the management of wounds, including: Partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds, drainage wounds, and surgical wounds. Typical decellularization where tissues are immersed in a decellularization solution is a diffusion-based process, and thereby limits the ability to fully decellularize thick, complex tissues such as the liver.

MIRODERM uses a perfusion decellularization process that rapidly removes cellular material while maintaining the native architecture, vasculature and tissue structure. Following decellularization, MIRODERM is isolated from partial thickness liver sections following slight compression of the liver. This allows for the retention of the native liver structure, including the vasculature, within MIRODERM. The applicant noted that the MIRODERM is the only acellular skin substitute product that is derived from the liver.

MIRODERM is recommended to completely contact the entire surface of the wound bed and extend slightly beyond all wound margins. As required, it is securely anchored to the wound site with a physician’s preferred fixation method. An appropriate, primary non-adherent wound dressing is then applied over the MIRODERM matrix. A secondary dressing (multi-layer compression bandage system), total contact cast, or other appropriate dressing that will manage the wound exudate should be applied in order to keep the MIRODERM matrix moist and keep all layers securely in place.

Additional applications of MIRODERM are applied as needed until the wound closes.

MIRODERM received FDA clearance for its use on January 27, 2015. The applicant submitted a request for an unique ICD–10–PCS procedure code and was granted approval for the following code: XLRPXL2 (Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2). The new
code is effective on October 1, 2016 (FY 2017).

Comment: One commenter asserted that an unique ICD–10–PCS procedure code for procedures involving the use of the MIRODERM is not necessary because the use of this product should coincide with the same coding used for all cellular and/or tissue-based products (CTPs).

Response: As noted above, an unique ICD–10–PCS procedure code was created for procedures involving the use of the MIRODERM in Section “X” of the ICD–10–PCS codes. As discussed in the FY 2016 IPPS/LTCH final rule (80 FR 49434), Section “X” of the ICD–10–PCS was created to identify and describe new technologies and medical services for purposes of new technology, or that capture other new technologies that are not currently classified within the ICD–10–PCS. The Section “X” codes identify new medical services and technologies that are not usually captured by coders, or do not usually have the desired specificity current ICD–10–PCS structure required to capture the use of these new services and technologies. We believe that the issuance of a unique ICD–10–PCS procedure code in Section “X” of the ICD–10–PCS for procedures involving the use of the MIRODERM is an example of why we created Section “X.”

As discussed earlier, if a technology meets all three of the substantial similarity criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

With regard to the first criterion, whether the product uses the same or a similar mechanism of action to achieve a therapeutic outcome, the applicant stated in its application that current wound healing therapies are provided in several different modalities, which include hyperbaric oxygen treatment, negative wound pressure therapy, and treatment with other bioengineered skin substitute products. The applicant noted that other products that have been commonly used for similar procedures are Oasis Wound Matrix, Primatrix Dermal Repair, and Theraskin. The applicant asserted that MIRODERM is different from these other products because it is the only product sourced from porcine liver and undergoes a unique, patented process of perfusion decellularization that rapidly removes cellular material, while maintaining the native architecture, vasculature and tissue structure. The applicant stated that MIRODERM is isolated from partial thickness liver sections following slight compression of the liver, which allows for the retention of the native liver structure, including the vasculature, within MIRODERM. The applicant stated that partial thickness allows for one surface of MIRODERM to retain the native liver capsule (an epithelial basement membrane) and the other opposite surface to be comprised of open liver matrix. The applicant further stated that case studies of the MIRODERM demonstrated accelerated healing, which is likely the result of the unique perfusion decellularization technology that retains a 3-dimensional extracellular matrix that includes the vasculature.

With regard to the first criterion, similar to other current wound matrix treatments, the MIRODERM uses a collagen matrix for tissue repair and regeneration. Therefore, we stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25042) that we were concerned that MIRODERM employs the same mechanism of action as other wound matrix treatments. Although the applicant had described how the MIRODERM differs from other wound matrix treatments due to the perfusion decellularization process, and is the first product that is derived from the porcine liver, we stated that we believe that the mechanism of action of MIRODERM may be substantially similar to the same as those employed by other wound treatment matrixes.

With regard to the second criterion, whether a product is assigned to the same or a different MS–DRGs, cases that may be eligible for treatment using MIRODERM map to the same MS–DRGs as other currently approved or cleared wound treatment matrixes. With regard to the third criterion, whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population, MIRODERM is used to treat the same patient population as other currently approved or cleared wound treatment matrixes. Because it appeared that the MIRODERM may be substantially similar to currently approved or cleared wound treatment matrixes, we stated that we were concerned the technology may not be considered “new” for the purposes of new technology add-on payments. We also invited public comments on whether MIRODERM meets the newness criterion in the proposed rule.

Comment: The applicant commented that, by definition, the native tissue reaction to liver tissue compressed into a biologic mesh will be different than other highly processed tissue sources. According to the applicant, the “gentleness” of the unique and patent-protected perfusion decellularization process results in a fully intact decellularized liver matrix, complete with a mix of proteins not contained in matrices decellularized by other means. The applicant further stated that the remaining large vascular structures in the perfusion decellularized liver matrix provide an entirely new and enhanced conduit for revascularization and remodeling.

The applicant noted that MIRODERM is the only wound matrix derived from the porcine liver utilizing perfusion decellularization technology, which has been highly published by numerous leading academic institutions for its ability to decellularize the whole liver while retaining the native architecture and vasculature. The applicant stated that preclinical studies have demonstrated the importance of the preexisting vasculature in cellular migration into the matrix and subsequent revascularization. The vascular density within liver tissue far exceeds that of other tissues that are used to derive acellular skin substitutes including dermis, urinary bladder, pericardial sac and small intestine submucosa. For these reasons, the applicant believed that MIRODERM is unique compared to other currently approved wound treatment matrixes.

One commenter stated that MIRODERM is substantially similar to existing wound matrix treatments because it supplies the wound bed an extracellular matrix (ECM). According to the commenter, treatments using an acellular matrix closely resemble native ECM. The commenter explained the following with regard to wound matrix treatments: While the ECM may act as a scaffold for matrix metalloproteinase (MMPs) to bind to and break down collagen in the product, epithelial cells, fibroblasts and vascular endothelial cells will migrate into the wound and proliferate; having reduced levels of MMPs to be released back into the wound as the collagen matrix breaks down, the ECM rebalances the protease and growth factor levels in the wound, thus allowing wound to heal.

The commenter stated that the source of skin wound matrix treatments is collagen and the only difference between MIRODERM and other wound matrix treatments is the source of the ECM. The commenter noted that recent skin wound matrix products such as Kerecis, an intact fish skin that is rich in naturally occurring Omega3 polyunsaturated fatty acids and is used to regenerate damaged human tissue, have both approved in the treatment of chronic wounds. According to the commenter, when grafted onto
damaged human tissue, such as a diabetic ulcer, the acellular material recruits the body’s cells from the wound perimeter and these cells are then ultimately converted into functional, living tissue. The commenter explained that fish skin structure resembles the native structure of human skin and studies have shown that cells and stem cells proliferate faster in this structure than in other materials such as amnion-membrane and other mammalian-sourced materials.

Response: After consideration of the public comments we received, we believe that MIRODERM’s mechanism of action is similar to other acellular skin substitutes currently available for wound healing. We note that MIRODERM provides a scaffold of collagen with a mix of matrix proteins, both of which are similar to other acellular skin substitutes. Therefore, although the applicant asserted that MIRODERM’s matrix proteins are different from the proteins found in other acellular skin substitutes, the mechanism of wound healing carried out by the body in the presence of the acellular substitutes is the same. We note that the applicant also indicated that the remaining large vascular structures in the perfusion decellularized liver matrix provide an entirely new and enhanced conduit for revascularization and remodeling. However, the applicant did not provide any data illustrating that MIRODERM’s acellular porcine liver skin substitute is a conduit for revascularization and remodeling. Therefore, we are unable to verify the applicant’s assertion.

We believe that the MIRODERM is substantially similar to currently approved or cleared wound treatment matrixes because it meets all three of the criteria identified above and, therefore, does not meet the newness criterion. Therefore, because the MIRODERM is not considered “new,” it is not eligible for new technology add-on payments for FY 2017.

With regard to the cost criterion, the applicant conducted the following analysis. The applicant began by researching the 2014 Medicare Inpatient Hospital Standard Analytical File (SAF) file for cases primarily associated with dermal regenerative grafts that may be eligible for treatment using MIRODERM. The applicant searched for claims that reported ICD–9–CM procedure code 86.67 (Dermal regenerative graft) that mapped to one of the following MS–DRGs: 463, 464, and 465 (Wound Debridement and Skin Graft Except Hand for Musculoskeletal System and Connective Tissue Disorders with MCC, with CC, or without CC/MCC, respectively); 573, 574, and 575 (Skin Graft for Skin Ulcer or Cellulitis with MCC, with CC, or without CC/MCC, respectively); 576, 577, and 578 (Skin Graft Except for Skin Ulcer or Cellulitis with MCC, with CC, or without CC/MCC, respectively); 622, 623, and 624 (Skin Grafts and Wound Debridement for Endocrine, Nutritional and Metabolic Diseases with MCC, with CC or without CC/MCC, respectively); and 904 and 905 (Skin Grafts for Injuries with CC/MCC or without CC/MCC, respectively). As a result, the applicant identified 1,130 cases across the MS–DRGs listed, which resulted in an average case-weighted charge per case of $83,059.

Included in the average case-weighted charge per case were charges for other previously used dermal regenerative grafts. According to the applicant, the MIRODERM would replace the need for other dermal regenerative grafts and, therefore, the applicant removed charges related to the use of other currently used dermal regenerative grafts from the average case-weighted charge per case. Specifically, using the February 2016 CMS Part B Drug Pricing File, the applicant first computed an average cost per square centimeter for currently used dermal regenerative grafts (Apigraft $31.207/cm², Oasis $10.676/cm², Integra DRT $21.585/cm², Dermagraft $32.858/cm², Integra skin substitute $35.627/cm², Primatrix $37.590/cm², and Theraskin $38.474/cm²), which equaled $29.72/cm². To determine the average amount of square centimeters of the other dermal regenerative grafts used for each case within the MS–DRG, given the vast complexity and variation in wounds, the applicant used clinical judgment based on experience, observation and typical sizes and depths of wounds that would present on different parts of the body. For an example, wounds on the hand would typically be smaller than those located on the lower extremities. The applicant also assumed that other dermal regenerative grafts would require three applications to close a wound as opposed to treatment using MIRODERM, which requires only two applications. Based on this assumption, the applicant noted that it assumed that the first application required 100 percent of the amount of skin substitute required to treat the original wound area, the second application required 70 percent, and the third application required 40 percent, totaling 210 percent. To compute the total amount of square centimeters used for each case within the MS–DRG, the applicant multiplied this percentage (210 percent) by the amount of square centimeters used for the first application for each case within the MS–DRG. The applicant then multiplied the average cost of the other previously used dermal regenerative grafts ($29.72/cm²) by the average amount of centimeters used for each case within the MS–DRG to determine the average cost of the other previously used dermal regenerative grafts for each case within the MS–DRG. To convert the costs to charges, the applicant computed an average CCR for each MS–DRG using CCRs from the FY 2014 Standardizing File of the hospitals indicated on each of the claims for each case within the MS–DRG. The applicant then divided the average cost of the other previously used dermal regenerative grafts for each MS–DRG by the average CCR for each MS–DRG to determine the average charges of the other previously used dermal regenerative grafts for each MS–DRG.

The applicant also reduced the charges for the number of days of hospitalization by 30 percent because the applicant believed that MIRODERM heals patients faster than the other currently used dermal regenerative grafts, resulting in a reduction in the average lengths of stay. The applicant then deducted the charges related to the other previously used dermal regenerative grafts and the charges for the reduction in the average lengths of stay from the average case-weighted charge per case and then standardized the charges, which resulted in an average standardized case-weighted charge per case of $34,279. The applicant then inflated the average standardized case-weighted charge per case by 7.7 percent, the same inflation factor used by CMS to update the FY 2016 outlier threshold (80 FR 49784).

After inflating the charges, it was necessary to add the associated charges for the use of MIRODERM. The applicant conducted a similar calculation to compute the charges for MIRODERM. Specifically, the applicant used clinical judgment based on experience, observation, and typical sizes and depths of wounds that would be present on different parts of the body. The applicant stated that because MIRODERM has shown greater efficacy in wound closure based on their case series, the applicant modeled for only two applications with 50 percent closure of the wound after the first application and full closure of the wound after the second application. Based on this assumption, the applicant noted that it assumed that the first application required 100 percent of the
amount of skin substitute required to treat the original wound area and the second application required 50 percent, totaling 150 percent. To compute the total amount of square centimeters used for each MS–DRG, the applicant multiplied this percentage (150 percent) by the amount of square centimeters used for the first application for each MS–DRG. The applicant then multiplied the cost per square centimeter for MIRODERM by the average amount of centimeters used for each case within the MS–DRG to determine the average cost of MIRODERM grafts used for each MS–DRG. Similar to above, to convert the costs to charges, the applicant used the same average CCRs for each MS–DRG and divided the average cost of MIRODERM for each MS–DRG by the average CCR for each MS–DRG to determine the average charges of MIRODERM for each MS–DRG. The applicant then added charges related to the use of MIRODERM to the inflated average standardized charges and determined a final inflated average standardized case-weighted charge per case of $94,409. Using these FY 2016 IPS Table 10 thresholds, the average case-weighted threshold amount was $67,559 (all calculations above were performed using unrounded numbers). Because the final inflated average standardized case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion.

We invited public comments on whether the MIRODERM technology meets the cost criterion in the proposed rule.

Comment: One commenter stated that the evaluation of the cost criterion using the average standardized case-weighted threshold amount to determine cost savings is not unique to the MIRODERM.

Response: We are not certain what the commenter is referring to with regard to the evaluation of the cost criterion for this technology because the criterion measures and determines whether a new technology is inadequately paid, but does not measure or determine cost savings. Based on the applicant’s analysis, it appears that the MIRODERM meets the cost criterion. However, because we believe that the MIRODERM is substantially similar to other wound treatment matrices for the reasons discussed earlier and, therefore, does not meet the newness criterion, it is not eligible for new technology add-on payments.

With regard to substantial clinical improvement, the applicant believed that the technology represents a substantial clinical improvement over existing technologies because patients treated with the MIRODERM for complicated wounds heal quicker and avoid additional surgeries. To demonstrate that the technology meets the substantial clinical improvement criterion, the applicant submitted the results of two actual case studies of a complicated wound from necrotizing fasciitis that was treated with the MIRODERM. According to the applicant, one case study involved a complicated wound that would typically be treated with a diverting colostomy. The applicant noted that the patient was discharged with intact anoplasty and good sphincter control after 35 days and four applications for MIRODERM. The applicant further stated that the use of MIRODERM demonstrated rapid healing and likely avoided at least two major debilitating surgeries, as well as the emotional and physical impact of a colostomy for 3 to 6 months. In the second case study, according to the applicant, the attending physician estimated the wound would likely take greater than 90 days to close using traditional wound care matrixes. The applicant stated that after 12 days and two applications of MIRODERM the patient was discharged and after 21 days the wound was sutured closed.

The applicant noted that additional patients have been treated with MIRODERM. According to the applicant, given the recent product launch, the case studies have not been completed, but similar results have been communicated to the applicant.

We stated in the proposed rule (81 FR 25044) that we were concerned that the clinical data the applicant submitted is from a very small sample with no comparisons to other currently approved wound treatment matrices. Specifically, the applicant submitted data from only two case studies. Also, the applicant compared the use of MIRODERM to the use of other treatments, such as diverting colostomy. While MIRODERM may represent an improvement in treatment options compared to the other treatment options such as diverting colostomy, we stated that we were unable to determine if use of MIRODERM represents a substantial clinical improvement when compared to other wound treatment matrices of other currently approved treatments. We invited public comments on whether MIRODERM meets the substantial clinical improvement criterion in the proposed rule.

Comment: The applicant submitted additional clinical data, including a case series of additional cases that were selected to receive MIRODERM as a treatment for diabetic foot ulcers (DFU). The commenter noted the following: the duration of the preexisting chronic wound prior to MIRODERM treatment ranged from 5 to 48 months and 3 of the 6 patients in the evaluation healed after treatment with MIRODERM within the 12-week study duration. The applicant stated that the results obtained by case series demonstrated a 50-percent closure rate of hard to heal DFUs that had previously failed advanced biologic wound care treatment.

The commenter also submitted one additional case study that had been submitted for presentation at a national wound conference. The patient was a 54-year-old male that sustained a myocardial infarction in November 2015. This necessitated a coronary artery bypass graft surgical procedure. A major postoperative complication of the CABG procedure was bilateral pulmonary embolism with respiratory failure. The patient also developed bilateral lower extremity deep venous thrombosis and initiated Heparin therapy. This triggered a Heparin-induced thrombocytopenia resulting in bilateral forefoot gangrene and bilateral lower extremity compartment syndrome.

The commenter noted the following: The patient underwent an open transmetatarsal (TMA) of the left forefoot and extensive skin and deep tissue of the plantar foot extending to the distal heel; the wound remained open due to a lack of appropriate plantar soft tissue coverage with exposed muscle and bone; local wound care consisted of negative pressure wound therapy (NPWT) initially which was discontinued due to severe pain; enzymatic debridement with local wound care continued until the initial application of a perfusion decellularized porcine hepatic wound matrix. The patient was healed to a functional outcome.

The commenter further stated that, with regard to perfusion decellularization technology, the MIRODERM encompasses a method to decellularize and recellularize whole or partial organs and tissues. The commenter explained that the technology is based on a proprietary method for removing all cells, while maintaining a non-cellular (called extracellular) matrix or scaffold with its original architecture, mechanical properties, and a vascular network capable of maintaining physiological pressures. The commenter noted that the most widely recognized method of preserving tissue is “immersion decellularization,” in which an organ is soaked in a vat of
harsh detergent, which migrates from the outer surface inward and then back out once the cells are dissolved. The commenter stated that this method damages the organ capsule through mechanical or enzymatic methods, and the cells within the organ begin to break down before being exposed to the detergent, releasing various enzymes that also degrade the surrounding scaffold with the end result a partially degraded scaffold with a compromised vascular network and an outer organ capsule that will not maintain physiological pressures when tested. The commenter further stated that cells will no longer recognize this degraded scaffold as the appropriate environment in which to become functional.

The commenter added that perfusion decellularization technology is in contrast to immersion decellularization and overcomes the hurdles of immersion by facilitating rapid access to the whole organ through the native vasculature by cannulating the vasculature and perfusing (running) a mild detergent solution through the native blood vessels, as opposed to immersing the organ. The commenter stated that scaffolds created with this technology are capable of receiving and incorporating a variety of cell types, depending on the organ scaffold utilized. Moreover, the commenter believed that as cell type discovery continues to grow, the fact that scaffolds created with this technology are of a natural biological design make them an ideal template to support the growth and differentiation of stem cells into functional tissues, organs and bioidentical test beds.

One commenter stated that there are other CTPs with substantiated evidence of a randomized clinical trial that also demonstrate healing in one or two applications (GraftJacket and DermACELL). Additionally, the commenter stated there has been no published randomized clinical trial regarding the use of the MIRODERM in the treatment of chronic wound applications. The commenter concluded that citing two case studies, one involving a diverting colostomy, is not sufficient evidence.

Response: We appreciate the commenters’ input. However, because we believe that the MIRODERM is substantially similar to other wound treatment matrices for the reasons discussed earlier and, therefore, does not meet the newness criterion, it is not eligible for new technology add-on payments.

c. Idarucizumab

Boehringer Ingelheim Pharmaceuticals, Inc. submitted an application for new technology add-on payments for FY 2017 for Idarucizumab; a product developed as an antidote to reverse the effects of PRADAXA® (Dabigatran), which is also manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. (We note that the applicant submitted an application for new technology add-on payments for FY 2016, but failed to obtain FDA approval prior to the July 1 deadline.) Dabigatran is an oral direct thrombin inhibitor currently indicated to: (1) Reduce the risk of stroke and systemic embolism in patients who have been diagnosed with nonvalvular atrial fibrillation (NVAF); (2) treat deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been administered a parenteral anticoagulant for 5 to 10 days; and (3) reduce the risk of recurrence of DVT and PE in patients who have been previously diagnosed with NVAF. Currently, unlike the anticoagulant Warfarin, there is no specific way to reverse the anticoagulant effect of Dabigatran in the event of a major bleeding episode.

Idarucizumab is a humanized fragment antigen binding (Fab) molecule, which specifically binds to Dabigatran to deactivate the anticoagulant effect, thereby allowing thrombin to act in blood clot formation. The applicant stated that Idarucizumab represents a new pharmacologic approach to neutralizing the specific anticoagulant effect of Dabigatran in emergency situations. Idarucizumab was approved by the FDA on October 16, 2015. The applicant noted that Idarucizumab is the only FDA-approved therapy available to neutralize the anticoagulant effect of Dabigatran. Before the FDA approval of Idarucizumab, the approach for the management of the anticoagulant effect of Dabigatran prior to an invasive procedure was to withhold administration of Dabigatran, when possible, for a certain duration of time prior to the procedure to allow sufficient time for the patient’s kidneys to flush out the medication. The duration of time needed to flush out the medication prior to the surgical procedure is based on the patient’s kidney function. According to the applicant, if surgery cannot be delayed to allow the kidneys the necessary time to flush out the traces of Dabigatran, there is an increased risk of bleeding. Based on the FDA indication for Idarucizumab, the product can be used in the treatment of patients who have been diagnosed with NVAF and administered Dabigatran to reverse life-threatening bleeding events, or who require emergency surgery or medical procedures and rapid reversal of the anticoagulant effects of Dabigatran is necessary and desired. The applicant received a unique ICD–10–PCS procedure code that became effective October 1, 2015. The approved procedure code is XW03331 (Introduction of Idarucizumab, Dabigatran reversal agent into central vein, percutaneous approach, New Technology Group 1). We invited public comments on whether Idarucizumab meets the newness criterion in the proposed rule.

Comment: Several commenters stated that there is currently no other reversal agent on the U.S. market for patients who are being treated with Dabigatran and experience severe bleeding. The applicant submitted public comments reiterating its assertion that Idarucizumab satisfies the newness criterion. The applicant emphasized that Idarucizumab was developed as a specific reversal agent to Dabigatran, an anticoagulant that works by directly inhibiting thrombin, thereby blocking the final step of the coagulation cascade. The applicant further defined the potential adverse effects of anticoagulant therapy and the increased risk of bleeding that may be life-threatening or fatal which may require emergent medical and surgical procedures and the need for rapid reversal of an anticoagulation to perform the procedure in a timely manner. The applicant reiterated that Idarucizumab was developed as a specific reversal agent to Dabigatran, and that Idarucizumab was granted FDA approval on October 16, 2015.

Response: We appreciate the details and input provided by the commenters and the applicant on whether Idarucizumab meets the newness criterion. After review of the information provided by the applicant and consideration of the public comments we received, we believe that Idarucizumab meets the newness criterion and we consider the technology to be “new” as of October 16, 2015, when the technology received FDA approval.

With regard to the cost criterion, in the proposed rule, we noted that the applicant conducted two analyses. The applicant began by researching claims data in the FY 2014 MedPAR file for cases that may be eligible for Idarucizumab using a combination of ICD–9–CM diagnoses and procedure codes. Specifically, the applicant searched the database for cases.
reporting anticoagulant therapy
diagnosis code E934.2 (Agents primarily
affecting blood constituents,
anticoagulants) or V58.61 (Long-term
(current) use of anticoagulants) in
combination with either current
standard of care procedure code 90.03
(Other transfusion of whole blood),
99.04 (Transfusion of packed cells),
99.05 (Transfusion of platelets), 99.06
(Transfusion of coagulation factors),
99.07 (Transfusion of other serum), or
39.95 (Hemodialysis), and Dabigatran
indication diagnosis code 427.31 (Atrial
fibrillation), 453.40 (Acute venous
embolism and thrombosis of
unspecified deep vessels of lower
extremity), 453.41 (Acute venous
embolism and thrombosis of deep
vessels of proximal lower extremity),
453.42 (Acute venous embolism and
thrombosis of deep vessels of distal
lower extremity), 453.50 (Chronic
venous embolism and thrombosis of
unspecified deep vessels of lower
extremity), 453.51 (Chronic venous
embolism and thrombosis of deep
vessels of proximal lower extremity),
453.52 (Chronic venous embolism and
thrombosis of deep vessels of distal
lower extremity), 415.11 (Iatrogenic
pulmonary embolism and infarction).
415.12 (Septic pulmonary embolism),
415.13 (Saddle embolus of pulmonary
artery), 415.19 (Other pulmonary
embolism and infarction), 416.2
(Chronic pulmonary embolism), V12.51
(Personal history of venous thrombosis
and embolism), or V12.55 (Personal
history of pulmonary embolism).

To further target potential cases that
may be eligible for Idarucizumab, the
applicant also excluded specific cases
based on Dabigatran contraindications,
including all cases representing patients
who have been diagnosed with chronic
kidney disease (CKD) stage V (diagnosis
code 585.5), end-stage renal disease
(diagnosis code 585.6), prosthetic heart
valves (diagnosis code V43.3), and cases
representing patients who have been
diagnosed with both CKD stage IV
diagnosis code 585.4) and either DVT
or PE (using the same ICD-9-CM
diagnoses listed above). As a
result, the applicant identified 84,224
cases that mapped to 684 MS–DRGs.
The applicant standardized the charges
and computed an average standardized
case-weighted charge per case of
$60,089.

The applicant then identified hospital
charges potentially associated with the
current treatments to reverse
anticoagulation, specifically charges
associated with pharmacy services,
dialysis services, and laboratory services
for blood work. Due to limitations
associated with the claims data, the
applicant was unable to determine the
specific drugs used to reverse
anticoagulation and if these cases
represented patients who required
laboratory services for blood work or
dialysis services unrelated to the
reversal of anticoagulation. Therefore,
the applicant subtracted 40 percent of
the charges related to these three
categories from the standardized charge
per case, based on the estimation that
the full amount of charges associated
with these services would not be
incurred by hospitals when
Idarucizumab is administered for use in
the treatment of patients who have been
diagnosed with NVAF and Dabigatran is
administered during treatment. The
applicant then inflated the standardized
charge per case by 7.665 percent, the
same inflation factor used by CMS to
update the FY 2016 outlier threshold
(80 FR 49784) and added charges for
Idarucizumab. This resulted in an
inflated average standardized case-
weighted charge per case of $67,617.
Using the FY 2016 IPPS Table 10
thresholds, the average case-weighted
threshold amount across all 684 MS–
DRGs is $55,586 (all calculations above
were performed using unrounded
numbers). Because the inflated average
standardized case-weighted charge per
case exceeds the average case-weighted
threshold amount, the applicant
maintained that the technology meets
the cost criterion under this analysis.

Further, the applicant conducted an
additional analysis using the same data
from the FY 2014 ModPAR file and
variables used in the previous analysis.
However, instead of using potentially
eligible cases that mapped to 100
percent of the 684 MS–DRGs identified,
the applicant used potentially eligible
cases that mapped to the top 75 percent
of the 684 MS–DRGs identified. By
applying this limitation, the applicant
identified 63,033 cases that mapped to
87 MS–DRGs. The applicant computed
an inflated average standardized case-
weighted charge per case of $55,872.
Using the FY 2016 IPPS Table 10
thresholds, the average case-weighted
threshold amount across all 87 MS–
DRGs is $63,323 (all calculations above
were performed using unrounded
numbers). Because the inflated average
standardized case-weighted charge per
case exceeds the average case-weighted
threshold amount, the applicant
maintained that the technology meets
the cost criterion.

With regard to substantial clinical
improvement, according to the
applicant, aside from Idarucizumab,
there are no other FDA-approved
antidotes to reverse the anticoagulant
effects of Dabigatran. Management of
the treatment of patients who have been
diagnosed with NVAF and administered
Dabigatran and experience bleeding may
often include supportive care such as
Hemodialysis and the use of fresh
frozen plasma, blood factor products
such as prothrombin complex
concentrates (PCC), activated
prothrombin complex concentrates,
and recombinant factor VIIa or delayed
intervention. Protamine sulfate and
Vitamin K are typically used to reverse
the effects of Heparin and Warfarin,
respectively. However, due to the
mechanism of action in Dabigatran, the
applicant maintained that the use of
protamine sulfate and Vitamin K may
not be effective to reverse the
anticoagulant effect of Dabigatran.

The applicant provided information
regarding the management of major
bleeding events experienced by patients
who were administered Dabigatran and
Warfarin during the RE–LY trial.9

9 Healy, et al.: Periprocedural bleeding and
thromboembolic events with dabigatran compared
with Warfarin: results from the randomized
evaluation of long-term anticoagulation therapy
During this study, most major bleeding events were only managed by supportive care. Patients who were administered 150 mg of Dabigatran were transfused with pack red blood cells more often when compared to patients who were administered Warfarin (61.4 percent versus 49.9 percent, respectively). However, patients who were administered Warfarin were transfused with plasma more often when compared to patients who were administered 150 mg of Dabigatran (30.2 percent versus 21.6 percent, respectively). In addition, the use of Vitamin K in the treatment of patients who were administered Warfarin was more frequent when compared to the frequency of use in the treatment of patients who were administered 150 mg of Dabigatran (27.3 percent versus 10.3 percent, respectively). The use of PCCs, recombinant factor VIIa and other coagulation factor replacements in the treatment of patients who were administered both Warfarin and 150 mg of Dabigatran was minimal, and did not significantly differ in frequency when compared among patients assigned to either group. Hemodialysis was used in a single case.

The applicant reported that, currently, it is recommended that the administration of Dabigatran be discontinued 1 to 2 days (CrCl ≥ 50 ml/min) or 3 to 5 days (CrCl < 50 ml/min), if possible, before invasive or surgical procedures because of the increased risk of bleeding. A longer period of discontinuation time should be considered for patients undergoing major surgery, spinal puncture, or placement of a spinal or epidural catheter or port, if complete hemonistasis is required. The applicant stated that delaying emergency medical or surgical procedures can cause urgent conditions to become more severe if intervention is not initiated. The applicant further maintained that delaying emergency medical or surgical procedures for an extended period of time can ultimately lead to negative healthcare outcomes and increased healthcare costs. The applicant asserted that rapidly reversing the anticoagulant effect of Dabigatran administered to patients that require an urgent medical procedure or surgery allows the medical procedure or surgery to be performed in a timely manner, which in turn may decrease complications and minimize the need for more costly therapies.

The applicant also provided interim data from an ongoing Phase III trial in patients who may have life-threatening bleeding, or require emergency procedures. The applicant noted that published results of the interim data based on 90 patients suggested the following: Reversal of the Dabigatran anticoagulant effect, which was evident immediately after administration; reversal was 100 percent in the first 4 hours and greater than 89 percent of patients achieved complete reversal; hemostasis in 35 patients in Group A was ≥ 8 grams. In median of 11.4 hours. Also, the 5 gram dose of Idarucizumab was calculated to reverse the total body load of Dabigatran that was associated with the 99th percentile of the Dabigatran levels measured in the RE–LY trial. The applicant provided safety data from three Phase I studies and interim data from the Phase III study. In the Phase I study, 110 healthy male patients enrolled in the study were administered dosages of Idarucizumab that ranged from 20 mg to 8 grams. In this study, 135 patients received placebo. The applicant reported that adverse events were generally mild in intensity and nonspecific. Healthy human volunteers enrolled in the Phase I study were administered Idarucizumab in dosages of 2 and 4 grams, which resulted in immediate and complete reversal of the anticoagulant effect of Dabigatran that was sustained for several hours. In the Phase III study, five thrombotic events occurred. One occurred 2 days after treatment and the remainder occurred 7, 9, 13, and 26 days after treatment. These patients were not receiving antithrombotic therapy when the events occurred, and complications or adverse events can be attributed to patients’ underlying medical conditions. Twenty-one patients (13 in Group A and 8 in Group B) had a serious adverse event. The most frequently reported adverse reactions in greater than or equal to 5 percent of the patients treated with Idarucizumab were hypokalemia, delirium, constipation, pyrexia, and neutropenia. The applicant noted that the data from these studies demonstrated that Idarucizumab effectively, safely, and potently reverses the anticoagulant effect of Dabigatran. We invited public comments on whether Idarucizumab meets the substantial clinical improvement criterion in the proposed rule.

Comment: Several commenters supported the substantial clinical improvement criterion for Idarucizumab. Several commenters stated that, aside from Idarucizumab, the only alternative for anticoagulation reversal in patients being treated with Dabigatran is withholding the drug and observing the patient for bleeding. The commenters noted that this approach is not ideal in the case of severe bleeding when rapid reversal is needed for emergent surgical procedures. The applicant also reiterated its assertion that Idarucizumab satisfies the clinical improvement criterion, citing that prior to the approval of Idarucizumab, patients treated with Dabigatran who experienced severe bleeding were often managed by supportive care alone, such as fluid administration and blood transfusions. The applicant stated that Idarucizumab has been shown to reverse the anticoagulant effect of Dabigatran immediately in patients needing rapid reversal of anticoagulation in emergency situations.

Response: We appreciate the comments supporting the substantial clinical improvement criterion for Idarucizumab. We agree that Idarucizumab meets the substantial clinical improvement criterion.

After consideration of the public comments we received, we have determined that Idarucizumab meets all of the criteria for approval of new technology add-on payments. Therefore, we are approving new technology add-on payments for Idarucizumab for FY 2017. Cases involving Idarucizumab that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure code WX03331.

In its application, the applicant estimated that the average Medicare beneficiary would require a dosage of 5 grams for Idarucizumab. According to the applicant, the wholesale acquisition cost for one dose is $3,500. Under 42 CFR 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the cost in excess of the Medicare payment for the case. As a result, the maximum new technology add-on payment amount for a case involving the use of Idarucizumab is $1,750 for FY 2017.

d. Titan Spine (Titan Spine Endoskeleton® nanoLOCK™ Interbody Device)

Titan Spine submitted an application for new technology add-on payments for the Titan Spine Endoskeleton® nanoLOCK™ Interbody Device (the Titan Spine nanoLOCK™) for FY 2017. The Titan Spine nanoLOCK™ is a
nanotechnology-based interbody medical device with a dual acid-etched titanium interbody system used to treat patients diagnosed with degenerative disc disease (DDD). One of the key distinguishing features of the device is the surface manufacturing technique and materials, which produce macro, micro, and nano surface textures. According to the applicant, the combination of surface topographies enables initial implant fixation, mimics an osteoclastic pit for bone growth, and produces the nano-scale features that interface with the integrins on the outside of the cellular membrane. Further, the applicant noted that these features generate better osteogenic and angiogenic responses that enhance bone growth, fusion, and stability. The applicant asserted that the Titan Spine nanoLOCK™’s clinical features also reduce pain, improve recovery time, and produce lower rates of device complications such as debris and inflammation.

On October 27, 2014, the Titan Spine nanoLOCK™ received FDA clearance for the use of five lumbar interbody devices and one cervical interbody device: The nanoLOCK™ TA-Sterile Packaged Lumbar ALIF Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy; the nanoLOCK™ TAS-Sterile Packaged Lumbar ALIF Stand Alone Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy; the nanoLOCK™ TL-Sterile Packaged Lumbar Lateral Approach Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy; the nanoLOCK™ TO-Sterile Packaged Lumbar Oblique/PLIF Approach Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy; the nanoLOCK™ TT-Sterile Packaged Lumbar TLIF Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy and the nanoLOCK™ TC-Sterile Packaged Cervical Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy. The applicant received FDA clearance on December 14, 2015, for the nanoLOCK™ TCS-Sterile Package Cervical Stand Alone Interbody Fusion Device with nanoLOCK™ surface, available in multiple sizes to accommodate anatomy. The applicant indicated that, due to manufacturing delays, all of the devices above were not available on the market until July 8, 2016. Therefore, the applicant believes that all of the devices above are new as of July 8, 2016.

The applicant submitted a request for a unique ICD–10–PCS procedure code and was granted approval for the following procedure codes under New Technology Group 2: XRG0092 (Fusion of occipital-cervical joint using nanotextured surface interbody fusion device, open approach); XRG1092 (Fusion of cervical vertebral joint using nanotextured surface interbody fusion device, open approach); XRG2092 (Fusion of 2 or more cervical vertebral joints using nanotextured surface interbody fusion device, open approach); XRG4092 (Fusion of cervicothoracic vertebral joint using nanotextured surface interbody fusion device, open approach); XRG6092 (Fusion of thoracic vertebral joint using nanotextured surface interbody fusion device, open approach); XRG7092 (Fusion of 2 to 7 thoracic vertebral joints using nanotextured surface interbody fusion device, open approach); XRG8092 (Fusion of 8 or more thoracic vertebral joints using nanotextured surface interbody fusion device, open approach); XRG9092 (Fusion of lumbar vertebral joint using nanotextured surface interbody fusion device, open approach); XRG092 (Fusion of lumbar interbody device using nanotextured surface interbody fusion device, open approach); and XRGD092 (Fusion of lumbosacral joint using nanotextured surface interbody fusion device, open approach). These new ICD–10–PCS procedure codes are effective on October 1, 2016.

We note that cases reporting procedures involving lumbar and cervical interbody devices map to different MS–DRGs. As discussed in the Inpatient New Technology Add-On Payment Final Rule (66 FR 46915), two separate reviews and evaluations of the technologies are necessary in this instance because cases representing patients receiving treatment for diagnoses associated with lumbar procedures that may be eligible for use of the technology under the first indication are not expected to be assigned to the same MS–DRGs as patients receiving treatment for diagnoses associated with cervical procedures using the technology under the second indication. Specifically, cases representing patients who have been diagnosed with lumbar DDD and received treatment that involved implanting a lumbar device map to MS–DRGs 028 (Spinal Procedures with MCC), 029 (Spinal Procedures with CC or Spinal Neurostimulators), 030 (Spinal Procedures without CC/MCC), 453 (Combined Anterior/Posterior Spinal Fusion with MCC), 454 (Combined Anterior/Posterior Spinal Fusion with CC), 455 (Combined Anterior/Posterior Spinal Fusion without CC/MCC), 456 (Spinal Fusion Except Cervical with Spinal Curvature or Malignancy or Infection or Extensive Fusions with MCC), 457 (Spinal Fusion Except Cervical with Spinal Curvature or Malignancy or Infection or Extensive Fusions without MCC), 458 (Spinal Fusion Except Cervical with Spinal Curvature or Malignancy or Infection or Extensive Fusions without CC/MCC), 459 (Spinal Fusion Except Cervical with MCC), and 460 (Spinal Fusion Except Cervical without MCC), while cases representing patients who have been diagnosed with cervical DDD and received treatment that involved implanting a cervical interbody device map to MS–DRGs 471 (Cervical Spinal Fusion with MCC), 472 (Cervical Spinal Fusion with CC), and 473 (Cervical Spinal Fusion without CC/MCC).

Procedures involving the lumbar and cervical interbody devices are assigned to separate MS–DRGs. Therefore, the devices categorized as lumbar devices and the devices categorized as cervical devices must distinctively (each category) meet the cost criterion and the substantial clinical improvement criterion in order to be eligible for new technology add-on payments beginning in FY 2017. We discuss application of these criteria following discussion of the newness criterion.

As discussed previously in this section, if a technology meets all three of the substantial similarity criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for the purposes of new technology add-on payments. We note that the substantial similarity discussion is applicable to both the lumbar and the cervical devices because all of the devices use the Titan Spine nanoLOCK™ technology.

With regard to the first criterion, whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome, the applicant stated that, for both interbody devices (the lumbar and the cervical interbody device), the Titan Spine nanoLOCK™’s surface stimulates osteogenic cellular response to assist in bone formation during fusion. During the manufacturing process, the surface produces macro, micro, and nano-surface textures. The applicant believed that this unique
combination and use of these surface topographies represents a new approach to stimulating osteogenic cellular response. The applicant asserted that the macro-scale textured features are important for initial implant fixation. The micro-scale textured features mimic an osteoclastic pit for supporting bone growth. The nano-scale textured features interface with the integrins on the outside of the cellular membrane, which generates the osteogenic and angiogenic mRNA responses necessary to promote healthy bone growth and fusion. The applicant provided the results from in vitro studies, using human mesenchymal cells (MSCs), which showed positive effects on bone growth related to cellular signaling achieved by using the device's surface, and osteoblasts exhibited a more differentiated phenotype and increased bone morphogenetic protein (BMP) production using titanium alloy substrates as opposed to poly-ether-ether-ketone (PEEK) substrates. The applicant stated that Titan Spine's proprietary and unique surface technology, the Titan Spine nanoLOCK interbody devices, contain optimized nano-surface characteristics, which generate the distinct cellular responses necessary for improved bone growth, fusion, and stability. The applicant further stated that the Titan Spine nanoLOCK's surface engages with the strongest portion of the endplate, which enables better resistance to subsidence because a unique dual acid-etched titanium surface promotes earlier bone in-growth. The Titan Spine nanoLOCK's surface is created by using a reductive process of the titanium itself. The applicant asserted that use of the Titan Spine nanoLOCK significantly reduces the potential for debris generated during impaction when compared to treatments using PEEK-based implants coated with titanium. According to the results of an in vitro study provided by the applicant, which compared angiogenic factor production using PEEK-based versus titanium alloy surfaces, osteogenic production levels were greater with the use of rough titanium alloy surfaces than the levels produced using smooth titanium alloy surfaces. The results of an additional study provided by the applicant examined whether inflammatory microenvironment generated by cells as a result of use of titanium aluminum-vanadium (Ti-alloy, TiAlV) surfaces is affected by surface microtexture, and whether it differs from the effects generated by PEEK-based substrates. The applicant noted that the use of microtextured surfaces has demonstrated greater promotion of osteoblast differentiation when compared to use of PEEK-based surfaces. With regard to the second criterion, whether a product is assigned to the same or a different MS–DRG, cases that may be eligible for treatment involving the Titan Spine nanoLOCK map to the same MS–DRGs as other (lumbar and cervical) interbody devices currently available to Medicare beneficiaries and also are used for the treatment of patients who have been diagnosed with DDD (lumbar or cervical). With regard to the third criterion, whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population, the applicant stated that the Titan Spine nanoLOCK can be used in the treatment of patients diagnosed with similar types of diseases, such as DDD, and for a similar patient population receiving treatment involving both lumbar and cervical interbody devices. In summary, the applicant maintained that the Titan Spine nanoLOCK technology has a different mechanism of action when compared to other spinal fusion devices. Therefore, the applicant did not believe that the Titan Spine nanoLOCK technology is substantially similar to existing technologies. After reviewing the applicant's statements regarding nonsubstantial similarity of its technology with other existing technologies, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25047), we stated that we were still concerned that there are other titaniumsurfaced devices currently available on the U.S. market. While these devices do not use the Titan Spine nanoLOCK technology, their surfaces also are made of titanium. Therefore, we stated that we believe that the Titan Spine nanoLOCK interbody devices may be substantially similar to currently available titanium interbody devices. We invited public comments on whether the Titan Spine Endoskeleton Interbody Devices meet the newness criterion. (1) Titan Spine Endoskeleton® nanoLOCK Interbody Device for Lumbar DDD As previously mentioned, the Titan Spine nanoLOCK received FDA clearance for the use of five lumbar interbody devices on October 27, 2014. To demonstrate that the Titan Spine nanoLOCK for Lumbar DDD technology meets the cost criterion, the applicant researched claims data in the FY 2014 MedPAR file for cases assigned to MS–DRGs 028, 029, 030, 453, 454, and 455 reporting any of the ICD–9–CM procedure codes within the code series 81.xx (Repair and plastic operations on joint structures) or code series 084.6x (Replacement of spinal disk), excluding cases reporting the following ICD–9–CM procedure codes describing cervical fusion: 81.01 (Atlas-axis spinal fusion), 81.02 (Other cervical fusion, anterior technique), 81.03 (Other cervical fusion, posterior technique), 81.31 (Refusion of atlas-axis spine), 81.32 (Refusion of other cervical spine, anterior technique), or 81.33 (Refusion of other cervical spine, posterior technique). As a result, the applicant found that all cases potentially eligible for treatment using
the technology mapped to MS–DRGs 456, 457, 458, 459, and 460. However, the applicant focused its analyses on MS–DRGs 028 through 030, 453 through 455, and 456 through 459 because these are the MS–DRGs to which cases treated with interbody fusion devices for degenerative disc disease would most likely be assigned. The applicant applied CMS’ relative weight filtering process as described in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49424) to ensure the correct claim types were used and the charge details across the cost centers were appropriate.

According to the applicant, 78.03 percent of the 96,281 cases found in the FY 2014 MedPAR file mapped to MS–DRG 460, while the remaining 21.97 percent of cases mapped to MS–DRGs 028 through 030, 453 through 455, and 456 through 459. This resulted in an average case-weighted charge per case of $127,082. The applicant then removed $15,766 for associated charges for other previously used spinal devices. The applicant determined the associated charges to be removed for other previously used devices based on current Titan Spine sales data for the Titan Spine nanoLock™ for Lumbar DDD various sizes. The applicant computed the associated charges by multiplying the weighted sales mix by the average sales price for each product in the Titan Spine nanoLock™ for Lumbar DDD product line. After the charges for other previously used technologies were removed, the applicant standardized the charges for all cases using the FY 2014 standardizing file posted on the CMS Web site. The applicant excluded all cases without standardized charges, resulting in a total of 96,281 cases. The applicant then inflated the average standardized case-weighted charges from 2014 to 2016 by applying a 2-year rate of inflation factor of 7.7 percent, which is the same inflation factor used by CMS to update the FY 2016 outlier threshold (80 FR 49784). To calculate the average standardized charge, the applicant inflated the average case-weighted charge for Lumbar DDD, the applicant used a case-weighted charge that was the equivalent to one patient and a single surgery. The applicant then added the device-related charges to the inflated average standardized charge per case, which resulted in an inflated average standardized case-weighted charge per case of $167,197. Using the FY 2016 IPPS Table 10 thresholds, the average case-weighted threshold amount was $112,825 (all calculations above were performed using unrounded numbers). Because the final inflated average standardized case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion.

We invited public comments on whether the Titan Spine nanoLock™ for Lumbar DDD meets the cost criterion, particularly with regard to the assumptions and methodology used in the applicant’s analyses in the proposed rule. We did not receive any public comments concerning costs for Titan Spine nanoLock™ for Lumbar DDD. We believe Titan Spine nanoLock™ for Lumbar DDD meets the cost criterion.

(2) Titan Spine Endoskeleton® nanoLOCK™ Interbody Device for Cervical DDD

As previously mentioned, Titan Spine received FDA clearance for the use of the nanoLock™ TC-Sterile Packaged Cervical Interbody Fusion Device with nanoLock™ surface on October 27, 2014, and the nanoLock™ TCS-Sterile Package Cervical Interbody Fusion Device with nanoLock™ surface on December 14, 2015. To demonstrate that the Titan Spine nanoLock™ for Cervical DDD meets the cost criterion, the applicant researched claims data in the FY 2014 MedPAR file for cases assigned to MS–DRGs 028, 029, 030, 453, 454, and 455 reporting any of the following ICD–9–CM cervical fusion procedure codes: 81.01, 81.02, 81.03, 81.32, 81.33. The applicant found that all of the cases mapped to MS–DRGs 471, 472, and 473. However, the applicant focused its analysis on MS–DRGs 028 through 030, 453 through 455, and 471 through 473 because these are the MS–DRGs to which cases treated with the implantation of cervical spinal devices for degenerative disc disease would most likely be assigned. Similar to the sensitivity analysis submitted for the Titan Spine nanoLock™ for Lumbar DDD, the applicant applied CMS’ relative weight filtering process as described in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49424) to ensure the correct claim types were used and the charge details across the cost centers were appropriate.

According to the applicant, 59.47 percent of the 48,187 cases mapped to MS–DRG 473 and 25.65 percent of the cases mapped to MS–DRG 472, while the remaining 14.88 percent of the cases mapped to MS–DRG 028 through 030, 453 through 455, and 471. This resulted in an average case-weighted charge per case of $83,841. Using the same methodology described above, the applicant removed $4,423 for associated charges for other previously used technologies from the average case-weighted charge per case using current Titan Spine sales data for cervical device sizes and then standardized the charges. The applicant then inflated the average standardized case-weighted charges from 2014 to 2016 by applying the same 2-year rate of inflation factor used above (7.7 percent). Similar to the methodology described above, the applicant calculated $36,023 for associated device related charges for the Titan Spine nanoLock™ for Cervical DDD and added this amount to the inflated average standardized case-weighted charge per case, which resulted in a final inflated average standardized case-weighted charge per case of $114,472. Using the FY 2016 IPPS Table 10 thresholds, the average case-weighted threshold amount was $79,827 (all calculations above were performed using unrounded numbers). Because the final inflated average standardized case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion.
The applicant noted that the cellular process that occurs after implantation of the Titan Spine nanoLOCK™ induces the body to produce and regulate its own bone morphogenetic proteins (BMP), which help stimulate bone growth naturally in the human body. According to the applicant, this result supports new bone growth without requiring use of exogenous BMP. The applicant explained that exogenous rhBMPs trigger a significant cytokine related anti-inflammatory reaction that has resulted in adverse side effects. The applicant stated that the Titan Spine nanoLOCK™’s proprietary surface and use promotes endogenous production of osteogenic growth factors, such as BMP–2, BMP–4, BMP–7, and TGF–β1,2, which produce only the physiologic amounts necessary for bone production without the concomitant cytokine related to anti-inflammatory reaction.

The applicant also stated that the unique surface of the TitanSpine nanoLOCK™ differentiates the technology from existing interbody devices, which use materials such as PEEK-based or ceramic surfaces. The applicant explained that these materials cause stem cells to flatten on the surface of the implant and primarily differentiate into fibroblasts (fiber-producing cells). This result is avoided by using the Titan Spine nanoLOCK™ because the nano-textured surface promotes differentiation of osteoblasts (bone-forming cells), which increases bone production around the implant site and increases the potential for a faster and more robust fusion. The applicant further stated that use of titanium and titanium alloy surfaces with rough microtopography demonstrate greater bone apposition, but use of macrotextured titanium and titanium alloy surfaces, such as the Titan Spine nanoLOCK™, promotes osteoblast differentiation and productions of factors that favor bone formation, whereas PEEK-based surfaces do not.

As previously noted, the applicant provided results from in vitro studies, using human MSCs, which showed positive effects on bone growth related to cellular signaling achieved from use of the device’s surface, and osteoblasts exhibited a more differentiated phenotype and increased bone morphogenetic protein BMP production using titanium alloy substrates as opposed to PEEK-based substrates. The applicant believed that the Titan Spine nanoLOCK™ substantially improves the treatment of Medicare beneficiaries, especially in terms of improved fusion, decreased pain, greater stability, faster recovery times, and lower rates of interbody device related complications, such as debris and inflammation.

We stated in the proposed rule (81 FR 25049) that we were concerned that the results of the in vitro studies may not necessarily correlate with the clinical results specified by the applicant. Specifically, because the applicant has only conducted in vitro studies without obtaining any clinical data from live subjects during a specific clinical trial, we further stated that we were unable to substantiate the clinical results that the applicant believed the technology achieved from a clinical standpoint based on the results of the studies provided. As a result, we stated that we were concerned that the results of the studies provided by the applicant do not demonstrate that the Titan Spine nanoLOCK™ technologies meet the substantial clinical improvement criterion. We invited public comments on whether the Titan Spine nanoLOCK™ technologies meet the substantial clinical improvement criterion in the proposed rule.

Comment: Several commenters supported that Titan Spine Endoskeleton® nanoLOCK™ Interbody Devices for Lumbar DDD and Cervical DDD represent a substantial clinical improvement over existing technologies. The commenters cited enhanced clinical outcomes with Titan Spine’s predicate devices. Commenters cited the success of both approved devices to show improved bone growth with nano-textured titanium surfaces. Several commenters have used Titan Spine’s predicate devices and stated satisfaction with these predicate devices.

Response: We appreciate the commenters’ statements concerning Titan Spine’s predicate devices. However, none of the commenters cited actual clinical data that used the Titan Spine Endoskeleton® nanoLOCK™ Interbody Device for Lumbar DDD and Cervical DDD. As mentioned above, the commenters cited data with regard to Titan Spine’s predicate devices. Therefore, our concerns stated in the proposed rule are still the same. Due to the lack of actual clinical data using the Titan Spine Endoskeleton® nanoLOCK™ Interbody Device for Lumbar DDD and Cervical DDD, we are unable to determine if Titan Spine Endoskeleton® meets the substantial clinical improvement criterion. Therefore, we are not approving new technologies, such as devices for the Titan Spine Endoskeleton® nanoLOCK™ Interbody Device for Lumbar DDD and Cervical DDD for FY 2017. The applicant can reapply in FY 2018 and provide additional clinical data supporting substantial clinical improvement.

e. Defitelio® (Defibrotide)

Jazz Pharmaceuticals submitted an application for new technology add-on payments for FY 2017 for defibrotide (Defitelio®), a treatment for patients diagnosed with hepatic veno-occlusive disease (VOD) with evidence of multi-organ dysfunction. VOD, also known as sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT), with an incidence rate of 8 percent to 15 percent. Diagnoses of VOD range in severity from what has been classically defined as a disease limited to the liver (mild) and reversible, to a severe syndrome associated with multi-organ dysfunction or failure and death.

Patients treated with HSCT who develop VOD with multi-organ failure face an immediate risk of death, with a mortality rate of more than 80 percent when only supportive care is used. The applicant asserts that Defitelio® improves the survival rate of patients with VOD with multi-organ failure by 23 percent.

VOD is believed to be the result of endothelial cell damage and hepatocellular injury from high-dose conditioning regimens administered prior to receiving treatment with HSCT. Preclinical data suggest that Defitelio® stabilizes endothelial cells by reducing endothelial cell activation and by protecting endothelial cells from further damage. Defitelio® is administered as a 2-hour intravenous infusion every 6 hours for a minimum of 21 days. The recommended dosage is 6.25 mg/kg body weight (25mg/kg/day). If after 21 days the signs and symptoms associated with hepatic VOD are not resolved, the administration of Defitelio® should be continued until clinical resolution.

In the proposed rule, we noted that the applicant had applied for a unique ICD–10–PCS procedure code to identify the use of Defitelio®. In this final rule, we note that the new ICD–10–PCS procedure codes WX03392 (Introduction of defibrotide sodium anticoagulant into peripheral vein, percutaneous approach) and WX04392 (Introduction of defibrotide sodium anticoagulant into central vein, percutaneous approach) were established in New Technology Group 2 as shown in Table 6B (New Procedure Codes) and will uniquely identify procedures involving the Defitelio® technology. More information on this
drug was not included in the data used for the determination of newness. Therefore, the period of newness does not necessarily start with the FDA approval date for the medical service or technology or the issuance of a distinct procedure code. Instead, the newness period begins with the date of availability of the product on the U.S. market, which is when data become available. The applicant confirmed that Defitelio® was not available on the U.S. market as of the FDA NDA approval date of March 30, 2016, which we believed to be the start of the newness period in the proposed rule. According to the applicant, commercial packaging could not be completed until the label for Defitelio® was finalized with FDA approval, and that commercial shipments of Defitelio® to hospitals and treatment centers began on April 4, 2016. We agree that, based on this information, the newness period for Defitelio® begins on April 4, 2016, the date of its first commercial availability.

As discussed earlier, if a technology meets all three of the criteria for newness, it would be considered substantially similar to an existing technology and would not be considered "new" for purposes of new technology add-on payments. With regard to the first criterion, whether the product uses the same or similar technology to achieve a therapeutic outcome, in the proposed rule, we stated that the applicant maintained that Defitelio® has a unique mechanism of action that is not shared by any other drug on the market used to treat patients diagnosed with VOD with multi-organ failure. According to the applicant, there are no FDA-approved treatments for VOD other than supportive care. Anticoagulants such as heparin, antithrombin, and tissue plasminogen factor have been used to treat patients diagnosed with VOD, but there is a lack of conclusive evidence that these treatments are effective and they also present a high risk of bleeding. The applicant maintained that Defitelio® addresses the underlying pathology of VOD with evidence of multi-organ failure and its use is effective as a treatment for this form of the disease. According to the applicant, it is speculated that the mechanism of action of the Defitelio® revolves around the stabilization of endothelial cells because of endothelial cell damage is believed to be a major contributing factor to the development of VOD.

However, we stated in the proposed rule that we were concerned that this mechanism of action is not well understood by the manufacturer and we are unable to determine whether Defitelio® is substantially similar to the other drugs on the market without full understanding of its distinct mechanism of action.

With regard to the second criterion, whether a product is assigned to the same or a different MS–DRG, in the proposed rule, we stated that the applicant maintained that cases potentially eligible for treatment using Defitelio® and representing the target patient population mainly belong to two MS–DRGs: MS–DRG 014 (Allogeneic Bone Marrow Transplant) and MS–DRG 016 (Autologous Bone Marrow Transplant with CC/MCC). We believe that the newness period for Defitelio® begins on April 4, 2016, the date of its first commercial availability. As discussed earlier, if a technology meets all three of the criteria for newness, it would be considered substantially similar to an existing technology and would not be considered "new" for purposes of new technology add-on payments.

With regard to the third criterion, whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population, in the proposed rule, we stated that the applicant asserted that there are no FDA-approved treatments for VOD other than supportive care, such as dialysis or ventilation. In addition, the applicant stated that poor outcomes have been reported for patients treated with non-approved pharmacological treatments for VOD. These treatments have largely been discontinued because of the high incidence of hemorrhagic complications, particularly among patients diagnosed with multi-organ failure. According to the applicant, Defitelio® would be the first and only FDA-approved treatment for VOD with evidence of multi-organ failure. However, we stated our concern that the applicant did not include in its application data comparing the outcomes of patients treated with Defitelio® to outcomes of patients treated only for supportive care. We also stated in the proposed rule that we were concerned that Defitelio® may not produce outcomes that are significantly different than the outcomes of patients treated with supportive care.

We invited public comments on whether Defitelio® is substantially similar to existing technologies and whether it meets the newness criterion. Comment: With regard to our concern that we cannot determine whether Defitelio® is substantially similar to other technologies without a full understanding of its mechanism of action, the applicant provided additional information about the
pathophysiology of VOD and how it is addressed by Defitelio®’s dual mechanism of action consisting of: (1) Endothelial cell protection and stabilization, and (2) enhancement of plasmin enzymatic activity to restore thrombo-fibrinolytic balance. According to the applicant, this two-pronged mechanism of action sets Defitelio® apart from supportive care agents available to treat VOD with multi-organ failure.

The applicant described the damage, detachment, and death of endothelial cells as triggered first by conditioning chemotherapy and/or radiotherapy, a necessary part of the HSCT conditioning regimen, and then by complications related to the HSCT procedure itself. The applicant asserted that progressive deterioration of endothelial cells results in tissue damage characteristic of VOD with multi-organ failure. In particular, clots form at the site of endothelial cell damage and obstruct small veins in the liver. The hepatocellular necrosis and vascular occlusion resulting from endothelial cell damage ultimately leads to liver, pulmonary, and renal failure which can culminate in death.

The applicant provided additional information from numerous clinical studies that demonstrate Defitelio®’s robust and reproducible ability to protect endothelial cells from cell damage, particularly from chemotherapy-induced cell death, as well as its ability to restore the thrombo-fibrinolytic balance, improving blood circulation. The applicant reiterated that Defitelio® is the only FDA-approved treatment for VOD with multi-organ failure and that, prior to this approval, patients only received supportive care. While supportive care agents with anticoagulant activity are available, they do not have the unique dual mechanism of action that Defitelio® possesses, nor have they been proven to be effective in the treatment of VOD with multi-organ failure.

With regard to our concern that cases eligible for Defitelio® would be assigned to the same MS–DRGs that identify cases of patients treated with supportive care for VOD with multi-organ failure, the applicant noted that, prior to NDA approval of Defitelio®, patients with VOD with multi-organ failure would have received supportive care alone because there were no FDA-approved treatments for VOD. As a result, there are no charges for VOD treatment in MS–DRG 014, MS–DRG 016, or any other MS–DRG to which cases eligible for Defitelio® would map.

With regard to our concern that the applicant did not include in its application data comparing the outcomes of patients treated with Defitelio® to outcomes of patients treated only with supportive care and that Defitelio® may not produce outcomes that are significantly different than the outcomes of patients treated with supportive care, the applicant clarified that it did include such studies, including the Phase 3 Study #2005–01, which enabled a comparison of Defitelio® versus supportive care alone and demonstrated the statistically and clinically significant benefit of Defitelio® over supportive care. The results of Study #2005–01 are described below in our discussion of whether Defitelio® meets the substantial clinical improvement criterion.

Response: We appreciate the applicant’s input and the detailed explanation of Defitelio®’s mechanism of action and the pathophysiology of VOD with multi-organ failure. We acknowledge that, as the only FDA-approved treatment for VOD with multi-organ failure, the applicant believed there are no charges for VOD treatment in the MS–DRGs claims data. We also acknowledge that the applicant submitted data from the Phase 3 Study #2005–01 to demonstrate that the improved outcomes among patients treated with Defitelio® compared to patients treated only with supportive care are statistically significant and valid. After considering the additional information submitted by the applicant, we have determined that Defitelio® is not substantially similar to any other technologies currently on the U.S. market for the treatment of VOD with multi-organ failure, and we agree that Defitelio® meets the newness criterion.

With regard to the cost criterion, in the proposed rule, we stated that the applicant conducted sensitivity analyses using claims data from 2012 through 2014 and determined the results in aggregate and by year. The applicant researched 100 percent of the 2012 through 2014 Inpatient Standard Analytic Files (SAFs) for cases eligible for Defitelio®. Because an ICD–9–CM code specific to treatment for VOD does not exist, the applicant used an algorithm to identify cases to use in its sensitivity analyses. The most appropriate ICD–9–CM diagnosis codes were identified based on clinical criteria used to diagnose VOD and were used to identify cohorts of patients diagnosed with VOD and VOD with multi-organ dysfunction. The applicant first identified claims with an ICD–9–CM procedure code indicating an HSCT (Group A) within a 30-day window; VOD most commonly occurs after receipt of HSCT. The applicant then looked for cases with ICD–9–CM diagnosis codes related to liver injury (Group B) or clinical evidence of suspected VOD symptoms based on at least two relevant ICD–9 diagnosis codes (Group C). Lastly, the applicant filtered out cases that did not show clinical evidence of multi-organ dysfunction based on at least one relevant ICD–9–CM code (Group D).

The applicant submitted the following table indicating the ICD–9–CM codes used for each category of the algorithm.

<table>
<thead>
<tr>
<th>Group</th>
<th>Title</th>
<th>ICD–9–CM code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Hematopoietic Stem Cell Transplant (HSCT) (at least one code).</td>
<td>41.00</td>
<td>Bone marrow transplant, not otherwise specified.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.01</td>
<td>Autologous bone marrow transplant without purging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.02</td>
<td>Allogeneic bone marrow transplant with purging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.03</td>
<td>Allogeneic bone marrow transplant without purging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.04</td>
<td>Autologous hematopoietic stem cell transplant without purging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.05</td>
<td>Allogeneic hematopoietic stem cell transplant without purging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.06</td>
<td>Cord blood stem cell transplant.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.07</td>
<td>Autologous hematopoietic stem cell transplant with purging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.08</td>
<td>Allogeneic hematopoietic stem cell transplant.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>41.09</td>
<td>Autologous bone marrow transplant with purging.</td>
</tr>
</tbody>
</table>
Using the above algorithm, the applicant identified a total of 267 patient cases of VOD with multi-organ dysfunction in the 2012–2014 Inpatient SAFs, with 78 patient cases in 2012, 102 patient cases in 2013, and 87 patient cases in 2014, or an average annual patient case volume of 89. The applicant determined that these cases grouped mainly into two MS–DRGs: 014 and 016. The applicant noted that there were no cases in the data from MS–DRG 017 (Autologous Bone Marrow Transplant without CC/MCC). The applicant further noted that there were no cases from MS–DRG 017 because the ICD–9–CM codes identifying VOD with multi-organ dysfunction include serious medical conditions that are listed on the MCC and CC lists. In total, 38 MS–DRGs were represented in the patient cohort, with 27 percent of cases mapping to MS–DRG 014 and 42 percent of cases mapping to MS–DRG 016. The remaining cases mapped to 1 of the 36 remaining MS–DRGs with fewer than 11 cases.

For results in the aggregate, the applicant calculated an average case-weighted charge per case of $427,440 across 267 cases representing diagnoses of VOD with multi-organ dysfunction from 2012 through 2014. The applicant assumed there would be a reduction in the use of selected drugs as a result of using Defitelio® and removed 50 percent of the estimated charges for heparin, furosemide, and spironolactone. The charges for these drugs were estimated based on pricing taken from the Medispan PriceRx database, whose costs were marked up according to the inverse of CCRs from cost center 07300 (Drugs Charged to Patients) obtained from providers’ 2012, 2013, and 2014 cost reports. The applicant matched these CCRs with the provider numbers on each claim. The applicant removed an average of $2,631 in charges for these drugs from the overall unstandardized charges for Defitelio®.

The applicant then standardized the charges and calculated an average standardized case-weighted charge per case of $356,015. Using the FY 2016 IPPS Table 10 thresholds, the average case-weighted threshold amount was $157,951 (all calculations above were performed using unrounded numbers). Because the inflated average standardized case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion. The applicant noted that it did not include charges for Defitelio® in the inflated average standardized case-weighted charge per case because the inflated average standardized case-weighted charge per case exceeded the average case-weighted threshold amount without charges for Defitelio®.

The applicant provided a similar analysis for each individual year of the SAF data rather than combining all the data from all 3 years into one analysis. Under the other three analyses, the applicant noted that the average standardized case-weighted charge per case exceeded the average case-weighted threshold amount (as shown in the table below) without inflating the charges and without adding any charges for Defitelio®.

<table>
<thead>
<tr>
<th>SAF Year</th>
<th>Average case-weighted threshold amount</th>
<th>Average standardized case-weighted charge per case</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>$161,469</td>
<td>$347,910</td>
</tr>
<tr>
<td>2013</td>
<td>150,585</td>
<td>326,445</td>
</tr>
</tbody>
</table>
We invited public comments on whether Defitelio® meets the cost criterion in the proposed rule. 

**Comment:** The applicant submitted a technical correction to update its cost criterion analysis. According to the applicant, the 1-year inflation factor from the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24632) was used in the sensitivity analysis included in its application instead of the 1-year inflation factor from the FY 2016 IPPS/LTCH PPS final rule (80 FR 49784). The applicant maintained that, in the revised sensitivity analysis with the updated inflation factor, the average standardized case-weighted charge per case for the applicable MS–DRGs exceeded the average case-weighted threshold amount without adding any charges for Defitelio®. In the applicant’s initial analysis using the 1-year inflation factor of 1.048116 from the proposed rule, the average standardized case-weighted charges exceeded the average case-weighted MS–DRG thresholds by an average of $200,323. After applying the updated inflation factor of 1.037616, the average standardized case-weighted charges exceeded the average case-weighted MS–DRG thresholds by an average of $187,776 before adding charges for Defitelio®. The 1-year inflation factor was applied four times for 2012 claims, three times for 2013 claims, and two times for 2014 claims in order to compare 2012 through 2014 claims data to the FY 2016 IPPS/LTCH PPS final rule thresholds.

**Response:** We appreciate the applicant submitting the additional information. After reviewing the sensitivity analysis included in the original application and subsequent analysis included in the applicant’s public comment, we have determined that the Defitelio® meets the cost criterion.

With regard to the substantial clinical improvement criterion, in the proposed rule, we stated that the applicant maintained that Defitelio® is an effective treatment for VOD as an early onset cause of mortality following HSCT. According to the applicant, patients treated with Defitelio® have improved survival and efficacy rates compared to patients who were not treated with Defitelio®. In increasing the chances of post-HSCT survival, Defitelio® affords the transplant patient the opportunity for engraftment, which could be a potential cure for the underlying disease that required HSCT. The applicant supported these assertions with clinical evidence from pivotal trial 2005–01, a Phase III historical control study in which patients with VOD with multi-organ failure were given Defitelio® in doses of 25 mg/kg/day for the recommended minimum treatment duration of 21 days. Patients in the historical control group were selected by an independent medical review committee (MRC) from a pool of 6,867 medical charts of patients receiving HSCT that were hospitalized from January 1995 through November 2007. The trial consisted of 102 patients in the Defitelio® treated group and 32 patients in the historical control group. The trial used the survival rate and rate of Complete Response (CR) at Day+100 as clinical endpoints. The observed survival rate at Day+100 in the Defitelio® treated group was 38.2 percent compared to 25 percent in the historical control group. Moreover, the rate of CR by Day+100 post-HSCT for the Defitelio® treated group was 25.5 percent compared to 12.5 percent in the historical control group. The applicant conducted additional analyses that showed improvements in survival outcomes among subgroups of patients with baseline prognostic factors related to worse outcomes.

According to the applicant, running a controlled, blinded, and randomized trial in a patient population with high mortality rates would be unethical. We stated in the proposed rule that we are concerned that there are limitations to the historical control group used in pivotal trial 2005–01. We stated that we believe that the discrepancy between the size of the treatment group (N=102) and the historical control group (N=32) may skew the trial results in favor of the treatment group. We also were uncertain, given the small sample size and historical data used, whether the historical control group is representative of patients with VOD with multi-organ failure. According to the applicant, patients in the historical control group were hospitalized between January 1995 and November 2007. Because of advancements in medicine within this timeframe, we were concerned that the patients in the historical control group cannot be appropriately compared to patients in the treatment group. Moreover, we stated that we believe that it is difficult to attribute improved survival and CR rates only to Defitelio® treatment.

We invited public comments on whether Defitelio® meets the substantial clinical improvement criterion in the proposed rule. 

**Comment:** The applicant submitted public comments in response to CMS’ concerns presented in the proposed rule, which asserted that the small sample size and non-randomized trial design of Study #2005–01 is due to the rarity of conditions that require HSCT and the low incidence of severe VOD in patients who have undergone HSCT. In addition to the difficulty of enrolling large numbers of patients in any study of VOD, the high overall mortality rate among patients who develop VOD with multi-organ failure would make a randomized controlled trial that did not allow use of Defitelio® unethical. For these reasons, the applicant chose a study design with a Historical Control Group.

The applicant supported these reasons, the applicant chose a study design with a Historical Control Group. The applicant ensured that the Defitelio® treatment (n=102) and Historical Control (n=32) groups were comparable in baseline prognostic variables and disease characteristics using a propensity score adjustment based on baseline prognostic factors of survival. The applicant also ensured that the rate of VOD with multi-organ failure observed among patients screened for the Historical Control group in Study #2005–01 was consistent with overall incidence expected and validated from other sources. According to the applicant, the overall incidence of severe VOD in the screened population is estimated to be 1.5 percent, which was comparable to the incidence of 1.3 percent in an independent registry. Overall, the applicant stated that the incidence of VOD with multi-organ failure remains similar across diverse populations, indicating not only a consistently low incidence, but also that the Historical Control group for Study #2005–01 was representative of VOD with multi-organ failure.

With regard to our concern that patients in the Historical Control group cannot be appropriately compared to treatment group patients because of advancements in medicine within the timeframe of the patients in the
Dosing should be based on a patient’s baseline body weight, which is assumed to be 70 kg for an average adult patient. All vials contain 200 mg at a cost of $825 per vial. Therefore, we have determined that cases involving the use of the Defitelio® technology would incur an average cost per case of $151,800 (70 kg adult × 25 mg/kg/day × 21 days = 36,750 mg per patient/200 mg vial = 184 vials per patient × $825 per vial = $151,800). Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 50 percent of the average cost of the technology or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment amount for a case involving the use of Defitelio® is $75,900 for FY 2017.

f. GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE)

W. L. Gore and Associates, Inc. submitted an application for new technology add-on payments for the GORE® EXCLUDER® Iliac Branch Endoprosthesis (GORE IBE device) for FY 2017. The device consists of two components: The Iliac Branch Component (IBC) and the Internal Iliac Component (IIC). The applicant indicated that each endoprosthesis is pre-mounted on a customized delivery and deployment system allowing for controlled endovascular delivery via bilateral femoral access. According to the applicant, the device is designed to be used in conjunction with the GORE® EXCLUDER® AAA Endoprosthesis for the treatment of patients requiring repair of common iliac or aortoiliac aneurysms. When deployed, the GORE IBE device excludes the common iliac aneurysm from systemic blood flow, while preserving blood flow in the external and internal iliac arteries.

With regard to the newness criterion, the applicant received pre-market FDA approval of the GORE IBE device on February 29, 2016. The applicant submitted a request for a unique ICD–10–PCS procedure code and was granted approval for the following procedure codes: 04VC0EZ (Restriction of right common iliac artery with branched or fenestrated intraluminal device, one or two arteries, open approach); 04VC0FZ (Restriction of right common iliac artery with branched or fenestrated intraluminal device, three or more arteries, open approach); 04VC3EZ (Restriction of right common iliac artery with branched or fenestrated intraluminal device, one or two arteries, percutaneous approach); 04VC3FZ (Restriction of right common iliac artery with branched or fenestrated intraluminal device, three or more arteries, percutaneous approach).
arteries, percutaneous approach); 04VC4EZ (Restriction of right common iliac artery with branched or fenestrated intraluminal device, one or two arteries, percutaneous approach); 04VC4FZ (Restriction of right common iliac artery with branched or fenestrated intraluminal device, three or more arteries, percutaneous endoscopic approach); 04VD0EZ (Restriction of left common iliac artery with branched or fenestrated intraluminal device, one or two arteries, open approach); 04VD0FZ (Restriction of left common iliac artery with branched or fenestrated intraluminal device, three or more arteries, open approach); 04VD3EZ (Restriction of left common iliac artery with branched or fenestrated intraluminal device, one or two arteries, percutaneous approach); 04VD3FZ (Restriction of left common iliac artery with branched or fenestrated intraluminal device, three or more arteries, percutaneous endoscopic approach); 04VD4EZ (Restriction of left common iliac artery with branched or fenestrated intraluminal device, one or two arteries, percutaneous endoscopic approach); and 04VD4FZ (Restriction of left common iliac artery with branched or fenestrated intraluminal device, three or more arteries, percutaneous endoscopic approach). These new ICD–10–PCS procedure codes are effective on October 1, 2016.

As discussed earlier, if a technology meets all three of the substantial similarity criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

With regard to the first criterion, whether a product uses the same or a similar mechanism of action to achieve a therapeutic outcome, the applicant indicated that the GORE IBE device is based on the same design principles as other endovascular repair devices, and its use differs because of the specific target site for implantation. Consequently, it has a different shape and method of delivery from other endovascular devices. The GORE IBE device is similar to the GORE® EXCLUDER® AAA Endoprosthesis, primarily differing in device dimensions to fit within the iliac artery anatomy. With regard to the first criterion, we expressed concern in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion.

Comment: The manufacturer of the GORE IBE device commented that several characteristics of the GORE IBE demonstrate that the technology is new, including differentiated delivery mechanisms to allow for effective use in the specific anatomy, use of a technique specified by the manufacturer and the other limitations of current treatment methods, which may not preserve internal iliac artery perfusion. The applicant described current repair options for these patients as: (a) Intentional occlusion and coverage of the internal iliac artery; (b) undergoing a more extensive surgical operation to place a bypass graft; or (c) use of combinations of devices in a nonindicated, variable, and inconsistent manner. With regard to the third criterion, we expressed concern that this device appears to treat a similar type of disease to existing stent grafts.

Based on the statements above, the applicant maintained that the GORE IBE device is not substantially similar to other stent-grafts used to treat patients with AAAs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion. The manufacturer of the GORE IBE device commented that several characteristics of the GORE IBE demonstrate that the technology is new, including differentiated delivery mechanisms to allow for effective use in the specific anatomy, use of a technique specified by the manufacturer and the other limitations of current treatment methods, which may not preserve internal iliac artery perfusion. The applicant described current repair options for these patients as: (a) Intentional occlusion and coverage of the internal iliac artery; (b) undergoing a more extensive surgical operation to place a bypass graft; or (c) use of combinations of devices in a nonindicated, variable, and inconsistent manner. With regard to the third criterion, we expressed concern that this device appears to treat a similar type of disease to existing stent grafts.

Based on the statements above, the applicant maintained that the GORE IBE device is not substantially similar to other stent-grafts used to treat patients with AAAs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion. The applicant maintained that the GORE IBE device is not substantially similar to other stent-grafts used to treat patients with AAAs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion. The applicant maintained that the GORE IBE device is not substantially similar to other stent-grafts used to treat patients with AAAs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion. The applicant maintained that the GORE IBE device is not substantially similar to other stent-grafts used to treat patients with AAAs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion. The applicant maintained that the GORE IBE device is not substantially similar to other stent-grafts used to treat patients with AAAs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25057 through 25059), we invited public comments on whether the GORE IBE device is substantially similar to existing technologies and whether the technology meets the newness criterion.

With regard to the cost criterion, the applicant indicated that the GORE IBE device received premarket approval on February 29, 2016. With respect to the mechanism of action, the applicant indicated that all FDA-approved endovascular aneurysm repair (EVAR) devices designed to treat AAAs share the same fundamental mechanism of action, but that devices must be specifically designed to address anatomical constraints and specific pathophysiology. Another commenter also indicated that the GORE IBE differs from standard EVAR in that it is a bifurcated graft that requires increased work to deploy.

Response: We appreciate the additional information provided to us by the manufacturer and the other commenter. After reviewing the comments, we believe that the GORE IBE is a treatment option for a new patient population because it is the first stent-graft in its class for patients with iliac branch involvement. As a result, there is no other device to which to compare its mechanism of action because the GORE IBE is unique to the patient population that it is approved for use by the FDA. Therefore, the GORE IBE is not substantially similar to any existing technologies because it does not meet all three of the substantial similarity criteria.

After consideration of the public comments we received, we believe that the GORE IBE device meets the newness criterion, and we consider the technology to be “new” as of February 29, 2016, the date that the GORE IBE device received premarket approval. With regard to the cost criterion, the applicant researched the FY 2014 MedPAR claims data to identify patients who may be eligible for treatment using the GORE IBE device. The applicant noted that cases eligible for the GORE IBE device would map to MS–DRGs 268 (Aortic and Heart Assist Procedures Except Pulsation Balloon with MCC) and 269 (Aortic and Heart Assist Procedures Except Pulsation Balloon without MCC). The applicant provided two analyses. The first analysis searched for cases that may be potentially eligible for the GORE IBE device by identifying cases with endovascular aneurysm repair (EVAR) with iliac diagnoses. To identify these cases, the applicant searched for cases that had an ICD–9–CM primary procedure code of 39.71 (Endovascular implantation of other graft in abdominal aorta) in combination with a primary diagnosis code of 441.4 (Abdominal aneurysm without mention...
of rupture) or 441.02 (Dissection of aorta, abdominal). The applicant excluded cases with a diagnosis code of 441.3 (Abdominal aneurysm, ruptured), and cases with atherosclerosis of the lower extremities (ICD–9–CM diagnosis code 440.20 through 440.28). The applicant then identified a subset of cases (1,615 cases) with significant iliac involvement (which indicated use of the prior technology as well as disease extent where the new technology could be used) by searching for cases with a secondary ICD–9–CM diagnosis code of 442.2 (Aneurysm of iliac artery) or 443.22 (Dissection of iliac artery). This subset of cases was used in the analysis with 205 cases that mapped to MS–DRG 268 and 1,410 cases that mapped to MS–DRG 269. As discussed below, the remaining cases (11,926 cases) were used to help evaluate and compare subsequent offset charge calculations (base EVAR cases).

Using the 1,615 cases, the applicant calculated an average unstandardized case-weighted charge per case of $121,527. Charges for the prior technology (implants), which would be offset by the new technology were established by subtracting the average implant charge in the 1,615 cases from the average implant charge in the base EVAR sample. The excess implant charge represents current implant charges being used in EVAR cases with iliac involvement, and was subtracted from the average unstandardized case-weighted charge per case.

The applicant compared the average unstandardized OR and radiology charges associated with the new technology from the clinical trial data with the unstandardized OR and radiology charges associated with the prior technology from the MedPAR data and noted that O.R. and radiology charges for resources related to the new technology and the prior technology were similar. However, with regard to charges in the intensive care unit (ICU), there was a reduction of 56 percent in ICU associated charges for the new technology. Therefore, the applicant offset the ICU associated charge by 56 percent and deducted this amount from the average unstandardized case-weighted charge per case. The applicant then standardized the charges, but noted that it did not inflate the charges. The applicant added charges for the GORE IBE device by converting the costs of the device to charges using the average CCR for implantable devices (0.337) as reported in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49429). The applicant noted that the technology was proprietary information. Based on the FY 2016 IPPS/LTCH PPS Table 10 thresholds, the average case-weighted threshold amount was $109,241. The applicant computed an average standardized case-weighted charge per case of $124,129. Because the average standardized case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion.

The second analysis was similar to the first analysis, but searched the MedPAR claims data file for cases with an EVAR with an iliac diagnosis and procedure instead of cases with EVAR and only an iliac diagnosis. The applicant used the same ICD–9–CM procedure and diagnoses codes as used in the first analysis, but used the following ICD–9–CM procedure codes to identify cases that had an iliac procedure: 39.29 (Other endovascular procedures on other vessels) in combination with 39.29 (Other (peripheral) vascular shunt or bypass), 39.79 in combination with 39.90 (Insertion of non-drug-eluting peripheral (non-coronary) vessel stent(s)) without 39.29, 39.90 in combination with 39.79 and 39.29. The applicant noted that the expected distribution of cases for the GORE IBE device is that 20 percent of the cases would map to MS–DRG 268 and 80 percent of the cases would map to MS–DRG 269. Because this analysis represents cases that had an actual iliac procedure, the applicant applied this distribution to the cases. The applicant then followed the same methodology above and removed charges for the prior technology and resources related to the prior technology, standardized the charges, and then added charges related to the GORE IBE device. Based on the FY 2016 IPPS/LTCH PPS Table 10 thresholds, the average case-weighted threshold amount was $113,015. The applicant computed an inflated average standardized case-weighted charge per case of $138,179. Because the inflated average case-weighted charge per case exceeds the average case-weighted threshold amount, the applicant maintained that the technology meets the cost criterion.

With regard to the second analysis, the applicant imputed the distribution of cases. We indicated that we were not sure how the applicant determined which cases would map to MS–DRG 268 or MS–DRG 269, if the distribution was imputed. Also, the applicant did not disclose how many cases were found in the claims data after filtering the case volume using ICD–9–CM procedure codes identifying cases that had an iliac procedure. We invited public comments on whether the GORE IBE device meets the cost criterion, including with regard to the concerns we raised in the proposed rule.

Comment: The manufacturer of the GORE IBE device clarified the basis for the assumption regarding the DRG distribution of cases involving the IBE. According to the manufacturer, its analysis utilized a sample of 100 cases where a combination of the ICD–9 procedure and diagnosis codes strongly suggested the use of current alternative methods, that is, physician-developed methods, for preservation of internal iliac flow in conjunction with EVAR. The manufacturer reported that 80 percent were in the No MCC severity level, while 20 percent were in the MCC severity level. The manufacturer also examined a more conservative distribution of all EVAR cases, in which it found 87 percent with no MCC, and 13 percent with MCC. The manufacturer indicated that, using the conservative assumption, the threshold was still met.

Response: We appreciate the manufacturer’s clarification of the basis for the assumption regarding the MS–DRG distribution of cases. After consideration of the public comments we received, we believe that the GORE IBE meets the cost criterion.

With regard to the substantial clinical improvement criterion, the applicant indicated that current treatment approaches have substantial risks of complications that can negatively impact quality of life. Available treatment methods that do not preserve internal iliac artery perfusion increase risks for negative clinical outcomes; compared to methods that preserve the internal iliac artery, those that use contralateral hypogastric embolization result in a higher incidence of buttock claudication (15–55 percent), sexual dysfunction (5–45 percent), ischemia of the colon (2.6 percent), and rarely, ischemia of the spine. The applicant cited the “12–04” study,7 which the applicant suggested showed the GORE IBE device to have 0 percent rates of buttock claudication, new onset erectile dysfunction, colonic ischemia, and spinal cord ischemia. The applicant also suggested that the 12–04 study showed the GORE IBE device to have reduced procedure time, reduced fluoroscopy time, reduced reintervention rates, and increased patency rates.

---

asserted that because the GORE IBE device preserves flow to the internal iliac artery, the risk of complications is reduced, which represents a substantial clinical improvement relative to current treatment approaches. The applicant also stated that, compared with historical data for procedures done using contralateral hypogastric embolization, the GORE IBE device is associated with reduced procedure time, reduced fluoroscopy time, reduced reintervention rates, reduced incidence of aneurysm enlargement, and improved patency rates.

The applicant submitted several research articles with its application, which consisted of a few very small case series of 23 total patients published as some abstracts of other case series. These publications describe the procedural results of using the device, with angiographic endpoints, and demonstrate the feasibility of insertion. The applicant also indicated that other treatment approaches, including open surgery, are done infrequently, while other approaches are not approved for this purpose. Therefore, the applicant indicated that it would be impractical to conduct comparative studies.

After reviewing the information provided by the applicant, we stated in the proposed rule that we have the following concerns: We stated that we were concerned about the lack of clinical studies comparing the GORE IBE device with alternative methods of treatment, and noted that the application did not provide data that supported its assertions that the GORE IBE device is associated with reduced procedure time, reduced fluoroscopy time, reduced reintervention rates, reduced incidence of aneurysm enlargement, and improved patency rates. We also noted that the applicant’s assertions about decreased rates of complications appear to compare a small number of published cases of the use of the GORE IBE device with complication rates cited in the literature, which does not indicate whether there is a valid basis for comparison. We invited public comments on whether the GORE IBE device meets the substantial clinical improvement criterion in the proposed rule.

Comment: The manufacturer of the GORE IBE device indicated that the FDA-approved study design was appropriate and reflected real-world limitations associated with clinical studies in small, targeted populations. The manufacturer also noted that it was impractical to incorporate off-label alternatives, and that the surgical alternative is not preferred; therefore, neither of these approaches could be used as a comparison arm. However, the manufacturer provided an abstract of the IBE pivotal trial, described in the June 2016 supplement to the Journal of Vascular Surgery, which included a built-in control subgroup consisting of those patients that had bilateral aneurysms.

According to the manufacturer, these patients received the IBE device on one side, while flow on the other side was either sacrificed via coil or plug, or preserved with surgical bypass. Of the 21 patients in which the flow was sacrificed on one side, 29 percent experienced new-onset claudication on the side where the flow was sacrificed. There were no reports of claudication on the IBE treatment side. The manufacturer stated that this finding supports the benefit of flow preservation.

Another commenter also referred to a Society for Vascular Surgery practice guideline which described the importance of preserving internal iliac flow on at least one side, which supports the benefit of the GORE IBE device in improving quality of life. Another commenter supported the approval of a new technology add-on payment for the GORE IBE in that it allows for higher quality of care and improved quality of life.

Response: We appreciate the manufacturer’s explanation of the built-in control subgroup, and we agree that this group represents a good comparison group for the GORE IBE device. We believe that the information presented by the manufacturer and other commenters demonstrates that the GORE IBE device represents a substantial clinical improvement over current treatment approaches.

After consideration of the public comments we received, we have determined that the GORE IBE device system meets all of the criteria for approval of new technology add-on payments for FY 2017. As discussed above, cases involving the GORE IBE device that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure codes: 04VC0EZ; 04VC0FZ; 04VC3EZ; 04VC3FZ; 04VC4EZ; 04VC4FZ; 04VD0EZ; 04VD0FZ; 04VD3EZ; 04VD3FZ; 04VD4EZ; and 04VD4FZ. In its new technology add-on payment application, the applicant stated that the projected cost of the GORE IBE device is $10,500. Under § 412.86(a)(2), new technology add-on payments are limited to the lesser of 50 percent of the average cost of the device or 50 percent of the costs in excess of the MS–DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of the GORE IBE device is $5,250 for FY 2017.

g. Vistogard™ (Urdinone Tricatate)

BTG International Inc., submitted an application for new technology add-on payments for the Vistogard™ for FY 2017. Vistogard™ (Urdinone Tricatate) was developed as an antidote to fluorouracil toxicity. Chemotherapeutic agent 5-fluorouracil (5–FU) is used to treat specific solid tumors. It acts upon deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the body, as uracil is a naturally occurring building block for genetic material. Fluorouracil is a fluorinated pyrimidine. As a chemotherapy agent, Fluorouracil is absorbed up by cells and causes the cell to metabolize into byproducts that are toxic and used to destroy cancerous cells. The byproducts fluorodeoxyuridine monophosphate (F–dUMP) and fluorodeoxy triphosphate (FUTP) are believed to do the following: Reduce DNA synthesis, lead to DNA fragmentation, and disrupt RNA synthesis. Fluorouracil is used to treat a variety of solid tumors such as colorectal, head and neck, breast, and ovarian cancer. With different tumor treatments, different dosages, and different dosing schedules, there is a risk for toxicity in these patients. Patients may suffer from fluorouracil toxicity/death if 5–FU is delivered in different dosing schedules, there is a risk for toxicity in these patients. Patients may suffer from fluorouracil toxicity/death if 5–FU is delivered in slight excess or at faster infusion rates than prescribed. The cause of overdose can happen for a variety of reasons including: Pump malfunction, incorrect pump programming or miscalculated doses, and accidental or intentional ingestion.

According to the applicant, current treatment for fluorouracil toxicity is supportive care, including discontinuation of the drug, hydration, filgrastim for neutropenia, as well as antibiotics, antiemetics, and treatments that are required for potential...
gastrointestinal and cardiovascular compromise. Vistogard™ is an antidote to Fluorouracil toxicity and is a prodrug of uridine. Once the drug is metabolized into uridine, it competes with the toxic byproduct FUTP in binding to RNA, thus reducing the impact FUTP has on cell death.

With regard to the newness criterion, in the proposed rule, we stated that Vistogard™ received FDA approval on December 11, 2015. The applicant noted that Vistogard™ is the first FDA approved antidote used to reverse fluorouracil toxicity. The applicant submitted a request for a unique ICD–10–PCS procedure code and was granted approval for the following procedure code: XW0D8X82 (Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2). The new code is effective on October 1, 2016.

Comment: The manufacturer commented that the start of the newness period for Vistogard™ should be established as March 2, 2016. The manufacturer explained that the FDA approved Vistogard™ on December 11, 2015 under Priority Review. The manufacturer stated that this approval was granted approximately 3 months earlier than the PDUFA (Prescription Drug User Fee Act) User Fee goal date of March 10, 2016. Commercial availability of Vistogard™ occurred March 2, 2016 due to the need for receipt of final labeling, contracting manufacturing schedules, and final packaging.

Response: We agree with the commenter that, due to the delay in availability described above, the date the newness period begins for Vistogard™ is March 2, 2016, instead of December 11, 2015.

As discussed earlier, if a technology meets all three of the substantial similarity criteria, it would be considered substantially similar to an existing technology and would not be considered “new” for purposes of new technology add-on payments.

With regard to the first criterion, whether the product uses the same or a similar mechanism of action to achieve a therapeutic outcome, in the proposed rule, we stated that the applicant explained that Vistogard™ is the first FDA-approved antidote used to reverse fluorouracil toxicity. The applicant maintained that Vistogard™ has a unique mechanism of action that is not comparable to any other drug’s mechanism of action that is currently available on the U.S. market. The applicant described in technical detail how the novel and unique mechanism of action provides bioavailable uridine, a direct biochemical antagonist of 5–FU toxicity; quickly absorbs into the gastrointestinal tract due to its lipophilic nature; in normal cells, stops the process of cell damage and cell destruction caused by 5–FU and counteracts the effects of 5–FU toxicity; protects normal cells and allows recovery from damage caused by 5–FU, without interfering with the primary antitumor mechanism of 5–FU; and uses uridine derived from Vistogard™ to convert it into uridine triphosphate (UTP), which competes with FUTP for incorporation into RNA, preventing further cell destruction and dose-limiting toxicities.

With regard to the second criterion, whether the product is assigned to the same or a different MS–DRG, in the proposed rule we stated that the applicant noted that Xuriden (uridine triacetate) was also approved by the FDA on September 4, 2015, as a pyrimidine analog for uridine replacement indicated for the treatment of hereditary ornithic aciduria (HOA). According to the applicant, HOA is a rare, potentially life-threatening, genetic disorder in which patients (primarily pediatric patients) lack the ability to synthesize adequate amounts of uridine and consequently can suffer from hematologic abnormalities, failure to thrive, a range of developmental delays, and episodes of crystalluria leading to obstructive uropathy. The applicant stated that Xuriden is approved as a chronic, once daily medication (not to exceed 8 grams) that is administered orally in the patient’s home and also used to replace uridine, Xuriden is not administered in a hospital setting and cases involving the use of Xuriden would not be assigned to the same MS–DRGs associated with the use of Vistogard™ in the treatment of patients experiencing 5–FU overdose or severe toxicity. Therefore, the applicant maintained that no other technology similar to Vistogard™ would map to the same MS–DRGs as cases involving the use of Vistogard™.

With regard to the third criterion, whether the new use of the technology involves the treatment of the same or similar type of disease and the same or similar patient population, similar to above, in the proposed rule we stated that the applicant maintained that Vistogard™ is the first FDA approved antidote to reverse fluorouracil toxicity and, therefore, no other technology treats this disease or patient population to reverse fluorouracil toxicity. Therefore, the applicant believed that Vistogard™ is not substantially similar to any other currently approved technology. We invited public comments on whether Vistogard™ is substantially similar to existing technologies and whether it meets the newness criterion in the proposed rule.

Comment: The manufacturer reiterated that Vistogard™ is not substantially similar to any existing technology and that it meets the newness criterion.

Response: After consideration of the information provided by the applicant, we agree that Vistogard™ is not substantially similar to any existing technology and meets the newness criterion.

With regard to the cost criterion, in the proposed rule, we stated that the applicant searched the claims data from the 2013 and 2014 Inpatient SAFs for cases that may be eligible for treatment involving Vistogard™. Specifically, the applicant searched for cases reporting a primary ICD–9–CM diagnosis code for colorectal cancer, head and neck cancer, gastric cancers and pancreatic cancer.

The applicant further narrowed the potential target patient population by identifying cases reporting toxicity due to an antineoplastic. In order to include only patients diagnosed with severe toxicity that would be eligible for treatment using Vistogard™, using revenue center codes and ICD–9–CM V codes, the applicant included an additional cohort of cases representing patients admitted from the emergency department, an observation unit, another short-term, acute care hospital, or who have received chemotherapy treatment during the inpatient stay included on the claim. Because 5–FU toxicity is associated with a high mortality rate, the applicant identified a subgroup of patients diagnosed with chemotherapy toxicity who expired during their inpatient visit or within 7 days of discharge. The applicant provided two analyses to determine that the technology meets the cost criterion: One analysis of patients that experienced toxicity with mortality and a second analysis using the broader chemotherapy toxicity cohort, which includes patients who did not expire. The table below provides the diagnosis codes and information the applicant used to identify cases for both of these analyses.
Under the first analysis, the applicant found 76 cases with 18.42 percent of those cases mapping to MS–DRG 871 (Septicemia or Severe Sepsis without Mechanical Ventilation >96 hours with MCC), and the remaining number of cases mapping to MS–DRGs with less than 11 cases. According to the applicant, the results of the analysis of the MS–DRGs with less than 11 cases could not be discussed separately because of the small sample sizes. The applicant believed that it was unnecessary to remove any charges for other previously used technologies because although Vistogard™ is singular in its ability to treat 5-FU toxicity, the associated charges for palliative care would continue to be necessary to treat the symptoms of the toxicity, even though it is possible that the use of Vistogard™ may reduce a patient’s hospital length of stay. To update the charge data to the current fiscal year, the applicant inflated the charges based on the charge inflation factor of 1.048116 in the FY 2016 IPPS/LTCH final rule (80 FR 49784). We noted in the proposed rule that we believed that it is likely that the applicant would still meet the cost criterion under both analyses even if it used the lower inflation factor from the FY 2016 final rule. We invited public comments on whether Vistogard™ meets the cost criterion under both analyses.

**Comment:** The manufacturer commented that it agreed with our analysis that, regardless of the inflation factor used, Vistogard™ would still meet the cost criterion. The manufacturer supplied revised data with the correct inflation factor that demonstrated that the inflated average standardized case-weighted charge per case exceeded the average case-weighted threshold amount, without including charges for Vistogard™.

**Response:** We thank the commenter for providing a revised analysis, and we agree that Vistogard™ meets the cost criterion.

With regard to substantial clinical improvement, the applicant maintained that Vistogard™ represents a substantial clinical improvement. The applicant noted that Vistogard™ is the first and only antidote indicated to treat adult and pediatric patients following a fluorouracil overdose, regardless of the presence of symptoms or whether a severe or life-threatening toxicity within 96 hours following the conclusion of fluorouracil
We invited public comments on whether Vistogard™ meets the substantial clinical improvement criterion in the proposed rule. 

Comment: The manufacturer reiterated the points described above and asserted that Vistogard™ meets the substantial clinical improvement criterion.

Response: After consideration of the information provided by the applicant, we agree that Vistogard™ meets the substantial clinical improvement criterion.

The applicant noted that 130 patients treated with Vistogard™ survived through the 30-day treatment and observation period (95 percent Confidence Interval: 0.92, 0.99). Of the 135 patients, 30 percent were 65 years old and older, including 11 percent of patients who were 75 years old and older.

According to the applicant, the studies’ results demonstrate that Vistogard™ reduced the incidence, severity and virulence of toxicities associated with 5–FU toxicity due to overdose or rapid onset. Specifically, the applicant noted the following results:

- Vistogard™ ameliorated the progression of mucositis, leukopenia and thrombocytopenia; leukopenia and thrombocytopenia were resolved in almost all patients by the 4th week, indicating recovery of the hematopoietic system; mucositis also was resolved in almost all patients within the 30-day observation period with the incidence of serious (Grade 3 or 4) mucositis being very low; and no grade 4 mucositis was observed in any patients who received treatment using Vistogard™ within 96 hours after 5–FU.

- Thirty-eight percent of patients who experienced 5–FU overdose were able to resume chemotherapy treatment in less than 30 days after 5–FU toxicity, with the majority of these patients resuming treatment within 21 days. According to the applicant, 21 percent of the patients who presented with rapid onset of serious toxicities resumed chemotherapy treatment (typically with a different agent than 5–FU) in less than 30 days, with an overall median time to resumption of chemotherapy of 19 days.

- The safety and tolerability profile of Vistogard™ is consistent with what would be expected for patients diagnosed with cancer following 5–FU chemotherapy treatment, but is generally less in severity and incidence when compared to what would be expected with patients who experience a 5–FU overdose. Specifically, during Study 1, there were no patients that discontinued uridine triacetate treatment as a result of adverse events, and during Study 2, three patients discontinued uridine triacetate treatment as a result of adverse events, one of which was considered possibly related to uridine triacetate (nausea and vomiting).

or capecitabine administration. The applicant provided data from two studies (Study 1, an open-label, single arm, multi-center expanded access study and Study 2, an open-label, single arm, multi-center emergency use study), which combined enrolled 135 patients. The applicant noted that 130 patients treated with Vistogard™ survived through the 30-day treatment and observation period with the incidence of serious (Grade 3 or 4) mucositis being very low; and no grade 4 mucositis was observed in any patients who received treatment using Vistogard™ within 96 hours after 5–FU.

- Thirty-eight percent of patients who experienced 5–FU overdose were able to resume chemotherapy treatment in less than 30 days after 5–FU toxicity, with the majority of these patients resuming treatment within 21 days. According to the applicant, 21 percent of the patients who presented with rapid onset of serious toxicities resumed chemotherapy treatment (typically with a different agent than 5–FU) in less than 30 days, with an overall median time to resumption of chemotherapy of 19 days.

- The safety and tolerability profile of Vistogard™ is consistent with what would be expected for patients diagnosed with cancer following 5–FU chemotherapy treatment, but is generally less in severity and incidence when compared to what would be expected with patients who experience a 5–FU overdose. Specifically, during Study 1, there were no patients that discontinued uridine triacetate treatment as a result of adverse events, and during Study 2, three patients discontinued uridine triacetate treatment as a result of adverse events, one of which was considered possibly related to uridine triacetate (nausea and vomiting).
section II.A.4.b. of the Addendum to this final rule. We also note that, under section III.J.2. of the preamble of this final rule, we are finalizing an April 21, 2016 interim final rule with comment period that addressed modifications to limitations on redesignation by the Medicare Geographic Classification Review Board (MGCRRB), and included regulatory changes to codify the application and interpretation of two judicial decisions.

Section 1866(d)(3)(E) of the Act also provides for the collection of data every 3 years on the occupational mix of employees for short-term, acute care hospitals participating in the Medicare program, in order to construct an occupational mix adjustment to the wage index. A discussion of the occupational mix adjustment that we are applying to the FY 2017 wage index appears under sections III.E.3. and F. of the preamble of this final rule.

2. Core-Based Statistical Areas (CBSAs)/Revisions for the FY 2017 Hospital Wage Index

The wage index is calculated and assigned to hospitals on the basis of the labor market area in which the hospital is located. Under section 1886(d)(3)(E) of the Act, beginning with FY 2005, we delineate hospital labor market areas based on OMB-established Core-Based Statistical Areas (CBSAs). The current statistical areas (which were implemented beginning with FY 2015) are based on revised OMB delineations issued on February 28, 2013, in OMB Bulletin No. 13–01. OMB Bulletin No. 13–01 established revised delineations for Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas in the United States and Puerto Rico based on the 2010 Census, and provided guidance on the use of the delineations of these statistical areas using standards published on June 28, 2010 in the Federal Register (75 FR 37246 through 37252). We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 through 49963) for a full discussion of our implementation of the new OMB labor market area delineations beginning with the FY 2015 wage index. Generally, OMB issues major revisions to statistical areas every 10 years, based on the results of the decennial census. However, OMB occasionally issues minor updates and revisions to statistical areas in the years between the decennial censuses. As we discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25062), on July 15, 2015, OMB issued OMB Bulletin No. 15–01, which provides updates to and supersedes OMB Bulletin No. 13–01 that was issued on February 28, 2013. The attachment to OMB Bulletin No. 15–01 provides detailed information on the update to statistical areas since February 28, 2013. The updates provided in OMB Bulletin No. 15–01 are based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2012 and July 1, 2013. The complete list of statistical areas incorporating these changes is provided in the attachment to OMB Bulletin No. 15–01. According to OMB, “[t]his bulletin establishes revised delineations for the Nation’s Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas. The bulletin also provides delineations of Metropolitan Divisions as well as delineations of New England City and Town Areas.” A copy of this bulletin may be obtained on the Web site at: https://www.whitehouse.gov/omb/bulletins_default.

OMB Bulletin No. 15–01 made the following changes that are relevant to the IPPS wage index:

- Garfield County, OK, with principal city Enid, OK, which was a Micropolitan (geographically rural) area, now qualifies as an urban new CBSA 21420 called Enid, OK.
- The county of Bedford City, VA, a component of the Lynchburg, VA CBSA 31340, changed to town status and is added to Bedford County. Therefore, the county of Bedford City (SSA State county code 49088, FIPS State County Code 51515) is now part of the county of Bedford, VA (SSA State county code 49090, FIPS State County Code 51019). However, the CBSA remains Lynchburg, VA 31340.
- The name of Macon, GA, CBSA 31420, as well as a principal city of the Macon-Warner Robins, GA combined statistical area, is now Macon-Bibb County, GA. The CBSA code remains as 31420.

We believe that it is important for the IPPS to use the latest labor market area delineations available as soon as is reasonably possible in order to maintain a more accurate and up-to-date payment system that reflects the reality of population shifts and labor market conditions (79 FR 28055). Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25062), we proposed to implement these revisions, effective October 1, 2016, beginning with the FY 2017 wage indexes. We proposed to use these new definitions to calculate area wage index in a manner that is generally consistent with the CBSA-based methodologies finalized in the FY 2005 and the FY 2015 IPPS final rules. For FY 2017, Tables 2 and 3 for the proposed rule and the County to CBSA Crosswalk File and Urban CBSAs and Constituent Counties for Acute Care Hospitals File posted on the CMS Web site reflected these CBSA changes. We invited public comments on these proposals.

We did not receive any public comments on our proposal to implement the revisions to the CBSAs effective October 1, 2016, beginning with the FY 2017 hospital wage index, as proposed in the FY 2017 IPPS/LTCH PPS proposed rule. Therefore, we are finalizing our proposal without modification. Tables 2 and 3 for this final rule and the County to CBSA Crosswalk File and Urban CBSAs and Constituent Counties for Acute Care Hospitals File posted on the CMS Web site reflect these CBSA changes.

B. Worksheet S–3 Wage Data for the FY 2017 Wage Index

The FY 2017 wage index values are based on the data collected from the Medicare cost reports submitted by hospitals for cost reporting periods beginning in FY 2013 (the FY 2016 wage indexes were based on data from cost reporting periods beginning during FY 2012).

1. Included Categories of Costs

The FY 2017 wage index includes all of the following categories of data associated with costs paid under the IPPS (as well as outpatient costs):

- Salaries and benefits for short-term, acute care hospitals (including paid lunch hours and hours associated with military leave and jury duty);
- Home office costs and hours;
- Certain contract labor costs and hours, which include direct patient care, certain top management, pharmacy, laboratory, and non-teaching physician Part A services, and certain contract indirect patient care services (as discussed in the FY 2008 final rule with comment period (72 FR 47315 through 47317)); and
- Wage-related costs, including pension costs (based on policies adopted in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51586 through 51590)) and other deferred compensation costs.

2. Excluded Categories of Costs

Consistent with the wage index methodology for FY 2016, the wage index for FY 2017 also excludes the direct and overhead salaries and hours for services not subject to IPPS payment, such as skilled nursing facility (SNF) services, home health services, costs related to GME (teaching physicians and
residents) and certified registered nurse anesthetists (CRNAs), and other subprovider components that are not paid under the IPPS. The FY 2017 wage index also excludes the salaries, hours, and wage-related costs of hospital-based rural health clinics (RHCs), and Federally qualified health centers (FQHCs) because Medicare pays for these costs outside of the IPPS (68 FR 45395). In addition, salaries, hours, and wage-related costs of CAHs are excluded from the wage index for the reasons explained in the FY 2004 IPPS final rule (68 FR 45397 through 45398).

3. Use of Wage Index Data by Suppliers and Providers Other Than Acute Care Hospitals Under the IPPS

Data collected for the IPPS wage index also are currently used to calculate wage indexes applicable to suppliers and other providers, such as SNFs, home health agencies (HHAs), ambulatory surgical centers (ASCs), and hospices. In addition, they are used for prospective payments to IRFs, IPFs, and LTCHs, and for hospital outpatient services. We note that, in the IPPS rules, we do not address comments pertaining to the wage indexes of any supplier or provider except IPPS providers and LTCHs. Such comments should be made in response to separate proposed rules for those suppliers and providers.

C. Verification of Worksheet S–3 Wage Data

The wage data for the FY 2017 wage index were obtained from Worksheet S–3, Parts II and III of the Medicare cost report (Form CMS–2552–10, OMB control number 0938–0050) for cost reporting periods beginning on or after October 1, 2012, and before October 1, 2013. For wage index purposes, we refer to cost reports during this period as the “FY 2013 cost report,” the “FY 2013 wage data,” or the “FY 2013 data.” Instructions for completing the wage index sections of Worksheet S–3 are included in the Provider Reimbursement Manual (PRM), Part 2 (Pub. No. 15–2), Chapter 40, Sections 4005.2 through 4005.4. The data file used to construct the FY 2017 wage index includes FY 2013 data submitted to us as of June 28, 2016. As in past years, we performed an extensive review of the wage data, mostly through the use of edits for reasonableness designed to identify aberrant data.

We asked our MACs to revise or verify data elements that result in specific edit failures. For the proposed FY 2017 wage index, we identified and excluded 62 providers with aberrant data that should not be included in the wage index. We stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25063) that, of these 62 providers that we excluded from the proposed wage index, 47 have data that we did not expect to change such that the data would be included in the final wage index (for example, among the reasons these providers were excluded are the following: they are low Medicare utilization providers, they closed and failed edits for reasonableness, or they have extremely high or low average hourly wages that are atypical for their CBSAs). We stated in the proposed rule that if data elements for some of these providers were corrected, we intend to include those providers in the calculation of the final FY 2017 wage index (81 FR 25063).

We also adjusted certain aberrant data and included these data in the proposed wage index. For example, in situations where a hospital did not have documentable salaries, wages, and hours for housekeeping and dietary services, we imputed estimates, in accordance with policies established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967). In constructing the proposed FY 2017 wage index, we included the wage data for facilities that were IPPS hospitals in FY 2013, inclusive of those facilities that have since terminated their participation in the program as hospitals, as long as those data did not fail any of our edits for reasonableness. We believed that including the wage data for these hospitals is, in general, appropriate to reflect the economic conditions in the various labor market areas during the relevant past period and to ensure that the current wage index represents the labor market area’s current wages as compared to the national average of wages. However, we excluded the wage data for CAHs as discussed in the FY 2004 IPPS final rule (68 FR 45397 through 45398). For the proposed rule, we removed 3 hospitals that converted to CAH status on or after February 5, 2015, the cut-off date for CAH exclusion from the FY 2016 wage index, and through and including January 22, 2016, the cut-off date for CAH exclusion from the FY 2017 wage index. After removing hospitals that converted to CAH status, we calculated the proposed FY 2017 wage index based on 3,345 hospitals.

Comment: One commenter expressed appreciation for CMS’ efforts over the past 2 years to “refine and augment its area wage index audit protocols to ensure more consistency across the MACs,” and observed that this has resulted in fewer hospitals being excluded from the final wage index. The commenter stated that several member hospitals had a “very positive experience in working with their MACs, despite a very challenging timeline.” For those hospitals that are excluded due to a higher than average average hourly wage, the commenter requested that CMS make transparent the audit thresholds it uses to exclude these hospitals, as hospitals remain concerned that, in some instances, having a higher than average average hourly wage will remain unacceptable to CMS.

Response: We appreciate the commenter’s acknowledgement of the efforts we and the MACs invest in the wage index review process, and recognize the improved collaboration between hospitals and the MACs. As part of our efforts to assure that hospitals are aware of whether or not their wage data are excluded from the development of the wage index, we note that, for the FY 2017 wage index development cycle, we have added additional tabs to the Public Use Files (PUFs) that we post on our Web site. These tabs specifically list the hospitals and their respective wage data and occupational mix data that have been removed from the wage index (the various FY 2017 PUFs are available at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcutelnPatientIPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html). As we explained in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49490 through 49491), section 1886(d)(3)(E) of the Act requires the Secretary to adjust the proportion of hospitals’ costs attributable to wages and wage-related costs for area differences reflecting the relative hospital wage level in the geographic areas of the hospital compared to the national average hospital wage level. We believe that, under this section of the Act, we have discretion to remove aberrant hospital data from the wage index PUFs to help ensure that the costs attributable to wages and wage-related costs in fact reflect the relative hospital wage level in the hospitals’ geographic area. We appreciate that hospitals remain concerned that, in some instances, having a higher than average average hourly wage would be unacceptable to CMS, depending on the circumstances, but reasonableness and relativity to each area’s average hourly wages have been longstanding tenets of the wage index development process that CMS has articulated in rulemaking. Therefore, for the FY 2017 wage index, as we have done in previous years, we have exercised our discretion to remove certain hospitals from the wage index that have unusually high or unusually low average hourly wages relative to the
average hourly wages of the hospitals in the same geographic area. We note that it has never been CMS’ policy to disclose audit protocol; the protocol is for CMS and MAC internal use only. In addition, we note that foreknowledge of an audit threshold should not in any way influence the wages and hours that hospitals report on Worksheet S–3; as with all cost report data, hospitals must attest to the accuracy of what they report on the Medicare cost reports, without regard to whether or not their data will be subjected to an audit. 

Since the development of the FY 2017 proposed wage index, as a result of further review by the MACs and the April and May appeals processes, we received improved data for 11 hospitals. Therefore, we are including the wage data of these 11 hospitals in the final wage index. However, we also have deleted the wage data of 2 additional hospitals whose data were determined to be aberrant, and the hospitals were not responsive to requests by the MAC to provide supporting documentation. For this final rule, we learned of an additional 4 hospitals that converted to CAH status on or after February 5, 2015, and through and including January 22, 2016, the cut-off date for CAH exclusion from the FY 2017 wage index. Thus, for this final rule, we removed 7 hospitals that converted to CAH status on or after February 5, 2015, and through and including January 22, 2016 (3 CAHs removed for the proposed rule, and 4 additional CAHs removed for this final rule). Hospitals that are excluded from the wage index remain excluded for a variety of reasons, such as, but not limited to, unresponsiveness to requests for documentation or insufficiently documented data, terminated hospitals’ failed edits for reasonableness, or low Medicare utilization. Accordingly, the final FY 2017 wage index is based on the wage data of 3,350 hospitals (3,345 + 11 – 2 – 4 = 3,350).

For the final FY 2017 wage index, we allotted the wages and hours data for a multicampus hospital among the different labor market areas where its campuses are located in the same manner that we allotted such hospitals’ data in the FY 2016 wage index (80 FR 49489 through 49491). Table 2, which contains the final FY 2017 wage index associated with this final rule (available via the Internet on the CMS Web site), includes separate wage data for the campuses of 9 multicampus hospitals.

D. Method for Computing the FY 2017 Unadjusted Wage Index

The method used to compute the FY 2017 wage index without an occupational mix adjustment follows the same methodology that we used to compute the FY 2012, FY 2013, FY 2014, FY 2015, and FY 2016 final wage indexes without an occupational mix adjustment (76 FR 51591 through 51593, 77 FR 53366 through 53367, 78 FR 50587 through 50588, 79 FR 49967 and 80 FR 49491 through 49492, respectively).

Comment: One commenter requested CMS to consider developing a process for determining a wage index that would reward hospitals that invest in the workforce and raise the wages of the lowest paid workers, rather than relying primarily on the average hourly wages of the labor market area as a whole.

Response: Section 1886(d)(3)(E) of the Act requires the Secretary to adjust for area differences in hospital wage levels by a factor reflecting the relative hospital wage level in the geographic area of the hospital compared to the national average hospital wage level. The statute does not direct the Secretary to develop a wage index that rewards hospitals for workforce investment or other labor initiatives.

Comment: One commenter requested that CMS establish a floor wage index for providers in Puerto Rico that is not lower than the ratio of Puerto Rico nonhealth care wages to U.S. nonhealth care wages, using data from the Occupational Employment Statistics (OES) of the U.S. Bureau of Labor Statistics (BLS).

Response: We appreciate this comment. However, we consider it to be outside the scope of the FY 2017 IPPS/LTCH PPS proposed rule. Therefore, we are not responding to the comment at this time.

As discussed in the FY 2012 IPPS/LTCH PPS final rule, in “Step 5,” for each hospital, we adjust the total salaries plus wage-related costs to a common period to determine total adjusted salaries plus wage-related costs. To make the wage adjustment, we estimate the percentage change in the employment cost index (ECI) for compensation for each 30-day increment from October 14, 2012, through April 15, 2014, for private industry hospital workers from the BLS’ Compensation and Working Conditions. We have consistently used the ECI as the data source for our wages and salaries and other price proxies in the IPPS market basket, and as discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25063 through 25064), we did not propose any changes to the usage for FY 2017, nor have received any public comments on this issue. Therefore, for FY 2017, we used the ECI as the data source for our wages and salaries and other price proxies in the IPPS market basket. The factors used to adjust the hospital’s data were based on the midpoint of the cost reporting period, as indicated in the following table.

### Table: Midpoint of Cost Reporting Period

<table>
<thead>
<tr>
<th>After</th>
<th>Before</th>
<th>Adjustment factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/14/2012</td>
<td>11/15/2012</td>
<td>1.02321</td>
</tr>
<tr>
<td>11/14/2012</td>
<td>12/15/2012</td>
<td>1.02183</td>
</tr>
<tr>
<td>12/14/2012</td>
<td>01/15/2013</td>
<td>1.02040</td>
</tr>
<tr>
<td>01/14/2013</td>
<td>02/15/2013</td>
<td>1.01894</td>
</tr>
<tr>
<td>02/14/2013</td>
<td>03/15/2013</td>
<td>1.01743</td>
</tr>
<tr>
<td>03/14/2013</td>
<td>04/15/2013</td>
<td>1.01592</td>
</tr>
<tr>
<td>04/14/2013</td>
<td>05/15/2013</td>
<td>1.01443</td>
</tr>
<tr>
<td>05/14/2013</td>
<td>06/15/2013</td>
<td>1.01297</td>
</tr>
<tr>
<td>06/14/2013</td>
<td>07/15/2013</td>
<td>1.01152</td>
</tr>
<tr>
<td>07/14/2013</td>
<td>08/15/2013</td>
<td>1.01006</td>
</tr>
<tr>
<td>08/14/2013</td>
<td>09/15/2013</td>
<td>1.00859</td>
</tr>
<tr>
<td>09/14/2013</td>
<td>10/15/2013</td>
<td>1.00711</td>
</tr>
<tr>
<td>10/14/2013</td>
<td>11/15/2013</td>
<td>1.00561</td>
</tr>
<tr>
<td>11/14/2013</td>
<td>12/15/2013</td>
<td>1.00408</td>
</tr>
<tr>
<td>12/14/2013</td>
<td>01/15/2014</td>
<td>1.00260</td>
</tr>
<tr>
<td>01/14/2014</td>
<td>02/15/2014</td>
<td>1.00124</td>
</tr>
<tr>
<td>02/14/2014</td>
<td>03/15/2014</td>
<td>1.00000</td>
</tr>
<tr>
<td>03/14/2014</td>
<td>04/15/2014</td>
<td>0.99878</td>
</tr>
</tbody>
</table>

For example, the midpoint of a cost reporting period beginning January 1, 2013, and ending December 31, 2013, is June 30, 2013. An adjustment factor of 1.01152 would be applied to the wages of a hospital with such a cost reporting period.

Using the data as previously described, the FY 2017 national average hourly wage (unadjusted for occupational mix) is $41.1982.

Previously, we also would provide a Puerto Rico overall average hourly wage. As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25076) and in section IV.A. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. As a result, we calculated a Puerto Rico-specific wage index that was applied to the labor share of the Puerto Rico-specific standardized amount. Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016, shall use 100 percent of the national standardized amount. As we stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25064), because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount as of January 1, 2016, under section 1886(d)(9)(E) of the Act, as
amended by section 601 of the Consolidated Appropriations Act, 2016, there is no longer a need to calculate a Puerto Rico-specific average hourly wage and wage index. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the national average hourly wage (unadjusted for occupational mix) which is $41.1982 for this FY 2017 final rule) and the national wage index, which is applied to the national labor share of the national standardized amount. We did not receive any public comments on this issue. Accordingly, for FY 2017, we as proposed (81 FR 25064), we are not establishing a Puerto Rico-specific overall average hourly wage or wage index.

E. Occupational Mix Adjustment to the FY 2017 Wage Index

As stated earlier, section 1886(d)(3)(E) of the Act provides for the collection of data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program, in order to construct an occupational mix adjustment to the wage index, for application beginning October 1, 2004 (the FY 2005 wage index). The purpose of the occupational mix adjustment is to control for the effect of hospitals’ employment choices on the wage index. For example, hospitals may choose to employ different combinations of registered nurses, licensed practical nurses, nursing aides, and medical assistants for the purpose of providing nursing care to their patients. The varying labor costs associated with these choices reflect hospital management decisions rather than geographic differences in the costs of labor.

1. Use of 2013 Occupational Mix Survey for the FY 2017 Wage Index

Section 304(c) of Public Law 106–554 amended section 1886(d)(3)(E) of the Act to require CMS to collect data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program. We collected data in 2013 to compute the occupational mix adjustment for the FY 2016, FY 2017, and FY 2018 wage indexes. A new measurement of occupational mix is required for FY 2019. The 2013 survey included the same data elements and definitions as the previous 2010 survey and provided for the collection of hospital-specific wages and hours data for nursing employees for calendar year 2013 (that is, payroll periods ending between January 1, 2013 and December 31, 2013). We published the 2013 survey in the Federal Register on February 28, 2013 (78 FR 13679 through 13680). This survey was approved by OMB on May 14, 2013, and is available on the CMS Web site at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/Medicare-Wage-Index-Occupational-Mix-Survey2013.html. The 2013 Occupational Mix Survey Hospital Reporting Form CMS–10079 for the Wage Index Beginning FY 2016 (in Excel format) is available on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/Medicare-Wage-Index-Occupational-Mix-Survey2013.html. Hospitals were required to submit their completed 2013 surveys to their MACs by July 1, 2014. The preliminary, unaudited 2013 survey data were posted on the CMS Web site on July 11, 2014. As with the Worksheet S–3, Parts II and III cost report wage data, we asked our MACs to revise or verify data elements in hospitals’ occupational mix surveys that result in certain edit failures.

2. Development of the 2016 Medicare Wage Index Occupational Mix Survey for the FY 2019 Wage Index

As stated earlier, section 304(c) of Public Law 106–554 amended section 1886(d)(3)(E) of the Act to require CMS to collect data every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program. We collected data in 2013 to compute the occupational mix adjustment for the FY 2016, FY 2017, and FY 2018 wage indexes. A new measurement of occupational mix is required for FY 2019. The FY 2019 occupational mix adjustment will be based on a new calendar year (CY) 2016 survey. The CY 2016 survey (CMS Form CMS–10079) is currently awaiting approval by OMB, and can be accessed at https://www.reginfo.gov/public/do/PRAViewCR?ref_nbr=201512-0938-011.

3. Calculation of the Occupational Mix Adjustment for FY 2017

In the FY 2017 IPPS/LTCPPS proposed rule (81 FR 25065), for FY 2017, we proposed to calculate the occupational mix adjustment factor using the same methodology that we used for the FY 2012, FY 2013, FY 2014, FY 2015, and FY 2016 wage indexes (76 FR 51582 through 51586, 77 FR 53367 through 53368, 78 FR 50588 through 50591, 80 FR 49492 through 49493, respectively) and to apply the occupational mix adjustment to 100 percent of the FY 2017 wage index. Because the statute requires that the Secretary measure the earnings and paid hours of employment by occupational category not less than once every 3 years, all hospitals that are subject to payments under the IPPS, or any hospital that would be subject to the IPPS if not granted a waiver, must complete the occupational mix survey, unless the hospital has no associated cost report wage data that are included in the FY 2017 wage index. For the proposed FY 2017 wage index, we used the Worksheet S–3, Parts II and III wage data of 3,345 hospitals, and we used the occupational mix surveys of 3,143 hospitals for which we also have Worksheet S–3 wage data, which represented a “response” rate of 94 percent (3,143/3,345). For the proposed FY 2017 wage index, we applied proxy data for noncompliant hospitals, new hospitals, or hospitals that submitted erroneous or aberrant data in the same manner that we applied proxy data for such hospitals in the FY 2012 wage index occupational mix adjustment (76 FR 51586).

Comment: One commenter stated that all hospitals should be obligated to submit the occupational mix survey because failure to complete the survey jeopardizes the accuracy of the wage index. The commenter suggested that a penalty be instituted for nonsubmitters. This commenter also requested that, pending CMS’ analysis of the Commuting Based Wage Index and given the Institute of Medicine’s study on geographic variation in hospital wage costs, CMS eliminate the occupational mix survey and the significant reporting burden it creates.

Response: We appreciate the commenter’s concern about the accuracy of the wage index. We have continually requested that all hospitals complete and submit the occupational mix surveys. We did not establish a penalty for hospitals that did not submit the 2013 occupational mix survey. However, we are continuing to consider for future rulemaking various options for ensuring full compliance with future occupational mix surveys. Regarding the commenter’s request that CMS eliminate the occupational mix survey, this survey is necessary to meet the provisions of section 1886(d)(3)(E) of the Act, which requires us to measure the earnings and paid hours of employment by occupational category.

After consideration of the public comments we received, for FY 2017, we are adopting as final our proposal to calculate the occupational mix adjustment factor using the same methodology that we have used since
the FY 2012 wage index. For the final FY 2017 wage index, we are using the Worksheet S–3, Parts II and III wage data of 3,350 hospitals, and we are using the occupational mix surveys of 3,149 hospitals for which we also have Worksheet S–3 wage data, which represents a “response” rate of 94 percent (3,149/3,350). For the final FY 2017 wage index, we applied proxy data for noncompliant hospitals, new hospitals, or hospitals that submitted erroneous or aberrant data in the same manner that we applied proxy data for such hospitals in the FY 2012 wage index occupational mix adjustment (76 FR 51586). As a result of applying this methodology, the FY 2017 occupational mix adjusted national average hourly wage is $41.1615.

F. Analysis and Implementation of the Occupational Mix Adjustment and the FY 2017 Occupational Mix Adjusted Wage Index

As discussed in section III.E. of the preamble of this final rule, for FY 2017, we are applying the occupational mix adjustment to 100 percent of the FY 2017 wage index. We calculated the occupational mix adjustment using data from the 2013 occupational mix survey data, using the methodology described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51582 through 51586).

Using the occupational mix survey data and applying the occupational mix adjustment to 100 percent of the FY 2017 wage index results in a national average hourly wage of $41.1615. Previously, we would also provide a Puerto Rico overall average hourly wage. As discussed in the proposed rule (81 FR 25076) and in section IV.A. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. As a result, we calculated a Puerto Rico-specific wage index that was applied to the labor-related share of the Puerto Rico-specific standardized amount. Section 601 of the Consolidated Appropriations Act, 2016, there is no longer a need to calculate a Puerto Rico-specific average hourly wage and wage index. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the national average hourly wage (adjusted for occupational mix) (which is $41.1615 for this FY 2017 final rule) and the national wage index, which is applied to the national labor share of the national standardized amount.

Accordingly, for FY 2017, we did not propose a Puerto Rico-specific overall average hourly wage or wage index in the proposed rule (81 FR 25065), nor are we establishing such for this final rule.

The FY 2017 national average hourly wages for each occupational mix nursing subcategory as calculated in Step 2 of the occupational mix calculation are as follows:

<table>
<thead>
<tr>
<th>Occupational mix nursing subcategory</th>
<th>Average hourly wage</th>
</tr>
</thead>
<tbody>
<tr>
<td>National RN ..........................</td>
<td>$38.83416971</td>
</tr>
<tr>
<td>National LPN and Surgical Technician</td>
<td>22.73766832</td>
</tr>
<tr>
<td>National Nurse Aide, Orderly, and Attendant</td>
<td>15.95353295</td>
</tr>
<tr>
<td>National Medical Assistant ...</td>
<td>18.04809696</td>
</tr>
<tr>
<td>National Nurse Category ......</td>
<td>32.5859243</td>
</tr>
</tbody>
</table>

The national average hourly wage for the entire nurse category as computed in Step 5 of the occupational mix calculation is $32.5859243. Hospitals with a nurse category average hourly wage (as calculated in Step 4) of greater than the national nurse category average hourly wage receive an occupational mix adjustment factor (as calculated in Step 6) of less than 1.0. Hospitals with a nurse category average hourly wage (as calculated in Step 4) of less than the national nurse category average hourly wage receive an occupational mix adjustment factor (as calculated in Step 6) of greater than 1.0.

Based on the occupational mix survey data, we determined (in Step 7 of the occupational mix calculation) that the national percentage of hospital employees in the nurse category is 42.6 percent, and the national percentage of hospital employees in the all other occupations category is 57.4 percent. At the CBSA level, the percentage of hospital employees in the nurse category ranged from a low of 25.7 percent in one CBSA to a high of 80.5 percent in another CBSA.

We compared the FY 2017 occupational mix adjusted wage indexes for each CBSA and the unadjusted wage indexes for each CBSA. As a result of applying the occupational mix adjustment to the wage data, the final wage index values for 221 (54.2 percent) urban areas and 24 (51.1 percent) rural areas will increase. The final wage index values for 104 (25.5 percent) urban areas will increase by greater than or equal to 1 percent but less than 5 percent, and the final wage index values for 6 (1.5 percent) urban areas will increase by 5 percent or more. The final wage index values for 10 (21.3 percent) rural areas will increase by greater than or equal to 1 percent but less than 5 percent, and no rural areas’ final wage index values will increase by 5 percent or more. However, the wage index values for 186 (45.6 percent) urban areas and 23 (48.9 percent) rural areas will decrease. The final wage index values for 89 (21.8 percent) urban areas will decrease by greater than or equal to 1 percent and less than 5 percent, and no rural areas’ final wage index value will decrease by 5 percent or more. The final wage index values of 7 (14.9 percent) rural areas will decrease by greater than or equal to 1 percent and less than 5 percent, and no rural areas’ final wage index values will decrease by 5 percent or more. The largest positive impacts will be 17.4 percent for an urban area and 2.9 percent for a rural area. The largest negative impacts will be 4.9 percent for an urban area and 2.1 percent for a rural area. One urban area’s wage index, but no rural area wage indexes, will remain unchanged by application of the occupational mix adjustment. These results indicate that a larger percentage of urban areas (54.2 percent) will benefit from the occupational mix adjustment than will rural areas (51.1 percent).

G. Transitional Wage Indexes

1. Background

In the FY 2015 IPPS/LTCH PPS proposed rule and final rule (79 FR 28060 and 49957, respectively), we stated that, overall, we believed implementing the new OMB labor market area delineations would result in wage index values being more representative of the actual costs of labor in a given area. However, we recognized that some hospitals would experience decreases in wage index values as a result of the implementation of these new OMB labor market area delineations. We also realized that some hospitals would have higher wage index values due to the implementation of the new OMB labor market area delineations. The FY 2015 IPPS/LTCH PPS final rule (79 FR 49957) explained the methodology utilized in implementing prior transition periods when adopting
changes that have significant payment implications, particularly large negative impacts. Specifically, for FY 2005, in the FY 2005 IPPS final rule (69 FR 49032 through 49034), we provided transitional wage indexes when the OMB definitions were implemented after the 2000 Census. The FY 2015 IPPS/LTCH PPS final rule (79 FR 49957 through 49962) established similar transition methodologies to mitigate any negative payment impacts experienced by hospitals due to our adoption of the new OMB labor market area delineations for FY 2015.

As finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49957 through 49960) and as discussed below, for FY 2017, we will be in the third and final year of two 3-year transition periods for wage index: (1) For hospitals that, for FY 2014, were located in an urban county that became rural under the new OMB delineations, and had no form of wage index reclassification or redesignation in place for FY 2015 (that is, MGCRB reclassifications under section 1886(d)(8)(B) of the Act, redesignations under section 1886(d)(8)(E) of the Act, or rural reclassifications under section 1886(d)(8)(B) of the Act); and (2) for hospitals deemed urban under section 1886(d)(8)(B) of the Act where the urban area became rural under the new OMB delineations.

2. Transition for Hospitals in Urban Areas That Became Rural

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49957 through 49959), for hospitals that, for FY 2014, were located in an urban county that became rural under the new OMB delineations, and had no form of wage index reclassification or redesignation in place for FY 2015 (that is, MGCRB reclassifications under section 1886(d)(10) of the Act, redesignations under section 1886(d)(8)(B) of the Act, or rural reclassifications under section 1886(d)(8)(E) of the Act), we adopted a policy to assign them the urban wage index value of the CBSA in which they were physically located for FY 2014 for a period of 3 fiscal years (with the rural and imputed floors applied and with the rural floor budget neutrality adjustment applied to the area wage index). FY 2017 will be the third year of this transition policy. We did not propose to make any changes to this policy in the FY 2017 IPPS/LTCH PPS proposed rule, and therefore we are not making any changes to this policy in this final rule. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49957) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49495), we stated our belief that it is appropriate to apply a 3-year transition period for hospitals located in urban counties that would become rural under the new OMB delineations, given the potentially significant payment impacts for these hospitals. We continue to believe that assigning the wage index of the hospitals’ FY 2014 area for a 3-year transition is the simplest and most effective method for mitigating negative payment impacts due to the adoption of the new OMB delineations.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49959), we noted that there were situations where a hospital could not be assigned the wage index value of the CBSA in which it was geographically located in FY 2014 because CBSA split and no longer exists and some or all of the constituent counties were added to another urban labor market area under the new OMB delineations. If the hospital could not be assigned the wage index value of the CBSA in which it was geographically located in FY 2014 because CBSA split apart and no longer exists, and some or all of its constituent counties were added to another urban labor market area under the new OMB delineations, we established that hospitals located in such counties that became rural under the new OMB delineations were assigned the wage index of the urban labor market area that contained the urban county in their FY 2014 CBSA to which they were closest (with the rural and imputed floors applied and with the rural floor budget neutrality adjustment applied). Any such assignment made in FY 2015 and continued in FY 2016 will continue for FY 2017, except as discussed later in this section. We continue to believe this approach minimizes the negative effects of the change in the OMB delineations.

Under the policy adopted in the FY 2015 IPPS/LTCH PPS final rule, if a hospital for FY 2014 was located in an urban county that became rural beginning in FY 2015 under the new OMB delineations and such hospital sought and was granted reclassification or redesignation for FY 2015 or FY 2016, or such hospital seeks and is granted any reclassification or redesignation for FY 2017, the hospital will permanently lose its 3-year transitional assigned wage index status, and will not be eligible to reinstate it. We established the transition policy to assist hospitals if they experience a negative payment impact specifically due to the adoption of the new OMB delineations in FY 2015. If a hospital chooses to forego this transition adjustment for the same form of reclassification or redesignation, we do not believe reinstatement of this transition adjustment would be appropriate. The purpose of the transition adjustment policy is to assist hospitals that may be negatively impacted by the new OMB delineations in transitioning to a wage index based on these delineations. By obtaining a redesignation, we believe that the hospital has made the determination that the transition adjustment is not necessary because it has other viable options for mitigating the impact of the transition to the new OMB delineations.

As we did for FY 2015 (79 FR 49959) and FY 2016 (80 FR 49495), with respect to the wage index computation for FY 2017, we followed our existing policy regarding the inclusion of a hospital’s wage index data in the CBSA in which it is geographically located (we refer readers to Step 6 of the method for computing the unadjusted wage index in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51592)). Accordingly, for FY 2017, the wage data of all hospitals receiving this type of 3-year transition adjustment were included in the statewide rural area in which they are geographically located under the new OMB labor market area delineations. After the 3-year transition period, beginning in FY 2018, these formerly urban hospitals will receive their statewide rural wage index, absent any reclassification or redesignation.

In addition, we established in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49959) that the hospitals receiving this 3-year transition because they are in counties that were urban under the FY 2014 CBSA definitions, but are rural under the new OMB delineations, will not be considered urban hospitals. Rather, they will maintain their status as rural hospitals for other payment considerations. This is because our application of a 3-year transitional wage index for these newly rural hospitals only applies for the purpose of calculating the wage index under our adoption of the new OMB delineations.

We did not receive any public comments regarding the 3-year transition policy for hospitals that were located in an urban county that became rural under the new OMB delineations. Fiscal year 2017 is the third and final year of this 3-year transition period. We also remind hospitals that if any affected hospital is approved for any wage index reclassification or redesignation in FY 2017, it will no longer be eligible for the remaining year of this transitional wage index.
3. Transition for Hospitals Deemed Urban Under Section 1886(d)(8)(B) of the Act Where the Urban Area Became Rural Under the New OMB Delineations

As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49959 through 49960) and FY 2016 IPPS/LTCH PPS final rule (80 FR 49495 through 49496), there were some hospitals that, for FY 2014, were geographically located in rural areas but were deemed to be urban under section 1886(d)(8)(B) of the Act. For FY 2015, some of these hospitals redesignated under section 1886(d)(8)(B) of the Act were no longer eligible for deemed urban status under the new OMB delineations, as discussed in detail in section III.H.3. of the preamble of the FY 2015 IPPS/LTCH PPS final rule. Similar to the policy implemented in the FY 2005 IPPS final rule (69 FR 49050), and consistent with the FY 2015 policy we established for other hospitals in counties that were urban and became rural under the new OMB delineations, we finalized a policy to apply a 3-year transition to hospitals redesignated to urban areas under section 1886(d)(8)(B) of the Act for FY 2014 that are no longer deemed urban under the new OMB delineations and revert to being rural.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25067), for FY 2017, we did not propose to make any changes to this policy. We will continue the third and final year of the implementation of our policy to provide a 3-year transition adjustment to hospitals that are deemed urban under section 1886(d)(8)(B) of the Act under the FY 2014 labor market area delineations, but are considered rural under the new OMB delineations, assuming no other form of wage index reclassification or redesignation is granted. We assign these hospitals the area wage index value of hospitals reclassified to a CBSA because hospitals deemed urban under section 1886(d)(8)(B) of the Act are treated as reclassified under current policy, under which such hospitals receive an area wage index that includes wage data of all hospitals reclassified to the area. This wage index assignment will be forfeited if the hospital obtains any form of wage index reclassification or redesignation.

We did not receive any public comments regarding the 3-year transition policy for hospitals deemed urban under section 1886(d)(8)(B) of the Act where the urban area became rural under the new OMB delineations. Fiscal year 2017 is the third and final year of this 3-year transition period. We also remind hospitals that if any affected hospital is approved for any wage index reclassification or redesignation in FY 2017, it will no longer be eligible for the remaining year of this transitional wage index.

4. Budget Neutrality

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50372 through 50373), for FY 2015, and in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49496), for FY 2016, we applied the 3-year transition wage index adjustments in a budget neutral manner. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25067), for FY 2017, we proposed to apply the 3-year transition adjustments in a budget neutral manner. We proposed to make an adjustment to the standardized amount to ensure that the total payments, including the effect of the transition provisions, would equal what payments would have been if we were not providing for any transitional wage indexes under the new OMB delineations. For a complete discussion on the budget neutrality adjustment for FY 2017, we refer readers to section II.A.4.b. of the Addendum to this final rule, where we also address any public comments we received.

We did not receive any public comments on these proposals. In this final rule, for FY 2017, we are applying the 3-year transition adjustments in a budget neutral manner. We are making an adjustment to the standardized amount to ensure that the total payments, including the effect of the transition provisions, will equal what payments would have been if we were not providing for any transitional wage indexes under the new OMB delineations.
such section to any hospital which is not located in a rural area (as defined in section 1886(d)(2)(D) of such Act) may not be less than the area wage index applicable under such section to hospitals located in rural areas in the State in which the hospital is located.

Comment: Many commenters expressed concern about the decline in the proposed Massachusetts rural wage index, due partially to preliminary audit adjustments made by the MAC to Nantucket Cottage Hospital’s FY 2017 wage data, and certain errors identified by Nantucket Cottage Hospital in the FY 2017 wage data it submitted. The commenters stated that an abrupt decline in payment would have a negative impact for Massachusetts hospitals, particularly for hospitals in parts of the State lagging economically. In addition, several commenters noted that because of the calculation of the alternative methodology for the imputed floor, a decline in the Massachusetts rural floor would have a negative payment impact on hospitals in Rhode Island.

The commenters urged CMS to exercise its discretion in this situation to grant wage data correction requests outside of the prescribed FY 2017 Wage Index Timeline and accept Nantucket Cottage Hospital’s request to correct its data errors, which were submitted to the MAC after the specified deadline. Many commenters also believed it would be “sound public policy” for CMS to use the most accurate data available in order to prevent one hospital’s data errors from have effect on Medicare payments of other hospitals. One commenter did not believe CMS should knowingly use the incorrect wage data and cautioned that Massachusetts hospitals’ efforts at cost reform may be jeopardized due to the negative financial impact of finalizing the proposed rural wage index.

Several commenters believed that, because the rural floor is subject to a budget neutrality adjustment, the impact of accepting Nantucket Cottage Hospital’s wage data correction would be spread across hospitals nationwide and would minimally impact any particular hospital, but the effects of not correcting the data error would be significant for hospitals in Massachusetts.

Conversely, other commenters requested that CMS deny Nantucket Cottage Hospital’s request to correct its wage index data, as the request was submitted nearly 2 months after the agency’s deadline. The commenters emphasized that Nantucket Cottage Hospital should be held to the same standards as hospitals nationwide.

Several commenters stated that CMS would establish a “troubling” precedent by disregarding CMS rules and regulations, which provide ample opportunity to correct wage data through the agency’s normal review process and deadlines.

Commenters also noted that the redistributive effect of nationwide rural floor budget neutrality would further lower wage index values for hospitals nationwide to pay for additional increases in Massachusetts’s rural floor. One commenter requested that CMS deny Nantucket Cottage Hospital’s request in order to ensure access to care in rural hospitals in States other than Massachusetts that the commenter stated are struggling in part due to receipt of a wage index that is lower than it would be in the absence of a high Massachusetts rural floor.

Response: We appreciate all of the commenters’ concerns about the Massachusetts rural wage index. It is our intent to ensure that the wage index is calculated from the best available data, consistent with our wage index policies and development timeline. We have determined that the corrections requested by Nantucket Cottage Hospital fall outside the applicable deadline set forth in the FY 2017 Wage Index Development Timetable finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49967 through 49990) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49506 through 49507), and available on the CMS Web site at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Downloads/FY2017WI-Time-Table.pdf. The annual Wage Index Development Timetable has been established through rulemaking, and plays an important role in maintaining the integrity and fairness of the wage index calculation. We have consistently stated in annual IPPS rulemaking that hospitals that do not meet the procedural deadlines set forth in the IPPS rule will not be afforded a later opportunity to submit wage index data corrections or to dispute the MAC decision with respect to requested changes (for example, 79 FR 28081, 79 FR 49986, 80 FR 24473, 80 FR 49503, and 81 FR 25073). Therefore, we are not incorporating the adjustments requested by Nantucket Cottage Hospital for the FY 2017 final rule wage index.

Separately, we also have determined that the adjustments made by the MAC in this situation could ideally have been made earlier in the process, and we are not incorporating those adjustments for the FY 2017 final wage index. We note that the average hourly wage of Nantucket Cottage Hospital that was used in calculating the proposed FY 2017 wage index did not include the MAC’s nor the hospital’s requested adjustments. Accordingly, we are finalizing Nantucket Cottage Hospital’s unadjusted average hourly wage as proposed for the Massachusetts’s rural wage index, which is the same unadjusted average hourly wage that was used in the FY 2017 IPPS/LTCH PPS proposed rule wage index (which neither incorporated the MAC audit adjustment nor additional adjustment requests by the hospital).

Comment: Commenters opposed the continued application of a nationwide rural floor budget neutrality adjustment, noting that the policy allows for manipulation of the wage index system so that hospitals in some States benefit at the expense of many hospitals in other States. Commenters pointed to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74192) where CMS expressed concern that a change in hospital status can significantly inflate wage indexes in a State, resulting in a reduction of payment to all hospital wage indexes as a result of nationwide budget neutrality for the rural floor. One commenter specifically disagreed with what it called the “political maneuvers” used to unfairly manipulate the rural floor in Massachusetts and other States. Commenters reiterated that the wage index system is in need of reform to ensure that payments accurately reflect actual wage costs.

Response: We appreciate the commenters’ concerns about application of the nationwide rural floor budget neutrality policy. However, for discharges occurring on or after October 1, 2010, for purposes of applying the rural floor and the imputed rural floor, section 3141 of the Affordable Care Act replaced the statewide budget neutrality adjustment policy with the national budget neutrality adjustment policy that was in place during FY 2008. That is, section 3141 required that budget neutrality for the rural and imputed floor be applied “through a uniform, national adjustment to the area wage index” instead of within each State beginning in FY 2011 (75 FR 50160). Accordingly, we do not have the authority to calculate rural floor budget neutrality in a State-specific manner.

After consideration of the public comments we received, and based on the final FY 2017 wage index associated with this final rule (which is available via the Internet on the CMS Web site), we estimate that 307 hospitals will receive an increase in their FY 2017 wage index due to the application of the rural or imputed floor.
2. Imputed Floor for FY 2017

In the FY 2005 IPPS final rule (69 FR 49109 through 49111), we adopted the “imputed floor” policy as a temporary 3-year regulatory measure to address concerns from hospitals in all-urban States that have argued that they are disadvantaged by the absence of rural hospitals to set a wage index floor for those States. Since its initial implementation, we have extended the imputed floor policy six times, the last of which was adopted in the FY 2016 IPPS/LTCH PPS final rule and is set to expire on September 30, 2016. (We refer readers to further discussions of the imputed floor in the FY 2014, FY 2015, and FY 2016 IPPS/LTCH PPS final rules (76 FR 50589 through 50590, 79 FR 49969 through 49970, and 80 FR 49497 through 49498, respectively) and to the regulation at § 412.64(h)(4).) Currently, there are three all-urban States—Delaware, New Jersey, and Rhode Island—with a range of wage indexes assigned to hospitals in those States, including through reclassification or redesignation. (We refer readers to discussions of geographic reclassifications and redesignations in section III.B. of the preamble of this final rule.)

In computing the imputed floor for an all-urban State under the original methodology, which was established beginning in FY 2005, we calculated the ratio of the lowest-to-highest CBSA wage index for each all-urban State as well as the average of the ratios of lowest-to-highest CBSA wage indexes of those all-urban States. We then compared the State’s own ratio to the average ratio for all-urban States and whichever is higher is multiplied by the highest CBSA wage index value in the State—the product of which establishes the imputed floor for the State. As of FY 2012, there were only two all-urban States—New Jersey and Rhode Island—and only New Jersey benefitted under this methodology. Under the previous OMB labor market area delineations, Rhode Island had only one CBSA (Providence-New Bedford-Fall River, RI-MA) and New Jersey had 10 CBSAs. Therefore, under the original methodology, Rhode Island’s own ratio equaled 1.0, and its imputed floor was equal to its original CBSA wage index value. However, because the average ratio of New Jersey and Rhode Island was higher than New Jersey’s own ratio, this methodology provided a benefit for New Jersey, but not for Rhode Island. In the FY 2013 IPPS/LTCH PPS final rule (78 FR 50589 through 50590), we extended the imputed floor policy (both the original methodology and the alternative methodology) for 1 additional year, through September 30, 2014. In that final rule, we revised the regulations at § 412.64(h)(4) and (h)(4)(vi) to reflect this additional 1-year extension. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25068), for FY 2017, we proposed to extend the imputed floor policy (under both the original methodology and the alternative methodology) for 1 additional year, through September 30, 2017. We proposed to revise the regulations at § 412.64(h)(4) and (h)(4)(vi) to reflect this proposed additional 1-year extension. We invited public comments on the proposed additional 1-year extension of the imputed floor through September 30, 2017. Comment: Several commenters supported CMS’ proposal to extend the imputed floor for 1 year, stating that it establishes an approach to remedy the competitive disadvantage suffered by all-urban States due to several unique factors common to these areas. However, these commenters urged CMS to make the imputed rural floor policy permanent rather than continue the policy through 1-year extensions, and to reevaluate the imputed floor policy only in the context of broader wage index reform. Other commenters opposed the proposed 1-year extension, stating that this type of floor should apply only when required by statute. One commenter questioned CMS’ statutory authority for extending the imputed rural floor. Response: We appreciate the positions of commenters that both support and oppose the proposal to extend the
imputed floor. We adopted the imputed floor policy to address concerns from hospitals in all-urban States and subsequently extended it through notice-and-comment rulemaking. As we stated in the FY 2005 IPPS final rule (69 FR 49110), we note that the Secretary has broad authority under section 1886(d)(3)(E) of the Act to adjust the proportion (as estimated by the Secretary from time to time) of hospitals’ costs which are attributable to wage and wage-related cost of the DRG prospective payment rates for area differences in hospital wage levels by a factor (established by the Secretary). Therefore, we believe that we do have the discretion to adopt a policy that would adjust wage indexes in the stated manner.

However, we also understand the commenters’ opposition to extending the imputed floor. In the FY 2008 IPPS final rule (72 FR 47322) and FY 2009 IPPS final rule (73 FR 48570 through 48574), we expressed our concern that the imputed rural floor creates a disadvantage in the application of the wage index to hospitals in States with rural hospitals but no urban hospitals receiving the rural floor. Therefore, we have not made the imputed rural floor policy permanent. We will give further consideration to all public comments if and when wage index reform is considered.

After consideration of the public comments we received, we are finalizing our proposal without modification to extend the imputed floor policy under both the original methodology and the alternative methodology for an additional year, through September 30, 2017. We also are adopting as final the proposed revisions to §§ 412.64(h)(4) and (h)(4)(vi) to reflect the 1-year extension of the imputed floor. The wage index and impact tables associated with this FY 2017 IPPS/LTCH PPS final rule (which are available on the Internet via the CMS Web site) reflect the continued application of the imputed floor policy under both methodologies.

There are 18 hospitals in New Jersey that will receive an increase in their FY 2017 wage index due to the continued application of the imputed floor policy under the original methodology, and 10 hospitals in Rhode Island that will benefit under the alternative methodology. In the proposed rule (81 FR 25068), we stated that no providers in Delaware would benefit under the original methodology or the alternative methodology. However, for the final FY 2017 wage index, we have determined that, in fact, 2 hospitals in Delaware will benefit under the alternative methodology. Therefore, for this final rule, we are applying the imputed floor to these hospitals in Delaware using the alternative methodology. Tables 2 and 3 associated with this final rule (which are available via the Internet on the CMS Web site) reflect the application of the imputed floor to 2 hospitals in Delaware.

3. State Frontier Floor for FY 2017

Section 10324 of Public Law 111–148 requires that hospitals in frontier States cannot be assigned a wage index of less than 1.0000 (we refer readers to regulations at 42 CFR 412.64(m) and to a discussion of the implementation of this provision in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50160 through 50161)). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25068), we did not propose any changes to the frontier floor for FY 2017. We stated in the proposed rule that 50 hospitals would receive the frontier floor value of 1.0000 for their FY 2017 wage index in the proposed rule. These hospitals are located in Montana, Nevada, North Dakota, South Dakota, and Wyoming.

We did not receive any public comments on the application of the State frontier floor for FY 2017. In this final rule, 50 hospitals will receive the frontier floor value of 1.0000 for their FY 2017 wage index. These hospitals are located in Montana, Nevada, North Dakota, South Dakota, and Wyoming. The areas affected by the rural, imputed, and frontier floor policies for the FY 2017 wage index are identified in Table 2 associated with this final rule, which is available via the Internet on the CMS Web site.

I. FY 2017 Wage Index Tables

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49498 and 49807 through 49808), we finalized a proposal to streamline and consolidate the wage index tables associated with the IPPS proposed and final rules for FY 2016 and subsequent fiscal years. Prior to FY 2016, the wage index tables had consisted of 12 tables (Tables 2, 3A, 3B, 4A, 4B, 4C, 4D, 4E, 4F, 4J, 9A, and 9C) that were made available via the Internet on the CMS Web site. Effective beginning FY 2016, with the exception of Table 4E, we streamlined and consolidated 11 tables (Tables 2, 3A, 3B, 4A, 4B, 4C, 4D, 4F, 4J, 9A, and 9C) into 2 tables (Tables 2 and 3). We refer readers to section VI. of the Addendum to this final rule for a discussion of the final wage index tables for FY 2017.

J. Revisions to the Wage Index Based on Hospital Redesignations and Reclassifications

1. General Policies and Effects of Reclassification and Redesignation

Under section 1886(d)(10) of the Act, the Medicare Geographic Classification Review Board (MGCRB) considers applications by hospitals for geographic reclassification for purposes of payment under the PPS. Hospitals must apply to the MGCRB to reclassify not later than 13 months prior to the start of the fiscal year for which reclassification is sought (usually by September 1). Generally, hospitals must be proximate to the labor market area to which they are seeking reclassification and must demonstrate characteristics similar to hospitals located in that area. The MGCRB issues its decisions by the end of February for reclassifications that become effective for the following fiscal year (beginning October 1). The regulations applicable to reclassifications by the MGCRB are located in 42 CFR 412.230 through 412.280. (We refer readers to a discussion in the FY 2002 IPPS final rule (66 FR 39874 and 39875) regarding how the MGCRB defines mileage for purposes of the proximity requirements.) Except as discussed in section III.J.2. of the preamble of this final rule, the general policies for reclassifications and redesignations for FY 2017, and the policies for the effects of hospitals’ reclassifications and redesignations on the wage index, are the same as those discussed in the FY 2012 IPPS/LTCH PPS final rule for the FY 2012 final wage index (76 FR 51595 and 51596). In addition, in the FY 2012 IPPS/LTCH PPS final rule, we discussed the effects on the wage index of urban hospitals reclassifying to rural areas under 42 CFR 412.103. Hospitals that are geographically located in States without any rural areas are ineligible to apply for rural reclassification in accordance with the provisions of 42 CFR 412.103.

2. Finalization of Interim Final Rule With Comment Period on Provisions Related To Modification of Limitations on Redesignation by the Medicare Geographic Classification Review Board (MGCRB)

On April 21, 2016, CMS published an interim final rule with comment period (IFC) in the Federal Register (81 FR 23428 through 23438) which included provisions amending our regulations to allow hospitals nationwide to reclassify based on acquired rural status, effective with recategorization applications due to the MGCRB on September 1, 2016 for reclassifications first effective for FY
2018. In addition, effective with the display date of the IFC, eligible hospitals with an existing MGCRB reclassification also may seek rural reclassification under §412.103 for IPPS payment (such as DSH) and other purposes (such as eligibility for the section 340B program), but keep their existing MGCRB reclassification (which would control for wage index purposes). We also finalized and began to apply the policies in the IFC when deciding timely appeals before the Administrator for FY 2017 that were denied by the MGCRB due to the application of the superseded regulations, which did not permit simultaneous rural reclassification and MGCRB reclassifications. These additional regulatory changes were implemented to codify the application and interpretation of the judicial decisions resulting from the adjudication of Geisinger Community Medical Center v. Secretary, United States Department of Health and Human Services, 794 F.3d 383 (3d Cir. 2015) and Lawrence + Memorial Hospital v. Burwell, No. 15–164, 2016 WL 423702 (2d Cir. February 4, 2015) in a nationally consistent manner.

We note that, in the April 21, 2016 IFC, we found good cause for waiving notice-and-comment rulemaking and the 60-day delay in effective date, given the decisions of the courts of appeals and the public interest in consistent application of a Federal policy nationwide. We stated that revising the regulation text at § 412.230(a)(5)(iii) and removing the regulation text at § 412.230(a)(5)(iii) through an IFC and subsequent final rule rather than through the normal notice-and-comment rulemaking cycle and waiving the 60-day delay of effective date would ensure a uniform national reclassification policy. By reason of the court decisions, this policy has already been effective since July 23, 2015, in the Third Circuit and February 4, 2016 in the Second Circuit. Absent such a policy, the wage index for acute care hospitals paid under the IPPS would have remained confusingly inconsistent across jurisdictions. Even though we waived notice of proposed rulemaking requirements and issued the provisions on an interim basis with subsequent issuance of a final rule, we provided a 60-day public comment period. In this section of this final rule, we are responding to the public comments that we received on these provisions in the April 21, 2016 IFC and finalizing the interim policies.

a. Background

Hospitals may seek to have their geographic designation reclassified. Under section 1886(d)(8)(E) of the Act, a qualifying inpatient prospective payment hospital located in an urban area may apply for rural status. Specifically, section 1886(d)(8)(E) of the Act states that not later than 60 days after the receipt of an application (in a form and manner determined by the Secretary) from a subsection (d) hospital, the Secretary shall treat the hospital as being located in the rural area (as defined in the statute) of the State in which the hospital is located if certain criteria are met. The regulations governing these geographic redesignations are codified under §412.103. We also refer readers to the final rule published in the August 1, 2000 Federal Register entitled, “Medicare Program; Provisions of the Balanced Budget Refinement Act of 1999: Hospital Inpatient Payments and Rates and Costs of Graduate Medical Education” (65 FR 47029 through 47031) for a discussion of the general criteria for reclassifying from urban to rural under this statute. In addition, in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51596), we discussed the effects on the wage index of an urban hospital reclassifying to a rural area of its State, if the urban hospital meets the requirements under §412.103. Hospitals that are located in States without any geographically rural areas are ineligible to apply for rural reclassification in accordance with the provisions of §412.103.

In addition, as discussed under section III.J.1. of the preamble of this final rule, under section 1886(d)(10) of the Act, the MGCRB considers applications by hospitals for geographic reclassification for purposes of payment under the IPPS. Hospitals must apply to the MGCRB to reclassify not later than 13 months prior to the start of the fiscal year for which reclassification is sought (generally by September 1). Generally, hospitals must be proximate to the labor market area to which they are seeking reclassification and must demonstrate characteristics similar to hospitals located in that area. The MGCRB issues its decisions by the end of February for reclassifications that become effective for the following fiscal year (beginning October 1). The regulations applicable to reclassifications by the MGCRB are located in §§ 412.230 through 412.280. (We refer readers to a discussion in the FY 2000 IPPS final rule (65 FR 39874 and 39875) regarding how the MGCRB defines mileage for purposes of the proximity requirements.) The general policies applicable to reclassifications under the MGCRB process are also discussed in the FY 2012 IPPS/LTCH PPS final rule for the FY 2012 final wage index (76 FR 51595 and 51596).

b. Criteria for an Individual Hospital Seeking Redesignation to Another Area (§412.103)—Application of Policy Provisions

Our policy in effect prior to the issuance of the April 21, 2016 IFC limited certain redesignations in order to preclude hospitals from obtaining urban to rural redesignation under §412.103, and then using that obtained rural status to receive an additional reclassification through the MGCRB. In the April 21, 2016 IFC, we referred readers to §412.230(a)(5)(iii) as it existed at that time, which stated that an urban hospital that has been granted redesignation as rural under §412.103 cannot receive an additional reclassification by the MGCRB based on this acquired rural status for a year in which such redesignation is in effect. In other words, §412.230(a)(5)(iii) prohibited a hospital from simultaneously receiving an urban to rural redesignation under §412.103 and a reclassification under the MGCRB.

As discussed in the April 21, 2016 IFC, on July 23, 2015 the Court of Appeals for the Third Circuit issued a decision in Geisinger Community Medical Center v. Secretary, United States Department of Health and Human Services, 794 F.3d 383 (3d Cir. 2015). Geisinger Community Medical Center (“Geisinger”), a hospital located in a geographically urban CBSA, obtained rural status under §412.103, but was unable to receive additional reclassification through the MGCRB while still maintaining its rural status under §412.230(a)(5)(iii). Under the regulations prior to the April 21, 2016 IFC, to receive reclassification through the MGCRB under existing regulations, Geisinger would have had to first cancel its §412.103 urban-to-rural redesignation and use the proximity requirements for an urban hospital rather than take advantage of the broader proximity requirements for reclassification granted to rural hospitals. (In the April 21, 2016 IFC, we referred readers to §412.230(b)(1), which states that a hospital demonstrates a close proximity with the area to which it seeks redesignation if the distance from the hospital to the area is no more than 15 miles for an urban hospital and no more than 35 miles for a rural hospital.) Geisinger challenged as unlawful the regulation at §412.230(a)(5)(iii) requiring cancelation of its rural reclassification prior to
applying for reclassification through the MGCRB. In Geisinger Community Medical Center v. Burwell, 73 F. Supp.3d 507 (M.D. Pa. 2014), the District Court for the Middle District of Pennsylvania upheld the regulation at §142.230(a)(5)(iii) and granted summary judgment in favor of CMS. The Court of Appeals for the Third Circuit reversed the decision of the District Court, holding that the language of section 1886(d)(8)(E)(i) of the Act is unambiguous in its plain intent that “the Secretary shall treat the hospital as being located in the rural area,” inclusive of MGCRB reclassification purposes, thus invalidating the regulation at §412.230(a)(5)(iii). On February 4, 2016, the Court of Appeals for the Second Circuit issued its decision in Lawrence + Memorial Hospital v. Burwell, No. 15–164, 2016 WL 423702 (2d Cir. February 4, 2016), essentially following the reasoning of the Third Circuit Geisinger decision.

We stated in the IFC that while these decisions currently apply only to hospitals located within the jurisdictions of the Second and Third Circuits, we believed that maintaining the regulations at §412.230(a)(5)(iii) in other jurisdictions would constitute inconsistent application of the reclassification policy based on jurisdictional regions. In the interest of creating a uniform national reclassification policy, in the IFC, we removed the regulation text at §412.230(a)(5)(iii). We also revised the regulation text at §412.230(a)(5)(ii) to allow more than one reclassification for those hospitals redesignated as rural under §412.103, and simultaneously seeking reclassification through the MGCRB. Specifically, we revised §412.230(a)(5)(ii) to state that a hospital may not be redesignated to more than one area, except for an urban hospital that has been granted redesignation as rural under §412.103 and receives an additional redesignation by the MGCRB. Therefore, effective for reclassification applications due to the MGCRB by September 1, 2016, for reclassification first effective for FY 2018, a hospital may apply for a reclassification under the MGCRB while still being redesignated from urban to rural under §412.103. Such hospitals are eligible to use distance and average hourly wage criteria designated for rural hospitals at §412.230(b)(1) and (d)(1). In addition, we provided that, effective with the public display date of the IFC, a hospital that has an active MGCRB reclassification and is then approved for redesignation under §412.103 will not lose its MGCRB reclassification; that is, a hospital with an active MGCRB reclassification can simultaneously maintain rural status under §412.103, and receive a reclassified urban wage index during the years of its active MGCRB reclassification and will still be considered rural under section 1886(d) of the Act and for other purposes. We also stated that we will apply the policy adopted in the April 21, 2016 IFC when deciding timely appeals before the Administrator under §412.278 for FY 2017 that were denied by the MGCRB due to existing provisions of §412.230(a)(5)(ii) and (iii), which did not permit simultaneous §412.103 and MGCRB reclassifications.

Apart from the direct impact on reclassifying hospitals previously discussed in this section, we also considered how to treat the wage data of hospitals that maintain simultaneous reclassifications under both the §412.103 and the MGCRB processes. Under the wage index calculation procedures that applied prior to issuance of the IFC, the wage data for a hospital geographically located in an urban area under a §412.103 redesignation was included in the wage index for its home geographic area. It is also included in its State rural wage index, if including wage data for hospitals with rural reclassification raises the state’s rural floor. In addition, the wage data for a hospital located in an urban area, and that is approved by the MGCRB to reclassify to another urban area (or another State’s rural area), are included in its home area wage index calculation, and in the calculation for the reclassified “attaching” area. In the IFC, we referred readers to the FY 2012 IPPS final rule (76 FR 59595 through 59596) for a full discussion of the effect of reclassification on wage index calculations. Furthermore, as discussed in the FY 2007 IPPS final rule (71 FR 48020 through 48022), hospitals could not simultaneously maintain more than one wage index status (for example, a hospital could not simultaneously maintain a §412.103 rural redesignation and an MGCRB reclassification, nor could a hospital receive an outmigration adjustment while also maintaining MGCRB or Lugar status). However, as a consequence of the court decisions previously discussed, we revised our regulations and created a rule that applies to all hospitals nationally, regarding the treatment of the wage data of hospitals that have both a §412.103 redesignation and an MGCRB reclassification. We established that if a hospital with a §412.103 redesignation is approved for an additional reclassification through the MGCRB process, and the hospital accepts its MGCRB reclassification, the Core-Based Statistical Area (CBSA) to which the hospital is reclassified under the MGCRB prescribes the area wage index that the hospital will receive; the hospital will not receive the wage index associated with the rural area to which the hospital is redesignated under §412.103. That is, when there is both a §412.103 redesignation and an MGCRB reclassification, the MGCRB reclassification will control for wage index calculation and payment purposes. Therefore, although we amended our policy with the IFC to allow a hospital to simultaneously have a reclassification under the MGCRB and an urban to rural redesignation under §412.103, we separately clarified that we will exclude hospitals with §412.103 redesignations from the calculation of the reclassified rural wage index if they also have an active MGCRB reclassification to another area. In these circumstances, we stated that we believe it is appropriate to rely on the urban MGCRB reclassification to include the hospital’s wage data in the calculation of the urban CBSA wage index. Further, we stated that we believe it is appropriate to rely on the urban MGCRB reclassification to ensure that the hospital is paid based on its urban MGCRB wage index. That is, while rural reclassification confers other rural benefits besides the wage index under section 1886(d) of the Act, a hospital that chooses to pursue reclassification under the MGCRB (while also maintaining a rural redesignation under §412.103) would do so solely for wage index payment purposes.

As previously stated, when there is both a §412.103 redesignation and an MGCRB reclassification, the MGCRB reclassification will control for wage index calculation and payment purposes. That is, if a hospital submits an application for urban reclassification through the MGCRB is approved, and is not withdrawn or terminated by the hospital within the established timelines, we will consider, as is current practice, the hospital’s geographic CBSA and the urban CBSA to which the hospital is redesignated under the MGCRB for the wage index calculation. We indicated that the hospital’s geographic CBSA and reclassified CBSA would be reflected accordingly in Tables 2 and 3, associated with the annual IPPS/LTCH PPS proposed and final rules, which are available through the Internet on the CMS Web site.) However, in the absence of an active MGCRB reclassification, if
the hospital has an active §412.103 redesignation, CMS will treat the hospital as rural under §412.103 redesignation for IPPS payment and other purposes, including purposes of calculating the wage indices reflected in Tables 2 and 3 of the annual IPPS/LTC
PPS proposed and final rules

Comment: One commenter requested that, as part of the IPPS rulemaking process, CMS release data on the hospitals that have been granted redesignation under §412.103 and receive an additional reclassification by the MGCRB. The commenter noted that while, in the payment impact file, there is a “401 hospital” field that indicates whether a hospital has been redesignated as rural under §412.103, it appears that hospitals that have both a §412.103 redesignation and an MGCRB reclassification do not have a “Yes” in the “401 hospital” field. The commenter requested that this field be labeled “Yes” when a hospital with a §412.103 redesignation also receives an MGCRB reclassification.

Response: We agree with the commenter’s request and will include a column in the public use impact file posted on the CMS Web site in conjunction with the IPPS rules to indicate that a hospital has a §412.103 redesignation when it also has an MGCRB reclassification. This file can be located by visiting the following link https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS/index.html and selecting that IPPS regulation’s home page from the drop-down menu.

The impact files are located under “Impact File and Data Files”.

Comment: Two commenters noted that the regulations at §412.103 still require that an urban hospital requesting rural status use the statewide rural wage index for at least a 12-month period before the facility can be reclassified using the rural proximity requirement. The commenters requested that CMS clarify that those hospitals that have already used the rural wage index for one or more previous 12-month periods are allowed to choose to use their home geographic wage index, rather than the §412.103 rural wage index, for the 12 months prior to receiving a MGCRB reclassification for FY 2018 or years beyond.

Response: We are unsure of the meaning of the commenter’s statement “the regulations at §412.103 still require that an urban hospital requesting rural status use the statewide rural wage index for at least a 12-month period before the facility can be reclassified using the rural proximity requirement.” The regulations at §412.103 do not indicate a time period for using the statewide rural wage index before a hospital can be reclassified using the rural proximity requirement; rather, the 12-month time period referenced at §412.103 pertains to cancellation of rural reclassification for a hospital classified as a rural referral center based on a §412.103 reclassification. We also do not understand the commenter’s request for clarification that hospitals that have received the rural wage index for 12 months be allowed to use their geographic home wage index prior to receiving an MGCRB reclassification for FY 2018 and after, because the regulations do not address payment at the rural wage index for a period of time in order to receive an MGCRB reclassification based on a §412.103 redesignation. We reiterate that, as indicated in the IFC, when there is both an MGCRB reclassification and a §412.103 redesignation, the MGCRB reclassification will control for wage index calculation and payment purposes; the hospital will not receive the wage index associated with the rural area to which the hospital is redesignated under §412.103. We also reiterate that for any period of time that a hospital has a §412.103 redesignation but not a MGCRB reclassification, the hospital will be paid using the rural wage index, and not its geographic home wage index.

Comment: One commenter requested clarification as to whether a hospital redesignated as rural under §412.103 can use that rural status to reclassify to a nearby rural area. The commenter asked that CMS clarify whether a hospital redesignated as rural will be treated as rural for purposes of a rural to rural reclassification application.

Response: We are clarifying that a hospital redesignated as rural under §412.103 can use that rural status to reclassify via the MGCRB to another rural or urban area, provided it meets the distance and average hourly wage criteria under §412.230(b)(1), (d)(1)(iii)(C), and (d)(1)(iv)(E).

Comment: One commenter requested clarification on several aspects of the amended regulations. The commenter requested that CMS clarify that—
• The rural distance and average hourly wage criteria will be used for hospitals with a §412.103 redesignation;
• The hospital’s average hourly wage data are to be compared to the average hourly wage data for the State’s rural area for purposes of determining whether the hospital meets the criterion in §412.230(d)(1)(iii)(C);
• A rural redesignated hospital can undergo an MGCRB reclassification back to the CBSA in which it is physically located;
• Hospitals redesignated as rural can have dual MGCRB reclassifications, with the termination or withdrawal of one of the reclassifications after the issuance of the IPPS proposed rule, consistent with §412.273;
• Hospitals redesignated as rural can still be part of an urban group seeking redesignation to another urban area for the geographic area where they are physically located, in accordance with §412.234;
• In all future years, hospitals that already have an MGCRB reclassification can receive a §412.103 redesignation without losing their MGCRB reclassification; and
• If a hospital has both an MGCRB redesignation and a §412.103 redesignation, the wage data will be included in the urban area to which it is redesignated, rather than the rural area.

Response: The commenter is correct that the rural distance and average hourly wage criteria will be used for hospitals with a §412.103 redesignation. However, the commenter’s statement that the average hourly wage of a hospital with a §412.103 redesignation is compared to the average hourly wage of hospitals in the State’s rural area under §412.230(d)(1)(iii)(C) is incorrect. Instead, the hospital’s average hourly wage would be compared to the average hourly wage of all other hospitals in its urban geographic location using the rural distance and average hourly wage criteria. The commenter is correct that a §412.103 rural redesignated hospital can undergo an MGCRB reclassification back to the CBSA in which it is physically located if it meets the criteria for use of an urban or other rural area’s wage index at §412.230(d) using the average hourly wage criteria specified for rural hospitals. We are unsure of the meaning of “dual MGCRB reclassifications” because a hospital can only have one MGCRB reclassification at a time.

We refer the commenter to the regulations at §412.273 which describe the policies for withdrawing an MGCRB application, terminating an approved 3-year MGCRB reclassification, or canceling a previous withdrawal or termination. The policies at §412.273 apply to all MGCRB reclassifications, including those that are held in addition to a §412.103 redesignation.

The commenter is correct that a geographically urban hospital redesignated as rural under §412.103 can still apply for group reclassification
with other urban hospitals located in the same geographically urban area to another urban area via the MGCRB, in accordance with § 412.234, and that effective with the IFC display date (April 18, 2016) and for future years, hospitals that already have an MGCRB recategorization can receive a § 412.103 redesignation without losing their MGCRB recategorization. Finally, we are reiterating that wage data for a hospital with both an MGCRB recategorization and a § 412.103 redesignation would be included in the post-reclassified wage index of the area to which it is reclassified under the MGCRB, and not the rural area to which it is reclassified under § 412.103.

**Comment:** One commenter requested that CMS repeal the provision § 412.103(g)(2) because the new policy has rendered this provision irrelevant. The commenter referenced CMS’ discussion of this issue in the FY 2008 IPPS final rule (72 FR 47371 through 47373), and stated that the goal of creating this minimum time period was to disincentivize hospitals to receive a rural redesignation, obtain rural referral center status to achieve favorable MGCRB treatment, and then terminate their rural status. The commenter believed that because hospitals can now be both an urban and a rural referral center, this disincentive is no longer necessary.

**Response:** We appreciate the commenter’s suggestion. The discussion in the FY 2008 IPPS final rule referenced by the commenter addressed a revision to § 412.103(g) to require that, for a hospital that obtains rural referral center status based on acquired rural status under § 412.103, the hospital’s cancellation of its acquired rural status under § 412.103 is effective after it has been paid as rural for at least one 12-month cost reporting period, and not until the beginning of a Federal fiscal year following both the request for cancellation and the 12-month cost reporting period. The discussion in the FY 2008 IPPS final rule noted our concerns about hospitals that acquire rural status to become rural referral centers and then cancel acquired rural status after a brief period of time in order to take advantage of special MGCRB recategorization rules, which was the basis for the revisions to the regulation at § 412.103(g). Because we did not propose a change in the regulation regarding the interplay of rural redesignations and rural referral center status in particular, we are not amending these regulations at this time, but may address this issue in future rulemaking.

In summary, for recategorizations effective beginning FY 2018, a hospital may acquire rural status under § 412.103 and subsequently apply for a recategorization under the MGCRB using distance and average hourly wage criteria designated for rural hospitals. In addition, effective with the public display date of the IFC (April 18, 2016), a hospital with an active MGCRB recategorization may also acquire rural status under § 412.103. We stated that we also will apply the policy in the April 21, 2016 IFC when deciding timely appeals before the Administrator under § 412.278 for FY 2017 that were denied by the MGCRB due to then existing provisions of § 412.230(a)(5)(ii) and (iii), which did not permit simultaneous § 412.103 redesignation and MGCRB recategorizations. When there is both an MGCRB recategorization and a § 412.103 recategorization, the MGCRB recategorization will control for wage index calculation and payment purposes. For a discussion regarding budget neutrality adjustments for FY 2017 and subsequent years for hospitals that have a recategorization under § 412.103 and an MGCRB recategorization, we refer readers section II.A.4. of the Addendum to this FY 2017 IPPS/LTCPPPS final rule.

**c. Final Rule Provisions**

In this final rule, we are finalizing the provisions of the April 21, 2016 IFC without modification. We also are finalizing without modification our removal of § 412.230(a)(5)(iii) and the revisions to § 412.230(a)(5)(ii).

**d. Impact**

In the April 21, 2016 IFC (81 FR 23436 through 23438), we presented the following impact analysis for the IPPS wage index portion of the IFC. We are not making any changes to this IFC impact analysis in this final rule. We did not conduct an in-depth impact analysis because our revision to the regulatory text is a consequence of court decisions. The Geisinger decision invalidated the regulation at § 412.230(a)(5)(ii), effective July 23, 2015, for hospitals in States within the Third Circuit’s jurisdiction, and the Lawrence + Memorial decision invalidated the regulation at § 412.230(a)(5)(ii), effective February 4, 2016, for hospitals in States within the Second Circuit’s jurisdiction. That is, we did not have a choice to maintain the previously uniform regulations at § 412.230(a)(5)(ii) for hospitals in States within the Second and Third Circuits.

Furthermore, we indicated that we do not believe that we could reasonably estimate the national impact of removing the regulation at § 412.230(a)(5)(iii). We noted that of the 3,586 IPPS hospitals listed on wage index Table 2 associated with the proposed rule and available via the Internet on the CMS Web site, 867 hospitals already had an MGCRB recategorization, and 57 hospitals had a recategorization to a rural area under § 412.103. (This table is discussed in the FY 2017 IPPS/LTCPPPS proposed rule and is available on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled, “FY 2017 IPPS Proposed Rule Home Page”. We could not estimate how many additional hospitals will elect to apply to the MGCRB by September 1, 2016, for recategorization beginning FY 2018, and we could not predict how many hospitals may elect to retain or acquire § 412.103 urban-to-rural recategorization over and above the hospitals that have already recategorized. In addition, under § 412.230(a)(5)(ii), (iii), and (iv), increases in the wage index due to recategorization and other wage index adjustments are implemented in a budget neutral manner (that is, wage index adjustments are made in a manner that ensures that aggregate payments to hospitals are unaffected through the application of a wage index budget neutrality adjustment described more fully in the FY 2017 IPPS/LTCPPPS proposed rule). Therefore, as a result of the Third Circuit’s decision in Geisinger, even though an urban hospital that may or may not already have a recategorization to another urban area under the MGCRB may be able to qualify for a recategorization to a more distant urban area with an even higher wage index, this would not increase aggregate IPPS payments (although the wage index budget neutrality factor applied to IPPS hospitals could be larger as a result of additional recategorizations occurring to higher wage index areas).

However, we noted in the IFC that these are other Medicare payment provisions potentially impacted by rural status, such as payments to disproportionate share hospitals (DSHs), and non-Medicare payment provisions, such as the 340B Drug Pricing Program administered by HRSA, under which payments are not made in a budget neutral manner. We noted that additional hospitals acquiring rural status under § 412.103 could, therefore, potentially increase Federal expenditures. Nevertheless, taking all of these factors into account, we indicated that we could not accurately determine an impact analysis as a result of the
Third Circuit’s decision in Geisinger and the Second Circuit’s decision in Lawrence + Memorial.  

Comment: One commenter stated that because the 340B Drug Pricing Program is not a government payment program, Federal expenditures would not be expected to increase as a result of this change to CMS’ regulations. The commenter noted that other possible impacts on Federal expenditures would be unrelated to the 340B Drug Pricing Program. The commenter requested that CMS clarify that Federal expenditures would not be increased as a result of the 340B Drug Pricing Program.  

Response: We agree with the commenter that because the 340B Drug Pricing Program is not a Federal payment program, Federal expenditures would not be expected to increase as a result of any increased eligibility for the 340B Drug Pricing Program resulting from this change to our regulations. The Regulatory Flexibility Act (RFA) also requires agencies to analyze options for regulatory relief of small entities if a rule has a significant impact on a substantial number of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. We estimate that most hospitals and most other providers and suppliers are small entities as that term is used in the RFA. The great majority of hospitals and most other health care providers and suppliers are small entities, either by being nonprofit organizations or by meeting the SBA definition of a small business (having revenues of less than $7.5 million to $38.5 million in any 1 year). (For details on the latest standards for health care providers, we refer readers to page 36 of the Table of Small Business Size Standards for NAIC 622 found on the SBA Web site at: https://www.sba.gov/sites/default/files/files/Size_Standards_Table.pdf.)  

For purposes of the RFA, all hospitals and other providers and suppliers are considered to be small entities. Individuals and States are not included in the definition of a small entity. MACs are not considered to be small entities. We believe that the provisions of this final rule may have an impact on some small entities, but for the reasons previously discussed in this final rule, we cannot conclusively determine the number of such entities impacted. Because we lack data on individual hospital receipts, we cannot determine the number of small proprietary hospitals. Therefore, we are assuming that all hospitals are considered small entities for the purpose of the RFA. Because we acknowledge that many of the potentially affected entities are small entities, the discussion in this section regarding potentially impacted hospitals constitutes our regulatory flexibility analysis.  

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside a metropolitan statistical area and has fewer than 100 beds. Section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98–21) designated hospitals in certain New England counties as belonging to the adjacent urban area. Thus, for purposes of the IPPS and the LTCH PPS, we continue to classify these hospitals as urban hospitals. For this final rule, no geographically rural hospitals are directly affected because only urban hospitals can reclassify to a rural area under § 412.103. However, we note that with regard to the wage index budget neutrality adjustments applied under § 412.64(e)(1)(ii), (e)(2), and (e)(4), rural IPPS hospitals will be affected to the extent that the reclassification budget neutrality adjustment increases, but this impact is no different than on urban IPPS hospitals, as the same budget neutrality factor is applied to all IPPS hospitals.  

3. Other MGCRB Reclassification and Redesignation Issues for FY 2017  

a. FY 2017 Reclassification Requirements and Approvals  

As previously stated, under section 1886(d)(10) of the Act, the MGCRB considers applications by hospitals for geographic reclassification for purposes of payment under the IPPS. The specific procedures and rules that apply to the geographic reclassification process are outlined in regulations under 42 CFR 412.230 through 412.280.  

At the time this final rule was constructed, the MGCRB had completed its review of FY 2017 reclassification requests. Based on such reviews, there are 265 hospitals approved for wage index reclassifications by the MGCRB starting in FY 2017. Because MGCRB wage index reclassifications are effective for 3 years, for FY 2017, hospitals reclassified beginning in FY 2015 or FY 2016 to a wage index to continue to be reclassified to a particular labor market area based on such prior reclassifications for the remainder of their 3-year period. There were 294 hospitals approved for wage index reclassifications in FY 2015 that will continue for FY 2017, and 258 hospitals approved for wage index reclassifications in FY 2016 that will continue for FY 2017. Of all the hospitals approved for reclassification for FY 2015, FY 2016, and FY 2017, based upon the review at the time of this final rule, 817 hospitals are in a MGCRB reclassification status for FY 2017. We note that the number of hospitals with active reclassifications changed between the proposed rule and the final rule because hospitals had the opportunity to withdraw or terminate their reclassification within 45 days of the publication of the FY 2017 proposed rule.  

Under the regulations at 42 CFR 412.273, hospitals that have been reclassified by the MGCRB are permitted to withdraw their applications within 45 days of the publication of a proposed rule. For information about withdrawing, terminating, or canceling a previous withdrawal or termination of a 3-year reclassification for wage index purposes, we refer readers to 42 CFR 412.273, as well as the FY 2002 IPPS final rule (66 FR 39887 through 39888) and the FY 2003 IPPS final rule (67 FR 50065 through 50066). Additional discussion on withdrawals and terminations, and clarifications regarding reinstating reclassifications and “fallback” reclassifications, were included in the FY 2008 IPPS final rule (72 FR 47333).  

Changes to the wage index that result from withdrawals of requests for reclassification, terminations, wage index corrections, appeals, and the Administrator’s review process for FY 2017 are incorporated into the wage index values published in this FY 2017 IPPS/LTCH PPS final rule. These changes affect not only the wage index value for specific geographic areas, but also the wage index value that redesignated/reclassified hospitals receive; that is, whether they receive the wage index that includes the data for both the hospitals already in the area and the redesignated/reclassified hospitals. Further, the wage index value for the area from which the hospitals are redesignated/reclassified may be affected.  

Comment: One commenter stated that CMS’ policy that hospitals must request to withdraw or terminate MGCRB reclassifications within 45 days of the proposed rule is problematic because a hospital could terminate a reclassification based on information in
the proposed rule, and with the publication of the final rule, discover that its original reclassified status was more desirable. The commenter stated that hospitals cannot make informed decisions concerning their reclassification status based on values in a proposed rule that are likely to change and, therefore, recommended that CMS revise its existing policy to permit hospitals to withdraw or terminate their reclassification status within 45 days of the publication of the final rule.

Several other commenters requested that CMS revise group reclassification rules at § 412.234(a)(3)(iv) so that urban county groups would no longer be required to be within the same CSA or CBSA as the desired labor market area.

Response: We did not make any proposals to change any of the reclassification regulations for FY 2017. Any changes to the reclassification regulations would need to be first proposed through notice-and-comment rulemaking. Consequently, we are not making any changes to address the commenters’ concerns at this time. We maintain that information provided in the proposed rule constitutes the best available data to assist hospitals in making reclassification decisions. The values published in the final rule represent the final wage index values reflective of reclassification decisions.

b. Requirements for FY 2018

Applications and Revisions Regarding Paper Application Requirements

Applications for FY 2018 reclassifications are due to the MGCRB by September 1, 2016 (the first working day of September 2016). We note that this is also the deadline for canceling a previous wage index reclassification withdrawal or termination under 42 CFR 412.273(d). Applications and other information about MGCRB reclassifications may be obtained, beginning in mid-July 2016, via the Internet on the CMS Web site at https://www.cms.gov/Regulations-and-Guidance/Review-Boards/MGCRB/index.html, or by calling the MGCRB at (410) 786–1174. The mailing address of the MGCRB is: 2520 Lord Baltimore Drive, Suite L, Baltimore, MD 21244–2670.

Under existing regulations at 42 CFR 412.256(a)(1), applications for reclassification must be mailed or delivered to the MGCRB, with a copy to CMS, and may not be submitted through the facsimile (FAX) process or by other electronic means. While existing regulations exclusively require paper applications, we believe this policy to be outdated and overly restrictive. Therefore, to promote ease of application for FY 2018 and subsequent years, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25069), we proposed to revise this policy to require applications and supporting documentation to be submitted via the method prescribed in instructions by the MGCRB, with an electronic copy to CMS. Therefore, we proposed to revise § 412.256(a)(1) to specify that an application must be submitted to the MGCRB according to the method prescribed by the MGCRB, with an electronic copy of the application sent to CMS. We specified that CMS copies should be sent via email to wageindex@cms.hhs.gov. We invited public comments on this proposal.

Comment: Commenters supported CMS’ proposal to require electronic copies for wage index reclassification materials. Commenters requested that CMS provide email confirmation upon receipt of these copies, and further request CMS to provide additional guidance on how to submit files that may be too large for some email systems.

Response: We appreciate the commenters’ support of our proposal, and we are finalizing the regulation change as proposed. We reiterate that MGCRB application requirements will be published separately from this rulemaking process, and paper applications will likely still be required. The MGCRB makes all initial determinations for geographic reclassification requests, but CMS requests copies of all applications to assist in verifying a reclassification status during the wage index development process. We believe that requiring electronic versions would better aid CMS in this process, and would reduce the overall burden upon hospitals. We appreciate the commenters’ request for email verification that an application was received in the wageindex@cms.hhs.gov mailbox, and we will endeavor to provide such validation in a timely manner. Regarding issues with email size, we believe that a scanned PDF copy of an application should rarely exceed the size limitations of most email systems. In circumstances when this may be an issue, we request that hospitals notify the wage index mailbox to arrange for an alternate delivery method. We also request that all correspondence with the wage index mailbox clearly identify the hospital’s CCN (or the county and state for group reclassification requests) in the subject line, and that emails include a name, email address, and phone number of a responsible party at the hospital, should CMS need to contact the hospital to request or clarify certain information.

Comment: Commenters requested additional guidance regarding acceptable materials for a variety of MGCRB application requirements, specifically for documenting proximity requirements.


We are finalizing our proposal to revise § 412.256(a)(1), without modification, to specify that an application must be submitted to the MGCRB according to the method prescribed by the MGCRB, with an electronic copy of the application sent to CMS. We are specifying that CMS copies should be sent via email to wageindex@cms.hhs.gov.

c. Other Policy Regarding Reclassifications for Terminated Hospitals

Under longstanding CMS policy, if a hospital that has an approved reclassification by the MGCRB terminates its CMS certification number (CCN), we terminate the reclassification status for that hospital when calculating the wage index, because the CCN is no longer active, and because the MGCRB makes its reclassification decisions based on CCNs. We believe this policy results in more accurate reclassifications when compiling CBSA labor market wage data, as it is often the case that hospitals that have terminated their CCNs have also terminated operations, and can no longer make timely and informed decisions regarding reclassification statuses, which could have ramifications for various wage index floors and labor market values.

However, as discussed in response to a comment in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49499 through 49500), in the case of a merger or acquisition where the acquiring hospital accepted the Medicare provider agreement of the acquired hospital located in a different market area that has an existing MGCRB reclassification, we do believe that the acquiring hospital should be able to make determinations regarding the reclassification status of the subordinate campus. While the original CCN for the acquired hospital would be considered terminated or “tied out” by CMS, in the specific situations where a hospital merges with or acquires another hospital located in a different labor market area to create a “multicampus”
hospital and accepts the Medicare provider agreement of the acquired hospital, the reclassification status of the subordinate campus remains in effect. The acquired campus (that is, the hospital whose CCN is no longer active) may continue to receive its previously approved reclassification status, and the acquiring hospital is authorized to make timely requests to terminate, withdraw, or reinstate any reclassification for the subordinate campus for any remaining years of the reclassification. We stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25070) that we believe this policy is consistent with existing regulations regarding reclassification status of “multicampus” hospitals at § 412.230(d)(2)(v). We further stated that hospitals should take care to review their status on Table 2 associated with the proposed rule (which is available via the Internet on the CMS Web site) and notify CMS if they believe a reclassification for a hospital was mistakenly terminated by CMS. We did not receive any public comments on our clarification regarding the treatment of reclassifications of terminated hospitals.

4. Redesignation of Hospitals Under Section 1886(d)(8)(B) of the Act

Section 1886(d)(8)(B)(i) of the Act requires the Secretary to treat a hospital located in a rural county adjacent to one or more urban areas as being located in the urban MSA to which the greatest number of workers in the county commute if certain adjacency and commuting criteria are met. The criteria utilize standards for designating MSAs published in the Federal Register by the Director of the Office of Management and Budget (OMB) based on the most recently available decennial population data. Effective beginning FY 2015, we use the OMB delineations based on the 2010 Decennial Census data to identify counties in which hospitals qualify under section 1886(d)(8)(B) of the Act to receive the wage index of the urban area. Hospitals located in these counties are referred to as “Lugar” hospitals and the counties themselves are often referred to as “Lugar” counties. The chart for this FY 2017 final rule with the listing of the rural counties containing the hospitals designated as urban under section 1886(d)(8)(B) of the Act is available via the Internet on the CMS Web site.

We refer readers to section III.J.2. of the preamble of this final rule for discussion and the finalization of the April 2015 CMS–1664–IFC (81 FR 23428) in which CMS made regulatory changes in order to implement the decisions in Geisinger Community Medical Center v. Secretary, United States Department of Health and Human Services, 794 F.3d 383 (3d Cir. 2015) and Lawrence + Memorial Hospital v. Burwell, No. 15–164, 2016 WL 423702 (2d Cir. Feb. 4, 2015) in a nationally consistent manner. Specifically, the IFC revised the regulations at § 412.230(a)(5)(iii) and removed the regulatory provision at § 412.230(a)(5)(iii) to allow hospitals nationwide to reclassify based on their acquired rural status, effective with reclassifications beginning with FY 2018. The IFC also gave hospitals with an existing MGCRB reclassification the opportunity to seek rural reclassification under § 412.103 and keep their existing MGCRB reclassification.

As a consequence of the regulatory changes in the IFC that allow a hospital to have more than one reclassification simultaneously, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25070), we clarified that a hospital with Lugar status may simultaneously receive an urban to rural reclassification under § 412.103. The IFC provides that when there is both a § 412.103 reclassification and an MGCRB reclassification, the MGCRB reclassification controls for wage index calculation and payment purposes. Similarly, in the FY 2017 proposed rule, we also clarified that we are treating the wage data of hospitals with simultaneous Lugar status and § 412.103 reclassification as Lugar for wage index calculation and wage index payment purposes. We stated that we believe it is appropriate to apply a similar policy for simultaneous MGCRB reclassification and § 412.103 reclassifications, and simultaneous Lugar and § 412.103 reclassifications, because CMS treats Lugar status as a reclassification for purposes of calculating the wage index in accordance with section 1886(d)(8)(B)(ii) of the Act. (Section 1886(d)(8)(B)(ii) of the Act states that the application of section 1886(d)(8)(B) of the Act or a decision of the MGCRB or the Secretary under section 1886(d)(10) of the Act may not result in the reduction of any county’s wage index to a level below the wage index for rural areas in the State in which the county is located.) The wage index associated with the Lugar status, and not the wage index associated with the § 412.103 reclassification, is reflected accordingly in Table 2 associated with this final rule (which is available via the Internet on the CMS Web site). We note that, for payment purposes other than the wage index, a hospital with simultaneous § 412.103 status and Lugar reclassification receives payment as a rural hospital.

Comment: Commenters supported the policy to allow Lugar hospitals to retain their reclassified wage index when they obtain a rural reclassification under § 412.103.

Response: We appreciate the commenters’ support.

After consideration of public comments we received, we are again clarifying that a hospital with Lugar status may simultaneously receive an urban to rural reclassification under § 412.103. As discussed above, we are assigning hospitals that qualify under section 1886(d)(8)(B) of the Act while simultaneously maintaining rural status obtained under § 412.103 the wage index associated with their Lugar status.

5. Waiving Lugar Redesignation for the Out-Migration Adjustment

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51599 through 51600), we adopted the policy that, beginning with FY 2012, an eligible hospital that waives its Lugar status in order to receive the out-migration adjustment has effectively waived its deemed urban status and, thus, is rural for all purposes under the IPPS, including being considered rural for the DSH payment adjustment, effective for the fiscal year in which the hospital receives the out-migration adjustment. (We refer readers to a discussion of DSH payment adjustment under section IV.F. of the preamble of this final rule.)

In addition, we adopted a minor procedural change in that rule that allows a Lugar hospital that qualifies for and accepts the out-migration adjustment (through written notification to CMS within 45 days from the publication of the proposed rule) to waive its urban status for the full 3-year period for which its out-migration adjustment is effective. By doing so, such a Lugar hospital would no longer be required during the second and third years of eligibility for the out-migration adjustment to advise us annually that it prefers to continue being treated as rural and receive the out-migration adjustment. Therefore, under the procedural change, a Lugar hospital that requests to waive its urban status in order to receive the rural wage index in addition to the out-migration adjustment would be deemed to have accepted the out-migration adjustment and agrees to be treated as rural for the duration of its 3-year eligibility period, unless, prior to its second or third year of eligibility, the hospital explicitly notifies CMS in writing, within the required period (generally 45 days from the publication of the proposed rule),
that it instead elects to return to its deemed urban status and no longer wishes to accept the out-migration adjustment. If the hospital does notify CMS that it is electing to return to its deemed urban status, it would again be treated as urban for all IPPS payment purposes.

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51599 through 51600) for a detailed discussion of the policy and process for waiving Lugar status for the out-migration adjustment. We did not receive any public comments on this issue. In the FY 2017 IPPS/LTCH PPS proposed rule, we did not propose a change to the rules regarding waiving Lugar designation for the out-migration adjustment. Therefore, the process remains unchanged at this time. However, as a separate matter, we are taking the opportunity to clarify that a request to waive Lugar status, received within 45 days of the publication of the proposed rule, is valid for the full 3-year period for which the hospital’s out-migration adjustment is effective. If a hospital wishes to reinstate Lugar status for any fiscal year within this 3-year period, it must send a request to CMS within 45 days of the proposed rule for that particular fiscal year. These requests may be sent electronically to wageindex@cms.hhs.gov. CMS will not consider reinstatements of Lugar status for a future fiscal year. For example, if a hospital requests to waive Lugar status for FY 2017 and also to reinstate Lugar status for FY 2018 and 2019, CMS will disregard the reinstatement requests for FY 2018 and FY 2019. Instead, the hospital must request the reinstatement of Lugar status for FY 2018 within 45 days of the FY 2018 IPPS/LTCH PPS proposed rule. If the hospital does this, by default, the hospital would retain Lugar status for FY 2019, although the hospital may once again opt to waive Lugar status for the out-migration adjustment by sending a new request to CMS within 45 days of the FY 2019 IPPS/LTCH PPS proposed rule.

K. Out-Migration Adjustment Based on Commuting Patterns of Hospital Employees for FY 2017

In accordance with section 1886(d)(13) of the Act, as added by section 505 of Public Law 108–173, beginning with FY 2005, we established a process to make adjustments to the hospital wage index based on commuting patterns of hospital employees (the “out-migration” adjustment). The process, outlined in the FY 2006 IPPS final rule (69 FR 49061), provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county but work in a different county (or counties) with a higher wage index.

Section 1886(d)(13)(B) of the Act requires the Secretary to use data the Secretary determines to be appropriate to establish the qualifying counties. When the provision of section 1886(d)(13) of the Act was implemented for the FY 2005 wage index, we analyzed commuting data compiled by the U.S. Census Bureau that were derived from a special tabulation of the 2000 Census journey-to-work data for all industries (CMS extracted data applicable to hospitals). These data were compiled from responses to the “long-form” survey, which the Census Bureau used at the time and which contained questions on where residents in each county worked (69 FR 49062). However, the 2010 Census was “short form” only; information on where residents in each county worked was not collected as part of the 2010 Census. The Census Bureau worked with CMS to provide an alternative dataset based on the latest available data on where residents in each county worked in 2010, for use in developing a new out-migration adjustment based on new commuting patterns developed from the 2010 Census data beginning with FY 2016.

To determine the out-migration adjustments and applicable counties for FY 2016, we analyzed commuting data compiled by the Census Bureau that were derived from a custom tabulation of the American Community Survey (ACS), an official Census Bureau survey, utilizing 2008 through 2012 (5-Year) Microdata. The data were compiled from responses to the ACS questions regarding the county where workers reside and the county to which workers commute. As we discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49500), the same policies, procedures, and computation that were used for the FY 2012 out-migration adjustment were applicable for FY 2016, and we proposed to use them again for FY 2017. As we stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25071), we have applied the same policies, procedures, and computations since FY 2012, and we believe they continue to be appropriate for FY 2017. We did not receive any comments on these proposals. We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49500 through 49502) for a full explanation of the revised data source. For FY 2017, until such time that CMS finalizes out-migration adjustments based on the next Census, the out-migration adjustment continues to be based on the data derived from the custom tabulation of the ACS utilizing 2008 through 2012 (5-Year) Microdata. For FY 2017, we did not propose any changes to the methodology or data source that we used for FY 2016 (81 FR 25071). (We refer readers to a full discussion of the out-migration adjustment, including rules on deeming hospitals reclassified under section 1886(d)(6) or section 1886(d)(10) of the Act to have waived the out-migration adjustment, in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51601 through 51602).) Table 2 associated with this final rule (which is available via the Internet on the CMS Web site) includes the final out-migration adjustments for the FY 2017 wage index.

L. Notification Regarding CMS “Lock-In” Date for Urban to Rural Reclassifications Under § 412.103

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25071 through 25072), under section 1886(d)(6)(E) of the Act, a qualifying prospective payment hospital located in an urban area may apply for rural status for payment purposes separate from reclassification through the MGCRB. Specifically, section 1886(d)(6)(E) of the Act provides that, not later than 60 days after the receipt of an application (in a form and manner determined by the Secretary) from a subsection (d) hospital that satisfies certain criteria, the Secretary shall treat the hospital as being located in the rural area (as defined in paragraph (2)(D)) of the State in which the hospital is located. We refer readers to the regulations at 42 CFR 412.103 for the general criteria and application requirements for a subsection (d) hospital to reclassify from urban to rural status in accordance with section 1886(d)(8)(E) of the Act. The FY 2012 IPPS/LTCH PPS final rule (76 FR 51595 through 51596) includes our policies regarding the effect of wage data from reclassified or redesignated hospitals. Hospitals must meet the criteria to be reclassified from urban to rural status under § 412.103, as well as fulfill the requirements for the application process. However, under existing § 412.103(b), there is no timeframe requirement as to when hospitals must apply for the urban to rural reclassification. Therefore, a hospital can apply for the urban to rural reclassification at any time, and under § 412.103(d), the effective date of the hospital’s rural status, once approved, is the filing date of the application. There may be one exception: the Act provides that a hospital applies for the urban to
rural reclassification, and the timeframe that a hospital submits an application is often dependent on those reason(s). Because there are no timeframes for when a hospital must submit its application under §412.103, it is the hospital’s prerogative as to when it files the application with the CMS Regional Office. Because the wage index is part of the methodology for determining the prospective payments to hospitals for each fiscal year, we believe there should be a definitive timeframe within which a hospital should apply for rural status in order for the reclassification to be reflected in the wage indexes and other IPPS rates. As hospitals are aware, the IPPS ratesetting process that CMS undergoes each proposed and final rulemaking is complex and labor-intensive, and subject to a compressed timeframe in order to issue the final rule each year within the timeframes for publication. Accordingly, CMS must ensure that it receives, in a timely fashion, the necessary data, including, but not limited to, the list of hospitals that are reclassified from urban to rural status under §412.103, in order to calculate the wage indexes and other IPPS rates.

Therefore, in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25071 through 25072), we proposed a date by when we would “lock in” the list of hospitals that are reclassified from urban to rural status under §412.103 in order to include them in the upcoming Federal fiscal year’s wage index calculation provided for at §412.64(h) and budget neutrality calculations provided for at §§412.64(e)(1)(ii), (e)(2), and (e)(4) that are part of the ratesetting process. The ratesetting process is described in the Addendum of the annual proposed and final rules and includes the budget neutrality adjustments in accordance with the regulations at §§412.64(e)(1)(ii), (e)(2), and (e)(4), as well as adjustments for differences in area wage levels provided for at §412.64(h). We stated in the proposed rule (81 FR 25072) that we believe this proposal would introduce additional transparency and predictability regarding the timing of accounting for urban or rural status in the IPPS ratesetting each Federal fiscal year. We proposed that this date for “locking in” the list of hospitals with rural status achieved under §412.103 would be the second Monday in June of each year. Therefore, if a hospital is applying for an urban to rural reclassification under §412.103 for the purpose and expectation that its rural status be reflected in the wage index and budget neutrality calculations for setting payment rates for the next Federal fiscal year, the hospital would need to file its application with the CMS Regional Office not later than 70 days prior to the second Monday in June. Because, under §412.103(c), the CMS Regional Office must notify the hospital of its approval or disapproval of the application within 60 days of the hospital’s filing date (the date it is received by the CMS Regional Office, in accordance with §412.103(b)(5)), we stated that we would expect that the extra 10 days would provide the CMS Regional Office with sufficient processing and administrative time to notify the CMS Central Office of the reclassification status of the applications by the second Monday in June of each year. This is the latest date that CMS would need the information in order to ensure that reclassified hospitals would be included as such in the wage index and budget neutrality calculations for setting payment rates for the next Federal fiscal year. As discussed in the proposed rule, this does not preclude a hospital from applying for reclassification under §412.103 earlier or later than the proposed deadline. Nor does the proposed deadline change the fact that the rural reclassification is effective as of its filing date, in accordance with §412.103(d). However, in order to ensure that a reclassification is reflected in the wage index and budget neutrality calculations for setting payment rates for the next Federal fiscal year, applications must be received by the CMS Regional Office (the filing date) by no later than 70 days prior to the second Monday in June of the current Federal fiscal year. If the CMS Central Office is informed of a reclassification status after the second Monday in June, for wage index and budget neutrality purposes, the reclassification would not be reflected in the payment rates until the following Federal fiscal year; that is, the Federal fiscal year following the next Federal fiscal year. We proposed to revise §412.103(b) by adding a new paragraph (6) to specify that, in order for a hospital to be treated as rural in the wage index and budget neutrality calculations under §§412.64(e)(1)(ii), (e)(2), (e)(4), and (h) for payment rates for the next Federal fiscal year, the hospital’s filing date must be no later than 70 days prior to the second Monday in June of the current Federal fiscal year and the application must be approved by the CMS Regional Office in accordance with the requirements of §412.103.

Comment: One commenter believed that the proposal to specify a lock-in date for urban to rural reclassification under §412.103 for wage index and budget neutrality calculation purposes was reasonable and supported the need to have a “cutoff” date. However, the commenter requested clarification that the lock-in date for wage index and ratesetting purposes would have no impact on the timing of payment changes at the hospital-specific level.

Response: We appreciate the commenter’s support. We proposed to set a lock-in date by which a hospital must file for urban to rural reclassification under §412.103 in order to be treated as rural in the upcoming fiscal year’s wage index and budget neutrality calculations. Thus, if a hospital wants its rural status to be reflected in the wage index and budget neutrality calculations for setting payment rates for the upcoming fiscal year, the hospital would need to file its reclassification application with the CMS Regional Office not later than 70 days prior to the second Monday in June of the current Federal fiscal year. As we stated in the proposed rule, we did this to introduce additional transparency and predictability regarding the timing of accounting for urban or rural status in the IPPS ratesetting each fiscal year. As the commenter indicated, reclassification under §412.103 also affects payment at the hospital-specific level. We are clarifying that the lock-in date does not affect the timing of payment changes occurring at the hospital-specific level as a result of reclassification from urban to rural under §412.103. As we indicated in the proposed rule, this lock-in date does not change the current regulation that allows hospitals that qualify under §412.103(a) to request, at any time during a cost reporting period, to reclassify from urban to rural. A hospital’s rural status and claims payment reflecting its rural status continue to be effective on the filing date of its reclassification application, which is the date the CMS Regional Office receives the application, in accordance with §412.103(d). The hospital’s IPPS claims would be paid reflecting its rural status on the filing date (the effective date) of the reclassification, regardless of when the hospital applies.

After consideration of the public comment we received, we are finalizing, without modification, our proposal that, in order for a hospital that applies for reclassification under §412.103 to be treated as rural in the wage index and budget neutrality calculations under §§412.64(e)(1)(ii), (e)(2), (e)(4), and (h) for payment rates for the next Federal fiscal year, the hospital’s filing date
must be no later than 70 days prior to the second Monday in June of the current Federal fiscal year and the application must be approved by the CMS Regional Office in accordance with the requirements of § 412.103. We also are finalizing our proposal to add a paragraph (6) to § 412.103 to specify this new lock-in date.

M. Process for Requests for Wage Index Data Corrections

The preliminary, unaudited Worksheet S–3 wage data files for the proposed FY 2017 wage index were made available on May 15, 2015, and the preliminary CY 2013 occupational mix data files on May 15, 2015, through the Internet on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html. On January 29, 2016, we posted a public use file (PUF) at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html containing FY 2017 wage index data available as of January 28, 2016. This PUF contains a tab with the Worksheet S–3 wage data (which includes Worksheet S–3, Parts II and III wage data from cost reporting periods beginning on or after October 1, 2012 through September 30, 2013; that is, FY 2013 wage data), a tab with the occupational mix data (which includes data from the CY 2013 occupational mix survey, Form CMS–10079), and new for FY 2017, a tab containing the Worksheet S–3 wage data of hospitals deleted from the January 29, 2016 wage data PUF and a tab containing the CY 2013 occupational mix data (if any) of the hospitals deleted from the January 29, 2016 wage data PUF. In a memorandum dated January 21, 2016, we instructed all MACs to inform the IPPS hospitals that they service of the availability of the January 29, 2016 wage index data PUFs, and the process and timeframe for requesting revisions in accordance with the FY 2017 Wage Index Timetable.

In the interest of meeting the data needs of the public, beginning with the proposed FY 2009 wage index, we post an additional PUF on our Web site that reflects the actual data that are used in computing the proposed wage index. The release of this file does not alter the current wage index process or schedule. We notify the hospital community of the availability of these data as we do with the current wage index data through our Hospital Open Door Forum. We encourage hospitals to sign up for automatic notifications of information about hospital issues and about the dates of the Hospital Open Door Forums at the CMS Web site at: http://www.cms.gov/Outreach-and-Education/Outreach/OpenDoorForums/index.html. In a memorandum dated April 30, 2015, we instructed all MACs to inform the IPPS hospitals that they service of the availability of the wage index data files and the process and timeframe for requesting revisions (including the specific deadlines listed later in this section). We also instructed the MACs to advise hospitals that these data were also made available directly through their representative hospital organizations.

If a hospital wished to request a change to its as shown in May 15, 2015 wage data files and May 15, 2015 occupational mix data files, the hospital was to submit corrections along with complete, detailed supporting documentation to its MAC by September 2, 2015. Hospitals were notified of this deadline and of all other deadlines and requirements, including the requirement to review and verify their data as posted in the preliminary wage index data files on the Internet, through the letters sent to them by their MACs.

November 4, 2015 was the date by which MACs notified State hospital associations regarding hospitals that failed to respond to issues raised during the desk reviews. The MACs notified the hospitals by mid-January 2016 of any changes to the wage index data as a result of the desk reviews and the resolution of the hospitals’ revision requests. The MACs also submitted the revised data to CMS by January 22, 2016. CMS published the proposed wage index PUFs that included hospitals’ revised wage index data on January 29, 2016. Hospitals had until February 16, 2016, to submit requests to the MACs for reconsideration of adjustments made by the MACs as a result of the desk review, and to correct errors made by CMS or the MAC’s mishandling of the wage index data. Hospitals also were required to submit sufficient documentation to support their requests.

After reviewing requested changes submitted by hospitals, MACs were required to transmit to CMS any additional revisions resulting from the hospitals’ reconsideration requests by March 24, 2016. The deadline for a hospital to request CMS intervention in cases where a hospital disagreed with a MAC’s policy interpretation was April 5, 2016. We note that, as we did for the FY 2016 wage index, for the FY 2017 wage index, in accordance with the FY 2017 wage index timeline posted on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html, the April appeals have to be sent via mail and email. We refer readers to the wage index timeline for complete details.

Hospitals were given the opportunity to examine Table 2, which is listed in section VI. of the Addendum to the proposed rule and available via the Internet on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html. Table 2 associated with the proposed rule contained each hospital’s proposed adjusted average hourly wage used to construct the wage index values for the past 3 years, including the FY 2013 data used to construct the proposed FY 2017 wage index. We noted in the proposed rule (81 FR 25073) that the proposed hospital average hourly wages shown in Table 2 only reflected changes made to a hospital’s data that were transmitted to CMS by late February 2016.

We posted the final wage index data PUFs on April 21, 2016 on the Internet at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html. The April 2016 PUFs were made available solely for the limited purpose of identifying any potential errors made by CMS or the MAC in the entry of the final wage index data that resulted from the correction process previously described (revisions submitted to CMS by the MACs by March 24, 2016).

After the release of the April 2016 wage index data PUFs, changes to the wage and occupational mix data could only be made in those very limited situations involving an error by the MAC or CMS that the hospital could not have known about before its review of the final wage index data files. Specifically, neither the MAC nor CMS will approve the following types of requests:

- Requests for wage index data corrections that were submitted too late to be included in the data transmitted to CMS by the MACs or on or before March 24, 2016.
- Requests for correction of errors that were not, but could have been, identified during the hospital’s review of the January 29, 2016 wage index PUF.
- Requests to revisit factual determinations or policy interpretations
made by the MAC or CMS during the wage index data correction process. If, after reviewing the April 2016 final wage index data PUFs, a hospital believed that its wage or occupational mix data were incorrect due to a MAC or CMS error in the entry or tabulation of the final data, the hospital was given the opportunity to notify both its MAC and CMS regarding why the hospital believed an error exists and provide all supporting information, including relevant dates (for example, when it first became aware of the error). The hospital was required to send its request to CMS and to the MAC no later than May 23, 2016. Similar to the April appeals, beginning with the FY 2015 wage index, in accordance with the FY 2017 wage index timeline posted on the CMS Web site at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Wage-Index-Files-Items/FY2017-Wage-Index-Home-Page.html, the May appeals were required to be sent via mail and email to CMS and the MACs. We refer readers to the wage index timeline for complete details.

Verified corrections to the wage index data received timely by CMS and the MACs (that is, by May 23, 2016) were incorporated into the final FY 2017 wage index in this FY 2017 IPPS/LTCPPS final rule, which is effective October 1, 2016.

We created the processes previously described to resolve all substantive wage index data correction disputes before we finalize the wage and occupational mix data for the FY 2017 payment rates. Accordingly, hospitals that did not meet the procedural deadlines set forth above will not be afforded a later opportunity to submit wage index data corrections or to dispute the MAC’s decision with respect to requested changes. Specifically, our policy is that hospitals that do not meet the procedural deadlines set forth above will not be permitted to challenge later, before the PRRB, the failure of CMS to make a requested data revision. We refer readers also to the FY 2000 IPPS final rule (64 FR 41513) for a discussion of the parameters for appeals to the PRRB for wage index data corrections.

Again, we believe the wage index data correction process described earlier provides hospitals with sufficient opportunity to bring errors in their wage and occupational mix data to the MAC’s attention. Moreover, because hospitals had access to the final wage index data PUFs by late April 2016, they had the opportunity to detect any data entry or tabulation by the MAC or CMS before the development and publication of the final FY 2017 wage index by August 2016, and the implementation of the FY 2017 wage index on October 1, 2016. Given these processes, the wage index implemented on October 1 should be accurate. Nevertheless, in the event that errors are identified by hospitals and brought to our attention after May 23, 2016, we retain the right to make midyear changes to the wage index under very limited circumstances.

Specifically, in accordance with 42 CFR 412.64(k)(1) of our regulations, we make midyear corrections to the wage index for an area only if a hospital can show that: (1) The MAC or CMS made an error in tabulating its data; and (2) the requesting hospital could not have known about the error or did not have an opportunity to correct the error, before the beginning of the fiscal year. For purposes of this provision, “before the beginning of the fiscal year” means by the May deadline for making corrections to the wage data for the following fiscal year’s wage index (for example, May 23, 2016 for the FY 2017 wage index). This provision is not available to a hospital seeking to revise another hospital’s data that may be affecting the requesting hospital’s wage index for the labor market area. As indicated earlier, because CMS makes the wage index data available to hospitals on the CMS Web site prior to publishing both the proposed and final IPPS rules, and the MACs notify hospitals directly of any wage index data changes after completing their desk reviews, we do not expect that midyear corrections will be necessary. However, under our current policy, if the correction of a data error changes the wage index value for an area, the revised wage index value will be effective prospectively from the date the correction is made.

In the FY 2006 IPPS final rule (70 FR 47385 through 47387 and 47485), we revised 42 CFR 412.64(k)(2) to specify that, effective on October 1, 2005, that is, beginning with the FY 2006 wage index, a change to the wage index can be made retroactively to the beginning of the Federal fiscal year only when CMS determines all of the following: (1) The MAC or CMS made an error in tabulating data used for the wage index calculation; (2) the hospital knew about the error and requested that the MAC and CMS correct the error using the established process and within the established schedule for requesting corrections to the wage index data, before the beginning of the fiscal year for the applicable IPPS update (that is, by the May 23, 2016 IPPS deadline for the FY 2017 wage index); and (3) CMS agreed before October 1 that the MAC or CMS made an error in tabulating the hospital’s wage index data and the wage index should be corrected.

In those circumstances where a hospital requested a correction to its wage index data before CMS calculated the final wage index (that is, by the May 23, 2016 deadline for the FY 2017 wage index), and CMS acknowledges that the error in the hospital’s wage index data was caused by CMS’ or the MAC’s mishandling of the data, we believe that the hospital should not be penalized by our delay in publishing or implementing the correction. As with our current policy, we indicated that the provision is not available to a hospital seeking to revise another hospital’s data. In addition, the provision cannot be used to correct prior years’ wage index data; and it can only be used for the current Federal fiscal year. In situations where our policies would allow midyear corrections other than those specified in 42 CFR 412.64(k)(2)(ii), we continue to believe that it is appropriate to make prospective-only corrections to the wage index.

We note that, as with prospective changes to the wage index, the final retroactive correction will be made irrespective of whether the change increases or decreases a hospital’s payment rate. In addition, we note that the policy of retroactive adjustment will still apply in those instances where a final judicial decision reverses a CMS denial of a hospital’s wage index data revision request.

N. Labor Market Share for the FY 2017 Wage Index

Section 1886(d)(3)(E) of the Act directs the Secretary to adjust the proportion of the national prospective payment system base payment rates that are attributable to wages and wage-related costs by a factor that reflects the relative differences in labor costs among geographic areas. It also directs the Secretary to estimate from time to time the proportion of hospital costs that are labor-related and to adjust the proportion (as estimated by the Secretary from time to time) of hospitals’ costs which are attributable to wages and wage-related costs of the DRG prospective payment rates. We refer to the portion of hospital costs attributable to wages and wage-related costs as the labor-related share. The labor-related share of the prospective payment rate is adjusted by an index of relative labor costs, which is referred to as the wage index.

Section 403 of Public Law 108–173 amended section 1886(d)(3)(E) of the Act to provide that the Secretary must employ 62 percent as the labor-related
share unless this would result in lower payments to a hospital than would otherwise be made. However, this provision of Public Law 108–173 did not change the legal requirement that the Secretary estimate from time to time the proportion of hospitals’ costs that are attributable to wages and wage-related costs. Thus, hospitals receive payment based on either a 62-percent labor-related share, or the labor-related share estimated from time to time by the Secretary, depending on which labor-related share results in a higher payment.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50596 through 50607), we rebased and revised the hospital market basket. We established a FY 2010-based IPPS hospital market basket to replace the FY 2006-based IPPS hospital market basket, effective October 1, 2013. In that final rule, we presented our analysis and conclusions regarding the frequency and methodology for updating the labor-related share for FY 2014. Using the FY 2010-based IPPS market basket, we finalized a labor-related share for FY 2014, FY 2015, and FY 2016 of 69.6 percent. In addition, in FY 2014, we implemented this revised and rebased labor-related share in a budget neutral manner (78 FR 51016). However, consistent with section 1886(d)(3)(E) of the Act, we did not take into account the additional payments that would be made as a result of hospitals with a wage index less than or equal to 1.0000 being paid using a labor-related share lower than the labor-related share of hospitals with a wage index greater than 1.0000.

The labor-related share is used to determine the proportion of the national IPPS base payment rate to which the area wage index is applied. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25074), for FY 2017, we did not propose to make any further changes to the national average proportion of operating costs that are attributable to wages and salaries, employee benefits, contract labor, the labor-related portion of professional fees, administrative and facilities support services, and all other labor-related services. Therefore, for FY 2017, we proposed to continue to use a labor-related share of 69.6 percent for discharges occurring on or after October 1, 2016.

We did not receive any public comments on our proposal and are finalizing our proposal, without modification, to continue to use a labor-related share of 69.6 percent for discharges occurring on or after October 1, 2016.

As discussed in section IV.A. of the preamble of the proposed rule (81 FR 25074) and section IV.A. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. As a result, we applied the Puerto Rico-specific labor-related share percentage and nonlabor-related share percentage to the Puerto Rico-specific standardized amount. Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016, shall use 100 percent of the national standardized amount. Because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount as of January 1, 2016, under section 1886(d)(9)(E) of the Act as amended by section 601 of the Consolidated Appropriations Act, 2016, there is no longer a need for us to calculate a Puerto Rico-specific labor-related share percentage and nonlabor-related share percentage for application to the Puerto Rico-specific standardized amount. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the national labor-related share and nonlabor-related share percentages that are applied to the national standardized amount. Accordingly, for FY 2017, we did not propose a Puerto Rico-specific labor-related share percentage or a nonlabor-related share percentage in the proposed rule (81 FR 25074).

Tables 1A and 1B, which are published in section VI. of the Addendum to this FY 2017 IPPS/LTCH PPS final rule and available via the Internet on the CMS Web site, reflect the national labor-related share, which is also applicable to Puerto Rico hospitals. For FY 2017, for all IPPS hospitals (including Puerto Rico hospitals) whose wage index is less than or equal to 1.0000, we are applying the wage index to a labor-related share of 62 percent of the national standardized amount. For all IPPS hospitals (including Puerto Rico hospitals) whose wage indexes are greater than 1.0000, for FY 2017, we are applying the wage index to a labor-related share of 69.6 percent of the national standardized amount.

O. Public Comments on Treatment of Overhead and Home Office Costs in the Wage Index Calculation as a Result of Our Solicitation

Section III.D. of the preamble of this final rule states that the method used to compute the FY 2017 wage index without an occupational mix adjustment follows the same methodology that we used to compute the FY 2012, FY 2013, FY 2014, FY 2015, and FY 2016 final wage indexes without an occupational mix adjustment (76 FR 51591 through 51593, 77 FR 53366 through 53367, 78 FR 50587 through 50588, 79 FR 49967, and 80 FR 49491 through 49492, respectively).

As discussed in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51592), in “Step 4” of the calculation of the unadjusted wage index, each hospital reporting both total overhead salaries and total overhead hours greater than zero, we allocate overhead costs to areas of the hospital excluded from the wage index calculation. We also compute the amounts of overhead wage-related costs to be allocated to excluded areas. Finally, we subtract the computed overhead salaries, overhead wage-related costs, and hours associated with excluded areas from the total salaries (plus allowable wage-related costs) and hours derived in “Steps 2 and 3” of the calculation of the unadjusted wage index. (We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51592) for a description of the calculation of the unadjusted wage index.) As stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25075), we first began to remove from the wage index the overhead salaries and hours allocated to excluded areas beginning with the FY 1999 wage index calculation (63 FR 40971 and 40972). Beginning with the FY 2002 wage index calculation, we estimated and removed overhead wage-related costs allocated to excluded areas in addition to removing overhead salaries and hours allocated to excluded areas (66 FR 39863 and 39864). We began to estimate and remove overhead wage-related costs associated with excluded areas because we realized that without doing so, the formula resulted in large and inappropriate increases in the average hourly wages of some hospitals, particularly hospitals with large overhead and excluded area costs. These findings led us to believe that not all hospitals were fully or consistently allocating their overhead salaries among the lines on Worksheet S–3, Part II, of the hospital cost report for allowable wage-related costs (Worksheet S–3, Part II, lines 13 and 14 on CMS Form 2552–96, and lines 17 and 18 on CMS Form...
results show that the problem manifested in the formula prior to FY 2002 continues to be a concern; that is, while the average hourly wages of all hospitals with excluded areas are impacted, hospitals that have particularly large excluded areas experience large and inappropriate increases to their average hourly wages. For example, one hospital with an excluded area percentage of 95 percent that has an average hourly wage of approximately $32 under our current methodology would have an average hourly wage of $128 under the formula in effect prior to FY 2002 (that is, without removal of excluded area overhead wage-related costs).

Accordingly, as stated in the proposed rule (81 FR 25075), we believe that, at this point, there is a need for CMS to continue to estimate and remove the overhead wage-related costs associated with excluded areas from the unadjusted wage index calculation. However, in an effort to improve consistency in hospital cost reporting practices and to improve the accuracy of the wage index, we indicated in the proposed rule that we are considering the possibility of future rulemaking or cost reporting changes, or a combination of both, where hospitals would apply a single allocation methodology between Worksheet S–3, Part IV and Worksheet S–3, Part II, lines 17 through 25. For example, one possibility is the modification and expansion of Worksheet S–3, Part IV to add columns that would correspond to each line 17 through 25 of Worksheet S–3, Part II. In addition, Worksheet S–3, Part IV could employ one or more statistical allocation methods, facilitating a direct flow of the allocated amounts to each line 17 through 25 of Worksheet S–3, Part II.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25075), we solicited comments from stakeholders to gain a better understanding of the nature of hospitals’ reporting of wage-related costs on Worksheet S–3, Part IV, and in turn, on Worksheet S–3, Part II, it is possible to conclude that hospitals’ own allocation methodologies are properly allocating an accurate amount of wage-related costs for both direct cost centers and overhead areas to line 19 for the excluded areas. Accordingly, the question has been raised whether it continues to be necessary for CMS to estimate and remove the overhead wage-related costs associated with excluded areas from the unadjusted wage index calculation.

We have tested the effect on the average hourly wages of hospitals if we would not estimate and remove the overhead wage-related costs associated with excluded areas from the unadjusted wage index calculation. The results show that the problem most, if not all cases, hospitals are not self-identifying and removing the excluded area amounts. The commenter noted that while current cost report instructions for line 17 of Worksheet S–3, Part II instruct hospitals that wage-related costs associated with excluded areas be removed, the cost report instructions do not state that hospitals should remove overhead wage-related costs associated with excluded areas from Line 17 (CMS emphasis added). The commenter believed that any plan to require hospitals to perform their own calculation to estimate and remove excluded area overhead could create inconsistent results unless very specific cost report instructions are provided and adhered to.

Response: We agree with the commenter that, at this point, there is a need for CMS to continue to estimate and remove the overhead wage-related costs associated with excluded areas from the unadjusted wage index calculation. As we stated in the proposed rule (81 FR 25075), we have tested the effect on the average hourly wages of hospitals if we would not estimate and remove the overhead wage-related costs associated with excluded areas from the unadjusted wage index calculation. The results show that the problem manifested in the formula prior to FY 2002 continues to be a concern; that is, while the average hourly wages of all hospitals with excluded areas are impacted, hospitals that have particularly large excluded areas experience large and inappropriate increases to their average hourly wages. While we believe that existing cost report instructions for lines 17 and 18 for wage-related costs state clearly that lines 17 and 18 must "not include wage-related costs applicable to the excluded areas reported on lines 9 and 10; instead, these costs are reported on line 19," we may consider further specifying that hospitals must also not include on lines 17 and 18 overhead wage-related costs applicable to excluded areas. When revising the cost report instructions, we will consider whether more precise and uniform instructions for estimating and removing overhead wage-related costs should be incorporated directly into the cost report for hospitals to complete, rather than CMS estimating and removing the overhead wage-related costs associated with excluded areas from the unadjusted wage index calculation. Comment: In regard to CMS’ solicitation of comments related to reporting of wage-related costs on lines 17 through 25 of Worksheet S–3, Part II, one commenter believed that most hospitals allocate their wage-related cost
on lines 17 through 25 based on salaries, and therefore, this should be the preferred allocation method. The commenter stated that if a hospital wishes to use a wage-related cost allocation method other than one based on salaries, the hospital should be required to document to the MAC that an alternative method would be more accurate than salaries. The commenter added that if CMS chooses to pursue building the “Step 4” overhead allocation into the cost report, CMS should simultaneously add lines to the cost report that perform the complete average hourly wage calculation that CMS uses to calculate the unadjusted wage index. The commenter pointed out that the addition of these lines to the cost report should not require extra administrative burden because all the additional data elements would be drawn from existing lines on Worksheet S–3, Parts II and III. However, the commenter noted that the disadvantage to incorporating the complete average hourly wage calculation into the cost report is that the cost report would need to be updated if the wage index calculation is revised.

Response: We appreciate the information provided by the commenter that most hospitals allocate their wage-related cost on lines 17 through 25 based on salaries. We also appreciate the commenter’s suggestion regarding adding lines to Worksheet S–3, Part III to incorporate the complete unadjusted average hourly wage calculation (meaning, the average hourly wage unaffectuated for occupational mix). We will consider these suggestions further in future rulemaking and/or cost report revisions as appropriate.

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25075 through 25076), another issue about which we are concerned and for which we solicited public comments in the proposed rule relates to inconsistent reporting of home office salaries and wage-related costs. Worksheet S–2, Part I, line 140, requires hospitals to complete Worksheet A–8–1 if they have any related organization or home office costs claimed as defined in the Provider Reimbursement Manual, CMS Pub. 15–1, Chapter 10, Section 1002, and 42 CFR 413.17. Then, line 14 of Worksheet S–3, Part II instructs hospitals to enter the salaries and wage-related costs paid to personnel who are affiliated with a home office and/or related organization, who provide services to the hospital, and whose salaries are not included on Worksheet A, Column 1. Because home office salaries and wage-related costs are not included on Worksheet A, Column 1, we are concerned that hospitals are not including home office costs on Worksheet A, Column 2 or Column 6 in the appropriate cost centers on lines 4 through 17, adjusted from Worksheet A–8 or Worksheet A–8–1. Another concern is a hospital’s inadvertent inclusion on line 14 of the home office salaries or wage-related costs associated with excluded areas on Worksheet S–3, Part II, lines 9 or 10. In addition, we are concerned about the amalgam of personnel costs that hospitals report on line 14, particularly when another more precise line exists for those personnel costs to be reported. For example, if cafeteria services are provided through the home office, those wages and hours should not be reported on line 14, but instead should be reported on the more specific cost center for Cafeteria, Worksheet S–3, Part II, line 36 (corresponding to Cafeteria on Worksheet A, line 11). We note that, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49965 through 49967), we reiterated our requirement that all hospitals must document salaries, wages, and hours for the purpose of reporting this information on Worksheet S–3, Part II, lines 32, 33, 34, and/or 35 (for either directly employed housekeeping and dietary employees on lines 32 and 34, and contract labor on lines 33 and 35). We have learned of instances where housekeeping or dietary services are provided through the home office, and the hospital reported those wages and hours on line 14. This is inconsistent with other hospitals’ reporting of housekeeping and dietary services on lines 32 through 35. As stated in the FY 2015 IPPS/LTCH PPS final rule, we have instructed the MACs to impute housekeeping or dietary wages and hours when hospitals have not properly completed those lines 32 through 35. Hospitals whose housekeeping or dietary services (either direct or under contract) are provided through their home office are not exempt from this requirement to report wages and hours on the specific cost centers for housekeeping and dietary.

Hospitals should also take care to report housekeeping and dietary services in the appropriate cost centers on Worksheet A, lines 9 and 10 respectively. As stated in the proposed rule (81 FR 25076), because the nature of services provided by home office personnel are for general management or administrative services related to the provision of patient care (CMS Pub. 15–1, Chapter 21, Section 2150), and may be provided to multiple areas of the hospital, we are considering ending reporting of home office costs on line 14 of Worksheet S–3, Part II, and instead we may require reporting of home office costs as part of the overhead lines, possibly by adding lines or columns, or subscribing existing line 27 (Administrative & General), and line 28 (Administrative & General for contract labor). In the FY 2017 proposed rule (81 FR 25076), we solicited public comments to gain a better understanding of hospitals’ reporting of home office salaries and wage-related costs for possible future revisions to the cost report instructions and lines.

Comment: One commenter recognized the problem of inconsistent reporting of home office salaries and wage-related costs, and supported the idea of reporting these costs in the overhead lines, as long as the home office salaries and wage-related costs are delineated separately from other overhead costs. The commenter stated that it is important to retain transparency on home office costs versus other hospital-specific overhead costs, and that CMS should also explore the possibility of penalties for the filing of incomplete or inconsistent cost reports to increase compliance.

Response: We appreciate the commenter’s support, and acknowledge that it may be useful to separately track home office wages and hours from other overhead wages and hours. We are in favor of measures to increase transparency and accuracy of cost reporting, which we are attempting to do as part of the solicitation of public comments to gain a better understanding of hospitals’ reporting practices regarding overhead and home office costs and hours. We will consider the commenter’s suggestions in the future as appropriate.

Comment: One commenter stated that most hospitals report home office salaries on Worksheet A–8–1 with an appropriate adjustment in Column 6 of Worksheet A. In addition, the commenter believed that most hospitals report their entire home office salary and hour allocation on line 14 of Worksheet S–3 Part II without removing an amount for excluded areas. The
commenter recommended that if CMS decides that an allocation is needed to remove overhead cost associated with excluded areas contained within the home office costs, CMS subscript line 14 into overhead and nonoverhead cost and hours. The overhead portion could then be allocated in the same manner that the hospital overhead cost is currently allocated.

Response: We appreciate the information provided by the commenter, although we are disinconcerted to learn that the commenter believes that most hospitals report their entire home office salary and hour allocation on line 14 of Worksheet S–3, Part II, without performing an allocation to remove costs and hours associated with excluded areas. This means that hospitals are inappropriately including wages and hours associated with excluded areas in the wage index. We will take these comments into consideration for future rulemaking and/or cost report revisions as appropriate.

Comment: One commenter disagreed with CMS’ suggestion in the proposed rule that it may require reporting of home office cost as part of the overhead lines, instead of line 14 of Worksheet S–3, Part II, because the nature of services provided by home office personnel are for general management or administrative services related to the provision of patient care (81 FR 25076). The commenter stated that the cost report instructions (CMS Pub. 15–2, Chapter 40, Section 4005.2) for Worksheet S–3, Part II, Line 14 do not specify that the home office and/or related party organizations costs need to only be administrative and general costs. The commenter stated that, as a hospital system with multiple hospitals, it reports ancillary services such as physical, occupational, and speech therapy personnel costs, particularly when those personnel costs are included on Worksheet S–3, Part II, lines 9 or 10, and inclusion of an amalgam of personnel costs, particularly when another more precise line exists for those personnel costs. We do not specify that the home office and/or related party organizations costs need to only be administrative and general costs. However, the fact that the commenter, a hospital system with multiple hospitals, stated that it reports ancillary services such as physical, occupational, and speech therapy personnel costs on Worksheet S–3, Part II, line 14, is evidence of the inconsistent and disparate types of services that hospitals are reporting on line 14. It seems apparent that hospitals are treating line 14 as they would an overhead cost center, supporting the need for CMS to consider ending reporting of home office costs on line 14 and to instead require reporting of home office costs as part of the overhead lines 27 and 28 (Administrative & General).

Response: We will take the comments into consideration for future rulemaking and/or cost report revisions as appropriate.

Comment: One commenter suggested that any change in the wage index calculation be evaluated after the additional information is gathered, similar to CMS efforts in relation to the solicitation of comments regarding the overhead allocation. The commenter stated that CMS should disclose its findings and any proposed changes to the wage index calculation through notice-and-comment rule making.

Response: We will take the commenter’s suggestions into consideration as appropriate.

Because we did not make specific proposals in the proposed rule regarding treatment of overhead and home office costs in the wage index calculation, that is, we only solicited comments to gain a better understanding of hospitals’ reporting practices, we are not making any changes at this time. However, we will take the comments into consideration for future cost reporting changes and/or rulemaking as appropriate.

IV. Other Decisions and Changes to the IPPS for Operating Costs and Direct Graduate Medical Education (GME) and Indirect Medical Education (IME) Costs

A. Changes to Operating Payments for Subsection (d) Puerto Rico Hospitals as a Result of Section 601 of Public Law 114–113

Prior to January 1, 2016, Puerto Rico hospitals were paid with respect to operating costs of inpatient hospital services for inpatient hospital discharges based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges occurring on or after January 1, 2016, shall use 100 percent of the national standardized amount. As a result of the amendment made by section 601 of Public Law 114–113, on February 4, 2016, we issued Change Request 9523 which updated the payment rates for subsection (d) Puerto Rico hospitals for discharges occurring on or after January 1, 2016. Change Request 9523 can be downloaded from the CMS Web site at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2016-Transmittals-Items/R3449CP.html.

For operating costs for inpatient hospital discharges occurring in FY 2017 and subsequent fiscal years, consistent with the provisions of section 1886(d)(9)(E) of the Act as amended by section 601 of Public Law 114–113, subsection (d) Puerto Rico hospitals will continue to be paid based on 100 percent of the national standardized amount. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25076), we proposed to make conforming changes to the regulations at 42 CFR 412.204 to reflect the current law that is effective for discharges occurring on or after January 1, 2016. Specifically, we proposed to add a new paragraph (e) to §412.204 to reflect that, beginning January 1, 2016, subsection (d) Puerto Rico hospitals are paid based on 100 percent of the national standardized amount. We also proposed to revise paragraph (d) of §412.204 to specify that subsection (d) Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount for discharges occurring through December 31, 2015.
We did not receive any public comments on our proposed changes to the regulations at § 412.204 and, therefore, are finalizing these proposed changes without modification in this final rule.

B. Changes in the Inpatient Hospital Update for FY 2017 (§ 412.64(d))

1. FY 2017 Inpatient Hospital Update

In accordance with section 1886(b)(3)(B)(i) of the Act, each year we update the national standardized amount for inpatient hospital operating costs by a factor called the “applicable percentage increase.” As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25076 through 25077), for FY 2017, we are setting the applicable percentage increase by applying the adjustments listed in this section in the same sequence as we did for FY 2016. Specifically, consistent with section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are setting the applicable percentage increase by applying the following adjustments in the following sequence. The applicable percentage increase under the IPPS is equal to the rate-of-increase in the hospital market basket for IPPS hospitals in all areas, subject to—

(a) A reduction of one-quarter of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that fail to submit quality information under rules established in accordance with section 1886(b)(3)(B)(viii) of the Act;

(b) A reduction of three-quarters of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that submit quality data under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user), there are four possible applicable percentage increases that can be applied to the standardized amount. Based on the most recent data described above, we determined final applicable percentage increases to the standardized amount for FY 2017, as specified in the table that appears later in this section.

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through 51692), we finalized our methodology for calculating and applying the MFP adjustment. As we explained in that rule, section 1886(b)(3)(B)(ix)(III) of the Act, as added by section 3401(a) of the Affordable Care Act, defines this productivity adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business MFP (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, calendar year, cost reporting period, or other annual period). The Bureau of Labor Statistics (BLS) publishes the official measure of private nonfarm business MFP. We refer readers to the BLS Web site at http://www.bls.gov/mfp for the BLS historical published MFP data. MFP is derived by subtracting the contribution of labor and capital input growth from output growth. The projections of the components of MFP are currently produced by IGI, a nationally recognized economic forecasting firm with which CMS contracts to forecast the components of the market baskets and MFP. As we discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49509), beginning with the FY 2016 rulemaking cycle, the MFP adjustment is calculated using the revised series developed by IGI to proxy the aggregate capital inputs. Specifically, in order to generate a forecast of MFP, IGI forecasts BLS aggregate capital inputs using a regression model. A complete description of the MFP projection methodology is available on the CMS Web site at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch.html As discussed in the FY 2016 IPPS/LTCH PPS final rule, if IGI makes changes to the MFP methodology, we will announce them on our Web site rather than in the annual rulemaking.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25077), for FY 2017, we proposed an MFP adjustment of 6.5 percentage points to the market basket update, for the proposed rule, we used the most recent data...
available to compute the MFP adjustment. As noted previously, we proposed that if more recent data subsequently became available, we would use such data, if appropriate, to determine the FY 2017 market basket update and MFP adjustment for the final rule. Based on the most recent data available for this final rule, we have determined an MFP adjustment of 0.3 percentage point for FY 2017.

We did not receive any public comments on our proposal to use the most recent available data to determine the final market basket update and the MFP adjustment. Therefore, for this final rule, we are finalizing a market basket update of 2.7 percent and an MFP adjustment of 0.3 percentage point based on the most recent available data.

Based on the most recent data available for this final rule, as described previously, we have determined four applicable percentage increases to the standardized amount for FY 2017, as specified in the following table:

<table>
<thead>
<tr>
<th>FY 2017 APPROPRIATE PERCENTAGE INCREASES FOR THE IPPS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Market Basket Rate-of-Increase</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(vii) of the Act</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User under Section 1886(b)(3)(B)(ix) of the Act</td>
</tr>
<tr>
<td>MFP Adjustment under Section 1886(b)(3)(B)(x) of the Act</td>
</tr>
<tr>
<td>Statutory Adjustment under Section 1886(b)(3)(B)(xii) of the Act</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Standardized Amount</td>
</tr>
</tbody>
</table>

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25078), we proposed to revise the existing regulations at 42 CFR 412.64(d) to reflect the current law for the FY 2017 update. Specifically, in accordance with section 1886(b)(3)(B) of the Act, we proposed to add a new paragraph (vii) to § 412.64(d)(1) to reflect the applicable percentage increase to the FY 2017 operating standardized amount as the percentage increase in the market basket index, subject to the reductions specified under § 412.64(d)(2) for a hospital that does not submit quality data and § 412.64(d)(3) for a hospital that is not a meaningful EHR user, less an MFP adjustment and less an additional reduction of 0.75 percentage point.

We did not receive any public comments on our proposed changes to the regulations at § 412.64(d)(1) and, therefore, are finalizing these proposed changes without modification in this final rule.

Section 1886(b)(3)(B)(vii) of the Act provides that the applicable percentage increase to the hospital-specific rates for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). Therefore, the update to the hospital-specific rates for SCHs and MDHs also is subject to section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. We note that section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114–10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25078), for FY 2017, we proposed the updates to the hospital-specific rates applicable to SCHs and MDHs based on IGI’s first quarter 2016 forecast of the FY 2010-based IPPS market basket update and the MFP adjustment. We proposed that if more recent data subsequently became available (for example, a more recent estimate of the market basket increase and the MFP adjustment), we would use such data, if appropriate, to determine the update for SCHs and MDHs in the final rule. We did not receive any public comments with regard to our proposal. Therefore, we are finalizing the proposal to determine the update to the hospital-specific rates for SCHs and MDHs in this final rule using the most recent data available.

For this final rule, based on most recent available data, we are finalizing the following updates to the hospital-specific rates applicable to SCHs and MDHs using IGI’s second quarter 2016 forecast of the FY 2010-based IPPS market basket update and the MFP adjustment (as described previously in this section): An update of 1.65 percent for a hospital that submits quality data and is a meaningful EHR user; an update of −0.375 percent for a hospital that submits quality data and is not a meaningful EHR user; an update of 0.975 percent for a hospital that fails to submit quality data and is a meaningful EHR user; and an update of −1.05 percent for a hospital that fails to submit quality data and is not a meaningful EHR user.

2. FY 2017 Puerto Rico Hospital Update

As discussed in section IV.A. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. Section 601 of Public Law 114–113 amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016, shall use 100 percent of the national standardized amount. Because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount under the amendments to section 1886(d)(9)(E) of the Act, there is no longer a need for us to determine an update to the Puerto Rico standardized amount. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the same update to the national standardized amount discussed under section IV.B.1. of the preamble of this final rule. Accordingly, in the proposed rule (81 FR 25078), for FY
2017, we determined a proposed applicable percentage increase of 1.55 percent to the standardized amount for hospitals located in Puerto Rico. We note that we did not receive any public comments with regard to our proposal. Based on the most recent data available for this final rule (as discussed in section IV.B.1. of the preamble of this final rule), we are finalizing an applicable percentage increase of 1.65 percent to the standardized amount for hospitals located in Puerto Rico.

We note that section 1886(b)(3)(B)(ix) of the Act, which specifies the adjustment to the applicable percentage increase for “subsection (d)” hospitals that do not submit quality data under the rules established by the Secretary, is not applicable to hospitals located in Puerto Rico.

In addition, section 602 of Public Law 114–113 amended section 1886(u)(6)(B) of the Act to specify that Puerto Rico hospitals are eligible for incentive payments for the meaningful use of certified EHR technology, effective beginning FY 2016, and also to apply the adjustments to the applicable percentage increase under section 1886(b)(3)(B)(ix) of the Act to Puerto Rico hospitals that are not meaningful EHR users, effective FY 2022. Accordingly, because the provisions of section 1886(b)(3)(B)(ix) of the Act are not applicable to hospitals located in Puerto Rico until FY 2022, the adjustments under this provision are not applicable for FY 2017.

C. Rural Referral Centers (RRCs): Annual Updates to Case-Mix Index and Discharge Criteria (§ 412.96)

Under the authority of section 1886(d)(5)(C)(i) of the Act, the regulations at § 412.96 set forth the criteria that a hospital must meet in order to qualify under the IPPS as a rural referral center (RRC). RRCs receive some special treatment under both the DSH payment adjustment and the criteria for geographic reclassification. Section 402 of Public Law 106–173 raised the DSH payment adjustment for RRCs such that they are not subject to the 12-percent cap on DSH payments that is applicable to other rural hospitals. RRCs also are not subject to the proximity criteria when applying for geographic reclassification. In addition, they do not have to meet the requirement that a hospital’s average hourly wage must exceed, by a certain percentage, the average hourly wage of the labor market area in which the hospital is located.

Section 4202(b) of Public Law 105–33 states, in part, that any hospital classified as an RRC by the Secretary for FY 1991 shall be classified as such an RRC for FY 1998 and each subsequent fiscal year. In the August 29, 1997 IPPS final rule with comment period (62 FR 45999), we reinstated RRC status for all hospitals that lost that status due to triennial review or MGCRB reclassification. However, we did not reinstate the status of hospitals that lost RRC status because they were now urban for all purposes because of the OMB designation of their geographic area as urban. Subsequently, in the August 1, 2000 IPPS final rule (65 FR 47089), we indicated that we were revisiting that decision. Specifically, we stated that we would permit hospitals that previously qualified as an RRC and lost their status due to OMB redesignation of the county in which they are located from rural to urban, to be reinstated as an RRC. Otherwise, a hospital seeking RRC status must satisfy all of the other applicable criteria. We use the definitions of “urban” and “rural” specified in Subpart D of 42 CFR part 412. One of the criteria under which a hospital may qualify as an RRC is to have 275 or more beds available for inpatients, or referral volume. (We refer readers to § 412.96(c)(1) through (c)(5) for additional discussion.) With respect to the two mandatory prerequisites, a hospital may be classified as an RRC if—

- The hospital’s CMI is at least equal to the lower of the median CMI for urban hospitals in its census region, excluding hospitals with approved teaching programs, or the median CMI for all urban hospitals nationally; and
- The hospital’s number of discharges is at least 5,000 per year, or, if fewer, the median number of discharges for urban hospitals in the census region in which the hospital is located. The number of discharges criterion for an osteopathic hospital is at least 3,000 discharges per year, as specified in section 1886(d)(5)(C)(i) of the Act.

1. Case-Mix Index (CMI)

Section 412.96(c)(i) provides that CMS establish updated national and regional CMI values in each year’s final rule. For purposes of determining RRC status, the methodology we used to determine the national and regional CMI values is set forth in the regulations at § 412.96(c)(1)(ii). The national median CMI value for FY 2017 is based on the CMI values of all urban hospitals nationwide, and the regional median CMI values for FY 2017 are based on the CMI values of all urban hospitals within each census region, excluding those hospitals with approved teaching programs (that is, those hospitals that train residents in an approved GME program as provided in § 413.75). These values are based on discharges occurring during FY 2015 (October 1, 2014 through September 30, 2015), and include bills posted to CMS’ records through March 2016.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25079), we proposed that, in addition to meeting other criteria, if rural hospitals with fewer than 275 beds are to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2016, they must have a CMI value for FY 2015 that is at least—

- 1.6125 (national—all urban); or
- The median CMI value (not transfer-adjusted) for urban hospitals (excluding hospitals with approved teaching programs as identified in § 413.75) calculated by CMS for the census region in which the hospital is located.

The proposed median CMI values by region were set forth in a table in the proposed rule (81 FR 25079). We stated in the proposed rule that we intended to update the CMI values in the FY 2017 final rule to reflect the updated FY 2015 MedPAR file, which would contain data from additional bills received through March 2016.

Based on the latest available data (FY 2015 bills received through March 2016), in addition to meeting other criteria, if rural hospitals with fewer than 275 beds are to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2016, they must have a CMI value for FY 2015 that is at least:

- 1.6111; or
- The median CMI value (not transfer-adjusted) for urban hospitals (excluding hospitals with approved teaching programs as identified in § 413.75) calculated by CMS for the census region in which the hospital is located.

The final CMI values by region are set forth in the following table.

<table>
<thead>
<tr>
<th>Region</th>
<th>Case-mix index value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. New England (CT, ME, MA, NH, RI, VT)</td>
<td>1.3633</td>
</tr>
</tbody>
</table>
A hospital seeking to qualify as an RRC should obtain its hospital-specific CMI value (not transfer-adjusted) from its MAC. Data are available on the Provider Statistical and Reimbursement (PS&R) System. In keeping with our policy on discharges, the CMI values are computed based on all Medicare patient discharges subject to the IPPS MS–DRG-based payment.

2. Discharges

Section 412.96(e)(2)(i) provides that CMS set forth the national and regional numbers of discharges criteria in each year’s annual notice of prospective payment rates for purposes of determining RRC status. As specified in section 1886(d)(5)(C)(ii) of the Act, the national standard is set at 5,000 discharges. In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25079), we proposed to update the regional standards based on discharges for urban hospitals’ cost reporting periods that began during FY 2014 (that is, October 1, 2013 through September 30, 2014), which were the latest cost report data available at the time the proposed rule was developed. Therefore, in the FY 2017 IPPS/LTC PPS proposed rule, we proposed that, in addition to meeting other criteria, a hospital, if it is to qualify for initial RRC status for cost reporting periods beginning on or after October 1, 2016, must have, as the number of discharges for its cost reporting period that began during FY 2014, at least—

- 5,000 (3,000 for an osteopathic hospital); or
- The median number of discharges for urban hospitals in the census region in which the hospital is located. (We refer readers to the table set forth in the FY 2017 IPPS/LTC PPS proposed rule at 81 FR 25079.) In the proposed rule, we stated that we intended to update these numbers in the FY 2017 final rule based on the latest available cost report data.

Based on the latest discharge data available at this time, that is, for cost reporting periods that began during FY 2015, the final median number of discharges for urban hospitals by census region are set forth in the following table:

<table>
<thead>
<tr>
<th>Region</th>
<th>Case-mix index value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. New England (CT, ME, MA, NH, RI, VT)</td>
<td>1.4409</td>
</tr>
<tr>
<td>2. Middle Atlantic (PA, NJ, NY)</td>
<td>1.5079</td>
</tr>
<tr>
<td>3. South Atlantic (DE, DC, FL, GA, MD, NC, SC, VA, WV)</td>
<td>1.5331</td>
</tr>
<tr>
<td>4. East North Central (IL, IN, MI, OH, WI)</td>
<td>1.4472</td>
</tr>
<tr>
<td>5. East South Central (AL, KY, MS, TN)</td>
<td>1.5946</td>
</tr>
<tr>
<td>6. West North Central (IA, KS, MN, MO, NE, ND, SD)</td>
<td>1.64525</td>
</tr>
<tr>
<td>7. East South Central (AR, LA, OK, TX)</td>
<td>1.6944</td>
</tr>
<tr>
<td>8. Mountain (AZ, CO, ID, MT, NV, NM, UT, WY)</td>
<td>1.6165</td>
</tr>
<tr>
<td>9. Pacific (AK, CA, HI, OR, WA)</td>
<td>56941 Federal Register</td>
</tr>
</tbody>
</table>

We note that the median number of discharges for hospitals in each census region is greater than the national standard of 5,000 discharges. Therefore, under this final rule, 5,000 discharges is the minimum criterion for all hospitals, except for osteopathic hospitals for which the minimum criterion is 3,000 discharges.

We did not receive any public comments on our proposals.

D. Payment Adjustment for Low-Volume Hospitals (§ 412.101)

1. Background

Section 1886(d)(12) of the Act provides for an additional payment to each qualifying low-volume hospital that is paid under IPPS beginning in FY 2005, and the low-volume hospital payment policy is set forth in the regulations at 42 CFR 412.101. Sections 3125 and 10314 of the Affordable Care Act provided for a temporary change in the low-volume hospital payment policy for FYs 2011 and 2012. Specifically, the provisions of the Affordable Care Act amended the qualifying criteria for low-volume hospitals to specify, for FYs 2011 and 2012, that a hospital qualifies as a low-volume hospital if it is more than 15 road miles from another subsection (d) hospital and has less than 1,600 discharges of individuals entitled to, or enrolled for, benefits under Medicare Part A during the fiscal year.

Under section 1886(d)(12) of the Act, as amended by section 204 of the MACRA, the temporary changes in the low-volume hospital payment policy originally provided by the Affordable Care Act and extended through subsequent legislation, are effective through FY 2017. In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25080 through 25081), consistent with our historical approach, we proposed to update the discharge data source used to compute hospital-specific CMI values. Therefore, in the proposed rule, we proposed to adjust the payment adjustment policy at § 412.101 to reflect the changes to the qualifying criteria and the calculation of the payment adjustment for low-volume hospitals according to the provisions of the Affordable Care Act in the FY 2011 IPPS/LTC PPS final rule (75 FR 50238 through 50275 and 50414).

The temporary changes to the low-volume hospital qualifying criteria and the payment adjustment originally provided for by the Affordable Care Act have been extended by subsequent legislation as follows: Through FY 2013, by the American Taxpayer Relief Act of 2012 (ATRA), Public Law 112–240; through March 31, 2014, by the Pathway for SGR Reform Act of 2013, Public Law 113–167; through March 31, 2015, by the Protecting Access to Medicare Act of 2014 (PAMA), Public Law 113–93; and most recently through FY 2017, by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Public Law 114–10. For additional details on the implementation of the previous extensions of the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided for by the Affordable Care Act, we refer readers to the following Federal Register documents: The FY 2013 IPPS notice (78 FR 14689 through 14691); the FY 2014 IPPS/LTC PPS final rule (78 FR 50611 through 50612); the FY 2014 IPPS interim final rule with comment period (79 FR 15022 through 15025); the FY 2014 IPPS notice (79 FR 34444 through 34446); the FY 2015 IPPS/LTC PPS final rule (79 FR 49998 through 50001); and the FY 2016 IPPS interim final rule with comment period (80 FR 49594 through 49595).

2. Low-Volume Hospital Definition and Payment Adjustment for FY 2017

Under section 1886(d)(12) of the Act, as amended by section 204 of the MACRA, the temporary changes in the low-volume hospital payment policy originally provided by the Affordable Care Act and extended through subsequent legislation, are effective through FY 2017. In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25080 through 25081), consistent with our historical approach, we proposed to update the discharge data source used to...
Identify qualifying low-volume hospitals and calculate the payment adjustment (percentage increase) for FY 2017. Under §412.101(b)(2)(ii), for the applicable fiscal years, a hospital’s Medicare discharges from the most recently available MedPAR data, as determined by CMS, are used to determine if the hospital meets the discharge criteria to receive the low-volume payment adjustment in the current year and to determine the applicable low-volume percentage increase for qualifying hospitals. The applicable low-volume percentage increase for FY 2017 is determined using a continuous linear sliding scale equation that results in a low-volume hospital payment adjustment ranging from an additional 25 percent for hospitals with 200 or fewer Medicare discharges to a zero percent additional payment adjustment for hospitals with 1,600 or more Medicare discharges. For FY 2017, consistent with our historical policy, we proposed that qualifying low-volume hospitals and their payment adjustment would be determined using the most recently available Medicare discharge data, which at the time of the proposed rule was from the December 2015 update of the FY 2015 MedPAR file, as these data were the most recent data available at that time. Table 14 listed in the Addendum of the proposed rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) listed the “subsection (d)” hospitals with fewer than 1,600 Medicare discharges based on the claims data from the December 2015 update of the FY 2015 MedPAR file and their potential proposed low-volume hospital payment adjustment for FY 2017. Consistent with past practice, we noted in the proposed rule that the list of hospitals with fewer than 1,600 Medicare discharges in Table 14 did not reflect whether or not the hospital meets the mileage criterion. Eligibility for the low-volume hospital payment adjustment for FY 2017 also is dependent upon meeting the mileage criterion specified at §412.101(b)(2)(ii); that is, the hospital must be located more than 15 road miles from any other IPPS hospital. In other words, eligibility for the low-volume hospital payment adjustment for FY 2017 also is dependent upon meeting (in the case of a hospital that did not qualify for the low-volume hospital payment adjustment in FY 2016) or continuing to meet (in the case of a hospital that did qualify for the low-volume hospital payment adjustment in FY 2016) the mileage criterion specified at §412.101(b)(2)(ii). Consistent with historical practice, we proposed that if more recent Medicare discharge data became available, we would use that updated data to determine qualifying low-volume hospitals and their payment adjustment in the final rule, and update Table 14 to reflect that updated data.

In order to receive a low-volume hospital payment adjustment under §412.101 for FY 2017, consistent with our previously established procedure, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25080 through 25081), we proposed that a hospital must notify and provide documentation to its MAC that it meets the discharge and mileage criteria under §412.101(b)(2)(ii). Specifically, for FY 2017, we proposed that a hospital must make a written request for low-volume hospital status that is received by its MAC no later than September 1, 2016, in order for the applicable low-volume hospital payment adjustment to be applied to payments for its FY 2017 discharges occurring on or after October 1, 2016. Under this procedure, a hospital that qualified for the low-volume hospital payment adjustment in FY 2016 may continue to receive a low-volume hospital payment adjustment for FY 2017 without reapplying if it continues to meet the Medicare discharge criterion established for FY 2017 and the mileage criterion. However, we proposed that the hospital must send written verification that is received by its MAC no later than September 1, 2016, stating that it continues to be located more than 15 miles from any other subsection (d) hospital. This written verification could be a brief letter to the MAC stating that the hospital continues to meet the low-volume hospital mileage criterion as documented in a prior low-volume hospital status request. We also proposed that if a hospital’s written request for low-volume hospital status for FY 2017 was received after September 1, 2016, and if the MAC determines that the hospital meets the criteria to qualify as a low-volume hospital, the MAC would apply the applicable low-volume hospital payment adjustment to determine the payment for the hospital’s FY 2017 discharges effective prospectively within 30 days of the date of its low-volume hospital status determination, consistent with past practice. (For additional details on our established process for the low-volume hospital payment adjustment, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 50000 through 50001)).

Comment: Commenters supported the actions taken by CMS related to the extension of the modified criteria to qualify for the low-volume hospital adjustment through FY 2017. Commenters also expressed their support for legislative action that would make permanent the criteria that a hospital qualifies as a low-volume hospital if it is more than 15 road miles from another subsection (d) hospital and has less than 1,600 discharges of individuals entitled to or enrolled for benefits under Medicare Part A. Response: We appreciate the commenters’ support of our implementation of the low-volume hospital payment adjustment for FY 2017, which is consistent with the statutory provisions under section 1886(d)(12) of the Act.

After consideration of the public comments we received, we are finalizing our proposals, without modification. Consistent with our proposal to use the most recent Medicare discharge data available for the final rule, we are using data from the March 2016 update of the FY 2015 MedPAR files to determine qualifying low-volume hospitals and their payment adjustment in this final rule, and updating Table 14 to reflect these updated data. Accordingly, Table 14 listed in the Addendum of this final rule (which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html) lists the “subsection (d)” hospitals with fewer than 1,600 Medicare discharges based on the claims data from the March 2016 update of the FY 2015 MedPAR file and their potential low-volume hospital payment adjustment for FY 2017. Consistent with past practice, we note that this list of hospitals with fewer than 1,600 Medicare discharges in Table 14 does not reflect whether or not the hospital meets the mileage criterion. Eligibility for the low-volume hospital payment adjustment for FY 2017 also is dependent upon meeting the mileage criterion specified at §412.101(b)(2)(ii); that is, the hospital must be located more than 15 road miles from any other IPPS hospital. In other words, eligibility for the low-volume hospital payment adjustment for FY 2017 also is dependent upon meeting (in the case of a hospital that did not qualify for the low-volume hospital payment adjustment in FY 2016) or continuing to meet (in the case of a hospital that did qualify for the low-volume hospital payment adjustment in FY 2016) the mileage criterion specified at §412.101(b)(2)(ii).
order to receive a low-volume hospital payment adjustment under § 412.101 for FY 2017, consistent with our previously established procedure, a hospital must notify and provide documentation to its MAC that it meets the discharge and mileage criteria under § 412.101(b)(2)(ii). Specifically, for FY 2017, a hospital must make a written request for low-volume hospital status that is received by its MAC no later than September 1, 2016, in order for the applicable low-volume hospital payment adjustment to be applied to payments for its FY 2017 discharges occurring on or after October 1, 2016. Under this procedure, a hospital that qualified for the low-volume hospital payment adjustment in FY 2016 may continue to receive a low-volume hospital payment adjustment for FY 2017 without reapplying if it continues to meet the Medicare discharge criterion established for FY 2017 and the mileage criterion. However, as we proposed, the hospital must send written verification that is received by its MAC no later than September 1, 2016, stating that it continues to be located more than 15 miles from any other subsection (d) hospital. This written verification could be a brief letter to the MAC stating that the hospital continues to meet the low-volume hospital mileage criterion as documented in a prior low-volume hospital status request. Also, as we proposed, if a hospital’s written request for low-volume hospital status for FY 2017 is received after September 1, 2016, and if the MAC determines that the hospital meets the criteria to qualify as a low-volume hospital, the MAC will apply the applicable low-volume hospital payment adjustment to determine the payment for the hospital’s FY 2017 discharges effective prospectively within 30 days of the date of its low-volume hospital status determination, consistent with past practice. (As noted above, for additional details on our established process for the low-volume hospital payment adjustment, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53408) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50000 through 50001).)

We note that, in an interim final rule with comment period (IFC) in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49595), we revised the regulations at § 412.101 to conform the text to the provisions of section 204 of the MACRA, which extended the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2017 (that is, through September 30, 2017). We are finalizing the provisions of that IFC without modification, as discussed in section IV.N. of this final rule.

E. Indirect Medical Education (IME) Payment Adjustment Factor for FY 2017 (§ 412.105)

1. IME Adjustment for FY 2017

Under the IPPS, an additional payment amount is made to hospitals with residents in an approved graduate medical education (GME) program in order to reflect the higher indirect patient care costs of teaching hospitals relative to nonteaching hospitals. The payment amount is determined by use of a statutorily specified adjustment factor. The regulations regarding the calculation of this additional payment, known as the IME adjustment, are located at § 412.105. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51680) for a full discussion of the IME adjustment and IME adjustment factor. Section 1886(d)(5)(B)(ii)(XII) of the Act provides that, for discharges occurring during FY 2008 and fiscal years thereafter, the IME formula multiplier is 1.35. Accordingly, for discharges occurring during FY 2017, the formula multiplier is 1.35. We estimate that application of this formula multiplier for the FY 2017 IME adjustment will result in an increase in IPPS payment of 5.5 percent for every approximately 10 percent increase in the hospital’s resident to bed ratio.

Comment: One commenter requested that CMS take into consideration IME costs across all provider settings and correspondingly increase the IPPS payment to account for higher indirect patient costs. The commenter requested that CMS not eliminate or decrease the formula modifier for the FY 2017 IME adjustment.

Response: The IME adjustment factor is set by statute. Therefore, we do not have discretion to make any changes to the formula multiplier.

2. Other Policies Related to IME

We refer readers to section IV.I. of the preamble of this final rule for a discussion of the finalized policy changes for FY 2017 relating to medical residency training programs (specifically, rural training tracks) at urban hospitals that also affect payments for IME.

F. Payment Adjustment for Medicare Disproportionate Share Hospitals (DSH) for FY 2017 and Subsequent Years (§ 412.106)

1. General Discussion

Section 1886(d)(5)(F) of the Act provides for additional Medicare payments to subsection (d) hospitals that serve a significantly disproportionate number of low-income patients. The Act specifies two methods by which a hospital may qualify for the Medicare disproportionate share hospital (DSH) adjustment. Under the first method, hospitals that are located in an urban area and have 100 or more beds may receive a Medicare DSH payment adjustment if the hospital can demonstrate that, during its cost reporting period, more than 30 percent of its net inpatient care revenues are derived from State and local government payments for care furnished to needy patients with low incomes. This method is commonly referred to as the “Pickle method.” The second method for qualifying for the DSH payment adjustment, which is the most common, is based on a complex statutory formula under which the DSH payment adjustment is based on the hospital’s geographic designation, the number of beds in the hospital, and the level of the hospital’s disproportionate patient percentage (DPP). A hospital’s DPP is the sum of two fractions: the “Medicare fraction” and the “Medicaid fraction.” The Medicare fraction (also known as the “SSI fraction” or “SSI ratio”) is computed by dividing the number of the hospital’s inpatient days that are furnished to patients who were entitled to both Medicare Part A and Supplemental Security Income (SSI) benefits by the hospital’s total number of patient days furnished to patients entitled to benefits under Medicare Part A.

Because the DSH payment adjustment is part of the IPPS, the DSH statutory references (under section 1886(d)(5)(F) of the Act) to “days” apply only to hospital acute care inpatient days. Regulations located at § 412.106 govern the Medicare DSH payment adjustment and specify how the DPP is calculated as well as how beds and patient days are counted in determining the Medicare DSH payment adjustment. Under § 412.106(a)(1)(i), the number of beds for the Medicare DSH payment adjustment is determined in accordance with bed counting rules for the IME adjustment under § 412.105(b).

Section 3133 of the Patient Protection and Affordable Care Act, as amended by section 10316 of the same Act and section 1104 of the Health Care and Education Reconciliation Act (Pub. L. 111–152), added a section 1886(r) to the
Act that modifies the methodology for computing the Medicare DSH payment adjustment. (For purposes of this final rule, we refer to these provisions collectively as section 3133 of the Affordable Care Act.) Beginning with discharges in FY 2014, hospitals that qualify for Medicare DSH payments under section 1886(d)(5)(F) of the Act receive 25 percent of the amount they previously would have received under the statutory formula for Medicare DSH payments. This provision applies equally to hospitals that qualify for DSH payments under section 1886(d)(5)(F)(I) of the Act and those hospitals that qualify under the Pickle method under section 1886(d)(5)(F)(I) of the Act.

The remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals under age 65 who are uninsured, is available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. The payments to each hospital for a fiscal year are based on the hospital’s amount of uncompensated care for a given time period relative to the total amount of uncompensated care for that same time period reported by all hospitals that receive Medicare DSH payments for that fiscal year.

As provided by section 3133 of the Affordable Care Act, section 1886(r)(1) of the Act requires that, for FY 2014 and each subsequent fiscal year, a subsection (d) hospital that would otherwise receive DSH payments made under section 1886(d)(5)(F) of the Act receives two separately calculated payments. Specifically, section 1886(r)(1) of the Act provides that the Secretary shall pay to such subsection (d) hospital (including a Pickle hospital) 25 percent of the amount the hospital would have received under section 1886(d)(5)(F) of the Act for DSH payments, which represents the empirically justified amount for such payment, as determined by the MedPAC in its March 2007 Report to the Congress. We refer to this payment as the “empirically justified Medicare DSH payment.”

In addition to this empirically justified Medicare DSH payment, section 1886(r)(2) of the Act provides that, for FY 2014 and each subsequent fiscal year, the Secretary shall pay to such subsection (d) hospital an additional amount equal to the product of three factors. The first factor is the difference between the aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if subsection (r) did not apply and the aggregate amount of payments that are made to subsection (d) hospitals under section 1886(r)(1) of the Act for each fiscal year. Therefore, this factor amounts to 75 percent of the payments that would otherwise be made under section 1886(d)(5)(F) of the Act.

The second factor is, for FYs 2014 through 2017, 1 minus the percent change in the percent of individuals under the age of 65 who are uninsured, determined by comparing the percent of such individuals who were uninsured in 2013, the last year before coverage expansion under the Affordable Care Act (as calculated by the Secretary based on the most recent estimates available from the Director of the Congressional Budget Office before a vote in either House on the Health Care and Education Reconciliation Act of 2010 that, if determined in the affirmative, would clear such Act for enrollment), and the percent of individuals who were uninsured in the most recent period for which data are available (as so calculated) minus 0.1 percentage point for FY 2014, and minus 0.2 percentage point for FYs 2015 through 2017. For FYs 2014 through 2017, the baseline for the estimate of the change in uninsurance is fixed by the most recent estimate of the Congressional Budget Office before the final vote on the Health Care and Education Reconciliation Act of 2010, which is contained in a March 20, 2010 letter from the Director of the Congressional Budget Office to the Speaker of the House. (The March 20, 2010 letter is available for viewing on the following Web site: http://www.cbo.gov/sites/default/files/cbofiles/fpd/113xx/doc11379/amendreconprop.pdf.)

For FY 2018 and subsequent fiscal years, the second factor is 1 minus the percent change in the percent of individuals who are uninsured, as determined by comparing the percent of individuals who were uninsured in 2013 (as estimated by the Secretary, based on data from the Census Bureau or other sources the Secretary determines appropriate, and certified by the Chief Actuary of CMS), and the percent of individuals who were uninsured in the most recent period for which data are available (as so estimated and certified), minus 0.2 percentage point for FYs 2018 and 2019. Therefore, for FY 2018 and subsequent fiscal years, the statute provides some greater flexibility in the choice of the data source to be used for the estimate of the change in the percent of uninsured individuals.

The third factor is a percent that, for each subsection (d) hospital, represents the quotient of the amount of uncompensated care for such hospital for a period selected by the Secretary (as estimated by the Secretary, based on appropriate data), including the use of alternative data where the Secretary determines that alternative data are available which are a better proxy for the costs of subsection (d) hospitals for treating the uninsured, and the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(r) of the Act. Therefore, this third factor represents a hospital’s uncompensated care amount for a given time period relative to the uncompensated care amount for that same time period for all hospitals that receive Medicare DSH payments in the applicable fiscal year, expressed as a percent.

For each hospital, the product of these three factors represents its additional payment for uncompensated care for the applicable fiscal year. We refer to the additional payment determined by these factors as the “uncompensated care payment.”

Section 1886(r) of the Act applies to FY 2014 and each subsequent fiscal year. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50620 through 50647) and the FY 2014 IPPS interim final rule with comment period (78 FR 61191 through 61197), we set forth our policies for implementing the required changes to the Medicare DSH payment methodology made by section 3133 of the Affordable Care Act for FY 2014. In those rules, we noted that, because section 1886(r) of the Act modifies the payment required under section 1886(d)(5)(F) of the Act, it affects only the DSH payment under the operating IPPS. It does not revise or replace the capital IPPS DSH payment provided under the regulations at 42 CFR part 412, subpart M, which were established through the exercise of the Secretary’s discretion in implementing the capital IPPS under section 1886(g)(1)(A) of the Act.

Finally, section 1886(r)(3) of the Act provides that there shall be no administrative or judicial review under section 1869, section 1878, or otherwise of any estimate of the Secretary for purposes of determining the factors described in section 1886(r)(2) of the Act or of any period selected by the Secretary for the purpose of determining those factors. Therefore, there is no administrative or judicial review of the estimates developed for purposes of applying the three factors used to determine uncompensated care.
payments, or the periods selected in order to develop such estimates.

2. Eligibility for Empirically Justified Medicare DSH Payments and Uncompensated Care Payments

As indicated earlier, the payment methodology under section 3133 of the Affordable Care Act applies to “subsection (d) hospitals” that would otherwise receive a DSH payment made under section 1886(d)(5)(F) of the Act. Therefore, hospitals must receive empirically justified Medicare DSH payments in a fiscal year in order to receive an additional Medicare uncompensated care payment for that year. Specifically, section 1886(r)(2) of the Act states that, in addition to the payment made to a subsection (d) hospital under section 1886(r)(1) of the Act, the Secretary shall pay to such subsection (d) hospitals an additional amount. Because section 1886(r)(1) of the Act refers to empirically justified Medicare DSH payments, the additional payment under section 1886(r)(2) of the Act is limited to hospitals that receive empirically justified Medicare DSH payments in accordance with section 1886(r)(1) of the Act for the applicable fiscal year.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and the FY 2014 IPPS interim final rule with comment period (78 FR 61193), we provided that hospitals that are not eligible to receive empirically justified Medicare DSH payments in a fiscal year will not receive uncompensated care payments for that year. We also specified that we would make a determination concerning eligibility for interim uncompensated care payments based on each hospital’s estimated DSH status for the applicable fiscal year (using the most recent data that are available). We indicated that our final determination on the hospital’s eligibility for uncompensated care payments will be based on the hospital’s actual DSH status at cost report settlement for that payment year.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50622) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50006), we specified our policies for several specific classes of hospitals within the scope of section 1886(r) of the Act. We refer readers to those two final rules for a detailed discussion of our policies. In summary, we specified the following:

- Subsection (d) Puerto Rico hospitals that are eligible for DSH payments also are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under the new payment methodology (78 FR 50623 and 79 FR 50006).
- Maryland hospitals are not eligible to receive empirically justified Medicare DSH payments and uncompensated care payments under the payment methodology of section 1886(r) of the Act because they are not paid under the IPPS. As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50007), effective January 1, 2014, the State of Maryland elected to no longer have Medicare pay Maryland hospitals in accordance with section 1814(b)(3) of the Act and entered into an agreement with CMS that Maryland hospitals will be paid under the Maryland All-Payer Model. However, under the Maryland All-Payer Model, Maryland hospitals still are not paid under the IPPS. Therefore, they remain ineligible to receive empirically justified Medicare DSH payments or uncompensated care payments under section 1886(r) of the Act.
- SCHs that are paid under their hospital-specific rate are not eligible for Medicare DSH payments. SCHs that are paid under the IPPS Federal rate receive interim payments based on what we estimate and project their DSH status to be prior to the beginning of the Federal fiscal year (based on the best available data at that time) subject to settlement through the cost report, and if they receive interim empirically justified Medicare DSH payments in a fiscal year, they also will receive interim uncompensated care payments for that fiscal year on a per discharge basis, subject as well to settlement through the cost report. Final eligibility determinations will be made at the end of the cost reporting period at settlement, and both interim empirically justified Medicare DSH payments and uncompensated care payments will be adjusted accordingly (78 FR 50624 and 79 FR 50007).
- MDHs are paid based on the IPPS Federal rate or, if higher, the IPPS Federal rate plus 75 percent of the amount by which the Federal rate is exceeded by the updated hospital-specific rate from certain specified base years (76 FR 51684). The IPPS Federal rate used in the MDH payment methodology is the same IPPS Federal rate that is used in the SCH payment methodology. Section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Public Law 114–10, enacted April 16, 2015, extended the MDH program for discharges on or after April 1, 2015, through September 30, 2017. Because MDHs are paid based on the IPPS Federal rate, for FY 2017, MDHs will continue to eligible to receive empirically justified Medicare DSH payments and uncompensated care payments if their DPP is at least 15 percent. We will apply the same process to determine MDHs’ eligibility for empirically justified Medicare DSH and uncompensated care payments, as we do for all other IPPS hospitals, through September 30, 2017. Moreover, we will continue to make a determination concerning eligibility for interim uncompensated care payments based on each hospital’s estimated DSH status for the applicable fiscal year (using the most recent data that are available). Our final determination on the hospital’s eligibility for uncompensated care payments will be based on the hospital’s actual DSH status at cost report settlement for that payment year.

In addition, as we do for all IPPS hospitals, we calculate a numerator for Factor 3 for all MDHs, regardless of whether they are projected to be eligible for Medicare DSH payments during the fiscal year, but the denominator for Factor 3 will be based on the uncompensated care data from the hospitals that we have projected to be eligible for Medicare DSH payments during the fiscal year.

- IPPS hospitals that have elected to participate in the Bundled Payments for Care Improvement initiative continue to be paid under the IPPS (77 FR 53342) and, therefore, are eligible to receive empirically justified Medicare DSH payments and uncompensated care payments (78 FR 50625 and 79 FR 50008).
- Hospitals participating in the Rural Community Hospital Demonstration Program under section 410A of the Medicare Modernization Act do not receive DSH payments and, therefore, are excluded from receiving empirically justified Medicare DSH payments and uncompensated care payments under the new DSH payment methodology (78 FR 50625 and 79 FR 50008). There are 14 hospitals currently participating in the program; 10 will continue to participate through the end of FY 2016, and 4 will continue to participate through the scheduled end of the program on December 31, 2016. Once a hospital’s participation in the demonstration program ends, the hospital will be treated like a subsection (d) hospital and subject to the IPPS. Therefore, once their participation ends, these hospitals could be eligible to receive empirically justified Medicare DSH payments and uncompensated care payments and, if so, will be treated accordingly for interim and final payments. We will apply the same process for determining their eligibility as we do for all other IPPS hospitals, and will make interim and final DSH and uncompensated care payments accordingly.
3. Empirically Justified Medicare DSH Payments

As we have discussed earlier, section 1886(r)(1) of the Act requires the Secretary to pay 25 percent of the amount of the Medicare DSH payment that would otherwise be made under section 1886(d)(5)(F) of the Act to a subsection (d) hospital. Because section 1886(r)(1) of the Act merely requires the program to pay a designated percentage of these payments, without revising the criteria governing eligibility for DSH payments or the underlying payment methodology, we stated in the FY 2014 IPPS/LTCH PPS final rule that we did not believe that it was necessary to develop any new operational mechanisms for making such payments. Therefore, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50626), we implemented this provision by advising MACs to simply adjust the interim claim payments to the requisite 25 percent of what would have otherwise been paid. We also made corresponding changes to the hospital cost report so that these empirically justified Medicare DSH payments can be settled at the appropriate level at the time of cost report settlement. We provided more detailed operational instructions and cost report instructions following issuance of the FY 2014 IPPS/LTCH PPS final rule that are available on the CMS Web site at: http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2014-Transmittals-Items/R5P240.html.

4. Uncompensated Care Payments

As we discussed earlier, section 1886(r)(2) of the Act provides that, for each eligible hospital in FY 2014 and subsequent years, the uncompensated care payment is the product of three factors. These three factors represent our estimate of 75 percent of the amount of Medicare DSH payments that would otherwise have been paid, an adjustment to this amount for the percent change in the national rate of uninsurance compared to the rate of uninsurance in 2013, and each eligible hospital’s estimated uncompensated care amount relative to the estimated uncompensated care amount for all eligible hospitals. Below we discuss the data sources and methodologies for computing each of these factors, our final policies for FYs 2014 through 2016, and our proposed and final policies for FY 2017.

a. Calculation of Factor 1 for FY 2017

Section 1886(r)(2)(A) of the Act establishes Factor 1 in the calculation of the uncompensated care payment. Section 1886(r)(2)(A) of the Act states that this factor is equal to the difference between (1) the aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply for such fiscal year (as estimated by the Secretary); and (2) the aggregate amount of payments that are made to subsection (d) hospitals under section 1886(r)(1) of the Act for such fiscal year (as so estimated). Therefore, section 1886(r)(2)(A)(i) of the Act represents the estimated Medicare DSH payments that would have been made under section 1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply for such fiscal year. Under a prospective payment system, we would not know the precise aggregate Medicare DSH payment amount that would be paid for a Federal fiscal year until cost report settlement for all IPPS hospitals is completed, which occurs several years after the end of the Federal fiscal year. Therefore, section 1886(r)(2)(A)(i) of the Act provides authority to estimate this amount, by specifying that, for each fiscal year to which the provision applies, such amount is to be estimated by the Secretary. Similarly, section 1886(r)(2)(A)(ii) of the Act represents the estimated empirically justified Medicare DSH payments to be made in a fiscal year, as prescribed under section 1886(r)(1) of the Act. Again, section 1886(r)(2)(A)(ii) of the Act provides authority to estimate this amount.

Therefore, Factor 1 is the difference between our estimate of (1) the amount that would have been paid in Medicare DSH payments for the fiscal year, in the absence of the new payment provision; and (2) the amount of empirically justified Medicare DSH payments that are made for the fiscal year, which takes into account the requirement to pay 25 percent of what would have otherwise been paid under section 1886(d)(5)(F) of the Act. In other words, this factor represents our estimate of 75 percent (100 percent minus 25 percent) of our estimate Medicare DSH payments that would otherwise be made, in the absence of section 1886(r) of the Act, for the fiscal year.

As we did for FY 2016, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25084), in order to determine Factor 1 in the uncompensated care payment formula for FY 2017, we proposed to continue the policy established in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50626 through 50630) and in the FY 2014 IPPS final rule with comment period (78 FR 61194) of determining Factor 1 by developing estimates of both the aggregate amount of Medicare DSH payments that would be made in the absence of section 1886(r)(1) of the Act and the aggregate amount of empirically justified Medicare DSH payments to hospitals under 1886(r)(1) of the Act. These estimates will not be revised or updated after we know the final Medicare DSH payments for FY 2017.

Therefore, in order to determine the two elements of Factor 1 for FY 2017 (Medicare DSH payments prior to the application of section 1886(r)(1) of the Act, and empirically justified Medicare DSH payments after application of section 1886(r)(1) of the Act), for the proposed rule, we used the most recently available projections of Medicare DSH payments for the fiscal year, as calculated by CMS’ Office of the Actuary using the most recently filed Medicare hospital cost report with Medicare DSH payment information and the most recent Medicare DSH patient percentages and Medicare DSH payment adjustments provided in the IPPS Impact File.

For purposes of calculating Factor 1 and modeling the impact of the FY 2017 IPPS/LTCH PPS proposed rule, we used the Office of the Actuary’s March 2016 Medicare DSH estimates, which are based on data from the December 2015 update of the Medicare Hospital Cost Report Information System (HCRIS) and the FY 2016 IPPS/LTCH PPS final rule IPPS Impact file, published in conjunction with the publication of the FY 2016 IPPS/LTCH PPS final rule. Because SCHs that are projected to be paid under their hospital-specific rate are excluded from the application of section 1886(r) of the Act, these hospitals also were excluded from the March 2016 Medicare DSH estimates. Furthermore, because section 1886(r) of the Act specifies that the uncompensated care payment is in addition to the empirically justified Medicare DSH payment (25 percent of DSH payments that would be made without regard to section 1886(r) of the Act), Maryland hospitals participating in the Maryland All-Payer Model that do not receive DSH payments were also excluded from the Office of the Actuary’s Medicare DSH estimates. Because the Rural Community Hospital Demonstration program is scheduled to end on December 31, 2016, hospitals that were participating in the program were included in this estimate for FY 2017. However, for the proposed rule, we excluded 25 percent of our estimate of DSH payments that would otherwise be made to the 4 hospitals with participation in the program will continue through December 31, 2016, as
these hospitals will be excluded from receiving DSH payments until that time. The estimate included the total DSH payments that would be made to the 10 hospitals whose participation in the Rural Community Hospital Demonstration program will continue only through September 30, 2016.

For the proposed rule, using the data sources discussed above, the Office of the Actuary used the most recently submitted Medicare cost report data to identify Medicare DSH payments and the most recent Medicare DSH payment adjustments provided in the IPPS Impact File, and applied inflation updates and assumptions for future changes in utilization and case-mix to estimate Medicare DSH payments for the upcoming fiscal year. The March 2016 Office of the Actuary estimate for Medicare DSH payments for FY 2017, without regard to the application of section 1886(r)(1) of the Act, was approximately $14.227 billion. This estimate excluded Maryland hospitals participating in the Maryland All-Payer Model SCH paid under their hospital-specific payment rate, and 25 percent of DSH payments to the 4 hospitals whose participation in the Rural Community Hospital Demonstration program will continue through December 31, 2016. Therefore, based on the March 2016 estimate, the estimate for empirically justified Medicare DSH payments for FY 2017, with the application of section 1886(r)(1) of the Act, was approximately $3.556 billion (or 25 percent of the total amount of estimated Medicare DSH payments for FY 2017). Under § 412.106(g)(1)(i) of the regulations, Factor 1 is the difference between these two estimates of the Office of the Actuary. Therefore, in the proposed rule, we proposed that Factor 1 for FY 2017 was $10,670,529,595.84, which is equal to 75 percent of the total amount of estimated Medicare DSH payments for FY 2017 ($14,227,372,794.46 minus $3,556,843,198.62).

We invited public comments on our proposed calculation of Factor 1 for FY 2016. Comment: A number of commenters requested greater transparency in the methodology used by the OACT to estimate aggregate DSH payments that would have been paid absent implementation of the Affordable Care Act, particularly with respect to the calculation of estimated DSH payments for purposes of determining Factor 1. The commenters urged CMS to clarify the methodology and provide additional information on the assumptions used to make these projections. The commenters also requested that this information be provided in advance of the publication of the FY 2017 IPPS/LTCH PPS final rule and in future proposed rules each year. The commenters stated that hospitals do not have sufficient information to understand or replicate the relevant projections and estimates for Factor 1. Many commenters stated that there is variability in the “Other” factors that are used to estimate Medicare DSH expenditures and requested full disclosure of the methodology and the various components used to estimate the catch-all “Other” column, such as the factor for Medicaid expansion due to the Affordable Care Act. Specifically, the commenters expressed concern that the value in the “Other” column for FY 2016 changed from 1.045 in the FY 2016 IPPS/LTCH PPS final rule to 0.9993 in the FY 2017 IPPS/LTCH PPS proposed rule, when CMS used the exact same 0.9993 factor from the “Other” column for FY 2014, the first year of the Medicaid expansion. The commenters expressed concern that they believed this was updated to 1.04795 without explanation in the version of the table that appeared in the FY 2017 IPPS/LTCH PPS proposed rule. The commenters requested that CMS provide clarification regarding these changes.

Some commenters asked CMS to explain how Medicaid and CHIP expansion is accounted for in the “Other” column used to determine the Factor 1 estimate. The commenters stated that CMS appears to have applied internally inconsistent assumptions as to the effect of Medicaid expansion on Factor 1, with no explanation or support. One commenter stated that the effect of Medicaid expansion on the agency’s projection of what the traditional DSH payment would have been for FY 2014, absent of the Affordable Care Act, has varied erratically in the agency’s successive rulemakings for FYs 2014 through 2017. Another commenter noted that the most recent Congressional Budget Office report showed a 32-percent increase in Medicaid/CHIP enrollment as a result of Medicaid expansion, and expected that this increase in enrollment would result in a substantial increase in reported DSH payments that is not reflected in OACT’s DSH estimate for Factor 1. A second commenter provided its own estimates of how the Medicaid expansion would affect DSH payments, and noted that these estimates do not align with CMS’ figures.

Commenters objected to CMS’ statement from prior rulemaking that “the increase due to Medicaid expansion is not as large as commenters contended due to the actuarial assumption that the new enrollees are healthier than the average Medicaid recipient, and, therefore, use fewer hospital services.” Commenters noted that this assumption has the effect of reducing the estimate of total Medicare DSH spending under prior law, which in turn reduces the estimates of both the empirically justified amount and the amount available to be distributed as uncompensated care payments. Some commenters asserted that there is no solid evidentiary basis for the assumption that new Medicaid enrollees are healthier, and requested that CMS reconsider and discontinue use of this assumption. Some commenters asserted that CMS should by now have accurate information regarding States that have expanded Medicaid, and that CMS should utilize the available enrollment and/or utilization information from Medicaid expansion programs either to support or refute the assumption that the Medicaid expansion population is healthier than the average Medicaid recipient. One commenter stated that, in the FY 2015 IPPS/LTCH PPS final rule, CMS provided a table comparing pre-Affordable Care Act versus post-Affordable Care Act Medicaid enrollment and the corresponding estimated percentage increase in Medicare DSH, but those data were not provided in the FY 2016 IPPS/LTCH PPS proposed rule or the FY 2017 IPPS/LTCH PPS proposed rule.

Several commenters believed there was incomplete information in the FY 2017 IPPS/LTCH PPS proposed rule regarding the “completion factor” and requested further detail. These commenters suggested that CMS publish the “completion factor” used to adjust the FY 2014 and FY 2015 claims data for purposes of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25085). In addition, the commenters suggested that CMS publish information on the “preliminary data for 2016” used by the OACT to determine the discharge figure for FY 2016, as well as the “assumptions” used to determine the FY 2017 discharge figure. The commenters requested that CMS also share detailed calculations of the discharge and case-mix values as well as the inflation factor update used for FY 2014 through FY 2017. One commenter noted that, according to the FY 2017 IPPS/LTCH PPS proposed rule, the data source for the change in 2015 case-mix is actual data adjusted for a completion factor, but the value is the same for 2016 and 2017 based on the 2010–2011 Medicare Technical Review Panel
report. The commenter questioned whether a more current data source could be used for this calculation.

Several commenters expressed concern about the sustainability of continued reductions to aggregate uncompensated care payments. The commenters noted that, as insurance coverage increases, the aggregate amount available for uncompensated care payments will decline and thus reduce the amount of payments to be distributed which they believe will help cover the cost of uncompensated care. These commenters believed that it would be appropriate to adjust the “Other” column in a manner that supports safety-net hospitals in order to reflect the growing number of hospitals that are becoming eligible for DSH payments. Furthermore, commenters noted that hospitals in States that have not expanded Medicaid are not experiencing a decrease in uncompensated care costs and that reductions in Medicare DSH payments are detrimental to these hospitals. Some commenters noted the reductions in payments they would experience due to CMS’ uncompensated care proposal in totality and observed that the hospitals that are disproportionately impacted may not have the resources necessary to successfully transform care, maintain high quality care, and continue in the commitment to meet the needs of patients and communities.

Response: We thank the commenters for their input. As in previous years, we would like to clarify that Factor 1 is not estimated in isolation. The Factor 1 estimates for proposed rules are generally consistent with the economic assumptions and actuarial analysis used to develop the President’s Budget estimates under current law, and the Factor 1 estimates for the final rule are generally consistent with those used for the Midsession Review of the President’s Budget. For additional information on the development of the President’s Budget, we refer readers to the Office of Management and Budget Web site at: https://www.whitehouse.gov/omb/budget.

For additional information on the specific economic assumptions used in the Midsession Review of the President’s FY 2017 Budget, we refer readers to the “Midsession Review of the President’s FY 2017 Budget” available on the Office of Management and Budget Web site at: https://www.whitehouse.gov/omb/budget/MSR. For a general overview of the principal steps involved in projecting future inpatient costs and utilizing, we refer readers to the “2016 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds” available on the CMS Web site at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/index.html?redirect=/reportstrustfunds/ under “Downloads.”

As we did in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49519), later in this section, we provide additional information regarding the data sources, methods, and assumptions employed by the actuaries in determining the OACT’s updated estimate of Factor 1 for FY 2017. We believe that this discussion addresses the methodological concerns raised by commenters regarding the various assumptions used in the estimate, including the “Other” and “Discharges” assumptions and also provides additional information regarding how we address the Medicaid and CHIP expansion. However, we note that, with regard to the commenters’ questions and concerns on the completion factor, the OACT assumed a discharge completion factor of 99 percent for FY 2014 and 98 percent for FY 2015. Similarly, the OACT assumed that case-mix was stabilized at the time of the estimate and no additional completion factor adjustment was needed. These assumptions are consistent with historical patterns of completion factors that were determined for discharge and case-mix numbers.

Regarding the commenters’ assertion that Medicaid expansion is not adequately accounted for in the “Other” column, we note that, based on data from the Midsession Review of the President’s Budget, the OACT assumed per capita spending for Medicaid beneficiaries who enrolled due to the expansion to be 50 percent of the average per capita of the pre-expansion Medicaid beneficiary due to the better health of these beneficiaries. This assumption is consistent with recent internal estimates of Medicaid per capita spending pre-expansion and post-expansion.

In response to the commenters who requested that we adjust the “Other” assumption to reflect the growing number of disproportionate share hospitals in a manner that supports safety-net hospitals, particularly in States that do not have a Medicaid or CHIP expansion, we note that our proposed methodology includes assumptions regarding how DSH payments will change in aggregate, regardless of how many hospitals qualify for DSH payments. The statute is clear that the computation of Factor 1 begins with an aggregate amount of payments that would be made to subsection (d) hospitals under section 1886(d)(5)(F) of the Act if section 1886(r) of the Act did not apply for such fiscal year. In our view, the most appropriate way to estimate this amount is to project, to the best of our ability, how DSH payments will change in aggregate, based on the programs and policies that will be in effect during the fiscal year, rather than focusing on changes in payments to specific hospitals. Thus, there is no need to adjust our estimate of the “Other” factors to reflect new DSH hospitals. Furthermore, in response to concerns about the decrease in the amount available to make uncompensated care payments, we believe that the intent of the statute is to reduce the amount available to make uncompensated care payments to reflect the decline in the number of uninsured individuals and the corresponding decrease in the amount of uncompensated care costs.

Comment: In addition to requesting that the methodology and assumptions used for Factor 1 be made public before the publication of the final rule and with the proposed rule each subsequent year, commenters requested that CMS furnish interested parties with advance opportunity to comment on new calculations based on the more recent data that CMS intends ultimately to use for the final rule. One commenter believed that CMS’ rulemaking is flawed because different data and calculations are used in the final rule without any opportunity for the hospitals to comment. This commenter requested that CMS make clear that it will use different or updated data to determine DSH payments for uncompensated care in the final rule. The commenter believed that the proposal to determine the amount of hospitals’ new DSH payment based on data first released with the final rule and on which hospitals will have no meaningful opportunity to comment violates notice-and-comment rulemaking requirements. As discussed above, several commenters noted the variability in the values of the “Other” column as well as in the factor applied to account for Medicaid expansion; one of the commenters called on CMS to explain why these values were allowed to change from one rulemaking to the next when the agency has otherwise taken the position that the estimates used to determine uncompensated care payments should be fixed when made and not be reconciled with data that become available later.

Response: We believe that stakeholders had notice and a full opportunity to comment on methodology that would be used to
determine uncompensated care payments, including the data sources that would be used. As a result, commenters had a full opportunity to raise any concerns regarding the appropriateness of the data generally, even if the actual data were not yet available, consistent with the requirements for notice and comment under the Administrative Procedure Act. With respect to concerns about the variability of the factors used to estimate Factor 1, we note that, in the FY 2014 IPPS/LTCH PPS final rule (76 FR 50630), using the discretion afforded in the statute to estimate the aggregate amount of DSH payments that would be made in the absence of section 1886(r) of the Act, we finalized a policy of defining the methodology for calculating Factor 1 using the OACT’s biannual Medicare DSH payment projections, which are typically available in February of each year (based on data from December of the previous year) as part of the President’s Budget, and in July (based on data from June) as part of the Midsession Review of the President’s Budget.

Comment: Some commenters requested that, in light of their concerns about the data sources and methods used to estimate Factor 1, CMS adopt a process of reconciling the initial estimates of Factor 1 with actual data for the payment year in conjunction with the final settlement of hospital cost reports for the applicable year. The commenters believed that a “true-up” process would ensure that Medicare DSH payments are determined using the best data.

Response: We continue to believe that applying our best estimates prospectively is most conducive to administrative efficiency, finality, and predictability in payments (78 FR 50628; 79 FR 50010; and 80 FR 49518).

As we noted in the FY 2014 IPPS/LTCH PPS final rule, we do not know the aggregate Medicare DSH payment amount that would be paid for each Federal fiscal year until the time of cost report settlements, which occur several years after the end of the fiscal year. Furthermore, the statute provides that Factor 1 shall be determined based on estimates of the aggregate amount of DSH payments that would be made in the absence of section 1886(r) of the Act and the aggregate amount of empirically justified DSH payments that are made under section 1886(r)(1) of the Act. We believe that, in affording the Secretary the discretion to estimate the amount of these payments and by including a prohibition against administrative and judicial review of those estimates in section 1886(r)(3) of the Act, Congress recognized the importance of finality and predictability in payments and sought to avoid a situation in which the uncompensated care payments would be subject to change over a period of a number of years. Accordingly, we do not agree with the commenters that we should establish a process for reconciling our estimates of Factor 1. We note that, in reviewing the OACT’s prior estimates for DSH payments compared to more updated estimate and/or actual experience, from FY 2005 to FY 2017, the original estimates have been higher than either the more updated estimates and/or actual experience for 7 of the 13 years and lower than actual experience in only 6 years.

Comment: Commenters indicated that the estimated DSH payments do not account for the impact of the D.C. Circuit Court decision in Allina by excluding Medicare Advantage days from the SSI ratio and including dual eligible Medicare Advantage days in the Medicaid fraction. The commenters believed that this understates the estimate of Factor 1. The commenters stated that CMS cannot use prior year data for its calculations without adjusting that data to reflect what it should have been under binding D.C. Circuit precedent.

Response: We do not believe the Allina decision has any bearing on our estimate of Factor 1 for FY 2017. The holding in Allina addresses traditional DSH payments made to a group of providers between 2004 and 2010. The Allina decision did not address the FY 2014 IPPS/LTCH PPS final rule (78 FR 50614 through 50620) in which we readopted the policy of counting Medicare Advantage days in the SSI ratio for FY 2014 and all subsequent fiscal years. In its estimate of Factor 1 for FY 2017 for the FY 2017 IPPS/LTCH PPS proposed rule, the Office of the Actuary was making an estimate of difference between the aggregate amount of DSH payments that would be made under section 1886(d)(15)(F) of the Act in FY 2017 if section 1886(r) of the Act did not apply and the aggregate amount of empirically justified DSH payments that will be made to hospitals in FY 2017 under section 1886(r)(1) of the Act. Thus, although the Office of the Actuary used the December 2015 update of the Medicare Hospital Cost Report Information System (HCRIS) in making this estimate, it also applied inflation adjustments and assumptions regarding future changes in utilization and case-mix in order to estimate Medicare DSH payments for FY 2017. Because Medicare Advantage days will be counted in the SSI fraction in FY 2017 for purposes of determining empirically justified DSH payments, we believe it is more appropriate to use data that also include Medicare Advantage days in the SSI fraction when determining Factor 1 for FY 2017. Accordingly, consistent with § 412.106(b)(2), as readopted in the FY 2014 IPPS/LTCH PPS final rule, in estimating DSH payments for FY 2017, the OACT did not remove patients enrolled in Medicare Advantage plans from SSI ratios or make any other adjustments to the hospital cost report data from the December 2015 update of the HCRIS database. We believe this methodology is consistent with the statute and our regulations.

After consideration of the public comments we received, we are finalizing, as proposed, the methodology for calculating Factor 1 for FY 2017. Using this methodology, we discuss the resulting Factor 1 amount for FY 2017 below.

To determine Factor 1 and to model the impact of this provision for FY 2017, we used the Office of the Actuary’s June 2016 Medicare DSH estimates based on data from the March 2016 update of 2013 cost report data included in the HCRIS and the Impact File published in conjunction with the publication of the FY 2016 IPPS/LTCH PPS final rule. Because SCHs that are projected to be paid under their hospital-specific rate are excluded from the application of section 1886(r) of the Act, these hospitals also were excluded from the June 2016 Medicare DSH estimates. Furthermore, because Maryland hospitals participating in the Maryland All-Payer Model do not receive DSH payments, these hospitals also are excluded from the OACT’s Medicare DSH estimates. Because the Rural Community Hospital Demonstration program is scheduled to end on December 31, 2016, hospitals that are participating in the program are included in this estimate for FY 2017. However, for this final rule, we are excluding 25 percent of our estimate of DSH payments that would otherwise be made to the 4 hospitals whose participation in the program will continue through December 31, 2016, as these hospitals will be excluded from receiving DSH payments until that time. The estimate includes the total DSH payments that would be made to the 10 hospitals whose participation in the Rural Community Hospital Demonstration program will continue only through September 30, 2016.

For this final rule, using the data sources discussed above, the Office of the Actuary used the most recently submitted Medicare cost report data for 2013 to identify Medicare DSH
payments and the most recent Medicare DSH payment adjustments provided in the Impact File published in conjunction with the publication of the FY 2016 IPPS/LTCH PPS final rule, and applied inflation updates and assumptions for future changes in utilization and case-mix to estimate Medicare DSH payments for the upcoming fiscal year. The June 2016 Office of the Actuary estimate for Medicare DSH payments for FY 2017, without regard to the application of section 1886(r)(1) of the Act, is approximately $14,396,635,710.16 billion. This estimate excludes Maryland hospitals participating in the Maryland All-Payer Model, SCHs paid under their hospital-specific payment rate, and 25 percent of DSH payments for the 4 hospitals whose participation in the Rural Community Hospital Demonstration program will continue through December 31, 2016. Therefore, based on the June 2016 estimate, the estimate for empirically justified Medicare DSH payments for FY 2017, with the application of section 1886(r)(1) of the Act, is approximately $3,599,158,927.54 billion (or 25 percent of the total amount of estimated Medicare DSH payments for FY 2017). Under §412.106(g)(1)(i) of the regulations, Factor 1 is the difference between these two estimates of the Office of the Actuary. Therefore, in this final rule, Factor 1 for FY 2017 is $10,797,476,782.62, which is equal to 75 percent of the total amount of estimated Medicare DSH payments for FY 2017 ($14,396,635,710.16 minus $3,599,158,927.54).

The Office of the Actuary’s final estimates for FY 2017 began with a baseline of $12,277 billion in Medicare DSH expenditures for FY 2013. The following table shows the factors applied to update this baseline through the current estimate for FY 2017:

### FACTORS APPLIED FOR FY 2014 THROUGH FY 2017 TO ESTIMATE MEDICARE DSH EXPENDITURES USING 2013 BASELINE

<table>
<thead>
<tr>
<th>FY</th>
<th>Update</th>
<th>Discharge</th>
<th>Case-Mix</th>
<th>Other</th>
<th>Total</th>
<th>Estimated DSH payment (in billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>1.009</td>
<td>0.9553</td>
<td>1.015</td>
<td>1.0586</td>
<td>1.035688</td>
<td>$12.715</td>
</tr>
<tr>
<td>2015</td>
<td>1.014</td>
<td>0.9897</td>
<td>1.005</td>
<td>1.0705</td>
<td>1.079678</td>
<td>13.738</td>
</tr>
<tr>
<td>2016</td>
<td>1.009</td>
<td>0.9868</td>
<td>1.025</td>
<td>0.9999</td>
<td>1.020471</td>
<td>14.009</td>
</tr>
<tr>
<td>2017</td>
<td>1.0015</td>
<td>1.0084</td>
<td>1.005</td>
<td>1.0125</td>
<td>1.027649</td>
<td>14.397</td>
</tr>
</tbody>
</table>

In this table, the discharge column shows the increase in the number of Medicare FFS inpatient hospital discharges. The figures for FYs 2014 and 2015 are based on Medicare claims data that have been adjusted by a completion factor. The discharge figure for FY 2016 is based on preliminary data for 2016. The discharge figure for FY 2017 is an assumption based on recent trends recovering back to the long-term trend and assumptions related to how many beneficiaries will be enrolled in Medicare Advantage (MA) plans. The case-mix column shows the increase in case-mix for IPPS hospitals. The case-mix figures for FYs 2014 and 2015 are based on actual data adjusted by a completion factor. The FY 2016 increase is based on preliminary data adjusted by a completion factor. The FY 2017 increases are based on the recommendation of the 2010–2011 Medicare Technical Review Panel. The “Other” column shows the increase in other factors that contribute to the Medicare DSH estimates. These factors include the difference between the total inpatient hospital discharges and the IPPS discharges, various adjustments to the payment rates that have been included over the years but are not reflected in the other columns (such as the change in rates for the 2-midnight stay policy). In addition, the “Other” column includes a factor for the Medicaid expansion due to the Affordable Care Act.

The table below shows the factors that are included in the “Update” column of the above table:

<table>
<thead>
<tr>
<th>FY</th>
<th>Market basket percentage</th>
<th>Affordable Care Act payment reductions</th>
<th>Multifactor productivity adjustment</th>
<th>Documentation and coding</th>
<th>Total update percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2.5</td>
<td>−0.3</td>
<td>−0.5</td>
<td>−0.8</td>
<td>0.9</td>
</tr>
<tr>
<td>2015</td>
<td>2.9</td>
<td>−0.2</td>
<td>−0.5</td>
<td>−0.8</td>
<td>1.4</td>
</tr>
<tr>
<td>2016</td>
<td>2.4</td>
<td>−0.2</td>
<td>−0.5</td>
<td>−0.8</td>
<td>0.9</td>
</tr>
<tr>
<td>2017</td>
<td>2.7</td>
<td>−0.75</td>
<td>−0.3</td>
<td>−1.5</td>
<td>0.15</td>
</tr>
</tbody>
</table>

**Note:** All numbers are based on Midsession Review of FY 2017 President’s Budget projections.

**b. Calculation of Factor 2 for FY 2017**

Section 1886(r)(2)(B) of the Act establishes Factor 2 in the calculation of the uncompensated care payment. Specifically, section 1886(r)(2)(B)(i) of the Act provides that, for each of FYs 2014, 2015, 2016, and 2017, a factor equal to 1 minus the percent change in the percent of individuals under the age of 65 who are uninsured, as determined by comparing the percent of such individuals (1) who were uninsured in 2013, the last year before coverage expansion under the Affordable Care Act (as calculated by the Secretary based on the most recent estimates available from the Director of the Congressional Budget Office before a vote in either House on the Health Care and Education Reconciliation Act of 2010 that, if determined in the affirmative, would clear such Act for enrollment); and (2) who are uninsured in the most recent period for which data are available (as so calculated), minus 0.1 percentage point for FY 2014 and minus 0.2 percentage point for each of FYs 2015, 2016, and 2017.

Section 1886(r)(2)(B)(ii) of the Act further indicates that the percent of individuals under 65 without insurance in 2013 must be the percent of such individuals who were uninsured in 2013, the last year before coverage expansion under the Affordable Care Act (as calculated by the Secretary...
based on the most recent estimates available from the Director of the Congressional Budget Office before a vote in either House on the Health Care and Education Reconciliation Act of 2010 that, if determined in the affirmative, would clarify such Act for enrollment). The Health Care and Education Reconciliation Act (Pub. L. 111–152) was enacted on March 30, 2010. It was passed in the House of Representatives on March 21, 2010, and by the Senate on March 25, 2010. Because the House of Representatives was the first House to vote on the Health Care and Education Reconciliation Act of 2010 on March 21, 2010, we have determined that the most recent estimate available from the Director of the Congressional Budget Office “before a vote in either House on the Health Care and Education Reconciliation Act of 2010 . . .” (emphasis added) appeared in a March 20, 2010 letter from the director of the CBO to the Speaker of the House. Therefore, we believe that only the estimates in this March 20, 2010 letter meet the statutory requirement under section 1886(r)(2)(B)(i) of the Act. (To view the March 20, 2010 letter, we refer readers to the Web site at: http://www.cbo.gov/sites/default/files/cbofiles/fjdocc/113x/doc11379/amendreconprop.pdf.)

In its March 20, 2010 letter to the Speaker of the House of Representatives, the CBO provided two estimates of the “post-policy uninsured population.” The first estimate is of the “Insured Share of the Nonelderly Population Including All Residents” (82 percent) and the second estimate is of the “Insured Share of the Nonelderly Population Excluding Unauthorized Immigrants” (83 percent). In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50631), we used the first estimate that includes all residents, including unauthorized immigrants. We stated that we believe this estimate is most consistent with the statute, which requires us to measure “the percent of individuals under the age of 65 who are uninsured” and provides no exclusions except for individuals over the age of 65. In addition, we stated that we believe that this estimate more fully reflects the levels of uninsurance in the United States that influence uncompensated care for hospitals than the estimate that reflects only legal residents. The March 20, 2010 CBO letter reports these figures as the estimated percentage of individuals with no insurance. However, because section 1886(r)(2)(B)(i) of the Act requires that we compare the percent of individuals who are uninsured in the most recent period for which data are available with the percent of individuals who were uninsured in 2013, in the FY 2014 IPPS/LTCH PPS final rule, we used the CBO insurance rate figure and subtracted that amount from 100 percent (that is the total population without regard to insurance status) to estimate the 2013 baseline percent of individuals without insurance. Therefore, for FYs 2014 through 2017, our estimate of the uninsurance percentage for 2013 is 18 percent.

Section 1886(r)(2)(B)(i) of the Act requires that we compare the baseline uninsurance rate to the percent of such individuals who are uninsured in the most recent period for which data are available (as so calculated). In the FY 2014, FY 2015, and FY 2016 IPPS/LTCH PPS final rules (78 FR 50634, 79 FR 50014, and 80 FR 49522, respectively), we used the same data source, CBO estimates, to calculate this percent of individuals without insurance. In response to public comments, we also agreed that we should normalize the CBO estimates, which are based on the calendar year, for the Federal fiscal years for which each calculation of Factor 2 is made (78 FR 50633).

Therefore, for the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 24486), we used the most recently available estimate of the uninsurance rate, which was based on the CBO’s March 2015 estimates of the effects of the Affordable Care Act on health insurance coverage (which are available at http://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2014-04-ACAtables2.pdf). The CBO’s March 2015 estimate of individuals under the age of 65 with insurance in CY 2016 was 89 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2016 was 11 percent (that is, 100 percent minus 89 percent.) Similarly, the CBO’s March 2015 estimate of individuals under the age of 65 with insurance in CY 2017 was 90 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2017 available for the proposed rule was 10 percent (that is, 100 percent minus 90 percent.) The calculation of the proposed Factor 2 for FY 2017, employing a weighted average of the CBO projections for CY 2016 and CY 2017, was as follows:

- CY 2016 rate of insurance coverage (March 2015 CBO estimate): 89 percent.
- CY 2017 rate of insurance coverage (March 2015 CBO estimate): 90 percent.
- FY 2015 rate of insurance coverage: (89 percent * .25) + (90 percent * .75) = 89.75 percent.
- Percent of individuals without insurance for 2013 (March 2010 CBO estimate): 18 percent.
- Percent of individuals without insurance for FY 2017 (weighted average): 10.25 percent.

\[
1 - \frac{[(0.1025–0.18)/0.18]}{0.5694} = 1 - \frac{0.5694}{0.5694} = 0.002 (0.2
\]

percentage points for FY 2017 under section 1886(r)(2)(B)(i) of the Act = 0.5674 or 56.74 percent

\[
0.5674 = \text{Factor 2}
\]

Therefore, we proposed that Factor 2 for FY 2017 would be 56.74 percent.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25046), we stated that the FY 2017 Proposed Uncompensated Care amount was $10,470,529,595.84 = $6,654,458,492.68.

Comment: A number of commenters expressed concern about the accuracy and transparency of the methodology used to calculate Factor 2. The commenters questioned whether CMS has accounted for factors that affect the percentage of insured individuals, such as the Supreme Court’s ruling on Medicaid expansion in National Federation of Independent Business v. Sebelius, which resulted in some States not expanding their Medicaid programs. One commenter specifically asserted that CMS’ methodology for the uncompensated care component of the Medicare DSH calculation does not account for those States that have not yet expanded Medicaid, resulting in an overstated percentage of uninsured individuals. Another commenter supported using the most recently available CBO estimates for the uninsured, including any revised estimates issued before the final rule. A third commenter believed the CBO estimates to be within reason. This commenter suggested that CMS true-up the factors based on actual data in order to yield the most accurate determination of the factors and the amount available to make uncompensated care payments.

Response: In the FY 2014 IPPS/LTCH PPS final rule, we finalized a policy to employ the most recent available CBO estimate of the rate of uninsurance in the calculation of Factor 2 for FY 2014. We stated that we believe that this approach is consistent with the language of section 1886(r)(2)(B)(i) of the Act. In addition, it is preferable from a statistical point of view to calculate the percent change in the rate of insurance over time using a consistent data source (78 FR 50632). We also used the most recent CBO estimates in the calculation of Factor 2 for FY 2015 and FY 2016, and we continue to believe
that the CBO projections of the insurance coverage are the most appropriate and consistent basis on which to calculate Factor 2 for FY 2017. We note that CBO’s coverage projections for CY 2016 and CY 2017 reflect changes in the rate of uninsurance arising from participation in the health insurance exchanges, Medicaid and CHIP enrollment, and changes in employer-sponsor, nongroup, and other insurance coverage. In addition, the estimate reflects other individuals who choose to remain uninsured, despite being eligible for Medicaid or having access to care through an employer, the exchange, or from an insurer.

Therefore, the CBO estimates do take into account some uncertainties under the Affordable Care Act, including the decisions by States as to whether to expand their Medicaid programs, the different outcomes of Medicaid expansions and changes in insurance coverage status over time. For detailed explanations outlining the methodology and assumptions used by CBO, we refer readers to the CBO Web site and particularly in the Appendix of the March 2016 Updated Budget Projections: 2016–2026 (which are available at https://www.cbo.gov/sites/default/files/114th-congress-2015-2016/reports/51384-MarchBaseline.pdf).

With respect to the commenter’s concern about employing actual data to reconcile the projections employed to determine Factor 2, in the FY 2014 IPPS/LTCH PPS final rule, we stated that employing actual data would impose an unacceptable delay in the final determination of uncompensated care payments (78 FR 50632). Actual data on the rates of insurance and uninsurance do not become available until several years after the payment year, and the initial data for a year will continue to be adjusted for several years after that as further data become available. Furthermore, by stating that the Secretary’s calculations should be based on “estimates” provided by the CBO, the statute clearly contemplates the use of such estimates on a prospective basis without reconciliation. Accordingly, we continue to believe that determining Factor 2 prospectively is consistent with the statute and conducive to administrative efficiency, finality, and predictability in payments.

Comment: Several commenters requested that CMS work with Congress to take steps to mitigate the effect of the reduction in the overall amount available to make uncompensated care payments for FY 2017. Some commenters requested that CMS use its authority to decrease the magnitude of the proposed reduction in uncompensated care payments. One commenter requested that CMS maintain the percentage of uninsurance that it had applied in the 2015 calculation until more accurate projections can be made, accounting for those States that have not yet expanded Medicaid. Several commenters asked CMS to ensure the payment methodology does not harm access to care in rural areas.

Response: We thank the commenters for their alternative suggestions. The statute requires us to implement the uncompensated care payment methodology in its entirety for FY 2014 and each subsequent fiscal year. Therefore, we do not believe there is a statutory basis to delay or modify the implementation of Factor 2. The statute also does not provide us with a basis to use the percentage of uninsurance we applied for FY 2015 because section 1886(r)(2)(B) requires us to use the data on the percent of individuals who are uninsured in the most recent period for which data are available, and such data are available for FY 2017. Finally, although we understand the commenters’ concerns regarding access to care in rural areas, the statute does not include any exception to the methodology for computing uncompensated care payments for hospitals by geographic location or geographic classification. Therefore, hospitals in rural areas are subject to the same reductions as hospitals elsewhere in the country.

Comment: Several commenters requested that any proposed changes to the methodology that will be used to calculate Factor 2 for FY 2018 and subsequent years be transparent and open for comment in next year’s proposed rule. One commenter asked CMS to elaborate on future changes and questioned whether using the CBO’s projections of the rate of uninsurance would still be a viable option for determining Factor 2 for future years.

Response: The statute permits the use of a data source other than the CBO estimates to determine the percent change in the rate of uninsurance beginning in FY 2018. Because we did not make a proposal to change the Factor 2 methodology for FY 2018 and subsequent years in the FY 2017 IPPS/LTCH PPS proposed rule, we do not believe it is appropriate to discuss any potential changes to the methodology or the viability of potential alternative data sources in this final rule. We plan to address this issue in the FY 2018 IPPS/LTCH PPS proposed rule.

After consideration of the public comments we received, we calculated the final Factor 2 as follows:

For this FY 2017 IPPS/LTCH PPS final rule, we used the most recently available estimate of the uninsurance rate, which is based on the CBO’s March 2016 estimates of the effects of the Affordable Care Act on health insurance coverage (which are available at http://www.cbo.gov/sites/default/files/cbofiles/attachments/43900-2014-04-ACAtables2.pdf). The CBO’s March 2016 estimate of individuals under the age of 65 with insurance in CY 2016 is 90 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2016 is 10 percent (that is, 100 percent minus 90 percent). The CBO’s March 2016 estimate of individuals under the age of 65 with insurance in CY 2017 is also 90 percent. Therefore, the CBO’s most recent estimate of the rate of uninsurance in CY 2017 available for the final rule is 10 percent (that is, 100 percent minus 90 percent.).

The calculation of the final Factor 2 for FY 2017, employing a weighted average of the CBO’s projections for CY 2016 and CY 2017, is as follows:

- CY 2016 rate of insurance coverage (March 2016 CBO estimate): 90 percent.
- CY 2017 rate of insurance coverage (March 2016 CBO estimate): 90 percent.
- CY 2016 rate of insurance coverage: (90 percent * .25) + (90 percent * .75) = 90 percent.
- Percent of individuals without insurance for FY 2013 (March 2010 CBO estimate): 18 percent.
- Percent of individuals without insurance for FY 2017 (weighted average): 10 percent.
- Final Factor 2 for FY 2017 is 55.36 percent.

The FY 2017 Final Uncompensated Care Amount is: $10,797,476,782.62 x 0.5536 = $5,977,483,146.86.

<table>
<thead>
<tr>
<th>FY 2017 Uncompensated Care</th>
<th>Total Available</th>
<th>$5,977,483,146.86</th>
</tr>
</thead>
</table>

c. Calculation of Factor 3 for FY 2017

Section 1886(r)(2)(C) of the Act defines Factor 3 in the calculation of the uncompensated care payment. As we have discussed earlier, section 1886(r)(2)(C) of the Act states that Factor 3 is equal to the percent, for each subsection (d) hospital, that represents
the quotient of (1) the amount of uncompensated care for such hospital for a period selected by the Secretary (as estimated by the Secretary, based on appropriate data (including, in the case where the Secretary determines alternative data are available that are a better proxy for the costs of subsection (d) hospitals for treating the uninsured, the use of such alternative data)); and (2) the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(f) of the Act for such period (as so estimated, based on such data).

Therefore, Factor 3 is a hospital-specific value that expresses the proportion of the estimated uncompensated care amount for each subsection (d) hospital and each subsection (d) Puerto Rico hospital with the potential to receive Medicare DSH payments relative to the estimated uncompensated care amount for all hospitals estimated to receive Medicare DSH payments in the fiscal year for which the uncompensated care payment is to be made. Factor 3 is applied to the product of Factor 1 and Factor 2 to determine the amount of the uncompensated care payment that each eligible hospital will receive for FY 2014 and subsequent fiscal years. In order to implement the statutory requirements for this factor of the uncompensated care payment formula, it was necessary to determine: (1) The definition of uncompensated care or, in other words, the specific items that are to be included in the numerator (that is, the estimated uncompensated care amount for an individual hospital) and the denominator (that is, the estimated uncompensated care amount for all hospitals estimated to receive Medicare DSH payments in the applicable fiscal year); (2) the data source(s) for the estimated uncompensated care amount; and (3) the timing and manner of computing the quotient for each hospital estimated to receive Medicare DSH payments. The statute instructs the Secretary to estimate the amounts of uncompensated care for a period based on appropriate data. In addition, we note that the statute permits the Secretary to use alternative data in the case where the Secretary determines that such alternative data are available that are a better proxy for the costs of subsection (d) hospitals for treating individuals who are uninsured.

In the course of considering how to determine Factor 3 during the rulemaking process for FY 2014, we considered defining the amount of uncompensated care for a hospital as the uncompensated care costs of each hospital and determined that Worksheet S–10 of the Medicare cost report potentially provides the most complete data regarding uncompensated care costs for Medicare hospitals. However, because of concerns regarding variations in the data reported on the Worksheet S–10 and the completeness of these data, we did not propose to use data from the Worksheet S–10 to determine the amount of uncompensated care for FY 2014, the first year this provision was in effect, or for FY 2015 and FY 2016. We instead employed the utilization of insured low-income patients, defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients as defined in §412.106(b)(4) and §412.106(b)(2)(i) of the regulations, respectively, to determine Factor 3. We believed that these alternative data, which are currently reported on the Medicare cost report, would be a better proxy for the amount of uncompensated care provided by hospitals. We also indicated that we were expecting reporting on the Worksheet S–10 to improve over time and remained convinced that the Worksheet S–10 could ultimately serve as an appropriate source of more direct data regarding uncompensated care costs for purposes of determining Factor 3. In section IV.F.4.d. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25089), we explained our belief that since the introduction of the uncompensated care payment in FY 2014, hospitals have been submitting more accurate and consistent data through Worksheet S–10 on the Medicare cost report (OMB control number 0938–0050) and that it would be appropriate to begin incorporating Worksheet S–10 data for purposes of calculating Factor 3 starting in FY 2018. As discussed in greater detail in section IV.F.4.d. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25089) and in section IV.F.4.d. of this final rule, we proposed a methodology and timeline for incorporating Worksheet S–10 data and invited public comments on that proposal. We address the public comments we received on the proposal to incorporate Worksheet S–10 data for purposes of determining Factor 3 starting in FY 2018 in that section of this final rule.

In the FY 2017 IPPS/LTCH PPS proposed rule, we stated that we believe it remains premature to propose the use of Worksheet S–10 data for purposes of determining Factor 3 for FY 2017 because hospitals were not on notice that Worksheet S–10 would be used for purposes of computing uncompensated care payments prior to FY 2014, which could affect the accuracy and completeness of the information reported on Worksheet S–10. As described more fully below regarding the time period of the data used to calculate Factor 3, for FY 2017, we are using data from hospital cost reports that precede FY 2014 to determine Factor 3 of the uncompensated care payment methodology. Therefore, we indicated that, for FY 2017, we remain concerned about the accuracy and consistency of the data reported on Worksheet S–10 and proposed to continue to employ the utilization of insured low-income patients (defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients as defined in §412.106(b)(4) and §412.106(b)(2)(i), respectively) to determine Factor 3 (81 FR 25087). We also proposed to continue the policies that were finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50020) to address several specific issues concerning the process and data to be employed in determining Factor 3 in the case of hospital mergers for FY 2017 and subsequent fiscal years (81 FR 25087).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25087), we also proposed to make a change to the data that will be used to calculate Factor 3 for Puerto Rico hospitals. We received a comment in response to the FY 2016 IPPS/LTCH PPS proposed rule requesting that CMS create a proxy for the SSI days used in the Factor 3 calculation for Puerto Rico hospitals (80 FR 49526). Specifically, commenters were concerned that residents of Puerto Rico are not eligible for SSI benefits. Although we did not have logical outgrowth to adopt any change for FY 2016, we indicated that we planned to address this issue in the FY 2017 IPPS/LTCH PPS proposed rule if we also proposed to continue using inpatient days of Medicare SSI patients as a proxy for uncompensated care in FY 2017. We stated in the proposed rule that because we were proposing to continue using insured low-income patient days as a proxy for uncompensated care in FY 2017, we believed it was important to consider the commenter’s request regarding the data used to calculate Factor 3 for Puerto Rico hospitals. Accordingly, we proposed to create a proxy for SSI days for Puerto Rico hospitals for use in the Factor 3 calculation. The commenter specifically mentioned the use of inpatient days for Medicare beneficiaries receiving Medicaid as this proxy. We examined this concept but were unable to identify a systematic source for these data for
Puerto Rico hospitals. Specifically, we noted that inpatient utilization for Medicare beneficiaries entitled to Medicaid is not reported by hospitals on the Medicare cost report. Therefore, we sought an alternative method using publicly available Medicare data for determining a proxy to account for the fact that residents of Puerto Rico are not eligible for SSI, and therefore Puerto Rico hospitals have a relatively low number of Medicare SSI days in the Factor 3 computation. We stated that we believe it is appropriate to use data from the Medicare cost report to develop a Puerto Rico Medicare SSI days proxy because they are publicly available, used for payment purposes, and subject to audit. However, we acknowledged that there are other data sources that could be included to develop such a proxy, in particular the SSI ratios posted on the Medicare DSH Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html, and therefore solicited public comment on their use.

To develop a Puerto Rico Medicare SSI days proxy using data from the Medicare cost report, our Office of the Actuary examined data from 2013 cost reports and analyzed the relationship between Medicare SSI days (estimated using SSI ratios on the cost report and Medicare days from the same cost report) and Medicaid days (reported by the hospitals in accordance with § 412.106(b)(4)). Nationally, excluding Puerto Rico, the Office of the Actuary found that, on average and across States, for every 100 Medicaid inpatient days, hospitals had 14 Medicare SSI days. In other words, the relationship between Medicare SSI days and Medicaid days reported by hospitals in States, excluding Puerto Rico, was approximately 14 percent. We believe it would be appropriate to extrapolate this relationship to Puerto Rico hospitals to approximate the many patient days for these hospitals would be Medicare SSI days if Puerto Rico residents were eligible to receive SSI. Therefore, to calculate Factor 3 for FY 2017, we proposed to use a proxy for Medicare SSI days for each Puerto Rico hospital equal to 14 percent (or 0.14) of its Medicaid days. In other words, for each Puerto Rico hospital, we would compute a value that is equal to 14 percent of its Medicaid days, where Medicaid days are determined in accordance with § 412.106(b)(4).

Because this is a proposed proxy for the Puerto Rico hospital’s Medicare SSI days, we stated that this value would replace whatever value would otherwise be computed for the hospital under § 412.106(b)(2)(i). Specifically, we would first remove any Medicare SSI days that a Puerto Rico hospital has from our calculation for purposes of determining the numerator of Factor 3 for the hospital and, if the hospital is projected to be eligible for DSH payments in FY 2017, the denominator of Factor 3. Second, we would add the proxy to the hospital’s Medicaid days for purposes of determining the numerator of Factor 3 for the hospital and, if the hospital is projected to be eligible for DSH payments in FY 2017, the denominator of Factor 3. We noted that we continue to encourage Puerto Rico hospitals to report uncompensated care costs on Worksheet S–10 of the Medicare cost report completely and accurately in light of our proposal to begin incorporating data from Worksheet S–10 in the computation of hospitals’ uncompensated care payments starting in FY 2018, as described in more detail in section IV.F.4.d. of the preamble of the proposed rule.

In summary, we invited public comments on the proposal to continue to use insured low-income days (that is, to use data for Medicare and Medicare SSI patient days determined in accordance with § 412.106(b)(2)(i) and (b)(4) as a proxy for uncompensated care, as permitted by statute, including a proxy for Medicare SSI days for Puerto Rico hospitals), under § 412.106(b)(2)(i) as a proxy for uncompensated care costs. The commenter stated that there will be no direct payments for uncompensated care costs in FY 2017 because Medicare and Medicare SSI days will continue to be used as a proxy for uncompensated care costs. The commenter asserted that the net result is that the Medicare Part A Trust Fund will, in effect, provide significant payments for treating Medicare patients, which are more numerous in Medicaid expansion States.

Some commenters who opposed the low-income insured days proxy believed that using data from Worksheet S–10, coupled with selective auditing, would lead to better estimates of uncompensated care costs than the low-income insured days proxy. These commenters asserted that the use of Worksheet S–10 to distribute uncompensated care payments, coupled with distributing traditional DSH payments based on the disproportionate patient percentage formula, would create more balance between Medicare support of Medicaid patients and Medicare support of the uninsured. Some commenters recommended that CMS consider modifications to the low-income insured days proxy that the commenter believed would more accurately measure each hospital’s uncompensated care burden. The commenter suggested CMS weight each hospital’s SSI and Medicaid days in relation to its total patient days, rather than using the SSI and Medicaid days without any weights. In addition, many commenters who objected to the proposal to use the low-income insured days proxy for FY 2017 believed that its continued use rewards providers in States where Medicaid has expanded, and it is thus inappropriate as a proxy for uncompensated care costs. One commenter stated that using Medicaid and Medicare SSI days to calculate Factor 3 harms hospitals in States with lower Medicaid income eligibility limits and high uncompensated care costs. As an example, this commenter stated that hospitals in Wisconsin have comparably lower Medicaid days, as the State government lowered Medicaid income eligibility limits to 100 percent of the Federal poverty level, yet losses associated with uninsured or underinsured patients remain high. Another commenter stated that, in using low-income insured days to determine a hospital’s disproportionate patient percentage, most of the dollars in empirically justified Medicare DSH payments are distributed to hospitals with high Medicaid shares because in the commenter’s view Medicaid days are much more common than Medicare SSI days. The commenter stated that there will be no direct payments for uncompensated care costs in FY 2017 because Medicare and Medicare SSI days will continue to be used as a proxy for uncompensated care costs. The commenter asserted that the net result is that the Medicare Part A Trust Fund will, in effect, provide significant payments for treating Medicaid patients, which are more numerous in Medicaid expansion States.
CMS transition as soon as possible away from the low-income insured days proxy and towards the use of Worksheet S–10 data to determine uncompensated care costs, as any delay would perpetuate current inaccuracies and inequities. However, several commenters who disagreed with the use of the low-income insured days proxy for FY 2017 were also not comfortable using data from Worksheet S–10 until CMS changes the form and instructions to improve the accuracy and consistency of the data it collects. Several commenters who disagreed with the use of continued use of the low-income insured days proxy recommended that CMS use a new data source for obtaining data on uncompensated care costs. Potential data sources identified by commenters included a federally administered DSH survey and proxy data from the Bureau of Labor Statistics.

Response: For the reasons we stated in the FY 2014, FY 2015, and FY 2016 IPPS/LTCH PPS final rules, we believe that data on utilization for insured low-income patients are a reasonable proxy for the treatment costs of uninsured patients in FY 2017. Moreover, due to the concerns that continue to be expressed by a large majority of commenters regarding the accuracy and consistency of the data reported on the Worksheet S–10 in its current form, we continue to believe that these alternative data on utilization for insured low-income patients, which are currently reported on the Medicare cost report, remain a better proxy for the amount of uncompensated care provided by hospitals in FY 2017. However, we remain convinced that Worksheet S–10 can ultimately serve as an appropriate source of more direct data regarding uncompensated care costs for purposes of determining Factor 3, as discussed in section IV.F.4.d of the preamble of this final rule.

As discussed in the FY 2016 IPPS/LTCH PPS final rule, in using Medicaid and Medicare SSI days as a proxy for uncompensated care, we recognize it would be possible for hospitals in States that choose to expand Medicaid to receive higher uncompensated care payments because they may have more Medicaid patient days than hospitals in a State that does not choose to expand Medicaid. We note that the earliest Medicaid expansions pursuant to the Affordable Care Act began in 2014. The data that will be used to determine Factor 3 for FY 2017 are from 2011, 2012, and 2013, and therefore do not reflect the effects of these Medicaid expansions. Thus, for the reasons discussed above, we believe that data on insured low-income days remain the best proxy for uncompensated care costs currently available to determine Factor 3 for FY 2017.

Comment: One commenter requested that CMS consider using a proxy for Puerto Rico hospitals’ SSI days in computing the empirically justified DSH payment amount, or 25 percent of the amount that would have been paid for Medicare DSH prior to implementation of Section 3133 of the Affordable Care Act. The commenter stated that the use of a proxy in the traditional Medicare DSH formula is a logically and naturally derived conclusion of the proposal to use the overall national average ratio of Medicare SSI days to Medicaid days as a proxy for SSI days in the calculation of Factor 3 for Puerto Rico hospitals. The commenter stated that there is sufficient precedent and legal support for CMS to use a proxy for SSI days for empirically justified Medicare DSH payments to Puerto Rico. Specifically, the commenter stated that the law requires CMS to apply the formula in the same manner and to the same extent in each jurisdiction. The commenter also asserted that by not addressing the inability of beneficiaries in the Territories, including Puerto Rico, to receive SSI, the empirically justified DSH payment formula and its resulting payments are not consistent with the requirement to make these payments in the same manner and to the same extent as they apply to subsection (d) hospitals. The commenter stated that the result is that the jurisdiction with the highest proportion of low income beneficiaries gets the lowest disproportionate share payment, within the context of the empirically justified DSH payment.

Another commenter believed that the use of a proxy for SSI days to calculate Factor 3 for Puerto Rico hospitals should be accompanied by a corresponding increase in Factor 1. The commenter stated that the increase in Factor 1 is long overdue. The commenter noted that traditional Medicare DSH payments are based in part on the Medicare/SSI fraction, established under 42 U.S.C. 1395ww(d)(5)(D)(vii)(I), which is the percentage of a hospital’s inpatients who were entitled to Medicare Part A benefits and were also entitled to Supplemental Security Income (SSI) benefits under Title XVI of the Social Security Act when they were receiving inpatient services at the hospital. The commenter asserted that the problem for Puerto Rico is that it does not have an SSI program, as Congress did not extend that program to Puerto Rico when enacting the Title XVI RI program.

The commenter further suggested that Congress had addressed Puerto Rico’s lack of an SSI program in 42 U.S.C. 1395ww(d)(9)(D), which they interpreted to provide that Puerto Rico hospitals are paid DSH “in the same manner and to the extent” as hospitals in the 50 States, and as such, inpatient days should be included for Puerto Rico Medicare beneficiary residents who would qualify for SSI benefits if they were residents of a State. The commenter concluded that CMS’ interpretation of that only Title XVI SSI program days “count” when calculating the DSH payment for Puerto Rico hospitals turns the provision at 42 U.S.C. 1395ww(d)(9)(D) from one that was intended to provide for a DSH payment to Puerto Rico hospitals into one that prohibits such a payment.

Response: In the FY 2017 IPPS/LTCH PPS proposed rule, we did not propose to adopt a proxy for Puerto Rico hospitals’ SSI days in the calculation of the empirically justified Medicare DSH payment. Therefore, we consider this comment to be outside the scope of the proposed rule. We note, however, that while section 1886(r)(1) of the Act allows for the use of alternative data as a proxy to determine the costs of subsection (d) hospitals for treating the uninsured for purposes of determining uncompensated care payments, section 1886(r)(1) of the Act requires the Secretary to pay an empirically justified DSH payment that is equal to 25 percent of the amount of the Medicare DSH payment that would otherwise be made under section 1886(d)(5)(F) of the Act to a subsection (d) hospital. Because section 1886(d)(5)(F)(vi) of the Act, which prescribes the disproportionate patient percentage used to determine empirically justified Medicare DSH payments, specifically calls for the use of SSI days in the Medicare fraction and does not allow the use of alternative data, we disagree with the commenter that there is legal support for CMS to use a proxy for Puerto Rico hospitals’ SSI days in the calculation of the empirically justified Medicare DSH payment. As a result, there is also no basis for us to change our estimate of Factor 1.

Comment: Several commenters supported the proposal to use 14 percent of Medicaid days as a proxy for Medicare SSI days for Puerto Rico Hospitals. These commenters stated that they appreciated the attention and effort of CMS to develop a fair and appropriate method to estimate SSI days for Puerto Rico, as the SSI program is statutorily unavailable to U.S. citizens residing in the Territories. One commenter believed, however, that using a 50 State average ratio of Medicare SSI days to Medicaid days did
not constitute an appropriate proxy in light of Puerto Rico’s current economic crisis.

One commenter recognized the Puerto Rico proxy as a positive step taken by CMS, but reiterated its view that Puerto Rico hospitals have been undercompensated since the beginning of the Medicare program in 1986. This commenter noted that the use of SSI eligibility as an indicator of low-income Medicare patients effectively extends the statutory exclusion of Puerto Rico from the SSI program to other Federal programs from which U.S. citizens residing in the Territories are clearly not excluded by statute. This commenter recommended that CMS examine data to evaluate future proxy alternatives, such as using data for Medicare beneficiaries with Medicaid eligibility (dual beneficiaries). The commenter proposed that CMS initiate a plan to work with hospitals in Puerto Rico to formally review and define cost report data for recent years in relation to the documentation of hospital days for dual beneficiaries. As a second step, the commenter recommended that CMS allow hospitals in Puerto Rico to resubmit the pertinent worksheets of the cost reports for past years, to appropriately document the hospital days for dual beneficiaries, including those in the integrated Medicare Platino program that works through membership in the Medicare Advantage program.

Response: We appreciate the support for our proposal to use 14 percent of a Puerto Rico hospital’s Medicaid days as a proxy for SSI days. Because we are continuing to use insured low-income patient days as a proxy for uncompensated care in FY 2017 and residents of Puerto Rico are not eligible for SSI benefits, we believe it is important to create a proxy for SSI days for Puerto Rico hospitals in the Factor 3 calculation. Regarding the comment recommending that we use inpatient days for Medicare beneficiaries receiving Medicaid as this proxy, we have examined this concept and have been unable to identify a systematic source for these data for Puerto Rico hospitals. Specifically, we note that inpatient utilization for Medicare beneficiaries entitled to Medicaid is not reported by hospitals on the Medicare cost report, either within or outside Puerto Rico. We may further address issues related to estimating the amount of uncompensated care for hospitals in Puerto Rico in future rulemaking.

As we have done for every proposed and final rule beginning in FY 2014, in conjunction with the FY 2017 IPPS/LTCH PPS proposed rule, we published on the CMS Web site a table listing Factor 3 for all hospitals that we estimate would receive empirically justified Medicare DSH payments in FY 2017 (that is, hospitals that we projected would receive interim uncompensated care payments during the fiscal year), and for the remaining subsection (d) hospitals and subsection (d) Puerto Rico hospitals that have the potential of receiving a Medicare DSH payment in the event that they receive an empirically justified Medicare DSH payment for the fiscal year as determined at cost report settlement. This table also contained a list of the mergers that we are aware of and the computed uncompensated care payment for each merged hospital. Hospitals had 60 days from the date of public display of the FY 2017 IPPS/LTCH PPS proposed rule to review this table and notify CMS in writing of any inaccuracies. Comments could be submitted to the CMS inbox at Section3133DSH8@cms.hhs.gov. We have addressed these comments as appropriate in the table that we are publishing on the CMS Web site in conjunction with the publication of this FY 2017 IPPS/LTCH final rule.

Hospitals will have until August 31, 2016, to review and submit comments on the accuracy of the table. Comments can be submitted to the CMS inbox at Section3133DSH8@cms.hhs.gov through August 31, 2016, and any changes to Factor 3 will be posted on the CMS Web site prior to October 1, 2016.

Comment: Some commenters provided detailed information regarding specific merger situations involving their hospitals and requested that CMS consider these mergers in determining Factor 3 for FY 2016. One commenter expressed appreciation for the actions CMS took in the FY 2015 rulemaking to combine the low-income insured days of hospitals that merged, where the surviving hospital has accepted assignment of the provider agreement of the retired provider.

Response: We thank the commenters for their input. We have updated our list of mergers based on information submitted by the MACs as of June 2016. In addition, we have reviewed the commenters’ submissions of mergers not previously identified in the proposed rule and have updated our list accordingly.

The statute also allows the Secretary the discretion to determine the time periods from which we will derive the data to estimate the numerator and the denominator of the Factor 3 quotient. Specifically, section 1886(r)(2)(C)(ii) of the Act defines the numerator of the quotient as the amount of uncompensated care for each hospital for a period selected by the Secretary. Section 1886(r)(2)(C)(ii) of the Act defines the denominator as the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under section 1886(r) of the Act for such period. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50638), we adopted a process of making interim payments with final cost report settlement for both the empirically justified Medicare DSH payments and the uncompensated care payments required by section 3133 of the Affordable Care Act. Consistent with that process, we also determined the time period from which to calculate the numerator and denominator of the Factor 3 quotient in a way that would be consistent with making interim and final payments. Specifically, we must have Factor 3 values available for hospitals that we estimate will qualify for Medicare DSH payments and for those hospitals that we do not estimate will qualify for Medicare DSH payments but that may ultimately qualify for Medicare DSH payments at the time of cost report settlement.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50638) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50018), we finalized a policy of using the most recent available full year of Medicare cost report data for determining Medicaid days and the most recently available SSI ratios to calculate Factor 3. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49528), we held constant the cost reporting years used to determine Medicaid days in the calculation of Factor 3. That is, instead of calculating the numerator and the denominator of Factor 3 for hospitals based on the most recently available full year of Medicare cost report data with respect to a Federal fiscal year, we used data from the most recent of the cost report years (2012/2011) used to determine Medicaid days in FY 2015. We made this change in order to refine the balance between the recency and accuracy of the data used in the Factor 3 calculation. Because we make prospective determinations of the uncompensated care payment without reconciliation, we believed this change would increase the accuracy of the data used to determine Factor 3, and accordingly each eligible hospital’s allocation of the overall uncompensated care amount by providing hospitals with more time to submit these data before they are used in the computation of Factor 3. As in prior years, if the more recent of the two cost reporting periods did not reflect data for a 12-month
period, we used data from the earlier of the two periods so long as that earlier period reflected data for a period of 12 months. If neither of the two periods reflected 12 months, we used the period that reflected a longer amount of time. We also finalized a proposal to continue to extract Medicaid days from the most recent HCRIS database update and to use Medicare SSI days from the most recent SSI ratios available to us during the time of rulemaking to calculate Factor 3. In the FY 2016 IPPS/LTCH PPS final rule, we stated that, for subsequent fiscal years, if we propose and finalize a policy of using insured low-income days in computing Factor 3, we would continue to use the most recent HCRIS database extract at the time of the annual rulemaking cycle, and to use the subsequent year of cost reports (that is, to advance the 12-month cost reports by 1 year). In addition, we stated that for any subsequent fiscal years in which we finalize a policy to use insured low-income days to compute Factor 3, our intention would be to continue to use the most recently available SSI ratio data at the time of annual rulemaking to calculate Factor 3.

We believed that it was appropriate to state our intentions regarding the specific data we would use in the event Factor 3 was determined on the basis of low-income insured days for subsequent years to provide hospitals with as much guidance as possible so they may best consider how and when to submit cost report information in the future. We noted that we would make proposals with regard to our methodology for calculating Factor 3 for subsequent fiscal years through notice-and-comment rulemaking.

Since the publication of the FY 2016 IPPS/LTCH PPS final rule, we have learned that some members of the hospital community have been disadvantaged by our policy of using only one cost reporting period to determine their Factor 3 uncompensated care. Specifically, many hospitals have reported unpredictable swings and anomalies in their low-income insured days between cost reporting periods. These hospitals expressed concern that the use of only one cost reporting period is a poor predictor of their future uncompensated care burden and results in inadequate payments. We stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25089) that, because the data used to make uncompensated care payment determinations are not subject to reconciliation after the end of the fiscal year, we believed that it would be appropriate to expand the time period for the data used to calculate Factor 3 from one cost reporting period to three cost reporting periods. We stated that using data from more than one cost reporting period would mitigate undue fluctuations in the amount of uncompensated care payments to hospitals from year to year and smooth over anomalies between cost reporting periods. Moreover, we believed this policy would have the benefit of supplementing the data of hospitals that filed cost reports that are less than 12 months, such that the basis of their uncompensated care payments and those of hospitals that filed full-year 12-month cost reports would be more equitable. We stated that we believed that computing Factor 3 using data from three cost reporting periods would best stabilize hospitals’ uncompensated care payments while maintaining the recency of the data used in the Factor 3 calculation. We indicated that we believe using data from two cost reporting periods would not be as stable while using data from more than three cost reporting periods could result in using overly dated information.

Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25089), we proposed to use an average of data derived from three cost reporting periods instead of one cost reporting period to compute Factor 3 for FY 2017. That is, we would calculate a Factor 3 for each of the three cost reporting periods and calculate the average. We would calculate the average by adding these amounts together, and dividing the sum by three, in order to calculate Factor 3 for FY 2017. Consistent with the policy adopted in the FY 2016 IPPS/LTCH PPS final rule, we proposed to advance the most recent cost report years used to obtain Medicaid days and Medicare SSI days in FY 2017 by one year and to continue to extract Medicaid days data from the most recent update of HCRIS. We note that, in the FY 2017 IPPS/LTCH PPS proposed rule, we inadvertently stated that the most recent update of HCRIS would be the March 2015 update of HCRIS. We clarify here that the most recently available data for purposes of determining Factor 3 in FY 2017 is from the March 2016 update of HCRIS. If the hospital does not have data for one or more of the three cost reporting periods, we proposed to compute Factor 3 for the periods available and average those. In other words, we would divide the sum of the individual Factor 3s by the number of cost reporting periods for which there are data. If two hospitals have merged, we would combine data from both hospitals for the cost reporting periods in which the merger is not reflected in the surviving hospital’s cost report data to compute Factor 3 for the surviving hospital. Moreover, to further reduce undue fluctuations in a hospital’s uncompensated care payments, if a hospital filed multiple cost reports beginning in the same fiscal year, we proposed to combine data from the multiple cost reports so that a hospital may have a Factor 3 calculated using more than one cost report within a cost reporting period. We invited public comments on this proposal, which we describe more fully below.

For the FY 2016 IPPS/LTCH PPS final rule, we used the most recent of hospitals’ 12-month 2012 or 2011 cost reports and 2012 cost report data submitted to CMS by IHS hospitals to obtain the Medicaid days to calculate Factor 3. In addition, we used Medicare SSI days from the FY 2013 SSI ratios published on the following CMS Web site to calculate Factor 3: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html. Under our proposal to calculate Factor 3 for FY 2017 using data from three cost reporting periods, we proposed to use data from hospitals’ FY 2011, FY 2012, and FY 2013 cost reporting periods extracted from the most recent update of the hospital cost report data in the HCRIS database and the FY 2011 and FY 2012 cost report data submitted to CMS by IHS hospitals to obtain the Medicaid days to calculate Factor 3. (We note that, starting with the FY 2013 cost reports, data for IHS hospitals will be included in the HCRIS database and will no longer be submitted separately.) In addition, to calculate Factor 3 for FY 2017, we anticipated that, under our proposal discussed earlier to use the most recent available 3 years of data on Medicare SSI utilization, we would obtain Medicare SSI days from the FY 2012, FY 2013, and FY 2014 SSI ratios (or, for Puerto Rico hospitals, substitute Medicare SSI days with a proxy as described earlier). We indicated that we expected the FY 2014 SSI ratios to be published on the CMS Web site when available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html. Under this proposal, we would calculate Factor 3 as follows:

Step 1: Calculate Factor 3 for FY 2011 by summing a hospital’s FY 2011 Medicaid days and FY 2012 SSI days and dividing by all DSH eligible hospitals’ FY 2011 Medicaid days and FY 2012 SSI days.

Step 2: Calculate Factor 3 for FY 2012 by summing a hospital’s FY 2012 Medicaid days and FY 2013 SSI days.
and dividing by all DSH eligible hospitals’ FY 2012 Medicaid days and FY 2013 SSI days.

Step 3: Calculate Factor 3 for FY 2013 by summing a hospital’s FY 2013 Medicaid days and FY 2014 SSI days and dividing by all DSH eligible hospitals’ FY 2013 Medicaid days and FY 2014 SSI days.

Step 4: Sum the Factor 3 calculated for FY 2011, FY 2012, and FY 2013 and divide by the number of cost reporting periods with data to compute an average Factor 3.

For illustration purposes, in Table 18 associated with the FY 2017 IPPS/LTCH PPS proposed rule (which is available via the Internet on the CMS Web site), we computed Factor 3 using hospitals’ FY 2011, FY 2012, and FY 2013 cost reports from the December 2015 update of HCRIS to obtain Medicaid days and the FY 2012 and FY 2013 SSI ratios published on the following CMS Web site to determine Medicare SSI days: http://www.Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html.

As discussed in the proposed rule (81 FR 25089), the FY 2014 SSI ratios were not available in time to be used in the proposed rule. Therefore, for the proposed rule, we computed Factor 3 for FY 2013 using FY 2013 Medicaid days and FY 2013 SSI days. However, we noted that we expected the FY 2014 SSI ratios to be available to calculate Factor 3 for the FY 2017 IPPS/LTCH PPS final rule.

For subsequent years, we proposed to continue to use the most recent HCRIS database extract at the time of the annual rulemaking cycle and to advance the three cost reporting periods used to determine Factor 3 by 1 year as appropriate. For instance, if we were to finalize a proposal to continue using the proxy in FY 2018, we would use FY 2012, FY 2013, and FY 2014 cost reports from the most recent available extract of HCRIS for Medicaid days and FY 2013, FY 2014, and FY 2015 SSI ratios to obtain the Medicare SSI days and follow the same methodology outlined earlier to determine Factor 3. However, we also stated that we believed that it would be possible to begin incorporating data from Worksheet S–10 into the computation of Factor 3 starting in FY 2018 and outlined a proposal for doing so using data from three cost reporting periods in section IV.F.4.d. of the preamble of the proposed rule.

Comment: Many commenters supported the proposal to expand the time period for the data used to calculate Medicare and Medicare Supplemental Security Income (SSI) inpatient days from one year to three years, and specifically to use an average of data derived from three cost reporting periods instead of one cost reporting period to compute Factor 3 for FY 2017. The commenters believed that using 3 years of data would provide assurance that hospitals’ uncompensated care payments remain stable and predictable, and would not be subject to unpredictable swings and anomalies in a hospital’s low-income insured days.

Response: We thank the commenters for their input. We appreciate the commenters’ support for the use of a 3-year blend in the low-income insured days proxy methodology.

Comment: Several commenters expressed concern about the method CMS has proposed to attribute data to each year when performing the calculation of Factor 3 in the three-year proxy model for FY 2017. Commenters noted that the proposed methodology could pose a problem for some hospitals that file multiple cost reports in a single fiscal year. Commenter stated, for example, that a hospital might file a 6-month cost report and an 18-month cost report as the result of a merger midway through the cost reporting period. The commenter noted that this keeps the data separate for the individual and merged facilities but also enables them to preserve the surviving hospital’s cost-reporting period in the future. The commenter believed that, in such an instance, the proposed methodology would attribute 2 years of data to a single year and no data to the following year. Thus, the commenter asserted that, under the 3-year average methodology, the hospital’s data would be overstated because 3 years of data would be used to calculate two Factor 3s that would then be averaged together to determine the final Factor 3.

Conversely, the commenter noted that if a hospital has only a short cost reporting period beginning in a year, the hospital could be disadvantaged by the calculation. This commenter asked CMS to modify its proposal to appropriately attribute portions of the cost reporting period to the period for which it is calculating Factor 3.

Another commenter opposed the use of multiple cost reporting periods if it would result in a hospital having more than 12 months of data in the Factor 3 calculation for a year, and recommended that CMS prorate the data down to a 12-month period. Similarly, commenters recommended that CMS annualize cost report data for any cost reporting period that is less than 12 months calculated during the fiscal year from which the data is taken. One commenter suggested that if a hospital has two cost reporting periods that began during the same fiscal year and one of those cost reporting periods is a 12-month cost reporting period, only the 12-month cost reporting period should be utilized.

One commenter questioned whether the rules pertaining to “New Hospitals” adopted in previous rules apply to FY 2017. This commenter asked specifically whether new hospitals will be paid through an alternative methodology if 12-month cost reports are not available for one or more of the three cost reporting periods used to calculate Factor 3. The commenter believed that using a partial cost reporting period under this averaging methodology will harm new facilities, and suggested that for new hospitals a partial cost reporting year should be removed from the calculation. The commenter stated that this methodology would be the most consistent with the payment it has received through the Medicare Cost Report filing calculations related to “New Hospitals” in the past.

Response: We appreciate the commenters raising these data concerns and areas of needed clarification. We are finalizing our proposal to calculate Factor 3 for FY 2017 using the average of data from three cost reporting periods. To further reduce undue fluctuations in a hospital’s uncompensated care payments, if a hospital filed multiple cost reports beginning in the same fiscal year, we are finalizing our proposal to combine data from the multiple cost reports so that a hospital may have a Factor 3 calculated using more than one cost report within a cost reporting period.

We are clarifying that if the hospital does not have data for one or more of the three cost reporting periods, we will compute Factor 3 for the periods available and average those. In other words, we will divide the sum of the individual Factor 3s by the number of cost reporting periods for which there are data. For new hospitals that do not have data for any of the three cost reporting periods used in the proposed Factor 3 calculation, we will apply the new hospital policy finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50643). That is, the hospital will not receive either interim empirically justified Medicare DSH payments or interim uncompensated care payments; however, if it is later determined to be eligible to receive empirically justified Medicare DSH payments based on its FY 2017 cost report, the hospital will also receive an uncompensated care payment calculated using the proposed Factor 3, where the numerator is the sum of Medicaid days and Medicare SSI days.
reported on the hospital’s FY 2017 cost report. We did not make a proposal to annualize cost reports to calculate Factor 3 in the FY 2017 IPPS/LTC PPS proposed rule. We note that section 1886(r)(2)(c) of the Act specifies that Factor 3 is equal to the percent that represents the amount of uncompensated care for such hospital for a period selected by the Secretary (as estimated by the Secretary, based on appropriate data) divided by the aggregate amount of uncompensated care for all subsection (d) hospitals that receive a payment under this subsection for such period (as so estimated). In implementing this provision, we believe it is appropriate to first select the period—in this case, 3 separate years of data—and then to utilize data from all cost reports that align with these periods. However, we acknowledge that the situations presented by commenters, including both long and short cost reporting periods, pose unique challenges in the context of estimating Factor 3. As a result, this is an issue that we intend to consider further and may address in future rulemaking.

Response: One commenter expressed concern about our policy of distributing uncompensated care payments as a per-discharge add-on. The commenter believed this policy is problematic because the per-discharge add-on varies widely from hospital to hospital. The commenter noted that the variability of the add-on payments in turn distorts the MS–DRG prices and creates problematic incentives for MA plans. Therefore, the commenter believed that it would be better to make a uniform interim add-on payment to all DSH hospitals in a county, and any underpayments or overpayments to an individual hospital could be corrected at year-end settlement or on an interim basis during the year (as is already necessary under the current system). Alternatively, the commenter suggested that DSH payments be distributed to hospitals on a periodic basis for their FFS and MA payments be distributed to hospitals on an interim basis during the year (as is already necessary under the current system). Alternatively, the commenter believed that it would be better to make a uniform interim add-on payment to all DSH hospitals in a county, and any underpayments or overpayments to an individual hospital could be corrected at year-end settlement or on an interim basis during the year (as is already necessary under the current system). Alternatively, the commenter suggested that DSH payments be distributed to hospitals on a periodic basis for their FFS and MA payments.

Response: We consider this comment to be outside the scope of the proposed rule, as we did not propose any revision in our method of making interim payments for uncompensated care. However, we would like to make two observations in response to this recommendation. The first observation is that we have received very few comments from the hospital industry indicating that the problem cited by this commenter actually exists. We would expect that, if hospitals were truly disadvantaged in the manner cited by these commenters by our methodology for making interim payments, we would have received many more comments to that effect. The second observation is that adopting the recommendation may pose, for some hospitals, serious problems that may conceivably exceed the problem that the recommendation is designed to solve. For example, reducing the interim uncompensated care payments to high DSH hospitals to a countywide average payment might cause serious cash flow problems during the period before the interim payments could be adjusted or settled. Similarly, low DSH hospitals might receive significantly higher interim payments than would be warranted by their actual uncompensated care data. As a result, these hospitals would have to take financial management steps to ensure that they are capable of making significant repayments when interim payments are adjusted or settled.

Comment: One commenter stated that some of the participants in the Allina litigation have been advised to include beneficiaries that are enrolled in Medicare Part C and eligible for Medicaid on their cost report as Medicaid days. However, the commenter noted that, rather than reporting dually eligible MA days as Medicaid days in their cost report, some providers are protesting these days and are not including them when they file their filed cost reports. The commenter believed that those providers who are protesting these days rather than including them as Medicaid days are being harmed compared to the providers that include them. The commenter requested that CMS clarify its policy and adjust the days that are reported on Worksheet S–2 as necessary for use in uncompensated care payment calculations. The commenter asserted that hospitals are not being fairly paid for uncompensated care because some providers are including dually eligible MA days in their Medicare cost report.

Response: If hospitals are inappropriately reporting dually eligible MA claims in the cost report as Medicaid days, the commenter is correct that, absent review and/or adjustment by the MAC, it would result in Factor 3 overestimating the amount of uncompensated care provided by those hospitals relative to other hospitals. We reiterate our policy that MA beneficiaries who are also eligible for Medicaid are patients entitled to Medicare Part A. Accordingly, their patient days are included in the Medicare SSI ratio and therefore should not be reported in the cost report as Medicaid days. Hospitals that exclude the MA days of patients who are also eligible for Medicaid from Worksheet S–2 are reporting these days appropriately.

After consideration of the public comments we received, we continue to believe that using low-income insured days as a proxy for uncompensated care costs provides a reasonable basis to determine Factor 3 for FY 2017, as we work to improve Worksheet S–10 to accurately and consistently capture uncompensated care costs. Accordingly, in this final rule, we are finalizing for FY 2017 the policy that we originally adopted in the FY 2014 IPPS/LTC PPS final rule, of employing the utilization of insured low-income patients, defined as inpatient days of Medicaid patients plus inpatient days of Medicare SSI patients as defined in § 412.106(b)(4) and § 412.106(b)(2)(i), respectively, to determine Factor 3 for FY 2017. We also are finalizing our proposal to use 14 percent of Medicaid days as a proxy for SSI days for Puerto Rico hospitals when determining Factor 3 for FY 2017; our proposal to continue the policies concerning the process and data to be employed in determining Factor 3 in the case of hospital mergers; our proposal to expand the time period of the data used to determine Factor 3 from one cost reporting period to three cost reporting periods as well as the accompanying methodology; and our proposal to combine cost reports for hospitals with more than one cost report within a cost reporting period. We are codifying these changes for FY 2017 by amending the regulation at § 412.106(g)(1)(iii)(C).

d. Calculation of Factor 3 for FY 2018 and Subsequent Years

(1) Background

In response to commenters’ requests for a timeline and transition for introducing Worksheet S–10 data into the calculation of Factor 3 (for example, we refer readers to the FY 2016 IPPS/LTC PPS final rule (80 FR 49524)), in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25089 through 25094), we discussed our proposed plans for how to begin incorporating hospitals’ Worksheet S–10 data into the calculation of Factor 3, in order to allocate payments based on a hospital’s share of overall uncompensated care costs reported on Worksheet S–10. When we first discussed using Worksheet S–10 to allocate hospitals’ shares of uncompensated care costs in the FY 2014 IPPS/LTC PPS final rule (78 FR 50638), we explained why we believed that it was premature to use uncompensated care costs reported on Worksheet S–10 for FY 2014. Specifically, at that time, the most recent available cost reports would have
been from FYs 2010 and 2011, which were submitted on or after May 1, 2010, when the new Worksheet S–10 went into effect. We believed that “[...] concerns about the standardization and completeness of the Worksheet S–10 data could be more acute for data collected in the first year of the Worksheet’s use” (78 FR 50635). In addition, we believed that it would be most appropriate to use data elements that have been historically publicly available, subject to audit, and used for payment purposes (or that the public understands will be used for payment purposes) to determine the amount of uncompensated care for purposes of Factor 3 (78 FR 50635). At the time we issued the FY 2014 IPPS/LTCH PPS final rule, we did not believe that the available data regarding uncompensated care from Worksheet S–10 met these criteria and, therefore, we believed they were not reliable enough to use for determining FY 2014 uncompensated care payments. Accordingly, for FY 2014, we concluded that utilization of insured low-income patients would be a better proxy for the costs of hospitals in treating the uninsured. For FYs 2015, 2016, and 2017, the cost reports used for calculating uncompensated care payments (that is, FYs 2011, 2012, and 2013) were also submitted prior to the time that hospitals were on notice that Worksheet S–10 could be the data source for calculating uncompensated care payments. Therefore, we believe it is also appropriate to use proxy data to calculate Factor 3 for these years.

We stated in the proposed rule that we believe that, for FY 2018, many of these concerns would no longer be relevant. That is, as described more fully below regarding the use of Worksheet S–10 from FY 2014, hospitals were on notice as of FY 2014 that Worksheet S–10 could eventually become the data source for CMS to calculate uncompensated care payments. Hospitals’ cost reports from FY 2014 have been publically available for some time now. Furthermore, MedPAC has provided analyses that found that current Worksheet S–10 data are a better proxy for predicting audited uncompensated care costs than Medicaid/Medicare SSI days.

Specifically, MedPAC submitted a public comment discussed in the FY 2016 IPPS/LTCH PPS final rule that cited its 2007 analysis of data from the Government Accountability Office (GAO) and data from the American Hospital Association (AHA), which suggested that Medicare days and low-income Medicare days are not a good proxy for uncompensated care costs (80 FR 49525). Analysis performed by MedPAC showed that the correlation between audited uncompensated care data from 2009 and the data from the FY 2011 Worksheet S–10 was over 0.80, as compared to a correlation of approximately 0.50 for 2011 Medicare SSI and Medicaid days. MedPAC concluded that use of Worksheet S–10 data was already better than using Medicare SSI and Medicaid days as a proxy for uncompensated care costs, and that the data on Worksheet S–10 would improve over time as the data are actually used to make payments.

As we discussed in the FY 2017 IPPS/LTCH PPS proposed rule, we also have undertaken an extensive analysis of the Worksheet S–10 data, benchmarking it against the data on uncompensated care costs reported to the Internal Revenue Service (IRS) on Form 990 by for-profit hospitals. The purpose of this analysis, performed by Dobson DaVanzo & Associates, LLC, under contract to CMS, was to determine if Worksheet S–10 uncompensated care data are becoming more stable over time. (This analysis, included in a report entitled “Improvements to Medicare Disproportionate Share Hospital (DSH) Payments Report: Benchmarking S–10 Data Using IRS Form 990 Data and Worksheet S–10 Trend Analyses,” is available on the CMS Web site at: https://www.cms.gov/Medicare/ Medicare-GO/Dsh-Downloads/Dsh.html) Although we acknowledge that the analysis was limited to not-for-profit hospitals, we believe it is relevant to our assessment of the overall quality of the data reported on Worksheet S–10. Because many not-for-profit hospitals are eligible for empirically justified Medicare DSH payments and, therefore, uncompensated care payments, they represent a suitable standard of comparison. We conducted an analysis of 2010, 2011, and 2012 Worksheet S–10 data and IRS Form 990 data from the same years. Using IRS Form 990 data for tax years 2010, 2011, and 2012 (the latest available years) as a benchmark, we compared key variables derived from Worksheet S–10 and IRS Form 990 data, such as charity care and bad debt. The analysis was completed using data from hospitals that had completed both Worksheet S–10 and IRS Form 990 across all study years. We used a sample of 788 not-for-profit hospitals (representing 668 unique Taxpayer Identification Numbers). Because Factor 3 is used to determine the Medicare uncompensated care payment amount for each hospital, we calculated the amounts for Factor 3 for the matched hospitals using charity care and bad debt, and compared the Factor 3 distributions calculated using data from IRS Form 990 and Worksheet S–10. Key findings indicate that the amounts for Factor 3 derived using the IRS Form 990 and Worksheet S–10 data are highly correlated. In addition, the correlation coefficient between the amounts for Factor 3 calculated from the IRS Form 990 and Worksheet S–10 has increased over time, from 0.71 in 2010 to 0.80 in 2012, suggesting some convergence in the data sources over time. In the proposed rule, we stated that this strong correlation indicates that Worksheet S–10 data would be a statistically valid source to use as part of the calculation of the uncompensated care payments in FY 2018. Accordingly, because hospitals have been on notice since the FY 2014 rulemaking that CMS intended eventually to use Worksheet S–10 as the data source for calculating uncompensated care payments, and in light of growing evidence that Worksheet S–10 data are improving over time, at the time of development of the proposed rule, we believed it would be appropriate to use Worksheet S–10 as a data source for determining Factor 3 starting in FY 2018. We discuss below our proposed methodology for how we would begin to incorporate Worksheet S–10 data into the calculation of Factor 3 of the uncompensated care payment methodology.

(2) Data Source and Time Period for FY 2018 and Subsequent Years, Including Methodology for Incorporating Worksheet S–10 Data

For the reasons explained in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25090), we believed that it would be appropriate to begin to incorporate Worksheet S–10 data into the computation of Factor 3 and the allocation of uncompensated care payments, starting with Worksheet S–10 data reported for FY 2014. Below is a description of the proposal set forth in the proposed rule. Specifically, we proposed to continue to use low-income insured patient days as a proxy for uncompensated care for cost reporting periods before FY 2014 and to use Worksheet S–10 data for FY 2014 and subsequent fiscal years to calculate uncompensated care payments for FY 2018 and subsequent fiscal years, which, when combined with our proposal to use data from three cost reporting periods to calculate Factor 3 starting in FY 2017, would have the effect of transitioning toward exclusive
use of Worksheet S–10 data. Under this proposed approach, we would use only Worksheet S–10 data to calculate Factor 3 for FY 2020 and subsequent fiscal years.

As discussed previously, for FY 2017, we proposed and are finalizing a policy of calculating a hospital’s share of uncompensated care based on the proxy of its share of low-income insured days using a time period that includes three cost reports (that is, FY 2011, FY 2012, and FY 2013 cost reports). For the reasons we described earlier, we believe it would not be appropriate to use Worksheet S–10 data for periods prior to FY 2014. For cost reporting periods prior to FY 2014, we believe it is appropriate to continue to use low-income insured days for the reasons we have previously described. Accordingly, to determine Factor 3 for FY 2018, with a time period that includes three cost reporting periods consisting of FY 2014 and two preceding periods, we proposed to use Worksheet S–10 data for the FY 2014 cost reporting period and the low-income insured days proxy data for the two earlier cost reporting periods, drawing three sets of data from the most recently available HCRIS extract. That is, for FY 2018, to compute Factor 3, we proposed to continue to advance the 3-year time period we are using by 1 year and therefore to use FY 2012, FY 2013, and FY 2014 cost report data from the most recent update of HCRIS. In addition, for FY 2018, we proposed to use Medicaid days from FY 2012 and FY 2013 cost reports and FY 2014 and FY 2015 SSI ratios. We stated our belief that this approach would have a transitioning effect of incorporating data from Worksheet S–10 into the calculation of Factor 3 starting in FY 2018.

Consistent with our proposal to determine Factor 3 using data over a period of 3 cost reporting periods, we proposed to calculate a Factor 3 for each of the three cost reporting periods. Specifically, we proposed to calculate Factor 3 for FY 2018 based on an average of Factor 3 calculated using low-income insured days (proxy data) determined using Medicaid days from FY 2012 and FY 2013 cost reports and FY 2014 and FY 2015 SSI ratios, and Factor 3 calculated using uncompensated care data based on FY 2014 Worksheet S–10. We proposed to compute this average for each hospital by—

• Step 1: Calculating Factor 3 using the low-income insured days proxy based on FY 2012 cost report data and the FY 2014 SSI ratio;
• Step 2: Calculating Factor 3 using the insured low-income days proxy based on FY 2013 cost report data and the FY 2015 SSI ratio;
• Step 3: Calculating Factor 3 based on the FY 2014 Worksheet S–10 data; and
• Step 4: Averaging the Factor 3 values that are computed in Steps 1, 2, and 3; that is, adding the Factor 3 values from FY 2012, FY 2013, and FY 2014 for each hospital, and dividing that amount by the number of cost reporting periods with data to compute an average Factor 3.

The denominator would be the sum of the averages of the FY 2012, FY 2013, and FY 2014 amounts from Step 4 for each hospital that is estimated to be eligible for Medicare DSH payments in FY 2018. For example, assuming there are only three hospitals in the IPPS and Hospitals A and B are estimated to be eligible for Medicare DSH payments in FY 2018, while Hospital C is estimated as ineligible for Medicare DSH payments in FY 2018, each hospital’s proposed share of the overall amount available for uncompensated care payments would be calculated as follows:

\[
\text{[(Hospital A FY 2012 Factor 3 proxy)} + \left(\text{Hospital A FY 2013 Factor 3 proxy} \right) + \left(\text{Hospital A FY 2014 Factor 3 S–10}\right)\]/3 = X
\]

\[
\text{[(Hospital B FY 2012 Factor 3 proxy)} + \left(\text{Hospital B FY 2013 Factor 3 proxy} \right) + \left(\text{Hospital B FY 2014 Factor 3 S–10}\right)\]/3 = Y
\]

\[
\text{[(Hospital C FY 2012 Factor 3 proxy)} + \left(\text{Hospital C FY 2013 Factor 3 proxy} \right) + \left(\text{Hospital C FY 2014 Factor 3 S–10}\right)\]/3 = Z
\]

Hospital A’s Factor 3 or proposed share of the overall uncompensated care amount in FY 2018 would be equal to \(\frac{\text{X}}{\text{Y}}\).

Hospital B’s Factor 3 or proposed share of the overall uncompensated care amount in FY 2018 would be equal to \(\frac{\text{Y}}{\text{X}}\).

Hospital C’s Factor 3 or proposed share of the overall uncompensated care amount in FY 2018 would be equal to \(\frac{\text{Z}}{\text{X}}\).

We noted that, under this proposal, the methodology for calculating Factor 3 for each subsequent year would remain unchanged (such as using all cost reports for eligible hospitals that begin during the relevant cost reporting years, including cost reporting periods that are not 12 months in length, and using a proxy for Medicare SSI days for hospitals in Puerto Rico, as described earlier for the calculation of Factor 3 for FY 2017). With regard to FY 2019 and subsequent years, we stated our belief that it would continue to be appropriate to advance the 3-year time period used to compute Factor 3 by one year. Accordingly, we proposed to use FY 2013, FY 2014, and FY 2015 cost report data from the most recent available update of HCRIS to compute Factor 3 and allocate uncompensated care payments for FY 2019. As we stated earlier, with regard to the data used to compute Factor 3, we believed that it would be appropriate to use Worksheet S–10 data from FY 2014 and subsequent periods to calculate Factor 3 and hospitals’ uncompensated care payments for FY 2018 and subsequent fiscal years. Because we proposed to use FY 2013, FY 2014, and FY 2015 cost reports to determine Factor 3 for FY 2019, we proposed to calculate Factor 3 with a proxy calculated based on FY 2013 cost report data and FY 2015 SSI ratios and based on Worksheet S–10 uncompensated care costs from FY 2014 and FY 2015 cost reports. We proposed to calculate Factor 3 for FY 2019 based on an average of Factor 3 amounts calculated using data from the three cost reporting periods in the manner described earlier for FY 2018. For FY 2020, we proposed to continue to advance the three cost reports used by 1 year, and we proposed to calculate Factor 3 using only data from the Worksheet S–10, from cost reports from FY 2014, FY 2015, and FY 2016. For FY 2021 and subsequent fiscal years, we proposed to continue to base our estimates of the amount of hospital uncompensated care costs, using three cost reporting periods from the most recently available HCRIS database, and in each fiscal year, the cost reporting periods would be advanced forward by 1 year (for example, for FY 2021, FY 2015, FY 2016, and FY 2017 cost reports would be used). We solicited comments on the proposed data sources, time periods, and method for calculating uncompensated care costs in FY 2018 and subsequent years.

Although we proposed to calculate Factor 3 for FY 2018 based on an average of the Factor 3 amounts calculated using 2 years of proxy data and 1 year of data from the FY 2014 Worksheet S–10, we stated that readers might find it useful to review a file posted on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html under the Downloads section, which shows preliminary uncompensated care costs calculated by hospital using only Worksheet S–10 data from FY 2014 cost reports and subsequent years. We also noted that, although the previously available December 2015 update of HCRIS. To the extent that hospitals had either not submitted
a Worksheet S–10 with their FY 2014 cost report or found errors on a submitted Worksheet S–10, we encouraged hospitals to work with MACs to complete and revise, as appropriate, their FY 2014 Worksheet S–10 as soon as possible. Comment: A few commenters supported CMS’ proposal to transition to the use of Worksheet S–10 to derive uncompensated care costs for the calculation of Factor 3. MedPAC stated that using Worksheet S–10 data, in conjunction with select auditing of cost reports of hospitals reporting the highest levels of uncompensated care, would lead to better estimates of uncompensated care costs than the continued use of the current proxy of Medicaid and SSI days. Several commenters including MedPAC supported using Worksheet S–10 beginning in FY 2018 with a 3-year phase in. Other commenters recommended accelerating the timeline for implementation of Worksheet S–10, for example, beginning the transition in FY 2017 or shortening the phase in period. These commenters noted that the metrics from Worksheet S–10 appear to provide a better assessment of a hospital’s uncompensated care costs than the current metrics used, which assess low-income insured days.

Response: We appreciate the support for our proposal to begin to incorporate Worksheet S–10 data into the computation of Factor 3 for FY 2018. However, as explained in more detail in response to comments below, after considering the overwhelming amount of comments urging additional delay in implementation of Worksheet S–10 data, we are not finalizing our proposal to begin to incorporate Worksheet S–10 data into the computation of Factor 3 for FY 2018. Instead, we believe it is important that we have the opportunity to consider further the concerns raised by commenters regarding the use of Worksheet S–10 data to determine Factor 3. We expect to re-propose a policy of incorporating Worksheet S–10 data into the computation of Factor 3 no later than FY 2021, as explained further below.

Comment: Many commenters opposed the use of Worksheet S–10 to compute Factor 3 and allocate uncompensated care costs beginning in FY 2018. Commenters believed that the form does not measure the amount of uncompensated care that section 3133 of the Affordable Care Act is designed to compensate. These commenters stated that in their view, data from Worksheet S–10 are not presently a reliable and accurate reflection of uncompensated care costs. Many commenters expressed concern about the lack of accurate and consistent data being reported on Worksheet S–10, primarily due to what they perceive as a lack of clear and concise line level instructions. Commenters stated that significant modifications should be made to Worksheet S–10 and the corresponding instructions as to how to report information for each line to clarify the intent. Commenters also called for audits of Worksheet S–10 and audit guidelines for charity care and bad debt. These commenters supported the transition through a phase-in approach once CMS ensures the accuracy and consistency of the data from Worksheet S–10. One commenter noted that CMS may wish to monitor changes in hospital-specific data from Worksheet S–10 from year to year to determine if further guidance is needed regarding how to accurately complete the form and monitor Worksheet S–10 data for accuracy.

Many commenters cited the report from the DaVanzo study, “Benchmarking S–10 Data Using IRS Form 990 Data and Worksheet S–10 Trend Analyses,” which concluded that hospitals are doing a better job of reporting their uncompensated care data on Worksheet S–10 than they did a few years ago. However, these commenters disagreed with CMS about the significance of this observation. One commenter stated that even if it is true in the aggregate that hospitals are reporting data more accurately on Worksheet S–10, the zero-sum nature of the calculation of uncompensated care payments is such that the remaining inaccuracy and lack of uniformity in the data reported can have a very large impact on hospitals. The commenter asserted that if hospitals, for whatever reason, over-report their uncompensated care, they benefit financially from doing so, while those that do not aggressively report suffer financial harm. The commenter concluded that, for this reason, the possibility that some hospitals are generally “doing better” with reporting data is not good enough. All hospitals must do better, and until they do, the commenter believed that data from Worksheet S–10 are not accurate enough for public policymaking purposes. Other commenters asserted that the DaVanzo study does not illustrate or even evaluate whether data from Worksheet S–10 are a reasonable proxy for the costs hospitals incur in providing care to the uninsured. These commenters pointed out that their own analyses indicate that the most notable aberrations in Worksheet S–10 data reporting occur among public hospitals, which do not file a Form 990 and are therefore missing from the Dobson/ DaVanzo analysis.

Many commenters shared observations regarding concerns and anomalies they identified in data from Worksheet S–10. A number of commenters shared their own analyses that looked at the small proportion of hospitals receiving a large share of uncompensated care payments, and the proportion of hospitals that reported aberrant data relating to uncompensated care costs. Along those lines, some commenters noted that the current Worksheet S–10 can result in negative uncompensated care values for some hospitals.

One commenter noted that it has been monitoring how hospitals have been reporting data from Worksheet S–10 for the last 5 years and has concluded that there is no single, uniform manner in which hospitals report their uncompensated care costs. This commenter stated that the aberrant numbers reported by some hospitals illustrate some combination of misinterpretation of Worksheet S–10 instructions, the lack of clarity of those instructions, and the possible attempts from providers to maximize their Medicare DSH dollars.

Because many commenters were concerned that unclear reporting instructions on Worksheet S–10 would result in inconsistent and inaccurate reporting of data, commenters overwhelmingly requested that, after more precise instructions are provided, CMS apply a strict auditing process for information reported on the Worksheet S–10 before it is used to determine uncompensated care costs. They believed that simply tying information reported on Worksheet S–10 to payment and requiring its regular use will not improve the accuracy of the data. Other commenters indicated that if CMS finalizes a FY 2018 start date, audits with the existing instructions and interpretation would need to commence immediately. In addition, commenters requested that CMS ensure that its contractors administer an auditing process consistently and make the instructions for such an audit public. Some commenters requested that instructions be provided to MACs on how to update hospitals’ 2014 Worksheet S–10 data, and that CMS provide guidance and documentation to MACs clarifying that CMS expects MACs to accept amended and/or corrected cost reports. They suggested that CMS look to the Medicare DSH process and schedule an audit and review the data used for the Medicare wage index annually.
Specifically, the commenters requested that CMS develop timetables for the cut-off of submissions or changes to the data; validate reporting against hospital policies; create a separate audit protocol for all-inclusive rate providers (AIRPs) in order to ensure uncompensated care costs are adequately captured; address the appropriateness of reporting variability from year to year; and that MACs be engaged to audit these data to ensure validity. A commenter also suggested that CMS institute a fatal edit in the cost report audit process for negative or zero uncompensated care costs, or consider including Level 1 cost report edit checks in the cost report software to flag unusual and missing data. Similarly, commenters requested that CMS provide hospitals with FAQs and host educational events to ensure proper cost reporting, while also providing a means to appeal adjustments to the Worksheet S–10.

One commenter added that, currently, there are no published audit instructions for Medicare contractors to follow when reviewing non-Medicare charity care and non-Medicare bad debt. The commenter stated that it had undergone “meaningful use audits” in which the Medicare contractor disallowed charity care costs, and that, based on that experience, this commenter believed that an FY 2018 start date would not provide sufficient time for hospitals to improve their Worksheet S–10 reporting. In addition, commenters recommended that CMS perform an in-depth review of the FY 2014 data for a limited number of hospitals to identify key issues for a full review of FY 2015 and later data. The commenters believed that such a review should be performed by a single MAC for consistency and should include: hospitals with unusual data on Worksheet S–10, including CCRs and different charges as compared to Worksheet C; selective auditing of cost reports of hospitals reporting the highest levels of uncompensated care; and a random mix of other hospitals by type location, or other criteria as applicable.

Commenters requested that CMS implement a process for providing hospitals an opportunity to comment on proposed revisions to clarify the instructions for the completion of Worksheet S–10 to ensure that hospitals receive clear guidance on how to report uncompensated care costs. One commenter suggested that CMS institute a supplemental data collection because CMS chose to use a time period that already has passed as the Worksheet S–10 reporting period for the Factor 3 calculation for FY 2018.

Another commenter suggested that CMS change the instruction for line 22 of Worksheet S–10 from “Enter payments received or expected for services delivered during this cost report period” to “Payments received during the period covered by the cost report.”

Response: In previous rulemaking cycles, commenters both in favor of and opposed to use of a proxy for calculation of Factor 3, requested that CMS provide a timeline and implementation process for when and how the Worksheet S–10 would be used for determining uncompensated care costs (for example, we refer readers to the FY 2016 IPPS/LTCPP final rule (80 FR 49524)). In response to those requests, and based on what appeared to be growing evidence that Worksheet S–10 was improving over time, and based on the fact that hospitals were made aware as of FY 2014 that Worksheet S–10 could eventually become the data source for computing Factor 3, we proposed starting to incorporate Worksheet S–10 data from FY 2014 cost reports into the calculation of Factor 3 for FY 2018. Specifically, using a timeframe that includes three cost reports (that is, FY 2012, FY 2013, and FY 2014) to compute Factor 3 for FY 2018 based on a 3-year average, we proposed to use low-income insured patient days from FY 2012 and FY 2013 cost reports as a proxy for uncompensated care costs, and Worksheet S–10 data from the FY 2014 cost report. We stated that this averaging approach would have a transition effect by incorporating data from Worksheet S–10 into the calculation of Factor 3 starting in FY 2018 (81 FR 25991).

However, after reviewing and considering all comments, we believe it would be appropriate to institute certain additional quality control and data improvement measures prior to moving forward with incorporating Worksheet S–10 data into the calculation of Factor 3. Consequently, we are not finalizing our proposal to begin to incorporate Worksheet S–10 data into the computation of Factor 3 at this time. Instead, our intent is to begin to incorporate Worksheet S–10 data into the computation of Factor 3 once these additional measures are in place, and no later than FY 2021. We believe additional time may be needed to make certain modifications and clarifications to the cost report instructions for Worksheet S–10, as well as explore suggestions made by the commenters for ensuring the submission of Worksheet S–10 by hospitals when filing their cost reports (such as software edits to flag negative, unusual, or missing data or a missing worksheet S–10). As commenters recommended, we will consider issuance of FAQs and hosting of educational seminars for hospitals and MACs as appropriate, coinciding with the issuance of revised cost report instructions. We also intend to explore development of more specific instructions and more uniform review protocols for Worksheet S–10 data. We believe that postponing the final decision as to how and when to incorporate Worksheet S–10 data into the calculation of Factor 3 is necessary, given the significant concerns expressed by commenters regarding the Worksheet S–10 data. Substantive cost report changes may not realistically be implemented in time for FY 2018, as originally proposed. Furthermore, after we complete the substantive work to revise and issue cost report revisions and attending policy clarifications, we would prefer to provide sufficient time for hospitals to report data using the revised instructions and for the results of cost report changes and MAC reviews to be reflected in the data reported on Worksheet S–10. Under normal circumstances, commenters are aware that there is typically a 3- to 4-year lag between the ratesetting year and the cost report data that CMS is using to develop those rates. For example, to develop the FY 2017 wage index, we are using FY 2013 cost report data. Accordingly, there could be a 4-year lag before prospective changes to Worksheet S–10 would result in data that could be used to calculate Factor 3. That is, we would need time to draft and implement cost report revisions, hospitals would need time to file cost reports reflecting those cost report revisions, and the MACs would need time to review those cost reports. While some cost report clarifications could apply retroactively, some revisions to Worksheet S–10 must apply prospectively to ensure consistent application to other policies impacted by Worksheet S–10, such as EHR or Medicare bad debt payments. Accordingly, we believe that cost reporting periods beginning during FY 2017 would be the first cost reports available that would reflect revised Worksheet S–10 data. Thus, we anticipate that the revised Worksheet S–10 data, as first reflected for cost reporting periods starting during FY 2017, would be available for use in determining uncompensated care costs no later than in FY 2021. We will consider further whether the current Worksheet S–10 data or a proxy should be used to calculate Factor 3 for years
between FY 2017 and FY 2021 in future rulemaking.

With regard to the commenters’ request for additional information about the review process that we will instruct the MACs to institute, it may not be identical to the annual desk review process for the IPPS wage index that many commenters have recommended, but we intend to provide standardized instructions to the MACs to guide them in determining when and how often a hospital’s Worksheet S–10 should be reviewed. Although it may be relatively simple to provide guidance to MACs to flag and review negative or missing data on the Worksheet S–10, we intend to give consideration to establishment of measures to identify “aberrant” data for further review, such as, but not necessarily limited to, hospitals with unusual data on Worksheet S–10, including different CCRs and charges as compared to Worksheet C. In addition, we will consider the commenters’ recommendation that we instruct MACs to audit selectively the cost reports of hospitals reporting the highest levels of uncompensated care, as well as a random mix of other hospitals by type location or other criteria as appropriate. Accordingly, the instructions for the MACs for review of Worksheet S–10 will include not only general guidance for review, but also, where appropriate, special instructions for review of certain unique categories of hospitals, such as the All Inclusive Rate Providers (AIRPs), and other mostly government-owned hospitals with unique charity care or charging practices (CMS Pub 15–1, Section 2208.1 describes AIRPs as “hospitals having an all-inclusive rate (one charge covering all services) or a no-charge structure,” for whom the “approved methods for apportioning allowable cost between Medicare and non-Medicare patients” are not readily adaptable, and therefore, provides for “alternative methods of apportionment” for these facilities). However, we will not make the MACs’ review protocol public, as commenters have requested. All CMS desk review and audit protocols are confidential and are for CMS and MAC use only. We also refer readers to Change Request 9648, Transmittal 1681, titled “The Supplemental Security Income (SSI)/Medicare Beneficiary Data for Fiscal Year 2014 for Inpatient Prospective Payment System (IPPS) Hospitals, Inpatient Rehabilitation Facilities (IRFs), and Long Term Care Hospitals (LTCH),” issued on July 15, 2016, available at www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2016-Transmittals-Items/R1681OTN.html. In this transmittal, as a first step in the process of ensuring complete submission of Worksheet S–10 by all eligible DSH hospitals, we instruct MACs to accept amended Worksheets S–10 of FY 2014 cost reports submitted by hospitals (or initial submissions of Worksheet S–10 if none have been submitted previously) and to upload them to the Health Care Provider Cost Report Information System (HCRIS) in a timely manner. The transmittal states that, for revisions to be considered, hospitals must submit their amended FY 2014 cost report containing the revised Worksheet S–10 (or a completed Worksheet S–10 if no data were included on the previously submitted cost report) to the MAC no later than September 30, 2016.

The issuance of these special instructions in CR 9648 is one of multiple steps we intend to take over the next several years to ensure more accurate and uniform reporting of uncompensated care costs on Worksheet S–10. As a result of taking these steps and instituting Worksheet S–10 modifications, clarifications, and MAC reviews, we believe that revised Worksheet S–10 data will be available for use in the calculation of Factor 3 in the near future, and no later than FY 2021. With regard to how Factor 3 will be computed in FY 2018 and subsequent years, we intend to explore whether there is an appropriate proxy for uncompensated care that could be used to calculate Factor 3 until we determine that data from the revised Worksheet S–10 form and instructions are adequate for this purpose. We will undertake notice-and-comment rulemaking to address the issue of the appropriate data to use to determine Factor 3 for FY 2018 and subsequent fiscal years. We also anticipate proposing to continue to use data from three cost reports, as we are doing to calculate Factor 3 for FY 2017, which would have a transitioning effect as we described in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25091).

Comment: Many commenters stated that the proposed 3-year phase in period for Worksheet S–10 is not long enough, and requested that CMS consider alternative lengths. Commenters suggested a variety of lengths for a transition, such as 5 years or 10 years, to mitigate wide swings in hospital payments from year to year and to allow hospitals more time to ensure accurate reporting based on any revised instructions CMS may issue.

Some commenters suggested alternative schedules and methods for the phase-in of data from Worksheet S–10 to calculate Factor 3. Summaries that illustrate the breadth of commenters’ suggestions for alternative schedules and methods for transitioning to Worksheet S–10 are presented below.

• Commenters cited the 10-year transition to the capital PPS, the 4-year transition for indirect medical education reduction in the Balanced Budget Act, and the 5-year transition of certain data elements out of the wage index calculation as examples that could be used as a model for the transition to Worksheet S–10 data.

• One commenter suggested a 5-year phase-in period in which S–10 data would be used to allocate 20 percent of the payments in 2018, 40 percent in 2019, 60 percent in 2020, 80 percent in 2021, and would account for 100 percent of payments in 2022. This transition would involve using 3 years of Medicare SSI days and Medicaid days in each year, and transitioning to using 3 years of S–10 data over the 5-year phase-in. Specifically, under a 5-year phase-in approach, 2018 would use 2014 S–10 cost report data, 2019 would use 2014 and 2015 S–10 cost report data, 2020 would use 2014, 2015, and 2016, and so forth.

• Another commenter suggested a 6-year transition beginning in FY 2019 with Worksheet S–10 data accounting for 5 percent of the Factor 3 for each hospital in FY 2019, and then doubling each year, to 10, 20, 40, and 80 percent, and finally full adoption of Worksheet S–10 data in 2024. The commenter argued that this transition would allow time for initial revisions to the Worksheet S–10 form and instructions and further revisions based on reporting and audit experience before the Worksheet S–10 data become the sole source for the Factor 3 calculation. The commenter added that it would also provide States more time to expand their Medicaid programs.

• Several commenters suggested adopting a stop-loss policy that mitigates losses to those most negatively impacted by the incorporation of Worksheet S–10 data, using percentiles or other statistical measures to define and cap losses to certain hospitals in a budget-neutral manner.

• One commenter suggested CMS consider a series of transition policies such that no hospital sees more than a 5-percent change in overall uncompensated care payments in any given year, and one commenter requested that CMS implement a maximum cap of 10 percent on any redistribution of uncompensated care funds for a minimum of 10 years.

• One commenter stated that CMS should commit to smoothing variability by using no fewer than 2 years’ worth of Worksheet S–10 data, as opposed to...
Medicare DSH uncompensated care payments would offer four advantages over the proposed regulation for FY 2018: It would maintain the incentives under the IPPS for the efficient and high-quality delivery of health care services; it would avoid the use of CCRs; it would better align Medicare and Medicaid DSH; and it would better reflect the costs for which the Factor 3 data are intended to be a proxy, as defined in the statute.

Response: As we stated in the proposed rule (81 FR 25089), we believe that using data from more than one cost reporting period, instead of prorating short or long cost report data to 12 month equivalents, mitigates undue fluctuations in the amount of uncompensated care payments to hospitals from year to year and provides a stabilizing effect from one year to the next. In addition, as discussed above in the section related to the calculation of Factor 3 for FY 2017, in the instance where a hospital has more than one cost report period starting within a fiscal year, we are finalizing our proposal to combine data from multiple cost reports so that a hospital would have a Factor 3 calculated using more than one cost report starting within the fiscal year, as doing so would provide the most complete dataset for the hospital for that fiscal year, and would smooth out fluctuations in the data. At this point, we expect to propose to continue to use three cost reports of data to calculate Factor 3 in FY 2018 and subsequent years, although we may reevaluate this approach if warranted.

In summary, we are not finalizing our proposal to begin to incorporate Worksheet S–10 data into the computation of Factor 3 for FY 2018, and we are not finalizing the proposed regulations text changes at § 412.106(g)(3)(4) through (7) regarding FY 2018 and subsequent fiscal years. In light of the significant concerns expressed by commenters, we are postponing the decision regarding when to begin incorporating data from Worksheet S–10 and proceeding with revisions to the cost report instructions to address the commenters’ concerns in an appropriate manner. We believe that revised Worksheet S–10 data will be available to use in the calculation of Factor 3 in the near future, and no later than FY 2021. With regard to how Factor 3 will be computed in FY 2018 hospitals included Worksheet S–10 data from multiple cost reporting periods within their FY 2014 Worksheet S–10 data. Some of these cost reporting periods represent more than 12 months of data. In the commenter’s view, individual hospital data on the Worksheet S–10 need to represent a 12-month period so that the data are evenly weighted among all DSH hospitals for purposes of determining Factor 3. The commenter believed that inconsistencies in the length of cost report periods would result in erroneous uncompensated care payment allocations. The commenter suggested that, to resolve this, CMS could prorate the data down to an equivalent 12-month period.

Several commenters believed that there is a need to develop alternative methods or data sources for calculating Factor 3. One commenter suggested a new Factor 3 calculation that would be equal to the quotient of a hospital’s cost-adjusted discharges attributable to uninsured patients for a year divided by the average cost-adjusted discharges in the base year for all hospitals eligible for Medicare DSH uncompensated care payments.

Several commenters believed that CMS consider using a hybrid methodology that includes both a hospital’s low-income insured days and uncompensated care costs from Worksheet S–10 to calculate Factor 3. For example, one commenter recommended that, beginning in FY 2020, when CMS proposed to transition entirely to Worksheet S–10 data, CMS instead use a weighted average of low-income insured days and uncompensated care costs from Worksheet S–10, with the low-income insured days weighted 25 percent and the Worksheet S–10 data weighted 75 percent. Other commenters urged CMS to consider a permanent blend of the current proxy of Medicaid days and SSI days, and Worksheet S–10 data, weighted equally in the calculation of Factor 3 for distribution of uncompensated care payments to begin at a future date.

Several commenters believed that revising Worksheet S–10 to require hospitals to report the number of discharges and outpatient visits attributable to uninsured patients for a year divided by the average cost-adjusted discharges in the base year for all hospitals eligible for Medicare DSH uncompensated care payments would offer four advantages over the proposed regulation for FY 2018: It would maintain the incentives under the IPPS for the efficient and high-quality delivery of health care services; it would avoid the use of CCRs; it would better align Medicare and Medicaid DSH; and it would better reflect the costs for which the Factor 3 data are intended to be a proxy, as defined in the statute.

Response: As we stated in the proposed rule (81 FR 25089), we believe that using data from more than one cost reporting period, instead of prorating short or long cost report data to 12 month equivalents, mitigates undue fluctuations in the amount of uncompensated care payments to hospitals from year to year and provides a stabilizing effect from one year to the next. In addition, as discussed above in the section related to the calculation of Factor 3 for FY 2017, in the instance where a hospital has more than one cost report period starting within a fiscal year, we are finalizing our proposal to combine data from multiple cost reports so that a hospital would have a Factor 3 calculated using more than one cost report starting within the fiscal year, as doing so would provide the most complete dataset for the hospital for that fiscal year, and would smooth out fluctuations in the data. At this point, we expect to propose to continue to use three cost reports of data to calculate Factor 3 in FY 2018 and subsequent years, although we may reevaluate this approach if warranted.

In summary, we are not finalizing our proposal to begin to incorporate Worksheet S–10 data into the computation of Factor 3 for FY 2018, and we are not finalizing the proposed regulations text changes at § 412.106(g)(3)(4) through (7) regarding FY 2018 and subsequent fiscal years. In light of the significant concerns expressed by commenters, we are postponing the decision regarding when to begin incorporating data from Worksheet S–10 and proceeding with revisions to the cost report instructions to address the commenters’ concerns in an appropriate manner. We believe that revised Worksheet S–10 data will be available to use in the calculation of Factor 3 in the near future, and no later than FY 2021. With regard to how Factor 3 will be computed in FY 2018...
and subsequent years, we intend to explore whether there is an appropriate proxy for uncompensated care that could be used to calculate Factor 3 until we determine that data from the revised Worksheet S–10 data can be used for this purpose. We will undertake further notice-and-comment rulemaking to address the issue of the appropriate data to use to determine Factor 3 for FY 2018 and subsequent fiscal years. We also anticipate proposing to continue to use data from three cost reports to calculate Factor 3, as we are doing for the calculation of Factor 3 for FY 2017, which would have a transitioning effect as we described in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25091).

(3) Definition of Uncompensated Care for FY 2018 and Subsequent Fiscal Years

In the FY 2014 IPPS/LTCH PPS rulemaking, we considered three potential definitions of uncompensated care: Charity care; charity care + bad debt; and charity care + bad debt + Medicaid shortfalls. As we explained in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50634), we considered proposing to define the amount of uncompensated care for a hospital as the uncompensated care costs of that hospital and considered potential data sources for those costs. We examined the literature on uncompensated care and the concepts of uncompensated care used in various public and private programs, and considered input from stakeholders and public comments in various forums, including the national provider call that we held in January 2013. Our review of the information from these sources indicated that there is some variation in how different States, provider organizations, and Federal programs define “uncompensated care.” However, a common theme of almost all these definitions is that they include both “charity care” and “bad debt” as components of “uncompensated care.” Therefore, a definition that incorporates the most commonly used factors within uncompensated care as reported by stakeholders would include charity care costs and bad debt costs. Worksheet S–10 employs the definition of charity care plus non-Medicare bad debt. Specifically:

\[
\text{Cost of charity care} = \text{Cost of initial obligation of patients approved for charity care (line 21) minus partial payment by patients approved for charity care (line 22).}
\]

\[
\text{Cost of non-Medicare bad debt expense} = \text{Cost to charge ratio (line 1) times non-Medicare and nonreimbursable bad debt expense (line 28).}
\]

As we stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25092), we believe a definition that incorporates the most commonly used factors within uncompensated care as reported by stakeholders would include charity care costs and non-Medicare bad debt costs which correlates to line 30 of Worksheet S–10. Therefore, we proposed that, for purposes of calculating Factor 3 and uncompensated care costs beginning in FY 2018, “uncompensated care” would be defined as the amount on line 30 of Worksheet S–10, which is the cost of charity care and the cost of non-Medicare bad debt.

In the FY 2017 IPPS/LTCH PPS proposed rule, we discussed that we have received many comments and questions from hospitals and hospital associations regarding whether Medicaid payment shortfalls should be included in the definition of uncompensated care. Some stakeholders argue that such payment shortfalls are unreimbursed care for low-income patients and that the definition of uncompensated care should be consistent across Medicare and Medicaid (where the longstanding Medicaid definition of uncompensated care used for Medicaid hospital-specific DSH limits includes Medicaid payment shortfalls). Proponents of including Medicaid shortfalls advance two arguments:

• Medicaid payment shortfalls represent uncovered care; therefore, hospitals have unmet costs when treating these patients.

• The goal of Medicare DSH payments is to provide partial relief from charity care that is provided to (primarily) low-income patients. Because Medicaid enrollees are low-income persons, the underpayments associated with their care are a form of charity care.

In contrast, there are several arguments to support excluding Medicaid shortfalls from the definition of uncompensated care:

• Several government agencies and key stakeholders define uncompensated care as bad debt plus charity care, without consideration for Medicaid payment shortfalls. Specifically, MedPAC, GAO, and the AHA exclude Medicaid underpayments from the definition of uncompensated care.

• Including Medicaid shortfalls in the calculation of Medicare uncompensated care payments would represent a form of cross-subsidization from Medicare to cover Medicaid costs. In the past, CMS and MedPAC have not supported such action.

• Excluding Medicaid shortfalls from the uncompensated care definition allows Medicare DSH payments to better target hospitals with a disproportionate share of uncompensated care for patients with no insurance coverage.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25092), we stated that we believe these arguments for excluding Medicaid shortfalls from the definition of uncompensated care are compelling. In addition, we stated that we believe it is advisable to adopt a definition that is used by several government agencies and key stakeholders. Therefore, we proposed that, for purposes of calculating Factor 3 and the amount of uncompensated care for a hospital beginning in FY 2018, “uncompensated care” would be defined as the cost of charity care and the cost of non-Medicare bad debt. We also proposed to exclude Medicaid shortfalls reported on Worksheet S–10 from the definition of uncompensated care for purposes of calculating Factor 3. We proposed to codify this definition in the regulation at §412.106(g)(1)(iii)(C) and invited public comment on our proposed definition. We stated that we believe that uncompensated care costs as reported on line 30 of Worksheet S–10 best reflect our proposed definition of uncompensated care, but we welcomed public input on this issue.

Comment: Many commenters provided a broad range of detailed suggestions related to reporting requirements for specific lines of Worksheet S–10. Commenters suggested the following general modifications to the manner in which uncompensated care costs are captured on Worksheet S–10:

• A number of commenters observed that the instructions for Worksheet S–10 are inconsistent with generally accepted accounting principles (GAAP) and differ from the accounting practices of the majority of hospitals. Therefore, the commenters requested that CMS amend the cost reporting instructions to require hospitals to report amounts based on GAAP. Commenters suggested that the Worksheet S–10 instructions be amended to require hospitals to report the same bad debt and charity care amounts they report on their financial
Comments noted that because Worksheet S–10 is derived from data reported on the Medicare cost report, charges and payments for physician services are currently excluded. However, the commenters stated that hospitals provide physician services to patients with little or no access to private physicians. They noted that safety-net hospitals in low-income communities particularly provide these services. The commenters believed that establishing an uncompensated care cost methodology that takes these services into account would encourage providers to furnish these services.

- Commenters requested clarification of whether charity care charges should be reported for inpatient hospital services, outpatient hospital services, or both. They requested the ability to report these charges on separate lines and to apply separate CCRs to these separate sets of costs.

- Commenters questioned whether the instructions for line 26 include Medicare bad debts for services provided beyond the inpatient and outpatient setting, and interpreted this to mean that hospitals should include non-Medicare bad debts for services provided in the following settings for which expenses are included on the hospital cost report: Skilled nursing beds (both swing beds and distinct part facilities), distinct part inpatient rehabilitation units, distinct part LTCFs, distinct part psychiatric units, dialysis centers, CMHCs, RHCs and FQHCs. The commenters asked CMS to confirm in the final rule that this interpretation is correct.

- Similarly, commenters requested that CMS define any additional distinct part units or services that are not listed in the instructions for line 26 but should be included in that line when reporting non-Medicare bad debt. As an example, one commenter noted that there is no cost sharing for home health services in the Medicare benefit design and therefore it is not listed as an item/service to include in line 26. However, if CMS truly intends for the bad debt expense to represent the “entire hospital complex,” the commenter stated that distinct part home health agencies should be included, as a hospital could still accrue related bad debt from home health services furnished to the uninsured or underinsured.

- Commenters advised requiring Medicaid DSH payments and Medicaid supplemental payment information to be reported on Worksheet S–10, and to offset all of these payments against Medicaid costs reported on Worksheet S–10. Commenters requested separate reporting of a number of payments, including direct payments to hospitals, Medicaid DSH, and supplementary payments including upper payment limits, intergovernmental transfers, certified government expenditures, provider taxes, other government payments, and payments for local or state indigent care.

- One commenter suggested that CMS should integrate payer mix into Worksheet S–10, as providers with a substantial commercial payer mix often have operating margins that help offset uncompensated care costs. The commenter recommended that CMS examine methods to adjust the uncompensated care amount for payer mix.

- One commenter noted that CCRs in Worksheet S–10 are reported with Reasonable Compensated Equivalency (RCE) limits applied. The commenter cited the discussion in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50161), and that RCE limits have no effect on IPPS provider payments. Therefore, the commenter believed that if the CCR in Worksheet S–10 is used, IPPS hospital’s payments would be affected by RCE limits, and RCE disallowances should therefore be removed from the CCR on Line 1 of Worksheet S–10.

- Commenters observed that CCRs for “parts of hospitals” such as facility-based skilled nursing facilities and inpatient rehabilitation facilities are very different from the CCRs for acute care hospitals paid under the IPPS. The commenters questioned the appropriateness of including parts of hospitals in the CCR in Worksheet S–10.

Response: Some of the comments express concerns and raise questions that have not been raised before, while others have been raised in previous rulemaking. We intend to address many of these comments as part of our planned clarifications and revisions to Worksheet S–10. As mentioned above in response to previous comments, at this time, we are not finalizing the proposed regulations text changes at § 412.106(g)(IC)(4) through (7) regarding the data that would be used to estimate the amount of hospital uncompensated care for FY 2018 and subsequent fiscal years. In these proposed regulation text changes, we had proposed to define uncompensated care costs for FY 2018 and subsequent years to mean charity care costs plus non-Medicare bad debt costs. Our intent is still to begin to incorporate Worksheet S–10 data into the calculation of charity care in the near future, and no later than FY 2021. When we undertake rulemaking to propose to incorporate Worksheet S–10 data, we also expect to propose the same definition of uncompensated care costs—charity care costs plus non-Medicare bad debt costs, because we believe it is advisable to adopt a definition that is used by several government agencies and key stakeholders.

With regard to the comments asking whether Worksheet S–10 data should reflect inpatient or outpatient services, or both, we note that the cost report instructions at Section 4012 of the POM–II, Pub. 15–2, state: “Worksheet S–10—Hospital Uncompensated and Indigent Care Data—Section 112(b) of the Balanced Budget Refinement Act (BBRA) requires that short-term acute care hospitals (§ 1886(d) of the Act) submit cost reports containing data on the cost incurred by the hospital for providing inpatient and outpatient hospital services for which the hospital is not compensated” (emphasis added). In a similar vein, the CCR used on Worksheet S–10, line 1 is from Worksheet C, Part I, line 202. This CCR reflects costs and charges of all hospital inpatient departments and outpatient department and clinics. Thus, Worksheet S–10 is designed to capture uncompensated care costs associated with the hospital under all of the hospital’s Medicare provider agreements, including provider-based facilities. However, Worksheet S–10 is not intended to capture uncompensated care related to physician services. We note that at various points on Worksheet S–10, the instructions state, “Include payments for all covered services except physician or other professional services” (emphasis added).

Finally, with regard to the comment that the CCRs on Worksheet S–10 are reported with the RCE limits applied, we believe the commenter is mistaken. Line 1 of Worksheet S–10 instructs hospitals to compute the CCR by dividing the costs from Worksheet C, Part I, line 202, column 3, by the charges on Worksheet C, Part I, line 202, column 8. The RCE limits are applied in column 4, not in column 3; thus, the RCE limits do not affect the CCR on line 1 of Worksheet S–10.

Comment: Many commenters expressed concerns relating to, and provided suggestions for, calculating charity care and bad debt as captured on Worksheet S–10:

- Commenters expressed confusion about what is identified as an indigent care program, and when charity care and Medicaid uncompensated charges are reported. Some commenters stated that the instructions for line 20 in Worksheet S–10 provide...
that “Charges for non-covered services provided to patients eligible for Medicaid or other indigent care program . . . can be included, if such inclusion is specified in the hospital’s charity care policy and the patient meets the hospital’s charity care criteria.””

Commenters believed that government providers are misreporting data related to charity care by including all charges for their indigent care/general relief patient populations in the definition while not accounting for offsetting payments. The commenters expressed their view that these programs are not uncompensated, but are funded through State and local tax assessments. Therefore, the commenters requested that CMS require that patient charges cannot be included in the cost of charity care unless the related services are not covered by an indigent care program.

- Commenters raised a similar concern about line 20 regarding a possible discrepancy between considering noncovered charges for Medicaid patients as eligible for charity care, but not allowing noncovered charges for patients that have some commercial coverage to be considered charity care. Some commenters believed that this approach understates charity care costs for patients who participate in high deductible plans, which is becoming more common.

- One commenter stated that CMS’ instructions for reporting charity care on Worksheet S–10 are inconsistent with the instructions given by other State and Federal programs which instruct hospitals to report charity care based upon the hospital’s financial policy and consistent with its mission statement, financial ability, and other circumstances. Another commenter stated that because section 501(r) of the Internal Revenue Code requires hospitals to establish financial assistance policies and to reduce charges for services furnished to individuals who qualify for assistance under those policies as a requirement for tax-exemption as a charitable hospital organization, those policies, including the eligibility criteria established under those policies, necessarily must be regarded as the hospital’s “charity care criteria” for purposes of Worksheet S–10, to ensure consistency in reporting.

- Commenters stated that hospitals report charity care amounts for patients that qualify for partial charity care, for both an uninsured individual as well as a patient with financial responsibility after his or her insurance pays.

- Many commenters believed that the definition of bad debt is unclear and that the methodology CMS uses to arrive at the cost of bad debt significantly understates the uncompensated care expense that hospitals incur as a result of uncollectable amounts. For example, commenters requested that CMS clarify whether recoveries received during the cost reporting period should be deducted from the non-Medicare bad debt claimed on line 26.

- In addition, commenters expressed their view that line 26 comingles bad debt for both uninsured patients and patients who have some form of insurance but are not able to meet their cost sharing responsibility. Commenters stated that applying a CCR to calculate cost is not accurate when the amounts have already been reduced from gross charges. These commenters believed that applying the hospital’s CCR to the amount on line 26 understates the costs associated with deductibles and coinsurance for insured patients written off to bad debt. They noted that, given the increased cost sharing many insured individuals currently face, a growing portion of a hospital’s bad debt is related to unpaid deductibles, coinsurance, and copayments. The commenters recommended that CMS revise Worksheet S–10 to require separate reporting for bad debt written off for the uninsured and for those who are insured but cannot afford their cost sharing, similar to the instructions for line 20.

Response: The commenters have raised various issues that directly relate to reporting of charity care and bad debt costs on Worksheet S–10. We intend to consider these issues as we review Worksheet S–10 and will make clarifications or revisions to the Worksheet S–10 instructions, as appropriate, to address these concerns.

Comment: Commenters noted that using data from Worksheet S–10 to calculate Factor 3, as opposed to using the current low-income insured days proxy, has serious implications for entire States. One commenter stated that the proposed policy to transition to Worksheet S–10 would result in a $3 billion shift in Medicare DSH funding across providers and States. This commenter believed that the reductions in payments resulting from this redistribution would have a significant deleterious impact on hospitals in parts of the country that have relied on DSH funding to support services for vulnerable populations. The commenter stated that, given unforeseeable factors that have affected Medicaid and insurance expansion across States, these massive funding redistributions are not aligned with the goals of the Affordable Care Act and could not have been predicted or intended by Congress.

Another commenter provided specific examples from its own analysis of how the use of Worksheet S–10 data to estimate hospital uncompensated care costs would reward hospitals in States that have chosen not to expand their Medicaid programs and punish those that have done so. Many commenters noted that the States losing DSH dollars are States that have expanded their Medicaid programs, as the current proxy captures Medicaid days and Worksheet S–10 does not. Meanwhile, the commenters stated, States that would likely gain the most Medicare uncompensated care dollars are those States that have not expanded their Medicaid programs, and as a result their uncompensated care is relatively high. Many commenters generally believed it should not be public policy to harm States that have responded positively to new opportunities created through legislation and to reward those that have rejected them.

Response: We understand the commenters’ concerns regarding the effects on hospitals’ payments of moving from calculating Factor 3 using a proxy based on low-income days to the use of uncompensated care data from Worksheet S–10. We believe that postponing the decision regarding when to begin incorporating data from Worksheet S–10 data into the calculation of Factor 3 will allow us time to consider what revisions to the cost reporting instructions may be necessary to ensure that uncompensated care cost data are reported appropriately and consistently.

Comment: Many commenters expressed opinions regarding the definition of uncompensated care as captured by Worksheet S–10. Numerous commenters believed that shortfall from Medicaid underpayment should be included in the definition of uncompensated care. These commenters argued that from a policy perspective, it is vitally important to include Medicaid losses to ensure that hospitals in Medicaid-expansion states are not disadvantaged vis-à-vis hospitals in non-expansion States, as noted by commenters that described the differential impact of the use of Worksheet S–10 data in States that have expanded Medicaid compared to States that have not. The commenters stated that including Medicaid losses in the definition of uncompensated care would align with the Medicaid DSH program and the IRS method of calculating the
community benefit provided by nonprofit hospitals. Other commenters requested that, in addition to Medicaid shortfall, shortfall from SCHIP and State and local indigent care programs should be included in uncompensated care costs.

However, other commenters supported the exclusion of Medicaid shortfalls from the definition of uncompensated care. These commenters believed that section 3133 does not allow for the inclusion of Medicaid shortfalls in the Factor 3 calculation, based on the statutory language at section 1886(r)(2)(C)(i) of the Act, which refers to the costs of hospitals treating the “uninsured.” One commenter noted that, under section 3133, Congress required that the Factor 2 calculation include a reduction of the amount determined under Factor 1 (that is, the amount by which the aggregate amount of DSH payments that would have been made under section 1886(d)(5)(F) of the Act for the fiscal year exceeds the aggregate amount of empirically justified DSH payments under section 1886(r)(1) for that fiscal year) equal to the growth in the insured population from a base year, and it does so by reference to specific CBO estimates of the insured patient rate. The commenter stated that Congress was well aware that the CBO includes the growth in the Medicaid population within the insured rate, and therefore Congress did not intend that Medicaid patients would be considered uninsured for purposes of determining Factor 3. Another commenter believed that it is inappropriate for Medicare to include Medicaid shortfall when estimating uncompensated care costs because the “shortfall” will depend on a specific hospital’s cost structure and the Medicaid payments they receive. In addition, the commenter stated that computing losses for Medicaid patients is operationally problematic for several reasons. The commenter indicated that one operational complexity stems from Medicaid paying hospitals a single DSH payment that in part covers costs of the uninsured and in part covers estimates of a hospital’s Medicaid “shortfall,” and it is not clear how CMS would determine how much Medicaid “shortfall” is left after the Medicaid DSH payments are made. In addition, the commenter noted that hospitals in some states return a portion of their Medicaid revenue to the state through provider taxes. The commenter stated that it would be difficult for CMS to arrive at a “shortfall” figure given the lack of reported data on the net value of Medicaid DSH payments less provider taxes. Commenters also noted that compensating hospitals for Medicaid shortfalls as part of a Medicare payment could provide an incentive for Medicaid to underpay hospitals for services provided to Medicaid patients.

In addition to comments about Medicaid shortfalls, commenters stated that the Affordable Care Act directed that the uncompensated care payments should account for uncompensated care costs for the uninsured, and argued that the data reported on the Worksheet S–10 do not include all costs for treating the uninsured. One of these commenters stated that Worksheet S–10 needs to be amended to allow for reporting discounts provided to the uninsured as part of the total uncompensated care costs. The commenter noted that on Worksheet S–10, uncompensated care costs are specifically defined to “not include courtesy allowances or discounts given to patients” (the cost report instructions at CMS Pub. 15–2, Section 4012). The commenter stated that this definition has created confusion, and it is unclear if “courtesy” applies to both “allowance” and “discounts,” or whether the term “discounts” is unmodified by “courtesy.” Commenters observed that States differ in how they define uncompensated care costs, and that not all costs incurred by hospitals in treating the uninsured are categorized as charity care and bad debt, such as discounts to the uninsured who are unable to pay or unwilling to provide income information. The commenters requested that all costs related to treating the uninsured be included in the definition of uncompensated care costs, including discounts to the uninsured, regardless of whether they are officially called “discounts.” Commenters noted that Worksheet S–10 does not distinguish discounts to the uninsured from charity care and bad debt; it simply focuses on the uncompensated care costs that includes charity care and bad debt, such as discounts to the uninsured who are unwilling to discount care over those that do, and could create a disincentive for hospitals to “maintain generous uninsured discount programs.”

Commenters noted that section 3133 of the Affordable Care Act does not mention charity care or even gross non-Medicare bad debt; it simply focuses on the uncompensated care costs of the uninsured. These commenters noted that the instructions of Worksheet S–10 appear to exclude uninsured status explicitly: “Do not include charges for . . . uninsured patients given discounts without meeting the hospital’s charity care criteria.” The commenters believed that because the instructions to Worksheet S–10 state that “this worksheet does not produce the estimate of the cost of treating uninsured patients required for disproportionate share payments under the Medicaid program” (the instructions at the beginning of Worksheet S–10, section 4012 of CMS Pub. 15–2), this indicates that Worksheet S–10 does not capture the information relevant to the purposes of section 3133 of the Affordable Care Act.

Response: In general, we will endeavor to address commenters’ concerns in future cost report clarifications so as to ensure that Worksheet S–10 is an appropriate instrument to use to implement section 3133 of the Affordable Care Act. With regard to the comments regarding Medicaid shortfalls, as we stated in the proposed rule (81 FR 25092), we believe Worksheet S–10 is an appropriate instrument to use to implement section 3133 of the Affordable Care Act. With regard to the comments regarding Medicaid shortfalls, as we stated in the proposed rule (81 FR 25092), we believe there are compelling arguments for excluding Medicaid shortfalls from the definition of uncompensated care, including the fact that several key stakeholders do not consider Medicaid shortfalls in their definition of uncompensated care, and that it is best to allow Medicare uncompensated care payments to target hospitals that have a disproportionate share of uncompensated care for patients with no insurance coverage. Accordingly, as discussed above in response to previous comments, we anticipate re-proposing through rulemaking a definition of uncompensated care costs that includes charity care and non-Medicare bad debt as part of our intent to begin to incorporate Worksheet S–10 data into the computation of Factor 3, no later than FY 2021. With regard to the comments that States differ in how they define uncompensated care costs, and that hospitals’ costs of treating the uninsured are not always categorized as charity care and bad debt, such as discounts to the uninsured who are...
unable to pay or unwilling to provide income information, we believe the commenters are referring to the Worksheet S–10 instructions for Line 20, which state, in part, “Do not include charges for either uninsured patients given discounts without meeting the hospital’s charity care criteria or patients given courtesy discounts.” We believe that hospitals have the discretion to design their charity care policies as appropriate, and may include discounts offered to uninsured patients as “charity care.” However, we will also further consider the concern raised by the commenter as to whether inadvertent disincentives may be occurring under CMS’ current instructions, and we may consider revisions to the instructions on line 20 of Worksheet S–10 to further clarify when patient discounts would be considered charity care versus bad debt.

(4) Other Methodological Considerations for FY 2018 and Subsequent Fiscal Years

In the past several years, we have received technical comments from stakeholders regarding the timing of reporting charity care and the CCRs used in determining uncompensated care costs. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25093), we discussed these issues and how we proposed to incorporate them into the calculation of uncompensated care costs for purposes of determining uncompensated care payments for FY 2018 and subsequent fiscal years as follows:

• Timing of Reporting Charity Care. The determination and write-off of charity care often happens outside of the hospital fiscal year in which the services are provided. Some commenters have requested that the charity care captured on Line 20 of Worksheet S–10 include only the charity care that was written off in the particular cost reporting year, regardless of when the services were provided, consistent with charity write-offs that hospitals report in accordance with GAAP. In addition, hospitals currently report non-Medicare bad debt without regard to when the services were provided. The current Worksheet S–10 does not follow this hospital practice, and specifies that charity care provided (not necessarily written off) during the period should to be recorded on Line 20. (Instructions for Line 20 of Worksheet S–10 of the Medicare cost report CMS-Form-2552–10, “Enter the total initial payment obligation of patients not written off as a full or partial discount based on the hospital’s charity care criteria (measured at full charges), for care delivered during this cost reporting period for the entire facility…” (emphasis added) are included in CMS Pub. 15–2, Chapter 40, Section 4012.) While these differences in reporting should average out over time for a hospital, consistency in reporting has been requested by some stakeholders. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25093), we acknowledged these concerns, and stated that we intend to revise the current Worksheet S–10 cost report instructions for Line 20 concerning the timing of reporting charity care, such that charity care will be reported based on date of write-off, and not based on date of service.

Comment: Many commenters supported the proposal to revise the current Worksheet S–10 cost report instructions for line 20 concerning the timing of reporting charity care, such that charity care will be reported based on date of write-off, and not based on date of service. Commenters requested clarification about how CMS intends to implement the change. One commenter asked whether the revision to Worksheet S–10 to report charity care based on the date of the write-off would be a prospective change, or whether it would change previously filed reports from 2014, 2015, or 2016. Another commenter requested that CMS clarify whether charity care should exclude accounts reported in previously filed cost reports to avoid a double reporting of charity care costs. Commenters noted that providers will need additional time to implement the change. As hospitals will need to revisit numbers reported in 2012 and 2013 to accurately report 2014 costs.

Response: We will revise line 20 of Worksheet S–10 to instruct hospital to report the payment obligation for care “that was written off during this cost reporting period, regardless of when the services were provided.” This change must be effective prospectively for cost reporting periods beginning on or after October 1, 2016, because line 20 as it currently exists is used to calculate EHR incentive payments (in accordance with the policy stated in the final rule for the Electronic Health Record Incentive Program (75 FR 44456), and instituting a change to the instructions on line 20 without a prospective effective date would constitute retroactive rulemaking. Additional clarifications regarding charity care exclusions reported in previously filed cost reports may be forthcoming.

• Revision to the CCR on Line 1 of Worksheet S–10. Many commenters have requested that the CCR used to convert charges to costs should include the cost of training residents (direct GME costs). The CCR on line 1 of Worksheet S–10 currently does not include GME costs, while the charges of teaching hospitals do include charges for GME. Thus, the CCR excludes GME costs in the cost component (or numerator), but includes GME costs in the charge component (or denominator). In the FY 2017 IPPS/LTCH PPS proposed rule, we noted that the commenter requested that CMS consider using the GME costs reported in Worksheet B Part I (column 24, line 118) to capture these additional costs. Unless these GME costs are included, commenters have maintained that the CCRs of teaching hospitals are artificially low, not capturing true uncompensated care costs, thereby disadvantage teaching hospitals in the calculation of their uncompensated care costs.

Using data from FY 2011 and 2012 cost reports, we analyzed the effect on all hospitals’ uncompensated care costs when GME costs are included in the numerator. Specifically, instead of calculating the CCRs as specified currently on line 1 of Worksheet S–10 (which pulls the CCR from Worksheet C, Part I, column 3, line 202/Worksheet C, column 8, line 202), we calculated the CCRs using Worksheet B, Part I, column 24, line 118/Worksheet C, Part I, column 8, line 202. As can be seen on the file posted on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html under the Downloads section, and as expected, including GME costs in the numerator of the CCR results in an increased share of uncompensated care payments being made to teaching hospitals. Of the more than 1,000 teaching hospitals included in the analysis, the CCRs of 830 hospitals increase by less than 5 percent, 178 hospitals’ CCRs increase by more than 5 percent but less than 10 percent, 71 hospitals’ CCRs increase by 10 percent or more. Thirty-three hospitals experience a decrease in their CCRs, with 32 hospitals experiencing a decrease of less than 5 percent, and 1 hospital experiencing a decrease of more than 5 percent, but less than 10 percent. As we have stated previously in response to this issue, we believe that the purpose of uncompensated care payments is to provide additional payment to hospitals for treating the uninsured, not for the costs incurred in training residents. In addition, because the CCR on line 1 of Worksheet S–10 pulled from Worksheet C, Part I, is also used in other IPPS ratsetting contexts (such as high-cost outliers and the
calculation of the MS–DRG relative weights) from which it is appropriate to exclude GME because GME is paid separately from the IPPS, we are hesitant to adjust the CCRs in the narrower context of calculating uncompensated care costs. Therefore, in the proposed rule, we stated that we do not believe it is appropriate at this time to modify the calculation of the CCR on line 1 of Worksheet S–10 to include GME costs in the numerator.

Comment: Commenters noted that the CCR used on Worksheet S–10 to convert uncompensated care costs implicitly includes direct GME charges in the denominator, and therefore requested that the CCR on Worksheet S–10 be revised to include direct GME payments in the cost numerator. One commenter noted that because GME costs are a significant component of inpatient and outpatient services at teaching hospitals, not including GME in the numerator of the CCR significantly understates the cost of care and thus the losses incurred by these hospitals as a result of uncompensated care. The commenter pointed out that Medicare and State Medicaid programs contribute their share of GME costs, and CMS permits teaching hospitals to revise their CCRs to include GME costs under the Medicaid DSH program because Medicaid payments cover GME. Finally, the commenter stated that Schedule H Medicaid payments cover GME. The commenter suggested including the costs of teaching hospitals as a result of uncompensated care. Several commenters also noted that uncompensated care costs reported on Worksheet S–10 should be audited due to the extremely high values consistently reported by some hospitals. We believe that, just as we apply trims to hospitals’ CCRs used to calculate high-cost outlier payments to eliminate anomalies in payment determinations (§ 412.84(h)(3)(ii)), it is appropriate to apply statistical trims to the CCRs that are considered anomalies on Worksheet S–10. Line 1. Specifically, § 412.84(h)(3)(ii) states that the Medicare contractor may use a statewide CCR for hospitals whose operating costs are in excess of 3 standard deviations above the corresponding national geometric mean (that is, the CCR “ceiling”).

First Trim

Step 1: Prior to calculating the statewide average CCRs, all hospitals with a CCR reported on Worksheet S–10, line 1, of greater than the corresponding CCR “ceiling” (that is, the CCR “ceiling” published in the final rule for the fiscal year that is contemporaneous to the particular Worksheet S–10 data) would be removed from the calculation. We proposed to remove the hospitals with a CCR of greater than 3 standard deviations above the corresponding national geometric mean in order to calculate the statewide average CCRs so that these aberrant CCRs do not skew the statewide average CCR.

Step 2: Using the CCRs for the remaining hospitals in Step 1, determine the statewide average CCRs using line 1 of Worksheet S–10 for hospitals within each State (including non-DSH eligible hospitals).

Step 3: Calculate the simple average CCR (not weighted by hospital size) for each State.

Step 4: First CCR Trim—Assign the statewide average CCR calculated in Step 3 to all hospitals with a CCR greater than 3 standard deviations above the corresponding national geometric mean (that is, the CCR “ceiling”).

Second Trim

Step 5: Calculate the natural logarithm of the CCR for all hospitals (including those with replaced CCRs and those not eligible for Medicare DSH payments).

Step 6: Calculate the geometric mean and standard deviation of the log values across all hospitals (including those not eligible for Medicare DSH payments).

Step 7: Second CCR Trim—Assign the statewide average CCR calculated in Step 3 to each Medicare DSH eligible hospital with a CCR greater than 3.0 standard deviations above the geometric mean. All hospitals not eligible for Medicare DSH payments should be excluded from further analyses.

The analysis that we performed under this “double trim” approach was based on CCRs from FY 2012 Worksheet S–10, Line 1. Under Step 1, we used the FY 2013 CCR “ceiling” of 1.146 published in the FY 2013 IPPS/LTC PPS final rule (77 FR 53697). (We used the FY 2013 CCR “ceiling” because it was computed from the March 2012 update of the Provider Specific File, which contained CCRs that are relatively contemporaneous to the CCRs in the FY 2012 cost reports.) Our analysis showed that 27 hospitals would receive their respective statewide average CCR. (We refer readers to our analysis posted on the CMS Web site at: https://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/dsh.html under the “Downloads” section, and as expected, we found that including GME costs in the numerator of the CCR results in an increased share of uncompensated care payments being made to teaching hospitals. As we have stated previously in response to this issue, we believe that the purpose of uncompensated care payments is to provide additional payment to hospitals for treating the uninsured, not for the costs incurred in training residents. In addition, because the CCR on line 1 of Worksheet S–10 pulled from Worksheet C, Part I, is also used in other IPPS rate-setting contexts (such as high-cost outliers and the calculation of the MS–DRG relative weights) from which it is appropriate to exclude GME because GME is paid separately from the IPPS, we hesitate to adjust the CCRs in the narrower context of calculating uncompensated care costs. Therefore, we continue to believe that it is not appropriate at this time to modify the calculation of the CCR on line 1 of Worksheet S–10 to include GME costs in the numerator.

Accordingly, we do not anticipate proposing to include GME costs in the numerator of the CCR when we begin to incorporate Worksheet S–10 data into the calculation of Factor 3.

• Trims to Apply to CCRs on Line 1 of Worksheet S–10. In the FY 2017 IPPS/LTC PPS proposed rule, we noted that commenters also have suggested that uncompensated care costs reported on Worksheet S–10 should be audited due to the extremely high values consistently reported by some hospitals. We believe that, just as we apply trims to hospitals’ CCRs used to calculate high-cost outlier payments to eliminate anomalies in payment determinations (§ 412.84(h)(3)(ii)), it is appropriate to apply statistical trims to the CCRs that are considered anomalies on Worksheet S–10. Line 1. Specifically, § 412.84(h)(3)(ii) states that the Medicare contractor may use a statewide CCR for hospitals whose operating costs are in excess of 3 standard deviations above the corresponding national geometric mean (that is, the CCR “ceiling”). We recalculated annually by CMS and published in the proposed and final IPPS rules each year. To control for data anomalies, we stated in the proposed rule that we are considering proposals that would trim hospitals’ CCRs to ensure reasonable CCRs are used to convert charges to costs for purposes of determining uncompensated care costs. One approach we considered as a possible process for FY 2018 and subsequent years would be a “double trim” methodology as follows:

First Trim

Step 1: Prior to calculating the statewide average CCRs, all hospitals with a CCR reported on Worksheet S–10, line 1, of greater than the corresponding CCR “ceiling” (that is, the CCR “ceiling” published in the final rule for the fiscal year that is contemporaneous to the particular Worksheet S–10 data) would be removed from the calculation. We
urban or rural hospital above the applicable CCR “ceiling” for a given fiscal year would be replaced by its respective urban or rural statewide average CCR. As a reference, the FY 2013 IPPS statewide average urban and rural CCRs are in Table 8A included on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Acute-Inpatient-Files-for-Download-Items/FY2013-FinalRule-CorrectionNotice-Files.html.

After applying the applicable trims to a hospital’s CCR as appropriate, we would calculate a hospital’s uncompensated care costs as being equal to line 30, which is the sum of line 23 and line 29, as follows:

Hospital Uncompensated Care Costs = line 30 (= line 23 + line 29), which is equal to—

[[Line 1 CCR adjusted by trim if applicable x charity care line 20]—
(Payments received for charity care line 22)]

+ [[Line 1 CCR adjusted by trim if applicable x Non-Medicare and non-reimbursable Bad Debt line 28)].

Comment: Several commenters supported CMS’ proposal to trim hospitals’ CCRs to ensure reasonable CCRs are used to convert charges to costs for purposes of determining uncompensated care costs. These commenters agreed with CMS that this trim will prevent some of the large variance outliers from artificially influencing the distribution percentages. While some commenters agreed that identifying aberrant CCRs through an edit is appropriate, many commenters objected to the “double trim” methodology outlined in the FY 2017 IPPS/LTCH PPS proposed rule for FY 2018 and subsequent years. One commenter recommended that hospitals with extremely high CCRs be audited and an appropriate CCR determined, versus arbitrarily trimming these high CCRs to a statewide average. Several commenters expressed concern over the proposed CCR trim methodology because hospitals that are considered “all-inclusive rate providers” are not required to complete Worksheet C, Part I, which is used for reporting CCR on Line 1 of Worksheet S–10. Commenters expressed their view that the proposed CCR trim methodology inappropriately modifies the uncompensated care costs for these hospitals, and that a high CCR could be accurate if the hospital’s charges are close to costs, as is usually the case for “all-inclusive rate providers.” Commenters believed that CMS should correct the methodology to ensure these hospitals are not inappropriately captured in this double trim methodology. Similarly, commenters recommended that CMS not apply a trim to hospital CCRs until it identifies the reasons for variations in CCRs and gives hospitals that have legitimate reasons for having higher CCRs adequate time to produce CCRs that are usable for converting costs to charges on the cost report. One commenter suggested that, instead of applying a trim, CMS evaluate CCRs on cost reports to identify misreported, erroneous values and not penalize hospitals that are accurately reporting information under a CMS-sanctioned methodology. The commenter recommended that if CMS intends to require that hospitals revise their charge structures and cost apportionment methodologies, CMS provide hospitals sufficient lead time to bring their systems in line with these requirements.

Several commenters provided alternative approaches to the CCR trim methodology. These commenters recommended using the ceiling derived from the 2014 CCRs, which was published in the FY 2015 IPPS/LTCH PPS final rule. Commenters also recommended that CMS use the sum of the operating and capital CCR ceilings because the CCRs derived in Worksheet C are based on both operating and capital costs. Under this methodology, the commenter-recommended ceiling for the first trim was 1.402 instead of 1.146 as proposed. Commenters also suggested that CMS truncate CCRs at the second trim ceiling unless a hospital’s MAC validates the reported CCR.

Response: We appreciate the support and additional information provided by the commenters related to applying trims to the CCRs. We intend to further explore which trims are appropriate to apply to the CCRs on line 1 of Worksheet S–10, including whether it is appropriate to apply a unique trim to certain subsets of hospitals, such as All Inclusive Rate Providers. With regard to the comment recommending that CMS use the sum of the operating and capital CCR ceilings because the CCRs derived in Worksheet C are based on both operating and capital costs, after considering this matter, we agree that Worksheet C CCRs do reflect both the operating and capital costs of a hospital, and it may be appropriate to apply a CCR ceiling that is the sum of both the operating and capital CCRs. We intend to consider this recommendation further when preparing to use Worksheet S–10 data to compute Factor 3, and will undertake rulemaking in advance on this matter.

Other Related Comments

Comment: Several commenters expressed concern that the use of data from Worksheet S–10 to calculate uncompensated care costs does not take into account the Indian Health Service’s (IHS’) unique funding structure and therefore may jeopardize all of IHS’s uncompensated care payments. The commenters stated that CMS has indicated that due to their unique funding structure, Indian Health Care Providers (IHCPS) do not have uncompensated care costs under Worksheet S–10. The commenters indicated that because funding for the costs of patient care is provided through congressional appropriations, all care is considered compensated, even though appropriations fund only approximately 59 percent of the health care needs for American Indians/Alaska Natives. The commenters also stated that many Tribes and Tribal organizations invest non-Federal resources in their health care programs to furnish care that could easily be classified as uncompensated care because IHCPS may not charge beneficiaries to receive care and thus, may not have the accounting methods to track these costs. As a result, the commenters stated that IHCPS hospitals are currently unable to support charity care and non-Medicare bad debt consistent with the proposed definition of uncompensated care in the proposed rule. The commenters estimated that if the proposals in the proposed rule are finalized, they will decrease IHS’s collections significantly, negatively impacting an already underfunded health system and leading to reduced quality of care and the loss of life.

Commenters acknowledged a previous conversation with CMS and IHS to attempt to resolve these issues, but requested that CMS engage in further analysis and meaningful Tribal consultation before issuing the final rule. The commenters stated that comments on the rulemaking process are not considered meaningful consultation per Executive Order 13175 or in CMS Tribal consultation policy approved December 5, 2015, and that additional Tribal consultation is necessary.

Response: We appreciate these comments and acknowledge that the use of data from Worksheet S–10 to calculate uncompensated care costs does not take into account the unique funding structure of IHS hospitals and therefore using these data to determine Factor 3 may have an unintended impact on the uncompensated care payments to these hospitals. We intend to continue working with IHS and
Tribal stakeholders to devise an appropriate solution for estimating uncompensated care for these facilities and will undertake further rulemaking as appropriate to address this issue.

Comment: One commenter requested that Puerto Rico hospitals be excluded from the use of Worksheet S–10 to calculate uncompensated care costs. The commenter noted that Puerto Rico’s socioeconomic reality and the statutory treatment of its hospitals under Medicaid and Medicare Part A may result in an unintended penalty for its providers, and standard forms, data collections or categories may not be appropriate in Puerto Rico. As an alternative, the commenter supported delaying the use of Worksheet S–10 data to calculate Factor 3 for hospitals in Puerto Rico until disparities are addressed. The commenter noted that CMS work with Puerto Rico to conduct a specific study of undercompensated care before moving hospitals to conduct a specific study of uncompensated care in Puerto Rico. As an alternative, the commenter suggested that CMS work with Puerto Rico to conduct a specific study of undercompensated care before moving hospitals in Puerto Rico for FY 2017. In the event that we continue to use Medicare SSI days as a proxy for uncompensated care in subsequent years, we anticipate that we would propose to continue to employ this proxy for Puerto Rico.

Response: We understand the unique challenges faced by hospitals in Puerto Rico with regard to calculating uncompensated care costs. We note that we are finalizing our proposal to use a proxy for Medicare SSI days for hospitals in Puerto Rico for FY 2017. In the event that we continue to use Medicare SSI days as a proxy for uncompensated care in subsequent years, we anticipate that we would propose to continue to employ this proxy for Puerto Rico.

In summary, we are not finalizing our proposal to begin incorporating Worksheet S–10 data into the computation of Factor 3 for FY 2018, and we are not finalizing the proposed regulations text changes at §412.106(gl)(4) through (7) regarding FY 2018 and subsequent fiscal years. In light of the significant concerns expressed by commenters, we are postponing the decision regarding when to begin incorporating data from Worksheet S–10 and proceeding with revisions to the cost report instructions to address the commenters’ concerns in an appropriate manner. We believe that revised Worksheet S–10 data will be available to use in the calculation of Factor 3 in the near future, and no later than FY 2021. With regard to how Factor 3 will be computed in FY 2018 and subsequent fiscal years, we intend to explore whether there is an appropriate proxy for uncompensated care that could be used to calculate Factor 3. Regardless of the calculation that revised Worksheet S–10 data can be used for this purpose. We will undertake further notice-and-comment rulemaking to address the issue of the appropriate data to use to determine Factor 3 for FY 2018 and subsequent fiscal years. We also anticipate proposing to continue to use data from three cost reports to calculate Factor 3, as we are doing for the calculation of Factor 3 for FY 2017, which would have a transitioning effect as we described in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25091).

G. Hospital Readmissions Reduction Program: Updates and Changes (§§412.150 Through 412.154)

1. Statutory Basis for the Hospital Readmissions Reduction Program

Section 3025 of the Affordable Care Act, as amended by section 10309 of the Affordable Care Act, added section 1886(q) to the Act, which establishes the “Hospital Readmissions Reduction Program” effective for discharges from “applicable hospitals” beginning on or after October 1, 2012. Under the Hospital Readmissions Reduction Program, payments to applicable hospitals may be reduced to account for certain excess readmissions. We refer readers to section IV.E.1. of the FY 2016 IPPS/LTCH PPS final rule (80 FR 49530 through 49531) for a detailed discussion and additional information on the statutory history of the Hospital Readmissions Reduction Program.

2. Regulatory Background

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51660 through 51676), we addressed the issues of the selection of readmission measures and the calculation of the excess readmissions ratio, which are used, in part, to calculate the readmissions adjustment factor. Specifically, in that final rule, we finalized policies that relate to the portions of section 1886(q) of the Act that address the selection of and measures for the applicable conditions, the definitions of “readmission” and “applicable period,” and the methodology for calculating the excess readmissions ratio. We also established policies with respect to measures for readmission for the applicable conditions and our methodology for calculating the excess readmissions ratio.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53374 through 53401), we finalized policies that relate to the portions of section 1886(q) of the Act that address the calculation of the hospital readmission payment adjustment factor and the process by which hospitals can review and correct their data. Specifically, in that final rule, we addressed the base operating DRG payment amount, aggregate payments for excess readmissions and aggregate payments for all discharges, the adjustment factor, applicable hospital, limitations on review, and reporting of hospital-specific information, including the process for hospitals to review readmission information and submit corrections. We also established a new Subpart I under 42 CFR part 412 (§§412.150 through 412.154) to codify rules for implementing the Hospital Readmissions Reduction Program.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50649 through 50676), we finalized our policies that relate to refinement of the readmissions measures and related methodology for the current applicable conditions, the expansion of the “applicable conditions” for FY 2015 and subsequent fiscal years, and clarified the process for reporting hospital-specific information, including the opportunity to review and submit corrections. We also established policies related to the calculation of the adjustment factor for FY 2014.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50024 through 50048), we made refinements to the readmissions measures and related methodology for applicable conditions for FY 2015 and subsequent fiscal years, discussed the maintenance of technical specifications for quality measures, and described a waiver from the Hospital Readmissions Reduction Program for hospitals formerly paid under section 1814(b)(3) of the Act (§412.154(d)). We also specified the “applicable period” for FY 2015 and made changes to the calculation of the aggregate payments for excess readmissions to include two additional applicable conditions for the FY 2015 payment determination.

Finally, we expanded the list of applicable conditions for the FY 2015 payment determination to include the Hospital-Level, 30-Day, All-Cause, Unplanned Readmission Following Coronary Artery Bypass Graft (CABG) Surgery measure.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49530 through 49543), we made a refinement to the pneumonia readmissions measure that expanded the measure cohort for the FY 2017 payment determination and subsequent years (80 FR 49532 through 49536); adopted an extraordinary circumstance exception policy to address hospitals that experience a disaster or other extraordinary circumstance beginning in FY 2016 and for subsequent years (80 FR 49542 through 49543); and specified the calculation of aggregate payments for excess readmissions for FY 2016 (80 FR 49537 through 49542).
3. Policies for the FY 2017 Hospital Readmissions Reduction Program

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25094 through 25098), we:

- Proposed that the public reporting of excess readmission ratios be posted on an annual basis to the Hospital Compare Web site as soon as is feasible following the preview period.
- Discussed the methodology to include the addition of the CABG category, as applicable condition in the calculation of the readmissions payment adjustment for FY 2017.

We note that, during the comment period for the FY 2017 IPPS/LTCH PPS proposed rule, we received public comments that were not related to our specific proposals for the Hospital Readmissions Reduction Program and therefore considered out of the scope of the proposed rule. Some of the out of scope comments were related to a wide range of aspects of the Hospital Readmissions Reduction Program and its readmissions measures. For example, there were recommendations that we risk-adjust for socioeconomic and sociodemographic status; that statutory changes be made to the program payment structure and previously finalized program definitions; and that we consider adjusting for skilled nursing facilities' (SNF) quality in calculating scores under the Hospital Readmissions Reduction Program.

While we appreciate the commenters' feedback, we consider these topics to be out of the scope of the proposed rule. Therefore, we are not addressing most of these comments in this final rule.

Comment: Several commenters appreciated that CMS did not propose new conditions or make substantial changes to the program in this year's rule and suggested that this may be an indication that further improvements in aggregate readmission rates may not be achievable.

Response: We appreciate the input and will take this feedback into consideration in future measure selection and rulemaking.

4. Maintenance of Technical Specifications for Quality Measures

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50039) for a discussion of the maintenance of technical specifications for quality measures for the Hospital Readmissions Reduction Program. Technical specifications of the readmission measures are provided on our Web site in the Hospital Compare Methodology Reports at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-

Instruments/HospitalQualityInitis/
Measure-Methodology.html. Additional resources about the Hospital Readmissions Reduction Program and measure technical specifications are on the QualityNet Web site on the Resources page at: http://www.quality
net.org/dcs/ContentServer?c=Page&
pagename=QnetPublic%2FPage%2F
QnetTier3&cid=1228772412995.

We want to remind readers that, in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49532), we discussed our policies regarding the use of sociodemographic factors in quality measures. We understand the important role that socioeconomic and sociodemographic status (SES/SDS) plays in the care of patients. However, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of diverse sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures.

The National Quality Forum (NQF) is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of sociodemographic factors on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

5. Applicable Period for FY 2017

Under section 1886(q)(5)(D) of the Act, the Secretary has the authority to specify the applicable period with respect to a fiscal year under the Hospital Readmissions Reduction Program. In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51671), we finalized our policy to use 3 years of claims data to calculate the readmission measures. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53675), we codified the definition of “applicable period” in the regulations at 42 CFR 412.152 as the 3-year period from which data are collected in order to calculate excess readmissions ratios and adjustments for the fiscal year, which includes aggregate payments for excess readmissions and aggregate payments for all discharges used in the calculation of the payment adjustment.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49537), for FY 2016, consistent with the definition specified at §412.152, we established an “applicable period” for the Hospital Readmissions Reduction Program of the 3-year period from July 1, 2011 through June 30, 2014. In other words, the excess readmissions ratios and the payment adjustment (including aggregate payments for excess readmissions and aggregate payments for all discharges) for FY 2016 were determined using data from the 3-year time period of July 1, 2011 through June 30, 2014.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25095), for FY 2017, consistent with the definition specified at §412.152, we proposed that the “applicable period” for the Hospital Readmissions Reduction Program will be the 3-year period from July 1, 2012 through June 30, 2015. In other words, we proposed that the excess readmissions ratios and the payment adjustment (including aggregate payments for excess readmissions and aggregate payments for all discharges) for FY 2017 would be calculated using data from the 3-year time period of July 1, 2012 through June 30, 2015.

We did not receive public comments related to this proposal. Therefore, we are finalizing as proposed, without modification, the applicable period of the 3-year time period of July 1, 2012 to June 30, 2015 to calculate the excess readmission ratios and the readmission payment adjustment factors for FY 2017.
under the Hospital Readmissions Reduction Program.

6. Calculation of Aggregate Payments for Excess Readmissions for FY 2017

Section 1886(q)(4)(B) of the Act specifies the ratio used to calculate the adjustment factor under the Hospital Readmissions Reduction Program. It states that the ratio is equal to 1 minus the ratio of (i) the aggregate payments for excess readmissions and (ii) the aggregate payments for all discharges. The definition of "aggregate payments for excess readmissions" and "aggregate payments for all discharges," as well as a methodology for calculating the numerator of the ratio (aggregate payments for excess readmissions) and the denominator of the ratio (aggregate payments for all discharges) are codified at §412.154(c)(2).

Section 1886(q)(4) of the Act sets forth the definitions of "aggregate payments for excess readmissions" and "aggregate payments for all discharges" for an applicable hospital for the applicable period. The term "aggregate payments for excess readmissions" is defined in section 1886(q)(4)(A) of the Act and §412.152 of our regulations as, for a hospital for an applicable period, the sum, for applicable conditions of the product, for each applicable condition, of: (i) The base operating DRG payment amount for such hospital for such applicable period for such condition; (ii) the number of admissions for such condition for such hospital for such applicable period; and (iii) the excess readmissions ratio for such hospital for such applicable period minus 1.

The excess readmissions ratio is a hospital-specific ratio calculated for each applicable condition. Specifically, section 1886(q)(4)(C) of the Act defines the excess readmissions ratio as the ratio of "risk-adjusted readmissions based on actual readmissions" for an applicable hospital for each applicable condition, to the "risk-adjusted expected readmissions" for the applicable hospital for the applicable period. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51673) for additional information on the methodology for the calculation of the excess readmissions ratio. "Aggregate payments for excess readmissions" is the numerator of the ratio used to calculate the adjustment factor under the Hospital Readmissions Reduction Program.

The term "aggregate payments for all discharges" is defined at section 1886(q)(4)(B) of the Act as for a hospital for any applicable period, the sum of the base operating DRG payment amounts for all discharges for all conditions from such hospital for such applicable period. We codified this definition of "aggregate payments for all discharges" under the regulations at §412.152. "Aggregate payments for all discharges" is the denominator of the ratio used to calculate the adjustment factor under the Hospital Readmissions Reduction Program.

The Hospital Readmissions Reduction Program currently includes the following five applicable conditions: Acute myocardial infarction (AMI), heart failure (HF), pneumonia (PN), total hip arthroplasty/total knee arthroplasty (THA/TKA), and chronic obstructive pulmonary disease (COPD). In the FY 2015 IPPS/LTCH PPS final rule effective for FY 2017 (79 FR 50033 through 50039), we finalized the inclusion of an additional applicable condition, Hospital-Level, 30-Day, All-Cause, Unplanned Readmission Following Coronary Artery Bypass Graft (CABG) Surgery.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25095 through 25098), we discussed the proposed methodology to include this additional measure in the calculation of the readmissions payment adjustment for FY 2017. Specifically, we proposed how the addition of CABG applicable conditions would be included in the calculation of the aggregate payments for excess readmissions (the numerator of the readmissions payment adjustment). We note that this proposal does not alter our established methodology for calculating aggregate payments for all discharges (that is, the denominator of the ratio).

When calculating the numerator (aggregate payments for excess readmissions), we determine the base operating DRG payments for the applicable period. "Aggregate payments for excess readmissions" (the numerator) is defined as the sum, for applicable conditions, of the product, for each applicable condition, of: (i) The base operating DRG payment amount for such hospital for such applicable period for such condition; (ii) the number of admissions for such condition for such hospital for such applicable period; and (iii) the excess readmissions ratio for such hospital for such applicable period minus 1.

When determining the base operating DRG payment amount for an individual hospital for such applicable period for such condition, we use Medicare inpatient claims from the MedPAR file with discharge dates that are within the same applicable period to calculate the excess readmissions ratio. We use MedPAR claims data as our data source for determining aggregate payments for excess readmissions and aggregate payments for all discharges, as this data source is consistent with the claims data source used in IPPS rulemaking to determine IPPS rates.

For FY 2017, we proposed to use MedPAR claims with discharge dates that are on or after July 1, 2012, and no later than June 30, 2015, consistent with our historical use of a 3-year applicable period. Under our established methodology, we use the update of the MedPAR file for each Federal fiscal year, which is updated 6 months after the end of each Federal fiscal year within the applicable period, as our data source (that is, the March updates of the respective Federal fiscal year MedPAR files) for the final rules.

The FY 2012 through FY 2015 MedPAR data files can be purchased from CMS. Use of these files allows the public to verify the readmissions adjustment factors. Interested individuals may order these files through the CMS Web site at: http://www.cms.hhs.gov/LimitedDataSets/ by clicking on MedPAR Limited Data Set (LDS)-Hospital (National). This Web page describes the files and provides directions and detailed instructions for how to order the data sets.

In the proposed rule, for FY 2017, we proposed to determine aggregate payments for excess readmissions and aggregate payments for all discharges using data from MedPAR claims with discharge dates that are on or after July 1, 2012, and no later than June 30, 2015. However, we noted that, for the purpose of modeling the proposed FY 2017 readmissions payment adjustment factors for the proposed rule, we used excess readmissions ratios for applicable hospitals from the FY 2016 Hospital Readmissions Reduction Program applicable period. For this FY 2017 IPPS/LTCH PPS final rule, applicable hospitals have had the opportunity to review and correct data used in IPPS rulemaking to determine IPPS rates. Since the MedPAR claims with discharge dates that are on or after July 1, 2012, and no later than June 30, 2015, before they are made public under our policy regarding the preview and reporting of hospital-specific information, which we discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53374 through 53401), we modeled the proposed FY 2017 readmissions payment adjustment factors for the proposed rule, we used excess readmissions ratios for applicable hospitals from the FY 2016 Hospital Readmissions Reduction Program applicable period. For this FY 2017 IPPS/LTCH PPS final rule, applicable hospitals have had the opportunity to review and correct data used in IPPS rulemaking to determine IPPS rates. Since the MedPAR claims with discharge dates that are on or after July 1, 2012, and no later than June 30, 2015, before they are made public under our policy regarding the preview and reporting of hospital-specific information, which we discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53374 through 53401), we modeled the proposed FY 2017 readmissions payment adjustment factors for the proposed rule, we used excess readmissions ratios for applicable hospitals from the FY 2016 Hospital Readmissions Reduction Program applicable period. For this FY 2017 IPPS/LTCH PPS final rule, applicable hospitals have had the opportunity to review and correct data used in IPPS rulemaking to determine IPPS rates.

For FY 2017, we proposed to use MedPAR data from July 1, 2012 through June 30, 2015. Specifically, for the proposed rule, we used the March 2013 update of the FY 2012 MedPAR file to identify claims within FY 2012 with discharge dates that are on or after July 1, 2012, the March 2014 update of the FY 2013 MedPAR file to identify claims within FY 2013, the March 2015 update of the FY 2014 MedPAR file to identify
claims within FY 2014, and the December 2015 update of the FY 2015 MedPAR file to identify claims within FY 2015 with discharge dates no later than June 30, 2015. For this final rule, as we proposed, we used the same MedPAR files as listed above for claims within FY 2012, FY 2013 and FY 2014, and for claims within FY 2015, we used the March 2016 update of the FY 2015 MedPAR file.

For a discussion of how we identified the applicable conditions to calculate the aggregate payments for excess readmissions for FY 2016, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49538 through 49541). For FY 2017, with the addition of the CABG measure to the applicable conditions under the Hospital Readmissions Reduction Program, we proposed to follow this same approach.

In the proposed rule, for FY 2017, we proposed to continue to apply the same exclusions to the claims in the MedPAR file as we applied for FY 2016 for the AMI, PN, COPD, Stroke, CABG applicable conditions. We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49539) for a list of these exclusions. Updates to these exclusions will be posted on the QualityNet Web site at: http://www.QualityNet.org > Hospital-Inpatient > Claims-Based Measures > Readmission Measures > Measure Methodology.

In addition to the exclusions described above, for FY 2017, we proposed the following steps to identify admissions specifically for CABG for the purposes of calculating aggregate payments for excess readmissions. These exclusions were previously finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50037):

• Admissions for patients who are discharged against medical advice (excluded because providers do not have the opportunity to deliver full care and prepare the patient for discharge);

• Admissions for patients who die during the initial hospitalization (these patients are not eligible for readmission);

• Admissions for patients with subsequent qualifying CABG procedures during the measurement period (a repeat CABG procedure during the measurement period very likely represents a complication of the original CABG procedure and is a clinically more complex and higher risk surgery; therefore, we select the first CABG admission for inclusion in the measure and exclude subsequent CABG admissions from the cohort); and

• Admissions for FY 2017 for patients without at least 30 days post-discharge enrollment in Medicare FFS (excluded because the 30-day readmission outcome cannot be assessed in this group).

As noted previously, these exclusions are consistent with our current methodology, and any updates to these exclusions will be posted on the QualityNet Web site at: http://www.QualityNet.org > Hospital-Inpatient > Claims-Based Measures > Readmission Measures > Measure Methodology.

Furthermore, under our proposal, we would only identify Medicare FFS claims that meet the criteria (that is, claims paid for under Medicare Part C, Medicare Advantage, would not be included in this calculation), consistent with the methodology to calculate excess readmissions ratios based solely on admissions and readmissions for Medicare FFS patients. Therefore, consistent with our established methodology, for FY 2017, we proposed to continue to exclude admissions for patients enrolled in Medicare Advantage as identified in the Medicare Enrollment file, and consistent with the policies used in previous years, all additions for Medicare Advantage patients are identified in the calculation of the excess readmissions ratios under our established methodology.

In order to identify the admissions for each applicable condition for FY 2017 to calculate the aggregate payments for excess readmissions for an individual hospital, we proposed to identify each applicable condition, including the CABG condition, using the appropriate ICD–9–CM codes. (Although the compliance date for the ICD–10–CM and ICD–10–PCS code sets was October 1, 2015, the proposed policies apply to data submitted prior to this compliance date.) Under our existing policy, we identify eligible hospitalizations and readmissions of Medicare patients discharged from an applicable hospital having a principal diagnosis for the measured condition in an applicable period (76 FR 51609). The discharge diagnoses for each applicable condition are based on a list of specific ICD–9–CM codes for that condition. The ICD–9–CM codes for the AMI, HF, PN, Stroke, THA/TKA, and CABG applicable conditions can be found on the QualityNet Web site at: http://www.QualityNet.org > Hospital-Inpatient > Claims-Based Measures > Readmission Measures > Measure Methodology. Consistent with our established policy (76 FR 51673 through 51676), we proposed to use the ICD–9–CM codes to identify the applicable conditions in calculation of the excess readmissions ratios, which are provided within the methodology reports on the QualityNet Web site, to identify each applicable condition to calculate the aggregate payments for the excess readmissions ratios for FY 2017. For a complete list of the ICD–9–CM codes we proposed to use to identify the applicable conditions, we refer readers to the following tables of those reports:

  • Table D.1.1—ICD–9–CM Codes for AMI Cohort (page 74).
  • Table D.2.1—ICD–9–CM Codes for HF Cohort (page 78).
  • Table D.3.1—ICD–9–CM Codes for Pneumonia Cohort (page 82).
  • Table D.4.1—ICD–9–CM Codes for COPD Cohort (page 87).

- 2015 Measure Updates: THA/TKA and CABG Readmission (THA and/or TKA—Version 4.0, CABG—Version 2.0: 2015 Procedure-Specific Readmission Measures Updates and Specifications Report)—
  • Table D.1.1—ICD–9–CM Codes Used to Identify Eligible THA/TKA Procedures (page 45).
  • Table D.2.1—ICD–9–CM Codes Used to Identify Eligible CABG Procedures (page 53).

For FY 2017, we proposed to calculate aggregate payments for excess readmissions, using MedPAR claims from July 1, 2012 to June 30, 2015, to identify applicable conditions based on the same ICD–9–CM codes used to identify the conditions for the readmissions measures, and to apply the proposed exclusions for the types of admissions (as previously discussed). To calculate aggregate payments for excess readmissions for each hospital, we proposed to calculate the base operating DRG payment amounts for all claims in the 3-year applicable period for each applicable condition (AMI, HF, PN, COPD, Stroke, THA/TKA, and CABG) based on the claims we identified as described above. Once we have calculated the base operating DRG amounts for all the claims for the six applicable conditions, we proposed to sum the base operating DRG payments amounts by each condition, resulting in six summed amounts, one amount for each of the six applicable conditions. We proposed to then multiply the amount for each condition by the respective excess readmissions ratio minus 1 when that excess readmissions ratio is greater than 1, which indicates that a hospital has performed, with respect to readmissions for that condition, worse than the national average.
We invited public comment on these proposals.

Comment: Commenters supported the proposed calculation for the new CABG readmission measure, and program efforts to maintain focus on cardiology and cardiovascular care. Another commenter noted that the proposed calculation will include the CABG readmission measure in the payment formula in alignment with other program measures. One commenter expressed concern that the addition of the CABG measure may result in double counting of cases under both CABG and AMI, and recommended that cases should only count under either AMI or CABG to prevent double counting.

Response: We appreciate the commenters’ support and will continue to monitor and analyze the impact of our measure selection for further adjustments to the Hospital Readmissions Reduction Program. We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53376) for further discussion on preventing double counting.

We are finalizing, as proposed and without modification, the methodology to include the addition of the CABG applicable condition in the calculation of the readmissions payment adjustment for FY 2017.

7. Extraordinary Circumstance Exception Policy

We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49542 through 49543) for a detailed discussion of our Extraordinary Circumstance Exception policy for the Hospital Readmissions Reduction Program.

During the review of a hospital’s request for an extraordinary circumstance exception, we maintain the general principle that providing high quality of care and ensuring patient safety is of paramount importance. We intend to provide relief only for hospitals whose ability to accurately or timely submit all of their claims (from which readmission measures data are derived) has been negatively impacted as a direct result of experiencing a significant disaster or other extraordinary circumstance beyond the control of the hospital. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49542 through 49543) we finalized that the request process for an extraordinary circumstance exception begins with the submission of an extraordinary circumstance exception request form by a hospital within 90 calendar days of the natural disaster or other extraordinary circumstance. Under this policy, a hospital is able to request a Hospital Readmissions Reduction Program extraordinary circumstance exception at the same time it may request a similar exception under the Hospital IQR Program, the Hospital VBP Program, and the HAC Reduction Program. The extraordinary circumstance exception request form is available on the QualityNet Web site.

The following information is required to submit the request:

• Hospital CCN;
• Hospital name;
• Hospital Chief Executive Officer (CEO) and any other designated personnel contact information, including name, email address, telephone number, and mailing address (must include a physical address; a post office box address is not acceptable);
• Hospital’s reason for requesting an exception, including:
  • CMS program name (for example, the Hospital Readmissions Reduction Program)}
Program, the Hospital VBP Program, or the Hospital IQR Program);  
++ The measure(s) and submission quarters affected by the extraordinary circumstance that the hospital is seeking an exception for should be accompanied with the specific reasons why the exception is being sought; and  
++ How the extraordinary circumstance negatively impacted performance on the measure(s) for which an exception is being sought;  
• Evidence of the impact of the extraordinary circumstances, including but not limited to, photographs, newspaper, and other media articles; and  
• The request form must be signed by the hospital’s CEO or designated non-CEO contact and submitted to CMS.

The same set of information is currently required under the Hospital IQR Program and the Hospital VBP Program on the request form from a hospital seeking an extraordinary circumstance exception with respect to these programs. The specific list of required information is subject to change from time to time at the discretion of CMS.

Following receipt of the request form, CMS will: (1) Provide a written acknowledgement of receipt of the request using the contact information provided in the request form to the CEO and any additional designated hospital personnel; and (2) provide a formal response to the CEO and any additional designated hospital personnel using the contact information provided in the request notifying them of our decision. We review each request for an extraordinary circumstance exception on a case-by-case basis at our discretion. To the extent feasible, we also review requests in conjunction with any similar requests made under other IPPS quality reporting and payment programs, such as the Hospital IQR Program and the Hospital VBP Program.

This policy does not preclude CMS from granting extraordinary circumstance exceptions to hospitals that do not request them if we determine at our discretion that a disaster or other extraordinary circumstance has affected an entire region or locale. If CMS makes such a determination to grant an extraordinary circumstance exception to hospitals in an affected region or locale, we would convey this decision through routine communication channels to hospitals, vendors, and QIOs, including, but not limited to, issuing memos, emails, and notices on the QualityNet Web site. This provision aligns with the Hospital IQR Program’s extraordinary circumstances extensions or exemptions policy.

8. Timeline for Public Reporting of Excess Readmission Ratios on Hospital Compare for the FY 2017 Payment Determination

Section 1886(q)(6) of the Act requires the Secretary to make information available to the public regarding readmission rates of each subsection (d) hospital under the program, and states that such information shall be posted on the Hospital Compare Internet Web site in an easily understandable format. Accordingly, in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53401), we indicated that public reporting for excess readmission ratios could be available on the Hospital Compare Web site as early as mid-October. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25098), we clarified that public reporting of excess readmission ratios will be posted on an annual basis to the Hospital Compare Web site as soon as is feasible following the review period. This may occur as early as October, but it could occur later for a particular year in order to streamline reporting and align with other hospital quality reporting and performance programs.

Comment: Numerous commenters urged CMS to continue to ensure there is an adequate period of at least 30 days for hospitals to review their rate calculations and make necessary corrections before the rates are publicly displayed. One commenter supported the opportunities to allow hospitals to review their readmission data in a timelier fashion as part of the formal review period. Several commenters requested that CMS calculate and more frequently report to hospitals their performance on the readmission measures.

Response: We appreciate the commenters’ input and support. In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51672 through 51673), we adopted the same preview and correction process and timeframe used for subsection (d) hospitals for the rates calculated for the Hospital Readmissions Reduction Program. That is, we provide hospitals with an opportunity to review their readmission rates for 30 days prior to posting them on the Hospital Compare Web site. We note that hospitals have the opportunity to correct the rate calculations and not the underlying data. This process meets the statutory requirement in section 1886(q)(6)(B) of the Act which requires the Secretary to ensure that a subsection (d) hospital has the opportunity to review and submit corrections before the information is made public. In addition to the statutory requirements, we also considered hospitals’ experience with the measure and the data production timeline when proposing the 30-day preview period. While the Hospital Readmissions Reduction Program is fairly new, subsection (d) hospitals are already familiar with the three 30-day risk-standardized readmission measures that the program uses to determine payment adjustment. Because hospitals are working with measures in which they have prior experience from the Hospital IQR Program, we believe that a 30-day preview period is sufficient for hospitals to review and correct their excess readmission ratios.

Due to the complexity of these measures and the need for bootstrapping in measure calculations, significant programming resources are required. It takes several months to complete the production and extensive quality assurance procedures needed to calculate results for more than 3,500 hospitals. As a result, we will not be able to begin the preview period earlier than late June. Also, we will not be able to extend the preview period to more than 30 days. This is because if hospitals find data problems that we determine to be attributable to our calculation or programming errors, we will need adequate time between mid-July and the end of September to: (1) Recalculate the excess readmission ratios; (2) regenerate and redisseminate corrected results to hospitals in time for payment adjustment in early October (the beginning of the fiscal year); and (3) publicly report the excess readmission ratios on the Hospital Compare Web site to meet the statutory reporting requirements under section 1886(q)(6) of the Act.

Comment: A few commenters asked that CMS establish a regular deadline for the release of annual data on hospital excess readmission ratios and also make clear when the data will be made available to the public on the Hospital Compare Web site. Our commenter specifically requested that excess readmission ratios be posted to the Hospital Compare Web site more often than annually and prior to October.

Response: We appreciate the commenters’ feedback. The public reporting of excess readmission ratios will be posted on an annual basis to the Hospital Compare Web site as soon as is feasible following the review period. This may occur as early as October, but it could occur later for a particular year in order to streamline reporting and align with other hospital quality reporting and performance programs.
AHRQ PSI Composite Measure’’) for Patient Safety for Selected Indicators (Composite Measure) (then referred to as PSI 90 Measure Performance Period for the PSI 90: Patient Safety for Selected Indicators (Composite Measure) (then referred to as the ‘‘PSI 90 measure’’) for the FY 2018 program year (78 FR 50694). We have calculated and finalized performance standards for the FY 2018 program year based on a baseline period that uses ICD–9–CM claims data. The previously finalized performance period for the FY 2018 program year runs from July 1, 2014 through June 30, 2016. Because hospitals began ICD–10–CM/PCS implementation on October 1, 2015, the performance period as currently finalized for the FY 2018 program year would necessitate using both ICD–9 and ICD–10 claims data to calculate performance standards for the PSI 90 measure.

Since the ICD–10 transition was implemented on October 1, 2015, we have been monitoring our systems, and claims are processing normally. Currently, the measure steward, AHRQ, is reviewing any potential issues related to ICD–10 conversion of coded operating room procedures (https://www.cms.gov/icd10manual/fullcode_cms/P1616.html), which directly impact the AHRQ PSI 90 component indicators. Nevertheless, given the complexity of converting the PSI 90 component indicators from ICD–9 to ICD–10 and considering that there are approximately 70,00024 ICD–10 codes, the measure steward has recommended against combining measure performance data that use both ICD–9 and ICD–10 data at this time. In addition, to meet program requirements and implementation schedules, our system requires an ICD–10 risk-adjusted version of the AHRQ QI PSI software25 by December 2016 for use in the FY 2018 payment year. However, AHRQ needs a full year of nationally representative ICD–10 coded data before it can complete development of risk-adjusted modified models based on a national reference population. At this time, a risk adjusted ICD–10 version of the modified PSI 90 component indicators is not expected to be available until late CY 2017. We refer readers to section VIII.A.6.b. of the preamble of this final rule relating to the Hospital IQR Program for a discussion of the modified PSI 90 measure update.

To address the above issues, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25099 through 25100), we proposed to shorten the performance period for the FY 2018 program year. We proposed...
to use a 15-month performance period from July 1, 2014 through September 30, 2015 for the FY 2018 program year. The 15-month performance period would only apply to the FY 2018 program year and would only use ICD–9 data. For the FY 2018 program year, the performance standards that were previously established and announced in past rules would not change because they were calculated based on the baseline period of July 1, 2010 through June 30, 2012, which would remain the same. In order to align the use of this measure with other hospital quality programs, we proposed (and are finalizing) similar modifications to the FY 2018 reporting period for the PSI 90 measure for the HAC Reduction Program, as discussed in section IV.I.3.b. of the preamble of this final rule, and for the Hospital IQR Program, as discussed in section VIII.A.6.b.(4) of the preamble of this final rule.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25100), we discussed that we are aware that the FY 2018 program year also has a performance period that contains ICD–9 and ICD–10 data and that we would continue to review our options for calculating the performance period for the FY 2019 program year and further address this in next year’s rulemaking. Because an ICD–10 version of the current PSI 90 is not being developed, we intend to propose to remove the PSI 90 measure from the Hospital VBP Program beginning with the FY 2019 program year in next year’s rulemaking.

We noted that in proposing a shortened performance period for the PSI 90 measure, a prior reliability analysis of the PSI 90 measure showed that the majority of hospitals attain a moderate or high level of reliability for the PSI 90 measure after a 12-month period.26 Further, this reliability analysis is based on older data that does not include improvements in present on admission (POA) coding, which is likely to improve reliability. We believe that the data we will collect is likely to be reliable during a 15-month performance period. We do not anticipate any delay for hospitals to review their TPSs for the FY 2018 program year during the review and correction period.

Prior to deciding to propose an abbreviated performance period for the FY 2018 program year, we took several factors into consideration, including the recommendations of the measure steward, the feasibility of using a combination of ICD–9 and ICD–10 data without the availability of the appropriate measure software, minimizing provider burden, program implementation timelines, and the reliability of using shortened performance periods, as well as the importance of continuing to publicly report this measure. We stated our belief that using a 15-month performance period for FY 2018 best serves the need to provide important information on hospital patient safety and adverse events by allowing sufficient time to process the claims data and calculate the measures, while minimizing the reporting burden and program disruption.

Furthermore, we stated that we plan to propose to adopt the modified PSI 90 measure, which includes several substantive measure updates, for the Hospital VBP Program in subsequent rulemaking, as soon as it is feasible. We discussed this future proposed adoption in section IV.H.2.b. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25100) and reaffirm this intention in section IV.H.2.b. of the preamble of this final rule.

We invited public comments on this proposed plan to shorten the performance period for the PSI 90 measure for the FY 2018 program year. Comment: A few commenters supported the proposal to adopt a 15-month performance period for FY 2018 to account for the transition from ICD–9–CM to ICD–10–CM/PCS.

Response: We thank the commenters for their support.

Comment: Many commenters did not support the proposal to shorten the performance period for PSI 90 in the FY 2018 program year to 15 months of data because commenters are concerned that shortening the performance period will degrade the measure’s reliability. In addition, several commenters were concerned that only 81 percent of hospitals achieve median reliability with 12 months of data and 86 percent achieve median reliability with 18 months of data. Many commenters recommended suspending or removing the use of PSI 90 in the Hospital VBP Program beginning with the FY 2018 program year. Some commenters also recommended suspending or removing the measure for at least the FY 2018 and FY 2019 program years because of the inability to calculate the measure using ICD–10 data. One commenter recommended that CMS change the PSI performance period to a 14-month performance period (October 1, 2013 through September 30, 2015) because this comment did not believe that 24 months would ensure the measure results are more reliable and enable the use of only ICD–9–CM data.

Response: We note that the measure reliability analysis the commenters have cited does not apply a case minimum threshold like the one the Hospital VBP Program applies. Thus, we believe that a 15-month performance period is sufficiently reliable, particularly in light of the case minimum of three cases for any of the underlying PSI 90 indicators as finalized in the FY 2013 IPPS/LTCH PPS final rule (78 FR 53600). Because we believe the measure is sufficiently reliable with 15 months of data, we do not believe we need to suspend or remove the measure or extend the measure’s performance period for the FY 2018 program year. We appreciate the commenter’s suggestion that we use October 1, 2013 to September 30, 2015 as a 24-month performance period for the PSI 90 measure in the FY 2018 program year, but it overlaps substantially with the performance period for the PSI 90 measure in the FY 2017 program year (which runs from October 1, 2013 to June 30, 2015 (78 FR 50692)).

Comment: Many commenters did not support shortening the performance period for the FY 2018 program year because commenters believe there are numerous flaws in the measure, including gaming, selective reporting, and surveillance/ascertainment bias. Several commenters recommended that CMS remove the PSI 90 measure from the program and replace it with more reliable measures of patient safety. One commenter recommended that if CMS retains the PSI 90 measure in the FY 2018 program year, CMS change the measure so that the PSI 07 Central Venous Catheter-related Bloodstream Infection Rate excludes cases with a length of stay of less than 2 days. This commenter further recommended extending the length of stay exclusion criterion for PSI 07 Central Venous Catheter-related Bloodstream Infection Rate to 4 days to remain consistent with the length of stay outlined in other PSI components.

Response: We thank the commenters for their suggestions, but we do not believe the PSI 90 measure is flawed. The PSI 90 measure was developed using a scientifically rigorous process that involved the input of technical experts and stakeholders. Further, AHRQ has supported a series of validation studies, based on detailed abstraction of medical records, that have informed AHRQ’s PSI development process, including making further refinements to indicators and working.

with others to improve coding practices. We refer commenters to the AHRQ PSI Development zip file and AHRQ Composite Measures Workgroup document available at: http://www.qualityindicators.ahrq.gov/modules/psi_resources.aspx. We believe that the PSI 90 measure in its current form is reliable, valid, and appropriate to retain in the Hospital VBP Program for the FY 2018 program year because it appropriately encourages robust hospital attention to patient safety. We also believe that the length of stay exclusion criterion of 2 days in the PSI 07 Central Venous Catheter-related Bloodstream Infection Rate is adequate because positive blood cultures within the first 2 days of admission are likely to reflect a bloodstream infection that was present on admission, rather than a bloodstream infection associated with care provided by the hospital. We note that the modified PSI 90 no longer includes PSI 07 Central Venous Catheter-related Bloodstream Infection Rate. However, AHRQ plans to maintain PSI 07 Central Venous Catheter-related Bloodstream Infection Rate as a separate PSI and it is included in an 11-indicator version of PSI 90 that is not NQF-endorsed. Suggestions regarding potential PSI measure revisions can be made directly to: QSupport@ahrq.hhs.gov.

Comment: A few commenters did not support the continued use of the PSI 90 measure in the Hospital VBP Program for the FY 2018 and FY 2019 program years because the Hospital VBP Program will be misaligned with the Hospital IQR Program and the HAC Reduction Program, which have both proposed to adopt the modified PSI 90 measure in the FY 2017 IPPS/LTCH PPS proposed rule. A few commenters recommended that CMS adopt the modified PSI 90 measure in the Hospital VBP Program beginning with the FY 2018 program year.

Response: We thank the commenters for their suggestions, but we note that we are unable to adopt the modified PSI 90 measure beginning with the FY 2018 program year due to certain statutory requirements in the Hospital VBP Program that are not required in the Hospital IQR Program or the HAC Reduction Program. As we noted in the proposed rule, section 1886(o)(2)(A) of the Act requires the Hospital VBP Program to select measures that have been specified for the Hospital IQR Program. The Hospital IQR Program is finalizing the modified PSI 90 measure in this FY 2017 IPPS/LTCH PPS final rule (see section VII.A.6.b. of the preamble of this final rule). In addition, section 1886(o)(2)(C)(i) of the Act requires the Hospital VBP Program to refrain from beginning the performance period for a new measure until data on the measure have been posted on Hospital Compare for at least one year. The Hospital IQR Program is finalizing the modified PSI 90 measure in this final rule but measure data have not yet been posted on Hospital Compare, and we are required to wait one full year after data has been posted before that measure’s performance period may begin in the Hospital VBP Program. Finally, section 1886(o)(3)(C) of the Act requires that the Hospital VBP Program establish performance standards for each measure not later than 60 days prior to the beginning of the performance period. We anticipate adopting the modified PSI 90 measure in future rulemaking as soon as we have met the statutory requirements laid out in the Act.

Comment: One commenter expressed concern with the currently adopted PSI 90 measure because it may penalize hospitals that have a robust surveillance program or that have strict policies on what physicians include in their notes.

Response: We acknowledge commenter’s concerns regarding the currently adopted PSI 90, but note that there is little evidence that hospitals that may have a less robust surveillance program underreport diagnoses for the PSI 90 indicators. Further, there is high degree of sensitivity (true positives) with respect to indicator diagnoses among hospitals.

Comment: Numerous commenters requested that we remove the currently adopted version of the PSI 90 measure. Specifically, many commenters noted that using the currently adopted version of the measure in the Hospital VBP Program would not align with the Hospital IQR Program and the HAC Reduction Program, both of which are using the modified PSI 90 measure in their programs.

Response: While we understand commenters’ concerns, we have decided to retain the currently adopted version of the PSI 90 measure for the FY 2018 program year because we have the option to shorten the performance period so that performance standards can be calculated using the ICD-9 AHRQ QI software. We believe that this measure meets the program goal of providing important information on hospital performance on patient safety and adverse events. We recognize that the performance period for the current PSI 90 measure cannot be shortened in the FY 2018 program year because ICD-10 AHRQ QI software for the currently adopted measure will not be available. In light of this, we intend to propose to remove the PSI 90 measure from the Hospital VBP Program beginning with the FY 2019 program year in next year’s rulemaking. We also intend to propose to adopt the modified PSI 90 measure for the Hospital VBP Program in future rulemaking as soon as it is feasible, which we discuss further in section IV.H.2.b. of the preamble of this final rule.

After consideration of the public comments we received, we are finalizing the proposal to shorten the performance period for the PSI 90 measure in the FY 2018 program so that it runs from July 1, 2014 through September 30, 2015 as proposed.

b. Intent To Propose in Future Rulemaking To Adopt the Modified PSI 90 Measure

The PSI 90 measure underwent NQF maintenance review in 2014. The 2014 NQF maintenance review process led to several measure changes. Due to statutory requirements in the Hospital VBP Program, we would not be able to adopt the NQF-endorsed modified PSI 90 measure, now known as Patient Safety and Adverse Events Composite, until a future program year. We refer readers to section VIII.A.6.b. of the preamble of this final rule relating to the Hospital IQR Program for a discussion of the modified PSI 90 measure update.

Comment: Several commenters supported CMS’ intent to propose to adopt the modified PSI 90 measure. One commenter specifically supported the modified specification of component indicators PSI 12 Perioperative Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) Rate and PSI 15 Unrecognized Abdominopelvic Accidental Puncture/Laceration Rate as well as the removal of PSI 07 Central Venous Catheter-related Bloodstream Infection Rate. One commenter encouraged CMS to adopt the modified PSI 90 measure as soon as possible because this measure has been reordered by the NQF following modification. One commenter noted...

27 National Quality Forum QPS Measure Description for “Patient Safety for Selected Indicators (modified version of PS90) (Composite Measure)” found at: https://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=321&print=0&entityTypeID=3.

28 First, section 1886(o)(2)(A) of the Act requires the Program to select measures that have been specified for the Hospital IQR Program. Second, section 1886(o)(2)(C)(i) of the Act requires the Hospital VBP Program to refrain from beginning the performance period for a new measure until data on the measure have been posted on Hospital Compare for at least one year. Finally, section 1886(o)(3)(C) of the Act requires that the Hospital VBP Program establish performance standards for each measure not later than 60 days prior to the beginning of the performance period.
that the modifications to the measure identify harmful healthcare events that are potentially preventable. One commenter believed that the modified measure addresses prior concerns including the weighting of components, issues with public reporting, and biases in the distribution of incentive payments.

Response: We thank commenters for their support of our intent to propose the modified PSI 90 in future rulemaking. Comment: Several commenters expressed concern that the software hospitals use to monitor and assess their performance has not yet been updated to reflect ICD–10 coding, which hinders hospitals' ability to monitor performance and continually improve their quality of care. The commenter urged CMS to work with AHRQ to have the ICD–10 measure software available as soon as possible.

Response: We acknowledge the comments received and are working with AHRQ to have the ICD–10 measure software available as soon as possible. Comment: Several commenters recommended that CMS reevaluate the PSI 90 measure for appropriateness in the program because it is susceptible to surveillance bias, measures components that may not be preventable through evidence-based practices, lacks appropriate and necessary exclusions associated primarily with large academic centers, and is based on administrative claims data that do not capture the full scope of patient-level risk factors. The commenters also believe that it may disproportionately impact teaching hospitals because they tend to have a larger volume of surgical cases.

Response: While we acknowledge commenters’ preference for chart-abstracted measures, administrative claims data are valid for quality measurement and significantly less burdensome on hospitals for quality reporting. Many teaching hospitals do as well or better on the measure than non-teaching hospitals, and many of the PSI components are preventable through evidenced-based practices. We have previously addressed commenters’ concerns regarding the use of administrative claims, coding issues, and the impact on academic hospitals.

We refer commenters to this discussion in the FY 2014 IPPS/LTC HH PPS final rule (78 FR 50684) and the FY 2015 IPPS/LTC HH PPS final rule (79 FR 50064).

Comment: One commenter did not support CMS’ intent to propose to adopt the modified PSI 90 measure because this commenter believed the measure, despite modifications, continues to lack the level of accuracy, reliability, and validity necessary to ascertain high-performing facilities.

Response: We acknowledge commenter’s concerns and will consider them when we consider a future proposal to adopt the modified PSI 90 measure for the Hospital VBP Program. We refer the commenter to section VIII.A.6.b. of the preamble of this final rule where we discuss the modified PSI 90 and similar concerns in the context of the Hospital IQR Program and section IV.I.3.a. of the preamble of this final rule in the context of the HAC Reduction Program.

Comment: One commenter did not support CMS’ intent to propose to adopt the modified PSI 90 measure in the Hospital VBP Program because the underlying PSIIs rely on administrative claims data and are inaccurate in assessing postoperative complications. The commenter believed the component indicators of the modified PSI 90 are flawed by gaming, selective reporting, and contamination bias.

Specifically, the commenter did not support PSI 12 Perioperative PE or DVT Rate because the commenter believed it is susceptible to surveillance bias and not a valid measure of quality. The commenter suggested using a comprehensive prophylaxis measure because it is a better measure of quality in VTE prevention and more widely used. While the commenter supported the decreased weighting of PSI 12 Perioperative PE or DVT Rate and PSI 15 Unrecognized Abdominopelvic Accidental Puncture/Laceration because they were still weighted too high and that high-quality hospitals may be unfairly deemed poor performers due to methodological flaws in the weighting. The commenter did not support the continued inclusion of PSI 15 Unrecognized Abdominopelvic Accidental Puncture/Laceration because no large-scale assessment has been done to assess the validity of the component indicator and it is difficult to determine if a reoperation was directly related to the accidental puncture/laceration.

The commenter recommended that the exclusion criteria in PSI 04 Stratum 4A be broadened to include diagnoses that reflect a hypercoagulable state. The commenter recommended broadening the exclusion criteria in Stratum 4B to include cases that started in Major Diagnostic Category (MDC) 4 but advanced to Pre-MDC. The commenter recommended broadening the exclusion criteria in Stratum 4C to include sepsis diagnosis codes that are present on admission. The commenter recommended broadening the exclusion criteria of Stratum 4D to include cases that started in MDC 4 or 5 but advanced to Pre-MDC and cases that are present on admission. The commenter recommended removing the inclusion criteria of K92.1 to include cases that started in Major Diagnostic Category (MDC) 4 but advanced to Pre-MDC.
Stratum 4E to focus on the Present on Admission Indicator rather than the principal diagnosis position and also exclude Pre-MDC.

The commenter recommended broadening the exclusion criteria of PSI 03 Pressure Ulcer Rate to include those from Appendix I-Immune Compromised State Diagnosis and Procedure Code in the PSI Technical Specifications Update manual. The commenter recommended broadening PSI 06 Iatrogenic Pneumothorax Rate to include pneumothorax related to CPR. The commenter recommended broadening the exclusion criteria of PSI 07 Central Venous Catheter-related Blood Stream Infection Rate to include cases with a length of stay of less than 2 days. The commenter recommended broadening the exclusion criteria of PSI 08 In-Hospital Fall with Hip Fracture Rate to include anything falling within Appendix H: Cancer Diagnosis Codes regardless of metastasis and regardless of Present on Admission status. The commenter recommended broadening the exclusion criteria of PSI 09 Postoperative Hemorrhage and Hematoma Rate to include Abnormal Coagulation Profile R79.1 as an exclusion criterion with present on admission, and creating a new seroma ICD–10 code. The commenter recommended changing the exclusion criteria of PSI 10 Postoperative Acute Kidney Injury Rate to a time based element in hours as opposed to the number of postoperative days and including sinus bradycardia and sinus tachycardia cardiac arrhythmias in the exclusion criteria.

The commenter recommended changing the numerator inclusion criteria of the PSI 11 Postoperative Respiratory Failure Rate to vent time, reintubation criteria, and broadening the exclusion criteria to include cases that started in MDC 4 or 5 but advanced to the Pre-MDC. The commenter recommended broadening the exclusion criteria of PSI 12 Perioperative PE or DVT Rate to include inheritable hypercoagulable conditions: Factor V Leiden, Factor VIII, Factor IX, Factor XI, and the acquired hypercoagulable conditions: Cancer, recent trauma or surgery, central venous catheter placement, obesity, supplemental estrogen use including oral contraceptives, hormone replacement therapy, prolonged bed rest or immobility, heparin induced thrombocytopenia, previous history of DVT/PE, myeloproliferative disorders such as polycythemia vera or essential thrombocytosis, inflammatory bowel syndrome, HIV/AIDS, and nephrotic syndrome. For PSI 13 Postoperative Sepsis Rate, the commenter recommended deleting the inclusion criteria of post-procedural shock, unspecified T8110XXA as it may not be related to sepsis and does not reflect the true spirit of the measure. For PSI 14 Postoperative Wound Dehiscence, the commenter recommended extending the exclusion criteria to a length of stay of 4 days to remain consistent with criteria in other PSI components.

Response: We thank the commenter for the suggestions, especially with regard to measure specifications, such as weighting of components and inclusion and exclusion criteria, and we will share them with the measure steward, AHRQ. We acknowledge commenter’s concerns and will consider them when we consider a future proposal to adopt the modified PSI 90 measure in the Hospital VBP Program; however, as we noted above, the PSI 90 measure was developed using a scientifically rigorous process that involved the input of technical experts and stakeholders.

We refer the commenter to section VIII.A.6.b. of the preamble of this final rule where we discuss the modified PSI 90 and similar concerns in the context of the Hospital IQR Program and section IV.I.3.a. of the preamble of this final rule in the context of the HAC Reduction Program.

Comment: One commenter did not support the use of the modified PSI 90 measure in the program as a composite measure because the commenter believed each of the component indicators should be reported separately, which will increase transparency for consumers and providers.

Response: We appreciate commenter’s suggestion. However, since we have adopted the composite measure for the Hospital VBP Program, we believe it is appropriate to publish hospitals’ performance on that measure as a composite score, rather than its individual components, as a reflection of performance measured and scored under the Hospital VBP Program. The composite measure is the basis for awarding achievement and improvement points, not its underlying indicators, and we believe it is appropriate to focus the public reporting of Hospital VBP Program scores on the measures that receive points. We note that hospital performance on the individual component indicators of PSI 90 as calculated in the Hospital IQR Program are publicly available in downloadable datasets located at: https://data.medicare.gov/data/hospital-compare because we agree with the commenter about the importance of this information to consumers and providers.
3. Retention Policy, Domain Name Change, and Updating of Quality Measures for the FY 2019 Program Year

a. Retention of Previously Adopted Hospital VBP Program Measures

Since the FY 2013 IPPS/LTCH PPS final rule (77 FR 53502), we have retained measures from prior program years for each successive program year, unless otherwise proposed and finalized. We are not proposing any changes to this policy.

b. Domain Name Change

We strive to align quality measurement and value-based purchasing programs with the NQS priority and the CMS Quality Strategy. Value-based purchasing programs in particular allow us to link the CMS Quality Strategy with Medicare payments to providers and suppliers on a national scale. Given this objective, as well as our objective to focus quality measurement on the patient-centered outcome to the extent possible, we reclassified the Hospital VBP Program measures into domains based on the 6 priorities of the CMS Quality Strategy. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50702), we combined the priorities of Care Coordination and Patient- and Caregiver-Centered Experience of Care into one domain for purposes of aligning the Hospital VBP Program domains with the CMS Quality Strategy. The domain name is often shortened to say PCCECC/CC. The HCAHPS measure, which includes the care transitions measure (CTM–3), currently comprises the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain.

This domain name has proven to be long and unwieldy. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25100 through 25101), we proposed to change the domain name from Patient- and Caregiver-Centered Experience of Care/Care Coordination to, more simply, Person and Community Engagement. We stated our belief that renaming the domain name captures 2 goals of the CMS Quality Strategy, as shown in the table below:

<table>
<thead>
<tr>
<th>Hospital VBP program domain</th>
<th>CMS quality strategy goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>Make Care Safer by Reducing Harm Derived from the Delivery of Care.</td>
</tr>
<tr>
<td>Clinical Care</td>
<td>Promote Effective Prevention and Treatment of Chronic Disease.</td>
</tr>
<tr>
<td>Person and Community Engagement</td>
<td>Promote Effective Communication and Coordination of Care. Strengthen Persons and Their Families as Partners in Their Care.</td>
</tr>
<tr>
<td>Efficiency and Cost Reduction</td>
<td>Work with Communities to Promote Best Practices of Healthy Living.</td>
</tr>
<tr>
<td>N/A.</td>
<td>We invited public comments on this proposal.</td>
</tr>
</tbody>
</table>

We continue to believe this expansion of the measures would allow all hospitals, including hospitals that do not have ICU locations, to use the tools and resources of the CMS quality strategy. One commenter noted because it simplifies the domain name change from the Patient- and Caregiver-Centered Experience of Care/Care Coordination to the Person and Community Engagement domain because it simplifies the domain reference and aligns with the CMS Quality Strategy. One commenter noted that the name change accurately represents the purpose of the measures included in the domain.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing the proposed domain name change from the Patient- and Caregiver-Centered Experience of Care/Care Coordination to the Person and Community Engagement domain. We will begin referring to the domain by its new name beginning with the FY 2019 program year.

c. Inclusion of Selected Ward Non-Intensive Care Unit (ICU) Locations in Certain NHSN Measures Beginning With the FY 2019 Program Year

The Hospital VBP Program has used the CLABSI measure since the FY 2013 program year and has used the CAUTI measure since the FY 2016 program year. Both measures use adult, pediatric, and neonatal intensive care unit (ICU) data to calculate performance standards and measure scores (79 FR 50061). In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50787), we expanded the CAUTI and CLABSI measures to selected ward (non-ICU) locations in the CAUTI and CLABSI measures for the Hospital VBP Program beginning with the FY 2019 program year, noting that CLABSI and CAUTI measures are important targets for dedicated surveillance and prevention efforts outside the ICU setting (80 FR 49566).

Based on the public comments we have received in prior rulemaking, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25101), we proposed to include the selected ward (non-ICU) locations in the CAUTI and CLABSI measures for the Hospital VBP Program beginning with the FY 2019 program year, with a baseline period of January 1, 2015 through December 31, 2015 and a performance period of January 1, 2016 through December 31, 2017. This expansion of the CAUTI and CLABSI measures aligns with the Hospital IQR Program. It also aligns with the HAC Reduction Program, which adopted the expansion of the CAUTI and CLABSI measures beginning with its FY 2018 program year (80 FR 49576 through 49578). This expansion is also consistent with the NQF reendorsement update to these measures, which allows application of the measures beyond ICU locations (78 FR 50787). The MAP conditionally supported the expansion of the CAUTI (MUC–S0138) and CLABSI (MUC–S0139) measures for the Hospital VBP Program on the condition of gaining experience publicly reporting these measure data, as detailed in the “Spreadsheet of MAP 2015 Final Recommendations.”

We continue to believe this expansion of the measures would allow all hospitals, including hospitals that do not have ICU locations, to use the tools and resources of the
NHSN for quality improvement and public reporting efforts.

We invited public comments on this proposal.

Comment: Many commenters supported the inclusion of selected ward non-ICU locations for the CAUTI and CLABSI measures beginning with the FY 2019 program year. Several commenters noted that the expansion will reduce confusion by aligning these measures with the Hospital IQR Program. Several commenters believed the expansion will encourage system-wide adoption of infection prevention protocols and allow hospitals that do not have ICU locations to use NHSN tools and resources in their quality improvement efforts. One commenter noted that a significant proportion of community hospitals have smaller ICUs, meaning lower total number of device days, which can lead to the inability to calculate standardized infection ratios because the expected number of infection events is < 1. The commenter believed that the inclusion of ward (non-ICU) locations will lessen this limit in calculation of this measure.

Response: We thank the commenters for their support.

Comment: One commenter recommended that, before implementing these measures in selected ward (non-ICU) locations, CMS provide these locations with the mechanisms to begin voluntarily collecting data in order to use that data in calculating performance standards for subsequent years of the program.

Response: The refined NHSN CAUTI and CLABSI measures that include select ward locations were finalized in the Hospital IQR Program in the FY 2014 IPPS/LTCH PPS final rule and data collection began on January 1, 2015 (78 FR 50787). Because the Hospital VBP Program uses Hospital IQR Program data, and hospitals have been publicly reporting on this measure for greater than one year, we do not believe additional voluntary reporting is necessary.

After consideration of the public comments we received, we are finalizing the proposal to expand the NHSN CAUTI and CLABSI measures to include the selected ward (non-ICU) locations beginning with the FY 2019 program year.

d. Summary of Previously Adopted Measures and Newly Finalized Measure Refinements for the FY 2019 Program Year

In summary, for the FY 2019 program year, we are adopting the following measure set:

<table>
<thead>
<tr>
<th>PREVIOUSLY ADOPTED MEASURES AND NEWLY FINALIZED MEASURE REFINEMENTS FOR THE FY 2019 PROGRAM YEAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short name</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td><strong>Person and Community Engagement Domain</strong></td>
</tr>
<tr>
<td>HCAHPS</td>
</tr>
<tr>
<td><strong>Clinical Care Domain</strong></td>
</tr>
<tr>
<td>MORT–30–AMI</td>
</tr>
<tr>
<td>MORT–30–HF</td>
</tr>
<tr>
<td>MORT–30–PN</td>
</tr>
<tr>
<td>THA/TKA</td>
</tr>
<tr>
<td><strong>Safety Domain</strong></td>
</tr>
<tr>
<td>CAUTI**</td>
</tr>
<tr>
<td>CLABSI**</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
</tr>
<tr>
<td>CDI</td>
</tr>
<tr>
<td>PSI 90</td>
</tr>
<tr>
<td><strong>Efficiency and Cost Reduction Domain</strong></td>
</tr>
<tr>
<td>MSPB</td>
</tr>
</tbody>
</table>

* We are changing some of the short names for measures from previous years’ rulemakings to align these names with the usage in the Hospital IQR Program, and we are changing some measure names from previous years’ rulemakings to use complete NQF-endorsed measure names.

* In section IV.H.3.b. of the preamble of this final rule, we finalized changing the name of this domain from Patient- and Caregiver-Centered Experience of Care/Care Coordination domain to Person and Community Engagement domain beginning with the FY 2019 program year.

** As discussed in section IV.H.3.c. of the preamble of this final rule, we are finalizing inclusion of selected ward (non-ICU) locations in the measure.
4. Finalized Measures and Measure Refinements for the FY 2021 Program Year and Subsequent Years

We consider measures for adoption based on the statutory requirements, including specification under the Hospital IQR Program, posting dates on the Hospital Compare Web site, and our priorities for quality improvement as outlined in the current CMS Quality Strategy, available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityInitiativesGenInfo/CMS-Quality-Strategy.html.

Due to the time necessary to adopt measures, we often adopt policies for the Hospital VBP Program well in advance of the program year for which they will be applicable (for example, 76 FR 26490 through 26547; 76 FR 51653 through 51660; 77 FR 74527 through 74547; 77 FR 53567 through 53614; 78 FR 50676 through 50707; 78 FR 75120 through 75121; 79 FR 50048 through 50087; 80 FR 49556 through 49559).

a. Condition-Specific Hospital Level, Risk-Standardized Payment Measures

Providing high-value care is an essential part of our mission to provide better health care for individuals, better health for populations, and lower healthcare costs. Our aim is to encourage higher value care where there is the most opportunity for improvement, the greatest number of patients to benefit from improvements, and the largest sample size to ensure reliability. In order to incentivize innovation that promotes high-quality care at high value, we believe it is critical to examine measures of resource use, efficiency, and cost reduction.

In prior rules we have discussed our interest in expanding the Hospital VBP Program’s Efficiency and Cost Reduction domain to include condition-specific or treatment-specific Medicare payment measures, and we have sought public comments (78 FR 50688; 79 FR 50066). In response to comments, we have stated that risk-adjusted standardized Medicare payments, viewed in light of other quality measures in a program, are an appropriate indicator of efficiency because they allow us to compare hospitals without regard to factors such as geography and teaching status. This comparison is particularly important with clinically coherent episodes because it distinguishes the degree to which practice pattern variation influences the cost of care. In addition, we have stated that the granularity of condition-specific or treatment-specific payment measures may provide specific actionable feedback to hospitals to implement targeted improvements. The observed differences in episode payments revealed by these measures may also encourage hospitals to assess local, postacute health care services (for example, SNF and home health services) to ensure that efficient services are available to all patients. Given these factors, we believe that the addition of condition-specific or treatment-specific payment measures to the Hospital VBP Program is necessary not only to facilitate a better understanding of service utilization and costs associated with conditions or treatments, but also as an important next step in the evolution of value-based purchasing to transform how Medicare pays for care and services.

We recognize that high or low payments to hospitals are difficult to interpret in isolation. Some high payment hospitals may produce better clinical outcomes when compared with low payment hospitals, while other high payment hospitals may not produce better outcomes. In the fiscal year 2018 program year, payment measure results viewed in isolation are not necessarily an indication of quality. However, by viewing such information along with quality measure results, we believe that consumers, payers, and providers would be able to better assess the value of care. We believe that adopting condition-specific or treatment-specific payment measures for the Hospital VBP Program that can be more directly paired with clinical outcome measures, aligned by comparable populations, performance periods, or risk-adjustment methodologies, help move toward achievement of this goal. We also believe that adopting condition-specific or treatment-specific payment measures would create stronger incentives for appropriately reducing practice pattern variation to achieve the aim of lowering the cost of care and creating better coordinated care for Medicare beneficiaries.

In the Hospital VBP Program, we adopted the MSPB measure beginning with the FY 2015 program year to incentivize hospitals to redesign care systems in order to provide coordinated, high-quality, and cost-efficient care (77 FR 53590). Currently, the Hospital VBP Program measures efficiency by weighting and combining the MSPB measure with other quality measures in order to calculate each hospital’s TPS. However, we have previously expressed our interest in expanding the Efficiency and Cost Reduction domain and continue to believe that additional supplemental measures would create incentives for greater coordination between hospitals and physicians to optimize the care they provide to Medicare beneficiaries (78 FR 50688; 79 FR 50066).

We believe that when examining variation in payments, an episode-of-care triggered by admission is meaningful for several reasons. First, hospitalizations represent brief periods of illness that require ongoing management postdischarge, and decisions made at the admitting hospital affect payments for care in the immediate postdischarge period. Second, attributing payments for a continuous episode-of-care to admitting hospitals may reveal variations in care decision-making and resource utilization. Third, an episode-of-care with a specified time period (30 days in the case of the measures discussed below) provides a standard observation period by which to compare all hospitals. For all of the reasons described above, in the FY 2017 IPPS/LTCPPS proposed rule (81 FR 25102 through 25105), we proposed to add 2 condition-specific payment measures in the Hospital VBP Program that can be directly paired with existing clinical outcome measures in the program.

We invited public comments on the proposed measures as detailed below. We further invited public comment on the addition of other condition-specific or treatment-specific payment measures that are directly paired with quality measures, as well as episode-based payment measures not directly paired with quality measures, for future program years.

Comment: Several commenters supported the continued use of the MSPB measure in the Hospital VBP Program and the development of additional measures to add to the Efficiency and Cost Reduction domain to create incentives for greater coordination between hospitals and physicians. One commenter recommended that CMS seek to broaden the scope of its efficiency measures for the FY 2018 rulemaking cycle. One commenter recommended that CMS adopt additional cost and efficiency measures and that any new cost and efficiency measures be paired with corresponding quality measures because they provide a link to balance cost and quality. Another commenter recommended that CMS consider adopting other macro-level measures of efficiency and cost reduction, such as: (1) Total Medicare cost per capita; (2) Medicare spending per beneficiary in the last 2 years of life; and (3) Medicare spending per beneficiary in the last 6 months of life.
Commenters noted that the proposed payment measures, when paired with the mortality measures, can help to incentivize the incorporation of evidence-based processes of care to reduce cost-per-episode while improving quality of care, potentially through improved patient monitoring and management. One commenter believed the proposed measures are appropriate indicators of efficiency since they allow for clinical comparisons without external factors like age and comorbidities. One commenter believed these measures may encourage the use of innovative technologies that assist in providing high quality care while reducing overall costs. One commenter believed these measures allow for specific actionable feedback to hospitals to implement improvements. One commenter believed these measures increase incentives for hospitals to better manage patients’ chronic conditions after discharge and avoid subsequent visits to the emergency department and readmissions.

Response: We appreciate the commenters’ support. We note that we are unable to adopt any additional efficiency measures for the FY 2018 program year due to statutory restrictions. We thank the commenters for the suggestions of future measures to adopt for the domain, and we will take that into account for future measure development and rulemaking. We encourage commenters to submit any fully developed measures for consideration for the Measures Under Consideration List as part of the pre-rulemaking process (details available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/QualityMeasures/Pre-Rule-Making.html).

Comment: One commenter recommended that CMS take advantage of the agency’s development of episode groupers, which are intended to assign specific services to a particular episode, when implementing any measure of episode costs.

Response: The episode groupers define episodes by DRGs and not ICD-10-CM codes. The goal of the AMI Payment and HF Payment measures is to provide information on the value of care by comparing payments for an episode of care with performance on quality measures, like CMS’ 30-day mortality measures. Thus, it is important that the patient cohorts are as closely aligned as possible between payment and quality measures. This would not be possible if we used the AMI or HF episode grouper.

Comment: One commenter supported expansion of the domain to include condition-specific payment measures but recommended that CMS standardize the process for validating elements on claims submitted for the purpose of quality reporting because, without a standardized validation process, observed differences in performance rates cannot be assumed to reflect differences in care alone.

Response: We appreciate commenter’s support of the payment measures. We interpret the commenter’s recommendation regarding validating elements on claims to refer to the claims review process. All claims data submitted by hospitals for the Hospital VBP Program are reviewed by Medicare Claims Review Programs, which are a collection of initiatives responsible for reviewing claims according to Medicare rules and regulations.

(1) New Measure for the FY 2021 Program Year: Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI) (NQF #2431)

Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for AMI (NQF #2431) (AMI Payment) is an NQF-endorsed measure assessing hospital risk-standardized payment associated with a 30-day episode-of-care for AMI. We adopted this measure in the Hospital IQR Program in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50802 through 50805). The measure includes Medicare FS patients aged 65 or older admitted for an AMI and calculates payments for these patients over a 30-day episode-of-care, beginning with the index admission, using administrative claims data. In general, the measure uses the same approach to risk-adjustment as our 30-day outcome measures previously adopted for the Hospital VBP Program, including the AMI mortality measure. Initial measure data were posted on Hospital Compare in December 2014 and the full measure specifications are available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

AMI remains a high-volume condition that is one of the top 20 conditions contributing to Medicare costs. There is evidence of variation in payment for AMI patients among hospitals; median 30-day risk-standardized payment (in 2013 dollars) for AMI was $21,620 and ranged from $12,862 to $29,802 for the July 2011 through June 2014 reporting period in the Hospital IQR Program. This variation in payment suggests there is opportunity for improvement.

We believe it is important to adopt the AMI Payment measure because variation in payment may reflect differences in care decision-making and resource utilization (for example, treatment, supplies, or services) for patients with AMI both during hospitalization and immediately postdischarge. The AMI Payment measure also addresses the NQS priority and CMS Quality Strategy goal to make quality care more affordable. Lastly, the AMI Payment measure is intended to be paired with our 30-day AMI mortality measure, MORT–30–AMI (NQF #0230), thereby directly linking payment to quality by the alignment of comparable populations and risk-adjustment methodologies to facilitate the assessment of efficiency and value of care.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25103), we proposed to adopt the AMI Payment measure beginning with the FY 2021 program year. The AMI Payment measure would be added to the Efficiency and Cost Reduction domain. The proposed measure fulfills all statutory requirements for the Hospital VBP Program based on our adoption of the measure in the Hospital IQR Program, and our posting of measure data on Hospital Compare for at least one year before the beginning of the performance period. The AMI Payment measure (MUC15–369) was reviewed by the MAP in December 2015 and did not receive support for adoption into the Hospital VBP Program. The result of the MAP vote was 27 percent support, 15 percent conditional support, and 58 percent do not support. MAP members expressed concern that treatment-specific or condition-specific payment measures may overlap and double count services that are already captured in the MSPB measure. In addition, stakeholders expressed a desire to have...
more experience with the measure in the Hospital IQR Program to understand whether there may be unintended consequences or a need to adjust for sociodemographic status (SDS) factors.

With respect to MAP stakeholder concerns that treatment-specific or condition-specific payment measures may overlap and double count services, we noted that these measures cover topics of critical importance to quality improvement in the inpatient hospital setting. As discussed above, we selected these measures because we believe that it is appropriate to provide stronger incentives for hospitals to provide high-value and efficient care. We believe that even if some services were double counted, hospitals that offer quality service and maintain better results on the MSPB and condition-specific payment measures relative to other hospitals in the Hospital VBP Program could receive an increased benefit by performing well on both quality measures and payment measures. Furthermore, because hospitals could have bigger financial incentives, they would strive to perform better, which would lead to better quality. At the same time, however, we proposed that the Efficiency and Cost Reduction domain remain weighted at 25 percent of the TPS even as additional payment measures may be adopted for this domain in the FY 2021 program year; therefore, the impact of poor performance on the MSPB measure or on any other particular payment measure would be reduced. In regard to MAP stakeholder concerns regarding the need to adjust for SDS, we noted that the AMI Payment measure already incorporates a risk-adjustment methodology that accounts for age and comorbidities. We understand the important role that SDS plays in the care of patients. However, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of diverse SDS because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of SDS on hospitals’ results on our measures; however, we remain committed to monitoring for unintended consequences.

We invited public comments on this proposal.

Comment: A few commenters supported the addition of the AMI Payment measure. Two commentators noted it will be linked to the MORT—30–AMI measure, which will allow CMS to begin comparing quality and efficiency in treating this condition. One commenter supported the measure because it is NQF-endorsed and addresses a condition that is a significant driver of cost for the Medicare program.

Response: We thank the commenters for their support.

Comment: One commenter did not support the addition of the AMI Payment measure because patients can have different types of AMI which would be treated differently with varying costs. The commenter noted that the measure specifications do not delineate between the 2 types of AMI admissions, and therefore will not provide hospitals with information on whether the hospital successfully managed resource utilization with respect to the treatment received.

Response: While we recognize there are subtypes of myocardial infarction, the goal of the AMI Payment measure is to provide information on the value of care for a specific-condition rather than subtypes of a condition. This measure is meant to be paired with the MORT—30–AMI measure in order to gain a better understanding of the value of care for a hospital’s patients.

Comment: One commenter did not support adding the AMI Payment measure to the Hospital VBP Program because AMI is a high-volume condition that commenter believed, particularly with the overlap in the MSPB measure, would disproportionately impact hospital performance in the Efficiency and Cost Reduction domain and mask performance around other conditions.

Response: While performance on the MSPB measure may correlate with performance on the condition-specific payment measures for some hospitals, we continue to believe that the AMI Payment measure will provide condition-specific information to hospitals that can be interpreted in the context of overall payment and incentivize targeted improvements in care. Though the adoption of the AMI Payment and HF Payment measures will dilute the weight of the MSPB measure in the Efficiency and Cost Reduction domain (from 25 percent of the TPS to 8.33 percent of the TPS), we continue to believe they are important new measures for the Hospital VBP Program.

Comment: One commenter did not support adding the AMI Payment measure to the Hospital VBP Program because this commenter believed the predictive models used in developing the measure do not apply equally well to hospitals providing complex services, such as advanced heart failure care.

Response: As we noted in the FY 2017 IPPS/LTCH PPS proposed rule, the NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures
developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, ASPE is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

For more details regarding risk adjustment of the AMI Payment and HF Payment measures, we refer the commenter to the measure methodology reports and measure risk adjustment statistical model available in the AMI, HF, and PN Payment Updates zip file at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

Comment: Many commenters did not support the addition of condition-specific payment measures because they will overlap with the MSPB measure in the Efficiency and Cost Reduction domain. Several commenters recommended that we remove episodes of AMI Payment and HF Payment from the MSPB calculation, such as excluding costs associated with episode-based payment measures from broader payment measures. Several other commenters recommended removing the MSPB measure if CMS adopts the condition-specific payment measures. One commenter believed the overlap between these condition-specific measures and the MSPB measure may lead to unnecessary confusion among hospitals, sending mixed signals to hospitals about their resource use performance, rather than facilitating a meaningful assessment of resource use. One commenter also noted that it will be possible for hospitals to score well on the MSPB measure, but poorly on the AMI Payment or HF Payment measures, even though the measures will capture many of the same services.

Response: While we acknowledge that there may be some overlap between the MSPB and condition-specific payment measures, we believe that the condition-specific measures are of critical importance to improving efficiency of care. Including condition-specific measures alongside the MSPB measure provides hospitals with actionable feedback that will better equip them to implement targeted improvements, in comparison to an overall payment measure alone. Moreover, these condition-specific measures will allow consumers, providers, and payers to make a more fully informed assessment of value of care.

Comment: Many commenters did not support the addition of condition-specific payment measures because the commenters believed the measures inappropriately assign costs to the hospitals. A few commenters believed that it is physicians that control the majority of decisions that impact spending across an episode of care and it will be difficult to isolate and ascribe responsibility for a beneficiary’s overall spending to a given hospital. Another commenter noted that the measures capture all costs associated with the patient, including postdischarge care, which may be outside the scope of the admitting hospital. One commenter noted that hospitals have little control over spending during the defined episode with the exception of preventable readmissions. A few commenters recommended CMS work with the hospital community to develop and implement efficiency metrics of spending that hospitals directly influence. Other commenters recommended limiting inclusion of payments used in the calculation of the measures to only payment directly related to the condition-specific index admission, because commenters believed this would be a more accurate proxy for factors within a hospital’s control than all spending over a 30-day period.

Response: We continue to believe that hospitals that provide quality inpatient care and conduct appropriate discharge planning can work with providers and suppliers in coordinating efficient follow-up care among variation in payments, consideration of the episode-of-care triggered by admissions is meaningful for several reasons. First, hospitalizations represent a brief period of illness that require ongoing management postdischarge, and decisions made at the admitting hospital affect payments for care in the immediate postdischarge period. Second, attributing payments for a continuous episode-of-care to admitting hospitals may reveal practice variations in the full care of the illness that can result in increased payments. Third, a 30-day preset window provides a standard observation period by which to compare all hospitals. Lastly, the AMI Payment and HF Payment measures are meant to be paired with the MORT–30-AMI measure and the MORT–30-HF measure, respectively, to capture payments for Medicare patients across all care settings, services, and supplies, except for Medicare Part D (that is, inpatient, outpatient, skilled nursing facility, home health, hospice, physician/clinical laboratory/ambulance services, durable medical equipment, prosthetics/orthotics, and supplies).

We thank commenters for the recommendations and note that we have developed, and will continue to develop, efficiency measures in consultation with clinical and measurement experts, key stakeholders (including the hospital community), and the public. We disagree with commenters that all payment measures should be limited to only payments directly related to the index admission because, as noted above, we continue to believe that inclusion of payments on a broad range of services does incentivize quality care and care coordination. Transitions to outside facilities and readmissions to the hospitals may be the result of quality failures that have led to poor clinical outcomes.

Comment: A few commenters expressed concern about adding the condition-specific payment measures into the Hospital VBP Program because the commenters believe these measures do not capture quality of care, despite directly pairing with the mortality measures, and will not provide hospitals with actionable data for quality improvement efforts. One commenter did not believe the payment measures are appropriately aligned by comparable populations/performance periods/risk-adjusted methodologies.

Response: We disagree with the commenters that the condition-specific payment measures will not provide hospitals with actionable data for quality improvement efforts. By adopting condition-specific payment measures and viewing results alongside quality measure results, we believe that consumers, payers, and providers will be able to better assess the overall value of care. We believe that adopting condition-specific payment measures for the Hospital VBP Program that are directly paired with clinical outcome measures, aligned by comparable populations, performance periods, or risk-adjustment methodologies, helps move toward achievement of this goal. We also believe that adopting condition-specific payment measures creates stronger incentives for appropriately reducing practice pattern variation to
achieve the aim of lowering the cost of care and creating better coordinated care for Medicare beneficiaries.

In regard to the commenter who did not believe the payment measures are appropriately aligned, we note that the AMI Payment and HF Payment measures do have populations, outcome timeframes, and approaches to risk adjustment that are comparable with the MORT–30–AMI and MORT–30–HF outcome measures. We refer the commenter to the measure methodology reports in the AMI, HF, PN, COPD, and Stroke Mortality Update zip file and the AMI, HF, and PN Payment Updates zip file at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

Comment: A few commenters recommended that CMS adjust the Efficiency and Cost Reduction domain to mitigate the impact of quality of care in SNFs and other postacute settings on the hospitals’ performance in the Efficiency and Cost Reduction domain because hospitals are not able to proactively steer beneficiaries to high-quality SNFs. The commenters also noted that receiving patients from low-quality postacute care settings may impact hospitals’ performance on the Efficiency and Cost Reduction domain.

Response: We disagree with commenters’ recommendation to adjust the Efficiency and Cost Reduction domain to mitigate the potential impact of low quality SNFs or other postacute care settings. Payment measures are not risk-adjusted for patients’ admission source (for example, SNFs) because admission source factors are associated with the structure of the healthcare system, rather than solely patients’ clinical comorbidities. The payment measures are, however, appropriately risk-adjusted for patient comorbidities that are clinically relevant and have a strong relationship with the outcome. Further, we have established several postacute care quality programs, including SNF VBQ Program, to assist hospitals and the public in identifying high-value postacute care providers. We continue to believe that hospitals that are committed to providing quality inpatient care can work with SNFs and other postacute care providers and suppliers to ensure efficient postdischarge care for the patients they serve.

Comment: A few commenters did not support the use of condition-specific payment measures because they took issue with the NQF endorsement of the measures. One commenter believed the condition-specific payment measures are not endorsed by NQF. Another commenter did not support the addition of the condition-specific measures because the commenter and others have appealed the measures’ NQF endorsement on the grounds that the NQF measure review committee did not consider appropriate risk adjustment for SDs factors. These commenters recommended that CMS not adopt condition-specific measures in the Hospital VBQ Program, but instead provide condition-specific cost of care data to hospitals to help them understand what is driving MSPB performance.

Response: The AMI Payment (NQF #2431) and HF Payment (NQF #2436) measures are NQF-endorsed as reliable and valid as of 2014. We continue to believe it is important to publicly report this data in order to allow consumers, providers, and payers to make a more fully informed assessment of value of care.

Comment: One commenter recommended that CMS reach out to stakeholders for feedback during the development of payment measures.

Response: We routinely solicit public comment on our payment measures and other measures under development. For current and future opportunities, we encourage the commenter to visit the CMS Quality Measures Public Comment page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallsforPublicComment.html. In addition, there are also opportunities for stakeholders to serve on Technical Expert Panels and provide technical input to CMS and the measure contractors on the development, selection, and maintenance of measures. We refer the commenter to the following Web site for more information: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/TechnicalExpertPanels.html.

Comment: One commenter expressed concern that condition-specific measures do not capture all outcomes relevant to understanding the care that patients received, such as readmissions and subsequent cardiac events.

Response: We disagree that the condition-specific measures do not capture all outcomes like readmissions and subsequent cardiac events. The condition-specific payment measures do capture payments for all care, including readmissions and subsequent cardiac events, across multiple care settings, services, and supplies during the 30-day episode of care.

Response: We believe that adding the AMI Payment and HF Payment measures now will provide actionable feedback to hospitals on the overall value of their services to beneficiaries.

After consideration of the public comments we received, we are finalizing the proposal to add the AMI Payment measure to the Hospital VBQ Program beginning with the FY 2021 program year.

(2) New Measure for the FY 2021 Program Year: Hospital-Level, Risk-Standardized Payment Associated With a 30-Day Episode-of-Care for Heart Failure (HF) (NQF #2436)

Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for HF (NQF #2436) (HF Payment) is an NQF-endorsed measure assessing hospital risk-standardized Medicare payment associated with a 30-day episode-of-care for heart failure. The measure includes Medicare FFS patients aged 65 or older admitted for heart failure and calculates payments for these patients over a 30-day episode-of-care, beginning with the index admission, using administrative claims data. In general, the measure uses the same approach to risk-adjustment as our 30-day outcome measures previously adopted for the Hospital VBQ Program, including the HF mortality measure. We adopted this measure in the Hospital IQR Program in the FY 2015 IPPS/LTCPP final rule (79 FR 50231 through 50235). Initial measure data were posted
Heart failure is one of the leading causes of hospitalization for Americans 65 and over and costs roughly $34 billion annually. There is evidence of variation in Medicare payments at hospitals for heart failure patients; median 30-day risk-standardized payment (in 2013 dollars) among Medicare FFS patients aged 65 or older was $15,139, and ranged from $11,086 to $21,867 for the July 2011 through June 2014 reporting period in the Hospital IQR Program. This variation in payment suggests there is an opportunity for improvement.

We believe it is important to adopt the HF Payment measure because variation in payment may reflect differences in care decision-making and resource utilization (for example, treatment, supplies, or services) for patients with heart failure both during hospitalization and immediately postdischarge. The HF Payment measure also addresses the NQS priority and CMS Quality Strategy goal to make quality care more affordable. Lastly, the HF Payment measure is intended to be paired with our 30-day HF mortality measure, MORT–30–HF, thereby directly linking payment to quality by the alignment of comparable populations and risk-adjustment methodologies to facilitate the assessment of efficiency and value of care.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25104), we proposed to adopt the HF Payment measure with the FY 2021 program year. The HF Payment measure would be added to the Efficiency and Cost Reduction domain. The measure fulfills all statutory requirements for the Hospital VBP Program based on our adoption of the measure in the Hospital IQR Program and our posting of measure data on Hospital Compare for at least one year before the beginning of the performance period for this measure. The HF Payment measure (MUC15–322) was reviewed by the MAP in December 2015 and did not receive support for adoption into the Hospital VBP Program, due to the same concerns that we noted in our discussion of the AMI Payment measure. The result of the MAP vote was 27 percent support, 8 percent conditional support, and 65 percent do not support. Although the final MAP decision was “do not support,” we continue to believe that the NQF-endorsed HF Payment measure provides beneficiaries and hospitals with valuable information about relative value for an episode-of-care. We support the HF Payment measure for the same reasons that we noted in our general discussion of condition-specific payment measures in section IV.H.4.a. of the preamble of this final rule and in our discussion of the AMI Payment measure in section IV.H.4.a.(2) of the preamble of this final rule.

We noted that some MAP members did express support for the HF Payment measure and other condition-specific payment measures. Members agreed that the increased granularity provided by condition-specific payment measures will provide valuable feedback to hospitals for targeted improvement. In addition, we believe that the condition-specific payment measures we are proposing, which directly pair with clinical outcome measures already in the Hospital VBP Program, follow the recommended approach outlined in the NQF white paper on how best to measure efficiency. Based on our analysis of the issues surrounding condition-specific payment measures, we believe that the benefits of adopting this measure into the Hospital VBP program outweigh any potential risks. However, we remain committed to monitoring for unintended consequences.

We invited public comments on this proposal.

Comment: Several commenters supported the addition of the HF Payment measure. One commenter supported the addition of the HF Payment measure because it links the HF Payment measure to the MORT–30–HF (NQF #0229) measure and will allow CMS to begin comparing quality and efficiency in treating this condition. One commenter supported the measure because it is NQF-endorsed and addresses conditions that are significant drivers of cost for the Medicare program.

Response: We thank the commenters for their support.

Comment: One commenter supported the use of a 3-year baseline period for the HF Payment measure because a longer baseline period can account for the longer-term predictive value of health events such as HF better than a 1-year baseline period.

Response: We thank the commenter for its support. We note that the HF Payment measure will only have a 24-month performance period for its first year in the program, but we are adopting a 36-month performance period for future program years in section IV.H.6.c.(2) of this final rule.

Comment: One commenter expressed general concern about the HF Payment measure’s risk adjustment methodology and requested additional information regarding the discrimination and calibration for the measure’s predictive models.

Response: We note that the HF Payment measure was submitted before NQF, which endorsed the measure with the current risk adjustment methodology. For more information regarding the risk adjustment methodology, we refer readers to the AMI, HF, PN, and Hip and Knee Arthroplasty Payment Updates zip file available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

Comment: One commenter asked CMS to clarify whether patients in advanced stages discharged into palliative or hospice care are excluded from the HF Payment measure’s denominator.

Response: The HF Payment measure does not exclude heart failure patients discharged into palliative care or hospice care or who transition to hospice or palliative care during the index admission. Instead, the measure excludes index admissions for patients enrolled in the Medicare hospice program any time in the 12 months prior to the index admission, including the first day of the index admission. We adopted this policy because the transition of patients to hospice or palliative care during the admission may be the result of quality failures that have led to poor clinical outcomes. After considering the public comments we received, we are finalizing the proposal to add the HF
payment to the hospital VBP Program beginning with the FY 2021 program year.

(3) Finalized Scoring Methodology for the AMI Payment and HF Payment Measures

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25105 through 25106), we proposed to score the proposed AMI Payment and HF Payment measures using the same methodology we use to score the MSPB measure, so that all measures in the Efficiency and Cost Reduction domain are scored in the same manner and have the same case minimum threshold.

For achievement points, we proposed to calculate a spending ratio of AMI spending and HF spending for each hospital to the median AMI spending and median HF spending, respectively, across all hospitals during the performance period. We would then use each hospital’s AMI spending ratio and HF spending ratio to calculate between 0 and 10 achievement points. We proposed to set the achievement thresholds at the median AMI spending ratio and median HF spending ratio across all hospitals during the performance period. We proposed to set the benchmarks at the mean of the lowest decile of the AMI spending ratios and the HF spending ratios during the performance period. Therefore, a hospital whose individual AMI spending or HF spending ratios fall above the achievement threshold would score 0 achievement points on the measure. A hospital whose individual AMI spending or HF spending ratios fall at or below the benchmark would score the maximum 10 achievement points on the measure. A hospital whose individual AMI spending or HF spending ratios fall at or below the achievement threshold but above the benchmark would score between 1 and 9 points according to the following formula:

\[
9 \times \frac{(\text{Hospital's AMI spending ratio} - \text{Hospital's performance period ratio})}{(\text{Benchmark} - \text{Hospital's performance period ratio})} + 0.5
\]

For improvement points, we proposed to calculate a spending ratio of AMI spending and HF spending for each hospital to the median AMI spending and median HF spending, respectively, across all hospitals during the performance period. We would then use each hospital’s AMI spending ratio and the HF spending ratio to calculate between 0 and 9 improvement points by comparing each hospital’s ratio to its own performance during the baseline period. We proposed to set the improvement benchmark as the mean of the lowest decile of AMI spending and HF spending ratios across all hospitals. Therefore, a hospital whose AMI spending or HF spending ratios are equal to or higher than its baseline period ratios would score 0 improvement points on the measure. If a hospital’s score on the measure during the performance period is less than its baseline period score but above the benchmark, the hospital would receive a score of 0 to 9 according to the following formula:

\[
[10 \times \frac{\text{Hospital baseline period ratio} - \text{Hospital performance period ratio}}{\text{Hospital baseline period ratio} - \text{Benchmark})} - 0.5
\]

For more information about the proposed scoring methodology for the AMI Payment and HF Payment measures, we referred readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51654 through 51656) and to 42 CFR 412.160 where we discussed the MSPB measure’s identical scoring methodology in detail.

In order to codify this scoring methodology for the proposed payment measures, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25105 through 25106), we proposed to amend our regulations at 42 CFR 412.160 to revise the definitions of “Achievement threshold” and “Benchmark” to reflect this methodology, not just for the MSPB measure, but more generally for all measures in the Efficiency and Cost Reduction domain.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25106), we also considered and sought public feedback on scoring the AMI Payment and HF Payment measures using the same methodology that we use to score most other measures, including the MORT–30–AMI and MORT–30–HF measures. Under that scoring methodology, hospitals receive achievement points along an achievement range, which is a scale between the achievement threshold (the minimum level of hospital performance required to receive achievement points) and the benchmark (the mean of the top decile of hospital performance the baseline period). A hospital receives improvement points for a measure if the hospital improves upon its measure score from its own baseline period measure score (76 FR 26514). We stated that we decided to propose the scoring methodology that more closely aligns with the MSPB measure because we believe it would be helpful for hospitals to be compared against performance standards constructed from more current performance period data, given potential changes in Medicare payment policy, changes in market forces, and changes in utilization practices.

We invited public comment on the proposed scoring methodology in the calculation of achievement and improvement points for the AMI Payment and HF Payment measures beginning with the FY 2021 program year.

Comment: Several commenters did not support the addition of the AMI Payment and HF Payment measures because few conditions have large enough volume to support a reliable metric. The commenters recommended that CMS use condition-specific cost measures broadly and that CMS not base financial incentives on them. One commenter asserted that because not all hospitals will have sufficient volume to be scored on each condition-specific measure, the statistical reliability of the condition-specific measures is likely to be weaker than the MSPB measure.

Response: We disagree with the commenter that hospitals will not be able to report statistically reliable information on the condition-specific payment measures because, as we proposed in the FY 2017 IPPS/LTCH PPS proposed rule, hospitals must report a minimum number of 25 cases to receive a payment measure score (81 FR 25117). We believe the case minimum will ensure that each hospital’s payment measure rate is sufficiently reliable to generate a score that meaningfully distinguishes hospital performance on the measures. We also disagree with the commenter’s assertion that the statistical reliability of the condition-specific payment measures is likely to be weaker than the MSPB measure. The statistical model that CMS uses to calculate the payment measures allows for the inclusion of hospitals with relatively few cases by taking into account the uncertainty associated with sample size.

Comment: A few commenters did not support the proposed scoring methodology for the payment measures because half of hospitals will receive no achievement points on these measures. The commenters recommended that CMS score the payment measures the same way that other quality measures are scored, with the achievement threshold set based on the median during the baseline period.

Response: While we acknowledge the commenter’s concerns regarding the potential to achieve maximum achievement points, we believe scoring the payment measures in the same way as the MSPB measure is important. We continue to believe it is more helpful for hospitals to be compared against
performance standards constructed from more current performance period data, rather than baseline period data, given potential changes in Medicare payment policy, changes in market forces, and changes in utilization practices.

Comment: One commenter expressed concern that the current structure does not provide hospitals with meaningful information to improve efficiency because it does not allow for interpretation of cost and quality measures in tandem.

Response: We are aware that the quality measures and payment measures are not scored in tandem at this moment, but we believe the information provided by the payment measures provides more granular information to hospitals that can be interpreted in the context of overall payment and in conjunction with their performance on the mortality measures.

After consideration of the public comments we received, we are finalizing to score the AMI Payment and HF Payment measures using the same scoring methodology as the MSPB measure and to amend our regulations at 42 CFR 412.160 to reflect this policy.

In addition, we are considering adopting a scoring methodology for a future program year that would assess quality measures and efficiency measures in tandem to produce a composite score reflective of value. To support the goals of value-based purchasing and to provide consumers and purchasers with information about value of care provided by hospitals, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 21505), we solicited public comments on ways we can incorporate scoring value into the Hospital VBP Program. The concept of value reflects highest quality achieved with most efficiency or least costs. Currently, the Hospital VBP Program assesses quality and efficiency separately through distinct performance measures and domains. Because each domain is weighted and combined to determine each hospital’s TPS, a hospital could earn a higher payment adjustment relative to other hospitals by performing well on the quality-related domains but without performing well in the Efficiency and Cost Reduction domain, or vice versa. Without a measure or score for value that reflects both quality and costs, our ability to assess value is limited.

There are various different ways value could be incorporated into the Hospital VBP Program. We sought public comments on 2 general approaches. First, specific measures of value could be developed by measure developers and incorporated into the Hospital IQR Program and then the Hospital VBP Program through the measure development process. This may be a lengthy process and will depend upon interest from measure developers. However, specific measures of value could be more interpretable by consumers, and would have rates that could be trended, benchmarked, and scored using the current Hospital VBP Program scoring methodology for assessing achievement and improvement.

A second potential approach is for the Hospital VBP Program to use the Program’s scoring methodology to incorporate value based on the performance of hospitals by either: (a) Comparing scores on specific quality and cost measures; or (b) comparing quality and efficiency domain scores. First, the measure-specific approach could target high-cost, high-clinical-impact conditions by pairing condition-specific quality and cost measures, such as by assessing a ratio of a hospital’s reported quality over costs. A value score based on the paired clinical outcome and cost measures could be incorporated into the existing Efficiency and Cost Reduction domain (or Clinical Care or Safety domains) or included in a separate new ‘Value’ domain. Alternatively, a domain-based value scoring approach could be similar to the current quality/cost tiering approach in the Physician Value-Based Modifier Program, which tiers providers into high, average, or low cost and quality (or “value”) domains. The domain-based value score could be weighted and incorporated into the calculation of a hospital’s overall Hospital VBP Program TPS along with the other existing domains, or potentially as a multiplier or adjuster to additionally reward higher value hospitals.

We welcomed the public’s feedback and suggestions on how to appropriately incorporate the concept of value in the Hospital VBP Program, and we invited specific suggestions on how to measure or score value that will be meaningful to consumers, purchasers, and providers.

Comment: Several commenters supported CMS’ intent to explicitly assess value of care. A few commenters further supported CMS’ proposal to develop and implement specific measures of value because commenters believe it will result in a program that is simple, uncomplicated, and easily understood by consumers and providers. One commenter recommended that CMS resolve issues regarding SDS factors before implementing value scoring into the program.

Response: We thank the commenters for their suggestions, and we will take them into consideration in the future if we choose to propose to adopt value scoring.

Comment: One commenter recommended that CMS develop a value scoring methodology that would not reward hospitals with high mortality rates and low spending per patient. The commenter recommended that CMS use performance and baseline periods to score the value measures.

Response: We thank the commenter for its suggestions and will take them into consideration for future rulemaking.

Comment: A few commenters did not support CMS’ proposed approach to measuring value by creating a ratio using paired condition-specific quality and cost measures. One commenter noted that this would further complicate the Medicare VBP Program’s structure and could result in hospitals diverting more resources toward analyzing performance rather than focusing on improvement. A few commenters believe that such an approach could incentivize the provision of care that unintentionally leads to longer-term negative outcomes: Use of lower-cost/lower-quality implants; decreased length of stay; and insufficient use of physical therapy or home health care. A few commenters noted that the existing measures are limited in scope and were not designed to measure value; for example, THA/TKA is too narrow to capture the value of the underlying procedure, which should include factors like quality of life, duration of implant, and other issues beyond the 90-day timeframe of the THA/TKA measure. One commenter recommended CMS develop a measure that draws from patient-reported outcome measures, the American Joint Replacement Registry, and other sources to capture the value to the patient of the full life of a joint implant. These commenters generally suggested that if CMS implements value scoring, that CMS develop new value measures.

Response: We thank the commenters for their suggestions, and we will take them into consideration for future rulemaking.

Comment: A few commenters expressed general support for adopting a scoring methodology using composite “value” scores and recommended that CMS submit any newly developed composite measures to NQF for external endorsement, as well as use them in the Hospital IQR Program before adding them to the Hospital VBP Program.
Response: We thank the commenters for their suggestions, and we note that any new measures the Hospital VBP Program considers for adoption, including any composite measures of “value,” will be submitted to the MAP and adopted into the Hospital IQR Program before we adopt it in the Hospital VBP Program, as required by statute.

Comment: A few commenters recommended that CMS explore using a scoring methodology that provides tandem scores for quality and cost measures, but they noted that implementing such a methodology would require additional work to identify and adopt quality and cost measures that can be aggregated into value scores. A few commenters would not support using a scoring methodology resembling the Physician Value-Based Payment Modifier in the Hospital VBP Program because the Physician Value-Based Payment Modifier uses broad categories to assess performance, which commenters believed would not capture hospital performance as precisely as the current linear-based methodology. One commenter expressed concern with value scoring in the program because CMS will have difficulty identifying controllable expenses for the denominator and defining meaningful quality metrics for the numerator.

Response: We thank all of the commenters for their suggestions, and we will take them into consideration in the future if we choose to propose to adopt a new value scoring methodology or otherwise modify the existing scoring methodology of the Hospital VBP Program.

b. Finalized Update to an Existing Measure for the FY 2021 Program Year: Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization (NQF #0468) (Updated Cohort)

The Hospital 30-Day, All-Cause, RSMR Following Pneumonia Hospitalization (NQF #0468) [MORT–30–PN (updated cohort)] measure is a risk-adjusted, NQF-endorsed mortality measure monitoring mortality rates following pneumonia hospitalizations. As part of the CMS measure reevaluation process, the MORT–30–PN measure underwent a substantive revision, which expanded the measure cohort to include: (1) Patients with a principal discharge diagnosis of pneumonia (the current reported cohort); (2) patients with a principal discharge diagnosis of aspiration pneumonia; and (3) patients with a principal discharge diagnosis of sepsis (excluding severe sepsis) with a secondary diagnosis of pneumonia coded as present on admission. For the purposes of describing the refinement of this measure, we note that “cohort” is defined as the hospitalizations, or “index admissions,” that are included in the measure and evaluated to ascertain whether the patient subsequently died within 30 days of the index admission. This cohort is the set of hospitalizations that meet all of the inclusion and exclusion criteria.

The Hospital IQR Program adopted this measurement of MORT–30–PN (updated cohort) in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49653 through 49660), with initial MORT–30–PN (updated cohort) data to be posted on Hospital Compare on or around July 21, 2016 (now on or about July 27, 2016). The MORT–30–PN (updated cohort) measure (MUC-E0468) was included on the “List of Measures Under Consideration for December 1, 2014” and received conditional support from the MAP, pending NQF endorsement of the updated cohort as detailed in the “Spreadsheet of MAP 2015 Final Recommendations.” The full measure specifications are available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Mortality-Mortality.html.

This refinement to the MORT–30–PN measure was adopted to more accurately reflect quality and outcomes for patients with pneumonia. Recent evidence has shown an increase in the use of sepsis as a principal diagnosis code among patients hospitalized with pneumonia. In response to this emerging evidence, we examined coding patterns across hospitals caring for Medicare patients and sought to forecast the impact of enhancing or broadening the measure cohort to include the complete patient population, at each hospital, who are receiving clinical management and treatment for pneumonia. Our findings were consistent with a published study. That is, our results suggested

Response: No response.

that there is: (1) An increasing use of sepsis as a principal discharge diagnoses for pneumonia patients; and (2) wide variation across hospitals in the use of these codes. These published studies and CMS analyses also show that hospitals that use sepsis codes for the principal diagnosis frequently have better performance on the currently adopted MORT–30–PN measure. This coding practice improves performance on the measure because patients with greatest severity of illness (for example, those with sepsis) are systematically excluded from the measure under current measure specifications, leaving only patients with less severity of illness in the cohort.

In addition to assessing the use of the principal diagnosis codes of sepsis, we also analyzed coding patterns and the impact of expanding the pneumonia measure to include patients with the principal diagnosis of aspiration pneumonia. We noted after our analyses that aspiration pneumonia: (1) Is a common reason for pneumonia hospitalization, particularly among the elderly; (2) is currently not included in the CMS hospital outcome measure specifications for pneumonia patients; and (3) appears to be similarly subject to variation in diagnosis, documentation, and coding. The findings of published studies and CMS analyses suggested that a MORT–30–PN measure with an enhanced or broader cohort would ensure that the population of patients with pneumonia is more complete and comparable across hospitals.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25106 through 25107), we proposed this measure refinement for the Hospital VBP Program based on our adoption of the measure refinement in the Hospital IQR Program, and our posting of measure data on Hospital Compare for at least one year prior to the start of the measure performance period. In addition, the MORT–30–PN (updated cohort) measure addresses a high volume, high cost condition. The measure aligns with the NQS priority and CMS Quality Strategy Goal of “Effective Prevention and Treatment of Chronic Disease.”

Based on the continued high risk of mortality after pneumonia hospitalizations, we proposed to add it to the Clinical Care domain beginning with the FY 2021 program year.

We invited public comments on this proposal.

Comment: Several commenters supported CMS’ proposal to expand the
MORT–30–PN measure because this update will align the Hospital VBP Program and Hospital IQR Program measures. One commenter noted that the expansion addresses coding variations and will ensure better collection of complete and comparable data across hospitals.

Response: We thank the commenters for their support.

Comment: One commenter recommended that CMS have the American Hospital Association ICD–10 clinic review pneumonia coding for ICD–10 to see if changes are needed in these codes to capture coding variation for causes of aspiration pneumonia.

Response: We thank commenter for the recommendation and note that CMS is currently updating all measures from ICD–9 to ICD–10 through a systematic process of assessing the changes in all codes used in measure cohorts to ensure that the cohorts remain valid and capture the intended conditions. For those individuals who are interested in participating in future ICD–10 Coordination and Maintenance Committee meetings, information on the Committee can be found on the CMS Web site at: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-CM-C-and-M-Meeting-Materials.html. We encourage public participation at these meetings either in person, by conference lines, or by the livestream provided by CMS.

Comment: Many commenters did not support the addition of the MORT–30–PN updated measure because it is not NQF-endorsed. These commenters believe the endorsement process will allow the field to better understand the potential causes of coding differences. Specifically, many commenters are concerned that the inclusion of: (1) Patients with a principal discharge diagnosis of aspiration pneumonia; and (2) patients with a principal discharge diagnosis of sepsis (excluding severe sepsis) with a secondary diagnosis of pneumonia coded as present on admission may inadvertently confound pneumonia as a discrete medical event with other underlying disease conditions.

Response: The MORT–30–PN measure with the expanded cohort was submitted to the NQF Pulmonary and Critical Care Project 2015–2016, with information on the project available at: http://www.qualityforum.org/Projects/nr/Pulmonary_and_Critical_Care_Measures/Pulmonary_and_Critical_Care_Project.aspx. The MAP condition was developed by the MAP measure, pending NQF endorsement. Because the original measure was previously endorsed and the intent of the measure has not changed, we anticipate the measure will be reendorsed with the expanded cohort.

We agree with commenters that aspiration pneumonia may be the result of a range of potential causes. We expanded the cohort to include the aspiration pneumonia population to more fully capture the complete population of hospital patients receiving management and treatment for pneumonia, and thereby capture the morbidity and mortality of this important cohort. We appreciate the commenters’ concerns that community acquired pneumonia and aspiration pneumonia have different causes and associated risks (for example, recurrent aspiration due to other comorbidities).

While the pathological causes of aspiration pneumonia are slightly different from the causes of community acquired pneumonia, in routine clinical practice, evidence shows it can be very challenging for physicians to differentiate aspiration syndromes, including pneumonitis and pneumonia, from other types of pneumonia included in the measure. This is reflected in the tremendous variation across hospitals in the use of aspiration pneumonia diagnosis codes. This variation suggests that hospitals are not consistently distinguishing between these conditions as distinct subtypes regardless of patients’ comorbid conditions. Thus, we continue to believe the modified expanded cohort for the measure balances the need to be more clinically comprehensive while also accurately capturing pneumonia mortality.

Comment: Several commenters did not support the inclusion of the MORT–30–PN update in the Hospital VBP Program because it does not adjust for differences in patient population.

Response: We disagree with commenters that the updated MORT–30–PN measure does not adjust for differences in patient population. The risk adjustment model adequately accounts for the varying severity and comorbidities of patients across the modified cohort; therefore, we believe that hospitals will not be unfairly penalized for treating sicker patients. We refer the commenter to the measure methodology report and measure risk adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Mortality Update zip file at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

Comment: A few commenters did not support the MORT–30–PN update because the impact of the update has not yet been publicly reported. The commenters noted that the measure developer indicated that an increase in mortality rates may be attributed to the expanded cohort, but no information is available about how specific hospitals perform. The commenters suggested waiting to adopt the new measure until hospitals have had sufficient time to review and analyze their performance on the expanded measure. One commenter recommended that CMS implement a phased-in approach to the expanded measure that would first allow for public reporting before implementing the expanded measure in the Hospital VBP Program.

Response: We acknowledge that hospitals will not have an opportunity to review publicly reported data before the measure is finalized in the Hospital VBP Program; however, the measure has been refined to more fully capture the mortality of patients with pneumonia, which we believe is important to capture in the Hospital VBP Program as soon as possible.

We also note that hospitals will have time to review and analyze their performance on the expanded measure prior to the FY 2021 program year because the update to the MORT–30–PN measure was implemented in the Hospital IQR Program before we are finalizing it in the Hospital VBP Program.
believed penalizing hospitals treating morbidity and mortality, such as different baseline factors that influence different cohorts of patients with also noted that the measure will capture prevention strategies. The commenters despite evidence-based treatment and also with antibiotics, IV fluids, and symptom pneumonia are medically frail patients the majority of patients with aspiration expansion to include aspiration performance period. will not begin until September 1, 2017 for the updated MORT–30–PN measure Hospital Compare on or around July 27, 2016. Because the performance period for the updated MORT–30–PN measure will not begin until September 1, 2017 (instead of August 1, 2017, discussed in more detail below), hospitals will have one full year to review and assess their performance on the expanded measure prior to the beginning of the performance period.

Comment: A few commenters did not support the MORT–30–PN measure’s expansion to include aspiration pneumonia because commenters believe the majority of patients with aspiration pneumonia are medically frail patients with comorbidities that predispose them to recurrent aspiration events and therefore represent a higher risk for complications, readmissions, and death despite evidence-based treatment and prevention strategies. The commenters also noted that the measure will capture different cohorts of patients with different baseline factors that influence morbidity and mortality, such as patients with psychiatric and substance abuse comorbidities, and commenter believed penalizing hospitals treating these patients may impact availability of services for these patients.

Response: We appreciate the commenters’ concerns about the extent of the refinement of this measure and the inclusion of patients with greater illness severity. In particular, we understand commenters’ concerns that aspiration pneumonia can have different causes and associated risks (for example, recurrent aspiration due to other comorbidities). However, while the pathological causes of aspiration pneumonia are slightly different from the causes of community acquired pneumonia, in routine clinical practice, evidence shows it can be very challenging for physicians to differentiate aspiration syndromes including pneumonitis and pneumonia, from other types of pneumonia included in the measure. This is reflected in the tremendous variation across hospitals in the use of aspiration pneumonia diagnosis codes. This variation suggests that hospitals are not consistently distinguishing between these conditions as distinct subtypes regardless of patients’ comorbid conditions. Expanding the measure cohort would ensure that the measure is clinically comprehensive.

Moreover, the treatment of patients hospitalized for pneumonia, aspiration pneumonia, or sepsis due to pneumonia is very similar and involves treatment with antibiotics, IV fluids, and symptom management. In addition, although some patients with aspiration pneumonia, such as medically frail patients, have a higher predicted mortality risk, many of the associated comorbidities are captured in the MORT–30–PN (updated cohort) measure’s risk-adjustment methodology. Of note, due to the increased number of patients that are included in the expanded cohort, we reselected risk-adjustment variables to ensure that the measure does not bias hospital performance as well as accounts for the differences in risk among the subgroup of patients. For example, the risk model includes clinical history of stroke, as well as conditions associated with frailty, such as neuromuscular disease, and dementia. We refer readers to the measure methodology report and measure risk adjustment statistical model, Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Mortality Measures—Pneumonia Mortality Version 10, in the AMI, HF, PN, COPD, and Stroke Mortality Update zip file available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

After consideration of the public comments we received, we are finalizing the proposal to add the MORT–30–PN (updated cohort) to the Hospital VBP Program beginning with the FY 2021 program year.

5. New Measure for the FY 2022 Program Year: Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery (NQF #2558)

The Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following CABG Surgery (NQF #2558) (MORT–30–CABG) measure is a risk-adjusted, NQF-endorsed mortality measure monitoring mortality rates following CABG hospitalizations. This measure includes Medicare FFS patients aged 65 or older who receive a qualifying CABG procedure and assesses hospitals’ 30-day, all-cause risk-standardized rate of mortality, beginning with the date of the index procedure. The measure is calculated using administrative claims data. In general, the measure uses the same approach to risk adjustment as our 30-day outcome measures previously adopted for the Hospital VBP Program. We adopted this measure in the Hospital IQR Program in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50224 through 50227). Initial measure data were posted on Hospital Compare in July 2015 and the full measure specifications are available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

CABG is a priority area because it is a common procedure associated with considerable morbidity, mortality, and healthcare spending. In the United States, over 200,000 CABG procedures are performed annually, and the majority of procedures are performed on Medicare beneficiaries. In 2012, Medicare beneficiaries had 121,744 CABG surgery admissions, with or without percutaneous coronary intervention or valve surgery. CABG surgeries are costly procedures that account for a large percentage of cardiac surgeries performed nationally. For example, isolated CABG surgeries accounted for almost half (40.02 percent) of all cardiac surgery hospital admissions in Massachusetts in FY 2012. This provides an example of the frequency in which a CABG is performed for a patient who needed cardiac surgery. The average Medicare payment was $32,564 for CABG without valve and $48,461 for CABG plus valve surgeries in 2011.

Mortality rates following CABG surgery are not insignificant and vary across hospitals. For the July 2011 through June 2014 Hospital IQR Program reporting period, the median hospital-level risk-standardized mortality rate after CABG was 3.1 percent and ranged from 1.6 percent to 7.2 percent. Variation in mortality rates following CABG surgery can be seen not only nationally, but also within a single State. Within the State of New York, the risk-adjusted mortality rate

among patients who were discharged after CABG surgery (without any other major heart surgery earlier in the hospital stay) ranged from 0.0 percent to 4.58 percent in 2011.46 Variation in risk-standardized mortality rates among U.S. hospitals suggests that there is room for improvement.

An all-cause, risk-adjusted mortality measure for patients who undergo CABG surgery would provide hospitals with an incentive to reduce mortality through improved coordination of perioperative care and discharge planning. This is further supported by the success of registry-based mortality measures in reducing CABG mortality rates. For example, CABG mortality in California declined from 2.9 percent in 2003, the first year that the State implemented a mandatory CABG mortality reporting measure, to 2.1 percent in 2012.47

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25107), we proposed the MORT–30–CABG measure for the Hospital VBP Program beginning with the FY 2022 program year because it addresses a high-volume, high-cost procedure with variation in performance. The measure also aligns with the CMS Quality Strategy Goal of Effective Prevention and Treatment of Chronic Disease. The measure fulfills all statutory requirements for the Hospital VBP Program based on our adoption of the measure in the Hospital IQR Program and our posting of measure data on Hospital Compare for at least one year before the beginning of the measure performance period. The MAP supported the inclusion of the MORT–30–CABG measure (MUC15–395) in the Hospital VBP Program as detailed in the “Spreadsheet of MAP 2016 Final Recommendations.”48 Based on the continued high risk of mortality after CABG hospitalizations, we proposed to add this measure to the Clinical Care domain beginning with the FY 2022 program year.

We invited public comments on this proposal.

Comment: Many commenters supported the MORT–30–CABG measure because it is NQF-endorsed and MAP-supported, noting that the measure addresses a high-volume, high-cost procedure with performance variation and including the measure will reduce mortality through improved coordination and planning. One commenter noted that an all-cause, risk-adjusted mortality measure for patients who undergo CABG surgery will provide hospitals with an incentive to reduce mortality through improved coordination of perioperative care and discharge planning. One commenter supported adding the MORT–30–CABG measure because the commenter believed the measure increases incentives for hospitals to better manage patients’ chronic conditions after discharge.

Response: We thank the commenters for their support.

Comment: One commenter did not support the addition of the MORT–30–CABG measure because it captures mortality that could be unrelated to the procedure and beyond the hospital’s control. The commenter suggested adding language excluding cases where patients die from causes unrelated to the CABG procedure.

Response: The measure assesses all-cause mortality rather than CABG-specific mortality for several reasons. First, limiting the measure to CABG-related mortalities may limit the focus of efforts to improve care to a narrow set of approaches as opposed to encouraging broader initiatives and innovative approaches aimed at improving the overall in-hospital care. Second, cause of death may be unreliable recorded and it is often not possible to exclude quality issues and accountability based on the documented cause of mortality.

Comment: Several commenters did not support the addition of the MORT–30–CABG for the FY 2022 program year. Commenters expressed concern that the MORT–30–CABG measure’s reliability is inadequate and depends heavily upon whether a hospital has a sufficient volume of eligible patients. One commenter stated the measure is not NQF-endorsed. One commenter believed the data the MORT–30–CABG measure captures will overlap with the MORT–30–AMI measure.

Response: We disagree with commenter’s concern regarding the overlap between the MORT–30–AMI and MORT–30–CABG measures, we believe it is important that both measures represent the full spectrum of admissions eligible for the cohort for each individual measure to ensure the validity of the individual measures as endorsed by the NQF. We also find that the overlap is minimal between the measures, with prior analysis showing less than 7 percent of the AMI cohort included in the CABG measure cohort.

Comment: Some commenters recommended that CMS include adequate risk-adjustment modifications to the measure that addresses both SDs and clinical factors.

Response: The NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, ASPE is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the impact of the ASPE reports and related Secretarial recommendations and consider how...
they apply to our quality programs at such time as they are available.

Comment: A few commenters expressed concern that the MORT–30–CABG measure, as well as other previously finalized measures, does not exclude patients that desire comfort care, such as hospice services, because these patients have been found to impact mortality measure data and hospital performance for patients with pneumonia. One commenter recommended that CMS modify the measure to exclude patients that desire comfort care rather than treatment. Likewise, another commenter recommended that CMS exclude hospice patients from all mortality measures.

Response: The MORT–30–CABG measure does not exclude patients who transition to hospice care following the index admission because such transitions may be the result of quality failures that have led to poor clinical outcomes. However, all mortality measures proposed and finalized for the Hospital VBP Program, except for the MORT–30–CABG measure, do exclude index admissions for patients enrolled in the Medicare hospice program any time in the 12 months prior to the index admission, including the first day of the index admission, because these patients are likely continuing to seek comfort care only; thus, mortality is not necessarily an adverse outcome or signal of poor quality care for these patients. We note, however, that the MORT–30–CABG measure does not exclude hospice patients because any patient undergoing CABG surgery likely has survival as the primary goal.

After consideration of the public comments we received, we are finalizing the proposal to add the MORT–30–CABG measure beginning with the FY 2022 program year.

6. Previously Adopted and Newly Finalized Baseline and Performance Periods

a. Background

Section 1886(o)(4) of the Act requires the Secretary to establish a performance period for the Hospital VBP Program that begins and ends prior to the beginning of such fiscal year. We refer readers to the FY 2016 IPPS/LTC PPS final rule (80 FR 49561 through 49562) for the baseline and performance periods for the Clinical Care, Person and Community Engagement, Safety, and Efficiency and Cost Reduction domains that we have adopted for the FY 2018 program year. In this final rule, we have proposed and adopted a new baseline and performance period for each program year for each domain in each final rule. In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25107 through 25110), we proposed to adopt the following baseline and performance periods for all future program years, unless otherwise noted in future rulemaking.

b. Patient- and Caregiver-Centered Experience of Care/Care Coordination Domain (Person and Community Engagement Domain Beginning With the FY 2019 Program Year)

Since the FY 2015 program year, we have adopted a 12-month baseline period and a 12-month performance period for measures in the re-named Person and Community Engagement domain (previously referred to as the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain) (77 FR 53598; 78 FR 50692; 79 FR 50072; 80 FR 49561). We continue to believe that a 12-month period provides us sufficient data on which to score hospital performance.

In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25108), we proposed to adopt this baseline and performance period length for the FY 2019 program year and all future program years, unless otherwise noted in future rulemaking. Therefore, for the FY 2019 program year and future program years, we proposed to adopt a performance period that runs on the calendar year 2 years prior to the applicable program year. We proposed to adopt baseline period that runs on the calendar year 4 years prior to the applicable program year.

Applying these new policies, for the FY 2019 program year, the baseline period for the MSPB measure would run from January 1, 2015 through December 31, 2017. The performance period would run from January 1, 2017 through December 31, 2017.

We received no public comments on this proposal. Therefore, we are finalizing the proposal to adopt a performance period for the MSPB measure that runs on the calendar year 2 years prior to the applicable program year and to adopt a baseline period that runs on the calendar year 4 years prior to the applicable program year, for the FY 2019 program year and all future program years.

(2) AMI and HF Payment Measures in the FY 2021 Program Year

In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25103 through 25105), we also proposed to adopt the AMI Payment and HF Payment measures as 2 new measures for the Efficiency and Cost Reduction domain beginning in the FY 2021 program year. In order to adopt the measures as early as feasible into the Hospital VBP Program, in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25108 through 25109), we proposed to adopt a 36-month baseline period and a 24-month performance period. Therefore, for the FY 2021 program year, we proposed to adopt a 24-month performance period that runs from July 1, 2017 to June 30, 2019. We proposed to adopt a 36-month baseline period that runs from July 1, 2012 to June 30, 2015.

We believe that using a 24-month performance period for the AMI Payment and HF Payment measures, rather than a 36-month performance period, in the FY 2021 program year would accurately assess the quality of
care provided by hospitals and would not substantially change hospitals’ performance on the measure. To determine the viability of using a 24-month performance period to calculate the AMI Payment and HF Payment measures’ scores, we compared the measure score reliability for a 24-month and 36-month performance period. We calculated the Intraclass Correlation Coefficient (ICC) to determine the extent to which assessments of a hospital using different but randomly selected subsets of patients produces similar measures of hospital performance.

We calculated the risk-standardized payment (RSP) using a random split-sample of a 36-month performance period (we used July 1, 2012 through June 30, 2015).

For both the 36-month and the 24-month performance periods, we obtained 2 RSPs for each hospital, using an entirely distinct set of patients from the same time period. If the RSPs for both the 36-month and the 24-month performance periods agree, we can demonstrate that the measure assesses the quality of the hospital rather than the types of patients treated. To calculate agreement between these measure subsets, we calculated the ICC (2,1) for both the 36-month and 24-month performance periods.

For the AMI Payment measure, there were 459,874 index admissions and 2,342 hospitals that met the minimum threshold for reporting a measure result (at least 25 cases) in the 36-month performance period. We also calculated the RSP using a random split-sample of the combined 24-month performance period (we used July 1, 2012 through June 30, 2014). There were 309,067 index admissions and 2,141 hospitals that met the minimum threshold for reporting a measure result in the 24-month performance period.

For the 36-month performance period, the ICC for the 2 independent assessments of each hospital was 0.775. For the 24-month performance period, the ICC for the 2 independent assessments of each hospital was 0.742. Therefore, the data subsets showcase “substantial” agreement of hospital performance, and we can demonstrate that, even with a 24-month performance period, the measure assesses the quality of care provided at the hospital rather than the types of patients that these hospitals treat.

To assess whether using 24 months of data instead of 36 months of data changes the performance in the same hospital, we compared the percent change in a hospital’s predicted/expected (P/E) ratio. For hospitals that met the minimum case threshold in the 24-month performance period, the median percent change was −0.06 percent (with an interquartile range of −1.7 percent to 1.5 percent). These results suggest minimal difference in same-hospital performance when using a 24-month measurement period.

To determine the viability of using a 24-month performance period to calculate the HF Payment measure’s score, we assessed reliability and change in hospital performance for a 24-month and 36-month performance period using the same process as the AMI Payment measure. For the HF Payment measure, there were 877,856 index admissions and 2,981 hospitals that met the minimum threshold for reporting a measure result (at least 25 cases) in the 36-month performance period. We also calculated the RSP using a random split-sample of a 24-month performance period (we used July 1, 2012 through June 30, 2014). There were 580,741 index admissions and 2,883 hospitals that met the minimum threshold for reporting a measure result in the 24-month performance period.

For the 36-month performance period, the ICC for the 2 independent assessments of each hospital was 0.83. For the 24-month performance period, the ICC for the 2 independent assessments of each hospital was 0.81. Therefore, the data subsets showcase “almost perfect” agreement of hospital performance, and we can demonstrate that, even with a 24-month performance period, the measure assesses the quality of care provided at the hospital rather than the types of patients that these hospitals treat.

To assess whether using a 24-month performance period instead of a 36-month performance period changes the performance in the same hospital, we compared the percent change in a hospital’s P/E ratio. For hospitals that met the minimum case threshold in the 24-month performance period, the median percent change was 0.02 percent (with an interquartile range of −1.9 percent to 1.8 percent). These results suggest minimal difference in same-hospital performance when using a 24-month measurement period.

Therefore, we believe that using a 24-month performance period rather than a 36-month performance period would not substantially change hospitals’ performance on the AMI Payment and HF Payment measures. In sum, based on the analyses described earlier, we believe that using 24-month performance periods, rather than 36-month performance periods, for the initial performance period for this measure would accurately assess the quality of care provided by that hospital and would not substantially change that hospital’s performance on the measure.

Comment: A few commenters did not support the proposal to adopt the AMI Payment and HF Payment measures with a 24-month performance period in the FY 2021 program year because commenters believe the measures should have consistent baseline and performance periods across program years in order to fairly and accurately compare performance from program year to program year. Several commenters recommended that CMS delay adoption of the AMI Payment and HF Payment measures until the FY 2022 program year when CMS can adopt 36-month performance periods. One commenter supported the use of a three-year baseline period because a longer baseline period can account for the longer-term predictive value of health events such as AMI or HF better than a one-year baseline period.

Response: We note that the AMI Payment and HF Payment measures will only have a 24-month performance period for the FY 2021 program year, the first year these measures are in the program, but we are adopting a 36-month performance period for the FY 2022 program year, as detailed in the next section below. We continue to believe that the 24-month performance period for FY 2021 is sufficiently reliable to accurately assess the resource use by hospitals and would not substantially change hospitals’ performance on the measure.

After consideration of the public comments we received, we are finalizing the proposal to adopt a 24-month performance period and 36-month baseline period for both the AMI Payment and HF Payment measures for the FY 2021 program year.

(3) AMI Payment and HF Payment Measures in the FY 2022 Program Year

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25109), for the FY 2022 program year, we proposed to adopt a 36-month performance period and a 36-month baseline period for the
AMI Payment and HF Payment measures. We have stated in past rules that we would strive to adopt 36-month performance periods and baseline periods when possible to accommodate the time needed to process measure data and to ensure that we collect enough measure data for reliable performance scoring for all mortality measures (80 FR 49588; 79 FR 50057; 78 FR 50074). Therefore, for the FY 2022 program year, we proposed to adopt a 36-month performance period that runs from July 1, 2017 to June 30, 2020. We proposed to adopt a 36-month baseline period that runs from July 1, 2012 to June 30, 2015.

After consideration of the public comments we received, we are finalizing the proposal to adopt a 36-month performance period and 36-month baseline period for the AMI Payment and HF Payment for the FY 2022 program year.

d. Safety Domain

Since the FY 2016 program year, we have adopted a 12-month baseline period and 12-month performance period for all measures in the Safety domain, with the exception of the PSI 90 measure (78 FR 50692; 79 FR 50071; 80 FR 49562). We continue to believe that a 12-month period for these measures provides us sufficient data on which to score hospital performance. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25109), we proposed to adopt a 12-month baseline period and a 12-month performance period for all measures in the Safety domain for the FY 2019 program year and all future program years, unless otherwise noted in future rulemaking. Under this proposed policy, for the FY 2019 program year and future program years, we proposed to adopt a performance period that runs on the calendar year 2 years prior to the applicable program year. We proposed to adopt a baseline period that runs on the calendar year 4 years prior to the applicable program year. Applying these new policies, for the FY 2019 program year, the baseline period for all measures in the Safety domain would run from January 1, 2015 through December 31, 2015. The performance period would run from January 1, 2017 through December 31, 2017.

We received no public comments on this proposal. Therefore, we are finalizing the proposal to adopt a performance period for all remaining measures in the Safety domain (we refer readers to the discussion below regarding the PSI 90 measure) that runs on the 2 years prior to the applicable program year and to adopt a baseline period that runs on the calendar year 4 years prior to the applicable program year, for the FY 2019 program year and all future program years.

As discussed in section IV.H.2.a. of the preamble of this final rule, we are finalizing our proposal to adopt a shortened performance period for the PSI 90 measure in the FY 2018 program year, which will be July 1, 2014 through September 30, 2015. As stated earlier, the baseline period for the PSI 90 measure for FY 2018 that we previously established would not change.

e. Clinical Care Domain

(1) Currently Adopted Measures in the Clinical Care Domain

For the FY 2019, FY 2020, and FY 2021 program years, we have adopted a 36-month baseline period and a 36-month performance period for currently adopted measures in the Clinical Care domain (78 FR 50692 through 50694; 79 FR 50073; 80 FR 49563). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25109), for the FY 2022 program year, we proposed to adopt a 36-month performance period and a 36-month baseline period for each of the other measures in the Clinical Care domain, the MORT–30–AMI, MORT–30–HF, and MORT–30–COPD measures, as well as the new MORT–30–CABG measure. The performance periods for these measures would run for 36-months from July 1, 2017 through June 30, 2020. The baseline period would run from July 1, 2012 through June 30, 2015. We proposed that the THA/TKA measure performance period would run from April 1, 2017 through March 31, 2020. The baseline period would run from April 1, 2013 through March 31, 2015.

We received no public comments on this proposal. Therefore, we are finalizing the proposal to adopt a 36-month performance period and 36-month baseline period for the FY 2022 program year for the measures currently adopted in the Clinical Care domain.

(2) MORT–30–PN (Updated Cohort) Measure in the FY 2021 Program Year

In order to adopt the new MORT–30–PN (updated cohort) measure into the Hospital VBP Program as early as feasible, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25110), we proposed to adopt a 36-month baseline period and a 23-month performance period for the FY 2021 program year. We proposed to adopt a 23-month performance period because the measure will not have been posted on Hospital Compare for one year until July 21, 2017 (now on or about July 27, 2017). We proposed to begin the performance period on August 1, 2017 to accommodate this statutory requirement.

We believe that using a 23-month performance period for the MORT–30–PN (updated cohort) measure, rather than a 36-month performance period, in the FY 2021 program year would accurately assess the quality of care provided by hospitals and would not substantially change hospitals’ performance on the measure. To determine the viability of using a 23-month performance period to calculate the MORT–30–PN (updated cohort) measure’s score, we compared the measure score reliability for a 23-month and a 36-month performance period. We calculated the ICC to determine the extent to which assessments of a hospital using different but randomly selected subsets of patients produces similar measures of hospital performance. We calculated the RSMR using a random split-sample of the combined 36-month performance period (we used July 1, 2012 through June 30, 2015). There were 1,292,701 index admissions and 3,103 hospitals that met the minimum threshold for reporting a measure result (at least 5 cases) in the 36-month performance period. We also calculated the RSMR using a random split-sample of the combined 23-month performance period (we used July 1, 2012 through May 31, 2014). There were 798,746 index admissions and 3,043 hospitals that met the minimum threshold for reporting a measure result in the 23-month performance period.

For both the 36-month data and the 23-month performance periods, we obtained 2 RSMRs for each hospital, using an entirely distinct set of patients from the same time period. If the RSMRs for both the 36-month subset and the 23-month performance periods agree, we can demonstrate that the measure assesses the quality of the hospital rather than the types of patients treated. To calculate agreement between these measure subsets, we calculated the ICC for both the 36-month and 23-month performance periods.

For the 36-month data performance period, the agreement between the 2 independent assessments of each hospital was 0.69. For the 23-month data performance period, the agreement...
between the 2 independent assessments of each hospital was 0.58. Therefore, the data subsets showcase “moderate” agreement of hospital performance, and we can demonstrate that, even with a 23-month performance period, the measure modestly assesses the quality of care provided at the hospital rather than the types of patients that these hospitals treat.\(^\text{34}\)

To assess whether using a 23-month performance period instead of a 36-month performance period changes the performance in the same hospital, we compared the percent change in a hospital’s RSMR. In some cases, changing the performance period from 36 months to 23 months results in hospitals failing to meet the case threshold to report a measure score; therefore, these hospitals were removed from the measure. For the remaining hospitals, the median percent change was 1.52 percent (with an interquartile range of 2.32 percent to 5.32 percent). These results suggest minimal difference in hospital performance when using a 23-month measurement period.

Therefore, we believe that using 23 months of data rather than 36 months of data would not substantially change hospitals’ performance on this measure. In summary, based on the analyses described earlier, we believe that using 23 months of data, rather than 36 months of data, for the initial performance period for this measure would, with moderate accuracy, assess the quality of care provided by that hospital. In addition, it would not substantially change that hospital’s performance on the measure.

Further, adopting this performance period will enable us to include the updated measure cohort in the FY 2021 Hospital VBP Program, which would ensure that MORT–30–PN more accurately reflects quality and outcomes for patients with pneumonia. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25110), for the MORT–30–PN (updated cohort) measure, we proposed a performance period that would run from August 1, 2017 through June 30, 2019 for the FY 2021 program year. The baseline period would run from July 1, 2017 through June 30, 2021 program year. Comment: One commenter supported our inclusion of the MORT–30–PN measure for the FY 2021 program year with a 23-month performance period. Response: We thank the commenter for its support.


Comment: A few commenters did not support the 23-month performance period for the MORT–30–PN measure in the FY 2021 program year because commenters believed the measure is only moderately reliable, which is insufficient for a payment program. One commenter did not believe CMS has proven that the measure is reliable with a shorter performance period, and the commenter recommended that CMS refrain from pushing to adopt measures for the Hospital VBP Program when doing so would require using shortened performance periods.

Response: As we note in the proposed rule (81 FR 25108), we calculated the Intraclass Correlation Coefficient (ICC) to determine the extent to which assessments of a hospital using different but randomly selected subsets of patients produces similar measures of hospital performance.\(^\text{35}\)

For the 23-month performance period the ICC was 0.58, which is consistent with other NQF-endorsed claims-based measures in the Hospital VBP Program. Therefore, we believe the measure is sufficiently reliable to include in the program.

Since publication of the FY 2017 IPPS/LTCH PPS proposed rule, we have become aware of operational issues that may delay publication of MORT–30–PN measure data on Hospital Compare by 1–2 weeks but past August 1, 2016. Under section 1886(o)(2)(C)(i) of the Act, the Hospital VBP Program must refrain from beginning the performance period for a new measure until data on the measure have been posted on Hospital Compare for at least one year. As a result, we believe it is necessary to delay the beginning of the performance period for the MORT–30–PN measure one additional month, from August 1, 2017 to September 1, 2017. We continue to believe the MORT–30–PN measure will be sufficiently reliable using 22 months of data because this is not a significant reduction in the amount of data used to calculate performance scores under the measure.

After consideration of the public comments we received, we are finalizing our proposal to adopt the MORT–30–PN (updated cohort) measure with a 23-month performance period and 36-month baseline period for the FY 2021 program year.

(3) MORT–30–PN (Updated Cohort) Measure in the FY 2022 Program Year

For the FY 2022 program year and subsequent years, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25110), we proposed to lengthen the MORT–30–PN (updated cohort) performance period to nearly a 36-month performance period (35 months) and continue to adopt a 36-month baseline period. For the FY 2022 program year, we proposed a performance period that would run from August 1, 2017 through June 30, 2020. The baseline period would run from July 1, 2012 through June 30, 2015.

Comment: A few commenters did not support the 35-month performance period for the MORT–30–PN measure in the FY 2022 program year because the commenters believe that CMS has not demonstrated that the measure is highly accurate.

Response: Since the MORT–30–PN measure was found to be statistically reliable at 23 months, we believe that the measure will be even more reliable at 35 months. As noted above, due to operational concerns associated with timely publication of MORT–30–PN data on Hospital Compare, we are delaying the start of the FY 2021 performance period by one month, to September 1, 2017. For these same reasons, we are finalizing that instead of beginning the performance period for the MORT–30–PN measure for FY 2022 on August 1, 2017, the performance period will begin on September 1, 2017. We do not believe shortening the FY 2022 MORT–30–PN performance period by one month will affect the reliability of the measure because it will not significantly impact the amount of data used to calculate performance scores under the measure.

After consideration of the public comments we received, we are finalizing our proposal to adopt the MORT–30–PN (updated cohort) measure with a 34-month performance period and 36-month baseline period for the FY 2022 program year. In the FY 2023 program year and subsequent years, we intend to lengthen the MORT–30–PN (updated cohort) performance period to a full 36-month performance period beginning in July, instead of September.

f. Summary of Previously Adopted and Newly Finalized Baseline and Performance Periods for the FY 2018, FY 2019, FY 2020, FY 2021, and FY 2022 Program Years

The tables below summarize the baseline and performance periods that
we are adopting in this final rule (and
include previously adopted baseline
Care domain).

**PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2018 PROGRAM YEAR**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline period</th>
<th>Performance period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*We are adopting a shortened performance period for the PSI 90 measure for the FY 2018 program year, as discussed in section IV.H.2.a. of the preamble of this final rule.

**PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2019 PROGRAM YEAR**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline period</th>
<th>Performance period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Person and Community Engagement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• HCAHPS + 3-Item Care Transition</td>
<td>January 1, 2015–December 31, 2015</td>
<td>January 1, 2017–December 31, 2017</td>
</tr>
<tr>
<td>Clinical Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• PSI 90</td>
<td>July 1, 2011–June 30, 2013</td>
<td>July 1, 2015–June 30, 2017</td>
</tr>
<tr>
<td>Efficiency and Cost Reduction</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Previously adopted baseline and performance periods that remain unchanged (80 FR 49562 through 49563).

**PREVIOUSLY ADOPTED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2020 PROGRAM YEAR**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline period</th>
<th>Performance period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• THA/TKA*</td>
<td>July 1, 2010–June 30, 2013</td>
<td>July 1, 2015–June 30, 2018</td>
</tr>
</tbody>
</table>

*Previously adopted baseline and performance periods that remain unchanged (80 FR 49562 through 49563).

**PREVIOUSLY ADOPTED AND NEWLY FINALIZED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2021 PROGRAM YEAR**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline period</th>
<th>Performance period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• THA/TKA*</td>
<td>April 1, 2011–March 31, 2014</td>
<td>April 1, 2011–March 31, 2019</td>
</tr>
<tr>
<td>Efficiency and Cost Reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• MSPB</td>
<td>January 1, 2017–December 31, 2017</td>
<td>January 1, 2019–December 31, 2019</td>
</tr>
<tr>
<td>• Payment (AMI Payment and HF Payment)</td>
<td>July 1, 2012–June 30, 2015</td>
<td>July 1, 2017–June 30, 2019</td>
</tr>
<tr>
<td>• THA/TKA*</td>
<td>April 1, 2011–March 31, 2014</td>
<td>April 1, 2016–March 31, 2019</td>
</tr>
<tr>
<td>Efficiency and Cost Reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• MSPB</td>
<td>January 1, 2017–December 31, 2017</td>
<td>January 1, 2019–December 31, 2019</td>
</tr>
<tr>
<td>• Payment (AMI Payment and HF Payment)</td>
<td>July 1, 2012–June 30, 2015</td>
<td>July 1, 2017–June 30, 2019</td>
</tr>
</tbody>
</table>

*Previously adopted baseline and performance periods that remain unchanged (80 FR 49562 through 49563).
NEWLY FINALIZED BASELINE AND PERFORMANCE PERIODS FOR THE FY 2022 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Domain</th>
<th>Baseline period</th>
<th>Performance period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• THA/TKA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• MORT–30–PN (updated cohort)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Efficiency and Cost Reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• MSPB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Payment (AMI Payment, HF Payment)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7. Immediate Jeopardy Policy Changes
   a. Background

Section 1886(o)(1)(C) of the Act states that the Hospital VBP Program applies to subsection (d) hospitals (as defined in section 1886(d)(1)(B) of the Act), but excludes from the definition of the term “hospital” with respect to a fiscal year a hospital “for which, during the performance period for such fiscal year, the Secretary has cited deficiencies that pose immediate jeopardy to the health or safety of patients.”

In 42 CFR 412.160 of our Hospital VBP Program regulations, we defined the term “Cited for deficiencies that pose immediate jeopardy” to mean that “during the applicable performance period, the Secretary cited the hospital for immediate jeopardy on at least 2 surveys using the Form CMS–2567, Statement of Deficiencies and Plan of Correction” (OMB Control Number 0938–0391). In 42 CFR 412.160, we also adopted the definition of “immediate jeopardy” found in 42 CFR 489.3 of our regulations.

Our current interpretation of the Hospital VBP Program’s statute is that a hospital cited for deficiencies that pose immediate jeopardy during any part of the finalized performance period for the applicable program year does not meet the definition of the term “hospital,” and thus is excluded from the Hospital VBP Program for that program year. Because the Hospital VBP Program currently uses measures with 12-month, 24-month, and 36-month performance periods, a hospital’s immediate jeopardy citations could result in its exclusion from the Hospital VBP Program for multiple program years.

b. Increase of Immediate Jeopardy Citations From Two to Three Surveys

In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25111 through 25112), we proposed to amend our regulations at 42 CFR 412.160 to change the definition of the term “Cited for deficiencies that pose immediate jeopardy” to increase the number of surveys where a hospital must be cited for immediate jeopardy before being excluded from the Hospital VBP Program pursuant to section 1886(o)(1)(C) of the Act from 2 to 3. In other words, we proposed that a hospital must be cited on Form CMS–2567, Statement of Deficiencies and Plan of Correction, for immediate jeopardy on at least three surveys during the performance period in order to meet the standard for exclusion from the Hospital VBP Program under section 1886(o)(1)(C)(ii)(II) of the Act. Beginning on the effective date of this change, hospitals would be excluded from the Hospital VBP Program for a particular program year if, during the performance period for that fiscal year, they were cited three times by the Secretary for deficiencies that pose immediate jeopardy to the health or safety of patients. Because we expect that the effective date of this change will be October 1, 2016 (the first day of the FY 2017 Hospital VBP program year), only hospitals that were cited 3 times during the performance period that applies to the FY 2017 program year would be excluded from the Hospital VBP Program. Hospitals that were, as of October 1, 2016, cited for immediate jeopardy on 2 surveys during the performance period that applies to the FY 2017 program year could participate in the Hospital VBP Program for the FY 2017 program year.

We proposed this change to be more inclusive of hospitals and to ensure that we are not too quickly excluding a hospital from participation in the Hospital VBP Program. After reviewing the survey and certification data, we have determined that limiting exclusion to those hospitals that have been cited for immediate jeopardy 3 or more times during the applicable performance period, rather than 2, would continue to appropriately exclude hospitals that are cited for jeopardizing patient safety while allowing hospitals with a lower number of immediate jeopardy citations over significantly longer performance periods to continue to participate in the Hospital VBP Program. Many immediate jeopardy citations involve systematic issues of patient safety, and we believe that hospitals that are, during the performance period, cited by the Secretary for 3 or more deficiencies that pose immediate jeopardy should be excluded from the Hospital VBP Program. We stated in the proposed rule that this proposal would ensure that we continue to assure high quality care while being as inclusive of hospitals as possible.

We invited public comments on this proposal.

Comment: Many commenters supported CMS’ proposal to increase the number of immediate jeopardy citations required to trigger Hospital VBP Program exclusion from 2 to 3 during the applicable performance period because hospitals should be encouraged to participate in the program and because such citations could result in excluding a hospital from the program for several program years. One commenter supported the proposal to increase the number of citations, and noted that an immediate jeopardy citation could be too broad and far-reaching under the current policy.

Response: We thank the commenters for their support.

Comment: One commenter did not support the proposal to increase the number of citations before being excluded from the program because it sets a low bar so that hospitals that average 1 immediate jeopardy citation per year or less can participate in the Hospital VBP Program. The commenter noted that an immediate jeopardy situation is a serious citation for a hospital to receive.

Response: We agree with the commenter that an immediate jeopardy citation should be considered seriously. Many immediate jeopardy citations have involved systematic issues of patient safety. However, they can also vary by level of patient safety risk and by location. We therefore believe that limiting exclusion from the Hospital VBP Program to those hospitals that have been cited for immediate jeopardy 3 or more times during the applicable performance period, rather than 2, would continue to appropriately
exclude hospitals that are cited for jeopardizing patient safety without excluding a hospital from participation in the Hospital VBP Program prematurely. In addition, when the immediate jeopardy policy was initially implemented in the Hospital VBP Program, the performance periods were shorter. Now, with significantly longer performance periods (up to 36 months), we believe it is more appropriate to allow hospitals with up to 3 immediate jeopardy citations to continue to participate in the Hospital VBP Program.

Comment: One commenter recommended that CMS limit ineligibility for hospitals cited for deficiencies that pose immediate jeopardy to one fiscal year at most because commenter believed this reflects Congress’ statutory intent in the Act.

Response: In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53611), we interpreted the statute to mean that a hospital that meets the definition of “cited for deficiencies that pose immediate jeopardy” during any of the finalized performance periods for any measure in a given program year would be excluded from participating in that program year. Several commenters objected to the interpretation of the statute based on the possibility of immediate jeopardy citations during a relatively wide date range, resulting in hospitals being excluded from several program years (77 FR 53614). We responded by stating in that final rule (77 FR 53614) that we believe that we must exclude hospitals so cited during any finalized performance period for a fiscal year regardless of the length of the applicable performance period.” We continue to believe that is the correct interpretation of section 1886(o)(1)(C) of the Act.

Comment: One commenter recommended several additional policies for CMS to consider with regard to the immediate jeopardy policy in the Hospital VBP Program. First, commenter recommended that CMS adopt an immediate jeopardy appeals process through which hospitals can appeal citations before an objective entity outside of HHS without being excluded from Medicare or the Hospital VBP Program because commenter believed this reflects Congress’ statutory intent in the Act. Second, commenter requested that CMS interpret and change the regulatory definitions at 42 CFR 412.160 such that the word “cited” would mean after appeal rights have been exhausted and the decision has been upheld as valid. The commenter also requested that appeal rights be guaranteed separate from any appeal rights under the Medicare condition of participation (CoP) and EMTALA. Third, commenter requested that when a hospital is issued multiple immediate jeopardy citations for the same factual findings, that is, the same patient issues, they be counted as one immediate jeopardy citation.

Response: We thank the commenter for its suggestions and we will take them into consideration if we decide to make additional changes to the immediate jeopardy policies in the future.

After consideration of the public comments we received, we are finalizing our proposal to amend our regulations at 42 CFR 412.160 to change the definition of the term “Cited for deficiencies that pose immediate jeopardy” to increase the number of surveys where a hospital must be cited for immediate jeopardy before being excluded from the Hospital VBP Program pursuant to section 1886(o)(1)(C) of the Act from 2 to 3.

c. EMTALA-Related Immediate Jeopardy Citations

Hospitals are often alerted to immediate jeopardy situations when a surveyor or team of surveyors is in the process of conducting a survey of compliance with the Medicare CoP at the hospital and identifies those situations that immediately jeopardize the health and safety of patients (77 FR 53610). Following the survey, the Form CMS–2567, Statement of Deficiencies and Plan of Correction, is sent to the hospital, which contains the survey findings, including any immediate jeopardy situations. For EMTALA-related immediate jeopardy situations, however, the CMS Regional Office determines whether there was an EMTALA violation after reviewing the State Survey Agency’s report and an expert physician review’s findings, and, if so, whether it constituted an immediate jeopardy (77 FR 53610). The CMS Regional Office then sends the Form CMS–2567 to the hospital.

Currently, the Automated Survey Processing Environment (ASPEN) system, an electronic system that supports our survey and certification activity, catalogs deficient practices (that is, noncompliance) identified during a survey and generates the Form CMS–2567 that is sent to the hospital after the survey. The survey end date generated in ASPEN is currently used as the date for assignment of the immediate jeopardy citation to a particular performance period (77 FR 53613). The additional processes for EMTALA-related immediate jeopardy citations can result in significant notification delays to hospitals (often several months or longer).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25112), in the case of EMTALA-related immediate jeopardy citations only, we proposed to change our policy regarding the date of the immediate jeopardy citation for possible exclusion from the Hospital VBP Program from the survey end date generated in ASPEN to the date of CMS’ final issuance of Form CMS–2567 to the hospital. Form CMS–2567 is not considered final until it is transmitted to the healthcare facility, either by the State Survey Agency, or, in all EMTALA cases and certain other cases, by the CMS Regional Office. The date of final issuance is also tracked in ASPEN. The date the Form CMS–2567 is sent by the CMS Regional Office to the hospital (via mail, electronically, or both) is the date of final issuance recorded in ASPEN. We believe this change would accurately reflect the date hospitals receive official notification of an immediate jeopardy citation based on the issuance date of Form CMS–2567 as this date will be weeks, if not months, after the survey end date. Hospitals may continue to receive preliminary notice during the onsite EMTALA investigation survey that they may receive an immediate jeopardy citation based on survey findings. However, because the decision-making responsibility in EMTALA investigations always rests with the CMS Regional Office, the final determination and notification of immediate jeopardy citations will always be delayed. The Form CMS–2567 constitutes the official notice to a healthcare facility of the survey findings.

Finally, in instances where one onsite hospital survey resulted in both hospital CoP immediate jeopardy citation(s) as well as EMTALA immediate jeopardy citation(s), the survey end date would be the default date for potential exclusion from the Hospital VBP Program. We recognize the hospital will receive notification of the EMTALA immediate jeopardy citation(s) at a later date than the CoP immediate jeopardy citation(s). However, because the hospital was notified of the CoP immediate jeopardy citation(s) at the time of survey, this date will be used for the performance period for potential exclusion from the Hospital VBP Program. Even though there may be separate enforcement actions resulting from the same survey, we will consider each Form CMS–2567 with immediate jeopardy findings to be an exclusion for purposes of the Hospital VBP Program (77 FR 53613).
In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25112), we proposed to revise our regulations at 42 CFR 412.160 to reflect the above proposal and specify use of the date of CMS’ final issuance of Form CMS–2567 to the hospital for EMTALA immediate jeopardy citation(s). We also proposed to specify that in instances where one onsite hospital survey resulted in both hospital CoP immediate jeopardy citation(s) as well as EMTALA immediate jeopardy citation(s), the survey end date would be the default date for potential exclusion from the Hospital VBP Program.

We invited public comments on this proposal.

We did not receive any public comments on this proposal. Therefore, we are finalizing our proposal to amend our regulations at 42 CFR 412.160 to change our policy regarding the date of the immediate jeopardy citation for possible exclusion from the Hospital VBP Program from the survey end date generated in ASPEN to the date of CMS’ final issuance of Form CMS–2567 to the hospital. We are also finalizing our proposal to use the survey end date as the default date for potential exclusion from the Hospital VBP Program when one onsite hospital survey results in both hospital CoP immediate jeopardy citation(s) as well as EMTALA immediately jeopardy citation(s).

8. Performance Standards for the Hospital VBP Program

a. Background

Section 1886(o)(3)(A) of the Act requires the Secretary to establish performance standards for the measures selected under the Hospital VBP Program for a performance period for the applicable fiscal year. The performance standards must include levels of achievement and improvement, as required by section 1886(o)(3)(B) of the Act, and must be established no later than 60 days before the beginning of the performance period for the fiscal year involved, as required by section 1886(o)(3)(C) of the Act. We refer readers to the Hospital Inpatient VBP Program final rule (76 FR 26511 through 26513) for further discussion of achievement and improvement standards under the Hospital VBP Program.

In addition, when establishing the performance standards, section 1886(o)(3)(D) of the Act requires the Secretary to consider appropriate factors, such as: (1) Practical experience with the measures, including whether a significant proportion of hospitals failed to meet the performance standard during previous performance periods; (2) historical performance standards; (3) improvement rates; and (4) the opportunity for continued improvement.

We refer readers to the FY 2013, FY 2014, and FY 2015 IPPS/LTCH PPS final rules (77 FR 53604 through 53605; 78 FR 50694 through 50698; and 79 FR 50077 through 50079) for a more detailed discussion of the general scoring methodology used in the Hospital VBP Program.

We note that the performance standards for the following measures are calculated with lower values representing better performance:

• The NHSN measures (the CLABSI, CAUTI, CDI, Colon and Abdominal Hysterectomy SSI, and MRSA Bacteremia measures);
• The PSI 90 measure;
• The THA/TKA measure;
• The PC–01 measure;
• The MSPB measure; and
• The HF and AMI Payment measures.

This distinction is made in contrast to other measures for which higher values indicate better performance. As discussed further in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50684), the performance standards for the Colon and Abdominal Hysterectomy SSI measure are computed separately for each procedure stratum, and we first award achievement and improvement points to each stratum separately, then compute a weighted average of the points awarded to each stratum by predicted infections.

The numerical values for the performance standards displayed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25113 through 25116) represented estimates based on the most recently available data, and we have updated the numerical values in this final rule to reflect new data in the charts below.

Comment: A few commenters did not support the PC–01 benchmark of 0 because The Joint Commission states that 2 to 4 percent is an expected rate for early elective delivery and commenters believed that some hospitals (such as academic medical centers and obstetric hospitals) experience a higher number of uncommon or rare conditions justifying the need for early-term elective delivery and, therefore, unable to meet the current benchmark.

Response: As stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49549), in response to similar comments, we disagree with the assertion that the benchmark of 0 percent is unrealistic because not all justifications for an elective delivery are included in the ICD–10–CM Justification Table. As we previously noted, the benchmark is intended to represent a level of excellent performance to which hospitals generally should aspire. While no measure can account for every possible situation, the measure specifications (available at: https://manual.jointcommission.org/releases/TJC2015B2/MIF0166.html) provide a large number of ICD–10–CM Principal Diagnosis Code or Other Diagnosis Codes for conditions possibly justifying elective delivery prior to 39 weeks gestation. Furthermore, the 0 percent benchmark for PC–01 was calculated from the mean of the top 10 percent for all hospitals during the baseline period; therefore, attaining this benchmark is not unrealistic. We continue to believe that hospitals should aspire to prevent elective deliveries from being performed before the gestational age of 39 weeks without a medical indication.

b. Previously Adopted and Newly Finalized Performance Standards for the FY 2019 Program Year

In accordance with our finalized methodology for calculating performance standards (discussed more fully in the Hospital Inpatient VBP Program final rule (76 FR 26511 through 26513)), in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25113), we proposed to adopt the following additional performance standards for the FY 2019 program year. We noted that the numerical values for the performance standards displayed in the proposed rule represented estimates based on the most recently available data, and that we intended to update the numerical values in this final rule. We noted further that the MSPB measure’s performance standards are based on performance period data; therefore, we are unable to provide numerical equivalents for the standards at this time. The table below has been updated from the FY 2017 IPPS/LTCH PPS proposed rule and represents the most recently available data.
### PREVIOUSLY ADOPTED AND NEWLY FINALIZED PERFORMANCE STANDARDS FOR THE FY 2019 PROGRAM YEAR: SAFETY, CLINICAL CARE, AND EFFICIENCY AND COST REDUCTION MEASURES

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTI*</td>
<td>National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure.</td>
<td>0.464 0.427</td>
<td>0.000 0.000</td>
</tr>
<tr>
<td>CLABSI*</td>
<td>National Healthcare Safety Network (NHSN) Central line-associated Bloodstream Infection (CLABSI) Outcome Measure.</td>
<td>0.816</td>
<td>0.012</td>
</tr>
<tr>
<td>CDI*</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset <em>Closstridium Difficile</em> Infection (CDI) Outcome Measure.</td>
<td>0.823</td>
<td>0.000</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI**</td>
<td>American College of Surgeons—Centers for Disease Control and Prevention (ACS–CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC–01*</td>
<td>Elective Delivery</td>
<td>0.010038</td>
<td>0.000000</td>
</tr>
<tr>
<td>PSI 90**</td>
<td>Patient Safety for Selected Indicators (Composite)</td>
<td>0.840335 0.840335</td>
<td>0.589462 0.589462</td>
</tr>
</tbody>
</table>

### Clinical Care Measures

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI*</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization.</td>
<td>0.850671</td>
<td>0.873263</td>
</tr>
<tr>
<td>MORT–30–HF*</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization.</td>
<td>0.883472</td>
<td>0.908094</td>
</tr>
<tr>
<td>MORT–30–PN*</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization.</td>
<td>0.882334</td>
<td>0.907906</td>
</tr>
<tr>
<td>THA/TKA*</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSMR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA).</td>
<td>0.032229</td>
<td>0.023178</td>
</tr>
</tbody>
</table>

### Efficiency and Cost Reduction Measure

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSPB*</td>
<td>Payment-Standardized Medicare Spending Per Beneficiary (MSPB)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Median Medicare Spending Per Beneficiary ratio across all hospitals during the performance period.</th>
<th>Mean of the lowest decile Medicare Spending Per Beneficiary ratios across all hospitals during the performance period.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Lower values represent better performance.

Previously adopted performance standards.

In the past, we have used the “normalization” approach to scoring the Patient- and Caregiver-Centered Experience of Care/Care Coordination domain (which we are renaming the Person and Community Engagement domain beginning with the FY 2019 program year, as discussed in section IV.H.3.b. of the preamble of this final rule). The 9 dimensions of the HCAHPS measure, one of which is the CTM–3 measure, are calculated to generate the HCAHPS Base Score. For each of the 9 dimensions, Achievement Points (0–10 points) and Improvement Points (0–9 points) are calculated, the larger of which is summed across the 9 dimensions to create a prenormalized HCAHPS Base Score (0–90 points). The prenormalized HCAHPS Base Score is then multiplied by 8/9 (0.88889) and rounded according to standard rules (values of 0.5 and higher are rounded up, values below 0.5 are rounded down) to create the normalized HCAHPS Base Score. Each of the 9 dimensions is of equal weight, so that the normalized HCAHPS Base Score would range from 0 to 80 points. HCAHPS Consistency Points are then calculated and range from 0 to 20 points. The Consistency Points consider scores across all 9 of the Person and Community Engagement dimensions. The final element of the scoring formula is the sum of the HCAHPS Base Score and the HCAHPS Consistency Points and ranges from 0 to 100 points. The table below has been updated from the FY 2017 IPPS/LTCH PPS proposed rule and represents the most recently available data.

### PERSON AND COMMUNITY ENGAGEMENT DOMAIN *

<table>
<thead>
<tr>
<th>HCAHPS survey dimension</th>
<th>Floor (percent)</th>
<th>Achievement threshold (percent)</th>
<th>Benchmark (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication with Nurses</td>
<td>28.10</td>
<td>78.69</td>
<td>86.97</td>
</tr>
</tbody>
</table>
We invited public comments on the proposed HCAHPS performance standards.

Comment: One commenter recommended reweighting the Communication about Medicines dimension of the proposed performance standards within the HCAHPS Survey because this commenter believed that medication mix-ups with opioid drugs are a leading cause of readmissions of senior citizens after a hospital stay.

Response: We disagree with the commenter that we should reevaluate the weighting of the Communication about Medicines dimension within the HCAHPS Survey because we do not believe there is a link between the three questions on the HCAHPS Survey that comprise the Communication about Medicines dimension and the rate of senior citizens’ readmission to hospitals. The three questions include: “During this hospital stay, were you given any medicine that you had not taken before?” “Before giving you any new medicine, how often did hospital staff tell you what the medicine was for?” and “Before giving you any new medicine, how often did hospital staff describe possible side effects in a way you could understand?” We believe that asking questions on communications about medicines will encourage hospitals to ensure their staff are properly communicating medication information to patients. Patients’ understanding of their medication is critical to reducing medication errors and improving quality and safety.

Comment: One commenter expressed concern about the HCAHPS Survey’s ability to form a valid assessment of patient experience, based in part on its low response rate.

Response: Hospitals must report a minimum number of 100 completed HCAHPS surveys for a hospital to receive a Patient and Community Engagement domain score (see section IV.H.9.b. of the preamble of this final rule). We continue to believe that this requirement appropriately balances our desire to enable as many hospitals as possible to participate in the Hospital VBP Program and the need for the TPSs to be sufficiently reliable to provide meaningful distinction between hospitals’ performance on quality measures.

Comment: Several commenters recommended disassociating the Pain Management dimension questions from the HCAHPS Survey because commenters believe it is linked to the over-prescription of pain medication in the United States. One commenter suggested modifying the question based on the Emergency Department Patient Experience of Care (ED PEC) survey tool (currently being developed) which allows for different levels of pain and discomfort.

Response: With regard to comments related to the Pain Management dimension in the Hospital VBP Program, we refer readers to the Hospital VBP Program proposal in the CY 2017 OPPS/ASC PPS proposed rule (81 FR 45755 through 45757).

PREVIOUSLY ADOPTED PERFORMANCE STANDARDS FOR CERTAIN CLINICAL CARE DOMAIN AND SAFETY DOMAIN MEASURES FOR THE FY 2020 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSI 90 *</td>
<td>Patient Safety for Selected Indicators (Composite)</td>
<td>0.778761</td>
<td>0.545903</td>
</tr>
</tbody>
</table>
PREVIOUSLY ADOPTED PERFORMANCE STANDARDS FOR CERTAIN CLINICAL CARE DOMAIN AND SAFETY DOMAIN MEASURES FOR THE FY 2020 PROGRAM YEAR—Continued

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization.</td>
<td>0.853715</td>
<td>0.875869</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization.</td>
<td>0.881090</td>
<td>0.906068</td>
</tr>
<tr>
<td>MORT–30–PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization.</td>
<td>0.882266</td>
<td>0.909532</td>
</tr>
<tr>
<td>THA/TKA *</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA).</td>
<td>0.032229</td>
<td>0.023178</td>
</tr>
</tbody>
</table>

* Lower values represent better performance.

PREVIOUSLY ADOPTED AND NEWLY FINALIZED PERFORMANCE STANDARDS FOR THE FY 2021 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization.</td>
<td>0.860355</td>
<td>0.879714</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization.</td>
<td>0.883803</td>
<td>0.906144</td>
</tr>
<tr>
<td>MORT–30–PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization.</td>
<td>0.886443</td>
<td>0.910670</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization.</td>
<td>0.923253</td>
<td>0.938664</td>
</tr>
<tr>
<td>THA/TKA *</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA).</td>
<td>0.031157</td>
<td>0.022418</td>
</tr>
</tbody>
</table>

Efficiency and Cost Reduction Measures

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI Payment *#</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI).</td>
<td>Median Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
<td>Mean of the lowest decile Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
</tr>
<tr>
<td>HF Payment *#</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Heart Failure (HF).</td>
<td>Median Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
<td>Mean of the lowest decile Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
</tr>
</tbody>
</table>

± Previously adopted performance standards.
* Lower values represent better performance.
† After publication of the FY 2016 IPPS/LTCH PPS final rule, we determined there was a display error in the performance standards for this measure. We have since undertaken a technical update for these performance standards in order to ensure that hospitals have the correct performance standards for the applicable performance period. The corrected performance standards are displayed here.

# Finalized to be scored the same as the MSPB measure, as discussed in section IV.H.4.a.(3) of the preamble of this final rule.

We did not receive any public comments on the proposed performance standards for the FY 2021 program year. Therefore, we are adopting the performance standards listed above.

e. Performance Standards for Certain Measures for the FY 2022 Program Year

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25116), we proposed the following performance standards for the FY 2022 program year for the Clinical Care domain measures (THA/TKA, MORT–30–AMI, MORT–30–HF, MORT–30–PN, MORT–30–COPD), and the proposed MORT–30–CABG, which we are adopting as discussed in section IV.H.5. of the preamble of this final rule. The table below has been updated from the FY 2017 IPPS/LTCH PPS proposed rule and represents the most recently available data.

### NEWLY FINALIZED PERFORMANCE STANDARDS FOR THE FY 2022 PROGRAM YEAR

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following (RSMR) Acute Myocardial Infarction (AMI) Hospitalization.</td>
<td>0.861793</td>
<td>0.881305</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization.</td>
<td>0.879869</td>
<td>0.903608</td>
</tr>
<tr>
<td>MORT–30–PN (updated cohort)</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization.</td>
<td>0.836122</td>
<td>0.870506</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization.</td>
<td>0.920058</td>
<td>0.936962</td>
</tr>
<tr>
<td>THA/TKA*</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA).</td>
<td>0.029833</td>
<td>0.021493</td>
</tr>
<tr>
<td>MORT–30–CABG</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery.</td>
<td>0.979000</td>
<td>0.968210</td>
</tr>
</tbody>
</table>

**Clinical Care Measures**

<table>
<thead>
<tr>
<th>Measure ID</th>
<th>Description</th>
<th>Achievement threshold</th>
<th>Benchmark</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI Payment*#</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI).</td>
<td>Median Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
<td>Mean of the lowest decile Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
</tr>
<tr>
<td>HF Payment*#</td>
<td>Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Heart Failure (HF).</td>
<td>Median Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
<td>Mean of the lowest decile Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care across all hospitals during the performance period.</td>
</tr>
</tbody>
</table>

* Lower values represent better performance.

# Finalized to be scored the same as the MSPB measure, as discussed in section IV.H.4.a.(3) of the preamble of this final rule.

We did not receive any public comments on the proposed FY 2022 performance standards. Therefore, we are finalizing our proposal to adopt the performance standards listed above.

9. FY 2019 Program Year Scoring Methodology

a. Domain Weighting for the FY 2019 Program Year for Hospitals That Receive a Score on All Domains

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49568 through 49570), we adopted equal weight of 25 percent for each of the 4 domains in the FY 2018 program year for hospitals that receive a score in all domains. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25117), for the FY 2019 program year, we noted that we did not propose to remove any measures nor did we propose to adopt any new measures. We
also did not propose any changes to the domain weighting for hospitals receiving a score on all domains.

**DOMAIN WEIGHTS FOR THE FY 2019 PROGRAM YEAR FOR HOSPITALS RECEIVING A SCORE ON ALL DOMAINS**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Weight (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>25</td>
</tr>
<tr>
<td>Clinical Care</td>
<td>25</td>
</tr>
<tr>
<td>Efficiency and Cost Reduction</td>
<td>25</td>
</tr>
<tr>
<td>Person and Community Engagement*</td>
<td>25</td>
</tr>
</tbody>
</table>

*We are finalizing the re-naming of this domain from Patient- and Caregiver-Centered Experience of Care/Coordination of Care domain to Person- and Community Engagement domain beginning with the FY 2019 program year, as discussed in section IV.H.3.b. of the preamble of this final rule.

**Comment:** One commenter supported CMS' weighting of the Efficiency and Cost Reduction domain in the scoring methodology.

**Response:** We thank the commenter for its support.

**Comment:** A few commenters did not support the proposed weighting of the Person and Community Engagement domain for the FY 2018 program year because evidence has shown significant variation in scores due to differences in acuity level and region of the country and because one study found that patient satisfaction was independent of hospital compliance with quality of care processes and safety culture. The commenters recommended that CMS conduct a patient-level study to better understand the relationship between HCAHPS scores and outcomes, looking at factors like patient severity, SDS factors, and region.

**Response:** We disagree that the Person and Community Engagement domain is weighted too heavily in hospitals' TPSs because we believe this domain measures important elements of the patient’s experience of inpatient care. We have adjusted HCAHPS scores for certain patient-level factors that are beyond the hospital’s control but which affect survey responses. These factors include patient severity, as indicated by self-reported overall health, and patient’s highest level of education, considered the most accurate single measure of socioeconomic status for older adults. Meterko, Wright et al. found that clinical measures of severity mattered little in adjusting patient experience scores that already accounted for standard HCAHPS adjustors. Because valid adjustors must vary within hospitals, it is not possible to adjust for region without removing true regional variation in quality. More information about HCAHPS patient-mix adjustment can be found on the official HCAHPS Web site at: [http://www.hcahpsonline.org/modeadjustment.aspx](http://www.hcahpsonline.org/modeadjustment.aspx). HCAHPS scores are not adjusted for hospital-level factors. While we have conducted and published research on the relationship between HCAHPS scores and hospital-level factors, patient outcomes cannot be directly assessed because the HCAHPS surveys submitted to CMS are not patient-identifiable.

**Comment:** One commenter recommended that, in the future, CMS increase the weight of the Efficiency and Cost Reduction domain to equal that of the Clinical Care and Safety domains because the commenter believed doing so would balance the Hospital VBP Program’s focus on cost and quality equally.

**Response:** While we agree that the Hospital VBP Program should encourage providers to improve patient outcomes, we believe that equally weighting the 4 domains is inappropriate for the FY 2019 program year based on the distribution of the measures we are finalizing in this final rule. We believe the Efficiency and Cost Reduction domain is appropriately weighted, despite not directly addressing patient outcomes, because it encourages hospitals to assess cost in conjunction with quality of care. We note that we are adopting the AMI and HF Payment measures, as discussed in section IV.H.4. of the preamble of this final rule, so that beginning with the FY 2021 program year, MSPB will no longer be the only measure in the Efficiency and Cost Reduction domain. We believe expanding the number of measures in this domain will further improve the link between payment and patient health outcomes as the program moves towards value scoring. We also believe that hospitals can effect change through the measures in each of the four domains in the Hospital VBP Program.

**b. Domain Weighting for the FY 2019 Program Year and Future Years for Hospitals Receiving Scores on Fewer Than Four Domains**

For the FY 2017 program year and subsequent years, we adopted a policy that hospitals must receive domain scores on at least 3 of 4 quality domains in order to receive a TPS, and hospitals with sufficient data on only 3 domains will have their TPSs proportionately reweighted (79 FR 50084 through 50085). We did not propose any changes in the FY 2017 IPPS/LTC FFS proposed rule. Under these policies, in order to receive a TPS for the FY 2019 program year and future years:

---


In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), we finalized and codified at 42 CFR 412.170 a 2-year period during which we collect data used to calculate the Total HAC Score. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49574), we finalized the 2-year time periods for the calculation of HAC Reduction Program measure results for FY 2017. For the Domain 1 measure (PSI 90 measure), we will use the data collected during the 24-month period from July 1, 2013 through June 30, 2015. Claims for all Medicare FFS beneficiaries discharged during this period would be included in the calculations of measure results for FY 2017. For the CDC NHSN measures previously finalized for use in the FY 2017 HAC Reduction Program (CLABSI, CAUTI, Colon and Abdominal Hysterectomy SSI, MRSA Bacteremia, and CDI), we are using data collected during CYs 2014 and 2015.
We anticipate we will be able to provide hospitals with their confidential hospital-specific reports and discharge level information used in the calculation of their FY 2017 Total HAC Score in late summer 2016 via the QualityNet Secure Portal.\textsuperscript{58} In order to access their hospital-specific reports, hospitals must register for a QualityNet Secure Portal account. We did not make any changes to the review and correction policies for FY 2016. Hospitals have a period of 30 days after the information is posted to the QualityNet Secure Portal to review and submit corrections for the calculation of their HAC Reduction Program measure scores, domain scores, and Total HAC Score for the fiscal year.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25118 through 25119), for FY 2017, we proposed updates to the following HAC Reduction Program policies: (1) A proposal to clarify data requirements for Domain 1; and (2) a proposal for NHSN CDC HAI data submission requirements for newly opened hospitals. Each policy is described in more detail below.

We received public comments on the design of the HAC Reduction Program, requests to modify the payment adjustment computation, and for CMS to work with Congress to amend the law to create a phased-in or sliding-scale penalty. While we appreciate the commenters’ feedback, we consider these topics to be out of the scope of the proposed rule. Therefore, we are not addressing most of them in this final rule. All other topics out of scope of the proposed rule will be taken into consideration when developing policies and program requirements for future years.

\begin{enumerate}
\item Clarification of Complete Data Requirements for Domain 1

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50722) we finalized our plan to use the PSI 90 measure for Domain 1. Because hospitals may not have complete data for every AHRQ indicator in the PSI 90 measure, we decided to use the same methodology used for the Hospital VBP Program to determine the minimum number of indicators with complete data to be included in the calculation of the Domain 1 measure. In addition, we finalized the following rules to determine the number of AHRQ indicators to be included in the calculation for a hospital’s Domain 1 score. For Domain 1, we defined “complete data” as whether a hospital has enough eligible discharges to calculate a rate for a measure. In order to have complete data for the PSI 90 measure, a hospital must have three or more eligible discharges for at least one component indicator.

In establishing the performance period for the PSI 90 measure, we relied upon an analysis by Mathematica Policy Research, a CMS contractor, which found the measure was most reliable with a 24-month performance period. This analysis also indicated the measure was unreliable with a performance period of less than 12 months.\textsuperscript{58} We have since determined that the current definition for “complete data” may result in facilities with less than 12 months of data being eligible to receive a score on the PSI 90 measure, and that the resulting score may not be reflective of the hospital’s clinical performance.

While the PSI 90 measure continues to play a vital role in patient safety and is an integral part of the HAC Reduction Program, we believe that reliable data is a critical component of accurately assessing hospital performance.

To address this concern, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25118 through 25119), we proposed to clarify the term “complete data” for the PSI 90 measure within Domain 1 to require that hospitals have three or more eligible discharges for at least one component indicator and 12 months or more of data to receive a Domain 1 score. Under this proposal, hospitals with less than 12 months of PSI 90 data would not receive a Domain 1 score, regardless of the number of eligible discharges at the hospital. If a hospital has 12 months or more of PSI 90 data, the hospital would need to have three or more eligible discharges for at least one component indicator to receive a Domain 1 score. We believe this is the most favorable method for scoring measure results for hospitals.

We believe, after weighing the considerations, that this additional policy should be incorporated into the HAC Reduction Program for FY 2017 and subsequent years, primarily because this approach greatly improves the measure’s assessment of quality and, therefore, its implementation should not be unnecessarily delayed. This clarification would be a change to the Domain 1 criteria and would not change our current scoring policy for Domain 2. As previously finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50722 through 50723), if a hospital does not have enough data to calculate the PSI 90 measure score for Domain 1 but has “complete data” for at least one measure in Domain 2, its Total HAC Score will depend entirely on its Domain 2 score. Similarly, if a hospital has “complete data” to calculate the PSI 90 measure score for Domain 1 or any of the measures in Domain 2, we will not calculate a Total HAC Score for this hospital. We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50722 through 50723) for a detailed discussion of Domain 2 scoring.

We invited public comments on our proposal to require that hospitals have three or more eligible discharges for at least one component indicator and 12 months or more of data to receive a Domain 1 score beginning in the FY 2017 HAC Reduction Program.

\textbf{Comment:} Many commenters supported the proposal to clarify the term “complete data” and agreed that using less than 12 months of measure data may not provide a statistically valid reflection of hospital performance. Commenters commended CMS’ efforts to ensure data reliability as a critical component of accurately assessing performance. One commenter recommended that complete data should require at least 24 months of data. Commenters noted that in the proposed rule, CMS stated that the PSI 90 measure was most reliable with a 24-month performance period.

\textbf{Response:} We understand that reliable data is a critical component of accurately assessing hospital performance and thank commenters for their support. We note that the analysis performed by Mathematica showed that PSI composite achieves moderate reliability at a majority of hospitals for reporting periods of 6 months or longer. We further note that the proposed data requirements establish a minimum data requirement of at least 12 months.\textsuperscript{60} We believe the proposed requirements balance the needs of the program and allows the composite measure to continue to play a vital role in ensuring patient safety and provide alignment across our value-based and quality reporting programs.

After consideration of the public comments we received, we are finalizing the definition of complete data discussed above as proposed.

\textsuperscript{58} Available at: \url{https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPPage%2FQnetBasic&cid=122577334596}.

\textsuperscript{60} Ibid.
b. Clarification of NHSN CDC HAI Data Submission Requirements for Newly Opened Hospitals

We have encountered issues with some newly opened hospitals that do not appear to understand that they must submit CDC NHSN HAI data for the HAC Reduction Program, even when they may not be required to report under the Hospital IQR Program. As set forth in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50098), a hospital that does not have an ICU waiver or other waiver for the CDC NHSN HAI measures and does not submit data will receive the maximum of 10 points for that measure. We noted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50723) that, for Domain 2, we will obtain measure results that hospitals submitted to the CDC NHSN HAI Data submission requirements for the Hospital IQR Program.\(^6\) However, we note that participation in the Hospital IQR Program is voluntary, while participation in the HAC Reduction Program is mandatory for almost all IPPS hospitals (we refer readers to section 1886(d)(1)(B) of the Act; 42 CFR 412.170 (definition of the term “applicable hospital”); and 42 CFR 412.172(e)). The HAC Reduction Program does not apply to hospitals and hospital units that are excluded from the IPPS, such as LTCHs, cancer hospitals, children’s hospitals, IRFs, IPFs, CAHs, and Puerto Rico hospitals (79 FR 50087 through 50088).

We believe that it is important to establish data submission requirements for all applicable hospitals under the HAC Reduction Program. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25119), we proposed the following requirements for newly opened hospitals for CDC NHSN HAI data submissions. We note that these requirements do not affect any requirements for facilities in States that are required by law to report HAI data to NHSN.

* If a hospital files a notice of participation (NOP) with the Hospital IQR Program within 6 months of opening, the hospital would be required to begin submitting data for the CDC NHSN HAI measures no later than the first day of the quarter following the end of the 6-month period to file the NOP. For example, if a subsection (d) hospital opened on January 1 and it intended to participate in the Hospital IQR Program, the hospital would be required to file a Hospital IQR Program NOP no later than July 1, and begin submitting data to NHSN no later than October 1. If a subsection (d) hospital opened on January 1 and it did not intend to participate in the Hospital IQR Program (that is, no NOP is filed), it would have to begin submitting data to NHSN no later than July 1 of that year. We believe that these data submission requirements are clear, align with the Hospital IQR Program, and are fair and equitable for all newly opened hospitals.

Hospitals that are not required to submit data within the respective HAC Reduction Program year will not receive a score. These hospitals will receive a designation of “NEW,” and will not receive any points for CDC NHSN HAI measures. We further note that this clarification does not affect the narrative rules used in calculation of the Domain 2 Score. We will continue to follow all Domain 2 scoring procedures as previously finalized, and we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49575) for further discussion of the narrative rules used in calculation of the Domain 2 Score. We believe that this proposal should be incorporated into the HAC Reduction Program for FY 2017 and subsequent years.

We invited comments on our proposal to adopt these policies related to the data submission requirements beginning in the FY 2017 HAC Reduction Program.

Comment: Commenters supported and applauded CMS for establishing a reasonable deadline for beginning the submission of measure data following the opening of a new hospital. Commenters noted that clarifying and establishing a process for new hospitals affords patients who receive care at those facilities the same benefits to transparent quality data that has been available in long established facilities. One commenter recommended that CMS establish a single date under which HAC Reduction Program reporting must begin, regardless of a hospital’s decision about participation in the Hospital IQR Program.

Response: We thank commenters for their input and support. We believe these submission requirements support our continued goal of aligning our value-based and quality reporting programs in an effort to minimize provider burden and incentivize high-quality care. We note that the intent of the submission requirements is to make use of the available data for each hospital and encourage hospitals to report HAI data to CDC NHSN.

After consideration of the public comments we received, we are finalizing the data submission requirements discussed above as proposed.

3. Implementation of the HAC Reduction Program for FY 2018

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25119 through 25121), for FY 2018, we proposed the following HAC Reduction Program policies: (1) Adoption of the modified version of the NQF-endorsed PSI 90: Patient Safety and Adverse Events Composite; (2) defining the applicable time periods for the FY 2018 HAC Reduction Program and the FY 2019 HAC Reduction Program; (3) changes to the scoring methodology; and (4) a request for comments on additional measures for potential future adoption.

a. Adoption of Modified PSI 90: Patient Safety and Adverse Events Composite (NQF #0531)

(1) Background

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25119 through 25121) we proposed to adopt refinements to the Agency for Healthcare Research and Quality (AHRQ) Patient Safety and Adverse Events Composite (NQF #0531) for the HAC Reduction Program beginning with the FY 2018 payment determination and subsequent years. In summary, the PSI 90 measure was refined to reflect the relative importance and harm associated with each component indicator to provide a more reliable and valid signal of patient safety events. We believe the modified PSI 90 will provide strong incentives for hospitals to ensure that patients are not harmed by the medical care they receive, a critical consideration in quality improvement.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50712 through 50717), we adopted the PSI 90 measure (NQF #0531) in the HAC Reduction Program as an important measure of patient safety and adverse events. As previously adopted, PSI 90 consisted of eight component indicators: (1) PSI 03 Pressure Ulcer Rate; (2) PSI 06 Iatrogenic Pneumothorax Rate; (3) PSI 07 Central Venous Catheter-Related Blood Stream Infections Rate; (4) PSI 08 Postoperative Hip Fracture Rate; (5) PSI 12 Perioperative Pulmonary Embolism/Deep Vein Thrombosis Rate; (6) PSI 13 Postoperative Sepsis Rate; (7) PSI 14 Postoperative Wound Dehiscence Rate;
and (8) PSI 15 Accidental Puncture and Laceration Rate.

The currently adopted eight-indicator version of the measure underwent extended NQF maintenance reendorsement in the 2014 NQF Patient Safety Committee due to concerns with the underlying component indicators and their composite weights. In the NQF-Endorsed Measures for Patient Safety, Final Report, the NQF Patient Safety Committee deferred its final decision for the PSI 90 measure until the following measure evaluation cycle. In the meantime, AHRQ worked to address many of the NQF stakeholders’ concerns about PSI 90, which subsequently completed NQF maintenance re-review and received reendorsement on December 10, 2015.

The PSI 90 measure’s extended NQF reendorsement led to several changes to the measure. First, the name of the PSI 90 measure has changed to “Patient Safety and Adverse Events Composite” (NQF #0531) (herein referred to as the “modified PSI 90”). Second, the modified PSI 90 measure includes three new indicators: (1) PSI 09 Perioperative Hemorrhage or Hematoma Rate; (2) PSI 10 Postoperative Acute Kidney Injury Requiring Dialysis Rate (formerly titled “Physiologic and Metabolic Derangement Rate”); and (3) PSI 11 Postoperative Respiratory Failure Rate. Third, the measure PSI 12 Perioperative Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) Rate and PSI 15 Accidental Puncture or Laceration Rate have been rescoped in the modified PSI 90. Fourth, PSI 07 Central Venous Catheter-Related Blood Stream Infection Rate has been removed in the modified PSI 90. Fifth, the weighting of component indicators in the modified PSI 90 is based not only on the volume of each of the patient safety and adverse events, but also the harms associated with the events.

We consider these changes to the modified PSI 90 to be substantive changes to the measure. Therefore, we proposed to adopt the modified PSI 90 for the HAC Reduction Program beginning with the FY 2018 payment determination and subsequent years. We explain the modified PSI 90 more fully below, and also refer readers to the measure description on the NQF Web site at: https://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=321&print=0&entityTypeID=3. We note that the proposed modified PSI 90 (MUC ID 15–604) was included on a publicly available document entitled “2015 Measures Under Consideration for December 1, 2015” in compliance with section 1890A(a)(2) of the Act, and was reviewed by the Measures Application Partnership (MAP). The MAP supported this measure, stating that “the PSI measures were developed to identify harmful healthcare related events that are potentially preventable. Three additional PSIs have been added to this updated version of the measure. PSIs were better linked to important changes in clinical status with ‘harm weights’ that are based on diagnoses that were assigned after the complication. This is intended to allow the measure to more accurately reflect the impact of the events.” The measure received support for inclusion in the HAC Reduction Program as referenced in the MAP Final Recommendations Report.

(2) Overview of the Measure Changes

First, the name of the PSI 90 measure has changed from the “Patient Safety for Selected Indicators Composite Measure” to the “Patient Safety and Adverse Events Composite” (NQF #0531) to more accurately capture the indicators included in the measure.

Second, the PSI 90 measure has expanded from 8 to 10 component indicators. The modified PSI 90 is a weighted average of the following 10 indicators: PSI 09 Pressure Ulcer Rate; PSI 06 Iatrogenic Pneumothorax Rate; PSI 08 In-Hospital Fall With Hip Fracture Rate; PSI 07 Perioperative Hemorrhage or Hematoma Rate; PSI 10 Postoperative Acute Kidney Injury Requiring Dialysis Rate; PSI 11 Postoperative Respiratory Failure Rate; PSI 12 Perioperative Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) Rate; PSI 13 Postoperative Sepsis Rate; PSI 14 Postoperative Wound Dehiscence Rate; and PSI 15 Unrecognized Abdominopelvic Accidental Puncture/Laceration Rate. (* Denotes new component for the modified PSI 90 measure.)

As stated above, the modified PSI 90 measure also removed PSI 07, Central Venous Catheter-Related Blood Stream Infection Rate, because of potential overlap with the CLABSI measure (NQF #0139) which has been included in the Hospital IQR Program since the FY 2011 IPPS/LTCH PPS final rule (75 FR 50201 through 50202), the HAC Reduction Program since the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), and the Hospital VBP Program since the FY 2013 IPPS/LTCH PPS final rule (77 FR 53597 through 53598).

In response to stakeholder concerns, highlighted in the NQF 2014 Patient Safety Report, the modified PSI 90 also rescoped two component indicators, PSI 12 and PSI 15.

Specifically, for PSI 12 Perioperative PE or DVT rate, the NQF received public comments concerning the inclusion of: (1) Extracorporeal membrane oxygenation (ECMO) procedures in the denominator; and (2) intra-hospital variability in the documentation of calf vein thromboses (which have uncertain clinical significance). As such, the revised PSI 12 component indicator no longer includes ECMO procedures in the denominator or isolated deep vein thrombosis of the calf veins in the numerator. PSI 15 was also rescoped further to focus on the most serious intraoperative injuries—those that were unrecognized until they required a subsequent reparative procedure. The modified denominator of PSI 15 now is limited to discharges with an abdominal/pelvic operation, rather than including all medical and surgical discharges. In addition, to identify events that are more likely to be clinically significant and preventable, the PSI 15 numerator was modified to require both: (1) A diagnosis of an accidental puncture and/or laceration; and (2) an abdominal/pelvic reoperation one or more days after the index surgery.

64 National Quality Forum QPS Measure Description for “Patient Safety for Selected Indicators (modified version of PSI90) (Composite measure)” found at: https://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=321&print=0&entityTypeID=3.
67 Ibid.
68 Previously titled “Postoperative Hip Fracture” prior to v6.0.
69 Previously titled “Postoperative Physiologic and Metabolic Derangement” prior to v6.0.
70 Previously titled “Accidental Puncture or Laceration Rate” prior to v6.0.
Finally, the NQF Patient Safety Review Committee raised concerns about the weighting scheme of the component indicators. In prior versions of the measure, the weights of each component PSI were based solely on volume (numerator rates). In the modified PSI 90, the rates of each component PSI are weighted based on statistical and empirical analyses of volume, level of excess clinical harm associated with the PSI, and disutility (the measure of the severity of the adverse events associated with each of the harms, that is, outcome severity, or least preferred states from the patient perspective). The final weight for each component indicator is the product of harm weights and volume weights (numerator weights). Harm weights are calculated by multiplying empirical estimates of excess harms associated with the patient safety event by utility weights linked to each of the harms. Excess harms are estimated using statistical models comparing patients with a safety event to those without a safety event in a Medicare FFS sample. Volume weights are calculated based on the number of safety events for the component indicators in an all-payer reference population.

For more information on the modified PSI 90 measure and component indicators, we refer readers to the Quality Indicator Empirical Methods available online at: www.qualityindicators.ahrq.gov.

(3) Risk Adjustment

The risk adjustment and statistical modeling approaches of the models remain unchanged in the modified PSI 90. In summary, the predicted value for each case is computed using a modeling approach that includes, but is not limited to, applying a Generalized Estimating Equation (GEE) hierarchical model (logistic regression with hospital random effect) and covariates for gender, age, Modified MS–DRG (MDRG), Major Diagnostic Category, transfer in, point of origin not available, procedure days not available, and AHRQ Elixhauser Comorbidity Software (COMORB).

The expected rate for each of the indicators is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (that is, hospital). The risk-adjusted rate for each of the indicators is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate. For more detail about risk adjustment, we refer readers to: http://www.qualityindicators.ahrq.gov/Downloads/Resources/Publications/2015/Empirical_Methods_2015.pdf.

(4) Adoption of the NQF-Endorsed Version of the Modified PSI 90

In summary, the PSI 90 measure was revised to reflect the relative importance and harm associated with each component indicator to provide a more reliable and valid signal of patient safety events. We believe that adopting the modified PSI 90 would continue to provide strong incentives for hospitals to ensure that patients are not harmed by the medical care they receive, which is a critical consideration in quality improvement. We proposed to adopt the modified PSI 90 for the HAC Reduction Program for FY 2018 and subsequent years. We will continue to use the currently adopted eight-indicator version of the PSI 90 measure for the HAC Reduction Program for FY 2017. We invited public comment on our proposal to adopt the modified PSI 90 measure (NQF #0531) for the HAC Reduction Program for FY 2018.

Comment: Many commenters supported adopting the modified measure, noting that the modified PSI 90 measure was recently endorsed by NQF, addresses past measure concerns, and reflects events within the hospital’s control. Commenters appreciated that the measure was modified to incorporate harms associated with safety events into the weighting of the component indicators. Commenters also noted that the components currently include significant indicators of patient safety events that hospitals could prevent through incorporation of evidence-based processes including enhanced patient monitoring. Finally, commenters stated that this modified version is an improvement and strongly supported its use as a component for evaluation of safety and payment incentives for the reduction of medical harm.

Response: We thank commenters for their support and continue to believe that the HAC Reduction Program encourages improvement in patient safety over the long-term for all hospitals. HACs are often preventable conditions like central line associated bloodstream infections, catheter associated urinary tract infections, and other complications or conditions that arise after a patient was admitted to the hospital for the treatment of another condition. These conditions cost Medicare and the private sector billions of dollars each year and take a significant toll on patients and families. In most cases, hospitals can prevent HACs when they follow protocols, procedures and evidenced-based guidelines. We base our measure selection decisions for the HAC Reduction Program on measures currently available, risk adjusted, and reflective of hospital performance. Factors such as endorsement by the NQF and support by the NQF-convened MAP, which represents stakeholder groups, are also taken into account in deciding which measures to adopt. All the measures finalized for inclusion in the HAC Reduction Program are NQF-endorsed and were recommended for inclusion in the program by the MAP. We have identified patient safety and the reduction of HACs as a high priority through our CMS and National Quality Strategies.

Comment: One commenter thanked CMS for the proposed removal of PSI 07 from the PSI 90 measure. Response: We thank the commenter for its support.

Comment: Commenters appreciated that the revised measure re-weights individual component PSIs to better reflect the importance and preventability of particular safety events. However, numerous commenters stated that these updates do not address the serious deficiencies with the measure noted by MedPAC and academic researchers. Commenters also expressed concern that CMS continues to use claims data to determine payment adjustments. Commenters specifically noted that claims-based measures are risk-adjusted based on diagnostic codes and specificity of coding on an administrative claim, not on any clinical data related to a patient. These commenters stated that claims data cannot and do not fully reflect the details of a patient’s history, course of care and clinical risk factors. As a result, the commenters stated that the rates derived from the measures are highly inexact. Commenters stated that PSI data may assist hospitals in identifying patients whose particular cases merit deeper investigation, but that they are poorly suited to drawing meaningful conclusions about hospital performance on safety issues. These commenters stated that the measure does not drive quality improvement. Commenters recommended that CMS review this measure to determine the appropriateness of both the current and modified measures in the performance programs moving forward and strongly urged CMS to phase the measure out of the HAC Reduction Program and other programs.

Response: We continue to believe the PSI 90 measure is an important measure of patient safety and modifications help to broaden and strengthen the measure. We disagree with commenters.
that claims-based measures in general and PSIs in particular have not demonstrated that they are accurate, reliable, and valid indicators of quality and safety of care. Regarding the administrative data elements of PSI 90, we note that there are previously conducted studies that validate the relationship between administrative claims data and medical records. These studies demonstrate that administrative claims data can provide sufficient clinical information to assess patient safety. We refer readers to the FY 2015 IPPS/LTC final rule (79 FR 50091) for a further discussion of this issue. Further, over the past decade, AHRQ has supported a series of validation studies based on detailed abstraction of medical records.74 These validation studies informed AHRQ’s PSI development process, including further refinements to indicators, working with others to improve coding practices, and retirement of a few indicators. We disagree with commenters that the PSIs are not accurate, reliable, and valid indicators of quality and safety of care. Many of these claims-based indicators have been endorsed by the NQF, which includes a review process that assesses reliability and validity.75 We note that NQF endorsed the modified PSI 90, including the risk-adjustment methodology of the component indicators, as reliable and valid (NQF #0531).76 Further, we believe the modified PSI 90 does provide actionable information and specific direction for prevention of patient safety events, because hospitals can track and monitor individual PSI rates and develop targeted improvements to improve patient safety. For further guidance on PSI monitoring and strategies for applying quality improvements to PSI data, we refer readers to the Toolkit for Using the AHRQ Quality indicators available at: http://www.ahrq.gov/professionals/systems/hospital/gitoolkit/index.html.

We emphasize that improving patient safety is our primary objective for the HAC Reduction Program. Comment: One commenter noted that a recent study published in Medical Care found there was limited validity for the AHRQ PSI and HAC Reduction Program measures when measured against the reference standard of a medical chart review. Commenters stated that only 5 of the measures had sufficient data for pooled meta-analysis. These commenters stated that only PSI 15 (Accidental Puncture and Laceration) met the proposed threshold for validity, based on a positive predictive value (PPV) of 0.80. Commenters also stated that coding errors were found to be the most common reasons for discrepancies between the medical record review and administrative databases. Commenters requested that CMS reevaluate the appropriateness of including the PSI 90 measure for use in its future public reporting and pay-for-performance programs.

Response: We appreciate the commenters’ input and would like to emphasize that improving patient safety is our primary objective for the HAC Reduction Program. We note that NQF endorsed the modified PSI 90 measure as a valid measure (NQF #0531); further, experts agree that this measure is scientifically rigorous. We also note that NQF reviewed the risk-adjustment methodology of the component indicators during its last cycle of NQF endorsement, and endorsed the modified PSI 90 measure as valid and reliable. We continue to work with the measure stewards to improve the measure. We also continually review alternative measures, related to patient safety, to determine their appropriateness for inclusion in the HAC Reduction Program. We also refer readers to the AHRQ Quality Improvement Toolkit for additional guidance to facilitate improvements to documentation and coding at: http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/systems/hospital/gitoolkit/b4-documentation-coding.pdf.

Comment: Commenters recommended that use of the modified PSI 90 measure in any of the CMS pay-for-performance programs start no sooner than October 1, 2016, noting that this timeline will give organizations time to understand and prepare for the newly revised measure. Commenters further noted that the software which AHRQ has made available to hospitals for the purpose of monitoring performance has not been updated to reflect ICD–10 coding. Commenters expressed concern about the proposed performance period, claiming that adding indicators after the performance period has ended do not allow for concurrent coding correction or concurrent process improvement. Commenters recommended CMS work with AHRQ to make this software available as soon as possible so that hospitals are able to monitor performance in an ongoing way in order to provide for continuous quality improvement. Commenters further recommended that CMS temporarily remove this measure from public reporting and inclusion in any pay-for-performance scoring and reimbursement until the ICD–10 version of PSI 90 is available.

Response: We understand that there are concerns regarding the transition to ICD–10. However, we disagree that the use of the modified PSI 90 measure should start no sooner than October 1, 2016. Hospitals and other healthcare facilities have known about ICD–10 coding for some time and have had the opportunity to implement ICD–10 coding procedures. All measure specifications have been translated to and updated for corresponding ICD–10 code specifications and we were fully prepared to accept ICD–10-based claims data beginning October 1, 2015 in accordance with established program timelines. AHRQ originally sought public comment in the Federal Register on November 26, 2013 (78 FR 70558 through 70559) on the proposed conversion of the AHRQ QIs to ICD–10 CM/PCS codes. At that time, the proposed ICD–10 CM/PCS mappings and specifications were posted on the AHRQ QI Web site for review at: http://www.qualityindicators.ahrq.gov/icd10/default.aspx. Since that time, the AHRQ QIs and the ICD–10 mappings have been continuously updated and refined, as new ICD–10 codes are released and CMS’ MS–DRG classification of ICD–10 codes is refined.

We further note that we are finalizing the proposal to use only ICD–9 claims data for FY 2018. This will provide the necessary time for AHRQ to develop a
risk adjusted software version capable of using ICD–10 claims data for FY 2019. One of the factors in the decision to delay the use of ICD–10 claims data until FY 2019 was to allow for the necessary one year of ICD–10 data collection required for AHRQ to create a risk adjusted software version. We will also monitor and assess measure specifications with respect to ICD–10 code specifications and potential impacts on measure performance and payment incentive programs.

Comment: Commenters recommended that CMS revise ICD–10 codes to more appropriately capture PSI measures. For PSI 12, commenters noted that ICD–10 codes do not currently exist to appropriately code DVT in the soleal vein or peroneal vein. Commenters recommended the addition of codes for the appropriate capture of PSI 12. For PSI 13, commenters noted the Third International Consensus Definition Task Force published a recommended new definition of sepsis in March 2016.78 These commenters recommended that, as this new definition is adopted as a medical standard, revised ICD–10 codes be developed that reflect the new definition, to appropriately capture and report PSI 13.

Response: Many claims-based measures have updated ICD–10 codes contained in the Measure Information Forms (MIFs) on the QOF Web site. We also note that AHRQ’s proposed changes for ICD–10–CM/PCS conversion of its quality indicators are available at: http://www.qualityindicators.ahrq.gov/icd10/default.aspx. AHRQ reviews all ICD–10–CM/PCS coding updates and integrates new codes regularly. AHRQ is also working with CMS to align coding classification systems.

Comment: One commenter expressed concern with the inclusion of PSI 03. Commenters noted that the measure is inconsistent with recent work completed by the National Pressure Ulcer Advisory Panel (NPUAP) in April 2016 and may be providing misleading information to the public if not corrected. In addition, commenters stated that the coding of data is further complicated by inconsistencies between existing ICD codes and current practice, making it difficult to report accurately. Commenters believed that it would be a serious error to continue to collect misleading information, which arbitrarily skews reports and can hinder rather than facilitate patient understanding in their review of this measure. Commenters requested CMS suspend data collection for PSI 03 until such time this measure can be brought in line with NPUAP’s definitions. Commenters further requested CMS request of AHRQ the following: Modification of PSI 03 to include only stage III and IV pressure injuries (ulcers); modification of pressure injuries (ulcers) to be consistent with the April 2016 NPUAP definitions, in particular, the consideration that not all deep tissue pressure injury (DTPI) wounds evolve into a significant tissue injury; and that DPTI should be generally excluded from the PSI 03 measure definition and only included once they reveal the actual extent of pressure injury.

Response: As noted in the technical specifications (http://www.qualityindicators.ahrq.gov/Modules/PSI_TechSpec.aspx and http://www.qualityindicators.ahrq.gov/Modules/PSI_TechSpec_ICD10.aspx), PSI 03 is currently limited to stage III and IV pressure injuries as well as unstageable injuries (which are considered clinically equivalent to stage III or IV, because they represent “obscured full-thickness skin and tissue loss”). We appreciate the suggestion to review the April 2016 revisions by the NPUAP. AHRQ has already considered the revisions and its potential impact on PSI 03 with ICD–10 coding guidelines. At this time, we do not believe the revisions have a material impact on the incidence of PSI 03. Because it is not yet clear whether all deep tissue pressure injuries (DTPI) should be counted in quality measurement programs, or only those that evolve into ulcers, and NPUAP noted that DPTI “results from intense and/or prolonged pressure and shear forces at the bone-muscle interface,” AHRQ believes that it is still appropriate to count DPTI as a significant pressure-related soft tissue injury and to capture it in PSI 03 based on current ICD–10 indexing. All of the PSIs are reviewed, refined, and updated annually. AHRQ will continue to monitor the coding guidelines with respect to the NPUAP revisions and its potential impact on the technical specifications of PSI 03.

Comment: One commenter recommended that the exclusion criteria of PSI 04 Stratum 4A be broadened to include diagnoses that reflect a hypercoagulable state. The commenter recommended broadening the exclusion criteria in Stratum 04B to include cases that started in MDC 4 or 5 but advanced to the Pre-MDC and cases that are present on admission. In addition, the commenter recommended broadening the exclusion criteria of Stratum 04B to focus on the Present on Admission Indicator rather than the principal diagnosis position and also excluding Pre-MDC.

Response: We will continue to monitor and analyze the impact of our measure selection for further adjustments to the HAC Reduction Program. Suggestions regarding potential PSI measure revisions can be made directly to Qsupport@ahrq.hhs.gov.

Comment: One commenter supported the inclusion of PSI 09 in the modified PSI 90 measure. This commenter noted that perioperative hemorrhage is a high-volume condition, with up to five percent of cardiac surgery patients potentially requiring additional surgery to control bleeding. The commenter also noted that perioperative hemorrhage is a high-cost condition, with complications that require an increased hospital length of stay and longer ICU time resulting in an increased economic burden relative to patients without these events. The commenter stated that in many instances these conditions can be prevented in many surgeries through appropriate use of a flowable hemostatic matrix which will help to improve patient safety and reduce the costs of care.

Response: We thank the commenter for its feedback and we continue to believe that the HAC Reduction Program encourages improvement in patient safety over the long-term for all hospitals.

Comment: Commenters expressed concern that the PSI 09 component may apply to a number of transplant patients. Commenters indicated that perioperative hemorrhage or hematoma is normal after liver transplant, and is frequent after kidney transplant, and the repercussions of these and other transplantation procedures are not indicative of poor quality care. Commenters further noted that liver transplants result in significant blood loss in nearly every case, and poor performance on this measure can be driven by the number of liver transplants performed. Commenters recommend that transplantation should be added to the exclusion list a priori criteria in Stratum 4C to include sepsis diagnosis codes that are present on admission. The commenter also recommended broadening the exclusion criteria of Stratum 4D to include cases that started in MDC 4 or 5 but advanced to the Pre-MDC and cases that are present on admission. In addition, the commenter recommended removing inclusion criteria of K921 melena in Stratum 04E. The commenter also recommended broadening the exclusion criteria for Stratum 04E to focus on the Present on Admission Indicator rather than the principal diagnosis position and also excluding Pre-MDC.

Response: We will continue to monitor and analyze the impact of our measure selection for further adjustments to the HAC Reduction Program. Suggestions regarding potential PSI measure revisions can be made directly to Qsupport@ahrq.hhs.gov.

Comment: One commenter supported the inclusion of PSI 09 in the modified PSI 90 measure. This commenter noted that perioperative hemorrhage is a high-volume condition, with up to five percent of cardiac surgery patients potentially requiring additional surgery to control bleeding. The commenter also noted that perioperative hemorrhage is a high-cost condition, with complications that require an increased hospital length of stay and longer ICU time resulting in an increased economic burden relative to patients without these events. The commenter stated that in many instances these conditions can be prevented in many surgeries through appropriate use of a flowable hemostatic matrix which will help to improve patient safety and reduce the costs of care.
and requested that that liver transplant patients be excluded from the PSI 09 denominator.

Response: We do not agree with the commenter’s recommendation that liver transplant patients should be excluded from the PSI 09 denominator. While we appreciate commenter’s observation that transplant patients may have an elevated risk of hemorrhage or hematoma, we note that the risk-adjustment model for PSI 09 explicitly accounts for the increased risk associated with solid organ transplantation. For more information on the PSI 09 risk model, we refer readers to: http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Comment: One commenter expressed concern that the PSI 10 component of the measure is inappropriate for liver transplantation. The commenter stated that while the measure excludes patients with preoperative renal failure, many liver transplant patients with relatively normal baseline renal function get Acute Renal Failure after transplant despite high quality care, due to hemodynamic factors and the nature of the drugs involved in the performance of the procedure and its aftermath. The commenter recommended that liver transplantation be added to the exclusion list.

Response: We do not agree with commenter that liver transplant patients should be excluded from the PSI 10 denominator. While we appreciate commenter’s observation that liver transplant patients may have an elevated risk of acute kidney failure, we note that the risk-adjustment model for PSI 10 explicitly accounts for the increased risk associated with hepatic failure. For more information on the PSI 10 risk model, we refer the commenter to: http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Comment: One commenter expressed concern with the PSI 11 component of the measure because acute respiratory failure, mechanical ventilation, and reintubation are fairly common for both liver and kidney transplantation. The commenter stated that liver and kidney transplantation should be added to the exclusion list for this measure. Response: We understand commenter’s concerns, however, we disagree with the commenter that liver and kidney transplantation should be added to the exclusion list. We note that the risk-adjustment model for PSI 11 explicitly accounts for the increased risk associated with solid organ transplantation. Liver transplantation (MDRG 7702) is associated with an adjusted odds ratio of 48.3 in AHRQ’s v5.0 risk model for PSI 11, whereas kidney transplantation (MDRG 1101) is not empirically associated with increased odds of PSI 11. For more information, we refer the commenter to: http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Comment: One commenter expressed concern about the vulnerability of PSI 12 to surveillance bias. Commenters noted that studies have shown that hospitals with increasing numbers of structural quality characteristics (that is, larger hospitals with more accreditations, more complex patients, and engagement in quality initiatives that typically suggest high quality care) have better venous thromboembolism (VTE) prophylaxis, but actually have higher VTE rates, or an increase in PSI 12 event rates. Commenters stated that hospitals with more sophisticated tools and technology used to track VTE show higher rates of VTE and are being penalized for doing a better job at detection. Commenters stated that performance on PSI 12 may reflect differences in VTE imaging use rather than differences in quality of care, and the inclusion of PSI 12 could unfairly penalize hospitals with increased vigilance in VTE detection. One commenter recommended that PSI 12 be removed from pay-for-performance programs.

Response: CMS and AHRQ recognize the commenters’ concerns about surveillance bias for PSI 12 Perioperative PE or DVT Rate and the issue was addressed in the NQF Patient Safety Steering Committee in 2015. Surveillance bias is a non-random type of systemic bias where a diagnosis is more likely to be observed the more vigilant one is in looking for it. In the case of DVT or PE, hospitals may underdiagnose or over diagnose DVT or PE depending how often they screen or perform diagnostic testing to look for these diagnoses. Several research teams have examined DVT and PE rates and surveillance bias. However, studies have not specifically examined whether the observed rates reflect underdiagnoses of DVT or PE at low-testing hospitals, over diagnosis of DVT or PE at high-testing hospitals, or the underlying true incidence of symptomatic DVT or PE.

While some hospitals might hypothesize that increased surveillance is desirable, there is no evidence to support the hypothesis that “increased vigilance in DVT or PE detection” is desirable, from the perspective of patients and their families. Over diagnosis of DVT or PE among patients may lead to overtreatment, and overtreatment is not consequential as there are known adverse effects associated with treatment of DVT and PE. Thus, while we acknowledge commenter’s concerns regarding surveillance bias, we believe that PSI 12 is an important component indicator of the modified PSI 90 measure, because it encourages hospitals not only to prevent DVT or PE, but also to appropriately assess a patient’s risk for DVT and PE to prevent over diagnosis and underdiagnoses. Because of the negative economic and health consequences associated with DVT or PE diagnosis, we believe that preventing underdiagnoses and over diagnosis is critical to improving patient safety.

Lastly we disagree with commenter that PSI 12 Perioperative PE or DVT Rate lacks appropriate exclusions. Measure exclusions were reviewed by the NQF Patient Safety Steering Committee in 2015 and the measure was re-endorsed as reliable and valid. We note that AHRQ removed isolated thrombosis of calf veins (ICD–9–CM

disorders including DVT after transplant procedures and also may be caused by large bore IVs.\textsuperscript{81} In addition, transplant patients often get products that promote clotting due to inherent coagulopathy, and some patients have clotting disorders that cause hypercoagulability. The commenter noted that this measure excludes surgeries involving interruption of the vena cava, and stated that all liver transplants involve such interruption. This commenter recommended that liver and kidney transplant be added to the exclusion list because DVT is not indicative of poor quality care for these procedures due to the frequency of DVT in transplantation.

Response: We appreciate commenter’s observation that PSI 12 excludes cases where a procedure for interruption of the vena cava occurs before or on the same day of the first operating room procedure; cases meeting this criterion should be excluded, because inferior vena cava (IVC) filter placement (which is by far the most common example of surgical interruption of the vena cava) is appropriate only for patients who cannot tolerate, or have already failed, conventional pharmacologic prophylaxis. IVC filters are placed in high-risk patients with the knowledge that they increase the risk of deep vein thrombosis distal to the device while decreasing the risk of embolization to the pulmonary circulation.

We disagree with commenter that liver and/or kidney transplants must be placed on the exclusion list, just because these patients have an elevated risk of thrombosis. We note that the risk-adjustment model for PSI 12 explicitly accounts for the increased risk associated with solid organ transplantation. For example, liver transplantation (MDRG 7702) is associated with an adjusted odds ratio of 3.2 in AHRQ’s v5.0 risk model for PSI 12. For more information, we refer the commenter to: http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Response: We thank the commenter for its feedback. Suggestions regarding potential PSI measure revisions can be made directly to: QIsupport@ahrq.hhs.gov. Comments: Commenters appreciated the modifications to PSI 15, but requested that CMS update its guidance regarding the correct coding of PSI 15 to ensure that abdominopelvic punctures or lacerations inherent to a surgery are not incorrectly coded as accidental.

Response: Suggestions regarding potential PSI measure revisions can be made directly to: QIsupport@ahrq.hhs.gov. Comment: One commenter did not support PSI 15 because no large-scale assessment has been done to assess the validity of the measure component, and it is difficult to determine if a reoperation was directly related to the accidental puncture/laceration. The commenter recommended that PSI 15 (Accidental Puncture or Laceration) be improved considerably by adding the requirement for a reoperation to occur that is related to the accidental puncture or laceration.

Response: We thank the commenter for its feedback. Suggestions regarding potential PSI measure revisions can be made directly to: QIsupport@ahrq.hhs.gov. Comment: One commenter recommended broadening the PSI 03 Pressure Ulcer Rate exclusion criteria to include those from Appendix I: Immunocompromised State Diagnosis and Procedure Code; broadening the PSI 06 Iatrogenic Pneumothorax Rate to include pneumothorax related to CPR; broadening the PSI 07 CVC Related Blood Stream Infection Rate exclusion criteria to include cases with a length of stay of less than 2 days; broadening the PSI 08 Post Op Hip Fracture exclusion criteria to include anything falling within Appendix H: Cancer Diagnosis Codes regardless of metastasis and regardless of Present on Admission status; broadening the PSI 09

\textsuperscript{81} A tracheostomy or a tracheostomy is an opening surgically created through the neck into the trachea (windpipe) to allow direct access to the breathing tube and is commonly done in an operating room under general anesthesia. Definition obtained from: http://www.hopkinsmedicine.org/tracheostomy/about/what.html.
Perioperative Hemorrhage and Hematoma Rate exclusion criteria to include Abnormal Coagulation Profile R79.1 as an exclusion criterion with present on admission and creating a new seroma ICD–10 code; changing the exclusion criteria of PSI 10 Postoperative Physiologic and Metabolic Derangement Rate to a time based element in hours as opposed to the number of postoperative days and including Sinus Bradycardia and Sinus Tachycardia cardiac arrhythmias in the exclusion criteria; changing the inclusion criteria of the PSI 11 Postoperative Respiratory Failure Rate in the numerator inclusion criteria, vent time, reintubation criteria and broadening the exclusion criteria to include cases that started in MDC 4 or 5 but advanced to the Pre-MDC; broadening the PSI 12 Perioperative Pulmonary Embolism or Deep Vein Thrombosis exclusion criteria to include inheritable hypercoagulable conditions, acquired hypercoagulable conditions, present on admission status; excluding PSI 12 from public reporting and pay-for-performance programs; modifying the PSI 13 Postoperative Sepsis Rate to delete the inclusion criteria for post-procedural shock; and extending the exclusion criteria of PSI 14 Postoperative Wound Dehiscence Rate to a length of state of four days.

Response: We thank the commenter for its feedback. Suggestions regarding potential PSI measure revisions can be made directly to: QSupport@ahrq.hhs.gov

After consideration of the public comments we received, we are finalizing the adoption of the modified PSI 90: Patient Safety and Adverse Events Composite (NQF #0531) discussed above as proposed.

b. Applicable Time Periods for the FY 2018 HAC Reduction Program and the FY 2019 HAC Reduction Program

Section 1886(p)(4) of the Act gives the Secretary the statutory authority to determine the “applicable period” during which data are collected for the HAC Reduction Program. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), we finalized and codified at 42 CFR 412.170 that we would use a 2-year time period of performance data to calculate the Total HAC Score. We believe the 24-month performance period provides hospitals and the public with the most current data available, while allowing sufficient time to complete the complex calculation process for these measures. The 24-month performance period was chosen because it tended to show that between 50 to 90 percent of hospitals attained a moderate or high level of reliability for AHRQ measures (78 FR 50717). Although we believe the 24-month time is the preferred length of time for performance data, there may be situations, discussed in more detail below, where the collection of 24 months of data is not operationally feasible.

Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25121 through 25122), we proposed, beginning in FY 2017 and for subsequent years, to permit flexibility to use a period other than 2 years from which data are collected in order to calculate the Total HAC Score under the HAC Reduction Program. We also proposed to change the definition of “applicable period,” in 42 CFR 412.170, to reflect this proposed change.

Since the ICD–10 transition was implemented on October 1, 2015, we have been monitoring our systems and so far claims are processing normally. The measure steward, AHRQ, has been reviewing the measure for any potential issues related to the conversion of approximately 70,000 ICD–10 coded operating room procedures83 (https://www.cms.gov/icd10manual/fullcode_cms/P1616.html), which could directly affect the modified PSI 90 component indicators. In addition, to meet program requirements and implementation schedules, our system would require an ICD–10 risk-adjusted version of the AHRQ QI PSI software84 by December 2016 for the FY 2018 payment determination year. At this time, a risk-adjusted ICD–10 version of the PSI 90 Patient Safety and Adverse Events Composite software is not expected to be available until late CY 2017. A full year of nationally representative ICD–10 coded data must be available for the development risk-adjusted models based on a national reference population.

To address these issues, for the current Domain 1 measure (PSI 90 Patient Safety and Adverse Events Composite), we proposed to use the 15-month performance period from July 1, 2014 through September 30, 2015, for the FY 2018 HAC Reduction Program. This 15-month performance period would utilize only ICD–9–CM data and only apply to the FY 2018 payment year. The claims for all Medicare FFS beneficiaries discharged during this period would be included in the calculations of measure results for FY 2018. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25121), we erroneously referenced the incorrect date for the end of the FY 2019 performance period. We had stated that “For the FY 2019 HAC Reduction Program, we proposed to use the 21-month performance period from October 1, 2015 through September 30, 2017.” Accordingly, we issued a correction notice (81 FR 37176). The 21-month performance period should be October 1, 2015 through June 30, 2017. This 21-month performance period would utilize only ICD–10 data and only apply to the FY 2019 payment year. The claims for all Medicare FFS beneficiaries discharged during this period would be included in the calculations of measure results for FY 2019.

Prior to deciding to propose abbreviated data collection periods for the FY 2018 and the FY 2019 payment determinations, we took several factors into consideration. These included the recommendations of the measure steward, the feasibility of using a combination of ICD–9 and ICD–10 data, the impact of suspending the measure, minimizing provider burden, program implementation timelines, and the reliability of using shortened data collection periods, as well as the importance of continuing to publicly report this measure. We believe that using a 15-month data collection period for FY 2018 and a 21-month data collection period for FY 2019 best serve the need to provide important information on hospital patient safety and adverse events by allowing sufficient time to process the claims data and calculate the measures, while minimizing reporting burden and program disruption.

Because this issue only impacts the PSI 90 Patient Safety and Adverse Events Composite in Domain 1, for the CDC NHSN measures previously finalized for use in the FY 2017 HAC Reduction Program (CLABSI, CAUTI, Colon and Abdominal Hysterectomy SSI, MRSA Bacteremia, and CDI), we would use the 24-month performance period from January 1, 2015 through December 31, 2016 (CYs 2015 and 2016) for the FY 2018 HAC Reduction Program. For the FY 2019 HAC Reduction Program, we proposed to use the 24-month performance period from January 1, 2016 through December 31, 2017 (CYs 2016 and 2017).

We believe that using a 15-month (FY 2018 only) and a 21-month (FY 2019...
only) performance period for Domain 1 and a 24-month performance period for Domain 2 balances the needs of the HAC Reduction Program and allows sufficient time to process the claims data and calculate the measures. We will continue to test ICD–10 data that are submitted in order to ensure the accuracy of measurement calculations and to monitor and assess the translation of measure specifications to ICD–10, potential coding variation, and impacts on measure performance and payment incentive programs.

We invited public comment on the proposals to update the definition of “applicable period” codified at 42 CFR 412.170 for FY 2017 and subsequent years and to use these updated performance periods for calculation of measure results for the FY 2018 and the FY 2019 HAC Reduction Programs.

Comment: Many commenters supported the proposal to limit the performance periods. Commenters stated that although many hospitals typically report on a longer reporting period, in this case they recognize that combining ICD–9 and ICD–10 data would create confusion. One commenter recommended that CMS transition quality measures to full ICD–10 and not rely upon ICD–9 codes in the new performance periods.

Response: We thank commenters for their feedback and agree that combining ICD–9 and ICD–10 data would create confusion. We believe this policy best serves the need to provide important information on hospital patient safety and adverse events by allowing sufficient time to process the claims data and calculate the measures, while minimizing reporting burden and program disruption.

Comment: Many commenters expressed concern that reducing the performance period to 15 months in FY 2018 will undermine the reliability of the results. Commenters supported CMS’ decision of not combining claims data for ICD–9 and ICD–10. However, commenters believe that all measures should be reported first in the Hospital IQR Program for one year before the performance period in a payment program begins. Commenters stated that reporting measures in the Hospital IQR Program provides transparency, allows stakeholders to gain experience submitting measures, and allows time to identify errors and unintended consequences. Commenters recommended that CMS suspend PSI 90 from inclusion in calculating scores for the Hospital VBP Program and HAC Reduction Program and suspend it from public reporting on Hospital Compare until a 24-month performance period can be re-established, or until AHRQ has satisfactorily demonstrated that the shorter performance period will produce equitable results.

Response: We understand stakeholder concerns about the potential impacts to hospital performance on quality measures when ICD–10 was implemented on October 1, 2015, as well as suggestions for more extensive testing to understand the impacts before any payments or penalties are implicated. As part of the ICD–10 transition planning that has taken place over the past several years, we have performed testing and analyses across the agency with respect to system readiness and claims payment, and continue to provide extensive education and outreach to providers, vendors, and other payers through the CMS ICD–10 Web site. All measure specifications have been translated to and updated for corresponding ICD–10 code specifications and we were fully prepared to accept ICD–10-based claims data beginning October 1, 2015 in accordance with established program timelines.

In response to commenters’ specific concerns regarding PSI 90, we note that the NQF found the modified PSI 90 to be reliable using 12 months of data. We further note that we base our measure selection decisions for the HAC Reduction Program on measures currently available, risk adjusted, and reflective of hospital performance. We also take NQF endorsement and support by the MAP into account in deciding which measures to adopt. All the measures finalized for inclusion in the HAC Reduction Program are NQF-endorsed and were recommended for inclusion in the HAC Reduction Program by the MAP.

We further note that the HAC Reduction Program and the other value-based and quality reporting programs are separate programs with different purposes and policy goals. We note that the PSI 90 measure covers topics of critical importance to quality improvement in the inpatient hospital setting and to patient safety. We selected this quality measure because we believe that hospital acquired conditions comprise some of the most critical patient safety areas, therefore justifying the use of the measure in more than one program. Although the measure exists in more than one program, the measure is used and calculated for very distinct purposes. Accordingly, we believe that the critical importance of this measure to patient safety warrants inclusion in the HAC Reduction Program.

Comment: One commenter noted that the reduced performance period of 21 months for FY 2019 payment determination listed in the proposed rule indicates the period October 1, 2015 through September 30, 2017, which is a total of 24 months. The commenter requested that CMS provide clarification as to which months will be used to determine performance for FY 2019.

Response: In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25121), we erroneously referenced the incorrect date for the end of the FY 2019 performance period. Accordingly, we issued a correction notice updating September 30, 2017 to read June 30, 2017 (81 FR 37716). We are confirming that the FY 2019 HAC Reduction Program will use the 21-month performance period from October 1, 2015 through June 30, 2017.

Comment: Commenters requested that CMS continue working with hospitals, measure developers and all other stakeholders to address the potential unintended consequences of combining measure data collected under ICD–9 and ICD–10. Commenters recommended that CMS undertake an analysis of any performance differences resulting from the transition to ICD–10 for all of the measures used in the pay-for-performance program, with the results of those analyses be made publicly available. Commenters noted that such data would help inform about any potential unintended biases and measure performance changes resulting from the use of the new codes.

Response: We will continue to work with stakeholders during the ICD–10 transition to monitor and assess impacts and to address any potential issues that may occur. We continue to publish comprehensive documentation of all ICD–10 resources by quality program and/or measure type. We also plan to continue to conduct national provider calls and other presentations to help stakeholders understand the potential impact of ICD–10 on their measure performance. We encourage stakeholders to subscribe to our listserv titled “Hospital Inpatient Value-Based Purchasing (HVBP) and Improvement” to receive notification of scheduled events. Stakeholders may join at: https://www.qualityforum.org/ContentServer?pagename=QnetPublic/ListServe/Register. For those individuals

who are interested in participating in future ICD–10 Coordination and Maintenance Committee meetings, information on the Committee can be found on the CMS Web site at: https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/ICD-9-CM-C-and-M-Meeting-Materials.html. We encourage public participation at these meetings either in person, by conference lines, or by the livestream provided by CMS.

After consideration of the public comments we received, we are finalizing the definition of applicable period at 42 CFR 412.170 and the 15-month FY 2018 performance period discussed above as proposed. We are finalizing the FY 2019 performance period as the 21-month performance period October 1, 2015 through June 30, 2017.

c. Changes to the HAC Reduction Program Scoring Methodology

(1) Current Scoring Policy

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50721), we finalized a scoring methodology that aligns with the achievement scoring methodology currently used in the Hospital VBP Program. Our intent was to reduce confusion associated with multiple scoring methodologies by aligning the scoring for the Hospital VBP Program and the HAC Reduction Program. We note that alignment benefits the hospital stakeholders who have prior experience with the Hospital VBP Program. Accordingly, we implemented a methodology for assessing the top quartile of applicable hospitals for HACs based on performance standards.

We indicated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50720 through 50725) that points will be assigned to hospitals’ performance for each measure. We finalized a decile-based methodology for assigning points, depending on the specific measures.

- For Domain 1, point assignment is based on a hospital’s score for the PSI 90 measure.
- For the Domain 1 score, 1 to 10 points are assigned to the hospital.
- For the measures in Domain 2, point assignment for each measure is based on the SIR for that measure.
- For each SIR, 1 to 10 points are assigned to the hospital for each measure.
- The Domain 2 score consists of the average of points assigned to each measure.

To calculate a Total HAC Score for each hospital, we multiply each domain score by a weighting and add together the weighted domain scores to determine the Total HAC Score (§ 412.172(e)(3)). We use each hospital’s Total HAC Score to determine the top quartile of subsection (d) hospitals that are subject to the payment adjustment beginning with discharges on or after October 1, 2014.

(2) Program Evaluation Efforts

As part of our ongoing efforts to evaluate the HAC Reduction Program, we recently conducted a review of our scoring methodology and assessed opportunities to strengthen the program. As part of that review, our Hospital Quality Reporting Program Support (HQRPS) contractors convened a technical expert panel (TEP) on October 19–20, 2015, with a follow-up call on December 11, 2015. The TEP examined multiple areas of the HAC Reduction Program and focused on identifying a scoring methodology that provides an incentive to hospitals to reduce HACs and distinguishes top performers from low performers. The TEP identified concerns with the current decile-based scoring methodology that included: Ties at the penalty threshold; hospitals with a limited amount of data being identified as poor performers; and situations in which hospitals with no adverse events and no Domain 2 data nonetheless become eligible for penalty.

During the FY 2016 HAC Reduction Program, a small subset of hospitals that had zero adverse events in Domain 1 and no Domain 2 score were identified as part of the worst-performing quartile. These hospitals received Domain 1 scores of 7.0, meaning they were in the 7th decile of hospitals for the PSI 90 measure despite being close to the PSI 90 measure mean value. As this subset of hospitals had no Domain 2 scores, they received a Total HAC Score equal to their Domain 1 score of 7.0. This Total HAC Score was greater than the 75th percentile cutoff for penalty determination of 6.75. CMS waived the penalty for these zero adverse event hospitals so they would not be treated as poor performers. These hospitals were potentially disadvantaged because their Total HAC Scores were determined solely on their Domain 1 Score. Because Domain 2 scores tend to be lower on average than Domain 1 scores, other hospitals without Domain 2 scores are potentially treated the same as low performers in the same decile.

In addition, scoring using deciles can make it more difficult to distinguish top performers from low performers by creating a large number of ties on measure scores. For example, two hospitals with meaningfully different measure results may fall into the same decile bin and therefore be ultimately indistinguishable under the current scoring methodology. Conversely, two hospitals with performance that is not statistically distinguishable may fall into different decile bins. Furthermore, ties at the penalty threshold complicate the adjudication of payment adjustments; in both the FY 2015 and FY 2016 programs, less than 25 percent of all hospitals had Total HAC Scores above the threshold for penalties. Specifically, only 21.9 percent of hospitals in FY 2015 and 23.7 percent of hospitals in FY 2016 were subject to a payment adjustment.

To address stakeholder concerns regarding the current scoring methodology, we evaluated a number of alternatives and recommendations from the TEP. We refer readers to the Project Title: Hospital-Acquired Condition (HAC) Reduction Program Scoring Methodology Reevaluation located at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/TechnicalExpertPanels.html for a summary of the TEP’s discussion. These alternatives included replacement of the current decile-based scoring approach with the use of Winsorized z-scores. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25122 through 25123), we proposed to use Winsorized z-scores for FY 2018.

(3) Winsorized Z-Score Method

The Winsorized z-score method (z-score) uses a continuous measure score rather than forcing measure results into deciles. Z-scores represent a hospital’s distance from the national mean for a measure in units of standard deviations. Under the z-score approach, poor-performing hospitals earn a positive z-score, reflecting measure values above the national mean, and better-performing hospitals earn a negative z-score, reflecting measure values below the national mean. Winsorized z-score measure results are truncated to the 5th and 95th percentiles, replacing values between the minimum and the 5th percentile with the 5th percentile value and replacing values between the 95th percentile and the maximum with the 95th percentile value. Z-scores are then calculated based on these values.

67 This is because hospitals are assigned the minimum of one point for any measure for which they have a measure result of zero. For example, for the CAUTI measure, if 13 percent of hospitals have an SIR of zero, one point is assigned to each of these hospitals, even though the decile approach is intended to assign 10 percent of hospitals to each decile. Two points would be assigned to the remaining seven percent of hospitals that fall in the second decile. This phenomenon does not affect Domain 1 scores, since the reliability-adjusted PSI 90 measure result is not equal to zero in any hospital.

68 Winsorized measure results are truncated to the 5th and 95th percentiles, replacing values between the minimum and the 5th percentile with the 5th percentile value and replacing values between the 95th percentile and the maximum with the 95th percentile value. Z-scores are then calculated based on these values.
the national mean. For each measure, a hospital’s z-score is based on the following equation that expresses the hospital’s measure value minus the average value for that measure, divided by the standard deviation of the measure values across all hospitals:
\[
Z\text{-Score} = \frac{\text{Hospital's Measure Value} - \text{National Mean}}{\text{Standard Deviation}}
\]

standardization gained by implementing this approach, there is no penalization of hospitals that had zero adverse events and no Domain 2 score in either the actual results from FY 2016 or in the results based on the FY 2016 data supplemented with MRSA Bacteremia and CDI results.

Among the 184 hospitals with fewer than 25 beds, the proportion of hospitals penalized would fall from 33 percent to 18 percent. Among the 213 hospitals with more than 500 beds, the proportion of hospitals penalized would fall from 50 percent to 42 percent. The approach leaves the proportion of teaching, urban, and high-DSH hospitals penalized largely unchanged, with one exception. The z-score approach slightly increases the penalization rate among moderately high (50 to 64 percent) DSH hospitals, from 28 percent to 35 percent. Only 172 hospitals fall into this group; therefore, the increase reflects only 11 additional hospitals in that group being penalized. We believe that differences in performance reflect true differences in performance. In addition, hospitals must be able to clearly understand performance scoring methods and performance expectations to maximize their quality improvement efforts. Therefore, we invited public comments on our proposal to adopt the z-score method for calculating measure results beginning in the FY 2018 HAC Reduction Program.

Comment: Many commenters commended CMS’ willingness to consider changes to the underlying scoring methodology. Commenters noted that the shift away from the decile-based scoring approach to a Winsorized z-score more accurately represents a hospital’s performance in relation to the national mean, rather than forcing scores into deciles. Commenters stated that this transition promotes a better statistical methodology, resulting in a smoother distribution of scores and avoiding unintended anomalies that result from the current decile-based scoring method.

Response: We thank commenters for their support and agree that the transition promotes a better statistical methodology.

Comment: Commenters recommended that CMS closely monitor the effects the new scoring methodology may have among essential hospitals that serve a wide range of stakeholders. Continuous measures within Domain 2 and assign the z-score for PSI 90 for Domain 1 to determine the Total HAC Score. We would use each hospital’s Total HAC Score to determine the top quartile of subsection (d) hospitals that are subject to the payment adjustment.

(4) Impact and Implementation

This z-score approach is straightforward to implement, easily adapted as measures are added or removed from the HAC Reduction Program, transparent, and familiar to a wide range of stakeholders. Continuous values address the limitations of decile scoring and preserve the magnitude of differences among hospitals’ measure results. Thus, hospitals that differ meaningfully on their measure results will also differ meaningfully on their Total HAC Scores. Unlike the decile approach, continuous measure scores would substantially reduce ties of Total HAC Scores, which have prevented CMS from penalizing exactly 25 percent of hospitals in previous program years. The use of z-scores also improves alignment between Domains 1 and 2 and creates a more level playing field for hospitals with data in only Domain 1.

Based on FY 2016 data supplemented with MRSA Bacteremia and CDI results, the z-score approach affects the penalty status of slightly more than 200 hospitals, relative to the decile approach. This approach brings 114 hospitals into the penalty zone and 103 hospitals out of the penalty zone and reduces the HAC Reduction Program’s impact on the largest and smallest hospitals. Most importantly, because of the improvements in precision and
sufficient data requirements in Domain 1.

Comment: Commenters supported the proposal to change the scoring methodology. However, commenters expressed concern that this new methodology increases the penalization rate among moderately high DSH hospitals (50 to 64 percent) from 28 percent to 35 percent. Commenters noted that while this increase may only affect 11 additional hospitals, it shifts the penalties for this program towards academic hospitals, which are already at a disadvantage in other value-based programs.

Response: We appreciate commenters’ concerns and note that rather than reducing the penalty burden on any particular category of hospitals, the proposed scoring change aims to correct an identified limitation in the HAC Reduction Program: The penalization of hospitals with no Domain 2 score and zero adverse events in Domain 1. Hospitals with only Domain 1 data received higher Total HAC Scores than hospitals contributing data in both domains contributing to a misalignment. We believe that the proposed scoring approach corrects this misalignment and along with previously finalized modifications to Domain 2, including additional measures, expansion of patient care locations, and re-baselining, will substantially reduce the number of hospitals with no Domain 2 score moving forward.

Comment: Some commenters did not support the use of Winsorized z-scores and expressed concern that neither the proposed z-score approach nor the current decile-based scoring is adequate to identify meaningful differences in performance across hospitals. These commenters stated that an AHA-commissioned analysis estimating the impact of the proposed scoring changes and comparing them to the current decile-based approach found that the percentages of large hospitals, high-DSH payment hospitals, and teaching hospitals penalized under the z-score method are minimally different from the current scoring method.

Commenters further conducted a simulation analysis to determine whether hospitals in particular performance categories had Total HAC Scores that are statistically different from the payment penalty threshold score. These commenters placed hospitals into ventiles (that is, division of the population into 20 approximately equal groups) (with higher ventiles indicating worse performance) of Total HAC Scores and calculated the percentage of hospitals whose performance was statistically different from the penalty threshold score in each ventile. Commenters found that as the performance ventile increased, the percentage of hospitals whose performance scores are statistically different from the performance threshold score declined. In some cases, (that is, the 15th and 16th ventiles under the decile scoring method and the 17th ventile under the z-score method), virtually no hospitals had Total HAC Scores that were statistically different from the payment penalty threshold score.

Commenters also stated that it does not appear that the z-score approach would make it any more likely that CMS would penalize 25 percent of hospitals. Commenters stated their analysis showed that under either method, 25 percent of hospitals would be penalized in FY 2017. Commenters recommend that CMS consider adopting a scoring methodology that recognizes both improvement and achievement but noted that the current legislative language does not permit that kind of flexibility. Commenters stated they saw little merit to changing the scoring approach at this time, given that hospitals have gained an understanding of the decile-based scoring approach and that there are minimal differences in the distribution of penalties.

Response: We thank commenters for their input and note that a TEP convened in late 2015 and early 2016 supported this approach. Rather than reducing the penalty burden on any particular category of hospitals, the proposed scoring change aims to correct an identified limitation in the HAC Reduction Program: The penalization of hospitals with no Domain 2 score and zero adverse events in Domain 1. We note that under decile-based scoring, hospitals with insufficient data to calculate a Domain 2 score received higher Total HAC Scores due to only having a Domain 1 score. The proposed scoring change aims to correct this problem by applying Winsorized z-scores, a continuous scoring approach that brings the domains into alignment. The proposed approach essentially eliminates ties in Total HAC Scores, reduces effects on outliers, and enhances the ability to distinguish among hospitals of varying quality and ensuring consistent penalization of exactly 25 percent of hospitals. This approach also enhances our ability to distinguish among hospitals of varying quality, unlike deciles, where two hospitals with very different scores might be in the same decile. Coupled with Winsorization, this diminishes the impact of outlying measure scores on the program while preserving information about hospitals’ relative performance, the proposed methodology represents a substantial improvement in the HAC Reduction Program.

Comment: Some commenters recommended that CMS explore additional scoring methods that could adjust for skewed distributions and avoid penalizing hospitals with no adverse events. Commenters agreed with CMS that the z-score will reduce ties. However, commenters noted that z-scores are best used with a normal distribution and are not appropriate for the CDC NHSN measures in Domain 2, which are skewed to the left (that is, many hospitals have low infection rates), unlike Domain 1, which has an approximately normal distribution. Commenters recommend CMS consider scoring methods that account for the skew in the distribution and do not penalize hospitals with zero adverse events, including p-values for the CDC NHSN measures in Domain 2.

Response: We thank commenters for their input and recommendations. Although Winsorized z-scores do not directly account for this skew, the methodology preserves information about hospitals’ relative performance and reduces the likelihood of penalization for hospitals with zero adverse events. We note that Winsorization is not intended to produce a symmetric distribution; rather, it aims to reduce the impact of extreme values. We will continue to monitor the HAC Reduction Program and take the commenters’ concerns under consideration as we strive to improve the Program.

Comment: Commenters expressed concern that the program’s scoring methodology is extremely complex and requires a greater degree of transparency so hospitals can understand how this potential change could impact their Medicare payments as well as how they benchmark against peer hospitals. Commenters requested that CMS perform additional analysis on the proposed scoring methodology to determine whether certain types of hospitals are disproportionately impacted under the new approach. Commenters noted that grouping all hospitals into one population to be analyzed is not statistically sound. Commenters stated that there are simply too many differences between hospitals across the nation to perform accurate risk adjustments so that all hospitals are evaluated and scored fairly. Commenters recommend that CMS utilize peer cohorts, groupings, or stratification and consider only hospitals with similar volumes and demographics. One commenter
requested that CMS release a public use file showing the impact of the switch to the Winsorized z-score to allow hospitals to prepare for financial impacts.

Response: We understand commenters’ concerns, however, we disagree with commenters’ argument that the scoring methodology is extremely complex. We note that TEP members emphasized the proposed methodology offers ease of implementation, transparency, and familiarity to a wide range of stakeholders given their use in other quality measurement initiatives. We also note that the Five-Star Quality Rating System has already adopted Winsorization as part of its rating methodology. To address commenters’ specific concerns about peer cohorts, groupings, or stratification, we remind readers that we discussed the ongoing work of NQF, ASPE, MedPAC and other stakeholders regarding risk adjustment in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49572). We will closely examine these findings and recommendations and consider how they apply to our quality programs.

Comment: Commenters expressed concern about the continuing shifts in all of the three performance-based programs due to measures moving in and out of the programs, changing domain weights, and performance and base years. Commenters noted that hospitals are overwhelmed with competing methodologies, varying target rates, and multiple confusing and mixed messages that these measures present when applied under different programs.

Response: We understand commenters’ concerns and note that we work to provide education and outreach, as well as public materials, to assist stakeholders with understanding each program. We strive to make the HAC Reduction Program as transparent and straightforward as possible and note that the HAC Reduction Program, the Hospital VBP Program, and the Hospital Readmission Reduction Program have different policy goals. The measures and methodology selected for the HAC Reduction Program cover topics of critical importance to quality improvement in the inpatient hospital setting and to patient safety.

After consideration of the public comments we received, we are finalizing the changes to the scoring methodology discussed above as proposed.

4. Comments on Additional Measures for Potential Future Adoption

We view the addition of other quality measures as a critical component of value-based purchasing, and we are seeking public comments on what additional measures should be considered adopting in the future. We believe that our continued efforts to reduce HACs are vital to improving patients’ quality of care and reducing complications and mortality, while simultaneously decreasing costs. The reduction of HACs is an important marker of quality of care and has a positive impact on both patient outcomes and cost of care. Our goal for the HAC Reduction Program is to heighten the awareness of HACs and reduce the number of incidences that occur. We seek to adopt measures for the HAC Reduction Program that promote better, safer, and more efficient care. Our overarching purpose is to support the NQS’ three-part aim of better health care for individuals, better health for populations, and lower costs for health care.

To the extent practicable, all HAC Reduction Program measures should be nationally endorsed by a multi-stakeholder organization. Measures should align with best practices among other payers and the needs of the end users of the measures. Measures should take into account widely accepted criteria established in medical literature. We note that all measures proposed for the HAC Reduction Program should follow the criteria established by the DRA of 2005 in that they consist of high-volume or high-cost conditions that could be prevented by the use of evidence-based guidelines. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25123), we welcomed public comment and suggestions for additional HAC Reduction Program measures that will help achieve the program goals in these or other measurement areas.

Comment: Commenters recommended that CMS not include measures based solely on current availability, but rather to include measures that: (1) Have standardized data collection processes; (2) external data validation programs to ensure the accuracy of the data; and (3) have support and endorsement of providers as valid measures to assess quality and cost of care. Commenters noted that by including measures that meet this criteria, CMS will ensure provider engagement and implement a process of assessing quality, cost, and value of care that is transparent. Commenters noted that quality measurement should become more focused on a small number of metrics that emphasize patient-reported and patient-generated data.

Response: We encourage CMS to add additional measures that address adverse drug events, ventilator-associated events, diagnostic errors, and a broader scope of surgical site infections. One commenter believes that more can be done to improve the early detection and treatment of sepsis in the inpatient setting. One commenter recommended that CMS should add the Severe Sepsis and Septic Shock Management Bundle (NQF #5050) to the HAC Reduction Program. One commenter recommended CMS include measures that incorporate appropriate imaging technology. One commenter noted that there are numerous guidelines regarding the use of ultrasound and a reduction in HACs such as punctures, ruptures, pneumothorax, excessive bleeding, lacerations.

One commenter requested that CMS encourage quality-related activities around blood management and urged CMS to adopt a blood and blood products quality strategy that recognizes blood as a valuable resource that should be preserved through blood management and monitored via quality measures. One commenter recommended that CMS adopt quality measures that pertain to wound care in general and continue to work with healthcare professionals and industry in the development of new wound care measures. One commenter stated that the U.S. Wound Registry would serve as an excellent resource in this regard, as it includes numerous wound care measures, some of which could be adopted for inpatient hospital quality programs with little or no modifications to the specifications. One commenter believed that the HAC Reduction Program should include an additional option for Domain 1 that would provide hospitals the ability to report an electronic measure of patient harm derived from electronic health records (EHRs). Finally, one commenter recommended that CMS create a quality measure on Surgical Site Infection (SSI) rates following C-section because it would further drive hospitals to boost their quality of care initiatives around this high-volume surgery.

Response: We thank the public for these views and we will consider them as we develop future policy.

5. Maintenance of Technical Specifications for Quality Measures

Technical specifications for AHRQ’s PSI 90 measure in Domain 1 can be found at AHRQ’s Web site at: http://qualityindicators.ahrq.gov/Modules/PSI_TechSpec.aspx. Technical specifications for the CDC NHSN HAI measures in Domain 2 can be found at CDC’s NHSN Web site at: http://www.cdc.gov/nhsn/acute-care-hospital/
Section 1886(d)(5)(B) of the Act provides for a payment adjustment known as the indirect medical education (IME) adjustment under the IPPS for hospitals that have residents in an approved GME program, in order to account for the higher indirect patient care costs of teaching hospitals relative to nonteaching hospitals. The regulations regarding the calculation of this additional payment are located at 42 CFR 412.105. The hospital’s IME adjustment applied to the DRG payments is calculated based on the ratio of the hospital’s number of FTE residents training in either the inpatient or outpatient departments of the IPPS hospital to the number of inpatient hospital beds.

The calculation of both direct GME payments and the IME payment adjustment is affected by the number of FTE residents that a hospital is allowed to count. Generally, the greater the number of FTE residents a hospital counts, the greater the amount of Medicare direct GME and IME payments the hospital will receive. In an attempt to end the implicit incentive for hospitals to increase the number of FTE residents, Congress, through the Balanced Budget Act of 1997 (Pub. L. 105–33), established a limit on the number of allopathic and osteopathic residents that a hospital may include in its FTE resident count for direct GME and IME payment purposes. Under section 1886(h)(4)(F) of the Act, for cost reporting periods beginning on or after October 1, 1997, a hospital’s unweighted FTE resident count for purposes of direct GME may not exceed the hospital’s unweighted FTE count for direct GME in its most recent cost reporting period ending on or before December 31, 1996. Under section 1886(d)(5)(B)(v) of the Act, a similar limit based on the FTE count for IME during that cost reporting period is applied, effective for discharges occurring on or after October 1, 1997. Dental and pediatric residents are not included in this statutorily mandated cap.

The Affordable Care Act made a number of statutory changes relating to the determination of a hospital’s FTE resident limit for direct GME and IME payment purposes and the manner in which FTE resident limits are calculated and applied to hospitals under certain circumstances. Section 5503(a)(4) of the Affordable Care Act added a new section 1886(h)(8) to the Act to provide for the reduction in FTE resident caps for direct GME under Medicare for certain hospitals training fewer residents than their caps, and to authorize the redistribution of the estimated number of excess FTE resident caps to other qualified hospitals. In addition, section 5503(b) amended section 1886(d)(5)(B)(v) of the Act to require the application of the section 1886(h)(8) of the Act provisions in the same manner to the IME FTE resident caps. The policy implementing section 5503 of the Affordable Care Act was included in the November 24, 2010 CY 2011 OPPS/ASC final rule with comment period (75 FR 72214 through 72238), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53434 through 53448), and the FY 2015 IPPS/LTCH final rule (79 FR 50122–50140).

2. Change in New Program Growth From 3 Years to 5 Years

a. Urban and Rural Hospitals

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25124), section 1886(h)(4)(H)(ii) of the Act requires CMS to establish rules for calculating the direct GME caps of teaching hospitals training residents in new programs established on or after January 1, 1995. Under section 1886(d)(5)(B)(viii) of the Act, these rules also apply to the establishment of a hospital’s IME cap. CMS implemented these statutory requirements in the August 29, 1997 Federal Register (62 FR 46005) and in the May 12, 1998 Federal Register (63 FR 26333). Generally, when CMS (then HCFA) implemented the regulations at 42 CFR 413.79(e)(1) and 42 CFR 412.105(f)(1)(vii), these regulations provided that if a hospital did not train any allopathic or osteopathic residents in its most recent cost reporting period ending on or before December 31, 1996, and it begins to participate in training residents in a new residency program (allopathic or osteopathic) on or after January 1, 1995, the hospital’s unweighted FTE resident cap (which would otherwise be zero) may be adjusted based on the sum of the product of the highest number of FTE residents in any program year during...
the third year of the first new program, for each new residency training program established during that 3-year period, and the minimum accredited length for each type of program. This 3-year period, which we refer to as the “3-year window” for ease of reference in the proposed rule and this final rule, started when a new program began, and the teaching hospital first began to train residents for the first time in that new program, typically on July 1, and ending when the third program year of that first new program ends.

Prior to development of the FY 2013 IPPS/LTCH PPS proposed rule, the teaching hospital community expressed concerns that 3 years do not provide for a sufficient amount of time for a hospital to “grow” its new residency programs and to establish FTE resident caps that are properly reflective of the number of FTE residents that it will actually train, once the programs are fully grown. Hospitals explained that 3 years is an insufficient amount of time primarily because a period of 3 years is not compatible with program accreditation requirements, particularly in instances where the qualifying teaching hospital wishes to start more than one new program. Therefore, in the FY 2013 IPPS/LTCH PPS proposed rule and final rule, we proposed and finalized changes to the regulations at 42 CFR 413.79(k) (and which, in turn, would also change the regulations at 42 CFR 412.105(f)(1)(x) for IME that revised the “3-year window” to a “5-year window,” for a new teaching hospital to establish and grow a new program, and thus begin training residents for the first time in new programs that are started on or after October 1, 2012. Thus, for urban hospitals that begin to train residents in a new medical residency training program for the first time on or after October 1, 2012, the cap will not be adjusted for new programs established more than 5 years after residents begin training in the first new program. However, rural hospitals are permitted to receive new cap adjustments for participating in training residents in new medical residency training programs at any time, and therefore, under §413.79(e)(3), if a rural hospital participates in new medical residency training programs on or after October 1, 2012, the hospital’s cap is adjusted for each new program based on a 5-year growth window. We refer readers to the FY 2013 IPPS/LTCH PPS final rule for more details on this change in the regulations regarding the 5-year window for urban hospitals and in rural hospitals in new medical residency training programs for the first time and for rural hospitals participating in new medical residency training programs (77 FR 53416 through 53424).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50111), we changed our policy regarding implementation of the FTE resident caps for new programs to be effective with the beginning of the applicable hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the first new program started for hospitals for which the FTE cap may be adjusted in accordance with §413.79(e)(1), and beginning with the applicable hospital’s cost reporting period that coincides with or follows the start of the sixth program year of each individual new program started for rural hospitals for which the FTE cap may be adjusted in accordance with §413.79(e)(3). In the same final rule, we also made the effective dates of the 3-year rolling average and IME IRB ratio cap consistent with the effective date of the new program FTE resident caps. That is, beginning with the applicable hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the first new program started for hospitals for which the FTE cap may be adjusted in accordance with §413.79(e)(1), and beginning with the applicable hospital’s cost reporting period that coincides with or follows the start of the sixth program year of each individual new program started for rural hospitals for which the FTE cap may be adjusted in accordance with §413.79(e)(3). FTE residents participating in medical residency training programs are included in the hospital’s IRB ratio cap and the 3-year rolling average.

b. Policy Changes Relating to Rural Training Tracks at Urban Hospitals

To encourage the training of residents in rural areas, section 407(c) of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (Pub. L. 106–113) amended section 1886(h)(4)(H) of the Act to add a provision (subsection (iv)) that, in the case of a hospital that is not located in a rural area (an urban hospital) that establishes separately accredited approved medical residency training programs (or rural tracks) in a rural area or has an accredited training program with an integrated rural track, the Secretary shall adjust the urban hospital’s cap on the number of FTE residents under subsection (F), in an appropriate manner in order to encourage training of physicians in rural areas. As noted, in Pub. L. 106–113 was made effective for direct GME payments to hospitals for cost reporting periods beginning on or after April 1, 2000, and for IME payments applicable to discharges occurring on or after April 1, 2000. We refer readers to the August 1, 2000 interim final rule with comment period (65 FR 47033 through 47037) and the FY 2002 IPPS final rule (66 FR 39902 through 39909) where we implemented section 407(c) of Pub. L. 106–113. The regulations for establishing rural track FTE limitations are located at 42 CFR 413.79(k) for direct GME and at 42 CFR 412.105(f)(1)(x) for IME.

In the August 1, 2003 IPPS final rule (68 FR 45456 through 45457), we clarified our existing policy that although the rural track provision allows an increase to the urban hospital’s FTE cap, sections 1886(h)(4)(H)(iv) and 1886(d)(5)(B) of the Act do not provide for an exclusion from the rolling average for the urban hospital for those FTE residents training in a rural track. These provisions are interpreted to mean that, except for new rural track programs begun by urban teaching hospitals that are establishing an FTE cap for the first time, when an urban hospital with an FTE resident cap establishes a new rural track program or expands an existing rural track program, FTE residents in the rural track that are counted by the urban hospital are included in the hospital’s rolling average calculation immediately. This policy is reflected in the regulation at §412.105(f)(1)(y)(F) for IME and §413.79(d)(7) for direct GME, and applies for IME and direct GME to cost reporting periods beginning on or after April 1, 2000.

We received questions asking whether the change in the 3-year window to the 5-year window for new programs also applies to the establishment of rural training tracks. In the FY 2013 IPPS/LTCH PPS final rule, when we amended the regulations to provide for a 5-year new program growth window at §413.79(e) for direct GME and at §412.105(f)(1)(vi) for IME, and in the FY 2015 IPPS/LTCH PPS final rule when we made the FTE resident caps of new programs to be effective with the applicable hospital’s cost reporting period that coincides with or follows the start of the sixth program year, we inadvertently did not also change the growth window and effective date of FTE limitations for rural training tracks, which, under existing §413.79(k) for direct GME and §412.105(f)(1)(x) for IME, is 3 program years, and is effective after 3 program years, respectively.

In the FY 2017 IPPS/LTCH PPS proposed rule, we proposed to revise the regulations at §413.79(k) (and which, in turn, would
The rural track FTE limitation would be effective for these hospitals after the effective date regarding the change in the growth window for rural track training programs from 3 years to 5 years also be effective for rural track training programs started on or after October 1, 2012. We acknowledged that there could be urban hospitals that started a rural track training program started on or after October 1, 2012. We proposed that the effective date regarding the change in the growth window for rural track training programs in FY 2013 IPPS/LTCH PPS final rule and regarding the additional changes we made in the FY 2015 IPPS/LTCH PPS final rule, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25126), we proposed that the effective date regarding the change in the growth window for rural track training programs from 3 years to 5 years also be effective for rural track training programs started on or after October 1, 2012.

Affect IME adjustments under § 412.105(f)(1)(x)) to permit that, in the first 5 program years (rather than the first 3 program years) of the rural track’s existence, the rural track FTE limitation for each urban hospital would be the actual number of FTE residents training in the rural training track at the urban hospital, and beginning with the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural training track’s existence, the rural track FTE limitation would take effect. This proposed change addresses concerns expressed by the hospital community that rural training tracks, like any program, should have a sufficient amount of time for a hospital to “grow” and to establish a rural track FTE limitation that reflects the number of FTE residents that it will actually train, once the program is fully grown.

However, as stated above, due to the statutory language at sections 1886(d)(5)(B) and 1886(h)(4)(H)(iv) of the Act as implemented in our regulations at §§ 412.105(f)(1)(x) and 413.79(d)(7), except for new rural track programs begun by urban teaching hospitals that are establishing an FTE cap for the first time, FTE residents in a rural track training program at the urban hospital are subject immediately to the 3-year rolling average for direct GME and IME. In addition, under the regulations at § 412.105(a)(1)(i), no exception to the IME intern- and resident-to-bed (IRB) ratio cap is provided for residents in a rural track training program (except for new rural track programs begun by urban teaching hospitals that are establishing an FTE cap for the first time). Accordingly, while we proposed that the urban hospital’s rural track FTE limitation would first be effective beginning with the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track training program’s existence, the rural track training program’s FTEs are included in the 3-year rolling average and are subject to the IME IRB ratio cap. These limitations that would have become effective for these hospitals after 3 program years. Instead, the rural track FTE limitations for these hospitals would be the actual number of FTE residents training in the rural track (subject to the rolling average at § 413.79(d)(7) and the IME IRB ratio cap at § 412.105(a)(1)(i), if applicable) for an additional 2 years (from July 1, 2016 through June 30, 2018), and the rural track FTE limitations would become effective with the cost reporting period that coincides with or follows the start of the sixth program year, which in this example would be July 1, 2018.

In summary, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25126), we proposed to revise the direct GME regulations at § 413.79(k) (and which, in turn, would affect IME adjustments under § 412.105(f)(1)(x)) to permit that, effective with rural track training programs started on or after October 1, 2012, in the first 5 program years of the rural track’s existence, the rural track FTE limitation for each urban hospital would be the actual number of FTE residents (subject to the rolling average at § 413.79(d)(7) and the IME IRB ratio cap at § 412.105(a)(1)(i), if applicable), training in the rural track at the urban hospital, and the rural track FTE limitation would take effect because the policy providing a 5-year growth period for establishing the FTE resident caps (§§ 413.79(e)(1) and (e)(3)) was also effective for new programs started on or after October 1, 2012.

We finalized this as the effective date for the policy providing a 5-year growth period for establishing the FTE resident caps (§§ 413.79(e)(1) and (e)(3)) was also effective for new programs started on or after October 1, 2012.
effect beginning with the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track training program’s existence.

We invited public comment on this proposal.

Comment: Commenters supported the policy changes as proposed.

Response: We appreciate the commenters’ support.

Comment: Some commenters objected to the fact that CMS did not exempt rural training track programs from the 3-year rolling average and the IME IRB ratio cap in the proposal. These commenters claimed that immediate implementation of the rolling average and the IME IRB ratio cap are “extremely detrimental” to hospitals’ ability to establish new rural tracks, as the training costs would not be fully paid in the initial years of the program’s establishment.

Response: We understand the payment concerns resulting from immediate application of the rolling average and IRB cap to rural track programs. However, we note that we did not propose any changes with regard to these policies. Rather, we reiterated our current policy, as reflected in the regulations at § 412.105(f)(1)(v)(F) for IME and § 413.79(d)(7) for direct GME, effective for cost reporting periods beginning on or after April 1, 2000. In the FY 2017 IPPS/LTCH proposed rule (81 FR 25125), we referred to the August 1, 2003 IPPS final rule (68 FR 45456 through 45457), where we clarified our existing policy that sections 1886(h)(4)[H][iv] and 1886(h)(5)[B] of the Act do not provide for an exclusion from the rolling average for the urban hospital for those FTE residents training in a rural track. These provisions are interpreted to mean that, except for new rural track programs begun by urban teaching hospitals that are establishing an FTE cap for the first time, when an urban hospital with an FTE resident cap establishes a new rural track program or expands an existing rural track program, FTE residents in the rural track that are counted by the urban hospital are included in the hospital’s rolling average calculation immediately.

Comment: One commenter requested that CMS confirm that a FTE resident cap adjustment for a rural teaching hospital participating in the rural track is only permitted in those cases where the approved residency program meets the CMS criteria for being a newly established program.

Response: We confirm the commenter’s statement. Section 1886(h)(4)[H][iv] of the Act provides for a FTE resident cap adjustment for an urban hospital that establishes separately accredited rural tracks; the statute does not provide for a similar adjustment to rural hospitals participating in rural tracks. Accordingly, only if the program is considered new for Medicare payment purposes can the rural teaching hospital also receive a resident cap adjustment for the program. Under § 413.79(e)(3), any time that a rural hospital participates in training residents in a new program, the rural hospital may receive an increase to its FTE resident caps. We refer readers to the FY 2010 IPPS/LTCH PPS final rule for the criteria identifying a new program for Medicare payment purposes (74 FR 43908 through 43917).

Comment: Many commenters expressed concern about the future of primary care and family practice in rural areas of the country. The commenters requested that CMS make additional policy changes that result in greater numbers of primary care physicians. One commenter specifically requested changes that would facilitate increased training of residents in emergency medicine. The commenters also requested that CMS allow additional opportunities through which rural hospitals, as well as urban hospitals that form rural training track programs, can increase their FTE resident caps and direct GME PRAs. Along those lines, some commenters requested that CMS revise its definition of a teaching hospital so that hospitals can choose to train residents but remain exempt from limits like FTE resident caps and PRAs. A number of commenters suggested that CMS relax its definition of “newly established program” to allow urban hospitals to establish new rural tracks that can establish their own cap limits. Another commenter requested that CMS allow any approved residency program in any specialty that meets the definition of “rural track or integrated rural track” at § 413.75 to be treated as such, even if it does not have approval as a rural track from the relevant accrediting body.

Response: We believe that these comments are outside of the scope of our proposal. The proposal was limited to conforming the window in which rural training track programs can establish their rural track FTE limitation to the 5-year window in which a new teaching hospital can establish new FTE resident caps, as described in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53416 through 53424). Therefore, we are not addressing these comments in this final rule.

Comment: Commenters asked CMS to clarify the circumstances under which rural hospitals can increase their FTE resident caps.

Response: Rural hospitals are permitted to receive cap adjustments for participating in training residents in new medical residency training programs at any time. Therefore, under § 413.79(e)(3), if a rural hospital participates in new medical residency training programs on or after October 1, 2012, the hospital’s cap is adjusted for each new program based on a 5-year growth window. We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53416 through 53424) for more details on this change in the regulations regarding the 5-year window for urban hospitals training residents in new medical residency training programs for the first time and for rural hospitals participating in new medical residency training programs. In addition, to determine if a program is a new medical residency training program for which a rural hospital could receive cap adjustments, as opposed to an expansion of an existing program, we refer readers to the discussion and criteria in the FY 2010 IPPS/LTCH PPS final rule (74 FR 43908 through 43917). In that final rule, we explained that in order to determine whether a program is new and whether, as a result, a hospital qualifies for an FTE cap adjustment, the supporting factors that a hospital should consider are (but not limited to) as follows:

- Is the program director new?
- Is the teaching staff new?
- Are there new residents?

In determining whether a particular program is a newly established one, it may also be necessary to consider factors such as the relationship between hospitals (for example, common ownership or a shared medical school or teaching relationship) and the degree to which the hospital with the original program continues to operate its own program in the same specialty. In addition, the following factors could also be considered:

- Has this program been relocated from a hospital that closed?
- If so, was this program part of the closed hospital’s FTE cap determination?
- More generally, is this program part of any existing hospital’s FTE cap determination?

We would not consider a transferred program to be new in the case where the program director, teaching staff, and residents are the same as another program that closed in another hospital and the first hospital remains open, or where an FTE cap that was associated with the first program is still available for use by an existing provider.
Comment: One commenter requested that CMS provide a detailed example of how the urban cap adjustment and (if applicable) the rural cap adjustment are calculated at the start of the sixth year of the rural training track. The commenter requested that the example specify how the cap calculation is impacted by time spent by residents in the urban training site versus the rural training site.

Response: We appreciate the commenter’s request for a detailed example of the calculation of the urban (and rural, if applicable) FTE resident caps adjustments after the close of the fifth program year of the rural track, as it provides the opportunity to clarify this calculation in the context of rural tracks, which we did not do in the proposed rule. The rural track FTE limitation for the urban hospital, and the FTE resident cap adjustment for the rural hospital (if the rural track is a new program), would be calculated in the same manner as the FTE resident caps are calculated for urban hospitals first participating in training residents in new programs and rural hospitals participating in new programs at §§ 413.79(e)(1) and (e)(3). Because the goal of our proposal was to conform the policies for calculating the rural track FTE limitation and FTE resident cap adjustment to those adopted in FYs 2013 and 2015, effective for rural track training programs started on or after October 1, 2012, we are conforming the methodology for calculating the rural track FTE limitations at § 413.79(k) to the methodology that is already at §§ 413.79(e)(1) and (c)(3) for calculating the FTE resident caps of new teaching hospitals. The regulations at §§ 413.79(e)(1) and (c)(3) state that the FTE resident cap adjustment is the sum of the product of 3 factors: (1) The highest total number of FTE residents trained in any program year, during the fifth year of the first new program’s existence at all of the hospitals to which the residents in that program rotate; (2) the number of years in which residents are expected to complete the program, based on the minimum accredited length for each type of program; and (3) the ratio of the number of FTE residents in the new program that trained at the hospital over the entire 5-year period to the total number of FTE residents that trained at all hospitals over the entire 5-year period. This methodology accounts for the common scenario where residents spend time training at more than one hospital (and also nonprovider settings) during the 5-year growth window, and apportions the total FTE resident caps between or among the participating hospitals. The FY 2015 IPPS/LTCH PPS final rule (79 FR 50106 through 50107) contains an example of how the FTE resident caps are calculated after 5 years, and are apportioned between participating hospitals, one hospital being a new teaching hospital that qualifies for FTE resident cap adjustments, and one being an existing teaching hospital with an already established FTE resident caps. The formula requires determining the share of the overall FTE resident caps at both hospitals to ensure proper apportionment. Therefore, this methodology is used to determine and apportion the FTE resident caps of the urban hospital, when the rural track is not a new program, or the urban and rural hospitals, when the rural track program is a new program. Although the example in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50106 through 50107) illustrates the methodology, we are providing an additional example where residents train at an urban hospital, a rural hospital, and at a rural nonprovider site. Under § 413.78(g), if a hospital (or hospitals, urban or rural) incurs the cost of the resident’s salary and fringe benefits while training at the nonprovider site and meets the other conditions set forth in the regulations, the hospital may count that FTE training time for IME and direct GME purposes, on the hospital’s cost report in the current training year, but also when determining the hospital’s share of the new program FTE resident cap adjustments. Following is the example:

Urban Hospital and Rural Hospital jointly sponsor a separately accredited rural track program. The program is in family medicine (3 years minimum accredited length), and is accredited for a total of 6 residents, 2 in each program year (PGY). The Urban Hospital and Rural Hospital do have previously existing FTE resident caps; however, neither trains residents in an existing family medicine program. The family medicine rural track is newly created, and meets the newness criteria as described in the FY 2010 IPPS/LTCH PPS final rule (74 FR 43908 through 43917) and other applicable requirements at § 413.78(g). Therefore, Rural Hospital may receive an increase to its FTE resident caps for the rural track program. In addition, Urban Hospital complies with the criteria at § 413.79(k)(5). The residents spend PGY1 at Urban Hospital, and then the PGY2s and PGY3s rotate to a rural area, to train at both Rural Hospital and Rural Clinic (a nonprovider site). The PGY2 and PGY3 residents, while mostly assigned to the rural area, do come back to the Urban Hospital for some required training. However, the residents spend more than 50 percent of the duration of the 3 year program in the rural area. Therefore, Urban Hospital qualifies to receive a rural track FTE limitation. Rural Hospital incurs the cost of the salaries and fringe benefits of the residents for the time spent training at Rural Clinic and meets other applicable requirements at § 413.78(g) to be able to count the time residents spend training at the Rural Clinic. The rotations and the cap calculation are as follows:

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGY1 2.0 Urban Hospital</td>
<td>PGY1 2.0 Urban Hospital</td>
<td>PGY1 2.0 Urban Hospital</td>
<td>PGY1 2.0 Urban Hospital</td>
<td>PGY1 2.0 Urban Hospital</td>
</tr>
<tr>
<td>PGY2 0</td>
<td>PGY2 2 @ .90 Rural Hospital and Rural Clinic (1.8), 2 @ .10 Urban Hospital (20)</td>
<td>PGY2 2 @ .90 Rural Hospital and Rural Clinic (1.8), 2 @ .10 Urban Hospital (20)</td>
<td>PGY2 2 @ .90 Rural Hospital and Rural Clinic (1.8), 2 @ .10 Urban Hospital (20)</td>
<td>PGY2 2 @ .90 Rural Hospital and Rural Clinic (1.8), 2 @ .10 Urban Hospital (20)</td>
</tr>
<tr>
<td>PGY3 0</td>
<td>PGY3 0</td>
<td>PGY3 2 @ .95 Rural Hospital and Rural Clinic (1.9), 2 @ .05 Urban Hospital (10)</td>
<td>PGY3 2 @ .95 Rural Hospital and Rural Clinic (1.9), 2 @ .05 Urban Hospital (10)</td>
<td>PGY3 2 @ .95 Rural Hospital and Rural Clinic (1.9), 2 @ .05 Urban Hospital (10)</td>
</tr>
<tr>
<td>TOTAL 2.0</td>
<td>TOTAL 4.0</td>
<td>TOTAL 6.0</td>
<td>TOTAL 6.0</td>
<td>TOTAL 6.0 5 Year Total = 24.</td>
</tr>
</tbody>
</table>

Urban Hospital’s 5 YEAR FTE TOTAL = 11.1.  
Rural Hospital’s 5 YEAR FTE TOTAL (includes time at Rural Clinic) = 12.9.  
5 Year FTE Total = 24.  

Step 1: Highest number of FTE residents training in any program year
During fifth year across all participating hospitals is 2.0:

\[
\text{PGY } 1s = 2.0 \\
\text{PGY } 2s = 2.0 \\
\text{PGY } 3s = 2.0
\]

\[
\text{Step 2: } 2.0 \times 3 \text{ (minimum accredited length) } = 6.
\]

\[
\text{Step 3: Urban Hospital’s cap adjustment is based on the ratio of training at Urban Hospital over all 5 years to the total training that is occurring at all sites over all 5 years: } 6 \times \left(\frac{11.1}{24}\right) = 2.76.
\]

\[
\text{Step 4: Rural Hospital’s cap adjustment is based on the ratio of training at Rural Hospital and Rural Clinic over all 5 years to the total training that is occurring at all sites over all 5 years: } 6 \times \left(\frac{12.9}{24}\right) = 3.24.
\]

\[
2.76 + 3.24 = 6.0, \text{ the total cap assignment does not exceed the total number of accredited slots. Urban Hospital’s rural track FTE limitation is } 2.76. \text{ Rural Hospital’s FTE cap adjustment is } 3.24. \text{ (We note that this calculation is done separately for IME and direct GME caps respectively.)}
\]

We also proposed to amend the regulations at § 413.79(k) (and which, in turn, would affect IME adjustments under § 412.105(f)(1)(x)) to reflect that, effective with rural track programs started on or after October 1, 2012, the rural track FTE limitation is calculated consistent with the methodology for new programs at § 413.79(e)(1) for urban hospitals and (e)(3) for rural hospitals.

After consideration of the public comments we received, we are finalizing our proposed revision of the regulations at § 413.79(k) (and which, in turn, will affect IME adjustments under § 412.105(f)(1)(x)), with the technical corrections described below, to permit that, in the first 5 program years (rather than the first 3 program years) of the rural track’s existence, the rural track FTE limitation for each urban hospital will be the actual number of FTE residents training in the rural training track at the urban hospital (subject to the rolling average at § 413.79(d)(7)) and the IME ratio cap at § 412.105(a)(1)(i), if applicable.

Beginning with the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural training track’s existence, the rural track FTE limitation will take effect.

In finalizing the proposed revisions to § 413.79, we reviewed the regulatory text as a whole and are making some technical corrections to the regulations text throughout § 413.79(k) as follows:

- At § 413.79(k)(1)(ii), we are removing the phrase “or the rural hospital[s]” from this paragraph because it is technically inaccurate:

  § 413.79(k)(1) specifies what the urban hospital may include in its FTE count and the regulation text at § 413.79(k)(1)(ii) inadvertently references training at the rural hospital, which cannot be included. Therefore, we are revising the regulation text by removing the phrase “or the rural hospital[s]”. The provision now specifies that, for rural track programs started prior to October 1, 2012, beginning with the fourth year of the rural track’s existence, the rural track FTE limitation is equal to the product of the highest number of residents, in any program year, who during the third year of the rural track’s existence are training in the rural track at the urban hospital and are designated at the beginning of their training to be rotated to the rural hospital(s) for at least two-thirds of the duration of the program for cost reporting periods beginning on or after April 1, 2000, and before October 1, 2002, or for more than one-half of the duration of the program effective for cost reporting periods beginning on or after October 1, 2003, and the number of years those residents are training at the urban hospital.

  - Throughout § 413.79(k), we are replacing the term “nonhospital” site with “nonprovider” site, consistent with section 5504 of the Affordable Care Act, entitled “Counting Resident Time in Non-Provider Settings,” which refers to “nonprovider setting[s]” instead of “nonhospital setting.”

  - At § 413.79(k)(4), we are updating and correcting the reference to counting time in nonprovider settings from “§ 413.78(d)” to “§ 413.78(d) through (g)”.

  - At § 413.79(k)(4)(ii)(B)(2), we are inserting the italicized language above to clarify the mathematical calculation.

  3. Notice of Closure of Teaching Hospital and Opportunity To Apply for Available Slots

a. Background

Section 5506 of the Patient Protection and Affordable Care Act (Pub. L. 111–148), as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111–152) (collectively, the “Affordable Care Act”), “Preservation of Resident Cap Positions from Closed Hospitals,” authorizes the Secretary to redistribute residency slots after a hospital that trained residents in an approved medical residency program closes. Specifically, section 5506 of the Affordable Care Act amended the Act by adding subsection (vi) to section 1886(b)(4)(H) of the Act and modifying language at section 1886(d)(5)(B)(y) of the Act, to instruct the Secretary to establish a process to increase the FTE resident caps for other hospitals based upon the FTE resident caps in teaching hospitals that closed “on or after a date that is 2 years before the date of enactment” (that is, March 23, 2008). In the November 24, 2010 CY 2011 Outpatient Prospective Payment System (OPPS) final rule (75 FR 72212), we established regulations and an application process for qualifying hospitals to apply to CMS to receive direct graduate medical education (GME) and indirect medical education (IME) FTE resident cap slots from the hospital that closed. We made certain modifications to those regulations in the FY 2013 IPPS/LTCPPS final rule (77 FR 53434), and we made changes to the Section 5506 application process in the FY 2015 IPPS/LTCPPS final rule (79 FR 50122 through 50134). The procedures we established apply both to teaching hospitals that closed on or after March 23, 2008, and on or before August 3, 2010, and to teaching hospitals that closed after August 3, 2010.

b. Notice of Closure of the Pacific Hospital of Long Beach, CA and Application Process—Round 8

CMS has learned of the closure of Pacific Hospital of Long Beach, Long Beach, CA (CCN 050277). The purpose of this notice is to notify the public of the closure of this teaching hospital, and to initiate another round of the application and selection process described in section 5506 of the Affordable Care Act. This round will be the eighth round (“Round 8”) of the application and selection process. The table below contains the identifying information and IME and direct GME
caps for the closed teaching hospital, which is part of the Round 8 application process under section 5506 of the Affordable Care Act.

<table>
<thead>
<tr>
<th>CCN</th>
<th>Provider name</th>
<th>City and state</th>
<th>CBSA code</th>
<th>Terminating date</th>
<th>IME cap (including +/- MMA Sec. 422 adjustments)</th>
<th>Direct GME cap (including +/- MMA Sec. 422 adjustments)</th>
</tr>
</thead>
<tbody>
<tr>
<td>050277</td>
<td>Pacific Hospital of Long Beach.</td>
<td>Long Beach, CA</td>
<td>31084</td>
<td>August 1, 2013</td>
<td>14.47 + 6.00 section 422 increase = 20.47.2</td>
<td>19.92 + 6.00 section 422 increase = 25.92.3</td>
</tr>
</tbody>
</table>

2. Pacific Hospital's 1996 IME FTE cap is 14.47. Under section 422 of the MMA, the hospital received an increase of 6 to its IME FTE cap: 14.47 + 6.00 = 20.47. We note that, under 42 CFR 412.105(d)(4), IME cap slots associated with an increase received under section 422 of the MMA are to be paid with a multiplier of 0.66.
3. Pacific Hospital's 1996 direct GME FTE cap is 19.92. Under section 422 of the MMA, the hospital received an increase of 6 to its direct GME FTE cap: 19.92 + 6.00 = 25.92. We note that under 42 CFR 413.77(g), direct GME FTE cap slots associated with an increase received under section 422 of the MMA are to be paid using the appropriate locality-adjusted national average PRA.

Notice of Closure of the Huey P. Long Medical Center, Pineville, LA and Application Process—Round 9

CMS has learned of the closure of Huey P. Long Medical Center, Pineville, LA (CCN 190009). The purpose of this notice is to notify the public of the closure of this teaching hospital, and to initiate another round of the application and selection process described in section 5506 of the Affordable Care Act. This round will be the ninth round (“Round 9”) of the application and selection process.

<table>
<thead>
<tr>
<th>CCN</th>
<th>Provider name</th>
<th>City and state</th>
<th>CBSA code</th>
<th>Terminating date</th>
<th>IME Cap (including +/- ACA Sec. 5503 adjustments)</th>
<th>Direct GME Cap (including +/- ACA Sec. 5503 adjustments)</th>
</tr>
</thead>
<tbody>
<tr>
<td>190009</td>
<td>Huey P. Long Medical Center.</td>
<td>Pineville, LA</td>
<td>10780</td>
<td>June 30, 2014</td>
<td>13.00 – 1.96 section 5503 reduction = 11.04.2</td>
<td>13.00 – 1.96 section 5503 reduction = 11.04.3</td>
</tr>
</tbody>
</table>

2. Huey P. Long Medical Center's 1996 IME FTE cap is 13.00. Under section 5503 of the ACA, the hospital received a reduction of 1.96 to its IME FTE cap: 13.00 – 1.96 = 11.04.
3. Huey P. Long Medical Center's 1996 direct GME FTE cap is 13.00. Under section 5503 of the ACA, the hospital received a reduction of 1.96 to its direct GME FTE cap: 13.00 – 1.96 = 11.04.

d. Notice of Closure of St. Joseph's Hospital, Philadelphia, PA and Application Process—Round 10

CMS has learned of the closure of St. Joseph's Hospital, Philadelphia, PA (CCN 390132). The purpose of this notice is to notify the public of the closure of this teaching hospital, and to initiate another round of the application and selection process described in section 5506 of the Affordable Care Act. This round will be the tenth round (“Round 10”) of the application and selection process.

<table>
<thead>
<tr>
<th>CCN</th>
<th>Provider name</th>
<th>City and state</th>
<th>CBSA code</th>
<th>Terminating date</th>
<th>IME Cap (including +/- MMA Sec. 422 and ACA Sec. 5503 adjustments)</th>
<th>Direct GME Cap (including +/- MMA Sec. 422 and ACA Sec. 5503 adjustments)</th>
</tr>
</thead>
<tbody>
<tr>
<td>390132</td>
<td>St. Joseph's Hospital.</td>
<td>Philadelphia, PA</td>
<td>37964</td>
<td>March 13, 2016</td>
<td>9.51 – 0.43 section 422 reduction – 0.73 section 5503 reduction = 8.35 3</td>
<td>9.51 – 0.43 section 422 reduction – 0.73 section 5503 reduction = 8.35.4</td>
</tr>
</tbody>
</table>

2. Section 5503 of the Affordable Care Act of 2010 (ACA), Public Laws 111–148 and 111–152, redistributed unused IME and direct GME residency slots effective July 1, 2011.
3. St. Joseph's Hospital's 1996 IME FTE cap is 9.51. Under section 422 of the MMA, the hospital received a reduction of 0.43 to its IME FTE cap, and under section 5503 of the ACA, the hospital received a reduction of 0.73 to its IME FTE cap: 9.51 – 0.43 – 0.73 = 8.35.
4. St. Joseph's Hospital's 1996 direct GME FTE cap is 9.51. Under section 422 of the MMA, the hospital received a reduction of 0.43 to its direct GME FTE cap, and under section 5503 of the ACA, the hospital received a reduction of 0.73 to its direct GME FTE cap: 9.51 – 0.43 – 0.73 = 8.35.
e. Application Process for Available Resident Slots

The application period for hospitals to apply for slots under section 5506 is 90 days following notification to the public of a hospital closure. Therefore, hospitals wishing to apply for and receive slots from the above hospitals’ FTE resident caps must submit applications directly to the CMS Central Office no later than October 31, 2016. The mailing address for the CMS Central Office is included on the application form. Applications must be received by the October 31, 2016 deadline date. It is not sufficient for applications to be postmarked by this date.

We note that an applying hospital may apply for any or all of the three rounds of section 5506 applications that were identified in this final rule. However, a separate application must be submitted for each round for which a hospital wishes to apply.

After an applying hospital sends a hard copy of a section 5506 application to the CMS Central Office mailing address, it must also send an email to: AGA5506application@hhs.gov. In the email, the hospital should state: “On behalf of [insert hospital name and Medicare CCN], I, [insert your name], am sending this email to notify CMS that I have mailed to CMS a hard copy of a section 5506 application under Round [8, or 9, or 10] due to the closure of [Pacific Hospital of Long Beach, or Huey P. Long Medical Center, or St. Joseph’s Hospital]. If you have any questions, please contact me at [insert phone number] or [insert your email address].” An applying hospital should not attach an electronic copy of the application to the email. The email will only serve to notify the CMS Central Office to expect a hard copy application, which should be mailed to the CMS Central Office.

In the CY 2011 OPPS/ASC final rule with comment period, we did not establish a deadline by when CMS will issue the final determinations to hospitals that receive slots under section 5506 of the Affordable Care Act. However, we review all applications received by the deadline, and notify applicants of our determinations as soon as possible.

We refer readers to the CMS Web site at http://www.cms.gov/Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/dgme.html to download a copy of the application form (Section 5506 CMS Application Form) that hospitals are to use to apply for slots under section 5506. We also refer readers to this same Web site to access a copy of the FY 2015 IPPS/LTCH PPS final rule (79 FR 50122 through 50140) and a list of additional section 5506 guidelines for an explanation of the policy and procedures for applying for slots, and the redistribution of the slots under sections 1886(h)(4)(H)(vi) and 1886(d)(5)(B)(v) of the Act.

K. Rural Community Hospital Demonstration Program

1. Background

Section 410A(a) of Pub. L. 108–173 required the Secretary to establish a demonstration program to test the feasibility and advisability of establishing “rural community” hospitals to furnish covered inpatient hospital services to Medicare beneficiaries. The demonstration pays rural community hospitals under a reasonable cost-based methodology for Medicare payment purposes for covered inpatient hospital services furnished to Medicare beneficiaries. A rural community hospital, as defined in section 410A(f)(1), is a hospital that—

• Is located in a rural area (as defined in section 1886(d)(2)(D) of the Act) or is treated as being located in a rural area under section 1886(d)(8)(E) of the Act;
• Has fewer than 51 beds (excluding beds in a distinct part psychiatric or rehabilitation unit) as reported in its most recent cost report;
• Provides 24-hour emergency care services; and
• Is not designated or eligible for designation as a CAH under section 1820 of the Act.

Section 410A(a)(4) of Pub. L. 108–173 specified that the Secretary was to select for participation no more than 15 rural community hospitals in rural areas of States that the Secretary identified as having low population densities. Using 2002 data from the U.S. Census Bureau, we identified the 10 States with the lowest population density in which rural community hospitals were to be located in order to participate in the demonstration: Alaska, Idaho, Montana, Nebraska, Nevada, New Mexico, North Dakota, South Dakota, Utah, and Wyoming (Source: U.S. Census Bureau, Statistical Abstract of the United States: 2003).

CMS originally solicited applicants for the demonstration in May 2004; 13 hospitals began participation with cost reporting periods beginning on or after October 1, 2004. In 2005, 4 of these 13 hospitals withdrew from the program and converted to CAH status. This left 9 hospitals participating at that time. In 2008, we announced a solicitation for up to 6 additional hospitals to participate in the demonstration program. Four additional hospitals were selected to participate under this solicitation. These 4 additional hospitals began under the demonstration payment methodology with the hospital’s first cost reporting period starting on or after July 1, 2008. At that time, 13 hospitals were participating in the demonstration.

Five hospitals (3 of the hospitals were among the 13 hospitals that were original participants in the demonstration program and 2 of the hospitals were among the 4 hospitals that began the demonstration program in 2008) withdrew from the demonstration program during CYs 2009 and 2010. (Three of these hospitals indicated that they would be paid more for Medicare inpatient hospital services under therebasing option allowed under the SCH methodology provided for under section 122 of the Medicare Improvements for Patients and Providers Act of 2008 (Pub. L. 110–275). One hospital restructured to become a CAH, and one hospital closed.) In CY 2011, one hospital that was among the original set of hospitals that participated in the demonstration withdrew from the demonstration. These actions left seven of the originally participating hospitals (that is, hospitals that were selected to participate in either 2004 or 2008) participating in the demonstration program as of June 1, 2011.

Sections 3123 and 10313 of the Affordable Care Act (Pub. L. 111–148) amended section 410A of Pub. L. 108–173, changing the rural community hospital demonstration program in several ways. First, the Secretary is required to conduct the demonstration program for an additional 5-year period, to begin on the date immediately following the last day of the initial 5-year period. Further, the Affordable Care Act requires, in the case of a rural community hospital that is participating in the demonstration program as of the last day of the initial 5-year period, the Secretary to provide for the continued participation of such hospital in the demonstration program during the 5-year extension period, unless the hospital makes an election to discontinue participation.

In addition, the Affordable Care Act provides that, during the 5-year extension period, the Secretary shall expand the number of States with low population densities determined by the Secretary to 20. Further, the Secretary is required to use the same criteria and data that the Secretary used to determine the States eligible for bonuses of the initial 5-year period. The Affordable Care Act also allows not more than 30
rural community hospitals in such States to participate in the demonstration program during the 5-year extension period.

We published a solicitation for applications for additional participants in the rural community hospital demonstration program in the Federal Register on August 30, 2010 (75 FR 52960). Applications were due on October 14, 2010. The 20 States with the lowest population density that were eligible for the demonstration program are: Alaska, Arizona, Arkansas, Colorado, Idaho, Iowa, Kansas, Maine, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Utah, and Wyoming (Source: U.S. Census Bureau, Statistical Abstract of the United States: 2003). We approved 19 new hospitals for participation in the demonstration program. We determined that each of these new hospitals would begin participating in the demonstration with its first cost reporting period beginning on or after April 1, 2011.

Three of these 19 hospitals declined participation prior to the start of the cost reporting periods for which they would have begun the demonstration. In addition to the 7 hospitals that were selected in either 2004 or 2008, the new selection led to a total of 23 hospitals in the demonstration. During CY 2013, one additional hospital among the set selected in 2011 withdrew from the demonstration, similarly citing a relative financial advantage to returning to the customary SCH payment methodology, which left 22 hospitals participating in the demonstration, effective July 1, 2013. In October 2015, another hospital among those selected in 2011 closed, leaving 14 among this cohort still participating. (By this date, as described below, the 7 hospitals that were selected in either 2004 or 2008 had completed the 5-year extension period mandated by the Affordable Care Act.)

Section 410A(c)(2) of Public Law 108–173 required that, in conducting the demonstration program under this section, the Secretary shall ensure that the aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration program under this section was not implemented. This requirement is commonly referred to as “budget neutrality.” Generally, when we implement a demonstration program on a budget neutral basis, the demonstration program is budget neutral in its own terms; in other words, the aggregate payments to the participating hospitals do not exceed the amount that would be paid to those same hospitals in the absence of the demonstration program. Typically, this form of budget neutrality is viable when, by changing payments or aligning incentives to improve overall efficiency, or both, a demonstration program may reduce the use of some services or eliminate the need for others, resulting in reduced expenditures for the demonstration program’s participants. These reduced expenditures offset increased payments elsewhere under the demonstration program, thus ensuring that the demonstration program as a whole is budget neutral or yields savings. However, the small scale of this demonstration program, in conjunction with the payment methodology, makes it extremely unlikely that this demonstration program could be viable under the usual form of budget neutrality.

Specifically, cost-based payments to participating small rural hospitals are likely to increase Medicare outlays without producing any offsetting reduction in Medicare expenditures elsewhere. Therefore, a rural community hospital’s participation in this demonstration program is unlikely to yield benefits to the participant if budget neutrality were to be implemented by reducing other payments for these same hospitals. In the past 12 IPPS final rules, spanning the period for which the demonstration program has been implemented, we have adjusted the national inpatient PPS rates by an amount sufficient to account for the added costs of this demonstration program, thus applying budget neutrality across the payment system as a whole rather than merely across the participants in the demonstration program. As we discussed in the FYs 2005 through 2016 IPPS final rules (69 FR 49183; 70 FR 47462; 71 FR 48100; 72 FR 47392; 73 FR 48670; 74 FR 43922; 75 FR 50343, 76 FR 51698, 77 FR 53449, 78 FR 50740, 79 FR 50145, and 80 FR 49585, respectively), we believe that the language of the statutory budget neutrality requirements permits the agency to implement the budget neutrality provision in this manner.


a. Fiscal Years 2005 Through 2013

In general terms, in each of these previous years from FYs 2005 through 2016, we used available cost reports for the participating hospitals to derive an estimate of the additional costs attributable to the demonstration. For FYs 2005 through 2012, we used finalized, or settled, cost reports, as available, and “as submitted” cost reports for hospitals for which finalized cost reports were not available to derive this estimate of the additional costs attributable to the demonstration. Annual market basket percentage increase amounts provided by the CMS Office of the Actuary reflecting the growth in the prices of inputs for inpatient hospitals were applied to cost amounts obtained from these cost reports. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53452), we initiated two general changes to the methodology for estimating the costs of the demonstration (which we have continued to apply through FY 2016). First, we used “as submitted” cost reports for each hospital participating in the demonstration in estimating the costs of the demonstration (for FY 2013, we used cost reports for cost reporting periods ending in CY 2010). Second, in FY 2013, we incorporated different update factors (the market basket percentage increase and the applicable percentage increase, as applicable, to several years of data as opposed to solely using the market basket percentage increase) for the calculation of the budget neutrality offset amount.

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53449 through 53453) for a detailed discussion of the methodology initiated in FY 2013. In each of these fiscal years, an annual update factor provided by the CMS Office of the Actuary reflecting growth in the volume of inpatient operating services was also applied to update the estimated costs. For the budget neutrality calculations in the IPPS final rules for FYs 2005 through 2011, the annual volume adjustment applied was 2 percent; for the IPPS final rules forFYs 2012 through 2016, it was 3 percent. For a detailed discussion of our budget neutrality offset calculations, we refer readers to the IPPS final rule applicable to the fiscal year involved.

In general, for FYs 2005 through 2013, we based the budget neutrality offset estimate on the estimated cost of the demonstration in an earlier given year. For these periods, we derived that estimated cost by subtracting the estimated amount that would otherwise be paid without the demonstration in an earlier given year from the estimated amount for the same year that would be paid under the demonstration without the demonstration. For FYs 2005 through 2012, we used finalized, or settled, cost reports, as available, and “as submitted” cost reports for hospitals for which finalized cost reports were not available to derive this estimate of the additional costs attributable to the demonstration.
earlier given year from finalized or “as submitted” cost reports as discussed earlier.) For FYs 2005 through 2012, we then updated the estimated costs described earlier to the upcoming year by multiplying them by the market basket percentage increases applicable to the years involved and the applicable annual volume adjustment. Beginning in FY 2013, as discussed earlier, we began incorporating different update factors—we used the IPPS market basket percentage increases applicable to the years involved to update the estimated amount that would be paid under the demonstration under the reasonable cost-based methodology, and the applicable percentage increases applicable to the years involved to update the amounts that would otherwise be paid without the demonstration. We continued to apply the annual volume adjustment as discussed earlier.

For the FY 2010 IPPS/RY 2010 LTCH PPS final rule, data from finalized cost reports reflecting the participating hospitals’ experience under the demonstration were available. Specifically, the finalized cost reports for the first 2 years of the demonstration, that is, cost reports for cost reporting years beginning in FYs 2005 and 2006 (CYs 2004, 2005, and 2006) were available. These data showed that the actual costs of the demonstration for these years exceeded the amounts originally estimated in the respective final rules for the budget neutrality adjustment. In the FY 2010 IPPS/LTCH PPS final rule, we included an additional amount in the budget neutrality offset amount in that fiscal year. This additional amount was based on the amount that the costs of the demonstration for FYs 2005 and 2006 exceeded the budget neutrality offset amounts finalized in the IPPS rules applicable for those years.

In the final rules for FYs 2011 through 2013, we continued to use a methodology for calculating the budget neutrality offset amount consisting of two components: (1) The estimated demonstration costs in the upcoming fiscal year; and (2) the amount by which the actual demonstration costs corresponding to an earlier, given year (which would be known once finalized cost reports became available for that year) exceeded the budget neutrality offset amount finalized in the corresponding year’s IPPS final rule. However, we noted in the FYs 2011, 2012, and 2013 IPPS final rules that, because of a delay affecting the settlement process for cost reports for IPPS hospitals occurring on a larger scale than merely for the demonstration, we were unable to finalize this component of the budget neutrality offset amount accounting for the amount by which the actual demonstration costs in an earlier given year exceeded the budget neutrality offset amount finalized in the corresponding year’s IPPS final rule for cost reports of demonstration hospitals dating to those beginning in FY 2007.

b. Fiscal Years 2014 and 2015

In the final rules for FYs 2014 and 2015, we continued to apply the general methodology discussed earlier (with the modifications initiated in FY 2013) in estimating the costs of the demonstration for the specific fiscal year, using the set of “as submitted” cost reports from the most recent calendar year for which they are available (cost reporting periods ending in 2011 and 2012, respectively), and updating the cost amounts according to the factors discussed earlier. In addition, in these final rules, because finalized cost reports for FYs 2007 and 2008 had become available, we were able to include in the budget neutrality offset adjustment the amount by which the actual demonstration costs in each of those years exceeded the budget neutrality offset amounts finalized in the IPPS final rules for those years.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50742 through 50744), we determined the final budget neutrality offset amount to be applied to the FY 2014 IPPS rates to be $52,589,741. This amount was comprised of the two distinct components identified earlier: (1) The final result differing between the total estimated FY 2014 reasonable cost amount to be paid under the demonstration to the 22 participating hospitals for covered inpatient hospital services, and the total estimated amount that would otherwise be paid to such hospitals without the demonstration (this amount was $46,549,861); and (2) the amount by which the actual costs for the demonstration for FY 2007 (as shown in the finalized cost reports for cost reporting periods beginning in FY 2007 for the nine hospitals that participated in the demonstration during FY 2007) exceeded the budget neutrality offset amount that was finalized in the FY 2007 IPPS final rule (this amount was $6,039,880).

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50141 through 50145), we determined the final budget neutrality offset amount to be applied to the FY 2015 IPPS rates to be $64,566,915. This amount consisted of the two components of the earlier referenced components: (1) The final resulting difference between the total estimated FY 2015 reasonable cost amount to be paid under the demonstration to the 22 participating hospitals for covered inpatient hospital services, and the total estimated amount that would otherwise be paid to such hospitals in FY 2015 without the demonstration (this amount was $54,177,144); and (2) the amount by which the actual costs of the demonstration for FY 2008 (as shown in the finalized cost reports for the hospitals that participated in the demonstration during FY 2008) exceeded the budget neutrality offset amount that was finalized in the FY 2008 IPPS final rule (this amount was $10,389,771).

c. Fiscal Year 2016

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49586 through 49591), we continued to apply the general methodology discussed earlier for FYs 2014 and 2015 in estimating the costs of the demonstration for FY 2016, with some modifications. For FY 2016, we used the set of “as submitted” cost reports from the most recent calendar year for which they were available (cost reporting periods ending in CY 2013), and updated the cost amounts using the IPPS market basket percentage increase and applicable percentage increase applicable to the years involved as discussed earlier. Although the methodology for FY 2016 was similar to that for the previous several rules, because the demonstration began to phase out prior to the beginning of FY 2016, appropriate changes to the calculations were made. The 7 “originally participating hospitals,” that is, those hospitals that were selected for the demonstration in either 2005 or 2008, were scheduled to end their participation in the 5-year extension period authorized by the Affordable Care Act prior to the start of FY 2016. Therefore, we did not include the financial experience of these hospitals in the calculation of either the estimated reasonable cost amount or the estimated amount that would otherwise be paid without the demonstration for FY 2016. In addition, 8 hospitals that entered the demonstration in 2011 and 2012 through the solicitation that followed the Affordable Care Act amendments expanding the demonstration, and that were still participating in the demonstration at the time of the FY 2016 IPPS/LTCH PPS final rule, were scheduled to end their participation on a rolling basis before September 30, 2016. As discussed in the FY 2016 IPPS/ LTCH PPS final rule, for these 8 hospitals, the estimated reasonable cost amount and the estimated amount that
would otherwise be paid without the demonstration were prorated according to the ratio of the number of months between October 1, 2015, and the end of the hospital’s cost reporting period in relation to the entire 12-month period. We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49586 through 49588) for a discussion of these additional calculations.

The resulting estimate of costs for the demonstration for FY 2016 for the 15 hospitals participating in the demonstration for FY 2016 was $26,044,620.

In addition, in the FY 2016 IPPS/LTCH PPS final rule, we were able to finalize the amounts by which the actual demonstration costs for FYs 2009 and 2010 differed from the budget neutrality offset amount finalized in the corresponding final rules for these years using the approach described below.

We identified the difference between the actual cost of the demonstration for FY 2009 and 2010 in the finalized cost reports for hospitals that participated in FY 2009 and that had cost reporting periods beginning in FY 2009 (this amount was $14,332,936), and the budget neutrality offset amount that was identified in the FY 2009 IPPS final rule (73 FR 48671) (this amount was $22,790,388). Analysis of this set of cost reports showed that the budget neutrality offset amount that was finalized to account for the demonstration costs in FY 2009 (as set forth in the FY 2009 IPPS final rule) exceeded the actual cost of the demonstration for FY 2009 by $8,457,452.

We included the amount by which the actual costs of the demonstration for FY 2010 (as shown in the finalized cost reports for the nine hospitals that completed a cost reporting period beginning in FY 2010) ($16,817,922) differed from the amount that was finalized as the costs of the demonstration for FY 2010 as set forth in the FY 2010 IPPS/LTCH PPS final rule and the FY 2011 IPPS/LTCH PPS final rule ($21,569,472). Analysis of this set of cost reports showed that the budget neutrality offset amount that was finalized to account for the demonstration costs in FY 2010 (as set forth in the FY 2010 IPPS/RY 2010 LTCH PPS final rule and the FY 2011 IPPS/LTCH PPS final rule) exceeded the actual cost of the demonstration for FY 2010 by $4,751,550.

Unlike in previous years, because the budget neutrality offset amount identified in the corresponding final rules for each of FYs 2009 and 2010 exceeded the actual costs of the demonstration, we subtracted the differences between these amounts for each fiscal year (that is, $8,457,452 applicable to FY 2009 and $4,751,550 applicable to FY 2010) from the estimated amount of the costs of the demonstration for FY 2016 (that is, $26,044,620). Thus, the final budget neutrality offset amount for which the adjustment to the national IPPS rates was calculated was $12,835,618.


As described earlier, we have generally incorporated two components into the budget neutrality offset amounts identified in the final IPPS rules in previous years. First, we have estimated the costs of the demonstration for the upcoming fiscal year, generally determined from historical, “as submitted” cost reports for the hospitals participating in that year. Update factors representing nationwide trends in cost and volume increases have been incorporated into these estimates, as specified in the methodology described in the final rule for each fiscal year. Second, as finalized cost reports have become available, we have determined the amount by which the actual costs of the demonstration for an earlier, given year differed from the estimated costs for the demonstration set forth in the final IPPS rule for the corresponding fiscal year, and we incorporated that amount into the budget neutrality offset amount for the upcoming fiscal year. If the actual costs for the demonstration for the earlier fiscal year exceeded the estimated costs of the demonstration identified in the final rule for that year, this difference was added to the estimated costs of the demonstration for the upcoming fiscal year when determining the budget neutrality adjustment for the upcoming fiscal year. Conversely, if the estimated costs of the demonstration set forth in the final rule for a prior fiscal year exceeded the actual costs of the demonstration for that year, this difference was subtracted from the estimated cost of the demonstration for the upcoming fiscal year when determining the budget neutrality adjustment for the upcoming fiscal year. We note that we have calculated this difference between the actual costs of the demonstration for FYs 2005 through 2010, as determined from finalized cost reports once available, and estimated costs of the demonstration as identified in the applicable IPPS final rules for these years.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25130), we proposed a different methodology as compared to previous years for analyzing the costs attributable to the demonstration for FY 2017. We noted that the demonstration will have substantially phased out by the beginning of FY 2017. The 7 “originally participating hospitals,” that is, those that were selected for the demonstration in 2004 and 2008, ended their participation in the 5-year extension period authorized by the Affordable Care Act prior to the start of FY 2016. In addition, we stated in the proposed rule that the participation period for the 14 hospitals that entered the demonstration following the mandate of the Affordable Care Act and that were still participating was to end on a rolling basis according to the end dates of the hospitals’ cost report periods, respectively, from April 30, 2016 through December 31, 2016. (As noted earlier, 1 hospital among this cohort closed in October 2015.) Of these 14 hospitals, 10 will end participation on or before September 30, 2016, leaving 4 hospitals participating for the last 3 months of FY 2016 (that is, the first 3 months of FY 2017). As discussed in the proposed rule, we believe that, given the small number of participating hospitals and the limited time of participation for such hospitals during FY 2017, a revised methodology is appropriate for determining the costs of the demonstration during this period as discussed below.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25130), we noted that estimating the costs of the demonstration for these 4 hospitals for their extent of participation in the demonstration in FY 2017 would entail a prorating calculation if we followed the methodology we used for FY 2016 as described earlier, as well as application of update factors to project increases in cost. We further noted that, for the 4 hospitals that will end their participation in the demonstration effective December 31, 2016, the financial experience of the last 3 months of the calendar year (that is, the first 3 months of FY 2017) will be included in the finalized cost reports for FY 2016. (Consistent with the methodology used for the final rules for previous years, a hospital’s cost report is included in the analysis of a given fiscal year if the cost reporting period begins in that fiscal year.) We believe that examining the finalized cost reports for FY 2016 for these hospitals would lead to a more...
accurate and administratively feasible calculation of budget neutrality for the demonstration in FY 2017 than conducting an estimate of the costs of the demonstration for this 3-month period based on “as submitted cost reports” (as would occur according to the budget neutrality methodology currently in effect).

In addition, as we stated in the proposed rule, given that the extent of covered services for FY 2017 subject to the payment methodology under the demonstration is a small fraction of that in previous fiscal years, we believe that it is appropriate to forego the process of estimating the costs attributable to the demonstration for FY 2017 and to instead analyze the set of finalized cost reports for cost reporting periods beginning in FY 2016, which will reflect the actual cost of the demonstration, when they become available. Such an approach also would eliminate the need to perform for FY 2017 the second component of the budget neutrality methodology discussed earlier that is, determining the amount by which the actual costs of the demonstration for the fiscal year, as determined in finalized cost reports once available, differed from the estimated costs for the demonstration set forth in the final IPPS rule for the corresponding fiscal year). Thus, for the reasons discussed earlier, we proposed to calculate the costs of the demonstration and the resulting budget neutrality adjustment factor for the demonstration for FY 2017 once the finalized cost reports for cost reporting periods beginning in FY 2016 become available. We invited public comments on this proposal.

We did not receive any public comments on this proposal. Therefore, in this final rule, we are finalizing our proposal, without modification, to reconcile, at one time, the budget neutrality offset amounts identified in the IPPS final rules for FYs 2011 through 2016 with the actual costs of the demonstration for those years, when all of the finalized cost reports for cost reporting periods beginning in FYs 2011 through 2016 are available.

As discussed in the proposed rule, we also note that, in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49591), we indicated that we were considering whether to propose in future rulemaking that the calculation of the final costs of the demonstration for a fiscal year reflect that some of the participating hospitals would otherwise have been eligible for the payment adjustment for low-volume hospitals in that fiscal year if they had not participated in the demonstration. Our policy under the demonstration is that hospitals participating in the demonstration are not able to receive the low-volume adjustment in addition to the reasonable cost-based payment authorized by section 410A of Public Law 108–173. We refer readers to Change Request 7505 dated July 22, 2011, available on the CMS Web site at: http://www.cms.gov. Section 1886(d)(12) of the Act provides for a payment adjustment to account for the higher costs per discharge for low-volume hospitals under the IPPS, effective FY 2005 (69 FR 49099 through 49102). We note that sections 3125 and 10314 of the Affordable Care Act provided for temporary changes in the qualifying criteria and payment adjustment for low-volume hospitals for FYs 2011 and 2012, which have been extended through subsequent legislation: Through FY 2013, by the American Taxpayer Relief Act of 2012 (ATRA) (Pub. L. 112–240) (78 FR 50610 through 50613), through March 31, 2014, by the Pathway for SGR Reform Act (Pub. L. 113–67) (79 FR 15022 through 15025); through March 21, 2015, by the Protecting Access to Medicare Act of 2014 (Pub. L. 113–93) (79 FR 49998 through 50001); and most recently through September 30, 2017, by section 204 of the Medicare Access and CHIP Reauthorization Act of 2015 (Pub. L. 114–10). These temporary changes have increased the number of hospitals that are eligible to receive the low-volume hospital payment adjustment.

We further stated in the FY 2016 IPPS/LTCH PPS final rule that taking the low-volume hospital payment adjustment into account in determining the costs of the demonstration would require detailed consideration of the data sources and methodology that would be used to determine which among the demonstration hospitals would have otherwise been eligible for the low-volume payment adjustment and to estimate the amount of the adjustment. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 24521), we invited public comments on this issue.

We stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25130), we stated that we believe it would be appropriate to conduct this analysis for FYs 2011 through 2016 at one time, when all of the finalized cost reports for cost reporting periods beginning in FYs 2011 through 2016 are available. Such an aggregate analysis encompassing the cost experience through the end of the period of performance of the demonstration represents an administratively streamlined method, allowing for the determination of any appropriate adjustment to the IPPS rates and obviating the need for multiple fiscal-year-specific calculations and regulatory actions. Given the general lag of 3 years in finalizing cost reports, we expect any such analysis to be conducted in FY 2020.

We did not receive any public comments on this proposal. Therefore, in this final rule, we are finalizing our proposal, without modification, to reconcile, at one time, the budget neutrality offset amounts identified in the IPPS final rules for FYs 2011 through 2016 with the actual costs of the demonstration for those years, when all of the finalized cost reports for cost reporting periods beginning in FYs 2011 through 2016 are available.

As discussed in the proposed rule, we also note that, in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49591), we indicated that we were considering whether to propose in future rulemaking that the calculation of the final costs of the demonstration for a fiscal year reflect that some of the participating hospitals would otherwise have been eligible for the payment adjustment for low-volume hospitals in that fiscal year if they had not participated in the demonstration. Our policy under the demonstration is that hospitals participating in the demonstration are not able to receive the low-volume adjustment in addition to the reasonable cost-based payment authorized by section 410A of Public Law 108–173. We refer readers to Change Request 7505 dated July 22, 2011, available on the CMS Web site at: http://www.cms.gov. Section 1886(d)(12) of the Act provides for a payment adjustment to account for the higher costs per discharge for low-volume hospitals under the IPPS, effective FY 2005 (69 FR 49099 through 49102). We note that sections 3125 and 10314 of the Affordable Care Act provided for temporary changes in the qualifying criteria and payment adjustment for low-volume hospitals for FYs 2011 and 2012, which have been extended through subsequent legislation: Through FY 2013, by the American Taxpayer Relief Act of 2012 (ATRA) (Pub. L. 112–240) (78 FR 50610 through 50613), through March 31, 2014, by the Pathway for SGR Reform Act (Pub. L. 113–67) (79 FR 15022 through 15025); through March 21, 2015, by the Protecting Access to Medicare Act of 2014 (Pub. L. 113–93) (79 FR 49998 through 50001); and most recently through September 30, 2017, by section 204 of the Medicare Access and CHIP Reauthorization Act of 2015 (Pub. L. 114–10). These temporary changes have increased the number of hospitals that are eligible to receive the low-volume hospital payment adjustment.

We further stated in the FY 2016 IPPS/LTCH PPS final rule that taking the low-volume hospital payment adjustment into account in determining the costs of the demonstration would require detailed consideration of the data sources and methodology that would be used to determine which among the demonstration hospitals would have otherwise been eligible for the low-volume payment adjustment and to estimate the amount of the adjustment. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 24521), we invited public comments on this issue.

We stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25130), we stated that we are continuing to examine this issue and are considering whether to incorporate the low-volume payment adjustment amounts that would have otherwise been made into the calculation of the difference between the actual costs of the demonstration and budget neutrality offset amounts for FYs 2011 through 2016. We note that applying such a methodology may lower the calculated amounts of the actual costs of the demonstration compared to not applying such a methodology, making it more likely that the actual costs of the demonstration for a year will not exceed the estimated costs of the demonstration identified in the final rule for that year. We again invited public comments on this issue.

We did not receive any public comments on this issue. We will continue to examine this issue.

L. Hospital and CAH Notification Procedures for Outpatients Receiving Observation Services

1. Background
a. Statutory Authority

On August 6, 2015, the Notice of Observation Treatment and Implication for Care Eligibility Act (the NOTICE Act), Public Law 114–42 was enacted. Section 2 of the NOTICE Act amended
The notification was presented. Finally, the notification and include the name and behalf is refused, section 1866(a)(1) of the Act lists requirements for providers of services to participate in the Medicare program and be eligible for payments under Medicare pursuant to provider agreements.

Section 1866(a)(1)(Y) of the Act, as added by section 2 of the NOTICE Act, specifies that the notification process must consist of a written notification as specified by the Secretary through rulemaking and containing such language as the Secretary prescribes consistent with the statutory provision, and an oral explanation of the written notification and documentation of the provision of the explanation, as the Secretary determines to be appropriate. Notification to each individual who receives observation services as an outpatient for more than 24 hours must be provided no later than 36 hours after observation services are initiated (or sooner, if upon release from the hospital or CAH). Section 1866(a)(1)(Y)(ii) of the Act provides that the written notice must explain that the individual is an outpatient receiving observation services, and is not an inpatient of a hospital or CAH. In addition, the written notice must include the reason(s) the individual is an outpatient receiving observation services and must explain the implications of being an outpatient receiving observation services, such as cost-sharing requirements and post-hospitalization eligibility for coverage of skilled nursing facility (SNF) services under Medicare. The written notification also must include any additional information as deemed appropriate by the Secretary. Moreover, the written notification must be signed by either the individual receiving observation services as an outpatient, or a person acting on the individual’s behalf, to acknowledge receipt of the notification. In cases where a signature by the individual or the person acting on the individual’s behalf is refused, section 1866(a)(1)(Y)(i)(V)(bb) of the Act stipulates that the notification be signed by the staff member of the hospital or CAH who presented the written notification and include the name and title of the staff member, a certification statement that the notification was presented, the date and time that the notification was presented. Finally, section 1866(a)(1)(Y)(ii)(V) of the Act provides that the notification be written and formatted using plain language and is made available in appropriate languages as determined by the Secretary.

b. Effective Date

As discussed in the proposed rule (81 FR 25131), section 2 of the NOTICE ACT provides the effective date for this notification requirement as effective beginning 12 months after the date of enactment of the NOTICE Act; that is, effective on August 6, 2016. Since the date the NOTICE Act was enacted, CMS has been working to implement the statutory requirement in a timely manner. On December 14, 2015, CMS released an electronic mailbox address for individuals who wished to submit email comments on the provisions of the NOTICE Act. In addition, CMS held a listening session on December 21, 2015, to provide stakeholders further opportunity to provide comment on the NOTICE Act. We thank those individuals who shared their input. The agency reviewed all comments submitted, as well as those comments provided during the public listening session in developing the provisions of the proposed rule. This final rule is effective as specified in the “Effective Date” section of this final rule. The standardized notice, the MOON, is going through the PRA approval process and is subject to a 30-day public comment period that begins on the date of publication of this final rule. Following review of comments and final approval of the MOON under the PRA process, hospitals and CAHs must fully implement use of the MOON no later than 90 calendar days from the date of PRA approval of the MOON.


a. Notice Process

We proposed to implement section 1866(a)(1)(Y) of the Act by revising the requirements that providers agree to as part of participating in Medicare under a provider agreement, by establishing regulations (at proposed 42 CFR 489.20(y)) that would specify a process for hospitals and CAHs to notify an individual, orally and in writing, of the individual’s receipt of observation services as an outpatient and the implications of receiving such services as set forth below. Under this proposed process, hospitals and CAHs would be required to furnish notice to such an individual entitled to Medicare benefits if the individual received observation services as an outpatient for more than 24 hours. We proposed the use of a standardized notice, referred to as the Medicare Outpatient Observation Notice (MOON), to be used by all applicable hospitals and CAHs. The MOON would include all of the informational elements required by section 1866(a)(1)(Y)(ii) of the Act to fulfill the written notice requirement of the NOTICE Act.

Comment: One commenter stated the NOTICE Act and MOON will continue to increase the cost of care and suggested that CMS require hospitals and CAHs to provide the information required by the NOTICE Act to patients in a lower cost environment. The commenter recommended that patients receive the NOTICE Act required information when signing up for Medicare, or as part of an annual visit.

Response: We appreciate the commenter’s recommendation and interest in providing the notice required by the NOTICE Act in a less costly setting. The NOTICE Act specifically requires hospitals and CAHs to deliver both a written notice and an explanation of the notice to individuals who receive observation services as an outpatient for more than 24 hours. The statute does not afford an alternative method of delivering the required notice, for example, during an annual wellness or other visit to a doctor, or to beneficiaries when signing up for Medicare. Consistent with the NOTICE Act, we believe that furnishing information related to being an outpatient receiving observation services when those services are furnished will have the most impact.

After consideration of the public comments we received, we are finalizing the notification process provisions of the proposed rule with respect to the method of delivery without modification.

b. Notification Recipients

Section 1866(a)(1)(Y) of the Act requires hospitals and CAHs to furnish notice to each individual who receives observation services as an outpatient at such hospital or CAH for more than 24 hours. Throughout section 1866 of the Act, “individual” generally refers to a person entitled to have payment made for services under Title XVIII of the Act, or a person not entitled to have payment made for services under Title XVIII if certain conditions are met. The provisions of the NOTICE Act specify that notice must be provided to individuals receiving observation services as an outpatient for more than 24 hours; the provisions do not specify qualifications related to payment for such services as a condition of notice. Accordingly, we proposed under the...
new § 489.20(y) that the notification required by section 1866(a)(1)(Y) of the Act must be provided to individuals entitled to benefits under Title XVIII of the Act, whether or not the services furnished are payable under Title XVIII, when individuals receive observation services as an outpatient for more than 24 hours. For example, an individual receiving Medicare Part A benefits who has not enrolled in Medicare Part B would still receive notice even though the observation services received as an outpatient fall under the Part B benefit and would not be covered or payable by Medicare for that person.

A beneficiary enrolled in a Medicare Advantage (MA) or other Medicare health plan would receive the required notice under the existing rules that apply to hospitals and CAHs under a provider agreement governed by the provisions of section 1866(a)(1)(Y) of the Act. MA regulations related to selection and credentialing of contract providers at § 422.204(b)(2) require that, with respect to providers that meet the definition of “provider of services” as defined in section 1861(u) of the Act, basic benefits may only be provided by these providers if they have a provider agreement with CMS permitting them to provide services under original Medicare. Under section 1861(u) of the Act, the term “provider of services” means a hospital, CAH, skilled nursing facility, comprehensive outpatient rehabilitation facility, home health agency, hospice program, or, for purposes of section 1814(g) and section 1835(e) of the Act, a fund.

Observation services are required to be provided under a physician’s order that specifies the initiation of observation services. As a general matter, hospital observation services are defined in the Medicare Benefits Policy Manual (Pub. 100–02), Chapter 6, Section 20.6, as services that are medically reasonable and necessary, specifically ordered by a physician or other nonphysician practitioner authorized by State licensure law and hospital bylaws to admit patients to the hospital or to order outpatient services, and meet other published Medicare criteria for payment. The term “physician” encompasses these authorized qualified nonphysician practitioners for the purposes of our proposed and final policy regarding implementation of the NOTICE Act provisions in the proposed and final rules. Individuals receiving observation services must be registered as outpatients; however, not all outpatients receive observation services. “Outpatient,” as defined in the Medicare Claims Processing Manual (Pub. 100–04), Chapter 1, Section 50.3.1, means “a person who has not been admitted as an inpatient but who is registered in the hospital or critical access hospital (CAH) records as an outpatient and receives services (rather than supplies alone) directly from the hospital or CAH.” We proposed that the provisions in the proposed rule would apply to the subset of individuals entitled to benefits under Title XVIII of the Act who are receiving treatment as outpatients and are receiving observation services for more than 24 hours. For outpatients who are not receiving observation services, or who are receiving observation services but not for more than 24 hours, hospitals and CAHs would not be required to deliver notification.

Comment: Many commenters suggested that CMS expand delivery of the MOON beyond Medicare beneficiaries who receive observation services as an outpatient at hospitals or CAHs for more than 24 hours. A few commenters requested clarification of who was required to receive a notice. In terms of expanding the delivery requirements, some commenters suggested that CMS require hospitals and CAHs to provide the MOON to all Medicare beneficiaries in outpatient status. Other commenters suggested that CMS require delivery of the MOON to any outpatient who has spent a night in the hospital, is in the hospital over 24 hours, and has not been admitted or had a long stay.

One commenter requested clarification about whether the NOTICE Act requires delivery of the MOON to a patient in extended outpatient recovery requiring an overnight stay, which the commenter explained were not observation services. Similarly, another commenter requested that CMS clarify that the NOTICE Act provisions do not apply to outpatients without an order for observation services.

Response: We appreciate the recommendations and acknowledge that, in some States, notice of outpatient status is required for all outpatients, regardless of the payer and irrespective of whether the patient has received observation services. We understand the commenters’ interest in minimizing duplication of effort and information provided to a Medicare beneficiary who requires care in a hospital or CAH. However, the NOTICE Act specifically requires hospitals and CAHs to deliver notice (written and oral), as prescribed by the Secretary, to Medicare beneficiaries who receive observation services as an outpatient for more than 24 hours. The MOON satisfies the written NOTICE Act requirement for a designated population of Medicare beneficiaries receiving a specific set of services, as provided for at section 1866(a)(1)(Y) of the Act. In some cases, delivering the MOON may also fulfill State notice requirements for the Medicare population. Hospitals and CAHs will need to make that determination on a State-by-State basis. Where State law, in pertinent part, requires notification to Medicare beneficiaries who receive observation services as an outpatient for more than 24 hours and requires such notice to
contain content that is not included in the MOON, hospitals may utilize the free text field in the MOON’s “Additional Information” section for communicating such additional content. Hospitals and CAHs will need to determine whether providing such additional information in this field of the MOON will satisfy State law requirements. Hospitals and CAHs subject to State law notice requirements may also attach an additional page to the MOON to supplement the “Additional Information” section in order to communicate additional content required under State law, or may attach the notice required under State law to the MOON. Nevertheless, we do not believe it would be appropriate to require hospitals and CAHs to deliver the MOON, or an amended version of the MOON, to patients who have not received observation services and who are not entitled to benefits under the Medicare program because the NOTICE Act was not aimed at some other, larger patient population. The MOON contains information specific to individuals entitled to receive benefits through Medicare that receive observation services in the hospital outpatient setting. Therefore, we are not accepting the commenters’ recommendation.

Comment: One commenter asserted that proposed § 489.20(y) requiring hospitals and CAHs to deliver notice (the MOON) to individuals receiving observation services as an outpatient for more than 24 hours, even if the individual is subsequently admitted as an inpatient, violates the intent of the NOTICE Act. The commenter stated that requiring hospitals and CAHs to provide the MOON to an individual subsequently admitted as an inpatient is unduly burdensome, serves no purpose, and provides no informational benefit to beneficiaries or their families. Another commenter agreed with CMS’ proposal to require hospitals and CAHs to deliver notice to individuals receiving observation services as an outpatient for more than 24 hours, even if the individual is subsequently admitted as an inpatient, because the time an outpatient receiving observation services does not count toward the 3 consecutive day inpatient hospital stay requirement for coverage of post-hospital SNF care. However, the commenter stated that the MOON did not adequately explain the implications on cost-sharing and coverage of post-hospital SNF care in such a situation.

Response: We appreciate these comments. However, we disagree with the suggestion that providing the MOON to an individual who is subsequently admitted as an inpatient serves no purpose and provides no informational benefit to beneficiaries or their families. We agree with the commenter who asserted that it is important to provide the MOON to individuals who are subsequently admitted as an inpatient because the time the individual spent as an outpatient receiving observation services does not count toward the 3 consecutive day inpatient hospital stay requirement for coverage of post-hospital SNF care. While not all patients who are admitted ultimately receive post-hospital SNF care following discharge, the implications of receiving observation services on an outpatient basis for individuals who eventually receive such care can be significant, which is why information is required to be included in the notice to beneficiaries (that is, written notification that explains the implications of such status on subsequent eligibility for coverage for services furnished by a SNF, as specified in section 1866(a)(1)(Y)(ii)(II) of the Act). Moreover, we believe the NOTICE Act requires hospitals and CAHs to deliver notice to individuals who receive more than 24 hours of observation services, and are subsequently admitted as an inpatient.

We acknowledge that cost-sharing for an individual receiving observation services as an outpatient will change if the individual is subsequently admitted as an inpatient. Related outpatient services directly preceding an inpatient admission may fall under the payment window for outpatient services for which the costs are treated as costs of inpatient services (also known as the 3-day payment window), as discussed in the Medicare Claims Processing Manual (Pub. 100–4), Chapter 3, Section 40.3 and Chapter 4, Section 10.12.

Outpatient services that fall under the 3-day payment window prior to an inpatient admission will be subject to Part A cost-sharing rules. We expect that this information will be communicated by hospital staff to the individual during the oral explanation of the notification. In addition, if an individual who receives more than 24 hours of observation services as an outpatient is admitted as an inpatient prior to the delivery of the MOON, in the “Additional Information” section of the MOON the hospital should explain that, as an inpatient, the individual may have Part A cost-sharing responsibilities. Therefore, we are not accepting the recommendations of the commenters suggesting that the hospitals and CAHs be able to forego the delivery of the MOON in cases where individuals receiving observation services as outpatients are later admitted as inpatients.
initiated, or sooner if the individual is transferred, discharged, or admitted as an inpatient. If, as described in the commenter’s example, the individual is initially admitted to a hospital or CAH as an inpatient, the requirement to deliver the MOON does not apply (in cases where the individual receives outpatient observation services for fewer than 24 hours prior to the inpatient admission), notwithstanding any later determination by the MA plan (following the individual’s discharge) related to the inpatient hospital admission. It is our expectation that a contracted hospital and the MA plan coordinate and communicate regarding the appropriate level of care while the enrollee is receiving care in the contracted hospital in accordance with the requirements at §422.112 related to continuity of care and integration of services.

As noted in the preamble to the proposed rule, a beneficiary enrolled in a MA or other Medicare health plan would receive the required notice under the existing rules that apply to hospitals and CAHs under a provider agreement governed by the provisions of section 1866(a)(1)(Y) of the Act. The MA regulations related to selection and credentialing of contract providers at §422.204(b)(3) require that, with respect to providers that meet the definition of “provider of services” as defined in section 1861(u) of the Act, basic benefits may only be provided by these providers if they have a provider agreement with CMS permitting them to provide services under original Medicare. Under section 1861(u) of the Act, the term “provider of services” means a hospital, critical access hospital, skilled nursing facility, comprehensive outpatient rehabilitation facility, home health agency, hospice program, or, for purposes of section 1814(g) and section 1835(e) of the Act, a fund. Given the statutory language in section 1866 of the Act and the regulatory requirements in 42 CFR part 422 related to provider agreements, we do not agree with commenters, and do not believe it would be appropriate to exclude hospitals and CAHs from the NOTICE Act requirements with respect to MA enrollees. Therefore, hospitals and CAHs must furnish the MOON to MA enrollees who receive observation services as an outpatient for more than 24 hours as set forth in this final rule.

Comment: One commenter requested that CMS remove the requirement that hospitals and CAHs deliver the MOON to Medicare beneficiaries who are not enrolled in Medicare Part B. The commenter believed it would be inappropriate to provide information on the rules for insurance coverage to individuals who do not have that coverage.

Response: We appreciate the commenter’s suggestion. However, one intent of the NOTICE Act is to inform beneficiaries of costs they might not otherwise be aware of relating to their classification as either an outpatient receiving observation services or an inpatient. A beneficiary who receives observation services as an outpatient (which are covered under Medicare Part B), who is enrolled in Medicare Part A, but does not have Part B coverage, may be unaware that he or she may be financially responsible for the full cost of the services he or she is receiving, due to lack of Part B coverage. We believe providing the MOON to beneficiaries who do not have Part B coverage will serve to inform such beneficiaries of the financial consequences consistent with the NOTICE Act. Therefore, we are not adopting the commenter’s recommendation.

Comment: One commenter requested that CMS explain whether hospitals and CAHs must deliver the MOON when the primary payer is a commercial plan and the secondary payer is Medicare or MA.

Response: The provisions of the NOTICE Act amended section 1866 of the Act and apply to hospitals and CAHs furnishing services to individuals entitled to benefits under Title XVIII of the Act, whether or not the services are payable under Title XVIII. If an individual is entitled to benefits under Title XVIII (and receives observation services as an outpatient for more than 24 hours), the notice requirement applies, regardless of whether Medicare is the secondary payer. The applicability of the notice requirement depends on whether the individual is entitled to benefits under Title XVIII, not on whether Medicare makes payment (primary or otherwise).

After consideration of the public comments we received, we are finalizing the notification recipients provisions of the proposed rule without modification.

c. Timing of Notice Delivery

As discussed in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25132), and as provided at section 1866(a)(1)(Y) of the Act, we proposed under proposed new §489.20(y) that hospitals and CAHs must provide notice to an individual who receives observation services as an outpatient for more than 24 hours and that have not received no later than 36 hours after observation services are initiated, or sooner if the individual is transferred, discharged, or admitted as an inpatient.

For purposes of our proposed and final policy regarding implementation of the NOTICE Act provisions in the FY 2017 IPPS/LTC PPS proposed and final rules, consistent with existing billing rules, observation services are initiated when a physician orders such services. According to the Medicare Claims Processing Manual (Pub. 100–04), Chapter 4, Section 290.2.2, hospital reporting for observation services “begins at the clock time documented in the patient’s medical record, which coincides with the time that observation services are initiated in accordance with a physician’s order.” Because valid medical documentation for observation services will always contain the time when observation services are initiated, we believe hospitals and CAHs will be able to readily determine the timeframe within which the notice must be delivered. We expect that there will be cases where an individual receives more than 24 hours of observation services and has not yet received the MOON, but there are imminent plans for discharge to home or another facility, transfer to another unit or facility to receive care that does not include observation services, or admission to the hospital or another facility as an inpatient. In these cases, pursuant to section 1866(a)(1)(Y) of the Act, which provides that notice be provided not later than 36 hours after the time such an individual begins receiving such services (or, if sooner, upon release), we proposed that the MOON must be delivered no later than 36 hours of the initiation of observation services.

In rare circumstances where a physician initially orders inpatient services, but following internal utilization review (UR) performed while the patient is hospitalized, the hospital determines that the services do not meet its inpatient criteria and the physician concurs with UR and orders the discontinuation of inpatient services and initiation of outpatient observation services (that is, a Condition Code 44 situation), we stated in the proposed rule that the MOON would be delivered as required by the NOTICE Act (when outpatient observation services have been ordered and furnished for more than 24 hours). If observation services are ordered when Condition Code 44
applies, the 24-hour time period for observation notification commences at the same time that observation services are initiated under a physician's order, consistent with existing policy for observation services furnished to outpatients. (We refer readers to the Medicare Claims Processing Manual (Pub. 100–04), Chapter 1, Section 50.3.) As discussed in the proposed rule and as stated in the notice announcing CMS Ruling CMS–1455–R (78 FR 16614), the Part B Inpatient Billing Ruling, in cases where reviewers find that an inpatient admission was not medically reasonable and necessary after the beneficiary is discharged, and thus, not appropriate for payment under Medicare Part A, the beneficiary's patient status remains “inpatient” as of the time of the inpatient admission. The patient's status is not changed to outpatient because the beneficiary was formally admitted as an inpatient, and there is no provision to change a beneficiary's status after he or she is discharged from the hospital. Where CMS denies a claim after the beneficiary has been discharged because the inpatient admission was not medically reasonable and necessary, there would be no need to issue the MOON because the individual's status remains inpatient, despite the fact that the inpatient admission was improper. Similarly, where a hospital determines through UR after a beneficiary is discharged that his or her inpatient admission was not reasonable and necessary and the hospital bills the services that were provided on a Medicare Part A claim, the NOTICE Act notification requirements would not apply for these individuals because their status would also remain inpatient.

Comment: Several commenters indicated that it would be difficult from an operational perspective to deliver the MOON within a narrow window of 12 hours following the beneficiary’s receipt of more than 24 hours of observation services and the requirement that the notice be furnished within 36 hours of the initiation of observation services. Some commenters recommended the notice be furnished within 24 hours or 48 hours following the initiation of observation services as an outpatient. Other commenters indicated that if State regulations require notice of observation services as an outpatient be furnished to patients within 24 hours of the initiation of observation services as an outpatient, the State policy should be followed in order to provide the most protection possible to the consumer. Another commenter requested that CMS clarify whether there are consequences for having the MOON delivered and signed before 24 hours of observation services are furnished. The commenters urged CMS to use its regulatory discretion and create flexibility on the timing of delivery of the notice and to establish clear standards for consistent implementation across State lines.

One commenter opined that the statute provides latitude for CMS to permit an earlier delivery of the MOON to the Medicare beneficiary. The commenter explained that the NOTICE Act requires delivery of notice to outpatients who receive observation services for more than 24 hours, but does not preclude a hospital or CAH from voluntarily deliver of the notice prior to an individual's receipt of 24 hours of observation services. The commenter further explained, given that some of the implications to be explained in the notice are present from the initiation of observation services, it may be beneficial for beneficiaries to receive the notice earlier. Earlier delivery of the notice, in the commenter’s opinion, would provide flexibility for hospitals and CAHs in States with conflicting laws to satisfy both Federal and State requirements, while minimizing provider burden. The commenter recommended that CMS allow hospitals and CAHs to provide the MOON to a patient prior to furnishing 24 hours of observation services but no later than 36 hours following the initiation of observation services. Several other commenters made a similar recommendation.

Response: We appreciate the many comments submitted on the issue of the timing of delivery of notice under the NOTICE Act. Section 1866(a)(1) of the Act, as amended by the NOTICE Act, requires hospitals and CAHs to deliver notice, consisting of a written notice (as specified by the Secretary of HHS following promulgation of rules) and an oral explanation of the notice, to each individual who receives observation services as an outpatient for more than 24 hours. Under the statute, the notice and explanation must be delivered no later than 36 hours after the time such individual begins receiving observation services (or, if sooner, upon release). We specified in proposed § 489.20(y) that the notification required by section 1866(a)(1)(Y) of the Act must be provided to individuals entitled to benefits under Title XVIII of the Act, whether or not the services furnished are payable under Title XVIII, when individuals receive observation services as an outpatient for more than 24 hours. As we stated in the proposed rule, for outpatient services as an outpatient, nothing in the statute precludes hospitals and CAHs from delivering notice before an individual has received more than 24 hours of observation services as an outpatient, provided the information contained in the notice is accurate. Hospitals and CAHs that are subject to State laws requiring written notice to outpatients receiving observation services within 24 hours of the initiation of services, for example, may deliver the MOON to those individuals it believes will trigger the required notice under the NOTICE Act during the State-mandated timeframes and still be in compliance with the timing of notice delivery requirement of the NOTICE Act (provided the MOON is delivered not later than 36 hours after the time such individual begins receiving outpatient observation services, or, if sooner, upon release (that is, sooner, if transferred, discharged, or admitted as an inpatient)). Accordingly, we are revising proposed § 489.20(y) to clarify that hospitals and CAHs may deliver the MOON before an individual has received more than 24 hours of observation services as an outpatient.

However, we reiterate that the notice required by the NOTICE Act must be delivered within the timeframe established in statute; that is, no later than 36 hours after the time an individual begins receiving observation services as an outpatient, or if sooner, upon release. As specified in proposed § 489.20(y), the notice must be provided to the individual not later than 36 hours after observation services are initiated or sooner if the individual is transferred, discharged, or admitted. Delivering notice after this timeframe (for example, within 48 hours of the initiation of observation services, as suggested by one commenter) would not comply with the NOTICE Act requirement for timing of notice delivery. Therefore, we are not accepting the commenters’ recommendations to allow hospitals and CAHs to deliver the notice as required by the NOTICE Act later than 36 hours after the individual entitled to notice...
begins receiving observation services as an outpatient.

While, as previously stated, nothing in the statute precludes hospitals and CAHs from delivering notice before an individual has received more than 24 hours of observation services as an outpatient, provided the information contained in the notice is accurate, we note that we do not encourage hospitals and CAHs to deliver the MOON at the initiation of outpatient observation services. Routine and systematic delivery of the MOON by a hospital or CAH at the initiation of observation services would, in effect, render the MOON a notice of receiving outpatient observation services, as all patients receiving observation services would be given the MOON independent of the length of time they received observation services. In addition, at the initiation of outpatient observation services, patients may be completely preoccupied with concern for their safety and well-being, as they may be unsure of their diagnosis at a time when the signs and symptoms of their presenting condition(s) may be at the height of their clinical acuity. At the initiation of outpatient observation services, patients also may be overwhelmed and confused by notices and hospital paperwork that are presented at the time, often simultaneously. For these reasons, we reiterate that the NOTICE Act requires notice be provided to individuals who receive observations services as an outpatient for more than 24 hours, not later than 36 hours after the time the individual begins receiving such services, or, if sooner, upon release, but that the statute does not preclude earlier delivery, and that we encourage hospitals and CAHs to not deliver the MOON at the initiation of outpatient observation services.

Comment: Several commenters requested that CMS clarify when the 24 hour timeframe for receiving observation services as an outpatient begins. The commenters requested clarification as to whether the timeframe starts: (1) After services begin following the written order for observation services; (2) when related services commence if such services commence before the written order was executed and the patient occupies an outpatient bed count; or (3) based on the documentation of when nursing care began. Several commenters requested that CMS clarify, in situations where a resident orders observation services, whether the commencement of the 24-hour period for determining eligibility for the MOON begins when the resident writes the order or when the attending physician “confirms” that order.

Response: We appreciate the commenters’ request for clarification regarding the time at which outpatient observation services are initiated for the purpose of determining when more than 24 hours of outpatient observation services have been received. In the proposed rule, we stated, “For purposes of this proposed rule, consistent with existing billing rules, observation services are initiated when a physician orders such services” (81 FR 25132). We then explained our existing billing rules contained in the CMS Internet Only Manual (IOM). “According to the Medicare Claims Processing Manual (Pub. 100–04), Chapter 4, Section 290.2.2, hospital reporting for observation services ‘begins at the clock time documented in the patient’s medical record, which coincides with the time that observation services are initiated in accordance with a physician’s order.’”

As the commenters noted, there may be times when an individual is subject to an order for observation services, but is not actually receiving observation services. For example, following an order for observation services in an emergency department, a hospital may need to wait to begin furnishing observation services until a bed is available for the patient. In this situation, services are considered initiated when observation services commence.

In this final rule, we are clarifying our explanation in the preamble of the proposed rule that the start of observation services, for the purposes of determining when more than 24 hours of observation services have been received, is the clock time as documented in the patient’s medical record at which observation services are initiated (furnished to the patient) in accordance with a physician’s order. With respect to the request for clarification of the effect of a resident’s order for services on the counting of hours of observation care, we stated the following in our proposed rule that “hospital observation services are defined in the Medicare Benefits Policy Manual (Pub. 100–02), Chapter 6, Section 20.6, as services that are medically reasonable and necessary, specifically ordered by a physician or other nonphysician practitioner authorized by State licensure law and hospital staff bylaws to admit patients to the hospital or to order outpatient services, and meet other published Medicare criteria for payment. The term ‘physician’ will encompass these other nonphysician practitioners for the purposes of this proposed rule” (81 FR 25132).

Therefore, to the extent that a resident is authorized by State licensure law and hospital staff bylaws to order outpatient services, once observation services are initiated in accordance with the resident’s order, the 24 hour time period will commence.

Comment: One commenter stated that, for the purpose of determining when a hospital or CAH must notify a patient under the NOTICE Act, that is, when an individual receives observation services as an outpatient for more than 24 hours, the counting of hours to trigger the notification requirement could be interpreted as elapsed or clock time (meaning starting the 24-hour clock at the time of the physician’s order for observation services as an outpatient and ending with the discharge order from observation), or billable time (meaning tracking and counting only those hours which would be billable as outpatient observation services upon claim submission). The commenter recommended that CMS require hospitals and CAHs to use billable time when counting the hours of observation services received for the purpose of triggering the notification requirement. Another commenter recommended that CMS use elapsed time and not billable observation hours to determine when an individual has received 24 hours of observation services.

Response: We appreciate the comments and recommendations submitted on this issue. The NOTICE Act requires hospitals and CAHs to deliver notice to an individual who receives observation services as an outpatient for more than 24 hours, and requires delivery of the notice no later than 36 hours after the time such individual begins receiving observation services (or, if sooner, upon release). We believe using elapsed time rather than billed time is more consistent with the plain language of the statute for the purpose of determining when an individual is required to receive notice and when such notice must be delivered. Therefore, for purposes of identifying the 24-hour timeframe for which an individual has received observation services, and thus is required by the NOTICE Act to receive notice by the hospital or CAH, observation time will be measured as the elapsed time in hours beginning at the clock time documented in the patient’s medical record, which coincides with the time that observation care is initiated in accordance with a physician’s order. For example, an individual for whom observation services are initiated in accordance with a physician order at 3:19 p.m. on Monday would meet the more than 24-
hour threshold to require delivery of notice, after 3:19 p.m. the following day (Tuesday), and delivery of the notice would be required by 3:19 a.m. on the subsequent day (Wednesday), or sooner, if the individual is discharged, transferred, or admitted.

Comment: One commenter requested that CMS clarify when the 24-hour time period ends for the purposes of determining whether a patient has received more than 24 hours of observation services as an outpatient, when the physician orders the discharge of the patient or when the patient leaves the building.

Response: Observation time ends when all medically necessary observation services are completed. To be clear, this could be before discharge when the need for observation services has ended, but other medically necessary services not meeting the definition of hospital observation services are provided (in which case, the additional medically necessary services received after the completion of observation services would be billed separately or be included as part of the emergency department or clinic visit). Alternatively, the end time of observation services may coincide with the time the patient is actually discharged from the hospital or admitted as an inpatient.

Comment: One commenter requested CMS to clarify how the MOON will work with the 2-midnight policy.

Response: The NOTICE Act established a requirement for notice specifically to an individual who receives observation services as an outpatient for more than 24 hours, and no later than 36 hours after the time such individual begins receiving observation services (or, if sooner, upon release), do not impact or change the current requirements and guidance related to the 2-midnight policy previously issued by CMS. Hospitals will be required to adhere to all existing requirements of the 2-midnight policy, as well as adhere to the requirements set forth by the NOTICE Act. We remind commenters that the 2-midnight policy has been put forth by CMS to give hospitals and physicians guidance as to when an inpatient admission is eligible for Part A payment. The NOTICE Act requires hospitals to inform patients who have remained outpatients of the hospital and received observation services for more than 24 hours that they are not hospital inpatients and are subject to potentially different cost-sharing requirements and postacute care benefits than someone who has been admitted as an inpatient. We note that a scenario could arise whereby a patient is admitted to the hospital immediately after being a hospital outpatient receiving observation services for greater than 24 hours. In such a scenario, the inpatient admission may be payable under Medicare Part A under the 2-midnight policy and, as stated earlier, the hospital or CAH would still be required to furnish the MOON to the patient within 36 hours after the time the individual begins receiving observation services.

Comment: One commenter recommended that CMS require delivery of notice before the initiation of observation services, similar to the Advance Beneficiary Notice of Noncoverage (ABN), so that a patient can decide prior to incurring financial liability whether to receive the services or leave the hospital. The commenter believed that if the hospital does not notify the patient in advance of the initiation of observation services, the patient should be relieved of financial liability.

Response: We appreciate the recommendations of the commenter. However, the NOTICE Act established a requirement for notice specifically to an individual who receives observation services as an outpatient for more than 24 hours. We are not adopting the commenter’s recommendation.

Comment: One commenter indicated that CMS significantly misstated when and how observation status is used. The commenter stated that use of Condition Code 44 is not rare and despite the 2-midnight policy, patients who remain in the hospital for multiple days often are coded as outpatients.

Response: As we have previously stated in Chapter 1, Section 50.3 of the Medicare Claims Processing Manual, CMS set the policy for the use of Condition Code 44 to address those relatively infrequent occasions, such as a late-night weekend admission when no case manager is on duty to offer guidance, when internal review subsequently determines that an inpatient admission does not meet hospital criteria and that the patient would have been registered as an outpatient under ordinary circumstances. Use of Condition Code 44 is not intended to serve as a substitute for adequate staffing of utilization management personnel or for continued education of physicians and hospital staff about each hospital’s existing policies and admission protocols. As education and staffing efforts continue to progress, the need for hospitals to correct inappropriate admissions and to report Condition Code 44 should become increasingly rare.

After consideration of the public comments we received, we are finalizing the provisions of the proposed rule for timing of notice delivery with modifications as noted above.

d. Requirements for Written Notice

In the proposed rule (81 FR 25133), we proposed to implement section 1866(a)(1)(Y)(ii) of the Act, the requirement for written notification, under proposed new §489.20(y)(1) by proposing the basic requirements for the written notice that hospitals and CAHs must use to notify individuals receiving outpatient observation services.

Specifically, we proposed that hospitals and CAHs would be required to use a proposed standardized notice (the MOON) for written notification to an individual who receives observation services as an outpatient under the appropriate circumstances. By requiring use of a standardized notice, hospitals and CAHs would be assured that they are providing all of the statutorily required elements in a manner that is understandable to individuals receiving the notice. As provided at section 1866(a)(1)(Y)(ii)(1) of the Act, we proposed at §489.20(y)(1)(i) that the MOON would explain to individuals that they are outpatients receiving observation services and not inpatients of the hospital or CAH, and the reason(s) for such status as an outpatient receiving observation services. By definition (as specified in the Medicare Benefits Policy Manual (Pub. 100–02), Chapter 6, Section 20.6), the reason for ordering observation services will always be the result of a physician’s decision that the individual does not currently require inpatient services and observation services are needed for the physician to make a decision regarding whether the individual needs further treatment as a hospital inpatient or if the individual is able to be discharged from the hospital. We proposed at §489.20(y)(1)(ii) that the proposed MOON also would provide an explanation of the implications of receiving observation services furnished by a hospital or CAH as an outpatient, including services furnished on an inpatient basis, such as those related to cost-sharing requirements for the patient under Medicare, and posthospitalization eligibility for Medicare-covered SNF care, in standardized language to ensure that all Medicare eligible individuals receive accurate information. We proposed the inclusion of a blank “Additional Information” section on the MOON so that hospitals and CAHs may insert any additional information. Finally, as required by section 1866(a)(1)(Y)(ii)(V) of the Act,
the proposed MOON would include this information in plain language written for beneficiary comprehension.  

Comment: Numerous commenters submitted comments regarding the general formatting and readability of the MOON. Several commenters expressed concern that the MOON was too complex for patients to have a full understanding of the issues included in the notice and the implications of being an outpatient receiving observation services. Some commenters did not consider the MOON to be written in "plain language." Some commenters suggested the reading level of the MOON was too advanced for the typical beneficiary. Another commenter noted that the MOON is written at a 12.1 grade level and cited a study that claims that the average American's reading level proficiency is generally to be considered to be 5th to 7th grade level. Some commenters made suggestions on how the MOON could be reordered and simplified to improve understandability and effectiveness. Commenters also believe that there were duplicative time and date fields as well as unnecessary fields for physician and hospital names when that information can be found in the beneficiary's medical record, or can be otherwise printed on the top of the notice, in the case of the hospital name. One commenter requested that the MOON have more room for the beneficiary's name and date of birth, while another commenter requested that the MOON be limited to one page. Another commenter provided copies of State-issued observation notices as examples that CMS may wish to consider during this notice development process. Other commenters suggested specific language for revising the notice. One commenter proposed incorporating a question and answer format on the MOON. Some commenters were concerned with which physician (admitting or attending) name should be included on the MOON. Other commenters did not want a requirement to include a physician name on the notice, as many physicians at a hospital can be involved with a beneficiary's outpatient care.

Response: We agree with the commenters that some fields are unnecessary when the information is contained in the patient's medical record. To that end, we have reduced the number of fillable fields on the MOON. Specifically, the fields for physician name and the date and time observation services began are no longer on the notice. In addition, we removed the field for the hospital name. Consistent with requirements for current beneficiary notices, and as will be detailed in future guidance, hospitals will be permitted to preprint the MOON to include their hospital name and logo at the top of the notice.

In response to the suggestion to condense the MOON into a single page, we are unable to do so, as condensing the notice, as suggested, would negatively affect its readability; for example, reducing the notice to one page would require use of an extremely small font size. However, we note that hospitals may print the MOON as two sides of a single page. Finally, we have drafted the MOON to contain all of the elements of notice we believe are required under the NOTICE Act. We have taken commenters' suggestions for specific wording changes under advisement and note that CMS' Office of Communications has performed a plain language review, and we have incorporated appropriate changes, wherever possible. The MOON has been revised and the updated draft is subject to a 30-day comment period in accordance with the requirements of the Paperwork Reduction Act (PRA). This revised MOON will not be final until any public comments have been received and considered. We do not routinely use specific readability tests on beneficiary publications. We appreciate the commenters' concerns and have made changes to the MOON, as discussed above, in order to help ensure maximum readability and comprehension. We believe the notice is now more streamlined and easier to comprehend. In addition to these revisions, as with most beneficiary notices, we expect that the MOON will be updated periodically based on our continued experience with the notice, through the PRA renewal process, which requires reapproval every 3 years.

Comment: Numerous commenters submitted comments related to the notice section containing contact information to express quality of care concerns to QIOs. Some commenters suggested moving this section further down or to the end of the notice. Other commenters suggested removing this information entirely. Some commenters explained that inclusion of this contact information would be confusing to beneficiaries and could mislead them as to the purpose of this notice. One commenter recommended revising the language to specifically state that QIOs do not have the authority to change a patient's status from outpatient to inpatient. Some commenters believed that the inclusion of QIO contact information may encourage calls to the QIO expressing that the beneficiary should be an inpatient, rather than outpatient, and regard the outpatient status as a quality of care issue, rather than a level of service issue. Another commenter suggested that CMS amend the QIO scope of work to account for additional inquiries that may result when required MOON delivery begins. One commenter believed the information about filing complaints about quality of care with MA plans is unnecessary. That commenter expressed concern that because outpatient status is not appealable, this contact information may cause unnecessary confusion.

Response: We agree with the commenters' suggestion to keep the focus of the MOON on status as an outpatient and related coverage and cost-sharing implications. Therefore, we have removed the QIO contact section from the MOON.

Comment: One commenter suggested that CMS remove the requirement directing a patient to contact 1–800–MEDICARE with questions, and replace that entire paragraph with hospital contact information. The commenter reasoned that because hospitals provide robust financial counseling services, physician advisors, care management teams, among others, they can better answer beneficiary questions in a friendly, in-person manner. Conversely, another commenter recommended removing the language referring beneficiaries with questions to hospital staff and physicians. This commenter believed that beneficiary questions regarding coverage and financial responsibility for receiving observation services as an outpatient are more appropriately directed to 1–800–MEDICARE. Another commenter suggested that CMS establish a point of contact in addition to 1–800–MEDICARE for questions related to the MOON.

Response: We disagree with the comments summarized above. The inclusion on the MOON of 1–800–MEDICARE contact information is consistent with other beneficiary notices. In addition to observation stay questions, beneficiaries may have other concerns related to Medicare billing, coverage, and associated issues. We are maintaining the MOON’s direction of patients to hospital personnel, in general, rather than to specific hospital contacts, to afford hospitals flexibility in the contact information they provide. However, hospitals may use the “Additional Information” section to specify particular hospital staff members and their contact information.

Finally, we believe that beneficiary information needs are satisfied by the existing options of using 1–800–MEDICARE as well as using hospital staff.
Beneficiaries have access to broad benefit and coverage information through 1–800–Medicare, and case-specific information from their hospitals. Therefore, we do not believe an additional point of contact is not necessary.

Comment: Several commenters explained that the MOON does not clearly state that the patient is not an inpatient for the purposes of meeting the 3 consecutive day inpatient hospital qualifying stay for coverage of post-hospital SNF care. One commenter suggested that the MOON explain the potential financial implications of being classified as an outpatient, rather than an inpatient, in simple, easy to understand terms. Another commenter noted that the MOON includes complex phrases such as “observation stay” and “prior qualifying inpatient hospital stay” without explanation. The commenter stated if these specific terms must be used, they should be defined in the notice. Many commenters suggested clarifying Part B coverage information and moving that language up in the ordering of the notice. One commenter suggested specific language to more clearly convey the information contained in this section.

Response: We agree with the commenters that this important information regarding coverage of post-hospital SNF care and Part B coverage should be more clearly stated and prominently displayed on the notice. To that end, we have simplified this language as part of the MOON’s plain language effort and moved it near the top of the MOON.

Comment: Several commenters indicated that the NOTICE Act requires hospitals to explain the reason patients are classified as outpatients rather than inpatients. The commenters recommended that the MOON include a section for physicians to indicate the reason for outpatient status. Another commenter suggested that the MOON contain standard language explaining that the decision to classify a beneficiary as an outpatient, rather than admit as an inpatient, is based on Medicare regulations, without regard to cost-sharing responsibilities or skilled nursing facility eligibility. One commenter requested that CMS provide standard narratives to be used by hospitals when explaining the possible reasons for outpatient classification. Conversely, another commenter was satisfied with the MOON’s standard language regarding the “reason” for observation services. However, this commenter stated this language was not clearly and prominently communicated on the notice.

Response: We agree with the commenters who suggested that the MOON should contain a field where a hospital will be required to state the specific reason a beneficiary is an outpatient, rather than inpatient. We believe this recommendation is consistent with the statute, specifically section 1866(a)(1)(Y)(ii)(I) of the Act. The MOON now contains a free text field where the specific reason for receiving observation services as an outpatient shall be completed by the hospital or CAH. We may consider, in the future, the other suggestions commenters made to improve the MOON, such as checkboxes with common reasons for the patient’s outpatient status or suggested narratives for insertion in this section.

Comment: Several commenters asked that CMS clarify what additional information is expected to be included in the “Additional Information” section on the MOON.

Response: We generally do not specify expected language for the additional information sections of beneficiary notices. However, we believe hospitals and CAHs may use this section to include information such as unique circumstances regarding the particular patient (such as Medicare Accountable Care Organization (ACO) information), notation that a beneficiary refused to sign the MOON, hospital waivers of the beneficiary’s responsibility for the cost of self-administered drugs, Part A cost-sharing responsibilities if the beneficiary is subsequently admitted as an inpatient, or specific information for contacting hospital staff.

Comment: Several commenters urged CMS to clarify whether hospitals and CAHs will be required to provide the MOON to Medicare beneficiaries in States that already have a requirement to notify all patients of their status as an outpatient receiving observation services. The commenters expressed concern that furnishing two separate notices to beneficiaries would be counterproductive, burdensome on providers, and potentially confusing for patients. Some commenters requested CMS provide flexibility to hospitals to create their own notice that would comply with the requirements of the NOTICE Act. Some commenters requested CMS to address whether a hospital that complies with substantially equivalent requirements imposed under State law could be considered to be in compliance with the requirements of the NOTICE Act when furnishing a State-mandated notice. Some commenters recommended that where a hospital meets applicable State requirements related to observation notification, CMS deem the hospital to have met the NOTICE Act requirements. One commenter requested that where there is an existing State law that overlaps the requirements of the NOTICE Act, CMS clarify which requirements take precedence and expressly preempt the State law.

Response: The NOTICE Act requires hospitals and CAHs to furnish written notice specified by the Secretary pursuant to rulemaking, containing such language as the Secretary prescribes, consistent with the statute. Given the statutory language of the NOTICE Act, we believe the Federal standardized notice (the MOON) must be delivered to Medicare beneficiaries entitled to notice under the NOTICE Act, consistent with the provisions of this final rule, notwithstanding any similar notice that hospitals may previously had to deliver to such patients under State law or otherwise. In some cases, delivering the MOON may also fulfill State notice requirements for the Medicare population. Hospitals and CAHs will need to make that determination on a State-by-State basis. As we previously explained, where State law requires content that is not included in the MOON, hospitals may utilize the free text field in the MOON (“Additional Information”) for communicating such additional content. Hospitals and CAHs subject to State law notice requirements may also attach an additional page to the MOON to supplement the free text field in order to communicate additional content required under State law, or may attach the notice required under State law to the MOON. To the extent that there are requirements in a State law that directly conflict with or contradict requirements in the NOTICE Act, we will expect to address those issues of preemption as they are brought to our attention. However, at this time, we are not aware of any such State laws that contradict or conflict with the provisions of the NOTICE Act.

We believe the delivery of the MOON, an OMB standardized notice with consistent language, to all Medicare beneficiaries entitled to notice under the NOTICE Act best fulfills the requirements of the statute. Requiring the use of an OMB standardized notice ensures that all required statutory language is included, that the notice is written and formatted to be easily understandable to beneficiaries, and that the specific notice has been subject to public comment and input through the PRA process. Therefore, we are not adopting the commenters’ recommendations.

Comment: One commenter asked whether hospitals that provide their
own notice to all patients receiving observation services as outpatients would still need to provide the MOON to Medicare beneficiaries who have received 24 hours of observation services as an outpatient.

Response: We recognize that some hospitals may voluntarily issue a notice to outpatients, or in some cases to outpatients who have received observation services, informing patients of the implications of being an outpatient on cost-sharing and benefits. However, the NOTICE Act requires hospitals and CAHs to furnish written notice specified by the Secretary through rulemaking, containing such language as the Secretary prescribes consistent with the statute. Given the statutory language and intent of the NOTICE Act, we believe the Federal standardized notice (the MOON) must be delivered to Medicare beneficiaries entitled to notice under the NOTICE Act, consistent with the provisions of this final rule, notwithstanding any similar notice that hospitals may previously have had to deliver to such patients pursuant to State law or otherwise.

Comment: One commenter recommended that, if an inpatient admission occurs prior to delivery of the MOON, the MOON be annotated with date and time of the inpatient admission so the patient is aware that outpatient status has ended and inpatient status has begun.

Response: We agree with the commenter that, if an inpatient admission occurs prior to delivery of the MOON, the MOON should be annotated with date and time of the inpatient admission. Therefore, we are requiring that, in the event that a patient is subsequently admitted as a hospital inpatient directly after receiving observation services for more than 24 hours, and the inpatient admission occurs prior to delivery of the MOON, the MOON be annotated with the date and time of the inpatient admission. Additional guidance regarding elements for the free text field of the MOON will be provided in the CMS Internet Only Manual.

Comment: One commenter indicated that the MOON does not include language specific to beneficiaries aligned with certain Medicare Accountable Care Organizations (ACO), such as Pioneer and Next Generation, where certain eligibility requirements for post-hospital SNF care may have been waived. The commenter recommended that CMS clarify that, in these situations, it is not necessary to include information related to post-hospital SNF care coverage implications of outpatient status where the 3 consecutive day inpatient hospital stay requirement has been waived.

Response: We appreciate the information from the commenter. As required by the NOTICE Act, we have created a notice that includes statutorily required information and other information needed for patients to understand their status as an outpatient, the distinction between being an outpatient and an inpatient, and the implications for being an outpatient receiving observation services. In addition, the NOTICE Act requires hospital and CAH staff to provide an oral explanation of the information contained in the written notice. We expect that, as part of the oral explanation, hospital staff will be available to answer questions that patients may have to assist them in understanding these concepts and the effects on their financial responsibility. Where there are exceptions to general rules for a very limited beneficiary population, such as waivers of the 3 consecutive day inpatient hospital stay requirement for beneficiaries aligned with particular ACOs, we would expect this information to be conveyed as part of the oral explanation or included in the “Additional Information” section of the MOON if the hospital or CAH is aware of the applicable exception. Because the MOON is a standard form approved by OMB, hospitals and CAHs will not be permitted to alter the included language, only the information to be included in the free text fields. To the extent that waivers of the post-hospital SNF coverage requirements become more prevalent and apply to a broader segment of the Medicare population, we will reconsider including such information in the MOON.

Comment: Several commenters suggested that the MOON be revised to reflect a recent policy statement issued by the HHS Office of Inspector General (OIG) regarding hospitals that discount or waive amounts owed by Medicare beneficiaries for self-administered drugs dispensed in outpatient settings. Other commenters suggested language related to the outpatient setting be removed in light of the OIG policy statement. The OIG policy statement is located at: http://oig.hhs.gov/compliance/alerts/guidance-policy-10302015.pdf. The OIG policy statement assures hospitals that they will not be subject to OIG administrative sanctions if they discount or waive amounts that Medicare beneficiaries owe for self-administered drugs they receive in outpatient settings when those drugs are not covered by Part B, subject to certain specified conditions.

Response: We appreciate the commenters’ recommendation. While we disagree that the language in the MOON should be omitted based on the referenced OIG policy permitting hospitals to discount or waive amounts owed by Medicare beneficiaries for self-administered drugs dispensed in outpatient settings, we agree that revisions to the MOON instructions are needed. Hospitals have discretion to take such actions based on the OIG policy statement, and the information on self-administered drugs that we proposed to be included in the MOON will be relevant for beneficiaries receiving care in hospitals that have not elected to waive or discount such amounts. In circumstances where the hospital does waive or discount costs for self-administered drugs, the hospital can include an explanation in the free-text field of the MOON (“Additional Information”) and/or provide an oral explanation to the individual. However, this is not required by the NOTICE Act. We have added language to the MOON instructions indicating that the hospital waiving or discounting the beneficiary’s responsibility for the cost of self-administered drugs will have appropriate use of the “Additional Information” free text field of the MOON.

Comment: Several commenters requested specification on whether it was necessary for hospitals to retain a signed copy of the completed MOON in the patient’s medical record and the requirements for doing so. One commenter asked whether hospitals could document in the medical record that the MOON was provided to the patient and an oral explanation was furnished without retaining a copy of the notice. Another commenter requested that CMS clarify hospitals can obtain an electronic signature and retain the MOON only in electronic form. One commenter requested CMS to clarify if there is a mechanism for hospitals to provide, when necessary, evidence the notice was delivered to the patient.

Response: Consistent with longstanding practice in implementing beneficiary notices, we will require that hospitals and CAHs retain a signed copy of the MOON. Such a practice assures both hospitals and CAHs and surveyors that the appropriate notices have been delivered as required. However, in the past, we have permitted providers to determine the method of storage. This same flexibility will be extended to hospitals and CAHs delivering the MOON. Hospitals and CAHs may
choose to retain a signed notice as a hard copy or electronically.

After consideration of the public comments we received, we are finalizing the proposed requirements for written notice without modification.

e. Outpatient Observation Services and Beneficiary Financial Liability

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25133 through 25134), Section 20.6, Chapter 6, of the Medicare Benefit Policy Manual (Pub. 100–2) specifies that observation services furnished by hospitals and CAHs are “a well-defined set of specific, clinically appropriate services, which include ongoing short-term treatment, assessment, and reassessment before a decision can be made regarding whether patients will require further treatment as hospital inpatients or if they are able to be discharged from the hospital.” Typically, observation services are ordered for individuals who present to the emergency department (ED) and who then require a significant period of treatment and monitoring to determine whether or not their condition warrants inpatient admission or discharge. Individuals also may receive outpatient observation services in other areas of a hospital or CAH when necessary. For example, a patient who receives a drug infusion in a hospital’s outpatient infusion center and then experiences post-infusion hypertension may require observation services. In the majority of cases, the decision whether to discharge a patient from the hospital following the resolution of the reason for the observation care or to admit the patient as an inpatient can be made in less than 48 hours, and usually in less than 24 hours. In only rare and exceptional cases do reasonable and necessary outpatient observation services span more than 48 hours. All hospital observation services, regardless of duration of care, that are medically reasonable and necessary are covered by Medicare.

In some cases, Medicare beneficiaries receiving observation services while in a hospital or CAH may not be aware of their status as an inpatient or an outpatient, and thus may not be aware that there are significant differences in financial liability between inpatient status and outpatient status. CMS has published educational materials for Medicare beneficiaries to help inform them of financial and coverage liabilities associated with inpatient and outpatient services. Receiving observation services, a beneficiary may incur financial liability for Medicare Part B copayments, the cost of self-administered drugs that are not covered under Part B, and the cost of post-hospital SNF care because section 1861(i) of the Act requires a prior 3-day hospital inpatient consecutive stay to be eligible for coverage of post-hospital SNF care under Medicare Part A. In contrast, as a hospital inpatient under Medicare Part A, a beneficiary pays an annual deductible ($1,288 in CY 2016) for all inpatient services provided during the first 60 days in the hospital of each benefit period for the year. Cost-sharing requirements for individuals enrolled in Medicare Part C, known as MA health plans, are dependent on the particular plan’s policies. In addition, Medicare beneficiaries qualified through their State Medicaid program (QMBs) have different cost-sharing rules. For example, QMBs cannot be billed for Medicare Part A or Part B deductibles, coinsurance, or copayments and may have different rules regarding qualifying for SNF services. CMS has published informational publications for beneficiaries that advise Medicare Advantage enrollees to check with their plans for information on coverage of observation services furnished to an outpatient.

As mentioned earlier, a beneficiary’s liability for medication costs also is likely affected by whether the individual is hospitalized as an inpatient or receiving care as an outpatient. When an individual is hospitalized under a covered Medicare Part A inpatient stay, payment for medically reasonable and necessary medications that are provided by the hospital are covered under Medicare Part A. Generally, Medicare Part B covers drugs that are usually not self-administered. Based on the statutory prohibition at section 1861(s)(2) of the Act and its implementing regulation at §410.29(a), Medicare Part B generally does not cover or pay for any drug or biological that can be self-administered. “Self-administered drugs” are considered prescription and over-the-counter medications that beneficiaries routinely take on their own. For safety reasons, many hospitals do not allow patients to take medications brought from home. Medicare prescription drug plans (Part D) may help pay for drugs provided by the hospital. Individuals with Medicare Part D will likely need to pay out-of-pocket costs to the hospital for these drugs and request reimbursement from their Part D plan.

In addition, whether an individual is receiving treatment or care as an inpatient admitted to the hospital or is receiving observation services as an outpatient pursuant to a doctor’s orders may impact Medicare coverage for post-hospital SNF services. Section 1861(i) of the Act requires a beneficiary to be an inpatient of a hospital for not less than 3 consecutive days before discharge from the hospital in order to be eligible for coverage of post-hospital extended care services in a SNF under Medicare. For purposes of Medicare SNF coverage, the time spent receiving observation services as an outpatient does not count towards the requirement of a 3-day hospital inpatient stay because these services are outpatient.

Comment: Several commenters suggested that CMS revise language on the MOON regarding cost-sharing to reflect the fact that claims for most patients who receive observation services as an outpatient for 24 hours will be paid under a comprehensive APC (C–APC) under the OPPS that imposes a single copayment rather than a copayment for every service received. Other commenters also recommended that CMS remove or simplify the language included in the MOON regarding Part B cost-sharing for doctor services as the copayment requirement for doctor services are not affected by the decision to admit the patient as an inpatient or order observation services as an outpatient.

Response: The comments are correct that, effective January 1, 2016, CMS established a C–APC for comprehensive observation services (C–APC 8011). To qualify for the C–APC payment, beneficiaries must have received 8 or more hours of hospital observation services in conjunction with a qualifying hospital visit, during a nonsurgical encounter. Under the C–APC payment policy, we note that, instead of paying copayments for a number of separate services that are generally individually subject to the copayment liability cap at section 1833(t)(6)(C)(i) of the Act, beneficiaries can expect to pay a single copayment for their comprehensive observation care that would be subject to the copayment liability cap. As a result, we expect that this

90 “Are You a Hospital Inpatient or Outpatient? If You Have Medicare—Ask!” CMS Product No. 11435. May 2014.
91 A beneficiary who receives hospital outpatient services typically pays 20 percent of the Medicare payment amount for outpatient items and services after paying the annual Part B deductible ($166 in CY 2016). The coinsurance amount for an outpatient CAH service is based on 20 percent of charges. In most cases, the cost-sharing for each individual outpatient service should not be more than the inpatient deductible. However, Medicare beneficiaries who receive several separately payable outpatient services, or are treated for extended periods of time as hospital outpatients, may have greater cost-sharing liabilities as an outpatient under observation than they may have if they were admitted as an inpatient to the hospital.
policy likely reduces the possibility that the overall beneficiary liability exceeds the copayment liability cap for most of these outpatient encounters involving observation services. Observation services that do not meet the criteria for payment under C–APC 8011 will not be paid under the C–APC and cost-sharing requirements for each individual separately payable service (up to the copayment liability cap at section 1833(t)(8)(C)(i) of the Act) will apply. While Part B cost-sharing amounts for physician services do not differ based on the inpatient or outpatient status of the beneficiary, we still believe it is required to include information about the Part B cost-sharing for physician services as it is part of the total cost-sharing for which the beneficiary is responsible.

Comment: One commenter referenced the statement in the preamble of the proposed rule that CMS has produced informational publications for beneficiaries that advise MA enrollees to contact their plan for information on coverage of outpatient observation services. The commenter recommended that hospitals and CAHs be required to distribute copies of this publication to beneficiaries as part of the standard notice procedures.

Response: The MOON contains language advising MA enrollees to contact their plan for specific information on coverage for outpatient observation services. The language in the MOON was based on the language used in the referenced CMS publication on observation services (“Are You a Hospital Inpatient or Outpatient?”). As such, we do not believe there is value in requiring hospitals and CAHs to assume the burden of distributing a CMS publication that is readily available to Medicare beneficiaries and which includes the same instruction as the MOON regarding the importance of contacting the individual’s plan for specific coverage information. Therefore, we are not accepting the commenter’s suggestion.

f. Delivering the Medicare Outpatient Observation Notice

As discussed in the proposed rule (81 FR 25134), an English language version of the proposed MOON was submitted to OMB for approval. We stated in the proposed rule that once we receive OMB approval, a Spanish language version of the MOON will be made available. If the individual receiving the notice is unable to read its written contents and/or comprehend the information, we expect hospitals and CAHs to employ their usual procedures to ensure notice comprehension. (We refer readers, for example, to the Medicare Claims Processing Manual (Pub. 100–4), Chapter 30, Section 40.3.4.3., for similar existing procedures related to notice comprehension for the Advance Beneficiary Notice of Noncoverage (ABN).) Usual procedures may include, but are not limited to, the use of translators, interpreters, and assistive technologies. Hospitals and CAHs are reminded that recipients of Federal financial assistance have an independent obligation to provide language assistance services to individuals with limited English proficiency (LEP) consistent with section 1557 of the Affordable Care Act and Title VI of the Civil Rights Act of 1964. In addition, recipients of Federal financial assistance have an independent obligation to provide auxiliary aids and services to individuals with disabilities free of charge, consistent with section 1557 of the Affordable Care Act and section 504 of the Rehabilitation Act of 1973.

Comment: A number of commenters recommended that CMS provide the MOON in additional languages other than English and Spanish. Some commenters specifically requested that the MOON be provided in languages spoken by the lower of 5 percent or 1,000 Medicare beneficiaries. Other commenters recommended that CMS provide translation of the document into at least the top 15 languages nationally. Some commenters more generally requested that CMS make the notice available in additional languages over time.

Response: We appreciate commenters’ concerns that beneficiaries have access to the MOON in a language they understand. As stated above and in the proposed rule, we will provide the MOON in both English and Spanish. We believe hospitals and CAHs already have in place various procedures to ensure that beneficiaries are able to understand notices and information delivered to them, and we expect they can further utilize those procedures to deliver the MOON. In addition, we believe that the requirements under section 1557 of the Affordable Care Act and Title VI of the Civil Rights Act of 1964, as listed above, mandate that hospitals and CAHs have the responsibility to provide language assistance to LEP individuals, and that these requirements apply to delivery of the MOON. Therefore, we are not accepting the commenters’ recommendations.

Comment: Some commenters recommended that CMS allow hospitals and CAHs to provide solely oral interpretation of the English-based version of the MOON for at least 6 months after the MOON is finalized for more common languages (except Spanish once the Spanish-based version is finalized) and permanently for less common languages.

Response: As noted above and in the proposed rule, we expect hospitals and CAHs to employ their usual procedures to ensure beneficiaries are able to comprehend language included in the MOON. We understand that these procedures may include use of oral interpretation using translators. We believe it is the responsibility of hospitals and CAHs to ensure they are fulfilling statutory requirements regarding the provision of the notice.

Comment: Numerous commenters expressed concern that hospitals and CAHs will not have sufficient time to prepare for MOON implementation. The commenters recommended that CMS provide transition time for hospitals to implement the provisions of this final rule; recommended implementation periods ranged from at least 3 to more than 6 months. Several commenters requested that CMS delay monitoring and enforcement until the MOON is translated into the requisite number of foreign languages to meet anti-discrimination requirements for individuals with limited English proficiency. One commenter requested that CMS specify the date when MOON delivery must begin. In addition, the commenter requested clarification of whether a hospital would be required to deliver the notice only to outpatients whose observation services begin on or after the implementation date, or if hospitals must also include patients already receiving outpatient services as of the implementation date.

Response: We are clarifying that the MOON is on a separate approval track from this implementing regulation, as discussed above. The MOON is following the established OMB notice approval process under the PRA and is being published for the 30-day comment period along with this final rule as part of the PRA process.

We expect final PRA approval of the MOON around the time the implementing regulations are effective. Therefore, the implementation period for hospitals and CAHs will begin sometime after the effective date of this final rule and will be announced on the CMS Beneficiary Notices Initiative Web site at: https://www.cms.gov/Medicare/Medicare-General-Information/BNI/index.html and in an HPMS memorandum. During this implementation period, hospitals and CAHs will have time to prepare for
implementation, consistent with past implementation practices for beneficiary notices. Hospitals and CAHs will be required to deliver the MOON to applicable patients who begin receiving observation services as outpatients on or after the notice implementation date. As we stated in the proposed rule, we have been working toward implementation since the NOTICE Act was passed. We recognize that the effective date of this final rule will be at some date after the statutory implementation date of August 6, 2016, has passed. We are striving to balance the statutory requirements to provide notice to the specified population with the desire to provide the affected industry sufficient time to put systems and business processes in place to implement the NOTICE Act requirements. Under the PRA approval process, the public will have 30 days to comment on the revised MOON following publication of this final rule and, OMB will review the MOON after the comment period. Once the MOON has been approved, hospitals and CAHs must fully implement use of the MOON and comply with all of the NOTICE Act requirements no later than 90 calendar days from the date of PRA approval of the MOON. This implementation schedule takes into consideration the statutory requirements of the NOTICE Act, as well as our longstanding experience in developing implementation schedules for new beneficiary notices.

Comment: Many commenters requested a delay in monitoring and enforcement of MOON delivery. Several commenters recommended graduated enforcement. One commenter requested that CMS explain the repercussions for a hospital failing to provide proper notice to Medicare beneficiaries, and whether failure to provide this notification would result in termination of the hospital from participation in the Medicare program. The commenter recommended that CMS only sanction hospitals for a pattern of notice delivery failure, and follow the same process currently in place for conditions of participation enforcement regarding substantial condition level violations. One commenter requested clarification of the consequences for failure to obtain or retain a signed notification prior to the patient being discharged. Several commenters suggested that CMS impose a graduated enforcement scheme beginning with notice and education of regulatory requirements and potential noncompliance so the hospital or CAH may develop and carry out a corrective action plan. Another commenter recommended that CMS establish a clear standard—developing consistent implementation across State lines and providing necessary audit protocols to surveyors. One commenter recommended that in cases where the MOON was not delivered to an individual as required, the beneficiary receive covered inpatient care paid under Medicare Part A. Finally, one commenter requested auditing guidelines published before the end of a "grace period" prior to the implementation date.

Response: We appreciate the commenters’ interest in the oversight of MOON delivery. All monitoring and enforcement of the MOON will be consistent with our oversight procedures for other hospital delivered notices. We are reviewing our surveying protocols to identify changes that may be needed to facilitate effective monitoring and enforcement of these requirements. These revised procedures will be developed and implemented in the normal course of business. Comment: One commenter noted that CMS did not provide guidance in the proposed rule specifying the hospital or CAH staff responsible for MOON delivery. The commenter believed that hospitals and CAHs should be responsible for this determination. Another commenter requested that CMS clarify what staff would be appropriate for delivering the MOON. One commenter believed that any trained member of the hospital staff should be permitted to deliver the MOON, but stated that the CMS burden estimate in the proposed rule appears to anticipate that it will be a nurse. The commenter explained that, in its experience, hospitals are more likely to use social workers, discharge planners, or administrative staff.

Response: We generally do not prescribe what staff must deliver a notice to a beneficiary. We agree with the commenter that the hospital or CAH is in the best position to determine the appropriate staff member to deliver the MOON. We clarify that inclusion of a particular occupation in a burden estimate reflects our attempts to best approximate, while not underestimating, the anticipated costs of notice delivery. This occupation choice does not serve as a notice delivery staff requirement.

After consideration of the public comments we received, we are finalizing the proposed provisions for delivering the MOON without modification.

g. Oral Notice

In the proposed rule (81 FR 25134), pursuant to the statutory requirement at section 1866(a)(1)(Y)(i) of the Act, we proposed under proposed new regulation at § 489.20(y)(2) that hospitals and CAHs provide an oral explanation of the written notice furnished to individuals who receive observation services as outpatients. We stated in the proposed rule that we will provide guidance for oral notification in our forthcoming Medicare manual provisions. Hospitals and CAHs are familiar with providing oral explanations of written notices (for example, surgical and procedural consent notices and the Important Message from Medicare), and we expect that oral notification will occur in conjunction with delivery of the MOON. Again, hospitals and CAHs are reminded that recipients of Federal financial assistance have an independent obligation to provide language assistance services to individuals with LEP consistent with section 1557 of the Affordable Care Act and Title VI of the Civil Rights Act of 1964. In addition, recipients of Federal financial assistance have an independent obligation to provide auxiliary aids and services to individuals with disabilities free of charge, subject to section 1557 of the Affordable Care Act and section 504 of the Rehabilitation Act of 1973.

Comment: Some commenters questioned how hospitals should handle and document the oral explanation required by the NOTICE Act. One commenter requested that CMS allow public comment on any guidance issued on the oral explanation in CMS operating manuals. This commenter questioned if the oral component is required, and whether the patient’s signature on the MOON would be considered sufficient documentation that the oral notice was given and understood by the patient or the patient’s representative. Another commenter stated that delivery of the MOON is unnecessary and suggested that the intent of the notice requirement should be satisfied by the oral explanation by the hospital staff followed by documentation and confirmation of the explanation in the patient’s electronic medical record. One commenter recommended that CMS allow hospitals to deliver the oral explanation with a video presentation. The commenter indicated that staff would be present to answer questions and provide additional explanation where necessary, in addition to the video explanation.

Response: The statute requires that there be an oral explanation of the written notification, or MOON. We believe it is essential that hospital staff...
are available to provide a verbal explanation and answer questions in the interest of beneficiaries fully understanding the MOON. A video presentation of the MOON is acceptable if an individual is available to answer questions. Finally, the NOTICE Act requires hospitals and CAHs to deliver both a written notice and an oral explanation of the notice when notice delivery is required. Therefore, we do not believe providing only an oral notice is permissible under the statute.

Comment: One commenter expressed concern that hospitals [and CAHs] would be required to maintain around the clock staff who are trained to deliver the MOON. The commenter stated that it would place an enormous burden on hospitals [and CAHs] and would be costly to implement.

Response: We believe that hospitals and CAHs furnishing observation services are sufficiently staffed to furnish such observation services and that hospitals and CAHs would appropriately train the staff that furnishes observation services to deliver the MOON, as required, in the applicable cases.

After consideration of the public comments we received, we are finalizing the proposed provisions for oral notice without modification.

h. Signature Requirements

As specified in the proposed rule (81 FR 25134), as set forth at section 1866(a)(1)(Y)(ii)(IV) of the Act, the written notification must be either signed by the individual receiving observation services as an outpatient or a person acting on such individual’s behalf to acknowledge receipt of notification. Moreover, the statute provides that if such individual or person refuses to provide a signature, the written notification is to be signed by the staff member of the hospital or CAH who presented the written notification and certain information needs to be included with such signature. Accordingly, we proposed under proposed new § 489.20(y)(3), that the written notice be signed, as described above, in order to acknowledge receipt and understanding of the notice. The MOON would include a dedicated signature area for this purpose. In cases where the individual receiving the MOON refuses to sign the notice, we proposed that the MOON must be signed by the staff member who presents the notice to the individual. The staff signature would include the staff member’s name and title, a certification statement that the notice was presented, and the date and time that the notice was presented.

Comment: Several commenters requested that CMS clarify procedures for obtaining a signature when a patient is unable to sign the MOON due to a medical or mental condition or when someone is under duress and no representative is available. One commenter found the MOON to be unclear with respect to how providers can determine when it is appropriate to seek alternative signatures and who (patient family member or other caregiver) should be engaged to sign the MOON. Some commenters recommended that CMS allow a hospital representative to annotate the notice to indicate the patient was unable to sign and that no patient representative was available, in the same manner CMS proposed to permit staff to sign and date the MOON when a beneficiary refuses to sign. Other commenters believed that a notice that is not understandable is defective. Several commenters recommended that CMS require that a hospital or CAH deliver the MOON only to a patient able to comprehend it, and, if not, provide the notice to a representative able to do so. The commenters suggested that failure to do so will result in a defective notice. Another commenter recommended that hospitals be required to provide written and oral notification to the patient’s family member, caregiver, or power of attorney, similar to existing procedures related to notice delivery and comprehension for the ABN. One commenter expressed concern that the proposed rule did not set standards for assuring competency of the patient who is given the notice and “acknowledges receipt.” The commenter explained that patients who have diminished capacity due to pain or medication or other conditions may not understand either the notice or its implications, and recommended that CMS address competency and assuring that the patient understands the notice in the final rule.

Response: The NOTICE Act requires hospitals and CAHs to deliver written notice to an individual who has received more than 24 hours of observation services as an outpatient, and requires hospitals and CAHs to document acknowledgment of receipt of the notice by obtaining a signature of the individual or the person acting on the individual’s behalf. The NOTICE Act also provides a mechanism for hospitals and CAHs to comply with the acknowledgment requirement if the individual or person acting on behalf of the individual refuses to sign the written notice. To the extent that additional guidance related to delivery of notice is necessary, we will issue instructions in the CMS Internet Only Manual.

Comment: One commenter stated that requiring a signature of the hospital staff when a patient refuses to sign the MOON raises ethical concerns for physicians and other hospital providers who may believe they do not have the right to sign a document when they are not financially responsible for, or legally acting on the patient’s behalf. The commenter recommended that CMS instead include a check or initial box to indicate that a patient or caregiver refused to sign.

Response: We appreciate the concerns raised by the commenter. However, the NOTICE Act expressly requires that if such individual entitled to notice or person acting on such individual’s behalf refuses to provide signature, the MOON be signed by the staff member of the hospital or CAH who presented the written notification and includes the name and title of such staff member, a certification that the notification was presented, and the date and time the notification was presented (in accordance with section 1866(a)(1)(Y)(ii)(IV)(bb) of the Act). We believe accepting something in lieu of signature of the individual, person acting on individual’s behalf, or relevant staff member would not be appropriate. Therefore, we are maintaining this proposed signature requirement in this final rule.

Comment: Several commenters suggested that the signature of a beneficiary reflect notice comprehension as well as receipt of the notice.

Response: We clarify that a notice signature will reflect notice receipt as well as comprehension, consistent with statutory requirements that the notice be written and formatted using plain language, be made available in appropriate languages, and be accompanied by an oral explanation. The MOON makes clear that the signature attests to both receipt and understanding of the notice. We will be publishing guidance, pursuant to our usual approval process, to further guide hospitals and CAHs in delivery of the MOON. We plan for this guidance to be available to hospitals and CAHs before notice delivery is required, which will be at the end of the implementation period after the MOON receives final approval.

After consideration of the public comments we received, we are finalizing the proposed signature requirements without modification.
i. No Appeal Rights Under the NOTICE Act

As indicated in the proposed rule (81 FR 25134), section 1866(a)(1)(Y) of the Act, as added by the NOTICE Act, does not afford appeal rights to beneficiaries regarding the notice provided pursuant to that statutory provision. To provide clarity to this point, we proposed to amend the regulations at § 405.926 relating to actions that are not initial determinations, by adding new paragraph (u) to explain that issuance of the MOON by a hospital or CAH does not constitute an initial determination and therefore does not trigger appeal rights under 42 CFR part 405, subpart I.

Comment: Several commenters submitted comments regarding appeal rights and the MOON. One commenter expressed concern that the proposed rule explicitly prevents Medicare beneficiaries from appealing their "observation status determination." The commenter stated that the proposed MOON is the only instance in which Medicare beneficiaries receiving a notice of denial of coverage are not given a process to appeal the determination, and further stated that delivery of the MOON corresponds with noncoverage of post-hospital SNF care upon hospital discharge and impacts coverage of care while in the hospital. The commenter recommended CMS remove proposed regulatory language in § 405.926(u) that states Medicare beneficiaries receiving the MOON do not have appeal rights. Another commenter believed that the MOON should inform beneficiaries of their right to appeal observation services received as an outpatient. Another commenter believed that the MOON should explain that a patient does not have an immediate right to appeal their status as an outpatient receiving observation services as well as the fact that their physician does not have the authority to change their status. One commenter recommended that CMS clarify why beneficiaries may not challenge their status as an outpatient and the provision of observation services.

Response: We thank the commenters for the recommendations. However, we believe that the comments reflect concerns outside the scope of the NOTICE Act or a misunderstanding of the nature of the notice required under the legislation. We disagree with the commenter's assertion that delivery of the MOON constitutes a determination of noncoverage of post-hospital SNF care. We agree with the commenter's characterization of the proposed MOON constituting a notice of denial of coverage in general. Finally, we do not believe the MOON is the appropriate document to communicate appeal rights: the Medicare Summary Notice (MSN) fulfills that purpose. Therefore, we are not accepting the commenters' recommendations.

The MOON is a required informational/educational notice regarding patient status provided by a hospital or CAH when the beneficiary is still in the hospital or CAH and receives observation services as an outpatient for more than 24 hours. The MOON explains the current status of the patient as an outpatient and not an inpatient, in addition to the implications of being an outpatient receiving observation services. As we explained in the proposed rule, delivery of the MOON does not constitute an initial determination issued in response to a claim for benefits, and the MOON itself is not a notice of an initial determination (81 FR 25134).

Furthermore, delivery of the MOON by a hospital or CAH does not constitute a denial of coverage of any services, and does not constitute a noncoverage decision with respect to post-hospital SNF care as asserted by the commenter. In fact, generally beneficiaries will still be receiving care when the MOON is delivered and will sometimes be formally admitted as inpatients after delivery of the MOON.

The NOTICE Act does not provide for appeal rights regarding the notice itself, which makes sense given the nature of the document, as explained above. The NOTICE Act also does not afford any new appeal rights beyond those already available (under section 1869 of the Social Security Act), nor does the NOTICE Act limit or restrict currently available appeal rights. Consistent with the legislation, the proposed rule did not propose to expand or limit appeal rights. For the reasons discussed above, we are not adopting the various recommendations with respect to amending the MOON to include appeal rights or an explanation of the lack of appeal rights.

As we have stated repeatedly, the decision to admit a beneficiary as an inpatient is a complex medical decision made by the physician in consideration of various factors, including the beneficiary's age, disease processes, comorbidities, and the potential impact of sending the beneficiary home. It is the responsibility of the physician to make the complex medical determination of whether the beneficiary's risk of morbidity or mortality need to remain at the hospital because the risk of an adverse event would otherwise be unacceptable under reasonable standards of care, or whether the beneficiary may be discharged. We expect that the NOTICE Act and implementing policies will result in beneficiaries having a better understanding of the care they are receiving.

After consideration of the public comments we received, we are finalizing the proposed revision to § 405.926(u) without modification.

j. Out of Scope Public Comments

We received several comments that were outside the scope of the provisions of the proposed rule, and we are not responding to them in this final rule. These comments were related to (1) defining inpatient care; (2) alternate notification for transition to inpatient status; (3) increased protection for inappropriate placement; (4) beneficiary education and outreach; (5) standardized language for hospitals to use when a beneficiary does not meet inpatient criteria after internal utilization review; (6) requirement for hospital pharmacies to work with MA and Part D plans on an in-network basis; (7) waiver of therapy cap; (8) waiver of functional limitation reporting; and (9) physician education and outreach in regards to handling beneficiary concerns and complaints.

k. Provisions of the Final Regulations

After consideration of the public comments we received, we are finalizing the addition of paragraph (u) to § 405.926 as proposed. The proposed addition of paragraph (y) to § 489.20 is being revised to clarify that hospitals and CAHs may deliver the MOON before an individual has received more than 24 hours of observation services as an outpatient.

M. Technical Changes and Correction of Typographical Errors in Certain Regulations Under 42 CFR Part 413 Relating to Costs to Related Organizations and Medicare Cost Reports

1. General Background

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25134 through 25135), as part of our ongoing review of the Medicare regulations, we have identified a number of technical changes or corrections of typographical errors in 42 CFR part 413 relating to costs to related organizations and Medicare cost reports that need to be made. Below we are summarizing these proposed changes or corrections, with our corresponding final policy decisions.
2. Technical Change to Regulations at 42 CFR 413.17(d)(1) on Cost to Related Organizations

Prior to the enactment of section 911(b) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. 108–173), a provider had the right to nominate a fiscal intermediary (currently known as a Medicare Administrative Contractor (MAC) and referred to in this section as a “contractor”) of its choice. Public Law 108–173 repealed the nomination provisions formerly found in section 1816 of the Act and added section 1874A (Contracts with Medicare Administrative Contractors). Currently, a provider will be assigned to the contractor that covers the geographic locale where the provider is located, as specified in the regulations at 42 CFR 421.404(b). Because a provider is no longer permitted to select a contractor of its choice, and a contractor is now assigned to a provider, the parenthetical language of the regulation at 42 CFR 413.17(d)(1) referring to a provider’s nomination of a contractor is obsolete. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25134), we proposed to revise §413.17(d)(1) to remove the parenthetical reference to a provider’s nomination of a contractor.

We did not receive any public comments regarding this proposal. Therefore, we are finalizing our proposal to correct the entity title of a “Federally qualified health center” in §413.24(f)(4)(i). We are also finalizing our proposal to add “histocompatibility laboratories” to the list of providers required to submit cost reports in a standardized electronic format


In §413.24(f)(4)(ii), we incorrectly refer to a “Federally qualified health clinic.” The correct entity title under section 1861(aa) of the Act is “Federally qualified health center.” In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25135), we proposed to correct this error.

In addition, §413.200(c)(1)(i) requires a histocompatibility laboratory to file a Medicare cost report in accordance with the regulations at §413.24(f). For cost reporting periods ending on or after March 31, 2005, organ procurement organizations (OPOs) and histocompatibility laboratories are required to submit Medicare cost reports in a standardized electronic format, but histocompatibility laboratories were inadvertently omitted from the list of providers in the regulations at §413.24(f). As evidenced by the reference in the August 22, 2003 Federal Register document (68 FR 50729) to the Office of Management and Budget (OMB) approval number 0938–0102 of the Paperwork Reduction Act request for the cost reporting form entitled “Organ Procurement Agency/Laboratory Statement of Reimbursable Costs,” histocompatibility laboratories were intended to be included in the regulation text. Both OPOs and histocompatibility laboratories have used that Medicare cost report form to report their statements of reimbursable costs since its approval by OMB for use for cost reporting periods ending on or after March 31, 2005. To correct this omission, we proposed a technical change to §413.24(f)(4)(ii) to add “histocompatibility laboratories” to the list of providers required to submit cost reports in a standardized electronic format.

We did not receive any public comments regarding these proposals. Therefore, we are finalizing our proposal to make a technical correction in §413.24(f)(4)(ii) to the effective date for the submission of Medicare cost reports in a standardized electronic format for SNFs and HHAs from cost reporting periods ending on or after December 31, 1996 to cost reporting periods ending on or after February 1, 1997, to accurately reflect the regulation text finalized in the January 2, 1997 final rule published in the Federal Register at 62 FR 26 through 31. We also are finalizing our proposal to revise §413.24(f)(4)(ii) by adding histocompatibility laboratories to the list of providers required to file electronic cost reports for the same reasons provided in section IV.M.3. of the preamble of this final rule. In addition, we are correcting a typographical error to §413.24(f)(4)(ii) by removing the duplicate word “contractor” from the second sentence of this paragraph.


In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25135), we proposed to revise §413.24(f)(4)(iv) to make a technical correction to the effective date for SNFs and HHAs to submit hard copies of a settlement summary, a statement of certain worksheet totals found within the electronic file, and a certifying statement signed by its administrator or chief financial officer, from cost reporting periods ending on or after December 31, 1996, to cost reporting periods ending on or after February 1, 1997, to accurately reflect the regulation text finalized in the January 2, 1997 final rule (62 FR 26 through 31).

We proposed to revise §413.24(f)(4)(iv) by adding histocompatibility laboratories to the list of providers required to file electronic cost reports for the same reasons provided in section IV.M.3. of the preamble of the proposed rule (81 FR 25135). In addition, we proposed to add histocompatibility laboratories to the list of providers required to submit hard copies of a settlement summary, a statement of certain worksheet totals found within the electronic file, and a certifying statement signed by its administrator or chief financial officer, for cost reporting periods ending on or after March 31, 2005, for the same reasons.

We also proposed to correct a typographical error that occurred in the Medicare cost report certification statement set forth in §413.24(f)(4)(iv)
by adding the word “and” between the words “Sheet” and “Statement” to denote the two separate financial documents required to be submitted with the cost report; that is, the Balance Sheet and the Statement of Revenue and Expenses. The cost report certification statement historically correctly denoted the two separate and distinct financial forms, the Balance Sheet and the Statement of Revenue and Expenses. The cost report certification statement was later incorporated into § 413.24(f)(4)(iv) in a final rule with comment period (59 FR 26964 through 26965) issued in response to public comments received following the Uniform Electronic Cost Reporting System for Hospitals proposed rule (56 FR 41110). A typographical error excluding the word “and” occurred during the incorporation of the certification statement into the regulations text at § 413.24(f)(4)(iv).

We did not receive any public comments regarding these proposals. Therefore, we are finalizing our proposals without modification to revise § 413.24(f)(4)(iv) to make a technical correction to the effective date for SNFs and HHAs to submit hard copies of a settlement summary, a statement of certain worksheet totals found within the electronic file, and a certifying statement signed by its administrator or chief financial officer, from cost reporting periods ending on or after December 31, 1996 to cost reporting periods ending on or after February 1, 1997, to accurately reflect the regulation text finalized in the January 2, 1997 final rule (62 FR 26 through 31). We also are finalizing our proposal to revise § 413.24(f)(4)(iv) by adding histocompatibility laboratories to the list of providers required to file electronic cost reports for the same reasons provided in section IV.M.3. of the preamble of this final rule. In addition, we are finalizing our proposal to add histocompatibility laboratories to the list of providers required to submit hard copies of a settlement summary, a statement of certain worksheet totals found within the electronic file, and a certifying statement signed by its administrator or chief financial officer, for cost reporting periods ending on or after March 31, 2005, for the same reasons.

Furthermore, we are finalizing our proposal to correct a typographical error that occurred in the Medicare cost report certification statement set forth in the regulations text at § 413.24(f)(4)(iv) by inserting the word “and” between the words “Sheet” and “Statement” to denote the two separate financial documents required to be submitted with the cost report; that is, the Balance Sheet and the Statement of Revenue and Expenses.

6. Technical Correction to 42 CFR 413.200(c)(1)(i) Relating to Medicare Cost Report Due Dates for Organ Procurement Organizations and Histocompatibility Laboratories

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25135), we proposed to make a technical correction to the reference in § 413.200(c)(1)(i) to the due date for the Medicare cost report for organ procurement organizations (OPOs) and histocompatibility laboratories from “three months” to “5 months” after the end of the fiscal year. Section 413.200(c)(1)(i) requires independent OPOs and histocompatibility laboratories to file a cost report in accordance with § 413.24(f). In the 1995 final rule (60 FR 33137), we revised § 413.24(f) to extend the Medicare cost report due date for all providers required to file a cost report from 3 months to 5 months after the end of a provider’s fiscal year end, but inadvertently neglected to make a conforming change to § 413.200(c)(1)(i), which we proposed to correct in the proposed rule.

We did not receive any public comments regarding these proposals. Therefore, we are finalizing our proposal to make a technical correction to the reference in § 413.200(c)(1)(i) to the due date for the Medicare cost report for organ procurement organizations (OPOs) and histocompatibility laboratories from “three months” to “5 months” after the end of the fiscal year.

N. Finalization of Interim Final Rule With Comment Period Implementing Legislative Extensions Relating to the Payment Adjustments for Low-Volume Hospitals and the Medicare-Dependent, Small Rural Hospital (MDH) Program

In the interim final rule with comment period (IFC) that appeared in the Federal Register on August 17, 2015 (80 FR 49594 through 49597), we addressed the legislative extension of the MDH program as well as certain provisions relating to payment to low-volume hospitals under the IPPS made by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Public Law 114–10. (For the remainder of this section, we will refer to this IFC as the “August 2015 IFC.”) Section 204 of the MACRA extended the temporary changes to the hospital qualifying criteria and payment adjustment under the IPPS, originally provided for by the Affordable Care Act, for discharges occurring on or after April 1, 2015 through FY 2017 (September 30, 2017). Section 205 of the MACRA extended the MDH program for hospital discharges occurring on or after April 1, 2015 through FY 2017 (September 30, 2017).

In this final rule, we discuss the provisions of the August 2015 IFC, acknowledge the public comments received (which we determined were all outside the scope of the provisions of the IFC), and state the final policy (which we are not modifying from the IFC).

1. Payment Adjustment for Low-Volume Hospitals (§ 412.101)

a. Background

Section 1886(d)(12) of the Act provides for an additional payment to each qualifying low-volume hospital that is paid under IPPS beginning in FY 2005, and the low-volume hospital payment policy is set forth in the regulations at 42 CFR 412.101. Sections 3125 and 10314 of the Affordable Care Act provided for a temporary change in the low-volume hospital payment policy for FYs 2011 and 2012. Specifically, the provisions of the Affordable Care Act amended the qualifying criteria for low-volume hospitals to specify, for FYs 2011 and 2012, that a hospital qualifies as a low-volume hospital if it is more than 15 road miles from another subsection (d) hospital and has less than 1,600 discharges of individuals entitled to, or enrolled for, benefits under Medicare Part A during the fiscal year. In addition, the statute as amended by the Affordable Care Act, provides that the low-volume hospital payment adjustment (that is, the percentage increase) is to be determined using a continuous linear sliding scale ranging from 25 percent for low-volume hospitals with 200 or fewer discharges of individuals entitled to, or enrolled for, benefits under Medicare Part A in the fiscal year to 0 percent for low-volume hospitals with greater than 1,600 discharges of such individuals in the fiscal year. We revised the regulations governing the low-volume hospital policy at § 412.101 to reflect the changes to the qualifying criteria and the payment adjustment for low-volume hospitals according to the provisions of the Affordable Care Act in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50238 through 50275 and 50414).

The temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided for by the Affordable Care Act have been extended by subsequent legislation as
follows: Through FY 2013 by the American Taxpayer Relief Act of 2012 (ATRA), Public Law 112–240; through March 31, 2014, by the Pathway for SGR Reform Act of 2013, Public Law 113–167; through March 31, 2015, by the Protecting Access to Medicare Act of 2014 (PAMA), Public Law 113–93; and most recently through FY 2017 by section 204 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), Public Law 114–10. The extension provided by section 204 of the MACRA is discussed in greater detail in section IV.L.2.b. of the preamble of the August 2015 IFC and this final rule. For additional details on the implementation of the previous extensions, through March 31, 2015, of the temporary changes to the low-volume hospital qualifying criteria and payment adjustment originally provided for by the Affordable Care Act, we refer readers to the following Federal Register documents: The FY 2013 IPPS notice (78 FR 14689 through 14691); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50611 through 50612); the FY 2014 IPPS interim final rule with comment period (79 FR 15022 through 15025); the FY 2014 IPPS notice (79 FR 34444 through 34446); and the FY 2015 IPPS/LTCH PPS final rule (79 FR 49998 through 50001).

b. Implementation of Provisions of the MACRA for FY 2015

Section 204 of the MACRA provided for an extension of the temporary changes to the low-volume hospital qualifying criteria and payment adjustment for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017). As discussed in the August 2015 IFC (80 FR 49594), we addressed the extension of the temporary changes to the low-volume hospital payment policy for the last half of FY 2015, that is, for discharges occurring on or after April 1, 2015, through September 30, 2015, in issues that occurred in Change Request 9197, Transmittals 3263 and 3281. Generally, hospitals that were receiving the low-volume hospital payment adjustment for FY 2015 as of March 31, 2015 continued to receive the adjustment for the second half of FY 2015, as long as the hospital continued to meet the applicable qualifying low-volume hospital criteria.

In the instructions issued in Change Request 9197, for discharges occurring on or after April 1, 2015, through September 30, 2015, consistent with the existing criteria at § 412.101(b)(2)(ii), we stated that the same discharge data used for the low-volume adjustment for discharges occurring during the first half of FY 2015 will continue to be used for discharges occurring during the last half of FY 2015, as these data were the most recent available data at the time of the development of the FY 2015 payment rates. Specifically, for FY 2015 discharges occurring on or after April 1, 2015, through September 30, 2015, the low-volume hospital qualifying criteria and payment adjustment (percentage increase) is determined using FY 2013 Medicare discharge data from the March 2014 update of the MedPAR files. These discharge data can be found in Table 14 of the Addendum to the FY 2015 IPPS/LTCH PPS final rule, which is available via the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page-Items/FY2015-Final-Rule-Tables.html. We note that, consistent with past practice, Table 14 is a list of IPPS hospitals with fewer than 1,600 Medicare discharges and is not a listing of the hospitals that qualify for the low-volume adjustment for FY 2015; it does not reflect whether or not the hospital meets the mileage criterion (that is, the hospital must also be located more than 15 road miles from any other IPPS hospital). In order to receive the applicable low-volume hospital payment adjustment (percentage increase) for FY 2015 discharges, a hospital must meet both the discharge and mileage criteria. We discussed the conforming changes to the regulations at § 412.101 consistent with the temporary changes in the low-volume hospital definition and payment adjustment provided by section 204 of the MACRA in section IV.L.2.c. of the preamble of the August 2015 IFC.

c. Low-Volume Hospital Definition and Payment Adjustment for FY 2016

As discussed in the August 2015 IFC (80 FR 49595) and above, under section 1886(d)(12) of the Act, as amended by section 204 of the MACRA, the temporary changes in the low-volume hospital payment policy originally provided by the Affordable Care Act and extended through subsequent legislation, are effective through FY 2017. Under the prior extension, in accordance with section 105 of PAMA, those temporary changes in the low-volume hospital payment policy were to be in effect for discharges on or before March 31, 2015 only. We stated in the August 2015 IFC that, due to the timing of the development of the FY 2016 IPPS/LTCH PPS proposed rule and the enactment of the MACRA, we were unable to address the extension of the changes in the low-volume hospital payment policy for FY 2016 (or the last half of FY 2015, as discussed in section IV.L.2.b. of the preamble of the August 2015 IFC) in that proposed rule. In the August 2015 IFC, we revised the regulations at § 412.101 to conform to the provisions of section 204 of the MACRA.

To implement the low-volume hospital payment adjustment for FY 2016 consistent with provisions of the MACRA, in accordance with existing § 412.101(b)(2)(ii) and consistent with our historical approach, we updated the discharge data source used to identify qualifying low-volume hospitals and calculate the payment adjustment (percentage increase). Under existing § 412.101(b)(2)(ii), for the applicable fiscal years, a hospital’s Medicare discharges from the most recently available MedPAR data, as determined by CMS, are used to determine if the hospital meets the discharge criteria to receive the low-volume payment adjustment in the current year. The applicable low-volume percentage increase, as originally provided for by the Affordable Care Act, is determined using a continuous linear sliding scale equation that results in a low-volume hospital payment adjustment ranging from an additional 25 percent for hospitals with 200 or fewer Medicare discharges to a zero percent additional payment adjustment for hospitals with 1,600 or more Medicare discharges. For FY 2016, consistent with our historical policy, qualifying low-volume hospitals and their payment adjustment are determined using the most recently available Medicare discharge data from the March 2015 update of the FY 2014 MedPAR file, as these data are the most recent data available at the time of the development of the FY 2016 IPPS/LTCH PPS final rule and the August 2015 IFC. Table 14 listed in the Addendum of the FY 2016 IPPS/LTCH PPS final rule (which is available via the Internet on the CMS Web site at: http://www.cms.hhs.gov/AcuteInpatientPPS/01_overview.asp) listed the “subsection (d)” hospitals with fewer than 1,600 Medicare discharges based on the claims data from this FY 2014 MedPAR file and their potential low-volume payment adjustment for FY 2016. Consistent with past practice, we noted that this list of hospitals with fewer than 1,600 Medicare discharges in Table 14 did not reflect whether or not the hospital meets the mileage criterion. Eligibility for the low-volume hospital payment adjustment for FY 2016 also is dependent upon meeting the mileage...
criteria specified at §412.101(b)(2)(ii); that is, the hospital must be located more than 15 road miles from any other IPPS hospital. In other words, eligibility for the low-volume hospital payment adjustment for FY 2016 also is dependent upon meeting (in the case of a hospital that did not qualify for the low-volume hospital payment adjustment in FY 2015) or continuing to meet (in the case of a hospital that did qualify for the low-volume hospital payment adjustment in FY 2015) the mileage criterion specified at revised §412.101(b)(2)(ii) (that is, the hospital is located more than 15 road miles from any other subsection (d) hospital).

In order to receive a low-volume hospital payment adjustment under §412.101 for FY 2016, consistent with our previously established procedure, a hospital must notify and provide documentation to its MAC that it meets the discharge and distance requirements under §412.101(b)(2)(ii), as revised. Specifically, for FY 2016, a hospital must have made a written request for low-volume hospital status that was received by its MAC no later than September 1, 2015, in order for the applicable low-volume hospital payment adjustment to be applied to payments for its FY 2016 discharges occurring on or after October 1, 2015. Under this procedure, a hospital that qualified for the low-volume payment adjustment in FY 2015 may continue to receive a low-volume payment adjustment for FY 2016 without reapplying if it continues to meet the Medicare discharge criterion established for FY 2016 and the mileage criterion. However, the hospital had to send written verification that was received by its MAC no later than September 1, 2015, stating that it continues to be more than 15 miles from any other “subsection (d)” hospital. This written verification could be a brief letter to the MAC stating that the hospital continues to meet the low-volume hospital distance criterion as documented in a prior low-volume hospital status request. We stated that if a hospital’s written request for low-volume hospital status for FY 2016 was received after September 1, 2015, and if the MAC determines that the hospital meets the criteria to qualify as a low-volume hospital, the MAC will apply the applicable low-volume hospital payment adjustment to determine the payment for the hospital’s FY 2016 discharges, effective prospectively within 30 days of the date of its low-volume determination, consistent with past practice. (For additional details on our established process for the low-volume hospital payment adjustment, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53408) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50000 through 50001)).

In the August 2015 IFC, we made conforming changes to the existing regulations text at §412.101 to reflect the extension of the changes to the qualifying criteria and the payment adjustment methodology for low-volume hospitals through FY 2017 (that is, through September 30, 2017) in accordance with section 204 of the MACRA. In general, these conforming changes consisted of replacing the phrase “through FY 2014, and the portion of FY 2015 before April 1, 2015” with “through FY 2017” each place it appears, and replacing the phrase “the portion of FY 2015 beginning on April 1, 2015, and subsequent fiscal years” with the phrase “FY 2018 and subsequent fiscal years” each place it appears. Specifically, we revised paragraphs (b)(2)(ii), (b)(2)(iii), (c)(1), (c)(2), and (d) of §412.101. Under these revisions to §412.101, beginning with FY 2018, consistent with section 1886(d)(12) of the Act, as amended, the low-volume hospital qualifying criteria and payment adjustment methodology will revert to that which was in effect prior to the amendments made by the Affordable Care Act and subsequent legislation (that is, the low-volume hospital payment adjustment policy in effect for FYs 2005 through 2010).

2. Medicare-Dependent, Small Rural Hospital (MDH) Program (§412.108)

a. Background for MDH Program

Section 1886(d)(5)(G) of the Act provides special payment protections, under the IPPS, to a Medicare-dependent, small rural hospital (MDH). (For additional information on the MDH program and the payment methodology, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51683 through 51684).) Since the extension of the MDH program through FY 2012 provided by section 3124 of the Affordable Care Act, the MDH program has been extended by subsequent legislation as follows: First, section 606 of the ATRA (Pub. L. 112–240) extended the MDH program through FY 2013 (that is, for discharges occurring before October 1, 2013). Second, section 1106 of the Pathway for SGR Reform Act of 2013 (Pub. L. 113–67) extended the MDH program through the first half of FY 2014 (that is, for discharges occurring before April 1, 2014). Third, section 106 of the PAMA (Pub. L. 113–93) extended the MDH program through the first half of FY 2015 (that is, for discharges occurring before April 1, 2015). Most recently, section 205 of the MACRA (Pub. L. 114–10) extended the MDH program through FY 2017 (that is, for discharges occurring before October 1, 2017). For additional information on the extensions of the MDH program after FY 2012, we refer readers to the following Federal Register documents: The FY 2013 IPPS/LTCH PPS final rule (77 FR 53404 through 53405 and 53413 through 53414); the FY 2013 IPPS notice (78 FR 14689); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50647 through 50649); the FY 2014 interim final rule with comment period (79 FR 15025 through 15027); the FY 2014 notice (79 FR 34446 through 34449); the FY 2015 IPPS/LTCH PPS final rule (79 FR 50022 through 50024); and the August 2015 IFC (80 FR 49596).

b. MACRA Provisions for Extension of the MDH Program

Section 205 of the MACRA provided for an extension of the MDH program for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017). Specifically, section 205 of the MACRA amended sections 1886(d)(5)(G)(i) and 1886(d)(5)(G)(ii)(II) of the Act by striking “April 1, 2015” and inserting “October 1, 2017”. Section 205 of the MACRA also made conforming amendments to sections 1886(b)(3)(D)(i) and 1886(b)(3)(D)(iv) of the Act.

In the August 2015 IFC (80 FR 49596), we made conforming changes to the regulations at §412.108(a)(1) and (c)(2)(iii) to reflect the extension of the MDH program provided for by the MACRA. We stated in that IFC that, due to the timing of the development of the FY 2016 IPPS/LTCH PPS proposed rule and the enactment of the MACRA, we were unable to address the extension of the MDH program for FY 2016 (or the last half of FY 2015) in that proposed rule. After the MACRA was enacted, we addressed the extension of the MDH program for the last half of FY 2015 (that is, for discharges occurring on or after April 1, 2015, through September 30, 2015) in instructions issued in Change Request 9197, Transmittals 3263 and 3281. As explained in Change Request 9197, consistent with the previous extensions of the MDH program and the regulations at §412.108, generally, a provider that was classified as an MDH as of March 31, 2015, was reinstated as an MDH effective April 1, 2015, with no need to reapply for MDH classification. However, if the MDH had classified as
an SCH or cancelled its rural classification under § 412.103(g) effective on or after April 1, 2015, the effective date of MDH status may not be retroactive to April 1, 2015. For more details regarding MDH status for the second half of FY 2015, we refer the reader to Change Request 9197.

3. Statement of Final Policy

We received 14 timely pieces of correspondence in response to the August 2015 IFC. We have determined that all of this correspondence contains public comments on issues that were outside the scope of the provisions of the IFC. Therefore, we are finalizing the provisions of the August 2015 IFC without modification.

4. Collection of Information Requirements

The August 2015 IFC and this final rule do not impose information collection and recordkeeping requirements. Consequently, it need not be reviewed by the Office of Management and Budget under the authority of the Paperwork Reduction Act of 1995 (44 U.S.C. 35).

5. Impact of Legislative Extensions

In the August 2015 IFC, we presented the estimated effects of the provisions. This impact has not changed. Therefore, below we are presenting the impact as set forth in that IFC.

a. Effects of the Payment Adjustment for Low-Volume Hospitals for FY 2016

Based on the latest available data at the time of the August 2015 IFC, we estimated that approximately 593 hospitals will qualify as a low-volume hospital in FY 2016. We projected that the extension for FY 2016 of the temporary changes to the low-volume hospital definition and the payment adjustment methodology provided for by the MACRA will result in an increase in payments of approximately $322 million in FY 2016 as compared to payments to qualifying hospitals without the extension of the temporary changes to the low-volume hospital definition and the payment adjustment methodology.

b. Effects of the Extension of the MDH Program for FY 2016

Hospitals that qualify as MDHs receive the higher of operating IPPS payments made under the Federal standardized amount or the payments made under the Federal standardized amount plus 75 percent of the amount by which the hospital-specific rate (a hospital-specific cost-based rate) exceeds the Federal standardized amount. Based on the latest available data we had for 163 MDHs at the time of the August 2015 IFC, we projected that 90 MDHs will receive the blended payment (that is, the Federal standardized amount plus 75 percent of the amount by which the hospital-specific rate exceeds the Federal standardized amount) for FY 2016. We estimated that those hospitals will experience an overall increase in payments of approximately $96 million as compared to payments they would have received had the MDH program not been extended for FY 2016.

O. Clarification Regarding the Medicare Utilization Requirement for Medicare-Dependent, Small Rural Hospitals (MDHs) (§ 412.108)

Section 1886(d)(5)(G)(iv) of the Act defines an MDH as a hospital that is located in a rural area, has not more than 100 beds, is not an SCH, and has a high percentage of Medicare discharges (that is, not less than 60 percent of its inpatient days or discharges during the cost reporting period beginning in FY 1987 or two of the three most recently audited cost reporting periods for which the Secretary has a settled cost report were attributable to inpatients entitled to benefits under Part A). The regulations at 42 CFR 412.108 set forth the criteria that a hospital must meet to be classified as an MDH.

The Medicare utilization requirement is set forth at section 1886(d)(5)(G)(iv)(IV) of the Act and implemented by regulation at 42 CFR 412.108(a)[1][i][ii]. Consistent with the policy noted in the FY 1991 IPPS final rule (55 FR 35995) and further discussed in the FY 2011 IPPS/LTC PPS final rule (75 FR 50287), in order not to disadvantage hospitals that receive payment from a Medicare Advantage (MA) organization under Medicare Part C for inpatient care provided to Medicare beneficiaries enrolled in Medicare Part C plans, we count the days and discharges for those stays toward the 60-percent Medicare utilization requirement for MDH classification.

As discussed in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25135 through 25136), in accordance with the regulations at § 412.108(b)(5), MACs evaluate, on an ongoing basis, whether or not a hospital continues to qualify for MDH status. For hospitals that qualify for MDH status under § 412.108(a)(1)(iii)(C) and in accordance with the regulations at § 412.108(b)(5), at each cost reporting period, the MAC will determine whether the hospital has a Medicare utilization of at least 60 percent in at least two of the last three most recent audited cost reporting periods for which the Secretary has a settled cost report by including the newly settled cost report in the evaluation.

Medicare policy requires hospitals that receive certain additional payments such as IME, direct GME, and DSH, to submit claims for services furnished to individuals enrolled in a MA plan under Medicare Part C. Specifically, teaching hospitals that provide services to individuals enrolled in a MA plan under Medicare Part C must submit timely claims in order to receive the supplemental IME and direct GME payments for services provided to these individuals. Likewise, hospitals that operate nursing or allied health education programs and incur costs associated with those days or discharges associated with individuals enrolled in a MA plan under Medicare Part C also must submit timely claims in order to receive the additional payment amount for those MA enrollees. In addition, hospitals that are eligible for DSH payments are required to submit claims in a timely manner for individuals enrolled in a MA plan under Medicare Part C in order for those days to be captured in the DSH calculation. We refer readers to the FY 2013 IPPS/LTC PPS final rule (77 FR 53409) for more information and background on the requirements for filing no pay bills for services furnished to individuals enrolled in a MA plan under Medicare Part C.

Consistent with this policy, for a hospital that is eligible for IME, direct GME, or DSH payments, CMS only includes MA days or discharges as reported on the cost report and verified by the proper and timely submitted claims for the services furnished to individuals enrolled in a MA plan under Medicare Part C associated with those days or discharges in calculating Medicare utilization for MDH purposes. CMS verifies the accuracy of the MA days and discharges reported on the cost report using claims data; once verified, the cost report data can then be properly applied in the Medicare utilization calculation.

For a hospital that is not eligible for IME, direct GME, or DSH payments and is not required to submit bills for services furnished to individuals enrolled in a MA plan under Medicare Part C, we clarified in the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25136) that CMS will include the MA days or discharges associated with those services in the Medicare utilization calculation, regardless of whether the hospital submitted claims for services associated with those days or discharges...
provided that the hospital submits proper documentation, such as provider logs, that allow the MAC to verify the MA days or discharges as reported on the hospital’s cost report. However, as we noted in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25136), while not required, timely submission of claims for the services furnished to individuals enrolled in a MA plan under Medicare Part C allows CMS to establish whether the hospital meets the MDH classification criteria in an expeditious and timely manner. We note that we did not receive any public comments on this clarification.

P. Adjustment to IPPS Rates Resulting From 2-Midnight Policy

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50906 through 50954), we adopted the 2-midnight policy, effective for dates of admission on or after October 1, 2013. As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25136 through 25138), under the 2-midnight policy inpatient admission is generally appropriate for Medicare Part A payment if the physician (or other qualified practitioner) admits the patient as an inpatient based upon the reasonable expectation that the patient will need hospital care that crosses at least 2 midnights. In assessing the expected duration of necessary care, the physician (or other qualified practitioner) may take into account outpatient hospital care received prior to inpatient admission. If the patient is expected to need less than 2 midnights of care in the hospital, the services furnished should generally be billed as outpatient services. We note that revisions were made to this policy in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70545). Our actuaries estimated that the 2-midnight policy would increase expenditures by approximately $220 million in FY 2014 due to an expected net increase in inpatient encounters. We used our authority under section 1886(d)(5)(I)(i) of the Act to make a reduction of 0.2 percent to the standardized amount, the Puerto Rico standardized amount, and the hospital-specific payment rates, and we used our authority under section 1886(g) of the Act to make a reduction of 0.2 percent to the national capital Federal rate and the Puerto Rico-specific capital rate, in order to offset this estimated $220 million in additional IPPS expenditures in FY 2014. We indicated that although our exceptions and adjustments authority should not be routinely used in the IPPS system, we believed the rare, unprecedented, and widespread nature of this issue justified an overall adjustment to the IPPS rates and such an adjustment is authorized under section 1886(d)(5)(I)(i) of the Act. In Shands Jacksonville Medical Center, Inc. v. Burwell, No. 14–263 (D.D.C.) and related cases, hospitals challenged the 0.2 percent reduction in IPPS rates to account for the estimated $220 million in additional FY 2014 expenditures resulting from the 2-midnight policy. In its Memorandum Opinion, issued September 21, 2015, the Court found that the “Secretary’s interpretation of the exceptions and adjustments provision is a reasonable one” for this purpose. However, the Court also ordered the 0.2 percent reduction remanded back to the Secretary, without vacating the rule, to correct certain procedural deficiencies in the promulgation of the 0.2 percent reduction and reconsider the adjustment. The Court did not believe it would be appropriate to vacate the rule because such action would, in effect, dictate a substantive outcome based on a procedural error and concluded that the disruptive consequences would be considerable.

In accordance with the Court’s order, we published a notice with comment period that appeared in the December 1, 2015 Federal Register (80 FR 75107), which discussed the basis for the 0.2 percent reduction and its underlying assumptions and invited comments on the same in order to facilitate our further consideration of the FY 2014 reduction. We received numerous public comments on the notice with comment period. In considering these public comments, and those on the same topic received in response to the CY 2016 OPPS/ASC proposed rule, we continued to recognize that the 0.2 percent reduction issue is unique in many ways. The underlying question of patient status, which resulted in the creation of the 2-midnight policy, is a complex one with a long history, including large improper payment rates in short-stay hospital inpatient claims, requests to provide additional guidance regarding the proper billing of those services, and concerns about increasingly long stays of Medicare beneficiaries as outpatients due to hospital uncertainties about payment. (For further discussion of this history, we refer readers to the FY 2014 IPPS/LTCH PPS proposed and final rules (78 FR 27644 through 27649 and 78 FR 50906 through 50954, respectively.)

The 2-midnight policy itself and our implementation and enforcement of it have also evolved over time as a result of a combination of operational, regulatory, and operational changes. For example, as part of our efforts to provide education to stakeholders on the new 2-midnight policy, CMS hosted numerous “Open Door Forums.” conducted national provider calls, and shared information and answers to frequently asked questions on the CMS Web site. In addition, we instructed MACs to conduct a “Probe and Educate” process for inpatient claims with dates of admission on or after October 1, 2013 through September 30, 2014, to assess provider understanding and compliance with the new 2-midnight policy. We also prohibited Recovery Auditor’s post-payment medical reviews of inpatient hospital patient status for claims with dates of admission between October 1, 2013 and September 30, 2014. On April 1, 2014, the Protecting Access to Medicare Act of 2014 (Pub. L. 113–93) was enacted. Section 111 of Public Law 113–93 permitted CMS to continue medical review activities under the Inpatient Probe and Educate process through March 31, 2015. The same law also extended the prohibition on Recovery Auditor reviews of inpatient hospital patient status for claims with dates of admission through March 31, 2015, absent evidence of systematic gaming, fraud, abuse, or delays in the provision of care by a provider of services. On April 16, 2015, the Medicare Access and CHIP Reauthorization Act of 2015 (Pub. L. 114–10) was enacted. Section 521 of Public Law 114–10 permitted CMS to further extend the medical review activities under the Inpatient Probe and Educate process for inpatient claims through September 30, 2015, and extended the prohibition of Recovery Auditor reviews of inpatient hospital patient status for claims with dates of admission through September 30, 2015. CMS then announced in August 2015 that it would not approve Recovery Auditors to conduct patient status reviews for dates of admission of October 1, 2015 through December 31, 2015.

As we indicated in the CY 2016 OPPS/ASC final rule with comment period throughout the Probe and Educate process, we saw positive effects and improved provider understanding of the 2-midnight policy. We also discussed in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70545 through 70549) a number of additional changes we had made and were continuing to make to the Recovery Audit Program and changes to the medical review responsibilities for Quality Improvement Organizations (QIOs) in regard to short hospital stay claims.

With respect to the 2-midnight policy itself, in light of stakeholder concerns...
and in our continued effort to develop the most appropriate and applicable framework for determining when payment under Medicare Part A is appropriate for inpatient admissions, in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70545), we modified the original “rare and unusual” exceptions policy under the 2-midnight policy to allow for Medicare Part A payment on a case-by-case basis for inpatient admissions that do not satisfy the 2-midnight benchmark, if the documentation in the medical record supports the admitting physician’s determination that the patient requires inpatient hospital care despite an expected length of stay that is less than 2 midnights.

We also recognized in reviewing the public comments we received on the 0.2 percent reduction in response to the December 1, 2015 notice with comment period and the CY 2016 OPPS/ASC proposed rule that, in addition to the long history of the question of patient status underlying the 2-midnight policy and the statutory, regulatory, and operational changes that have occurred since its initial implementation, the original estimate for the 0.2 percent reduction had a much greater degree of uncertainty than usual. As indicated in the Office of the Actuary’s August 19, 2013 memorandum (which was included as Appendix A of the December 1, 2015 notice with comment period (80 FR 75112 through 75114)), the estimate depended critically on the assumed utilization changes in the inpatient and outpatient hospital settings, relatively small changes would have a disproportionate effect on the estimated net costs, the estimate was subject to a much greater degree of uncertainty than usual, and the actual results could differ significantly from the estimate.

Lastly, in reviewing the public comments we received on the December 1, 2015 notice with comment period, we also considered the fact that our actuaries’ most recent estimate of the impact of the 2-midnight policy varies between a savings and a cost over the FY 2014 to FY 2015 time period. The memorandum describing this new analysis is available on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html.

We still believe the assumptions underlying the 0.2 percent reduction to the rates put in place beginning in FY 2014 were reasonable at the time we made them in 2013. Nevertheless, taking all the foregoing factors into account, we stated in the FY 2017 IPPS/ASC proposed rule that we believe it would be appropriate to use our authority under sections 1886(d)(5)(U)(I) and 1886(g) of the Act to prospectively remove, beginning in FY 2017, the 0.2 percent reduction to the rates put in place beginning in FY 2014. The 0.2 percent reduction was implemented by including a factor of 0.998 in the calculation of the FY 2014 standardized amount, the hospital-specific payment rates, and the national capital Federal rate, permanently reducing the rates for FY 2014 and future years until the 0.998 is removed. In the FY 2017 IPPS/ASC proposed rule (81 FR 25138), we proposed to permanently remove the 0.998 reduction beginning in FY 2017 by including a factor of (1/0.998) in the calculation of the FY 2017 standardized amount, the hospital-specific payment rates, and the national capital Federal rate.

In addition, taking all the foregoing factors into account, and given the unique nature of this situation, we stated in the proposed rule that we believe it would be appropriate to use our authority under sections 1886(d)(5)(U)(I) and 1886(g) of the Act to temporarily increase the rates, only for FY 2017, to address the effect of the 0.2 percent reduction to the rates in effect for FY 2014, the 0.2 percent reduction to the rates in effect for FY 2015 (recall the 0.998 factor included in the calculation of the FY 2014 rates permanently reduced the rates for FY 2014 and future years until it is removed), and the 0.2 percent reduction to the rates in effect for FY 2016. We believe that the 0.998 reduction beginning in FY 2014, and making a temporary one-time prospective increase to the FY 2017 rates to address the effect of the 0.2 percent reduction to the rates for FYs 2014 through 2016, is appropriate for inpatient admissions, in part, because the reduction was in place over the 3-year FY 2014–FY 2016 time period.

Response: We appreciate the commenters’ recognition of the unique nature of this situation and their support for prospectively removing, beginning in FY 2017, the 0.2 percent reduction to the rates put in place beginning in FY 2014, and making a temporary one-time prospective increase to the FY 2017 rates to address the effect of the 0.2 percent reduction to the rates for FYs 2014 through 2016. One commenter suggested that, instead of a temporary one-time prospective increase to the FY 2017 rates, CMS adjust over a 3-year FY 2017–FY 2019 time period because the reduction was in place over the 3-year FY 2014–FY 2016 time period.

Comment: The vast majority of commenters recognized the unique nature of this situation and supported prospectively removing the 0.2 percent reduction to the rates and making a temporary one-time prospective increase to the FY 2017 rates to address the effect of the 0.2 percent reduction to the rates for FYs 2014 through 2016. We do not agree with the commenter who suggested that we should adjust over a 3 year FY 2017–FY 2019 time period because the reduction was in place over the 3-year FY 2014–FY 2016 time period. The nearest prospective time period that we can use to address the effect of the 0.2 percent reduction to the rates for FYs 2014 through 2016 is FY 2017. As we stated in the proposed rule, our goal is a transparent, expedient, and administratively feasible method. Delaying addressing the effect for FYs 2014 through 2016 over 3 years rather than the more immediate 1 year method we proposed is not an expedient method of resolving this issue.
did not address the utilization shift between inpatient and outpatient cases caused by the 2-midnight policy which CMS referred to in the FY 2014 proposed and final rules and which is in the opposite direction of what CMS assumed; CMS should adopt a rate increase to offset an asserted decline in expenditures resulting from the 2-midnight policy; contrary to CMS' assumptions about the 2-midnight policy, rather than cases shifting between inpatient and outpatient, the entire population of relevant hospital episodes declined over time; and CMS actuary's analysis was flawed for numerous reasons, including because it assumed that the entire deviation from the historical trend line was attributable to the 2-midnight policy.

Response: We believe these commenters are mischaracterizing our proposal. In making our proposal, we were not attempting to determine a new point estimate of the effect of the 2-midnight policy for the purposes of then proposing (1) a prospective adjustment to the rates for the net effect of that new estimate relative to the −0.2 percent adjustment we put in place in FY 2014 and (2) a temporary one-time adjustment to the rates in FY 2017 to address the net effects of that new estimate over the FY 2014–FY 2016 time period. Rather than determine a new point estimate, we proposed to remove the −0.2 percent adjustment we did make and address the effect of that adjustment for FYs 2014 through 2016. As we have indicated in prior rulemaking, we were not required by statute to make an adjustment to the rates for the effect of the 2-midnight policy. We chose to do so at the time for the reasons stated in the prior rulemaking. However, for the reasons stated in the proposed rule, we proposed to no longer make any adjustment for the 2-midnight policy and address the FY 2014–FY 2016 effects of the adjustment we did make.

For many of the reasons commenters presented to us in prior rulemaking, we no longer are confident that the effect of the 2-midnight policy on the number of discharges paid under the IPPS may be measured in this context. As a result, we proposed to make no adjustment (and account for the past effects of the adjustment we had made), not to make a new adjustment.

We currently do not intend to revisit the issue of making an adjustment for the 2-midnight policy in future rulemaking. However, if we were to make a proposal in future rulemaking, we would take into account all of the public comments received to date on the impact of the 2-midnight policy and any public comments received on a future proposal.

Comment: Commenters indicated that a very small number of hospitals would not benefit from the adjustments to the FY 2017 rates. Hospitals that were paid under the IPPS for all or part of FY 2014, 2015, or 2016, but will not be paid under the IPPS for all of FY 2017 (either because they closed or converted to a different type of hospital) would not receive the full benefit of the payment adjustments. The commenters requested that CMS establish an exceptions process to address this issue.

Response: We recognize that for closed, converted, or new hospitals, our proposed prospective method generally has a differential positive or negative impact compared to hospitals that were IPPS hospitals for the FY 2014–FY 2017 time period. We generally believe that, given the prospective nature of our method and our goal to adopt a transparent, expedient, and administratively feasible approach, these differential impacts are an appropriate consequence. However, after considering the public comments received, we agree that we should provide a process to address the situation of closed or converted hospitals. Due to the small number of hospitals impacted, we will address closed and converted hospitals as part of the cost report settlement process. These hospitals should identify themselves to their MACs so that the appropriate cost report adjustment can be applied.

Comment: Some commenters stated that attempts to make prospective adjustments to the 1.006 factor would need to rely on estimates of factors that have been objected to by commenters in the prior rulemaking related to the −0.2 percent adjustment, such as estimates regarding projected inpatient utilization levels.

Response: Some commenters stated that the FY 2017 adjustment to address the effects of the −0.2 percent adjustment for FYs 2014, 2015, and 2016 does not compensate hospitals that are party to the lawsuit for interest and/or all hospitals for the time value of money. Some commenters suggested that CMS refine the 1.006 percent adjustment to account for this or otherwise address the issue.

Response: We will not contest that hospitals that are party to the Shands Jacksonville Medical Center, Inc. v. Burwell, No. 14–263 (D.D.C.) and other currently pending cases that challenge the −0.2 percent adjustment should receive interest under section 1878(f)(2) of the Act. For these hospitals, we will slightly increase the 1.006 factor by a uniform factor consistent with the interest rates used for this purpose in effect for the relevant time periods for paying interest. We disagree with commenters who indicated that we should pay all hospitals interest or for the time value of money.

After consideration of the public comments we received, we are finalizing our proposal to adjust the FY 2017 IPPS rates through a permanent adjustment of 1.002 and temporary one-time prospective adjustment of 1.006, which will be removed by including a factor of (1/1.006) in the calculation of the FY 2018 rates.

V. Changes to the IPPS for Capital-Related Costs

A. Overview

Section 1886(g) of the Act requires the Secretary to pay for the capital-related costs of inpatient acute hospital services in accordance with a prospective payment system established by the Secretary. Under the statute, the Secretary has broad authority in establishing and implementing the IPPS for acute care hospital inpatient capital-related costs. We initially implemented the IPPS for capital-related costs in the FY 1992 IPPS final rule (56 FR 43358). In that final rule, we established a 10-year transition period to change the payment methodology for Medicare hospital inpatient capital-related costs from a reasonable cost-based payment methodology to a prospective payment
methodology (based fully on the Federal rate).

FY 2001 was the last year of the 10-year transition period that was established to phase in the IPPS for hospital inpatient capital-related costs. For cost reporting periods beginning in FY 2002, capital IPPS payments are based solely on the Federal rate for almost all acute care hospitals (other than hospitals receiving certain exception payments and certain new hospitals). (We refer readers to the FY 2002 IPPS final rule (66 FR 39910 through 39914) for additional information on the methodology used to determine capital IPPS payments to hospitals both during and after the transition period.)

The basic methodology for determining capital prospective payments using the Federal rate is set forth in the regulations at 42 CFR 412.312. For the purpose of calculating payments using the Federal rate is set to remain constant through the 2002 IPPS final rule (66 FR 39910 through 39914) for additional payments using the Federal rate. (For additional details on the methodology, we refer readers to the FY 2005 IPPS final rule (69 FR 49185 and 49186).

2. New Hospitals

Under the capital IPPS, the regulations at 42 CFR 412.300(b) define a new hospital as a hospital that has operated (under previous or current ownership) for less than 2 years and lists examples of hospitals that are not considered new hospitals. In accordance with §412.304(c)(2), under the capital IPPS, a new hospital pays 85 percent of its allowable Medicare inpatient hospital capital-related costs through its first 2 years of operation, unless the new hospital elects to receive full prospective payment based on 100 percent of the Federal rate. We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725) for additional information on payments to new hospitals under the capital IPPS.

3. Changes in Payments for Hospitals Located in Puerto Rico

The existing regulations at 42 CFR 412.374 relating to the capital IPPS provide for the use of a blended payment amount for prospective payments for capital-related costs to hospitals located in Puerto Rico. Accordingly, under the capital IPPS, we have historically computed a separate payment rate specific to Puerto Rico hospitals using the same methodology used to compute the national Federal rate for capital-related costs. The capital-related payment rate for hospitals located in Puerto Rico was derived using only the costs of hospitals located in Puerto Rico, while the national Federal rate for capital-related costs is derived using the costs of all acute care hospitals participating in the IPPS (including hospitals located in Puerto Rico). In general, hospitals located in Puerto Rico are paid a blended payment rate for capital-related costs that parallels the statutory calculation of operating IPPS payments to hospitals located in Puerto Rico. Under existing regulations at 42 CFR 412.374, capital IPPS payments to hospitals located in Puerto Rico are computed based on a blend of 25 percent of the capital IPPS Puerto Rico rate and 75 percent of the capital IPPS Federal rate. Historically, we have established a capital IPPS blended payment rate structure for hospitals located in Puerto Rico that parallels the statutory calculation of operating IPPS payments to hospitals located in Puerto Rico. Under existing regulations at 42 CFR 412.374, capital IPPS payments to hospitals located in Puerto Rico are computed based on a blend of 25 percent of the capital IPPS Puerto Rico rate and 75 percent of the capital IPPS Federal rate. (For additional details on capital IPPS payments to hospitals located in Puerto Rico, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51725).

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25139), section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) increased the applicable Federal percentage of the operating IPPS payment for hospitals located in Puerto Rico from 75 percent to 100 percent and decreased the applicable Puerto Rico percentage of the operating IPPS payments for hospitals located in Puerto Rico from 25 percent to zero percent, applicable to discharges occurring on or after January 1, 2016. (For additional information on section 601 of the Consolidated Appropriations Act, 2016, we refer readers to section IV.A. of the preamble of this final rule.) As a result of the amendment made by section 601 of Public Law 114–113, on February 4, 2016, we issued Change Request 9523 which updated the payment rates for subsection (d) Puerto Rico hospitals for discharges occurring on or after January 1, 2016. Change Request 9523 can be downloaded from the CMS Web site at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2016-Transmittals-Items/R3449CP.html.

Consistent with historical practice, under the broad authority of the Secretary granted under section 1886(g) of the Act, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25139), we proposed to revise the calculation of capital IPPS payments to hospitals located in Puerto Rico to parallel the change in the statutory calculation of operating IPPS payments to hospitals located in Puerto Rico, beginning in FY 2017. Accordingly, we proposed to revise §412.374 of the regulations to provide that, for discharges occurring on or after October 1, 2016, capital IPPS payments to hospitals located in Puerto Rico would be based on 100 percent of the capital Federal rate; that is, payments would no longer be derived from a blend of the capital Puerto Rico rate and the capital Federal rate.

We did not receive any public comment on this proposal or the proposed revisions to §412.374. Therefore, we are finalizing our proposal, with one technical correction to the proposed revisions to §412.374. We are making a technical correction to the heading of §412.374(e) to comport with our finalized policies and the finalized text of paragraph (e). In the proposed rule, we inadvertently stated in the heading of proposed §412.374(e) that the policies in that paragraph are for FYs 2016 and later, instead of FY 2017 and later. In this final rule, we are revising the heading of §412.374(e) to read “FY 2017 and subsequent fiscal years,” consistent with the effective date of our finalized policies, which are for discharges on or after October 1, 2016 (that is, FY 2017).
As such, under revised §412.374, for discharges occurring on or after October 1, 2016, capital IPPS payments to hospitals located in Puerto Rico will be based on 100 percent of the capital Federal rate. As we noted in the proposed rule and are noting in this final rule, this change is similar to the changes in capital IPPS payments to hospitals located in Puerto Rico beginning in FY 1998 and FY 2005 that paralleled the corresponding statutory changes in the blended payment amount calculation required for operating IPPS payments to hospitals located in Puerto Rico, as provided by section 4406 of Public Law 105–33 (62 FR 46048) and section 504 of Public Law 108–173 (69 FR 49185), respectively. As discussed in section I.I. of Appendix A (Economic Analyses) of this final rule, this change will result in a slight increase in capital IPPS payments to hospitals located in Puerto Rico because adjusted capital IPPS payments based on the capital Federal rate are generally higher than capital IPPS payments based on the capital Puerto Rico rate.

C. Annual Update for FY 2017

The annual update to the capital PPS Federal rate, as provided for at §412.308(c), for FY 2017 is discussed in section III. of the Addendum to this final rule. Consistent with our finalized policy discussed under section V.B.3. of the preamble of this final rule to revise the calculation of capital IPPS payments to hospitals located in Puerto Rico to be based on 100 percent of the capital Federal rate (and no longer based on a blend of the capital Puerto Rico rate and the capital Federal rate), we are discontinuing the use of the Puerto Rico capital rate in the calculation of capital IPPS payments to hospitals located in Puerto Rico, effective October 1, 2016 (FY 2017).

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50906 through 50954), we adopted the 2-midnight policy effective for dates of admission on or after October 1, 2013, under which an inpatient admission is generally appropriate for Medicare Part A payment if the physician (or other qualified practitioner) admits the patient as an inpatient based upon the reasonable expectation that the patient will need hospital care that crosses at least 2 midnights. At that time, our actuaries estimated that the 2-midnight policy would increase expenditures by approximately $220 million in FY 2014 due to an expected net increase in inpatient encounters. In that same final rule, we also considered the fact that our actuaries’ estimate of the impact of the 2-midnight policy varies between a savings and a cost over the FY 2014 to FY 2015 time period. (For additional details, we refer readers to section IV.O. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25136 through 25138) and section IV.P. of the preamble of this final rule.)

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25139 through 25140), we still believe the 2-midnight policy will result in a slight increase in capital IPPS payments to hospitals located in Puerto Rico beginning in FY 2017.

Nevertheless, taking all of these factors into account, consistent with the approach proposed for the operating IPPS rates, we stated that we believe it would be appropriate to use our authority under section 1886(g) of the Act to permanently remove the 0.2 percent reduction to the capital IPPS rate beginning in FY 2017. (As explained in section V.B.3. of the proposed rule, we proposed to discontinue use of the Puerto Rico capital rate in the calculation of capital IPPS payments to hospitals located in Puerto Rico beginning in FY 2017.)

Specifically, we proposed to make an adjustment of (1/0.998) to the national capital Federal rate to remove the 0.2 percent reduction, consistent with the proposed adjustment to the operating IPPS standardized amount and the hospital-specific payment rates. In addition, consistent with the approach proposed for the operating IPPS standardized amount and hospital-specific payment rates and for the reasons discussed in section IV.O. of the preamble of the proposed rule, we stated that we believe it would be appropriate to use our authority under section 1886(g) of the Act to adjust the FY 2017 capital IPPS rate to address the effects of the 0.2 percent reduction to the national capital Federal rates in effect for FY 2014, FY 2015, and FY 2016 by proposing a one-time prospective adjustment of 1.006 in FY 2017 to the national capital Federal rate. For FY 2018, we also proposed to remove the effects of this one-time prospective adjustment through an adjustment of (1/1.006) to the national capital Federal rate, consistent with the approach proposed for the operating IPPS standardized amount and hospital-specific payment rates. We invited public comments on these proposals.

In section IV.P. of the preamble of this final rule, we summarize and respond to public comments on our proposals to include a permanent factor of (1/0.998) and a temporary one-time factor of (1.006) in the calculation of the FY 2017 standardized amount, the hospital-specific payment rates, and the national capital Federal rate and to include a factor of (1/1.006) in the calculation of the FY 2018 standardized amount, the hospital-specific payment rates, and the national capital Federal rate to remove the temporary one-time factor of 1.006. After consideration of the public comments and for the reasons described in section IV.P. of the preamble of this final rule, we are finalizing the following proposals. We note that we did not receive any public comments that
specifically addressed our proposed adjustments to the national capital Federal rate. Accordingly, as stated in section IV.P. of this final rule, we are finalizing our proposal to adjust the FY 2017 national capital Federal rate through a permanent adjustment of 1.002 and temporary one-time prospective adjustment of 1.006, which will be removed by including a factor of (1/1.006) in the calculation of the FY 2018 rates.

As we noted in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25140), in section II.D. of the preamble of that rule, we presented a discussion of the MS–DRG documentation and coding adjustment, including previously finalized policies and historical adjustments, as well as the recoupment adjustment to the standardized amounts under section 1886(d) of the Act that we proposed for FY 2017 in accordance with the amendments made to section 7(b)(1)(B) of Public Law 110–90 by section 631 of the ATRA. Because section 631 of the ATRA requires us to make a recoupment adjustment only to the operating IPPS standardized amount, we did not propose to make a similar adjustment to the capital IPPS rate (or to the operating IPPS hospital-specific rates). This approach is consistent with our historical approach regarding the application of the recoupment adjustment authorized by section 7(b)(1)(B) of Public Law 110–90.

We refer readers to section II.D. of the preamble of this final rule for a discussion of the recoupment adjustment to the operating IPPS standardized amount for FY 2017.

VI. Changes for Hospitals Excluded From the IPPS

A. Rate-of-Increase in Payments to Excluded Hospitals for FY 2017

Certain hospitals excluded from a prospective payment system, including children’s hospitals, 11 cancer hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) receive payment for inpatient hospital services they furnish on the basis of reasonable costs, subject to a rate-of-increase ceiling. A per discharge limit (the target amount as defined in §413.40(a) of the regulations) is set for each hospital based on the hospital’s own cost experience in its base year, and updated annually by a rate-of-increase percentage. For each cost reporting period, the updated target amount is multiplied by total Medicare discharges during that period and applies as an aggregate upper limit (the ceiling as defined in §413.40(a) of Medicare reimbursement for total inpatient operating costs for a hospital’s cost reporting period. In accordance with §403.752(a) of the regulations, RNHCIs also are subject to the rate-of-increase limits established under §413.40 of the regulations discussed previously.

As explained in the FY 2006 IPPS final rule (70 FR 47396 through 47398), beginning with FY 2006, we have used the percentage increase in the IPPS operating market basket to update the target amounts for children’s hospitals, cancer hospitals, and RNHCIs. Consistent with §§412.23(g), 413.40(a)(2)(ii)(A), and 413.40(c)(3)(viii), we also have used the percentage increase in the IPPS operating market basket to update the target amounts for short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. As we finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50156 through 50157), for FY 2017, we will continue to use the percentage increase in the FY 2010-based IPPS operating market basket to update the target amounts for children’s hospitals, cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa.

Accordingly, for FY 2017, the rate-of-increase percentage to be applied to the target amount for these children’s hospitals, cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa is the FY 2017 percentage increase in the FY 2010-based IPPS operating market basket.

For the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25140), based on IHS Global Insight, Inc.’s 2016 first quarter forecast, we estimated that the FY 2010-based IPPS operating market basket update for FY 2017 was 2.8 percent (that is, the estimate of the market basket rate-of-increase). We indicated in the proposed rule that if more recent data became available for the final rule, we would use them to calculate the IPPS operating market basket update for FY 2017. For this FY 2017 IPPS/LTCH PPS final rule, based on IHS Global Insight, Inc.’s 2016 second quarter forecast (which is the most recent data available), we calculated the FY 2010-based IPPS operating market basket update for FY 2017 to be 2.7 percent. Therefore, the FY 2017 rate-of-increase percentage that is applied to the FY 2016 target amounts in order to calculate the FY 2017 target amounts for children’s hospitals, cancer hospitals, RNHCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa is 2.7 percent, in accordance with the applicable regulations at 42 CFR 413.40.

B. Report on Adjustment (Exceptions) Payments

Section 4419(b) of Public Law 105–33 requires the Secretary to publish annually in the Federal Register a report describing the total amount of adjustment payments made to excluded hospitals and hospital units by reason of section 1886(b)(4) of the Act during the previous fiscal year.

The process of requesting, adjusting, and awarding an adjustment payment is likely to occur over a 2-year period or longer. First, generally, an excluded hospital must file its cost report for the fiscal year in accordance with §413.24(f)(2) of the regulations. The MAC reviews the cost report and issues a notice of provider reimbursement (NPR). Once the hospital receives the NPR, if its operating costs are in excess of the ceiling, the hospital may file a request for an adjustment payment. After the MAC receives the hospital’s request in accordance with applicable regulations, the MAC or CMS, depending on the type of adjustment requested, reviews the request and determines if an adjustment payment is warranted. This determination is sometimes not made until more than 180 days after the date the request is filed because there are times when the request applications are incomplete and additional information must be requested in order to have a completed request application. However, in an attempt to provide interested parties with data on the most recent adjustment payments for which we have data, we are publishing data on adjustment payments that were processed by the MAC or CMS during FY 2015.

The table below includes the most recent data available from the MACs and CMS on adjustment payments that were adjudicated during FY 2015. As indicated above, the adjustments made during FY 2015 only pertain to cost reporting periods ending in years prior to FY 2015. Total adjustment payments given to excluded hospitals during FY 2015 are $19,959,036. The table depicts for each class of hospitals, the number of adjustment requests adjudicated, the excess operating costs over the ceiling, and the amount of the adjustment payments.
C. Critical Access Hospitals (CAHs)

1. Background

Section 1820 of the Act provides for the establishment of Medicare Rural Hospital Flexibility Programs (MRHFPs), under which individual States may designate certain facilities as critical access hospitals (CAHs). Facilities that are so designated and meet the CAH conditions of participation under 42 CFR part 485, subpart F, will be certified as CAHs by CMS. Regulations governing payments to CAHs for services to Medicare beneficiaries are located in 42 CFR part 413.

2. Frontier Community Health Integration Project (FCHIP) Demonstration

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25140 through 25141), section 123 of the Medicare Improvements for Patients and Providers Act of 2008 (Pub. L. 110–275), as amended by section 3126 of the Affordable Care Act of 2010, authorizes a demonstration project to allow eligible entities to develop and test new models for the delivery of health care services in eligible counties in order to improve access to and better integrate the delivery of acute care, extended care and other health care services to Medicare beneficiaries. The demonstration is titled “Demonstration Project on Community Health Integration Models in Certain Rural Counties,” and is commonly known as the Frontier Community Health Integration Project (FCHIP) demonstration.

The authorizing statute states the eligibility criteria for entities to be able to participate in the demonstration. An eligible entity, as defined in section 123(d)(1)(B) of Public Law 110–275, as amended, is an MRHFP grantee under section 1820(g) of the Act (that is, a CAH); and is located in a State in which at least 65 percent of the counties in the State are counties that have 6 or less residents per square mile.

The authorizing statute stipulates several other requirements for the demonstration, Section 123(d)(2)(B) of Public Law 110–275, as amended, limits participation in the demonstration to eligible entities in not more than 4 States. Section 123(f)(1) of Public Law 110–275 requires the demonstration project to be conducted for a 3-year period. In addition, section 123(g)(1)(B) of Public Law 110–275 requires that the demonstration be budget neutral. Specifically, this provision states that in conducting the demonstration project, the Secretary shall ensure that the aggregate payments made by the Secretary do not exceed the amount which the Secretary estimates would have been paid if the demonstration project under the section were not implemented. Furthermore, section 123(i) of Public Law 110–275 states that the Secretary may waive such requirements of titles XVIII and XIX of the Act as may be necessary and appropriate for the purpose of carrying out the demonstration project, thus allowing the waiver of Medicare payment rules encompassed in the demonstration.

In January 2014, CMS released a request for applications (RFA) for the FCHIP demonstration. We refer readers to the RFA on the CMS Web site at: https://innovation.cms.gov/initiatives/Frontier-Community-Health-Integration-Project-Demonstration/. Using 2013 data from the U.S. Census Bureau, CMS identified Alaska, Montana, Nevada, North Dakota, and Wyoming as meeting the statutory eligibility requirement for participation in the demonstration. The RFA solicited CAHs in these five States to participate in the demonstration, stating that participation would be limited to CAHs in four of the States. To apply, CAHs were required to meet the eligibility requirements in the authorizing legislation, and, in addition, to describe a proposal to enhance health-related services that would complement those currently provided by the CAH and better serve the community’s needs. In addition, in the RFA, CMS interpreted the eligible entity definition in the statute as meaning a CAH that receives funding through the Rural Hospital Flexibility Program. The RFA identified four intervention prongs, under which specific waivers of Medicare payment rules would allow for enhanced payment for telemedicine, nursing facility, ambulance, and home health services, respectively. These waivers were formulated with the goal of increasing access to care with no net increase in costs.

Since the due date for applications on May 5, 2014, we have assessed the feasibility of the applying CAHs’ service delivery proposals, as well as the potential impacts of the payment enhancement interventions on the overall expenditures for Medicare services. In the FY 2017 IPPS/LTCH PPS proposed rule, we indicated that we would be selecting CAHs to participate in the demonstration, with the period of performance for each CAH expected to start August 1, 2016.

In the proposed rule, we indicated that we had specified the payment enhancements for the demonstration, and were basing our selection of CAHs for participation, with the goal of maintaining the budget neutrality of the demonstration on its own terms (that is, the demonstration would produce savings from reduced transfers and admissions to other health care providers, thus offsetting any increase in payments resulting from the demonstration). However, because of the small size of this demonstration and uncertainty associated with projected Medicare utilization and costs, in the proposed rule, we proposed a contingency plan to ensure that the budget neutrality requirement in section 123 of Public Law 110–275 is met. Accordingly, if analysis of claims data for Medicare beneficiaries receiving services at each of the participating CAHs, as well as of other data sources, including cost reports for these CAHs, shows that increases in Medicare payments under the demonstration during the 3-year period are not sufficiently offset by reductions elsewhere, we indicated that we would recoup the additional expenditures attributable to the demonstration through a reduction in payments to all CAHs nationwide. Because of the small scale of the demonstration, we stated that we did not believe it would be feasible to implement budget neutrality by reducing payments to only the participating CAHs. Therefore, in the event that this demonstration is found to result in aggregate payments in excess of the amount that would have been paid if this demonstration were not
implemented, we proposed to comply with the budget neutrality requirement by reducing payments to all CAHs, not just those participating in the demonstration. We stated that we believe it is appropriate to make any payment reductions across all CAHs because the FCHIP demonstration is specifically designed to test innovations that affect delivery of services by the CAH provider category. We believe that the language of the statutory budget neutrality requirement at section 123(g)(1)(B) of Public Law 110–275 permits the agency to implement the budget neutrality provision in this manner. The statutory language merely refers to ensuring that aggregate payments made by the Secretary do not exceed the amount which the Secretary estimates would have been paid if the demonstration project was not implemented, and does not identify the range across which aggregate payments must be held equal.

Based on actuarial analysis using cost report settlements for FYs 2013 and 2014, the demonstration is projected to satisfy the budget neutrality requirement and likely yield a total net savings. For the FY 2017 IPPS/LTCH PPS, the proposed rule, estimated that the total impact of the payment recoupment would be no greater than 0.03 percent of CAHs’ total Medicare payments within 1 fiscal year (that is, Medicare Part A and Part B). We stated in the proposed rule that the final budget neutrality estimates for the FCHIP demonstration would be based on the demonstration period, which is August 1, 2016 through July 31, 2019. The demonstration is projected to impact payments to participating CAHs under both Medicare Part A and Part B. Therefore, we proposed that, in the event the demonstration is found not to have been budget neutral, any excess costs would be recouped over a period of 3 cost reporting years, beginning in CY 2020. We proposed a 3-year period for recoupment to allow for a reasonable timeframe for the payment reduction and to minimize any impact on CAHs’ operations.

Comment: Two commenters supported the FCHIP demonstration, but believed that it is inappropriate to recoup Medicare payments from all CAHs nationwide in order to achieve budget neutrality, especially because such a reduction will apply to CAHs that are not eligible to participate in the demonstration.

Response: We appreciate the commenters’ support for the FCHIP demonstration and acknowledge the concerns expressed regarding recoupment of Medicare payments from all CAHs nationwide. We emphasize that the recoupment would apply only as a contingency plan, in the event that the demonstration costs exceed savings. Our actuarial analysis has estimated that the impact would be no greater than 0.03 percent of CAHs’ total Medicare payments within 1 fiscal year. In addition, we will conduct any such recoupment over a period of 3 cost reporting years, in order to allow for a reasonable timeframe for any payment reduction and minimize the impact on CAHs’ operations.

We refer readers to the CMS Web site at: https://innovation.cms.gov/initiatives/Frontier-Community-Health-Integration-Project-Demonstration/ for up-to-date information on the FCHIP demonstration. We are finalizing, as proposed, a policy that, in the event we determine that aggregate payments under the demonstration exceed the payments that would otherwise have been made, CMS will recoup payments through reductions of Medicare payments to all CAHs under both Medicare Part A and Part B. Given the 3-year period of performance for the FCHIP demonstration and the time needed to conduct the budget neutrality analysis, in the event the demonstration is found not to have been budget neutral, any excess costs will be recouped over a period of 3 cost reporting years, beginning in CY 2020.

VII. Changes to the Long-Term Care Hospital Prospective Payment System (LTCH PPS) for FY 2017

A. Background of the LTCH PPS

1. Legislative and Regulatory Authority

Section 123 of the Medicare, Medicaid, and SCHIP (State Children’s Health Insurance Program) Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113) as amended by section 307(b)(1) of the BIPA. Among other things, mandates that the Secretary shall examine, and may provide for, adjustments to payments under the LTCH PPS, including adjustments to DRG weights, area wage adjustments, geographic reclassification, outliers, updates, and a disproportionate share adjustment. In the August 30, 2002 Federal Register, we issued a final rule that implemented the LTCH PPS authorized under the BBRA and BIPA (67 FR 55954). For the initial implementation of the LTCH PPS (FYs 2003 through FY 2007), the system used information from LTCH patient records to classify patients into distinct long-term care diagnosis-related groups (LTCDRGs) based on clinical characteristics and expected resource needs. Beginning in FY 2008, we adopted the Medicare severity long-term care diagnosis-related groups (MS-LTC–DRGs) as the patient classification system used under the LTCH PPS. Payments are calculated for each MS-LTC–DRG and provisions are made for appropriate payment adjustments. Payment rates under the LTCH PPS are updated annually and published in the Federal Register.

The LTCH PPS replaced the reasonable cost-based payment system under the Tax Equity and Fiscal Responsibility Act of 1982 (TEFRA) (Pub. L. 97–248) for payments for inpatient services provided by an LTCH with a cost reporting period beginning on or after October 1, 2002. (The regulations implementing the TEFRA reasonable cost-based payment provisions are located at 42 CFR part 413.) With the implementation of the PPS for acute care hospitals authorized by the Social Security Amendments of 1983 (Pub. L. 98–21), which added section 1886(d) to the Act, certain hospitals, including LTCHs, were excluded from the PPS for acute care hospitals and were paid their reasonable
costs for inpatient services subject to a per discharge limitation or target amount under the TEFRA system. For each cost reporting period, a hospital-specific ceiling on payments was determined by multiplying the hospital’s updated target amount by the number of total current year Medicare discharges. (Generally, in this section of the preamble of this proposed rule, when we refer to discharges, we describe Medicare discharges.) The August 30, 2002 final rule further details the payment policy under the TEFRA system (67 FR 55954).

In the August 30, 2002 final rule, we provided for a 5-year transition period from payments under the TEFRA system to payments under the LTCH PPS. During this 5-year transition period, an LTCH’s total payment under the PPS was based on an increasing percentage of the Federal rate with a corresponding decrease in the percentage of the LTCH PPS payment that is based on reasonable cost concepts, unless an LTCH made a one-time election to be paid based on 100 percent of the Federal rate. Beginning with LTCHs’ cost reporting periods beginning on or after October 1, 2006, total LTCH PPS payments are based on 100 percent of the Federal rate.

In addition, in the August 30, 2002 final rule, we presented an in-depth discussion of the LTCH PPS, including the patient classification system, relative weights, payment rates, additional payments, and the budget neutrality requirements mandated by section 123 of the BBRA. The same final rule that established regulations for the LTCH PPS under 42 CFR part 412, subpart O, also contained LTCH provisions related to covered inpatient services, limitation on charges to beneficiaries, medical review requirements, furnishing of inpatient hospital services directly or under arrangement, and reporting and recordkeeping requirements. We refer readers to the August 30, 2002 final rule for a comprehensive discussion of the research and data that supported the establishment of the LTCH PPS (67 FR 55954).

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623), we implemented the provisions of the Pathway for Sustainable Growth Rate (SGR) Reform Act of 2013 (Pub. L. 113–67), which mandated the application of the “site neutral” payment rate under the LTCH PPS for discharges that do not meet the statutory criteria for exclusion beginning in FY 2016. For cost reporting periods beginning on or after October 1, 2015, discharges that do not meet certain statutory criteria for exclusion are paid based on the site neutral payment rate. Discharges that do meet the statutory criteria continue to receive payment based on the LTCH PPS standard Federal payment rate. For more information on the statutory requirements of the Pathway for SGR Reform Act of 2013, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623).

Section 231 of Consolidated Appropriations Act, 2016 (Pub. L. 114–113) provides for a temporary exception to the application of the site neutral payment rate for certain discharges representing severe wound care cases from specific LTCHs. We refer readers to the interim final rule with comment period (IFC) published in the Federal Register (which we will refer to as the April 21, 2016 IFC for the remainder of this preamble) implementing this provision (81 FR 23428). We are responding to public comments and finalizing the provisions of the April 21, 2016 IFC implementing this provision in section VII.A.3. of this final rule.

We received several comments that were outside the scope of the proposed rule requesting modifications to our existing regulations. We appreciate the commenters’ feedback, and we will take these comments into consideration as we contemplate future revisions to the LTCH PPS that we would make through the notice-and-comment rulemaking process.

2. Criteria for Classification as an LTCH
   a. Classification as an LTCH

   Under the regulations at §412.23(e)(1), to qualify to be paid under the LTCH PPS, a hospital must have a provider agreement with Medicare. Furthermore, §412.23(e)(2)(i), which implements section 1886(d)(1)(B)(iv)(I) of the Act, requires that a hospital have an average Medicare inpatient length of stay of greater than 25 days to be paid under the LTCH PPS. Alternatively, §412.23(e)(2)(ii) states that, for cost reporting periods beginning on or after August 5, 1997, a hospital that was first excluded from the PPS in 1986 and can demonstrate that at least 80 percent of its annual Medicare inpatient discharges in the 12-month cost reporting period ending in FY 1997 have a principal diagnosis that reflects a finding of neoplastic disease must have an average inpatient length of stay for all patients, including both Medicare and non-Medicare inpatients, of greater than 20 days (referred to as “subclass II” LTCHs).

   b. Hospitals Excluded From the LTCH PPS

   The following hospitals are paid under special payment provisions, as described in §412.22(c) and, therefore, are not subject to the LTCH PPS rules:
   • Veterans Administration hospitals.
   • Hospitals that are reimbursed under State cost control systems approved under 42 CFR part 403.
   • Hospitals that are reimbursed in accordance with demonstration projects authorized under section 402(a) of the Social Security Amendments of 1967 (Pub. L. 90–248) (42 U.S.C. 1395b–1) or section 222(a) of the Social Security Amendments of 1972 (Pub. L. 92–603) (42 U.S.C. 1395b–1 (note)) (Statewide all-payer systems, subject to the rate-of-increase test at section 1814(b) of the Act).
   • Nonparticipating hospitals furnishing emergency services to Medicare beneficiaries.

3. Limitation on Charges to Beneficiaries

   In the August 30, 2002 final rule, we presented an in-depth discussion of beneficiary liability under the LTCH PPS (67 FR 55974 through 55975). This discussion was further clarified in the FY 2005 LTCH PPS final rule (69 FR 25676). In keeping with those discussions, if the Medicare payment to the LTCH is the full LTC–DRG payment amount, consistent with other established hospital prospective payment systems, §412.507 currently provides that an LTCH may not bill a Medicare beneficiary for more than the deductible and coinsurance amounts as specified under §§409.82, 409.83, and 409.87 and for items and services specified under §489.30(a). However, under the LTCH PPS, Medicare will only pay for days for which the beneficiary has coverage until the short-stay outlier (SSO) threshold is exceeded. If the Medicare payment was for a SSO case (§412.529), and that payment was less than the full LTC–DRG payment amount because the beneficiary had insufficient remaining Medicare days, the LTCH is currently also permitted to charge the beneficiary for services delivered on those uncovered days (§412.507). In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49623), we amended our regulations to limit the charges that may be imposed on beneficiaries whose discharges are paid at the site neutral payment rate under the LTCH PPS.

   In section VII.G. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25173), we proposed to amend the existing regulations relating to the limitation on charges to address...
beneficiary charges for LTCH services provided by subclause (II) LTCHs as part of our realignment of the payment adjustment for subclause II LTCHs under § 412.526. We also proposed to amend the regulations under §412.507 to clarify our existing policy that blended payments made to an LTCH during its transitional period (that is, payment for discharges occurring in cost reporting periods beginning in FY 2016 or 2017) are considered to be a site neutral payment rate payment.

We note that, as discussed in section VII.C. of the preamble of this final rule, we did not receive any public comments in response to these proposals and are finalizing them as proposed, without modification.

4. Administrative Simplification Compliance Act (ASCA) and Health Insurance Portability and Accountability Act (HIPAA) Compliance

Claims submitted to Medicare must comply with both the Administrative Simplification Compliance Act (ASCA) (Pub. L. 107–105), and the Health Insurance Portability and Accountability Act of 1996 (HIPAA) (Pub. L. 104–191). Section 3 of the ASCA requires that the Medicare Program deny payment under Part A or Part B for any expenses incurred for items or services for which a claim is submitted other than in an electronic form specified by the Secretary. Section 1862(b) of the Act (as added by section 3(a) of the ASCA) provides that the Secretary shall waive such denial in two specific types of cases and may also waive such denial in such unusual cases as the Secretary finds appropriate (68 FR 48805). Section 3 of the ASCA operates in the context of the HIPAA regulations, which include, among other provisions, the transactions and code sets standards requirements codified under 45 CFR parts 160 and 162 (generally known as the Transactions Rule). The Transactions Rule requires covered entities, including covered health care providers, to conduct certain electronic health care transactions according to the applicable transactions and code sets standards.

The Department of Health and Human Services (HHS) has a number of initiatives designed to encourage and support the adoption of health information technology (health IT) and promote nationwide health information exchange to improve health care. The Office of the National Coordinator for Health Information Technology (ONC) leads interagency collaboration with other agencies, including CMS and the Office of the Assistant Secretary for Planning and Evaluation (ASPE). Through a number of activities, including several open government initiatives, HHS is promoting the adoption of health IT products, including electronic health record (EHR) technology certified under the ONC Health IT Certification Program (https://www.healthit.gov/policy-researchers-implementers/2015-edition-final-rule) developed to support secure, interoperable, health information exchange. We believe that the use of certified EHRs by LTCHs (and other types of providers that are ineligible for the Medicare and Medicaid EHR Incentive Programs) can effectively and efficiently help providers improve internal care delivery practices, support the exchange of important information across care partners and during transitions of care, and enable the reporting of electronically specified clinical quality measures (eCQMs) (as described elsewhere in this proposed rule). In 2015, ONC released a document entitled “Connecting Health and Care for the Nation: A Shared Nationwide Interoperability Roadmap” (available at: https://www.healthit.gov/sites/default/files/hie-interoperability/nationwide-interoperability-roadmap-final-version-1.0.pdf). In the near term, the Roadmap focuses on actions that will enable individuals and providers across the care continuum to send, receive, find and use a common set of electronic clinical information at the nationwide level by the end of 2017. The Roadmap’s goals also align with the Improving Medicare Post-Acute Care Transformation Act of 2014 (Pub. L. 113–185) (IMPACT Act), which requires assessment data to be standardized and interoperable to allow for exchange of the data. Moreover, the vision described in the Roadmap significantly expands the types of electronic health information, information sources, and information users well beyond clinical information derived from EHRs. The Roadmap identifies four critical pathways that health IT stakeholders should focus on now in order to create a foundation for long-term success: (1) Improve technical standards and implementation guidance for priority data domains and associated elements; (2) rapidly shift and align Federal, State, and commercial payment policies from fee-for-service to value-based models to stimulate the demand for interoperability; (3) clarify and align Federal and State privacy and security requirements that enable interoperability; (4) align and promote the use of consistent policies and business practices that support interoperability and address those that impede interoperability, in coordination with stakeholders. To support of the goals of the Roadmap, ONC released the 2016 Interoperability Standards Advisory (ISA) (available at: https://www.healthit.gov/sites/default/files/2016-interoperability-standards-advisory-final-508.pdf), which suggests the best available standards and implementation specifications for health IT, terminology, content/structure, and services to enable interoperability. The ISA also includes emerging standards to enable priority health information exchange functions. Providers, payers, and vendors are encouraged to take these “best available standards” into account as they implement interoperable health information exchange across the continuum of care. A Draft 2017 Interoperability Standards Advisory will be published this summer, and will have a 60-day public comment period. The Final Interoperability Standards Advisory will be published in December 2016.

B. Modifications to the Application of the Site Neutral Payment Rate (§ 412.522)

1. Background

Section 1206 of Pathway for SGR Reform Act (Pub. L. 113–57) mandated significant changes to the LTCH PPS beginning with LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015. Specifically, section 1206 required the establishment of a site neutral payment rate (as an alternative to the LTCH PPS standard Federal payment rate) for Medicare inpatient discharges from an LTCH that fails to meet certain statutorily defined criteria. Discharges that meet the statutory criteria for exclusion from the site neutral payment rate continue to be paid based on the LTCH PPS standard Federal payment rate. Discharges that do not meet the statutory criteria for exclusion are paid based on the site neutral payment rate. We implemented the application of the site neutral payment rate in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623) and codified the requirements in the regulations at 42 CFR 412.522. The criteria for exclusion from the site neutral payment rate specified under section 1886(m)(6)(A)(ii) of the Act and as implemented at §412.522(b) are as follows: (1) The discharge from the LTCH does not have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation; (2) admission to the LTCH was immediately preceded by discharge...
from a subsection (d) hospital; and (3) the immediately preceding stay in a subsection (d) hospital included at least 3 days in an intensive care unit (ICU) (referred to as the ICU criterion) or the discharge from the LTCH is assigned to an MS–LTCH–DRG based on the patient’s receipt of ventilator services of at least 96 hours (referred to as the ventilator criterion). (We note that, for the remainder of this section of the preamble, the phrase “LTCH PPS standard Federal payment rate case” refers to an LTCH PPS case that meets the criteria for exclusion from the site neutral payment rate as specified under § 412.522(a)(2), and the phrase “site neutral payment rate case” refers to an LTCH PPS case that does not meet the statutory patient-level criteria as specified under § 412.522(a)(1) and, therefore, is paid the applicable site neutral payment rate.)

In response to the proposed rule, we received several comments related to the specific mechanics of the site neutral payment rate. However, because we did not make any proposals concerning the mechanics of the site neutral payment rate in the proposed rule, we consider these comments to be outside the scope of the proposed rule. We will take these comments under consideration for future rulemaking and provide subregulatory guidance as necessary and appropriate.

2. Technical Correction of Definition of “Subsection (d) Hospital” for the Site Neutral Payment Rate (§ 412.503)

In the FY 2016 IPPS/LTCH PPS final rule, we implemented section 1206(a) of Public Law 113–67, which established the new dual payment rate structure under the LTCH PPS that began with LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2015. Section 1206(a) required the establishment of a site neutral payment rate (as an alternate to the LTCH PPS standard Federal payment rate) under the LTCH PPS for Medicare inpatient LTCH discharges that fail to meet certain statutorily defined criteria for exclusion. Discharges that meet the statutory criteria for exclusion from the site neutral payment rate continue to be paid based on the LTCH PPS standard Federal payment rate. Discharges that do not meet the statutory criteria for exclusion are paid based on the new site neutral payment rate. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623), we codified the requirements for the application of the site neutral payment rate under the LTCH PPS under the regulations at § 412.522. The statutory criteria for exclusion from the site neutral payment rate include a criterion that requires that the admission to the LTCH was immediately preceded by discharge from a “subsection (d) hospital.” To implement this criterion for purposes of the application of the site neutral payment rate under § 412.522, we added a definition of a “subsection (d) hospital” under § 412.503 of the regulations. However, we made an inadvertent cross-reference error under § 412.503 by referencing “§ 412.526” (payment provisions regarding subclause (II) LTCH) instead of referencing “§ 412.522” (payment provisions regarding the site neutral payment rate) (80 FR 49767). That is, currently § 412.503 specifies that a subsection (d) hospital means “for purposes of § 412.526,” when the language should have read “for purposes of § 412.522.”

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25144), we proposed to revise § 412.503 to correct this cross-reference error.

Comment: Several commenters supported our proposed technical correction of the definition of a “subsection (d) hospital” in § 412.503. Some commenters further requested that CMS make additional changes, for example, including specific categories of hospitals in addition to hospitals paid under the IPPS, which meet the statutory and regulatory definition of a “subsection (d) hospital.” to this definition in order to ensure that all hospitals meeting the regulatory and statutory definition of a “subsection (d) hospital.”

determination for purposes of the LTCH PPS. Other commenters requested that CMS make similar changes to a subregulatory transmittal related to this definition.

Response: We appreciate the commenters’ support for our proposed technical correction. We believe that our regulations are sufficiently clear to ensure that all hospitals meeting the statutory definition of a “subsection (d) hospital.” are treated appropriately for purposes of the LTCH PPS. Despite the fact that certain categories of hospitals are not expressly mentioned in our regulatory definition and that our regulatory definition of a “subsection (d) hospital.” in § 412.503, as corrected, is fully consistent with the statutory definition. However, we will take into consideration the commenters’ requests as we review and amend, as appropriate, our subregulatory guidance on this issue in order to ensure that we appropriately apply the regulatory and statutory definition of a “subsection (d) hospital.”

exclusion from the LTCH PPS structure at § 412.522.

3. Finalization of Interim Final Rule With Comment Period: Temporary Exception to the Site Neutral Payment Rate Under the LTCH PPS for Certain Severe Wound Discharges From Certain LTCHs

In the interim final rule with comment period (IFC) that appeared in the Federal Register on April 21, 2016 (81 FR 23428 through 23438) (referred to as the “April 21, 2016 IFC” for the remainder of this section), we implemented the provisions of section 231 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) and amended our regulations at 42 CFR 412.522 to reflect those policies. Section 231 of Public Law 114–113 amended section 1886(m)(6) of the Act by revising subparagraph (A)(i) and adding new subparagraph (E), which established a temporary exception to the site neutral payment rate for certain severe wound care discharges occurring prior to January 1, 2017, from LTCHs identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997 that are located in a rural area (as defined in section 1886(d)(2)(D) of the Act) or treated as being so located pursuant to section 1886(d)(8)(E).

Because the statute contained no effective date and required rulemaking to implement, we determined that the issuance of an IFC was the most appropriate mechanism to use to ensure that the affected LTCHs received the longest period of relief under the statute.

In this final rule, we summarize the provisions of the April 21, 2016 IFC relating to the temporary exception to the site neutral payment rate for certain severe wound care discharges from certain LTCHs, summarize the public comments received, present our responses to those public comments, and state the final policies, which reflect limited modifications of the policies set forth in the April 21, 2016 IFC. However, as we did not receive any public comments on our implementing regulation text, and as the limited modifications of our policies in response to public comments do not necessitate any changes to the implementing regulation text, we are finalizing those regulatory provisions without further discussion or modification.
b. Interpretation of the Phrase 
"Identified by the Amendment Made by Section 4417(a) of the Balanced Budget Act of 1997"

As discussed in the April 21, 2016 IFC (81 FR 23426), the phrase “identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997” has been interpreted by CMS to mean hospitals within hospitals (HwHs) that were participating in Medicare, but excluded from the hospital IPPS on or before September 30, 1995 (that is, hospitals which are described under §412.23(e)(2)(i)) that meet the criteria of §412.22(f) (81 FR 23430 through 23432).

As further discussed in the April 21, 2016 IFC, §412.22(f) generally requires that, in order to have grandfathered status, an HwH must continue to operate under the same terms and conditions, including, but not limited to, the number of beds. A limited exception to this general policy allowed eligible hospitals to increase beds between October 1, 1995, and September 30, 2003, without loss of their grandfathered status. A second exception allows grandfathered HwHs to increase square footage or decrease the number of beds for cost reporting periods beginning on or after October 1, 2006, while still retaining grandfathered status.

As the phrase “identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997” had already been interpreted in this manner, the April 21, 2016 IFC adopted the same meaning of the phrase for purposes of implementing section 231 of Public Law 114–113. For additional information on hospitals “identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997,” we refer readers to the April 21, 2016 IFC (81 FR 23431 through 23432).

Comment: While we did not receive any public comments in response to our interpretation “identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997” set forth in the April 21, 2016 IFC, one commenter requested clarification as to whether certain hospitals would be considered “identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997” (that is, a grandfathered HwH) for the purposes of the 25-percent threshold policy (discussed in section VII.F. of the preamble of this final rule). Specifically the commenter asked whether: (1) An LTCH which changed host hospitals, (2) an LTCH which is no longer co-located, (3) an LTCH which did not increase overall beds, but moved some to a remote location, and (4) an LTCH which did not increase overall beds, but moved some to a satellite location would be considered a grandfathered HwH. The commenter requested CMS to consider all of these hospitals “grandfathered HwHs” so long as they did not increase their overall bed capacity.

Response: We appreciate the commenter’s support for excluding LTCHs which expanded bed capacity from grandfathered HwHs that are eligible for the temporary exception, consistent with the April 21, 2016 IFC. However, as we explained in that IFC, none of the hospitals described by the commenter would be considered grandfathered HwHs because none of those hospitals would meet the requirements of §412.22(f) (requiring, with limited exceptions, that the LTCH continue to operate under the same terms and conditions). By changing host hospitals, the hospital described in scenario (1) would have changed the terms and conditions under which it operated and, therefore, does not meet the requirements of §412.22(f). Furthermore, the LTCHs described in scenarios (2), (3), and (4) would not meet the definition of an “HwH” LTCH as the LTCHs in scenario (2) would become a freestanding LTCH, and LTCH configurations in scenarios (3) and (4) would be satellite LTCH facilities, none of which are HwHs. As the requirements of §412.22(f) can only be met by HwHs, and the LTCH configurations in scenarios (2), (3) and (4) are not HwHs they are not grandfathered HwHs.

After consideration of the public comments we received, we are finalizing our interpretation of the phrase “identified by the amendment made by section 4417(a) of the Balanced Budget Act of 1997” as set forth in the April 21, 2016 IFC, without modification.

c. Meaning of the Phrase “Located in a Rural Area or Treated as Being So Located”

Section 1886(m)(6)(E)(ii)(I)(bb) of the Act, as added by section 231 of Public Law 114–113, limits application of the temporary exception to LTCHs that are located in a rural area (as defined in subsection (d)(2)(D)) or “treated as being so located” pursuant to subsection (d)(6)(E). As discussed in the April 21, 2016 IFC, section 1886(d)(2)(D) of the Act establishes a geographic definition of “rural” based on location outside of OMB’s MSAs. This statutory definition of rural area is consistent with the existing definition of rural area under the LTCH IPPS set forth at §412.503. Therefore, in the April 21, 2016 IFC (81 FR 23432), we established that “located
in a rural area” in section 1886(m)(6)(E)(i)(II)(bb) of the Act refers to LTCHs which are currently located in a rural area as defined under § 412.503 (81 FR 23432). As discussed in the April 21, 2016 IFC, the phrase “treated as being so located pursuant to subsection (d)(8)(E)” required interpretation as section 1886(d)(8)(E) of the Act only applies to subsection (d) hospitals, and LTCHs, by definition at section 1886(b)(1) of the Act, are not subsection (d) hospitals.

Section 1886(d)(8)(B) of the Act, as applied to urban subsection (d) hospitals is implemented at § 412.103, and establishes the procedures by which an urban PPS hospital may apply for reclassification as a rural hospital, the process for reviewing such applications, and the conditions under which applications will be approved (81 FR 23432). To apply these policies and procedures to LTCHs in the context of the temporary exception, we revised our LTCH regulations at § 412.522(b)(2) to—

• Limit reclassification applications under the LTCH PPS to grandfathered HwHs.
  • Limit the application and effect of any reclassifications granted to grandfathered HwHs to the eligibility determination for the temporary exception, and
  • Adopt the existing rural PPS reclassification process and procedures as stated under § 412.103 for the LTCH PPS.

Furthermore, in adopting these policies and procedures, we highlighted that a reclassified grandfathered HwH LTCH will not be treated as rural for any other reason, including, but not limited to, the 25-percent threshold policy and wage index, and that any rural treatment under these LTCH PPS policies and procedures will expire at the same time as the temporary exception (that is, December 31, 2016).

Comment: MedPAC opposed allowing LTCHs to seek rural “reclassification” based on the Commission’s general opposition to the current wage index system.

Response: As we explained in the April 21, 2016 IFC, we were required to give meaning to an LTCH being “treated as being so located” under section 1886(d)(8)(E) of the Act. We achieved this by allowing limited reclassification in the LTCH PPS context, by having it apply solely for the purpose of eligibility for the temporary exception established under section 231 of Public Law 114–113. As implemented, we believe that our policy had no effect on the MedPAC’s wage index related reclassification concerns. It merely allows eligible LTCHs to reclassify as rural for the purposes of qualifying for the temporary exception to the site neutral payment rate under the LTCH PPS for certain severe wound care discharges from certain LTCHs. It is not applicable in the LTCH PPS for any other purpose, including but not limited to, the 25-percent threshold policy and the wage index, and such treatment is effective only until the expiration of the temporary exception (that is, December 31, 2016).

Furthermore, as MedPAC offered no alternative that would give meaning to the phrase “treated as being so located”, under section 1886(d)(8)(E) of the Act, we continue to believe our interpretation to be the most appropriate way to interpret “treated as being so located” in this context.

Comment: One commenter supported our interpretation of “treated as being so located” under section 1886(d)(8)(E) of the Act in relation to section 231 of Public Law 114–113. Other commenters requested that CMS expand the scope of the temporary exception to either allow additional hospitals or discharges to be excluded from the site neutral payment rate.

Response: We appreciate the commenter’s support for our implementation of the phrase “treated as being so located” under section 1886(d)(8)(E) of the Act in relation to section 231 of Public Law 114–113. In response to the commenters who requested expansion of the temporary exception beyond the LTCHs and discharges defined in section 231 of Public Law 114–113, as we stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49602), we do not have the authority to pay LTCH discharges that fail to meet the patient-level criteria for payment at the LTCH PPS standard Federal payment rate at a rate other than the site neutral payment rate unless the discharge meets the eligibility criteria for the temporary exception for certain severe wound discharges. Therefore, we lack the authority to implement additional exceptions as the commenters suggested.

After consideration of the public comments we received, we are finalizing our implementation of the meaning of the phrases “located in a rural area” under section 1886(d)(2)(D) of the Act and “treated as being so located” under section 1886(d)(8)(E) of the Act, without change.

d. Interpretation of the Phrase “Individual Discharged Has a Severe Wound”

Section 1886(m)(6)(E)(ii) of the Act, as added by section 231 of Public Law 114–113, provides that the temporary exception for certain discharges from the application of the payment policy for site neutral payment rate cases discharged from certain LTCHs is applicable when the “individual discharged has a severe wound.” We stated in the April 21, 2016 IFC (81 FR 23433) that the use of the present tense in regard to the word “has” when addressing a severe wound is internally inconsistent. A strict and literal read of the statute would require temporary exception from the application of the payment policies for site neutral payment rate cases only representing an individual who, presently, “has a severe wound” at the time of his or her discharge from the LTCH and, therefore, payments for cases representing patients whose wounds are either healed or no longer severe at the time of discharge would be made under our existing regulations (that is, the LTCH would receive payment for the case discharge at the site neutral payment rate unless the discharge met the existing exclusion criteria). As we stated in the April 21, 2016 IFC (81 FR 23433), we interpreted this phrase in the provision of the statute to include discharges for cases representing patients who received treatment for a “severe wound” at the LTCH, regardless of whether the wound was present and severe at the time of discharge.

Comment: One commenter supported the interpretation.

Response: We appreciate the commenter’s support and are finalizing our interpretation of a patient who “has” a severe wound as a patient who “had” a severe wound, without modification.

e. Statutory Definition of the Term “Severe Wound”

Section 1886(m)(6)(E)(ii) of the Act, as added by section 231 of Public Law 114–113, defines a “severe wound” as a Stage 3 wound, Stage 4 wound, unstageable wound, non-healing surgical wound, infected wound, fistula, osteomyelitis or wound with morbid obesity as identified in the claim from the LTCH. For purposes of implementing this statutory definition in the April 21, 2016 IFC (81 FR 23433), after consultation with our clinical advisors, we interpreted the term “wound” as: An injury, usually involving division of tissue or rupture of the integument or mucous membrane with exposure to the external environment. In that same IFC, we also established that the phrase “as identified in the claim” to mean as identified based on the ICD-10–CM diagnosis codes reported on the claim where—
The ICD–10–CM diagnosis codes contain sufficient specificity for this purpose; or through the use of a payer-specific condition code where the ICD–10–CM diagnosis codes lack sufficient specificity for this purpose.

For six of the eight statutory categories included in the statutory definition of “severe wound” (Stage 3 wound, Stage 4 wound, unstageable wound, non-healing surgical wound, fistula, and osteomyelitis), we stated that we believe these types of severe wounds can be identified through the use of specific ICD–10–CM diagnosis codes, which are reported on the LTCH claim. We indicated that the list of ICD–10–CM diagnosis codes that we will use to identify severe wounds for this group of six statutory categories can be found in the table entitled “Severe Wound Diagnosis Codes by Category for Implementation of Section 231 of Public Law 114–113” posted on the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html under the regulation “CMS–1664–IFC.”

Our clinical advisors compiled this list of codes by reviewing ICD–10–CM diagnosis codes for the statutorily enumerated categories of severe wounds and selecting the codes that satisfied our definition of a “wound.” We noted in the April 21, 2016 IFC that under our definition of a wound, the ICD–10–CM diagnosis codes used to identify severe wounds in the osteomyelitis category are also part of the ICD–10–CM diagnosis codes used to identify severe wounds in the fistula category and, therefore, no separate identification of ICD–10–CM diagnosis codes for osteomyelitis is necessary (81 FR 23433).

The remaining two statutory categories included in the definition of “severe wound” (infected wound and wound with morbid obesity), as stated in the April 21, 2016 IFC, lack ICD–10–CM diagnosis codes with sufficient specificity to identify the presence of a “severe wound.” This is a result of the number of codes that are used to identify wounds and infections being too numerous to identify and compile such an exhaustive list. We stated that because we cannot specify ICD–10 diagnosis codes to appropriately identify severe wounds classified in these categories, for the purposes of this provision, in the April 21, 2016 IFC, we defined a “wound with morbid obesity” as a wound in those with morbid obesity that require complex care including local wound care occurring multiple times a day, and an “infected wound” as a wound with infection requiring complex, continuing care including local wound care occurring multiple times a day. In order to operationalize these definitions in the absence of ICD–10–CM diagnosis codes, we utilize payer-only condition codes on the claim for processing (81 FR 23433).

As we stated we would in the April 21, 2016 IFC, we issued additional operational instructions regarding the use of the designated payer-only condition code in Change Request 9599, Transmittals 1654 and 1675. (We note that Change Request 9599 was originally issued on April 29, 2015 as Transmittal 1654, and reissued on June 16, 2016, as Transmittal 1675 to correct certain technical errors.) We note, as we did in the April 21, 2016 IFC, that while the use of this payer-only condition code is the most expedient operational method we have of implementing the statutory definition provided by the provisions of section 231 of Public Law 114–113 in the timeframe allowed, the continued use of a payer-only condition code may not be feasible if the scope of this provision is ever expanded. Given the current limitations on the number of LTCHs that meet the requirements to qualify for the exception granted by this provision under the statutory criteria (that is, grandfathered HwHs that are located in a rural area or reclassify as rural, as previously described in this section), the ability to identify the other statutory categories of severe wounds, and the limited timeframe of the exception’s duration, we stated that we expected the number of claims necessitating the use of this payer-only condition code will be minimal.

Comment: Several commenters objected to the use of “including local wound care occurring multiple times a day” in the definitions of “infected wound” and “wound with morbid obesity.” These commenters stated that the best clinical practices do not necessarily call for local wound care multiple times a day, and, although severe, in those instances, medically appropriate care for what they believed were “severe” wounds would not be considered for a “severe wound” under the provisions implementing section 231 of Public Law 114–113. For example, some commenters construed our “including local wound care occurring multiple times a day” to require multiple dressing changes as a necessary criterion under these categories, and expressed concern that the use of “including local wound care occurring multiple times a day” would exclude discharges that did not involve dressing changes from the definition of a severe wound (and from the exclusion from the site neutral payment rate).

Response: Our use of the phrase “including local wound care occurring multiple times a day” was intended to be illustrative, not demonstrative. In other words, it is our intent that “local wound care occurring multiple times a day” is an example of a wound with infection or a wound with morbid obesity “requiring complex, continuing care.” To address commenters’ concerns and alleviate further confusion, we are modifying the definitions of “infected wound” and “wound with morbid obesity” included in the April 21, 2016 IFC as follows. For the purposes of determining whether a discharge included treatment for a severe wound eligible for the temporary exception provided by section 231 of Public Law 114–113, in this final rule, we are establishing that an “infected wound” is “a wound with infection requiring complex, continuing care” and a “wound with morbid obesity” is “a wound in those with morbid obesity that requires complex, continuing care.” Local wound care occurring multiple times a day (which may involve dressing changes) is one way to demonstrate that a wound requires “complex, continuing care,” but not the only way.

Comment: Several commenters submitted requests for the inclusion of additional ICD–10 diagnosis codes that they believe qualify as descriptions of severe wounds under the categories of Stage 3 wounds, Stage 4 wounds, unstageable wounds, non-healing surgical wounds, fistula, and osteomyelitis, and, as such, should be added to the list of codes presumptively considered as “severe wounds” in our ICD–10 diagnosis code-based automated claims processing implementation approach (that is, they asked us to add the codes they identified to the table of “Severe Wound Diagnosis Codes by Category for Implementation of Section 231 of Pub. L. 114–113” posted on the CMS Web site). Several commenters also asserted that the ICD–10 diagnosis codes for necrotizing fasciitis and gangrene should be presumptively considered as “severe wounds” under the category of an “infected wound” (and, therefore, be added to the table), and should not require the use of the payer-only condition codes to identify such discharges as meeting the exception from payment at the site neutral payment rate.

Response: We reviewed all of the ICD–10 diagnosis codes requested by commenters and found that that some of those codes do meet the definition of a severe wound set forth in the April 21, 2016 IFC. These codes will be added to the final table, which will be posted on
the CMS Web site. Other suggested codes, did not meet the definition of a “severe wound,” and will not be added to the final table.

For example, we disagree with commenters’ assertions regarding ICD–10 diagnosis codes for necrotizing fasciitis and gangrene. While we acknowledge that necrotizing fasciitis and gangrene may be serious enough to qualify as a “severe wound” in some cases, the ICD–10 diagnosis codes for these types of infections do not capture the severity of the wound sufficiently enough to ensure that every use of the code represents a case which would meet our definition of an “infected wound” under our implementation of the provisions of section 231 of Public Law 114–113. Therefore, we conclude that the suggested codes for necrotizing fasciitis and gangrene lack sufficient clinical specificity to ensure that their every use would be for a wound which meets our definition (which would be required to merit prescriptive application of the statutory exception for certain severe wounds). We will continue to apply the payer-only condition code in instances in which wounds associated with necrotizing fasciitis and gangrene (or other infection) do qualify as severe wounds under the category of “infected wounds.”

Comment: One commenter noted that, under the ICD–10–CM classification system, there are coding conventions that require specific sequencing of codes based on instructional notes such as “code the additional code.” According to the commenter, these diagnosis codes describe conditions that should be reported as the principal diagnosis, followed by the code identifying a severe wound. This commenter recommended the addition of certain ICD–10 codes to account for these coding conventions.

Response: We appreciate the commenter’s review of the list of ICD–10–CM diagnosis codes used to identify severe wounds for purposes of implementing section 231 of Public Law 114–113. While coding guidance is outside the scope of this final rule, we note that we collaborate with the American Hospital Association through the Coding Clinic for ICD–10–CM and ICD–10–PCS to promote proper coding. With that said, our implementation of the exception for certain “severe wounds” provided by the provisions of section 231 of Public Law 114–113 only requires the presence of an ICD–10 code on the claim. The sequence of the diagnosis codes is not relevant for purposes of the provision. For these reasons, we are not adopting the commenter’s recommendation, but we will continue to encourage LTCHs to follow official ICD–10–CM/PCS Coding Guidelines and conventions, which can be found on the Web sites at: http://www.cdc.gov/nchs/icd10cm.htm and http://www.cms.gov/medicare/coding/icd10/.

Comment: One commenter believed that CMS was granted no discretion with regard to what constitutes a “severe wound” under the statute because the term was defined by the statute. The commenter requested that CMS add every ICD–10 code that identified any of the categories of wounds in our table.

Response: While we agree that the term “severe wound” was defined in the statute, that fact did not obviate the need to interpret the terms used by the statute to define “severe wound.” While the statute enumerated the universe of categories into which severe wounds would be classified, it did not define how they should be “identified in the claim.” Nor did the statute define what a “wound” is.

Thus, in order to implement the statute, we found it necessary to define “wound,” and to give meaning to Congress’ use of the phrase “severe wound” in the context of the named categories. “Infected wound” and “wound with morbid obesity” cannot be interpreted in the abstract—they must be read in context, and the context is a provision granting exceptions to certain “severe wound” discharges. As we stated in the April 21, 2016 IFC, in order to do that, we implemented a definition of a “wound” (as, logically, there must be a wound in order for there to be a severe wound) and that definition must be distinct from the definition of a “severe wound” lest the word “severe” be rendered superfluous (meaning that we must define a “wound” in such a way as to distinguish between “severe” wounds, which are to be excluded from the site neutral payment rate, and “nonsevere” wounds, which are not to be excluded from the site neutral payment rate). We continue to believe that interpreting the statute so as to require that each of the enumerated categories require a demonstration of the condition being a “severe” wound is a reasonable interpretation of the statute. This is particularly important for the infected wounds and wounds with morbid obesity, as these categories lack any clinically standard definition, and represent a gambit of clinical circumstances, from a paper cut on a patient with morbid obesity or an infected that meets the definition of a “wound,” but neither of which would be expected to require complex, continuing care” or would be labeled “severe”) to necrotizing fasciitis (which can represent a severe wound which requires complex, continuing care). Therefore, in developing the list of ICD–10 diagnosis codes for identifying, on the LTCH claim, Stage 3 wounds, Stage 4 wounds, unstageable wounds, non-healing surgical wounds, fistula, and osteomyelitis solely based on the presence of an ICD–10 diagnosis code, we include only such codes with sufficient clinical specificity to first, indicate the presence of a “wound,” and second, differentiate between severe and non-severe wounds, due to the statutory requirement that we determine what constitutes a “severe wound” as “identified in the claim” (that is, from information on the LTCH claim). As we are identifying infected wounds and wounds with morbid obesity through the use of a payer-only condition code, we established our regulatory definition of these categories so that all uses identify wounds which are severe. For these reasons, we disagree with the commenter and are not including every ICD–10 code, which could represent one of the statutory categories of wounds. To the extent that any code requested by any commenter was sufficiently specific so as to indicate a severe wound of the types listed, we have added it to our table.

Comment: Several commenters requested that CMS apply the temporary exception to all discharges where the claim includes a code for a body mass index (BMI) that indicates morbid obesity.

Response: As stated in the April 21, 2016 IFC, the mere presence of ICD–10–CM diagnosis codes for morbid obesity paired with a code for a wound does not provide any information on the severity of the wound; that is, ICD–10 diagnosis codes do not differentiate between a diagnosis that is a “severe” wound and a diagnosis that is a “nonsevere” wound. As such, we are not making any changes to our approach for identifying wounds with morbid obesity, and will continue to identify severe wounds in the category of “wounds with morbid obesity” solely through the use of the payer-only condition code as established in the April 21, 2016 IFC.

After consideration of the public comments we received, as discussed previously in this section, we are revising our definitions of an “infected wound” and a “wound with morbid obesity,” and including additional ICD–10 diagnosis codes to the listing that identifies codes that will be presumptively considered severe wounds for purposes of our automated
claims processing implementation approach. All other policies implementing the provisions of section 231 of Public Law 114–113 remain the same as implemented in the April 21, 2016 IFC, without modification.

g. Waived Proposed Rulemaking and Delay of Effective Date

In the April 21, 2016 IFC (81 FR 23435), we found notice-and-comment rulemaking and a delay in the effective date to be both unnecessary as well as impracticable and contrary to public interest. Section 231 of Public Law 114–113 required revision of the existing regulations to implement the LTCH wound care exception, thereby limiting any discretion we might otherwise have had to immediately implement the statutory mandate as a self-implementing statute. In addition, given the statutory expiration of the provisions of section 231 of Public Law 114–113 on January 1, 2016, we noted that the use of notice-and-comment rulemaking in the face of the congressionally imposed end date of the relief would have significantly limited the qualifying discharges to which the statute applies. We stated that by implementing and codifying the provisions of the statute through an IFC and subsequent final rule rather than full notice-and-comment rulemaking and waiving the usual 60-day delay of effective date requirement, we believed that our implementation of the waiver would ensure the maximum period of relief, consistent with our interpretation of the statute. We found, on these bases, that there was good cause to waive notice-and-comment rulemaking and the delay in effective date that would otherwise be required.

Comment: Several commenters requested that CMS make the effective date of the provision implemented in the April 21, 2016 IFC retroactive to January 1, 2016. One commenter stated that implementing the statute through an IFC is contrary to Congressional intent.

Response: As the statute did not contain an effective date and required rulemaking to implement, having a regulation with an effective date prior to the date of the rulemaking would require retroactive rulemaking. While we have the authority to engage in retroactive rulemaking, that authority is limited to situations where it is necessary to comply with a statutory requirement or for the public interest. Had the statute contained an effective date, we may have been required to perform retroactive rulemaking in order to comply with that requirement. However, as the statute did not contain an effective date, retroactive rulemaking was not required. Additionally, we do not believe that retroactive rulemaking is necessary for the public interest as, by implementing the statutory requirement through an IFC, we were able to provide a meaningful period of relief without engaging in retroactive rulemaking. With respect to the commenter’s statement regarding Congressional intent, we note that the commenter provided no evidence of our having violated the Congressional intent of this statutory provision. The materials cited by the commenter, while related to wound care, rural health, and/or the LTCH PPS, were not directly related to section 231 of Public Law 114–113, nor were they Congressionally authorized. In implementing section 231 of Public Law 114–113, we reviewed the legislative history and found nothing in that history that provides insight into Congress’ intent. Therefore, we believe that we are not required to engage in retroactive rulemaking in implementing section 231 of Public Law 114–113.

h. Collection of Information Requirements

Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information. Interested persons are invited to send comments regarding our burden estimates or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

However, in the April 21, 2016 IFC (81 FR 23435), we stated that we had requested an emergency review of the information collection referenced later in this section. In compliance with the requirement of section 3506(c)(2)(A) of the PRA, we submitted the following for emergency review to the Office of Management and Budget (OMB). We requested an emergency approval under 5 CFR 1320.13(a)(2)(i) of the implementing regulations of the PRA in order to implement the provisions of section 231 of Public Law 114–113 as expeditiously as possible. We stated that public harm was reasonably likely to ensue if the normal clearance procedures were followed because the approval of this information collection is essential to ensuring that otherwise qualifying grandfathered urban HWHs are not unduly delayed in attempting to obtain relief provided by the LTCH PPS. The commenter stated that the approval under 5 CFR 1320.13(a)(2)(i) of the implementing regulations of the PRA is necessary for the public interest as, by applying to be treated as rural before the temporary exception expires on December 31, 2016.

We stated in the April 21, 2016 IFC that, for the purposes of implementing subparagraph (E) of section 1886(m)(6) of the Act as provided by Public Law 114–113, we revised our regulations at § 124.522(b)(2)(ii)(B)(2) to utilize the same administrative mechanisms used in the existing rural reclassification process for urban subsection (d) hospitals under § 124.103, described later in this section. We also stated that we will allow grandfathered LTCH HWHs (previously defined in that IFC) to apply to their CMS regional office for treatment as being located in a rural area for the sole purpose of qualifying for this temporary exception from the application of the site neutral payment rate.

We stated in the April 21, 2016 IFC that, for urban subsection (d) hospitals, and now temporarily LTCHs, we implemented the rural reclassification provision in the regulations at § 124.103. In general, the provisions of § 124.103 provides that a hospital located in an urban area may be reclassified as a rural hospital if it submits an application in accordance with our established criteria. The hospital must also meet certain conditions, which include being located in a rural census tract of a MSA, or in an area designated by any law or regulation of the State as a rural area, or designated by any State law or regulation. Paragraph (b) of § 124.103 sets forth application
requirements for a hospital seeking reclassification as rural under that section, which includes a written application mailed to the CMS regional office that contains an explanation of how the hospital meets the condition that constitutes the request for reclassification, including data and documentation necessary to support the request. As provided in paragraphs (c) and (d) of §412.103, the CMS regional office reviews the application and notifies the hospital of its approval or disapproval of the request within 60 days of the filing date, and a hospital that satisfies any of the criteria set forth §412.103(a) is considered as being located in the rural area of the State in which the hospital is located as of that filing date.

We noted in the April 21, 2016 IFC that this policy only allows grandfathered LTCH HwHs to apply for this reclassification, and the rural treatment will only extend to this temporary exception for certain wound care discharges from the site neutral payment rate (meaning a grandfathered HwH LTCH will not be treated as rural for any other reason, including, but not limited to, the 25-percent threshold policy and wage index policies). We also noted that the any rural treatment under §412.103 for a grandfathered HwH LTCH expires at the same time as this temporary provision (that is, December 31, 2016).

In the April 21, 2016 IFC (81 FR 23436), we estimated that each application will require 2.5 hours of work from each LTCH (0.5 hours to fill out the application and 2 hours of recordkeeping). Based on the current information we had received from the MACs, out of the approximately 120 current LTCHs that existed in 1995, which is a necessary but not sufficient condition to be a grandfathered HWH, there are approximately 5 hospitals that currently meet the criteria of being a grandfathered HWH, and would not be precluded from submitting an application. We noted that as the MACs continue to update the list of grandfathered HWH that the number of potential applicants could increase. Because it is possible that the number of applicants could rise to 10 or more, in an abundance of caution, we treated this information collection as being subject to the PRA. Therefore, we estimated that the aggregate number of hours associated with this request across all currently estimated eligible hospitals will be 12.5 (2.5 hours per hospital for 5 hospitals). We estimated a casual clerical salary of $29 per hour (based on the “2015 Median usual weekly earnings (second quartile),

employed full time, Wage and salary workers, Management, professional, and related occupations” from the Current Population Survey, available at the Web site: http://www.bls.gov/webapps/legacy/cpswkbta4.htm plus 100 percent for fringe benefits ($58 per hour). Therefore, we estimated the total one-time costs associated with this request will be $725 (12.5 hours × $58 per hour).

In the April 21, 2016 IFC, we stated that written comments and recommendations from the public would be considered for this emergency information collection request if received by April 28, 2016. We requested OMB review and approval of this information collection request by May 5, 2016, with a 180-day approval period. We gave two access Web sites and a telephone number in the IFC where the public could obtain copies of a supporting statement and any related forms for the proposed collection(s).

We did not receive any public comments in this information collection request and, therefore, are finalizing it as it was set forth in the April 21, 2016 IFC, without modification. OMB approved the Emergency PRA package on May 9, 2016, for the aforementioned burden, which is under OMB control number 0938–0907.

i. Regulatory Impact Analysis

We have examined the impact of the April 21, 2016 IFC as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (January 18, 2011), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96–354), section 1102(b) of the Social Security Act, section 202 of the Unfunded Mandates Reform Act of 1995 (March 22, 1995, Pub. L. 104–4), Executive Order 13132 on Federalism (August 4, 1999) and the Congressional Review Act (5 U.S.C. 804(2)).

Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects ($100 million or more in any 1 year). In the April 21, 2106 IFC, we projected that two rural LTCHs would qualify for the temporary exception to the site neutral payment rate for certain LTCHs for certain discharges provided by section 231 of Public Law 114–113, based on the best data available at that time. We were not able to determine which, if any, LTCHs may be treated as rural in the future by applying and being approved for a reclassification as rural under the provisions of §412.103. We stated that, given that LTCHs are generally concentrated in more densely populated areas, we did not expect any LTCHs to qualify under §412.103. As such, as indicated in the April 21, 2016 IFC (81 FR 23436 through 23436), at that time, our projections related to the temporary exception to the site neutral payment rate for certain LTCHs for certain discharges provided by section 231 of Public Law 114–113, were limited to LTCHs that are geographically located in a rural area. Based on the most recent data for these two LTCHs, including the identification of FY 2014 LTCH discharges with a “severe wound,” we estimated the monetary impact of the IFC with respect to that LTCH PPS provision is approximately a $5 million increase in aggregate LTCH PPS payments had this statutory provision not been enacted. This estimate did not reach the economic threshold and this provision did not cause the IFC to be considered a major rule. At this time, we continue to estimate that the implementation of section 231 of Public Law 114–113 will result in approximately a $5 million increase in aggregate LTCH PPS payments had this statutory provision not been enacted, which does not reach the economic threshold and this provision did not cause the IFC to be considered a major rule.

The RFA also requires agencies to analyze options for regulatory relief of small entities if a rule has a significant impact on a substantial number of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small governmental jurisdictions. We estimate that most hospitals and most other providers and suppliers are small entities as that term is used in the RFA. The great majority of hospitals and most other health care providers and suppliers are small entities, either by being nonprofit organizations or by meeting the SBA definition of a small business (average revenues of less than $7.5 million to $38.5 million in any 1 year).
for health care providers, we refer readers to page 36 of the Table of Small Business Size Standards for NAIC 622 found on the SBA Web site at: https://www.sba.gov/sites/default/files/files/Size_Standards_Table.pdf.

For purposes of the RFA, all hospitals and other providers and suppliers are considered to be small entities. Individuals and States are not included in the definition of a small entity. We stated that we believe the provisions of the April 21, 2016 IFC may have an impact on some small entities, but for the reasons previously discussed in that IFC and reiterated above, we could not conclusively determine the number of such entities impacted. Because we lack data on individual hospital receipts, we stated in the April 21, 2016 IFC that we could not determine the number of small proprietary LTCHs. Therefore, we assumed that all LTCHs are considered small entities for the purpose of the RFA. MAGs are not considered to be small entities. Because we acknowledged that many of the potentially affected entities are small entities, we stated that the discussion in this section regarding potentially impacted hospitals constituted our regulatory flexibility analysis. In stating our final policies in this final rule, we continue to acknowledge that many of the potentially affected entities are small entities and, therefore, the discussion in this section regarding potentially impacted hospitals, constitute our regulatory flexibility analysis.

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside a metropolitan statistical area and has fewer than 100 beds. Section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98–21) designated hospitals in certain New England counties as belonging to the adjacent urban area. Therefore, for purposes of the IPPS and the LTCH PPS, we will continue to classify these hospitals as urban hospitals.

The provisions of section 231 of Public Law 114–113, for which we are setting forth in this final rule, by definition affect rural LTCHs that qualify, and will result in an increase in payment for those qualifying LTCHs’ discharges that meet the definition of a severe wound. However, as discussed in the April 21, 2016 IFC and as previously discussed in this section, based on the data currently available, we estimate there are only two LTCHs that currently meet the criteria. Therefore, we do not believe that the provisions of section 231 of Public Law 114–113 set forth in this final rule will have a significant impact on the operations of a substantial number of small rural LTCHs.

Section 202 of the Unfunded Mandates Reform Act of 1995 also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. In 2016, that threshold is approximately $146 million. The April 21, 2016 IFC did not, and this final rule will not, have any consequential effect on State, local, or tribal governments, nor will they affect private sector costs.

Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a final rule that imposes substantial direct requirement costs on state and local governments, preempts state law, or otherwise has Federalism implications. Because the IFC and this final rule do not impose any costs on State or local governments, the requirements of Executive Order 13132 are not applicable.

In accordance with the provisions of Executive Order 12866, the April 21, 2016 IFC and this final rule were reviewed by the Office of Management and Budget.

C. Medicare Severity Long-Term Care Diagnosis-Related Group (MS–LTC–DRG) Classifications and Relative Weights for FY 2017

1. Background

Section 123 of the BBRA required that the Secretary implement a PPS for LTCHs to replace the cost-based payment system under TEFRA. Section 307(b)(1) of the BIPA modified the requirements of section 123 of the BBRA by requiring that the Secretary examine the feasibility and the impact of basing payment under the LTCH PPS on the use of existing (or refined) hospital DRGs that have been modified to account for different resource use of LTCH patients.

When the LTCH PPS was implemented for cost reporting periods beginning on or after October 1, 2002, we adopted the same DRG patient classification system utilized at that time under the IPPS. As a component of the LTCH PPS, we refer to this patient classification system as the “long-term care diagnosis-related groups (LTC–DRGs).” Although the patient classification system used under both the LTCH PPS and the IPPS are the same, the relative weights are different. The established relative weight methodology and data used under the LTCH PPS result in relative weights under the LTCH PPS that reflect the differences in patient resource use of LTCH patients, consistent with section 123(a)(1) of the BBRA (Pub. L. 106–113).

As part of our efforts to better recognize severity of illness among patients, in the FY 2008 IPPS final rule with comment period (72 FR 47130), the MS–DRGs and the Medicare severity long-term care diagnosis-related groups (MS–LTC–DRGs) were adopted under the IPPS and the LTCH PPS, respectively, effective beginning October 1, 2007 (FY 2008). For a full description of the development, implementation, and rationale for the use of the MS–DRGs and MS–LTC–DRGs, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47141 through 47175 and 47277 through 47299). (We note that, in that same final rule, we revised the regulations at §412.503 to specify that for LTCH discharges occurring on or after October 1, 2007, when applying the provisions of 42 CFR part 412, subpart O applicable to LTCHs for policy descriptions and payment calculations, all references to LTC–DRGs were considered a reference to MS–LTC–DRGs. For the remainder of this section, we present the discussion in terms of the current MS–LTC–DRG patient classification system unless specifically referring to the previous LTC–DRG patient classification system that was in effect before October 1, 2007.)

The MS–DRGs adopted in FY 2008 represent an increase in the number of DRGs by 207 (that is, from 538 to 745) (72 FR 47171). The MS–DRG classification systems are updated annually. There are currently 758 MS–DRG groupings. For FY 2017, there will be 758 MS–DRG groupings based on the changes discussed in section ILF of the preamble of this final rule. Consistent with section 123 of the BBRA, as amended by section 307(b)(1) of the BIPA, and §412.515 of the regulations, we use information derived from LTCH PPS patient records to classify LTCH discharges into distinct MS–LTC–DRGs based on clinical characteristics and estimated resource needs. We then assign an appropriate weight to the MS–LTC–DRGs to account for the difference in resource use by patients exhibiting the case complexity and multiple

Federal Register / Vol. 81, No. 162 / Monday, August 22, 2016 / Rules and Regulations 57075

57075
medical problems characteristic of LTCHs.

In this section of the final rule, we provide a general summary of our existing methodology for determining the FY 2017 MS–LTC–DRG relative weights under the LTCH PPS.

As we proposed, in this final rule, in general, for FY 2017, we are using our existing methodology to determine the MS–LTC–DRG relative weights (as discussed in greater detail in section VII.C.3. of the preamble of this final rule). As we established when we implemented the dual rate LTCH PPS payment structure codified under § 412.522, beginning with FY 2016, the annual recalibration of the MS–LTC–DRG relative weights are determined: (1) Using only data from available LTCH PPS claims that would have qualified for payment under the new LTCH PPS standard Federal payment rate if that rate were in effect when claims data from time periods before the dual rate LTCH PPS payment structure applies were excluded from the relative weights; and (2) using only data from available LTCH PPS claims that qualify for payment under the new LTCH PPS standard Federal payment rate when claims data from time periods after the dual rate LTCH PPS payment structure applies are used to calculate the relative weights (80 FR 49624). That is, under our current methodology, the MS–LTC–DRG relative weights are not used to determine the LTCH PPS payment for cases paid at the site neutral payment rate under §412.522(c)(1) and data from cases paid at the site neutral payment rate or that would have been paid at the site neutral payment rate if the dual rate LTCH PPS payment structure had been in effect are not used to develop the relative weights. For the remainder of this discussion, we use the phrase “applicable LTCH cases” or “applicable LTCH data” when referring to the resulting claims data set used to calculate the relative weights (as described later in greater detail in section VII.C.3. of the preamble of this final rule). In addition, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25145), we proposed to continue to exclude the data from all-inclusive rate providers and LTCHs paid in accordance with demonstration projects, as well as any Medicare Advantage claims from the MS–LTC–DRG relative weight calculations for the reasons discussed in section VII.C.3. of the preamble of the proposed rule.

Furthermore, for FY 2017, in using data from applicable LTCH cases to establish proposed MS–LTC–DRG relative weights, we proposed to continue to establish low-volume MS–LTC–DRGs (that is, MS–LTC–DRGs with less than 25 cases) using our quintile methodology in determining the MS–LTC–DRG relative weights because LTCHs do not typically treat the full range of diagnoses as do acute care hospitals. Therefore, for purposes of determining the relative weights for the large number of low-volume MS–LTC–DRGs, we proposed to group all of the low-volume MS–LTC–DRGs into five quintiles based on average charges per discharge. Then, under our existing methodology, we proposed to account for adjustments made to LTCH PPS standard Federal payments for short-stay outlier (SSO) cases (that is, cases where the covered length of stay at the LTCH is less than or equal to five-sixths of the geometric average length of stay for the MS–LTC–DRG), and to make adjustments to account for nonmonotonically increasing weights, when necessary. The methodology is premised on more severe cases under the MS–LTC–DRG system requiring greater expenditure of medical resources and higher average charges such that in the severity levels within a base MS–LTC–DRG, the relative weights should increase monotonically with severity from the lowest to highest severity level. (We discuss each of these components of our MS–LTC–DRG relative weight methodology in greater detail in section VII.C.3. of the preamble of this final rule.)

Comment: A few commenters expressed concern that a number of MS–LTC–DRGs that historically have had the greatest number of LTCH cases or those MS–LTC–DRGs with an increase in average charge of more than the increase in average charge across all MS–LTC–DRGs will experience a reduction in their relative weight because the average charge for each of those MS–LTC–DRGs is being divided by a larger number (that is, the average charge across all MS–LTC–DRGs). (Similarly, MS–LTC–DRGs with an increase in average charge of more than the increase in average charge across all MS–LTC–DRGs will experience an increase in their relative weight because the average charge for each of those MS–LTC–DRGs is being divided by a smaller number.) (70 FR 47335)

In light of the commenters’ concern, we reviewed the FY 2015 LTCH claims data used for the proposed rule and found that the average charge for the “high volume” MS–LTC–DRGs noted by commenters is increasing between the proposed FY 2017 relative weights as compared to the FY 2016 relative weights. However, many of these MS–LTC–DRGs experienced an increase in average charge that was less than the overall increase in the average charge for all MS–LTC–DRGs. Therefore, the overall average charge for all MS–LTC–DRGs increased by over 7.5 percent. Thus, because the average charge for MS–LTC–DRG 207 increased less as compared to the increase in the overall average charge, the proposed relative weight for FY 2017 decreased a small amount (approximately 0.7 percent). The overall average charge for an MS–LTC–DRG to the average charge of all MS–LTC–DRGs increase in the number of cases in an MS–LTC–DRG and the annual change in the relative weights after recalibration.

As provided under §412.515, each MS–LTC–DRG, is assigned an appropriate weight that reflects the estimated relative cost of hospital resources used within that group compared to discharges classified within other groups. Furthermore, §412.517(a) requires that the MS–LTC–DRG classifications and weighting factors are adjusted annually to reflect changes in treatment patterns; technology; number of discharges; and other factors affecting the relative use of hospital resources. The MS–LTC–DRG relative weights are designed to reflect the average of resources used to treat representative cases of the discharges within each MS–LTC–DRG. In general, the MS–LTC–DRG relative weights are determined by dividing the average charge for each MS–LTC–DRG by the average charge across all MS–LTC–DRGs. Accordingly, those MS–LTC–DRGs with an increase in average charge of less than the increase in average charge across all MS–LTC–DRGs will experience a reduction in their relative weight because the average charge for each of those MS–LTC–DRGs is being divided by a larger number (that is, the average charge across all MS–LTC–DRGs). (Similarly, MS–LTC–DRGs with an increase in average charge of more than the increase in average charge across all MS–LTC–DRGs will experience an increase in their relative weight because the average charge for each of those MS–LTC–DRGs is being divided by a smaller number.) (70 FR 47335)
reflects the resources (and costs) used by LTCHs to treat patients in a given MS–LTC–DRG relative to the resources (and costs) used by LTCHs to treat all patients. When updated LTCH claims data for a particular MS–LTC–DRG show either an increase in the average charge of the MS–LTC–DRG that is less than the overall increase in the average charge across all MS–LTC–DRGs or a decrease in the average charge of a particular MS–LTC–DRG, we believe that the decrease in the relative weights for such MS–LTC–DRGs is appropriate because the updated LTCH claims data reflect more recent changes in treatment patterns, technology, number of discharges, and other factors affecting the relative use of hospital resources.

Comment: One commenter questioned the use of the historical LTCH claims data in the ratesetting methodology, including calculation of the MS–LTC–DRG relative weights, given that these data predate the revised dual rate LTCH PPS payment structure.

Response: As we discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49615), we solicited stakeholder input during the FY 2015 rulemaking cycle regarding the calculation of the MS–LTC–DRG relative payment weights under the new dual rate statutory LTCH PPS payment structure. Most commenters recommended that the MS–LTC–DRG relative weights under the new statutory structure should be calculated using only the data from cases that meet the statutory patient-level criteria for exclusion from the site neutral payment rate (or cases that would have qualified for exclusion had the dual rate LTCH PPS payment structure been in effect at the time of discharge). As we discussed in that same final rule, we believe that the costs and resource use for cases paid at the site neutral payment rate in the future may be lower on average than the costs and resource use for LTCH cases in our historical data that would have been paid at the site neutral payment rate if the statutory changes were in place when the discharges occurred, even if the proportion of site neutral payment rate cases in future data remains similar to the historical data. Therefore, we believe that the MS–LTC–DRG relative weights could become distorted over time and could also lead to less stability in the MS–LTC–DRG relative weights. For these reasons, we established our methodology for calculating the FY 2016 MS–LTC–DRG relative weights under the new dual rate LTCH PPS payment structure using only data from cases that would have been LTCH PPS standard Federal payment rate cases had the new LTCH PPS statutory patient-level criteria been in effect at the time of the discharge (80 FR 49615). We proposed to continue to employ this approach to calculate the FY 2017 MS–LTC–DRG relative weights because we continue to believe that computing the MS–LTC–DRG relative weights using only data from LTCH PPS cases that are (or would have been) paid the LTCH PPS standard Federal payment rate will result in the most appropriate payments under LTCH PPS.

After consideration of the public comments we received, we are finalizing our proposals for calculating the MS–LTC–DRG relative weights for FY 2017, without modification.

2. Patient Classifications Into MS–LTC–DRGs
   a. Background

   The MS–DRGs (used under the IPPS) and the MS–LTC–DRGs (used under the LTCH PPS) are based on the CMS DRG structure. As noted previously in this section, we refer to the DRGs under the LTCH PPS as MS–LTC–DRGs although they are structurally identical to the MS–DRGs used under the IPPS.

   The MS–DRGs are organized into 25 major diagnostic categories (MDCs), most of which are based on a particular organ system of the body; the remainder involve multiple organ systems (such as MDC 22, Burns). Within most MDCs, cases are then divided into surgical DRGs and medical DRGs. Surgical DRGs are assigned based on a surgical hierarchy that orders operating room (O.R.) procedures or groups of O.R. procedures by resource intensity. The GROUPER software program does not recognize all ICD–10–PCS procedure codes as procedures affecting DRG assignment. That is, procedures that are not surgical (for example, EKGs), or minor surgical procedures (for example, a biopsy of skin and subcutaneous tissue (procedure code 86.11)) do not affect the MS–LTC–DRG assignment based on their presence on the claim. Generally, under the LTCH PPS, a Medicare payment is made at a predetermined specific rate for each discharge that varies based on the MS–LTC–DRG to which a beneficiary’s discharge is assigned. Cases are classified into MS–LTC–DRGs for payment based on the following six data elements:
   • Principal diagnosis;
   • Additional or secondary diagnoses;
   • Surgical procedures;
   • Age;
   • Sex; and
   • Discharge status of the patient.

   Currently, for claims submitted on the 5010 format, up to 25 diagnosis codes and 25 procedure codes are considered for an MS–DRG assignment. This includes one principal diagnosis and up to 24 secondary diagnoses for severity of illness determinations. (For additional information on the processing of up to 25 diagnosis codes and 25 procedure codes on hospital inpatient claims, we refer readers to section II.C.11.c. of the preamble of the FY 2011 IPPS/LTCH PPS final rule (75 FR 50127).)

   Under HIPAA transactions and code sets regulations at 45 CFR parts 160 and 162, covered entities must comply with the adopted transaction standards and operating rules specified in Subparts I through S of Part 162. Among other requirements, by January 1, 2012, covered entities were required to use the ASC X12 Standards for Electronic Data Interchange Technical Report Type 3—Health Care Claim: Institutional (837), May 2006, ASC X12N/005010X223, and Type 1 Errata to Health Care Claim: Institutional (837) ASC X12 Standards for Electronic Data Interchange Technical Report Type 3, October 2007, ASC X12N/005010X223A1 for the health care claims or equivalent encounter information transaction (45 CFR 162.1102(c)).

   HIPAA requires covered entities to use the applicable medical data code set requirements when conducting HIPAA transactions (45 CFR 162.1000).

   Currently, upon the discharge of the patient, the LTCH must assign appropriate diagnosis and procedure codes from the most current version of the Internal Classification of Diseases, 10th Revision, Clinical Modification (ICD–10–CM) for diagnosis coding and the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD–10–PCS) for inpatient hospital procedure coding, both of which were required to be implemented October 1, 2015 (45 CFR 162.1002(c)(2) and (3)). For additional information on the implementation of the ICD–10 coding system, we refer readers to section II.F.1. of the preamble of this final rule. Additional coding instructions and examples are published in the AHA’s Coding Clinic for ICD–10–CM/PCS.

   To create the MS–DRGs (and by extension, the MS–LTC–DRGs), base DRGs were subdivided according to the presence of specific secondary diagnoses designated as complications or comorbidities (CCs) into one, two, or three levels of severity, depending on the impact of the CCs on resources used for those cases. Specifically, there are sets of MS–DRGs that are split into 2 or 3 subgroups based on the presence or absence of a CC or a major complication or comorbidity (MCC). We refer readers
to section II.D. of the FY 2008 IPPS final rule with comment period for a detailed discussion about the creation of MS–LTC–DRGs based on severity of illness levels (72 FR 47141 through 47175).

MACs enter the clinical and demographic information submitted by LTCHs into their claims processing systems and subject this information to a series of automated screening processes called the Medicare Code Editor (MCE). These screens are designed to identify cases that require further review before assignment into a MS–LTC–DRG can be made. During this process, certain cases are selected for further development (74 FR 43949).

After screening through the MCE, each claim is classified into the appropriate MS–LTC–DRG by the Medicare LTCH GROUPER software on the basis of diagnosis and procedure codes and other demographic information (age, sex, and discharge status). The GROUPER software used under the LTCH PPS is the same GROUPER software program used under the IPPS. Following the MS–LTC–DRG assignment, the Medicare contractor determines the prospective payment amount by using the Medicare PRICER program, which accounts for hospital-specific adjustments. Under the LTCH PPS, we provide an opportunity for LTCHs to review the MS–LTC–DRG assignments made by the MAC and to submit additional information within a specified timeframe as provided in §412.513(c).

The GROUPER software is used both to classify past cases to measure relative hospital resource consumption to establish the MS–LTC–DRG relative weights and to classify current cases for purposes of determining payment. The records for all Medicare hospital inpatient discharges are maintained in the MedPAR file. The data in this file are used to evaluate possible MS–DRG and MS–LTC–DRG classification changes and to recalculate the MS–DRG and MS–LTC–DRG relative weights during our annual update under both the IPPS (§412.60(e)) and the LTCH PPS (§412.517), respectively.

b. Changes to the MS–LTC–DRGs for FY 2017

As specified by our regulations at §412.517(a), which require that the MS–LTC–DRG classifications and relative weights be updated annually, and consistent with our historical practice of using the same patient classification system under the LTCH PPS as is used under the IPPS, in the FY 2017 IPPS/LTCH PPS proposed rule, we proposed to update the MS–LTC–DRG classifications effective October 1, 2016, through September 30, 2017 (FY 2017), consistent with the proposed changes to specific MS–DRG classifications presented in section II.F. of the preamble of the proposed rule (81 FR 25146). Accordingly, the MS–LTC–DRGs for FY 2017 presented in the proposed rule and this final rule are the same as the MS–DRGs that will be used under the IPPS for FY 2017. In addition, because the MS–LTC–DRGs for FY 2017 are the same as the MS–DRGs for FY 2017, the other changes that affect MS–DRG (and by extension MS–LTC–DRG) assignments under GROUPER Version 34 as discussed in section II.G. of the preamble of this final rule, including the changes to the MCE software and the ICD–10–CM/PCS coding system, also will be applicable under the LTCH PPS for FY 2017. (We note the GROUPER Version 34 is based on ICD–10–CM/PCS diagnoses and procedure codes, consistent with the requirement to use ICD–10 beginning October 1, 2015.)

3. Development of the FY 2017 MS–LTC–DRG Relative Weights

a. General Overview of the Development of the MS–LTC–DRG Relative Weights

One of the primary goals for the implementation of the LTCH PPS is to pay each LTCH an appropriate amount for the efficient delivery of medical care to Medicare patients. The system must be able to account adequately for each LTCH’s case-mix in order to ensure both the fair distribution of Medicare payments and access to adequate care for those Medicare patients whose care is more costly (67 FR 55984). To accomplish these goals, we have annually adjusted the LTCH PPS standard Federal prospective payment system rate by the applicable relative weight in determining payment to LTCHs for each case. In order to make these annual adjustments under the dual rate LTCH PPS payment structure, beginning with FY 2016, we recalibrate the MS–LTC–DRG relative weighting factors annually using data from applicable LTCH case weights (80 FR 49614 through 49617). Under this policy, the resulting MS–LTC–DRG relative weights would continue to be used to adjust the LTCH PPS standard Federal payment rate when calculating the payment for LTCH PPS standard Federal payment rate cases.

The established methodology to develop the MS–LTC–DRG relative weights is generally consistent with the methodology established when the LTCH PPS was implemented in the August 30, 2002 LTCH PPS final rule (67 FR 55984). However, there have been some modifications of our historical procedures for assigning relative weights in cases of zero volume and/or nonmonotonicity resulting from the adoption of the MS–LTC–DRGs, along with the change made in conjunction with the implementation of the dual rate LTCH PPS payment structure beginning in FY 2016 to use LTCH claims data from only LTCH PPS standard Federal payment rate cases (or LTCH PPS cases that would have qualified for payment under the LTCH PPS standard Federal payment rate if the dual rate LTCH PPS payment structure were in effect at the time of the discharge). For details on the modifications to our historical procedures for assigning relative weights in cases of zero volume and/or nonmonotonicity, we refer readers to the FY 2008 IPPS final rule with comment period (72 FR 47289 through 47295) and the FY 2009 IPPS final rule (73 FR 48542 through 48550). For details on the change in our historical methodology to use LTCH claims data only from LTCH PPS standard Federal payment rate cases to determine the MS–LTC–DRG relative weights, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49614 through 49617). Under the LTCH PPS, relative weights for each MS–LTC–DRG are a primary element used to account for the variations in cost per discharge and resource utilization among the payment groups (§412.515). To ensure that Medicare patients classified to each MS–LTC–DRG have access to an appropriate level of services and to encourage efficiency, we calculate a relative weight for each MS–LTC–DRG that represents the resources needed by an average inpatient LTCH case in that MS–LTC–DRG. For example, cases in an MS–LTC–DRG with a relative weight of 2 would, on average, cost twice as much to treat as cases in an MS–LTC–DRG with a relative weight of 1.

b. Development of the MS–LTC–DRG Relative Weights for FY 2017

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49625 through 49634), we presented our policies for the development of the MS–LTC–DRG relative weights for FY 2016. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25147), we proposed to continue to use our current methodology to determine the MS–LTC–DRG relative weights for FY 2017, including the application of established policies related to: The hospital-specific relative value methodology, the treatment of severity levels in the MS–LTC–DRGs, low-volume and no-volume MS–LTC–DRGs, adjustments for nonmonotonicity, the steps for calculating the MS–LTC–DRG relative
weights with a budget neutrality factor, and only using data from applicable LTCH cases (which includes our policy of only using cases that would meet the criteria for exclusion from the site neutral payment rate (or, for discharges occurring prior to the implementation of the dual rate LTCH PPS payment structure, would have met the criteria for exclusion had those criteria been in effect at the time of the discharge).

In this section, we present our methodology for determining the MS–LTC–DRG relative weights for FY 2017, and we discuss the effects of our policies concerning the data used to determine the FY 2017 MS–LTC–DRG relative weights on the various components of our existing methodology in the discussion that follows.

c. Data
For this final rule, consistent with our proposals regarding the calculation of the MS–LTC–DRG relative weights for FY 2017, we obtained total charges from FY 2015 Medicare LTCH claims data from the March 2016 update of the FY 2015 MedPAR file, which are the best available data at this time, and we are using Version 34 of the GROUPER to classify LTCH cases. Consistent with our historical practice, we used those data and the Version 34 of the MS–LTC–DRGs in establishing the FY 2017 MS–LTC–DRG relative weights in this final rule. To calculate the FY 2017 MS–LTC–DRG relative weights under the dual rate LTCH PPS payment structure, as we proposed, we are continuing to use applicable LTCH data, which includes our policy of only using cases that meet the criteria for exclusion from the site neutral payment rate (or would have met the criteria had they been in effect at the time of the discharge) (80 FR 49624). Specifically, we began by first evaluating the LTCH claims data in the March 2016 update of the FY 2015 MedPAR file to determine which LTCH cases would meet the criteria for exclusion from the site neutral payment rate under §412.522(b) had the dual rate LTCH PPS payment structure been in effect at the time of discharge. We identified the FY 2015 LTCH cases that were not assigned to MS–LTC–DRGs 876, 880, 881, 882, 883, 884, 885, 886, 887, 894, 895, 896, 897, 945 and 946, which identify LTCH cases that do not have a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation; and that either—

• The admission to the LTCH was “immediately preceded” by discharge from a hospital and the immediately preceding stay was in that subsection (d) hospital included at least 3 days in an ICU, as we define under the ICU criterion; or
• The admission to the LTCH was “immediately preceded” by discharge from a subsection (d) hospital and the claim for the LTCH discharge includes the applicable procedure code that indicates at least 96 hours of ventilator services were provided during the LTCH stay, as we define under the ventilator criterion. Claims data from the FY 2015 MedPAR file that reported ICD–9–CM procedure code 96.72 were used to identify cases involving at least 96 hours of ventilator services in accordance with the ventilator criterion (as FY 2015 discharges occurred prior to the adoption of ICD–10–CM). (We note that the corresponding ICD–10–PCS code for cases involving at least 96 hours of ventilation services is 5A1955Z, effective October 1, 2016) (80 FR 49472 through 49627). We note that, for purposes of developing the FY 2017 MS–LTC–DRG relative weights using our current methodology, we did not make any proposals regarding the identification of cases that would have been excluded from the site neutral payment rate under the statutory provision that provided for temporary exception from the site neutral payment rate under the LTCH PPS for certain severe wound care discharges from certain LTCHs (or low) charges. This nonrandom distribution of cases with relatively high (or low) charges in specific MS–LTC–DRGs has the potential to inappropriately distort the measure of average charges. To account for the fact that cases may not be randomly distributed across LTCHs, consistent with the methodology we have used since the implementation of the LTCH PPS, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25148), we proposed to continue to use a hospital-specific relative value (HSRV) methodology to calculate the MS–LTC–DRG relative weights for FY 2017.

Furthermore, consistent with our historical methodology, as we proposed, we are excluding any claims in the resulting data set that were submitted by LTCHs that are all-inclusive rate providers and LTCHs that are reimbursed in accordance with demonstration projects authorized under section 402(a) of Public Law 92–248 or section 222(a) of Public Law 92–603. In addition, consistent with our historical practice and our proposals, we are excluding any Medicare Advantage (Part C) claims in the resulting data. Such claims were identified based on the presence of a GHO Paid indicator value of “1” in the MedPAR files. The claims that remained after these three trims (that is, the applicable LTCH data) were then used to calculate the MS–LTC–DRG relative weights for FY 2017.

In summary, in general, we identified the claims data used in the development of the FY 2017 MS–LTC–DRG relative weights in this final rule, as we proposed, by trimming claims data that would have been paid the site neutral rate had the dual payment rate structure been in effect (except for discharges which would have been excluded from the site neutral payment under the temporary exception for certain severe wound care discharges from certain LTCHs), as well as the claims data of 10 all-inclusive rate providers reported in the March 2016 update of the FY 2015 MedPAR file and any Medicare Advantage claims data. (We note that there were no data from any LTCHs that are paid in accordance with a demonstration project reported in the March 2016 update of the FY 2015 MedPAR file. However, had there been we would trim the claims data from those LTCHs as well, in accordance with our established policy.) We used the remaining data (that is, the applicable LTCH data) to calculate the relative weights for FY 2017.

d. Hospital-Specific Relative Value (HSRV) Methodology

By nature, LTCHs often specialize in certain areas, such as ventilator-dependent patients. Some case types (MS–LTC–DRGs) may be treated, to a large extent, in hospitals that have, from a perspective of charges, relatively high (or low) charges. This nonrandom distribution of cases with relatively high (or low) charges in specific MS–LTC–DRGs has the potential to inappropriately distort the measure of average charges. To account for the fact that cases may not be randomly distributed across LTCHs, consistent with the methodology we have used since the implementation of the LTCH PPS, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25148), we proposed to continue to use a hospital-specific relative value (HSRV) methodology to calculate the MS–LTC–DRG relative weights for FY 2017.
Specifically, under this methodology, we reduced the impact of the variation in charges across providers on any particular MS–LTC–DRG relative weight by converting each LTCH’s charge for an applicable LTCH case to a relative value based on that LTCH’s average charge for such cases.

Under the HSRV methodology, we standardize charges for each LTCH by converting its charges for each applicable LTCH case to hospital-specific relative charge values and then adjusting those values for the LTCH’s case-mix. The adjustment for case-mix is needed to rescale the hospital-specific relative charge values (which, by definition, average 1.0 for each LTCH). The average relative weight for an LTCH is its case-mix; therefore, it is reasonable to scale each LTCH’s average relative charge value by its case-mix. In this way, each LTCH’s relative charge value is adjusted by its case-mix to an average that reflects the complexity of the applicable LTCH cases it treats relative to the complexity of the applicable LTCH cases treated by all other LTCHs (the average LTCH PPS case-mix of all applicable LTCH cases across all LTCHs).

In accordance with our established methodology, for FY 2017, as we proposed, we are continuing to standardize charges for each applicable LTCH case by first dividing the adjusted charge for the case (adjusted for SSOs under § 412.529 as described in section VII.C.3.g. (Step 3) of the preamble of this final rule) by the average adjusted charge for all applicable LTCH cases at the LTCH in which the case was treated. SSO cases are cases with a length of stay that is less than or equal to five-sixths the average length of stay of the MS–LTC–DRG, as described in greater detail below. For FY 2017, we proposed to continue to use for all LTCH cases to establish the same volume-based categories to calculate the FY 2017 MS–LTC–DRG relative weights (81 FR 25148).

In determining the FY 2017 MS–LTC–DRG relative weights, when necessary, as we proposed, we made adjustments to account for nonmonotonicity, as discussed in greater detail later in Step 6 of section VII.C.3.g. of the preamble of this final rule. We refer readers to the discussion in the FY 2010 IPPS/RY 2010 LTCH PPS final rule for our rationale for including an adjustment for nonmonotonicity (74 FR 43953 through 43954).

f. Low-Volume MS–LTC–DRGs

In order to account for MS–LTC–DRGs with low-volume (that is, with fewer than 25 applicable LTCH cases), consistent with our existing methodology, we proposed to continue to employ the quintile methodology for low-volume MS–LTC–DRGs, such that we grouped MS–LTC–DRGs into quintiles (as described later in this section of the proposed rule) and assigned the relative weight of the quintile; and (3) no-volume MS–LTC–DRGs that are cross-walked to other MS–LTC–DRGs based on the clinical similarities and assigned the relative weight of the crosswalked MS–LTC–DRG (as described in greater detail below).

For FY 2017, we proposed to continue to use for all applicable LTCH cases to establish the same volume-based categories to calculate the FY 2017 MS–LTC–DRG relative weights (81 FR 25148).

In determining the FY 2017 MS–LTC–DRG relative weights, when necessary, we proposed, we continued to use for all applicable LTCH cases to establish the same volume-based categories to calculate the FY 2017 MS–LTC–DRG relative weights (81 FR 25148).

In determining the FY 2017 MS–LTC–DRG relative weights, when necessary, we proposed, we continued to use for all applicable LTCH cases to establish the same volume-based categories to calculate the FY 2017 MS–LTC–DRG relative weights (81 FR 25148).

In determining the FY 2017 MS–LTC–DRG relative weights, when necessary, we proposed, we continued to use for all applicable LTCH cases to establish the same volume-based categories to calculate the FY 2017 MS–LTC–DRG relative weights (81 FR 25148).

In determining the FY 2017 MS–LTC–DRG relative weights, when necessary, we proposed, we continued to use for all applicable LTCH cases to establish the same volume-based categories to calculate the FY 2017 MS–LTC–DRG relative weights (81 FR 25148).
section VII.C.3.g. of the preamble of this final rule. We assigned the same relative weight and average length of stay to each of the low-volume MS–LTC–DRGs that make up an individual low-volume quintile. We note that, as this system is dynamic, it is possible that the number and specific type of MS–LTC–DRGs with a low-volume of applicable LTCH cases will vary in the future.

Furthermore, we note that we continue to monitor the volume (that is, the number of applicable LTCH cases) in the low-volume quintiles to ensure that our quintile assignments used in determining the MS–LTC–DRG relative weights result in appropriate payment for LTCH cases grouped to low-volume MS–LTC–DRGs and do not result in an unintended financial incentive for LTCHs to inappropriately admit these types of cases.

g. Steps for Determining the FY 2017 MS–LTC–DRG Relative Weights

In this final rule, as we proposed, we are continuing to use our current methodology to determine the FY 2017 MS–LTC–DRG relative weights.

In summary, to determine the FY 2017 MS–LTC–DRG relative weights, we grouped applicable LTCH cases to the appropriate MS–LTC–DRG, while taking into account the low-volume quintiles (as described above) and cross-walked no-volume MS–LTC–DRGs (as described later in this section). After establishing the appropriate MS–LTC–DRG (or low-volume quintile), as proposed, we calculated the FY 2017 relative weights by first removing cases with a length of stay of 7 days or less and statistical outliers (Steps 1 and 2 below). Next, as we proposed, we adjusted the number of applicable LTCH cases in each MS–LTC–DRG (or low-volume quintile) for the effect of SSO cases (Step 3 below). After removing applicable LTCH cases with a length of stay of 7 days or less (Step 1 below) and statistical outliers (Step 2 below), which are the SSO-adjusted applicable LTCH cases and corresponding charges (step 3 below), as proposed, we calculated “relative weights” for each MS–LTC–DRG (or low-volume quintile) using the HSRV method.

Step 1—Remove cases with a length of stay of 7 days or less

The first step in our calculation of the FY 2017 MS–LTC–DRG relative weights is to remove cases with a length of stay of 7 days or less. The MS–LTC–DRG relative weights reflect the average of resources used on representative cases of a specific type. Generally, cases with a length of stay of 7 days or less do not belong in an LTCH because these stays do not fully receive or benefit from treatment that is typical in an LTCH stay, and full resources are often not used in the earlier stages of admission to an LTCH. If we were to include stays of 7 days or less in the computation of the proposed FY 2017 MS–LTC–DRG relative weights, the value of many relative weights would decrease and, therefore, payments would decrease to a level that may no longer be appropriate. We do not believe that it would be appropriate to compromise the integrity of the payment determination for those LTCH cases that actually benefit from and receive a full course of treatment at an LTCH by including data from these very short stays. Therefore, consistent with our existing relative weight methodology and as proposed, in determining the FY 2017 MS–LTC–DRG relative weights, we removed LTCH cases with a length of stay of 7 days or less from applicable LTCH cases. (For additional information on what is removed in this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.)

Step 2—Remove statistical outliers

The next step in our calculation of the FY 2017 MS–LTC–DRG relative weights is to remove statistical outlier cases from the LTCH cases with a length of stay of at least 8 days. Consistent with our existing relative weight methodology, as we proposed, we are continuing to define statistical outliers as cases that are outside of 3.0 standard deviations from the mean of the log distribution of both charges per case and the charges per day for each MS–LTC–DRG. These statistical outliers are removed prior to calculating the relative weights because we believe that they may represent aberrations in the data that distort the measure of average resource use. Including those LTCH cases in the calculation of the relative weights could result in an inaccurate relative weight that does not truly reflect relative resource use among those MS–LTC–DRGs. (For additional information on what is removed in this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.) After removing cases with a length of stay of 7 days or less and statistical outliers, we are left with applicable LTCH cases that have a length of stay greater than or equal to 8 days. In this final rule, we refer to these cases as “trimmed applicable LTCH cases.”

Step 3—Adjust charges for the effects of SSOs

As the next step in the calculation of the FY 2017 MS–LTC–DRG relative weights, we proposed to use our historical approach and as we proposed, we adjusted each LTCH’s charges per discharge for those remaining cases (that is, trimmed applicable LTCH cases) for the effects of SSOs (as defined in §412.529(a) in conjunction with §412.503). Specifically, we made this adjustment by counting an SSO case as a fraction of a discharge based on the ratio of the length of stay of the case to the average length of stay for the MS–LTC–DRG for non-SSO cases. This has the effect of proportionately reducing the impact of the lower charges for the SSO cases in calculating the average charge for the MS–LTC–DRG. This process produces the same result as if the actual charges per discharge of an SSO case were adjusted to what they would have been had the patient’s length of stay been equal to the average length of stay of the MS–LTC–DRG.

Counting SSO cases as full LTCH cases with no adjustment in determining the FY 2017 MS–LTC–DRG relative weights would lower the FY 2017 MS–LTC–DRG relative weight for affected MS–LTC–DRGs because the relatively lower charges of the SSO cases would bring down the average charge for all cases within a MS–LTC–DRG. This would result in an “underpayment” for non-SSO cases and an “overpayment” for SSO cases. Therefore, as we proposed, we are continuing to adjust for SSO cases under §412.529 in this manner because it will result in more appropriate payments for all LTCH PPS standard Federal payment rate cases. (For additional information on this step of the relative weight methodology, we refer readers to 67 FR 55989 and 74 FR 43959.)

Step 4—Calculate the FY 2017 MS–LTC–DRG relative weights on an iterative basis

Consistent with our historical relative weight methodology and as we proposed, we calculated the FY 2017 MS–LTC–DRG relative weights using the HSRV methodology, which is an iterative process. First, for each SSO-adjusted trimmed applicable LTCH case, we calculated a hospital-specific relative charge value by dividing the charge per discharge after adjusting for SSOs of the LTCH case (from Step 3) by the average charge per SSO-adjusted discharge for the LTCH in which the case occurred. The resulting ratio was then multiplied by the LTCH’s case-mix index to produce an adjusted hospital-specific relative charge value for the case. We used an initial case-mix index value of 1.0 for each LTCH.

For each MS–LTC–DRG, we calculated the FY 2017 relative weight by dividing the SSO-adjusted average of the hospital-specific relative charge values for applicable LTCH cases for the
MS–LTC–DRG (that is, the sum of the hospital-specific relative charge value from above divided by the sum of equivalent cases from Step 3 for each MS–LTC–DRG) by the overall SSO-adjusted average hospital-specific relative charge value across all applicable LTCH cases for all LTCHs (that is, the sum of the hospital-specific relative charge value from above divided by the sum of equivalent applicable LTCH cases from Step 3 for each MS–LTC–DRG). Using these recalculated MS–LTC–DRG relative weights, each LTCH’s average relative weight for all of its SSO-adjusted trimmed applicable LTCH cases (that is, its case-mix) was calculated by dividing the sum of all the LTCH’s MS–LTC–DRG relative weights by its total number of SSO-adjusted trimmed applicable LTCH cases. The LTCHs’ hospital-specific relative charge values (from previous) were then multiplied by the hospital-specific case-mix indexes. The hospital-specific case-mix adjusted relative charge values were then used to calculate a new set of MS–LTC–DRG relative weights across all LTCHs. This iterative process continued until there was convergence between the relative weights produced at adjacent steps, for example, when the maximum difference was less than 0.0001.

Step 5—Determine a FY 2017 relative weight for MS–LTC–DRGs with no applicable LTCH cases.

Using the trimmed applicable LTCH cases, consistent with our historical methodology and as we proposed, we identified the MS–LTC–DRGs for which there were no claims in the March 2016 update of the FY 2015 MedPAR file and, therefore, for which no charge data was available for these MS–LTC–DRGs. Because patients with a number of the diagnoses under those proposed MS–LTC–DRGs may be treated at LTCHs, consistent with our historical methodology, we generally assigned a relative weight to each of the no-volume MS–LTC–DRGs based on clinical similarity and relative costliness (with the exception of “transplant” MS–LTC–DRGs, “error” MS–LTC–DRGs, and MS–LTC–DRGs that indicate a principal diagnosis related to a psychiatric diagnosis or rehabilitation (referred to as the “psychiatric or rehabilitation” MS–LTC–DRGs), as discussed later in this section of the final rule). (For additional information on this step of the relative weight methodology, we refer readers to 67 FR 55991 and 74 FR 43959 through 43960.)

We cross-walked each no-volume MS–LTC–DRG to another MS–LTC–DRG for which we calculated a relative weight (determined in accordance with the methodology described above). Then, the “no-volume” MS–LTC–DRG was assigned the same relative weight (and average length of stay) of the MS–LTC–DRG to which it was cross-walked (as described in greater detail in this section of the final rule).

Of the 757 MS–LTC–DRGs for FY 2017, we identified 357 MS–LTC–DRGs for which there are no trimmed applicable LTCH cases (the number identified includes the 8 “transplant” MS–LTC–DRGs, the 2 “error” MS–LTC–DRGs, and the 15 “psychiatric or rehabilitation” MS–LTC–DRGs, which are discussed below). We assigned relative weights to each of the 357 no-volume MS–LTC–DRGs that contained trimmed applicable LTCH cases based on clinical similarity and relative costliness to 1 of the remaining 400 (757 – 357 = 400) MS–LTC–DRGs for which we calculated relative weights based on the trimmed applicable LTCH cases in the FY 2015 MedPAR file data using the steps described previously. (For the remainder of this discussion, we refer to the “cross-walked” MS–LTC–DRGs as the MS–LTC–DRGs to which cross-walked 1 of the 334 “no-volume” MS–LTC–DRGs.) Then, we generally assigned the 334 no-volume MS–LTC–DRGs the relative weight of the cross-walked MS–LTC–DRG. (As explained below in Step 6, when necessary, we made adjustments to account for nonmonotonicity.)

We cross-walked the no-volume MS–LTC–DRG to an MS–LTC–DRG for which we calculated relative weights based on the March 2016 update of the FY 2015 MedPAR file, and to which it is similar clinically in intensity of use of resources and relative costliness as determined by criteria such as care provided during the period of time surrounding surgery, surgical approach (if applicable), length of time of surgical procedure, postoperative care, and length of stay. (For more details on our process for evaluating relative costliness, we refer readers to the FY 2010 IPPS/RY 2010 LTCH PPS final rule (75 FR 48543).) We believe in the rare event that there would be a few LTCH cases grouped to one of the no-volume MS–LTC–DRGs in FY 2017, the relative weights assigned based on the cross-walked MS–LTC–DRGs will result in an appropriate LTCH PPS payment because the crosswalks, which are based on clinical similarity and relative costliness, are expected to generally require equivalent relative resource use.

We then assigned the relative weight of the cross-walked MS–LTC–DRG as the relative weight of the no-volume MS–LTC–DRG such that both of these MS–LTC–DRGs (that is, the no-volume MS–LTC–DRG and the cross-walked LTCH–DRGs) have the same relative weight for FY 2017. (As we noted previously, in the infrequent case where nonmonotonicity involving a no-volume MS–LTC–DRG resulted, additional adjustments as described in Step 6 are required in order to maintain monotonically increasing relative weights.)

For this final rule, a list of the no-volume MS–LTC–DRGs and the MS–LTC–DRGs to which each was cross-walked (that is, the cross-walked MS–LTC–DRGs) for FY 2017 is shown in Table 13B, which is listed in section VI. of the Addendum to this final rule and is available via the Internet on the CMS Web site.

To illustrate this methodology for determining the relative weights for the FY 2017 MS–LTC–DRGs with no applicable LTCH cases, we are providing the following example, which refers to the no-volume MS–LTC–DRGs crosswalk information for FY 2017 provided in Table 13B.

Example: There were no trimmed applicable LTCH cases in the FY 2015 MedPAR file that we are using for this final rule for MS–LTC–DRG 061 (Acute Ischemic Stroke with Use of Thrombolytic Agent with MCC). We determined that MS–LTC–DRG 070 (Nonspecific Cerebrovascular Disorders with MCC) is similar clinically and based on resource use to MS–LTC–DRG 061. Therefore, we assigned the same relative weight (and average length of stay) of MS–LTC–DRG 70 of 0.9098 for FY 2017 to MS–LTC–DRG 061 (we refer readers to Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the Internet on the CMS Web site).

Again, we note that, as this system is dynamic, it is entirely possible that the number of MS–LTC–DRGs with no volume will vary in the future.
Consistent with our historical practice, we used the most recent available claims data to identify the trimmed applicable LTCH cases from which we determined the relative weights in this final rule.

For FY 2017, consistent with our historical relative weight methodology and as we proposed, we are establishing a relative weight of 0.0000 for the following transplant MS–LTC–DRGs: Heart Transplant or Implant of Heart Assist System with MCC (MS–LTC–DRG 001); Heart Transplant or Implant of Heart Assist System without MCC (MS–LTC–DRG 002); Liver Transplant with MCC or Intestinal Transplant (MS–LTC–DRG 005); Liver Transplant without MCC (MS–LTC–DRG 006); Lung Transplant (MS–LTC–DRG 007); Simultaneous Pancreas/Kidney Transplant (MS–LTC–DRG 008); Pancreas Transplant (MS–LTC–DRG 010); and Kidney Transplant (MS–LTC–DRG 652). This is because Medicare only covers these procedures if they are performed at a hospital that has been certified for the specific procedures by Medicare and presently no LTCH has been so certified. At the present time, we include these eight transplant proposed MS–LTC–DRGs in the GROUPEr program for administrative purposes only. Because we use the same GROUPEr program for LTCHs as is used under the IPPS, removing these MS–LTC–DRGs would be administratively burdensome. (For additional information regarding our treatment of transplant MS–LTC–DRGs, we refer readers to the FY 2010 LTCH PPS final rule (74 FR 43964).) In addition, consistent with our historical policy and as we proposed, we are establishing a relative weight of 0.0000 for the 2 “error” MS–LTC–DRGs (that is, MS–LTC–DRG 998 (Principal Diagnosis Invalud as Discharge Diagnosis) and MS–LTC–DRG 999 (Ungroupable)) because applicable LTCH cases grouped to these MS–LTC–DRGs cannot be properly assigned to an MS–LTC–DRG according to the grouping logic.

In this final rule, for FY 2017, as we proposed, we are establishing a relative weight equal to the respective FY 2015 relative weight of the MS–LTC–DRGs for the following “psychiatric or rehabilitation” MS–LTC–DRGs: MS–LTC–DRG 876 (O.R. Procedure with Principal Diagnoses of Mental Illness); MS–LTC–DRG 880 (Acute Adjustment Reaction & Psychosocial Dysfunction); MS–LTC–DRG 881 (Depressive Neuroses); MS–LTC–DRG 882 (Neuroses Except Depressive); MS–LTC–DRG 883 (Disorders of Personality & Impulse Control); MS–LTC–DRG 884 (Organic Disturbances & Mental Retardation); MS–LTC–DRG 885 (Psychoses); MS–LTC–DRG 886 (Behavioral & Developmental Disorders); MS–LTC–DRG 887 (Other Mental Disorder Diagnoses); MS–LTC–DRG 894 (Alcohol/Drug Abuse or Dependence, Left Ama); MS–LTC–DRG 895 (Alcohol/Drug Abuse or Dependence, with Rehabilitation Therapy); MS–LTC–DRG 896 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy with MCC); MS–LTC–DRG 897 (Alcohol/Drug Abuse or Dependence, without Rehabilitation Therapy without MCC); MS–LTC–DRG 943 (Rehabilitation with CC/MCC); and MS–LTC–DRG 946 (Rehabilitation without CC/MCC). As we discussed when we implemented the dual rate LTCH PPS payment structure, LTCH discharges that are grouped to these 15 “psychiatric and rehabilitation” MS–LTC–DRGs do not meet the criteria for exclusion from the site neutral payment rate. As such, under the criterion for a principal diagnosis relating to a psychiatric diagnosis or to rehabilitation, there are no applicable LTCH cases to use in calculating a relative weight for the “psychiatric and rehabilitation” proposed MS–LTC–DRGs. In other words, any LTCH PPS discharges grouped to any of the 15 “psychiatric and rehabilitation” MS–LTC–DRGs will always be paid at the site neutral payment rate, and, therefore, those MS–LTC–DRGs will never include any LTCH cases that meet the criteria for exclusion from the site neutral payment rate. However, section 1886(m)(6)(B) of the Act establishes a transitional payment method for cases that would be paid at the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 or FY 2017. Under the transitional payment method for site neutral payment rate cases, for LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2016, and on or before September 30, 2017, site neutral payment rate cases are paid a blended payment rate, calculated as 50 percent of the applicable site neutral payment rate amount for the discharge and 50 percent of the applicable LTCH PPS standard Federal payment rate. Because the LTCH PPS standard Federal payment rate is based on the relative weight of the MS–LTC–DRG, in order to determine the transitional blended payment for site neutral payment rate cases grouped to one of the “psychiatric or rehabilitation” MS–LTC–DRGs in FY 2017, as we proposed, we assigned a relative weight for the MS–LTC–DRGs for FY 2017 that is the same as the FY 2015 relative weight (which is also the same as the FY 2016 relative weight). We believe that using the respective FY 2015 relative weight for each of the “psychiatric or rehabilitation” MS–LTC–DRGs results in appropriate payments for LTCH cases that are paid at the site neutral payment rate under the transition policy provided by the statute because there are no clinically similar MS–LTC–DRGs for which we were able to determine relative weights based on applicable LTCH cases in the FY 2015 MedPAR file data using the steps described above. Furthermore, we believe that it would be administratively burdensome and introduce unnecessary complexity to the MS–LTC–DRG relative weight calculation to use the LTCH discharges in the MedPAR file data to calculate a relative weight for those 15 “psychiatric and rehabilitation” MS–LTC–DRGs to be used for the sole purpose of determining half of the transitional blended payment for site neutral payment rate cases during the transition period (80 FR 49631 through 49632). In summary, for FY 2017, we are establishing a relative weight (and average length of stay thresholds) equal to the respective FY 2015 relative weight of the MS–LTC–DRGs for the 15 “psychiatric or rehabilitation” MS–LTC–DRGs listed previously (that is, MS–LTC–DRGs 876, 880, 881, 882, 883, 884, 885, 886, 887, 894, 895, 896, 897, 945, and 946). Table 11, which is listed in section VI. of the Addendum to this final rule and is available via the Internet on the CMS Web site, reflects this final policy.

Step 6—Adjust the FY 2017 MS–LTC–DRG relative weights to account for nonmonotonically increasing relative weights.

The MS–DRGs contain base DRGs that have been subdivided into one, two, or three severity of illness levels. Where there are three severity levels, the most severe level has at least one secondary diagnosis code that is referred to as an MCC (that is, major complication or comorbidity). The next lower severity level contains cases with at least one secondary diagnosis code that is a CC (that is, complication or comorbidity). Those cases without an MCC or a CC are referred to as “without CC/MCC.” When data do not support the creation of three severity levels, the base MS–DRG is subdivided into either two levels or the base MS–DRG is not subdivided. The two-level subdivisions may consist of the MS–DRG with CC/MCC and the MS–DRG without CC/MCC. Alternatively, the other type of two-level subdivision may consist of the MS–DRG with MCC and the MS–DRG without MCC.
In those base MS–LTC–DRGs that are split into either two or three severity levels, cases classified into the “without CC/MCC” MS–LTC–DRG are expected to have a lower resource use (and lower costs) than the “with CC/MCC” MS–LTC–DRG (in the case of a two-level split) or both the “with CC” and the “with MCC” MS–LTC–DRGs (in the case of a three-level split). That is, theoretically, cases that are more severe typically require greater expenditure of medical care resources and would result in higher average charges. Therefore, in the three severity levels, relative weights should increase by severity, from lowest to highest. If the relative weights decrease as severity increases (that is, if within a base MS–LTC–DRG, an MS–LTC–DRG with CC has a higher relative weight than one with MCC, or the MS–LTC–DRG “without CC/MCC” has a higher relative weight than either of the others), they are nonmonotonic. We continue to believe that utilizing nonmonotonic relative weights to adjust Medicare payments would result in inappropriate payments because the payment for the cases in the higher severity level in a base MS–LTC–DRG (which are generally expected to have higher resource use and costs) would be lower than the payment for cases in a lower severity level within the same base MS–LTC–DRG (which are generally expected to have lower resource use and costs). Therefore, in determining the FY 2017 MS–LTC–DRG relative weights, consistent with our historical methodology and as we proposed, we are continuing to combine MS–LTC–DRGs within a base MS–LTC–DRG for the purpose of computing a relative weight when necessary to ensure that monotonicity is maintained. For a comprehensive description of our existing methodology to adjust for nonmonotonicity, we refer readers to the FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43964 through 43966). Any adjustments for nonmonotonicity that were made in determining the FY 2017 MS–LTC–DRG relative weights in this final rule by applying this methodology are noted in Table 11, which is listed in section VI, of the Addendum to this final rule and is available via the Internet on the CMS Web site.

Step 7—Calculate the FY 2017 MS–LTC–DRG reclassification and recalibration budget neutrality factor. In accordance with the regulations at §412.517(b) (in conjunction with §412.503), the annual update to the MS–LTC–DRG classifications and relative weights is done in a budget neutral manner such that estimated aggregate LTCH PPS payments would be unaffected, that is, would be neither greater than nor less than the estimated aggregate LTCH PPS payments that would have been made without the MS–LTC–DRG classification and relative weight changes. (For a detailed discussion on the establishment of the budget neutrality requirement for the annual update of the MS–LTC–DRG classifications and relative weights, we refer readers to the FY 2008 LTCH PPS final rule (72 FR 26881 and 26882).) The MS–LTC–DRG classifications and relative weights are updated annually based on the most recent available LTCH claims data to reflect changes in relative LTCH resource use (§412.517(a) in conjunction with §412.503). To achieve the budget neutrality requirement at §412.517(b), under our established methodology, for each annual update, the MS–LTC–DRG relative weights are uniformly adjusted to ensure that estimated aggregate payments under the LTCH PPS would not be affected (that is, decreased or increased). Consistent with that provision of section 13, as we proposed, we are updating the MS–LTC–DRG classifications and relative weights for FY 2017 based on the most recent available LTCH data for applicable LTCH cases, and continuing to apply a budget neutrality adjustment in determining the FY 2017 MS–LTC–DRG relative weights. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25152 through 25153), to ensure budget neutrality in the update to the MS–LTC–DRG classifications and relative weights under §412.517(b), we proposed to continue to use our established two-step budget neutrality methodology. Comment: One commenter questioned how the low-volume MS–LTC–DRGs or MS–LTC–DRGs with no applicable LTCH cases impact the budget neutrality process. Response: Under our established two-step budget neutrality methodology, we first calculated and applied a normalization factor to the recalibrated relative weights; and then we calculated and applied a budget neutrality adjustment factor. Under both of these steps, the low-volume MS–LTC–DRGs are reflected in the budget neutrality calculation, and generally MS–LTC–DRGs with no applicable LTCH cases are not reflected in the budget neutrality calculation, as explained below. As described in the proposed rule (81 FR 25153), to calculate the proposed normalization factor for FY 2017, we grouped applicable LTCH cases using the proposed FY 2017 GROPER, and the recalibrated proposed FY 2017 MS–LTC–DRG relative weights to calculate the average case-mix index (CMI); we grouped the same applicable LTCH cases using the FY 2016 GROPER Version 33 and MS–LTC–DRG relative weights and calculated the average CMI; and computed the ratio by dividing the average CMI for FY 2016 by the average CMI proposed for FY 2017. That ratio was the proposed normalization factor. Because the calculation of the normalization factor involves the relative weights for the MS–LTC–DRGs that contained applicable LTCH cases to calculate the average CMIs, any low-volume MS–LTC–DRGs are included in the calculation (and the MS–LTC–DRGs with no applicable LTCH cases are not included in the calculation). As described in the proposed rule (81 FR 25153), to calculate the budget neutrality adjustment factor, we simulated estimated total FY 2017 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the proposed FY 2017 normalized relative weights and GROPER Version 33; simulated estimated total FY 2016 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the FY 2016 MS–LTC–DRG relative weights and the FY 2016 GROPER Version 33; and calculated the ratio of these estimated total payments by dividing the simulated estimated total LTCH PPS standard Federal payment rate payments for FY 2016 by the simulated estimated total LTCH PPS standard Federal payment rate payments for FY 2017. The resulting ratio was the proposed budget neutrality adjustment factor. The calculation of the budget neutrality factor involves the relative weights for the LTCH cases used in the payment simulation, which includes any cases grouped to low-volume or to MS–LTC–DRGs with no applicable LTCH cases, and generally does not include payments for cases MS–LTC–DRG with no applicable LTCH cases. (Occasionally, a few LTCH cases (that is, those with a covered length of stay of 7 days or less, which are removed from the relative weight calculation in step 2) that are grouped to an MS–LTC–DRG with no applicable LTCH cases are included in the payment simulations used to calculate the budget neutrality factor. However, the number and payment amount of such cases have a negligible impact on the budget neutrality factor calculation). In this final rule, to ensure budget neutrality in the update to the MS–LTC–DRG classifications and relative weights under §412.517(b), as we proposed, we are continuing to use our established calculated
two-step budget neutrality methodology. Therefore, in this final rule, in the first step of our MS–LTC–DRG budget neutrality methodology, for FY 2017, as we proposed, we calculated and applied a normalization factor to the recalibrated relative weights (the result of Steps 1 through 6 discussed previously) to ensure that estimated payments are not affected by changes in the composition of case types or the changes to the classification system.

That is, the normalization adjustment is intended to ensure that the recalibration of the MS–LTC–DRG relative weights (that is, the process itself) neither increases nor decreases the average case-mix index.

To calculate the normalization factor for FY 2017 (the first step of our budget neutrality methodology), we used the following three steps: (1.a.) Used the most recent available applicable LTCH cases from the most recent available data (that is, LTCH discharges from the FY 2015 MedPAR file) and grouped them using the FY 2017 GROUPER (that is, Version 34 for FY 2017) and the recalibrated FY 2017 MS–LTC–DRG relative weights (determined in Steps 1 through 6 above) to calculate the average case-mix index; (1.b.) grouped the same applicable LTCH cases (as are used in Step 1.a.) using the FY 2016 GROUPER (Version 33) and FY 2016 MS–LTC–DRG relative weights and calculated the average case-mix index; and (1.c.) computed the ratio of these average case-mix indexes by dividing the average CMI for FY 2016 (determined in Step 1.b.) by the average case-mix index for FY 2017 (determined in Step 1.a.). As a result, in determining the MS–LTC–DRG relative weights for FY 2017, each recalibrated MS–LTC–DRG relative weight was multiplied by the normalization factor of 1.28408 (determined in Step 1.c.) in the first step of the budget neutrality methodology, which produced “normalized relative weights.”

In the second step of our MS–LTC– DRG budget neutrality methodology, as we proposed, we calculated a second budget neutrality factor consisting of the ratio of estimated aggregate FY 2017 LTCH PPS standard Federal payment rate payments for applicable LTCH cases (the sum of all calculations under Step 1.a. mentioned previously) after reclassification and recalibration to estimated aggregate payments for FY 2017 LTCH PPS standard Federal payment rate payments for applicable LTCH cases before reclassification and recalibration (that is, the sum of all calculations under Step 1.b. mentioned previously).

That is, for this final rule, for FY 2017, under the second step of the budget neutrality methodology, we determined the budget neutrality adjustment factor using the following three steps: (2.a.) Simulated estimated total FY 2017 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the normalized relative weights for FY 2017 and GROUPER Version 34 (as described above); (2.b.) simulated estimated total FY 2016 LTCH PPS standard Federal payment rate payments for applicable LTCH cases using the FY 2016 GROUPER (Version 33) and the FY 2016 MS–LTC–DRG relative weights in Table 11 of the FY 2016 IPPS/LTCH PPS final rule available on the Internet, as described in section VI of the Addendum of that final rule; and (2.c.) calculated the ratio of these estimated total payments by dividing the value determined in Step 2.b. by the value determined in Step 2.a. In determining the FY 2017 MS–LTC–DRG relative weights, each normalized relative weight was then multiplied by a budget neutrality factor of 1.0011126 (the value determined in Step 2.c.) in the second step of the budget neutrality methodology to achieve the budget neutrality requirement at § 412.517(b).

Accordingly, in determining the FY 2017 MS–LTC–DRG relative weights in this final rule, consistent with our existing methodology, we applied a normalization factor of 1.28408 and a budget neutrality factor of 1.0011126. Table 11, which is listed in section VI of the Addendum to this final rule and is available via the Internet on the CMS Web site, lists the MS–LTC–DRGs and their respective relative weights, geometric mean length of stay, five-sixths of the geometric mean length of stay (used to identify SSO cases under § 412.529(a)), and the “IPPS Comparable Thresholds” (used in determining SSO payments under § 412.529(c)(3)), for FY 2017.

D. Rebasing of the LTCH Market Basket

1. Background

The input price index (that is, the market basket) that was used to develop the LTCH PPS for FY 2003 was the “excluded hospital with capital” market basket. That market basket was based on 1997 Medicare cost report data and included data for Medicare-participating IRFs, IPFs, LTCHs, cancer hospitals, and children’s hospitals. Although the term “market basket” technically describes the mix of goods and services used in providing hospital care, this term is also commonly used to denote the input price index (that is, cost category weights and price proxies combined) derived from that mix. Accordingly, the term “market basket,” as used in this section, refers to an input price index.

Beginning with RY 2007, LTCH PPS payments were updated using a 2002-based market basket reflecting the operating and capital cost structures for IRFs, IPFs, and LTCHs (hereafter referred to as the rehabilitation, psychiatric, and long-term care (RPL) market basket). We excluded cancer and children’s hospitals from the RPL market basket because their payments are based entirely on reasonable costs subject to rate-of-increase limits established under the authority of section 1886(b) of the Act, which are implemented in regulations at 42 CFR 413.40. Those types of hospitals are not paid under a PPS. Also, the 2002 cost structures for cancer and children’s hospitals are noticeably different from the cost structures for freestanding IRFs, freestanding IPFs, and LTCHs. A complete discussion of the 2002-based RPL market basket can be found in the FY 2007 LTCH PPS final rule (71 FR 27810 through 27817).

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51756), we finalized the rebasing and revising of the 2002-based RPL market basket by creating and implementing a 2008-based RPL market basket. We also discussed the creation of a stand-alone LTCH market basket and received several public comments, all of which supported deriving a stand-alone LTCH market basket (76 FR 51756 through 51757). In the FY 2013 IPPS/ LTCH PPS final rule, we finalized the adoption of a stand-alone 2009-based LTCH-specific market basket that reflects the cost structures of LTCHs only (77 FR 53467 through 53470).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25153 through 25167), we proposed to rebase and revise the 2009-based LTCH-specific market basket. The proposed LTCH market basket is primarily based on Medicare cost report data for LTCHs for 2013, which are for cost reporting periods beginning on and after October 1, 2012, and before October 1, 2013. We proposed to use data from cost reports beginning in FY 2013 because these data are the latest available complete data for purposes of calculating cost weights for the market basket. In the following discussion, we provide an overview of the proposed LTCH market basket and describe the methodologies we proposed to use for determining the operating and capital portions of the proposed 2013-based LTCH market basket.
2. Overview of the 2013-Based LTCH Market Basket

Similar to the 2009-based LTCH-specific market basket, the proposed 2013-based LTCH market basket is a fixed-weight, Laspeyres-type price index. A Laspeyres price index measures the change in price, over time, of the same mix of goods and services purchased in the base period. Any changes in the quantity or mix (that is, intensity) of goods and services purchased over time are not measured.

The index itself is constructed using three steps. First, a base period is selected (in the proposed rule, we proposed to use 2013 as the base period) and total base period expenditures are estimated for a set of mutually exclusive and exhaustive spending categories, with the proportion of total costs that each category represents being calculated. These proportions are called “cost weights” or “expenditure weights.” Second, each expenditure category is matched to an appropriate price or wage variable, referred to as a “price proxy.” In almost every instance, these price proxies are derived from publicly available statistical series that are published on a consistent schedule (preferably at least on a quarterly basis). Finally, the expenditure weight for each cost category is multiplied by the level of its respective price proxy. The sum of these products (that is, the expenditure weights multiplied by their price levels) for all cost categories yields the composite index level of the market basket in a given period. Repeating this step for other periods produces a series of market basket levels over time.

Dividing an index level for a given period by an index level for an earlier period produces a rate of growth in the input price index over that timeframe.

As noted above, the market basket is described as a fixed-weight index because it represents the change in price over time of a constant mix (quantity and intensity) of goods and services needed to furnish hospital services. The effects on total expenditures resulting from changes in the mix of goods and services purchased subsequent to the base period are not measured. For example, a hospital hiring more nurses to accommodate the needs of patients would increase the volume of goods and services purchased by the hospital, but would not be factored into the price change measured by a fixed-weight hospital market basket. Only when the index is rebased would changes in the quantity and intensity be captured, with those changes being reflected in the cost weights. Therefore, we rebase the market basket periodically so that the cost weights reflect a recent mix of goods and services that hospitals purchase (hospital inputs) to furnish inpatient care.

3. Development of the 2013-Based LTCH Market Basket Cost Categories and Weights

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25154), we invited public comments on our proposed methodology for deriving the 2013-based LTCH market basket. We received one general comment regarding our proposed 2013-based LTCH market basket.

Comment: One commenter supported CMS’ proposed methodology to revise and rebase the LTCH market basket.

Response: We appreciate the commenter’s support.

We summarize and respond to any public comments received regarding the specifics of our proposed methodology under the applicable sections below, and provide final decisions regarding each proposed methodology in the relevant section.

a. Use of Medicare Cost Report Data

The proposed 2013-based LTCH market basket consists of six major cost categories derived from the 2013 LTCH Medicare cost reports (CMS Form 2552–10), including wages and salaries, employee benefits, contract labor, pharmaceuticals, professional liability insurance, and capital. After we calculate these cost categories, we are left with a residual cost category, which reflects all other input costs other than those captured in the six cost categories above. This is the same number of cost categories derived for the 2009-based LTCH-specific market basket using the 2009 Medicare cost report data (CMS Form 2552–06). These 2013 Medicare cost reports include data for cost reporting periods beginning on and after October 1, 2012, and before October 1, 2013. We proposed to use 2013 as the base year because we believed that the 2013 LTCH cost reports represented the most recent, complete set of Medicare cost report data available to develop cost weights for an LTCH market basket. Medicare cost report data include costs for all patients, including Medicare, Medicaid, and private payer.

Because our goal is to measure cost shares for facilities that serve Medicare beneficiaries, and are reflective of case-mix and practice patterns associated with providing services to Medicare beneficiaries in LTCHs, we proposed to limit our selection of Medicare cost reports for those facilities that have a Medicare average length of stay (LOS) that is within a comparable range of their total facility average LOS. We define the Medicare average LOS based on data reported on the Medicare cost report (CMS Form 2552–10) Worksheet S–3, Part I, Line 14. We believe that applying the LOS edit results in a more accurate reflection of the structure of costs for Medicare covered days. For the 2009-based LTCH-specific market basket, we used the cost reports submitted by LTCHs with Medicare average LOS within 15 percent (that is, 15 percent higher or lower) of the total facility average LOS for the hospital.

Based on our analysis of the 2013 Medicare cost reports, for the proposed 2013-based LTCH market basket, we proposed to use the cost reports submitted by LTCHs with Medicare average LOS within 25 percent (that is, 25 percent higher or lower) of the total facility average LOS for the hospital (this edit excludes 6 percent of LTCH providers). Applying the proposed trim resulted in a subset of LTCH Medicare cost reports with an average Medicare LOS of 27 days, average facility LOS of 28 days, and aggregate Medicare utilization (as measured by Medicare inpatient LTCH days as a percentage of total facility inpatient LTCH days) of 66 percent. If we were to apply the same trim as was applied for the 2009-based LTCH-specific market basket, we would exclude 11 percent of LTCH providers, but the results would be very similar with an average Medicare LOS of 27 days, average facility LOS of 27 days, and aggregate Medicare utilization of 66 percent. The 6 percent of providers that were excluded from the proposed 2013-based LTCH market basket have an average Medicare LOS of 29 days, average facility LOS of 77 days, and aggregate Medicare utilization of 12 percent. We stated that we believe that the use of this proposed trim, instead of the trim used to develop the 2009-based LTCH-specific market basket, is a technical improvement because data from more LTCHs are used while still being reflective of case-mix and practice patterns associated with providing services to Medicare beneficiaries.

Comment: One commenter requested that CMS identify whether the 6 percent of total LTCH providers that CMS excluded when applying the LOS edit had any significant characteristics whereby their exclusion could have an impact on the calculation of rates and/ or weights. The commenter further inquired whether the exclusion of these providers is creating a biased system.

Response: As stated in the proposed rule, our goal when deriving cost shares from the market basket methodology is to use Medicare cost reports for those facilities that serve Medicare beneficiaries, and
are reflective of case-mix and practice patterns associated with providing services to Medicare beneficiaries in LTCHs. Therefore, we proposed to limit our selection of Medicare cost reports to those from LTCHs that have a Medicare average LOS that is within a comparable range of their total facility average LOS. We believe that applying the LOS edit results in a more accurate reflection of the structure of costs for Medicare covered days.

In response to the comment, we performed a sensitivity analysis where we recalculated the major cost weights using the Medicare cost report data for all LTCHs, as opposed to our proposed methodology of excluding approximately 6 percent of LTCH providers based on the Medicare and total facility LOS. We found that the effect on the cost weights was small; the difference from the proposed major cost weights ranged from 0.0 percentage point to 0.7 percentage point, in absolute terms, and averaged 0.1 percentage point across the six major cost weights. We then also derived a LTCH market basket using these recalculated cost weights and found that, in any given year of the projection period, there was no difference in the growth rates between this market basket and the proposed market basket (when rounded to the tenth of one percentage point).

In summary, our analysis does not support the commenter’s suggestion that the exclusion of those LTCH providers that had a Medicare LOS that was outside a comparable range of their total LOS resulted in estimates that were biased. We believe that these excluded providers are not reflective of case mix and practice patterns associated with providing services to Medicare beneficiaries in LTCHs, and therefore should be excluded as we proposed.

Furthermore, the exclusion of these providers does not have a material impact on the cost weights or market basket update.

After consideration of the public comments we received, we are adopting our proposed LOS trim methodology as final.

Using the resulting set of Medicare cost reports, we proposed to calculate cost weights for seven major cost categories of the proposed 2013-based LTCH market basket (wages and salaries, employee benefits, contract labor, professional liability insurance, pharmaceuticals, capital, and an “all other” residual cost category). The methodology used to develop the proposed 2013-based LTCH market basket cost weights is generally the same methodology used to develop the 2009-based LTCH-specific market basket cost weights. We describe the detailed methodology for obtaining costs for each of these seven cost categories below.

(1) Wages and Salaries Costs

We proposed to derive wages and salaries costs as the sum of inpatient salaries, ancillary salaries, and a proportion of overhead (or general service cost center) salaries as reported on Worksheet A, Column 1. Because overhead salary costs are attributable to the entire LTCH, we proposed to only include the proportion attributable to the Medicare allowable cost centers. Similar to the 2009-based LTCH-specific market basket major cost weights, we define Medicare allowable total costs (routine, ancillary and capital) as costs that are eligible for payment through the LTCH PPS. We proposed to estimate the proportion of overhead salaries that are attributable to Medicare allowable costs centers by multiplying the ratio of Medicare allowable cost centers’ salaries to total salaries (Worksheet A, Column 1, Line 200) by total overhead salaries. A similar methodology was used to derive wages and salaries costs in the 2009-based LTCH-specific market basket.

We did not receive any public comments on our proposed methodology for deriving wages and salaries costs. Therefore, we are adopting our proposed methodology as final.

(2) Employee Benefit Costs

Similar to the 2009-based LTCH-specific market basket, we proposed to calculate employee benefit costs using Worksheet S-3, Part II. The completion of Worksheet S-3, Part II is only required for IPPS hospitals. However, for 2013, we found that roughly 35 percent of all LTCHs voluntarily reported these data (similar to prior years). We note that this worksheet is only required to be completed by IPPS hospitals. Our analysis of the Worksheet S-3, Part II data submitted by these LTCHs indicates that we have a large enough sample to enable us to produce a reasonable employee benefit cost weight. Specifically, we found that when we recalculated the cost weight after weighting to reflect the characteristics of the universe of LTCHs (type of control (nonprofit, for-profit, and government) and by region), the recalculation did not have a material effect on the resulting cost weight. Therefore, as was done for the 2009-based LTCH-specific market basket, we proposed to use Worksheet S-3, Part II to calculate the contract labor cost weight in the proposed 2013-based LTCH market basket.

We did not receive any public comments on our proposed methodology for deriving contract labor costs. Therefore, we are adopting our proposed methodology as final.

(3) Contract Labor Costs

Contract labor costs are primarily associated with direct patient care services. Contract labor costs for services such as accounting, billing, and legal are estimated using other government data sources as described below. As was done for the 2009-based LTCH-specific market basket, we proposed to derive the contract labor cost weight for the 2013-based LTCH market basket using voluntarily reported data from Worksheet S-3, Part II. Approximately 48 percent of LTCHs voluntarily reported contract labor cost on the Worksheet S-3, Part II. Our analysis of these data indicates that we have a large enough sample to enable us to produce a reasonable contract labor cost weight. Specifically, we found that when we recalculated the cost weight after weighting to reflect the characteristics of the universe of LTCHs (type of control (nonprofit, for-profit, and government) and by region), the recalculation did not have a material effect on the resulting cost weight. Therefore, as was done for the 2009-based LTCH-specific market basket, we proposed to use Worksheet S-3, Part II to calculate the contract labor cost weight in the proposed 2013-based LTCH market basket.

We did not receive any public comments on our proposed methodology for deriving contract labor costs. Therefore, we are adopting our proposed methodology as final.

(4) Pharmaceutical Costs

We proposed to calculate pharmaceutical costs using costs reported on Worksheet A, Column 7, minus the amount on Worksheet A, Column 1, for the pharmacy cost center (Line 15) and drugs charged to patients
cost methodology was used for the 2009-based LTCH-specific market basket using the CMS Form 2552–96.

We did not receive any public comments on our proposed methodology for deriving pharmaceutical costs. Therefore, we are adopting our proposed methodology as final.

(5) Professional Liability Insurance Costs

We proposed that professional liability insurance (PLI) costs (often referred to as malpractice costs) be equal to premiums, paid losses and self-insurance costs reported on Worksheet S2, Part I, Line 118.10, Columns 1 through 3. A similar methodology was used for the 2009-based LTCH-specific market basket using the CMS Form 2552–96.

We did not receive any public comments on our proposed methodology for deriving capital costs. Therefore, we are adopting our proposed methodology as final.

(6) Capital Costs

We proposed that capital costs be equal to Medicare allowable capital costs as reported on Worksheet B, Part II, Column 26. We proposed to define Medicare allowable capital costs for contract centers: 30 through 35, 50 through 76 (excluding 52, 61, and 75), 90 through 91 and 93. A similar methodology was used for the 2009-based LTCH-specific market basket using the CMS Form 2552–96.

We did not receive any public comments on our proposed methodology for deriving capital costs. Therefore, we are adopting our proposed methodology as final.

The wages and salaries cost weight was approximately 1 percentage point higher than the wages and salaries cost weight for the 2009-based LTCH-specific market basket, while the contract labor cost weight is approximately 1 percentage point lower. The proposed 2013-based pharmaceuticals cost weight was roughly 1 percentage point lower than the cost weight for the 2009-based LTCH-specific market basket.

As we did for the 2009-based LTCH market basket, we proposed to allocate the contract labor cost weight to the wages and salaries and employee benefits cost weights based on their relative proportions under the assumption that contract labor costs are comprised of both wages and salaries and employee benefits. The contract labor allocation proportion for wages and salaries is equal to the wages and salaries cost weight as a percent of the sum of the wages and salaries cost weight and the employee benefits cost weight. This rounded percentage was 86 percent. Therefore, we proposed to allocate 86 percent of the contract labor cost weight to the wages and salaries cost weight and 14 percent to the employee benefits cost weight. We referred readers to Table VII–2 below that shows the proposed wages and salaries and employee benefit cost weights after contract labor cost weight allocation for both the proposed 2013-based LTCH market basket (which, as we indicate later, we are finalizing) and the 2009-based LTCH-specific market basket.

## Table VII–1—Major Cost Categories and Their Respective Cost Weights as Calculated from Medicare Cost Reports

<table>
<thead>
<tr>
<th>Major cost categories</th>
<th>Proposed and final 2013-based LTCH market basket cost weight (percent of total costs)</th>
<th>2009-based LTCH-specific market basket cost weight (percent of total costs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages and Salaries</td>
<td>41.5</td>
<td>40.4</td>
</tr>
<tr>
<td>Employee Benefits</td>
<td>6.5</td>
<td>7.0</td>
</tr>
<tr>
<td>Contract Labor</td>
<td>5.9</td>
<td>6.9</td>
</tr>
<tr>
<td>Professional Liability Insurance (Malpractice)</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>7.6</td>
<td>8.9</td>
</tr>
<tr>
<td>Capital</td>
<td>9.7</td>
<td>9.8</td>
</tr>
<tr>
<td>All Other</td>
<td>27.8</td>
<td>26.1</td>
</tr>
</tbody>
</table>

We then proposed to remove those providers whose derived cost weights fall in the top and bottom 5 percent of provider-specific derived cost weights to ensure the removal of costs for outlier cases. This trim was applied after first keeping only those providers that had a cost weight greater than zero and less than 100 percent. After the costs for outlier cases were removed in this manner, we proposed to sum the costs for each category across all remaining providers, and then divided this by the sum of total Medicare allowable costs across all remaining providers to obtain a cost weight for the proposed 2013-based LTCH market basket for the given category. Finally, we proposed to calculate a seventh major cost weight—the residual “All Other” cost weight to reflect all remaining costs that are not captured in the previous six cost categories listed. We referred readers to Table VII–1 below for the resulting proposed cost weights for these major cost categories (which, as we indicate later, we are finalizing).
After the allocation of the contract labor cost weight, the proposed 2013-based wages and salaries cost weight was 0.3 percentage point higher, while the employee benefit cost weight was 0.7 percentage point lower, relative to the respective cost weights for the 2009-based LTCH-specific market basket. As a result, in the proposed 2013-based LTCH market basket, the compensation cost weight was 0.4 percentage point lower than the compensation cost weight for the 2009-based LTCH-specific market basket.

We did not receive any public comments on our proposed methodology for deriving the major cost weights for the 2013-based LTCH market basket. Therefore, we are adopting our proposed methodology as final.

c. Derivation of the Detailed Operating Cost Weights

To further divide the “All Other” residual cost weight estimated from the 2013 Medicare cost report data into more detailed cost categories, we proposed to use the 2007 Benchmark Input-Output (I-O) “Use Tables/Before Redefinitions/Purchaser Value” for NAICS 622000, Hospitals, published by the Bureau of Economic Analysis (BEA). These data are publicly available at the following Web site: http://www.bea.gov/industry/io_annual.htm.

The BEA Benchmark I-O data are scheduled for publication every 5 years with the most recent data available for 2007. The 2007 Benchmark I-O data are derived from the 2007 Economic Census and are the building blocks for BEA’s economic accounts. Therefore, they represent the most comprehensive and complete set of data on the economic processes or mechanisms by which output is produced and distributed. BEA also produces Annual I-O estimates. However, while based on a similar methodology, these estimates reflect less comprehensive and less detailed data sources and are subject to revision when benchmark data become available. Instead of using the less detailed Annual I-O data, we proposed to inflate the 2007 Benchmark I-O data forward to 2013 by applying the annual price changes from the respective price proxies to the appropriate market basket cost categories that are obtained from the 2007 Benchmark I-O data. We repeated this practice for each year. We then calculated the cost shares that each cost category represents of the 2007 data inflating to 2013. These resulting 2013 cost shares were applied to the “All Other” residual cost weight to obtain the detailed cost weights for the 2013-based LTCH market basket. For example, the cost for “Food: Direct Purchases” represented 6.5 percent of the sum of the “All Other” 2007 Benchmark I-O Hospital Expenditures inflated to 2013. Therefore, the “Food: Direct Purchases” cost weight represented 6.5 percent of the proposed 2013-based LTCH market basket’s “All Other” cost category (27.8 percent), yielding a “final” “Food: Direct Purchases” proposed cost weight of 1.8 percent in the proposed 2013-based LTCH market basket (0.065 × 27.8 percent = 1.8 percent).

Using this methodology, we proposed to derive 18 detailed LTCH market basket cost category weights from the proposed 2013-based LTCH market basket residual cost weight (27.8 percent). These categories are:(1) Electricity; (2) Fuel, Oil, and Gasoline; (3) Water and Sewerage; (4) Food: Direct Purchases; (5) Food: Contract Services; (6) Chemicals; (7) Medical Instruments; (8) Rubber and Plastics; (9) Paper and Printing Products; (10) Miscellaneous Products; (11) Professional Fees: Labor-Related; (12) Administrative and Facilities Support Services; (13) Installation, Maintenance, and Repair Services; (14) All Other Labor-Related Services; (15) Professional Fees: Nonlabor-Related; (16) Financial Services; (17) Telephone Services; and (18) All Other Nonlabor-Related Services.

We did not receive any public comments on our proposed methodology for deriving the detailed operating cost weights for the 2013-based LTCH market basket. Therefore, we are adopting our proposed methodology as final.

d. Derivation of the Detailed Capital Cost Weights

As described in section VII.D.3.b. of the preamble of this final rule, we proposed a capital-related cost weight of 9.7 percent as calculated from the 2013 Medicare cost reports for LTCHs after applying the proposed trims described above. We proposed to then separate this total capital-related cost weight into more detailed cost categories.

Using 2013 Medicare cost reports, we were able to group capital-related costs into the following categories: Depreciation, Interest, Lease, and Other Capital-Related costs. For each of these categories, we proposed to determine what proportion of total capital-related costs the category represents using the data reported by the LTCH on Worksheet A–7, which is the same methodology used for the 2009-based LTCH-specific market basket.

We also proposed to allocate lease costs across each of the remaining detailed capital-related cost categories as was done in the 2009-based LTCH-specific market basket. This resulted in three primary capital-related cost categories in the proposed 2013-based LTCH market basket: Depreciation, Interest, and Other Capital-Related costs. Lease costs are unique in that they are not broken out as a separate cost category in the proposed 2013-based LTCH market basket. Rather, we proposed to proportionally distribute these costs among the cost categories of Depreciation, Interest, and Other Capital-Related, reflecting the assumption that the underlying cost structure of leases is similar to that of capital-related costs in general. As was done for the 2009-based LTCH-specific market basket, we proposed to assume that 10 percent of the lease costs as a proportion of total capital-related costs (62.3 percent) represents overhead and to assign those costs to the Other Capital-Related cost category accordingly. Therefore, we assumed that approximately 6.2 percent (62.3 percent...
× 0.1) of total capital-related costs represent lease costs attributable to overhead, and we proposed to add this 6.2 percent to the 5.9 percent Other Capital-Related cost category weight. We then proposed to distribute the remaining lease costs (56.1 percent, or 62.3 percent – 6.2 percent) proportionally across the three cost categories (Depreciation, Interest, and Other Capital-Related) based on the proportion that these categories comprised of the sum of the Depreciation, Interest, and Other Capital-Related cost categories (excluding lease expenses). For example, the Other Capital-Related capital cost category represented 15.5 percent of all three cost categories (Depreciation, Interest, and Other Capital-Related) prior to any lease expenses being allocated. This 15.5 percent was applied to the 56.1 percent of remaining lease expenses so that another 8.7 percent of lease expenses as a percent of total capital-related costs was allocated to the Other Capital-Related cost category. Therefore, the resulting proposed Other Capital-Related cost weight was 20.8 percent (5.9 percent + 6.2 percent + 8.7 percent). This is the same methodology used for the 2009-based LTCH-specific market basket. The proposed allocation of these lease expenses are shown in Table VII-3.

Finally, we proposed to further divide the Depreciation and Interest cost categories. We proposed to separate the Depreciation cost category into the following two categories: (1) Building and Fixed Equipment and (2) Movable Equipment. We also proposed to separate the Interest cost category into the following two categories: (1) Government/Nonprofit; and (2) For-profit.

To disaggregate the depreciation cost weight, we needed to determine the percent of total depreciation costs for LTCHs (after the allocation of lease costs) that are attributable to building and fixed equipment, which we hereafter refer to as the “fixed percentage.” We proposed to use depreciation and lease data from Worksheet A–7 of the 2013 Medicare cost reports, which is the same methodology used for the 2009-based LTCH-specific market basket. Based on the 2013 LTCH Medicare cost report data, we determined that depreciation costs for building and fixed equipment account for 39 percent of total depreciation costs, while depreciation costs for movable equipment account for 61 percent of total depreciation costs. As mentioned above, we proposed to allocate lease expenses among the Depreciation, Interest, and Other Capital-related cost categories. We determined that building and fixed equipment expenses accounted for 86 percent of total leasing expenses, while leasing movable equipment expenses accounted for 14 percent of total leasing expenses. We proposed to sum the depreciation and leasing expenses for building and fixed equipment, as well as sum the depreciation and leasing expenses for movable equipment. This resulted in the proposed building and fixed equipment depreciation cost weight (after leasing costs are included) representing 73 percent of total depreciation costs and the movable equipment depreciation cost weight (after leasing costs are included) representing 27 percent of total depreciation costs.

To disaggregate the interest cost weight, we needed to determine the percent of total interest costs for LTCHs that are attributable to government and nonprofit facilities, which we hereafter refer to as the “nonprofit percentage,” because price pressures associated with these types of interest costs tend to differ from those for for-profit facilities. We proposed to use interest costs data from Worksheet A–7 of the 2013 Medicare cost reports for LTCHs, which is the same methodology used for the 2009-based LTCH-specific market basket. The nonprofit percentage determined using this method was 23 percent.

As we stated in the proposed rule, ultimately, if finalized, these detailed capital cost shares would be applied to the total capital-related cost weight determined in section VII.D.3.b. of the preamble of this final rule to separate the total capital-related cost weight of 9.7 percent into more detailed cost categories and weights.

We did not receive any public comments on our proposed methodology for deriving the detailed capital cost weights for the 2013-based LTCH market basket. Therefore, we are adopting our proposed methodology as final. Table VII-3 below provides the proposed and final detailed capital cost shares obtained from the Medicare cost reports.

### TABLE VII–3—DETAILED CAPITAL COST WEIGHTS FOR THE 2013-BASED LTCH MARKET BASKET

<table>
<thead>
<tr>
<th>Cost categories</th>
<th>Proposed and final cost shares obtained from Medicare cost reports (percent of total costs)</th>
<th>Proposed and final detailed capital cost shares after allocation of lease expenses (percent of total costs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Depreciation</td>
<td>22.0</td>
<td>54.8</td>
</tr>
<tr>
<td>Building and Fixed Equipment</td>
<td>16.1</td>
<td>40.1</td>
</tr>
<tr>
<td>Movable Equipment</td>
<td>5.9</td>
<td>14.7</td>
</tr>
<tr>
<td>Interest</td>
<td>9.8</td>
<td>24.4</td>
</tr>
<tr>
<td>Government/Nonprofit</td>
<td>2.2</td>
<td>5.6</td>
</tr>
<tr>
<td>For-profit</td>
<td>7.6</td>
<td>18.8</td>
</tr>
<tr>
<td>Lease</td>
<td>62.3</td>
<td>20.8</td>
</tr>
<tr>
<td>Other</td>
<td>5.9</td>
<td></td>
</tr>
</tbody>
</table>

Note: Total may not add to 100 due to rounding.

e. 2013-Based LTCH Market Basket Cost Categories and Weights

Similar to the 2012-based IRF and 2012-based IPF market baskets, the proposed and final 2013-based LTCH market basket does not include separate cost categories for Apparel, Machinery and Equipment, and Postage. Due to the small weights associated with these detailed categories and relatively stable price growth in the applicable price proxy, we proposed to include the Apparel and Machinery and Equipment in the Miscellaneous Products cost category and the Postage in the All-Other Nonlabor-Related Services cost category. We note that the machinery...
and equipment expenses are for equipment that is paid for in a given year and not depreciated over the asset’s useful life. Depreciation expenses for movable equipment are reflected in the capital-related cost weight of the 2013-based LTCH market basket. For the 2013-based LTCH market basket, we also proposed to include a separate cost category for Installation, Maintenance, and Repair Services in order to proxy these costs by a price index that better reflects the price changes of labor associated with maintenance-related services.

We did not receive any public comments on our proposed detailed operating cost weights for the 2013-based LTCH market basket. Therefore, we are adopting our proposed detailed operating cost weights as final.

Table VII–4 below shows the proposed and final cost categories and weights for the final 2013-based LTCH market basket compared to the 2009-based LTCH-specific market basket.

**TABLE VII–4—2013-BASED LTCH COST WEIGHTS COMPARED TO 2009-BASED LTCH COST WEIGHTS**

<table>
<thead>
<tr>
<th>Cost category</th>
<th>Proposed and final 2013-based LTCH cost weight</th>
<th>2009-based LTCH cost weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Compensation</td>
<td>53.9</td>
<td>54.3</td>
</tr>
<tr>
<td>Wages and Salaries</td>
<td>46.6</td>
<td>46.3</td>
</tr>
<tr>
<td>Employee Benefits</td>
<td>7.3</td>
<td>8.0</td>
</tr>
<tr>
<td>Utilities</td>
<td>2.2</td>
<td>1.8</td>
</tr>
<tr>
<td>Electricity</td>
<td>1.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Fuel, Oil, and Gasoline</td>
<td>1.1</td>
<td>0.3</td>
</tr>
<tr>
<td>Water &amp; Sewerage</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Professional Liability Insurance</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>All Other Products</td>
<td>33.2</td>
<td>33.3</td>
</tr>
<tr>
<td>All Other Products</td>
<td>16.3</td>
<td>19.5</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>7.6</td>
<td>8.9</td>
</tr>
<tr>
<td>Food: Direct Purchases</td>
<td>1.8</td>
<td>3.4</td>
</tr>
<tr>
<td>Food: Contract Services</td>
<td>1.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Chemicals</td>
<td>0.7</td>
<td>1.3</td>
</tr>
<tr>
<td>Medical Instruments</td>
<td>2.4</td>
<td>2.1</td>
</tr>
<tr>
<td>Rubber &amp; Plastics</td>
<td>0.6</td>
<td>1.3</td>
</tr>
<tr>
<td>Paper and Printing Products</td>
<td>1.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Apparel</td>
<td>0.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Machinery and Equipment</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>All Other Services</td>
<td>16.9</td>
<td>13.7</td>
</tr>
<tr>
<td>Labor-Related Services</td>
<td>8.3</td>
<td>5.3</td>
</tr>
<tr>
<td>Professional Fees: Labor-related</td>
<td>3.5</td>
<td>2.3</td>
</tr>
<tr>
<td>Administrative and Facilities Support Services</td>
<td>2.4</td>
<td>0.9</td>
</tr>
<tr>
<td>Installation, Maintenance, and Repair Services</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>All Other: Labor-related Services</td>
<td>2.0</td>
<td>2.6</td>
</tr>
<tr>
<td>Nonlabor-Related Services</td>
<td>8.6</td>
<td>8.4</td>
</tr>
<tr>
<td>Professional Fees: Nonlabor-related</td>
<td>3.6</td>
<td>5.3</td>
</tr>
<tr>
<td>Financial services</td>
<td>2.9</td>
<td>1.0</td>
</tr>
<tr>
<td>Telephone Services</td>
<td>0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Postage</td>
<td>0.7</td>
<td>0.8</td>
</tr>
<tr>
<td>All Other: Nonlabor-related Services</td>
<td>1.4</td>
<td>0.7</td>
</tr>
<tr>
<td>Capital-Related Costs</td>
<td>9.7</td>
<td>9.8</td>
</tr>
<tr>
<td>Depreciation</td>
<td>5.3</td>
<td>5.7</td>
</tr>
<tr>
<td>Fixed Assets</td>
<td>3.9</td>
<td>3.8</td>
</tr>
<tr>
<td>Movable Equipment</td>
<td>1.4</td>
<td>1.9</td>
</tr>
<tr>
<td>Interest Costs</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Government/Nonprofit</td>
<td>0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>For Profit</td>
<td>1.8</td>
<td>1.7</td>
</tr>
<tr>
<td>Other Capital-Related Costs</td>
<td>2.0</td>
<td>1.7</td>
</tr>
</tbody>
</table>

**Note:** Detail may not add to total due to rounding.

4. Selection of Price Proxies

After computing the cost weights for the 2013-based LTCH market basket, it was necessary to select appropriate wage and price proxies to reflect the rate of price change for each expenditure category. With the exception of the proxy for Professional Liability Insurance, all of the proxies that we proposed for the operating portion of the 2013-based LTCH market basket are based on Bureau of Labor Statistics (BLS) data and are grouped into one of the following BLS categories:

- **Producer Price Indexes**—Producer Price Indexes (PPIs) measure price changes for goods sold in markets other than the retail market. PPIs are preferable price proxies for goods and services that hospitals purchase as inputs because PPIs better reflect the actual price changes encountered by hospitals. For example, we proposed to use a PPI for prescription drugs, rather than the Consumer Price Index (CPI) for prescription drugs, because hospitals generally purchase drugs directly from a wholesaler. The PPIs that we proposed to use measure price changes at the final stage of production.

- **Consumer Price Indexes**—Consumer Price Indexes (CPIs) measure change in the prices of final goods and
services bought by the typical consumer. Because they may not represent the price encountered by a producer, we proposed to use CPIs only if an appropriate PPI was not available, or if the expenditures were more like those faced by retail consumers in general rather than by purchasers of goods at the wholesale level. For example, the CPI for food purchased away from home is used as a proxy for contracted food services.

- Employment Cost Indexes—

Employment Cost Indexes (ECIs) measure the rate of change in employee wage rates and employer costs for employee benefits per hour worked. These indexes are fixed-weight indexes and strictly measure the change in wage rates and employee benefits per hour. Appropriately, they are not affected by shifts in employment mix.

We evaluated the price proxies using the criteria of reliability, timeliness, availability, and relevance. Reliability indicates that the index is based on valid statistical methods and has low sampling variability. Timeliness implies that the proxy is published regularly, preferably at least once a quarter. Availability means that the proxy is publicly available. Finally, relevance means that the proxy is applicable and representative of the cost category weight to which it is applied. We believe that the proposed PPIs, CPIs, and ECIs selected met these criteria.

Table VII–7 lists the price proxies that we proposed for the 2013-based LTCH market basket. Below we present a detailed explanation of the price proxies that we proposed for each cost category weight. We note that many of the proxies that we proposed to use for the 2013-based LTCH market basket are the same as those used for the 2009-based LTCH-specific market basket. For further discussion on the 2009-based LTCH market basket, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53467 through 53479).

a. Price Proxies for the Operating Portion of the 2013-Based LTCH Market Basket

(1) Wages and Salaries

We proposed to use the ECI for Wages and Salaries for All Civilian Workers in Hospitals (BLS series code CU101622000000001) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(2) Employee Benefits

We proposed to use the ECI for Total Benefits for All Civilian Workers in Hospitals to measure the price growth of this cost category. This ECI is calculated using the ECI for Total Compensation for All Civilian Workers in Hospitals (BLS series code CIU101622000000001) and the relative importance of wages and salaries within total compensation. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(3) Electricity

We proposed to use the PPI Commodity for Commercial Electric Power (BLS series code WPU0542) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(4) Fuel, Oil, and Gasoline

We proposed to change the proxy used for the Fuel, Oil, and Gasoline cost category. The 2009-based LTCH-specific market basket uses the PPI Industry for Petroleum Refineries (BLS series code PCU32411–32441) to proxy these expenses.

For the proposed 2013-based LTCH market basket, we proposed to use a blend of the PPI Industry for Petroleum Refineries (BLS series code PCU32411–32411) and the PPI Commodity for Natural Gas (BLS series code WPU0531). Our analysis of the Bureau of Economic Analysis’ 2007 Benchmark Input-Output data (use table before redefinitions, purchaser’s value for NAICS 622000 [Hospitals]), shows that petroleum refineries expenses accounts for approximately 70 percent and natural gas accounts for approximately 30 percent of the fuel, oil, and gasoline expenses. Therefore, we proposed to use a blended proxy of 70 percent of the PPI Industry for Petroleum Refineries (BLS series code PCU32411–32411) and 30 percent of the PPI Commodity for Natural Gas (BLS series code WPU0531). We believe that these two price proxies are the most technically appropriate indices available to measure the price growth of the Fuel, Oil, and Gasoline cost category in the 2013-based LTCH market basket.

(5) Water and Sewage

We proposed to use the CPI for Water and Sewage Maintenance (All Urban Consumers) (BLS series code CUUR0000SEHV01) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(6) Professional Liability Insurance

We proposed to use proxy price changes in hospital professional liability insurance premiums (PLI) using percentage changes as estimated by the CMS Hospital Professional Liability Index. To generate these estimates, we collected commercial insurance premiums for a fixed level of coverage while holding nonprice factors constant (such as a change in the level of coverage). This is the same price proxy used in the 2009-based LTCH-specific market basket.

(7) Pharmaceuticals

We proposed to use the PPI Commodity for Pharmaceuticals for Human Use, Prescription (BLS series code WPU5407003) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(8) Food: Direct Purchases

We proposed to use the PPI Commodity for Processed Foods and Feeds (BLS series code WPU002) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(9) Food: Contract Services

We proposed to use the CPI for Food Away From Home (All Urban Consumers) (BLS series code CUUR0000SEHV01) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(10) Chemicals

We proposed to continue to use a four-part blended PPI composed of the PPI Industry for Industrial Gas Manufacturing (BLS series code PCU325120325120P), the PPI Industry for Other Basic Inorganic Chemical Manufacturing (BLS series code PCU32518–32518), the PPI Industry for Other Basic Organic Chemical Manufacturing (BLS series code PCU32519–32519), and the PPI Industry for Soap and Cleaning Compound Manufacturing (BLS series code PCU32561–32561). We proposed to update the blended weights using 2007 Benchmark I–O data, which we also proposed to use for the 2013-based LTCH market basket. The 2009-based LTCH-specific market basket included the same blended chemical price proxy, but used the 2002 Benchmark I–O data to determine the weights of the blended chemical price index. The 2007 Benchmark I–O data show more weight for organic chemical products and less weight for inorganic chemical products compared to the 2002 Benchmark I–O data.
we are finalizing) weights for each of the four PPIs used to create the blended PPI.

**TABLE VII–5—BLENDED CHEMICAL PPI WEIGHTS**

<table>
<thead>
<tr>
<th>Name</th>
<th>Proposed and final 2013-based LTCH weights (percent)</th>
<th>2009-Based LTCH weights (percent)</th>
<th>NAICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPI Industry for Industrial Gas Manufacturing</td>
<td>32</td>
<td>35</td>
<td>325120</td>
</tr>
<tr>
<td>PPI Industry for Other Basic Inorganic Chemical Manufacturing</td>
<td>17</td>
<td>25</td>
<td>325180</td>
</tr>
<tr>
<td>PPI Industry for Other Basic Organic Chemical Manufacturing</td>
<td>45</td>
<td>30</td>
<td>325190</td>
</tr>
<tr>
<td>PPI Industry for Soap and Cleaning Compound Manufacturing</td>
<td>6</td>
<td>10</td>
<td>325610</td>
</tr>
</tbody>
</table>

(11) Medical Instruments

We proposed to use a blend for the Medical Instruments cost category. The 2007 Benchmark Input-Output data show an approximate 50/50 split between Surgical and Medical Instruments and Medical and Surgical Appliances and Supplies for this cost category. Therefore, we proposed to use a blend composed of 50 percent of the PPI Commodity for Surgical and Medical Instruments (BLS code WPU1562) and 50 percent of the PPI Commodity for Medical and Surgical Appliances and Supplies (BLS code WPU1563). The 2009-based LTCH-specific market basket used the single, higher level PPI Commodity for Medical, Surgical, and Personal Aid Devices (BLS series code WPU156). We stated in the proposed rule that we believe that the proposed price proxy better reflects the mix of expenses for this cost category as obtained from the 2007 Benchmark I-O data.

(12) Rubber and Plastics

We proposed to use the PPI Commodity for Rubber and Plastic Products (BLS series code WPU07) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(13) Paper and Printing Products

We proposed to use the PPI Commodity for Converted Paper and Paperboard Products (BLS series code WPU0915) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(14) Miscellaneous Products

We proposed to use the PPI Commodity for Finished Goods Less Food and Energy (BLS series code WPUFD4131) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(15) Professional Fees: Labor-Related

We proposed to use the ECI for Total Compensation for Private Industry Workers in Professional and Related (BLS series code CIU21000012000001) to measure the price growth of this category. It includes occupations such as legal, accounting, and engineering services. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(16) Administrative and Facilities Support Services

We proposed to use the ECI for Total Compensation for Private Industry Workers in Office and Administrative Support (BLS series code CIU21000022000001) to measure the price growth of this category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(17) Installation, Maintenance, and Repair Services

We proposed to use the ECI for Total Compensation for All Civilian Workers in Installation, Maintenance, and Repair (BLS series code CIU10100043000001) to measure the price growth of this new cost category. Previously, these costs were included in the ‘All Other: Labor-Related Services’ category and were proxied by the ECI for Total Compensation for Private Industry Workers in Service Occupations (BLS series code CIU21000030000001). We stated in the proposed rule that we believe that this index better reflects the price changes of labor associated with maintenance-related services and its incorporation represents a technical improvement to the market basket.

(18) All Other: Labor-Related Services

We proposed to use the ECI for Total Compensation for Private Industry Workers in Service Occupations (BLS series code CIU21000030000000) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(19) Professional Fees: Nonlabor-Related

We proposed to use the ECI for Total Compensation for Private Industry Workers in Professional and Related (BLS series code CIU21000012000001) to measure the price growth of this category. This is the same price proxy that we are using for the Professional Fees: Labor-related cost category and the same price proxy used in the 2009-based LTCH-specific market basket.

(20) Financial Services

We proposed to use the ECI for Total Compensation for Private Industry Workers in Financial Activities (BLS series code CIU210520A0000001) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(21) Telephone Services

We proposed to use the CPI for Telephone Services (BLS series code CUUR0000SEED) to measure the price growth of this cost category. This is the same price proxy used in the 2009-based LTCH-specific market basket.

(22) All Other: Nonlabor-Related Services

We proposed to use the CPI for All Items Less Food and Energy (BLS series code CUUR0000SA0L1E) to measure the price growth of this cost category. We stated in the proposed rule that we believe that using the CPI for All Items Less Food and Energy avoids double counting of changes in food and energy prices as they are already captured elsewhere in the market basket. This is the same price proxy used in the 2009-based LTCH-specific market basket.

We did not receive any public comments on our proposed price proxies for the operating portion of the 2013-based LTCH market basket. Therefore, we are adopting our proposed price proxies for the operating
portion of the 2013-based LTCH market basket as final.

b. Price Proxies for the Capital Portion of the 2013-Based LTCH Market Basket

(1) Capital Price Proxies Prior to Vintage Weighting

We proposed to apply the same price proxies to the detailed capital-related cost categories as were applied in the 2009-based LTCH-specific market basket, which are described and provided in Table VII–7. We also proposed to continue to vintage weight the capital price proxies for Depreciation and Interest to capture the long-term consumption of capital. This vintage weighing method is the same method that was used for the 2009-based LTCH-specific market basket and is described in section VII.D.4.b.(2) of the preamble of this final rule.

We proposed to proxy the Depreciation: Building and Fixed Equipment cost category by BEA’s Chained Price Index for Nonresidential Construction for Hospitals and Special Care Facilities (BEA Table 5.4.4. Price Indexes for Private Fixed Investment in Structures by Type); the Depreciation: Movable Equipment cost category by the PPI Commodity for Machinery and Equipment (BLS series code WPU11); the Nonprofit Interest cost category by the average yield on Moody’s Aaa bonds (Bond Buyer 20-bond index); the For-Profit Interest cost category by the average yield on domestic municipal bonds (Bond Buyer 20-bond index); and the Other Capital-Related cost category by the CPI–U for Rent of Primary Residence (BLS series code CUUS0000SEHA). We stated in the proposed rule that we believe that these are the most appropriate proxies for LTCH capital-related costs that meet our selection criteria of relevance, timeliness, availability, and reliability.

We did not receive any public comments on our proposed price proxies for the capital portion of the 2013-based LTCH market basket. Therefore, we are adopting our proposed price proxies for the capital portion of the 2013-based LTCH market basket as final.

(2) Vintage Weights for Price Proxies

Because capital is acquired and paid for over time, capital-related expenses in any given year are determined by both past and present purchases of physical and financial capital. We stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25161) that the vintage-weighted capital-related portion of the 2013-based LTCH market basket is intended to capture the long-term consumption of capital, using vintage weights for depreciation (physical capital) and interest (financial capital). These vintage weights reflect the proportion of capital-related purchases attributable to each year of the expected life of building and fixed equipment, movable equipment, and interest. We proposed to use vintage weights to compute vintage-weighted price changes associated with depreciation and interest expenses.

Capital-related costs are inherently complicated and are determined by complex capital-related purchasing decisions, over time, based on such factors as interest rates and debt financing. In addition, capital is depreciated over time instead of being consumed in the same period it is purchased. By accounting for the vintage nature of capital, we are able to provide an accurate and stable annual measure of price changes. Annual nonvintage price changes for capital are unstable due to the volatility of interest rate changes and, therefore, do not reflect the actual annual price changes for LTCH capital-related costs. The capital-related component of the proposed 2013-based LTCH market basket reflects the underlying stability of the capital-related acquisition process.

To calculate the vintage weights for depreciation and interest expenses, we first needed a time series of capital-related purchases for building and fixed equipment and movable equipment. We found no single source that provides an appropriate time series of capital-related purchases by hospitals for all of the above components of capital purchases. The early Medicare cost reports did not have sufficient capital-related data to meet this need. Data we obtained from the American Hospital Association (AHA) did not include annual capital-related purchases. However, we were able to obtain data on total expenses back to 1963 from the AHA. Consequently, we proposed to use data from the AHA Panel Survey and the AHA Annual Survey to obtain a time series of total hospital expenses for hospitals. We then proposed to use data from the AHA Panel Survey supplemented with the ratio of depreciation to total hospital expenses obtained from the Medicare cost reports to derive a trend of annual depreciation expenses for 1963 through 2013. We separated these depreciation expenses into annual amounts of building and fixed equipment depreciation and movable equipment depreciation as determined earlier. From these annual depreciation amounts, we derived annual end-of-year book values for building and fixed equipment and movable equipment using the expected life for each type of asset category. While data are not available that are specific to LTCHs, we believe that this information for all hospitals serves as a reasonable alternative for the pattern of depreciation for LTCHs. We used the AHA data and methodology to derive the FY 2010-based IPPS capital market basket (78 FR 50604), and the capital components of the 2012-based IRF (80 FR 47062) and 2012-based IPF market baskets (80 FR 46672).

To continue to calculate the vintage weights for depreciation and interest expenses, we also needed to account for the expected lives for building and fixed equipment, movable equipment, and interest for the 2013-based LTCH market basket. We proposed to calculate the expected lives using Medicare cost report data for LTCHs. The expected life of any asset can be determined by dividing the value of the asset (excluding fully depreciated assets) by its current year depreciation amount. This calculation yields the estimated expected life of an asset if the rates of depreciation were to continue at current year levels, assuming straight-line depreciation. Using this proposed method, we determined the average expected life of building and fixed equipment to be equal to 18 years, and the average expected life of movable equipment to be equal to 8 years. For the expected life of interest, we believe that vintage weights for interest should represent the average expected life of building and fixed equipment because, based on previous research described in the FY 1997 IPPS final rule (61 FR 46198), the expected life of hospital debt instruments and the expected life of buildings and fixed equipment are similar. We note that for the 2009-based LTCH-specific market basket, we used 2009 Medicare cost reports for LTCHs to determine the expected life of building and fixed equipment and movable equipment (77 FR 53467 through 53479). The 2009-based LTCH-specific market basket was based on an expected average life of building and fixed equipment of 20 years and an expected average life of movable equipment of 8 years.

Multiplying these expected lives by the annual depreciation amounts results in annual year-end asset costs for building and fixed equipment and movable equipment. We then calculated a time series, beginning in 1964, of annual capital purchases by subtracting the previous year’s asset costs from the current year’s asset cost. For the building and fixed equipment and movable equipment vintage
weights, we proposed to use the real annual capital-related purchase amounts for each asset type to capture the actual amount of the physical acquisition, net of the effect of price inflation. These real annual capital-related purchase amounts are produced by deflating the nominal annual purchase amount by the associated price proxy as provided earlier in this final rule. For the interest vintage weights, we proposed to use the total nominal annual capital-related purchase amounts to capture the value of the debt instrument (including, but not limited to, mortgages and bonds). Using these capital-related purchase time series specific to each asset type, we proposed to calculate the vintage weights for building and fixed equipment, for movable equipment, and for interest.

The vintage weights for each asset type are deemed to represent the average purchase pattern of the asset over its expected life (in the case of building and fixed equipment and interest, 18 years, and in the case of movable equipment, 8 years). For each asset type, we proposed to use the time series of annual capital-related purchase amounts available from 2013 back to 1964. These data allow us to derive thirty-three 18-year periods of capital-related purchases for building and fixed equipment and interest, and forty-three 8-year periods of capital-related purchases for movable equipment. For each 18-year period for building and fixed equipment and interest, or 8-year period for movable equipment, we proposed to calculate annual vintage weights by dividing the capital-related purchase amount in any given year by the total amount of purchases over the entire 18-year or 8-year period. This calculation was done for each year in the 18-year or 8-year period and for each of the periods for which we have data. We then calculated the average vintage weight for a given year of the expected life by taking the average of these vintage weights across the multiple periods of data.

We did not receive any public comments on our proposed vintage weights for the 2013-based LTCH market basket. Therefore, we are adopting our proposed vintage weights as final.

The vintage weights for the capital-related portion of the proposed and final 2013-based LTCH market basket and the 2009-based LTCH-specific market basket are presented in Table VII–6 below.

### Table VII–6—2013-Based LTCH Market Basket and 2009-Based LTCH-Specific Market Basket Vintage Weights for Capital-Related Price Proxies

<table>
<thead>
<tr>
<th>Year</th>
<th>Building and fixed equipment</th>
<th>Movable equipment</th>
<th>Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2013-Based 18 years</td>
<td>2009-Based 20 years</td>
<td>2013-Based 8 years</td>
</tr>
<tr>
<td>1</td>
<td>0.044</td>
<td>0.034</td>
<td>0.104</td>
</tr>
<tr>
<td>2</td>
<td>0.046</td>
<td>0.037</td>
<td>0.110</td>
</tr>
<tr>
<td>3</td>
<td>0.048</td>
<td>0.039</td>
<td>0.117</td>
</tr>
<tr>
<td>4</td>
<td>0.050</td>
<td>0.042</td>
<td>0.124</td>
</tr>
<tr>
<td>5</td>
<td>0.051</td>
<td>0.043</td>
<td>0.128</td>
</tr>
<tr>
<td>6</td>
<td>0.051</td>
<td>0.045</td>
<td>0.132</td>
</tr>
<tr>
<td>7</td>
<td>0.051</td>
<td>0.046</td>
<td>0.140</td>
</tr>
<tr>
<td>8</td>
<td>0.052</td>
<td>0.047</td>
<td>0.145</td>
</tr>
<tr>
<td>9</td>
<td>0.053</td>
<td>0.049</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>0.056</td>
<td>0.051</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>0.058</td>
<td>0.053</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>0.059</td>
<td>0.055</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>0.061</td>
<td>0.055</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>0.062</td>
<td>0.054</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>0.062</td>
<td>0.055</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>0.063</td>
<td>0.057</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>0.066</td>
<td>0.059</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>0.067</td>
<td>0.059</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>0.067</td>
<td>0.061</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>0.067</td>
<td>0.062</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>1.000</td>
<td>1.000</td>
<td>1.000</td>
</tr>
</tbody>
</table>

Note: Numbers may not add to total due to rounding.

* Vintage weight in the last year (for example, year 18 for the 2013-based LTCH market basket) is applied to the most recent data point and prior vintage weights are applied going back in time. For example, year 18 vintage weight is applied to the 2017q3 price proxy level, year 17 vintage weight is applied to the 2016q3 price proxy level, and so forth.

The process of creating vintage-weighted price proxies requires applying the vintage weights to the price proxy index where the last applied vintage weight in Table VII–6 is applied to the most recent data point. We have provided on the CMS Web site an example of how the vintage weighting price proxies are calculated, using example vintage weights and example price indices. The example can be found under the following CMS Web site link: [http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch.html](http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareProgramRatesStats/MarketBasketResearch.html) in the zip file titled “Weight Calculations as described in the IPPS FY 2010 Proposed Rule.”

c. Summary of Price Proxies of the 2013-Based LTCH Market Basket

Table VII–7 below shows both the operating and capital price proxies that we proposed and are using as final for the 2013-based LTCH market basket.
TABLE VII–7—PRICE PROXIES FOR THE 2013-BASED LTCH MARKET BASKET

<table>
<thead>
<tr>
<th>Cost description</th>
<th>Price proxies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>100.0</td>
</tr>
<tr>
<td>Compensation</td>
<td>53.9</td>
</tr>
<tr>
<td>Wages and Salaries</td>
<td>46.6</td>
</tr>
<tr>
<td>Employee Benefits</td>
<td>7.3</td>
</tr>
<tr>
<td>Utilities</td>
<td>2.2</td>
</tr>
<tr>
<td>Electricity</td>
<td>1.0</td>
</tr>
<tr>
<td>Fuel, Oil, and Gasoline</td>
<td>1.1</td>
</tr>
<tr>
<td>Water &amp; Sewerage</td>
<td>0.1</td>
</tr>
<tr>
<td>Professional Liability Insurance</td>
<td>0.9</td>
</tr>
<tr>
<td>Malpractice</td>
<td>0.9</td>
</tr>
<tr>
<td>All Other Products and Services</td>
<td>33.2</td>
</tr>
<tr>
<td>All Other Products</td>
<td>16.3</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>7.6</td>
</tr>
<tr>
<td>Food: Direct Purchases</td>
<td>1.8</td>
</tr>
<tr>
<td>Food: Contract Services</td>
<td>1.1</td>
</tr>
<tr>
<td>Chemicals</td>
<td>0.7</td>
</tr>
<tr>
<td>Medical Instruments</td>
<td>2.4</td>
</tr>
<tr>
<td>Rubber &amp; Plastics</td>
<td>0.6</td>
</tr>
<tr>
<td>Paper and Printing Products</td>
<td>1.2</td>
</tr>
<tr>
<td>Miscellaneous Products</td>
<td>0.8</td>
</tr>
<tr>
<td>All Other Services</td>
<td>16.9</td>
</tr>
<tr>
<td>Labor-Related Services</td>
<td>8.3</td>
</tr>
<tr>
<td>Professional Fees: Labor-related</td>
<td>3.5</td>
</tr>
<tr>
<td>Administrative and Facilities Support Services</td>
<td>3.5</td>
</tr>
<tr>
<td>Installation, Maintenance &amp; Repair Services ...</td>
<td>2.0</td>
</tr>
<tr>
<td>All Other: Labor-related Services</td>
<td>1.9</td>
</tr>
<tr>
<td>Nonlabor-Related Services</td>
<td>8.6</td>
</tr>
<tr>
<td>Professional Fees: Nonlabor-related</td>
<td>3.6</td>
</tr>
<tr>
<td>Financial services</td>
<td>2.9</td>
</tr>
<tr>
<td>Telephone Services</td>
<td>0.7</td>
</tr>
<tr>
<td>All Other: Nonlabor-related Services</td>
<td>1.4</td>
</tr>
<tr>
<td>Capital-Related Costs</td>
<td>9.7</td>
</tr>
<tr>
<td>Depreciation</td>
<td>5.3</td>
</tr>
<tr>
<td>Fixed Assets</td>
<td>3.9</td>
</tr>
<tr>
<td>Movable Equipment</td>
<td>1.4</td>
</tr>
<tr>
<td>Interest Costs</td>
<td>2.4</td>
</tr>
<tr>
<td>Government/Nonprofit</td>
<td>0.5</td>
</tr>
<tr>
<td>For Profit</td>
<td>1.8</td>
</tr>
<tr>
<td>Other Capital-Related Costs</td>
<td>2.0</td>
</tr>
</tbody>
</table>

Note: Sum of the cost weights for the detailed categories may not add to total cost weight for subcategory or total market basket due to rounding.

d. FY 2017 Market Basket Update for LTCHs

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25164), for FY 2017 (that is, October 1, 2016, through September 30, 2017), we proposed to use an estimate of the proposed 2013-based LTCH market basket to update payments to LTCHs based on the best available data. Consistent with historical practice, we estimate the LTCH market basket update for the LTCH PPS based on IHS Global Insight, Inc.’s (IGI)’s forecast using the most recent available data. IGI is a nationally recognized economic and financial forecasting firm that contracts with CMS to forecast the components of the market baskets.

Based on IGI’s first quarter 2016 forecast with history through the fourth quarter of 2015, the projected market basket update for FY 2017 was 2.7 percent. Therefore, consistent with our historical practice of estimating market basket increases based on the best available data, in the proposed rule, we proposed a market basket update of 2.7 percent for FY 2017. Furthermore, because the proposed FY 2017 annual update was based on the most recent market basket estimate for the 12-month period (2.7 percent) at the time of the proposed rule, we also proposed that if more recent data became subsequently available (for example, a more recent estimate of the market basket), we would use such data, if appropriate, to determine the FY 2017 annual update in the final rule.

Based on IGI’s second quarter 2016 forecast with history through the first quarter of 2016, the projected market basket update for FY 2017 is 2.8 percent. Therefore, consistent with our
The historical practice of estimating market basket increases based on the best available data, we are finalizing a market basket update of 2.8 percent for FY 2017 based on the 2013-based LTCH market basket. (As discussed in greater detail in section V.A.2. of the Addendum to this final rule, we are establishing an annual update of 1.75 percent to the LTCH PPS standard Federal payment rate for FY 2017 under §412.523(c)(3)(xiii) of the regulations.)

Using the current 2009-based LTCH-specific market basket and IGI’s second quarter 2016 forecast with history through the first quarter of 2016, the FY 2017 market basket update would also be 2.8 percent (before taking into account any statutory adjustment).

Table VII–8 below compares the final 2013-based LTCH market basket and the 2009-based LTCH-specific market basket percent changes.

**Table VII–8—2013-Based LTCH Market Basket and 2009-Based LTCH-Specific Market Basket Percentage Changes, FY 2011 Through FY 2019**

<table>
<thead>
<tr>
<th>Fiscal Year (FY)</th>
<th>2013-Based LTCH market basket index percent change</th>
<th>2009-Based LTCH market basket index percent change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Historical data:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2011</td>
<td>2.3</td>
<td>2.6</td>
</tr>
<tr>
<td>FY 2012</td>
<td>1.9</td>
<td>2.3</td>
</tr>
<tr>
<td>FY 2013</td>
<td>2.0</td>
<td>2.3</td>
</tr>
<tr>
<td>FY 2014</td>
<td>1.8</td>
<td>1.9</td>
</tr>
<tr>
<td>FY 2015</td>
<td>1.8</td>
<td>2.2</td>
</tr>
<tr>
<td>Average 2011–2015</td>
<td>2.0</td>
<td>2.3</td>
</tr>
</tbody>
</table>

**Forecast:**

| FY 2016          | 2.0                                           | 2.2                                           |
| FY 2017          | 2.8                                           | 2.8                                           |
| FY 2018          | 2.9                                           | 2.9                                           |
| FY 2019          | 3.1                                           | 3.1                                           |
| Average 2016–2019| 2.7                                           | 2.8                                           |

Note: That these market basket percent changes do not include any further adjustments as may be statutorily required.

Source: IHS Global Insight, Inc. second quarter 2016 forecast.

Over the time period covering 2011 through 2015, the average growth rate of the 2013-based LTCH market basket is roughly 0.3 percentage point lower than the 2009-based LTCH-specific market basket. The lower growth rate is primarily a result of the lower pharmaceutical cost weight in the 2013-based market basket compared to the 2009-based LTCH-specific market basket. Historically, the price growth of pharmaceutical costs has exceeded the price growth rates for most of the other market basket cost categories. Therefore, a lower pharmaceutical cost weight would, all else equal, result in a lower market basket update. As stated above, the pharmaceutical cost weights for the 2013-based LTCH market basket and the 2009-based LTCH-specific market basket are based on the 2013 and 2009 Medicare cost report data for LTCHs, respectively.

e. FY 2017 Labor-Related Share

As discussed in section V.B. of the Addendum to this final rule, under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, we established an adjustment to the LTCH PPS payments to account for differences in LTCH area wage levels (§ 412.525(c)). The labor-related portion of the LTCH PPS standard Federal payment rate, hereafter referred to as the labor-related share, is adjusted to account for geographic differences in area wage levels by applying the applicable LTCH PPS wage index.

The labor-related share is determined by identifying the national average proportion of total costs that are related to, influenced by, or vary with the local labor market. As discussed in more detail below and similar to the 2009-based LTCH-specific market basket, we classify a cost category as labor-related and include it in the labor-related share if the cost category is defined as being labor-intensive and its cost varies with the local labor market. As stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49798), the labor-related share for FY 2016 was defined as the sum of the FY 2016 relative importance of Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related Services; Administrative and Business Support Services; Installation, Maintenance, and Repair Services; All Other: Labor-related Services; and a portion of the Capital-Related cost weight from the proposed 2013-based LTCH market basket. As noted in section VII.D.3.e. of the preamble of this final rule, for the proposed 2013-based LTCH market basket, we proposed and are finalizing the creation of a separate cost category for Installation, Maintenance, and Repair services. These expenses were previously included in the “All Other Labor-related Services” cost category in the 2009-based LTCH-specific market basket, along with other services, including, but not limited to, janitorial, waste management, security, and dry cleaning/laundry services. Because these services tend to be labor-intensive and are mostly performed at the facility (and, therefore, unlikely to be purchased in the national market), we continue to believe that they meet our definition of labor-related services.

For the development of the 2009-based LTCH-specific market basket, in an effort to more accurately determine the share of professional fees for services such as accounting and auditing services, engineering services, legal services, and management and
consulting services that should be included in the labor-related share, we used data from a survey of IPPS hospitals regarding the proportion of those fees that go to companies that are located beyond their own local labor market. The results from this survey were then used to separate a portion of the Professional Fees cost category into labor-related and nonlabor-related costs. These results and our allocation methodology are discussed in more detail in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51766). For the proposed 2013-based LTCH market basket, we proposed to apply these survey results using this same methodology to separate the Professional Fees cost category into Labor-related and Professional Fees: Nonlabor-related cost categories. We stated in the proposed rule that we believe that using the survey results serves as an appropriate proxy for the purchasing patterns of professional services for LTCHs because they also are providers of institutional care.

In addition to the professional services listed above, we proposed to classify expenses under NAICS 55, Management of Companies and Enterprises, into the Professional Fees: Labor-related and Professional Fees: Nonlabor-related cost categories. We stated that 7 percent of these costs into the “Professional Fees: Labor-related Services” cost category and the remaining 87 percent into the “Professional Fees: Nonlabor-related Services” cost category. For a detailed discussion of this analysis, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53478).

For the proposed 2013-based LTCH market basket, we conducted a similar analysis of home office data. For consistency, we believe that it is important for our analysis on home office data to be conducted on the same LTCHs used to derive the proposed 2013-based LTCH market basket cost weights. The Medicare cost report includes data primarily from the Medicare cost reports and a CMS database of Home Office Medicare Records (HOMER) (a database that provides city and State information [addresses] for home offices) and determined that 13 percent of the total number of LTCHs that had home offices had those home offices located in their respective local labor markets—defined as being in the same Metropolitan Statistical Area (MSA). Therefore, we classified 13 percent of these costs into the “Professional Fees: Labor-related Services” cost category and the remaining 87 percent into the “Professional Fees: Nonlabor-related Services” cost category.

Using this proposed methodology to separate the Professional Fees: Labor-related Services” cost category and the remaining 93 percent of these costs into the “Professional Fees: Nonlabor-related Services” cost category.

We found that 7 percent of the LTCHs with home offices had those home offices located in the same MSA as their facilities. We then concluded that these providers were located in the same local labor market as their home office. As a result, we proposed to apportion the NAICS 55 expense data by this percentage. Therefore, we proposed to classify 7 percent of these costs into the “Professional Fees: Labor-related Services” cost category and the remaining 93 percent of these costs into the “Professional Fees: Nonlabor-related Services” cost category.

In addition to the proposed methodology to determine the FY 2017 labor-related share based on the 2013-based LTCH market basket, the proposed LTCH labor-related share for FY 2017 was the sum of the FY 2017 relative importance of each labor-related cost category.

We did not receive any public comments on our proposed methodology for determining the FY 2017 labor-related share based on the 2013-based LTCH market basket. Therefore, we are finalizing our methodology as proposed. Consistent with our policy to update the labor-related share with the most recent available data, the labor-related share for this final rule reflects IGI’s second quarter 2016 forecast of the 2013-based LTCH market basket. Table VII–9 below shows the FY 2017 relative importance labor-related share using the 2013-based LTCH market basket.

### Table VII–9—LTCH Labor-Related Share

<table>
<thead>
<tr>
<th>Description</th>
<th>FY 2017</th>
<th>FY 2017</th>
<th>FY 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Final</td>
<td>Proposed</td>
<td>Final</td>
</tr>
<tr>
<td></td>
<td>labor-related share</td>
<td>labor-related share</td>
<td>labor-related share</td>
</tr>
<tr>
<td>Wages and Salaries</td>
<td>46.5</td>
<td>46.6</td>
<td>44.6</td>
</tr>
<tr>
<td>Employee Benefits</td>
<td>7.3</td>
<td>7.3</td>
<td>8.1</td>
</tr>
<tr>
<td>Professional Fees: Labor-Related</td>
<td>3.5</td>
<td>3.5</td>
<td>2.2</td>
</tr>
<tr>
<td>Administrative and Facilities Support Services</td>
<td>0.9</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Installation, Maintenance, and Repair Services</td>
<td>2.1</td>
<td>2.1</td>
<td></td>
</tr>
<tr>
<td>All Other: Labor-Related Services</td>
<td>1.9</td>
<td>1.9</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>62.2</td>
<td>62.3</td>
<td>57.9</td>
</tr>
<tr>
<td>Labor-related portion of capital (46%)</td>
<td>4.3</td>
<td>4.3</td>
<td>4.1</td>
</tr>
<tr>
<td><strong>Total Labor-Related Share</strong></td>
<td>66.5</td>
<td>66.6</td>
<td>62.0</td>
</tr>
</tbody>
</table>

1 Based on the 2013-based LTCH market basket, IHS Global Insight, Inc. 2nd quarter 2016 forecast.
2 Based on the proposed 2013-based LTCH market basket, IHS Global Insight, Inc. 1st quarter 2016 forecast.
3 Federal Register, 80 FR 49478.
4 Installation, Maintenance, and Repair Services costs were previously included in the All Other: Labor-Related Services cost weight of the 2009-based LTCH-specific market basket.
The labor-related share for FY 2017 is the sum of the FY 2017 relative importance of each labor-related cost category, and reflects the different rates of price change for these cost categories between the base year (2013) and FY 2017. The sum of the relative importance for FY 2017 for operating costs (Wages and Salaries, Employee Benefits, Professional Fees: Labor-Related, Administrative and Facilities Support Services, Installation, Maintenance, and Repair Services, All Other: Labor-Related Services) is 62.2 percent, as shown in Table VII–9 above. As we proposed, we established that the portion of capital-related costs that is influenced by the local labor market is estimated to be 46 percent, which is the same percentage applied to the 2009-based LTCH-specific market basket (77 FR 53478). Because the relative importance for capital-related costs is 9.3 percent of the 2013-based LTCH market basket in FY 2017, as we proposed, we are taking 46 percent of 9.3 percent to determine the labor-related share of capital-related costs for FY 2017 (46 × 0.93). The result is 4.3 percent, which we added to 62.2 percent for the operating cost amount to determine the total labor-related share for FY 2017. Therefore, the labor-related share that we used for the LTCH PPS in FY 2017 is 66.5 percent. This labor-related share is determined using the same methodology as employed in calculating all previous LTCH labor-related shares.

The FY 2017 labor-related share using the 2013-based LTCH market basket is 4.5 percentage points higher than the FY 2016 labor-related share using the 2009-based LTCH-specific market basket. The primary reason for a higher labor-related share, which we describe in more detail below, is a result of the change in the quantity of labor, particularly for professional services, outpacing the change in quantity of products (which are not included in the labor-related share) between 2009 and 2013, which more than offsets the faster relative growth in prices for products.

Roughly three-quarters of the 4.5 percentage points difference is the result of higher base year cost weights for the Professional Fees: Labor-Related, Administrative and Facilities Support Services, All Other: Labor-Related services, and Installation, Maintenance, and Repair services cost categories for the 2013-based LTCH market basket compared to the 2009-based LTCH-specific market basket. We refer to these cost categories collectively as “Labor-Related Services.” As stated earlier, installation, maintenance and repair costs were previously classified in the All Other: Labor-Related Services cost category of the 2009-based LTCH-specific market basket.

In aggregate, the base year cost weights for the Labor-Related Services cost categories in the 2013-based LTCH market basket are 3.0 percentage points higher than the 2009-based LTCH-specific market basket cost weights. As described in section VII.D.3.e. of the preamble of this final rule, the detailed cost categories of the LTCH market basket (including the Labor-Related Services cost categories) are derived by multiplying the “All Other” residual cost weight (which reflects all remaining costs that are not captured in the six major cost category weights calculated using the LTCH Medicare Cost Report data (Wages and Salaries, Employee Benefits, Contract Labor, Professional Liability Insurance, Pharmaceuticals, and Capital)) by the detailed cost weights calculated from the Benchmark I–O data. Therefore, the differences between the Labor-Related Services cost weights between the 2013-based LTCH market basket and the 2009-based LTCH-specific market basket are a function of the change in the “All Other” residual cost category weight and changes to the Benchmark I–O data. Approximately 0.6 percentage point of the 3.0 percentage points difference is attributable to the higher “All Other” residual cost category weight of the 2013-based LTCH market basket compared to the 2009-based LTCH-specific market basket, while the remaining 2.4 percentage points is due to the changes in the Benchmark I–O cost weights derived from the 2007 data used in the 2013-based LTCH market basket and the 2002 data used in the 2009-based LTCH-specific market basket.

Roughly one-quarter of the 4.5 percentage points difference between the FY 2017 labor-related share using the 2013-based LTCH market basket and the FY 2016 labor-related share using the 2009-based LTCH-specific market basket is a result of the Compensation cost weight. Therefore, two key factors causing this differential. First, using the 2013 Medicare cost reports, we calculated a Compensation cost weight that is 53.9 percent for the 2013-based LTCH market basket, which reflects both the change in price and change in quantity of compensation. This is 0.9 percentage point higher than the FY 2013 relative importance moving average using the 2009-based LTCH-specific market basket (53.0 percent), which only reflects relative price changes between 2009 and 2013. Second, the relative price growth from FY 2013 to the payment year between the 2009-based LTCH-specific market basket and the 2013-based LTCH market basket also contributes to the difference. For the 2009-based LTCH-specific market basket, the relative importance for compensation decreases from 53.0 percent in FY 2013 to 52.6 percent in FY 2016, a reduction of 0.4 percentage point. For the 2013-based LTCH market basket, the base weight of 53.9 percent in 2013 is 0.1 percentage point lower than the relative importance in FY 2017 (53.8 percent). These two factors combined produce the 1.2 percentage point difference in the relative importance for compensation in FY 2016 and FY 2017 as shown in Table VII–9.

As noted above, the market basket is described as a fixed-weight index because it represents the change in price over time of a constant mix (quantity and intensity) of goods and services needed to furnish hospital services. The effects on total expenditures resulting from changes in the mix of goods and services purchased subsequent to the base period are not measured. Only when the index is rebased would changes in the quantity and intensity be captured, with those changes being reflected in the cost weights. Therefore, we rebased the market basket periodically so that the cost weights reflect recent mix of goods and services that hospitals purchase (hospital inputs) to furnish inpatient care.

E. Changes to the LTCH PPS Payment Rates and Other Changes to the LTCH PPS for FY 2017

1. Overview of Development of the LTCH PPS Standard Federal Payment Rates

The basic methodology for determining LTCH PPS standard Federal prospective payment rates is currently set forth at 42 CFR 412.515 through 412.536. In this section, we discuss the factors that are used to update the LTCH PPS standard Federal payment rate for FY 2017, that is, effective for LTCH discharges occurring on or after October 1, 2016 through September 30, 2017. Under the dual rate LTCH PPS payment structure required by statute, beginning with FY 2016, only LTCH discharges that meet the criteria for exclusion from the site neutral payment rate are paid based on the LTCH PPS standard Federal payment rate specified at § 412.523. (For additional details on our finalized policies related to the dual rate LTCH PPS payment structure required by statute, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623).)
For details on the development of the initial FY 2003 standard Federal rate, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56027 through 56037). For subsequent updates to the LTCH PPS standard Federal rate as implemented under § 412.523(c)(3), we refer readers to the following final rules: 

- FY 2004 LTCH PPS final rule (68 FR 34134 through 34140); 
- FY 2005 LTCH PPS final rule (68 FR 25682 through 25684); 
- FY 2006 LTCH PPS final rule (70 FR 24179 through 24180); 
- FY 2007 LTCH PPS final rule (71 FR 27819 through 27827); 
- FY 2008 LTCH PPS final rule (72 FR 26870 through 27029); 
- FY 2009 LTCH PPS final rule (73 FR 26800 through 26804); 
- FY 2010 IPPS/LTCH PPS final rule (74 FR 44021 through 44030); 
- FY 2011 IPPS/LTCH PPS final rule (75 FR 50443 through 50444); 
- FY 2012 IPPS/LTCH PPS final rule (76 FR 51769 through 51773); 
- FY 2013 IPPS/LTCH PPS final rule (77 FR 53479 through 53481); 
- FY 2014 IPPS/LTCH PPS final rule (78 FR 50760 through 50763); 
- FY 2015 IPPS/LTCH PPS final rule (79 FR 50176 through 50180) and 
- FY 2016 IPPS/LTCH PPS final rule (80 FR 49634 through 49637).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25167 through 25169), we presented our proposed policies related to the annual update to the LTCH PPS standard Federal payment rate for FY 2017, which includes the annual market basket update. Consistent with our historical practice of using the best data available, we also proposed to use more recent data to determine the FY 2017 annual market basket update to the LTCH PPS standard Federal payment rate in the final rule.

The application of the update to the LTCH PPS standard Federal payment rate for FY 2017 is presented in section V.A. of the Addendum to this final rule. The components of the proposed and final annual market basket update to the LTCH PPS standard Federal payment rate for FY 2017 are discussed below, including the reduction to the annual update for LTCHs that fail to submit quality reporting data for FY 2017 as required by the statute (as discussed in section VII.E.2.d. of the preamble of this final rule). In addition, we are making an adjustment to the LTCH PPS standard Federal payment rate to account for the estimated effect of the changes to the area wage level adjustment for FY 2017 on estimated aggregate LTCH PPS payments, in accordance with § 412.523(d)(4) (as discussed in section V.B. of the Addendum to this final rule).

2. FY 2017 LTCH PPS Standard Federal Payment Rate Annual Market Basket Update

a. Overview

Historically, the Medicare program has used a market basket to account for input price increases in the services furnished by providers. The market basket used for the LTCH PPS includes both operating and capital related costs of LTCHs because the LTCH PPS uses a single payment rate for both operating and capital-related costs. We adopted the 2009-based LTCH-specific market basket for use under the LTCH PPS beginning in FY 2013. For additional details on the historical development of the market basket used under the LTCH PPS, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53467 through 53476).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25153 through 25167), we proposed to rebase and revise the 2009-based LTCH-specific market basket, primarily based on Medicare cost report data for LTCHs for 2013, which we are adopting in this final rule after consideration of public comments. We refer readers to section VII.D. of the preamble of the proposed rule and this final rule for a complete discussion of the LTCH market basket and a description of the methodologies we used for determining the operating and capital-related portions of the 2013-based LTCH market basket.

Section 3401(c) of the Affordable Care Act provides for certain adjustments to any annual update to the LTCH PPS standard Federal payment rate and refers to the timeframes associated with such adjustments as a “rate year” (which are discussed in more detail in section VII.C.2.b. of the preamble of this final rule.) We note that because the annual update to the LTCH PPS policies, rates, and factors now occurs on October 1, we adopted the term “fiscal year” rather than “rate year” (RY) under the LTCH PPS beginning October 1, 2010, to conform with the standard definition of the Federal fiscal year (October 1 through September 30) used by other PPSs, such as the IPPS (75 FR 50396 through 50397). Although the language of sections 3004(a), 3401(c), 10319, and 1105(b) of the Affordable Care Act refers to years 2010 and thereafter under the LTCH PPS as “rate year,” consistent with our change in the terminology used under the LTCH PPS from “rate year” to “fiscal year,” for purposes of clarity, when discussing the annual update for the LTCH PPS standard Federal payment rate, including the provisions of the Affordable Care Act, we use “fiscal year” rather than “rate year” for 2011 and subsequent years.

b. Market Basket Under the LTCH PPS for FY 2017

Under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, we adopted a 2009-based LTCH-specific market basket for use under the LTCH PPS beginning in FY 2013. The 2009-based LTCH-specific market basket is based solely on the Medicare cost report data submitted by LTCHs and, therefore, specifically reflects the cost structures of only LTCHs. For additional details on the development of the 2009-based LTCH-specific market basket, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53467 through 53476). For FY 2017, as noted earlier, we are rebasing and revising the 2009-based LTCH-specific market basket to reflect a 2013 base year. As explained in section VII.D. of the preamble of this final rule, we used 2013 Medicare cost reports because these represent the most recent, complete set of Medicare cost report data for purposes of calculating cost weights for the LTCH market basket, and we believe that the 2013-based LTCH market basket appropriately reflects the cost structure of LTCHs. In this final rule, we are using the 2013-based LTCH market basket to update the LTCH PPS standard Federal payment rate for FY 2017, as we proposed.

c. Revision of Certain Market Basket Updates As Required by the Affordable Care Act

Section 1886(m)(3)(A) of the Act, as added by section 3401(c) of the Affordable Care Act, specifies that, for rate year 2010 and each subsequent rate year through 2019, any annual update to the LTCH PPS standard Federal payment rate shall be reduced:

- For rate year 2010 through 2019, by the “other adjustment” specified in sections 1886(m)(3)(A)(ii) and (m)(4)(F) of the Act; and
- For rate year 2012 and each subsequent year, by the productivity adjustment (which we refer to as “the multifactor productivity (MFP) adjustment”) described in section 1886(b)(3)(B)(xi)(II) of the Act.

Section 1886(m)(3) of the Act provides that the application of paragraph (3) of section 1886(m) of the Act may result in the annual update being less than zero for a rate year, and may result in payment rates for a rate year being less than such payment rates for the preceding rate year.

Section 1886(b)(3)(B)(xi)(II) of the Act defines the MFP adjustment as equal to the 10-year moving average of changes
in annual economy-wide, private nonfarm business multifactor productivity (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, calendar year, cost reporting period, or other annual period). Under our methodology, the end of the 10-year moving average of changes in the MFP coincides with the end of the appropriate fiscal year update period. In addition, the MFP adjustment that is applied in determining any annual update to the LTCH PPS standard Federal payment rate is the same adjustment that is required to be applied in determining the applicable percentage increase under the IPPS under section 1886(b)(3)(B)(i) of the Act, as they are both based on a fiscal year. (We refer readers to section IV.A.1. of the preamble of FY 2016 IPPS/LTCH PPS final rule for more information on the current MFP adjustment.)

d. Adjustment to the LTCH PPS Standard Federal Payment Rate Under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

In accordance with section 1886(m)(5) of the Act, as added by section 3004(a) of the Affordable Care Act, the Secretary established the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). The reduction in the annual update to the LTCH PPS standard Federal payment rate for failure to report quality data under the LTCH QRP (for FY 2014 and subsequent fiscal years) is codified under § 412.523(c)(4) of the regulations. (As previously noted, although the language of section 3004(a) of the Affordable Care Act refers to years 2011 and thereafter under the LTCH PPS as “rate year,” consistent with our change in the terminology used under the LTCH PPS from “rate year” to “fiscal year,” for purposes of clarity, when discussing the annual update for the LTCH PPS, including the provisions of the Affordable Care Act, we use “fiscal year” rather than “rate year” for 2011 and subsequent years.) The LTCH QRP, as required for FY 2014 and subsequent fiscal years by section 1886(m)(5)(A)(i) of the Act, applies a 2.0 percentage point reduction to any update under § 412.523(c)(3) for an LTCH that does not submit quality reporting data to the Secretary in accordance with section 1886(m)(5)(C) of the Act with respect to such a year (that is, in the form and manner and at the time specified by the Secretary under the LTCH QRP) (§ 412.523(c)(4)(ii)).

Section 1886(m)(5)(B) of the Act provides that the application of the 2.0 percentage points reduction may result in an annual update that is less than 0.0 for a year, and may result in LTCH PPS payment rates for a year being less than such LTCH PPS payment rates for the preceding year (§ 412.523(c)(4)(iii)). Furthermore, section 1886(m)(5)(B) of the Act specifies that the 2.0 percentage points reduction is applied in a noncumulative manner, such that any reduction made under section 1886(m)(5)(A) of the Act shall apply only with respect to the year involved, and shall not be taken into account in computing the LTCH PPS payment amount for a subsequent year (§ 412.523(c)(4)(ii)). We discuss the application of the 2.0 percentage point reduction under § 412.523(c)(4)(i) in our discussion of the annual market basket update to the LTCH PPS standard Federal payment rate for FY 2017 in section VII.E.2.e. of the preamble of this final rule. (For additional information on the history of the LTCH QRP, including the statutory authority and the selected measures, we refer readers to section VII.C. of the preamble of this final rule.)

e. Annual Market Basket Update Under the LTCH PPS for FY 2017

Consistent with our historical practice, we estimate the market basket update and the MFP adjustment based on IGI’s forecast using the most recent available data. Based on IGI’s second quarter 2016 forecast, the FY 2017 full market basket increase for the LTCH PPS using the finalized 2013-based LTCH market basket is 2.8 percent, as discussed in section VII.D.4.d. of the preamble of this final rule. The current estimate of the MFP adjustment for FY 2017 based on IGI’s second quarter 2016 forecast is 0.3 percent, as discussed in section VII.E.2.c. of the preamble of this final rule. Consistent with our historical practice, as we proposed, we used a more recent estimate of the market basket increase and the MFP adjustment to determine the FY 2017 market basket update and the MFP adjustment for FY 2017 in this final rule.

For FY 2017, section 1886(m)(3)(A)(i) of the Act requires that any annual update to the LTCH PPS standard Federal payment rate be reduced by the productivity adjustment ("the MFP adjustment") described in section 1886(b)(3)(B)(ii)(III) of the Act. Consistent with the statute, as we proposed, we reduced the full FY 2017 market basket increase by the FY 2017 MFP adjustment. To determine the market basket update for LTCHs for FY 2017, as reduced by the MFP adjustment, we used our established methodology, we subtracted the FY 2017 MFP adjustment from the FY 2017 market basket update. Furthermore, sections 1886(m)(3)(A)(ii) and 1886(m)(4)(F) of the Act requires that any annual update to the LTCH PPS standard Federal payment rate for FY 2017 be reduced by the “other adjustment” described in paragraph (4), which is 0.75 percentage point for FY 2017. Therefore, following application of the productivity adjustment, as we proposed, we further reduced the adjusted market basket update (that is, the full market basket increase less the MFP adjustment) by the “other adjustment” specified by sections 1886(m)(3)(A)(ii) and 1886(m)(4) of the Act. (For additional details on our established methodology for adjusting the market basket increase by the MFP and the “other adjustment” required by the statute, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51771).)

For FY 2017, section 1886(m)(5) of the Act requires that, for LTCHs that do not submit quality reporting data as required under the LTCH QRP, any annual update to an LTCH PPS standard Federal payment rate, after application of the adjustments required by section 1886(m)(3) of the Act, shall be further reduced by 2.0 percentage points. Therefore, the update to the LTCH PPS standard Federal payment rate for FY 2017 for LTCHs that fail to submit quality reporting data under the LTCH QRP, the full LTCH PPS market basket increase, subject to an adjustment based on changes in economy-wide productivity ("the MFP adjustment") as required under section 1886(m)(3)(A)(i) of the Act and an additional reduction required by sections 1886(m)(3)(A)(ii) and 1886(m)(4) of the Act, will also be further reduced by 2.0 percentage points.

In this final rule, in accordance with the statute, we reduced the FY 2017 full market basket increase of 2.8 percent (based on IGI’s second quarter 2016 forecast of the 2013-based LTCH market basket) by the FY 2017 MFP adjustment of 0.3 percentage point (also based on IGI’s second quarter 2016 forecast). Following application of the productivity adjustment, the adjusted market basket update of 2.5 percent (2.8 percent minus 0.3 percentage point) was then further reduced by 0.75 percentage point, as required by sections 1886(m)(3)(A)(ii) and 1886(m)(4)(F) of the Act. Therefore, under the authority of section 123 of the BBRA as amended by section 307(b) of the BIPA, we are establishing an annual market basket update under to the LTCH PPS standard Federal payment rate for FY 2017 of 1.75 percent (that is, the most recent estimate of the LTCH PPS market basket...
increase of 2.8 percent, less the MFP adjustment of 0.3 percentage point, and less the 0.75 percentage point required under section 1886(m)(4)(F) of the Act. Accordingly, we are finalizing our proposed revision to §412.523(c)(3) by adding a new paragraph (xiii), which specifies that the LTCH PPS standard Federal payment rate for FY 2017 is the LTCH PPS standard Federal payment rate for the previous LTCH PPS year updated by 1.75 percent, and as further adjusted, as appropriate, as described in §412.523(d). For LTCHs that fail to submit quality reporting data under the LTCH QRP, under §412.523(c)(3)(xiii) in conjunction with §412.523(c)(4), we further reduced the annual update to the LTCH PPS standard Federal payment rate by 2.0 percentage points in accordance with section 1886(m)(5) of the Act. Accordingly, we are establishing an annual update to the LTCH PPS standard Federal payment rate of –0.25 percent (that is, 1.75 percent minus 2.0 percentage points) for FY 2017 for LTCHs that fail to submit quality reporting data as required under the LTCH QRP. As stated above, consistent with our historical practice, we used a more recent estimate of the market basket and the MFP adjustment to establish an annual update to the LTCH PPS standard Federal payment rate for FY 2017 under §412.523(c)(3)(xiii) in this final rule. (We note that, consistent with historical practice, we also adjusted the FY 2017 LTCH PPS standard Federal payment rate by an area wage level budget neutrality factor in accordance with §412.523(d)(4) (as discussed in section V.B. of the Addendum to this final rule).)

3. Update Under the Payment Adjustment for “Subclause (II)” LTCHs

Under the LTCH PPS payment adjustment for “subclause (II) LTCHs” at §412.526(c)(1)(ii), we established that, for cost reporting periods beginning during fiscal years after FY 2015, the target amount (used to determine the adjusted payment for Medicare inpatient operating costs under reasonable cost-based reimbursement rules) will equal the hospital’s target amount for the previous cost reporting period updated by the applicable annual rate-of-increase percentage specified in §413.40(c)(3) for the subject cost reporting period (79 FR 50197). For FY 2017, in accordance with §412.526(c)(2)(ii) of the regulations, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25169), we proposed that, for cost reporting periods beginning during FY 2017, the update to the target amount for the payment adjustment for “subclause (II)” LTCHs would be 2.8 percent, which was the estimated market basket update for FY 2017 to the rate-of-increase limits for certain hospitals excluded from the IPPS that are paid on a reasonable cost basis (that is, the applicable annual rate-of-increase percentage under §413.40(c)(3)(viii)), which is discussed in section VI. of the preamble of the proposed rule, is the FY 2017 rate-of-increase percentage estimate for updating the target amounts, and is equal to the estimated percentage increase in the FY 2010-based IPPS operating market basket, in accordance with applicable regulations at §413.40(c)(3)(viii).

Based on IGI’s 2016 first quarter forecast, with historical data through the 2015 fourth quarter, in the proposed rule, we estimated that the FY 2010-based IPPS operating market basket update for FY 2017 was 2.8 percent (that is, the estimate of the market basket rate-of-increase). Therefore, we proposed that the rate-of-increase percentage that would be applied to the FY 2016 target amounts in order to determine the FY 2017 target amounts for “subclause (II) LTCHs” under §412.526(c)(1)(i) is 2.8 percent. This is the same applicable annual rate-of-increase percentage that would be provided for FY 2017 under §413.40(c)(3), as discussed in section VI. of the preamble of the proposed rule.

For a discussion of the calculation of the LTCH PPS that is applied to payments for Medicare patient discharges from an LTCH when the number of such patients originating from any single referring hospital is in excess of the applicable threshold for a given cost reporting period (such threshold is generally set at 25 percent, with exceptions for rural and urban single or MSA-dominant hospitals). If an LTCH exceeds the applicable threshold during a cost reporting period, payment for the discharge that puts the LTCH over its threshold and all discharges subsequent to that discharge in the cost reporting period from the referring hospital are adjusted at cost report settlement (discharges not in excess of the threshold are unaffected by the applicable percentage threshold requirements in a prior period).

The adjusted payment amount for those discharges that are subject to the current 25-percent threshold policy is calculated as the lesser of the applicable LTCH PPS payment amount or the IPPS equivalent amount. We note that the IPPS equivalent amount under the 25-percent threshold policy differs somewhat from the IPPS comparable per diem amount applicable under the site-neutral payment rate policy at §412.522(c)(1)(i) and the short-stay outlier (SSO) policy at §412.529(d)(4). For a discussion of the calculation of the IPPS comparable per diem amount under §412.529(d)(4) and the IPPS equivalent amount under existing §§412.534(f) and 412.536(e), including details on the differences in the calculations, we refer readers to our response to comments in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50772). The 25-percent threshold policy was originally established in the FY 2005 IPPS final rule for LTCH hospital-
within-hospitals (HwHs) and satellites (69 FR 49191 through 49214). It addressed patient shifting driven by financial considerations, rather than patient benefit. Specifically, it addressed the negative incentives that may result from the co-location of facilities which can create incentives for behaviors which result in two hospital stays, and two Medicare payments, for what was essentially one episode of patient care—and a financial windfall for both providers, as compared to acute care hospitals that were not co-located with an LTCH. It also addressed statutory limits for LTCHs, namely concerns that these LTCHs were, in essence, behaving as long-term care “units” of the co-located hospitals (an arrangement prohibited under section 1886(d)(1)(B) of the Act). In order to discourage such activities, CMS initially established a payment adjustment at § 412.534 for discharges in which the patient was admitted to the LTCH location from a co-located referring hospital in excess of an applicable percentage threshold. Implementation was phased in, but ultimately was generally set at a 25-percent threshold after specified phase-in periods. A full discussion of the original 25-percent threshold policy is contained in the FY 2005 IPPS final rule (69 FR 49191 through 49214).

While initially limited to co-located facilities, in keeping with the suggestions of MedPAC and other commenters, CMS noted that it would continue to monitor claims data for signs that common ownership between hospitals that did not share a location also encouraged discharge and admission decisions based on payment rather than clinical considerations (69 FR 49202 through 19203). This continued monitoring, including analysis of discharge patterns from the FY 2005 MedPAR files, identified additional patterns of patient shifting and worrisome admission practices between LTCHs and referring hospitals that were not co-located that were similar to the patterns identified in the FY 2004 MedPAR files between co-located LTCHs and their host hospitals. In response to these findings, we expanded the 25-percent threshold policy in the FY 2008 LTCH PPS final rule to include all LTCHs and LTCH satellite facilities through the amendment of § 412.534 (including those certain LTCHs which had been grandfathered from the original policy established in the FY 2005 rule) and the addition of § 412.536 (governing patients admitted from hospitals not co-located with the LTCH). A full discussion of this policy can be found in the FY 2008 LTCH PPS final rule (72 FR 26919 through 26944).

The resulting 25-percent threshold policy was to have been phased in over 3 years, and, when fully implemented, the 25-percent threshold policy would have applied to nearly all LTCHs or LTCH satellites and remote locations admitting patients from any hospital, regardless of the location or ownership of the referring hospital. (For the remainder of this section, we refer to the policies under § 412.534 and § 412.536 and new § 412.538 collectively as the “25-percent threshold policy” unless otherwise indicated.) However, several laws mandated delayed implementation of the policy, including, most recently, section 1206 of the Pathway for Sustainable Growth Rate (SGR) Reform Act (Pub. L. 113–67). Section 1206(b)(1)(B) provides a permanent exemption from the application of the 25-percent threshold policy for co-located LTCHs that were excluded from the original policy in the FY 2005 IPPS final rule. Section 1206(b)(1)(A) extended prior moratoria on the full implementation of the 25-percent threshold policy until cost reporting periods beginning on or after either July 1, 2016 (for LTCHs subject to 42 CFR 412.534) or October 1, 2016 (for LTCHs subject to 42 CFR 412.536). For more details on the various laws that delayed the full implementation of the 25 percent threshold policy, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50186). With the expiration of the most recent statutory delay of the full implementation of the 25-percent threshold policy and the recent implementation of a dual rate payment system for the revised LTCH PPS for cost reporting periods beginning on or after October 1, 2015, we have received many questions concerning the mechanics of the revised payment system, especially in relation to the application of the 25-percent threshold policy under § 412.534 and § 412.536, and how they will interact. The questions generally involved how CMS would implement the policy for LTCHs with multiple locations. Other questions included how site neutral payment rate discharges would be treated under the policy and how CMS would determine whether a hospital was located in a rural or MSA-dominant area. As a result of the confusion reflected in those questions, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25169 through 25173), we proposed to revise policies in an effort to simplify the application of the 25-percent threshold policy.

Specifically, we proposed to sunset both §§ 412.534 and 412.536 and adopt a unified 25-percent threshold policy at new § 412.538. We stated in the proposed rule that if finalized, this proposal would apply to payments for discharges occurring on or after October 1, 2016. The applicable percentage thresholds would generally remain at 25 percent. In keeping with our current policy at § 412.534(b) and § 412.536(a)(2), under proposed new § 412.538(a), we proposed that the adjustment would not be applicable to “subclause (II)” LTCHs described at section 1886(d)(1)(B)(iv)(II) of the Act and § 412.25(c)(2)(ii) or, consistent with the statute and as codified in the regulations at § 412.534(a) and § 412.536(a)(1)(ii), those HwHs described in § 412.23(e)(2)(ii) that meet the criteria in § 412.22(f) (“grandfathered HwHs”). (Section 1206(b)(1)(B) of the Pathway for SGR Reform Act provides for a statutory exclusion from the 25-percent threshold policy for “grandfathered HwHs,” which was codified in the regulations at § 412.534(a) and § 412.536(a)(1)(ii) in the FY 2015 IPPS/LTCH PPS final rule at (79 FR 50186).) In keeping with our current policy at § 412.534(c)(2) and § 412.536(b)(2), we further proposed that LTCH discharges that reached high-cost outlier status at the referring hospital would not be subject to the 25-percent threshold policy (that is, LTCH discharges which had been high-cost outlier cases at the referring hospital would only be included in an LTCH’s total Medicare discharges and, therefore, would not count as having been admitted from that referring hospital. In other words, LTCH discharges that were high-cost outlier cases at the referring hospital would not be counted in the numerator (but would be counted in the denominator) when determining whether the LTCH exceeded the applicable percentage threshold (that referring hospital).

As we discussed in the FY 2005 IPPS final rule, we continue to believe that it is appropriate to treat high-cost outlier cases as though they had come from a different hospital because a case which reaches high-cost outlier status has received a full complement of services and, therefore, any transfer from a hospital to an LTCH cannot be said to be premature or inappropriate. In addition, consistent with our current policy, under this proposal, both the LTCH PPS standard Federal payment rate cases and the site neutral payment rate cases would be subject to the 25-percent threshold policy at proposed new § 412.538 and, therefore, would be
included in the determination of whether an LTCH has exceeded its applicable threshold. In conjunction with this proposal, we proposed to make conforming changes to § 412.522(c)(2) (adjustments for payments under the site neutral payment rate) and § 412.525(d)(5) (adjustments for payments under the LTCH PPS standard Federal payment rate) to include the proposed adjustment for the limitation on LTCH admissions from referring hospitals (that is, the proposed revised 25-percent threshold policy) under new § 412.538. Lastly, we also proposed that Medicare Advantage (MA) discharges would not be considered under the revised 25-percent threshold policy at proposed new § 412.538, consistent with our current policy. (Consistent with these proposals, for the remainder of this section, when we refer to “Medicare discharges,” we mean a hospital’s Medicare discharges that were not paid under an MA plan (and in the case of an LTCH, all LTCH PPS discharges, that is, both the LTCH PPS standard Federal payment rate cases and the site neutral payment rate cases.)

Under our proposed revised 25-percent threshold policy at proposed new § 412.538, we proposed to calculate the numerator and denominator for the “applicable percentage threshold” by using the CMS Certification Number (CCN) on hospital claims submitted to Medicare. Specifically, we proposed determining whether the applicable percentage threshold was exceeded based on the Medicare discharges from the entire LTCH that were admitted from each referring hospital. The CCN is used on Medicare claims to identify the hospital that discharged the patient and, therefore, we believed that using the CCN to identify the discharging LTCH and the referring hospital is an appropriate and administratively straightforward process to implement this proposed revision. We stated that we believed that this approach would simplify the application of the 25-percent threshold policy because it would provide transparency in identifying both the discharging LTCH and the referring hospital. Under this proposed approach, an LTCH’s percentage of Medicare discharges from a given referring hospital would be determined during settlement of a cost report by dividing the LTCH’s total number of Medicare discharges in the cost reporting period (based on the CCN on the claims) that were admitted directly from a given referring hospital (again determined by the CCN on the referring hospital’s claims) that did not receive a high-cost outlier payment (based on the referring hospital’s claims) by the LTCH’s total number of Medicare discharges in the cost reporting period. In other words, at cost report settlement, each LTCH’s Medicare discharges from a given referring hospital (that did not receive a high-cost outlier payment) during that cost reporting period would be evaluated chronologically based on the discharge date from the LTCH, such that the Medicare discharge that results in the LTCH exceeding or remaining in excess of its applicable percentage threshold would be subject to the payment adjustment at proposed new § 412.538(c). We proposed that the applicable percentage threshold would be determined according to the CCN on the Medicare claim submitted by the provider (that is, the LTCH’s CCN would be determined from the LTCH’s claim; the referring hospital’s CCN by its claim), which generally comprises all locations of a single hospital (and for a single LTCH, includes satellite facilities and remote locations, as applicable). For example, the CCN of an LTCH with 3 locations is “902000” and the CCN of a specific referring hospital with 2 locations is “900001.” During its cost reporting period, LTCH “902000” has a total of 60 Medicare discharges (10 discharges from the first location, 20 discharges from the second location, and 30 discharges from the third location). Of those 60 Medicare discharges, 25 Medicare discharges (that did not receive a high-cost outlier payment) came directly from hospital “900001” (10 discharges from the first location, and 15 discharges from the second location). LTCH “902000’s” percentage of Medicare discharges from referring hospital “900001” would be calculated as 25 divided by 60, or 41.7 percent. The location of the discharging LTCH and the referring hospital is not relevant, and only the aggregate Medicare discharge counts would be used in the proposed calculation when determining if a payment adjustment under proposed new § 412.538 is applicable at cost report settlement.

Under proposed new §§ 412.538(b) and (c), we proposed, in general, that payment would be adjusted for LTCH Medicare discharges originating from a single referring hospital during a given cost reporting period when that Medicare discharge results in a percentage of Medicare discharges (that did not receive a high-cost outlier payment) from that referring hospital that exceeded the LTCH’s applicable percentage threshold (that is, exceeds “25 percent” of that LTCH’s total Medicare discharges). In other words, in general, we would continue to calculate separate percentages for each hospital from which an LTCH admits patients, and compare those referring hospitals’ percentage of Medicare discharges (excluding those cases that received a high-cost outlier payment) to the LTCH’s applicable percentage threshold, and the payment adjustment would then be applied to any of the Medicare discharges that cause the LTCH to exceed or remain in excess of the applicable percentage threshold. Medicare discharges not in excess of the applicable threshold (which includes those that received a high-cost outlier payment at the referring hospital) would continue to be unaffected by the 25-percent threshold policy. As adjusted, the net payment amount to an LTCH for each of its Medicare discharges beyond the applicable percentage threshold would continue to be the lesser of the applicable LTCH PPS payment amount or an IPPS equivalent amount. The IPPS equivalent amount under the current 25-percent threshold policy is set forth in existing regulations at § 412.534(f) and § 412.536(e). As we proposed to sunset these provisions, we proposed to codify the existing definition of “IPPS equivalent amount” under our proposed revised 25-percent threshold policy at proposed new § 412.538(f). (For a detailed description of the calculation of the IPPS equivalent amount, we refer readers to the RY 2007 LTCH PPS proposed rule (71 FR 4698 through 4700), which was finalized in the corresponding final rule (71 FR 27875)). As noted previously, IPPS equivalent amount under the 25-percent threshold policy differs somewhat from the IPPS comparable amount applicable under the site neutral payment rate and the SSO policy (78 FR 50772).

In addition, consistent with our existing policy at § 412.534(d) and § 412.536(c), under proposed new § 412.538(f), we proposed a 50-percent applicable threshold for rural LTCHs (as defined under § 412.503) in lieu of the generally applicable 25-percent threshold. We stated in the proposed rule that if finalized, payment to such LTCHs would not be adjusted unless the rural LTCH’s Medicare discharges from a single referring hospital (excluding those that received a high-cost outlier payment), exceeded 50 percent of the LTCH’s total Medicare discharges (that is, we would continue to apply an applicable percentage threshold of 50 percent from any single referring hospital to rural LTCHs). We also proposed to maintain at proposed new § 412.538(e)(3) the current special treatment of an LTCH...
located in an MSA with an MSA-
dominant hospital at § 412.534(e) and
§ 412.536(d). As defined in those
regulations, an MSA-dominant hospital
is a hospital that has discharged more
than 25 percent of the total hospital’s
Medicare discharges in the MSA in
which it is located. For LTCHs located
in an MSA-dominant area (that is
located in an MSA with an MSA-
dominant hospital), the LTCH’s
applicable percentage threshold would
continue to be the percentage of total
Medicare hospital discharges in the
MSA from the MSA-dominant hospital
during the LTCH’s applicable cost
reporting period, but in no case is less
than 25 percent or more than 50
percent. (That is, as is the case under
our current policy, for an LTCH located
in an MSA-dominant area, it would
have a single applicable percentage
threshold for all of that LTCH’s referring
hospitals under the special treatment
provided under proposed new
§ 412.538(e)(3).) We proposed to use our
existing definition of “MSA-dominant
hospital” under both § 412.534(e) and
§ 412.536(d) of the regulations to also
define the term under § 412.103.

Further, we proposed to codify
definitions for the terms “MSA” (which
we proposed to define as an
Metropolitan Statistical Area, as defined
by the Executive Office of Management
and Budget) and “MSA-dominant area”
(which we proposed to define as an
MSA in which an MSA-dominant
hospital is located) under § 412.103.
(Information on OMB’s MSA
delineations based on the 2010
standards can be found at: http://
www.whitehouse.gov/sites/default/files/omb/assets/fedreg/2010/06282010Metro_Standards-Complete.pdf.)

Under this proposed special treatment
at §§ 412.538(e)(2) and (3) for LTCHs
with multiple locations, we further
proposed that all locations of an LTCH
paid under the LTCH PPS must be rural
or located in an MSA-dominant area (as
applicable); otherwise the special
treatment would not apply and the
applicable percentage threshold would
be 25 percent. Under our existing
regulations, the applicable percentage
threshold for each location is
determined independently of any other
location of the hospital (meaning that,
if an LTCH had one rural and one urban
location, the applicable percentage
threshold for the rural location would
be 50 percent and the applicable
percentage threshold for the urban
location would be 25 percent). However,
under our proposed special treatment,
the applicable percentage threshold would apply to the
LTCH as a whole entity (based on its
CCN). Therefore, we stated that we
believe that it would be appropriate to
apply the rural and MSA-dominant
“special” applicable percentage
thresholds based on the LTCH as a
whole as well. Furthermore, we stated
that we believe that LTCHs with
locations that do not fall in these special
treatment categories would have
sufficient access across its locations to
admit patients from multiple hospitals
such that, as a whole, the LTCH should
be able to draw from a diverse enough
population to meet the proposed 25-
percent threshold policy criteria. For
these reasons, and that at that time we did not
believe that it would be appropriate or
necessary to apply these special percentages unless the LTCH is
exclusively rural or located exclusively in an MSA-dominant area (as
applicable). Therefore, we proposed to
require all locations of an LTCH to be
rural or located within an MSA-
dominant area in order to qualify for
special treatment under proposed new
§§ 412.538(e)(2) and (3) (that is, an
adjusted applicable percentage
threshold).

Comment: MedPAC supported CMS’
proposal to continue to apply the 25-
percent policy to all discharges,
including site neutral payment rate
cases. In addition, MedPAC noted that the effect of the new dual rate payment
system on LTCHs and their admission
practices, including their relationship
with referring hospitals, is not yet
understood, and therefore it is
appropriate to maintain the 25-percent
policy and apply it to all discharges.
Response: We appreciate MedPAC’s
support of our proposal.

Comment: Several commenters
requested that CMS rescind the 25-
percent policy. Many of these
commenters argued that because of the
new statutory patient-level criteria in
the LTCH PPS, the 25-policy threshold
policy is unnecessary. Some
commenters stated that CMS indicated
in prior rulemakings that the revised
LTCH PPS would render the 25-percent
threshold policy unnecessary. Other
commenters argued that the policy does
not specifically aid beneficiaries. Some
commenters suggested “updating” the
policy in light of changes in the statute
that occurred after the 25-percent
threshold policy was established, such
as the IMPACT Act, or to exclude
discharges from Centers for Medicare
and Medicaid Innovations (Innovation
Center) payment models from
application of the policy. One
commenter stated that repealing the
policy under the IMPACT Act or CMS’
decision to exclude grandfathered
HwFs from the policy. Some

some other commenters suggested, that as an
alternative to repealing the policy, CMS extend the statutory
moratorium on the implementation of the policy for an
additional 2 years, until the expiration of the moratorium of new LTCHs (under
current law, that moratorium expires
October 1, 2017), or, in the alternative,
until the transition to the application of the site neutral payment rate has been
completed and analyzed. Some other
commenters stated that CMS had told
Congress that CMS would not change
the 25-percent threshold policy until the
effects of the application of the site
neutral payment rate had been analyzed,
or until CMS had delivered its Report to
Congress on the 25-percent threshold
policy.

Response: As we stated both in the
proposed rule and many times during
our modifications to the 25-percent
threshold policy, there is a statutory
preclusion on LTCH units under section
1886(d)(1)(B) of the Act. The clinical
criteria are not relevant to this
preclusion (that is, the patient-level
criteria to determine which patients are “appropriate” for the LTCH
PPS standard Federal payment rate did
not change the statutory preclusion on
LTCH “units” in hospitals). The clinical
criteria also are not relevant to
preventing two Medicare payments for
what is essentially one episode of care.
Therefore, we believe that the 25-
percent threshold policy is still
warranted in order to ensure
compliance with this statutory
prohibition and to prevent Medicare
from making two payments for what is
essentially one episode of care. We
disagree with commenters’ arguments
that the 25-percent threshold policy
does not aid beneficiaries, given that
one of our goals in implementing the 25-
percent threshold policy is to protect
the Medicare Trust Fund, which will
help to ensure access to care for
Medicare beneficiaries. Additionally,
whether our policies that enforce the
statutory preclusion on LTCH units
benefits beneficiaries is not relevant to
our duty to enforce the preclusion on
LTCH units.

With regard to the commenters who
requested that we “update” the 25-
percent threshold policy in light of
changes in the statute, none of the
changes removed the statutory
preclusion on LTCH units or addressed
the prevention of two Medicare
payments for what is essentially one
episode of care. In response to the
request to exclude discharges paid
under an Innovation Center payment
model from the policy, to the extent the
payment under the model is based
partially on the LTCH PPS payment rates,
we believe it is appropriate for the LTCH PPS payment rates portion of the payment to be subject to the applicable 25-percent threshold policy. The Innovation Center payment model status is irrelevant to the establishment of PPS payment policy in other contexts as well, for example in IPPS ratessetting. The comment asserting that repeal of the 25-percent threshold policy is consistent with CMS’ decision to exclude grandfathered HwHs from that policy is factually inaccurate. As we stated in the proposed rule, CMS implemented the regulatory exclusion for grandfathered HwHs as that exclusion was required by section 1206(b)(1)(B) of the Pathway for SGR Reform Act (Pub. L. 113–67). Aside from subclause (II) LTCHs, no other LTCHs were provided such statutory exclusion. With respect to the comment that CMS indicated we would repeal the policy, we note that we received substantially similar comments in response to the FY 2016 IPPS/LTC PPS proposed rule. We reiterate what we stated in response to those comments that we did not indicate in prior rulemakings that these policies were unnecessary. We stated that, at that time, the policies may no longer be necessary in light of the intended changes to the LTCH PPS (80 FR 49613).

In regard to the suggestion that we extend the statutory moratorium on the full implementation of the 25-percent threshold policy, we do not believe it is necessary to further delay its application. As discussed previously, we believe the 25-percent threshold policy is still warranted to ensure compliance with this statutory prohibition and to prevent Medicare from making two payments for what is essentially one episode of care. Furthermore, we disagree with commenters that we made any assurances to keep the 25-percent threshold policy unchanged until the shift to the site neutral payment rate had been completed or analyzed. As we stated in the proposed rule, given the impending expiration on the statutory moratorium on the full implementation of the 25-percent threshold policy, we received many questions concerning the mechanics of the revised payment system, especially in relation to the application of the 25-percent threshold policy under § 412.534 and § 412.536, and how those sections will interact. The question generally involved how CMS would implement the policy for LTCHs with multiple locations. Other questions included how site neutral payment rate discharges would be treated under the policy and how CMS would determine whether a hospital was located in a rural or MSA-dominant area. In light of the widespread confusion expressed by stakeholders, we proposed revisions to our current 25-percent threshold policy that would clarify the policy and would allow for greater ease of understanding and implementation. We continue to believe that such modifications are appropriate and warranted. In regard to the commenter who requested that we wait until the Report to Congress on the 25-percent threshold policy has been delivered to Congress, we note that the referenced report was delivered in June 2015 and is, and has been, available upon request.

Comment: Several commenters requested that CMS exclude either site neutral payment rate or LTCH PPS standard Federal payment rate discharges from the 25-percent threshold policy. Many of the commenters who requested the exclusion of site neutral discharges asserted that applying the 25 percent policy to these discharges would result in “double penalization,” while commenters who requested the exclusion of LTCH PPS standard Federal rate payment rate discharges asserted that it was not appropriate to reduce payment for cases meeting the patient-level clinical criteria under the dual rate LTCH PPS payment structure. Some commenters asserted that it may be difficult for LTCHs to admit patients with at least 3 days of ICU treatment without exceeding their applicable percentage thresholds.

Response: As we stated earlier, the patient-level clinical criteria and site neutral payment rate are not relevant to the statutory preclusion on LTCH units. Excluding certain discharges paid under the LTCH PPS from the 25-percent threshold policy would fundamentally undermine the policy. In regard to concerns of “double penalization” for site neutral payment rate discharges under the 25-percent threshold policy, under our current regulations, in general, it is not possible for a site neutral payment rate discharge to receive a payment adjustment (that is, a lower payment) due to the 25-percent threshold policy. This is because site neutral payment rate discharges are generally paid the lower of the IPPS comparable amount or the estimated costs of the case, and, should the hospital’s applicable percentage threshold be exceeded, the hospital would generally be paid the lower of the IPPS comparable amount, the IPPS comparable amount, or the cost. However, the IPPS equivalent amount and the IPPS comparable amount would generally be expected to be equivalent to one another. As such, we would not expect those paid at the site neutral rate to suffer any consequence as a result of the adjustment under the 25-percent rule policy. We note that we considered excluding site neutral payment rate discharges from both the numerator and denominator of the calculation. However, we did not propose this policy because whether a discharge is paid at the LTCH PPS standard Federal payment rate or the site neutral payment rate is germane to whether an LTCH is behaving as a unit, and, given this overriding concern, we do not believe it is appropriate to exclude site neutral payment rate discharges from the 25-percent threshold policy. While we understand the concerns of commenters that, in certain areas, one or two IPPS hospitals may account for a disproportionate percentage of ICU days, we note, again, that the clinical criteria did not change the statutory preclusion on LTCH units. Furthermore, such IPPS hospital discharges admitted to the LTCH after receiving a high-cost outlier payment are treated as if they were admitted from another referring hospital for purposes of the 25-percent threshold policy (and therefore would not be counted as a discharge from that referring hospital). In addition, special treatment is provided for rural and MSA-dominant LTCHs, as discussed previously.

Comment: One commenter requested clarification as to why CMS did not include a specific exception under the proposed 25-percent threshold policy at new § 412.534 for LTCHs receiving admissions from urban-single IPPS hospitals, as is provided under the current 25-percent threshold policies at §§ 412.534 and 412.536, along with the proposed continued special treatment for rural and MSA-dominant LTCHs, which allows such LTCHs to have an increased applicable threshold. Other commenters requested that CMS modify the existing definition of “MSA-dominant hospital.” to allow additional hospitals to qualify for the increased applicable threshold, for example hospitals located in Micropolitan areas or “distinct regions” within MSAs to be subject to an increased threshold.

Response: As we stated in the proposed rule, our proposed modification of the 25-percent threshold policy is meant to provide simplicity and clarity. We proposed to maintain the current special treatment of an LTCH located in an MSA with an MSA-dominant hospital at § 412.534(e) and § 412.536(d). As defined by those regulations, an MSA-dominant hospital is a hospital that has discharged more
than 25 percent of the total hospitals’ Medicare discharges in the MSA in which it is located. This proposed definition of MSA-dominant hospitals encompass hospitals referred to in the current regulations as “single urban hospitals” (that is, the only other hospital in the MSA) because such a hospital, by definition, would have discharged more than 25 percent of the total hospital Medicare discharges in the MSA in that it would have discharged 100 percent of the total hospital Medicare discharges in the MSA. For this reason, we saw no reason to specifically mention urban-single hospitals as a separate category of hospitals subject to special treatment (that is, an increased applicable threshold). Although we are not changing the regulation text in response to this comment, we note that because urban-single hospitals are MSA-dominant hospitals, LTCHs receiving patients from urban-single hospitals will be subject to the same applicable threshold as all MSA-dominant hospitals. With respect to the commenter requesting an increased threshold for Micropolitan statistical areas, we note that these areas are treated as rural for the purposes of the 25-percent threshold policy. With respect to the request to provide an increased threshold for “distinct regions” of MSAs, although the commenter provided one anecdotal example of what it believed should be considered a “distinct region,” it did not offer a definition of the term or set out criteria for what would be considered a “distinct region” within an MSA, and, even if it had, adoption of such a concept is outside the scope of the proposed rule. With that said, as the commenter provided no policy specifics or recommendations, we cannot evaluate the “distinct region” suggestion and continue to believe that the use of MSAs is reasonable.

Comment: Several commenters objected to CMS’ proposal to identify LTCHs and referring hospitals based on CCNs, and to apply the policy to all locations operating under a CCN. Some commenters argued that this would make it harder for LTCHs with multiple locations to comply with the policy, while other commenters argued that this disadvantaged hospitals that may have multiple campuses operating under the same CCN because the application of the 25-percent threshold policy on a location-specific basis can allow an LTCH with multiple locations to discharge more patients admitted from a single referring hospital without receiving adjusted payment under the regulations. Other commenters requested that CMS continue applying the policy on a single location basis. Some commenters expressed concern for LTCHs with “one primary referring hospital.”

Response: As we stated in the proposed rule, we believe that identifying LTCHs and their referring hospitals based on CCN rather than individual location or locations would simplify the application of the 25-percent threshold policy because it provides transparency in identifying both the discharging LTCH and the referring hospital, and alleviates confusion in the industry. We proposed these changes in response to questions from the provider community which indicated a great deal of confusion surrounding the intricacy of the interactions between the current 25-percent threshold policies at § 412.534 and § 412.536. By basing the policy on LTCHs and referring hospitals as a whole, we believe that hospitals will more easily understand how a given discharge will be counted in the application of the policy. To the extent that the proposed changes make it “harder” for LTCHs to comply with the policy, we note that the goal of the policy is to prevent inappropriate patient shifting and LTCHs behaving as units of referring hospitals. In regard to LTCHs that may have been able to increase their overall admittance of patients from a single referring source under the location-based 25-percent threshold by spreading such admissions across locations, thereby increasing the opportunity for inappropriate patient shifting and allowing the LTCH as a whole to behave as a unit, such arrangements directly contradict our goals, and were a failing of the current policy. For these reasons, we believe that using CCNs rather than location as the basis for the 25-percent threshold policy is more appropriate, given our policy concerns and goals. While we understand that hospitals may operate multiple campuses under the same CCN, as explained previously, we nonetheless believe that application based on CCN is the simplest and generally most accurate way to determine the referral source of an LTCH discharge for both CMS and LTCHs. As for concerns about LTCHs with “one primary referring hospital,” we would like to state that this is the exact type of arrangement the 25-percent threshold policy is meant to deter as a way of ensuring the statutory prohibition of LTCH units is followed. Furthermore, we remind commenters that LTCH discharges that reach high cost outlier status at the referring hospital would not be subject to the 25-percent threshold policy (that is, such discharges would only be included in an LTCH’s total Medicare discharges and would not count as having been admitted from that referring hospital), and to the extent the LTCH is exclusively located in an MSA-dominant area or rural area, the LTCH would have an increased applicable threshold under proposed special treatment for exclusively MSA-dominant or exclusively rural LTCHs. As no commenters offered an alternative to CCN application (other than a request to maintain the current location-specific approach, which caused considerable confusion and proved problematic for the reasons discussed previously), we are not making changes in response to these comments.

Comment: Several commenters objected to CMS’ proposal to require all locations of an LTCH to be rural or MSA-dominant in order for the hospital to be subject to an increased applicable threshold. Many of these commenters stated that if one location of the LTCH was rural or MSA-dominant, the
hospital should be subject to the increased applicable threshold.

Response: The exception for rural and MSA-dominant LTCHs was made to address the reality that LTCHs in those circumstances may not have access to the range of referral sources other LTCHs do while achieving the policy goal of preventing the creation of de facto LTCH units. We believe that the increased applicable threshold initially established under the old policy and continued into the streamlined policy strikes the appropriate balance of these competing concerns. As we stated in the proposed rule, we believe that it would be appropriate to apply the rural and MSA-dominant “special” applicable percentage thresholds based on the LTCH as a whole because LTCHs with locations that do not fall in these special treatment categories would have sufficient access across its locations to admit patients from multiple hospitals such that, as a whole, the LTCH should be able to draw from a diverse enough population to meet the proposed 25-percent threshold policy criteria. We note that although commenters opposed our proposal to require all locations of an LTCH to be rural or MSA-dominant in order for the hospital to be subject to an increased applicable threshold, they did not offer any direct counter argument against our belief that multisite LTCHs should be able to draw as a whole from a diverse population. For these reasons, we continue to believe that it is appropriate to require all locations of LTCHs to be rural or MSA-dominant a hospital to be eligible for an increased applicable threshold, and are not adopting the commenters’ suggestions to provide for an increased applicable threshold if one location of the LTCH was either rural or MSA-dominant.

Comment: Several commenters objected to CMS’ proposal to apply the revised 25-percent threshold policy based on discharge date rather than cost reporting period. Some commenters argued this was inconsistent with the historical application of the 25-percent threshold policy. Other commenters stated that the proposed discharge-based start date of October 1, 2016 is inconsistent with the current statutory moratorium on the full application of the 25-percent threshold policy.

Response: Our intent in proposing to apply the 25-percent threshold policy based on discharge date rather than cost reporting period was to avoid perpetuation of the status quo in which different LTCHs are subject to the existing 25-percent threshold policies under § 412.534 and § 412.536 at different times. By proposing to apply the policy based on discharge date rather than cost reporting period, all LTCHs would be subject to the same policy at the same time, which we believed would provide for greater transparency and administrative simplicity of the policy for both LTCHs and CMS. However, upon review, we agree with commenters who stated that our proposed implementation based solely on discharge date is contrary to the current statutory moratorium on the full implementation of the current 25-percent threshold policy. Therefore, in this final rule, we are revising our regulations to specify that the revised 25-percent threshold policy at § 412.538 is applicable for discharges occurring on or after October 1, 2016, that occur in cost reporting periods beginning on or after July 1, 2016 (for hospitals that had not been subject to § 412.534), or October 1, 2016 (for hospitals that had been subject to § 412.534). This revision will allow us to comply with the current statutory moratorium and apply the new, revised 25-percent threshold policy at § 412.538 consistently to all LTCHs upon its expiration. Therefore, in this final rule, we are revising our regulations to specify that an LTCH will be subject to the revised 25-percent threshold policy at § 412.538 for discharges occurring on or after October 1, 2016, that occur in its cost reporting periods for which it is no longer subject to any statutory moratorium on the full implementation of the current 25-percent threshold policy. In other words, the first time an LTCH will be subject to the adjustment policy at § 412.538 is for its discharges occurring on or after October 1, 2016, that occur in its first cost reporting period that begins after the statutory moratorium on the full implementation of the current 25-percent threshold policy expires for the LTCH.

Specifically, we are revising our regulations to specify that the revised 25-percent threshold policy at § 412.538 is applicable for discharges occurring on or after October 1, 2016, that occur in cost reporting periods beginning on or after July 1, 2016 (for hospitals that had not been subject to § 412.534), or October 1, 2016 (for hospitals that had been subject to § 412.534). This revision will allow us to comply with the current statutory moratorium and apply the new, revised 25-percent threshold policy at § 412.538 consistently to all LTCHs upon the expiration of the current statutory moratorium. The current 25-percent threshold policy at § 412.534 is only applicable to LTCHs (other than “subclause (II)” LTCHs) that have at least one co-located location, that is, LTCH HwHs and satellite facilities of LTCHs (except “grandfathered HwHs” which are exempt as provided by the statute). The current 25-percent threshold policy at § 412.536 is applicable to all LTCHs (other than “subclause (II)” LTCHs and grandfathered HwHs” which are exempt as provided by the statute).

Considering the two 25-percent threshold policies contemporaneously, LTCHs that are not subject to § 412.534 (that is, LTCHs which do not include a co-located location) are only subject to the adjustments at § 412.536. On the other hand, LTCHs that are subject to the adjustment at § 412.534 also are subject to the adjustment at § 412.536 (that is, they are LTCHs subject to both policies at § 412.534 and § 412.536). Under current law, the moratorium on the full application of the 25-percent threshold policy under § 412.536 expires beginning with LTCH cost reporting periods beginning on or after July 1, 2016, while the moratorium on the full application of the 25-percent threshold policy under § 412.534 expires beginning with LTCH cost reporting periods beginning on or after October 1, 2016. Consequently, although LTCHs that are subject to both policies at § 412.534 and § 412.536 will no longer be under the moratorium on the full application of § 412.536 beginning with their cost reporting periods beginning on or after July 1, 2016, these LTCHs will continue to be under the moratorium on the full application of § 412.534 until their cost reports beginning on or after October 1, 2016. As such, for LTCHs that are subject to both policies at § 412.534 and § 412.536, the provision of new § 412.538 cannot apply to all of such LTCHs’ discharges until their cost reports beginning on or after October 1, 2016. Consistent with the premise of our proposal to simplify and consolidate the current 25-percent threshold policies under new § 412.536, we are establishing that, for LTCHs that have been subject to both policies at § 412.534 and § 412.536 (that is, those LTCHs that include co-located locations), § 412.538 will apply for discharges occurring in cost reporting periods beginning on or after October 1, 2016. Under our finalized policy, this means that § 412.536 will apply to all locations of all LTCHs upon the expiration of the LTCH’s statutory moratorium, which expires on a rolling cost reporting period basis (that is, an LTCH’s first cost reporting period beginning on or after July 1, 2016) until the LTCH becomes subject to the revised policy at § 412.538. For LTCHs that were not subject to the policy at
§ 412.534 (that is, those LTCHs that do not include co-located locations and, therefore, had only been subject to the policy at § 412.536), § 412.538 will apply for discharges occurring on or after October 1, 2016, in cost reporting periods beginning on or after July 1, 2016, which coincides with the statutory expiration on the full application of § 412.536. An LTCH will remain subject to the policies at § 412.534 and/or § 412.536 as applicable until it transitions to the new policy at § 412.538. We also are making conforming changes to our proposed sunset dates for §§ 412.534 and 412.536.

Comment: Several commenters supported the proposal to exclude Medicare Advantage discharges from the calculation of the 25-percent threshold policy.

Response: We appreciate the commenters’ support and are adopting our proposal as final, without modification, to exclude Medicare Advantage discharges in the application of the 25-percent threshold policy.

Comment: One commenter stated that paragraphs (g) and (h) of proposed new § 412.538 were missing from the proposed regulation text.

Response: Upon review of the proposed regulation text of § 412.538, we found that in the proposed text of paragraph (f)(3), which would codify the proposed special treatment for LTCHs located in an MSA with an MSA-dominant hospital, we found, as commenters noted, erroneous citations to a definition of “MSA-dominant hospital” in “paragraph (b)(3)(ii) of this section.” However, our proposal was to add the definition of “MSA-dominant hospital” to § 412.503, and new § 412.538 did not include paragraphs (g) or (h). We appreciate the commenter bringing this cross-reference error to our attention, and in this final rule we have corrected the text of paragraph (e)(3) of § 412.538 to cite the definition of “MSA-dominant hospital” as defined in § 412.503.

Comment: One commenter requested clarification about whether certain LTCHs would be considered grandfathered HwHs (and thus excluded from the 25-percent threshold policy).

Response: We respond to this comment in section VII.B.3. of the preamble of this final rule where we discuss finalization of an IFC (CMS–1664–IFC), which implements the temporary exception from the site neutral payment rate for certain severe wound discharges from certain LTCHs provided by the Consolidated Appropriations Act, 2016. Our “Out-of-Scope Comments: We note we also received several comments outside the scope of the proposed rule seeking subregulatory guidance which we intend to address in the future as appropriate.

We did not receive any public comments regarding our proposal to add definitions of “MSA,” “MSA-dominant area,” and “MSA-dominant hospital” to § 412.503 and, therefore, are adopting those proposals as final without modification.

After consideration of the public comments we received, we are adopting the new 25-percent threshold policy, as proposed, with one exception. In response to comments, we are revising §§ 412.534, 412.536, and 412.538 to reflect the cost reporting period-based end dates of the moratoria under the current statute, as discussed previously. For hospitals that had not been subject to the policy at § 412.534, the revised policy is effective for discharges occurring on or after October 1, 2016. For hospitals that had been subject to the policy at § 412.534, the revised policy is effective for discharges occurring on or after October 1, 2016, in cost reporting periods beginning on or after October 1, 2016. Prior to transition to the single 25-percent threshold policy, a hospital is subject to both policies at §§ 412.534 and 412.536 to the same extent it would have been absent the revisions to the policy. Under this single 25-percent threshold policy, LTCH PPS payment for LTCH discharges from a single referring hospital in excess of the LTCH’s applicable percentage threshold for that referring hospital will be adjusted, unless the LTCH is excepted from the adjustment under § 412.538(a)(2)(III). In addition, as we proposed, we are establishing that the applicable percentage threshold will generally be 25 percent (with special treatment for exclusively rural LTCHs and exclusively MSA-dominant LTCHs). The 25-percent threshold policy will be applicable to all LTCHs except “subclause (II)” LTCHs and “grandfathered HwHs.” Under these policies, LTCH discharges that reached high-cost outlier status at the referring hospital from which the patient was discharged directly to the LTCH will be treated as though they had come from a different referring hospital and, therefore, will not be counted as a Medicare discharge from that referring hospital. We also are establishing that MA discharges will not be included in this policy. In addition, the revised 25-percent threshold policy will apply to all LTCH PPS discharges (that is, both LTCH PPS standard Federal payment rate and site neutral payment rate cases).

Under this revised policy, we will evaluate the “applicable percentage threshold” based on the sum of the locations covered by the LTCH’s and referring hospitals’ Medicare provider agreement, and implement this policy using the LTCH’s and the referring hospitals’ CCN. As we proposed, we are establishing that an LTCH’s percentage of Medicare discharges from a given hospital will be determined by dividing the LTCH’s number of Medicare discharges in the cost reporting period (based on the LTCH’s CCN) that were admitted directly from a given referring hospital (based on the hospital’s CCN) that did not receive a high-cost outlier payment during the stay at that referring hospital by the LTCH’s total number of Medicare discharges in the cost reporting period (based on the LTCH’s CCN). Under new § 412.538, as applicable, the LTCH PPS payment will be adjusted at cost report settlement for the LTCH Medicare discharge that caused the LTCH to exceed its applicable threshold and all discharges subsequent to that discharge. Medicare discharges not in excess of the applicable percentage threshold will continue to be unaffected by the 25-percent threshold policy (that is, the payment for such discharges will not be adjusted). As adjusted, the payment amount for an LTCH Medicare discharge that is found to exceed the applicable percentage threshold will continue to receive the lesser of the applicable LTCH PPS payment amount or an IPPS equivalent amount.

G. Refinement to the Payment Adjustment for “Subclause II” LTCHs

As part of our FY 2015 IPPS/LTCH PPS rulemaking cycle, under the authority provided by section 1206(d)(2) of the Pathway to SGR Reform Act (Pub. L. 113–67), we adopted an adjustment to the LTCH PPS payment for LTCHs classified under section 1886(d)(1)(B)(iv)(II) of the Act (“subclause (II) LTCHs”), which are described in 42 CFR 412.230(2)(ii). Under this adjustment, subclause (II) LTCHs receive payment under the LTCH PPS that is generally equivalent to an amount determined under the reasonable cost-based payment rules for both operating and capital-related costs under 42 CFR part 413 (that is, an amount generally equivalent to an amount determined under the TEFRA payment system methodology, which could be called a “TEFRA-like” methodology). For more information on this adjustment, we refer readers to the FY 2015 IPPS/LTCH final rule (70 FR 50193 through 50197). As initially adopted, this “TEFRA-like” payment...
adjustment for subclause (II) LTCHs did not incorporate the limitation on charges to Medicare beneficiaries policies under the TEFRA payment system. Alignment of the limitation on charges to beneficiaries and related billing requirements would result in administrative simplification for the cost report submission and settlement process under the payment adjustment for subclause (II) LTCHs specified at §412.526.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25173), we therefore proposed to revise the limitation on charges to beneficiaries policy and related billing requirements for subclause (II) LTCHs to reflect what is done in the TEFRA payment system context for cost reporting periods beginning on or after October 1, 2016, which would align our beneficiary charge policies (and related billing procedures) with the reasonable cost-based “TEFRA-like” payment adjustment under §412.526. The adjusted LTCH PPS payment to subclause (II) LTCHs under $412.526 is considered the full LTCH PPS payment (that is, the LTCH PPS standard Federal payment rate or site neutral payment rate, as applicable), and as such, under current policy that payment applies to the LTCH’s costs for services furnished until the high-cost outlier threshold is met (existing §412.507(a)). Under this proposal, for a subclause (II) LTCH, the Medicare payment would only apply to the LTCH’s costs incurred for the days used to calculate the Medicare payment (that is, days for which the patient has a benefit day available). Furthermore, in addition to the applicable Medicare deductible and coinsurance amounts (and for items and services as specified under §489.20(a)), we proposed to specify that the LTCH may only charge the beneficiary for services provided during the stay that were not the basis for the adjusted LTCH PPS payment amount under §412.526.

Comment: Two commenters supported the proposal to modify §412.507 to provide that subclause (II) LTCHs would be subject to the same billing requirements applicable to hospitals that are paid on a reasonable-cost basis under the TEFRA payment system. The commenters also recommended that CMS make conforming changes to the applicable section of the Medicare Claims Processing Manual, the Medicare claims processing system, and cost report instructions.

Response: We appreciate the commenters’ support of our proposed changes to align our beneficiary charge policies under §412.507 with the reasonable cost-based “TEFRA” payment adjustments. As we indicated in the proposed rule and noted above, if finalized, subclause (II) LTCHs would be treated the same as IPPS-excluded hospitals paid under the TEFRA payment system for purposes of the limitation on charges to beneficiaries and related billing requirements.

In the FY 2017 proposed rule, using the broad authority conferred upon the Secretary under section 123(a)(1) of the BBRA, as amended by section 307(b) of the BIPA, in conjunction with the authority provided under section 1206(d)(2) of Pub. L. 113–67, we proposed to revise §412.507 to specify the limit on charges to beneficiaries treated at subclause (II) LTCHs as is done under the TEFRA payment system in order to align our beneficiary charge policies with the reasonable cost-based “TEFRA-like” payment adjustments under §412.526. Specifically, we proposed to revise §412.507 to specify that, for cost reporting periods beginning on or after October 1, 2016, the Medicare payment made to subclause (II) LTCHs (as defined at §412.23(e)(2)(i)) only applies to the hospital’s costs on the days used to calculate the Medicare payment (that is, days for which the patient has a benefit day available). Furthermore, we proposed under proposed revised §412.507 to specify that, for cost reporting periods beginning on or after October 1, 2016, the hospital may only charge the Medicare beneficiary for the applicable deductible and coinsurance amounts (under §§409.82, 409.83 and 409.87) for items and services as specified under §489.20(a), and for services provided during the stay that were not the basis for the adjusted LTCH PPS payment amount under §412.526.

VIII. Quality Data Reporting Requirements for Specific Providers and Suppliers

We seek to promote higher quality and more efficient healthcare for Medicare beneficiaries. This effort is supported by the adoption of widely agreed-upon quality measures. We have worked with relevant stakeholders to define quality measures for most settings and to measure various aspects of care for most Medicare beneficiaries. These measures assess structural aspects of care, clinical processes, patient experiences with care, care coordination, and improving patient outcomes.

We have implemented quality reporting programs for multiple care settings, including:
- Hospital inpatient services under the Hospital Inpatient Quality Reporting (IQR) Program (formerly referred to as the Reporting Hospital Quality Data for Annual Payment Update (RHQDAPU) Program);
- Hospital outpatient services under the Hospital Outpatient Quality Reporting (OQR) Program (formerly referred to as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP));
- Care furnished by physicians and other eligible professionals under the Physician Quality Reporting System (PQRS, formerly referred to as the Physician Quality Reporting Program Initiative (PQRI));
- Inpatient rehabilitation facilities under the Inpatient Rehabilitation Facility Quality Reporting Program (IRF QRP);
- Long-term care hospitals under the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) (also referred to as the LTCHQRP Program);
- PPS-exempt cancer hospitals under the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program;
- Ambulatory surgical centers under the Ambulatory Surgical Center Quality Reporting (ASCQR) Program;
- Inpatient psychiatric facilities under the Inpatient Psychiatric Facilities Quality Reporting (IPFQR) Program;
- Home health agencies under the home health quality reporting program (HH QRP); and
- Hospice facilities under the Hospice Quality Reporting Program.

We have also implemented the End-Stage Renal Disease Quality Incentive Program, Hospital Readmissions Reduction Program, HAC Reduction Program, and Hospital VBP Program (described further below) that link payment to performance.
In implementing the Hospital IQR Program and other quality reporting programs, we have focused on measures that have high impact and support CMS and HHS priorities for improved quality and efficiency of care for Medicare beneficiaries. Our goal for the future is to align the clinical quality measure requirements of the Hospital IQR Program with various other Medicare and Medicaid programs, including those authorized by the Health Information Technology for Economic and Clinical Health (HITECH) Act, so that the reporting burden on providers will be reduced. As appropriate, we will consider the adoption of clinical quality measures with electronic specifications so that the electronic collection of performance information is a seamless component of care delivery.

Establishing such a system will require interoperability between EHRs and CMS data collection systems, additional infrastructure development on the part of hospitals and CMS, and adoption of standards for capturing, formatting, and transmitting the data elements that make up the measures. However, once these activities are accomplished, adoption of measures that rely on data obtained directly from EHRs will enable us to expand the Hospital IQR Program measure set with less cost and reporting burden to hospitals. We believe that in the near future, collection and reporting of data elements through EHRs will greatly simplify and streamline reporting for various CMS quality reporting programs, and that hospitals will be able to switch primarily to EHR-based data for many measures that are currently manually charted and submitted to CMS for the Hospital IQR Program.

We also have implemented a Hospital VBP Program under section 1886(o) of the Act, described in the Hospital Inpatient VBP Program final rule (76 FR 26490 through 26547). We most recently adopted additional policies for the Hospital VBP Program in section IV.H. of the preamble of this final rule. Under the Hospital VBP Program, hospitals receive value-based incentive payments based on their performance with respect to performance standards for a performance period for the fiscal year involved. The measures under the Hospital VBP Program must be selected from the measures (other than readmission measures) specified under the Hospital IQR Program as required by section 1886(o)(2)(A) of the Act.

In selecting measures for the Hospital IQR Program, we are mindful of the conceptual framework we have developed for the Hospital VBP Program. Because measures adopted for the Hospital VBP Program must first have been adopted and reported under the Hospital IQR Program, these two programs are linked and the reporting infrastructure for the programs overlap. We view the Hospital VBP Program as the next step in promoting higher quality care for Medicare beneficiaries by transforming Medicare from a passive payer of claims into an active purchaser of quality healthcare for its beneficiaries. Value-based purchasing is an important step to revamping how care and services are paid for, moving increasingly toward rewarding better value, outcomes, and innovations. We also view the HAC Reduction Program, authorized by section 1886(p) of the Act, as added by section 3008 of the Affordable Care Act, and the Hospital VBP Program, as related but separate efforts to reduce HACs. The Hospital VBP Program is an incentive program that awards payments to hospitals based on quality performance on a wide variety of measures, while the HAC Reduction Program creates a payment adjustment resulting in payment reductions for poorly performing hospitals based on their rates of HACs.

In the FY 2017 IPPS/LTCH PPS proposed rule, we proposed changes to the following Medicare quality reporting systems:

- In section VIII.A. (81 FR 25174 through 25205), the Hospital IQR Program.
- In section VIII.B. (81 FR 25205 through 25213), the PCHQR Program.
- In section VIII.C. (81 FR 25213 through 25238), the LTCH QR.
- In section VIII.D. (81 FR 25238 through 25244), the IPPQR Program.
- In addition, in section VII.E. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25244 through 25247), we proposed changes to the Medicare and Medicaid EHR Incentive Programs for eligible hospitals and CAHs.

A. Hospital Inpatient Quality Reporting (IQR) Program

1. Background

a. History of the Hospital IQR Program

We refer readers to the FY 2010 IPPS/LTCH PPS final rule (74 FR 43860 through 43861) and the FY 2011 IPPS/LTCH PPS final rule (75 FR 50180 through 50181) for detailed discussions of the history of the Hospital IQR Program, including the statutory history, and to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50217 through 50249) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49660 through 49692) for the measures we have adopted for the Hospital IQR Program measure set through the FY 2019 payment determination and subsequent years.

b. Maintenance of Technical Specifications for Quality Measures

We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49640 through 49641) for a discussion of the maintenance of technical specifications for quality measures for the Hospital IQR Program. We also refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50202 through 50203) for additional detail on the measure maintenance process.

In addition, we believe that it is important to have in place a subregulatory process to incorporate nonsubstantive updates to the measure specifications for measures we have adopted for the Hospital IQR Program so that these measures remain up-to-date. We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53504 through 53505) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203) for our policy for using a subregulatory process to make nonsubstantive updates to measures used for the Hospital IQR Program. We recognize that some changes made to measures undergoing maintenance review are substantive in nature and might not be appropriate for adoption using a subregulatory process. We will continue to use rulemaking to adopt substantive updates made to measures we have adopted for the Hospital IQR Program.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25174), we did not propose any changes to our policies on the measures maintenance process or for using the subregulatory process to make nonsubstantive updates to measures used for the Hospital IQR Program.

c. Public Display of Quality Measures

Section 1886(b)(3)(B)(vii) of the Act was amended by the Deficit Reduction Act (DRA) of 2005. Section 5001(a) of the DRA requires that the Secretary establish procedures for making information regarding measures submitted available to the public after ensuring that a hospital has the opportunity to review its data before they are made public. We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50776 through 50778) for a more detailed discussion about public display of quality measures.

The Hospital Compare Web site is an interactive Web tool that assists beneficiaries by providing information on hospital quality of care to those who need to select a hospital. We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50776 through 50778).
the Web site at: http://www.medicare.gov/hospitalcompare. Other information not reported to Hospital Compare may be made available on other CMS Web sites, such as https://data.medicare.gov.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25174 through 25175), we did not propose any changes to these policies.

2. Process for Retaining Previously Adopted Hospital IQR Program Measures for Subsequent Payment Determinations

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53512 through 53513), for our finalized measure retention policy. Pursuant to this policy, when we adopt measures for the Hospital IQR Program beginning with a particular payment determination, we automatically readopt these measures for all subsequent payment determinations unless we propose to remove, suspend, or replace the measures. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175), we did not propose any changes to this policy.

3. Removal and Suspension of Hospital IQR Program Measures

a. Considerations in Removing Quality Measures From the Hospital IQR Program

As discussed above, we generally retain measures from the previous year’s Hospital IQR Program measure set for subsequent years’ measure sets except when we specifically propose to remove, suspend, or replace a measure. We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50185) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203 through 50204) for more information on the criteria we consider for removing quality measures. We refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49641 through 49643) for more information on the additional factors we consider in removing quality measures and the factors we consider in order to retain measures. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50203 through 50204), we also finalized our proposal to clarify the criteria for determining when a measure is “topped-out.” In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175), we did not propose any changes to these policies.

b. Removal of Hospital IQR Program Measures for the FY 2019 Payment Determination and Subsequent Years

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175 through 25178), we proposed to remove the following 15 measures for the FY 2019 payment determination and subsequent years. Some of these measures we proposed to remove in their entirety; one of these measures, VTE–6 Incidence of Potentially Preventable Venous Thromboembolism, we proposed to remove just in the electronic form as discussed further below:

- AMI–2: Aspirin Prescribed at Discharge for AMI (NQF #0142);
- AMI–7a: Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival;
- AMI–10: Statin Prescribed at Discharge;
- HTN: Healthy Term Newborn (NQF #0716);
- PN–6: Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients (NQF #0147);
- SCIP–Inf–1a: Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision (NQF #0527);
- SCIP–Inf–2a: Prophylactic Antibiotic Selection for Surgical Patients (NQF #0528);
- SCIP–Inf–9: Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero;
- STK–4 Thrombolytic Therapy (NQF #0437);
- VTE–3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy (NQF #0373);
- VTE–4: Venous Thromboembolism Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol (or Nomogram);
- VTE–5: Venous Thromboembolism Discharge Instructions;
- VTE–6: Incidence of Potentially Preventable Venous Thromboembolism; Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care; and Participation in a Systematic Clinical Database Registry for General Surgery.

We received general comments related to the collective removal of these 15 measures (13 eCQMs, including 2 measures in chart form, and 2 structural measures). We discuss these general comments first; comments specific to individual measures are discussed further below.

Comment: The majority of commenters supported the proposed removal of 13 eCQMs from the Hospital IQR Program beginning with the FY 2019 payment determination in an effort to move quality measurement toward outcomes. Many commenters stated their belief that these measures were toped out, and that the measures’ complexity could not be captured in an electronic form. A number of commenters also stated their belief that the eCQM measure specifications were not feasible to implement. Others noted removing these measures would decrease administrative burden, minimize confusion among providers regarding Hospital IQR Program data submission, and align the Hospital IQR Program with other quality measurement efforts.

Response: We thank the commenters for their support of our proposal to remove 13 eCQMs in an effort to move quality measurement toward outcomes measures.

Comment: Several commenters supported CMS’ efforts to reduce reporting burden on hospitals, but expressed concern with the timeline of the proposal to remove 13 eCQMs beginning with the FY 2019 payment determination because hospitals may need time to adjust workflows and work with IT vendors to add support for measures not previously supported and ensure valid eCQMs are submitted. Commenters encouraged CMS to consider the time, effort, and resources expended on reporting these measures when deciding to remove them from the Hospital IQR Program. One commenter noted that EHR vendors will phase out support for these measures and clinicians may become skeptical about benefits to workflow changes related to future measures if measures are continuously added and removed. Another commenter urged CMS to provide more lead time for the removal of measures that hospitals have dedicated so many resources to developing and implementing. Specifically, the commenter requested that for FY 2019, CMS maintain the current requirements of reporting 4 eCQMs out of the current list of 28, and remove the 13 measures proposed for removal for FY 2020 in order to give hospitals more time to plan and prepare for implementation.

Response: We understand the commenters’ concern with removing eCQMs that have been previously reported and implemented in an existing EHR workflow, and we acknowledge the time, effort, and resources that hospitals expend on reporting these measures. However, we believe that removal of the 13 eCQMs beginning with the FY 2019 payment determination will be less burdensome to hospitals overall than continuing to keep them in the Hospital IQR Program. Our decision to remove measures from the Hospital IQR Program is an extension of our programmatic goal to continually refine the measure set and development, and to focus on measures that provide the most meaningful and accurate information to consumers.
to ensure that it consists of quality performance standards as well as aligns with the Medicare and Medicaid EHR Incentive Program. It is one of our goals to expand electronic reporting in the Hospital IQR Program, which we believe will ultimately reduce burden on hospitals as compared with chart-abstracted data reporting and improve patient outcomes by providing more robust data to support quality improvement efforts. We intend to introduce additional eCQMs into the program as eCQMs that support our program goals become available.

In addition, we believe that the FY 2019 payment determination is the appropriate time to require eCQM reporting because hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and Hospital IQR Program (3 years of voluntary reporting and 3 years of reporting as part of a pilot).

Furthermore, for the CY 2016 reporting period/FY 2018 payment determination, hospitals are required to submit one quarter’s worth of data for 4 eCQMs for the Hospital IQR Program (80 FR 49694). As we stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49696), we believe that it is appropriate to require reporting and validation of eCQMs given that measures available now and those being developed for the future are increasingly based on electronic standards.

We will continue working to provide hospitals with the education, tools, and resources necessary to help reduce eCQM reporting burden and more seamlessly account for the removal/addition of eCQMs. Further, we will also consider the issues associated with new software, workflow changes, training, etcetera as we continue to improve our education and outreach efforts for eCQM submission and validation. We try to be as proactive as possible in providing lead time about the removal of measures from the Hospital IQR Program measure set. With regard to the measures being removed for the FY 2019 payment determination, we signaled our intent to remove these measures in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49644 through 49645). We refer readers to section VIII.A.8.a. of the preamble of this final rule for a discussion of our final policy regarding the number of eCQMs required for submission for the FY 2019 payment determination and subsequent years.

Comment: A few commenters suggested that topped-out measures not be removed from the Hospital IQR Program measure set. One commenter opposed the proposal to remove the eCQMs that are topped out, stating that the measures should not be retired until the eCQM reporting process and validation have matured. The commenter further stated that allowing hospitals the option to electronically report topped-out measures would provide them with an opportunity to test the accuracy of their EHR reporting systems. Another commenter requested that any topped-out eCQM that is removed from the Hospital IQR Program be kept on reserve so that performance can be monitored as necessary to ensure that performance and/or adherence to best practices do not decline. In addition, the commenter suggested that an alternative use of topped-out measures is inclusion as components of composite measures. Another commenter recommended that CMS implement a periodic auditing system of measures designated as topped-out. The commenter expressed the opinion that such a system would ensure that performance remains satisfactorily high and also detect reductions in the quality of care.

Response: We disagree that measures should not be retired until the eCQM reporting process and validation have matured. While we recognize the benefit of testing the accuracy of EHR reporting systems and performance monitoring to ensure best practices do not decline, we must balance the costs of continued inclusion of these measures in the program and monitoring of successful measures that have high levels of performance with the addition of other measures which have greater opportunities for improvement in clinical quality.

Comment: One commenter expressed concern that nine out of 15 eCQMs proposed for required reporting in the Hospital IQR Program are “topped-out” and suggested that CMS remove the following nine measures: AMI–8a—Primary PCI within 90 minutes of Hospital Arrival; STK–02—Discharged on Antithrombotic Therapy; STK–03—Anticoagulation Therapy for Atrial Fibrillation/Flutter; STK–05—Antithrombotic Therapy by End of Hospital Day 2; STK–06—Discharged on Statin; STK–08—Stroke Education; STK–10—Assessed for Rehab; VTE–01—Venous Thromboembolism Prophylaxis; VTE–02—ICU VTE Prophylaxis. The commenter also expressed concern about the audit requirements for these measures as EHRs are updated and requested clarification of the data field requirements.

Response: While we acknowledge commenter’s concern regarding retaining eCQMs that are topped-out in their chart-abstracted form, we note that we take several factors into consideration when retaining or removing measures from the program. We refer readers to the FY 2016 IPPS/LTCH PPS final rule where we discuss our measure removal and retention factors (80 FR 49641). These measures are not being considered for removal in this final rule because we believe that these measures have other valuable factors that warrant retention in the program, such as: Alignment with CMS Quality Strategy goals; alignment with other CMS programs, including other quality reporting programs, or the EHR Incentive Program; and supporting efforts to move facilities towards reporting electronic measures.

With regard to the commenter’s concerns regarding “audit requirements,” we interpret this to refer to changes in eCQM technical mapping that may need to occur after an EHR is updated/upgraded. All Hospital IQR Program eCQM electronic specifications and technical release notes are readily available at the eCQI (Electronic Clinical Quality Improvement) Resource Center: https://ecqi.healthit.gov/eh. We encourage hospitals to test electronic capture of data following updates and upgrades or to work with their vendors to do so. Further, we encourage hospitals to internally test their preparedness to submit eCQM data prior to annual reporting using an available presubmission testing tool for electronic reporting—such as the CMS Pre-Submission Validation Application (PSVA), which can be downloaded for free from the Secure File Transfer (SFT) section of the QualityNet Secure Portal at: https://eportal.qualitynet.org/QNet/pgm_select.jsp. We will also continue working to provide hospitals and vendors with education on eCQM data reporting fields and elements.

Comment: A few commenters did not support the removal of any of these 13 eCQMs because it would reduce the number of eCQMs available for hospitals to select for reporting. One commenter indicated that this proposal would reduce hospitals’ flexibility in choosing to report measures that are meaningful to them and that align with their internal efforts to improve quality.

Response: We understand the commenters’ concerns with respect to allowing hospitals’ flexibility to choose to report on measures that are meaningful to internal quality improvement efforts. However, as we stated in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49641), we strive to ensure that our measure set consists of quality standards that align with the

We understand the commenter’s concerns regarding the notion that removing measures from the program would reduce hospitals’ flexibility in choosing to report measures that are meaningful to them and that align with their internal efforts to improve quality.
National Quality Strategy and our priorities for quality improvement as outlined in the CMS Quality Strategy, available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/QualityInitiativesGenInfo/Downloads/CMSQuality-Strategy.pdf. Our decision to remove measures from the Hospital IQR Program measure set is an extension of our programmatic goal to continually refine the measure set and ensure that it consists of quality performance standards. We again refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49641) for our considerations in removing and retaining measures as well as section VIII.A.8.a. of the preamble of this final rule, where we finalize a policy to require submission of 8 eCQMs out of 15 available eCQMs for the CY 2017 reporting period/FY 2018 payment determination and the CY 2018 reporting period/FY 2020 payment determination.

Comment: A commenter did not support the removal of measures because it can hinder ongoing measurement and reduce performance improvements. The commenter requested that CMS maintain a library of measures that are not included in the Hospital IQR Program so that hospitals and vendors can still support monitoring and improving these removed measures.

Response: We disagree with commenter that the removal of these measures may hinder measurement and reduce performance improvement. Although hospitals are not publicly reporting data for measures that have been removed from the Hospital IQR Program, hospitals are encouraged to continue to monitor data for continuous quality improvement. We appreciate the commenter’s suggestion to maintain a library of eCQMs that have been removed from the Hospital IQR Program and will take it into consideration for the future.

Comments related to removal of specific measures are discussed in more detail below.

(1) Removal of Structural Measures

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175), we proposed to remove two structural measures for the FY 2019 payment determination and subsequent years: (1) Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care; and (2) Participation in a Systematic Clinical Database Registry for General/Specialist Based on Removal factor 4—performance on these measures does not result in better patient outcomes (80 FR 49641). These measures were originally adopted in the RHQDAPU Program FY 2010 IPPS/RY 2010 LTCH PPS final rule (74 FR 43870 through 43872) to monitor participation in systematic clinical database registries for the Hospital IQR Program. By design, the measures do not provide information on patient outcomes, because hospitals are asked only whether they participate in registries. In the future, we will consider other more effective measures to include in the program. As a result, we believe that the burden to retain these measures outweigh the benefits. Therefore, we proposed to remove these two structural measures from the Hospital IQR Program for the FY 2019 payment determination and subsequent years.

Comment: Many commenters supported the proposed removal of the two structural measures from the Hospital IQR Program because removing these measures ensures that the measure set only includes measures that result in better patient outcomes. A number of commenters asserted that the measures do not provide pertinent information on patient outcomes, do not reflect performance on process or outcomes, and do not add value to the Hospital IQR Program’s measure set. Some commenters also noted that removing these measures would decrease the annual reporting burden on hospitals.

Response: We thank the commenters for their support.

Comment: A few commenters supported the proposed removal of the two structural measures from the Hospital IQR Program, but suggested that this removal be implemented for the FY 2018 payment determination, instead of the FY 2019 payment determination.

Response: We thank the commenters for their support and suggestion. However, we will implement the removal of these measures for the FY 2019 payment determination as proposed, because the FY 2019 payment determination is the earliest we can feasibly operationalize the removal.

Comment: One commenter expressed concern with the proposed removal of the Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care measure, because it has seen improvement from this participation. The commenter suggested that any future quality measures should match the registry’s quality measures to encourage alignment.

Response: We continue to believe that registries may facilitate valuable quality improvement feedback to hospitals that may be more meaningful beyond the information reported to the Hospital IQR Program as structural measures. However, at this time we are unable to collect this additional quality improvement data since we do not maintain the registries. The structural measures themselves, as part of the Hospital IQR Program, do not provide information on patient outcomes; hospitals are asked only whether they participate in registries. Thus, we believe it is important to consider other measures that provide more meaningful and detailed information regarding quality of care and patient outcomes while balancing program burdens. We note that we are committed to promoting alignment in quality measures when feasible; however, many registry measures are proprietary.

Comment: One commenter opposed the proposed removal of the “Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care” because public reporting of this measure is a lever to promote continued hospital participation in a nursing-sensitive data registry. The commenter expressed concern that if this measure were not included in the Hospital IQR Program, the role of nursing professionals would be diminished in the program. The commenter further noted that this measure is low burden to report and urged CMS to retain this measure until nursing sensitive process and outcome measures are developed as eCQMs and reported in the Hospital IQR Program.

Response: We appreciate the commenter’s position to retain this measure, however, we note that the main intent of this structural measure was to assess the level of registry participation. Because this measure does not provide information on patient outcomes or quality of care, we believe it is important to remove it from the program at this time in light of the burden of reporting and consider other measures that provide more meaningful and detailed information regarding quality of care and patient outcomes. We believe that hospitals committed to participating in a nursing registry will continue to do so. We agree with the commenter that providing quality care requires all members of the care team, including nurses, and we will continue to consider measures for the Hospital IQR Program that incorporate the importance of communication and coordination among members of the care team. We will also consider the development of nursing sensitive process and outcome measures for the Hospital IQR Program in the future.
Database Registry for General Surgery” from the Hospital IQR Program because it believed that the inclusion of this measure encourages hospital participation in risk-adjusted, audited clinical data registries. Further, the commenter asserted that inclusion of such a measure helps CMS ensure that hospital and physician programs are in alignment.

Response: We note that the main intent of this structural measure was to assess the level of registry participation. When considering measures for the Hospital IQR Program, we attempt to align with other programs whenever feasible, but because this measure does not provide information on patient outcomes or quality of care, we believe it is important to remove it from the program at this time in light of the overall burden of reporting. We do not believe that the removal of this measure will dis-incentivize hospitals committed to participating in registries for quality improvement.

After consideration of the public comments we received, we are finalizing the removal of these two structural measures from the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(2) Removal of “Topped-Out” Chart-Abstracted Measures

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175), we proposed to remove two measures in their chart-abstracted forms: (1) STK–4: Thrombolytic Therapy (NQF #0437) and (2) VTE–5: VTE Discharge Instructions, including shorter hospital stays after major surgery, make clear discharge planning around VTE prevention more important moving forward. The commenter expressed the opinion that removing this measure would reduce accountability for appropriate performance at risk of VTE.

Response: Topped-out measures represent care standards that have been widely adopted by hospitals. Measure performance among hospitals is so high and unvarying for VTE–5 that meaningful distinctions and improvements in performance can no longer be made. We believe that hospitals committed to providing quality care will continue to provide good quality care consistent with standard practice. In the past, we have retained the electronic versions of some topped-out measures for reasons such as promoting alignment between programs or to provide an opportunity to monitor topped-out measures for performance decline. In this case, VTE–5 is not only topped-out, but also, as stated above, a majority of hospitals do not have the ability to capture the required eCQM data elements needed for VTE–5. In addition, removing VTE–5 promotes alignment with the Medicare and Medicaid EHR Incentive Programs.

Finally, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we received anecdotal comments about performance level differences between chart-abstracted and eCQM data. We do not have sufficient data to be able to confirm or refute the accuracy of those comments (79 FR 50258), but these comments have prompted us to reconsider our position that topped-out eCQMs provide an opportunity for CMS to meaningfully monitor topped-out measures for performance decline at this time. In consideration of all of these factors, we do not believe that the burden of retaining the electronic version to allow the comparison to old data outweighs the benefit. Therefore, we believe that removal of VTE–5 in both chart-abstracted and eCQM form is appropriate.

Comment: One commenter did not support the removal of the STK–4 chart-abstracted measure because the commenter believes there is still a performance gap among hospitals for this measure, and recent inclusion of admission and exclusion criteria released earlier this year may increase the number of patients eligible for this treatment. The commenter suggested that CMS retain the STK–4 measure.

Response: We disagree with the commenter that a performance gap among hospitals exists. We note that STK–4 is topped-out in its chart-abstracted form, which under our definition means that measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made.
While we acknowledge that revised measure specifications have been submitted to NQF, the revised measure would be required to proceed through the pre-rulemaking process for measure selection before it could be considered for adoption in the Hospital IQR Program. For details regarding the pre-rulemaking process we refer commenter to https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Pre-Rule-Making.html.

Comment: One commenter requested that any topped-out chart-abstracted measure that is removed from the Hospital IQR Program be kept on reserve so that performance can be monitored as necessary to ensure that performance and/or adherence to best practices do not decline. In addition, the commenter suggested that an alternative use of topped-out measures could instead be used as components of composite measures.

Response: We currently do not have authority to maintain a “reserve” status for quality measures in the Hospital IQR Program. If we interpret the commenter to mean that CMS should retain the measures in the program as is, we disagree, and a new composite measure would be required to proceed through the pre-rulemaking process for measure selection before it could be proposed in formal rulemaking. For details regarding the pre-rulemaking process we refer commenter to https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Pre-Rule-Making.html. We believe that topped-out measures represent quality care standards that have been widely adopted by hospitals, and retention of these measures, in the absence of other mitigating factors such as alignment with other programs, independently or as components of a composite measure, is unnecessary because hospitals will continue to perform well on these measures. Further, we must balance the costs and burden of continued reporting and monitoring of a successful measure with high levels of performance with the adoption of other measures where there are greater opportunities for improvement in clinical quality. As stated above, we also considered other factors such as alignment with other programs, and determined that removal of STK–4 and VTE–5 promotes alignment with the Medicare and Medicaid EHR Incentive Programs.

After consideration of the public comments we received, we are finalizing the removal of STK–4: Thrombolytic Therapy (NQF #0437) and VTE–5: VTE Discharge Instructions for the FY 2019 payment determination and subsequent years as proposed.

(3) Removal of Certain eCQMs

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175, we proposed to remove the electronic versions of AMI–7a, HTN, PN–6, SCIP–Inf–9, VTE–3, VTE–4, VTE–5, VTE–6, STK–4, AMI–2, AMI–10, SCIP–Inf–1a, and SCIP–Inf–2a, beginning with the FY 2019 payment determination. Each measure is discussed in more detail below.

(a) Removal of eCQMs in Alignment With the Medicare and Medicaid EHR Incentive Programs

We propose to remove 13 eCQMs from both the Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs in order for hospitals to focus on a smaller, more specific subset of eCQMs while keeping the programs aligned.

We refer readers to sections VIII.A.8.a. and VIII.A.10.d. of the preamble of this final rule for details on eCQM reporting requirements for the Hospital IQR Program in alignment with the Medicare and Medicaid EHR Incentive Programs. We also refer readers to section VIII.A.3.b.(3) of the preamble of this final rule for discussion on the removal of these 13 eCQMs from the Medicare and Medicaid EHR Incentive Programs. We believe that a coordinated reduction in the overall number of eCQMs in both programs would reduce burden on hospitals and improve the quality of reported data by enabling hospitals to focus on a smaller, more specific subset of eCQMs. We proposed these changes in response to public comments for the Hospital IQR Program in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49694), which recommended that CMS adopt a lesser number of eCQMs.

Comment: Many commenters supported the removal of 13 eCQMs from the Hospital IQR Program measure set.

Response: We thank the commenters for their support.

(i) AMI–7a

We proposed to remove the AMI–7a: Fibrinolytic Therapy Received Within 30 minutes of Hospital Arrival eCQM, because performance or improvement on this measure does not result in better patient outcomes—removal factor 4 (80 FR 49641). In the FY 2016 IPPS/LTCH PPS final rule, we removed the chart-abstracted version of AMI–7a because the reporting burden outweighed the benefit of posting very few hospitals’ measure rates. This measure’s specifications resulted in very high denominator exclusion rates. Consequently, the vast majority of abstracted AMI cases were excluded from AMI–7a measure rates. Most acute myocardial infarction (AMI) patients receive percutaneous coronary intervention (PCI) instead of fibrinolytic therapy (80 FR 49647). We do not believe that the mode of reporting (eCQM versus chart-abstracted) would cause the number of cases reported to differ since most AMI patients would still receive PCI instead of fibrinolytic therapy. In the FY 2016 IPPS/LTCH PPS final rule, we retained the electronic version of this measure for alignment purposes with the Medicare and Medicaid EHR Incentive Programs (80 FR 49644). As discussed above, we proposed to focus on a smaller, more specific subset of eCQMs in both the Hospital IQR and Medicare and Medicaid EHR Incentive Programs. As a result, the burdens related to retaining this measure outweigh the benefits. Therefore, we proposed to remove the AMI–7a eCQM from the Hospital IQR Program for the FY 2019 payment determination and subsequent years.

Comment: A commenter supported the removal of the AMI–7a because most AMI patients receive percutaneous coronary intervention instead of fibrinolytic therapy and the measure does not reflect current clinical practice.

Response: We thank the commenter for its support of our proposal to remove AMI–7a because it does not reflect current clinical practice.

Comment: One commenter did not support the proposal to remove the AMI–7a measure because fibrinolytic therapy is still recommended when PCI cannot be performed within 120 minutes of first medical contact. Because it is still an important process of care, the commenter recommended that CMS find ways to reduce collection burden instead of removing the measure from the Hospital IQR Program. The commenter also expressed concern that removing this measure could cause unintended consequences, particularly for patients in rural settings where there could be prolonged times to transfer a patient to a PCI-capable hospital.

Response: As discussed above, in the FY 2016 IPPS/LTCH PPS final rule, we previously removed the chart-abstracted version of AMI–7a because the reporting burden outweighed the benefit of posting very few hospitals’ measure rates. This measure’s specifications resulted in very high...
denominator exclusion rates, and consequently, the vast majority of abstracted acute myocardial infarction (AMI) cases were excluded from AMI–7a measure rates. Further, most AMI patients receive percutaneous coronary intervention (PCI) instead of fibrinolytic therapy (80 FR 49647). While we acknowledge the commenters’ concern regarding unintended consequences, particularly in rural settings, we carefully weighed the benefits and burden of retaining this eCQM in the program. Due to the high exclusion rates, we do not believe that trying to reduce the collection burden of AMI–7a will reduce the exclusion rates or otherwise outweigh the reporting costs to hospitals of retaining the measure in the Hospital IQR Program. As discussed above, we intend to focus on a smaller, more specific subset of eCQMs in both the Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs. We remain committed to monitoring for unintended consequences, such as changes in AMI patient outcomes over time, by examining the results of other outcome measures in the Hospital IQR Program, specifically MORT–30–AMI and READM–30–AMI. We will revise the measure set through future rulemaking if needed.

After consideration of the public comments we received, we are finalizing the removal of the AMI–7a: Fibrinolytic Therapy Received Within 30 minutes of Hospital Arrival eCQM from the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(ii) STK–4, AMI–2, AMI–10, SCIP–Inf–1a, and SCIP–Inf–2a

We proposed to remove the: (1) STK–4: Thrombolytic Therapy (NQF #0437); (2) AMI–2: Aspirin Prescribed at Discharge for AMI (NQF #0142); (3) AMI–10: Statin Prescribed at Discharge; (4) SCIP–Inf–1a: Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision (NQF #0527); and (5) SCIP–Inf–2a: Prophylactic Antibiotic Selection for Surgical Patients (NQF #0528) eCQMs, because measure performance among hospitals is so high and unvarying that meaningfully distinctions and improvements in performance can no longer be made—removal factor 1 (80 FR 49641). We note that the NQF has changed the endorsement designations of the AMI–2, AMI–10, SCIP–Inf–1a, and SCIP–Inf–2a chart-abstracted measures and eCQM versions to either "reserve status" or "endorsement removed" (available at: [http://www.qualityforum.org/QPS/QPSTool.aspx](http://www.qualityforum.org/QPS/QPSTool.aspx)), because there is no opportunity for improvement.

We refer readers to section VIII.A.3.b.(2) of the preamble of this final rule for discussion of our proposal also to remove the chart-abstracted form of the STK–4 measure due to "topped-out" status. The electronic version of the STK–4 measure was adopted into the Hospital IQR Program in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50784) to promote programmatic alignment, as it was a part of a measure set that was already included in the Medicare and Medicaid EHR Incentive Programs’ Electronic Reporting Pilot for Eligible Hospitals and CAHs (75 FR 44418 and 76 FR 74489).

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50781), we removed the chart-abstracted versions of AMI–2 and AMI–10 due to "topped-out" status. However, as noted in FY 2015 IPPS/LTCH PPS final rule (79 FR 50245), we readopted these measures, though only in the electronic form, because we believed that hospitals would continue aligning the Hospital IQR Program and the Medicare EHR Incentive Program in order to minimize reporting burden and to facilitate the transition to reporting of eCQMs. We believed that voluntary reporting of these measures would further that aim. In addition, we believed that allowing hospitals the option to electronically report "topped-out" measures would provide them with an opportunity to test the accuracy of their EHR reporting systems.

Similarly, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50208), we removed the chart-abstracted versions of SCIP–Inf–1a and SCIP–Inf–2a, previously referred to as SCIP–Inf–1 and SCIP–Inf–2 respectively, due to their "topped-out" status. However, as stated in that rule, we retained the electronic versions of these measures, because we believed this provided us with an opportunity to monitor "topped-out" measures for performance decline. It also simplified alignment between the Hospital IQR Program and Medicare EHR Incentive Program for eligible hospitals and provided a more straightforward approach to educate stakeholders on electronic reporting options (79 FR 50208).

As discussed above, we proposed to focus on a smaller, more specific subset of eCQMs for the Hospital IQR Program and both the Medicare and Medicaid EHR Incentive Programs. Therefore, in light of their "topped out" status, the burden of retaining these measures outweighs the benefits. Thus, we propose to remove the STK–4, AMI–2, AMI–10, SCIP–Inf–1a, and SCIP–Inf–2a eCQMs from the Hospital IQR Program for the FY 2019 payment determination and subsequent years.

Comment: A commenter supported the removal of the following eCQMs: SCIP–Inf–1a: Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision (NQF #0527), SCIP–Inf–2a: Prophylactic Antibiotic Selection for Surgical Patients (NQF #0528), SCIP–Inf–9: Urinary Catheter Removed on Postoperative Day 2 (POD2) With Day of Surgery Being Day Zero, and PN–6: Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP). The commenter stated that removing these measures from the Hospital IQR Program helps to reduce data collection burden, rid the program of measures that no longer add value, and allow hospitals to focus on measures that demonstrate areas for improvement.

Response: We thank the commenter for its support.

Comment: One commenter expressed concern regarding the proposed removal of the SCIP–Inf–1a: Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision (NQF #0527) measure due to a concern that the removal of this measure could result in unintended reduction in adherence to appropriate prophylactic antibiotic use prior to surgery. The commenter stated that the prophylactic antibiotic measure (NQF #0527) should be retained to supplement the proposed NHSN measure, since it is the aim of hospitals to minimize antimicrobial use.

Response: We disagree with the commenter that removal of SCIP–Inf–1a, which is topped-out, will result in the unintended reduction in adherence to appropriate prophylactic antibiotic use prior to surgery. Topped-out measures represent care standards that have been widely adopted by hospitals. We believe that hospitals committed to providing quality care will continue to provide good quality care consistent with standard practice. In the past, we have retained the electronic versions of some topped-out measures for reasons such as promoting alignment between programs or to provide an opportunity to monitor topped-out measures for performance decline. In this case, removing SCIP–Inf–1a promotes alignment with the Medicare and Medicaid EHR Incentive Programs. In addition, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we received anecdotal comments about performance level differences between chart-abstracted and eCQM data. We do not have sufficient data to be able to confirm or refute the accuracy of the comments (79 FR 50258), but these comments have prompted us to reconsider our position.
that topped-out eCQMs provide an opportunity for CMS to meaningfully monitor topped-out measures for performance decline at this time. In consideration of these factors, we do not believe that the burden of retaining the electronic version to allow the comparison to chart-abstracted data outweighs the benefit. Therefore, we believe that removal of SCIP–Inf–1a in eCQM form is appropriate.

We wish to clarify that we did not propose the NHSN Antimicrobial Use Measure, but rather sought comments regarding potential inclusion of the measure in the future. We do not agree that we should retain SCIP–Inf–1a to supplement the NHSN Antimicrobial Use measure, because if the NHSN measure is adopted into the Program in future years, surgical prophylactic antibiotic use will be captured by the NHSN measure. However, we applaud the commenter’s commitment to antibiotic stewardship and refer readers to the NHSN Antimicrobial Use and Resistance Module available at: http://www.cdc.gov/nhsn/acute-care-hospital/aur/.

Comment: One commenter supported the removal of the AMI–2 and AMI–10 eCQMs because removal would reduce the administrative burden on hospitals. However, the commenter suggested that these measures be kept on reserve for reimplementation if necessary because they are important processes in cardiovascular care.

Response: We thank the commenter for its support of our proposal to remove the AMI–2 and AMI–10 eCQMs because removal will reduce hospital administrative burden. We note that currently we do not have authority to maintain a “reserve” status for quality measures in the Hospital IQR Program. If we interpret the commenter to mean that CMS should retain the eCQMs in the program as is, we disagree. We must balance the costs and burden of continued reporting and monitoring of a successful measure with high levels of performance with the adoption of other measures where there are greater opportunities for improvement in clinical quality. As stated above, we also considered other factors such as alignment with other programs, and determined that removal of AMI–2 and AMI–10 promotes alignment with the Medicare and Medicaid EHR Incentive Programs. If we decide to reimplement these measures in the future, as the commenter suggests, we are required to proceed through the pre-rulemaking process for measure selection before they are adopted for adoption in the Hospital IQR Program. For details regarding the pre-rulemaking process we refer readers to: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Pre-Rule-Making.html.

Comment: Some commenters did not support the proposal to remove the STK–4 eCQM, and expressed concern that removing this eCQM may lead to poorer performance due to lack of accountability and reporting, as well as send a message that CMS does not consider this an important process of care for patients with ischemic stroke. Two commenters noted that the national averages for the STK–4 measure is only 83 percent, indicating an opportunity for hospitals to improve on this measure. One commenter noted retention of the STK–4 eCQM is necessary because it allows hospitals and CMS to compare the eCQM-reported rates with the historically reported chart-abstracted measure. Another commenter raised concerns with removing the STK–4 measure because it intended to submit this measure as part of the CY 2016 eCQM reporting requirement.

Response: STK–4 meets our topped-out criteria per our analysis of hospitals participating in the Hospital IQR Program. Further, because of the use of structured data fields in eCQMs, eCQM data and chart-abstracted data for the same measure may not always be one hundred percent comparable. We do not believe that removal of STK–4 will lead to poorer performance and accountability. As previously noted, we believe topped-out measures represent care standards that have been widely adopted by hospitals. We believe that hospitals committed to providing quality care will continue to provide quality care consistent with standard practice. In the past, we have retained the electronic versions of some topped-out measures for reasons such as promoting alignment between programs or to provide an opportunity to monitor topped-out measures for performance decline. In this case, removing STK–4 promotes alignment with the Medicare and Medicaid EHR Incentive Programs.

In addition, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we received anecdotal comments about performance level differences between chart-abstracted and eCQM data. We do not have sufficient data to be able to confirm or refute the accuracy of those comments (79 FR 50258), but these comments have prompted us to reconsider our position that topped-out eCQMs provide an opportunity for CMS to meaningfully monitor topped-out measures for performance decline at this time. In consideration of these factors, we do not believe that the burden of retaining the electronic version to allow the comparison to old data outweighs the benefit. Therefore, we believe that removal of STK–4 in eCQM form is appropriate. In regard to the commenter’s concern that it will not be able to submit the STK–4 eCQM as part of the CY 2016 reporting period eCQM requirement, we note that the STK–4 eCQM was proposed (and is being finalized) for removal for the FY 2019 payment determination, which affects the CY 2017 reporting period, not the CY 2016 reporting period. The commenter may still submit the STK–4 eCQM for the CY 2016 reporting period for the FY 2018 payment determination.

Comment: One commenter did not support the removal of AMI–10 and AMI–2 because these measures continue to provide useful data to hospitals.

Response: We refer readers to section VIII.A.3.b.(3)(a)(ii) of the preamble of this final rule where we note that measure performance for AMI–10 and AMI–2 is so high and varying that meaningful distinctions and improvements in performance can no longer be made. Therefore, per the Hospital IQR Program removal factor 1 (80 FR 49641), we have decided to remove these measures from the measure set. In addition to both measures being topped out, we also considered other factors such as alignment with other programs and determined that removing these two measures aligns the Hospital IQR Program measure set with the Medicare and Medicaid EHR Incentive Programs’ measure sets. We refer readers to section VIII.E.2.b. of the preamble of this final rule for the Medicare and Medicaid EHR Incentive Programs’ measure sets.

Further, these measures have had a change in endorsement designation by NQF (available at: http://www.qualityforum.org/QPS/QPSTool.aspx). In addition, as discussed above, we intend to focus on a smaller, more specific subset of eCQMs for the Hospital IQR Program and both the Medicare and Medicaid EHR Incentive Programs.

After consideration of the public comments we received, we are finalizing the removal of the STK–4, AMI–2, AMI–10, SCIP–Inf–1a, and SCIP–Inf–2a eCQMs from the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(b) HTN

We proposed to remove the HTN: Healthy Term Newborn (NQF #0716) eCQM, because it is no longer feasible to implement the measure.
specifications—removal factor 7 (80 FR 49642). In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50249), we added HTN, only as an eCQM, not as a claims-based measure. Although the claims-based version of the HTN measure has never been part of the Hospital IQR Program, the claims-based HTN measure concept was used to develop the HTN eCQM.

The measure steward has made substantial revisions to the claims-based version of this measure such that the focus is no longer on the number of healthy term newborns, but the number of unexpected complications in term newborns. The numerator of the revised measure has been restructured to assess the presence of severe or moderate complications after term birth, while the original measure looked for the absence of several types of complications after term birth. For the revised measure specifications, we refer readers to: https://www.cmqcc.org/focus-areas/quality-metrics/unexpected-complications-term-newborns. In addition, the measure steward is no longer maintaining the claims-based version of HTN or supporting the maintenance of the original eCQM version of HTN that was developed by CMS and adopted in the Hospital IQR Program. Therefore, it is not feasible to continue to include a measure that is no longer supported by the steward. As a result, we proposed to remove the HTN eCQM from the Program for the FY 2019 payment determination and subsequent years.

Comment: One commenter supported the proposal to remove HTN along with AMI–7a, VTE–3, VTE–4, VTE–5, VTE–6, SCIP–Inf–9, PN–6, and STK–4.

Response: We thank the commenter for its support.

After consideration of the public comment we received, we are finalizing the removal of the HTN: Healthy Term Newborn (NQF #0716) eCQM from the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(c) PN–6 and SCIP–Inf–9

We proposed to remove the: (1) PN–6: Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients (NQF #0147) and (2) SCIP–Inf–9: Urinary Catheter Removed on Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero eCQMs, because it is no longer feasible to implement the measure specifications—removal factor 7 (80 FR 49642). While the electronic versions were retained, the chart-abstracted versions of PN–6 and SCIP–Inf–9 were determined to be “topped-out” and were removed from the Hospital IQR Program measure set in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50204 through 50208).

These two eCQMs have undergone significant changes to their logic expression during the previous annual update.93 There are a number of data capture requirements that cannot be represented adequately in the eCQM form due to their conceptual complexity. Specifically, for PN–6, hospital feedback has indicated difficulties with interpreting several critical timing requirements, such as for intensive care unit populations, emergency department and inpatient admission transitions, steroid therapy, and pre-admission medications. In addition, hospitals raised concern about the inability to account for variation in recording of the interpretation of laboratory results. For SCIP–Inf–9, feedback from hospitals has indicated that it is difficult to interpret the appropriate timing of elements associated with the insertion and removal of a catheter. This is particularly problematic, because of the variety of patient locations encountered before and after surgery, as well as transfers among units. While these variations for both PN–6 and SCIP–Inf–9 can be accounted for through chart-based manual abstraction, we have had great difficulties in translating and maintaining these options for electronic reporting. Therefore, we proposed to remove both the PN–6 and SCIP–Inf–9 eCQMs from the Hospital IQR Program for the FY 2019 payment determination and subsequent years.

Comment: One commenter supported the removal of SCIP-Inf-9: Urinary Catheter Removed on Postoperative Day 2 (POD2) With Day of Surgery Being Day Zero and PN–6: Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) because removing these measures from the Hospital IQR Program helps to reduce data collection burden, rid the program of measures that no longer add value, and allow hospitals to focus on measures that demonstrate areas for improvement.

Response: We thank the commenter for its support.

After consideration of the public comment received, we are finalizing the removal of both PN–6: Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients (NQF #0147) and SCIP-Inf-9: Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 ((POD2) with Day of Surgery Being Day Zero) eCQMs from the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(d) VTE–3, VTE–4, VTE–5, and VTE–6

We proposed to remove the four VTE eCQMs: (1) VTE–3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy (NQF #0373); (2) VTE–4: Venous Thromboembolism Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol (or Nomogram); (3) VTE–5: Venous Thromboembolism Discharge Instructions; and (4) VTE–6: Incidence of Potentially Preventable Venous Thromboembolism, because it is no longer feasible to implement the measures specifications—removal factor 7 (80 FR 49642). Many of the chart-abstracted versions of these measures were determined to be “topped-out.” While the electronic versions of VTE–3 and VTE–4 were retained, the chart-abstracted versions were determined to be “topped-out” and were removed from the Hospital IQR Program measure set in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49643) and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50205), respectively. In addition, as described above in section VIII.A.3.b.(2) of the preamble of this final rule, we proposed to remove the chart-abstracted version of VTE–5 for the FY 2019 payment determination and subsequent years due to its “topped-out” status. The electronic version of VTE–5 was adopted in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50784). Finally, the chart-abstracted version of VTE–6, however, continues to be included in the Hospital IQR Program measure set because chart abstractors can manually find required data elements in clinical notes and not in structured data fields.

Nonetheless, a majority of hospitals do not have the ability to capture required data elements, such as diagnostic study results/reports and location of the specific vein in which deep vein thrombosis was diagnosed, in discrete structured data fields to support these eCQMs, because they are often found as free text in clinical notes instead. It is exceedingly difficult for hospitals to implement the measure specifications in the absence of these functional requirements. Furthermore, as discussed above, we proposed to focus on a smaller specific subset of eCQMs in the Hospital IQR Program and both the Medicare and Medicaid
EHR Incentive Programs. Therefore, in light of their “topped out” statuses and the infeasibility of implementing the measure specifications, the burden of retaining these measures outweighs the benefits. As a result, we proposed to remove the VTE–3, VTE–4, VTE–5, and VTE–6 eCQMs from the Hospital IQR Program for the FY 2019 payment determination and subsequent years.

Comment: One commenter supported the proposal to remove AMI–7a, VTE–3, VTE–4, VTE–5, VTE–6, SCIP-Inf-1a, SCIP-Inf-2a, SCIP-Inf-9, PN–6, STK–04, and HTIN. In addition to the reasons articulated by CMS for removing these eCQMs, the commenter expressed concern that AMI–7a and VTE–3, VTE–4, VTE–5, and VTE–6 require data produced and documented in non-certified radiology systems that lack an automated interface necessary to integrate data into certified EHRs for accurate measurement. As a result, the data must be entered manually and this process is very burdensome for providers and could result in great inaccuracies in measure calculations. Another commenter supported the removal of the VTE measures, because these measures have data elements that cannot be captured by electronic reporting.

Response: We thank the commenters for their support.

Comment: One commenter requested that CMS retain the eCQM version of the VTE–6 measure, stating that if CMS sees value in the chart-abstracted form of the measure, then there should also be value in the eCQM format. The commenter also offered that while many other entities have had difficulty implementing this measure in its electronic form, as noted in the proposed rule, it has had success with this measure.

Response: As we state in section VIII.A.3.b.(3)(d) of the preamble of this final rule, the chart-abstracted version of VTE–6 continues to be included in the Hospital IQR Program measure set because chart abstractors can manually find required data elements in clinical notes and not in structured data fields. While we support the commenter’s progress with successful data collection for this measure, a majority of hospitals do not have the ability to capture required data elements in discrete structured data fields to support this eCQM. Therefore, in light of their “topped out” statuses and the infeasibility of implementing the measure specifications, the burden of retaining these measures outweighs the benefits.

Comment: One commenter suggested that CMS consider future measures for venous thromboembolism, because it is a common condition for hospitalized patients. The commenter expressed concern that with the removal of VTE eCQMs, almost all of the measures related to VTE will be removed from the Hospital IQR Program and given the prevalence and impact of this condition, CMS should consider including more measures that assess VTE to facilitate a renewed focus on improvement in this area. The commenter is developing a comprehensive set of VTE guidelines and plans to reach out to CMS in the future to discuss their implementation in the context of quality measures.

Response: We recognize the importance of assessing VTE in relation to improved patient outcomes for hospital inpatients and will consider the addition of new measures of VTE in future rulemaking. We encourage the commenter to continue their efforts of developing guidelines related to VTE, and welcome future collaboration in this area of clinical quality measurement.

After consideration of the public comments we received, we are finalizing the removal of: (1) VTE–3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy (NQF #0373), (2) VTE–4: Venous Thromboembolism Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol (or Nomogram), (3) VTE–5: Venous Thromboembolism Discharge Instructions, and (4) VTE–6: Incidence of Potentially Preventable Venous Thromboembolism eCQMs from the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(4) Summary of Measures Finalized for Removal

The table below lists the measures we are finalizing for removal. We invite public comment on our proposals to remove these 15 measures (eCQMs, structural, and chart-abstracted) from the Hospital IQR Program for the FY 2019 payment determination and subsequent years. The comments we received are discussed above.

We note that STK–04 and VTE–5 are listed twice—once as an eCQM and again as a chart-abstracted measure.

MEASURES FINALIZED FOR REMOVAL FOR THE FY 2019 PAYMENT DETERMINATION AND SUBSEQUENT YEARS

Electronic Clinical Quality Measures:

- AMI–2: Aspirin Prescribed at Discharge for AMI (NQF #0142).
- AMI–7a: Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival.
- AMI–10: Statin Prescribed at Discharge.
- HTIN: Healthy Term Newborn (NQF #0716).
- SCIP-Inf–1a: Prophylactic Antibiotic Received within 1 Hour Prior to Surgical Incision (NQF #0527).
- SCIP-Inf–2a: Prophylactic Antibiotic Selection for Surgical Patients (NQF #0528).
- SCIP-Inf–9: Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero.
- STK–04: Thrombolytic Therapy (NQF #0437).
- VTE–3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy (NQF #0373).
- VTE–4: Venous Thromboembolism Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol (or Nomogram).
- VTE–5: Venous Thromboembolism Discharge Instructions.
- VTE–6: Incidence of Potentially Preventable VTE *.

Structural Measures:

- Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care.
- Participation in a Systematic Clinical Database Registry for General Surgery.

Chart-abstracted Measures:

- STK–4: Thrombolytic Therapy (NQF #0437).
- VTE–5: VTE Discharge Instructions.

* Retained in chart-abstracted form.
The Hospital IQR Program has previously finalized 65 measures for the

**PREVIOUSLY ADOPTED HOSPITAL IQR PROGRAM MEASURES FOR THE FY 2018 PAYMENT DETERMINATION AND SUBSEQUENT YEARS**

<table>
<thead>
<tr>
<th>Short name</th>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTI</td>
<td>National Healthcare Safety Network (NHSN) Catheter-associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
<td>0138</td>
</tr>
<tr>
<td>CDI</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset <em>Clostridium difficile</em> Infection (CDI) Outcome Measure</td>
<td>1717</td>
</tr>
<tr>
<td>CLABSI</td>
<td>National Healthcare Safety Network (NHSN) Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure</td>
<td>0139</td>
</tr>
<tr>
<td>Colon and Abdominal</td>
<td>American College of Surgeons—Centers for Disease Control and Prevention (ACS–CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure</td>
<td>0753</td>
</tr>
<tr>
<td>HGP</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel</td>
<td>0431</td>
</tr>
<tr>
<td>MRSA Bacteremia</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) Bacteremia Outcome Measure</td>
<td>1716</td>
</tr>
</tbody>
</table>

**Chart-abstracted**

<table>
<thead>
<tr>
<th>Short name</th>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED–1*</td>
<td>Median Time from ED Arrival to ED Departure for Admitted ED Patients</td>
<td>0495</td>
</tr>
<tr>
<td>ED–2*</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>Imm-2</td>
<td>Elective Delivery</td>
<td>1659</td>
</tr>
<tr>
<td>PC–01*</td>
<td>Severe Sepsis and Septic Shock: Management Bundle (Composite Measure)</td>
<td>0500</td>
</tr>
<tr>
<td>STK–04*</td>
<td>Thrombolytic Therapy</td>
<td>0437</td>
</tr>
<tr>
<td>VTE–5*</td>
<td>Venous Thromboembolism Discharge Instructions</td>
<td>(–)</td>
</tr>
<tr>
<td>VTE–6*</td>
<td>Incidence of Potentially Preventable Venous Thromboembolism</td>
<td>(–)</td>
</tr>
</tbody>
</table>

**Claims-based Outcome**

<table>
<thead>
<tr>
<th>Short name</th>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORT–30–AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization</td>
<td>0230</td>
</tr>
<tr>
<td>MORT–30–CABG</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2558</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization</td>
<td>1893</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization</td>
<td>0229</td>
</tr>
<tr>
<td>MORT–30–PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization</td>
<td>0468</td>
</tr>
<tr>
<td>MORT–30–STK</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Ischemic Stroke</td>
<td>N/A</td>
</tr>
<tr>
<td>READM–30–AMI</td>
<td>Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) Following Acute Myocardial Infarction (AMI) Hospitalization</td>
<td>0505</td>
</tr>
<tr>
<td>READM–30–CABG</td>
<td>Hospital 30-Day, All-Cause, Unplanned, Risk-Standardized Readmission Rate (RSRR) Following Coronary Artery Bypass Graft (CABG) Surgery</td>
<td>2515</td>
</tr>
<tr>
<td>READM–30–COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization</td>
<td>1891</td>
</tr>
<tr>
<td>READM–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Heart Failure (HF) Hospitalization</td>
<td>0330</td>
</tr>
<tr>
<td>READM–30–HWR</td>
<td>Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)</td>
<td>1789</td>
</tr>
<tr>
<td>READM–30–PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization</td>
<td>0506</td>
</tr>
<tr>
<td>READM–30–STK</td>
<td>30-Day Risk Standardized Readmission Rate Following Stroke Hospitalization</td>
<td>N/A</td>
</tr>
<tr>
<td>READM–30–THA/TKA</td>
<td>Hospital-Level 30-Day, All-Cause Risk-Standardized Readmission Rate (RSRR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1551</td>
</tr>
<tr>
<td>AMI Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction</td>
<td>N/A</td>
</tr>
<tr>
<td>HF Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure</td>
<td>N/A</td>
</tr>
<tr>
<td>Hip/knee complications</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA)</td>
<td>1550</td>
</tr>
<tr>
<td>PSI 04</td>
<td>Death Rate among Surgical Inpatients with Serious Treatable Complications</td>
<td>0351</td>
</tr>
<tr>
<td>PSI 90</td>
<td>Patient Safety for Selected Indicators (Composite Measure)</td>
<td>0531</td>
</tr>
</tbody>
</table>
In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25180), we did not propose to add or remove any measures for the FY 2018 payment determination.

5. Expansion and Updating of Quality Measures

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53510 through 53512) for a discussion of the considerations we use to expand and update quality measures under the Hospital IQR Program. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25180), we did not propose any changes to these policies.
6. Refinements to Existing Measures in the Hospital IQR Program for the FY 2018 Payment Determination and Subsequent Years

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25180 through 25185), we proposed refinements to two claims-based measures: (1) PN Payment: Hospital-Level, Risk-Standardized 30-Day Episode-of-Care Payment Measure for Pneumonia; and (2) PSI 90: Patient Safety and Adverse Events Composite (previously known as the Patient Safety for Selected Indicators Composite Measure), beginning with the FY 2018 payment determination and subsequent years. We discuss these refinements in more detail below. In addition, we refer readers to section VIII.A.9.a. of the preamble of this final rule where we discuss public comment on our intent to update the MORT–30–STK measure to include the NIH Stroke Scale as a measure of stroke severity in the risk-adjustment in future rulemaking.

- **Expansion of the Cohort for the PN Payment Measure:** Hospital-Level, Risk-Standardized Payment Associated With a 30-Day Episode-of-Care for Pneumonia (NQF #2579)

  **(1) Background**

  In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25180 through 25182), for the FY 2018 payment determination and subsequent years, we proposed a refinement of the CMS hospital-level, risk-standardized payment associated with a 30-day episode of care for pneumonia (NQF #2579) (PN Payment). The proposed refinement expands the measure cohort to align with the following Hospital IQR Program measures: (1) Hospital 30-day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization (NQF #0468) (MORT–30–PN); (2) Hospital 30-day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization (NQF #6306) (READM–30–PN); and (3) Excess Days in Acute Care After Hospitalization for Pneumonia (an improved measure to the previously developed measure entitled “30-day Post-Hospital Pneumonia Discharge Care Transition Composite”) (NQF #0707) (PN Excess Days). The expansion of the measure cohort for the MORT–30–PN and the READM–30–PN was finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49660) and is expected to be publicly reported beginning in July 2016. In addition, we refer readers to section VIII.A.7.b. of the preamble of this final rule where we discuss our adoption of the PN Excess Days measure in the Hospital IQR Program for FY 2019 payment determination and subsequent years.

- **Proposed PN Payment Measure Refinement**

  For the purposes of describing the refinement of this measure, we note that “cohort” is defined as the hospitalizations, or “index admissions,” that are included in the measure and evaluated to ascertain the total payments made on behalf of the Medicare beneficiary for a 30-day episode-of-care. The cohort is the set of hospitalizations that meets all of the inclusion and exclusion criteria. We proposed an expansion to this set of hospitalizations.

  The previously adopted PN Payment measure (79 FR 50227 through 50231) includes hospitalizations for patients with a principal discharge diagnosis of pneumonia using the International Classification of Diseases, 9th Edition, Clinical Modification (ICD–9–CM), which includes viral and bacterial pneumonia. For more cohort details on the measure as previously implemented, we refer readers to the measure methodology report, with the measure risk adjustment statistical model, in the AML, HF, PN, and Hip/Knee Arthroplasty Payment Updates zip file on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

  This proposed measure refinement would expand the measure cohort to include hospitalizations for patients with a: (1) Principal discharge diagnosis of pneumonia, including not only viral or bacterial pneumonia, but also aspiration pneumonia; and (2) principal discharge diagnosis of sepsis (but not severe sepsis) with a secondary diagnosis of pneumonia (including viral or bacterial pneumonia and aspiration pneumonia) coded as present on admission (POA). Moreover, expanding the PN Payment measure cohort would ensure that the measure captures the broader population of patients admitted for pneumonia that may have been excluded from the previously adopted measure. Finally, the expansion of the cohort for the PN Payment measure harmonizes the cohort of this measure with the MORT–30–PN, the READM–30–PN, and the newly adopted PN Excess Days measures.

- **The Proposed PN Payment Measure Refinement (MUC ID 15–378)**

  This expanded measure cohort was included on a publicly available document entitled “2015 Measures Under Consideration List” for December 1, 2015 (available at: http://www.qualityforum.org/ProjectMaterials.aspx?ProjectID=75367) and has been reviewed by the NQF MAP Hospital Workgroup. The revised measure was conditionally supported pending the examination of sociodemographic status (SDS) factors and NQF review and endorsement of the measure update, as referenced in the MAP 2016 Final Recommendations.


The refined PN Payment measure will be submitted to NQF for reendorsement as part of the next Cost and Resource Use project which is expected in the first quarter of 2017. We will work to minimize any potential confusion when publicly reporting the updated measure to ensure that the refined measure would not be confused with the originally adopted measure.

We received general comments related to the efforts underway to determine if risk-adjusting for SDS factors is appropriate for this and other measures in the Hospital IQR Program and would like to address them first.

Comment: Several commenters encouraged CMS to apply SDS factors to quality measures, noting that these factors impact patient outcomes.

Further, the commenters stated that SDS factors should be included in quality measures’ risk-adjustment models to ensure that hospitals are held accountable only for the factors under their control. In addition, commenters expressed the opinion that accountability programs should include risk adjustment for those SDS factors for which there is a conceptual relationship with outcomes or processes of care and empirical evidence of such an effect, for reasons unrelated to quality of care. Commenters also indicated that failing to adjust quality measures for SDS factors can result in unintended consequences and can mislead patients, payers, and policymakers who would be otherwise oblivious to community factors that contribute to worsened patient outcomes. Commenters suggested that CMS provide more in depth information related to the current efforts underway to assess the impact of SDS factors on quality measures. Some commenters noted that risk adjustment is of particular importance for measures that are not entirely within the control of the hospital such as resource use, readmissions, and 30-day mortality. However, some commenters stated that measures that are within the control of a hospital stay (that is, process measures) should not be subject to this type of risk adjustment.

One commenter believed that adjusting quality metrics in this way could result in a tiered health care system where consumers could not expect to receive the same quality of care regardless of where they live. A few commenters supported the concept of exploring the implications of risk-adjusting quality measures for SDS factors in the future, but requested that CMS work more readily to account for hospitals that disproportionately treat low-income and more vulnerable patient populations. In addition, the commenters expressed concern about the challenges associated with the feasibility of valid and reliable adjustment for SDS factors and noted that risk adjustment should not be used as an excuse for poor performance or a reason not to improve. The commenters expressed appreciation that CMS is abreast of the efforts underway by NQF and ASPE, but urged CMS to be more proactive with its own efforts to examine SDS factors in quality measures.

Response: With respect to commenters’ request that CMS work more readily to account for hospitals that disproportionately treat vulnerable patient populations and concerns about the challenges associated with the feasibility of valid and reliable adjustment for SDS factors, as noted above and in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25208), we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of diverse sociodemographic status, because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of SDS on providers’ differential performance on our outcome and payment measures. In response to commenters’ suggestion that CMS provide more in depth information related to the current efforts underway to assess the impact of SDS factors on quality measures, as discussed above, the NQF is currently conducting a 2-year trial, in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

Spreadsheet of MAP 2016 Final Recommendations Available at: http://www.qualityforum.org/mapi/
recommendations from the NQF and intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for SDS factors in our outcome measures. For more detailed information about measures in the NQF SDS trial period, we refer commenters to: http://www.qualityforum.org/SES_Trial_Peri  

Furthermore, we are awaiting the findings of an ASPE report on SDS factors in risk-adjustment, which is expected to be available in the fall of 2016. We will share the findings of these trials and reports with the public as soon as they become available. Therefore, we are not currently changing our risk-adjustment methodology with respect to SDS factors. We will continue to consider such factors in our ongoing measure development and maintenance activities.  

Comment: One commenter expressed concern that the newly proposed measures are not risk-adjusted for SDS factors, noting that they serve a patient population that is affected by these factors, and without risk adjustment, their hospital will be unfairly penalized under the current program. Commenters also encouraged CMS to adjust readmission measures for SDS factors because hospitals that care for vulnerable populations, who are at higher risk for readmissions, are disadvantaged when these factors are not considered for payment updates.  

Response: We appreciate the commenter’s concern that newly proposed measures are not risk-adjusted for SDS factors, but we continue to have concerns about holding hospitals to different standards for the outcomes of patients of diverse sociodemographic status, because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. Moreover, we do not think it is appropriate to include risk-adjustment for SDS factors at this time until more information is learned from the NQF trial period and ASPE’s report. However, we will continue to consider such factors in our ongoing measure development and maintenance activities.

With regard to the commenters’ concerns about being unfairly penalized or disadvantaged with regard to payment updates, we note that the Hospital IQR Program is a pay for reporting, not a pay for performance, quality program. This means that its payment determinations are based on hospitals’ performance on the reporting requirements, not performance on the measures, and that claims-based measures, such as the newly proposed measures and the existing readmission measures, have no additional reporting burden for hospitals since the data are derived from administrative data.  

Comment: One commenter urged CMS not to add any proposed measure until it is appropriately risk adjusted and should suspend or remove other readmission measures until they incorporate appropriate risk-adjustment methodology because SDS factors can skew performance on certain quality measures, such as those for readmissions. The commenter stated that outcome measures do not accurately reflect hospitals’ performance if they do not account for SDS factors outside the hospital’s control that can complicate care and influence patients’ health care outcomes.  

Response: We disagree with the commenter that we should not propose any measure until it is risk adjusted for SDS factors. As we have previously noted, we have not risk-adjusted measures for SDS factors because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. However, as noted in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25208), while we are monitoring providers’ differential performance on our outcome and payment measures, we are not currently changing our risk-adjustment methodology with respect to SDS factors. We will continue to consider such factors in our ongoing measure development and maintenance activities.

(2) Overview of Measure Change

The proposed measure refinement expands the cohort. As the measure is currently specified, the cohort includes hospitalizations for patients with a principal discharge diagnosis of pneumonia using the ICD–9–CM, which includes viral and bacterial pneumonia (79 FR 50227 through 50231). This refinement would expand the cohort to also include hospitalizations for patients with a: (1) Principal discharge diagnosis of pneumonia, including not only viral or bacterial pneumonia, but also aspiration pneumonia; and (2) principal discharge diagnosis of sepsis (but not severe sepsis) with a secondary diagnosis of pneumonia (including viral or bacterial pneumonia and aspiration pneumonia) coded as POA.  

For the ICD–9–CM and ICD–10–CM codes that define the expanded PN payment cohort, we refer readers to the 2016 Reevaluation and Re-specifications Report of the Hospital-Level 30-Day Risk-Standardized Pneumonia Payment Measure—Pneumonia Payment Version 3.1 in the AMI, HF, PN, and Hip/Knee Arthroplasty Payment Updates zip file on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.  

The data sources, exclusion criteria, assessment of the total payment outcome, and 3 year reporting period all remain unchanged.

(3) Risk Adjustment

The statistical modeling approach as well as the measure calculation remains unchanged from the previously adopted measure. The risk adjustment approach also remains unchanged. However, to maintain model performance, we conducted variable reselection, or reevaluation of the variables used, to ensure the model risk variables are appropriate for the discharge diagnoses included in the expanded cohort. The previously adopted pneumonia payment risk-adjustment model includes 48 variables. As a result of the variable reselection process, the revised risk-adjustment model includes a total of 57 variables—37 of the same variables that are in the previously adopted model as well as 20 additional variables. There are 11 variables from the previously adopted model that are not included in the revised model. For details on variable reselection and the full measure specifications of the proposed change to the measure, we refer readers to the 2016 Reevaluation and Re-specifications Report of the Hospital-Level 30-Day Risk-Standardized Pneumonia Payment Measure—Pneumonia Payment Version 3.1 in the AMI, HF, PN, and Hip/Knee Arthroplasty Payment Updates zip file on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

(4) Estimated Effects of the Cohort Expansion

Using administrative claims data for the FY 2016 payment determination (which included discharges between July 2011 and June 2014), we simulated and analyzed the effects of the proposed cohort refinements on the PN Payment measure (NQF #2579) as if these

changes had been applied for FY 2016 payment determination. We note that these statistics are for illustrative purposes only, and we did not propose to revise measure calculations for the FY 2016 payment determination. In the FY 2010 IPPS/LTCH PPS final rule (74 FR 43881), we established that if a hospital has fewer than 25 eligible cases combined over a measure’s reporting period, we would replace the hospital’s data with a footnote indicating that the number of cases is too small to reliably determine how well the hospital is performing. These cases are still used to calculate the measure; however, for hospitals with fewer than 25 eligible cases, the hospital’s Risk Standardization Payment (RSP) and RSP interval estimates are not publicly reported for the measure. We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50221), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53337), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50810), and the FY 2015 IPPS/LTCH PPS final rule (80 FR 24588) for details on our sampling and case thresholds for the FY 2016 payment determination and subsequent years. Expanding the measure cohort to include a broader population of patients as proposed would add a large number of patients, as well as additional hospitals (which would now meet the minimum threshold of 25 eligible cases for public display), to the PN Payment measure (NQF #2579). The increase in the size of the measure cohort as proposed is also estimated to change results for some hospitals as detailed below. The previously adopted PN Payment measure cohort includes 901,764 patients and 4,685 hospitals for the FY 2016 payment determination (administrative claims from July 2011-June 2014). We noted the following effects for the PN Payment measure if the proposed expanded cohort is applied for FY 2016 payment determinations: (1) The cohort would increase to include an additional 386,143 patients across all hospitals (creating a total measure cohort size of 1,287,907 patients); (2) an additional 81 hospitals would meet the minimum 25 patient case volume threshold over the 3-year reporting period and, as a result, would be publicly reported for the measure; and (3) 31.7 percent of the refined measure cohort would consist of patients who fall into the expanded set of hospitalizations. The expansion of the cohort leads to an overall increase in the mean national payment of $16,116 when compared to the mean national payment of $14,294 for the previously adopted cohort. This leads to an increase in the RSP outcome of $1,822 or 12.7 percent due to the higher mean payments for patients added to the cohort. An individual hospital’s average payment category or reclassification of outlier status of “higher than the U.S. national payment,” “no different than the U.S. national payment,” or “less than the U.S. national payment” may change as demonstrated in the 2016 Reevaluation and Re-specifications Report of the Hospital-Level 30-Day Risk-Standardized Pneumonia Payment measure—Pneumonia Payment Version 3.1, which can be found in the AMI, HF, PN, and Hip/Knee Arthroplasty Payment Updates zip file on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/HospitalQualityInits/Measure-Methodology.html.

Overall, we estimate that 1.4 percent of hospitals included in the previously adopted measure would change categorization from greater than average to average payment, 9.3 percent would change from average to greater than average payment, and 8.5 percent would change from average to less than average payment. Finally, 1.8 percent of hospitals would change from less than average to average payment. Therefore, there would be an increase in the number of hospitals considered outliers and a shift in some hospital’s outlier status classification. We reiterate that these statistics are for illustrative purposes only, and we did not propose to revise measure calculations for the FY 2016 payment determination; our proposal would affect the FY 2018 payment determination and subsequent years.

A detailed description of the refinements to the PN Payment measure (NQF #2579) and the estimated effects of the change are available in the 2016 Reevaluation and Re-specifications Report of the Hospital-Level 30-Day Risk-Standardized Pneumonia Payment Measure—Pneumonia Payment Version 3.1 in the AMI, HF, PN, and Hip/Knee Arthroplasty Payment Updates zip file on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

We invited public comment on our proposal to refine the Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia (NQF #2579) (PN Payment) measure for the FY 2018 payment determination and subsequent years as described above.

Comment: Some commenters supported the proposed expansion of the cohort definition for the PN Payment measure. Commenters noted the proposed measure refinement accommodates differences in coding patterns and aligns the measure cohort and specifications for the pneumonia population across the payment, readmission, and mortality outcome measures, which will mitigate measurement bias. Further, commenters noted that this measure would align the PN Payment measure with the other pneumonia measures used in CMS hospital quality programs. One commenter mentioned it would align the Hospital IQR Program with the Hospital VBP Program.

Response: We thank the commenters for their support. We note that the PN Payment measure is not currently included in the Hospital VBP Program, but we will take feedback on the PN Payment measure for the Hospital VBP Program into consideration for the future.

Comment: Several commenters urged CMS not to finalize the inclusion of the revised Pneumonia Payment measure in the Hospital IQR Program until the updated version has attained NQF endorsement.

Response: We acknowledge stakeholder concerns that these refinements to the PN Payment measure have not yet been endorsed by NQF, but we refer readers to our earlier discussion in section VIII.A.6.a.(1) of the preamble of this final rule that the MAP conditionally supported this refined measure during the 2016 MAP Hospital Workgroup Meeting pending NQF review of the examination of SDS factors and NQF review and endorsement of the measure update. The refined PN Payment measure will be submitted to NQF as part of the next Cost and Resource Use project which is expected to convene in the first quarter of 2017. The original hospital-level, risk-standardized payment associated with a 30-day episode-of-care for pneumonia (NQF #2579) measure was previously NQF-endorsed, and we do not believe the intent of this measure has changed.

Comment: A commenter encouraged CMS to properly risk adjust this measure for SDS factors so that hospitals that serve complex patients do not perform poorly.

Response: We appreciate the commenter’s concern that this measure be risk-adjusted so that hospitals that serve complex populations do not perform poorly, but an expanded measure to have concerns about holding hospitals to different standards for the outcomes of
their patients of diverse sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. Moreover, as described above, we do not think it is appropriate to include risk-adjustment for SDS factors at this time until more information is learned from the NQF trial period and ASPE’s report. However, we will continue to consider such factors in our ongoing measure development and maintenance activities.

Comment: Several commenters did not support the inclusion of aspiration pneumonia in the cohort. One commenter stated that the expansion of the measure cohort would capture relatively different cohorts of patients (particularly those with aspiration pneumonia), with different baseline factors that influence recovery times and could impact hospitals’ performance on this measure. Commenters noted aspiration pneumonia patients overall are a more complex population with higher mortality rates, and aspiration pneumonia could be attributable to a range of potential causes that are clinically distinct despite the coding variation issue.

Response: We appreciate the commenters’ concerns about the extent of the refinement of this measure and the inclusion of patients who are more complex (have greater illness severity). In particular, we understand commenters’ concerns that aspiration pneumonia can have different causes and associated risks (for example, recurrent aspiration due to other comorbidities). However, while the pathological causes of aspiration pneumonia are slightly different from the causes of community acquired pneumonia, in routine clinical practice, evidence shows it can be very challenging for physicians to differentiate aspiration syndromes including pneumonitis and pneumonia, from other types of pneumonia included in the measure.98 99 This is reflected in the tremendous variation across hospitals in the use of aspiration pneumonia diagnosis codes. This variation suggests that hospitals are not consistently distinguishing between these conditions as distinct subtypes regardless of patients’ comorbid conditions. Expanding the measure cohort would ensure that the measure is clinically comprehensive.

Moreover, the treatment of patients hospitalized for pneumonia, aspiration pneumonia, or sepsis due to pneumonia is very similar and involves treatment with antibiotics, IV fluids, and symptom management.100 In addition, although some patients with aspiration pneumonia, such as medically frail patients, have a higher predicted mortality risk (that is, are more complex), many of the associated comorbidities are captured in the PN Payment measure’s risk-adjustment methodology. Of note, due to the increased number of patients that are included in the expanded cohort, we reselected risk-adjustment variables to ensure that the measure does not bias hospital performance and it accounts for the differences in risk among the subgroup of patients. For example, the risk model includes clinical history of stroke, as well as conditions associated with frailty, such as neuromuscular disease, and dementia.

Comment: One commenter indicated that the impact of the cohort expansion on the other pneumonia measures remains unknown, as data is not yet publicly available on Hospital Compare.

Response: The expansion of the cohort for the PN Payment measure aligns this measure with the MORT–30–PN measure, READM–30–PN measure, and the newly adopted PN Excess Days measure. The cohort expansion for the CMS Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization measure (NQF #0506) and the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization measure were finalized in the FY 2016 IPPS–LTCH PPS final rule (80 FR 49660), and the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia Hospitalization measure were finalized in the FY 2016 IPPS–LTCH PPS final rule (80 FR 49660), and are expected to be publicly available on Hospital Compare beginning in 2016.

The 2016 measure results show that the mean RSMR for the MORT–30–PN measure decreased from 16.3 percent for July 2013–June 2014 to 15.9 percent for July 2014–June 2015. The mean RSMR for READM–30–PN measure decreased from 16.5 percent for July 2013–June 2014 to 16.4 percent for July 2014–June 2015.101 Additional information on the impact of the cohort change on the measures, including measure results, assessments of the revised model, and the impact of the cohort change on the categorization of hospital performance, can be found in the 2015 Reevaluation and Re-Specification Report of the Hospital-Level 30-Day Risk-Standardized Measures Following Hospitalization for Pneumonia—Version 8.2 (readmission) and 9.2 (mortality) (available in the AMI–HF–PN–COPD-and-Stroke-Readmission Updates zip file at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html). In addition, measure specifications can be found in the 2016 Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Mortality Measures—Pneumonia Mortality Version 10.0 (available in the AMI–HF–PN–COPD-and-Stroke-Mortality Updates zip file) and the 2016 Condition-Specific Measures Updates and Specifications Report Hospital-Level 30-Day Risk-Standardized Readmission Measures—Pneumonia Readmission Version 9.0 (available in the AMI–HF–PN–COPD-and-Stroke-Readmission Updates zip file) on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. Finally we note that, as established in the Hospital IQR Program, hospitals have the opportunity to review their data, including their performance on the refined versions of the measures, via their hospital-specific reports (HSRs) during the provider feedback period before public reporting of the measures.

Comment: One commenter expressed concern regarding the significant overlap between the PN Payment measure and Medicare Spending per Beneficiary (MSPB) measure. The commenter acknowledged the potential to create alignment with the physician value-modifier and later merit-based incentive payment system; however, the commenter indicated that there is still a significant need for better alignment between the hospital and physician specifications.

Response: The goal of the PN Payment measure is to complement other quality measures already adopted to provide more holistic and comprehensive information on the value of care provided for the pneumonia condition specifically, while the MSPB measure solely examines total Medicare spending per beneficiary and encompasses all conditions. The PN Payment measure is meant to be considered in conjunction with MORT–30–PN, READM–30–PN, and the newly

---

adopted PN Excess Days measures in order to gain a better understanding of the value of care for a hospital’s patients and the nation as a whole. Moreover, several commenters conveyed support and appreciation for the reporting of the PN Payment measure in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50229), noting that it provided a way to optimally measure care for these patients. Therefore, we believe that the PN Payment measure provides condition-specific feedback to hospitals and can incentivize targeted improvements in care for pneumonia patients.

Lastly, we acknowledge commenters request for better alignment between the hospital and physician specifications. We strive to align specifications across programs when feasible; however, some specifications will remain different to accommodate for the distinctions between quality care programs that focus on hospitals (for example, the Hospital IQR Program) versus eligible professionals (for example, the Physician Value-Based Payment Modifier Program).

After consideration of the public comments we received, we are finalizing the refinement of the Hospital-Level, Risk-Standardized Payment Associated with a 30-day Episode-of-Care For Pneumonia (NQF #2579) (PN Payment) measure for the FY 2018 payment determination and subsequent years as proposed.

b. Adoption of Modified PSI 90: Patient Safety and Adverse Events Composite Measure (NQF #0531)

(1) Background

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25182 through 25285), we proposed to adopt refinements to the Agency for Healthcare Research and Quality (AHRQ) Patient Safety and Adverse Events Composite (NQF #0531) for the Hospital IQR Program beginning with the FY 2018 payment determination and subsequent years. In summary, the PSI 90 measure was refined to reflect the relative importance and harm associated with each component indicator to provide a more reliable and valid signal of patient safety events. We believe refining the PSI 90 measure will provide strong incentives for hospitals to ensure that patients are not harmed by the medical care they receive, a critical consideration in quality improvement. In the FY 2009 IPPS/LTCH PPS final rule (73 FR 48610 through 48660), we adopted the Complication/Patient Safety for Selected Indicators Composite Measure (NQF #0531) in the Hospital IQR Program beginning with the FY 2010 payment determination as an important measure of patient safety and adverse events. In the FY 2015 IPPS/LTCH PPS final rule, we updated the title of the measure to Patient Safety for Selected Indicators Composite Measure (NQF #0531), to be consistent with the NQF (79 FR 50211). As previously adopted, the PSI 90 measure consisted of eight component indicators: (1) PSI 03 Pressure Ulcer Rate; (2) PSI 06 Iatrogenic Pneumothorax Rate; (3) PSI 07 Central Venous Catheter-Related Blood Stream Infections Rate; (4) PSI 08 Postoperative Hip Fracture Rate; (5) PSI 12 Perioperative Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) Rate; (6) PSI 13 Postoperative Sepsis Rate; (7) PSI 14 Postoperative Wound Dehiscence Rate; and (8) PSI 15 Accidental Puncture and Laceration Rate.102

The currently adopted eight-indicator version of the measure underwent an extended NQF maintenance reendorsement in the 2014 NQF Patient Safety Committee due to concerns with the underlying component indicators and their composite weights. In the NQF-Endorsed Measures for Patient Safety, Final Report,103 the NQF Patient Safety Committee deferred their final decision for the PSI 90 measure until the following measure evaluation cycle. In the meantime, AHRQ worked to address many of the NQF stakeholders’ concerns about the PSI 90 measure, which subsequently completed NQF maintenance re-review and received reendorsement on December 10, 2015.

The PSI 90 measure’s extended NQF reendorsement led to several changes to the measure.104 First, the name of the PSI 90 measure has changed to “Patient Safety and Adverse Events Composite” (NQF #0531) (herein referred to as the “modified PSI 90”).105 Second, the modified PSI 90 measure includes the addition of three indicators: (1) PSI 09 Perioperative Hemorrhage or Hematoma Rate; (2) PSI 10 Postoperative Acute Kidney Injury Requiring Dialysis Rate (formerly titled “Physiologic and Metabolic Derangement Rate”); and (3) PSI 11 Postoperative Respiratory Failure Rate. Third, PSI 12, Perioperative Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) Rate, and PSI 15, Unrecognized Abdominopelvic Accidental Puncture/Laceration Rate, have been rescinded in the modified PSI 90 measure. Fourth, PSI 07 Central Venous Catheter-Related Blood Stream Infection Rate has been removed in the modified PSI 90 measure. Fifth, the weighting of component indicators in the modified PSI 90 measure is based not only on the value of each of the patient safety and adverse events, but also the harms associated with the events. We consider these changes to the modified PSI 90 measure to be substantive changes to the measure.

Therefore, we proposed to adopt refinements to the PSI 90 measure for the Hospital IQR Program beginning with the FY 2018 payment determination and subsequent years. We explain the modified PSI 90 measure more fully below, and also refer readers to the measure description on the NQF Web site at: https://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=321&print=0&entityTypeID=3. We also proposed to modify the reporting periods for FYs 2018 and 2019 payment determinations and subsequent years as detailed further below.

We note that the proposed modified PSI 90 measure (MUC ID 15–604) was included on a publicly available document entitled 2015 Measures Under Consideration for December 1, 2015 106 in compliance with section 1890A(a)(2) of the Act, and was reviewed by the MAP. The MAP supported this measure stating that, “the PSI measures were developed to identify harmful healthcare related events that are potentially preventable. Three additional PSIs have been added to this updated version of the measure. PSIs were better linked to important changes in clinical status with ‘harm weights’ that are based on diagnoses that were assigned after the complication. This is intended to allow the measure to more accurately reflect the impact of the events.” 107 The measure received sufficient support for inclusion in the Hospital IQR Program as referenced in the MAP Final Recommendations Report.107

(2) Overview of the Measure Changes

First, the name of the PSI 90 measure has changed from the “Patient Safety for...
Selected Indicators Composite Measure” to the “Patient Safety and Adverse Events Composite” (NQF #0531) to more accurately capture the indicators included in the measure.

Second, the PSI 90 measure has expanded from eight to 10 component indicators. The modified PSI 90 measure is a weighted average of the following 10 risk-adjusted and reliability-adjusted individual component PSI rates:

- **PSI 03 Pressure Ucer Rate;**
- **PSI 06 Iatrogenic Pneumothorax Rate;**
- **PSI 08 In-Hospital Fall With Hip Fracture Rate;**
- **PSI 09 Perioperative Hemorrhage or Hematoma Rate;**
- **PSI 10 Postoperative Acute Kidney Injury Requiring Dialysis Rate;**
- **PSI 11 Postoperative Respiratory Failure Rate;**
- **PSI 12 Perioperative Pulmonary Embolism (PE) or Deep Vein Thrombosis (DVT) Rate;**
- **PSI 13 Postoperative Sepsis Rate;**
- **PSI 14 Postoperative Wound Dehiscence Rate; and**
- **PSI 15 Unrecognized Abdominopelvic Accidental Puncture/Laceration Rate.**

(* Denotes new component for the modified PSI 90 measure)

As stated above, the modified PSI 90 measure also removed PSI 07 Central Venous Catheter-Related Blood Stream Infection Rate, because of potential overlap with the CLABSI measure (NQF #0139), which has been included in the Hospital IQR Program since the FY 2011 IPPS/LTCH PPS final rule (75 FR 50201 through 50202), the HAC Reduction Program since the FY 2014 IPPS/LTCH PPS final rule (78 FR 50717), and the Hospital VBP Program since the FY 2013 IPPS/LTCH PPS final rule (77 FR 53597 through 53598).

In response to stakeholder concerns, highlighted in the NQF 2014 Patient Safety Review Committee raised concerns about the weighting scheme of the component indicators. In prior versions of the measure, the weights of each component PSI were based solely on volume (numerator rates). In the modified PSI 90 measure, the rates of each component PSI are weighted based on statistical and empirical analyses of volume, excess clinical harm associated with the PSI, and disutility (individual preference for a health state linked to a harm, such as death or disability). The final weight for each component indicator is the product of harm weights and volume weights (numerator weights). Harm weights are calculated by multiplying empirical estimates of excess harms associated with the patient safety event by the utility weights linked to each of the harms. Excess harms are estimated using statistical models comparing patients with a safety event to those without a safety event in a Medicare fee-for-service sample. Volume weights are calculated based on the number of safety events for the component indicators in an all-payer reference population. For more information on the modified PSI 90 measure and component indicators, we refer readers to Quality Indicator Empirical Methods available online at: www.qualityindicators.ahrq.gov.

(3) Risk Adjustment

The risk adjustment and statistical modeling approaches of the models remain unchanged in the modified PSI 90 measure. In summary, the predicted value for each case is computed using a modeling approach that includes, but is not limited to, applying a Generalized Estimating Equation (GEE) hierarchical model (logistic regression with hospital random effect) and covariates for gender, age, Modified MS–DRG (MDRG), Major Diagnostic Category, transfer in, point of origin not available, procedure days not available, and AHRQ comorbidity (COMORB).

The expected rate for each of the indicators is computed as the sum of the predicted value for each case divided by the number of cases for the unit of analysis of interest (that is, the hospital). The risk-adjusted rate for each of the indicators is computed using indirect standardization as the observed rate divided by the expected rate, multiplied by the reference population rate. For more details about risk adjustment, we refer readers to: https://www.qualityindicators.ahrq.gov/Downloads/Resources/Publications/2015/Empirical_Methods_2015.pdf. As stated above, we did not propose any changes to the risk adjustment for this measure.

(4) Reporting Periods

The PSI 90 measure is a claims-based measure that has been calculated using 24-months of data. For the FY 2018 and FY 2019 payment determinations, measure rates would be calculated using reporting periods of July 1, 2014 through June 30, 2016 and July 1, 2015 through June 30, 2017, respectively. However, because hospitals began ICD–10-PCS implementation on October 1, 2015, these reporting periods for the FY 2018 and FY 2019 payment determinations would require using both ICD–9 and ICD–10 claims data to calculate measure performance.

Since the ICD–10 transition was implemented on October 1, 2015, we have been monitoring our systems, and claims continue to be processed normally. The measure steward, AHRQ, has been reviewing the measure for any potential issues related to the conversion of approximately 70,000 ICD–10 coded operating room procedures (https://www.cms.gov/icd10manual/fullcode_cms/P1616.html), which could directly affect the modified PSI 90 component.
indicators. In addition, to meet program requirements and implementation schedules, our system would require an ICD–10 risk-adjusted version of the AHRQ QI PSI software by December 2016 for the FY 2018 and 2019 payment determination year. At this time, a risk adjusted ICD–10 version of the modified PSI 90 Patient Safety and Adverse Events Composite software is not expected to be available until late CY 2017.

To address the above issues, we proposed to modify the reporting periods for the FYs 2018 and 2019 payment determinations. For the FY 2018 payment determination, we proposed to use a 15-month reporting period spanning July 1, 2014 through September 30, 2015. The 15-month reporting period would only apply to the FY 2018 payment determination and would only use ICD–9 data. For the FY 2019 payment determination, we proposed to use a 21-month reporting period spanning October 1, 2015 through June 30, 2017. The 21-month reporting period would only apply to the FY 2019 payment determination and would only use ICD–10 data. For all subsequent payment determinations after FY 2019, we proposed to use the standard 24-month reporting period, which would only use ICD–10 data. In order to align the modified PSI 90 measure and the use of ICD–9 and ICD–10 data across CMS hospital quality programs, we proposed similar modifications for FYs 2018 and 2019 payment determinations in the HAC Reduction Program, as discussed in a section IV.3.h. of the preamble of this final rule, and similar modifications to the performance period for the Hospital VBP Program FY 2018 program year, as discussed in section IV.H.2. of the preamble of this final rule.

Prior to deciding to propose abbreviated reporting periods for the FY 2018 and FY 2019 payment determinations, we took several factors into consideration, including the feasibility of using a combination of ICD–9 and ICD–10 data without the availability of the appropriate measure software, minimizing provider burden, program implementation timelines, and the reliability of using shortened reporting periods, as well as the importance of continuing to publicly report this measure. We believe that using a 15-month reporting period for the FY 2018 payment determination and a 21-month reporting period for the FY 2019 payment determination best serves the need to provide important information on hospital patient safety and adverse events by allowing sufficient time to process the claims data and calculate the measures, while minimizing reporting burden and program disruption. We will continue to test ICD–10 data that are submitted in order to ensure the accuracy of measure calculations, to monitor and assess the translation of measure specifications to ICD–10 as well as potential coding variation, and to assess any impacts on measure performance.

We note that a prior reliability analysis of the PSI 90 measure (not the modified PSI 90 measure) showed that the majority of hospitals attain a moderate or high level of reliability after a 12-month reporting period. Although the modified PSI 90 measure has undergone substantial changes since this analysis, we believe that measure scores would continue to be reliable for the above proposed reporting periods, because the NQF, which reendorsed the modified version, found it to be reliable using 12 months of data.

In establishing the revised reporting periods for the modified PSI 90 measure, we also relied upon an analysis by Mathematica Policy Research (MPR), a CMS contractor, which found that the measure was most reliable with a 24-month reporting period and unreliable with a reporting period of less than 12 months. While not discussed in the proposed rule, we would like to elaborate on the reliability of the shortened reporting period. We took into account that the findings in the MPR analysis are based on older data (7 months of data from March 2010–September 2010), which do not reflect changes to current inter-hospital variation over time due to quality improvements. The findings also simulate results over a 2 year period based on 7 months of data; and use an older version of the PSIs (analysis uses v4.2; NQF-endorsed uses v6.0) that does not include improvements in POA coding, a composite with 10 component indicators with a revised weighting scheme or refinements to the component indicators. Therefore, we believe that the proposed abbreviated reporting periods for the modified PSI 90 measure would produce reliable data because the reporting periods are still greater than 12 months.

(5) Adoption of the Modified PSI 90 Measure

In summary, the PSI 90 measure was revised to reflect the relative importance and harm associated with each component indicator to provide a more reliable and valid signal of patient safety events. We believe that adopting the modified PSI 90 measure would continue to provide strong incentives for hospitals to ensure that patients are not harmed by the medical care they receive, which is a critical consideration in quality improvement.

We invited public comment on our proposal to adopt the modified PSI 90 measure (NQF #0531) for the Hospital IQR Program beginning with the FY 2018 payment determination. We will continue to use the currently adopted eight-indicator version of the PSI 90 measure in the Hospital IQR Program for the FY 2017 payment determination. We also invited public comment on the proposals to revise the reporting periods for this measure as described above: (1) A 15-month reporting period using only ICD–9 data for the FY 2018 payment determination; (2) a 21-month reporting period using only ICD–10 data for the FY 2019 payment determination; and (3) a 24-month reporting period using only ICD–10 data for the FY 2020 payment determination and subsequent years.

Comment: Several commenters supported the proposed adoption of the modified PSI 90, including the additional PSI components, the removal of PSI components, and the updated weighting convention. Specifically, commenters expressed support for the removal of PSI 07 Central Venous Catheter-Related Blood Stream Infection Rate from the measure because the removal of this indicator eliminates potential overlap with the CLABSI measure (NQF #0139). Commenters also specifically supported the inclusion of PSI 09 Perioperative Hemorrhage or Hematoma Rate and the refinements to the definition of PSI 15 Unrecognized Abdominopelvic Accidental Puncture/Laceration Rate. Commenters believed that changing the weighting factors that assess harm adds value to the measure. In addition, commenters agreed that mixing ICD–9 and ICD–10 data would

---


not be favorable for this measure. One commenter supported the proposal to shorten the PSI 90 measure reporting period to account for the transition from ICD–9–CM to ICD–10–CM/PCS. Finally, commenters noted that the inclusion of this modified measure would help align with other hospital quality programs.

Response: We appreciate the commenters’ support of the adoption of the modified PSI 90.

Comment: Some commenters suggested adding an exclusion criterion for PSI 12 Perioperative PE or DVT Rate for any patient who has a tracheostomy because it is not the surgery that places the patient at risk for PE or DVT, rather it is the medical problem that leads to tracheostomy that places the patient at increased risk for PE or DVT.

Response: We agree that some medical conditions, which lead to a tracheostomy,118 may also increase patients’ risk for PE or DVT. However, we do not believe that just because a patient has a tracheostomy they are at increased risk for DVT and should be excluded. We note that most of the medical conditions that can lead to tracheostomy are already captured by the extensive set of risk factor variables used in the risk adjustment for PSI 12. For more information on the PSI 12 risk model, we refer readers to: http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Further suggestions regarding potential PSI measure revisions can be made directly to: QISupport@ahrq.hhs.gov.

Response: We acknowledge the commenters’ concerns about the transition to ICD–10–CM/PCS codes has caused inaccuracies in PSI reporting and evaluation, there is no evidence of which we are aware that supports this assertion. However, we are actively monitoring for any potential issues related to ICD–10 conversion. We note that all measure specifications have been translated to and updated for corresponding ICD–10 code specifications. AHRQ’s changes for ICD–10–CM/PCS conversion of its patient safety indicators are available at: http://www.qualityindicators.ahrq.gov/Modules/PSI_ICD10.aspx.

Lastly, we interpret commenters’ concerns regarding “minor procedures” to refer to non-operating room (OR) procedures. As noted in the Frequently Asked Questions about using AHRQ Quality Indicators (QIs), www.qualityindicators.ahrq.gov/FAQs_Support/FAQ_QI.aspx#, the denominators of the AHRQ Patient Safety Indicators (PSIs) use the list of major OR procedures that is developed and maintained by CMS (see draft ICD–10 MS–DRG v32 definitions, Appendix E, at: https://www.cms.gov/ICD10Manual/version32-fullcode-cms/fullcode_cms/P0001.html). We acknowledge that some procedures that were previously classified as a non-OR procedure in the ICD–9–CM MS–DRG list are currently classified as an OR procedure in the draft ICD–10 MS–DRG v28. AHRQ has addressed these discrepancies as they relate to the PSIs going forward. Further, in the mid-July 2016 release of v6.0 ICD–10–CM/PCS software, AHRQ refined the list of major OR procedures. We believe this refined list of major OR procedures provides clear guidance regarding classifying OR procedures and non-OR procedures to ensure accurate reporting by all organizations. AHRQ welcomes input from the user community on AHRQ QI ICD–10–CM/PCS v6.0. Please provide suggestions/comments directly to: QISupport@ahrq.hhs.gov.

Comment: Several commenters did not support the proposed adoption of the modified PSI 90 because of the susceptibility of PSI 12 Perioperative PE or DVT Rate to surveillance bias and lack of appropriate measure exclusions.

Response: CMS and AHRQ recognize the commenters’ concerns about surveillance bias for PSI 12 Perioperative PE or DVT Rate and the issue was addressed in the NQF Patient Safety Steering Committee in 2015.

Surveillance bias is a non-random type of systemic bias where a diagnosis is more likely to be observed the more vigilant one is in looking for it.119 In the case of DVT or PE, hospitals may underdiagnose or over diagnose DVT or PE depending upon how often they screen or perform diagnostic testing to look for these diagnoses. Several research teams have examined DVT and PE rates and surveillance bias.120 However, studies have not specifically examined whether the observed rates reflect underdiagnosis of DVT or PE at low-testing hospitals, over diagnosis of DVT or PE at high-testing hospitals, or the underlying true incidence of symptomatic DVT or PE. While some hospitals might hypothesize that increased surveillance is desirable, there is no evidence to support the hypothesis that “increased vigilance in DVT or PE detection” is desirable, from the perspective of patients and their families. Over diagnosis of DVT or PE among patients may lead to overtreatment, and overtreatment is not inconsequential as there are known adverse effects associated with treatment of DVT and PE. Thus, while we acknowledge commenter’s concerns regarding surveillance bias, we believe that PSI 12 is an important component indicator of the modified PSI 90.

118 A tracheotomy or a tracheostomy is an opening surgically created through the neck into the trachea (windpipe) to allow direct access to the breathing tube and is commonly done in an operating room under general anesthesia. Definition obtained from http://www.hopkinsmedicine.org/tracheotomy/about/what.html.


measure, because it encourages hospitals not only to prevent DVT or PE, but also to appropriately assess a patient’s risk for DVT and PE to prevent over-diagnosis and under-diagnosis. Given the negative economic and health consequences associated with DVT or PE diagnosis, we believe that preventing under-diagnosis and over-diagnosis is critical to improving patient safety.

Lastly, we disagree with commenter that PSI 12 Perioperative PE or DVT Rate lacks appropriate exclusions. Measure exclusions were reviewed by the NQF Patient Safety Steering Committee in 2015 and the measure was re-endorsed as reliable and valid. We note that AHRQ removed isolated thrombosis of calf veins (ICD–9–CM 453.42) from the version 6.0 specification reviewed by the NQF Patient Safety Steering Committee in 2015 in order to minimize the impact of clinically unimportant distal thromboses on hospital-specific PSI 12 rates. However, suggestions regarding potential PSI measure revisions can be made directly to: QsSupport@ahrq.hhs.gov.

Comment: Several commenters noted that the modifications to the PSI 90 measure do not address the many, well-documented concerns about the reliability of individual claims data elements or the validity of the PSIs. Commenters expressed the opinion that claims-based measures in general, and PSIs in particular, have not demonstrated that they are accurate, reliable, and valid indicators of quality and safety of care. Other commenters cautioned against the measure’s use of claims data due to the composite structure because the composite lacks specific direction for prevention strategy focus. Commenters also expressed concern about the utility of the modified measure and its ability to provide actionable information to providers.

Lastly, commenters expressed concern that the shortened reporting period will not produce reliable data on hospital performance. Due to the modifications made to the component PSIs and the new weighting scheme, commenters believed that the previous reliability results do not provide sufficient information on the reliability of the modified measure when a shortened 15-month reporting period is used.

Response: We disagree with commenters that claims-based measures in general, and PSIs in particular, have not demonstrated that they are accurate, reliable, and valid indicators of quality and safety of care. Regarding the administrative data elements of PSI 90, we note that there are previously conducted studies that validate the relationship between administrative claims data and medical records. These studies demonstrate that administrative claims data can provide sufficient clinical information to assess patient safety. We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50091) for a further discussion of this issue in the context of the HAC Reduction Program. Further, over the past decade, AHRQ has supported a series of validation studies based on detailed abstraction of medical records. These studies informed AHRQ’s PSI development process, including further refinements to indicators, working with others to improve coding practices, and refinement of a few indicators.

Furthermore, many of these claims-based indicators have been endorsed by the NQF. This measure, which includes a review process that assesses reliability and validity, includes the modified PSI 90, including the risk-adjustment methodology of the component indicators, as reliable and valid (NQF #0531). Further, we believe the modified PSI 90 does provide actionable information and specific direction for prevention of patient safety events, because hospitals can track and monitor individual PSI rates and develop targeted improvements to improve patient safety. For further guidance on PSI monitoring and strategies for applying quality improvements to PSI data, we refer readers to the Toolkit for Using the AHRQ Quality indicators available at: http://www.ahrq.gov/professionals/systems/hospital/qitoolkit/index.html.

Lastly, while we acknowledge commenters’ concerns that the previous reliability results may not provide sufficient information on the reliability of the modified measure for a shortened 15-month reporting period, we note that this reliability analysis does not include the modifications to the PSI 90, such as improvements in POA coding, refinements to the component indicators, or a composite with 10 component indicators with a revised weighting scheme. We believe these refinements and improvements enhance the reliability of the measure. Moreover, we note that the NQF found the modified PSI 90 to be reliable using specifically 12 months of data. We continue to believe the modified PSI 90 measure is a scientifically rigorous measure that provides actionable feedback to hospitals to improve patient safety and quality of care.

Comment: One commenter expressed concern that PSI 09 Perioperative Hemorrhage or Hematoma Rate may apply to a number of transplant patients and recommended that transplantation should be added to the exclusion list a priori and requested that that liver transplant patients be excluded from the PSI 09 denominator. The commenter indicated that perioperative hemorrhage or hematoma is normal after liver transplant, and that frequently kidney transplant, and the repercussions of these and other transplantation procedures are not indicative of poor quality care. The commenter further noted that liver transplant results in significant blood loss in nearly every case, and poor performance on this measure can be driven by the number of liver transplants performed.

One commenter expressed concern with the PSI 11 Postoperative Respiratory Failure Rate because acute respiratory failure, mechanical ventilation, and reintubation are fairly common for both liver and kidney procedures and do not suggest poor quality of care. This commenter stated that transplant surgeries have a high incidence of acute respiratory failure, mechanical ventilation, and reintubation meeting the specifications set forth in this measure, due to fluid shifts, medications, neurological status, and potential for infection involved in this complex surgery. Another commenter expressed concern that PSI 09 Composite Measure Testing, 151022.pdf available in the Patient Safety for Selected Indicators (modified version of PS90) zip file at: http://www.qualityforum.org/ProjectMeasures.aspx?projectID=77836.
10 Postoperative Acute Kidney Injury

Requiring Dialysis Rate is inappropriate for liver transplantation. The commenter stated that while the measure excludes patients with preoperative renal failure, many liver transplant patients with relatively normal baseline renal function get acute renal failure after transplant despite high quality care, due to hemodynamic factors and the nature of the drugs involved in the performance of the procedure and its aftermath. These commenters recommended that liver and kidney transplantation should be added to the exclusion list for this measure.

Response: We do not agree with the commenters that liver transplant patients should be excluded from the PSI 09, PSI 10, and PSI 11 denominators. While we appreciate one commenter’s observation that transplant patients may have an elevated risk of hemorrhage or hematoma, we note that the risk-adjustment model for PSI 09 explicitly accounts for the increased risk associated with solid organ transplantation. For more information on the PSI 09 risk model, we refer readers to http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Similarly, the risk-adjustment models for PSI 10 and PSI 11 explicitly account for the increased risk associated with hepatic failure and solid organ transplantation, respectively. For more information on the PSI 10 risk model, we refer readers to http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

Comment: One commenter expressed concern that changes in coagulation in the early postoperative period may lead to increased incidence of clotting disorders including Deep Vein Thrombosis (DVT) after transplant procedures and also may be caused by large bore IVs. In addition, transplant patients often get products that promote clotting due to inherent coagulopathy, and some patients have clotting disorders that cause hypercoagulability. The commenter noted that this measure excludes surgeries involving interruption of the vena cava, and stated that all liver transplants involve such interruption. This commenter recommended that liver and kidney transplant be added to the exclusion list because DVT is not indicative of poor quality care for these procedures due to the frequency of DVT in transplantation.

Response: We appreciate commenter’s observation that PSI 12 Perioperative PE or DVT Rate excludes cases where a procedure for interruption of the vena cava occurs before or on the same day of the first operating room procedure. Cases meeting this criterion should be excluded, because inferior vena cava (IVC) filter placement (which is by far the most common example of surgical interruption of the vena cava) is appropriate only for patients who cannot tolerate, or have already failed, conventional pharmacologic prophylaxis. IVC filters are placed in high-risk patients with the knowledge that they increase the risk of deep vein thrombosis distal to the device while decreasing the risk of embolization to the pulmonary circulation.

However, we disagree with commenter that liver and/or kidney transplants must be placed on the exclusion list. Just because these patients may have clotting disorders, it does not mean they increase the risk of deep vein thrombosis. We note that the risk-adjustment model for PSI 12 Perioperative PE or DVT Rate explicitly accounts for the increased risk of thrombosis (clotting) associated with solid organ transplantation. Risk adjustment accounts for differences in patient populations (transplant patients, etc.) to allow for comparisons across providers. For example, liver transplantation (MDRG 7702) is associated with an adjusted odds ratio of 3.2 in AHRQ’s v5.0 risk model for PSI 12. PSI 12 is designed to improve surveillance prevention and awareness of perioperative DVT and pulmonary embolism. Because of the morbidity and mortality associated with these conditions, we continue to believe that PSI 12 is important to improving perioperative quality of care and patient safety. For more information on the PSI 12 risk model, we refer readers to http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V50/Parameter_Estimates_PSI_50.pdf.

The measure steward, AHRQ, carefully considers all suggestions of this type, and will consult with clinical experts as the Patient Safety Indicators are updated in the future. Suggestions regarding potential PSI measure revisions can be made directly to QISupport@ahrq.hhs.gov.

After consideration of the public comments we received, we are finalizing the adoption of the modified PSI 90 measure (NQF #40531) for the Hospital IQR Program for the FY 2017 payment determination.

7. Additional Hospital IQR Program Measures for the FY 2019 Payment Determination and Subsequent Years

In the FY 2017 IPPS/LTCPPS proposed rule (81 FR 25185 through 25193), we proposed to add four new measures to the Hospital IQR Program for the FY 2019 payment determination and subsequent years. We proposed to adopt three clinical episode-based payment measures:

- Aortic Aneurysm Procedure Clinical Episode-Based Payment (AA Payment) Measure;
- Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment (Chole and CDE Payment) Measure; and
- Spinal Fusion Clinical Episode-Based Payment (SFusion Payment) Measure.

In addition, we proposed to adopt one required outcome measure: Excess Days in Acute Care after Hospitalization for Pneumonia.

The proposed measures were included on a publicly available document entitled “2015 Measures Under Consideration” in compliance with section 1890A(a)(2) of the Act, and they were reviewed by the MAP as discussed in its MAP Pre-Rulemaking Report and Spreadsheet of MAP 2016 Final Recommendations. Below, we discuss each of the above measures in more detail.

a. Adoption of Three Clinical Episode-Based Payment Measures

(1) Background

Clinical episode-based payment measures are clinically coherent groupings of healthcare services that can be used to assess providers’ resource use. Combined with other clinical quality measures, they contribute to the overall picture of providers’ clinical performance. The proposed measures were included on a publicly available document entitled “2015 Measures Under Consideration” in compliance with section 1890A(a)(2) of the Act, and they were reviewed by the MAP as discussed in its MAP Pre-Rulemaking Report and Spreadsheet of MAP 2016 Final Recommendations.

Bore refers to the size of a needle used for an IV.
effectiveness and efficiency. Episode-based performance measurement allows meaningful comparisons between providers based on resource use for certain clinical conditions or procedures, as noted in the NQF report for the “Episode Grouper Evaluation Criteria” project available at: http://www.qualityforum.org/Publications/2014/09/Evaluating_Episode_Groupers_A_Report_from_the_National_Quality_Forum.aspx and in various peer-reviewed articles. We proposed three clinical episode-based payment measures for inclusion in the Hospital IQR Program beginning with the FY 2019 payment determination: (1) Aortic Aneurysm Procedure Clinical Episode-Based Payment (AA Payment) measure; (2) Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment (Cholecystectomy and CDE Payment) measure; and (3) Spinal Fusion Clinical Episode-Based Payment (SFusion Payment) measure. The proposed measures capture Medicare payment for services related to the episode procedure and take into account beneficiaries’ clinical complexity as well as geographic payment differences.

We proposed these clinical episode-based measures to supplement the Hospital IQR Program’s Medicare Spending per Beneficiary (MSPB) measure. The proposed measures also support our mission to provide better healthcare for individuals, better health for populations, and lower costs for healthcare. We note that these measures were reviewed by the MAP and did not receive support for adoption into the Hospital IQR Program, as discussed in its MAP Pre-Rulemaking Report and Spreadsheet of MAP 2016 Final Recommendations. The result of the MAP vote for the proposed measures was as follows: (1) Aortic Aneurysm Procedure Clinical Episode-Based Payment measure: 8 percent support, 32 percent conditional support, and 60 percent do not support; (2) Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment measure: 20 percent support, 28 percent conditional support, and 52 percent do not support; and (3) Spinal Fusion Clinical Episode-Based Payment measure: 16 percent support, 36 percent conditional support, and 48 percent do not support. MAP stakeholders expressed concerns that the proposed measures: (1) Overlap with the Medicare Spending per Beneficiary (MSPB) measure; (2) are not NQF-endorsed; (3) may need to be adjusted for SDS; and (4) fail to link outcomes to quality because they do not reflect appropriateness of care.

In response to MAP stakeholder concerns that the clinical episode-based payment measures overlap with the MSPB measure, we note that unlike the overall MSPB measure, the clinical episode-based payment measures assess payment variation at the procedure level and only include services that are clinically related to the named episode procedure (for example, the spinal fusion measure includes inpatient admissions for “medical back problems” that occur following the initial spinal fusion procedure since the admission is likely a result of complications from the initial procedure).

With respect to MAP stakeholder concerns that the clinical episode-based payment measures are not NQF-endorsed, section 1886(b)(3)(B)(IX)(bb) of the Act provides that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We considered other existing measures related to payment that have been endorsed by the NQF and other consensus organizations, but we were unable to identify any NQF-endorsed (or other consensus organization endorsed) payment measures that assess the aortic aneurysm procedure, cholecystectomy and common duct exploration, or spinal fusion. However, these proposed clinical episode-based payment measures will be submitted to NQF for endorsement as part of the next Cost and Resource Use project.

In regard to MAP stakeholder concerns that the clinical episode-based payment measures may need to be adjusted for SDS, we refer readers to section VIII.A.6.a.1 of the preamble of this final rule for a discussion of our policy on SDS factor risk adjustment. Finally, regarding MAP stakeholder concerns that the clinical episode-based payment measures fail to link outcomes to quality because they do not reflect appropriateness of care, we believe that the proposed measures cover topics of critical importance to quality in the inpatient hospital setting. Hospitals have a significant influence on Medicare spending during the episode surrounding a hospitalization, through the provision of appropriate, high-quality care before and during inpatient hospitalization, and through proper hospital discharge planning, care coordination, and care transitions. While we recognize that high or low payments to hospitals are difficult to interpret in isolation, high payments for services may implicitly be associated with poor quality of care (for example, preventable readmissions, procedure complications, or emergency room usage).

Although the MAP did not support inclusion of these clinical episode-based payment measures in the Hospital IQR Program, stakeholders have requested to have more condition-specific and procedure-specific measures, similar to the MSPB measure included in the Hospital IQR Program, as described in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51623). We believe that including condition- and procedure-specific payment measures will provide hospitals with actionable feedback that will better equip them to implement targeted improvements in comparison to an overall payment measure alone. Further, we believe that supplementing the MSPB measure with condition-specific and procedure-specific measures will provide both overall hospital-level and detailed information on high-cost and high-prevalence conditions and procedures to better inform their future spending plans. Moreover, the payment measures will help consumers and other payers and providers identify hospitals involved in the provision of efficient care for certain procedures.

The three procedures selected for the clinical episode-based payment measures were chosen based on the following criteria: (1) The condition constitutes a significant share of Medicare payments and potential savings for hospitalized patients during and surrounding a hospital stay; (2) there was a high degree of agreement among clinical experts consulted for this project that standardized Medicare payments for services provided during this episode can be linked to the care provided during the hospitalization; (3)
episodes of care for the condition are comprised of a substantial proportion of payments and potential savings for postacute care, indicating episode payment differences are driven by utilization outside of the MS–DRG payment; (4) episodes of care for the condition reflect high variation in postdischarge payments, enabling differentiation among hospitals; and (5) the medical condition is managed by general medicine physicians or hospitalists and the surgical conditions are managed by surgical subspecialists, enabling comparison between similar practitioners. These selection criteria were also used for the three clinical episode-based payment measures finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49664 through 49665).

The measures follow the general construction of episode-based measures previously adopted in the Hospital IQR Program: The NQF-endorsed MSPB measure finalized in the FY 2012 IPPS/LTCH PPS final rule for the Hospital IQR Program (76 FR 51626 through 74529); and the three clinical episode-based payment measures for kidney/UTI, cellulitis, and gastrointestinal hemorrhage finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49674). Similar to these previously adopted measures, the proposed measures include standardized payments for Medicare Part A and Part B services and are risk adjusted for individual patient characteristics and other factors (for example, the MS–DRG of the index inpatient stay). However, unlike the MSPB measure, the clinical episode-based payment measures only include Medicare Part A and Part B services that are clinically related to the named episode procedure. The clinical episode-based payment measures are price-standardized, risk-adjusted ratios that compare a provider’s resource use against the resource use of other providers within a reporting period (that is, the measurement calculation includes eligible episodes occurring within a 1-year timeframe). Similar to the MSPB measure though, the ratio allows for ease of comparison over time as it obviates the need to adjust for inflation.

Each clinical episode-based payment measure is calculated as the ratio of the Episode Amount for each provider divided by the episode-weighted median Episode Amount across all providers. To calculate the Episode Amount for each provider, one calculates the average of the ratio of the observed episode payment over the expected episode payment (as predicted in risk adjustment), and then multiplies this quantity by the average observed episode payment level across all providers nationally. The denominator for a provider’s measure is the episode weighted national median \(^{133}\) of Episode Amounts across all providers. A clinical episode-based payment measure of less than 1 indicates that a given provider’s resource use is less than that of the national median provider during a reporting period. Mathematically, this is represented in equation (A) below.

\[
\text{(A) Episode Measure}_j = \frac{\text{Episode Amount}_j}{\text{Median of All Providers’ Episode Amounts}} = \frac{\sum_{i \in \text{Episode}} \frac{O_{ij}}{E_{ij}}}{n_j} = \frac{\text{Episode-weighted Median of All Providers’ Episode Amounts}}{\text{Episode-weighted Median of All Providers’ Episode Amounts}}
\]

where
\(O_{ij}\) = observed episode payment for episode \(i\) in provider \(j\),
\(E_{ij}\) = expected episode payment for episode \(i\) in provider \(j\),
\(O_{ij}\) = average observed episode payment across all episodes \(i\) nationally, and
\(n_j\) = total number of episodes for provider \(j\).

Each of the three measures we proposed is described further below, followed by explanations of payment standardization and risk adjustment. For detailed measure specifications, we refer readers to the clinical episode-based payment measures report entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Procedure, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228775614447.

We invited public comment on our proposals to add three clinical episode-based payment measures for the FY 2019 payment determination and subsequent years. General comments related to all three measures are discussed below. Specific comments for each measure are discussed even further below.

Comment: Several commenters supported the adoption of the proposed clinical episode-based payment measures.

Response: We thank the commenters for their support.

Comment: Several commenters expressed concern that hospitals would not be able to report statistically reliable information on such a small number of hospital-specific observations, recommending instead that CMS use condition-specific cost measures broadly and not base financial incentives on them.

Commenters were also concerned that the majority of performance variation reflects differences in services used by patients, but the measures do not provide insight on whether the services were necessary and appropriate, arguing that cost is not indicative of quality of care. Some commenters believed that consumers are likely to associate higher cost with better quality.

\(^{133}\) Example of episode weighted median: if there are 2 hospitals and one hospital had an average episode payment level of 0.5 and another had one of 0.5, but the first had 4 episodes and the second only 1, then the episode-weighted median would be 1.5 (that is, 0.5, 1.5, 1.5, 1.5, 1.5).
We appreciate the commenter’s recommendation not to use episode-based cost measures for financial incentives, but note that the payment incentive in the Hospital IQR Program is for reporting only, therefore, there is no financial incentive associated with performance on these specific measures. We agree with commenters that some consumers may associate higher cost with better quality, and we will continue to explore options to improve the manner in which data is presented on Hospital Compare to enable consumers to make informed decisions about their healthcare.

Comment: One commenter noted that the Hospital IQR Program does not currently include appropriate outcome measures for many of these conditions, nor has CMS proposed inclusion of new outcome measures. This commenter urged CMS to identify and employ relevant outcome measures to provide context for these cost measures, so that the function of the cost measures is not to simply reduce spending, even when the spending is appropriate. Some commenters stated that there are no concurrent outcome measures in the Hospital IQR Program and thus the measures do not offer meaningful insight on whether or not outcomes are better in places where more or fewer services are used.

Response: We interpret the commenters’ reference to places where more or fewer services are used to refer to hospital resource use. While we agree that observation of cost alongside quality (outcome measures) is an important concept, we believe that resource use information, even in the absence of a corresponding (concurrent) quality measure, provides useful and valuable information for consumers and other stakeholders as they seek to make informed decisions about facilities involved in the provision of their care. Furthermore, the clinical episode-based payment measures only include costs from services/procedures related to the condition, which would include readmissions that are clinically related to the hospitalization. In that sense, certain outcomes would be captured in these measures through higher resource use. However, we appreciate the commenter’s suggestion and will consider it in future measure development.

Comment: One commenter observed that the proposed clinical episode-based payment measures would help to supplement the MSBP measure by tracking resource use within these particular episodes of care, but several commenters echoed the MAP’s concern that these measures overlap with the MSBP measure. One commenter expressed concern that these measures overlap with other efficiency measures. One commenter requested clarification about whether or not the proposed clinical episode-based payment measures will be used as part of the MSBP measure for the Hospital VBP Program in future payment years, stating that it is important for all stakeholders to be fully aware how cost collection under these measures may impact future quality scores and payment adjustments.

Response: We interpret the commenter’s reference to “non-Traditional Medicare patients” to refer to beneficiaries enrolled in MA plans. We note that we do not receive claims data for beneficiaries who are enrolled in the MA plans because Medicare pays these plans a fixed amount. Therefore, we cannot include or supplement MA claims data for measure calculation.

Comment: Some commenters did not support the measures because they are not NQF-endorsed, noting that the MAP also recommended that the measures be NQF-endorsed prior to being included in the Hospital IQR Program because the endorsement process identifies needed refinements or problems with measures which should be considered prior to program adoption. Some commenters suggested that the measures have full support of the clinical community prior to being included in the measure set.

Response: We believe the MAP provides valuable insights and we consider and carefully weigh all of their recommendations. We disagree with these recommendations, we take care to explain our rationale when proposing such measures. We refer readers to section VIII.A.7.a.(1) of the preamble of this final rule for a discussion of our rationale for including the Clinical Episode-Based Payment measures in the Hospital IQR Program measure set. Likewise, we attempt to engage stakeholders in the measure development process as much as possible, including by working with them on TEPs and Environmental Working Groups (EWGs).

Finally, whenever feasible, we adopt measures that are NQF-endorsed, but note that sometimes there are important areas of clinical concern for which NQF-endorsed measures do not exist. Section 1866(b)(3)(B)(IX)(bb) of the Act provides that in the case of a specified area or medical topic determined appropriate by the Secretary for which no measure has been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. We considered other existing measures related to payment that have been endorsed by the NQF and other consensus organizations, but we were unable to identify any NQF-endorsed (or other consensus organization endorsed) payment measures that assess the aortic aneurysm procedure, cholecystectomy and common duct exploration, or spinal fusion. However, these proposed clinical episode-based payment...
measures will be submitted to NQF for endorsement as part of the next Cost and Resource Use project.

**Comment:** Some commenters noted that the measures reflect the actions of a group of healthcare providers, rather than just hospitals. Other commenters also noted that the measures do not account for national variation in the mix of services and degree of integration in health care markets beyond the hospital’s control. Some commenters recommended that inclusion of these measures be delayed in the Hospital IQR Program until all settings of postacute care have similar measures.

**Response:** We believe these measures reflect the actions of hospitals and the care their patients receive postdischarge. Hospitals providing quality inpatient care, conducting appropriate discharge planning, and working with providers and suppliers on appropriate follow-up care will likely perform well, because the Medicare beneficiaries they serve will have a reduced need for excessive postdischarge services. The risk adjustment methodology used for these measures acknowledge the differences in a given hospital’s patient case mix, so that their performance can be compared to a national average. We recognize that the structure of health care markets and practice patterns vary geographically, beyond the variation in patient case mix. However, as mentioned above, we believe that the aforementioned opportunities for hospitals to exert control over postdischarge services exist, regardless of the degree of integration of a health system. In cases where systems are not well-integrated, there may be an even greater opportunity for redesign of care processes to achieve high performance on these measures. We are collaborating with our postacute care quality programs and will take the commenters’ suggestions that similar measures should be incorporated into those programs under consideration. However, we do not believe that it would be appropriate to delay adoption of this measure and the public reporting of this valuable and actionable payment information until such time as any similar, postacute care measures are implemented.

**Comment:** Some commenters did not believe claims data were adequate to calculate measure scores for these measures. Another commenter stated that the measure should be based on clinical data rather than claims data to refer to the risk adjustment methodology since payment information must come from a filed claim. We believe that using administrative claims data is a valid approach to risk adjustment that adequately assesses the difference in case-mix among hospitals. However, we also are continuing to explore the use of patient clinical data (core clinical data elements) derived from EHRs for risk adjustment in future measure development (80 FR 49698 through 49704).

**Response:** Some commenters cited concerns about the risk adjustment and scoring of these measures. One commenter noted that it is imperative to assess for risk-adjustment factors to ensure that facilities are not financially penalized for serving vulnerable populations and/or worsening care disparities. Another commenter specifically suggested that the measures be SDS risk-adjusted to account for the effects of poverty on the use of healthcare services.

**Comment:** Some commenters cited concerns about the risk adjustment and scoring of these measures. One commenter noted that it is imperative to assess for risk-adjustment factors to ensure that facilities are not financially penalized for serving vulnerable populations and/or worsening care disparities. Another commenter specifically suggested that the measures be SDS risk-adjusted to account for the effects of poverty on the use of healthcare services.

**Response:** Because the Hospital IQR Program is a quality reporting program and does not score measures for performance, we interpret commenters’ concerns regarding scoring to refer to measure calculation. In response to concerns regarding risk adjustment and measure calculation, we note that the steps used to calculate risk-adjusted payments align with the NQF-endorsed MSPB measure (NQF #2158) method as specified in the FY 2012 IPPS/LTC PPS final rule (76 FR 51624 through 51626). The risk adjustment model adjusts for age, severity of illness, and the MS–DRG of the hospitalization that triggers the episode. The risk adjustment model also includes clinical subtypes that distinguish relatively homogeneous subpopulations of patients whose health conditions significantly influence the form of treatment and the expected postdischarge outcomes and risks.

For each clinical subtype, the risk adjustment model is estimated separately such that the measure compares observed spending for an episode of a given clinical subtype only to expected spending among episodes of that subtype. The Aortic Aneurysm Procedure Clinical Episode-Based Payment Measure includes two clinical subtypes: (1) Abdominal Aortic Aneurysm Procedure; and (2) Thoracic Aortic Aneurysm Procedure. The Spinal Fusion Clinical Episode-Based Payment measure includes five clinical subtypes: (1) Anterior Fusion—Single; (2) Anterior Fusion—2 Levels; (3) Posterior/Posterior-Lateral Approach Fusion—Single; (4) Posterior/Posterior-Lateral Approach Fusion—2 or 3 Levels; and (5) Combined Fusions. In addition, postdischarge episode payment is limited to services that are clinically related to the reason for the initial hospitalization, which removes sources of variation in episode spending that are out of the hospital’s control.

The specifications for clinical subtypes and grouping rules for postdischarge services were based on consensus decisions by a team of clinical experts, which included CMS and non-CMS physicians. For a complete list of the clinical experts whose input considered, we refer readers to the report detailing the specifications of the episode-based payment measures, entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Procedure, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier4%40cid=122677594447.

In response to the comment about risk-adjustment factors that account for serving vulnerable populations and/or worsening care disparities, as stated in section VIII.A.6.a.(1) of the preamble of this final rule, several measures developed by CMS have been brought to NQF since the beginning of the SDS trial. CMS, in compliance with NQF’s guidance, has tested SDS factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for SDS factors in our outcome measures.

Furthermore, ASPE is conducting research to examine the impact of SDS on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

**Comment:** Despite concerns about these measures, some commenters noted the potential benefit of sharing confidential cost reports to providers, specifically those interested in bundled payments, so that these providers can assess the drivers of high-cost payment episodes and explore interventions. These commenters suggested that CMS provide these cost reports while the measures undergo NQF review. Some commenters suggested conducting a “dry run” of the measures in which CMS would provide hospitals with...
confidential reports, soliciting feedback on the usefulness of the information. Another commenter requested that CMS publish supplementary data demonstrating cost variations to better inform stakeholders of the appropriateness of tracking these costs and to evaluate whether the data show any evidence that higher quality hospital treatment may yield lower postdischarge payment.

Response: In the FY 2016 IPPS/LTCH final rule (80 FR 49672), we finalized a dry run for similar clinical episode-based payment measures, which will be conducted in the summer of 2017 using CY 2016 data. The purpose of this dry run is to allow hospitals to gain experience with clinical episode-based payment measures through confidential feedback reports. We believe this dry run will enable hospitals to gain experience with clinical episode-based payment measures, including the three payment measures being adopted in this final rule, and therefore another similar dry run is unnecessary.

We thank commenters for their support of the confidential hospital-specific feedback reports. We currently provide confidential hospital-specific feedback reports and supplemental files for the MSPB measure, and we intend to create similar reports and supplemental files for these clinical episode-based payment measures. We will coordinate with measure stewards to try to develop a process for making these reports available while measures are undergoing NQF review. We appreciate the commenter’s suggestion that we publish supplementary data of cost variations and will take it into future consideration.

Comment: One commenter encouraged CMS to work collaboratively with stakeholders to ensure that policies allow hospitals to provide the best care for patients in the most appropriate setting as determined by the physician.

Response: We thank the commenter for this suggestion and we will continue to seek and consider stakeholder input as we improve the Hospital IQR Program.

(b) Overview of Measure

The proposed AA Payment measure includes the set of medical services related to a hospital admission for an aortic aneurysm procedure, including treatment, follow-up, and postacute care. The measure includes two clinical subtypes: (1) Abdominal Aortic Aneurysm Procedure; and (2) Thoracic Aortic Aneurysm Procedure. Clinical subtypes are included in the measure construction to distinguish relatively homogeneous subpopulations of patients whose health conditions significantly influence the form of treatment and the expected postdischarge outcomes and risks. The risk adjustment model is estimated separately for each clinical subtype, such that the measure compares observed spending for an episode of a given clinical subtype only to expected spending among episodes of that subtype. This measure, like the NQF-endorsed MSPB measure (NQF #2158), assesses the payment for services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window,” discussed in more detail below). In contrast to the MSPB measure, however, this proposed measure includes Medicare payments for services during the episode window only if they are clinically related to the aortic aneurysm procedure that was performed during the index hospital stay.

(c) Data Sources

The proposed AA Payment measure is a claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized for an aortic aneurysm procedure. The reporting period for the measure is 1 year (that is, the measure calculation includes eligible episodes occurring within a 1-year timeframe). For example, for the FY 2019 payment determination, the reporting period would be CY 2017.

(d) Measure Calculation

The proposed AA Payment measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during the episode window and attributes them to the hospital at which the index hospital stay occurred. Medicare payments included in this episode-based measure are standardized and risk-adjusted. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of comparison over time, without the need to adjust for inflation.

The numerator is the Episode Amount, calculated as the average of the ratios of the observed episode payment over the expected episode payment (as predicted in risk adjustment), multiplied by the average observed episode payment level across all providers nationally. The denominator for a provider’s measure is the episode weighted national median of Episode Amounts across all providers. An aortic aneurysm procedure episode begins 3 days prior to the initial (index) admission and extends 30 days following the discharge from the index hospital stay. For detailed measure specifications, we refer readers to the clinical episode-based payment measures report entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Procedure, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” and available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228775614447.

(e) Cohort

The proposed AA Payment measure cohort includes Medicare FFS beneficiaries hospitalized for an aortic aneurysm procedure. Measure exclusions are discussed in more detail in section VIII.A.7.a.(5) of the preamble of this final rule.

We invited public comment on our proposal to adopt the Aortic Aneurysm
Procedure Clinical Episode-Based Payment (AA Payment) measure to the Hospital IQR Program measure set for the FY 2019 payment determination and subsequent years as discussed in this section.

Comment: One commenter specifically opposed the proposed inclusion of the AA Payment measure, noting that the measure is not NQF-endorsed or supported by the MAP.

Response: We refer readers to our response in the section above in which we respond to general comments on the clinical episode-based payment measures.

Comment: One commenter recommended that the measure should be subdivided into several different measures by: Location of the Aortic Aneurysm; Type of Surgery that is performed; and Emergent or Non Emergent Aortic Aneurysm.

Response: We disagree that the measure should be subdivided into several different measures. The measure already risk adjusts for the factors listed by the commenter, including through two clinical subtypes based on the location of the procedure: (1) Abdominal Aortic Aneurysm Procedure, and (2) Thoracic Aortic Aneurysm Procedure. Creating separate measures would substantially reduce hospitals’ sample size and limit the number of hospitals included in the measure after an episode case minimum is imposed.

After consideration of the public comments we received, we are finalizing the adoption of the Aortic Aneurysm Procedure Clinical Episode-Based Payment (AA Payment) measure to the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(3) Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment (Chole and CDE Payment) Measure

(a) Background

Inpatient hospital stays and associated services assessed by the proposed Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment (Chole and CDE Payment) measure have high payments with substantial variation. In CY 2014, Medicare FFS beneficiaries experienced more than 48,000 cholecystectomy and common duct exploration episodes triggered by related inpatient stays. Payment-standardized, risk-adjusted episode payment for these episodes (payment for the hospitalization plus the payment for clinically related services in the episode window) totaled nearly $690 million in CY 2014, with a mean episode payment of over $14,000. There is substantial variation in cholecystectomy and common duct exploration episode payment—ranging from approximately $11,000 at the 5th percentile to approximately $22,000 at the 95th percentile—that is partially driven by variation in postdischarge payment clinically-related to the inpatient hospitalization. These clinically-related postdischarge payments may be an indicator of the quality of care provided during the hospitalization. Specifically, higher quality hospital treatment may yield lower postdischarge payment.

(b) Overview of Measure

The proposed Chole and CDE Payment measure includes the set of medical services related to a hospital admission for a cholecystectomy and common duct exploration, including treatment, follow-up, and postacute care. This measure, like the NQF-endorsed MSPB measure (NQF #2158), assesses the payment for services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window,” discussed in more detail below). In contrast to the MSPB measure, however, this measure includes Medicare payments for services during the episode window only if they are clinically related to the cholecystectomy and common duct exploration that was performed during the index hospital stay.

(c) Data Sources

The proposed Chole and CDE Payment measure is a claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized for a cholecystectomy and common duct exploration. The reporting period for the measure is 1 year (that is, the measure calculation includes eligible episodes occurring within a 1-year timeframe). For example, for the FY 2019 payment determination, the reporting period would be CY 2017.

(d) Measure Calculation

The proposed Chole and CDE Payment measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during the episode window and attributes them to the hospital at which the index hospital stay occurred. Medicare payments included in this episode-based measure are standardized and risk-adjusted. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of comparison over time, without need to adjust for inflation. The numerator is the Episode Amount, calculated as the average of the ratios of the observed episode payment over the expected episode payment (as predicted in risk adjustment), multiplied by the average observed episode payment level across all providers nationally. The denominator for a provider’s measure is the episode weighted national median of Episode Amounts across all providers. A cholecystectomy and common duct exploration episode begins 3 days prior to the initial (index) admission and extends 30 days following the discharge from the index hospital stay. For detailed measure specifications, we refer readers to the clinical episode-based payment measures report entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Procedures, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” and available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier4&cid=1228775614447.

(e) Cohort

The proposed Chole and CDE Payment measure cohort includes Medicare FFS beneficiaries hospitalized for cholecystectomy and common duct exploration. Measure exclusions are discussed in more detail in section VIII.A.7.a.(5) of the preamble of this final rule below.

We invited public comment on our proposal to adopt the Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment (Chole and CDE Payment) measure to the Hospital IQR Program measure set for the FY 2019 payment determination and subsequent years as discussed in this section.

Comment: One commenter recommended that CMS modify the Chole and CDE Payment measure to only include Cholecystectomy procedures without CDE because of the low volume of these procedures in hospitals. The commenter cautioned that inclusion of CDE will diminish the measure’s reliability because hospitals will be accountable for payments on procedures they rarely perform.

Response: We thank the commenter, but believe it is important to incentivize cost efficient care for cholecystectomies whether performed with or without CDE. Reliability calculations on the Chole and CDE Payment measure show...
that a majority of hospitals have at or above moderate reliability (above 0.4) when using a 30-episode case minimum.

We recognize that reliability may be limited for hospitals that perform a small number of procedures; however, we select appropriate case minimums for reporting before these measures are publicly reported on Hospital Compare.

After consideration of the public comment we received, we are finalizing the adoption of the Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment (Chole and CDE Payment) measure to the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(4) Spinal Fusion Clinical Episode-Based Payment (SFusion Payment) Measure

(a) Background

Inpatient hospital stays and associated services assessed by the proposed Spinal Fusion Clinical Episode-Based Payment (SFusion Payment) measure have high payments with substantial variation. In CY 2014, Medicare FFS beneficiaries experienced nearly 60,000 spinal fusion episodes triggered by related inpatient stays. Payment-standardized, risk-adjusted episode payment for these episodes (payment for the hospitalization plus the payment for clinically related services in the episode window) totaled over $2 billion in CY 2014, with a mean episode payment of over $35,000. There is substantial variation in spinal fusion episode payment—ranging from approximately $27,000 at the 5th percentile to approximately $56,000 at the 95th percentile—that is partially driven by variation in postdischarge payment clinically-related to the inpatient hospitalization. These clinically-related postdischarge payments may be an indicator of the quality of care provided during the hospitalization. Specifically, higher quality hospital treatment may yield lower postdischarge payment.

(b) Overview of Measure

The SFusion Payment measure includes the set of medical services related to a hospital admission for a spinal fusion, including treatment, follow-up, and postacute care. The measure includes five clinical subtypes: (1) Anterior Fusion—Single; (2) Anterior Fusion—2 Levels; (3) Posterior/Posterior-Lateral Approach Fusion—Single; (4) Posterior/Posterior-Lateral Approach Fusion—2 or 3 Levels; and (5) Combined Fusions. The clinical subtypes are included in the measure construction to distinguish relatively homogeneous subpopulations of patients whose health conditions significantly influence the form of treatment and the expected outcomes and risks. The risk adjustment model is estimated separately for each clinical subtype, such that the measure compares observed spending for an episode of a given clinical subtype only to expected spending among episodes of that subtype. A similar measure, the Lumbar Spinal Fusion/Refusion Clinical Episode-Based Payment Measure, was proposed for inclusion in the Hospital IQR Program in the FY 2016 IPPS/LTCH PPS proposed rule (80 FR 24570 through 24571). Based on public comments regarding the heterogeneity of the spinal fusion patient population, we decided not to finalize the measure for the Hospital IQR Program at that time (80 FR 49668 through 49674). We have since refined the measure by including more granular subtypes of fusions of the lumbar spine to create more homogenous patient cohorts.

This proposed measure, like the NQF-endorsed MSPB measure (NQF #2158), assesses the payment for services initiated during an episode that spans the period immediately prior to, during, and following a beneficiary’s hospital stay (the “episode window,” discussed in more detail below). In contrast to the MSPB measure, however, this measure includes Medicare payments for services during the episode window only if they are clinically related to the spinal fusion procedure that was performed during the index hospital stay.

(c) Data Sources

The proposed SFusion Payment measure is a claims-based measure. It uses Part A and Part B Medicare administrative claims data from Medicare FFS beneficiaries hospitalized for spinal fusion. The reporting period for the measure is 1 year (that is, the measure calculation includes eligible episodes occurring within a 1-year timeframe). For example, for the FY 2019 payment determination, the reporting period would be CY 2017.

(d) Measure Calculation

The proposed SFusion Payment measure sums the Medicare payment amounts for clinically related Part A and Part B services provided during the episode window and attributes those to the hospital at which the index hospital stay occurred. Medicare payments included in this episode-based measure are standardized and risk-adjusted. Similar to the MSPB measure’s construction, this measure is expressed as a risk-adjusted ratio, which allows for ease of comparison over time, without need to adjust for inflation. The numerator is the Episode Amount, calculated as the average of the ratios of the observed episode payment over the expected episode payment (as predicted in risk adjustment), multiplied by the average observed episode payment level across all providers nationally. The denominator for a provider’s measure is the episode weighted national median of Episode Amounts across all providers. A spinal fusion episode begins 3 days prior to the initial (index) admission and extends 30 days following the discharge from the index hospital stay.

For detailed measure specifications, we refer readers to the clinical episode-based payment measures report entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Repair Procedure, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier4&crid=1228775614447.

(e) Cohort

The proposed SFusion Payment measure cohort includes Medicare FFS beneficiaries hospitalized for spinal fusion. Measure exclusions are discussed in more detail in section VIII.A.7.a.(5) of the preamble of this final rule below.

We invited public comment on our proposal to adopt the Spinal Fusion Clinical Episode-Based Payment (SFusion Payment) measure to the Hospital IQR Program measure set for the FY 2019 payment determination and subsequent years as discussed in this section.

Comment: Several commenters supported the proposed inclusion of the SFusion Payment measure, noting the measure aligns with the NQS and can help incentivize improved care coordination between hospitals and postacute providers since the cost for these episodes is largely driven by variation in postacute care utilization. One commenter stated that inclusion of such a measure will provide CMS and providers with the information necessary to narrow the growing variation in payment rates associated with spinal fusion procedures, and bring quality to the forefront in this important field. This commenter also
noted that studies conducted on the
utility of ACTIFUSE (a bone void filler) indicate that surgical adjunct
technologies exist that can help facilitate cost effectiveness while
preserving positive patient outcomes.

Another commenter noted that the
updated version makes the lumbar fusion cohort more homogeneous.

Response: We thank the commenters
for their support.

Comment: One commenter
recommended that CMS only include
subtypes 1, 2 and 3 in the proposed
Spinal Fusion Clinical Episode-Based
Payment Measure, noting that
measuring subtypes 4 and 5 (posterior/
posterior/lateral approach fusion—2 or 3
levels and combined fusions,
respectively) would compromise
validity because those subtypes include
a wide breadth of procedures and
heterogeneous patient population that
would make comparisons potentially unreliable.

Response: We thank the commenter
for the suggestion on the SFusion
Payment measure. We believe that the
Posterior/Posterior-lateral Approach
Fusion—2 or 3 Levels and Combined
Fusions subtypes do not include a wide
breadth of procedures or heterogeneous
populations. To create homogenous
cohorts of patients for which we can
reasonably compare resource use, the
subtypes focus on patients hospitalized
for fusions of the lumbar spine and
elective cases of degenerative disease
and do not include procedures that
might indicate treatment for other
clinical conditions such as trauma,
genital, neoplastic, or infectious
processes. In addition, the measure uses
risk adjustment to account for various
levels of clinical complexity in the
patient population that are beyond the
influence of the attributed provider. The
risk adjustment model aligns with the
NQF-endorsed MSPB measure (NQF
#2158) method as specified in the FY
2012 IPPS/LTCH PPS final rule (76 FR
51624 through 51626).

In response to concerns about
reliability, testing on the SFusion
Payment measure shows that a majority of
hospitals have at or above moderate
reliability (above 0.4) when using a 20-
episode case minimum.

Comment: One commenter expressed
concern that CMS has released the
grouping rules based on ICD–9 codes
whereas implementation will be
evaluating claims with ICD–10 codes for
specific items included in the Spinal
Fusion Grouping Rules.

Response: We thank the commenter
for its concern regarding the ICD–10
transition. We plan to update the
measure for ICD–10-CM/PCS diagnosis
and procedure codes prior to
implementation of the measures.

Comment: A few commenters
specifically did not support the
proposal to include the SFusion
Payment measure. One commenter
stated that the measure does not account
for the patient’s diagnosis and does not
appear to account for other important
patient complexity variables such as
SDS factors, obesity, tobacco use, and
population health variables. This
commenter noted that these factors are
outside of the provider’s control, add to
the complexity of the case, and clearly
impact patient outcomes and therefore
should be accounted for within the risk
adjustment of the measure.

Response: We thank the commenters
for their input and note that the measure
does account for the patient’s procedure
diagnosis to limit the cohort of
patients to those with high frequency
elective cases of degenerative disease.

To create homogenous patient cohorts,
MS–DRGs indicating spinal fusions
performed with the detailed clinical
conditions such as malignancy or
infection were not included in the list
of episode triggers. Of note, risk
adjustment methodology also
incorporates diagnostic information and
is discussed further below. Furthermore,
in developing the episodes, we
separated more complex cases (multi-
level fusions) from less complex cases
(single-level fusions) into clinical
subtypes. We also separated anterior,
posterior, and combined approach
fusions and limited our number of
levels involved in fusion. These
characteristics were related to the
indication for the fusion, and were a
reasonable way to infer more diagnostic
information. We removed procedures
and DRGs that were mostly used in
trauma, congenital, neoplastic, or
infectious cases, and concentrated on
cases that mostly occurred with
degenerative disease.

In response to the comments about
risk adjusting for SDS factors, we refer
readers to section VIII.A.6.a(1) in the
preamble of this final rule where we
respond to similar comments.

In regard to the concern about not
including population health variables,
these measures rely on Medicare
administrative data and therefore are
limited to variables found in this data
source. Codes for obesity and tobacco
are also not included in the risk
adjustment model, as the clinical
experts who specified the measure
determined that these codes were
unlikely to be uniformly coded on
Medicare claims. We refer readers to the
other risk adjustment variables
adequately adjust for patient case mix
by accounting for Hierarchical
Condition Categories (HCCs), clinical
case mix categories, and prior inpatient
and ICU length of stay. The measure’s
risk adjustment methodology does
account for a range of diagnoses
reflecting comorbidities that could
impact spinal fusion episode spending,
including diabetes and other organ
system disease. We refer readers to the
measure’s risk adjustment methodology
available at: https://www.qualitynet.org/
docs/ContentServer?c=Page&page=
46116.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

We thank the commenter
for their support.

Response: We thank the commenter
for their support.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

Comment: We thank the commenters
for their support.

Response: We thank the commenters
for their support.

Comment: We thank the commenters
for their support.
soliciting input on ways to refine these measures.

After consideration of the public comments we received, we are finalizing the adoption of the Spinal Fusion Clinical Episode-Based Payment (SFusion Payment) measure to the Hospital IQR Program for the FY 2019 payment determination and subsequent years as proposed.

(5) Exclusion Criteria

For a full list of the MS-DRG, procedure, and diagnosis codes used to identify beneficiaries included in the final cohort for each of the proposed episode-based payment measures, we refer readers to the report entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Procedure, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228775614447.

Episodes for beneficiaries that meet any of the following criteria are excluded from all three measures: (1) Lack of continuous enrollment in Medicare Part A and Part B from 90 days prior to the end of the episode with traditional Medicare fee-for-service as the primary payer; (2) Death date during episode window; or (3) Enrollment in Medicare Advantage anytime from 90 days prior to the episode through the end of the episode.

In addition, claims that meet any of the following criteria do not trigger, or open, an episode for all three measures: (1) Claims with data coding errors, including missing date of birth or death; (2) Claims with standard payment ≤0; (3) Admissions to hospitals that Medicare does not reimburse through the IPPS system (for example, cancer hospitals, critical access hospitals, hospitals in Maryland); or (4) Transfers (by which a transfer is defined as add-on payments that support broader Medicare program goals, such as add-on payments for indirect graduate medical education (IME) and add-ons for serving a disproportionate share of uninsured patients.137

(7) Risk Adjustment

Risk adjustment uses patient claims history to account for case-mix variation and other factors. The steps used to calculate risk-adjusted payments align with the NQF-endorsed MSPB measure (NQF #2158) method as specified in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51624 through 51626). For more details on the specifications for the risk adjustment employed in the proposed episode-based payment measures, we refer readers to the report entitled, “Measure Specifications: Hospital Clinical Episode-Based Payment Measures for Aortic Aneurysm Procedure, Cholecystectomy and Common Duct Exploration, and Spinal Fusion” available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier4&cid=1228775614447.

We did not receive any comments regarding the exclusion criteria for the three clinical episode-based payment measures. We refer readers to our discussions above, where we finalize the three clinical episode-based payment measures as proposed.

b. Adoption of Excess Days in Acute Care After Hospitalization for Pneumonia (PN Excess Days) Measure

(1) Background

Pneumonia is a priority area for outcomes measurement because it is a common condition associated with considerable morbidity, mortality, and healthcare spending. Pneumonia was the third most common principal discharge diagnosis among patients with Medicare in 2011.138 Pneumonia also accounts for a large fraction of hospitalization costs, and it was the seventh most expensive condition billed to Medicare, accounting for 3.7 percent of the total national costs for all Medicare hospitalizations in 2011.139

Some of the costs for pneumonia can be attributed to high acute care utilization for postdischarge pneumonia patients in the form of readmissions, observation stays, and emergency department (ED) visits. Patients admitted for pneumonia have disproportionately high readmission rates, and that readmission rates following discharge for pneumonia are highly variable across hospitals in the United States.140 141

For the previously adopted Hospital IQR Program measure, Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) following Pneumonia Hospitalization (NQF #0506) (hereinafter referred to as READM–30–PN) (80 FR 49654 through 49660), publicly report 30-day risk-standardized readmission rates for pneumonia ranged from 12.9 percent to 24.8 percent for the time period between July 2012 and June 2015.142 However, during the postdischarge period, patients are not only at risk of requiring readmission. ED visits represent a significant proportion of postdischarge acute care utilization. Two recent studies conducted in patients of all ages have shown that 9.5 percent of patients return to the ED within 30 days of hospital discharge and approximately 12 percent of these patients are discharged from the ED, and thus are not captured by the READM–30–PN Measure.143 144

144 Vashi AA, Fox JP, Carr BG, et al.: Use of hospital-based acute care among patients recently...
In addition, over the past decade, the use of observation stays has rapidly increased. Specifically, between 2001 and 2008, the use of observation services increased nearly three-fold, and significant variation has been demonstrated in the use of observation services. Thus, in the context of the previously adopted and publicly reported READM–30–PN measure, the increasing use of ED visits and observation stays has raised concerns that the READM–30–PN measure does not capture the full range of unplanned acute care in the postdischarge period. In particular, some policymakers and stakeholders have expressed concern that high use of observation stays in some cases could replace readmissions, and hospitals with high rates of observation stays in the postdischarge period may therefore have low readmission rates that do not more fully reflect the quality of care.

In response to these concerns, we improved on a previously developed measure, which is not currently part of the Hospital IQR Program measure set, titled “30-Day Post-Hospital Pneumonia Discharge Care Transition Composite” (NQF ID 1707—NQF endorsement removed). The improved measure entitled Excess Days in Acute Care after Hospitalization for Pneumonia (PN Excess Days) is a risk-adjusted outcome measure for pneumonia that incorporates the full range of acute care use that patients may experience postdischarge: hospital readmissions, observation stays, and ED visits. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25190 through 25192), we proposed this PN Excess Days measure for inclusion in the Hospital IQR Program for the FY 2019 payment determination and subsequent years.

The proposed PN Excess Days measure assesses all-cause acute care utilization for postdischarge pneumonia patients for several reasons. First, from the patient perspective, acute care utilization for any cause is undesirable. It is costly, exposes patients to additional risks of medical care, interferes with work and family care, and imposes significant burden on caregivers. Second, limiting the measure to inpatient utilization may make it susceptible to gaming. Finally, this measure includes all-cause acute care utilization because it is often hard to exclude quality concerns and accountability based on the documented cause of a hospital visit.

Although the original measure was NQF-endorsed, this improved measure has not yet been NQF-endorsed. Section 1886(b)(3)(B)(IX)(bb) of the Act provides that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. While we considered other existing measures related to care transitions and postdischarge acute care utilization that have been endorsed by NQF or other consensus organizations, we were unable to identify any NQF-endorsed (or other consensus organization endorsed) measures that assess the full range of postdischarge acute care use that patients may experience. Existing process measures capture many important domains of care transitions such as education, medication reconciliation, and follow-up, but all require chart review and manual abstraction. Existing outcome measures are focused entirely on readmissions or complications and do not include observation stays or ED visits. We are not aware of any other measures that assess the quality of transitional care by measuring 30-day risk-standardized days in acute care (hospital readmissions, observation stays, and ED visits) following hospitalization for pneumonia that have been endorsed or adopted by a consensus organization, and we have not found any other feasible and practical measures on this topic. However, we note that this measure has been submitted to NQF for endorsement proceedings as part of the All-Cause Admissions and Readmissions project in January 2016.

2 Overview of Measure

The proposed PN Excess Days measure is a risk-standardized outcome measure that compares the number of days that patients, discharged from a hospital for pneumonia, are predicted to spend in acute care across the full spectrum of possible events (hospital readmissions, observation stays, and ED visits) to the days that patients are expected to spend based on their degree of illness as defined using principal diagnosis and comorbidity data from administrative claims.

3 Data Sources

The proposed PN Excess Days measure is claims-based. It uses Part A and Part B Medicare administrative

146 Spreadsheet of MAP 2016 Final Recommendations Available at: http://www.qualityforum.org/map/.
claims data from Medicare FFS beneficiaries hospitalized for pneumonia. To determine eligibility for inclusion in the measure, we also use Medicare enrollment data. As proposed, the measure would use 3 years of data. For example, for the FY 2019 payment determination, the reporting period would be July 2014 through June 2017.

(4) Outcome

The outcome of the proposed PN Excess Days measure is the excess number of days patients spend in acute care (hospital readmissions, observation stays, and ED visits) per 100 discharges during the first 30 days after discharge from the hospital, relative to the number spent by the same patients discharged from an average hospital. The measure defines days in acute care as days spent: (1) In an ED; (2) admitted to observation status; or (3) admitted as an unplanned readmission for any cause within 30 days from the date of discharge from the index pneumonia hospitalization. Readmission days are calculated as the discharge date minus the admission date. Admissions that extend beyond the 30-day follow-up period are truncated on day 30. Observation days are calculated by the hours in observation, rounded up to the nearest half day. Based on the recommendation of our TEP convened as part of developing this measure, an ED treat-and-release visit is counted as one half day. ED visits are not counted as a full day because the majority of treat-and-release visits last fewer than 12 hours.

“Planned” readmissions are those planned by providers for anticipated medical treatment or procedures that must be provided in the inpatient setting. This measure excludes planned readmissions using the planned readmission algorithm previously developed for the READM–30–PN measure (78 FR 50786 through 50787). The planned readmission algorithm is a set of criteria for classifying admissions as planned among the general Medicare population using Medicare administrative claims data. The algorithm identifies admissions that are typically planned and may occur within 30 days of discharge from the hospital. The planned readmission algorithm has three fundamental principles: (1) A few specific, limited types of care are always considered planned (transplant surgery, maintenance chemotherapy/immunotherapy, rehabilitation); (2) otherwise, a planned readmission is defined as a non-acute readmission for a scheduled procedure; and (3) admissions for complications of care are never planned. A more detailed discussion of exclusions follows in section VIII.A.7.b.(6) of the preamble of this final rule.

The measure counts all use of acute care occurring in the 30-day postdischarge period. For example, if a patient returns to the ED three times, the measure counts each ED visit as a half-day. Similarly, if a patient has two hospitalizations within 30 days, the days spent in each are counted. We take this approach to capture the full patient experience of need for acute care in the postdischarge period.

(5) Cohort

We defined the eligible cohort using the same criteria as the previously adopted Hospital IQR Program measure, READM–30–PN (80 FR 49654 through 49660). The READM–30–PN cohort criteria are included in a report posted on our Measure Methodology Web page, under the “Downloads” section in the “AMI, HF, PN, COPD, and Stroke Readmission Updates” zip file on our Web site: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. The measure cohort is also defined using the previously adopted Hospital IQR Program measure, the MORT–30–PN measure (80 FR 49837), and the newly adopted refined cohort for the PN Payment measure discussed in section VIII.A.6.a. of the preamble of this final rule.

For the ICD–9–CM and ICD–10–CM codes that define the measure development cohort, we refer readers to the “Excess Days in Acute Care after Hospitalization for Pneumonia Version 1.0” in the Pneumonia Excess Days in Acute Care zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

(6) Exclusion Criteria

The proposed PN Excess Days measure excludes the following admissions from the measure cohort: (1) Hospitalizations without at least 30 days of postdischarge enrollment in Part A and Part B FFS Medicare, because the 30-day outcome cannot be assessed in this group since claims data are used to determine whether a patient was readmitted, was placed under observation, or visited the ED; (2) discharged against medical advice, because providers did not have the opportunity to deliver full care and prepare the patient for discharge; and (3) hospitalizations for patients with an index admission within 30 days of a previous index admission, because additional pneumonia admissions within 30 days are part of the outcome, and we choose not to count a single admission both as an index admission and a readmission for another index admission.

(7) Risk-Adjustment

The proposed PN Excess Days measure adjusts for variables that are clinically relevant and have strong relationships with the outcome. The measure seeks to adjust for case-mix differences among hospitals based on the clinical status of the patient at the time of the index admission. Accordingly, only comorbidities that convey information about the patient at that time or in the 12 months prior, and not complications that arise during the course of the index hospitalization, are included in the risk adjustment. The measure does not adjust for patients’ admission source or their discharge disposition (for example, skilled nursing facility) because these factors are associated with the structure of the healthcare system, not solely patients’ clinical comorbidities. Patients’ admission source and discharge disposition may be influenced by regional differences in the availability of postacute care providers and practice patterns. These regional differences might exert undue influence on results. In addition, patients’ admission source and discharge disposition are not audited and are not as reliable as diagnosis codes. The proposed PN Excess Days measure uses the same risk-adjustment variables as the READM–30–PN measure (73 FR 48614).

The outcome is risk adjusted using a two-part random effects model. This statistical model, often referred to as a “hurdle” model, accounts for the structure of the data (patients clustered within hospitals) and the observed distribution of the outcome.
Specifically, it models the number of acute care days for each patient as: (1) A probability that they have a non-zero number of days; and (2) a number of days, given that this number is non-zero. The first part is specified as a logit model, and the second part is specified as a Poisson model, with both parts having the same risk-adjustment variables and each part having a random effect. This is an accepted statistical method that explicitly estimates how much of the variation in acute care days is accounted for by patient risk factors, how much by the hospital where the patient is treated, and how much is explained by neither. This model is used to calculate the predicted (including random effects) and expected (assuming random effects are zero) number of days for each patient. The average difference between the predicted and expected number of days for each patient for each hospital is used to construct the risk-standardized Excess Days in Acute Care. For more details about risk-adjustment for this proposed measure, we refer readers to the “Pneumonia Excess Days in Acute Care” zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives-Measure-Methodology.html.

(8) Calculating Excess Acute Care Days

The proposed PN Excess Days measure is calculated as the difference between the average of the predicted number of days spent in acute care for patients discharged from each hospital and the average number of days that would have been expected if those patients had been cared for at an average hospital, and then the difference is multiplied by 100 so that the measure result represents PN Excess Days per 100 discharges. We multiply the final measure by 100 to be consistent with the reporting of the previously adopted READM—30—PN measure that is reported as a rate (that is, a 25 percent rate is equivalent to 25 out of 100 discharges) (80 FR 49654 through 49660), as well as the AMI Excess Days (80 FR 49690) and HF Excess Days (80 FR 49685) measures. A positive result indicates that patients spend more days in acute care postdischarge than expected if admitted to an average performing hospital with a similar case mix; a negative result indicates that patients spend fewer days in acute care than expected if admitted to an average performing hospital with a similar case mix. A negative PN Excess Days measure score reflects better quality.

We invite public comment on our proposal to adopt the PN Excess Days measure for the FY 2019 payment determination and subsequent years as described above.

Comment: Several commenters supported the proposed adoption of the PN Excess Days measure. Commenters noted adoption of this measure demonstrates a movement away from the use of clinical process measures and toward outcome measures in quality measurement. Commenters believed that the proposed measure addresses the unintended consequence of shifting patients outside of inpatient care. In addition, one commenter indicated that this measure aligns with the NQS and addresses a condition that is a significant driver of cost for the Medicare program. Lastly, one commenter noted that variation in measure performance resulting in excess days in acute care for pneumonia patients will likely be driven by exacerbation of pneumonia leading to more critical, and potentially preventable conditions, such as sepsis.

Response: We thank the commenters for their support.

Comment: Several commenters did not support the proposed inclusion of the PN Excess Days measure, stating that only measures that have been endorsed by the NQF should be considered for inclusion in the Hospital IQR Program measure set. Commenters encouraged CMS to work collaboratively with stakeholders to ensure that policies allow hospitals to provide the best care for patients in the most appropriate setting as determined by the physician.

Response: As we noted above, section 1886(b)(3)(B)(IX)(bb) of the Act provides that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary. While we considered other existing measures related to care transitions and postdischarge acute care utilization that have been endorsed by NQF or other consensus organizations, we were unable to identify any NQF-endorsed (or other consensus organization endorsed) measures that assess the full range of postdischarge acute care use that patients may experience.

Existing process measures capture many important domains of care transitions such as education, medication reconciliation, and follow-up, but all require chart review and manual abstraction. Existing outcome measures are focused entirely on readmissions or complications and do not include observation stays or ED visits. We are not aware of any other measures that assess the quality of transitional care by measuring 30-day risk-standardized days in acute care (hospital readmissions, observation stays, and ED visits) following hospitalization for pneumonia that have been endorsed or adopted by a consensus organization, and we have not found any other feasible and practical measures on this topic. However, we note that this measure has been submitted to NQF for endorsement proceedings as part of the All-Cause Admissions and Readmissions project in January 2016.

Furthermore, the PN Excess Days measure’s cohort was reviewed by clinical experts and a TEP and was subject to separate public input prior to being proposed for the Hospital IQR Program. This measure was also included on a publicly available document entitled “2015 Measures Under Consideration List” for December 1, 2015 (available at: http://www.qualityforum.org/ProjectMaterials.aspx?projectID=75367) and has been reviewed by the NQF MAP Hospital Workgroup. The measure was conditionally supported pending the examination of SDS factors and NQF review and endorsement of the measure update, as referenced in the MAP 2016 Final Recommendations Report (available at: http://www.qualityforum.org/map/).148 We will continue to work collaboratively with stakeholders in soliciting input on ways to refine this measure in the future.

Comment: Several commenters did not support the inclusion of the proposed measure, noting that the risk-adjustment mechanism does not take SDS factors into consideration.

Response: We refer readers to section VIII.A.6.a.(1) of the preamble of this final rule where we have previously responded to similar comments.

Comment: Some commenters did not support the proposal to adopt the PN Excess Days measure because they believe that the measure addresses outcomes already captured by the current readmission and MSPB measures. One commenter requested more information about how the impact and performance differs from the current readmission measure.

Response: Although the MSPB measure may include similar events, it is...
and does not address the effects of the “2-midnight” policy.

Response: We understand that commenters have concerns about the interaction between Medicare payment policy regarding admissions spanning two midnights and the PN Excess Days measure. The “2-midnight” policy provides guidance as to when an inpatient admission is appropriate for payment under Medicare Part A, but does not help beneficiaries to select providers or to understand postdischarge acute care use. The proposed PN Excess Days measure aims to capture all postdischarge acute care days, regardless of whether they are considered outpatient or inpatient. Therefore, the “2-midnight” policy or any changes to such policy will not influence the outcome of these measures, as all postdischarge days in acute care are captured whether they are billed as outpatient or inpatient days. When we finalized the AMI Excess Days and HF Excess Days measures for the FY 2018 payment determination and subsequent years, stakeholders expressed concern about the interaction between Medicare payment policy regarding admissions spanning two midnights and the AMI Excess Days and HF Excess Days measures (80 FR 49686 through 49687). We continue to believe that the “2-midnight” policy or any changes to such policy will not influence the outcome of Excess Days in Acute Care measures, as all postdischarge days in acute care are captured whether they are billed as inpatient or outpatient days (80 FR 49686 through 49687).

Comment: Several commenters expressed concern that hospitals might be penalized twice for the same readmission, once through the existing readmission measure in Hospital Readmissions Reduction Program and again through the “excess days” measure in Hospital VBP Program (if and when the “excess days” measures are incorporated into the Hospital VBP Program). Response: The Hospital VBP Program cannot adopt this measure, as section 1886(o)(2)(A) of the Act prohibits readmission measures under the Hospital VBP Program. With respect to commenters’ expressed concern that hospitals might be penalized twice for the same readmission, since readmission measures cannot be adopted into the Hospital VBP Program, hospitals cannot be penalized through the existing readmission measure in Hospital Readmissions Reduction Program and through the “excess days” measure for the same condition in Hospital VBP Program. For the Hospital IQR Program, the Excess Days measures are calculated using Medicare administrative claims data, and regardless of hospitals’ performance on the measures, hospitals would receive credit for submitting the information under the Hospital IQR Program. Therefore, we do not believe hospitals would be penalized twice because they are not being asked to submit additional information and payment will not be adjusted based on performance of this measure. The PN Excess Days measure is not being proposed for use in a pay-for-performance program (such as the Hospital VBP Program), only for use in the pay-for-reporting Hospital IQR Program.

Comment: Some commenters had reservations about the interpretability of the measure score and providers’ ability to take meaningful actions that would have an impact on patient outcomes. Response: We disagree that providers do not have the ability to take meaningful actions that would have an impact on patient outcomes as a result of adopting the PN Excess Days measure. The measure spotlights the excess number of days patients spend in acute care (hospital readmissions, observation stays, and ED visits) per 100 discharges during the first 30 days after discharge from the hospital, relative to the number spent by the same patients discharged from an average hospital. We believe the information provided to hospitals through this measure will help inpatient and outpatient providers better understand the trajectory of care for patients that have been discharged from their facility. Specifically, hospitals will be able to assess whether patients discharged from their facility have readmissions, observation stays, and/or ED visits during the first 30 days after discharge from the hospital. Because the measure provides more granular information regarding patient discharge outcomes, this will assist hospitals in developing targeted quality improvement activities aimed at improving transitions of care. We believe that the measure will reduce readmissions, observation stays, and/or ED visits by encouraging hospitals to further invest in interventions to improve hospital care by better assessing the readiness of patients for discharge and facilitating quality transitions to outpatient status.

Comment: Some commenters suggested that CMS provide hospital-specific, confidential reports to hospitals to allow them to undertake quality improvement efforts, without including the measure in the Hospital Readmissions Reduction Program.
IQR Program or publicly reporting measure data.

Response: We disagree that the measure should not be included in the program or publicly reported as this is an important aspect of quality that addresses the NQS and CMS Quality Strategy priority to promote effective communication and coordination of care that should be measured. Hospitals will have the opportunity to review their data via their hospital-specific reports (HSRs) during the preview period before public reporting of this measure.

Comment: Several commenters did not support the proposal to adopt the PN Excess Days measure due to a lack of clear or consistent evidence to suggest hospitals are using observation stays and ED visits to avoid being penalized for readmissions. Commenters also noted that recent research from ASPE suggests that hospitals are not using observation status as a way to avoid triggering a readmission or to decrease readmission rates.

Response: We understand the commenters’ concern regarding the uncertainty of hospitals’ use of observation stays in place of readmissions. The development of this measure was not primarily motivated by a concern that hospitals are using ED visits or observation stays to avoid readmission, but rather to provide a more comprehensive perspective on postdischarge events that are important to patients.

Comment: One commenter noted that the PN Excess Days measure does not account for situations when it may be appropriate for a patient to return to the hospital for care. The commenter stated that there are factors beyond the hospitals’ control that may contribute to higher excess days. A few commenters did not support the adoption of the proposed PN Excess Days measure because the measure combines readmissions, observation stays, and ED visits into a single number of days, but each of these episodes reflect widely different approaches to patient-centered care and cannot be interpreted from a single number. One commenter expressed concern with the decision to equate the costs and intensity in observation and ED care with that of inpatient care when they are treated differently for payment purposes.

Response: We do not dismiss the importance of hospital-level care and support hospitals using the level of care most appropriate for each particular patient is critical. We agree with the commenter that some returns to the acute care setting are necessary. The goal is not to avoid all postdischarge acute care service utilization, but to identify excess use of acute care postdischarge. Acute care utilization after discharge (that is, return to the ED, observation stay, and readmission), for any reason, is disruptive to patients and caregivers, costly to the healthcare system, and puts patients at additional risk of hospital-acquired infections and complications. Although some factors are outside hospitals’ control, when appropriate care transition processes are in place (for example, a patient is discharged to a suitable location, communication occurs between clinicians, medications are correctly reconciled, timely follow-up is arranged), fewer patients return to an acute care setting, whether for an ED visit, observation stay, or hospital readmission during the 30 days postdischarge. Numerous studies have found an association between quality of inpatient or transitional care and early (typically 30-day) readmission rates and ED visits for a wide range of conditions including PN.154

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49688), similar concerns were raised for two related measures, AMI and HF Excess Days, around combining readmissions, observations stays, and ED visits into a single number. We believe from a patient perspective, it is the count of total days that is most meaningful and representative of the disruption, which is why we combine day counts for each type of event and do not separately report rates of each type of event. This day count is also valuable for hospitals, because a hospital with a high number of ED visits may still be able to achieve a low number of total days in acute care by actively coordinating care from the ED and avoiding rehospitalizations. The measure combines these three visit types based on the concept that the rate of each type of event is not as relevant to patients as the total days that they spend in acute care settings. Therefore, the PN Excess Days measure provides a broader perspective on postdischarge events than the current READM–30–PN measure and is intended to incentivize improvements in care transitions from the hospital so that patients are less likely to return to the acute setting.

Regarding the commenter’s concern with the decision to equate the costs and intensity in observation and ED care with that of inpatient care, we agree that all acute care utilization is not equal in its disruption, cost, or risk to patients. In the PN Excess Days measure, the weight of events (such as observation or ED care) is determined by the intensity of care delivered to patients. Prolonged acute care is more costly and worse from a patient perspective than a brief ED visit. That is why we elected to report the PN Excess Days measure as a count of days: Events lasting longer with more cost and disruption (such as readmissions), therefore, naturally weigh more than brief events (such as ED visits) in the overall day count.

Comment: One commenter specifically disagreed with counting ED visits as half days, because the majority of ED visits last much less time than that.

Response: We appreciate the commenter’s concern on considering ED treat-and-release visits as half a day. The average length of stay for a treat-and-release patient from the ED is approximately four hours.155 156 Furthermore, based on this information, we received feedback from the TEP advising that we consider a treat-and-release ED visit to be equivalent to one half day. A shorter length of stay may not capture the full burden on the patient to return to the hospital (for example, travel time and lost work time).

Comment: Some commenters expressed concern that “excess days” do not represent an actionable or meaningful measure of quality for the provider because more complex patients with comorbidities may require more days in an acute care setting.

Response: We disagree with the commenters’ concern that “excess days” do not represent an actionable or meaningful measure of quality for the
provider. We have developed the PN Excess Days measure to try to provide important patient-centered information to providers. The measure supports existing hospital incentives to further invest in interventions and tools to improve hospital care, better respond to individual patient preferences, better assess patient readiness for discharge, and facilitate transitions to outpatient status. Such interventions and tools will reduce the likelihood of patients having any return to the hospital and make it more likely that patients who do return have less severe illnesses which may require fewer days of care.

Comment: Some commenters opposed the addition of the PN Excess Days measure, noting that the measure includes a cohort of patients with multiple risk levels and is not a clear indicator of quality.

Response: We understand that hospitals have complex patients with varying comorbidities. Although the cohort may contain patients with different disease severity, and therefore, different levels of risk, the measure accounts for this range of severity and risk because it is risk-adjusted for 41 factors that are clinically relevant and have strong relationships with the outcome of acute care utilization. Furthermore, the measure is intended to help patients and providers understand variations among hospitals in the days that are spent by patients in acute care settings following a discharge for pneumonia. The cohort for the PN Excess Days measure is aligned with the cohort for the READ–30–PN measure. For more details about the risk-adjustment methodology, we refer readers to the “Excess Days in Acute Care after Hospitalization for Pneumonia Version 1.0” methodology report in the Pneumonia Excess Days in Acute Care zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

The measure’s cohort was reviewed by clinical experts and a TEP and was subject to a separate period for public input that was publicly posted on CMS’ Public Comment Web site for measures under development, prior to being proposed for the Hospital IQR Program. During measure development, public comment is sought via several avenues of communication. These include: (1) Posting the call for public comment to the CMS Measures Management System (MMS) Web site (https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html); (2) sending emails to stakeholders, including via CMS listservs; and (3) conducting outreach through the Electronic Clinical Quality Improvement (eCQI) Resource Center. These stakeholders agreed with harmonizing the cohort and risk-adjustment model of the PN Excess Days measure with those of the READ–30–PN measure. As a result, we believe this is a clinically coherent cohort. As it is our practice, we will continue to monitor how hospital performance may be influenced by hospital type.

Comment: Commenters expressed concern that no link to measure specifications was provided in the proposed rule.

Response: As noted in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25192), for measure specifications, we refer readers to the “Excess Days in Acute Care after Hospitalization for Pneumonia Version 1.0” methodology report in the Pneumonia Excess Days in Acute Care zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html.

After consideration of the public comments we received, we are finalizing the adoption of Excess Days in Acute Care after Hospitalization for Pneumonia (PN Excess Days) measure for the FY 2019 payment determination and subsequent years as proposed.

c. Summary of Previously Adopted and Newly Finalized Hospital IQR Program Measures for the FY 2019 Payment Determination and Subsequent Years

The table below outlines the Hospital IQR Program measure set for the FY 2019 payment determination and subsequent years, and includes both previously adopted measures and measures newly finalized in this final rule. Measures finalized for removal in section VIII.A.3.b. of the preamble of this final rule are not included in this chart.

HOSPITAL IQR PROGRAM MEASURE SET FOR THE FY 2019 PAYMENT DETERMINATION AND SUBSEQUENT YEARS

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTI Tablet-Associated Urinary Tract Infection (CAUTI) Outcome Measure.</td>
<td>0138</td>
</tr>
<tr>
<td>CDI Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure.</td>
<td>1717</td>
</tr>
<tr>
<td>CLABSI Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure.</td>
<td>0139</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI. Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure.</td>
<td>0753</td>
</tr>
<tr>
<td>HCP Influenza Vaccination Coverage Among Healthcare Personnel.</td>
<td>0431</td>
</tr>
<tr>
<td>MRSA Bacteremia Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure.</td>
<td>1716</td>
</tr>
</tbody>
</table>

Chart-abstracted

<table>
<thead>
<tr>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median Time from ED Arrival to ED Departure for Admitted ED Patients.</td>
<td>0495</td>
</tr>
<tr>
<td>Admit Decision Time to ED Departure Time for Admitted Patients.</td>
<td>0497</td>
</tr>
<tr>
<td>Influenza Immunization.</td>
<td>1659</td>
</tr>
<tr>
<td>Elective Delivery</td>
<td>0469</td>
</tr>
<tr>
<td>Severe Sepsis and Septic Shock: Management Bundle (Composite Measure).</td>
<td>0500</td>
</tr>
<tr>
<td>Incidence of Potentially Preventable Venous Thromboembolism.</td>
<td>(∗)</td>
</tr>
</tbody>
</table>


## Hospital IQR Program Measure Set for the FY 2019 Payment Determination and Subsequent Years—Continued

<table>
<thead>
<tr>
<th>Short name</th>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Claims-based Outcome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MORT–30–AMI</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization.</td>
<td>0230</td>
</tr>
<tr>
<td>MORT–30–CABG</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery.</td>
<td>2558</td>
</tr>
<tr>
<td>MORT–30–COPD</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization.</td>
<td>1893</td>
</tr>
<tr>
<td>MORT–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Heart Failure (HF) Hospitalization.</td>
<td>0229</td>
</tr>
<tr>
<td>MORT–30–PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Pneumonia Hospitalization.</td>
<td>0468</td>
</tr>
<tr>
<td>MORT–30–STK</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate Following Acute Ischemic Stroke.</td>
<td>N/A</td>
</tr>
<tr>
<td>READM–30–AMI</td>
<td>Hospital 30-Day All-Cause Risk-Standardized Readmission Rate (RSRR) Following Acute Myocardial Infarction (AMI) Hospitalization.</td>
<td>0505</td>
</tr>
<tr>
<td>READM–30–CABG</td>
<td>Hospital 30-Day All-Cause, Unplanned, Risk-Standardized Readmission Rate (RSRR) Following Coronary Artery Bypass Graft (CABG) Surgery.</td>
<td>2515</td>
</tr>
<tr>
<td>READM–30–COPD</td>
<td>Hospital 30-Day All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Chronic Obstructive Pulmonary Disease (COPD) Hospitalization.</td>
<td>1891</td>
</tr>
<tr>
<td>READM–30–HF</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Heart Failure (HF) Hospitalization.</td>
<td>0330</td>
</tr>
<tr>
<td>READM–30–HWR</td>
<td>Hospital-Wide All-Cause Unplanned Readmission Measure (HWR)</td>
<td>1789</td>
</tr>
<tr>
<td>READM–30–PN</td>
<td>Hospital 30-Day, All-Cause, Risk-Standardized Readmission Rate (RSRR) Following Pneumonia Hospitalization.</td>
<td>0506</td>
</tr>
<tr>
<td>READM–30–STK</td>
<td>30-Day Risk Standardized Readmission Rate Following Stroke Hospitalization</td>
<td>N/A</td>
</tr>
<tr>
<td>READM–30–THA/TKA</td>
<td>Hospital-Level 30-Day, All-Cause Risk-Standardized Readmission Rate (RSRR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA).</td>
<td>1551</td>
</tr>
<tr>
<td>AMI Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Acute Myocardial Infarction.</td>
<td>N/A</td>
</tr>
<tr>
<td>HF Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Heart Failure.</td>
<td>N/A</td>
</tr>
<tr>
<td>PN Excess Days</td>
<td>Excess Days in Acute Care after Hospitalization for Pneumonia.</td>
<td>N/A</td>
</tr>
<tr>
<td>Hip/knee complications</td>
<td>Hospital-Level Risk-Standardized Complication Rate (RSCR) Following Elective Primary Total Hip Arthroplasty (THA) and/or Total Knee Arthroplasty (TKA).</td>
<td>1550</td>
</tr>
<tr>
<td>PSI 04</td>
<td>Death Rate among Surgical Inpatients with Serious Treatable Complications.</td>
<td>0351</td>
</tr>
<tr>
<td>PSI 90</td>
<td>Patient Safety for Selected Indicators Composite Measure, Modified PSI 90 (Updated Title: Patient Safety and Adverse Events Composite).</td>
<td>0531</td>
</tr>
</tbody>
</table>

## Claims-based Payment

<table>
<thead>
<tr>
<th>Measure name</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI Payment</td>
<td></td>
<td>2431</td>
</tr>
<tr>
<td>HF Payment</td>
<td></td>
<td>2436</td>
</tr>
<tr>
<td>PN Payment</td>
<td></td>
<td>2579</td>
</tr>
<tr>
<td>THA/TKA Payment</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>MSPB</td>
<td></td>
<td>2158</td>
</tr>
<tr>
<td>Cellulitis Payment</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>GI Payment</td>
<td></td>
<td>2158</td>
</tr>
<tr>
<td>Kidney/UTI Payment</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>AA Payment</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>Chole and CDE Payment</td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>SFusion Payment</td>
<td></td>
<td>N/A</td>
</tr>
</tbody>
</table>

## Electronic Clinical Quality Measures (eCQMs)

<table>
<thead>
<tr>
<th>Measure name</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI–8a</td>
<td>Primary PCI Received Within 90 Minutes of Hospital Arrival</td>
<td>0163</td>
</tr>
<tr>
<td>CAC–3</td>
<td>Home Management Plan of Care Document Given to Patient/Caregiver</td>
<td>(*)</td>
</tr>
<tr>
<td>ED–1</td>
<td>Median Time from ED Arrival to ED Departure for Admitted ED Patients</td>
<td>0495</td>
</tr>
<tr>
<td>ED–2</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>EHDI–la</td>
<td>Hearing Screening Prior to Hospital Discharge</td>
<td>1354</td>
</tr>
<tr>
<td>PC–01</td>
<td>Elective Delivery</td>
<td>0468</td>
</tr>
<tr>
<td>PC–05</td>
<td>Exclusive Breast Milk Feeding</td>
<td>0480</td>
</tr>
<tr>
<td>STK–02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0435</td>
</tr>
<tr>
<td>STK–03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0436</td>
</tr>
<tr>
<td>STK–05</td>
<td>Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>STK–06</td>
<td>Discharged on Statin Medication</td>
<td>0439</td>
</tr>
<tr>
<td>STK–08</td>
<td>Stroke Education</td>
<td>(*)</td>
</tr>
<tr>
<td>STK–10</td>
<td>Assessed for Rehabilitation</td>
<td>0441</td>
</tr>
<tr>
<td>VTE–1</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0371</td>
</tr>
</tbody>
</table>
### HOSPITAL IQR PROGRAM MEASURE SET FOR THE FY 2019 PAYMENT DETERMINATION AND SUBSEQUENT YEARS—Continued

<table>
<thead>
<tr>
<th>Short name</th>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTE–2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
</tbody>
</table>

**Patient Survey**

| HCAHPS | HCAHPS + 3-Item Care Transition Measure (CTM-3) | 0166, 0228 |

**Structural Measures**

<table>
<thead>
<tr>
<th>Patient Safety Culture</th>
<th>Hospital Survey on Patient Safety Culture</th>
<th>Safe Surgery Checklist Use</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Safe Surgery Checklist</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Measure listed twice, as both chart-abstracted and electronic clinical quality measure.

** Newly finalized measures for the FY 2019 payment determination and for subsequent years.

*** Measure name has been shortened. Please refer to annually updated electronically clinical quality measure specifications on the CMS eCQI Resource Center Page for further information: [https://www.healthit.gov/newsroom/ecqi-resource-center](https://www.healthit.gov/newsroom/ecqi-resource-center).

- NQF endorsement has been removed.

---

8. Changes to Policies on Reporting of eCQMs

For a discussion of our previously finalized eCQMs and policies, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50807 through 50810; 50811 through 50819), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50241 through 50249; 50250 through 50259; and 50273 through 50276), and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49692 through 49698; and 49704 through 49709).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25194 through 25196), we proposed two changes to our policies with respect to eCQMs reporting to require that hospitals: (1) Submit data for an increased number of eCQMs as further detailed below, and (2) report a full year of data. These proposals were made in conjunction with our proposals discussed in section VIII.A.3.b.(3) of the preamble of this final rule to remove 13 eCQMs from the Hospital IQR Program and proposals discussed in sections VIII.A.10.d. and VIII.E.2.b. of the preamble of this final rule to align requirements for the Hospital IQR and the Medicare and Medicaid EHR Incentive Programs.

In addition, we are clarifying that for three measures (ED–1, ED–2, and PC–01), our previously finalized policy that hospitals must submit a full year of chart-abstracted data on a quarterly basis, regardless of whether data also are submitted electronically, continues to apply.

a. Requirement That Hospitals Report on an Increased Number of eCQMs in the Hospital IQR Program Measure Set for the CY 2017 Reporting Period/FY 2019 Payment Determination and Subsequent Years

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49698), we finalized our policy to require hospitals to submit one quarter of data (either Q3 or Q4) for 4 self-selected eCQMs for the CY 2016 reporting period/FY 2018 payment determination by February 28, 2017. Furthermore, in that final rule (80 FR 49694), we signaled our intent to propose increasing the reporting requirement to 16 eCQMs in future rulemaking. In the proposed rule, we proposed to require reporting of a full calendar year of data for all available eCQMs in the Hospital IQR Program measure set for the CY 2017 reporting period/FY 2019 payment determination and subsequent years.

Requiring hospitals to electronically report a greater number of eCQMs furthers our goal of expanding electronic reporting in the Hospital IQR Program, which we believe will improve patient outcomes by providing more robust data to support quality improvement efforts. As stated above, this proposal is made in conjunction with our proposals discussed in section VIII.A.3.b.(3) of the preamble of this final rule to remove 13 eCQMs from the Hospital IQR Program and proposals discussed in sections VIII.A.10.d. and VIII.E.2.b. of the preamble of this final rule to align requirements for the Hospital IQR and the Medicare and Medicaid EHR Incentive Programs. In addition, as discussed in section VIII.A.3.b.(3) of the preamble of this final rule, we believe that removing certain eCQMs for which the chart-abstracted versions have been determined to be “topped-out” will reduce certification burden and implementation hurdles, enabling hospitals to focus efforts on successfully implementing a smaller subset of eCQMs. In the proposed rule, we stated that if our proposals to remove 13 eCQMs in section VIII.A.3.b.(3) of the preamble of the proposed rule were finalized as proposed, hospitals would be required to report on a total 15 eCQMs for the CY 2017 reporting period/FY 2019 payment determination. While the number of required eCQMs would increase as compared to that required for the CY 2016 reporting period/FY 2018 payment determination (that is, from 4 to 15 eCQMs), we believe that a coordinated reduction in the overall number of eCQMs (from 28 to 15 eCQMs) in both the Hospital IQR and Medicare and Medicaid EHR Incentive Programs will reduce certification burden on hospitals and improve the quality of reported data by enabling hospitals to focus on a smaller, more specific subset of eCQMs.

In crafting this proposal, we also considered proposing to require a lesser number of eCQMs—that hospitals submit 8 of the available eCQMs (that is, in other words, 8 of the proposed 15 eCQMs as discussed above) for the CY 2017 reporting period/FY 2019 payment determination. Specifically, hospitals would submit a full calendar year of data on an annual basis for 8 of the available eCQMs whether reporting only for the Hospital IQR Program or if reporting for both the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program for the CY 2017 reporting period/FY 2019 payment determination. Reporting on all eCQMs in the Hospital IQR Program measure set would begin with the CY 2018 reporting period/FY 2020 payment determination and subsequent years.

Ultimately, we chose to propose to require reporting on all the proposed eCQMs for the CY 2017 reporting period/FY 2019 payment determination, because we believe that requiring hospitals to report measures electronically is consistent with our goals to move towards eCQM reporting and to align with the Medicare and
Medicare EHR Incentive Programs. We believe that the FY 2019 payment determination is the appropriate time to require eCQM reporting because hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and Hospital IQR Program (3 years of voluntary reporting and 3 years of reporting as part of a pilot). Based upon data collected by CMS, currently, 95 percent of hospitals attest to successful eCQM reporting under the Medicare and Medicaid EHR Incentive Programs.

We invited public comment on our proposal to require hospitals to report on all eCQMs in the Hospital IQR Program measure set beginning with the CY 2017 reporting period/FY 2019 payment determination.

Comment: A few commenters supported the proposed requirement that hospitals report on all eCQMs in the Hospital IQR Program measure set because: (1) The majority of hospitals have invested in having implemented these eCQMs in the Meaningful Use program and many have now had five years of experience; (2) almost all performance related issues in these measures stem from difficulty aligning data sources, which in turn causes clinical workflow and data mapping as the main problems, but fixing these almost always improves the performance scores; (3) CMS will not use these data for payment adjustments and public reporting, which should give eligible hospitals and CAHs some level of comfort; (4) eligible hospitals and their vendors are unlikely to submit any eCQM data electronically on a volunteer basis; (5) CMS needs to have these data for the type of analysis necessary for improvement; and (6) the proposal aligns with the EHR Incentive Program and continues to tie hospital payment to submission of quality data.

Response: We thank the commenters for their support of our original proposal.

Comment: Many commenters supported the concept of electronic reporting but did not support the proposed requirement that hospitals report on all eCQMs in the Hospital IQR Program measure set beginning with the CY 2017 reporting period because they believed the significant increase in number of required eCQMs with such an aggressive timeline would pose an undue burden on hospitals.

Commenters raised specific issues such as difficulty making required changes to health IT systems, documentation or utilization of EHRs, much more granular detail than is often necessary for clinical care, and workflow process changes in the short period of time between the publication of this final rule and the beginning of the CY 2017 reporting period. Commenters expressed concern about the significant expenditure of resources that additional required eCQM reporting imposes on hospitals in terms of both staff time and finances. Several commenters did not support the proposed requirement that hospitals report on all eCQMs in the Hospital IQR Program because of concerns about general feasibility, accuracy, validity, and reliability of electronically-submitted measures.

Commenters also expressed concern that the rush to implement the changes necessary to satisfy reporting requirements for an additional nine eCQMs by CY 2017 would result in errors and unreliable, inaccurate data submissions. One commenter noted that the dramatic increase in number of required eCQMs over such a short period of time could cause delays in coding the files and therefore, cause delays in submitting the eCQMs by the established deadline. In addition, the proposed timeline fails to allow sufficient time if problems arise with the Quality Reporting Document Architecture Category I (QRDA I) files and/or pre-submission validation efforts. The commenter requested that CMS consider moving the deadline to a more feasible date such as March 31, 2018 or later. Another commenter expressed concern that hospitals currently are struggling with the degree of technical difficulty involved in extracting the measures from their EHRs and noted that hospitals have had limited experience with eCQM submission (the first required transmission of four measures is not until the third or fourth quarter of CY 2016). The commenter urged CMS to reconsider expansion of this requirement until a review of the CY 2016 transmission results has been completed and hospitals have received feedback.

Several commenters suggested that CMS consider amending the proposal to require an addition of 2 to 4 eCQMs required for a total of 6 to 8, for the CY 2017 reporting period. One commenter recommended that CMS reduce the proposed requirement to report on 8 eCQMs. Other commenters requested that CMS retain the current requirement of 4 eCQMs until hospitals have successfully operationalized reporting complete and accurate data on existing required eCQMs before adding new measures.

Response: We appreciate commenters sharing their concerns about the challenges associated with eCQM reporting, including the significant expenditure of resources required to make necessary changes to health IT systems, documentation or utilization of EHRs, and workflow process changes and acknowledge commenters’ feedback that many hospitals may not be ready to successfully report on all of the available eCQMs beginning with the CY 2017 reporting period/FY 2019 payment determination. In response to commenter concerns that the proposed timeline fails to allow sufficient time if problems arise with the QRDA I files and/or pre-submission validation efforts, that we should push back the deadline, and that hospitals have had limited experience with eCQM submission, we disagree. Hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and Hospital IQR Program (3 years of voluntary reporting and 3 years of reporting as part of a pilot).

More specifically, previously we have requested electronic QRDA I submission. As described in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50905), electronic reporting pilots for the EHR Incentive Program from 2012 and 2013 included electronic reporting using the QRDA I file format. Further, in that same rule, we encouraged the use of QRDA I files since we finalized a proposal that would allow hospitals to begin voluntarily reporting eCQMs (78 FR 50817 through 50818). Therefore, we believe that hospitals have had adequate time to understand and correct any processing issues that may arise during data submission and we believe that the CY 2017 reporting period/FY 2019 payment determination is the appropriate time to require additional eCQM reporting. Delaying the implementation of electronic reporting would hinder our efforts to validate, and thereby improve the reliability and validity of electronic data.

We believe that increasing the requirements for hospitals to report measures electronically is consistent with our goal to make progress towards eventual reporting on all eCQMs in the Hospital IQR Program, but we also appreciate commenters’ feedback to continue to do so in a stepwise manner. We believe that retaining the reporting requirements previously established for the CY 2016 reporting period/FY 2018 payment determination (that is, require reporting on 4 eCQMs) would not help in this improvement approach.

We believe that increasing the number of required eCQMs to be reported from 4, as currently required, but requiring a lesser number of eCQMs than originally proposed (that is, all available eCQMs)
would continue to allow hospitals flexibility and choice in reporting eCQMs, while still furthering our goal of moving towards full implementation of reporting on all eCQMs in a stepwise manner while being responsive to hospitals’ concerns about timing, readiness, and burden associated with the increased number of measures required to be reported. However, we note that it is still our intent to require reporting on all eCQMs in the Hospital IQR Program in the near future. We believe that reducing the required number of eCQMs from all, as proposed, to 8 for the CY 2017 and CY 2018 reporting periods balances hospitals’ request to have more time to improve and refine their eCQM reporting capabilities, including to address challenges such as data mapping issues, while still furthering CMS’ goals to expand electronic data reporting and validation.

In determining the number 8, we considered that reporting of 8 eCQMs is about midway between the current required reporting of 4 eCQMs and the proposed required reporting of all 15 eCQMs. We note that hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program (3 prior years of pilot reporting and 3 prior years of voluntary reporting). In addition, because 95 percent of hospitals currently attest to successful eCQM reporting under the EHR Incentive Program, we believe that the majority of hospitals should be ready to successfully report on more than 4 eCQMs beginning with the CY 2017 reporting period/FY 2019 payment determination. We believe that only requiring 6 eCQMs (only 2 more than already required) as suggested by some commenters, does not adequately advance our goal of moving toward requiring all eCQMs in the near future. We must balance the importance of keeping pace with evolving electronic standards and the timing cycle for the regulatory adoption of standards when adopting policies for the Hospital IQR Program.

As described in section VIII.A.11.b.(3) of the preamble of this final rule, we intend to address concerns about the reliability of electronic data through validation. In order to be able to effectively validate eCQM data, we need to continuously assess more data. Moreover, we believe that it is appropriate to require reporting and validation of eCQMs given that measures available now and those being developed for the future are increasingly based on electronic standards (80 FR 49696). Lastly, requiring 8 eCQMs promotes alignment between the Hospital IQR Program measure set and the Medicare and Medicaid EHR Incentive Programs.

Therefore, after consideration of the public comments we received, we are finalizing a modified version of our proposal. Instead of requiring hospitals to report on all eCQMs in the Hospital IQR Program measure set beginning with the CY 2017 reporting period/FY 2019 payment determination, we are finalizing a policy to require submission of 8 self-selected eCQMs out of the available eCQMs in the Hospital IQR Program for the CY 2017 reporting period/FY 2019 payment determination and CY 2018 reporting period/FY 2020 payment determination. In other words, hospitals would submit a full calendar year (that is, 4 quarters) of data by an annual submission deadline for 8 of the available eCQMs whether reporting only for the Hospital IQR Program or if reporting for both the Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs for both the FY 2019 and 2020 payment determinations. We intend to determine requirements for beyond the FY 2020 payment determination in future rulemaking.

Although we are not finalizing our original proposal to require reporting on all eCQMs, we encourage hospitals to continue refining their electronic reporting implementation activities to successfully achieve electronic data capture and reporting despite mapping and integration issues or to work with their vendors to do so. In addition, we encourage early testing and the use of presubmission testing tools to reduce errors and inaccurate data submissions in eCQM reporting. As time passes, we expect that hospitals will continue to build and refine their EHR systems and gain more familiarity with reporting eCQM data, resulting in more accurate data submissions with fewer errors. We believe that the best way to encourage hospitals to invest in improving their EHR systems is by requiring reporting of additional eCQMs.

Comment: Some commenters recommended that CMS increase its education and outreach efforts to help hospitals better prepare for eCQM reporting. Other commenters recommended that CMS continue outreach to EHR vendors, hospital quality staff, and other affected stakeholders to identify and address structural problems prior to increasing the number of required eCQMs. Further, one commenter suggested that CMS take into consideration the factors associated with difficulties in eCQM reporting, such as new software, changes to workflows, training staff, and testing, that may require additional time to vet as a means of ensuring hospital readiness.

Response: As we move forward with advancing electronic submission of quality measures and eCQM validation, we will bolster our education and outreach efforts and ensure that all affected stakeholders have the opportunity to provide feedback on the implementation of eCQM reporting. We will continue to share these results in education and outreach to hospitals. We will also consider the issues associated with new software, workflow changes, training, et cetera as we continue to improve our education and outreach efforts for eCQM submission and validation.

Comment: A few commenters did not support required reporting of any eCQMs in the Hospital IQR Program measure set because of challenges associated with eCQM reporting. Some commenters noted that the infrastructure and reporting functionality for eCQMs are not mature enough to facilitate mandatory electronic reporting for hospitals. Other commenters indicated that EHR vendors are not prepared for the functional and operational demands of an increase in eCQM reporting. A few commenters urged CMS to reach out to EHR vendors and other stakeholders to identify underlying structural problems and barriers to successful reporting on these measures. One commenter stated that the increase in required eCQMs may jeopardize hospitals’ efforts to meet the current requirements, as vendors are not prepared to handle providers’ requests to augment their eCQMs on an annual basis. Further, this commenter urged CMS to align vendors and providers requiring vendors to support all eCQMs in certified EHR products that are required by CMS. A few commenters expressed concern about the role of the EHR vendors, not the hospitals, in using the correct version of specifications. Another commenter expressed the opinion that although eCQMs are supposed to reduce provider burden for quality reporting, in reality they increase provider burden by disrupting workflow and requiring providers to document detailed information in structured fields which may not appropriately reflect the clinical situation, while negatively impacting the quality of the data being reported. The commenter urged CMS to set standards for EHR vendors to ensure the EHR is structured in a way that fits in with the clinical work flow to restore focus to patient-centered care that
promotes high quality outcomes and lower costs. One commenter also noted that the eCQM specifications have serious flaws that prove challenging with current clinical workflows, given how EHRs track orders and documentation and in some cases the measure specifications do not accurately measure the quality of care delivered, absent the development of manual workarounds that divert time and resources from patient care. These commenters recommended delaying any mandatory reporting of eCQMs until these concerns are resolved.

Response: We thank the commenters for their recommendations but note that we believe requiring electronic reporting aligns with CMS and HHS policy goals to promote quality through performance measurement and that in the intermediate- to long-term, electronic reporting will both improve the accuracy of the data and reduce reporting burden for providers. Our focus is to improve hospital quality. However, we encourage hospitals that retain vendors to work closely together to ensure that a contract is in place which supports the hospital’s quality reporting requirements and the annual update of quality measures. We believe that vendor retention would help to alleviate some of the concerns associated with the infrastructure and reporting functionality for eCQMs as expressed by some commenters.

When hospitals work with their vendors to ensure that EHRs are appropriately structured in a way that fits in with the clinical work flow to yield reliable data through eCQMs, we believe that eCQMs promote high quality outcomes and lower costs while ultimately decreasing reporting burden on hospitals.

In response to commenters’ concerns that EHR vendors are not prepared for the functional and operational demands of an increase in eCQM reporting, we note that hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program (3 years of pilot reporting and 3 years of voluntary reporting). As stated previously, 95 percent of hospitals attest to successful electronic clinical reporting under the Medicare EHR Incentive program. We thank commenters for their suggestion to reach out to EHR vendors and other stakeholders to identify underlying structural problems and barriers to successful reporting on these measures, and we will continue to work with stakeholders to overcome barriers to successful eCQM reporting.

We appreciate the commenter’s concern that an increase in required eCQMs may jeopardize hospitals’ efforts to meet the current requirements, as vendors are not prepared to handle providers’ requests to augment their eCQMs on an annual basis, but we believe that our finalized policy requiring a lesser number of eCQMs than originally proposed (that is, all available eCQMs) provides hospitals with sufficient time to augment their eCQMs and satisfy electronic reporting requirements. We will take the commenter’s note about the alignment of vendors and their concern about the role of the EHR vendors, not the hospitals, in using the correct version of specifications, into account as we work to improve our education and outreach efforts.

In response to concerns about the burden and difficulty with technical mapping, we recognize that technical mapping may initially be burdensome for some hospitals, however, we believe that the efforts to properly map data elements to structured data fields will be beneficial in both improved accuracy of the data reported and reduced reporting burden in the intermediate- to long-term. In addition, we believe that if hospitals and EHR vendors and health IT developers continue to refine EHR systems to appropriately structure them commensurate with the clinical work flow, this will lead to improved accuracy, reliability, and completeness of the eCQM data, which will promote high quality outcomes and lower costs while ultimately decreasing reporting burden on hospitals as compared with chart-abstraction of quality measure data.

Finally, we refer readers to our modified final policy to only require 8 eCQMs as discussed above. We believe this policy balances the burden on hospitals and vendors with our policy goal to move towards increased electronic reporting. In addition, as we describe in section VIII.A.11.b.(3) of the preamble of this final rule, we are modifying our validation process to include electronic clinical quality measures. The implementation of eCQM data validation will be able to better reconcile the observed measure specification issues.

Comment: A few commenters expressed concern that requiring reporting on all available eCQMs would require facilities to provide data for measures that reflect services they do not provide. Commenters acknowledged the “zero denominator” reporting option, but maintained that reporting a zero denominator would still place undue burden on facilities. One commenter stated that the increase in reporting would force facilities to implement new builds, new workflows, and could potentially have to do substantial rework with the Clinical Quality Language (CQL) implementation for measures not previously reported. A few commenters asked for clarification about whether they would be required to submit eCQM data for PC–05 and CAC–3 since they have not previously submitted data on these measures.

One commenter requested that CMS increase the minimum case exemption threshold for eCQMs because it is difficult to implement eCQMs when there are low benefits to the hospital due to small patient populations. Another commenter expressed the opinion that reporting on an increased number of eCQMs has no direct correlation to improvement in quality because there are instances where a facility would be required to report on an eCQM that refers to care that is not provided at that hospital. Some commenters suggested that reporting for all of the available eCQMs should not be mandatory and that hospitals should be allowed to select which specific eCQMs to report on to ensure the information captured would prove meaningful.

Response: We acknowledge the commenters’ concern with small patient populations and will explore the minimum case exemption threshold for eCQMs as we continue to evolve our electronic reporting requirements in future rulemaking. We currently allow hospitals to enter a value of zero to demonstrate that they had no clinical cases. We refer readers to the FY 2015 IPPS/LTCIPPS final rule (79 FR 50323 through 50324) where we discuss the details of our requirements for the minimum exemption threshold. As previously stated in the FY 2016 IPPS/ LTCIPPS final rule (80 FR 49695), for the CY 2017 reporting period/FY 2019 payment determination and CY 2018 reporting period/FY 2020 payment determination, utilization of the zero denominator declaration and case threshold exemptions are considered as part of the criteria for successful submissions when reporting eCQMs for the to the Hospital IQR and Medicare and Medicaid EHR Incentive Programs. Therefore, we do not believe any undue...

---

157 Clinical Quality Language (CQL) is an HL7 draft standard that is part of the effort to harmonize standards between electronic clinical quality measures (eCQMs) and clinical decision support (CDS). CQL provides the ability to express computer logic that is human readable yet structured enough for processing a query electronically. More information is available at the eCQI Resource Center at: https://ecqi.healthit.gov/cql.
burden will be placed on hospitals that elect to utilize this declaration, as it is a policy that has been in place for 2 calendar years of reporting. The submission of zero denominator declarations and case threshold exemptions for the CY 2016 reporting period continues to be completed through the QualityNet Secure Portal.

Further, as we learn more through eCQM validation, we intend to publicly report the eCQM data results so that hospitals that do not provide care for certain populations will be able to benchmark (evaluate by comparison with results provided by hospitals that do provide care for those populations) data. We understand the importance of having accurate measure data, however, the only way to readily identify issues is to review more data. We believe that our finalized policy to require submission of only 8 eCQMs serves to incrementally increase electronic reporting, as suggested by commenters, while also allowing us to collect data derived from EHRs to further our plans for electronic data collection and validation. In addition, the finalized policy to require submission of 8 eCQMs allows hospitals the flexibility to select the eCQMs that are least burdensome and do not require new builds, new workflows, or rework with the CQL implementation for measures not previously reported.

Implementation of any new measure not previously reported will impose some additional burden, but our finalized policy enables hospitals to choose and prioritize which eCQMs to build into their systems in the order most convenient for their particular circumstances and case mix. Moreover, allowing hospitals to select 8 eCQMs addresses the commenter’s concern that reporting on an increased number of eCQMs has no direct correlation to improvement in quality because there would not be instances where a facility would be required to report on an eCQM that refers to care that is not provided at that hospital; hospitals have the option of reporting those eCQMs that are most relevant to their patient population to ensure that information captured proves meaningful. We refer readers to section VIII.A.8.a of the preamble of this final rule for details about our finalized policy to require submission of only 8 eCQMs.

Comment: Some commenters stated that requiring hospitals to collect electronic data for measures that still have flawed specifications is inefficient and burdensome.

Response: We disagree that specifications are flawed and encourage hospitals to work with vendors to gain experience with the eCQM specifications and how to fully integrate them into their EHRs. We believe that our modified policy to require submission of 8 self-selected eCQMs out of the available eCQMs in the Hospital IQR Program provides hospitals flexibility to select eCQMs for which they have familiarity with the technical specifications and for services they do provide.

Comment: One commenter cited difficulty manipulating the reporting Structured Query Language (SQL), obscure or unnecessary measure data points, the redundancy of the measure data points, and the bottleneck created by the role of EHR vendors and developers in the reporting workflow. Specifically, the commenter stated that modifications of the SQL require the acquisition of professionals with specialized skills in the functionality and utility of CEHRT, a strong working knowledge of programming and an understanding of the eCQM process. The commenter asserted that highly-skilled professionals are expensive to acquire and difficult to retain within hospitals.

Response: In response to the commenter that cited difficulty manipulating the reporting SQL, obscure or unnecessary measure data points, the redundancy of the measure data points, and the bottleneck created by the role of CEHRT vendors in the reporting workflow, we believe that increased reporting would help to mature workflows, and over time, mitigate some, if not all, of these additional concerns. We acknowledge the commenter’s assertion that highly-skilled professionals are expensive to acquire and difficult to retain within hospitals, however, we believe that as more professionals gain knowledge, training, and experience with electronic standards and reporting and fill this need in the labor market, this challenge will be reduced. In addition, we encourage hospitals to work with and retain their vendors to fulfill their EHR system needs. When hospitals work more closely with their vendors to ensure that EHRs are appropriately structured in a way that fits in with the clinical work flow to yield reliable data through eCQMs, we believe that eCQMs promote high quality outcomes and lower costs while ultimately decrease reporting burden on hospitals. We encourage hospitals to be educated about the existing practices, while still retaining the right to establish protocols that most accurately and efficiently support their clinical workflows.

Comment: One commenter stated that the best practice guidelines released by the EHR vendor or developer often require use of EHR functions or physician documentation in a much more granular detail than is often necessary for clinical care.

Response: We disagree that the best practice guidelines released by the CEHRT vendor require physician documentation or utilization of EHR sections in a much more detailed manner than is necessary for clinical care. We believe that detailed documentation of care provided in EHRs will help bolster the clinical care that is offered and will provide information that is invaluable for quality reporting programs to facilitate better patient outcomes.

Comment: One commenter recommended that CMS develop a system or strategy for notification of eCQMs likely to be retired as well as eCQMs that are being considered for addition to the Hospital IQR Program in the next 2 years. Another commenter requested that CMS provide a 2-year lead time prior to eCQM requirements because it takes significant time to implement these measures.

Response: We appreciate the commenter’s recommendation to notify hospitals of eCQMs likely to be retired as well as eCQMs that are being considered for addition to the Hospital IQR Program in the next 2 years. We intend to continue using the rulemaking process with notice and comment period to establish and communicate timelines for implementation, as well as to remove and adopt new measures. In response to commenters’ request for more advance notice as to eCQM reporting requirements, in this final rule we are finalizing a modification from our proposal with requirements for both the CY 2017 reporting period/FY 2019 payment determination and the CY 2018 reporting period/FY 2020 payment determination. We note that in the FY 2016 IPPS/LTCH PPS final rule, we signaled our intent to increase the number of eCQMs required for reporting (80 FR 49693 through 49698) and to remove 13 eCQMs (80 FR 49644 through 49645) in future rulemaking. We also noted in that rule (80 FR 49698 through 49704) that we would consider alternative measure types (hybrid measures) in future rulemaking.

Further, in section VIII.A.9.c of the preamble of this final rule, we discuss future considerations of behavioral health measures, some of which could potentially be developed as eCQMs in the future. We also refer readers to the Hospital OQR Program discussion in the FY 2017 OPPS/ASC PPS proposed rule.
(81 FR 45721) for additional discussion of possible future eCQMs that are under development for the outpatient hospital setting. In addition to using the rulemaking process, we will continue to provide ongoing education and outreach to stakeholders through Special Open Door Forums (information available at: https://www.cms.gov/outreach-and-education/opendoorforums/ODFspecialODF.html) and periodic training sessions. In addition, stakeholders may learn about and provide feedback on newly developed eCQMs during the measure development process, the NQF public comment period, and/or the MAP’s pre-rulemaking public comment period.

Comment: One commenter suggested that AMI–8a not be included among the required eCQMs during the measure development process, the NQF public comment period, and/or the MAP’s pre-rulemaking public comment period.

Response: While we acknowledge that there may be challenges associated with electronic reporting of AMI–8a due to the non-discrete data which could pose collection problems because the values are spread over a range of data points, we do not believe these challenges warrant removal of the measure from the Hospital IQR Program at this time. As stated in section VIII.10.d.(2) of the preamble of this final rule, hospitals may continue to either use abstraction or pull the data from non-certified sources in order to then input these data into CEHRT for capture and reporting.

Comment: One commenter recommended that CMS launch an effort to develop a clinical quality measurement infrastructure necessary to transition federal pay-for-performance programs into utilizing both process improvement measurement and outcomes measurement derived from CEHRT to alleviate the reporting burden associated with collecting data from different parts of the EHR enterprise. Another commenter recommended that CMS include measures for which critical data elements are entered directly into the CEHRT or can be obtained through provider financial systems flowing to the CEHRT to minimize the need for data abstracted from non-certified systems which necessitates double data entry by providers. Further, one commenter believed that redundant structured data points require a duplication of work efforts.

Response: We thank the commenters for their suggestions. As we have previously stated, we believe that reporting measures as eCQMs is valuable and we are working to refine the eCQM measure set in the Hospital IQR and Medicare and Medicaid EHR Incentive Programs, as well as to develop and adopt eCQMs for other quality reporting programs, with the longer-term goal of using eCQMs for value-based purchasing programs. We continuously strive to develop strategies and systems to facilitate fully transitioning to eCQMs across providers and programs in a way that minimizes reporting burdens for hospitals and increases the validity of the data.

Comment: One commenter expressed concern that the proposed list of eCQMs does not allow for comparison with chart-abstracted measures and suggested that there should be greater overlap between eCQMs and chart-abstracted measures. Other commenters expressed concern that eCQM data submission to CMS has not been fully tested at this point and recommended that expanding the required number of eCQMs should be delayed until there has been successful transmission of data. Until EHR standards are better structured to yield reliable data through eCQMs, one commenter urged CMS to defer to chart abstraction so that the clinical team can focus on quality care and the abstractors can abstract and report high quality data without diverting the attention of the clinical team from patient care to documentation and quality reporting.

Response: As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we have received anecdotal comments about performance level differences between chart-abstracted and eCQM data. We do not have sufficient data to be able to confirm or refute the accuracy of those comments (79 FR 50258). In order to substantiate or refute the existence of performance-level differences between eCQM data and chart-abstracted measure data, we believe that we must collect more eCQM data and develop a process for validating the accuracy of that data. We believe that adopting an eCQM validation process in the Hospital IQR Program, as discussed in section VIII.11.b. of the preamble of this final rule and analyzing the results from eCQM data validation, beginning with an analysis of CY 2016 reported data, will allow us to examine concerns about the accuracy of eCQM data so that we may begin publicly reporting eCQM data in future years.

Comment: One commenter requested clarification about when eCQM data will be made publicly available. Several commenters explicitly supported CMS’ decision to continue to not publicly report eCQM data until the data are verified and reliable, noting that one quarter’s worth of data would not provide a statistically valid sample from which to assess a hospital’s performance and that it would be premature to report these data due to challenges associated with reliability and validity. Another commenter specifically recommended that the data collected by eCQMs not be publicly reported on Hospital Compare until electronic reporting improves and benchmarks are freely available.

One commenter made the following recommendations with respect to future public reporting of eCQM data: (1) One year prior to the proposed inclusion year, the eCQM should be announced in the proposed rule for the following year, with the opportunity for public comments; (2) in the first year, data should be reported to CMS to assure validity and plausibility, but not publicly reported; and (3) assuming that year one results are demonstrated to be valid and plausable, the data should be collected and reported publicly in year two and subsequent years. In addition, this commenter recommended that CMS provide additional education about how to interpret the publicly reported data because publicly reported scores can be confusing to consumers.

Response: We thank the commenters for their support. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50815 through 50818), we adopted a policy under which we would only publicly report eCQM data in the Hospital IQR Program if we deem that the data are accurate enough to be publicly reported (78 FR 50816). We believe that our current policy to delay public reporting of eCQM data submitted by hospitals for the CY 2017 reporting period/FY 2019 payment determination in conjunction with the adoption of an eCQM validation process in this final rule is consistent with our stated policy on eCQM public reporting.

We agree with the commenters that suggested we implement a quality process to ensure that eCQMs are accurate, which is why we are finalizing our proposal to examine electronic measures through our validation process and refer readers to section VIII.A.11.b.(3) of the preamble of this final rule for more details. We believe that implementing an eCQM validation process in the Hospital IQR Program and analyzing the results from eCQM data validation, beginning with an analysis of CY 2017 reported data, will allow us to examine concerns about the accuracy of eCQM data so that we may begin publicly reporting eCQM data in the future.
these recommendations into account as we continue to develop and refine our electronic reporting policies.

Comment: One commenter requested clarification on the meaning of “all available eCQMs.” The commenter asked if the term refers to submitting all the 2017 eCQMs in 2017, submitting all the 2017 eCQMs applicable to their patient populations, or only submitting the 2017 eCQMs currently built in their CEHRT systems. The commenter noted that if “all available eCQMs” means all available for 2017 (and not what is available in the current EHR build), hospitals will be required to reengage their vendors to allocate valuable HIT resources currently focused on complying with the new 2016 IPPS electronic submission requirements and timeline.

Response: We define the term “all available eCQMs” to mean all of the eCQMs included in the Hospital IQR Program measure set at the beginning of CY 2017 for the FY 2019 payment determination. We recognize these challenges associated with eCQM reporting and encourage hospitals to continue refining their electronic reporting implementation activities to successfully achieve electronic data capture and reporting despite mapping and integration issues or work with their vendors to do so. However, instead of requiring all available eCQMs as proposed, we are only requiring 8 eCQMs and refer readers to our final policy for eCQMs as discussed above.

Comment: Several commenters expressed concern that hospitals unable to submit eCQMs would be penalized under the Medicare EHR Incentive Program in addition to the Hospital IQR Program. The commenters believed that a provider that is unable to submit eCQMs data should only be penalized under the Medicare EHR Incentive Program and not by both programs.

Response: We disagree that the requirements for electronic reporting in the Hospital IQR Program duplicate penalties. In an effort to align with the Medicare and Medicaid EHR Incentive Programs, we have specified that hospitals meeting electronic reporting requirements for the Hospital IQR Program will be considered to have successfully reported the eCQM requirement to the Medicare and Medicaid EHR Incentive Programs as well. In addition, we note that our data show that 95 percent of hospitals already attest to successful eCQM reporting under the EHR Incentive Program and, accordingly, we believe that the hospitals will be able to successfully report eCQMs, meeting both the Medicare and Medicaid EHR Incentive Programs’ CQM reporting requirements and the Hospital IQR Program requirements. Finally, for hospitals that find they are unable to meet the eCQM submission deadline and meet our criteria for an eCQM-related Extraordinary Circumstances Extension/Exemption (ECE), we note that we are adopting our proposal to extend the deadline for requesting an eCQM-related ECE to April 1 following the end of the reporting calendar year, as discussed in section VIII.A.15.b. of the preamble of this final rule.

Comment: One commenter supported CMS’ efforts to align the Hospital IQR Program with the EHR Incentive Programs but did not support the proposed requirement that hospitals report on all eCQMs in the Hospital IQR Program measure set because providers invest considerable resources to revise and validate the eCQMs and face the following challenges: (1) Consistent with findings of CMS’ eCQM validation pilot, significant discrepancies between manually abstracted measures and eCQMs; (2) eCQM vendor tools are not able to generate accurate measure results because eCQMs were not designed to capture data elements required for eCQM reporting during the course of care requiring clinical staff to enter data in multiple places to ensure the data are available for eCQM reporting; and (3) hospitals with multiple vendor systems across clinical departments have encountered difficulty ensuring these disparate systems are interfacing appropriately with quality measure systems and appropriately mapping data fields in order to generate the required QRDA I files for submission to CMS. The commenter observed that as a result of these challenges, hospitals have not had an opportunity to strategically refine their systems to capture the necessary data elements and conduct the requisite testing. The commenter urged CMS to continue the 2016 reporting requirements in 2017 to give hospitals time to thoughtfully modify their internal processes in concert with their vendors to improve eCQM reporting.

Response: We thank the commenter for this support. As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we have received anecdotal comments about performance level differences between chart-abstracted and eCQM data. We stated that we did not have sufficient data to be able to confirm or refute the accuracy of those comments (79 FR 50258). In order to substantiate the existence of performance-level differences between eCQM data and chart-abstracted measure data, we believe that we must collect more eCQM data and develop a process for validating the accuracy of that data. Further, the 2015 eCQM Validation Pilot did not compare manual chart-abstracted data to eCQM data, rather, the data elements for validation were derived from the hospitals’ EHR. We received many comments that suggested we implement a quality process to ensure that eCQMs are accurate, which is why we are finalizing our proposal to implement an eCQM validation process in section VIII.A.11.b of the preamble of this final rule. We believe analysis of results from eCQM data validation will serve to alleviate concerns about the accuracy of eCQM data so that we may begin publicly reporting eCQM data in future years. We recognize the challenges associated with electronic reporting and encourage hospitals to work with their vendors to achieve electronic capture and reporting despite mapping and integration issues.

As stated above, we believe that the best way to encourage hospitals to invest in improving their EHR systems is by requiring reporting of additional eCQMs. Consequently, we believe that retaining the reporting requirements from FY 2016 would not help in this improvement approach. However, as previously stated, we are modifying our proposal to finalize requirement of 8 eCQMs in direct response to commenters’ suggestions that we incrementally increase the reporting requirements. Lastly, we believe that our finalized proposal to require the submission of only 8 eCQMs for the CY 2017 and CY 2018 reporting periods, which provides an additional full year for refining reporting capabilities on 8 eCQMs, will provide hospitals adequate time to address mapping issues.

Comment: Some commenters questioned whether the proposal to increase the number of required eCQMs for reporting functions to promote better quality care. The commenters expressed the opinion that this proposal seems to drive a particular data collection mechanism, and while they supported the continued use of EHRs to collect meaningful data, they are concerned about the feasibility and accuracy of eCQMs.

Response: While we appreciate the commenter’s concern about whether an increase in the number of eCQMs will promote better quality of care, we believe that if hospitals and EHR vendors continue to refine EHR systems to appropriately structure them commensurate with the clinical work flow, this will lead to improved accuracy, reliability, and completeness

57156 Federal Register / Vol. 81, No. 162 / Monday, August 22, 2016 / Rules and Regulations
of the eCQM data, which will promote higher quality outcomes and lower costs while ultimately decreasing reporting burden on hospitals as compared with chart-abstraction for quality measure data. We note that 2015 is not the first year CMS has requested eCQM data submission. As described in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50905), electronic reporting pilots for the EHR Incentive Program from 2012 and 2013 included eCQM reporting. We understand the importance of having feasible and accurate measure data, however, the only way that we will be able to readily identify issues is to assess more data. We believe that our policy to only require submission of 8 eCQMs serves to incrementally increase electronic reporting, as suggested by commenters, while also allowing us to collect data derived from EHRs to further our plans for electronic data collection and validation. Moreover, we believe that it is appropriate to require reporting and validation of eCQMs because measures available now and those being developed for the future are increasingly based on electronic standards (80 FR 49696).

Comment: A few commenters recommended that CMS maintain the current eCQM reporting requirement and allow hospitals to voluntarily report on additional eCQMs. The commenter stated that this approach would allow more time for the reconciliation and upgrading of the resources necessary (that is, EHRs) to handle additional measure specifications. One commenter suggested requiring a smaller number of eCQMs, specifically, the following six measures: CAC–3—Pediatric Asthma—Home Management Plan of Care Given to Patient/Caregiver; ED–1—Median Time from ED Arrival to ED Departure for Admitted ED Patients; ED–2—Admit Decision time to ED departure Time for Admitted Patients; EHDI–1a—Newborn Hearing Screening Prior to Discharge; PC–01—Early Elective Delivery; PC–05—Exclusive Breastfeeding.

Response: We appreciate the commenters’ recommendation to maintain the current eCQM reporting requirement and allow hospitals to voluntarily report on additional eCQMs, however hospitals have already had 3 years to voluntarily report on eCQMs. As stated above, we believe that mandatory reporting is necessary to advance our policy goal to move facilities towards reporting electronic measures. In response to overwhelming concern about the issues related to the proposal to require reporting on all available eCQMs, we direct the commenter to our finalized policy to require submission of 8 eCQMs, described in section VIII.A.8.a. of the preamble to this final rule. Rather than requiring hospitals to report on particular eCQMs, as suggested by one commenter, we hope that allowing hospitals to self-select 8 eCQMs based upon their own patient mix and consistent with internal quality improvement efforts will increase flexibility and reduce burden.

After consideration of the public comments we received, we are finalizing a modified version of our proposal. Specifically, instead of requiring hospitals to report on all available eCQMs for the CY 2017 reporting period/FY 2019 payment determination and subsequent years as proposed, we are finalizing a policy that hospitals must report on at least 8 self-selected eCQMs from the available eCQMs in the Hospital IQR Program for the CY 2017 reporting period/FY 2019 payment determination and subsequent years as proposed.

b. Requirement That Hospitals Report a Full Year of eCQM Data

In the FY 2016 IPPS/LTCH PPS final rule, we finalized our policy to require hospitals to submit one quarter of data (either Q3 or Q4) for 4 self-selected eCQMs for reporting in the IQR Program for the CY 2016 reporting period/FY 2018 payment determination and the CY 2018 reporting period/FY 2020 payment determination. We intend to propose to increase the number of required eCQMs for reporting in the IQR Program for the CY 2019 reporting period/FY 2021 payment determination and future years through rulemaking.

We sought to proactively address some stakeholder concerns associated with increasing the number of eCQMs for which reporting will be required by aligning data submission deadlines between the Hospital IQR Program and the Medicare EHR Incentive Program to help reduce some reporting burden on hospitals. We note that deadlines for the Medicaid EHR Incentive Program differ by State, and therefore our proposal to align data submission deadlines for eCQMs applies only to the Hospital IQR Program and the Medicare EHR Incentive Program and not to the Medicaid EHR Incentive Program. For more details on Hospital IQR Program reporting requirements and eCQM submission deadlines, we refer readers to section VIII.A.10.d.(5) of the preamble of this final rule.

We invited public comment on our proposal to require hospitals to report a full year of eCQM data.

Comment: Several commenters supported the proposed requirement that hospitals report a full year of eCQM data.

Response: We thank the commenters for their support.

Comment: Many commenters did not support the proposed requirement that hospitals report a full year of eCQM data because of the burden it would impose on hospitals. One commenter indicated that the increase would be four times greater than previous years and would cause increased difficulties for hospitals transitioning to a new EHR system.

Commenters noted that EHR vendors are still struggling to overcome the barriers encountered during the first year of eCQM reporting because the designing, building, reviewing, and testing that takes place between hospitals and vendors is extremely expensive and extensive. A few commenters suggested an incremental approach requiring reporting on only 8 eCQMs for two quarters for the first increase. Several commenters specifically expressed concern that the period of time between when the final rule is published and the beginning of the CY 2017 reporting period is too short to make the appropriate health IT and workflow adjustments to accommodate transmission of a full year of eCQM data.

One commenter noted that requiring hospitals to submit a full year of eCQM data for the CY 2017 reporting period would require hospitals to begin data collection on a full year of data prior to completion of the first deadline to report only one quarter of data which is February 28, 2017.

Another commenter acknowledged that once an eCQM is in place, it can continue to gather data beyond implementation, but expressed concern that the ability of EHR vendors and health care providers to have all 15 eCQMs in place by January 1, 2017 is unreasonable. The commenter suggested that CMS continue the current reporting
period of one of the two final quarters of the reporting year.

**Response:** We appreciate the commenters’ concerns that reporting a full year of eCQM data may impose a greater burden on hospitals than reporting one quarter of eCQM data, but in response to the commenter’s concern that the increase would be four times greater than previous years and would cause increased difficulties for hospitals transitioning to a new EHR system, we disagree. We believe that the burden associated with submitting a full year of eCQM data will not be substantially greater than the burden associated with transmission of a single quarter of data. As described in section VII.A.10.d of the preamble of this final rule, the CMS data receiving system requires that each QRDA I file include data for one patient, per quarter, per reporting CCN. Whether hospitals and vendors are transitioning to a new EHR or utilizing an established system, this reinforces the importance of reporting eCQMs from a properly certified and successfully mapped system. Once hospitals establish their protocols to ensure this is maintained, hospitals and vendors should not experience much added burden reporting an additional 3 quarters of data. The CMS data receiving system will re-open late spring 2017 to receive test QRDA I files and production QRDA I files for the CY 2017 reporting period eCQM data submissions. Providing this option allows hospitals and vendors greater flexibility to submit QRDA I files on a quarterly, semi-annual, or annual basis rather than waiting to submit all QRDA I files during the last two months of the submission period.

We encourage all hospitals to submit files early, as well as to use one of the available presubmission testing tools for electronic reporting—such as the CMS Pre-submission Validation Application (PSVA), which can be downloaded from the Secure File Transfer (SFT) section of the QualityNet Secure Portal at: https://cportal.qualitynet.org/QNet/pgm_select.jsp. We refer readers to section VII.A.10.b.(3) of the preamble of this of this final rule for more information about the PSVA.

In response to the commenter’s concern that EHR vendors are still struggling to overcome the barriers encountered during the first year of eCQM reporting because the designing, building, reviewing, and testing that takes place between hospitals and vendors is extremely expensive and extensive, we acknowledge the time, effort, and resources that hospitals expend building these measures. However, we disagree with commenters’ suggestion to take an incremental approach requiring reporting on only 8 eCQMs for two quarters for the first increase. Although reporting a full year of eCQM data for the CY 2017 reporting period would require hospitals to begin data collection on a full year of data prior to completion of the first deadline to report only one quarter of data which is February 28, 2017, we believe that hospitals have had adequate time to prepare. We disagree that the period of time between when the final rule is published and the beginning of the CY 2017 reporting period is too short to make the appropriate health IT and workflow adjustments to accommodate transmission of a full year of eCQM data. We believe that the FY 2019 payment determination is the appropriate time to require reporting of a full year of eCQM data because hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and Hospital IQR Program (3 years of voluntary reporting and 3 years of reporting as part of a pilot). In addition, we believe that our finalized policy requiring a lesser number of eCQMs than originally proposed (that is, 8 eCQMs instead of all available eCQMs) provides hospitals with sufficient time to augment their eCQMs and satisfy electronic reporting requirements. We believe this policy will also lessen burden on hospitals.

**Comment:** Some commenters expressed concern that the increase in the volume of information being reported might increase susceptibility to inaccurate data. A few commenters did not support the proposed requirement that hospitals report a full year of eCQM data because they believed the proposal is premature due to hospitals’ inability to ensure that eCQM data is accurate and reliable.

**Response:** We believe that collecting as much data from hospitals as feasible is an important step toward helping hospitals to report more accurate and reliable data. In section VIII.A.11.b. of the preamble of this final rule, we outline an addition to the Hospital IQR Program validation process to include validation of eCQM data. Analysis of validation results will help us to better understand the difficulties hospitals are experiencing in reporting eCQM data and help hospitals to provide assistance to help resolve those issues, ultimately resulting in more accurate and reliable data which will improve patient outcomes.

**Comment:** One commenter suggested that CMS should delay this proposal and focus more on validating eCQM data prior to requiring that hospitals report the data on all eCQMs for a full year in the Hospital IQR Program.

**Response:** We disagree with the commenter’s suggestion that we delay this proposal and focus more on validating eCQM data prior to requiring hospitals report data on all eCQMs for a full year in the Hospital IQR Program because we believe that collecting as much data from hospitals as feasible is an important step toward helping hospitals to report more accurate and reliable data.

**Comment:** Some commenters expressed concern that this effort will take resources away from true quality improvement efforts.

**Response:** We disagree and believe that when EHRs are appropriately structured in a way that fits in with the clinical work flow to yield reliable data through eCQMs, eCQMs promote higher quality outcomes and lower costs while ultimately decrease reporting burden on hospitals as compared with chart abstraction. Moreover, we believe that it is appropriate to require reporting and validation of eCQMs given that measures available now and those being developed for the future are increasingly based on electronic standards (80 FR 49696).

**Comment:** One commenter questioned whether CMS has considered its ability to receive data submissions for hundreds of thousands of cases from hospitals within a 2 month period (January 1 through the Feb 28).

**Response:** We are working to ensure that CMS infrastructure is in place to receive the full volume of eCQM data transmissions (for 8 eCQMs) from hospitals by the February 28, 2018 deadline for the CY 2017 reporting period and February 28, 2019 for the CY 2018 reporting period. As stated above, the CMS data receiving system will re-open late spring 2017 to receive test QRDA I files and production QRDA I files for the CY 2017 reporting period eCQM data submissions. Providing this option allows hospitals and vendors greater flexibility to submit QRDA I files on a quarterly, semi-annual, or annual basis rather than waiting to submit all QRDA I files during the last two months of the submission period. As of the publication of this final rule, the CMS data receiving system is open to receive QRDA I test file submissions to allow hospitals and vendors to prepare and test their files for CY 2016 eCQM reporting requirements before the system will be available to receive production files.

**Comment:** A few commenters noted that upgrading CEHRT to a new edition of certification criteria during the same reporting period (CY 2017) that would
require hospitals report a full year of eCQM data could pose additional implementation difficulties. Other commenters suggested as an alternative to annual reporting of a full year of eCQM data, that CMS require quarterly submission of the eCQM data, with submission being required four and a half months after the end of the reporting quarter to align the e-submission requirements with the Hospital IQR Program chart-abstracted reporting requirements and with other quality reporting programs, such as the SNF Quality Reporting Program and the EHR Incentive Program, to ensure sufficient time for providers to final-bill code all cases for a reporting quarter before being required to generate QRDA files for submission to CMS, and to alleviate pressure on providers, vendors, and the QualityNet team to put together and submit the required information for eCQM data submission. Finally, a few commenters noted that upgrading CEHRT to a new edition of certification criteria during the same reporting period (CY 2017) that would require hospitals report a full year of eCQM data could pose additional implementation difficulties. One commenter expressed the opinion that quarterly reporting would reduce the volume of data that vendors and CMS must process at one time, give providers more frequent benchmarking of their performance on these measures, and make the timing of electronic reporting consistent with reporting of chart-abstracted measures.

Response: We thank commenters for their suggestions. While we acknowledge that upgrading to a new edition of certified EHR during the same reporting period that would require hospitals report a full year of eCQM data could pose additional implementation difficulties, we believe that setting an annual submission deadline at two months following the end of the reporting calendar year provides hospitals more time to make necessary modifications to their health IT systems. This annual submission deadline will allow hospitals the flexibility to submit production data on a quarterly, semi-annual, or annual basis. In addition, we encourage hospitals to test their preparedness to submit eCQM data prior to the submission deadline of the applicable reporting period by using one of the available presubmission testing tools for electronic reporting as discussed in section VIII.A.11.b.(5) of the preamble of this final rule.

Comment: One commenter expressed concern that CMS would increase the amount of data electronically submitted without the benefit of lessons learned from the first year of the electronic submission requirement. The commenter urged CMS not to increase the amount of eCQM data reported for CY 2017 until experience from the 2016 data submission is available to inform proposals.

Response: We acknowledge the commenter’s concern that we are increasing the amount of data electronically submitted, by increasing the eCQM reporting requirement from one quarter of data to a full year of data, before data from the first year of required eCQM submission for CY 2016 are available for us to analyze and garner lessons learned, but we disagree that we should delay our proposal to require submission of a full year of data. Hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program (3 years of pilot reporting and 3 years of voluntary reporting). As stated previously, 95 percent of hospitals attest to successful electronic clinical reporting under the Medicare EHR Incentive Program. As stated above, we believe that collecting as much data from hospitals as feasible is an important step toward helping hospitals to report more accurate and reliable data.

In section VIII.A.11.b. of the preamble of this final rule, we outline an addition to the Hospital IQR Program validation process to include validation of eCQM data. Analysis of validation results will help us to better understand the difficulties hospitals are experiencing in reporting eCQM data and enable us to provide assistance to help resolve those issues, ultimately resulting in more accurate and reliable data which will improve patient outcomes. Therefore, we believe the CY 2017 reporting period is the appropriate time to move forward with our proposed requirement that hospitals report a full year of eCQM data.

Comment: One commenter expressed concern with the proposals to align the EHR Incentive Programs and the Hospital IQR Program because there are differences in the reporting time periods between the MU measure reporting and the eCQM reporting. The commenter requested that CMS change the eCQM reporting period in FY 2017 to one quarter to align with the MU.

Response: We refer readers to section VIII.E.2.b. of the preamble of this final rule in which reporting time periods for the Medicare and Medicaid EHR Incentive Programs are aligning with the Hospital IQR Program to require that hospitals report a full year of eCQM data by the same submission deadline.

After consideration of the public comments we received, we are finalizing the proposal that for the CY 2017 reporting period/FY 2019 payment determination and subsequent years, hospitals must submit one year’s worth (that is, 4 quarters) of eCQM data for each required eCQM by the annual submission deadline as proposed.

c. Clarification Regarding Data Submission for ED–1, ED–2, PC–01, STK–4, VTE–5, and VTE–6

In the FY 2016 IPPS/LTCH PPS final rule, we finalized our policy that hospitals must continue to submit data on ED–1, ED–2, PC–01, STK–4, VTE–5, and VTE–6 via chart abstraction as previously required and that the results will be publicly displayed (80 FR 49695 through 49698). We also finalized a policy that hospitals may choose to submit electronic data on any of these 6 measures in their eCQM form, in addition to the chart-abstraction requirements, in order to meet the eCQM reporting requirement to report 4 self-selected eCQMs out of 28 available eCQMs (80 FR 49695 through 49698).

For the FY 2019 payment determination and subsequent years, as discussed in section VIII.A.3.b.(3)(a)(ii) of the preamble of this final rule, we are finalizing our proposal to remove the electronic version of the STK–4 measure. As discussed in section VIII.A.3.b.(3)(d) of the preamble of this final rule, we are finalizing our proposal to remove the chart-abstraction versions of the STK–4 and VTE–5 measures. Because these proposals are being finalized as proposed, the STK–4 and VTE–5 measures are completely removed from the Hospital IQR Program measure set, but the VTE–6 measure continues to be included in its chart-abstracted form. Therefore, for the FY 2019 payment determination and subsequent years, we are clarifying that requirements for the chart-abstracted versions of ED–1, ED–2, PC–01, and VTE–6 remain the same as previously finalized—that hospitals must continue to submit data via chart abstraction (covering each of Q1, Q2, Q3, and Q4) as previously required and that the results will be publicly displayed.

We received the following comments on clarifying the reporting requirements for ED–1, ED–2, PC–01, and VTE–6.

Comment: A few commenters recommended that the Hospital IQR Program continue to require all hospitals to submit chart-abstracted data for measures ED–1, ED–2, and PC–01 and
that these measures should be prioritized for eCQM data collection as well to facilitate data validation. The commenters requested that CMS make publicly available the results of analysis comparing chart-abstracted data with eCQM data for measures that are reported in both forms because it would provide valuable information to inform decisions about keeping or retiring measures and it would highlight issues ascribed to differences between chart-abstractation methods and eCQM measure specifications to help vendors and providers understand these issues. Lastly, commenters encouraged CMS to require CEHRT to adopt a standardized definition of “admit decision” and recommended that CMS consult with existing consensus definitions and experts in the field to help identify potential variance in the chart-abstracted version and the eCQM versions of these measures.

Response: We thank the commenters for their support and suggestions and will take these into consideration in developing future policy. In addition, we direct readers to the Office of the National Coordinator for recommendations on developing or new standards for health IT which should be considered for future adoption.

Comment: Some commenters expressed concern that the submission of eCQM data would not replace chart-abstracted and claims-based measures, which must still be submitted in addition to eCQMs. The commenters suggested that CMS allow hospitals to select the format in which to report, to encourage more hospitals to make eCQMs more accurate. Further, the commenters suggested that if hospitals submit eCQM data for measures ED–1 and ED–2, that they not be required to submit chart-abstracted data for these measures because chart-abstractation is redundant and costly. The commenters requested that CMS consider flexibility in requirements for submission of different measures types because maintaining different reporting mechanisms is a daunting task for hospitals which require expertise in different areas of health IT, as well as in clinician workflow and medical coding. One commenter specifically requested that chart-abstracted measures be removed when an eCQM is available because reporting on the same measure in two forms duplicates efforts, creates variation in the data, and takes time away from hospitals improving their electronic medical record systems. Another commenter also noted that clinician documentation for the generation of clinical quality measures is no easy feat, and that CMS should be more cognizant of this. The commenter recommended that CMS slow the pace of eCQM reporting and focus on testing and validation of measures instead.

Response: We thank the commenters for their suggestion that we allow hospitals to select the format in which to report on measures specified both as eCQMs and as chart-abstracted measures, however, we believe that in order to collect the highest quality data, at this time, submission of data in both forms for the ED–1, ED–2, PC–01, and VTE–6 measures is necessary. As described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we have received anecdotal comments about performance-level differences between chart-abstracted and eCQM data. We do not have sufficient data to be able to confirm or refute the accuracy of those comments (79 FR 50258). In order to substantiate or refute the existence of performance-level differences between eCQM data and chart-abstracted measure data, we believe that we must collect more eCQM data and develop a process for validating the accuracy of that data.

Moreover, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50015 through 50818), we adopted a policy under which we would only publicly report eCQM data in the Hospital IQR Program if we determined that the data are accurate enough to be reported. We believe that our current policy to delay public reporting of eCQM data submitted by hospitals for the CY 2017 reporting period/FY 2019 payment determination in conjunction with the adoption of an eCQM validation process in this final rule is consistent with our stated policy on eCQM public reporting. Until we have determined that eCQM data are accurate enough to be publicly reported, we believe it is important to continue utilizing chart-abstractation for quality reporting until EHR systems are more mature, but as we stated in section VII.A.8.a. of the preamble of this final rule, when hospitals work with their vendors to ensure that EHRs are appropriately structured in a way that fits in with the clinical workflow to yield reliable data through eCQMs, we believe that eCQMs promote high quality outcomes and lower costs while ultimately decrease reporting burden on hospitals as compared with chart-abstractation.

In summary, for the FY 2019 payment determination and subsequent years, we

\[\text{Office of the National Coordinator, Health IT Certification Program www.healthit.gov}\]
clarify that requirements for the chart-abstracted versions of ED–1, ED–2, PC–01, and VTE–6 remain the same as previously finalized—that hospitals must continue to submit data via chart abstraction (covering each of Q1, Q2, Q3, and Q4) as previously required and that the results will be publicly displayed. This is regardless of whether data also are submitted electronically in accordance with the applicable submission requirements.

9. Possible New Quality Measures and Measure Topics for Future Years

In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25196 through 25199), we provided information about new quality measures and measure topics under consideration for future inclusion in the Hospital IQR Program. We are considering to propose in future rulemaking: (1) A refined version of the Stroke Scale for the Hospital 30-Day Mortality Following Acute Ischemic Stroke Hospitalization Measure; (2) a new measure, the National Healthcare Safety Network (NHSN) Antimicrobial Use Measure (NQF #2720); and (3) one or more potential measures of behavioral health for the inpatient hospital setting, including measures previously adopted for the IFRQOR Program (80 FR 46694), for adoption into the Hospital IQR Program measure set. Also, we are considering public reporting of Hospital IQR Program data stratified by race, ethnicity, sex, and disability on Hospital Compare. These topics are further discussed below.

a. Potential Inclusion of the National Institutes of Health (NIH) Stroke Scale for the Hospital 30-Day Mortality Following Acute Ischemic Stroke Hospitalization Measure Beginning as Early as the FY 2022 Payment Determination

(1) Background

Mortality following stroke is an important adverse outcome that can be measured reliably and objectively and is influenced by the quality of care provided to patients during their initial hospitalization; therefore, mortality is an appropriate measure of quality of care following stroke hospitalization.159 160 Specifically, post-stroke mortality rates have been shown to be influenced by critical aspects of care such as response to complications, speediness of delivery of care, organization of care, and appropriate imaging.161 162 163 164 Therefore, we are refining the previously adopted CMS Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) following Acute Ischemic Stroke Hospitalization Measure (hereafter referred to as the Stroke 30-day Mortality Rate) (78 FR 50802) by changing the measure’s risk adjustment to include stroke severity. We are considering proposing this refinement to the measure in the future. The previously adopted Stroke 30-day Mortality Rate (78 FR 50802) includes 42 risk variables, but does not include an assessment of stroke severity. For more details on the measure as currently adopted and implemented, we refer readers to its measure methodology report and measure risk-adjustment statistical model in the AMI, HF, PN, COPD, and Stroke Mortality Update zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

In the future, we are considering proposing a refinement to the Stroke 30-day Mortality Rate for several reasons. First, the refined measure would allow for more rigorous risk adjustment by incorporating the NIH Stroke Scale (discussed in more detail below) as an assessment of stroke severity.165 Second, the inclusion of the NIH Stroke Scale is aligned with and supportive of clinical guidelines, as use of the NIH Stroke Scale to assess stroke severity upon acute ischemic stroke patient presentation is Class I recommended in the American Heart Association and American Stroke Association (AHA/ASA) guidelines.166 Third, clinicians and stakeholders, including AHA, ASA, and other professional organizations, highlight the importance of including an assessment of stroke severity in risk-adjustment models of stroke mortality. Therefore, the refined Stroke 30-day Mortality Rate is responsive to comments received from the feedback of measure developers during measure development, the TEP, and the NQF endorsement process (78 FR 50802). Fourth, in addition to a modestly higher c-statistic, which evaluates the measure’s ability to discriminate or differentiate between high and low performing hospitals, the refined Stroke 30-day Mortality Rate includes a more parsimonious risk model than the publicly reported stroke mortality measure, with a total of 20 risk adjustment variables including the NIH Stroke Scale, compared to the current use of 42 risk adjustment variables.

Initial stroke severity score, such as the NIH Stroke Scale score, is one of the strongest predictors of mortality in ischemic stroke patients,167 168 169 and is part of the national guidelines on stroke care.170 The NIH Stroke Scale is a 15-item neurologic examination stroke scale used to provide a quantitative measure of stroke-related neurologic deficit. The NIH Stroke Scale evaluates the effect of acute ischemic stroke on a patient’s level of consciousness, language, neglect, visual-field loss, extra-ocular movement, motor strength, ataxia (the loss of full control of bodily movements), dysarthria (difficult or unclear articulation of speech), and sensory loss. The NIH Stroke Scale was designed to be a simple, valid, and reliable tool that can be administered at the bedside consistently by neurologists, physicians, nurses, or therapists. In

159 160 Weir NU, Sandercock PA, Lewis SC, Signorini DF, Warlow CP. Variations between countries in hospitalization.

159 160 Weir NU, Sandercock PA, Lewis SC, Signorini DF, Warlow CP. Variations between countries in hospitalization.


162 Lingsma HF, Dippel DW, Hoeks SE, et al. Variation between hospitals in patient outcome after stroke is only partly explained by differences in quality of care: Results from the Netherlands Stroke Survey. [Reprint in Ned Tijdschr Geneesk. 2008 Sep 27;152(39):2126–32; PMID: 18856030].


165 NIH Stroke Scale. Available at: http://www.nihstrokescale.org/.
October 2016, codes for the NIH Stroke Scale are expected to be added to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD–10). The currently adopted measure covers 3 years of claims data using administrative claims from July 2011–June 2014. In order to give hospitals time to adjust to reporting the NIH Stroke Scale, we are considering this measure refinement for as early as the July 2017 through June 2020 reporting period (3 years of data), which would correspond to the FY 2022 payment determination in the Hospital IQR Program.

The measure refinement was developed in collaboration with the AHA/ASA. We sought to update the current publicly reported measure to include an assessment of stroke severity at this time, because it has become feasible to do so due to both the increased use of the NIH Stroke Scale on all stroke patients, as well as due to the upcoming availability to obtain the scores through claims data (incorporation into ICD–10).

The Stroke 30-day Mortality Rate (MUC ID 15–294) with the refined risk adjustment was included on a publicly available document entitled “List of Measures under Consideration for December 1, 2015” with identification number MUC ID 15–294, (available at: http://www.qualityforum.org/ProjectMaterials.aspx?projectID=75367) and has been reviewed by the MAP. The MAP conditionally supported this measure pending NQF review and endorsement to ask that CMS consider a phased approach in regards to implementation to avoid multiple versions of the same measure. The MAP also noted that mortality is not the most meaningful outcome for stroke patients and to consider cognitive or functional outcomes such as impaired capacity. The Stroke 30-day Mortality Rate with the refined risk adjustment was submitted to NQF for endorsement in the neurology project on January 15, 2016.

(2) Overview of Measure Change

The measure cohort for the refined measure would not be substantively different from the currently adopted, publicly reported Stroke 30-day Mortality Rate. In addition, the data sources, three-year reporting period, inclusion and exclusion criteria, as well as the assessment of the outcome of mortality would all align with the currently adopted measure.

(3) Risk Adjustment

The statistical modeling, measure calculation, and risk-adjustment calculation for this refined measure would align with the currently adopted Stroke 30-day Mortality Rate. However, we reselected risk variables, resulting in a final model with 20 risk-adjustment variables including the NIH Stroke Scale as an assessment of stroke severity. For the full measure specifications of the refined measure, we refer readers to the AHA, HF, PN, COPD, and Stroke Mortality Update zip file on our Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html.

In summary, we are considering proposing in the future a refinement of the Stroke 30-Day Mortality Rate, which would change the risk adjustment to include an assessment of stroke severity, in the Hospital IQR Program for as early as the July 2017–June 2020 reporting period/FY 2022 payment determination and for subsequent years.

We invited comments on the possibility of a future proposal of refinements to the previously adopted Hospital 30-day Mortality Following Acute Ischemic Stroke Hospitalization Measure to include the NIH Stroke Scale beginning as early as the FY 2022 payment determination.

Comment: All commenters supported the inclusion of the NIH Stroke Scale score in the Stroke 30-day Mortality Rate measure for future inclusion in the Hospital IQR Program. Commenters noted it is a technical improvement, but is a significant improvement as an assessment of stroke severity. We refer readers to the current clinical guidelines describing the qualifications and appropriate administration of the NIH Stroke Scale.

Response: We thank the commenters for their support.

Comment: One commenter cautioned CMS in moving forward in the implementation of the refined Stroke 30-Day Mortality Rate measure, noting that data for the measure would not be required until FY 2020, which allows hospitals sufficient time to adjust to reporting NIH Stroke Scale scores. Response: We thank the commenters for their support.

Comment: One commenter recommended that CMS also account for decline or improvement in status that could be related to interventions, by incorporating the NIH Stroke Scale score administered at discharge. Commenters suggested that CMS consider whether the measure will risk adjust for the score taken upon admission, during the first 24 hours of the admission, or upon discharge. A commenter urged CMS to consider standardizing the qualifications of the individual administering the NIH Stroke Scale. In addition, one commenter requested clarification as to how the NIH Stroke Scale score would be reported to CMS. Response: In regard to the timing of the NIH Stroke Scale score, we note that the intent of the risk adjustment for stroke severity is to account for patients’ clinical status at the time they are admitted to the hospital. Therefore, the refined Stroke 30-Day Mortality Rate measure would utilize the initial NIH Stroke Scale score, administered upon admission. We refer readers to the current clinical guidelines describing the qualifications and appropriate administration of the NIH Stroke Scale. As noted in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25196), the NIH Stroke Scale is expected to be added to ICD–10 in October 2016, and could therefore be reported via claims submitted to CMS. We will take the additional suggestions into consideration for future policy.

Comment: A few of commenters supported the inclusion of the NIH Stroke Scale for the Stroke 30-day Mortality Rate measure for future inclusion in the Hospital IQR Program, pending NQF endorsement. One commenter added that it would also support using the refined Stroke 30-Day Morality Rate measure once it has been field-tested by hospitals. Commenters noted that mortality is not the only outcome for stroke patients that should be measured and recommended that CMS work with measurement stakeholders and developers to explore more measures that are highly meaningful to patients, such as cognitive or functional outcomes. These commenters acknowledged that the addition of the NIH Stroke Scale scores is a technical improvement, but cautioned CMS in moving forward in
implementation of this measure until it is clear that the measure provides an unambiguous and unbiased signal of the underlying quality of care provided by the hospital.

Response: We thank commenters for their suggestions and support. The refined Stroke 30-Day Morality Rate measure was submitted to the NQF neurology project on January 15, 2016. We will continue to move forward with the NQF endorsement process for the measure. We will take this feedback regarding the timing of implementation and future stroke outcomes measures into consideration as we conduct implementation planning for the measure. We thank the commenters for their feedback and we will consider it as we develop future policy.

b. Potential Inclusion of National Healthcare Safety Network (NHSN) Antimicrobial Use Measure (NQF #2720)

(1) Background

The emergence of antibiotic drug resistance is a clinical and public health problem that threatens the effective prevention and treatment of bacterial infections. The CDC estimates that each year at least two million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 people die as a direct result of these drug-resistant bacterial infections. In addition, antibiotic resistance contributes an estimated $20 billion in excess direct healthcare costs.

In order to promote the efficiency and coordination of efforts to detect, prevent, and control antibiotic resistance, HHS announced in 2015 the establishment of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (Advisory Council). The Advisory Council makes recommendations to the Secretary regarding policies to support the implementation of the National Strategy for Combating Antibiotic-Resistant Bacteria and the National Action Plan for Combating Antibiotic-Resistant Bacteria. Evidence is accumulating that programs dedicated to optimizing inpatient antibiotic use, known as antimicrobial stewardship programs (ASPs), may slow the emergence of antibiotic resistance and improve appropriateness of antimicrobial use and patient outcomes. Therefore, the CDC and several professional societies have published guidelines and resources to support hospitals in implementing antimicrobial stewardship programs.

In the future, we are considering proposing the NHSN Antimicrobial Use measure to advance national efforts to reduce the emergence of antibiotic resistance by enabling hospitals and CMS to assess national trends of antibiotic use to facilitate improved stewardship by comparing antibiotic use that hospitals report to antibiotic use that is predicted based on nationally aggregated data. The measure was included on a publicly available document entitled “List of Measures Under Consideration for December 1, 2015,” in compliance with section 1890A(a)(2) of the Act. The measure received conditional support, pending CDC recommendation that the measure is ready for use in public reporting as referenced in the MAP 2016 Final Recommendations. The MAP recognized the high importance of antimicrobial stewardship and conditionally supported the inclusion of this measure in the Hospital IQR Program while acknowledging that additional testing may be necessary to address feasibility issues for public reporting, quality implications of measuring the amount of antibiotics used versus appropriate use of antibiotics, and risk-adjustment. Further, MAP noted these issues should be addressed before the measure is reported on Hospital Compare. The measure received endorsement from NQF on December 10, 2015.

(2) Overview of Measure

The NHSN Antimicrobial Use measure assesses antibiotic use in hospitals based on medication administration data that hospitals collect electronically at the point of care. The measure compares antibiotic use that hospitals report, via electronic file submissions to the CDC’s NHSN, to antibiotic use that is predicted based on nationally aggregated data. Data on administered antibiotics are required to be extracted from an electronic medication administration record (eMAR) and/or bar coded medication administration (BCMA) system. The antibiotic use data that are in scope for this measure include antibiotic agents administered to adult and pediatric patients in a specified set of ward and intensive care unit (ICU) locations. Locations include adult and pediatric medical, medical/surgical, and surgical wards and adult and pediatric medical, medical/surgical, and surgical ICUs as defined by the NHSN at: http://www.cdc.gov/nhsn/PDFs/pscManual/15LocationsDescriptions_current.pdf.

The measure is comprised of a discrete set of risk-adjusted summary ratios, known as Standardized Antimicrobial Administration Ratios (SAARs), which summarize observed-to-predicted antibacterial use for one of sixteen antibiotic agent-patient care location combinations. The specific antibiotic agent-location combinations were selected based on extensive consultation with infectious disease physicians and pharmacists at the forefront of ASPs. The specified categories of antibiotic agents include:

- Broad spectrum agents predominantly used for hospital-onset/multi-drug resistant bacteria;

- Broad spectrum agents predominantly used for surgical site infection prophylaxis.


185 eMAR is defined as technology that automatically documents the administration of medication into CEHR using electronic tracking sensors (for example, radio frequency identification (RFID)) or electronically readable tagging such as bar coding (77 FR 54034).

186 Barcode Medication Administration (BCMA) System is defined as a system that allows users to electronically document administrations at the bedside or other points-of-care using an electronically readable format. More information. Available at: http://www.ahrq.gov/downloads/pub/advances/vol3/wideman.pdf.
The SAARs are designed to serve as high value targets or high-level indicators for hospital ASPs to assess hospital antimicrobial use. A SAAR that is not significantly different from 1.0 indicates “expected” antibiotic use. A SAAR that is above 1.0 may indicate excessive antibiotic use or a SAAR that is below 1.0 may indicate antibiotic underuse. We note that the SAARs do not provide a definitive indication of antibiotic appropriateness of use. Outlier SAAR values should prompt hospitals to do further analysis to assess overuse, underuse, or inappropriate use of antibacterial medications. In addition, the SAARs may be used by hospital ASPs to identify opportunities to improve antibiotic use and gauge the impact of stewardship efforts.

(3) Data Sources

The data submission and reporting standard procedures for the NHSN Antimicrobial Use measure have been set forth by the CDC for NHSN participation, in general, and for submission of measure data. We refer readers to the CDC’s NHSN Web site (http://www.cdc.gov/nhsn) for detailed data submission and reporting procedures. Although the NHSN Antimicrobial Use measure is not specified as an eCQM, manual data entry is not available. Data must be electronically extracted from an eMAR and/or BCMA system. The format for data submission must adhere to the data format prescribed by the CDC HL7 Clinical Data Architecture (CDA) Implementation Guide available at: http://www.cdc.gov/nhsn/cdaportal/toolkits/guidetocdaversion.html.

(4) Measure Calculation

Each SAAR is an observed to expected ratio and is calculated by dividing the numerator, or total number of observed antimicrobial days (days of therapy reported by a healthcare facility for a specified category of antimicrobial agents in a specified patient care location or group of locations) number of antimicrobial days, for each antibiotic agent category-patient care location combination. The total number of observed antimicrobial days for each patient care location is defined as the aggregated sum of days for which any amount of a specific antibiotic agent within an antibiotic agent category was administered as documented in the eMAR or BCMA system. The predicted number of antimicrobial days for each patient care location is determined by multiplying the observed days present by the corresponding antimicrobial use rate in the standard population obtained from the relevant regression model. Hospital patient care locations other than adult and pediatric medical, medical/surgical, and surgical wards and adult and pediatric medical, medical/surgical, and surgical ICUs are excluded from this measure. For more information regarding the specifications for the Antimicrobial Use measure, we refer readers to the NHSN Antimicrobial Use and Resistance Module (AUR): http://www.cdc.gov/nhsn/PDFs/pscManual/11pscAURcurrent.pdf.

We invited public comment on the possibility of future inclusion of the NHSN Antimicrobial Use measure (NQF #2720).

Comment: Many commenters supported the future inclusion of the NHSN Antimicrobial Use measure in the Hospital IQR Program indicating that it is critically important to reduce the amount of unnecessary antibiotic prescriptions, help practitioners and public health officials alike assess antibiotic use in hospitals based on medication administration data that hospitals collect thereby helping to combat a growing clinical and public health concern (antimicrobial resistance), and improve the appropriateness of both antimicrobial use and patient outcomes. In addition, one commenter noted that the measure will enable facilities to monitor antibiotic use and guide stewardship efforts in hospitals but recommended further validation and testing to ensure accurate and meaningful application of the measure prior to its inclusion. The commenter noted that inclusion of the measure would encourage facilities to: (1) Benchmark antibiotic use; (2) assess appropriateness of antibiotic prescribing; and (3) target stewardship interventions and gauge their impact.

Another commenter noted that in order for measures of this kind to become widespread, a broad interoperability standard needs to be adopted across all vendors providing accessibility to the requisite electronic drug administration data. A third commenter added that CMS is the only entity that can address the overuse of antibiotics through its Conditions of Participation and public reporting and payment accountability tools. The commenter encouraged CMS to target this measure for public reporting that is subsequently tied to payment incentive programs. Similarly, another commenter stated that reporting of antibiotic use data to the NHSN Antibiotic Use Reporting (AUR) module is of great importance because doing so would provide vital statistics on which stewardship of use of antibiotics can be assessed, and help facilities evaluate their antimicrobial utilization over time. The commenter noted that there are currently no national data on antibiotic use, and at the broadest level it is difficult to chart national improvement without having systematically collected antibiotic use data from all acute care hospitals in the U.S. Lastly, one commenter urged CMS to recognize that hospital antimicrobial stewardship is one only aspect of the multifaceted and worldwide efforts needed to address the increasing challenge of antimicrobial resistance.

Response: We thank the commenters for supporting the future inclusion of the Antimicrobial Use measure. We will take these comments and suggestions into consideration in developing future policy.

Comment: One commenter supported future inclusion of the NHSN Antimicrobial Use measure in the Hospital IQR Program, but suggested that this measure should be voluntary because required reporting at this time would place an undue burden on hospitals without a fully integrated IT system.

Response: We thank the commenter for supporting the proposed future inclusion of the Antimicrobial Use measure and will consider the commenter’s suggestion in developing future policy.

Comment: One commenter did not support future inclusion of the Antimicrobial Use Measure, because better methods are available for prescribing antibiotics than what is described in the measure text, such as adherence to the local facility antibiogram for the type of infection present and technologic identification of gene resistance markers. The commenter also suggested that the measure data that is provided is aged and indicated that the usage of the measure’s data for payment purposes is counterproductive to clinical improvement.
Response: We acknowledge the commenter’s concern, but note that the NHSN Antimicrobial Use Measure assesses antibiotic use (the amount of antibiotics used) rather than appropriateness of use. The measure result is not a definitive measure of appropriateness and should not be interpreted in isolation to assess prescribing practices. Instead, the Antimicrobial Use measure should prompt hospitals to do further analysis of prescribing practices to assess overuse, underuse, or appropriateness of use. This additional analysis to assess appropriateness of use may include consulting the facility antibiogram, the facility antimicrobial stewardship program, as well as other evidence based treatment guidelines as appropriate.

We disagree with commenter’s suggestion that NHSN measure data is “aged” and “counterproductive to clinical improvement.” The NHSN has various analytic functions that enable hospitals to analyze their own surveillance data anytime. We encourage hospitals to use these functions for continuous quality improvement efforts. Additional information regarding analysis is available on the NHSN Web site at: http://www.cdc.gov/nhsn/ps-analysis-resources/index.html.

Comment: One commenter questioned whether the use of “days of therapy” (DOT) is an adequate component of measurement, indicating that not all health information systems will be able to extract a clean result for this data point. Instead, the commenter suggested that the “defined daily dose” (DDD) be the unit of measurement, as it is more readily available, more easily obtained, and provides useful information.

Response: We appreciate the commenter’s observations about summarizing antimicrobial consumption using DDD. A major reason why NHSN opted to use DOT is that DDD is not applicable in children (aged >1 month) due to the large variation in body weight within this population. Further, NHSN’s experience with antimicrobial use surveillance—in which over 140 hospitals ranging widely in bed size, information technology resources, and geographic location have successfully submitted antimicrobial use data to NHSN—suggests that DOT data can be consistently collected and reported to NHSN. While investments in a technical solution are necessary to enable data extraction, aggregation, and reporting, the NHSN provides clear evidence that information technology vendors and, in some instances, health systems themselves, are capable of developing and deploying those solutions.

Comment: A few commenters expressed concern about the vendor tool currently used to collect data for the measure. Commenters indicated that the tool is inefficient and urged the CDC to correct the problems with the tool prior to program inclusion. One commenter noted that hospitals have difficulty reporting directly to the module which requires a direct HL7 feed, a functionality not offered by many EHR vendors, and because the measure requires additional testing and validation before introduction into public reporting or payment programs.

Response: While the CDC continuously strives to be abreast of issues that arise with vendor tools and to provide feedback as a method of aiding in the maintenance of vendor tools, we will share the commenters’ concerns with the CDC. We will also take these comments into consideration in developing future measures.

Comment: One commenter suggested that the NHSN Antimicrobial Use measure assess administration of antibiotics in the ED and those used pre-operatively, noting that if hospitals only gather data from eMAR or barcode-administration, the data on administration of antibiotics will be overlooked, and therefore, the overall measure results will be skewed. The commenter urged CMS to evaluate the administration of antibiotics in the ED and operating room.

Response: We appreciate commenter’s suggestion to include the emergency department (ED) and operating room (OR) in the measure and will share it with the CDC. Although the ED and OR are not included in the measure, the NHSN Antibiotic Use and Resistance Module does allow for optional submission of ED and OR data. For more information, we refer readers to: http://www.cdc.gov/nhsn/acute-care-hospital/aur/.

Comment: One commenter supported the potential inclusion of the NHSN Antimicrobial Use measure but recommended that the measure be specified as an eCQM rather than a chart-abstracted measure.

Response: We thank the commenter for this support and we will share the recommendation with the CDC.

Comment: A few commenters did not support the inclusion of the NHSN Antimicrobial Use measure. A few commenters believed the measure would place an information handling burden on smaller hospitals that would likely have to contract with an outside vendor. The commenter encouraged CMS to consider another alternative for reporting progress on antibiotic stewardship. Another commenter stated that the measure is too broad and the measure calculation is unclear.

Response: We acknowledge the commenters’ concerns and will consider them should we propose to adopt the measure in future rulemaking. For more information regarding measure calculation, we refer readers to the NHSN Web site manual at: http://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf.

Comment: Many commenters supported the concept of antimicrobial stewardship and inclusion of an antimicrobial use measure in the Hospital IQR Program, but did not support inclusion of this NHSN Antimicrobial Use measure for various reasons. Specifically, several commenters objected to the measure because Standardized Antimicrobial Administration Reasonable (SAARs) measure the amount of antibiotics used but does not account for the appropriateness of antibiotic use nor does it separate community hospitals from academic hospitals when defining the expected number. Commenters noted that including this measure in the Hospital IQR Program and publicly reporting it on Hospital Compare may create incentives for providers to lower the number of antimicrobial days to improve their SAAR irrespective of the appropriateness of antimicrobial use.

Commenters urged CMS to explore the use of a measure that looks at both number of antimicrobial days and the appropriateness of use to promote true antimicrobial stewardship and improved patient outcomes. Commenters suggested that CMS develop process metrics around the appropriate use of diagnostic test(s) that help determine if antibiotic use is appropriate by first identifying the microbe causing the infection prior to prescribing the antibiotic in cases where patient health status allows for the diagnostic first and also the time to effective treatment.

Some commenters also expressed concern that the testing sample used to develop the measure was too small which could lead to unintended consequences of reporting the measure on a nation scale and the use of the measure in public reporting may result in misleading comparisons complexity of the patient population can contribute to differences in antibiotic use rates. These commenters suggested CMS conduct large-scale pilot studies to further evaluate and validate the metric...
prior to including the SAAR as part of the measure set.

For all of these reasons, some commenters expressed concern that these data have a high probability of misinterpretation by the public and may provide inaccurate justification for hospitals to avoid dedicating resources to antimicrobial stewardship programs if their SAARs are already within goal. Other commenters expressed concern about issues related to feasibility of public reporting, risk-adjustment, and providing hospitals sufficient time for technical set-up required with this measure.

Response: We acknowledge commenters’ concerns regarding public reporting, risk adjustment, and technical feasibility and will consider the comments them should we propose to adopt the measure in future rulemaking.

Comment: One commenter suggested that CMS explore additional hospital strategies to support efforts to reduce the threat of multidrug resistant organisms in the hospital setting. One noted approach was addressing infection control through the use of technology that relies on antisepsics, such as ionic silver and molecular iodine. Another noted approach was the use of silver antimicrobial dressings, following surgeries conducted on geriatric patients. This tactic can be an important part of protocols to reduce surgical site infections and further combat antibiotic resistance. Lastly, the commenter mentioned that combining antimicrobial agents with anti-biofilm agents would be effective because the anti-biofilm would disrupt biofilm to expose associated organisms to antibiotics.

Response: We thank the commenter for these suggestions and we will consider them for the future.

Comment: Several commenters expressed the opinion that the NSHN Antimicrobial Use measure is appropriate for use in quality improvement efforts, but not for public reporting at this time. The commenters urged CDC and CMS to work together to refine the measure should it be considered in the future for public reporting.

Response: We thank the commenters for their suggestions and we will continue to work with colleagues at the CDC to improve the measure’s feasibility for potential future public reporting.

Response: We thank the commenters for their suggestions and we will continue to work with colleagues at the CDC to improve the measure’s feasibility for potential future public reporting.

c. Potential Measures for Behavioral Health in the Hospital IQR Program

Although the IPFQR Program incorporates measures of inpatient psychiatric treatment (80 FR 46694), the Hospital IQR Program does not include any measures directly related to behavioral health. Based on MedPAC analyses, over a third of Medicare inpatient psychiatric admissions are treated “in acute care hospital beds not within distinct-part psychiatric units.” Thus, there may be a gap in understanding the quality of care given to inpatient psychiatric patients not paid for under the IPFQR Program.

To address this gap, we invited public comments on potential behavioral health quality measures appropriate to include in the Hospital IQR Program in future years, including the possible use of one or more measures previously adopted in the IPFQR Program (80 FR 46417). The comments we received and our responses are set forth below.

Comment: Several commenters supported the future inclusion of behavioral health quality measures in the Hospital IQR Program. One commenter noted that in small community hospitals, patients with alcohol or drug abuse issues for medical detox, withdrawal, or overdose are not routinely admitted to psychiatry after medical treatment, which is largely problematic. Therefore, including measures of behavioral health in the Hospital IQR Program to address these behavioral issues will help to improve outcomes for this patient population. Another commenter was particularly interested in measures that examine health conditions such as schizophrenia and bipolar disorder and noted that successful implementation of behavioral health measures in the Hospital IQR Program should lead to subsequent inclusion in the Hospital VBP Program.

Response: We appreciate commenters’ recommendations and will consider them in developing future policy.

Comment: One commenter requested specific examples of measures from the IPFQR Program to be able to give feedback. The commenter recognized that there are measures from the IPFQR Program that may be appropriate for the Hospital IQR Program, but indicated that inclusion of these measures would require time to implement workflows. On the other hand, some commenters cautioned CMS about adopting measures from the IPFQR Program. Specifically, some commenters stated that while the hospital-based inpatient psychiatric services (HBIPS) measures are the most appropriate for this population, these measures have been phased-out over time in favor of measures that are less applicable to this specific patient population. Therefore, commenters urged CMS to collaborate with stakeholders to develop new measures of behavioral health.

Response: We thank commenters for sharing their suggestions and concerns. We understand that the addition of any new measures may cause workflow concerns, and we will consider these issues when evaluating any behavioral health measures we propose to adopt in future rulemaking.
Comment: One commenter did not support including quality measures of behavioral health in the Hospital IQR Program in the future because introducing these measures within an inpatient medical facility would introduce workflow documentation challenges and likely result in unintended consequences. Further, the commenter suggested that prior to any measure migration there be a review of the appropriate regulations (that is, HIPAA or State-specific guidance) regarding the sharing of sensitive mental health data.

Response: We acknowledge commenter’s concerns and recommendations regarding the use of behavioral health measures in the Hospital IQR Program and will consider them should we propose behavioral health measures in future rulemaking.

d. Potential Public Reporting of Quality Measures Data Stratified by Race, Ethnicity, Sex, and Disability and Future Hospital Quality Measures That Incorporate Health Equity

We sought comment on the possibility of including Hospital IQR Program measure data stratified by race, ethnicity, sex, and disability on Hospital Compare, if feasible and appropriate (that is, statistically appropriate, etc.) in the future. By stratification, we mean that we would report quality measures for each group of a given category (age, race, sex, and disability status). For example, if we were to report the Hospital-Wide All-Cause Unplanned Readmission Measure (HWR) (NQF #1789) stratified by sex, we would report a hospital’s measure result for females and then again separately for males, in addition to reporting a hospital’s unstratified rate, as is currently displayed. In addition, we also sought comment on potential hospital quality measures, including composite measures, for inclusion in the Hospital IQR Program measure set and thus, future postings on Hospital Compare, that could help consumers and stakeholders not only assess the measurement of the quality of care furnished by hospitals in inpatient settings, but also monitor trends in health equity. Any data pertaining to these areas that are recommended for collection through measure reporting for the Hospital IQR Program and public disclosure on Hospital Compare, would be addressed through a separate and future notice-and-comment rulemaking.

We invited public comment on the possibility of future inclusion of stratified measure data in Hospital Compare and on stratification categories, including any categories not specified in this preamble. We also sought comment on potential future hospital quality measures that incorporate health equity. The comments we received and our responses are set forth below.

Comment: Several commenters supported future reporting of measures in the Hospital IQR Program stratified by race, ethnicity, sex, and disability status if feasible and statistically appropriate. Commenters noted that stratification would contribute to greater transparency for consumers and provide an incentive for hospitals to improve the reporting of these factors. A few commenters recommended that CMS consider stratifying by additional factors including primary language and other social determinants of health because this type of data will enable more accurate evaluation in coverage gaps and disparities, particularly among minority and vulnerable populations, and are essential to improving the impact of adult immunization efforts and expanding coverage. Another commenter encouraged CMS to include age, income, and education level along with any of the above demographic factors it may use in stratification of measure reporting and suggested that CMS consider enabling multiple cross-cutting factors to be applied to any stratification to facilitate stratification by more than one factor at the same time. Another commenter recommended that CMS also consider stratification by age bands.

Several commenters also expressed the opinion that a uniform approach to data collection and stratification is necessary to ensure appropriate comparisons. One commenter suggested that, in order for the stratification information that would be shared to be meaningful, the standards used for the Hospital IQR Program for race, ethnicity, and sex must align with the Medicare and Medicaid EHR Incentive Programs. Further, this commenter stated that a standardized definition of “disability” needs to be developed, as currently it does not exist. Another commenter urged CMS to engage in a national dialogue on this important matter and to consider the Health Research and Educational Trust (HRET) Disparities Toolkit as an appropriate place to start discussion regarding a uniform data collection. Another commenter urged CMS to engage in a national dialogue on this important matter as these conversations are also ongoing across the health insurance exchange and MA markets.

Response: We thank the commenters for their support and suggestions. We will consider these recommendations should we propose to adopt stratified measure reporting in future rulemaking.

Comment: Several commenters supported use of performance measure stratification as a tool to identify and reduce health disparities, but urged CMS to continue to explore appropriate risk adjustment of measures, including risk adjustment for SDS factors. Commenters stated that differences in performance measure outcomes due to actual variation in the quality of care provided to subgroups of patients should not be tolerated.

Response: We thank the commenters for their support and recommendations. We will consider these recommendations should we propose to adopt stratified measure reporting in future rulemaking.

Comment: A few commenters did not support future reporting of measures in the Hospital IQR Program stratified by race, ethnicity, sex, or disability status. One commenter raised specific concerns about the method of data collection, indicating that patient demographic information is collected by entry level registration staff who are often not skilled in collecting sensitive information. In addition, the commenter stated that the inclusion of this information would pose additional administrative burden. Another commenter believed that the reasons for variation in performance by patient characteristics may or may not be related to hospital performance, and this type of reporting therefore raises more questions than it answers and could lead to misinterpretation and unintended consequences.

Response: We thank commenters for voicing their concerns and will consider them should we propose to adopt stratified measure reporting in future rulemaking.

Comment: One commenter suggested that CMS and AHRQ continue to conduct research on the impact of socioeconomic determinants upon health care outcomes. The commenter also requested that the results of this research be shared publicly.

Response: As we have previously noted, we have not risk-adjusted measures for SDS factors because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. However, as stated in section VIII.A.6.a.(1) of the preamble of this final rule, several measures developed by CMS have been brought to NQF since the beginning of the SDS trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not
to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, ASPE is conducting research to examine the impact of SDS on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available. Moreover, we will continue to collaborate with colleagues across HHS to evaluate the impact of SDS factors on healthcare outcomes and to develop an effective and transparent method for communicating results to the public.

Comment: Several commenters warned that it may not be a simple task to stratify measures by race, ethnicity, sex, and disability because specific considerations are required for every measure and each reporting mechanism to implement such a requirement. Specifically, one commenter noted that small denominator sample sizes are inherently problematic, and, if further stratified by factors such as race, age, and gender, will skew the reliability of the measure data. Therefore, the commenter stated that the stratified data should not be used for financial accountability programs. Instead, the commenter recommended that CMS develop educational material that will assist stakeholders in interpreting stratified quality measures. Another commenter supported the concept of CMS gathering data in the ways that can best lead to improved outcomes, but requested at minimum 18 months to implement changes.

Response: We thank commenters for voicing their concerns and will consider them in should we propose to adopt stratified measure reporting in future rulemaking.

Comment: One commenter acknowledged the importance of the policy aim to better understand health disparities and health equity, but recommended delaying the inclusion of stratified measures in the Hospital IQR Program until the collection of race, ethnicity, and disability data have matured. The commenter noted that CMS requires the capture of REAL data through the EHRs needs to be studied to determine whether it can be used for this purpose.

The commenter noted that Hospital Engagement Networks (HENs) are required to work with hospitals to standardize the collection of REAL data. This work, it stated, will continue in the future through the newly created Hospital Improvement Innovation Networks (HIINs), which will be required to identify gaps in the collection of REAL data in their network and to provide interventions and assistance to reduce these gaps leading to improvement of the quality of REAL data in the next few years.

Response: We appreciate the comments regarding ongoing efforts to standardize and improve the collection of race, ethnicity, age, and language data. In addition, we acknowledge commenter’s recommendation for delaying stratification and will consider these comments should we propose to adopt stratified measure reporting in future rulemaking.

Comment: One commenter expressed interest in learning the submission requirements for patient characteristics data provided for quality measures. The commenter also noted that the benefit of health equity data would need to be weighed against any new data collection burden.

Response: Submission requirements for patient characteristics vary from measure to measure. If in the future we move forward with a proposal to stratify measure data by race, ethnicity, sex, and disability on Hospital Compare, we will balance the benefit health equity data would provide against any new data collection burden associated with measures not currently subject to REAL requirements. We thank the commenters for their feedback and suggestions and we will consider them as we develop future policies.

10. Form, Manner, and Timing of Quality Data Submission

a. Background

Sections 1886(b)(3)(B)(viii)(I) and (b)(3)(B)(viii)(II) of the Act state that the applicable percentage increase for FY 2015 and each subsequent year shall be reduced by one-quarter of such applicable percentage increase (determined without regard to sections 1886(b)(3)(B)(ix), (xi), or (xii) of the Act) for any subsection (d) hospital that does not submit data required to be submitted on measures specified by the Secretary in a form and manner, and at a time, specified by the Secretary. Previously, the applicable percentage increase for FY 2007 and each subsequent fiscal year until FY 2015 was reduced by 2.0 percentage points for subsection (d) hospitals failing to submit data in accordance with the description above. In accordance with the statute, the FY 2016 payment determination began the second year that the Hospital IQR Program will reduce the applicable percentage increase by one-quarter of such applicable percentage increase.

In order to participate in the Hospital IQR Program, hospitals must meet specific procedural, data collection, submission, and validation requirements. For each Hospital IQR Program payment determination, we require that hospitals submit data on each specified measure in accordance with the measure’s specifications for a particular period of time. The data submission requirements, Specifications Manual, and submission deadlines are posted on the QualityNet Web site at: http://www.QualityNet.org/. Hospitals must register and submit quality data through the secure portion of the QualityNet Web site. There are safeguards in place in accordance with the HIPAA Security Rule to protect patient information submitted through this Web site.

b. Procedural Requirements for the FY 2019 Payment Determination and Subsequent Years

The Hospital IQR Program’s procedural requirements are codified in regulation at 42 CFR 412.140. We refer readers to these codified regulations for participation requirements, as further explained by the FY 2014 IPPS/LTCH PPS final rule (78 FR 50810 through 51641). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25199), we did not propose any changes to these procedural requirements.

However, as discussed below in section VIII.A.11. of the preamble of this final rule, we proposed to amend § 412.140(d)(2) in connection with our proposal to modify our validation processes beginning with the FY 2020 payment determination.

c. Data Submission Requirements for Chart-Absotred Measures

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51640 through 51641), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53536 through 53537), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50811) for details on the Hospital IQR Program data submission requirements for chart-absotred measures. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25199), we did not propose any changes to the data submission requirements for chart-absotred measures.
d. Alignment of the Hospital IQR Program With the Medicare and Medicaid EHR Incentive Programs for Eligible Hospitals and CAHs

(1) Background

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50256 through 50259) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49705 through 49709) for our policies aligning eCQM data reporting and submission periods on a calendar year basis for both the Medicare EHR Incentive Program for eligible hospitals and CAHs and the Hospital IQR Program for the FY 2017 payment determination and subsequent years for the Hospital IQR Program.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25199 through 25201), we proposed the following changes to the Hospital IQR Program to further align eCQM data reporting for the Hospital IQR Program with the Medicare and Medicaid EHR Incentive Programs:

(1) Maintaining the eCQM data certification process we previously adopted for the FY 2018 payment determination, including requiring hospitals to report eCQM data using EHR technology certified to either the 2014 or 2015 Edition beginning with the CY 2018 reporting period/FY 2020 payment determination and subsequent years.

In addition, we proposed to require eCQM data submission by the end of 2 months following the close of the reporting period calendar year for the CY 2017 reporting period/FY 2019 payment determination and subsequent years to further align eCQM data reporting for the Hospital IQR Program with the Medicare EHR Incentive Program. These proposals are discussed in more detail below.

(2) Continuation of eCQM Certification Processes for the FY 2019 Payment Determination and Requirements for Subsequent Years

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49705 through 49708), we finalized policies regarding eCQM certification for the FY 2018 payment determination. Specifically, we finalized the requirement that hospitals report using EHR technology certified to either the 2014 or 2015 Edition for the CY 2016 reporting period/FY 2018 payment determination since certification to the 2015 Edition is expected to be available in 2016; and (2) hospitals must submit eCQM data via Quality Reporting Document Architecture Category I (QRDA I) file format (80 FR 49706–49708). In addition, hospitals may use third parties to submit QRDA I files on their behalf (80 FR 49706) and can either use abstraction or pull the data from non-certified sources in order to then input these data into CEHRT for capture and reporting QRDA I (80 FR 49706).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25200), we proposed to continue these eCQM certification policies. Specifically, for the CY 2017 reporting period/FY 2019 payment determination (not subsequent years), we proposed to require that hospitals report using EHR technology certified to either the 2014 or 2015 Edition as previously required. We note that we proposed to change these policies, however, for the CY 2018 reporting period/FY 2020 payment determination as discussed in the following section.

In addition, for the CY 2017 reporting period/FY 2019 payment determination and subsequent years, we proposed that hospitals: (1) Must submit eCQM data via QRDA I files as previously required; (2) may continue to use a third party to submit QRDA I files on their behalf; and (3) may continue to either use abstraction or pull the data from non-certified sources in order to then input these data into CEHRT for capture and reporting QRDA I. This would align the Hospital IQR Program with the Medicare EHR Incentive Program. We refer readers to section VIII.E.2.c. of the preamble of this final rule for discussion of the certification requirements for the Medicare EHR Incentive Program. We invited comment on these proposals. In addition, we refer readers to section VIII.A.1.b.(5) of the preamble of this final rule where we encourage hospitals to take advantage of eCQM pre-submission testing tools to help reduce submission errors related to improperly formatted QRDA I files.

Comment: One commenter supported alignment with the Medicare and Medicaid EHR Incentive Programs to use the QRDA I standard, to permit the use of third party entities to submit QRDA I files, and to use CEHRT for capturing and reporting data in QRDA I. The commenter expressed concern that requiring electronic submission of eCQM data using the most recent version of eCQM data may create a disconnect in the timing cycle of the regulatory adoption of standards and the rapid evolution of electronic standards for eCQM reporting. The commenter recommended that CMS and ONC collaborate to establish a regulatory framework that is more responsive to the speed at which standards are developed, maintained, upgraded, and improved. One commenter supported the intent to align the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program reporting requirements to reduce provider burden and minimize confusion about reporting criteria across various quality reporting programs, but expressed concern about the expansion of eCQMs with the current state of EHR technology. One commenter urged CMS, as part of its certification process, to seek stakeholder input and to define standards for EHR organization and structure that allows for documentation to fit into the clinical workflow and interact with providers at the point-of-contact to guide them to provide timely and appropriate care.

Response: We thank the commenter for this support. We appreciate the commenter’s concerns about the current timeframe of evolving electronic standards and the timing cycle for the regulatory adoption of standards. We will continue to seek stakeholder input and collaborate with colleagues at ONC to define standards for EHR organization and structure that allows for documentation to fit into the clinical workflow and to ensure that our policies are responsive to evolving electronic standards to the greatest extent feasible.

Comment: One commenter recommended that CMS not require a hospital to combine eCQM data from two CEHRT solutions if a hospital switches vendors during a reporting quarter or year but rather to submit only one QRDA I file from the CEHRT solution on which the hospital was utilizing for a majority of the reporting quarter because QRDA I files do not allow for combining data from multiple sources while ensuring that patient data is not repeated as a result of the combination.

Response: We thank the commenter for this suggestion, but we disagree that QRDA I files do not allow for combining data from multiple sources while ensuring that patient data are not repeated. We expect that QRDA I files submitted for the Hospital IQR Program electronic reporting requirement are one patient per file per quarter and cumulative in nature, thus allow for the combination of data from multiple sources to contain all the episodes of care and the measures associated with the patient file for the same reporting quarter. When QRDA I files are
submitted, the following four key elements are utilized to identify the file:

- CMS Certification Number (CCN);
- CMS Program Name;
- EHR Patient ID; and
- Reporting period specified in the Reporting Parameters Section.

Utilization of the four key elements for file identification, and the requirement to ensure the QRDA I file is cumulative and representative of one quarter of data greatly reduces the likelihood of receiving repeated patient data. We note, however, that the system will overwrite the original file with the most recent submission if all four key elements are an exact match.


Comment: A few commenters requested clarification on the use of abstraction to extract data from non-certified sources into CEHRT for capture and reporting through QRDA I files. One commenter expressed concern that a hospital might chart-abstract data to complete the data set necessary to report on an eCQM because this duplicative transcription process could lead to errors and conflict with the medical record maintained in the certified EHR.

Some commenters expressed the opinion that clinical data used to satisfy eCQM reporting should originate from a credible source, and if not, abstraction of data from a non-certified source would undermine the integrity of the EHR Incentive Program. The commenters recommended that chart-abstract data should never be permitted for eCQMs and that reporting should be based solely on information available in CEHRT through the normal record management process in place at the hospital. One commenter urged CMS to utilize chart abstraction for quality reporting until the EHR transformation is made to allow clinicians to focus on delivering high quality patient focused care without the distraction of eCQM reporting using an EHR structure that has yet to evolve to support true meaningful use.

Response: We appreciate the commenter’s concerns about information from non-certified sources into CEHRT for capture and reporting through QRDA I files. Ideally, information available in CEHRT through normal record management process should be in place and used to report on eCQMs. However, many hospitals are still undergoing the time consuming and labor intensive process of data mapping their EHR systems. Data mapping is necessary in order to be able to capture required data elements, such as diagnostic study results/reports or other measure information, in discrete structured data fields to support the eCQMs because they are often found as free text in clinical notes or PDF documents attached to the medical record instead.

In recognition of the reality that hospitals are in a state of transition, it is our intent to allow hospitals some flexibility in reporting methods if necessary during this period of transition. Therefore, at this time, we will continue to permit the use of abstraction to extract data from non-certified sources into CEHRT for capture and reporting through QRDA I files. However, we encourage hospitals to continue making progress to fully achieve electronic data capture and reporting or to work with their vendors to do so. We acknowledge the commenters’ concerns that using chart-abstracted data to complete the data set necessary to report on an eCQM could result in a duplicative transcription process that could lead to errors and conflict with the medical record maintained in the CEHRT, but we believe that the potential for error exists any time providers or documents attached to the medical record are created.

In order to identify mismatches and inaccuracies in data, in this final rule we are finalizing a policy to validate eCQM data beginning with the FY 2020 payment determination. We refer readers to section VIII.A.11.b of the preamble of this final rule for more details on the validation process for eCQM data.

Comment: One commenter expressed concern with these proposals because a number of hospitals have not successfully submitted QRDA I files and CEHRT is not capable of generating QRDA I files for submission without modifications. The commenter suggested that CMS provide more detailed guidance, education, and support on QRDA I file generation and release lessons learned to improve the process.

Response: We note that our data show that 95 percent of hospitals already attest to successful eCQM reporting under the Medicare EHR Incentive Program. However, we believe that the majority of hospitals will successfully report eCQMs. We recognize that technical mapping may be potentially burdensome, but we disagree that CEHRT is not capable of generating QRDA I files for submission without modifications. We encourage hospitals to work with their vendors to overcome these issues. We encourage all hospitals to submit files early, as well as to use one of the available presubmission testing tools for electronic reporting—such as the CMS Pre-Submission Validation Application (PSVA), which can be downloaded from the Secure File Transfer (SFT) section of the Quality Net Secure Portal at https://cportal.qualitynet.org/QNet/pgm_select.jsp. We refer readers to section VIII.A.11.b.(5) of the preamble of this final rule for more information about the PSVA. In addition, we acknowledge the commenter’s suggestion to put additional focus on QRDA I file generation in our education and outreach activities for the Hospital IQR Program.

After consideration of the public comments we received, we are finalizing that hospitals must report using EHR technology certified to either the 2014 or 2015 Edition for the CY 2017 reporting period/FY 2019 payment determination (not subsequent years) as proposed. We also refer readers to section VIII.A.10.d.(5) of the preamble of this final rule, in which we finalize alignment of this policy in the Medicare and Medicaid EHR Incentive Programs.

We are also finalizing, for the CY 2017 reporting period/FY 2019 payment determination and subsequent years, that hospitals: (1) Must submit eCQM data via QRDA I files as previously required; (2) may use a third party to submit QRDA I files on their behalf; and (3) may either use abstraction or pull the data from non-certified sources in order to then input these data into CEHRT for capture and reporting QRDA I as proposed.

(3) Required Use of EHR Technology Certified to the 2015 Edition for the FY 2020 Payment Determination and Subsequent Years

As stated in the FY 2016 IPPS/LTCPPS final rule (80 FR 49705), some commenters requested that hospitals be given the opportunity to use the most recent version of CEHRT (2015 Edition) for the CY 2016 reporting period/FY 2018 payment determination if they are able. We believe this requirement will mitigate the existing vendor issue of system comparability between hospitals and vendors and facilitate consistency regarding the version of CEHRT to which vendors are certified by establishing uniformity in the version of the product used. Therefore, in the FY
require reporting on only 8 self-selected eCQMs (instead of all eCQMs) to reduce burden, in part so that hospitals and vendors can focus on implementation of the 2015 Edition. We refer readers to section VIII.A.8.a. of the preamble of this final rule for more details on this modification. We believe that these modified requirements provide sufficient time for hospitals to test and deploy CEHRT. While we appreciate the commenter’s suggestion that we strive to enact a “predictable” cycle from measure development to provider data submission, we must balance the importance of keeping pace with evolving electronic standards and the timing cycle for the regulatory adoption of standards when adopting policies for the Hospital IQR Program.

After consideration of the public comments we received, we are finalizing the required use of EHR technology certified to the 2015 Edition for the CY 2018 reporting period/FY 2020 payment determination and subsequent years as proposed. We also refer readers to section VIII.A.10.d.(5) of the preamble of this final rule, in which we finalize alignment of policies in the Medicare and Medicaid EHR Incentive Programs.

(4) Electronic Submission Deadlines for the FY 2019 Payment Determination and Subsequent Years

We refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50256 through 50259) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49705 through 49708) for our previously adopted policies to align eCQM data reporting and submission periods for both the Medicare EHR Incentive Program for eligible hospitals and CAHs and the Hospital IQR Program for the FY 2018 payment determination.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50249 through 50252), we finalized our policy that hospitals may voluntarily report 16 electronic measures by submitting one quarter of eCQM data from CY Q1 (January 1–March 31, 2015), CY Q2 (April 1–June 30, 2015), or CY Q3 (July 1–September 30) by November 30, 2015. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49693 through 49698), for the FY 2018 payment determination, we finalized a policy that hospitals must submit one quarter of data (either Q3 or Q4 of CY 2016) for at least 4 eCQMs by the submission deadline of February 28, 2017.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25200), in order to align the Hospital IQR Program eCQM data submission with that of the Medicare EHR Incentive Program, which requires eCQM data submission by the end of two months following the close of the reporting period calendar year (80 FR 62896 through 62897), we proposed to establish an eCQM submission deadline for the Hospital IQR Program which requires eCQM data submission by the end of two months following the close of the calendar year for the CY 2017 reporting period/FY 2019 payment determination and subsequent years. For example, for the CY 2017 reporting period/FY 2019 payment determination, hospitals would be required to submit eCQM data for the Hospital IQR Program by February 28, 2018, which is the end of 2 months following the close of the calendar year (December 31, 2017). This would align the Hospital IQR Program with the Medicare EHR Incentive Program deadlines. We note that deadlines for the Medicaid (not Medicare) EHR Incentive Program differ by State, and therefore our proposal to align data submission deadlines for eCQMs applies only to the Hospital IQR Program and the Medicare EHR Incentive Program and not to the Medicaid EHR Incentive Program. For more information about the Medicaid EHR Incentive Program for eligible hospitals and CAHs, we refer readers to: https://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/Eligible_Hospital_Information.html.

We invited public comment on our proposal to align the Hospital IQR Program eCQM submission deadline with that of the Medicare EHR Incentive Program for the CY 2019 reporting period/FY 2019 payment determination and subsequent years as discussed above.

Comment: One commenter expressed support for the policy that the submission period for reporting eCQMs electronically is the two months following the close of the calendar year because this policy allows for continued improvement over the course of the year without the interruption of submission. Response: We thank the commenter for its support. With regard to the submission period for eCQM reporting, however, we note that we are finalizing our proposal to require eCQM data submission by the end of 2 months following the close of the reporting period calendar year for the CY 2017 reporting period/FY 2019 payment determination and subsequent years. We wish to clarify that the submission period would not be limited to only a two-month submission window from the end of the reporting period to the end of 2 months following the close of the reporting period as commenter suggested (for example, for CY 2017...
reporting, a submission window of January 1, 2018 through February 28, 2018. We anticipate that following the close of the CMS data receiving system for CY 2016 reporting period eCQM data submissions, we will re-open the system in late spring 2017 to be able to receive both QRDA I test files and QRDA I production files for CY 2017 reporting period eCQM data submissions. This would allow hospitals and vendors greater flexibility to submit QRDA I files earlier as soon as each calendar quarter ends rather than waiting to submit all QRDA I files during the last two months of the submission period.

We encourage all hospitals and vendors to submit QRDA I files early, as well as to use one of the presubmission testing tools for electronic reporting, such as the CMS Pre-Submission Validation Application (PSVA), to allow additional time for testing and to make sure all required data files are successfully submitted by the deadline. The PSVA can be downloaded from the Secure File Transfer (SFT) section of the QualityNet Secure Portal at: https://cportal.qualitynet.org/QNet/pgm_select.jsp. We refer readers to section VIII.A.11.b. of the preamble of this final rule in which the submission deadline for the Medicare and Medicaid EHR Incentive Program is finalized.

*Comment:* A few commenters supported the effort to align the proposals for both the Hospital IQR Program and the EHR Incentive Programs, but expressed concern about the same challenges in reporting all eCQMs in both the Medicare and Medicaid EHR Incentive Programs and in the Medicare IQR Program.

The commenters urged CMS to maintain the current requirements in the Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs for CY 2017 to give hospitals time to plan and prepare.

*Response:* We thank the commenters for their support. We refer readers to section VIII.A.8.a. of the preamble of this final rule for our discussion of the modified required number of eCQMs and our final policy.

**ALIGNMENT OF HOSPITAL IQR PROGRAM WITH BOTH THE MEDICARE AND MEDICAID EHR INCENTIVE PROGRAMS**

- Removal of 13 eCQMs.
- Requirement for submission of 8 self-selected eCQMs out of the available eCQMs for the CY 2017 reporting period/FY 2019 payment determination.
- Requirement for annual submission of four quarters of eCQM data.

*The Hospital IQR Program is also finalizing the required reporting of 8 eCQMs for the CY 2018 reporting period/FY 2020 payment determination.*

**ALIGNMENT OF HOSPITAL IQR PROGRAM WITH ONLY THE MEDICARE EHR INCENTIVE PROGRAM**

- Required submission of eCQM data by the end of 2 months following the close of the reporting period calendar year.

*We note that in the proposed rule (81 FR 25200 through 25201), this chart stated “proposed submission of eCQM data 2 months following the close of the calendar year” and did not accurately capture our proposal and final policy that submission would be required by the end of 2 months following the close of the reporting period calendar year. Technical revisions made here for accuracy.*
e. Sampling and Case Thresholds for the FY 2019 Payment Determination and Subsequent Years

We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50220), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819) for details on our sampling and case thresholds for the FY 2016 payment determination and subsequent years. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 24588), we revised our sampling and case thresholds policy so that, for the FY 2018 payment determination and subsequent years, hospitals will be required to submit population and sample size data only for those measures that a hospital submits as chart-abstracted measures under the Hospital IQR Program. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25201), we did not propose any changes to our sampling and case thresholds policy; however, we did receive several comments related to this policy.

f. HCAHPS Requirements for the FY 2019 Payment Determination and Subsequent Years

We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50220), the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 through 51643), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 through 53558), and the FY 2014 IPPS/LTCH PPS final rule (78 FR 50819 through 50820) for details on previously-adopted HCAHPS requirements. We also refer hospitals and HCAHPS survey vendors to the official HCAHPS Web site at http://www.hcahpsonline.org for new information and program updates regarding the HCAHPS Survey, its administration, oversight, and data adjustments. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25201), we did not propose any changes to the HCAHPS requirements.

g. Data Submission Requirements for Structural Measures for the FY 2019 Payment Determination and Subsequent Years

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51641 through 51643) and the FY 2013 IPPS/LTCH PPS final rule (77 FR 53537 through 53558) for details on the data submission requirements for structural measures. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25201), we did not propose any changes to data submission requirements for structural measures.

h. Data Submission and Reporting Requirements for HAI Measures Reported via NHSN

For details on the data submission and reporting requirements for HAI measures reported via the CDC’s NHSN Web site, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51629 through 51633; 51644 through 51645), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53539), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50821 through 50822), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50259 through 50262). The data submission deadlines are posted on the QualityNet Web site at: http://wwwQualityNet.org/. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25201), we did not propose any changes to data submission and reporting requirements for HAI measures reported via the NHSN.

11. Modifications to the Existing Processes for Validation of Hospital IQR Program Data

a. Background

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53539 through 53553), we finalized the processes and procedures for validation of chart-abstracted measures in the Hospital IQR Program for the FY 2015 payment determination and subsequent years; the FY 2013 IPPS/LTCH PPS final rule also contains a comprehensive summary of all procedures finalized in previous years that are still in effect. We refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50822 through 50835), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50262 through 50273), and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49710 through 49712) for detailed information on the modifications to these processes finalized for the FY 2016, FY 2017, and FY 2018 payment determinations and subsequent years. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25201 through 25204), we proposed to update the validation process in order to incorporate a process for validating eCQM data.

b. Modifications to the Existing Processes for Validation of Hospital IQR Program Data

(1) Background

In the proposed rule, we proposed to update the existing process for validation of Hospital IQR Program data, which has previously included up to 600 hospitals for chart-abstracted validation, to also include eCQM validation of up to 200 hospitals, for a total of up to 800 hospitals for validation for the FY 2020 payment determination and subsequent years. Specifically, 200 hospitals would be randomly selected for eCQM validation but among those hospitals some may be granted Extraordinary Circumstances Exemption (ECEs) or meet other exclusion criteria (discussed in additional detail below) potentially resulting in a number totaling less than 200 hospitals that actually participate in eCQM validation. Furthermore, we proposed that hospitals would be required to submit timely and complete medical record information from the Electronic Health Records (EHRs) for at least 75 percent of sampled records, but would not be scored on the basis of measure accuracy for FY 2020 payment determinations.

As we stated in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53555), determining the equivalence of eCQM data and chart-abstracted measures data requires extensive testing given that the data for the Hospital IQR Program support public reporting for both the Hospital IQR and the Hospital VBP Programs; in addition, for the Hospital VBP Program, the data are used to calculate hospitals’ performance on a subset of measures which tie payment directly to measure performance. As described in the Hospital IQR Program discussion in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50258), we have received anecdotal comments about performance level differences between chart-abstracted and eCQM data. We stated that we did not have sufficient data to be able to confirm or refute the accuracy of those comments (79 FR 50258). In order to substantiate or refute the existence of performance-level differences between eCQM data and chart-abstracted measure data, we believe that we must collect more eCQM data and develop a process for validating the accuracy of those data.

As a result, we conducted a validation pilot test for eCQMs (discussed below). Our findings from this pilot test have informed what we believe the initial future direction of eCQM validation in the Hospital IQR Program should be. In the proposed rule, we proposed to adopt a validation process for eCQM data submissions beginning in spring of CY 2018, as further explained below.

(2) Validation Pilot Test

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50269 through 50273), we finalized a proposal to conduct a validation pilot test for eCQMs in FY 2015. The results of the pilot test yielded measure record matching rates (including the rates of medical record abstracted values as compared to the values reported in the QRDA I file) of
less than 50 percent for all of the measures reported. For all measures, the inconsistencies between abstracted values and values reported in the QRDA I files appear to be mainly due to missing data rather than actual differences in reported versus abstracted values. The highest rate of accuracy was 48 percent on both the STK–04 and VTE–01 eCQMs. In addition, all of the participating hospitals demonstrated significant difficulty in reporting the ED–1 and ED–2 eCQMs due to the ED Admit Date/Time data element, which contributed to the ED measure mismatch rates. Specifically, hospitals systematically reported a later date and time for the decision to admit a patient to the hospital in the QRDA I file than that identified by the Clinical Data Abstraction Center (CDAC) in the review of the medical record.

Follow-up interviews conducted by CDAC revealed that low accuracy rates and reporting difficulties were a result of a lack of targeted outreach and education efforts at the time of the pilot to adequately prepare participating hospitals for the specific reporting mechanisms. In order to improve data accuracy and diminish reporting difficulties, the CMS Education and Outreach contractor (EOC) as well as the Validation Support Contractor (VSC) plan to continue to conduct provider education follow-up and refine the validation process. We will work in conjunction with the EOC and VSC to enlarge the cohort of eligible hospitals that are able to successfully submit QRDA I files, as well as encourage hospitals that were not able to successfully submit QRDA I files to participate in follow-up interviews. These follow-up interviews will inform the eCQM validation process moving forward, and allow us to derive “best reporting practices” to consider once we begin scoring the measures. Additional details about the 2015 Validation Pilot are available at: https://www.qualitynet.org/dcs/Content Server/c=Pages&pagename=NetPublic%2FfPage%2FQnetTier3&cid=1140537256076.

(3) Validation of eCQMs Beginning Spring CY 2018/FY 2020 Payment Determination

In response to the findings of the pilot test and in light of our proposal to increase the number of eCQMs on which hospitals are required to submit data for the Hospital IQR Program discussed in section VIII.A.8.a. of the preamble of this final rule, we believe that it is increasingly important to validate eCQM data to ensure the accuracy of future information submitted by hospitals and reported to the public. Therefore, we proposed to adopt a validation process for eCQM data submissions beginning in Spring of CY 2018, as further explained below.

(a) Number and Selection of Hospitals

We proposed to validate eCQM data submitted by up to 200 hospitals selected via random sample. Furthermore, we proposed that the following hospitals be excluded from this random sample of 200 hospitals selected for eCQM validation:

• Any hospital selected for chart-abstracted measure validation; and
• Any hospital that has been granted a Hospital IQR Program “Extraordinary Circumstances Exemption” for the applicable eCQM reporting period.

We acknowledge that the burden associated with both the chart-abstracted and eCQM validation processes would be significant. We do not intend to impose an undue burden on any hospital by requiring that it be subject to more than one of these processes in a program year. Thus, if a hospital is selected for chart-abstracted targeted or random validation, we proposed that hospital would be excluded from the eCQM validation sample.

In addition, although our targeted criteria permit that a hospital may be selected for chart-abstracted validation even if it has been granted an Extraordinary Circumstances Exemption with respect to one or more chart-abstracted measures for the applicable data collection period (77 FR 53552 through 53553), if a hospital is granted an Extraordinary Circumstances Exemption with respect to eCQM reporting for the applicable eCQM reporting period, we proposed that the hospital would be excluded from the eCQM validation sample.

Adding the proposed eCQM validation would result in a total of up to 800 hospitals in the validation process, as described in the below tables.

<table>
<thead>
<tr>
<th>Proposed Validation Process Number of Hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chart-Abstracted Random</td>
</tr>
<tr>
<td>Chart-Abstracted Targeted</td>
</tr>
<tr>
<td>eCQM Random</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

We believe that as we expand the required reporting of eCQMs in the Hospital IQR Program, we need to validate eCQM data to ensure the accuracy of information submitted by hospitals and reported to the public, as well as for future consideration of eCQMs for potential use in the Hospital VBP Program. In addition, during the first round of eCQM validation, we could better assess strategies to offset the resources required to conduct a scored method of eCQM validation for future rulemaking cycles.

We invited public comment on our proposals for the FY 2020 payment determination and subsequent years to:

1. Validate eCQM data submitted by up to 200 hospitals selected via random sample; and
2. Exclude any hospital selected for chart-abstracted measure validation as well as any hospital that has been granted a Hospital IQR Program “Extraordinary Circumstances Exemption” for the applicable eCQM reporting period as discussed above.

Comment: Several commenters supported the proposal to modify the existing validation process for the Hospital IQR Program to include validation of eCQM data for a variety of reasons. One commenter believed validation of eCQM data will promote transparency about the quality of the eCQM data being submitted as well as identify challenges inherent with data validity and eCQM reporting. The commenter recommended that CMS validate the accuracy of the content in the structured fields to see how consistent it is with the rest of the medical record because unless the accuracy of the structured fields is assured, the quality of the data reported by eCQM reporting will continue to be suspect and unfit for use in public reporting or pay-for-performance programs.

Response: We thank the commenters for their support and we will take recommendations related to the validation of the content in the structured files and its impact on medical record accuracy into consideration as we implement the validation of eCQM data. We understand the importance of reliable and valid information and share the commenter’s desire to ensure the integrity of the data provided for public
reporting and pay-for-performance programs.

**Comment:** One commenter expressed concern that insufficient testing could result in unintended consequences to patient safety and health care quality, but expressed concern that the validation pilot may be too narrow for an accurate review. Another commenter noted that data extracted from EHRs differ from the data obtained from chart-abstracted measures and, therefore, currently are not reliable for display in a public reporting program.

**Response:** We acknowledge the commenter’s concern about insufficient testing resulting in unintended consequences. We recognize that we must thoroughly evaluate the electronic data provided to us in order to promote patient safety and health care quality. We appreciate the commenter’s concern that the validation pilot may be too narrow for an accurate review and to address this concern we are expanding the validation process for eCQM data to include CY 2018 initially. After the first year of validation data is evaluated, we will be able to more accurately determine the most appropriate mechanisms for validating the information and consider if we need to expand the number of participating hospitals.

In response to the commenter’s point about differing data extraction methods, we recognize that performance-level differences between eCQMs and chart-abstracted measures may exist, however, we believe that we must collect more eCQM data and develop a process for validating the accuracy of those data. Further, we do not intend to publicly report eCQM data from the CY 2017 reporting period.

**Comment:** One commenter supported the proposed modifications to the existing validation process to include the validation of eCQM data, but expressed concern that the validation pilot focused only on the apparent lack of outreach and education to explain the mismatch between QRDA I and medical record abstraction to explain low level of accuracy. The commenter noted that other possible explanations for low accuracy include: Process workflows; data definitional issues; non-structured data requiring manual input; and the level of data completeness and reliability captured in CEHRT. The commenter recommended that CMS pursue additional strategies to increase the validity and reliability of the QRDA I reported measures. Also, because of the demonstrably poor concordance between eCQMs and their chart-abstracted counterparts, the commenter recommended that penalties be limited to pay-for-reporting, rather than pay-for-performance, programs until there are significantly better results. A few commenters expressed concern with the proposal to begin validating eCQM data because hospitals and vendors require more education and guidance to accurately report eCQM data. The commenters suggested that CMS improve the resources available to healthcare organizations regarding the implementation of eCQMs beyond validation. Another commenter expressed interest in engaging with CMS to further provide education to ensure that providers and vendors alike are aligned.

**Response:** We thank the commenter for these observations and we will consider these factors as we implement the validation process for eCQM data. The findings of the validation pilot revealed that hospitals indicated that they encountered difficulties in mapping the information in the EHR systems to the QRDA I specifications due to the use of unstructured data fields and multiple sources of information for various events. As stated in the proposed rule (81 FR 25202), the inconsistencies between abstracted values and values reported in the QRDA I files appear to be mainly due to missing data rather than actual differences in reported versus abstracted values. The highest rate of accuracy was 48 percent on both the STK-04 and VTE-1 eCQMs. In addition, all of the participating hospitals demonstrated significant difficulty in reporting the ED-1 and ED-2 eCQMs due to the ED Admit Date/Time data element, which contributed to the ED measure mismatch rates. Specifically, hospitals systematically reported a later date and time for the decision to admit a patient to the hospital in the QRDA I file than that identified by the Clinical Data Abstraction Center (CDAC) in the review of the medical record. The difficulties in mapping, which were caused by missing information, resulted in failure of the data to be translated to QRDA I. During the pilot, hospitals also indicated that much of the required information is documented in the hospital EHR system through free text notes, dictation, and scanned PDF documents, rather than discrete data fields. For this reason, data elements could not be extracted or mapped to create the data elements in the QRDA I files. In addition, hospitals indicated that clinical workflows and the use of clinical terminology did not align with the eCQM specifications at the time of the pilot, which hindered efficient data mapping by hospitals and their vendors.

For more details on the eCQM validation pilot test, titled “The Hospital IQR eCQM Pilot Summary,” we refer readers to the pilot test findings available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier3&cid=1140537256076.

As a result of these findings, we have updated the eCQM specifications to improve implementation and will continue outreach and education efforts, particularly regarding data mapping techniques/requirements to improve submission efforts moving forward. We appreciate the commenter’s interest in education and outreach and encourage the commenter to engage with CMS. In addition, we will take the commenters’ feedback into consideration as we provide education and outreach to hospitals and vendors about the eCQM validation requirements and we will solicit feedback on additional strategies to increase the validity and reliability of the QRDA I reported measures. We intend to continuously evolve our resources to ensure that healthcare organizations are equipped with the tools and knowledge to not only successfully submit eCQM data for validation, but to ensure that accurate and reliable data are submitted as part of regular eCQM reporting, prior to validation.

We note that accuracy of the data submitted for eCQM validation will have no impact on determination of the hospital’s APU for at least the first year of validation in CY 2018; however, hospitals selected for eCQM validation still must submit their data within 30 days of the records request and sufficient (at least 75 percent complete) medical records to receive a full APU for the FY 2020 payment determination. We refer readers to section VIII.A.11.b.[3](e) of the preamble of this final rule where we finalize our eCQM validation scoring policies.

**Comment:** A few commenters recommended delaying implementation of the proposal to begin validating eCQM data because the current timeline does not allow providers enough time to implement new processes in order to prevent receiving a penalty under the proposed validation policies. One commenter specifically recommended delaying validation by 24 months to allow providers to learn the rules of validation. Another commenter noted that the EHR vendor guidance for mapping data elements is not sufficient for full automation of the data extraction process such that most of the mapping is completed by hospital staff using their own procedures, resulting in a heavy burden for hospitals as well as...
high potential for inconsistency in measure reporting output, even among hospitals using the same EHR vendor product. The commenter recommended delaying implementation of the eCQM data validation proposal to allow more time for vendors to develop standardized procedures and hospitals to implement efficient workflows based on these standardized procedures and encouraged CMS to ensure that hospitals are reasonably able to comply with these new requirements. A commenter stated that the experience of participants in the eCQM data validation pilot suggests that more time is needed before data validation can be successfully implemented in the broader Hospital IQR Program.

Response: We thank the commenters for their recommendations, but we disagree with the suggestion to delay implementation of an eCQM validation process. We note that we will not conduct the first validation of eCQM data until spring of 2018 to validate data from the CY 2017 reporting period and that the measures accuracy of data submitted for eCQM validation will have no impact on determination of the hospital’s APU for purposes of the Hospital IQR Program for at least the first year this validation process is in effect. We believe this timeline does allow providers enough time to implement new processes and to learn the requirements of validation in order to prevent receiving a penalty under the validation policies.

We acknowledge that the data extraction process has been such that most of the mapping is completed by hospital staff using their own procedures, resulting in a high potential for inconsistency in measure reporting output, even among hospitals using the same EHR vendor product. It is precisely those types of inconsistencies on which we would be able to provide feedback to participating hospitals when sharing their validation results. Precisely because the results of the validation pilot demonstrated that there were significant inaccuracies in reported eCQM data, we believe that validation of eCQM data is critically important in order to guide improvement efforts and to tailor education and outreach to help hospitals improve the quality of the data they submit.

To address the suggestion of the creation of standardized data extraction procedures, we will utilize any input provided from EHR vendors during our education and outreach efforts that might be beneficial in such procedures. We also recognize that hospitals may have their own unique workflows, so input from both hospitals and EHR vendors would be utilized to help establish “best practices.”

Comment: Some commenters acknowledged the importance of eCQM validation, but expressed concerns about the process, specifically, variable methods of recording data within the EHR at the user level, non-intuitive data collection requirements imposed by the measures and/or product design, the differences between manually-abstracted and electronically-abstracted measures, and the workflow changes required for chart review. One commenter recommended that CMS consider the EHR vendor role in the validation plan, and work with vendors to understand some of these variations, as well as to identify EHR system functional requirements and query vendors as to current product capabilities relative to these requirements.

Response: Our proposed eCQM validation process is intended to help hospitals identify and correct inconsistencies associated with varying methods of recording data within the EHR and different interpretations of data collection requirements at the user level in order to improve the accuracy of data reported. Instituting an eCQM validation process will help us to better understand how to help hospitals resolve these data reporting concerns. We acknowledge that many hospitals will most likely continue to have concerns about the accuracy of their data in the first few years of required eCQM reporting. It is for this reason that we have proposed and are finalizing that the measures accuracy of data submitted for eCQM validation will have no impact on determination of the hospital’s APU for at least the first year (that is, the FY 2020 payment determination).

In response to the commenter’s recommendation that we consider the EHR vendor role in the validation plan and work with vendors to understand some of these variations, identify EHR system functional requirements, and query vendors as to current product capabilities relative to these requirements, we acknowledge that EHR vendors could provide feedback invaluable to the eCQM validation process. We will make efforts, to the extent feasible, to include vendors in our outreach and education efforts, to provide them an opportunity to share their knowledge related to EHR system functional requirements and product capabilities that can inform the validation process and help to improve it over time.

Comment: One commenter recommended that, rather than focusing on validating eCQM data, CMS only include an eCQM in a quality reporting program if it has been fully tested by CMS to ensure the measure functions as intended, is deemed feasible by an appropriate process that considers the views of multiple applicable stakeholders, is fully field tested, and is endorsed by NQF.

Response: We note that our data show that 95 percent of hospitals already attest to successful eCQM reporting under the Medicare EHR Incentive Program and, accordingly, we believe that the majority of hospitals will successfully report eCQMs. Hospitals have had several years to report data electronically for the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program (3 years of pilot reporting and 3 years of voluntary reporting), which demonstrate that the eCQMs included in the Hospital IQR Program measure set function as intended and are feasible. In addition, as noted in the table in section VIII.A.7.e. of the preamble of this final rule, almost all of the eCQMs available in the Hospital IQR Program measure set for the FY 2019 payment determination are endorsed by the NQF (only the CAC–3 and STK–08 eCQMs are not NQF-endorsed). Whenever feasible, we adopt measures that are NQF-endorsed, but note that, sometimes, there are important areas of clinical concern for which NQF-endorsed measures do not exist. In these instances, we may elect to adopt measures that have not yet been NQF-endorsed.

Comment: A number of commenters recommended that CMS share the findings from the 2015 eCQM Validation Pilot as a method of keeping stakeholders informed about the validation process. The commenters noted that sharing this information will improve eCQM reporting accuracy and also facilitate an educational forum that allows hospitals and stakeholders to understand how to better implement eCQMs. One commenter also stated CMS’ transparency with the results will allow hospitals to better understand the results and their general applicability to the greater hospital community.

Response: We agree with commenters and note that a summary of the findings from the eCQM validation pilot test we conducted, titled “The Hospital IQR eCQM Pilot Summary,” is available on the QualityNet Web site at: http://www.QualityNet.org/. Stakeholders were notified of the availability of this summary of the findings on June 13, 2016 via email. To access the summary, select the “Data Validation” link from...
the “Hospitals-Inpatient” tab. On the Data Validation Overview page, select the “Resources” link in the left-side navigation pane. A list of communications regarding the Hospital IQR Program is available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228765304720.

Comment: One commenter recommended that CMS extend the EHR pilot testing beyond two hospitals and two EHR systems, to gather adequate information to understand how the eCQMs will work. The commenter further recommended that CMS collect a minimum of one year’s worth of data from all hospitals and vendors chosen to participate in the EHR pilot testing, and explained that these data should be considered “test” data and not released publicly, but instead be released to hospitals for feedback to CMS. One commenter recommended additional testing of the eCQMs to avoid the unnecessary use of resources by facilities and CMS. Another commenter recommended that the implementation of eCQM data validation be delayed and that CMS convene stakeholders to discuss issues arising from the pilot project, clarify operational validation procedures based on that input, and then implement a larger pilot test before proposing and finalizing a validation process.

Response: The CMS eCQM validation pilot included 29 hospitals and 29 EHR systems, which we believe is an adequate sample size for a pilot. We disagree that eCQM validation should be delayed or that we should conduct another pilot because implementation of a validation process is intended to help hospitals identify and correct inconsistencies in eCQM data to improve the accuracy of data reported. Instituting an eCQM validation process will help us to better understand how to help hospitals resolve these data reporting concerns. Additional validation pilots would rely on voluntary participation by hospitals, which will produce a small sample size, as noted above with the 29 participating hospitals in the previous pilot.

We believe that implementing a broader validation process with mandatory participation better serves to achieve our goals of improving the accuracy of data reported and help us to better understand how to help hospitals resolve data reporting concerns because it will include a larger sample size. The objective of eCQM validation is to be responsive to feedback related to the reliability and validity of eCQM data, and ultimately to be able to confirm the accuracy of data sufficient for public reporting. If we continue to conduct pilot studies, we will continue to have inconclusive results based on a small sample size. We note that our data show that 95 percent of hospitals already attest to successful eCQM reporting under the Medicare EHR Incentive Program and, accordingly, we believe that the majority of hospitals will successfully report eCQMs; therefore, we do not believe additional testing is necessary or that implementation of an eCQM data validation process be delayed.

We note that we will not conduct the first validation of eCQM data until spring of 2018 to validate data from the CY 2017 reporting period, that the measures accuracy of data submitted for eCQM validation will have no impact on determination of the hospital’s APU for at least the first year (that is, FY 2020 payment determination), and that the results of the validation will not be publicly reported. We believe that sharing eCQM validation results with hospitals will provide invaluable feedback that will enable them to identify issues and correct issues to improve their EHRs as well as the quality of their eCQM data.

Comment: One commenter expressed concern regarding the results of the eCQM validation pilot, which highlighted challenges for implementing eCQMs including the burden associated with mapping necessary data elements from the EHR to the appropriate QRDA format.

Response: We appreciate the commenter’s concerns and acknowledge the burden associated with mapping necessary data elements from the EHR to the appropriate QRDA format. We encourage hospitals to work with their vendors to resolve these issues. Precisely because the results of the validation pilot demonstrated that there were significant inaccuracies in reported eCQM data, we believe that validation of eCQM data is critically important in order to guide improvement efforts and to tailor education and outreach to help hospitals improve the quality of the data they submit.

Comment: One commenter opposed the eCQM validation proposal, stating that the addition of the eCQM validation process puts undue burden on facilities. The commenter noted that because QRDA I files contain information from the electronic medical record, submitting the complete medical record in PDF format will not provide the variation that is contained in the EHR. Further, the commenter added that the data reported will be more accurate and valuable if the rollout includes fewer, well-tested measures.

Response: We believe that appropriately mapped QRDA I files contain information from the EHR, and that submitting the complete medical record in PDF format will provide the various information contained in the EHR. We recognize that technical mapping may be potentially burdensome and we encourage hospitals to work with their vendors to overcome these issues. When hospitals work with their vendors to ensure that EHRs are appropriately structured in a way that fits in with the clinical work flow to yield reliable data through eCQMs, we believe that eCQMs promote higher quality outcomes and lower costs while ultimately decrease reporting burden on hospitals as compared with chart-abstraction of quality measure data.

We disagree that reporting or validation of eCQMs puts undue burden on facilities. We believe that it is appropriate to require reporting and validation of eCQMs given that measures available now and those being developed for the future are increasingly based on electronic standards (80 FR 49696). We also note that progress on the meaningful use of electronic health data is a national priority, as evidenced by the HITTECH Act and the EHR Incentive Programs’ Meaningful Use requirements. We believe that collection of eCQM data will enable hospitals to efficiently capture and calculate quality data that can be used to address quality at the point of care and track improvements over time. We also believe that the removal of 13 eCQMs, as detailed in section VIII.A.3.b. of the preamble of this final rule for the FY 2019 payment determination and subsequent years, appropriately addresses that implementation of the validation process includes fewer, well-tested measures as suggested by the commenter. We acknowledge that there are initial costs, but believe that long-term benefits associated with electronic data capture outweigh those costs. For these reasons, we believe that it is appropriate to require hospitals to report on an increasing number of eCQMs, as well as to implement a process to validate the data as these go hand-in-hand.

Comment: One commenter expressed concern with the proposal to validate eCQM data because the sample size may not be large enough to ensure selection of 200 hospitals. The commenter suggested that additional hospitals be included in the random sample to provide the ability to substitute hospitals into the sample if they are
needed and to ensure that the match rate is 90 percent.

Response: We acknowledge that among those hospitals selected for eCQM validation, some may be granted Extraordinary Circumstances Exemptions or meet other exclusion criteria (discussed in additional detail below) potentially resulting in a number totaling less than 200 hospitals that actually participate in eCQM validation. We believe that the sample size of 200 hospitals, consistent with the targeted sample size for chart-abstracted validation, will be sufficient even taking into account the possibility that some hospitals selected for validation may not participate in validation if they satisfy any of the exclusion criteria. We may consider increasing the sample size in the future.

Comment: One commenter supported the proposal to modify the existing validation process to include validation of eCQM data, but recommended changes to the proposed validation methodology. Specifically, the commenter recommended that CMS: compare performance rates for all populations within an eCQM to their chart-abstracted counterparts, which would require comparable chart abstracted specifications; convene a multi-stakeholder group to address the detailed methodology of comprehensive data validation prior to submission and conduct an audit post-submission; and establish a National Test Collaborative for fully testing new eCQMs prior to their implementation in CMS programs.

Response: We thank the commenter for its suggestions, and we will take them into consideration as we implement the validation process for eCQM data. In response to the commenter’s suggestion that we compare performance rates for all populations within an eCQM to their chart-abstracted counterparts, we do not have data available to conduct such comparisons at this time, but as our eCQM validation process matures, we will take this recommendation into consideration in the future. However, we note that eCQM data and chart-abstracted data are not always one hundred percent comparable due to the use of structured data fields in eCQMs and free text in chart-abstracted measures. In response to the commenter’s suggestion that we convene a multi-stakeholder group to address the detailed methodology of comprehensive data validation prior to submission and conduct an audit post-submission, we acknowledge the importance of having multi-stakeholder input to inform pre and post submission validation efforts, and we believe that input from such a group would be meaningful as we continue to evolve our validation policies. Currently, we gather this type of input from Technical Expert Panels (TEPs) that assist in evaluating the information collected during field testing as a part of the eCQM development process. In addition, we gather feedback from stakeholders via public comment during both the alpha and beta testing phases of measure development. As such, we will make every effort to engage stakeholders in a similar manner, through outreach and education about eCQM validation. In response to the commenter’s point about establishing a National Test Collaborative, we will take this recommendation into consideration in the future.

Comment: One commenter expressed concern that the validation methodology could negatively impact hospitals because the CMS contractor will look at free text fields, which likely are not reviewed by the CEHRT tool.

Response: We acknowledge the commenter’s concerns, but we disagree that the validation methodology could negatively impact hospitals because as we have stated above, accuracy of the data submitted for eCQM validation will have no impact on determination of the hospital’s APU for at least the first year and the results of the validation will not be publicly reported. Further, as discussed in section VIII.A.10.d.(5) of the preamble of this final rule, we are finalizing the required use of EHR technology certified to the 2015 Edition beginning with the CY 2018 reporting period, to better ensure that the information provided in the free text fields has been adequately reviewed.

After consideration of the public comments we received, for the FY 2020 payment determination and subsequent years, we are finalizing our proposals to: (1) Validate eCQM data submitted by up to 200 hospitals selected via random sample; and (2) to exclude any hospital selected for chart-abstracted measure validation as well as any hospital that has been granted a Hospital IQR Program “Extraordinary Circumstances Exemption” for the applicable eCQM reporting period as proposed.

(b) Number of Cases

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25203), we proposed to randomly select 32 cases (individual patient-level reports) from the QRDA I file submitted per hospital selected for eCQM validation for the FY 2020 payment determination and subsequent years as discussed above. We did not receive any comments on this proposal, and therefore, we are finalizing our proposal to randomly select 32 cases from the QRDA I file submitted per hospital selected for eCQM validation for the FY 2020 payment determination and subsequent years as proposed.

(c) Submission Requirements

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25203), we proposed to require hospitals selected for eCQM validation to submit timely and complete medical record information to CMS on eCQMs selected for the validation sample. These are defined below.

\footnote{A data element is a representation of a clinical concept that represents a patient state or attribute. This may be a diagnosis, lab value, sex, etc., which is encoded using standardized terminologies. The e-specifications for an eCQM include the data elements, logic, and definitions for that measure, available from: https://www.cms.gov/Regulations-and-Guidance/Legislation/EHHIncentivePrograms/Electronic_Reporting_Spec.html}
Consistent with the Hospital IQR Program chart-abstracted and NHSN validation submission deadline, which is 30 calendar days following the medical records request date listed on the CDAC request form (76 FR 51645), we proposed to require eCQM validation submission by 30 calendar days following the medical records request date listed on the CDAC request form for the FY 2020 payment determination and subsequent years. Also, we proposed to require sufficient patient level information (defined below) necessary to match the requested medical record to the original Hospital IQR Program submitted eCQM measure data record for the FY 2020 payment determination and subsequent years. Sufficient patient level information is defined as the entire medical record that sufficiently documents the eCQM measure data elements, which would include but would not be limited to, patient arrival date and time, inpatient admission date, and discharge date from inpatient episode of care. Lastly, we proposed that, if selected as part of the random sample for eCQM validation, a hospital would be required to submit records in PDF file format through QualityNet using the Secure File Transfer (SFT) for the FY 2020 payment determination and subsequent years. The data submission deadlines and additional details about the eCQM validation procedures would be posted on the QualityNet Web site at: http://www.QualityNet.org/.

We invited public comment on our proposals regarding eCQM validation submission requirements for the FY 2020 payment determination and subsequent years as discussed above.

Comment: A few commenters supported the validation of eCQM data, but recommended the timeline for submission be extended from 30 to 60 days to allow hospitals sufficient time to work with their EHR vendor on compiling data and to reduce overall administrative burden.

Response: We thank the commenters for their support and their recommendation to extend the submission timeline to 60 days. However, we have selected the 30 day timeline to be consistent with chart-abstracted and NHSN timelines for validation. We believe that aligning the timelines between chart-abstracted and eCQM validation will minimize confusion and burden on hospitals.

Comment: One commenter expressed concern about the timing of the request for the validation information for eCQMs. Specifically, the commenter took issue with the expansion of work required if a hospital is selected for both chart-abstracted and eCQM validation, since the selection for each process is random. Moreover, the commenter advised that the eCQM data request should not occur at the same time the quarterly request goes out for the chart-abstracted cases.

Response: As stated in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25202), we acknowledge that the burden associated with both the chart-abstracted and eCQM validation processes would be significant. We do not intend to impose an undue burden on any hospital by requiring that it be subject to more than one of these processes in a program year. For this reason, we proposed that if a hospital is selected for chart-abstracted targeted or random validation, that hospital would be excluded from the eCQM validation sample. We refer readers to section VIII.A.11.b.(3)(a) of the preamble of this final rule, above, where we finalize our exclusions.

Comment: A few commenters requested clarification about what constitutes “sufficient patient level information” to successfully pass validation, including a list of specific information to provide for each eCQM that can be consistently applied across vendors and providers. Commenters wanted to know which specific patient data would be required for validation purposes and whether the medical record data includes all encounters for a patient or only one encounter for a patient.

Response: As we stated in the proposed rule (81 FR 25203), sufficient patient level information is defined as the entire medical record that sufficiently documents the eCQM measure data elements, which would include but would not be limited to, patient arrival date and time, inpatient admission date, and discharge date from inpatient episode of care. Any patient information captured in the QRDA I file should also be reflected in the PDF submission of the patient’s EHR. Medical record data include all encounters for a patient. The data submission deadlines and additional details about the eCQM validation procedures will be posted on the QualityNet Web site at: http://www.QualityNet.org/.

Comment: A few commenters supported the proposal to validate eCQM data, but suggested that the data elements for validation be listed by data element per measure. The commenters stated that this approach of providing measure-specific details of the expected data elements needed for the purpose of eCQM validation would make it more apparent to hospitals which data are expected for eCQM validation. The commenters further stated that having this specified list will streamline the process of data submission by easing the burden of making sure the necessary information is supplied.

Response: We thank the commenters for their support and we will consider the suggestion that data elements for validation be listed by data element per measure in the future. At this time, we believe that providing measure-specific details would be premature. As we learn from the first year of validation results, we will refine the process to ensure it most efficiently captures the necessary information while easing burden on hospitals.

After consideration of the public comments we received, we are finalizing, for the FY 2020 payment determination and subsequent years, the requirements to: (1) Require eCQM validation submission by 30 calendar days following the medical records request date listed on the CDAC request form; (2) require sufficient patient level information necessary to match the requested medical record to the original Hospital IQR Program submitted eCQM measure data record; and (3) require hospitals selected as part of the random sample for eCQM validation to submit records in PDF file format through QualityNet using the Secure File Transfer (SFT) as proposed.

(d) Scoring: Summary of Previously Adopted Chart-Abstracted Measure Validation Scoring

We refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50226 through 50227), the FY 2013 IPPS/LTCH PPS final rule (77 FR 53539 through 53553), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50832 through 50833), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50268 through 50269), for a detailed description of our previously adopted scoring methodology for chart-abstracted measure data.

We note that in the proposed rule (81 FR 25203), we did not propose any changes to our chart-abstracted measures validation. We are providing this information as background for our discussion of eCQM validation scoring. Under the current validation process for the Hospital IQR Program there are 600 hospitals (400 randomly sampled and 200 targeted) selected for validation on a yearly basis. As stated above, those selected for chart-abstracted measure validation would not be eligible for selection to participate in eCQM validation. For chart-abstracted measure validation, the CDAC contractor requests hospitals submit eight randomly selected medical charts on a quarterly basis from which data were

http://www.QualityNet.org/
ab abstracted and submitted by the hospital to the Clinical Data Warehouse (for a total of 32 charts per year). Under the validation methodology, once the CDAC contractor receives the charts, it reabstracts the same data submitted by the hospitals and calculates the percentage of matching Hospital IQR Program measure numerators and denominators for each measure within each chart submitted by the hospital. Each selected case has multiple measures included in the validation score. Consistent with previous years, each quarter and clinical topic is treated as a stratum for variance estimation purposes (70 FR 47423).

As in previous years, for the FY 2020 payment determination, the overall validation score from the chart-abstracted measure validation will be used to determine a hospital’s overall annual payment update. Specifically, if a hospital fails chart-abstracted validation, it would not receive the full annual payment update. If a hospital passes chart-abstracted validation, and also meets the other Hospital IQR Program requirements, it would be eligible to receive the full annual payment update. Consistent with previous years, a hospital must attain at least a 75 percent validation score (the percentage of matching Hospital IQR Program measure numerators and denominators for each measure within each chart submitted by the hospital) based upon chart-abstracted data validation to pass the validation requirement and to be eligible for a full annual payment update, if all other Hospital IQR Program requirements are met.

(e) Scoring: eCQM Validation Scoring

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25203 through 25204), for the FY 2020 payment determination, for hospitals selected for eCQM validation, we proposed to require submission of at least 75 percent of sampled eCQM measure medical records in a timely and complete manner. However, unlike chart-abstracted validation, which requires a hospital to attain at least a 75 percent validation score, we proposed that the accuracy of eCQM data (the extent to which data abstracted for validation matches the data submitted in the QRDA I file) submitted for validation would not affect a hospital’s validation score for the FY 2020 payment determination only. This is further explained below.

Public comments on the FY 2015 IPPS/LTCH PPS final rule suggested further clarification to the process for eCQM validation. Specifically, several commenters urged CMS to implement the recommendations of a March 2014 Government Accountability Office (GAO) report to develop a comprehensive data collection strategy, which includes testing for and mitigation of reliability issues arising from variance in certified EHR systems tested to different CQM specifications (79 FR 50272). Commenters in the FY 2016 IPPS/LTCH PPS final rule (80 FR 4971) expressed concern over the barriers hospitals encounter associated with reporting eCQMs and encouraged CMS to ensure that a diverse group of hospitals and certified EHRs are represented to inform an assessment of the work required to make eCQM validation feasible, reliable, and valid. In response to these concerns, in light of operational capacity limitations, and due to the time necessary to analyze eCQM validation results, we proposed that eCQM data would be validated, but initially (meaning for the FY 2020 payment determination only), the measure accuracy would not affect hospitals’ validation scores.

In other words, although hospitals would be required to submit eCQM data in a timely and complete manner, we proposed that hospitals would not be required to attain at least a 75 percent validation score to pass the validation requirement and to be eligible for a full annual payment update. Hospitals that submit at least 75 percent of sampled eCQM measure medical records (even if those records do not produce a validation score of at least 75 percent) in a timely manner (that is, within 30 days of the date listed on the CDAC medical records request) would not be subject to payment reduction. However, hospitals that fail to submit timely and complete information for at least 75 percent of the requested records would not meet the eCQM validation requirement and would be subject to payment reduction. For example, if a hospital submits timely and complete information for at least 75 percent of requested records, but comparison of the QRDA I file and the abstracted data results in a validation score of 28 percent, the hospital would still pass validation and be eligible for a full annual payment update.

Hospitals that pass either chart-abstracted or eCQM validation requirements would receive their full annual payment update, assuming all other Hospital IQR Program requirements are met. Hospitals that fail to attain at least a 75 percent validation score for chart-abstracted validation or fail to submit timely and complete data for 75 percent of requested records for eCQM validation, would not receive their full annual payment update.

In addition, we proposed to update our regulations at 42 CFR 412.140(d)(2) to reflect the above proposals and to specify that the 75 percent score would only apply to chart-abstracted validation.

We invited public comment on our eCQM validation scoring proposals for the FY 2020 payment determination as discussed above.

Comment: A few commenters expressed support for the proposal that eCQM data submitted for validation would not affect a hospital’s validation score for the FY 2020 payment determination.

Response: We thank the commenters for their support.

Comment: One commenter did not support the policy that hospitals would not be penalized for failing to submit 75 percent of the sampled eCQM data because multiple factors beyond a hospital’s control, including failure on the part of the EHR vendor, can impact the capture of data. The commenter stated that hospitals should not be penalized if they have made a good faith effort to accurately submit the data.

Response: We disagree with the commenter that hospitals should not be penalized for failing to submit 75 percent of sampled records. If selected for validation, a hospital would be required to submit at least 75 percent of sampled records. The accuracy of that data will have no impact on determination of the hospital’s APU for at least the first year. In other words, if the data in those records does not match the data in the QRDA I files submitted, for example, if a data field in a patient’s EHR is not correctly mapped to the QRDA I file such that the EHR indicates arrival time in the Emergency Department at 11:00am but the QRDA I file indicates some other time or leaves the value of that data field blank, the hospital would not receive any penalty for the mismatch.

The purpose of these validation efforts is to ensure that the data provided is reliable, feasible and valid. We believe that submission of 75 percent of the requested records is a necessary threshold to ensure that we have an adequate amount of data to assess and validate. Some commenters expressed concern that the initial sample size of 200 hospitals potentially could be too small, but we believe that establishing a submission threshold of 75 percent of the requested records will ensure that we receive an adequate amount of data to provide reliable and valid results for the sample size of 200 hospitals. We encourage hospitals to work with their vendors to ensure that EHRs are appropriately structured in a...
way that fits in with the clinical work flow to yield reliable data through eCQMs. We believe that eCQMs promote high quality outcomes and lower costs while ultimately decrease reporting burden on hospitals. If, however, the hospital has experienced an unforeseen circumstance beyond the hospital’s control that may meet our criteria for an Extraordinary Circumstances Exemption (ECE), we suggest that the hospital submit an ECE request.

After consideration of the public comments we received, we are finalizing for the FY 2020 payment determination only and as proposed: (1) To require submission of at least 75 percent of sampled eCQM measure medical records in a timely and complete manner; and (2) that the accuracy of eCQM data submitted for validation would not affect a hospital’s validation score. We are also finalizing to update our regulations at 42 CFR 412.140(d)(2) to reflect the above proposals and to specify that the 75 percent score required to receive full APU would only apply to chart-abstracted validation as proposed.

(4) Reimbursement for eCQM Validation

To align with the chart-abstracted validation process, which reimburses hospitals at a rate of $3.00 per chart (78 FR 50956) for submitting charts electronically via Secure File Transfer (SFT) for eCQM validation for the FY 2020 payment determination and subsequent years. We also refer readers to section X.B.6. of the preamble of this final rule for more information regarding the collection of information for eCQM validation.

We invited public comment on our proposal to reimburse hospitals at a rate of $3.00 per chart for eCQM validation for the FY 2020 payment determination and subsequent years as discussed above. We did not receive any comments on this proposal, and therefore, we are finalizing our policy to reimburse hospitals at a rate of $3.00 per chart for eCQM validation for the FY 2020 payment determination and subsequent years as proposed.

(5) eCQM Pre-Submission Testing

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25204), we encouraged hospitals to test their eCQM submissions prior to annual reporting using an available CMS pre-submission validation tool for electronic reporting—the Pre-Submission Validation Application (PSVA), which can be downloaded from the Secure File Transfer (SFT) section of the QualityNet Secure Portal at: https://cportal.qualitynet.org/QNet/pgm_select.jsp. The PSVA is a downloadable tool that operates on a user’s system to allow submitters to catch and correct errors prior to data submission to CMS. It provides validation feedback within the submitter’s system and allows valid files to be separated and submitted while identifying invalid files for error correction. While the PSVA does not guarantee the accuracy of data in a hospital’s QRDA I file, it helps to reduce submission errors related to improperly formatted QRDA I files. Pre-submission testing would assist in proactively identifying inconsistencies in data mapping, a process used in data warehousing by which different data models are linked to each other using a defined set of methods to characterize the data in a specific definition.


Data Mapping Definition Available at: https://www.techopedia.com/definition/6750/data-mapping.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25204), we did not propose any changes to our public display requirements.

14. Reconsideration and Appeal Procedures for the FY 2019 Payment Determination and Subsequent Years

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51650 through 51651), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836 through 50837), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277), the FY 2016 IPPS/LTCH PPS final rule (80 FR 49713), and 42 CFR 412.140(c) for details on the reconsideration and appeal procedures for the FY 2017 payment determination and subsequent years. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25204 through 25205), we did not propose any changes to the reconsideration and appeals procedures.

15. Changes to the Hospital IQR Program Extraordinary Circumstances Extensions or Exemptions (ECE) Policy

We refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51651 through 51652), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50836 through 50837), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277), the FY 2016 IPPS/LTCH PPS final rule (80 FR 49713), and 42 CFR 412.140(c)(2) for details on the Hospital IQR Program ECE policy. We also refer readers to the QualityNet Web site at http://www.QualityNet.org/ for our current requirements for submission of a request for an extension or exemption.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25205), we proposed to update our ECE policy by: (1) Extending the general ECE request deadline for non-eCQM circumstances from 30 to 90 calendar days following an extraordinary circumstance; and (2) establishing a separate submission deadline for ECE requests related to eCQM reporting circumstances to be April 1 following the end of the reporting calendar year. We proposed that these policies would apply beginning in FY 2017 as related to extraordinary circumstance events that occur on or after October 1, 2016.

a. Extension of the General ECE Request Deadline for Non-eCQM Circumstances

In the past, we have allowed hospitals to submit an ECE request form for non-eCQM measures within 30 calendar days following an extraordinary event that prevents them from providing data for non-eCQM measures (76 FR 51652). In certain circumstances, however, it may be difficult for hospitals to timely evaluate the impact of a certain extraordinary event on their calendar days. We believe that extending the deadline to 90 calendar days would...
allow hospitals more time to determine whether it is necessary and appropriate to submit an ECE request and to provide a more comprehensive account of the “event” in their ECE request form to CMS. For example, if a hospital has suffered damage due to a hurricane on January 1, it would have until March 31 to submit an ECE form via the QualityNet Secure Portal, mail, email, or secure fax as instructed on the ECE form. This proposed timeframe (90 calendar days) also aligns with the ECE request deadlines for the Hospital VBP Program (77 FR 50706), the HAC Reduction Program (80 FR 49580), and the Hospital Readmissions Reduction Program (80 FR 49542 through 49543), all of which at least partially rely on the same data collection.

We invited public comment on our proposal related to the Hospital IQR Program’s ECE policy for non-eCQM circumstances beginning FY 2017 as related to extraordinary circumstance events that occur on or after October 1, 2016 as described above.

Comment: Several commenters supported the proposal to extend the current submission deadline for ECE requests for non-eCQM measures to 90 days because it promotes alignment with existing quality reporting programs.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal to extend the general ECE request deadline for non-eCQM circumstances to 90 calendar days following an extraordinary circumstance event beginning FY 2017 as related to extraordinary circumstance events that occur on or after October 1, 2016 as proposed.

b. Establishment of Separate Submission Deadline for ECE Requests Related to eCQMs

In addition, we proposed to establish a separate submission deadline for ECE requests with respect to eCQM reporting, such that hospitals must submit a request by April 1 following the end of the reporting calendar year. We proposed that this deadline for ECE requests with respect to eCQM reporting would first apply with an April 1, 2017 deadline and apply for subsequent eCQM reporting years. For example, for data collected for the CY 2016 reporting period (through December 31, 2016), hospitals would have until April 1, 2017 to submit an ECE request. This timeframe also aligns with the Medicare and Medicaid EHR Incentive Programs’ typical annual hardship request deadline (77 FR 54104 through 54109), which we believe would help reduce burden for hospitals.

We invited public comment on our proposal for the Hospital IQR Program’s ECE policy related to eCQMs beginning FY 2017 as related to extraordinary circumstance events that occur on or after October 1, 2016 as described above.

Comment: Several commenters supported the proposal to establish a submission deadline for ECE requests for eCQMs because it promotes alignment with the Medicare and Medicaid EHR Incentive Programs. In addition, commenters stated that this alignment would allow facilities to adequately respond to events and assure patient safety prior to submitting the request for an extension or exemption.

Response: We thank the commenters for their support.

Comment: A few commenters asked for clarification on the circumstance for which an ECE request would be granted. Specifically, the commenters asked if a hospital would be granted an exemption if its EMR is under transition due to a change in vendors during the reporting period. In addition, a commenter asked whether, during the transition phase, the hospital would be required to include and report on all the required eCQMs in both the older and newer EHR.

Further, some commenters recommended that CMS develop an expansive definition of “extraordinary circumstances,” which provides detail on applicable technology difficulties (that is, switching EHR or third-party data eCQM submission vendors during the reporting period).

Response: Our current policy allows hospitals to utilize the existing ECE form to request an exemption from the Hospital IQR Program’s eCQM reporting requirement for the applicable program year based on hardships preventing hospitals from electronically reporting. Such hardships could include, but are not limited to, infrastructure challenges (hospitals must demonstrate that they are in an area without sufficient internet access or face insurmountable barriers to obtaining infrastructure) or unforeseen circumstances, such as vendor issues outside of the hospital’s control (including a vendor product losing certification) (80 FR 49695). With respect to the question of whether a hospital would be required to include and report on all the required eCQMs in both the older and newer EHR during an EHR transition phase, we note that ECE requests are considered on a case by case basis. Our decision whether to grant an ECE will be based on the specific circumstances of the hospital and the evidence submitted to us as part of the ECE request form.

After consideration of the public comments we received, we are finalizing for beginning FY 2017 as related to extraordinary circumstance events that occur on or after October 1, 2016, our proposals to establish: (1) A separate submission deadline for ECE requests with respect to eCQM reporting; and (2) a deadline of April 1 following the end of the reporting calendar year for ECE requests related to eCQM reporting as proposed.

B. PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

1. Background

Section 3005 of the Affordable Care Act added new sections 1866(a)(1)(W) and (k) to the Act. Section 1866(k) of the Act establishes a quality reporting program for hospitals described in section 1886(d)(1)(B)(v) of the Act (referred to as “PPS-Exempt Cancer Hospitals” or “PCHs”) that specifically applies to PCHs that meet the requirements under 42 CFR 412.23(f). Section 1866(k)(1) of the Act states that, for FY 2014 and each subsequent fiscal year, a PCH must submit data to the Secretary in accordance with section 1866(k)(2) of the Act with respect to such fiscal year. For additional background information, including previously finalized measures and other policies for the PCHQR Program, we refer readers to the following final rules: FY 2013 IPPS/LTCH PPS final rule (77 FR 53556 through 53561); the FY 2014 IPPS/LTCH PPS final rule (78 FR 50838 through 50846); the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277 through 50288); and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49713 through 49723).

2. Criteria for Removal and Retention of PCHQR Program Measures

We have received public comments on past proposed rules asking that we clarify our policy for measure retention and removal. We generally retain measures from the previous year’s PCHQR Program measure set for subsequent years’ measure sets, except when we specifically propose to remove or replace a measure. With respect to measure removal, we believe it is important to be transparent in identifying criteria that we would use to evaluate a measure for potential removal from the PCHQR Program. We also believe that we should align these criteria between our programs whenever possible.

Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 52505)
through 25206), we proposed the following measure removal criteria for the PCHQR Program, which are based on criteria established in the Hospital IQR Program (80 FR 49641 through 49642):

- Measure performance among PCHs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out”) measures;
- A measure does not align with current clinical guidelines or practice;
- The availability of a more broadly applicable measure (across settings or populations) or the availability of a measure that is more proximal in time to desired patient outcomes for the particular topic;
- Performance or improvement on a measure does not result in better patient outcomes;
- The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic;
- Collection or public reporting of a measure leads to negative unintended consequences other than patient harm; and
- It is not feasible to implement the measure specifications.

For the purposes of considering measures for removal from the program, we would consider a measure to be “topped-out” if there is statistically indistinguishable performance at the 75th and 90th percentiles and the truncated coefficient of variation is less than or equal to 0.10.

However, we recognize that there are times when measures may meet some of the outlined criteria for removal from the program, but continue to bring value to the program. Therefore, we proposed the following criteria for consideration in determining whether to retain a measure in the PCHQR Program, which also are based on criteria established in the Hospital IQR Program (80 FR 49641 through 49642):

- Measure aligns with other CMS and HHS policy goals;
- Measure aligns with other CMS programs, including other quality reporting programs; and
- Measure supports efforts to move PCHs towards reporting electronic measures.

We welcomed public comments on these proposed measure removal and retention criteria.

Comment: One commenter supported the proposed criteria for the removal and retention of measures, and recommended flexibility in determining whether measures are “topped out,” expressing concern that the proposed criteria could lack validity when applied to the small cohort of PCHs.

Response: We thank the commenter for its support. Although there are only 11 PCHs, we believe if they are all achieving performance within the top quartile that it is reasonable to review the measure to determine whether it has been “topped out.”

Comment: A commenter recommended that, if the measure retention and removal criteria are adopted, CMS remove three existing PCHQR measures as topped out (NQF #0223, Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 Days) of Diagnosis to Patients Under the Age of 80 with AJCC III (Lymph Node Positive) Colon Cancer; NQF #0559, Combination Chemotherapy is Considered or Administered Within 4 Months (120 Days) of Diagnosis for Women Under 70 with AJCC T1cN0M0, or Stage IB–III Hormone Receptor Negative Breast Cancer; and NQF #0220, Adjuvant Hormonal Therapy).

Response: We thank the commenter for the recommendation and will consider this recommendation in the future.

After consideration of the public comments we received, we are finalizing the measure removal and retention policy as proposed.

3. Retention and Update to Previously Finalized Quality Measures for PCHs Beginning With the FY 2019 Program Year

a. Background

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53556 through 53561), we finalized five quality measures for the FY 2014 program year and subsequent years. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50837 through 50847), we finalized one new quality measure for the FY 2015 program year and subsequent years and 12 new quality measures for the FY 2016 program year and subsequent years. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50278 through 50280), we finalized one new quality measure for the FY 2017 program year and subsequent years. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49713 through 49719), we finalized three new CDC NHSN measures for the FY 2018 program year and subsequent years, and finalized the removal of six previously finalized measures for fourth quarter (Q4) 2015 discharges and subsequent years. We refer readers to the final rule referenced in section VIII.B.1. of the preamble of this final rule for more information regarding these previously finalized measures.

Comment: One commenter supported the continued inclusion of the Influenza Vaccination Coverage Among Healthcare Personnel (HCP) in the PCHQR Program.

Response: We thank the commenter for its support.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 32706), we did not propose for FY 2019 to remove any of the measures previously finalized for the FY 2018 program year from the PCHQR measure set. However, we did propose to update the Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382) measure, as described below.

b. Update of Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382) Measure for FY 2019 Program Year and Subsequent Years

Beginning with the FY 2019 program year, we proposed to update the specifications of the Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382) measure. This measure was originally finalized in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50841 through 50842). In November 2014, subsequent to our adoption of the measure in the PCHQR Program, updated specifications were endorsed by the NQF.

The updated measure specifications expand the patient cohort to include patients receiving 3D conformal radiation therapy for breast or rectal cancer in addition to patients receiving 3D conformal radiation therapy for lung or pancreatic cancers (the original cohort).194 For additional information about the original measure cohort, we refer readers to the FY 2014 IPPS/LTCH PPS final rule (78 FR 50842), in which we introduced the measure to the PCHQR Program. In 2012, breast cancer was the most common cancer among women, and the second most common cause of cancer related deaths for women.195 For 2016, the National Institutes of Health estimates that there will be approximately 135,000 new cases of colorectal cancer in the United States, with approximately 39,000 of these cases being rectal cancer.196 As these cancer types are so prevalent, we believe that the expansion of the measure cohort to include breast and rectal cancer patients is important.

194 Available at: http://www.qualityforum.org/QPS/0382.


to ensuring the delivery of high quality care in the PCH setting. In compliance with section 1890A(a)(2) of the Act, this measure update was included in a publicly available document, “List of Measures under Consideration for December 1, 2015.”197 The MAP, a multi-stakeholder group convened by the NQF, reviews the measures under consideration for the PCHQR Program, among other Federal programs, and provides input on those measures to the Secretary. The MAP’s 2016 recommendations for quality measures under consideration are captured in the following document: “Process and Approach for MAP Pre-Rulemaking Deliberations 2015–2016” (http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81599). The MAP expressed conditional support for the update of Oncology: Radiation Dose Limits to Normal Tissues. The MAP’s conditional support was solely pending annual NQF review, and was not based on significant concerns. We considered the input and recommendations provided by the MAP, and the importance of aligning with NQF-endorsed specifications of measures whenever possible in proposing this update for the PCHQR Program.

We welcomed public comments on this proposal for the Oncology: Radiation Dose Limits to Normal Tissues measure cohort expansion for the FY 2019 program year and subsequent years.

Comment: Two commenters supported the expansion of the Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382) measure specifications to include breast and rectal cancers. One commenter that supported the expansion urged delay until the expansion received NQF endorsement.

Response: We thank the commenters for their support. We believe it is important to continue to expand the PCHQR measures to provide meaningful information to patients and facilities. The NQF endorsed the measure with the expanded cohort in 2014. Our proposal would expand the cohort pursuant to NQF’s 2014 endorsement of the cohort expansion and is not impacted by the regular annual review process in which NQF engages on all measures. We considered the MAP’s recommendations, and the importance of aligning with NQF-endorsed specifications of measures whenever possible, when we proposed this update for the PCHQR Program.

After consideration of the public comments we received, we are finalizing the update to the measure specifications as proposed.

4. New Quality Measure Beginning With the FY 2019 Program Year

a. Considerations in the Selection of Quality Measures

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53556), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50837 through 50838), and the FY 2015 IPPS/LTCH PPS final rule (79 FR 50278), we indicated that we have taken a number of principles into consideration when developing and selecting measures for the PCHQR Program, and that many of these principles are modeled on those we use for measure development and selection under the Hospital IQR Program. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25206), we did not propose any changes to the principles we consider when developing and selecting measures for the PCHQR Program.

Section 1866(k)(3)(A) of the Act requires that any measure specified by the Secretary must have been endorsed by the entity with a contract under section 1890(a) of the Act (the NQF is the entity that currently holds this contract). Section 1866(k)(3)(B) of the Act provides an exception under which, in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25206 through 25210), using the principles for measure selection in the PCHQR Program, we proposed one new measure, described below.

b. Adoption of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy Measure

We proposed to adopt the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure for the FY 2019 program year and subsequent years. Cancer care is a priority area for outcome measurement because cancer is an increasingly prevalent condition associated with considerable morbidity and mortality. In 2015, there were more than 1.6 million new cases of cancer in the United States.198 Each year, about 22 percent of cancer patients receive chemotherapy,199 with Medicare payments for cancer treatment totaling $34.4 billion in 2011 or almost 10 percent of Medicare fee-for-service (FFS) spending.200 With an increasing number of cancer patients receiving chemotherapy in a hospital outpatient department,201 a growing body of peer-reviewed literature identifies unmet needs in the care provided to these patients. This gap in care may be due to reasons including: (1) Delayed onset of side effects that patients must manage at home; (2) patients assuming that little can be done and not seeking assistance; and (3) limited access to and communication with providers who can tailor care to the individual.202 As a result, cancer patients that receive chemotherapy in a hospital outpatient department require more frequent acute care in the hospital setting and experience more adverse events than cancer patients that are not receiving chemotherapy.203 204 205


202 203 204 205
Unmet patient needs resulting in admissions and ED visits related to chemotherapy treatment pose a heavy financial burden and affect patients’ quality of life. Based on available commercial claims data, in 2010 the national average cost of a chemotherapy-related admission was $22,000, and the average cost of a chemotherapy-related ED visit was $800. Furthermore, admissions and ED visits can reduce patients’ quality of life by affecting their physical and emotional well-being, disrupting their schedules, decreasing their desire to engage in work and social activities, and increasing the burden on their family.

Hospital admissions and ED visits among cancer patients are often caused by manageable side effects. Chemotherapy treatment can have severe, predictable side effects. Recent studies of cancer outpatients show the most commonly cited symptoms and reasons for unplanned hospital visits following chemotherapy treatment are pain, anemia, fatigue, nausea and/or vomiting, fever and/or febrile neutropenia, shortness of breath, dehydration, diarrhea, and anxiety/depression. These hospital visits may be due to conditions related to the cancer itself or to side effects of chemotherapy. However, treatment plans and guidelines exist to support the management of these conditions.


This proposed measure aligns with the two process measures we adopted in the FY 2014 IPPS/LTC FPS final rule (78 FR 50842 through 50843) for PY 2016 and uses (1) Clinical Process/Oncology Care—Plan of Care for Pain (NQF #0383); and (2) Clinical Process/Oncology: Medical and Radiation—Pain Intensity Quantified (NQF #0384). These NQF-endorsed measures focus on processes of care related to cancer care. Process measures NQF #0383 and NQF #0384, which are not risk-adjusted, support the purpose of the proposed measure by reinforcing that providers of outpatient care should screen for and manage symptoms such as pain. The proposed measure improves upon these two measures in two key ways: (1) It does not target a specific symptom, but rather assesses the overall management of 10 important symptoms that studies have identified as frequent reasons for ED visits and inpatient admissions in this population; and (2) it assesses the care outcomes that matter to patients, rather than measuring processes to detect and treat these conditions. Furthermore, we are not aware of any other measures a consensus organization has endorsed or adopted that assess the quality of outpatient cancer care by measuring unplanned inpatient admissions and ED visits.

The 2015 MAP supported this measure on the condition that it is reviewed and endorsed by NQF. We refer readers to the Spreadsheet of MAP 2016 Final Recommendations available at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81593. In particular, MAP members recommended considering the measure for sociodemographic status (SDS) adjustment in the ongoing NQF trial period and reviewing it to ensure that the detailed specifications meet the purpose of the measure and align with current cancer care practice.

We understand the important role that SDS plays in the care of patients. However, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of diverse sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures.

The NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors.
The proposed measure uses 1 year of Medicare FFS Part A and Part B administrative claims data with respect to beneficiaries receiving chemotherapy treatment in a PCH outpatient setting. The qualifying diagnosis on the admission or ED visit claim must be: (1) the primary diagnosis; or, (2) a secondary diagnosis accompanied by a primary diagnosis of cancer.

We limited the window for identifying the outcomes of admissions and ED visits to 30 days after PCH outpatient chemotherapy treatment encounters, as existing literature suggests the vast majority of adverse events occur within that time frame and we also observed this during testing. In addition, the technical expert panel (TEP) supported this time window because: (1) It helps link patients’ experiences to the facilities that provided their recent treatment while accounting for variations in time between outpatient treatment encounters; (2) It supports the idea that the admission is related to the management of side effects of treatment and ongoing care, as opposed to progression of the disease or other unrelated events; and (3) Clinically, 30 days after each outpatient chemotherapy treatment is a reasonable timeframe to observe related side effects.

The measure identifies outcomes separately for the inpatient admissions and ED visits. A patient can qualify only once for one of the two outcomes in each measurement period. If patients experience both an inpatient admission and an ED visit after outpatient chemotherapy during the measurement period, the measure counts them toward the inpatient admission outcome because this outcome represents a more significant deterioration in patient quality of life, and is more costly. Among those with no qualifying inpatient admissions, the measure counts qualifying standalone ED visits. As a result, the rates provide a comprehensive performance estimate of quality of care. We calculate the rates separately because the severity and cost of an inpatient admission differ from those of an ED visit, but both adverse events are significant quality indicators and represent outcomes of care that are important to patients.

The measure attributes the outcome to the PCH where the patient received chemotherapy treatment during the 30 days before the outcome. If a patient received outpatient chemotherapy treatment from more than one PCH in the 30 days before the outcome, the measure would attribute the outcome to all the PCHs that provided treatment. For example, if a patient received an outpatient chemotherapy treatment at PCH A on January 1, a second treatment at PCH B on January 10, and then experienced a qualifying inpatient admission on January 15, the measure would count this outcome for both PCH A and PCH B because both PCHs provided outpatient chemotherapy treatment to the patient within the 30-day window. However, if a patient received an outpatient chemotherapy treatment from PCH A on January 1, and a second treatment from PCH B on March 1, and then experienced a qualifying inpatient admission on March 3, the measure would attribute this outcome only to PCH B. In measure testing, using Medicare FFS claims data from July 1, 2012, to June 30, 2013, only 5 percent of patients in the cohort received outpatient chemotherapy treatment from more than one facility during that year.

For additional methodology details, including the code sets used to identify the qualifying outcomes, we refer readers to the CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html under "Hospital Outpatient Chemotherapy." This measure includes all adult Medicare FFS patients because this would enable us to more broadly assess the quality of care provided by the PCH. This measure focuses on treatments in the PCH outpatient setting because of the increase in hospital-based chemotherapy, which presents an opportunity to coordinate care. From 2008 to 2012, the proportion of Medicare patients receiving hospital-based outpatient chemotherapy increased from 18 to 29 percent, and this trend is likely to continue. As currently specified, the measure identifies chemotherapy treatment using ICD-9-CM procedure and encounter codes.
codes and Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding System (HCPCS) procedure and medication procedure codes. It excludes procedure codes for oral chemotherapy because it is challenging to identify oral chemotherapy without using pharmacy claims data and, according to our TEP, most oral chemotherapies have fewer adverse reactions that result in admissions. We have developed a “coding crosswalk” between the ICD–9–CM codes and the ICD–10 codes that became effective beginning on October 1, 2015, and we will test this crosswalk prior to implementation. For detailed information on the cohort definition, including the ICD–9–CM, ICD–10, CPT, and HCPCS codes that identify chemotherapy treatment, we refer readers to the Data Dictionary appendix to the measure Technical Report at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/HospitalQualityInits/Measure-Methodology.html under “Hospital Outpatient Chemotherapy.” The measure excludes three groups of patients: (1) Patients with a diagnosis of leukemia at any time during the measurement period because of the high toxicity of treatment and recurrence of disease, and because inpatient admissions and ED visits may reflect a relapse, rather than poorly managed outpatient care; (2) patients who were not enrolled in Medicare FFS Parts A and B in the year before the first outpatient chemotherapy treatment encounter during the measurement period (because the risk-adjustment model uses claims data for the year before the first chemotherapy treatment encounter during the period to identify comorbidities); and (3) patients who do not have at least one outpatient chemotherapy treatment encounter followed by continuous enrollment in Medicare FFS Parts A and B in the 30 days after the encounter (because the measure cannot assess the 30-day outcome in this group since it uses claims data to determine whether a patient had at least one ED visit or a hospital inpatient admission).

Risk adjustment takes into account important demographic and clinically-relevant patient characteristics that have strong relationships with the outcome. It seeks to adjust for differences in patient demographics, clinical comorbidities, and treatment exposure, which vary across patient populations and influence the outcome but do not relate to quality. Specifically, the measure adjusts for: (1) The patient’s age at the start of the measurement period; (2) sex; (3) comorbidities that convey information about the patient in the 12 months before his or her first outpatient chemotherapy treatment encounter during the measurement period; (4) cancer type; and (5) the number of outpatient chemotherapy treatments the patient received at the reporting PCH during the measurement period.

We developed two risk-adjustment models, one for each dependent variable described above—qualifying inpatient admissions and qualifying ED visits. The separate models are necessary to enable the use of the most parsimonious model with variables tailored to those that are most predictive for each of the measure’s two mutually exclusive outcomes. The measure algorithm first searches for a qualifying inpatient admission, and for those patients that do not have a qualifying inpatient admission, searches for a qualifying ED visit. Therefore, the patient-mix and predictive risk factors for each outcome is slightly different. The statistical risk-adjustment model for inpatient admissions includes 20 clinically relevant risk-adjustment variables that are strongly associated with the risk of one or more hospital admissions within 30 days following an outpatient chemotherapy treatment encounter in a hospital outpatient setting; the statistical risk-adjustment model for ED visits includes 15 clinically relevant risk-adjustment variables that are strongly associated with risk of one or more ED visits within 30 days following an outpatient chemotherapy treatment encounter in a hospital outpatient setting (3 comorbidities and 2 cancer types significant for inpatient admissions are not significant for ED visits). The measure uses hierarchical logistic modeling, similar to the approach used in the CMS inpatient hospital 30-day risk-standardized mortality and readmission outcome measures, such as the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Acute Myocardial Infarction (AMI) Hospitalization.114 This approach appropriately accounts for both differences in patient-mix and the clustering of observations within PCHs. The measure calculates the PCH-specific risk-adjusted rate as the ratio of the PCH’s “predicted” number of outcomes to “expected” number of outcomes multiplied by the national observed outcome rate. It estimates the expected number of outcomes for each PCH using the PCH’s patient-mix and the average PCH-specific intercept (that is, the average intercept among all PCHs in the sample). The measure estimates the predicted number of outcomes for each PCH using the same patient-mix, but an estimated PCH-specific intercept.

The measure calculates two rates, one for each mutually exclusive outcome (qualifying inpatient admissions and qualifying ED visits). It derives the two rates (also referred to as the PCH-level risk-standardized admission rate (RSAR) and risk-standardized ED visit rate (RSEDR)), from the ratio of the numerator to the denominator multiplied by the national observed rate. The numerator is the number of predicted (meaning adjusted actual) patients with the measured adverse outcome. The denominator is the number of patients with the measured adverse outcome the PCH is expected to have based on the national performance with the PCH’s case mix. The national observed rate is the national unadjusted number of patients who have an adverse outcome among all the qualifying patients who had at least one chemotherapy treatment encounter in a PCH. If the “predicted” number of outcomes is higher (or lower) than the “expected” number of outcomes for a given hospital, the risk-standardized rate will be higher (or lower) than the national observed rate.

For more detailed information on the calculation methodology, we refer readers to the methodology report at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/HospitalQualityInits/Measure-Methodology.html under “Hospital Outpatient Chemotherapy.”

We would publicly report the RSAR and RSEDR for all participating PCHs with 25 or more eligible patients per measurement period to maintain a reliability of at least 0.4 (as measured by the interclass correlation coefficient, ICC). If a PCH does not meet the 25 eligible patient threshold, we would include a footnote on the Hospital Compare Web site indicating that the number of cases is too small to reliably measure that PCH’s rate. These patients and PCHs would still be included when calculating the national rates for both the RSAR and RSEDR.

To prepare PCHs for public reporting, we would conduct a confidential national reporting (dry run) of measure results prior to public reporting. The objectives of the dry run are to: (1) Educate PCHs and other stakeholders about the measure; (2) allow PCHs to review their measure results and data prior to public report; (3) answer questions from PCHs and other stakeholders; (4) test the production and
reporting process; and (5) identify potential technical changes to the measure specifications that might be needed. We have not yet determined the measurement period to use for the dry run calculations, but acknowledge the importance of including some data based on ICD–10 codes to evaluate the success of the “coding crosswalk.”

We invited public comment on our proposal to adopt the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure for the FY 2019 program year and subsequent years.

**Comment:** A few commenters supported the inclusion of the Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy measure into the PCHQR program.

**Response:** We thank the commenters for their support.

**Comment:** Several commenters generally opposed the adoption of the proposed measure because the MAP conditionally supported it pending NFQ endorsement, and the NFQ has not formally announced its decision. Other commenters opposed the adoption of the measure because of general concerns with its validity and reliability, providing examples of ICD–10 codes not related to chemotherapy or inpatient admissions in which a patient received treatment for pain and nausea but in which the pain and nausea was not related to chemotherapy treatment. One commenter supported the measure provided it has been tested for validity and reliability.

**Response:** We thank the commenters for their views regarding the MAP review and NFQ endorsement. In evaluating and selecting the measure for inclusion in the PCHQR Program, we considered whether there were other available measures that have been endorsed or adopted by the NFQ, and were unable to identify any other NFQ-endorsed measures that assess admissions and ED visits following outpatient chemotherapy. We developed the measure using the same rigorous process that we have used to develop other publicly reported outcomes measures. As part of that process, we sought and received extensive input on the measure from stakeholders and clinical experts.

We disagree with commenters regarding the proposed measure’s reliability and believe that this measure is sufficiently reliable to be included in the PCHQR Program. Measure reliability was calculated using a split sample of one year of data. We randomly split the patient cohort at each hospital into two equal halves, calculated the measure using each half, and then calculated the agreement between these two (the “test” and the “retest”). Following this test-retest methodology, we calculated the Pearson correlation between the performance rate estimates in each half-year sample to assess reliability. We found the RSAR to have a reliability of 0.41 (95 percent confidence interval (CI): 0.37–0.45) and the RSEDR to have a reliability of 0.27 (95 percent CI: 0.22–0.33) which, according to Cohen’s classification, represent moderate and borderline weak-to-moderate reliability, respectively.

The 95 percent CI gives us a reasonable estimate of the true reliability range.

Our reliability estimate was arguably limited by our use of a half year of split data. We expected our reliability to be higher if we increased the amount of data we used. Therefore, after submitting the measure to NFQ for endorsement review, we conducted additional calculations of the reliability testing scoring the Intraclass Correlation Coefficient (ICC) and the Spearman-Brown prophecy formula. The Spearman-Brown prophecy formula is an accepted statistical method that estimates the ICC based on what would be expected if the sample size was increased. It therefore provides us with an estimate of what the reliability score would be if CMS were to use a full year of data for public reporting rather than the six months of data that we used. Using the Spearman-Brown prophecy formula, we estimated that our measure will have an ICC of 0.63 (95 percent CI: 0.58–0.68) for RSAR and 0.47 (95 percent CI: 0.40–0.53) for RSEDR using a full year of data.

The NFQ considers ICC values ranging from 0.41 to 0.60 as “moderate” reliability, and 0.61 to 0.80 as “strong” reliability. Our calculated ICC values of 0.63 for RSAR and 0.47 for RSEDR are interpreted as “strong” and “moderate” reliability, respectively.

We also disagree with the concerns regarding the validity of the measure. This measure is an important signal of high quality care and is specified in a way to appropriately differentiate between cancer hospitals providing high and low quality care for these patients. This measure assesses an aspect of care and symptoms that are the subject of the measure, such as pneumonia, could be due to causes other than chemotherapy side effects and are not appropriate to combine. One commenter also stated that the list of ICD–10 codes contained in the measure submission documents includes codes for diagnoses that are unrelated to chemotherapy, and further suggested that the measure does not differentiate between chemotherapy-related and unrelated admissions and emergency department visits.

**Response:** Given the increase in outpatient hospital-based chemotherapy, understanding and minimizing related unplanned admissions and ED visits is a high priority. The 10 conditions that the measure captures are commonly cited reasons for hospital outpatient visits among patients receiving chemotherapy in the hospital outpatient setting, and are potentially preventable through appropriately managed outpatient care and increased communication with the medical team. The NQF considers ICC values ranging from 0.41 to 0.60 as “moderate” reliability, and 0.61 to 0.80 as “strong” reliability. Our calculated ICC values of 0.63 for RSAR and 0.47 for RSEDR are interpreted as “strong” and “moderate” reliability, respectively.

We also disagree with the concerns regarding the validity of the measure. This measure is an important signal of high quality care and is specified in a way to appropriately differentiate between cancer hospitals providing high and low quality care for these patients. This measure assesses an aspect of care and symptoms that are the subject of the measure, such as pneumonia, could be due to causes other than chemotherapy side effects and are not appropriate to combine. One commenter also stated that the list of ICD–10 codes contained in the measure submission documents includes codes for diagnoses that are unrelated to chemotherapy, and further suggested that the measure does not differentiate between chemotherapy-related and unrelated admissions and emergency department visits.

**Response:** Given the increase in outpatient hospital-based chemotherapy, understanding and minimizing related unplanned admissions and ED visits is a high priority. The 10 conditions that the measure captures are commonly cited reasons for hospital outpatient visits among patients receiving chemotherapy in the hospital outpatient setting, and are potentially preventable through appropriately managed outpatient care and increased communication with the medical team. The NQF considers ICC values ranging from 0.41 to 0.60 as “moderate” reliability, and 0.61 to 0.80 as “strong” reliability. Our calculated ICC values of 0.63 for RSAR and 0.47 for RSEDR are interpreted as “strong” and “moderate” reliability, respectively.

We also disagree with the concerns regarding the validity of the measure. This measure is an important signal of high quality care and is specified in a way to appropriately differentiate between cancer hospitals providing high and low quality care for these patients. This measure assesses an aspect of care and symptoms that are the subject of the measure, such as pneumonia, could be due to causes other than chemotherapy side effects and are not appropriate to combine. One commenter also stated that the list of ICD–10 codes contained in the measure submission documents includes codes for diagnoses that are unrelated to chemotherapy, and further suggested that the measure does not differentiate between chemotherapy-related and unrelated admissions and emergency department visits.

**Response:** Given the increase in outpatient hospital-based chemotherapy, understanding and minimizing related unplanned admissions and ED visits is a high priority. The 10 conditions that the measure captures are commonly cited reasons for hospital outpatient visits among patients receiving chemotherapy in the hospital outpatient setting, and are potentially preventable through appropriately managed outpatient care and increased communication with the medical team. The NQF considers ICC values ranging from 0.41 to 0.60 as “moderate” reliability, and 0.61 to 0.80 as “strong” reliability. Our calculated ICC values of 0.63 for RSAR and 0.47 for RSEDR are interpreted as “strong” and “moderate” reliability, respectively.

We also disagree with the concerns regarding the validity of the measure. This measure is an important signal of high quality care and is specified in a way to appropriately differentiate between cancer hospitals providing high and low quality care for these patients. This measure assesses an aspect of care and symptoms that are the subject of the measure, such as pneumonia, could be due to causes other than chemotherapy side effects and are not appropriate to combine. One commenter also stated that the list of ICD–10 codes contained in the measure submission documents includes codes for diagnoses that are unrelated to chemotherapy, and further suggested that the measure does not differentiate between chemotherapy-related and unrelated admissions and emergency department visits.

**Response:** Given the increase in outpatient hospital-based chemotherapy, understanding and minimizing related unplanned admissions and ED visits is a high priority. The 10 conditions that the measure captures are commonly cited reasons for hospital outpatient visits among patients receiving chemotherapy in the hospital outpatient setting, and are potentially preventable through appropriately managed outpatient care and increased communication with the medical team. The NQF considers ICC values ranging from 0.41 to 0.60 as “moderate” reliability, and 0.61 to 0.80 as “strong” reliability. Our calculated ICC values of 0.63 for RSAR and 0.47 for RSEDR are interpreted as “strong” and “moderate” reliability, respectively.

We also disagree with the concerns regarding the validity of the measure. This measure is an important signal of high quality care and is specified in a way to appropriately differentiate between cancer hospitals providing high and low quality care for these patients. This measure assesses an aspect of care and symptoms that are the subject of the measure, such as pneumonia, could be due to causes other than chemotherapy side effects and are not appropriate to combine. One commenter also stated that the list of ICD–10 codes contained in the measure submission documents includes codes for diagnoses that are unrelated to chemotherapy, and further suggested that the measure does not differentiate between chemotherapy-related and unrelated admissions and emergency department visits.

**Response:** Given the increase in outpatient hospital-based chemotherapy, understanding and minimizing related unplanned admissions and ED visits is a high priority. The 10 conditions that the measure captures are commonly cited reasons for hospital outpatient visits among patients receiving chemotherapy in the hospital outpatient setting, and are potentially preventable through appropriately managed outpatient care and increased communication with the medical team.

---


patient. This measure will help identify unplanned admissions and ED visits in patients receiving outpatient chemotherapy by reviewing claims in which these 10 conditions, considered potentially preventable through appropriately-managed outpatient care, are listed as a primary diagnosis or a secondary diagnosis accompanied by a primary diagnosis of cancer. Admissions and emergency department visits for these conditions is a potential signal of poor quality care and poor care coordination. While the goal is not to reach zero admissions and ED visits, the premise is that reporting this information will promote an improvement in patient care over time for two reasons. First, transparency in publicly reporting this measure will raise hospital and patient awareness of unplanned hospital visits following chemotherapy. Second, this reporting will incentivize hospital outpatient departments to incorporate quality improvement activities into their chemotherapy care planning in order to improve care coordination and reduce the number of these visits. We also believe that making PCMHs aware of their performance, as well as the performance that might be expected given the PCMH’s case mix is helpful in supporting efforts to improve outcomes. The measure is intended to improve symptom management and care coordination for cancer patients who are undergoing chemotherapy.

We thank the commenter for its suggestion regarding the list of ICD–10 codes representing the 10 outcome conditions with input from cancer care experts following an inclusive and patient-centric approach to developing the code sets. Cancer and chemotherapy treatment can impact the entire body and it can be challenging to differentiate whether the condition is related to the treatment, cancer, or another disease. We will consider this feedback during ongoing measure evaluation.

Comment: A number of commenters recommended that there be additional or broader denominator exclusions from the measure. Specifically, commenters recommended that we exclude planned admissions and admissions/ED visits without a POA flag. Some commenters also recommended numerator exclusions for a wide variety of other factors including, but not limited to, surgeries within 30 days of admission, patients coded with non-adherence to medication, patients with pain due to disease, and admissions with an “elective” admission type.

Response: We thank the commenters for their consideration and feedback. During measure development, the technical expert panel recommended expanding the diagnoses and symptoms that are the subject of the measure to include both neutropenia and fever to avoid missing any diagnoses of neutropenic fever since a single ICD–9 code for neutropenic fever does not exist. Because the diagnosis of neutropenia requires lab results and is not codeable on a claim, we were further advised to expand the measure to include pneumonia and sepsis as the
most common sequelae of neutropenic fever. We limited the window for identifying the outcomes of admissions and ED visits to 30 days after hospital outpatient chemotherapy treatment because existing literature suggests the vast majority of adverse events occur within that time frame, as was observed during testing.

The decision to not include patients receiving only oral chemotherapy was made during development for several reasons, including attribution and timing. Attributing a prescription to a hospital-based outpatient setting is challenging; patients are likely to receive care from multiple physicians, in multiple settings, and not all physicians are employed by the hospital. Therefore, not all claims for that provider are attributable to the hospital. In addition, the measure algorithm uses the chemotherapy encounter date at the index for the 30-day window to follow patients to ascertain whether they experience an admission or ED visit. Identifying a specific index date on which oral chemotherapy was started is not feasible, since claims data only includes information on the date the prescription was filled, without information on what day the patient started taking the medication. We note, however, that patients receiving oral chemotherapy in combination with infusion-based chemotherapy are included in the cohort. We will take into consideration the inclusion of patients only receiving oral chemotherapy in future evaluation work.

Comment: One commenter recommended that if we adopt the measure for the PCHQR, we retire two currently active measures: NQF #0383, Plan of Care for Pain, and NQF #0384, Pain Intensity Quantified.

Response: We thank the commenter for the recommendation and will consider it in the future. The process measures, which are not risk-adjusted, support the purpose of the proposed measure by reinforcing that those providing outpatient care should screen for and manage symptoms such as pain and anemia/fatigue. We believe that having these process measures, which are directly within the control of the PCH, complements the newly adopted outcome measure. However, we recognize that having all three measures in the program may place undue burden on facilities. We will continue to assess the appropriateness of including all three measures after we have more data on the correlation between PCH performance on each of the three measures.

After consideration of the public comments we received, we are finalizing the adoption of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure as proposed.

In summary, the previously finalized and newly finalized measures for the PCHQR Program for the FY 2019 program year and subsequent years are listed in the table below.
PREVIOUSLY FINALIZED AND NEWLY FINALIZED PCHQR MEASURES FOR THE FY 2019 PROGRAM YEAR AND SUBSEQUENT YEARS—Continued

<table>
<thead>
<tr>
<th>Short name</th>
<th>NQF No.</th>
<th>Measure name</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy.**</td>
</tr>
</tbody>
</table>

* Finalized update in FY 2019 program year.
** Newly finalized for FY 2019 program year.
*** In previous final rules, this measure was titled “Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1c, or Stage II or III Hormone Receptor Negative Breast Cancer. This name change is consistent with NQF updates to the measure name and reflects an update in the AJCC staging, does not reflect a change in the measure inclusion criteria, and is not considered substantive.

5. Possible New Quality Measure Topics for Future Years

We discussed future quality measure topics and quality measure domain areas in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50280), and in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49979), we discussed public comment and specific suggestions for measure topics addressing the following CMS Quality Strategy domains: Making care affordable; communication and coordination; and working with communities to promote best practices of healthy living. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25211), we welcomed public comment and specific suggestions for measure topics that we should consider for future rulemaking.

Response: We thank the commenter for its support as we continuously work to develop and implement meaningful quality measures.

Comment: One commenter urged CMS to include stakeholders throughout the measure development process.

Response: We look forward to continuing collaboration efforts with stakeholders through the various mechanisms currently in place, such as the Technical Expert Panels and notice and comment periods during rulemaking.


We maintain technical specifications for the PCHQR Program measures, and we periodically update those specifications. The specifications may be found on the QualityNet Web site at: https://qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1228774479863.

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50281), we adopted a policy under which we use a subregulatory process to make nonsubstantive updates to measures used for the PCHQR Program. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25211), we did not propose any changes to this policy.

7. Public Display Requirements

a. Background

Under section 1866(k)(4) of the Act, we are required to establish procedures for making the data submitted under the PCHQR Program available to the public. Such procedures must ensure that a PCH has the opportunity to review the data that are to be made public with respect to the PCH prior to such data being made public. Section 1866(k)(4) of the Act also provides that the Secretary must report quality measures of process, structure, outcome, patients’ perspective on care, efficiency, and costs of care that relate to services furnished in such hospitals on the CMS Web site. The measures that we have finalized for public display are shown in the table below.

PREVIOUSLY FINALIZED MEASURES FOR PUBLIC DISPLAY

<table>
<thead>
<tr>
<th>Measure name</th>
<th>First year of public display</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer (NQF #0223).</td>
<td>2014.</td>
</tr>
<tr>
<td>Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1c, or Stage II or III Hormone Receptor Negative Breast Cancer (NQF #0559).</td>
<td>2015.</td>
</tr>
<tr>
<td>Adjuvant Hormonal Therapy (NQF #0220)</td>
<td>2016.</td>
</tr>
<tr>
<td>Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382)</td>
<td></td>
</tr>
<tr>
<td>Oncology: Oncology: Plan of Care for Pain—Medical Oncology and Radiation Oncology (NQF #0383).</td>
<td></td>
</tr>
<tr>
<td>Oncology: Medical and Radiation—Pain Intensity Quantified (NQF #0384).</td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients (NQF #0390).</td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (NQF #0389).</td>
<td></td>
</tr>
<tr>
<td>CLABSI (NQF #0139)</td>
<td></td>
</tr>
<tr>
<td>CAUTI (NQF #0138).</td>
<td></td>
</tr>
</tbody>
</table>

b. Additional Public Display Requirements

As we strive to publicly display data as soon as possible on a CMS Web site, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25211 through 25212), we proposed the following update to our public display polices. We believe it is best to not specify in rulemaking the exact timeframe during the year for publication as doing so may prevent earlier publication. In the FY 2017 IPPS/LTCH PPS proposed rule, we proposed, then, to make these data
available as soon as it is feasible during the year, starting with the first year for which we are publishing data for each measure. We will continue to propose in rulemaking the first year for which we intend to publish data for each measure. We intend to make the data available on at least a yearly basis.

As stated above, we are required to give PCHs an opportunity to review their data before the data are made public. Because we proposed to make the data for this program available as soon as possible, and the timeframe for this publication may change year-to-year, we did not propose to specify in rulemaking the exact dates for review. However, we proposed that the time period for review would be approximately 30 days in length. We proposed to announce the exact timeframes on a CMS Web site and/or on our applicable listservs.

We welcomed public comments on these updates to our public display and preview policies. We did not receive any public comments. Therefore, for the reasons discussed above, we are finalizing these proposals.

c. Public Display of Additional PCHQR Measure

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25212), we proposed to publicly display one additional PCHQR measure beginning with FY 2017 program year data (which is data collected during CY 2015). This proposal would mean that we would display the measure data during CY 2017, and that we would use a CMS Web site and/or our applicable listservs to announce the exact timeframe. This measure is External Beam Radiotherapy for Bone Metastases (NQF #1822), which we adopted in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50278 through 50280). We believe that it is important to share data collected under the PCHQR Program with healthcare consumers through publication on public Web sites to help inform healthcare choices. We intend to make this data publicly available at the first opportunity.

We welcomed public comment on our proposal to display this measure beginning with the FY 2017 program year data and for subsequent years.

Comment: One commenter supported the proposed public display of data related to the External Beam Radiotherapy for Bone Metastases measure beginning in 2017. The commenter indicated it would welcome the opportunity to collaborate with CMS on best ways to display the data.

Response: We thank the commenter for the support.

After consideration of the public comment we received, we are finalizing the public display of data related to the External Beam Radiotherapy for Bone Metastases measure beginning in 2017 as proposed.

d. Public Display of Updated Measure

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49720 through 49722), we finalized public display of the Oncology: Radiation Dose Limits to Normal Tissues measure in 2016 and subsequent years. In the proposed rule (81 FR 25212) we stated that we proposed that if our proposal to update this measure (described in section VIII.B.3.b. of the preamble of the proposed rule) was finalized, we proposed to begin displaying on Hospital Compare data using the updated measure cohort as soon as feasible after the updated data is collected in CY 2017. We intend to denote the cohort expansion on Hospital Compare to ensure that consumers are informed about the expansion.

We welcomed public comment on our proposals regarding public display of this updated measure.

Comment: One commenter asked that CMS clarify the data collection dates for the proposed cohort expansion.

Response: PCHs would submit data for the expanded cohort during CY 2017, this data will be submitted according to the data submission schedule that was finalized in the 2015 IPPS/LTCH PPS final rule (79 FR 50283).

After consideration of the public comment we received, we are finalizing this policy as proposed.

e. Postponement of Public Display of Two Measures

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50281 through 50282), we finalized public display of the CLABSI and CAUTI measures beginning no later than 2017 and subsequent years. However, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25212) we proposed to defer the public reporting of these two measures’ data. At present, all PCHs are reporting CLABSI and CAUTI data to the NHSN under the PCHQR Program; however, due to the low volume of data produced and reported by this small number of facilities, we need additional time to work with CDC to identify an appropriate timeframe for public reporting and collaborate on the analytic methods that will be used to summarize the CLABSI and CAUTI data for public reporting purposes.

We invited public comment on our proposal to defer the public reporting of the CLABSI and the CAUTI measures.

Comment: Two commenters supported CMS’s decision to defer the public display of CLABSI and CAUTI data pending collaboration with the CDC.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal to continue to defer public reporting of the CLABSI and CAUTI measures pending further collaboration with the CDC.

Our previously finalized and newly finalized public display requirements are summarized in the table below.

### PREVIOUSLY FINALIZED AND NEWLY FINALIZED PUBLIC DISPLAY REQUIREMENTS

<table>
<thead>
<tr>
<th>Measures</th>
<th>Public reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary of Finalized and Newly Finalized Public Display Requirements</strong></td>
<td></td>
</tr>
<tr>
<td>• Adjuvant Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer (NQF #0223).</td>
<td>2014 and subsequent years.</td>
</tr>
<tr>
<td>• Combination Chemotherapy is Considered or Administered Within 4 Months (120 days) of Diagnosis for Women Under 70 with AJCC T1cN0M0, or Stage IB—III Hormone Receptor Negative Breast Cancer (NQF #0559).</td>
<td></td>
</tr>
<tr>
<td>• Adjuvant Hormonal Therapy (NQF #0220)</td>
<td>2015 and subsequent years.</td>
</tr>
<tr>
<td>• Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382)*</td>
<td>2016 and subsequent years.</td>
</tr>
<tr>
<td>• Oncology: Plan of Care for Pain—Medical Oncology and Radiation Oncology (NQF #0383).</td>
<td></td>
</tr>
<tr>
<td>• Oncology: Medical and Radiation—Pain Intensity Quantified (NQF #0384)</td>
<td></td>
</tr>
<tr>
<td>• Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients (NQF #0390)</td>
<td></td>
</tr>
</tbody>
</table>
PREVIOUSLY FINALIZED AND NEWLY FINALIZED PUBLIC DISPLAY REQUIREMENTS—Continued

<table>
<thead>
<tr>
<th>Measures</th>
<th>Public reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (NQF #0389)</td>
<td>Deferred.</td>
</tr>
<tr>
<td>• HCAHPS (NQF #0166)</td>
<td>Beginning at the first opportunity in 2017 and for subsequent years.</td>
</tr>
<tr>
<td>• CLABSI (NQF #0139)</td>
<td></td>
</tr>
<tr>
<td>• CAUTI (NQF #0138)**</td>
<td></td>
</tr>
<tr>
<td>• External Beam Radiotherapy for Bone Metastases (NQF #1822)**</td>
<td></td>
</tr>
</tbody>
</table>

* Update newly finalized for display for the FY 2019 program year and subsequent years in this finalized rule—expanded cohort will be displayed as soon as feasible.
** Deferral newly finalized in this final rule.
*** Measure newly finalized for public display in this final rule.

8. Form, Manner, and Timing of Data Submission

Section 1866(k)(2) of the Act requires that, beginning with the FY 2014 PCHQR program year, each PCH must submit to the Secretary data on quality measures specified by section 1866(k)(3) of the Act in a form and manner, and at a time, as specified by the Secretary.

Data submission requirements and deadlines for the PCHQR Program are generally posted on the QualityNet Web site at: http://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier3&cid=122877264228.

The newly finalized measure for FY 2019 (Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy) is a claims-based measure; therefore, there are no additional data submission requirements for this measure. As this measure uses 1 year of Medicare administrative claims data, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25212 through 25213), we proposed to calculate this measure on a yearly basis, beginning with data from July 1, 2016 through June 30, 2017, and then to calculate the measure for subsequent years using data from July 1 through June 30.

We did not receive any comments on this proposal. Therefore, for the reasons discussed above, we are finalizing the reporting schedules as proposed.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25213), we did not propose any changes to previously finalized data submission requirements.

9. Exceptions From PCHQR Program Requirements

In our experience with other quality reporting and performance programs, we have noted occasions when providers have been unable to submit required quality data due to extraordinary circumstances that are not within their control (for example, natural disasters). We do not wish to increase their burden unduly during these times. Therefore, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50848), we finalized our policy that, for the FY 2014 program year and subsequent years, PCHs may request and we may grant exceptions (formerly referred to as waivers) with respect to the reporting of required quality data when extraordinary circumstances beyond the control of the PCH warrant. When exceptions are granted, we will notify the respective PCH.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25213), we did not propose any changes to this PCHQR exception process.

C. Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

1. Background and Statutory Authority

We seek to promote higher quality and more efficient health care for Medicare beneficiaries, and our efforts are furthered by quality reporting programs coupled with public reporting of that information.

Section 3004(a) of the Affordable Care Act amended section 1886(m)(5) of the Act, requiring the Secretary to establish the Long-Term Care Hospital Quality Reporting Program (LTCH QRP). The LTCH QRP applies to all hospitals certified by Medicare as LTCHs. Beginning with the FY 2014 payment determination and subsequent years, the Secretary is required to reduce any annual update to the LTCH PPS standard Federal rate for discharges occurring during such fiscal year by 2 percentage points for any LTCH that does not comply with the requirements established by the Secretary.

Section 1866(m)(5) of the Act requires that for the FY 2014 payment determination and subsequent years, each LTCH submit data on quality measures specified by the Secretary in a form and manner, and at a time, specified by the Secretary. For more information on the statutory history of the LTCH QRP, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50286).

The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) imposed new data reporting requirements for certain post-acute care (PAC) providers, including LTCHs. For information on the statutory background of the IMPACT Act, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49723 through 49724). In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49723 through 49728), we reviewed and finalized the activities and the timeline and sequencing of such activities that would occur under the LTCH QRP. In addition, we established our approach for identifying cross-cutting measures and process for the adoption of measures, including the application and purpose of the Measure Application Partnership (MAP) and the notice-and-comment rulemaking process. For information on these topics, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49723).

2. General Considerations Used for Selection of Quality, Resource Use, and Other Measures for the LTCH QRP

For a detailed discussion of the considerations we use for the selection of LTCH QRP quality measures, such as alignment with the CMS Quality Strategy, which incorporates the three broad aims of the National Quality Strategy, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50286 through 50287) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49723). Overall, we strive to promote high quality and efficiency in the delivery of health care to the beneficiaries we serve. Performance improvement leading to the highest

---

quality health care requires continuous evaluation to identify and address performance gaps and reduce the unintended consequences that may arise in treating a large, vulnerable, and aging population. Quality reporting programs, coupled with public reporting of quality information, are critical to the advancement of health care quality improvement efforts. Valid, reliable, relevant quality measures are fundamental to the effectiveness of our quality reporting programs. Therefore, selection of quality measures is a priority for us in all of our quality reporting programs.

In the FY 2017 IPPS/LTC PPS proposed rule (81 FR 25215), we proposed to adopt for the LTCH QRP one measure that we are specifying under section 1899B(c)(1) of the Act to meet the Medication Reconciliation domain, that is, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP.

Further, we proposed for the LTCH QRP to adopt three measures to meet the resource use and other measures domains identified in section 1899B(d)(1) of the Act. These measures include: (1) Total Estimated Medicare Spending Per Beneficiary (MSBP); MSBP-PAC LTCH QRP; (2) Discharge to Community: Discharge to Community-PAC LTCH QRP; and (3) Measures to reflect all-condition risk-adjusted potentially preventable hospital readmission rates: Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP.

In our development and specification of measures, we employ a transparent process in which we seek input from stakeholders and national experts and engage in a process that allows for pre-rulemaking input on each measure, as required by section 1890A of the Act. To meet this requirement, we provided the following opportunities for stakeholder input: Our measure development contractor convened technical expert panels (TEPs) that included stakeholder experts and patient representatives on July 29, 2015, for the Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP. In our development and specification of measures, we employ a transparent process in which we seek input from stakeholders and national experts and engage in a process that allows for pre-rulemaking input on each measure, as required by section 1890A of the Act. To meet this requirement, we provided the following opportunities for stakeholder input: Our measure development contractor convened technical expert panels (TEPs) that included stakeholder experts and patient representatives on July 29, 2015, for the Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP.

In addition, we sought public input from the NQF-convened MAP Post-Acute Care, Long-Term Care (PAC/LTC) Workgroup during the annual in-person meeting held December 14 and 15, 2015. The MAP, composed of multi-stakeholder groups, is tasked to provide input on the selection of quality and efficiency measures described in section 1890(b)(7)(B) of the Act.

The MAP reviewed each IMPACT Act-related measure proposed for use in the LTCH QRP in the FY 2017 IPPS/LTC PPS proposed rule. For more information on the MAP’s recommendations, we refer readers to the MAP 2016 Final Recommendations to HHS and CMS public report at: https://www.qualityforum.org/Publications/2016/02/MAP_2016.Considerations_for_Implementing_Measures_in_Federal_Programs_-_PAC-LTC.aspx.

For measures that do not have NQF endorsement, or which are not fully supported by the MAP for use in the LTCH QRP, we proposed for the LTCH QRP for the purposes of satisfying the measure domains required under the IMPACT Act measures that closely align with the national priorities identified in the National Quality Strategy (http://www.qualityforum.org) and for which the MAP supports the measure concept. Further discussion as to the importance and high-priority status of these proposed measures in the LTCH setting is included under each quality measure section in the preamble of this final rule.

Although we did not solicit feedback on General Considerations Used for Selection of Quality, Resource Use, and Other Measures for the LTCH QRP, we received one comment, which is summarized and discussed below.

Comment: Several commenters stated that CMS should recognize burden of data collection and focus on measures that are the most clinically relevant and actionable to the facility and patients. In addition, the commenter recommended that CMS use minimum standards in the development of new measures so that they are as clear and consistent across facilities as possible.

Response: We note that we strive to strike a balance between minimizing burden and addressing gaps in quality of care as we continue to expand the LTCH QRP. We interpret the commenter’s suggestion that CMS apply minimum standards in its measure development to suggest that we simplify our approach to quality measure development itself. We will take recommendations into consideration in future measure development.

We also received several comments related to the proposed measures, the IMPACT Act, NQF endorsement, the NQF MAP review process, and the use of TEPs, which are summarized and discussed below.

Comment: Several commenters expressed appreciation for CMS’ efforts to implement the requirements of the IMPACT Act and standardize quality measures across PAC settings as required by the IMPACT Act. One commenter noted the importance of functional measures and value of assessing patients’ functional status consistently, and is pleased that the IMPACT Act is moving in that direction. Also, one commenter indicated achieving standardized and interoperable patient assessment data will allow for better cross-setting comparisons of quality and will support the development of better quality measures with uniform risk standardization.

Response: We believe that standardizing patient assessment data will allow for the exchange of data among PAC providers in order to facilitate care coordination and improve patient outcomes. We appreciate the importance of functional status measures and will consider inclusion of additional measures.

Comment: Several commenters urged CMS to delay implementation of proposed measures until NQF has completed its review and had endorsed measures that are appropriate for the specific characteristics of the LTCH patient population. One commenter requested that CMS provide a timeline for submission of the proposed measures to NQF. In addition, commenters recommended NQF endorsement prior to public reporting. One commenter suggested that CMS seek NQF’s formal consensus development process instead of a time-
limited endorsement, as it was perceived the time-limited endorsement was not sufficient.  

Response: We received several comments regarding the NQF endorsement status for the proposed measures, and acknowledge the commenters’ recommendation to submit the measures to the NQF prior to implementation. We wish to clarify that the proposed measures are not currently under review for endorsement due to the rigorous timelines associated with the measure development process and meeting the statutory deadlines. However, we intend to seek NQF endorsement in the near future. While we appreciate the importance of consensus endorsement and intend to seek such endorsement, we must balance the need to address gaps in quality and adhere to statutorily required timelines as in the case of the quality and resource use measures as proposed to address the IMPACT Act. We further note that we consider and propose appropriate measures that have been endorsed by the NQF whenever possible. However, when this is not feasible because there is no NQF-endorsed measure, we utilize our statutory authority that allows the Secretary to specify a measure for the LTCH QRP that is not NQF-endorsed where, as in the case for the proposed measures, we have not been able to identify other measures that are endorsed or adopted by a consensus organization. While we appreciate the importance of consensus endorsement and intend to seek such endorsement, we must balance the need to address gaps in quality and adhere to statutorily required timelines as in the case of the quality and resource use measures that we proposed to address the IMPACT Act.

In regard to the comments regarding time-limited endorsement, NQF uses time-limited endorsement for measures that meet all of NQF’s endorsement criteria with the exception of field testing and that are critical to advancing quality improvement. When measures are granted this 2-year endorsement rather than the traditional 3-year period, measure developers must test the measure and return results to NQF within the 2-year window. We again note that we have not yet sought endorsement of the proposed measures, time-limited or otherwise.

Comment: Several commenters noted the NQF-convened MAP PAC/LTC Workgroup did not support the proposed measures; instead, it recommended that CMS delay measure implementation until the measures were fully developed and tested and brought back to the NQF for further consideration. One commenter further stated that TEP members and other stakeholders who provided feedback in the measure development process did not support measures moving forward without further testing.

Response: We interpret this comment to address the activities of the MAP, a multi-stakeholder partnership convened by NQF that provides input to the U.S. Department of Health and Human Services (HHS) on its selection of measures for certain Medicare programs. We would like to clarify that the MAP “encouraged continued development” for the proposed measure. According to the MAP, the term “encourage continued development” is applied when a measure addresses a critical program objective or promotes alignment and the measure is in an earlier stage of development. In contrast, the MAP uses the phrase “do not support” when it does not support the measures at all. Since the MAP provided a recommendation of “encourage continued development” for the proposed measures during the December 2015 NQF-convened MAP PAC/LTC Workgroup meeting, further refinement of measure specifications and testing of measure validity and reliability have been performed. These efforts have included: A pilot test in 12 PAC settings, including LTCHs, to determine the feasibility of assessment items for use in calculation of the measure Drug Regimen Review Conducted with Follow-Up for Identified Issues; and further development of risk-adjusted models for the measures, Discharge to Community, Medicare Spending per Beneficiary, and Potentially Preventable 30-Day Post-Discharge Readmission Measure. Additional information regarding testing is further described in the specific measure sections in the preamble of this final rule.

For these reasons, we believe that the measures have been fully and robustly developed, and believe they are appropriate for implementation and should not be delayed.

Comment: Several commenters, including MedPAC, expressed concern regarding the standardization and interoperability of the proposed measures as they perceived the measures to have different inclusion/exclusion criteria, episode constructions and risk factors, and, therefore, do not meet the mandate of the IMPACT Act. Commenters expressed further concern about future of such variations and recommend delaying implementation until measures are standardized and interoperable across PAC settings. One commenter further indicated that the measure titles were different for each setting, pointing out the words “LTCH QRP” or “Long-Term Care Hospital” to designate a difference in the measure. One commenter stated implementing the quality measures in an unstandardized fashion would result in additional costs in the future for aligning measures between PAC providers.

MedPAC suggested that the measures use uniform definitions, specifications, and risk-adjustment methods, conveying that findings from their work on a unified PAC payment system suggest there is overlap or similar care provided for Medicare beneficiaries with similar needs across PAC settings. As a result of this work, MedPAC urged that the IMPACT Act measures be standardized to facilitate quality comparison across PAC settings to inform a Medicare beneficiary’s choice of where to seek care and provide an opportunity for CMS to evaluate the value of PAC services, noting that differences in rates should reflect differences in quality of care rather than differences in the way rates are constructed.

Response: We wish to clarify that the IMPACT Act requires that the patient assessment instruments be modified to enable the submission of standardized data, for purposes such as interoperability. However, measures themselves are not “interoperable.” CMS, in collaboration with our measure contractors, developed the proposed measures with the intent to standardize the measure methodology so that we are able to detect variation among PAC providers in order to be able to assess differences in quality of care. For example, the patient assessment-based quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, was developed across PAC settings with uniform definitions and specifications. This measure is not risk adjusted. The standardized development of this assessment-based measure follows the mandate of the IMPACT Act to develop standardized patient assessment-based measures for the four PAC settings (section 1899B(c)(1) of the Act). The resource use and other measures, Discharge to the Community-PAC LTCH QRP and Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP, were developed to be uniform across the PAC settings in terms of their definitions, measure calculations, and risk-adjustment approach where applicable.

There is variation in each measure primarily due to the data sources for...
each PAC setting. The risk-adjustment approach for the resource use and other IMPACT Act measures is aligned, but is tailored to each measure based on measure testing results. Adjusting for relevant case-mix characteristics in each setting improves the validity and explanatory power of risk adjustment models, and helps ensure that any differences in measure performance reflect differences in the care provided rather than differences in patient case-mix. We employ this approach to measure development to enable appropriate cross-setting comparisons in PAC settings and to maximize measure reliability and validity. It should be noted that sections 1899B(c)(3)(B) and 1899B(d)(3)(B) of the Act require that quality measures and resource use and other measures be risk adjusted, as determined appropriate by the Secretary.

Comment: Several commenters expressed concerns regarding the validity and reliability of IMPACT Act measures and encouraged CMS to conduct further analysis of data to ensure comparability across PAC settings, prior to implementation and public reporting of data.

Response: We have tested for validity and reliability all of the IMPACT Act measures, and the results of that testing is available in the document, Measure Specifications for Measures Adopted in the FY 2017 LTCH QRP Final Rule, posted on the CMS LTCH QRP Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

Comment: A few commenters requested that CMS proceed cautiously to ensure new measures are associated with minimal administrative and data collection burden, but also expressed appreciation of CMS efforts to implement the IMPACT Act.

Response: We appreciate the importance of avoiding undue burden on providers and will continue to evaluate and consider any unnecessary burden associated with implementation of the LTCH QRP. We wish to note that the three resource measures are claims-based, and will require no additional data collection by providers and thus result in minimal increases in burden. The measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues—PAC LTCH QRP, is calculated using assessment data and requires the addition of three items to the LTCH Continuity Assessment Records Evaluation (CARE) Data Set, also requiring minimal additional burden. We address the issue of burden further under section I.M. of Appendix A of this final rule.

Comment: One commenter expressed concern regarding CMS’ approach to implementing the requirements of the IMPACT Act and requested CMS consider greater flexibility with regard to regulatory requirements.

Response: We appreciate the comment regarding the requirements associated with the proposed quality measures for the IMPACT Act. We note that any flexibility we may have with regard to regulatory requirements is constrained by the statutory requirements of the IMPACT Act. However, we do, and will continue to, monitor the effects of policy changes affecting PAC facilities to ensure appropriate patient access and care and will consider greater flexibility as feasible and appropriate.

Comment: Several commenters urged CMS to engage in several activities which would afford greater transparency with stakeholders regarding measure development. These commenters also requested that measures undergo field testing with providers prior to implementation. Commenters also requested that more detailed measure specifications be posted in order to enable providers to evaluate measure design decisions. Commenters requested that LTCH providers be provided with confidential preview reports as a part of a “dry run” process as this would enable providers to review data and provide CMS with feedback on potential technical issues with proposed measure. Finally, the commenters requested that measure data be provided to LTCHs on a patient level on a quarterly basis, similar to other quality reporting programs, in order to make effective use of the data and improve performance.

Response: With regard to the testing and analytic results provided for these measures, since the December 2015 MAP meeting, further refinement of measure specifications and testing of measure validity and reliability have been performed.

We refer readers to the Measure Specifications for Measures Adopted in the FY 2017 LTCH QRP Final Rule, posted on the CMS LTCH QRP Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html, which includes detailed information regarding measure specifications, including results of the final risk adjustment models for the resource use measures, our testing results are within range for similar outcome measures finalized in public reporting and value-based purchasing programs, including the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), previously adopted into the LTCH QRP.

We appreciate the comment requesting that we provide performance data on LTCH QRP measures on a more frequent, such as quarterly, basis in order to promote quality improvement. We wish to note that the proposed claims-based measures are based on 2 consecutive years of data in order to ensure a sufficient sample size to reliably assess LTCHs’ performance. However, we will investigate the feasibility and usability of providing LTCHs with information more frequently, such as unadjusted counts of potentially preventable readmissions (PPRs) and discharge data. We also appreciate the commenters’ suggestions related to the implementation of dry run activities, such as confidential reports, for the purposes of identifying any technical issues prior to public reporting. As was successfully provided in the fall of 2015 for the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512).

We intend to provide confidential feedback reports beginning in October 2017, as described in section VIII.C.15. of the preamble of this final rule, and we believe that the reports could serve as an opportunity for LTCHs to provide to us any technical issues they may discover. However, we note that, as described in section VIII.C.14. of the preamble of the proposed rule, we are unable at this time to provide patient level information for the claims-based measure, for example, the readmission measures, because such data comes from a separate entity. Finally, we wish to note that we intend to continue refining specifications and we will consider pilot testing in addition to the performance testing that we currently conduct.

3. Policy for Retention of LTCH QRP Measures Adopted for Previous Payment Determinations

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53614 through 53615), for the purpose of streamlining the rulemaking process, we adopted a policy that, when we initially adopt a measure for the LTCH QRP for a payment determination and all subsequent years, it would remain in effect until the measure was actively removed, suspended, or replaced. For further information, we note that measures are considered for removal, suspension, or replacement, we refer readers to the
FY 2013 IPPS/LTCH PPS final rule (77 FR 53614 through 53615). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25214), we did not propose any changes to the policy for retaining LTCH QRP measures adopted for previous payment determinations.

4. Policy for Adopting Changes to LTCH QRP Measures

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53615 through 53616), we adopted a subregulatory process to incorporate NQF updates to LTCH quality measure specifications that do not substantively change the nature of the measure. Substantive changes will be proposed and finalized through rulemaking. For further information on what constitutes a substantive versus a nonsubstantive change and the subregulatory process for nonsubstantive changes, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53615 through 53616). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25214), we did not propose any changes to the policy for adopting changes to LTCH QRP measures.

5. Quality Measures Previously Finalized for and Currently Used in the LTCH QRP

A history of the LTCH QRP quality measures adopted for the FY 2014 payment determinations and subsequent years is presented in the table below. The year in which each quality measure was first adopted and implemented, and then subsequently readopted or revised, if applicable, is displayed. The initial and subsequent annual payment determination years are also shown in this table. For more information on a particular measure, we refer readers to the IPPS/LTCH PPS final rule and associated page numbers referenced in this table.

### QUALITY MEASURES PREVIOUSLY FINALIZED FOR AND CURRENTLY USED IN THE LTCH QRP

<table>
<thead>
<tr>
<th>Measure title</th>
<th>IPPS/LTCH PPS Final rule</th>
<th>Data collection start date</th>
<th>Annual payment determination: Initial and subsequent APU years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678).</td>
<td>Adopted an application of the measure in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51745 through 51750). Adopted the NQF endorsed and expanded measure (with SIR) in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53616 through 53619).</td>
<td>October 1, 2012 January 1, 2013</td>
<td>FY 2014 and subsequent years. FY 2015 and subsequent years.</td>
</tr>
<tr>
<td>Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680).</td>
<td>Adopted an application of the measure in the FY 2012 IPPS/LTCH PPS final rule (76 FR 50861 through 50863). Adopted the NQF endorsed and expanded measure (with SIR) in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53616 through 53619). Adopted in the FY 2013 IPPS/LTCH PPS final rule (76 FR 53624 through 53627). Revised data collection timeframe in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50858 through 50861). Revised data collection timeframe in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50289 through 50290).</td>
<td>October 1, 2012 January 1, 2013 January 1, 2014</td>
<td>FY 2014 and subsequent years. FY 2015 and subsequent years. FY 2016 and subsequent years.</td>
</tr>
<tr>
<td>All-Cause Unplanned Readmission Measure for 30-Days Post-Discharge from Long-Term Care Hospitals (NQF #2512).</td>
<td>Adopted in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53615 through 53616). Revised data collection timeframe in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50868 through 50874).</td>
<td>October 1, 2014</td>
<td>N/A FY 2017 and subsequent years.</td>
</tr>
</tbody>
</table>
Although we did not solicit feedback, we received a comment about Quality Measures Previously Finalized for and Currently Used in the LTCH QRP. The comment is summarized and discussed below.

Comment: One commenter supported the continued inclusion of the previously adopted measure, Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) in the LTCH QRP for the FY 2018 payment determination and subsequent years.

Response: We thank the commenter for their support of this measure and its continued inclusion in the LTCH QRP.

6. LTCH QRP Quality, Resource Use and Other Measures Finalized for the FY 2018 Payment Determination and Subsequent Years

For the FY 2018 payment determinations and subsequent years, in addition to the quality measures we are retaining under our policy described in section VIII.C.3. of the preamble of this final rule, we proposed three new measures. These measures were developed to meet the requirements of the IMPACT Act. They are:

- MSPB–PAC LTCH QRP;
- Discharge to Community-PAC LTCH QRP; and
- Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP.

The measures are described in more detail below.

For the risk-adjustment of the resource use and other measures, we understand the important role that sociodemographic status plays in the care of patients. However, we continue to have concerns about holding providers to different standards for the outcomes of their patients of diverse sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on providers' results on our measures.

The NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF's guidance, has tested sociodemographic factors in the measures' risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

We received several comments on the impact of sociodemographic status (SDS) on quality measures, resource use, and other measures, which are summarized and discussed below.
Comment: Several commenters indicated their support for the inclusion of SDS adjustment in quality measures, resource use, and other measures. Commenters suggested that failure to account for these patient characteristics could penalize LTCHs for providing care to a more medically complex and socioeconomically disadvantaged patient population and affect provider performance. Some commenters expressed concerns about standardization and interoperability of the measures as it pertains to risk adjusting, particularly for SDS characteristics. Many commenters recommended incorporating socioeconomic status (SES) factors as risk-adjusters for the measures, and several commenters suggested conducting additional testing and/or NQF endorsement prior to implementation of these measures.

Several commenters, including MedPAC, did not support risk adjustment of measures by SES or SDS status. One commenter did not support such risk adjustment because it can hide disparities and create different standards of care for LTCHs based on the demographics in the facility. MedPAC reiterated that risk adjustment can hide disparities in care and suggests risk adjustment reduces pressure on providers to improve quality of care for low-income Medicare beneficiaries. Instead, MedPAC supported peer provider group comparisons with providers of similar low-income beneficiary populations. Another commenter stated that SDS factors should not be included in measures that examine the patient during an LTCH stay, but should only be considered for measures evaluating care after the LTCH discharge.

Response: We appreciate the considerations and suggestions conveyed regarding the measures and the importance in balancing appropriate risk adjustment along with ensuring access to high quality care. We note that in the measures that are risk-adjusted, we do take into account characteristics associated with medical complexity, as well as factors such as age where appropriate to do so. For those cross-setting PAC measures, such as those intended to satisfy the IMPACT Act domains that use the patient assessment-based data elements for risk adjustment, we have either made such items standardized, or intend to do so as feasible. With regard to the incorporation of additional factors, we have and will continue to take such factors into account, which would include further testing as part of our ongoing measure development monitoring activities. As discussed previously, we intend to seek NQF endorsement for our measures. 

With regard to the suggestions pertaining to the incorporation of socioeconomic factors as risk-adjusters for the measures, including in those measures that pertain to after the patient was discharged from the LTCH, additional testing and/or NQF endorsement prior to implementation of these measures, comments that pertain to potential consequences associated with such risk adjusters and alternative approaches to grouping comparative data, we wish to reiterate that as previously discussed. NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

a. Measure To Address the IMPACT Act Domain of Resource Use and Other Measures: Total Estimated MSPB–PAC LTCH QRP

We proposed an MSPB–PAC LTCH QRP measure for inclusion in the LTCH QRP for the FY 2018 payment determination and subsequent years. Section 1899B(d)(1)(A) of the Act requires the Secretary to specify resource use measures, including total estimated Medicare spending per beneficiary, on which PAC providers, consisting of LTCHs, Inpatient Rehabilitation Facilities (IRFs), Skilled Nursing Facilities (SNFs), and Home Health Agencies (HHAs), are required to submit necessary data specified by the Secretary.

Rising Medicare expenditures for PAC as well as wide variation in spending for these services underlies the importance of measuring resource use for providers rendering these services. Between 2001 and 2013, Medicare PAC spending grew at an annual rate of 6.1 percent and doubled to $59.4 billion, while payments to inpatient hospitals grew at an annual rate of 1.7 percent over this same period. A study commissioned by the Institute of Medicine found that variation in PAC spending explains 73 percent of variation in total Medicare spending across the United States.

We reviewed the NQF’s consensus-endorsed measures and were unable to identify any NQF-endorsed resource use measures for PAC settings. Therefore, we proposed this MSPB–PAC LTCH QRP measure under the Secretary’s authority to specify non-NQF-endorsed measures under section 1899B(e)(2)(B) of the Act. Given the current lack of resource use measures for PAC settings, our MSPB–PAC LTCH QRP measure will provide valuable information to LTCHs on their relative Medicare spending in delivering services to approximately 122,000 Medicare beneficiaries.

The MSPB–PAC LTCH QRP episode-based measure will provide actionable and transparent information to support LTCHs’ efforts to promote care coordination and deliver high quality care at a lower cost to Medicare. The MSPB–PAC LTCH QRP measure holds LTCHs accountable for the Medicare payments within an “episode of care” (episode), which includes the period during which a patient is directly under the LTCH’s care, as well as a defined period after the end of the LTCH treatment, which may be reflective of and influenced by the services furnished by the LTCH. MSPB–PAC


LTCH QRP episodes, constructed according to the methodology described below, have high levels of Medicare spending with substantial variation. In FY 2013 and FY 2014, Medicare FFS beneficiaries experienced 178,538 MSPB–PAC LTCH QRP episodes triggered by admission to an LTCH. The mean payment-standardized, risk-adjusted episode spending for these episodes is $67,181. There is substantial variation in the Medicare payments for these MSPB–PAC LTCH QRP episodes—ranging from approximately $27,502 at the 5th percentile to approximately $115,291 at the 95th percentile. This variation is partially driven by variation in payments occurring after LTCH treatment.

Evaluating Medicare payments during an episode creates a continuum of accountability between providers that should improve post-treatment care planning and coordination. While some stakeholders throughout the measure development process supported the MSPB–PAC measures and believed that measuring Medicare spending was critical for improving efficiency, others believed that resource use measures did not reflect quality of care in that they do not take into account patient outcomes or experience beyond those observable in claims data. However, LTCHs involved in the provision of high quality PAC care as well as appropriate discharge planning and post-discharge care coordination would be expected to perform well on this measure since beneficiaries would likely experience fewer costly adverse events (for example, avoidable hospitalizations, infections, and emergency room usage).

Further, it is important that the cost of care be explicitly measured so that, in conjunction with other quality measures, we can publicly report which LTCHs are involved in the provision of high quality care at lower cost.

We developed MSPB–PAC measures for each of the four PAC settings. We proposed an LTCH-specific MSPB–PAC measure in the FY 2017 IPPS/LTCH proposed rule (81 FR 25216 through 25220), an IRF-specific MSBP–PAC measure in the FY 2017 IRF proposed rule (81 FR 24197 through 24201), a SNF-specific MSPB–PAC measure in the FY 2017 SNF PPS proposed rule (81 FR 24258 through 24262), and an HHA-specific MSPB–PAC measure in the CY 2017 HH PPS proposed rule (81 FR 43760 through 43764). The four setting-specific MSPB–PAC measures are closely aligned in terms of episode construction and measure calculation. Each of these four measures assesses Medicare Part A and Part B spending during an episode, and the numerator and denominator are defined similarly. However, setting-specific measures allow us to account for differences between settings in payment policy, the types of data available, and the underlying health characteristics of beneficiaries. For example, the MSPB–PAC LTCH QRP measure reflects the dual payment rate of the LTCH PPS by comparing episodes triggered by each payment rate case only with episodes of the same type, as detailed below.

The MSPB–PAC measures mirror the general construction of the IPPS hospital MSPB measure, which was adopted for Hospital IQR Program beginning with the FY 2014 program, and was implemented in the Hospital VBP Program beginning with the FY 2015 program. The measure was endorsed by the NQF on December 6, 2013 (NQF #2158).

Similarly, the MSPB–PAC measures assess all Medicare Part A and Part B payments for fee-for-service (FFS) claims with a start date during the episode window (which, as discussed in this section, is the time period during which Medicare FFS Part A and Part B services are counted towards the MSPB–PAC LTCH QRP episode). There are differences between the MSPB–PAC measures and the hospital MSPB measure to reflect differences in payment policies and the nature of care provided in each PAC setting. For example, the MSPB–PAC measures exclude a limited set of services (for example, for clinically unrelated services) provided to a beneficiary during the episode window while the hospital MSPB measure does not exclude any services.

MSPB–PAC episodes may begin within 30 days of discharge from an inpatient hospital and once in the LTCH’s MSPB–PAC measure. Aligning the hospital MSPB and MSPB–PAC measures in this way creates continuous accountability and aligns incentives to improve care planning and coordination across inpatient and PAC settings.

We sought and considered the input of stakeholders throughout the measure development process for the MSPB–PAC measures. We convened a TEP consisting of 12 panelists with combined expertise in all of the PAC settings on October 29 and 30, 2015, in Baltimore, Maryland. A follow-up email survey was sent to TEP members on November 18, 2015, to which 7 responses were received by December 8, 2015. The MSPB–PAC TEP Summary Report is available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/Downloads/TEP-Expert-Panel-on-Medicare-Spending-Per-Beneficiary.pdf. The measures were also presented to the MAP PAC/LTC Workgroup on December 15, 2015. As the MSPB–PAC measures were under development, there were three voting options for members: encourage continued development; do not encourage further consideration; and insufficient information. The MAP PAC/LTC Workgroup voted to “encourage continued development” for each of the MSPB–PAC measures.

The MAP PAC/LTC Workgroup’s vote of “encourage continued development” was affirmed by the MAP Coordinating Committee on January 26, 2016. The MAP’s concerns about the MSPB–PAC measures, as outlined in their final report, “MAP 2016 Considerations for Implementing Measures in Federal Programs: Post-Acute Care and Long-Term Care,” and Spreadsheet of Final Recommendations were taken into consideration during the measure development process and are discussed.
as part of our responses to public comments, described below.\footnote{National Quality Forum, Measure Applications Partnership. “MAP 2016 Considerations for Implementing Measures in Federal Programs: Post-Acute Care and Long-Term Care” Final Report. (February 2016) http://www.qualityforum.org/Publications/2016/02/MAP_2016_Considerations_for_Implementing_Measures_in_Federal_Programs_-_PAC-LTC.aspx.} \footnote{National Quality Forum, Measure Applications Partnership. “Spreadsheet of MAP 2016 Final Recommendations” (February 1, 2016) http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81593.} Since the MAP’s review and recommendation of continued development, CMS continued to refine risk adjustment models and conduct measure testing for the IMPACT Act measures in compliance with the MAP’s recommendations. The IMPACT Act measures are both consistent with the information submitted to the MAP and support the scientific acceptability of these measures for use in quality reporting programs.

In addition, a public comment period, accompanied by draft measures specifications, was originally open from January 13 to 27, 2016 and extended to February 5, 2016. A total of 45 comments on the MSPB–PAC measures were received during this 3.5 week period. The comments received also covered each of the MAP’s concerns as outlined in their Final Recommendations.\footnote{National Quality Forum, Measure Applications Partnership. “Spreadsheet of MAP 2016 Final Recommendations” (February 1, 2016) http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81593.} The MSPB–PAC Public Comment Summary Report is available at: \footnote{https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/Downloads/2016_03_24_mspb_pac_public_comment_summary_report.pdf} and the MSPB–PAC Public Comment Supplementary Materials are available at: \footnote{https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/Downloads/2016_03_24_mspb_pac_public_comment_summary_report_supplementary_materials.pdf}. These documents contain the public comments (summarized and verbatim), along with our responses including statistical analyses. The MSPB–PAC LTCH QRP measure, along with the other MSPB–PAC measures, as applicable, will be submitted for NQF endorsement when feasible.

To calculate the MSPB–PAC LTCH QRP measure for each LTCH, we first define the construction of the MSPB–PAC LTCH QRP episode, including the length of the episode window as well as the services included in the episode. Next, we apply the methodology for the measure calculation. The specifications are discussed further in this section. More detailed specifications for the MSPB–PAC measures, including the MSPB–PAC LTCH QRP measure, are available at: \footnote{http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html}.

(1) Episode Construction

An MSPB–PAC LTCH QRP episode begins at the episode trigger, which is defined as the patient’s admission to an LTCH. The admitting facility is the attributed provider, for whom the MSPB–PAC LTCH QRP measure is calculated. The episode window is the time period during which Medicare FFS Part A and Part B services are counted towards the MSPB–PAC LTCH QRP episode. Because Medicare FFS claims are already reported to the Medicare program for payment purposes, LTCHs will not be required to report any additional data to CMS for calculation of this measure. Thus, there will be no additional data collection burden from the implementation of this measure.

Our MSPB–PAC LTCH QRP episode construction methodology differentiates between episodes triggered by standard payment rate cases and site neutral payment rate cases, reflecting the LTCH dual-payment policy detailed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49601 through 49623). Standard and site neutral episodes would be compared and analyzed separately. Differences in episode construction between standard and site neutral episodes respectively. Differences in episode construction between standard and site neutral episodes are noted in this section; they otherwise share the same definition.

The episode window is comprised of a treatment period and an associated services period. The treatment period begins at the trigger (that is, on the day of admission to the IRF) and ends on the day of discharge from that LTCH. Admissions to the same facility occurring within 7 or fewer days do not trigger a new episode, and instead are included in the treatment period of the original episode. When two sequential stays at the same LTCH occur within 7 or fewer days of one another, the treatment period ends on the day of discharge from that LTCH. The associated services period is the time during which Medicare Part A and Part B services (with certain exclusions) are counted towards the episode. The associated services period begins at the episode trigger and ends 30 days after the end of the treatment period. The distinction between the treatment period and the associated services period is important because clinical exclusions of services may differ for each period. Certain services are excluded from the MSPB–PAC LTCH QRP episodes because they are clinically unrelated to LTCH care, and/or because LTCHs may have limited influence over certain Medicare services delivered by other providers during the episode window. These limited service-level exclusions are not counted towards a given LTCH’s Medicare spending to ensure that beneficiaries with certain conditions and complex care needs receive the necessary care. Certain services that are determined to be outside of the control of an LTCH include planned hospital admissions, management of certain preexisting chronic conditions (for example, dialysis for end-stage renal disease (ESRD), and enzyme treatments for genetic conditions), treatment for preexisting cancers, organ transplants, and preventive screenings (for example, colonoscopy and mammograms).

Exclusion of such services from the MSPB–PAC LTCH QRP episode ensures that facilities do not have disincentives to treat patients with certain conditions or complex care needs.

An MSPB–PAC episode may begin during the associated services period of an MSPB–PAC LTCH QRP episode in the 30 days post-treatment. One possible scenario occurs where an LTCH discharges a beneficiary who is then admitted to an IRF within 30 days. The IRF claim would be included once as an associated service for the attributed provider of the first MSPB–PAC LTCH QRP episode and once as a treatment service for the attributed provider of the second MSPB–PAC LTCH QRP episode. As in the case of overlap between hospital and PAC episodes discussed earlier, this overlap is necessary to ensure continuous accountability between providers throughout a beneficiary’s trajectory of care, as both providers share incentives to deliver high quality care at a lower cost to Medicare. Even within the LTCH setting, one MSPB–PAC LTCH QRP episode may begin in the associated services period of another MSPB–PAC LTCH QRP episode in the 30 days post-treatment. The second LTCH claim would be included once as an associated service for the attributed LTCH of the first MSPB–PAC LTCH QRP episode and once as a treatment
service for the attributed LTCH of the second MSPB–PAC LTCH QRP episode. Again, this ensures that LTCHs have the same incentives throughout both MSPB–PAC LTCH QRP episodes to deliver quality care and engage in patient-focused care planning and coordination. If the second MSPB–PAC LTCH QRP episode were excluded from the second LTCH’s MSPB–PAC LTCH QRP measure, that LTCH would not share the same incentives as the first LTCH of the first MSPB–PAC LTCH QRP episode. The MSPB–PAC LTCH QRP measure was designed to benchmark the resource use of each attributed provider against what their spending is expected to be as predicted through risk adjustment. As discussed further in this section, the measure takes the ratio of observed spending to expected spending for each episode and then takes the average of those ratios across all of the attributed provider’s episodes. The measure is not a simple sum of all costs across a provider’s episodes, thus mitigating concerns about double counting.

(2) Measure Calculation

Medicare payments for Part A and Part B claims for services included in MSPB–PAC LTCH QRP episodes, defined according to the methodology above, are used to calculate the MSPB–PAC LTCH QRP measure. Measure calculation involves determination of the episode exclusions, the approach for standardizing payments for geographic payment differences, the methodology for risk adjustment of episode spending to account for differences in patient case mix, and the specifications for the measure numerator and denominator. The measure calculation is performed separately for MSPB–PAC LTCH QRP standard and site neutral episodes to ensure that they are compared only to other standard and site neutral episodes, respectively. The final MSPB–PAC LTCH QRP measure combines the two ratios to construct one LTCH score as described in this section.

(a) Exclusion Criteria

In addition to service-level exclusions that remove some payments from individual episodes, we exclude certain episodes in their entirety from the MSPB–PAC LTCH QRP measure to ensure that the MSPB–PAC LTCH QRP measure accurately reflects resource use and facilitates fair and meaningful comparisons between LTCHs. The episode-level exclusions are as follows:

• Any episode where the claim(s) constituting the attributed LTCH’s treatment have a standard allowed amount of zero or where the standard allowed amount cannot be calculated.
• Any episode in which a beneficiary is not enrolled in Medicare FFS for the entirety of a 90-day lookback period (that is, a 90-day period prior to the episode trigger) plus episode window (including where a beneficiary dies), or is enrolled in Part C for any part of the lookback period plus episode window.
• Any episode in which a beneficiary has a primary payer other than Medicare for any part of the 90-day lookback period plus episode window.
• Any episode where the claim(s) constituting the attributed LTCH’s treatment include at least one related condition code indicating that it is not a prospective payment system bill.

(b) Standardization and Risk Adjustment

Section 1899B(d)(2)(C) of the Act requires that the MSPB–PAC QRP measures are adjusted for the factors described under section 1886(o)(2)(B)(ii) of the Act, which include adjustment for factors such as age, sex, race, severity of illness, and other factors that the Secretary determines appropriate. Medicare payments included in the MSPB–PAC LTCH QRP measure are payment-standardized and risk-adjusted. Payment standardization removes sources of payment variation not directly related to clinical decisions and facilitates comparisons of resource use across geographic areas. We proposed to use the same payment standardization methodology as that used in the NQF-endorsed hospital MSPB measure. This methodology removes geographic payment differences, such as wage index and geographic practice cost index (GPCI), incentive payment adjustments, and other add-on payments that support broader Medicare program goals including indirect graduate medical education (IME) and hospitals serving a disproportionate share of uninsured patients (DSH).234

Risk adjustment uses patient claims history to account for case-mix variation and other factors that affect resource use but are beyond the influence of the attributed LTCH. To assist with risk adjustment, we create mutually exclusive and exhaustive clinical case-mix categories using the most recent institutional claim in the 60 days prior to the start of the MSPB–PAC LTCH QRP episode. The beneficiaries in these clinical case mix categories have a greater degree of clinical similarity than the overall LTCH patient population, and allow us to more accurately estimate Medicare spending. Our MSPB–PAC LTCH QRP measure, adapted for the LTCH setting from the NQF-endorsed hospital MSPB measure, uses a regression framework with a 90-day hierarchical condition category (HCC) lookback period and covariates including the clinical case mix categories, MS–LTC–DRGs, HCC indicators, age brackets, indicators for originally disabled, ESRD enrollment, and long-term care status, and selected interactions of these covariates where sample size and predictive ability make them appropriate. We sought and considered public comment regarding the treatment of hospice services occurring within the MSPB–PAC LTCH QRP episode window. Given the comments received, we proposed to include the Medicare spending for hospice services but risk adjust for them, such that MSPB–PAC LTCH QRP episodes with hospice are compared to a benchmark reflecting other MSPB–PAC LTCH QRP episodes with hospice services. We believe that this strikes a balance between the measure’s intent of evaluating Medicare spending and ensuring that providers do not have incentives against the appropriate use of hospice services in a patient-centered continuum of care.

We understand the important role that sociodemographic status, beyond age, plays in the care of patients. However, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of diverse sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We will monitor the impact of sociodemographic status on hospitals’ results on our measures.

The NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations as well
as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) is conducting research to examine the impact of sociodemographic status on quality measures, resource use, and other measures under the Medicare program as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

While we conducted analyses on the impact of age by sex on the performance of the MSPB–PAC LTCH QRP risk-adjustment model, we did not propose to adjust the MSPB–PAC LTCH QRP measure for socioeconomic factors at this time. As this MSPB–PAC LTCH QRP measure will be submitted for NQF endorsement, we prefer to await the results of this trial and study before deciding whether to risk adjust for socioeconomic factors. We will monitor the results of the trial, studies, and recommendations. We invited public comment on how socioeconomic and demographic factors should be used in risk adjustment for the MSPB–PAC LTCH QRP measure.

Comment: Several commenters recommended that the MSPB–PAC LTCH QRP risk adjustment model include variables for SES/SDS factors. A commenter recommended that a “fairer” approach than using SES/SDS factors as risk adjustment variables would be to compare resource use levels that have not been adjusted for SES/SDS factors across peer providers (that is, providers with similar shares of beneficiaries with similar SES characteristics).

Response: With regard to the suggestions that the model include sociodemographic factors and the suggestion pertaining to an approach with which to convey data comparisons we refer readers to section VIII.C.6. of the preamble of this final rule, where we also discuss these topics.

Comment: Some commenters recommended that additional variables be included in risk adjustment to better capture clinical complexity. A few commenters suggested the inclusion of functional and cognitive status and other patient assessment data. A few commenters suggested patients who transfer from one short stay hospital to another in the pre-admission period may indicate clinical complexity and should be excluded from the measure. One commenter recommended that caregiver support be included in the risk adjustment model.

Response: We thank the commenters for their suggestions. The MSPB–PAC LTCH QRP measure is claims-based and does not incorporate other sources of data which might indicate the availability of family or caregiver support. As noted in the MSPB–PAC Public Comment Summary Report, a link for which has been provided above, even where data on caregiver support is available, there may be inherent subjectivity in determining the availability of such support. We believe that the other risk adjustment variables already included in the risk adjustment model adequately adjust for patients who transfer from one short stay hospital to another prior to admission to the LTCH by accounting for HCCs, clinical case mix categories, and prior inpatient and ICU length of stay. More details of the MSPB–PAC LTCH QRP risk adjustment model are in the MSPB–PAC Measure Specifications, a link for which has been provided above.

We recognize the importance of accounting for beneficiaries’ functional and cognitive status in the calculation of predicted episode spending. We considered the potential use of functional status information in the risk adjustment models for the MSPB–PAC measures. However, we decided not to include this information derived from the current setting-specific assessment instruments given the move towards standardized data as mandated by the IMPACT Act. We will revisit the inclusion of functional status in these measures’ risk adjustment models in the future when the standardized functional status data mandated by the IMPACT Act become available. Once they are available, we will take a gradual and systematic approach in evaluating how they might be incorporated. We intend to implement any changes if appropriate based on testing.

(c) Measure Numerator and Denominator

The MSPB–PAC LTCH QRP measure is a payment-standardized, risk-adjusted ratio that compares a given LTCH’s Medicare spending against the Medicare spending of other LTCHs within a performance period. Similar to the hospital MSPB measure, the ratio allows for ease of comparison over time as it obviates the need to adjust for inflation or policy changes.

The MSPB–PAC LTCH QRP measure is calculated as the ratio of the MSPB–PAC Amount for each LTCH divided by the episode-weighted median MSPB–PAC Amount across all LTCHs. To calculate the MSPB–PAC Amount for each LTCH, one calculates the average of the ratio of the standardized spending for LTCH standard episodes over the expected spending (as predicted in risk adjustment) for LTCH standard episodes, and the average of the ratio of the standardized spending for LTCH site neutral episodes over the expected spending (as predicted in risk adjustment) for LTCH site neutral episodes. This quantity is then multiplied by the average episode spending level across all LTCHs nationally for standard and site neutral episodes. The denominator for an LTCH’s MSPB–PAC LTCH QRP measure is the episode-weighted national median of the MSPB–PAC Amounts across all LTCHs. An MSPB–PAC LTCH QRP measure of less than 1 indicates that a given LTCH’s Medicare spending is less than that of the national median LTCH during a performance period.

Mathematically, this is represented in equation (A) below:
(A) MSPB-PAC LTCH Measure\(_j\) = \(\frac{\text{MSPB-PAC Amount}_j}{\text{National Median MSPB-PAC Amount}}\)

\[
\left(\frac{1}{n} \sum_{i \in \{j\}} \frac{Y_{ij}}{Y_{ij}}\right) \left(\frac{1}{n} \sum_{j \in \{i\}} Y_{ij}\right)
\]

Episode – Weighted Median of LTCH Providers’ MSPB-PAC Amount

Where
- \(Y_{ij}\) = attributed standardized spending for episode \(i\) and provider \(j\)
- \(Y_{ij}\) = expected standardized spending for episode \(i\) and provider \(j\), as predicted from risk adjustment
- \(n_i\) = number of episodes for provider \(j\)
- \(n\) = total number of episodes nationally
- \(\{i\}\) = all episodes \(i\) in the set of episodes attributed to provider \(j\).

(3) Data Sources

The MSPB–PAC LTCH QRP resource use measure is an administrative claims-based measure. It uses Medicare Part A and Part B claims from FFS beneficiaries and Medicare eligibility files.

(4) Cohort

The measure cohort includes Medicare FFS beneficiaries with an LTCH treatment period ending during the data collection period.

(5) Reporting

We intend to provide initial confidential feedback to providers, prior to public reporting of this measure, based on Medicare FFS claims data from discharges in CY 2015 and CY 2016. We intend to publicly report this measure using claims data from discharges in CY 2016 and CY 2017.

We proposed to use a minimum of 20 episodes for reporting and inclusion in the LTCH QRP. For the reliability calculation, as described in the measure specifications identified and for which a link has been provided above, we used two years of data (FY 2013 and FY 2014) to increase the statistical reliability of this measure. The reliability results support the 20 episode case minimum, and 98.83 percent of LTCHs had moderate or high reliability (above 0.4).

We invited public comment on our proposal to adopt the MSPB–PAC LTCH QRP measure for the LTCH QRP.

Comment: Several commenters expressed concern about the lack of NQF endorsement for the MSPB–PAC LTCH QRP measure; some believed that the measure should not be finalized until NQF endorsement is obtained.

Response: We thank the commenters for their concern regarding the lack of NQF endorsement and refer readers to section VIII.C.2. of the preamble of this final rule, where we also discuss this topic.

Comment: Several commenters noted the MAP did not endorse the proposed measure, believing that the measure should not be finalized until the support of the MAP is obtained.

Response: We appreciate the comments about the NQF MAP committee and refer readers to section VIII.C.2. of the preamble of this final rule, where we also discuss this topic.

Comment: Several commenters supported a period during which providers would be able to preview and correct measure and quality data.

Response: We appreciate the comments, and refer readers to section VIII.C.14. of the preamble of this final rule, where we discuss this topic in detail.

Comment: Some commenters recommended an initial confidential data preview period for providers, prior to public reporting.

Response: Providers will receive a confidential preview report with 30 days for review in advance of their data and information being publically displayed.

Comment: Some commenters supported an LTCH-specific MSPB–PAC measure, citing important differences (for example, patient characteristics and nature of care provided) between LTCH and other PAC settings.

Response: We thank the commenters for their support.

Comment: Some commenters recommended that the measure be tested for reliability and validity prior to finalization.

Response: As noted in the proposed rule (81 FR 25220), the MSPB–PAC LTCH QRP measure has been tested for reliability using two years of data (FY 2013 and FY 2014). The reliability results support the 20 episode case minimum, and 98.83 percent of LTCHs had moderate or high reliability (above 0.4). Further details on the reliability calculation are provided in the MSPB–PAC Measure Specifications document, a link for which has been provided above.

Comment: A few commenters noted that the MSPB–PAC measures are resource use measures that are not a standalone indicator of quality.

Response: We appreciate the comment regarding the MSPB–PAC measures as resource use measures. The MSPB–PAC LTCH QRP measure is one of four QRP measures that were proposed in the FY 2017 IPPS/LTCH proposed rule for inclusion in the LTCH QRP. In addition to the MSPB–PAC LTCH QRP measure, these proposed measures were the Discharge to Community-PAC LTCH QRP (81 FR 25220 through 25223), the Potentially Preventable 30-day Post-Discharge Readmission Measure for LTCH QRP (81 FR 25223 through 25225), and the Drug Regimen Review Conducted With Follow-Up for Identified Issues—PAC LTCH QRP (81 FR 25225 through 25228). As part of the LTCH QRP, the MSPB–PAC LTCH QRP measure will be paired with quality measures; we refer readers to section VIII.C.5. of the preamble of this final rule for a discussion of quality measures previously finalized for use in the LTCH QRP. We believe it is important that the cost of care be explicitly measured so that, in conjunction with other quality measures, we can publicly report which LTCHs are involved in the provision of high-quality care at lower cost.

Comment: One commenter expressed general support for the MSPB–PAC LTCH QRP measure, provided it has been tested for reliability and validity.

Response: We thank the commenter for their support. We appreciate the thoughtful feedback and engagement with the development and finalization of the MSPB–PAC LTCH QRP measure.

Comment: One commenter believed that the measure is a burden for providers.

Response: We thank the commenter for their concern. The MSPB–PAC LTCH QRP measure relies on Medicare FFS claims, which are reported to the Medicare program for payment purposes. PAC providers will not be required to report additional data to CMS for calculation of this measure.
a uniform PPS for all the PAC settings currently. In the absence of a single PAC PPS, the commenter recommended a single MSPB–PAC measure for each setting that could be used to compare providers within a setting. Under a single measure, the episode definitions, service inclusions/exclusions, and risk adjustment methods would be the same across all PAC settings.

Response: We thank the commenter. The four separate MSPB–PAC measures reflect the unique characteristics of each PAC setting and the population it serves. The four setting-specific MSPB–PAC measures are defined as consistently as possible across settings given the differences in the payment systems for each setting, and types of patients served in each setting. We have taken into consideration these differences and aligned the specifications, such as episode definitions, service inclusions/exclusions and risk adjustment methods for each setting, to the extent possible while ensuring the accuracy of the measures in each PAC setting.

Each of the measures assess Medicare Part A and Part B spending during the episode window which begins upon admission to the provider’s care and ends 30 days after the end of the treatment period. The service-level exclusions are harmonized across settings. The definition of the numerator and denominator is the same across settings. However, specifications differ between settings when necessary to ensure that the measures accurately reflect patient care and align with each setting’s payment system. For example, LTCHs and IRFs are paid a stay-level payment based on the assigned MS–LTC–DRG and Case-Mix Group (CMG), respectively, while SNFs are paid a daily rate based on the Resource Utilization Group (RUG) level, and HHAs are paid a rate based on a 60-day period as determined by the Home Health Resource Group (HHRG) for standard home health claims. While the definition of the episode window is consistent across settings and is based on the period of time that a beneficiary is under a given provider’s care, the duration of the treatment period varies to reflect how providers are reimbursed under the PPS that applies to each setting. The length of the post-treatment period is consistent between settings.

There are also differences in the services covered under the PPS that applies to each setting: For example, durable medical equipment, prosthetics, orthotics, and supplies (DMPOSS) claims are covered at LTCH, IRF, and SNF services but are not covered HHA services. This affects the way certain first-day service exclusions are defined for each measure.

We recognize that beneficiaries may receive similar services as part of their overall treatment plan in different PAC settings, but believe that there are some important differences in beneficiaries’ care profiles that are difficult to capture in a single measure that compares resource use across settings.

Also, the risk adjustment models for the MSPB–PAC measures share the same covariates to the greatest extent possible to account for patient case mix. However, the measures also incorporate additional setting-specific information where available to increase the predictive power of the risk adjustment models. For example, the MSPB–PAC LTCH QRP risk adjustment model uses MS–LTC–DRGs and Major Diagnostic Categories (MDCs), and the MSPB–PAC IRF QRP model includes Rehabilitation Impairment Categories (RICs). The HH and SNF settings do not have analogous variables that directly reflect a patient’s clinical profile.

We will continue to work towards a more uniform measure across settings as we gain experience with these measures, and we plan to conduct further research and analysis about comparability of resource use measures across settings for clinically similar patients, different treatment periods and windows, risk adjustment, service exclusions and other factors.

Comment: One commenter recommended that proposed quality measures obtain the support of a TEP including LTCH representatives to ensure the applicability of the measures to the LTCH setting.

Response: We thank the commenter for their recommendation. As discussed in the proposed rule (81 FR 25217), we note that we convened a TEP consisting of 12 panelists with combined expertise in all of the PAC settings, including LTCHs, on October 29 and 30, 2015, in Baltimore, Maryland. While the TEPs do not formally support or endorse measures, their feedback on risk adjustment, episode windows, exclusions, and other key elements of measure construction were incorporated into measure development. The MSPB–PAC TEP Summary Report is available, a link for which has been provided above.

Comment: One commenter recommended that LTCH site neutral and standard payment rate episodes be reported separately, rather than being aggregated into one MSPB–PAC LTCH QRP measure. Commenters believed that this would more accurately reflect resource use and be more helpful for providers.

Response: We thank the commenter for their concerns. While LTCH site neutral and LTCH standard patients are paid based on different rates, high quality and efficient treatment of any LTCH patient requires similar processes of care as well as strong care coordination and care transition planning. We believe therefore that performance scores on this measure will offer LTCHs information that will enable them to make meaningful improvements to their care. We will, however, take this comment into consideration as we continue to refine the measure.

Comment: One commenter recommended that adjacent LTCH stays be collapsed based on a 9-day gap, rather than the 7-day gap as proposed. A 9-day gap length would align with the LTCH interrupted stays policy rather than the proposed 7-day gap.  

Response: We thank the commenter for their recommendation. As discussed in the MSPB–PAC Public Comment Summary Report, a link for which has been provided above, and to clarify the commenter’s concern, a 9-day gap length would not align with the interrupted stays policy as an LTCH interrupted stay is reimbursed by Medicare as one claim under the LTCH PPS. Therefore, the treatment period begins at the episode trigger (that is, admission to the LTCH) and ends at the beneficiary’s final discharge from the LTCH. The treatment period does not end when the patient leaves the LTCH for an acute care hospital, IRF, or SNF, nor does the patient’s return to the same LTCH from those settings within the allowed number of days under the interrupted stays policy, trigger a new episode. The period during which the beneficiary is away from the LTCH and covered by the interrupted stays policy is included in the treatment period as it is treated as a single, albeit interrupted, LTCH stay under the LTCH PPS.

Comment: One commenter suggested that a 180-day associated services period would better reflect the post-discharge pathways for LTCH patients.

Response: We thank the commenter for their feedback and engagement with the MSPB–PAC LTCH QRP measure. As discussed in the MSPB–PAC Public Comment Summary Report, a link for which has been provided above, the 30-day post-treatment period was favored by the TEP panelists as an appropriate length of time during which a PAC provider can be held accountable for Medicare Part A and Part B spending, subject to certain clinically unrelated service exclusions. This period such as 180 days may reflect care trajectory for an LTCH beneficiary, it...
would also capture services that may be less influenced by the attributed PAC provider. Also, the 30-day post-treatment period is consistent with the NQF-endorsed hospital MSPB measure and aligns with widely adopted quality measures for readmissions and mortality.

**Comment:** One commenter recommended that a geographic-specific (for example, State or regional) median, citing differences in cost, patient population, and regulation.

**Response:** We appreciate the commenter’s input. We clarify that, as noted in the proposed rule (81 FR 25219), we proposed to use the same payment standardization methodology as that used in the NQF-endorsed hospital MSPB measure to account for variation in Medicare spending. This methodology removes geographic payment differences, such as wage index and geographic practice cost index (GPCI), incentive payment adjustments, and other add-on payments that support broader Medicare program goals, including indirect graduate medical education (IME) and hospitals serving a disproportionate share of uninsured patients (DSH). We believe that this approach accounts for the differences that the commenter raises while also maintaining consistency with the NQF-endorsed hospital MSPB measure’s methodology for addressing regional variation through payment standardization.

**Comment:** One commenter suggested that descriptive statistics on the measure scores by provider-level characteristics (for example, rural/urban status and bed size) would be useful to evaluate measure design decisions.

**Response:** We thank the commenter for their input. The following table shows the MSPB–PAC LTCH provider scores by provider characteristics, calculated using FY 2013 and FY 2014 data.

### MSPB–PAC LTCH PROVIDER SCORES BY PROVIDER CHARACTERISTICS

<table>
<thead>
<tr>
<th>Provider characteristic</th>
<th>Number of providers</th>
<th>Mean score</th>
<th>Score percentile</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1st</td>
</tr>
<tr>
<td><strong>All Providers</strong></td>
<td>438</td>
<td>1.00</td>
<td>0.85</td>
</tr>
<tr>
<td>Urban/Rural:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>411</td>
<td>1.00</td>
<td>0.85</td>
</tr>
<tr>
<td>Rural</td>
<td>27</td>
<td>1.00</td>
<td>0.92</td>
</tr>
<tr>
<td>Ownership Type:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For profit</td>
<td>284</td>
<td>1.00</td>
<td>0.88</td>
</tr>
<tr>
<td>Non-profit</td>
<td>113</td>
<td>1.00</td>
<td>0.86</td>
</tr>
<tr>
<td>Government</td>
<td>24</td>
<td>0.91</td>
<td>0.29</td>
</tr>
<tr>
<td>Unknown</td>
<td>17</td>
<td>0.99</td>
<td>0.89</td>
</tr>
<tr>
<td>Census Division:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>17</td>
<td>0.91</td>
<td>0.53</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>32</td>
<td>1.02</td>
<td>0.86</td>
</tr>
<tr>
<td>East North Central</td>
<td>70</td>
<td>1.00</td>
<td>0.89</td>
</tr>
<tr>
<td>West North Central</td>
<td>27</td>
<td>1.00</td>
<td>0.92</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>63</td>
<td>0.99</td>
<td>0.88</td>
</tr>
<tr>
<td>East South Central</td>
<td>34</td>
<td>0.98</td>
<td>0.90</td>
</tr>
<tr>
<td>West South Central</td>
<td>137</td>
<td>1.00</td>
<td>0.88</td>
</tr>
<tr>
<td>Mountain</td>
<td>33</td>
<td>1.01</td>
<td>0.90</td>
</tr>
<tr>
<td>Pacific</td>
<td>25</td>
<td>1.00</td>
<td>0.29</td>
</tr>
<tr>
<td>Bed Count:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–49</td>
<td>238</td>
<td>0.99</td>
<td>0.88</td>
</tr>
<tr>
<td>50–99</td>
<td>140</td>
<td>1.01</td>
<td>0.88</td>
</tr>
<tr>
<td>100–199</td>
<td>102</td>
<td>1.02</td>
<td>0.86</td>
</tr>
<tr>
<td>200–299</td>
<td>14</td>
<td>0.95</td>
<td>0.53</td>
</tr>
<tr>
<td>300 +</td>
<td>6</td>
<td>0.93</td>
<td>0.85</td>
</tr>
<tr>
<td>No. of Episodes:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–99</td>
<td>25</td>
<td>0.99</td>
<td>0.29</td>
</tr>
<tr>
<td>100–249</td>
<td>105</td>
<td>0.99</td>
<td>0.89</td>
</tr>
<tr>
<td>250–499</td>
<td>206</td>
<td>0.99</td>
<td>0.88</td>
</tr>
<tr>
<td>500–1000</td>
<td>84</td>
<td>1.00</td>
<td>0.86</td>
</tr>
<tr>
<td>1000 +</td>
<td>18</td>
<td>1.01</td>
<td>0.94</td>
</tr>
</tbody>
</table>

**Comment:** One commenter expressed concern that the public may interpret the MSPB–PAC measures to be applicable across PAC settings.

**Response:** We appreciate the commenter’s concern. While the MSPB–PAC measures are defined as consistently as possible between settings, they compare only providers within each setting. We believe that this distinction is clear as each MSPB–PAC measure will be part of their respective setting's QRP, including the MSPB–PAC LTCH QRP measure which is being finalized as part of the LTCH QRP.

In summary, after consideration of the public comments we received, we are finalizing the specifications of the MSPB–PAC LTCH QRP resource use measure, as proposed. A link for the MSPB–PAC Measure Specifications has been provided above.

We are finalizing the definition of an MSPB–PAC LTCH QRP episode, beginning from episode trigger. An episode window comprises a treatment period beginning at the trigger and ended upon discharge, and associated services period beginning at the trigger and ending 30 days after the end of the treatment period. Readmissions to the same LTCH within 7 or fewer days do not trigger a new episode and are instead included in the treatment period of the first episode.

We exclude certain services that are clinically unrelated to LTCH care and/or because LTCHs may have limited influence over certain Medicare services delivered by other providers during the episode window. We also exclude certain episodes in their entirety from the MSPB–PAC LTCH QRP measure, such as where a beneficiary is not enrolled in Medicare FFS for the...
entirety of the lookback period plus episode window.

We are finalizing the inclusion of Medicare payments for Part A and Part B claims for services included in the MSPB–PAC LTCH QRP episodes to calculate the MSPB–PAC LTCH QRP measure.

We are finalizing our proposal to risk adjust using covariates including age brackets, HCC indicators, prior inpatient stay length, ICU stay length, clinical case mix categories, indicators for originally disabled, ESRD enrollment, and long-term care status, hospice claim in episode window, and MS–LTC–DRGs. The measure also adjusts for geographic payment differences such as wage index and GPCI, and adjust for Medicare payment differences resulting from IME and DSH.

We calculate the individual providers’ MSPB–PAC Amount which is inclusive of MSPB–PAC LTCH QRP observed episode spending over the expected episode spending as predicted through risk adjustment. Standard and site neutral episode spending is compared only with standard and site neutral episode spending, respectively. Individual LTCHs’ scores are calculated as their individual MSPB–PAC Amount divided by the median MSPB–PAC amount across all LTCHs.

b. Measure To Address the IMPACT Act Domain of Resource Use and Other Measures: Discharge to Community-Post Acute Care (PAC) Long-Term Care Hospital Quality Reporting Program

Sections 1899B(d)(1)(B) and 1899B(a)(2)(E)(ii) of the Act require the Secretary to specify a measure to address the domain of discharge to community by SNFs, LTCHs, and IRFs by October 1, 2016, and HHAs by January 1, 2017. In the FY 2017 IPPS/ LTCH PPS proposed rule (81 FR 25220 through 25223), we proposed to adopt the measure, Discharge to Community- PAC LTCH QRP, for the LTCH QRP for the FY 2018 payment determination and subsequent years as a Medicare FFS claims-based measure to meet this requirement.

This measure assesses successful discharge to the community from an LTCH setting, with successful discharge to the community including no unplanned rehospitalizations and no death in the 31 days following discharge from the LTCH. Specifically, this measure reports an LTCH’s risk-standardized rate of Medicare FFS patients who are discharged to the community following an LTCH stay, and do not have an unplanned readmission to an acute care hospital or LTCH in the 31 days following discharge to community, and who remain alive during the 31 days following discharge to community. The term “community,” for this measure, is defined as home or self care, with or without home health services, based on Patient Discharge Status Codes 01, 06, 81, and 86 on the Medicare FFS claim.235 236 This measure is conceptualized uniformly across the PAC settings, in terms of the definition of the discharge to community outcome, the approach to risk adjustment, and the measure calculation.

Discharge to a community setting is an important health care outcome for many patients for whom the overall goals of PAC include optimizing functional improvement, returning to a previous level of independence, and avoiding institutionalization. Returning to the community is also an important outcome for many patients who are not expected to make functional improvement during their LTCH stay, and for patients who may be expected to decline functionally due to their medical condition. The discharge to community outcome offers a multi-dimensional view of preparation for community life, including the cognitive, physical, and psychosocial elements involved in a discharge to the community.237 238

In addition to being an important outcome from a patient and family perspective, patients discharged to community settings, on average, incur lower costs over the recovery episode, compared with those discharged to institutional settings.239 240 Given the high costs of care in institutional settings, encouraging LTCHs to prepare patients for discharge to community, when clinically appropriate, may have cost-saving implications for the Medicare program.241 Also, providers have discovered that successful discharge to community was a major driver of their ability to achieve savings, where capitated payments for PAC were in place.242 For patients who require long-term care due to persistent disability, discharge to community could result in lower long-term care costs for Medicaid and for patients’ out-of-pocket expenditures.243

Analyses conducted for ASPE on PAC episodes, using a 5 percent sample of 2006 Medicare claims, revealed that relatively high average, unadjusted Medicare payments are associated with discharge to institutional settings from IRFs, SNFs, LTCHs or HHAs, as compared with payments associated with discharge to community settings.244 Average, unadjusted Medicare payments associated with discharge to community settings ranged from $0 to $4,017 for IRF discharges, $0 to $3,544 for SNF discharges, $0 to $4,706 for LTCH discharges, and $0 to $992 for HHA discharges. In contrast, payments associated with discharge to non-community settings were considerably higher, ranging from $11,847 to $25,364 for IRF discharges, $9,305 to $29,118 for SNF discharges, $12,465 to $18,205 for LTCH discharges, and $7,981 to $35,192 for HHA discharges.245

Measuring and comparing facility-level discharge to community rates is expected to help differentiate among facilities with varying performance in this important domain, and to help avoid disparities in care across patient groups. Variation in discharge to community rates has been reported within and across post-acute settings; across a variety of facility-level characteristics, such as geographic location (for example, regional location, urban or rural location), ownership (for example, integrated hospital systems, as an example, and for-profit vs. non-profit status), and financial characteristics (for example, hospital system affiliation).246


236 This definition is not intended to suggest that board and care homes, assisted living facilities, or other settings included in the definition of “community” for the purpose of this measure are the most integrated setting for any particular individual or group of individuals under the Americans with Disabilities Act (ADA) and Section 504.


243 Measuring and comparing facility-level discharge to community rates is expected to help differentiate among facilities with varying performance in this important domain, and to help avoid disparities in care across patient groups. Variation in discharge to community rates has been reported within and across post-acute settings; across a variety of facility-level characteristics, such as geographic location (for example, regional location, urban or rural location), ownership (for example, integrated hospital systems, as an example, and for-profit vs. non-profit status), and financial characteristics (for example, hospital system affiliation).246


245 Ibid.

example, for-profit or nonprofit), and freestanding or hospital-based units; and across patient-level characteristics, such as race and gender. Discharge to community rates in the IRF setting have been reported to range from about 60 to 80 percent, with variation in discharge to community rates is seen in the SNF setting, with rates ranging from 31 to 65 percent. A multi-center study of 23 LTCHs demonstrated that 28.8 percent of 1,061 patients who were ventilator-dependent on admission were discharged to home. A single-center study revealed that 31 percent of LTCH hemodialysis patients were discharged to home. In the LTCH Medicare FFS population, using CY 2012–2013 national data, we found that approximately 25 percent of patients were discharged to the community. One study noted that 64 percent of beneficiaries who were discharged from the home health episode did not use any other acute or post-acute services paid by Medicare in the 30 days after discharge. However, significant numbers of patients were admitted to hospitals (29 percent) and lesser numbers to SNFs (7.6 percent), IRFs (1.5 percent), home health (7.2 percent) or hospice (3.3 percent).

Discharge to community is an actionable health care outcome, as targeted interventions have been shown to successfully increase discharge to community rates in a variety of post-acute settings. Many of these interventions involve discharge planning or specific rehabilitation strategies, such as addressing discharge barriers and improving medical and functional status. The effectiveness of these interventions suggests that improvement in discharge to community rates among PAC patients is possible through modifying provider-led processes and interventions. A TEP convened by our measure development contractor was strongly supportive of the importance of measuring discharge to community outcomes, and implementing the measure. Discharge to Community-PAC LTCH QRP in the LTCH QRP. The panel provided input on the technical specifications of this measure, including the feasibility of implementing the measure, as well as the overall measure reliability and validity. A summary of the TEP proceedings is available on the PAC Quality Initiatives Downloads and Videos web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html.

We also solicited stakeholder feedback on the development of this measure.

---

260 Ibid.

The NQF-convened MAP met on December 14 and 15, 2015, and provided input on the use of this Discharge to Community-PAC LTCH QRP measure in the LTCH QRP. The MAP encouraged continued development of the measure to meet the mandate of the IMPACT Act. The MAP supported the alignment of this measure across PAC settings, using standardized claims data. More information about the MAP’s recommendations for this measure is available at: http://www.qualityforum.org/Publications/2016/02/MAP_2016_Considerations_for_Implementing_Measures_in_Federal_Programs_-_PAC-LTC.aspx.

Since the MAP’s review and recommendation of continued development, we have continued to refine risk-adjustment models and conduct measure testing for this measure, as recommended by the MAP. This measure is consistent with the information submitted to the MAP, and the ongoing MAP commission and our continued refinements support its scientific acceptability for use in quality reporting programs. As discussed with the MAP, we fully anticipate that additional analyses will continue as we submit this measure to the ongoing measure maintenance process.

We reviewed the NQF’s consensus-endorsed measures and were unable to identify any NQF-endorsed resource use or other measures for PAC focused on discharge to community. In addition, we are unaware of any other PAC measures for discharge to community that have been endorsed or adopted by other consensus organizations. Therefore, we proposed the measure, Discharge to Community-PAC LTCH QRP, under the Secretary’s authority to specify non—NQF-endorsed measures under section 1899(b)(2)(B) of the Act.

We proposed to use data from the Medicare FFS claims and Medicare eligibility files to calculate this measure. We proposed to use data from the “Patient Discharge Status Code” on Medicare FFS claims to determine whether a patient was discharged to a community setting for calculation of this measure. In all PAC settings, we tested the accuracy of determining discharge to a community setting using the “Patient Discharge Status Code” on the PAC claim by examining whether discharge to community coding based on PAC claim data agreed with discharge to community coding based on Medicare FFS claims data. We found excellent agreement between the two data sources in all PAC settings, ranging from 94.6 percent to 98.8 percent. Specifically, in the LTCH setting, using 2013 data, we found 95.6 percent agreement in coding of community and non-community discharges when comparing discharge status codes on claims and the Discharge Location (item A2100) codes on the LTCH Continuity Assessment Record and Evaluation (CARE) Data Set Version 1.01. We further examined the accuracy of the “Patient Discharge Status Code” on the PAC claim by assessing how frequently discharges to an acute care hospital were confirmed by follow-up acute care claims. We discovered that 88 percent to 91 percent of IRF, LTCH, and SNF claims with acute care discharge status codes were followed by an acute care claim on the day of, or day after, PAC discharge. We believed these data support the use of the claims “Patient Discharge Status Code” for determining discharge to a community setting for this measure. In addition, this measure can feasibly be implemented in the LTCH QRP because all data used for measure calculation are derived from Medicare FFS claims and eligibility files, which are already available to CMS.

Based on the evidence discussed above, we proposed to adopt the measure, Discharge to Community-PAC LTCH QRP, for the LTCH QRP for FY 2018 payment determination and subsequent years. This measure is calculated using 2 years of data. We proposed a minimum of 25 eligible stays in a given LTCH for public reporting of the measure for that LTCH. Because Medicare FFS claims data are already reported to the Medicare program for payment purposes, and Medicare eligibility files are also available, LTCHs will not be required to report any additional data to us for calculation of this measure. The measure denominator is the risk-adjusted expected number of discharges to community. The measure numerator is the risk-adjusted estimate of the number of patients who are discharged to the community, do not have an unplanned admission to an acute care hospital or LTCH in the 31-day post-discharge observation window, and who remain alive during the post-discharge observation window. The measure is risk-adjusted for variables such as age and sex, principal diagnosis, comorbidities, ventilator status, ESRD status, and dialysis, among other variables. For technical information about the proposed measure, including information about the measure calculation, risk adjustment, and denominator exclusions, we referred readers to the document titled, Proposed Measure Specifications for Measures Proposed in the FY 2017 LTCH QRP NPRM, available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

We stated in the proposed rule that we intend to provide initial confidential feedback to LTCHs, prior to public reporting of this measure, based on Medicare FFS claims data from discharges in CY 2015 and 2016. We intend to publicly report this measure using claims data from discharges in CY 2016 and 2017. We plan to submit this measure to the NQF for consideration for endorsement.

As noted above, in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53615 through 53616), we adopted a subregulatory process to incorporate updates to LTCH quality measure specifications that do not substantively change the nature of the measure. In that rule, we noted that we expect to make this determination on a measure-by-measure basis and that examples of non-substantive changes to measures might include exclusions for a measure. For the proposed Discharge to Community-PAC LTCH QRP measure, we have added an exclusion of patients/residents with a hospice benefit in the post-discharge observation window, in response to comments received during measure development and our ongoing analysis and testing. The rationale for the exclusion of patients/residents with a hospice benefit in the post-discharge observation window aligns with the rationale for exclusion of discharges to hospice. Based on testing, we found that patients/residents with a postdischarge hospice benefit have a much higher death rate in the postdischarge observation window compared with patients/residents without a hospice benefit. We determined that the addition of this hospice exclusion enhances the measure by excluding patients/residents with a high likelihood of postdischarge death and improves the national observed discharge to community rate for LTCHs by approximately 0.7 percent. With the
addition of this hospice exclusion, we do not believe burden is added, nor that the addition of this exclusion is a substantive change to the overall measure. Failure to include this hospice exclusion could lead to unintended consequences and access issues for terminally-ill patients/residents in our PAC populations.

We invited public comment on our proposal to adopt the measure, Discharge to Community-PAC LTCH QRP, for the LTCH QRP. The comments we received on this topic, with their responses, appear below.

Comment: Several commenters, including MedPAC, expressed support for the Discharge to Community-PAC LTCH QRP measure. Commenters stated that the discharge to community measure is very aligned with principles of patient-centered care as patients show a preference for care outside of institutional settings, and that successful transitions to the community are expected to decrease potentially preventable readmissions. One commenter noted that measuring the rate that the various PAC settings discharge patients to the community, without an admission (or readmission) to an acute care hospital within 30 days, is one of the most relevant patient-centered measures that exists in the PAC area. Another commenter stated that LTCHs should be encouraged to discharge patients to community-based care settings (home or self care, with or without home health services) where literature shows that average spending per beneficiary is less than in institutional based care settings. One commenter supported the proposed measure, provided it had been tested for validity and reliability. One commenter noted that achieving a standardized and interoperable patient assessment data set and stable quality measures as quickly as possible will allow for better cross-setting comparisons and the evolution of better quality measures with uniform risk standardization.

Response: We thank the commenters for their support of the Discharge to Community-PAC LTCH QRP measure, and appreciate their recognition of the patient-centeredness of this measure, its potential to decrease post-discharge readmissions, and its potential to reduce spending. In our measure development process, we conduct reliability and validity testing for all measures. We will continue to conduct this testing with all future measure development and/or modification. We also thank commenters for their support of standardized and interoperable patient assessment data and quality measures. As mandated by the IMPACT Act, we are moving toward the goal of standardized patient assessment data and quality measures across PAC settings.

Comment: Several commenters stated that the Discharge to Community-PAC LTCH QRP measure is not an appropriate measure of quality for the LTCH setting, stating that the primary function of LTCHs is to provide critical, acute, or sub-acute levels of care and to discharge patients to the appropriate lower acuity setting when they no longer require these levels of care. Commenters stated that keeping patients until they are ready to be discharged to the community is not a goal of LTCHs.

Response: We appreciate the commenters’ concerns. We understand that patient populations and goals of care differ across PAC settings, and that LTCHs care for higher acuity patients when compared with other PAC settings. Nonetheless, successful discharge to community, when appropriate, is an important goal many PAC patients, regardless of the provider from which they are receiving services. We would like to note that in order to account for differences in case-mix across settings, this measure is risk-adjusted.

We understand that discharge to community rates for LTCHs, on average, are expected to be lower compared with rates for other PAC settings, given the higher acuity case-mix in LTCHs. Our analysis has shown that approximately 26 percent of LTCH patients are discharged to the community. This measure will allow us to compare discharge to community rates across LTCHs, and monitor facilities with unexpectedly low rates given their case-mix. It is not our intention to attribute lower discharge to community rates of LTCHs to lower quality of care compared with other PAC settings. Further, we do not expect facilities to achieve a 100 percent discharge to community rate for this measure.

Comment: Several commenters emphasized that a lower acuity PAC setting is often an appropriate and successful discharge destination for LTCH patients. Some commenters recommended that discharges to lower acuity PAC settings, such as IRF or SNF, be considered successful discharges to community, while others recommended that discharges to lower acuity PAC settings be excluded from the measure because otherwise they would be wrongly treated as unfavorable outcomes. One commenter specifically recommended that patients who move from an SNF to an LTCH and back to SNF be considered an appropriate discharge outcome for this measure; this commenter also recommended that patients with such a trajectory be excluded from the measure. Another commenter specifically recommended that discharges from an LTCH to an IRF be considered successful discharges to community.

Response: We appreciate that for several LTCH patients, discharge to lower acuity PAC settings such as IRF or SNF represents a successful and positive discharge outcome. However, we would like to clarify that this measure is intended to specifically capture discharge to community settings, namely home or self care, with or without home health services, based on Patient Discharge Status Codes 01, 06, 81, and 86 on the Medicare FFS claim.276 This measure is not intended to capture discharges to all lower levels of care. Since IRFs and SNFs are not community settings, including IRF and SNF discharges in the definition of discharge to community would reduce the validity of our measure. Nonetheless, we recognize that discharge to a community setting is not an expected outcome for every PAC patient. Therefore, we risk adjust for baseline patient characteristics in this measure to adjust for case-mix in each setting. In addition to adjusting for variables such as principal diagnosis and comorbidities, in the LTCH setting we adjust for ventilator use. We believe it is important to track discharge destination outcomes of all LTCH patients. Therefore, we have not excluded discharges to lower acuity PAC settings from the measure, nor have we excluded patients who were in a SNF prior to their acute or LTCH stay.

As stated above, this measure will allow us to compare discharge to community rates across LTCHs, and monitor facilities with unexpectedly low rates given their case-mix. We believe that successful discharge to community, when appropriate, is an important goal many LTCH patients share.

Comment: Several commenters, including MedPAC, were concerned about the reliability and/or validity of the Patient Discharge Status Code on the PAC claim, some referencing MedPAC and other studies that questioned the accuracy of this code. They strongly recommended that CMS address inconsistencies in reporting of the Patient Discharge Status Code and confirm its accuracy through additional testing. MedPAC recommended that CMS confirm discharge to a community

---

setting with the absence of a subsequent claim to a hospital, IRF, SNF, or LTCH, in order to ensure that discharge to community rates reflect actual facility performance; other commenters supported this recommendation. One commenter shared its analysis that between 3.7 percent and 7.4 percent of those successfully discharged to the community as identified by the discharge status on the LTCH, IRF, or SNF claim had a subsequent short-term care hospital (STCH), LTCH, IRF, or SNF claim in the 31-day post-discharge window.

Response: We are committed to developing measures based on reliable and valid data. This measure does confirm the absence of hospital or LTCH claims following discharge to a community setting. Unplanned acute or LTCH readmissions following the discharge to community, including those on the day of LTCH discharge, are considered unfavorable outcomes. We will consider verifying the absence of IRF and SNF claims following discharge to a community setting as we continue to refine this measure. Nonetheless, we would like to note an ASPE report on PAC relationships found that, following discharge to community settings from IRFs, LTCHs, or SNFs in a 5 percent Medicare sample, IRFs or SNFs were very infrequently reported as the next site of PAC.

We would also like to clarify that an institutional claim that does not immediately follow a discharge to community would, in most instances, be indicative of a discharge to a community setting followed by a readmission. It should not be interpreted as evidence of an inaccurate discharge to community code on the PAC claim.

Because the discharge to community measure is a measure of discharge destination from the PAC setting, we have chosen to use the PAC-reported discharge destination (from the Medicare FFS claims) to determine whether a patient/resident was discharged to the community (based on discharge status codes 01, 06, 81, 86). We assessed the reliability of the claims discharge status code(s) by examining agreement between discharge status on claims and assessment instruments for the same stay in all four PAC settings. We found between 94 and 99 percent agreement in coding of community discharges on matched claims and assessments in each of the PAC settings. We also assessed how frequently discharges to acute care, as indicated on the PAC claim, were confirmed by follow-up acute care claims, and found that 88 percent to 91 percent of IRF, LTCH, and SNF claims indicating acute care discharge were followed by an acute care claim on the day of, or day after, PAC discharge. We believe that these data support the use of the "Patient Discharge Status Code" from the PAC claim for determining discharge to a community setting for this measure.

The use of the claims discharge status code to identify discharges to the community was discussed at length with the TEP convened by our measure development contractor. TEP members did not express significant concerns regarding the accuracy of the claims discharge status code in coding community discharges, nor about our use of the discharge status code for defining this quality measure. A summary of the TEP proceedings is available on the PAC Quality Initiatives Downloads and Videos Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html.

Comment: A few commenters recommended that baseline long-stay nursing facility residents be excluded from the measure, as they could not be reasonably expected to discharge to the community after their PAC stay. One commenter expressed concern that the discharge to community measure fails to consider when a patient’s "home" is a custodial nursing facility and the patient's post-acute episode involves a discharge back to his or her "home." The commenter encouraged CMS to modify the discharge to community measure so it is able to distinguish baseline custodial nursing facility residents who are discharged back to their nursing facility. One commenter cited data that discharge to community rates were much lower for LTCH patients who had an indication of a prior nursing home stay compared with those who did not. Another commenter noted that these residents have a very different discharge process back to the nursing facility compared with patients discharged to the community. This commenter recommended that different measures be developed for this population, such as return to prior level of function, improvement in function, prevention of further functional decline, development of pressure ulcers, or functional falls. This commenter also recognized CMS' current efforts in monitoring transitions of care and quality requirements in long-term care facilities. One commenter suggested that CMS use the Minimum Data Set to identify and exclude baseline nursing facility residents.

Similar to the above comments, other commenters emphasized the importance of risk adjustment for pre-hospitalization living setting, noting that some patients could reasonably never be expected to return to the community based on their permanent living setting prior to their acute care hospital stay. These commenters conveyed that it was unreasonable to expect PAC providers to discharge to the community those patients who may have permanently lived in a non-community setting prior to the acute hospital stay, and that risk adjustment should account for this.

Response: We appreciate the commenters' concerns and their recommendations to exclude baseline nursing facility residents from the discharge to community measure, to distinguish baseline custodial nursing facility residents who are discharged back to the nursing facility after their LTCH stay, and to risk adjust for pre-hospitalization living setting when assessing discharge to community outcomes. We recognize that patients/residents who permanently lived in a nursing facility or other long-term care facility at baseline may not be expected to discharge back to a home and community based setting after their PAC stay. We also recognize that, for baseline nursing facility residents, a discharge back to their nursing facility represents a discharge to their baseline residence. We agree with the commenter about the differences in discharge planning processes when discharging a patient/resident to the community compared with discharging them to a long-term nursing facility. However, using Medicare FFS claims alone, we are unable to accurately identify baseline nursing facility residents. In addition, there are no claims data on pre-hospital living setting that we could use for risk adjustment. Potential future modifications of the measure could include the assessment of the feasibility and impact of excluding baseline nursing facility residents from the measure or risk adjusting for pre-hospital living setting, through the addition of patient assessment-based data. However, we note that, currently, the IRF-Patient Assessment Instrument (IRF-PAI) is the only PAC assessment that contains an item related to pre-hospital baseline living setting.

Comment: One commenter recommended that the measure exclude patients who have been discharged to...
the community and expire within the post-discharge observation window. The commenter supported this recommendation by explaining that the types of patients treated in each PAC setting varied greatly and that including post-discharge death in the measure could lead to an inaccurate reflection of the quality of care furnished by the PAC. The commenter further cited MedPAC data indicating that, compared with other Medicare beneficiaries, the LTCH patient population is disproportionately more disabled, elderly, and frail.

Response: Including 31-day post-discharge mortality outcomes is intended to identify successful discharges to community, and to avoid the potential unintended consequence of inappropriate community discharges. We have found, through our analyses on our measure development sample, that death in the 31 days following discharge to community is an infrequent event; 2.73 percent of LTCH Medicare FFS beneficiaries discharged to community died in the 31 days following discharge. We do not expect facilities to achieve a 0 percent death rate in the measure’s postdischarge observation window; one focus of the measure is to identify facilities with unexpectedly high rates of death for quality monitoring purposes.

We agree with the commenter about the differences in case-mix across the PAC settings. Therefore, we risk adjust this measure for several case-mix variables, such as age, diagnoses from the prior acute stay, comorbidities in the year preceding PAC admission, length of prior acute stay, number of prior hospitalizations in the past year, and ventilator use.

Comment: Several commenters suggested that the discharge to community measure adjust for sociodemographic and socioeconomic factors. Commenters were concerned that provider performance on the measure will depend on patient-related sociodemographic and socioeconomic factors such as availability of home and community supports, financial resources, race, and dual eligibility, which are outside of the provider’s control.

Response: We understand the importance of home and community supports, sociodemographic, and socioeconomic factors for ensuring a successful discharge to community outcome. The discharge to community measure is a claims-based measure, and note that currently, there are no standardized variables such as living status or home and community supports across the four PAC settings. As we refine the measure in the future, we will consider testing and adding additional relevant data sources and standardized items for risk adjustment of this measure. With regard to the suggestions pertaining to risk adjustment for sociodemographic and socioeconomic factors, we refer the readers to section VIII.C.6. of the preamble of this final rule for a more detailed discussion of the role of SES/SDS factors in risk adjustment of our measures.

Comment: Some commenters emphasized the relationship between functional gains made by patients during their LTCH stay and their ability to discharge to the community. One commenter stated that return to one’s previous home represents part of the goal of care; in addition, it is also important that the patient is able to function to the greatest possible extent in the home and community setting and achieve the highest quality of life possible. The commenter recommended that CMS delay its proposal to adopt this measure until it incorporated metrics that assess whether patients achieved their functional and independence goals based on their plan of care and their specific condition.

Other commenters suggested that the measure include risk adjustment for functional status. One commenter noted that functional status is associated with increased risk of 30-day all-cause hospital readmissions, and since readmissions and discharge to community are closely related, functional status risk adjustment is also important for this measure. Another commenter suggested that, for cross-setting standardization, the SNF and LTCH measures should also include risk adjustment that is similar to the risk adjustment for Case-Mix Groups (CMGs) in the IRF setting and Activities of Daily Living in the HHA setting.

Response: We agree that it is important to assess various aspects of patient outcomes that are indicative of functional status and resource use in each PAC setting. We also agreed that functional status may be related to discharge to community outcomes, and that it is important to test admission functional status risk adjustment when assessing discharge to community outcomes. The discharge to community measure does include functional status risk adjustment in the IRF setting using CMGs from claims, and in the home health setting using Activities of Daily Living from claims. There are no data related to functional status in LTCH claims. We would like to note that, in other work, we have found admission functional status to not be as strong a predictor of resource use or functional outcomes in LTCHs relative to other PAC settings.

As mandated by the IMPACT Act, we are moving toward the goal of collecting standardized patient assessment data for functional status across PAC settings. The LTCH QRP includes three NQF endorsed functional status quality measures: Functional Outcome Measure: Change in Mobility among Long-Term Care Hospital Patients Requiring Ventilator Support (NQF #2632); Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631); and Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631). Once standardized functional status data become available across settings, it is our intent to use these data to assess patients’ functional gains during their PAC stay, and to examine the relationship between functional status, discharge destination, and patients’ ability to discharge to the community. As we examine these relationships between functional outcomes and discharge to community outcomes in the future, we will assess the feasibility of leveraging these standardized patient assessment data to incorporate functional outcomes into the discharge to community measure. Standardized cross-setting patient assessment data will also allow us to examine interrelationships between the quality and resource use measures in each PAC setting, and to understand how these measures are correlated.

Comment: One commenter suggested that CMS risk adjust for additional variables for the LTCH discharge to community measure, including principal diagnosis associated with the LTCH stay, multiple organ failure, do not resuscitate (DNR) status in the LTCH and prior short-term acute care hospital stay, and prior nursing home stay. The commenter noted that, in their analyses, they found that principal diagnosis groups such as cancer diagnoses, adult respiratory failure, and aspiration pneumonia based on the LTCH stay.


279 Long-Term Care Hospital [LTCH] Functional Outcome Measure: Change in Mobility Among Patients Requiring Ventilator Support (NQF #2632). http://www.qualityforum.org/QFS/2632.
were associated with significantly lower discharge to community rates.

Response: We thank the commenter for their suggestions. With regard to using principal diagnosis from the prior acute claim, our approach is consistent with that of claims-based NQF-endorsed readmissions measures for PAC settings. We are adjusting for the medical condition that was the precursor to the LTCH admission. Using surgical categories, we also adjust for whether the patient had surgery in the prior acute stay. Our risk adjustment models are comprehensive, and adjust for all diagnoses and procedures on the prior acute claim, as well as several comorbidities based on the year preceding PAC admission. We adjust for the principal diagnosis groups mentioned by the commenter including cancer diagnoses, adult respiratory failure, and aspiration pneumonia, all of which are significant predictors of lower discharge to community rates.

With regard to risk adjustment for prior nursing home stay, we plan to assess the feasibility and impact of identifying and excluding baseline long-stay nursing facility residents in future measure modifications. We will also consider other risk adjustment suggestions made by the commenters, as we refine the measure.

Comment: One commenter stated that ventilator use is included as a risk adjuster in the LTCH setting only, but should be used across all settings. This commenter also requested information on the hierarchical logistic regression modeling and variables that will be used for risk adjustment.

Response: We would like to clarify that risk adjustment for ventilator use is included in both LTCH and SNF settings. We investigated the need for risk adjustment for ventilator use in IRFs, but found that less than 0.01 percent of the IRF population (19 patient stays in 2012, and 9 patient stays in 2013) had ventilator use in the IRF. Given the low frequency of ventilator use in IRFs, any associated estimates would not be reliable, and therefore, ventilator use is not included as a risk adjuster in the IRF setting measure. However, we will continue to assess this risk adjuster for inclusion in the IRF model for this measure.

For details on measure specifications, modeling, and calculations, we refer readers to the Measure Specifications for Measures Adopted in the FY 2017 LTCH QRP Final Rule, posted on the CMS LTCH QRP Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measure-Information.html.

Further information about the AHRQ CCS procedure categories is available in the Measure Specifications for Measures-Information.html.

Comment: One commenter requested information on how planned discharges to an acute care hospital or LTCH were identified and excluded from the discharge to community measure. Specifically, the commenter asked whether discharges were considered planned if the discharge status code on the acute care claim preceding the PAC stay was “91” for LTCHs, “90” for IRFs, and “83” for SNFs, where code “91” indicates “Discharged/transferred to a Medicare certified long term care hospital (LTCH) with a planned acute care hospital inpatient readmission,” “90” indicates “Discharged/transferred to an inpatient rehabilitation facility (IRF) including rehabilitation distinct part units of a hospital with a planned acute care hospital inpatient readmission” and “83” indicates “Discharged/transferred to a skilled nursing facility (SNF) with Medicare certification with a planned acute care hospital inpatient readmission.”

Response: We would like to clarify that the determination of planned discharge is not based on the discharge status code on the prior acute care claim indicating a planned acute care readmission (that is, codes 81 through 95). These discharge status codes are not associated with a time frame for planned readmission, and are not used to determine whether a discharge was planned or unplanned. We determine inclusion even though the acute care stay did not immediately precede SNF admission.

Comment: One commenter requested information about how the surgical procedure categories in the risk adjustment variables are grouped from the Agency for Healthcare Research and Quality (AHRQ) Clinical Classifications Software (CCS) procedure categories listed in the Hospital-Wide All-Cause Unplanned Readmission Measure specifications.

Response: We appreciate the commenter's request for information. The surgical indicators are based on those developed for the Hospital-Wide All-Cause Unplanned Readmission (CMS/Yale) measure (NQF #1789). Further information about the AHRQ CCS procedure categories is available in the Measure Specifications for Measures Adopted in the FY 2017 LTCH QRP Final Rule, posted on the CMS LTCH QRP Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measure-Information.html.

Response: We would like to clarify for their comment, which touches on a number of measure aspects that interact. First, the preference expressed in expert panels has been to limit the time lag between the acute discharge and the provider being evaluated. Second, the presence of a long intervening PAC stay could either indicate a more severe patient, or alternatively a more recovered patient when the next PAC provider admits the patient; the bias cannot be assumed to be unidirectional. That said, the purpose of the commenter’s recommendation is to capture, in a limited way, some of the unmeasured severity distinguishing beneficiaries across different PAC settings. We agree with the commenter’s intent, but do not believe this would have a substantive effect when comparing settings, or improve comparisons of providers of the same type. Nonetheless, in future years, we will consider evaluating the impact of the commenter’s suggestion on measure performance.

To address the commenter’s question, the qualifying acute care stay within the past 30 days does not need to immediately precede the index PAC admission. For example, if a patient has an acute care stay, an LTCH stay, and a SNF stay within a 30-day window, the SNF stay is a candidate to for measure

280 Hospital-Wide All-Cause Readmission Measure (HWRR) (CMS/Yale).

www.qualityforum.org/QPS/1789 (NQF #1789).
whether an observed discharge was planned based on diagnosis and procedure codes reported on inpatient acute or LTCH claims following discharge to community. We identify planned admissions using the planned readmissions algorithm used in the following PAC readmission measures: (1) Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNF-RM) (NQF #2510); (2) All-Cause Unplanned Readmission Measure for 30 Days Post Discharge from Inpatient Rehabilitation Facilities (NQF #2520); and (3) All-Cause Unplanned Readmission Measure for 30 Days Post Discharge from Long Term Care Hospitals (NQF #2512).

For the IRF and SNF settings, we exclude stays with planned discharges to an acute care hospital or LTCH that occur on the day of, or day after, PAC discharge. For the LTCH setting, we exclude planned discharges to an acute care hospital on the day of, or day after, LTCH discharge. We note that PAC claims indicating discharge to a community are not excluded if they are followed by a subsequent planned acute care or LTCH admission; rather these stays are treated as successful discharge to community outcomes.

Comment: One commenter asked whether an unplanned readmission that follows a planned readmission in the post-discharge observation window would be considered an unfavorable outcome for the discharge to the community measure.

Response: An unplanned readmission that follows a planned readmission in the post-discharge observation window is not considered an unfavorable outcome for the discharge to the community measure. For this measure, we examine the first readmission that falls within the observation window following discharge to community. If the first readmission is unplanned, it is considered an unsuccessful discharge to community outcome. If the first readmission is planned, it is considered a successful discharge to community outcome. Any unplanned readmissions following the first planned readmission do not impact the discharge to community outcome.

Comment: One commenter requested information on the mapping of ICD–9 codes to the CMS-Hierarchical Condition Categories (HCCs) used as risk adjustment variables in the model.

Response: We appreciate the commenter’s request for information. We used Version 21 of the HCCs based on ICD–9 codes, but will transition to Version 22 with ICD–10 codes.

Comment: One commenter noted that the various PAC settings served patients with different levels of clinical severity, and the resulting standardized rates thus varied by patient mix as well as by care quality.

Response: We agree with the commenter that the different PAC settings serve patients with different levels of clinical severity. Using risk adjustment, it is not possible to capture the full clinical complexity of patients and the stage of their medical conditions across PAC settings. Therefore, the most appropriate way to capture the differences in the clinical complexity of patients is to separate the provider types and compare like providers to each other. Though there are occasions in which a beneficiary will be choosing the type of PAC provider, those choices are often limited by availability of providers and personal circumstances with regard to availability of caregivers. There is no implication in the measures that care in an LTCH is of lower quality than care in other PAC settings, because the average discharge to community rate for LTCH patients is lower than that of other PAC settings. At present, to capture case-mix differences that are unobservable by doing measure comparisons within provider type.

Comment: One commenter encouraged CMS to provide PAC settings with access to measure performance data as early as possible so providers have time to adequately review these data, and implement strategies to decrease readmissions where necessary.

Response: We intend to provide initial confidential feedback to PAC providers, prior to public reporting of this measure, based on Medicare FFS claims data from discharges in CY 2015 and 2016.

Comment: Several commenters were concerned that the measure may result in unintended consequences such as increased LTCH length of stay to get the patient ready for discharge to community, or inappropriate discharges to community for patients who may benefit from lower acuity PAC services.

Response: We thank the commenters for sharing their concerns about potential unintended consequences of increased LTCH length of stay or inappropriate community discharges for this measure. To avoid the unintended consequence of inappropriate discharges to community, we monitor unplanned acute and LTCH readmissions and death in the 31-day post-discharge observation window. We will consider monitoring IRF, SNF, and nursing facility admissions following discharge to community setting as we continue to refine this measure. As with all our measures, we will monitor for unintended consequences as part of measure monitoring and evaluation to ensure that measures do not reduce quality of care or access for patients, result in disparities for patient subgroups, or adversely affect healthcare spending.

Comment: One commenter expressed that use of data preceding measure implementation date to determine a baseline rate of discharge to community could be problematic because they expected changes in data following measure implementation and efforts to improve coding. The commenter recommended measure reporting using data collected after measure implementation.

Response: As stated in section VIII.C.6.b. of the preamble of the proposed rule, data from CY 2015–2016 will be used as the basis for initial confidential feedback reports, and data from CY 2016–2017 will be used for public reporting. We appreciate the recommendation to align the baseline period with the implementation date; however, in order to ensure the reliability of the measure we need two consecutive years of data, which requires us to use data from CY 2016–2017 for public reporting. We believe the reliability of the measure is more important than aligning the baseline and implementation dates.

Comment: Several commenters were concerned that the LTCH discharge to community measure was not NQF-endorsed before being adopted for the LTCH QRP. Some commenters noted that the LTCH patient population is different from those of other settings, making NQF endorsement particularly important. The commenters asked CMS to refrain from implementing the discharge to community measure for the LTCH QRP until it has been endorsed by NQF.

Response: We thank the commenters for their comments regarding NQF endorsement. We would like to clarify that the discharge to community measure has been fully developed and tested. We plan to submit the Discharge to Community-PAC LTCH QRP measure to the NQF for consideration for endorsement.

After consideration of the public comments we received, we are finalizing our proposal to adopt the measure, Discharge to Community-PAC LTCH QRP as a Medicare FFS claims-based measure for the FY 2018 payment determination and subsequent years, with the added exclusion of patients with a hospice benefit in the 31-day post-discharge observation window. For measure specifications, we refer readers to the Measure Specifications for...
Measures Adopted in the FY 2017 LTCH QRP Final Rule, posted on the CMS LTCH QRP Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCQuality-Reporting/LTC-Quality-Reporting-Measures-Information.html...

c. Measure To Address the IMPACT Act

Sections 1899B(a)(2)(E)(ii) and 1899B(d)(1)(C) of the Act require the Secretary to specify measures to address the domain of all-condition risk-adjusted potentially preventable hospital readmission rates by SNFs, LTCHs, and IRFs by October 1, 2016, and HHAs by January 1, 2017. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25223 through 25225), we proposed the measure Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP as a Medicare FFS claims-based measure to meet this requirement for the FY 2018 payment determination and subsequent years.

The measure assesses the facility-level risk-standardized rate of unplanned, potentially preventable hospital readmissions for Medicare FFS beneficiaries in the 30 days post-LTCH discharge. The LTCH admission must have occurred within up to 30 days of discharge from a prior proximal hospital stay which is defined as an inpatient admission to an acute care hospital (including IPPS, CAH, or a psychiatric hospital). Hospital readmissions include readmissions to a short-stay acute care hospital or an LTCH, with a diagnosis considered to be unplanned and potentially preventable. This measure is claims-based, requiring no additional data collection or submission burden for LTCHs. Because the measure denominator is based on LTCH admissions, each Medicare beneficiary may be included in the measure multiple times within the measurement period. Readmissions counted in this measure are identified by examining Medicare FFS claims data for readmissions to either acute care hospitals [IPPS or CAH] or LTCHs that occur during a 30-day window beginning two days after LTCH discharge. This measure is conceptualized uniformly across the PAC settings, in terms of the measure definition, the approach to risk adjustment, and the measure calculation. Our approach for defining potentially preventable hospital readmissions is described in more detail below.

Hospital readmissions among the Medicare population, including beneficiaries that utilize PAC, are common, costly, and often preventable.\textsuperscript{281,282} MedPAC and a study by Jencks et al. estimated that 17 to 20 percent of Medicare beneficiaries discharged from the hospital were readmitted within 30 days. MedPAC found that more than 75 percent of 30-day and 15-day readmissions and 84 percent of 7-day readmissions were considered “potentially preventable.”\textsuperscript{283} In addition, MedPAC calculated that annual Medicare spending on potentially preventable readmissions would be $12 billion for 30-day, $8 billion for 15-day, and $5 billion for 7-day readmissions in 2005.\textsuperscript{284} For hospital readmissions from one PAC setting, SNFs, MedPAC deemed 76 percent of readmissions as “potentially avoidable”—associated with $12 billion in Medicare expenditures.\textsuperscript{285} Mor et al. analyzed 2006 Medicare claims and SNF assessment data (Minimum Data Set), and reported a 23.5 percent readmission rate from SNFs, associated with $4.3 billion in expenditures.\textsuperscript{286} Fewer studies have investigated potentially preventable readmission rates from the remaining PAC settings.

We have addressed the high rates of hospital readmissions in the acute care setting as well as in PAC. For example, we developed the following measure: All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), as well as similar measures for other PAC providers (NQF #2502 for IRFs and NQF #2510 for SNFs).\textsuperscript{287} These measures are endorsed by the NQF, and the NQF endorsed LTCH measure (NQF #2512) was adopted into the LTCH QRP in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49730 through 49731). Note that these NQF endorsed measures assess all-cause unplanned readmissions. Several general methods and algorithms have been developed to assess potentially avoidable or preventable hospitalizations and readmissions for the Medicare population. These include the Agency for Healthcare Research and Quality’s (AHRQ’s) Prevention Quality Indicators, approaches developed by MedPAC, and proprietary approaches, such as the 3MTM algorithm for Potentially Preventable Readmissions.\textsuperscript{288,289,290} Recent work led by Kramer et al. for MedPAC identified 13 conditions for which readmissions were deemed as potentially preventable among SNF and IRF populations.\textsuperscript{291,292} Although much of the existing literature addresses hospital readmissions more broadly and potentially avoidable hospitalizations for specific settings like long-term care, these findings are relevant to the development of potentially preventable readmission measures for PAC.\textsuperscript{293,294,295}
Potentially Preventable Readmission Measure Definition: We conducted a comprehensive environmental scan, analyzed claims data, and obtained input from a TEP to develop a definition and list of conditions for which hospital readmissions are potentially preventable. The Ambulatory Care Sensitive Conditions and Prevention Quality Indicators, developed by AHRQ, served as the starting point in this work. For patients in the 30-day post-PAC discharge period, a potentially preventable readmission (PPR) refers to a readmission for which the probability of occurrence could be minimized with adequately planned, explained, and implemented post-discharge instructions, including the establishment of appropriate follow-up ambulatory care. Our list of PPR conditions is categorized by 3 clinical rationale groupings:

- Inadequate management of chronic conditions;
- Inadequate management of infection, and;
- Inadequate management of other unplanned events.


This measure focuses on readmissions that are potentially preventable and also unplanned. Similar to the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), this measure uses the current version of the CMS Planned Readmission Algorithm as the main component for identifying planned readmissions. A complete description of the CMS Planned Readmission Algorithm, which includes lists of planned diagnoses and procedures, can be found on the CMS Web site at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html. In addition to the CMS Planned Readmission Algorithm, this measure incorporates procedures that are considered planned in PAC settings, as identified in consultation with TEPs. Full details on the planned readmissions criteria used, including the CMS Planned Readmission Algorithm and additional procedures considered planned for PAC, can be found in the document titled, Proposed Measure Specifications for Measures Proposed in the FY 2017 LTCH QRP NPRM, available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

The measure, Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP, assesses potentially preventable readmission rates while accounting for patient demographics, principal diagnosis in the prior hospital stay, comorbidities, and other patient factors. While estimating the predictive power of patient characteristics, the model also estimates a facility-specific effect, common to patients treated in each facility. This measure is calculated for each LTCH based on the ratio of the predicted number of risk-adjusted, unplanned, potentially preventable hospital readmissions that occur within 30 days after an LTCH discharge, including the estimated facility effect, to the estimated predicted number of risk-adjusted, unplanned inpatient hospital readmissions for the same patients treated at the average LTCH. A ratio above 1.0 indicates a higher than expected readmission rate (worse) while a ratio below 1.0 indicates a lower than expected readmission rate (better). This ratio is referred to as the standardized risk ratio (SRR). The SRR is then multiplied by the overall national raw rate of potentially preventable readmissions for all LTCH stays. The resulting rate is the risk-standardized readmission rate (RSRR) of potentially preventable readmissions.

An eligible LTCH stay is followed until: (1) The 30-day post-discharge period ends; or (2) the patient is readmitted to an acute care hospital (IPPS or CAH) or LTCH. If the readmission is unplanned and potentially preventable, it is counted as a readmission in the measure calculation. If the readmission is planned, the readmission is not counted in the measure rate. This measure is risk adjusted. The risk adjustment modeling estimates the effects of patient characteristics, comorbidities, and select health care variables on the probability of readmission. More specifically, the risk-adjustment model for LTCHs accounts for demographic characteristics (age, sex, original reason for Medicare entitlement), principal diagnosis during the prior proximal hospital stay, body system specific surgical indicators, prolonged mechanical ventilation indications, length of stay during the patient’s prior proximal hospital stay, length of stay in the intensive care and coronary care unit (ICU and CU), and number of acute care hospitalizations in the preceding 365 days.

The measure is calculated using 2 consecutive calendar years of FFS claims data, to ensure the statistical reliability of this measure for facilities. In addition, we proposed a minimum of 25 eligible stays for public reporting of the measure.

A TEP convened by our measure contractor provided recommendations on the technical specifications of this measure, including the development of an approach to define potentially preventable hospital readmission for PAC. Details from the TEP meetings, including TEP members’ ratings of conditions proposed as being potentially preventable, are available in the TEP summary report available on the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html. We also solicited stakeholder feedback on the development of this measure through a public comment period held from November 2 through December 1, 2015. Comments on the measure varied, with some commenters supportive of the measure, while others either were not in favor of the measure, or suggested potential modifications to the measure specifications, such as including standardized function data. A summary of the public comments is also available on the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html.

The MAP encouraged continued development of the proposed measure. Specifically, the MAP stressed the need to promote shared accountability and ensure effective care transitions. More information about the MAP’s recommendations for this measure is available at: http://www.qualityforum.org/Publications/2016/02/MAP_2016_Considerations_for_Implementing_Measures_in_Federal_Programs_-_PAC-LTC.aspx. At the time, the risk-adjustment model was still under development. Following completion of that development work, we were able to test for measure validity and reliability as identified in the measure specifications document provided above. Test results are within range for similar outcome measures finalized in public reporting.
and value-based purchasing programs, including the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) adopted into the LTCH QRP.

We reviewed the NQF’s consensus endorsed measures and were unable to identify any NQF endorsed measures focused on potentially preventable hospital readmissions. We are unaware of any other measures for this IMPACT Act domain that have been endorsed or adopted by other consensus organizations. Therefore, we proposed the Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP, under the Secretary’s authority to specify non-NQF endorsed measures under section 1899B(e)(2)(B) of the Act, for the LTCH QRP for the FY 2018 payment determination and subsequent years, given the evidence previously discussed above.

We plan to submit the measure to the NQF for consideration of endorsement. We stated in the proposed rule that we intended to implement confidential feedback to LTCHs, prior to public reporting of this measure, based on 2 calendar years of data from discharges in CY 2015 and 2016. We also stated that we intended to publicly report this measure using data from CY 2016 and 2017.

We invited public comment on our proposal to adopt the measure, Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP. We received several comments, which are summarized with our responses below.

**Comment:** MedPAC supported this measure and believes that LTCHs should be held accountable for readmissions in the post-discharge readmission window.

**Response:** We thank commenters for their support of this measure.

**Comment:** One commenter specifically supported the inclusion of infectious conditions in the “inadequate management of infections” and “inadequate management of other unplanned events” categories in the measure’s definition of potentially preventable hospital readmissions, noting that many of these conditions are preventable using appropriate infection prevention interventions. Another commenter recommended the removal of several PPR conditions including influenza, dehydration/electrolyte imbalance, *C. difficile* infection, and urinary tract infection/kidney infection, and expressed concern that these conditions rely too heavily on patient and caretaker responsibility or may be caused by unforeseen circumstances after LTCH discharge.

One commenter stated that this measure will be particularly important for Medicare beneficiaries with chronic conditions, including diabetes, chronic obstructive pulmonary disorder, asthma, atrial fibrillation, and hypertension. Another commenter expressed concern over whether “penalized” for readmissions that are clinically unrelated to a patient’s original reason for LTCH admission. Another commenter recommended that only readmissions associated with active diagnoses being treated in the LTCH should be considered potentially preventable. Commenters also encouraged CMS to undertake additional empirical testing to ensure that the codes for readmissions are associated with the identified categories.

**Response:** We appreciate the comments in support of this measure domain and the list of PPR conditions developed for this measure. In response to the comment that suggested several conditions be removed from the definition, we note that as described in the proposed rule, the definition for potentially preventable readmissions for this measure was developed based on existing evidence and was reviewed by a TEP, which included clinicians and PAC experts. We also conducted a comprehensive environmental scan to identify conditions for which readmissions may be considered potentially preventable. Results of this environmental scan and details of the TEP input received were made available in the PPR TEP summary report available on the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html. We also made revisions to this list of conditions for which readmissions may be considered potentially preventable based on stakeholder feedback received during the public comment period. A summary of the public comments is also available on the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html.

Though readmissions may be considered potentially preventable even if they may not appear to be clinically related to the patient’s original reason for LTCH admission, there is substantial evidence that the conditions included in the definition may be preventable with adequately planned, explained, and implemented post-discharge instructions, including the establishment of appropriate follow-up ambulatory care. Furthermore, this measure is based on Medicare FFS claims data and it may not always be feasible to determine whether a subsequent readmission is or is not clinically related to the reason why the patient was receiving LTCH care. We intend to conduct ongoing evaluation and monitoring, and will assess the appropriateness and consequences of all PPR conditions, including infections and dehydration as mentioned specifically by one commenter.

**Comment:** MedPAC commented that the measure definition and risk adjustment should be identical across PAC settings so that potentially preventable readmission rates can be compared across settings. One commenter recommended that a measure for potentially preventable readmission post-discharge from an acute care hospital, regardless of PAC setting, would allow for better alignment across settings and clarity of potentially preventable readmissions. Another commenter recommended the measure be adjusted for patient clinical differences between PAC settings to allow for cross-setting quality comparisons. Other commenters expressed concern over adapting standards from other settings for LTCH, and recommended that the measure be tailored to LTCH patients.

**Response:** The PPR definition (that is, list of conditions for which readmissions would be considered potentially preventable) is aligned for measures with the same readmission window, regardless of PAC setting. Specifically, the post-PAC discharge PPR measures that were developed for each of the PAC settings contain the same list of PPR conditions. Although there are some minor differences in the specifications across these potentially preventable readmissions measures (for example, years of data used to calculate the measures to ensure reliability and some of the measure exclusions necessary to attribute responsibility to the individual settings), the IMPACT Act PPR measures are standardized. As described for all IMPACT Act measures in section VIII.C.2. of the preamble of this final rule, above, the statistical approach for risk adjustment is also aligned across the measures; however, there is variation in the exact risk adjusters. The risk adjustment models are empirically driven and differ between measures as a consequence of case mix differences, which is necessary to ensure that the estimates are valid.

**Comment:** Some commenters expressed concern over the overlap...
between the proposed PPR measure and the existing all-cause readmission measure adopted for the LTCH QRP. Commenters expressed concern that public reporting of more than one hospital readmission measure for LTCHs may result in confusion among the public and that this could potentially pose challenges for quality improvement for LTCHs. Some commenters believed that CMS should use one readmission measure in the LTCH QRP, rather than multiple readmission measures.

Response: The All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) was adopted for the LTCH QRP prior to the IMPACT Act. With regard to overlap with the existing LTCH QRP readmission measure, retaining the all-cause measure will allow us to monitor trends in both all-cause and PPR rates in order to assess the extent to which changes in facility performance for one measure are reflected in the other. We are committed to ensuring that measures in the LTCH QRP are useful in assessing quality and will evaluate the readmission measures in the future.

Comment: One commenter supported the risk adjustment methodology but several expressed concerns over the risk adjustment approach for the proposed PPR measure. Several commenters proposed additional clinical characteristics as risk adjusters including the LTCH primary diagnosis, presence of multiple chronic conditions, being “hospital dependent,” having multiple organ failure, and dialysis. Additional patient characteristics that commenters recommended for testing were patients identified as “do not resuscitate” during the prior acute stay, availability of home resources and supports, and functional status.

One commenter requested that CMS clarify whether patients with an artificial airway and no mechanical ventilation are included in the mechanical ventilation risk adjustment category. Another commenter requested detail on the AHRQ CCS groups included in the surgical procedure categories and also inquired about which version of the HCCs were used in the risk adjustment model.

Several commenters expressed concern that the measure is not adjusted for sociodemographic factors that may affect utilization. One commenter supported testing the measure for SDS, and cited research they conducted showing variation in race across PAC settings; they also found that dually eligible LTCH patients had significantly higher odds of PPRs.

Response: We appreciate the comments regarding the risk adjustment approach and suggestions for specific risk adjusters for the PPR measure. We wish to clarify that this measure is based on claims data and not all suggested risk adjusters are available. However, our measure development contractor (RTI International) conducted additional testing on some of the suggested risk adjusters and did not find strong evidence supporting the inclusion of these as risk adjusters in a potentially preventable readmission model. With regard to dialysis, this factor has been shown to be a significant predictor for PPR and the measure risk-adjusts for patients’ dialysis using the HCC. We intend to evaluate the feasibility of including functional and cognitive status when standardized assessment data become available.

LTCH patients with an artificial airway that are not on mechanical ventilation are not included in the prolonged mechanical ventilation risk adjuster, which is based on the procedure code 96.72 on the LTCH claim.

Response: We thank the commenter for their question regarding the verification of the measure exclusions. The commenter was correct in its interpretation of the measure exclusion of no short-term acute care hospital stay within the 30 days preceding a PAC admission. The exclusion does not require the short-term acute care hospital stay immediately preceding the PAC admission. For example, if a patient had a short-term acute care hospital stay, a SNF stay, and an LTCH stay within a 30-day window, the LTCH is a candidate to be an index admission even though it was immediately preceded by a SNF stay and not a short-term acute care hospital stay.

In response to the unplanned readmission question, we would like to reiterate that only the first readmission in the post-discharge window is examined in this measure. Since the second readmission was not captured for analysis, an unplanned readmission following a planned readmission would not count as an unfavorable outcome.

Comment: Several commenters expressed concern that the measure is not NQF-endorsed, and some commenters had additional concerns over measure testing and development. Some commenters recommended that CMS should only adopt measures endorsed by the NQF in quality reporting programs or urged CMS to submit the measures through the NQF endorsement process as soon as feasible and prior to LTCH reporting.

Response: With regard to NQF endorsement, as noted in the proposed rule, we intend to submit this measure to NQF for consideration of endorsement. In addition, we noted that we reviewed the NQF’s consensus endorsed measures and were unable to identify any NQF endorsed measures focused on potentially preventable hospital readmissions. We are unaware of any other measures for this IMPACT Act domain that have been endorsed or adopted by other consensus organizations. Therefore, we proposed the Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP, under the Secretary’s authority to specify non-NQF endorsed measures under section 1899B(e)(2)(B) of the Act, for the LTCH QRP.

We would like to clarify that the MAP encouraged continued development of the proposed measure. More information about the MAP’s recommendations for this measure is available at: [http://www.qualityforum.org/Publications/2016/02/MAP_2016_Considerations_...](http://www.qualityforum.org/Publications/2016/02/MAP_2016_Considerations...)
for Implementing Measures in Federal Programs - PAC-LTC.aspx.

We also wish to note that we conducted additional testing since the MAP meeting. We developed the risk adjustment model and evaluated facilities’ PPR rates. Results of these analyses were provided in the appendix of the measure specification made available at the time of the proposed rule. We found that testing results were similar to the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512). The finalized risk-adjustment models and coefficients are included in the final measure specifications available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html. We will make additional testing results available in the future.

**Comment:** A few commenters questioned the accuracy of claims data being used for this measure. One commenter suggested a baseline period concurrent with measure implementation to mitigate this concern. Another commenter recommended that CMS supplement claims data with validated administrative data.

**Response:** We appreciate the comment about the baseline period and implementation for the measure. As stated in section VIII.C.6.c. of the preamble of the proposed rule, data from CY 2015–2016 will be used as the basis for initial confidential feedback reports. The CY 2016–2017 would be used for public reporting. We appreciate the recommendation to align the baseline period with the implementation date; however, in order to ensure the reliability of the measure we need 2 consecutive years of data, which requires us to use data from CY 2016–2017 for public reporting. We believe the reliability of the measure is more important than aligning the baseline and implementation dates.

We appreciate the commenter’s concern over the accuracy of claims data. However, we wish to clarify that claims data have been validated for the purposes of assessing hospital readmissions and are used for several NQF-endorsed measures adopted for CMS programs, including the LTCH QRP. Several studies have been conducted to examine the validity of using Medicare hospital claims to calculate several NQF-endorsed quality measures for public reporting.296 297 298

In addition, although assessment and other data sources may be valuable for risk adjustment, we are not aware of another data source aside from Medicare claims data that could be used to reliably assess potentially preventable hospital readmissions for this measure. **Comment:** One commenter recommended that CMS use the potentially preventable readmission measure in order to determine best practices for LTCHs and inform LTCHs of their patient population. The commenter also urged CMS to review the impact of readmission measures used across PAC programs to ensure they create consistent improvement incentives across the system.

**Response:** We thank commenters for their comments related to the usability of the measure. We agree that this measure will be valuable in developing best practices and as a feedback mechanism assessing PPR outcomes for LTCHs. As we continually evaluate and monitor the PAC quality reporting programs, we will take the commenter’s suggestion in consideration to ensure that this and other readmission measures are creating consistent incentives for PAC providers.

After consideration of the public comments we received, we are finalizing our proposal to adopt the measure, Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP. For measure specifications, we refer readers to the Measure Specifications for Measures Adopted in the FY 2017 LTCH QRP Final Rule document available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

7. LTCH QRP Quality Measure Finalized for the FY 2020 Payment Determination and Subsequent Years

**a. Background**

We also proposed to adopt one new quality measure to meet the requirements of the IMPACT Act for the FY 2020 payment determination and subsequent years. The measure, Drug Regimen Review Conducted with 30-day mortality rates for pneumonia patients. PLoS One 2011;6(4):e17401.


Follow-Up for Identified Issues-PAC LTCH QRP, addresses the IMPACT Act quality domain of Medication Reconciliation.

**b. Quality Measure To Address the IMPACT Act Domain of Medication Reconciliation: Drug Regimen Review Conducted With Follow-Up for Identified Issues-Post Acute Care Long-Term Care Hospital Quality Reporting Program**

Sections 1899B(a)(2)(E)(i)(III) and 1899B(c)(1)(C) of the Act require the Secretary to specify a quality measure to address the domain of medication reconciliation by October 1, 2018 for IRFs, LTCHs, and SNFs, and by January 1, 2017 for HHAs. We proposed to adopt the quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, for the LTCH QRP as a patient-assessment based, cross-setting quality measure to meet the IMPACT Act requirements with data collection beginning April 1, 2018 for the FY 2020 payment determination and subsequent years.

This measure assesses whether PAC providers were responsive to potential or actual clinically significant medication issue(s) when such issues were identified. Specifically, the quality measure reports the percentage of patient stays in which a drug regimen review was conducted at the time of admission and timely follow-up with a physician occurred each time potential clinically significant medication issues were identified throughout that stay. For this quality measure, drug regimen review is defined as the review of all medications or drugs the patient is taking to identify any potential clinically significant medication issues. The quality measure utilizes both the processes of medication reconciliation and a drug regimen review, in the event an actual or potential medication issue occurred. The measure informs whether the PAC facility identified and addressed each clinically significant medication issue and if the facility responded or addressed the medication issue in a timely manner. Of note, drug regimen review in PAC settings is generally considered to include medication reconciliation and review of the patient’s drug regimen to identify potential clinically significant medication issues.299 This measure is applied uniformly across the PAC settings.

Medication reconciliation is a process of reviewing an individual’s complete

and current medication list. Medication reconciliation is a recognized process for reducing the occurrence of medication discrepancies that may lead to Adverse Drug Events (ADEs). Medication discrepancies occur when there is conflicting information documented in the medical records. The World Health Organization regards medication reconciliation as a standard operating protocol necessary to reduce the potential for ADEs that cause harm to patients. Medication reconciliation is an important patient safety process that addresses medication accuracy during transitions in patient care and in identifying preventable ADEs. The Joint Commission added medication reconciliation to its list of National Patient Safety Goals (2005), suggesting that medication reconciliation is an integral component of medication safety. The Society of Hospital Medicine published a statement in agreement of the Joint Commission’s emphasis and value of medication reconciliation as a patient safety goal. There is universal agreement that medication reconciliation directly addresses patient safety issues that can result from medication miscommunication and unavailable or incorrect information.

The performance of timely medication reconciliation is valuable to the process of drug regimen review. Preventing and responding to ADEs is of critical importance as ADEs account for significant increases in health services utilization and costs. Medication errors have the potential to cause patient harm. An estimated 50 percent of patients experienced presenting with adverse drug events. Annual health care costs from ADEs in the United States are estimated at $3.5 billion, resulting in 7,000 deaths annually.

Medication errors include the duplication of medications, delivery of an incorrect drug, inappropriate drug omissions, or errors in the dosage, route, frequency, and duration of medications. Medication errors are one of the most common types of medical errors and can occur at any point in the process of ordering and delivering a medication. Medication errors have the potential to result in an ADE. Inappropriately prescribed medications are also considered a major healthcare concern in the United States for the elderly population, with costs of roughly $7.2 billion annually.

There is strong evidence that medication discrepancies occur during transfers from acute care facilities to PAC facilities. Discrepancies occur when there is conflicting information documented in medical records. Almost one-third of medication discrepancies have the potential to cause patient harm. An estimated 50 percent of patients experienced presenting with adverse drug events. Annual health care costs from ADEs in the United States are estimated at $3.5 billion, resulting in 7,000 deaths annually.

Medication errors have the potential to cause patient harm. An estimated 50 percent of patients experienced presenting with adverse drug events. Annual health care costs from ADEs in the United States are estimated at $3.5 billion, resulting in 7,000 deaths annually.
complicated, \(^{332}\) and medication reconciliation and patient knowledge (medication literacy) can be inadequate post-discharge. \(^{333}\) The quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, provides an important component of care coordination for PAC settings and would affect a large proportion of the Medicare population who transfer from hospitals into PAC services each year. For example, in 2013, 1.7 million Medicare FFS beneficiaries had SNF stays, 338,000 beneficiaries had IRF stays, and 122,000 beneficiaries had LTCH stays. \(^{334}\)

A TEP convened by our measure development contractor provided input on the technical specifications of this quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, including components of reliability, validity and the feasibility of implementing the measure across PAC settings. The TEP supported the measure’s implementation across PAC settings and was supportive of our plans to standardize this measure for cross-setting development. A summary of the TEP proceedings is available on the PAC Quality Initiatives Downloads and Videos Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html.

We solicited stakeholder feedback on the development of this measure by means of a public comment period held from September 18 through October 6, 2015. Through public comments submitted by several stakeholders and organizations, we received support for implementation of this measure. The public comment summary report for the measure is available on the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html.

The NQF-convened MAP met on December 14 and 15, 2015 and provided input on the use of this measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP. The MAP encouraged continued development of the quality measure to meet the mandate added by the IMPACT Act. The MAP agreed with the measure gaps identified by CMS including medication reconciliation and stressed that medication reconciliation be present as an ongoing process. More information about the MAP’s recommendations for this measure is available at: http://www.qualityforum.org/Publications/2016/02/MAP_2016_Considerations_for_Implementing_Measures_in_Federal_Programs_-_PAC-LTC.aspx.

Since the MAP’s review and recommendation of continued development, we have continued to refine this measure in compliance with the MAP’s recommendations. The measure is consistent with the information submitted to the MAP and supports its scientific acceptability for use in quality reporting programs. Therefore, we proposed this measure for inclusion in the LTCH QRP as required by the IMPACT Act.

We reviewed the NQF’s endorsed measures and identified one NQF- endorsed cross-setting and quality measure related to medication reconciliation, which applies to the SNF, LTCH, IRF, and HHA settings of care: Care for Older Adults (COA), (NQF #0553). The quality measure, Care for Older Adults (COA), (NQF #0553) assesses the percentage of adults 66 years and older who had a medication review. The Care for Older Adults (COA), (NQF #0553) requires the identification of potential clinically significant medication issues at the beginning, during, and at the end of the patient’s stay to capture data on each patient’s complete PAC stay; whereas, the Care for Older Adults (COA) (NQF #0553) quality measure only requires annual documentation in the form of a medication list in the medical record of the target population.

The quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, requires the identification of potential clinically significant medication issues at the beginning, during, and at the end of the patient’s stay to capture data on each patient’s complete PAC stay; whereas, the Care for Older Adults (COA) (NQF #0553) quality measure does not include any follow-up or timeframe in which the follow-up would need to occur.

The quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, does not have age exclusions; whereas, the Care for Older Adults (COA) (NQF #0553) quality measure limits the measure’s population to patients aged 66 and older.

The quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, would be reported to LTCHs quarterly to facilitate internal quality monitoring and quality improvement in areas such as patient safety, care coordination, and patient satisfaction; whereas the Care for Older Adults (COA) (NQF #0553) quality measure would not enable quarterly quality updates, and thus data comparisons within and across PAC providers would be difficult due to the limited data and scope of the data collected.

Therefore, based on the evidence discussed above, we propose to adopt the quality measure entailed, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, for the LTCH QRP for the FY 2020 payment determination and subsequent years. We plan to submit the


quality measure to the NQF for consideration for endorsement.

The calculation of the quality measure would be based on the data collection of three standardized items to be included in the LTCH CARE Data Set. The collection of data by means of the standardized items would be obtained at admission and discharge. For more information about the data submission required for this measure, we refer readers to section VIII.C.9. of the preamble of this final rule.

The standardized items used to calculate this quality measure do not duplicate existing items currently used for data collection within the LTCH CARE Data Set. The measure denominator is the number of patient stays with a discharge or expired assessment during the reporting period. The measure numerator is the number of stays in the denominator where the medical record contains documentation of a drug regimen review conducted at: (1) Admission; and (2) discharge with a lookback throughout the entire patient stay, with all potential clinically significant medication issues identified during the course of care and followed up with a physician or physician designee by midnight of the next calendar day. This measure is not risk adjusted. For technical information about this measure, including information about the measure calculation and discussion pertaining to the standardized items used to calculate this measure, we refer readers to the document titled, Proposed Measure Specifications for Measures Proposed in the FY 2017 LTCH QRP NPRM, available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html.

Data for the quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, would be collected using the LTCH CARE Data Set with submission through the Quality Improvement Evaluation System (QIES) Assessment Submission and Processing (ASAP) system.

We invited public comment on our proposal to adopt the quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP for the LTCH QRP.

Comment: Several commenters, including MedPAC, expressed support for the quality measure. Commenters supported the medication reconciliation concept, and several commenters conveyed that preventing and responding to adverse drug events that account for increases in health service utilization and cost is critically important. Further, several commenters expressed appreciation to CMS for proposing a quality measure to address the IMPACT Act domain, Medication Reconciliation, acknowledging the importance of medication reconciliation for addressing patient safety issues. MedPAC further noted that the medication reconciliation and follow-up process can help reduce medication errors that are especially common among patients who have multiple health care providers and multiple comorbidities. One commenter recommended that CMS consider adopting the measure for FY 2019 payment determination.

Response: We agree that medication reconciliation is an important patient safety process for addressing medication accuracy during transitions in patient care and preventing preventable adverse drug events (ADEs), which may lead to reduced health services utilization and associated costs. We appreciate the commenter’s request that CMS adopt the measure for FY 2019 payment determination; however, the adoption of the measure has been proposed for adoption for the LTCH QRP for FY 2020 payment determination and subsequent years.

Comment: Several commenters requested guidance regarding the definition of “clinically significant medication issues.” Several commenters were concerned that the phrase could be interpreted differently by the many providers involved in a patient’s treatment, and that this could result in a challenge to collect reliable, accurate, and comparable data for this quality measure. One commenter stated that there are likely to be variations in measure performance that are not based on differences in care, but rather on differences in data collection. In addition, one commenter requested that CMS clarify when medication issues are identified, by providing further guidance regarding the definition of the term “identified.” Several commenters requested further clarification of the measure and conveyed their concern that there are four measures or sub-measures embedded in the description of the measure and stated that, without additional clarification, it may be difficult for providers to utilize the measure for quality improvement purposes.

Response: For this measure, potential clinically significant medication issues are defined as those issues that, in the clinician’s professional judgment, warrant improvement verification, such as alerting the physician and/or others, and the timely completion of any recommended actions (by midnight of the next calendar day) so as to avoid and mitigate any untoward or adverse outcomes. The definition of “clinically significant” in this measure was conceptualized during the measure development process. For purposes of the measure, the decision regarding whether or not a medication issue is “clinically significant” will need to be made on a case-by-case basis, but we also intend to provide additional guidance and training on this issue.

We would like to clarify that the measure is one measure, comprised of three assessment items used to calculate each LTCH facilities observed score. The items used to calculate the measure are collected by the LTCH CARE Data Set. Items used to calculate the proposed measure include: Items N2001 (Drug Regimen Review Item) and N2003 (Medication Follow-Up Item), collected at admission, and item N2005 (Medication Intervention Item) collected at discharge. Each of the three items are collected in order to report the percentage of patient/resident stays in which a drug regimen review was conducted at the time of admission and timely follow-up with a physician occurred each time potential clinically significant medication issues were identified throughout that stay. The measure is collected admission and at discharge to include data collected throughout the entire patient stay. LTCHs are able to use the data collected for this measure at admission, discharge, or at any time point for internal quality improvement purposes.

Comment: Several commenters expressed concern related to burden and expenses related to this measure. Specifically, the commenters expressed concern that the reporting and tracking requirements for the measure items will increase resource use and costs for LTCHs. The commenters also expressed concern that the costs will be cumulative since future PAC measures will be developed to fulfill the mandate of the IMPACT Act. Therefore, the commenters recommended that CMS narrow the scope of the measure to reduce costs for LTCHs.

Response: We are very sensitive to the issue of burden associated with data collection and have proposed only the minimal number of items needed to calculate the quality measure. We emphasize that this measure follows standard clinical practice requirements of ongoing review, documentation, and timely reconciliation of all patient medications, with appropriate follow-up to address all clinically significant medication concerns.
Comment: Several commenters expressed concerns that the measure is not NQF-endorsed and does not have full support from the NQF-convened MAP or the TEP. One commenter noted that the MAP recommended continued development for the measure. Several commenters recommended that CMS obtain NQF endorsement for the measure prior to implementation. Further, commenters requested that the measure be modified to address the specific needs of the LTCH population.

Response: Since the time of the MAP consideration, with our measure contractor, we tested this measure in a pilot test involving twelve PAC facilities (IRF, SNF and LTCH), representing variation across geographic location, size, profit status, and clinical record collection system. Two clinicians in each facility collected data on a sample of 10 to 20 patients for a total of 298 records (147 qualifying pairs). Analysis of agreement between coders within each participating facility indicated a 71 percent agreement for item DRR–01 \(^{335}\) Drug Regimen Review (admission); 69 percent agreement for item DRR–02 \(^{336}\) Medication Follow-up (admission); and 61 percent agreement for DRR–03 \(^{337}\) Medication Intervention (during stay and discharge). Overall, pilot testing enabled CMS to verify feasibility of the measure. Furthermore, measure development included convening a TEP to provide input on the technical specifications of this quality measure, including components of reliability, validity and the feasibility of implementing the measure across PAC settings. The TEP included stakeholders from the LTCH setting and supported the measure’s implementation across PAC settings and was supportive of our plans to standardize this measure for cross-setting development. A summary of the TEP proceedings is available on the PAC Quality Initiatives Downloads and Videos Web site at: [https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html](https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Post-Acute-Care-Quality-Initiatives/IMPACT-Act-of-2014/IMPACT-Act-Downloads-and-Videos.html)

As noted above, we plan to conduct further testing on this measure once we have started collecting data from the PAC settings. Once we have completed this additional measure performance testing, we plan to submit to NQF for endorsement.

Response: PAC facilities are expected to document information pertaining to the process of a drug regimen review, which includes medication reconciliation, in the patient’s discharge medical record. Further, it is standard practice for patient discharge records to include a medication list to be transferred to the admitting PAC facility. We will take the recommendation into consideration for future measure development in accordance with the IMPACT Act, which emphasizes the transfer of interoperable patient information across the continuum of care.

After consideration of the public comments we received, we are finalizing our proposal to adopt the measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP measure for the LTCH QRP for FY 2020 payment determination and subsequent years, as described in the Measure Specifications for Measures Adopted in the FY 2017 LTCH QRP Final Rule, available at: [https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html](https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Measures-Information.html).

### LTCH QRP Quality Measures Under Consideration for Future Years

<table>
<thead>
<tr>
<th>IMPACT Act Domain</th>
<th>NQS Priority</th>
<th>Measures</th>
<th>Patient Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMPACT Act Measure</td>
<td>NQF Priority</td>
<td>Measures</td>
<td>Transfer of health information and care preferences of an individual to the individual, family caregiver of the individual, and providers of services furnishing items and services to the individual, when the individual transitions.</td>
</tr>
<tr>
<td>- Percent of Patients with Moderate to Severe Pain.</td>
<td>- Percent of Patients with Moderate to Severe Pain.</td>
<td>Percent of Patients with Moderate to Severe Pain.</td>
<td></td>
</tr>
<tr>
<td>- Advance Care Plan.</td>
<td>- Advance Care Plan.</td>
<td>Advance Care Plan.</td>
<td></td>
</tr>
</tbody>
</table>

\(^{335}\) DRR pilot items DRR–01, DRR–02 and DRR–03 are equivalent to the proposed rule DRR PAC instrument items N. 2001, N. 2003 and N. 2005.

\(^{336}\) DRR pilot items DRR–01, DRR–02 and DRR–03 are equivalent to the proposed rule DRR PAC instrument items N. 2001, N. 2003 and N. 2005.

\(^{337}\) DRR pilot items DRR–01, DRR–02 and DRR–03 are equivalent to the proposed rule DRR PAC instrument items N. 2001, N. 2003 and N. 2005.
We received several comments about LTCH QRP quality measures under consideration for future years which are summarized with our responses below. 

Comment: Several commenters recommended that CMS adopt malnutrition-related quality measures in the LTCH QRP to promote early identification of Medicare beneficiaries diagnosed with or at risk for malnutrition, as identification of these conditions is critical to improving outcomes and patient safety by reducing complications such as infections, falls and pressure ulcers. Commenters also recommended that CMS require the inclusion of nutritional status and a nutrition care plan as necessary health information that is transferred to an individual, a caregiver, or provider of services as a component of the Transfer of Health Information for Individuals and Care Preferences quality measure. One commenter recommended that CMS adopt a malnutrition-related composite quality measure in the LTCH QRP and other related care settings and programs. Another commenter acknowledged CMS’ past recognition of malnutrition as an important patient safety issue. A commenter recommended that CMS adopt a disease-related malnutrition-related quality measure(s) in the LTCH QRP to reduce the risk of associated adverse outcomes. Specifically, the commenter encouraged the use of the American Society for Parenteral and Enteral Nutrition’s publication on malnutrition characteristics and diagnosis.

Response: We will take the suggestions into consideration as we develop future measures for the LTCH QRP and other quality reporting programs. We agree with the commenters’ rationale for consideration of adopting malnutrition quality measures, including a malnutrition care composite measure, and for including nutritional status and a nutrition care plan during transitions of care to an individual, a caregiver or provider as they are important components of care for LTCH patients.

Comment: One commenter remarked on the limited number of items in the LTCH CARE Data Set related to communication, cognition, and swallowing and noted that these domains are important in treating individuals with neurological disorders. The commenter encouraged CMS to adopt a specific screening instrument, the Montreal Cognitive Assessment (MoCA), or similar screening tools and assessment tools (CARE–C) to be best meet the needs of Medicare beneficiaries and the IMPACT Act. Another commenter requested that CMS add a functional cognition assessment item to the LTCH discharge assessment and that this information be provided to the next provider when a patient is transferred. The commenter also noted the important role that occupational therapists play in such an assessment. The commenter offered to collaborate with CMS to develop future measures in the area of cognitive function.

Response: We agree that future measure development should include other areas of function, such as communication, cognition, and swallowing, and are important components of functional assessment and improvement for patients who receive care in PAC settings, including LTCHs. We will continue to engage stakeholders as we develop and implement quality measures to meet the requirements of the IMPACT Act, and we will take these suggested quality measure concepts and recommendations into consideration in our ongoing measure development and testing efforts.

Comment: One commenter did not support the Venous Thromboembolism (VTE) Prophylaxis measure, since it was previously adopted by LTCHs and would add burden without adding usefulness.

Response: We thank the commenter for their comments on the Venous Thromboembolism (VTE) Prophylaxis measure, which was previously included in the LTCH QRP and will take into consideration the commenter’s recommendations.

Comment: One commenter supported the Ventilator Weaning (Liberation) Rate and Compliance with Spontaneous Breathing Trial (SBT) (including Tracheostomy Collar Trial (TCT) or Continuous Positive Airway Pressure (CPAP) Breathing Trial) by Day 2 of the LTCH Stay quality measures for implementation in LTCHs. The commenter emphasized the importance of specifying inclusion and exclusion criteria and risk adjustment.

Response: We will take the suggestions into consideration to inform our ongoing measure development efforts. Our measure development contractor, RTI International, will continue to engage members of a TEP originally convened in April 2014. This TEP is providing ongoing advice to our measure development contractor on all aspects of the measures, including the measures’ denominator, numerator, inclusion and exclusion criteria, risk adjustment, as well as development and feasibility of data elements.

Comment: One commenter recognized the importance of advance care planning in LTCHs to establish patient preferences regarding medical treatment, as many LTCH patients are unable to make medical care decisions on their own.

Response: We thank the commenter for the comment and agree with the importance of advanced care plans as they relate to the critically chronically ill and vulnerable patient population in LTCHs. We will take this comment into consideration as we develop future measures for the LTCH QRP.

Comment: One commenter expressed support for the inclusion of a patient-reported experience of care measure in the LTCH QRP. The commenter supported accepting proxy responses from family members and caregivers to support accurate and reliable results at the facility level due to the acuity of the patients in LTCHs. The commenter also recommended that CMS continue their efforts to develop a patient experience survey to collect this valuable data and incorporate voluntary reporting into the LTCH QRP as quickly as possible. Another commenter believes that data collection for the Patient Experience of Care quality measure would be difficult if the measure were dependent on collecting data from a patient satisfaction survey, such as the HCAHPS survey. The commenter stated that it would be difficult to assess patient experience by requiring LTCHs to collect data from these severely ill patients, since they are less likely to be satisfied with their care. In addition, the commenter stated that a patient satisfaction survey would create a significant cost burden for providers.
and require significant resources for data collection.

Response: While we recognize the difficulty in surveying this patient population, we also believe that patient experience of care is an important element of quality in the LTCH setting. We will continue to take these and future stakeholder inputs under advisement to inform our ongoing quality measure development.

Comment: One commenter supported the future proposal of the IMPACT Act Transfer of Health Information and Care Preferences measure. Another commenter encouraged the inclusion of measures that capture the role of family caregivers in supporting care transitions, quality outcomes, and individual care preferences. The commenter also emphasized the importance of acknowledging and measuring the unique needs of family members when making difficult care decisions, noting the particular importance in the LTCH setting due to the high acuity of LTCH patients. One commenter requested more information about the measure specifications before proposing the measure for the LTCH QRP.

Response: As we move through the development of this measure concept, we will consider the inclusion of the role of family caregivers in supporting care transitions, quality outcomes, and individual care preferences. In addition, we will take these recommendations regarding measure specifications into consideration in our ongoing measure development and testing efforts.

Comment: One commenter supported the inclusion of the antipsychotic quality measure in the LTCH QRP (measure listed on the Nursing Home Compare Web site). However, the commenter cautioned against adapting the pre-existing, non-NQF endorsed antipsychotic measures currently used in nursing homes, indicating that these process measures do not provide a linkage to clinical outcomes or intermediate outcomes. Another commenter also expressed concern about this measure not being appropriate for the LTCH setting.

Response: We appreciate commenters’ feedback on this potential measure development area. We acknowledge that measuring the use of antipsychotic medication is important for the aging Medicare population. However, as LTCH patients may differ from the general Medicare population, we recognize the importance of engaging stakeholders if we do adopt/develop such a measure for use in the LTCH setting. We will take the commenters’ recommendations into consideration in our measure development and testing efforts, as well as in our ongoing efforts to identify and propose appropriate measures for the LTCH QRP in the future.

SUMMARY DETAILS ON THE LTCH CARE DATA SET AND CDC NHSN DATA COLLECTION PERIOD AND DATA SUBMISSION TIMELINE FOR PREVIOUSLY ADOPTED QUALITY MEASURES AFFECTING THE FY 2018 PAYMENT DETERMINATION AND SUBSEQUENT YEARS *

<table>
<thead>
<tr>
<th>Quality measure</th>
<th>Submission method</th>
<th>Data Collection/submission quarterly reporting period(s)</th>
<th>Quarterly review and correction period and data submission deadlines for payment determination</th>
<th>First APU determination affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF #0678: Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (76 FR 51748 through 51750).</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>1/1/16–3/31/16, 4/1/16–6/30/16, 7/1/16–9/30/16, 10/01/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>8/15/16 (Q1), 11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Approximately 135 days after the end of each quarter.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>NQF #0138: NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (76 FR 51745 through 51747).</td>
<td>CDC NHSN ......</td>
<td>1/1/16–3/31/16, 4/1/16–6/30/16, 7/1/16–9/30/16, 10/01/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>8/15/16 (Q1), 11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Approximately 135 days after the end of each quarter.</td>
<td>FY 2018.</td>
</tr>
</tbody>
</table>
### SUMMARY DETAILS ON THE LTCH CARE DATA SET AND CDC NHSN DATA COLLECTION PERIOD AND DATA SUBMISSION TIMELINE FOR PREVIOUSLY ADOPTED QUALITY MEASURES AFFECTING THE FY 2018 PAYMENT DETERMINATION AND SUBSEQUENT YEARS—Continued

<table>
<thead>
<tr>
<th>Quality measure</th>
<th>Submission method</th>
<th>Data Collection/submission quarterly reporting period(s)</th>
<th>Quarterly review and correction period and data submission deadlines for payment determination</th>
<th>First APU determination affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF #0139: NHSN Central-Line Associated Bloodstream Infection (CLABSI) Outcome</td>
<td>CDC NHSN ......</td>
<td>1/1/16–3/31/16, 4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>8/15/16 (Q1), 11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Approximately 135 days after the end of each quarter.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>Measure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #1716: NHSN Facility-wide Inpatient Hospital-onset Methicillin-resistant</td>
<td>CDC NHSN ......</td>
<td>1/1/16–3/31/16, 4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>8/15/16 (Q1), 11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Approximately 135 days after the end of each quarter.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>Staphylococcus aureus (MRSA) Bacteremia Outcome Measure (78 FR 50863 through</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50865).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #1717: NHSN Facility-wide Inpatient Hospital-onset Clos-</td>
<td>CDC NHSN ......</td>
<td>1/1/16–3/31/16, 4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>8/15/16 (Q1), 11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Approximately 135 days after the end of each quarter.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>tridium difficile Infection (CDI) Outcome Measure (78 FR 50865 through 50868).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50305).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #0680: Percent of Residents or Patients Who Were Assessed and Appropriately</td>
<td>CDC NHSN ......</td>
<td>1/1/16–3/31/17, 10/1–3/31 for subsequent years.</td>
<td>5/15/17, 5/15 for subsequent years.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>Given the Seasonal Influenza Vaccine (Short Stay) (77 FR 53624 through 53627).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #0431: Influenza Vaccination Coverage Among Healthcare Personnel (77 FR 53630</td>
<td>CDC NHSN ......</td>
<td>10/1/16–3/31/16, 4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>8/15/16 (Q1), 11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Approximately 135 days after the end of each quarter.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>through 53631).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #2512: All-Cause Unplanned Readmission Measure for 30-Days Post-Discharge</td>
<td>Medicare FFS Claims Data.</td>
<td>N/A ........................................................................</td>
<td>N/A ................................................................</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>from Long-Term Care Hospitals (78 FR 50868 through 50874).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #0674: Application of Percent of Residents Experiencing One or More Falls</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Quarterly approximately 135 days after the end of each quarter for subsequent years.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>with Major Injury (Long Stay) (80 FR 49736 through 49739).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #2631: Percent of Long-Term Care Hospital Patients with an Admission and</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Quarterly approximately 135 days after the end of each quarter for subsequent years.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>Discharge Functional Assessment and a Care Plan That Addresses Function</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(79 FR 50298 through 50301).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #2631: Application of Percent of Long-Term Care Hospital Patients with an</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Quarterly approximately 135 days after the end of each quarter for subsequent years.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>Admission and Discharge Functional Assessment and a Care Plan That Addresses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Function (80 FR 49739 through 49747).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #2631: Functional Outcome Measure: Change in Mobility Among Long-Term Care</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>4/1/16–6/30/16, 7/1/16–9/30/16, 10/1/16–12/31/16; Quarterly for each subsequent calendar year.</td>
<td>11/15/16 (Q2), 2/15/17 (Q3), 5/15/17 (Q4); Quarterly approximately 135 days after the end of each quarter for subsequent years.</td>
<td>FY 2018.</td>
</tr>
<tr>
<td>Hospital Patients Requiring Ventilator Support (79 FR 50298 through 50301).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQF #2632: Functional Outcome Measure: Change in Mobility Among Long-Term Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital Patients Requiring Ventilator Support (79 FR 50298 through 50301).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* We refer readers to the table below for an illustration of the CY quarterly data collection/submission quarterly reporting periods and correction and submission deadlines for all APU years. ** For this measure, Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine, we refer readers to the proposals on data submission for this measure, which we are finalizing, in section VIII.C.9.d. of the preamble of this final rule. These proposals for the FY 2019 payment determination and for FY 2020 payment determination and subsequent years are illustrated in the tables in that section.
Further, in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49749 through 49752), we established that the LTCH CARE Data Set-based and CDC NHSN measures finalized for adoption into the LTCH QRP would follow a calendar year schedule with quarterly reporting periods, followed by quarterly review and correction periods and submission deadlines. This pattern is illustrated in the table below and is in place for all APU years unless otherwise specified. We also wish to illustrate that for the measures finalized for use in the LTCH QRP that use the LTCH CARE Data Set or CDC NHSN data sources, payment determination would subsequently use the data collection and deadlines shown below unless otherwise specified.

<table>
<thead>
<tr>
<th>ANNUAL CY LTCH CARE DATA SET AND CDC NHSN DATA COLLECTION/SUBMISSION REPORTING PERIODS AND DATA SUBMISSION/CORRECTION DEADLINES FOR PAYMENT DETERMINATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed CY data collection quarter</td>
</tr>
<tr>
<td>Quarter 1</td>
</tr>
<tr>
<td>Quarter 2</td>
</tr>
<tr>
<td>Quarter 3</td>
</tr>
<tr>
<td>Quarter 4</td>
</tr>
</tbody>
</table>

* The annual data submission timeframe for the measure, Influenza Vaccination Coverage among Healthcare Personnel, is October 1 through March 31 of the subsequent year with a reporting deadline of May 15 in that subsequent year.

** For the measure, Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine, we refer readers to the proposals on data submission for this measure, which we are finalizing in section VIII.C.9.d. of the preamble of this final rule. These proposals for the FY 2019 payment determination and for FY 2020 payment determination and subsequent years are illustrated in the tables in that section.

c. Timeline and Data Submission Mechanisms for the FY 2018 Payment Determination and Subsequent Years for the LTCH QRP Resource Use and Other Measures—Claims-Based Measures

The MSPB–PAC LTCH QRP measure; Discharge to Community-PAC LTCH QRP measure and Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP, which we are finalizing in this final rule, are Medicare FFS claims-based measures. Because claims-based measures can be calculated based on data that are already reported to the Medicare program for payment purposes, no additional information collection would be required from LTCHs. As discussed in section VIII.C.6. of the preamble of this final rule, these measures would use 2 years of claims-based data beginning with CY 2015 and CY 2016 claims to infuse confidential feedback reports for LTCHs, and CYs 2016 and 2017 claims data for public reporting.

We invited public comments on this proposal. We did not receive comments related to data submission mechanisms for these measures. For comments related to the measures, we refer readers to section VIII.C.6. of the preamble of this final rule, above. For comments related to the future public display of these measures, we refer readers to section VIII.C.14. of the preamble of this final rule.

We are finalizing the timeline and data submission mechanisms for FY 2018 payment determination and subsequent years as proposed.

d. Revisions to the Previously Adopted Data Collection Period and Submission Deadlines for Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) for the FY 2019 Payment Determination and Subsequent Years

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53624 through 53627), we adopted the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) measure for the FY 2016 payment determination and subsequent years. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50858 through 50861), we finalized the data submission timelines and submission deadlines for the measures for FY 2016 and FY 2017 payment determinations. We refer readers to the FY 2013 and FY 2014 IPPS/LTCH PPS final rules for a more detailed discussion of the measure, timelines and deadlines.

In these previous rules, we finalized that LTCHs were required to perform data collection in alignment with the influenza vaccination season (IVS); that is, obtaining the vaccination status of patients who are in an LTCH for one or more days between the dates of October 1 of a given year through March 31 of the subsequent year, or what the CDC terms the Influenza Vaccination Season (IVS), but for only those patients whose corresponding admissions and discharges occurred during the IVS. Through analysis of the quality data submitted for this measure, we discovered that only requiring LTCHs to submit patient influenza vaccination data during the IVS (October 1 of a given year through March 31 of the subsequent year) inadvertently limits the data collection to only a subset of patients whose stays at an LTCH qualify for inclusion in the measure calculation. This measure is structured in such a way that all patients in an LTCH for one or more days during the IVS are included in the measure. For those patients, an LTCH should have the opportunity to demonstrate the Influenza vaccination status of these patients on either their LTCH CARE Data Set admission assessment or on their discharge assessment (planned, unplanned, or expired). By limiting data collection to only those assessments obtained during the IVS, per our previously finalized policy, CMS inadvertently excluded the collection of Influenza vaccination status data on those patients who were in an LTCH for at least one day during the IVS, but for whom the associated LTCH CARE Data Set admission and/or discharge assessments occurred outside of the IVS (prior to October 1 or after March 31).

For these reasons, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25230 through 25232), we proposed that beginning with the FY 2019 payment determination and subsequent years, which includes the CY 2016/2017 IVS, data collection and submission for the measure Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) will be required year-round, thus including all patients in the LTCH one or more days during the IVS (October 1 of any given CY through March 31 of the subsequent CY), regardless of the associated LTCH
CARE Data Set admission and discharge dates. This includes, for example, a patient that was admitted September 15 of a given year, and discharged April 1 of the subsequent year (thus, in the LTCH during the IVS). This policy will enable the important data collection necessary to indicate that a patient who had an admission or a discharge outside of the IVS, but was in the facility during the vaccination season, ensuring that the data collected and submitted to CMS is representative of the status of all patients within the IVS, rather than only a subset of those who had both admissions and discharges within the IVS.

Further, our proposal effectively changes the data collection and submission timeline for this measure to include 4 calendar quarters, that is based on the influenza season (July 1 of any given year through June 30 of the subsequent year), rather than on the calendar year. For the purposes of APU determination and for public reporting, data calculation and analysis uses data from an influenza vaccination season, which takes place within the influenza season itself. While the influenza vaccination season is October 1 of a given year (or when the vaccine becomes available) through March 31 of the subsequent year, this timeframe rests within a greater time period of the influenza season, which spans 12 months—that is, July 1 of a given year through June 30 of the subsequent year, as defined by the CDC. Thus, for this measure, we utilize data from a timeframe of 12 months that mirrors the influenza season which is July 1 of a given year through June 30 of the subsequent year. In addition, for the APU determination, we review data submitted beginning on July 1 of the calendar year 2 years prior to the calendar year of the APU effective date and ending June 30 of the subsequent calendar year, one year prior to the calendar year of the APU effective date. For example, and as provided in the below for the FY 2020 (October 1, 2019) APU determination, we review data submission beginning July 1, 2017 through June 30, 2018 for the 2017/2018 influenza vaccination season (October 1, 2017 [or when the vaccine becomes available] through March 31, 2018), so as to capture all data that an LTCH will have submitted with regard to the 2017/2018 influenza vaccination season itself, which resides within the associated influenza season. We will use assessment data from the influenza season so as to ensure full capture of vaccination status in the IVS that resides within the influenza season period, as well for public reporting. Further, because we enable the opportunity to review and correct data for all assessment based LTCH CARE Data Set measures within the LTCH QRP, we continue to follow quarterly data collection/submission reporting period(s) and their subsequent quarterly review and correction periods with data submission deadlines for public reporting and payment determinations. However, rather than using a standard CY timeframe, these quarterly data collection/submission periods and their subsequent quarterly review and correction periods and submission deadlines begin with CY quarter 3, July 1, of a given year and end CY quarter 2, June 30, of the following year.

The revisions to the data collection period for the measure Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680), will ultimately have the effect of helping LTCHs capture influenza vaccination data on any LTCH patients that were in their hospital for one or more days during the IVS, by ensuring that such patient’s admission and discharge assessments, regardless of the date of those assessments, capture potential influenza vaccination data, and allow the appropriate inclusion of patients and thus the accurate calculation of data for this measure. Lastly, this clarification will also remove any ambiguity and ensure that LTCHs are receiving credit for recording the vaccination status of all patients that were in their hospital for at least one day during any given IVS, regardless of the date(s) of their admission and/or discharge.

We would like to note that in order to implement the newly proposed revision to the data collection timeframes and submission deadlines for this measure, the FY 2019 payment determination will only be based on three CY quarters, as this policy will not go into effect until October 1, 2016, which is the start of the 2016/2017 IVS. Because of this, we are not requiring LTCHs to respond to the Influenza vaccination items on the LTCH CARE Data Set admission or discharge assessments that take place during Q3 2016 (7/1/16–9/30/16), as this quarter will occur prior to the effective date of this policy, if finalized. This is illustrated in the table for the FY 2019 payment determination, below. All subsequent payment determinations will be based on four CY quarters, as discussed above, beginning with Q3 of CY 2017 for the FY 2020 payment determination. This is illustrated in table for the FY 2020 payment determination and subsequent years, below.

**FY 2019 Payment Determination:** *Summary Details on Data Collection Period and Data Submission Timeline for Previously Adopted Quality Measure, NQF #0680 Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine*

<table>
<thead>
<tr>
<th>Finalized Measure:</th>
<th>Data collection/submission quarterly reporting period(s)</th>
<th>Quarterly review and correction periods data submission deadlines for payment determination</th>
<th>APU determination affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 18 Q1 10/1/17–12/31/18.</td>
<td>CY 18 Q2 1/1/18–3/31/18.</td>
<td>7/1/17–11/15/17 deadline.</td>
<td></td>
</tr>
</tbody>
</table>

*This table refers to the FY 2019 payment determination only. We refer readers to the table below for all subsequent FY payment determinations for this measure.*
We invited comment on our proposal to revise the data collection and submission timeframe for the measure Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680), beginning with the FY 2019 payment determination and subsequent years.

Comment: One commenter supported the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) measure and the proposed revisions to data collection.

Response: We appreciate the commenter’s support for this measure and its continued inclusion in the LTCH QRP, and the proposed revisions to data collection.

After consideration of the public comment we received, we are finalizing our proposal to revise the data collection period and submission deadlines for Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) for the FY 2019 payment determination and subsequent years.

As discussed in section VIII.C.7. of the preamble of this final rule, we proposed that the data for the proposed quality measure, Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP, affecting the FY 2020 payment determination and subsequent years be collected by completing data elements that would be added to the LTCH CARE Data Set with submission through the QIES ASAP system. Data collection would begin on April 1, 2018. More information on LTCH reporting using the QIES ASAP system is located at: https://www.cms.gov/Medicare/Quality-Instruments/Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Technical-Information.html.

For the FY 2020 payment determination, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25232 through 25233), we proposed to collect CY 2018 Q2 through Q4 data, that is, beginning with admissions on April 1, 2018 through discharges on December 31, 2018, to remain consistent with the usual April release schedule for the LTCH CARE Data Set, to give LTCHs sufficient time to update their systems so that they can comply with the new data reporting requirements, and to give us sufficient time to determine compliance for the FY 2020 payment determination. The proposed use of 3 quarters of data for the initial year of assessment data reporting in the LTCH QRP, to make compliance determinations related to the applicable FY APU, is consistent with the approach we used previously for the SNF, IRF, and Hospice QRPs.

The table below presents the proposed data collection period and data submission timelines for the new proposed LTCH QRP quality measure for the FY 2020 payment determination. We invited public comments on this proposal.

Details on the Proposed Data Collection Period and Data Submission Timeline for Resource Use and Other Measures Affecting the FY 2020 Payment Determination

<table>
<thead>
<tr>
<th>Quality measure</th>
<th>Submission method</th>
<th>Data collection/submission quarterly reporting period</th>
<th>Quarterly review and correction periods and data submission deadlines for payment determination</th>
<th>APU determination affected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP.</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>4/1/18–6/30/18 (Q2), 7/1/18–9/30/18 (Q3), 10/1/18–12/31/18 (Q4).</td>
<td>11/15/18 (Q2), 2/15/19 (Q3), 5/15/19 (Q4).</td>
<td>FY 2020.</td>
</tr>
</tbody>
</table>
Following the close of the reporting quarters for the FY 2020 payment determination, LTCHs would have the already established additional 4.5 months to correct their quality data and that the final deadline for correcting data for the FY 2020 payment determination would be May 15, 2019 for these measures. We also proposed that for the FY 2021 payment determination and subsequent years, we would collect data using the calendar year reporting cycle as described in section VIII.C.9.c. of the preamble of this final rule, and illustrated in the table below. We invited public comments on this proposal.

**PROPOSED DATA COLLECTION PERIOD AND DATA CORRECTION DEADLINES AFFECTING THE FY 2021 PAYMENT DETERMINATION AND SUBSEQUENT YEARS**

<table>
<thead>
<tr>
<th>Quality measure</th>
<th>Submission method</th>
<th>Proposed CY data collection quarter</th>
<th>Proposed data collection/submission quarterly reporting period</th>
<th>Proposed quarterly review and correction periods and data submission deadlines for payment determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Regimen Review Conducted with Follow-Up for Identified Issues PAC LTCH QRP.</td>
<td>LTCH CARE Data Set/QIES ASAP.</td>
<td>Quarter 1 ..........</td>
<td>January 1–March 31 ..........</td>
<td>April 1–August 15.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quarter 3 ..........</td>
<td>July 1–November 15 ..........</td>
<td>October 1–February 15.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quarter 4 ..........</td>
<td>October 1–December 31 ..........</td>
<td>January 1–May 15.</td>
</tr>
</tbody>
</table>

We did not receive any public comments on the proposed data collection periods and data submission timelines for the new proposed LTCH QRP quality measure for the FY 2020 and FY 2021 payment determinations and subsequent years.

We are finalizing the timeline and data submission mechanisms for FY 2020 and FY 2021 payment determination and subsequent years as proposed. For comments related to the measure, we refer readers to section VIII.C.7. of the preamble of this final rule, above.

10. LTCH QRP Data Completion Thresholds for the FY 2016 Payment Determination and Subsequent Years

In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50311 through 50314), we finalized LTCH QRP thresholds for completeness of LTCH data submissions. To ensure that LTCHs are meeting an acceptable standard for completeness of submitted data, we finalized the policy that, beginning with the FY 2016 payment determination and for each subsequent year, LTCHs must meet or exceed two separate data completeness thresholds: One threshold set at 80 percent for completion of quality measures data collected using the LTCH CARE Data Set submitted through the QIES and a second threshold set at 100 percent for quality measures data collected and submitted using the CDC’s NHSN.

In addition, we stated that we would apply the same thresholds to all measures adopted as the LTCH QRP expands and LTCHs begin reporting data on previously finalized measure sets. That is, as we finalize new measures through the regulatory process, LTCHs will be held accountable for meeting the previously finalized data completion threshold requirements for each measure until such time that updated threshold requirements are proposed and finalized through a subsequent regulatory cycle.

Further, we finalized the requirement that an LTCH must meet or exceed both thresholds to avoid receiving a 2 percentage point reduction to their annual payment update for a given fiscal year, beginning with FY 2016 and for all subsequent payment updates. For a detailed discussion of the finalized LTCH QRP data completion requirements, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50311 through 50314). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25233), we did not propose any changes to these policies.

11. LTCH QRP Data Validation Process for the FY 2016 Payment Determination and Subsequent Years

Validation is intended to provide added assurance of the accuracy of the data that will be reported to the public as required by sections 1886(m)(5)(E) and 1899B(g) of the Act. In the FY 2015 IPPS/LTCH PPS proposed rule (79 FR 28275 through 28276), we proposed, for the FY 2016 payment determination and subsequent years, a process to validate the data submitted for quality purposes. However, in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50314 through 50316), we did not finalize the proposal; instead we decided to further explore suggestions from commenters before finalizing the LTCH data validation process that we proposed. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49752 through 49753), we did not propose any new policies related to data accuracy validation. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25233), we did not propose a data validation policy because we are developing a policy that would be applied to several PAC quality reporting programs. We intend to propose a data validation policy through future rulemaking.

Although we did not solicit feedback specifically regarding data validation, we received one comment which is summarized and discussed below.

Comment: One commenter supported CMS’ determination that it was not necessary to propose a data validation policy because there is a policy under development that could be applied to several PAC QRPs.

Response: We appreciate the commenter’s support. We intend to propose a data validation policy through the notice and comment process in the Federal Register through future rulemaking.

12. Change to Previously Codified LTCH QRP Submission Exception and Extension Policies

We refer readers to § 412.560(c) for requirements pertaining to submission exception and extension for the FY 2017 payment determination and subsequent years. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25233 through 25234), we proposed to revise § 412.560(c) to change the timing for submission of these exception and extension requests from 30 days to 90 days from the date of the qualifying event which is preventing an LTCH from submitting their quality data for the LTCH QRP. We proposed the increased time allotted for the submission of the requests from 30 to 90 days to be consistent with other quality reporting programs; for example, the Hospital IQR Program also proposed to extend the deadline to 90 days in section VIII.C.15.a. of the preamble of the proposed rule (81 FR 25205). We believe that this increased time will assist providers experiencing an event in having the time needed submit such a request. With the exception of this one change, we did not propose any
additional changes to the exception and extension policies for the LTCH QRP at this time.

We invited public comments on the proposal to revise § 412.560(c) to change the timing for submission of these exception and extension requests from 30 days to 90 days from the date of the qualifying event which is preventing an LTCH from submitting their quality data for the LTCH QRP.

Comment: Several commenters supported changing the timing for submission of exception and extension requests from 30 days to 90 days from the date of the qualifying event preventing an LTCH from submitting their LTCH QRP data. One commenter stated that it helps to align the LTCH QRP with other quality reporting programs, and allows LTCHs to better cope with unforeseeable events.

Response: We thank the commenter for their support.

After consideration of the public comments we received, we are finalizing our proposal to revise § 412.560(c) to change the timing for submission of these exception and extension requests from 30 days to 90 days from the date of the qualifying event which is preventing an LTCH from submitting their quality data for the LTCH QRP.

13. Previously Finalized LTCH QRP Reconsideration and Appeals Procedures

We refer readers to § 412.560(d) for a summary of our finalized reconsideration and appeals procedures for the LTCH QRP for FY 2017 payment determination and subsequent years. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25234), we did not propose any changes to this policy. However, we wish to clarify that in order to notify LTCHs found to be noncompliant with the reporting requirements set forth for a given payment determination, we may include the QIES mechanism in addition to U.S. mail, and we may elect to utilize the MACs to administer such notifications.

14. Policies Regarding Public Display of Measure Data for the LTCH QRP and Procedures for the Opportunity To Review and Correct Data and Information

a. Public Display of Measures

Section 1886(m)(5)(E) of the Act requires the Secretary to establish procedures for making the LTCH QRP data available to the public. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755), we finalized our proposals to display performance data for the LTCH QRP quality measures by fall 2016 on a CMS Web site, such as the Hospital Compare, after a 30-day preview period, and to give providers an opportunity to review and correct data submitted to the QIES ASAP system or to the CDC NHSN. The procedures for the opportunity to review and correct data are provided in the section VIII.C.14.b. of the preamble of this final rule, below. In addition, we finalized the proposal to publish a list of LTCHs that successfully meet the reporting requirements for the applicable payment determination on the LTCH QRP Web site at: https://www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/ltch-quality-reporting/. In the FY 2016 IPPS/LTCH PPS final rule, we also finalized that we would update the list after the reconsideration requests are processed on an annual basis.

Also, in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755), we finalized that the display of information for fall 2016 contains performance data on four quality measures:

- Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678);
- NHSN CAUTI Outcome Measure (NQF #0138);
- NHSN CLABSI Outcome Measure (NQF #0138); and
- All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512).

The measures Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678), NHSN CAUTI Outcome Measure (NQF #0138), and NHSN CLABSI Outcome Measure (NQF #0139) are based on data collected beginning with the first quarter of 2015 or discharges beginning on January 1, 2015. With the exception of the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512), rates are displayed based on 4 rolling quarters of data and would usually initiate discharges from January 1, 2015 through December 31, 2015 (CY 2015) for Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) and data collected from January 1, 2015 through December 31, 2015 for NHSN CAUTI Outcome Measure (NQF #0138) and NHSN CLABSI Outcome Measure (NQF #0139). For the readmissions measures, data will be publicly reported beginning with data collected for discharges beginning January 1, 2013, and rates would be displayed based on 2 consecutive years of data. For LTCHs with fewer than 25 eligible cases, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25234 through 25235), we proposed to assign the LTCH to a separate category: “The number of cases is too small (fewer than 25) to reliably tell how well the LTCH is performing.” If an LTCH has fewer than 25 eligible cases, the LTCH’s readmission rates and interval estimates would not be publicly reported for the measure.

Calculations for all four measures are discussed in detail in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755).

Comment: Several commenters, including MedPAC, supported public reporting of quality measures. MedPAC encouraged ongoing development and public reporting for cross-cutting measures for all provider settings.

Response: We appreciate MedPAC’s and other commenters’ support for the public reporting of LTCH quality measures. We will continue to move forward with cross-cutting data and public reporting of these measures to meet the mandate of the IMPACT Act.

Comment: A few commenters discussed the requirements of the Affordable Care Act and the IMPACT Act for publicly reporting the measures that are implemented into the LTCH QRP and expressed concern regarding such public reporting. The commenters suggested that previously finalized measures are not suited for cross-PAC provider comparison, as opposed to LTCH-to-LTCH comparison using comparable data that are risk adjusted, for example, as in the case with the use of the Standardized Infection Ratio, and that using such data for cross-comparison purposes could be misleading to those who use the publicly reported data.

Response: We appreciate commenters’ concern about the use of cross-setting quality measures and provider comparability in satisfaction of our requirements to publicly report the data and information. We interpret the commenters’ comments to suggest that the measures previously finalized in FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755), such as the CDC Healthcare Associated Infection (HAI) measures (which use the Standardized Infection Ratio) that is, NHSN CAUTI Outcome Measure (NQF #0138), NHSN CLABSI Outcome Measure (NQF #0139), and the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) are appropriate for LTCH-to-LTCH quality comparison. We wish to clarify that such comparison is their intended application at this time rather than across PAC provider comparison.
We further interpret the commenters to be expressing concern surrounding the other measure that we also finalized for public reporting, “The Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678),” inferring that the measure, which satisfies the IMPACT Act quality measure domain of Skin Integrity, would not be appropriate for cross-PAC comparison because it is not further risk adjusted for LTCHs. We note that this measure is risk adjusted uniformly across the PAC providers (LTCHs, IRFs, SNFs and HHAs) and, given that the measure’s risk adjustment factors take into account frailty and comorbidities, we did not believe that further setting-specific risk adjustment was warranted. The measure was finalized for use to satisfy the domain described; however as of fall 2016, the measure will initially be publicly reported for LTCH-based public reporting only. With regard to cross-PAC provider comparability, we will continue to examine risk adjustment and other factors as part of our ongoing measure development work and continue to monitor for additional factors that would take into account greater risk as we continue to collect the data.

Pending the availability of data, we proposed to publicly report data in CY 2017 on 4 additional measures beginning with data collected on these measures for the first quarter of 2015, or discharges beginning on January 1, 2015: (1) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure (NQF #1716); (2) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure (NQF #1717); and beginning with the 2015–16 influenza vaccination season these two measures; (3) Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431); and (4) Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680).

Standardized infection ratios (SIRs) for the Facility-wide Inpatient Hospital-onset MRSA Bacteremia Outcome Measure (NQF #1716) and Facility-wide Inpatient Hospital-onset CDI Outcome Measure (NQF #1717) will be displayed based on rolling quarters of data and will initially use MRSA Bacteremia and CDI events that occurred from January 1, 2015 through December 31, 2015 (CY 2015), for calculations. We proposed that the display of these ratios will be updated quarterly.

Rates for the Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) will initially be displayed for personnel working in the reporting facility October 1, 2015 through March 31, 2016. Rates for the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) will also initially be displayed for patients in the LTCH during the influenza vaccination season, from October 1, 2015, through March 31, 2016. We proposed that the display of these rates will be updated annually for subsequent influenza vaccination seasons.

Calculations for the MRSA Bacteremia and CDI Healthcare Associated Infection (HAI) measures adjust for differences in the characteristics of hospitals and patients using a Standardized Infection Ratio (SIR). The SIR is a summary measure that takes into account differences in the types of patients that a hospital treats. For a more detailed discussion about SIR, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753). The MRSA Bacteremia and CDI SIRs may take into account the laboratory methods, bed size of the hospital, and other facility-level factors. It compares the actual number of HAIs in a facility or State to a national benchmark based on previous years of reported data and adjusts the data based on several factors. A confidence interval with a lower and upper limit is displayed around each SIR to indicate that there is a high degree of confidence that the true value of the SIR lies within that interval. A SIR with a lower limit that is greater than 1.0 means that there were more HAIs in a facility or State than were predicted, and the facility is classified as “Worse than the U.S. National Benchmark.” If the SIR has an upper limit that is less than 1, the facility had fewer HAIs than were predicted and is classified as “Better than the U.S. National Benchmark.” If the confidence interval includes the value of 1, there is no statistical difference between the actual number of HAIs and the number predicted, and the facility is classified as “No Different than U.S. National Benchmark.” If the number of predicted infections is less than 1.0, the SIR and confidence interval are not calculated by CDC.

Calculations for the Influenza Vaccination Coverage Among Healthcare Personnel measure (NQF #0431) are based on reported numbers of personnel who received an influenza vaccine at the reporting facility or who provided written documentation of influenza vaccination outside the reporting facility. The sum of these two numbers is divided by the total number of personnel working at the facility for at least 1 day from October 1 through March 31 of the following year, and the result is multiplied by 100 to produce a compliance percentage (vaccination coverage). No risk adjustment is applicable to these calculations. More information on these calculations and measure specifications is available at: http://www.cdc.gov/nhsn/pdfs/hps-manual/vaccination/4-hcp-vaccination-module.pdf. We proposed that this data will be displayed on an annual basis and would include data submitted by LTCHs for a specific, annual influenza vaccination season. A single compliance (vaccination coverage) percentage for all eligible healthcare personnel will be displayed for each facility.

We invited public comment on our proposal to begin publicly reporting in CY 2017 pending the availability of data on Facility-wide Inpatient Hospital-onset MRSA Bacteremia Outcome Measure (NQF #1716); Facility-wide Inpatient Hospital-onset CDI Outcome Measure (NQF #1717); and Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431).

Comment: Several commenters specifically supported the public reporting of the CDC NHSN measures.

Response: We appreciate the commenters’ support for public reporting of healthcare-associated infections and shared commitment towards improving quality and promoting patient safety.

After consideration of the public comments we received, we are finalizing our proposal to begin publicly reporting in CY 2017 pending the availability of data on: The Facility-wide Inpatient Hospital-onset MRSA Bacteremia Outcome Measure (NQF #1716); the Facility-wide Inpatient Hospital-onset CDI Outcome Measure (NQF #1716); and the Influenza Vaccination Coverage Among Healthcare Personnel measure (NQF #0431). For the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680), we proposed to display rates annually based on the influenza season to avoid reporting for more than one influenza vaccination within a CY. For example, in 2017 we would display rates for the patient vaccination measure based on discharges starting on July 1, 2015, to June 30, 2016. We proposed this approach because it includes the entire influenza vaccination season (October 1, 2015, to March 31, 2016). Calculations for Percent of Residents or Patients Who Were Assessed and
reporting the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) in 2017 pending the availability of data.

Comment: Several commenters supported the public reporting of the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (NQF #0680) and Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) across settings. Commenters believed that surveillance is a key component in the prevention and management of influenza outbreaks and the need for a multi-faceted approach.

Response: We appreciate the commenters’ support for public reporting of the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (NQF #0680) and Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) across settings.

After consideration of the public comments we received, we are finalizing our proposal to begin publicly reporting the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) measure on discharges from July 1 of the previous calendar year to June 30th of the current calendar year in 2017 pending the availability of data.

In addition, we requested public comments on whether to include in the future, public display comparison rates based on CMS regions or U.S. census regions for Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678); All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512); and Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) for CY 2017 public display.

Comment: One commenter supported regional comparison for the LTCH quality measures. The commenter had no preference for the type of region and encouraged more granular evaluation such as State comparison.

Response: We appreciate the commenter’s support for publicly displaying regional comparison rates for these quality indicators and their encouragement on providing state comparison rates. We are currently determining the feasibility of including State comparison rates for these quality indicators.

b. Procedures for the Opportunity To Review and Correct Data and Information

Section 1899B(g) of the Act requires the Secretary to establish procedures for public reporting of LTCHs’ performance, including the performance of individual LTCHs, on quality measures specified under section 1899B(c)(1) of the Act and resource use and other measures specified under section 1899B(d)(1) of the Act (collectively, IMPACT Act measures) beginning not later than 2 years after the applicable specified application date under section 1899B(a)(2)(E) of the Act. Under section 1899B(g)(2) of the Act, the procedures must ensure, including through a process consistent with the process applied under section 1886(b)(3)(B)(viii)(VII) of the Act, which refers to public display and review requirements in the Hospital IQR Program, that each LTCH has the opportunity to review and submit corrections to its data and information that are to be made public prior to the information being made public.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25235 through 25237), we restated and proposed additional details surrounding procedures that would allow individual LTCHs to review and correct their data and information on measures that are to be made public before those measure data are made public.

For assessment-based measures, we proposed a process by which we will provide each LTCH with a confidential feedback report that will allow the LTCH to review its performance on such measures and, during a review and correction period, to review and correct the data the LTCH submitted to CMS via the CMS QIES ASAP system for each such measure. In addition, during the review and correction period, the LTCH will be able to request correction of any errors in the assessment-based measure rate calculations.

We proposed that these confidential feedback reports will be available to each LTCH using the Certification and Survey Provider Enhanced Reports (CASPER) system. We refer to these reports as the LTCH Quality Measure (QM) Reports. We proposed to provide monthly updates to the data contained in these reports as data become available. We proposed to provide the reports so that providers will be able to view their data and information at both the facility and patient level for its quality measures. The CASPER facility level QM Reports may contain information such as the numerator, denominator, facility rate, and national rate. The CASPER patient-level QM Reports may contain individual patient information which will provide information related to which patients were included in the quality measures.
to identify any potential errors for those measures in which we receive patient-level data. Currently, we do not receive patient-level data on the CDC measure data received via the NHSN system. In addition, we would make other reports available in the CASPER system, such as LTCH CARE Data Set assessment data submission reports and provider validation reports, which will disclose the LTCH’s data submission status providing details on all items submitted for a selected assessment and the status of records submitted.

We refer LTCHs to the CDC NHSN system Web site for information on obtaining reports specific to NHSN submitted data at: http://www.cdc.gov/nhsn/ltach/index.html. Additional information regarding the content and availability of these confidential feedback reports would be provided on an ongoing basis on our Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html.

As previously finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49750 through 49752) and illustrated in the second table in section VIII.C.9.c. of the preamble of this final rule, LTCHs will have approximately 4.5 months after the reporting quarter to correct any errors of their assessment-based data (that appear on the CASPER-generated QM reports) and NHSN data used to calculate the measures. During the time of data submission for a given quarterly reporting period and up until the quarterly submission deadline, LTCHs can review and perform corrections to errors in the assessment data used to calculate the measures and can request correction of measure calculations. However, as already established, once the quarterly submission deadline occurs, the data is “frozen” and calculated for public reporting and providers can no longer submit any corrections. We encourage LTCHs to submit timely assessment data during a given quarterly reporting period and review their data and information early during the review and correction period so that they can identify errors and resubmit data before the data submission deadline.

As noted above, the assessment data will be populated into the confidential feedback reports, and we intend to update the reports monthly with all data that have been submitted and are available. We believe that the data collection/submission quarterly reporting periods plus 4.5 months to review and correct the data is sufficient time for LTCHs to submit, review and, where necessary, correct their data and information. These timeframes and deadlines for review and correction of such measures and data satisfy the statutory requirement that LTCHs be provided the opportunity to review and correct their data and information and are consistent with the informal process hospitals follow in the Hospital IQR Program.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755), we finalized the data submission/correction and review period. Also, we afford LTCHs a 30-day preview period prior to public display during which LTCHs may preview the performance information on their measures that will be made public. We would like to clarify that we will provide the preview report using the CASPER system, with which LTCHs are familiar. The CASPER preview reports inform providers of their performance on each measure which will be publicly reported. Please note that the CASPER preview reports for the reporting quarter will be available after the 4.5 month correction period and the applicable data submission/correction deadline have passed and are refreshed on a quarterly basis for those measures publicly reported quarterly, and annually for those measures publicly reported annually. We proposed to give LTCHs 30 days to review the preview report beginning from the date on which they can access the report.

As already finalized, corrections to the underlying data will not be permitted during this time; however, LTCHs may ask for a correction to their measure calculations during the 30-day preview period. We proposed that if CMS determines that the measure, as it is displayed in the preview report, contains a calculation error, we can suppress the data on the public reporting Web site, recalculate the measure and publish it at the time of the next scheduled public display date. This process is consistent with informal processes used in the Hospital IQR Program. We stated that, if finalized, we intend to utilize a subregulatory mechanism, such as our LTCH QRP Web site, to provide more information about the preview reports, such as when they will be made available and explain the process for how and when providers may ask for a correction to their measure calculations. We invited public comment on these proposals to provide preview reports using the CASPER system, giving LTCHs 30 days review the preview report and ask for a correction, and to use a subregulatory mechanism to explain the process for how and when providers may ask for a correction.

In addition to assessment-based measures and CDC measure data received via the NHSN system, we have also proposed claims-based measures for the LTCH QRP. The claims-based measures include those proposed to meet the requirements of the IMPACT Act as well as the All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from LTCHs (NQF #2512) which was finalized for public display in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755). As noted in above, section 1899B(g)(2) of the Act requires prepublication provider review and correction procedures that are consistent with those followed in the Hospital IQR Program. Under the Hospital IQR Program’s informal procedures, for claims-based measures, we provide hospitals 30 days to preview their claims-based measures and data in a preview report containing aggregate hospital-level data. We proposed to adopt a similar process for the LTCH QRP.

Prior to the public display of our claims-based measures, in alignment with the Hospital IQR, HAC Reduction and Hospital VBP Programs, we proposed to make available through the CASPER system, a confidential preview report that will contain information pertaining to claims-based measure rate calculations, for example, facility and national rates. The data and information will be for feedback purposes only and could not be corrected. This information will be accompanied by additional confidential information based on the most recent administrative data available at the time we extract the claims data for purposes of calculating the measures. Because the claims-based measures are recalculated on an annual basis, these confidential CASPER QM reports for claims-based measures will be refreshed annually. As previously finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49753 through 49755), LTCHs will have 30 days from the date the preview report is made available in which to review this information.

The 30-day preview period is the only time when LTCHs will be able to see claims-based measures before they are publicly displayed. LTCHs will not be able to make corrections to underlying claims data during this preview period, nor will they be able to add new claims to the data extract. However, LTCHs may request that we correct our measure calculation if the LTCH believes it is incorrect during the 30-day preview period. We proposed that if we agree that the measure, as it is displayed in the preview report, contains a calculation error, we can suppress the
data on the public reporting Web site, recalculate the measure, and publish it at the time of the next scheduled public display date. This process will be consistent with informal policies followed in the Hospital IQR Program. If finalized, we intend to utilize a subregulatory mechanism, such as our LTCH QRP Web site, to explain the process for how and when providers may contest their measure calculations.

The proposed claims-based measures—The MSPB–PAC LTCH QRP; Discharge to Community–PAC LTCH QRP and Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP—use Medicare administrative data from hospitalizations for Medicare FFS beneficiaries. Public reporting of data will be based on 2 consecutive calendar years of data, which is consistent with the specifications of the proposed measures. We proposed to create data extracts using claims data for the proposed claims based measures—The MSPB–PAC LTCH measure; Discharge to Community–PAC LTCH QRP and Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP—at least 90 days after the last discharge date in the applicable period, which we will use for the calculations. For example, if the last discharge date in the applicable period for a measure is December 31, 2017 for data collection January 1, 2016 through December 31, 2017, we will create the data extract on approximately March 31, 2018 at the earliest, and use that data to calculate the claims-based measures for that applicable period. Since LTCHs will not be able to submit corrections to the underlying claims snapshot nor add claims (for those measures that use LTCH claims) to this data set at the conclusion of the at least 90-day period following the last date of discharge used in the applicable period, at that time we will consider LTCH claims data to be complete for purposes of calculating the claims-based measures.

We proposed that beginning with data that will be publicly displayed in 2018, claims-based measures will be calculated using claims data at least 90 days after the last discharge date in the applicable period, at which time we will create a data extract or snapshot of the available claims data to use for the measures calculation. This timeframe allows us to balance the need to provide timely program information to LTCHs with the need to calculate the claims-based measures using as complete a data set as possible. As noted, under this procedure, during the 30-day preview period, LTCHs will not be able to submit corrections to the underlying claims data or to add new claims to the data extract. This is for two reasons: first, for certain measures, the claims data used to calculate the measures may not be derived from the LTCH’s claims, but are from the claims of another provider. For example, the measure Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP uses claims data submitted by the hospital to which the patient was readmitted, which may not be the LTCH. For the claims that are not those of the LTCH, the LTCH cannot make corrections to them. Second, even where the claims used to calculate the measures are those of the LTCH, it will not be possible to correct the data after it is extracted for the measures calculation. This is because it is necessary to take a static “snapshot” of the claims in order to perform the necessary measure calculations.

We seek to have as complete a data set as possible. We recognize that the proposed at least 90 day “run-out” period when we would take the data extract to calculate the claims-based measures, is less than the Medicare program’s current timely claims filing policy under which providers have up to 1 year from the date of discharge to submit claims. We considered a number of factors in determining that the proposed at least 90 day run-out period is appropriate to calculate the claims-based measures. After the data extract is created, it takes several months to incorporate other data needed for the calculations (particularly in the case of risk-adjusted or episode-based measures). We then need to generate and check the calculations. Because several months lead time is necessary after acquiring the data to generate the claims-based calculations, if we were to delay our data extraction point to 12 months after the last date of the last discharge in the applicable period, we would not be able to deliver the calculations to LTCHs sooner than 18 to 24 months after the last discharge. We believe this would create an unacceptably long delay both for LTCHs and for us to deliver timely calculations to LTCHs for quality improvement.

We invited public comment on these proposals, which are summarized and discussed below.

**Comment:** One commenter supported CASPER monthly confidential feedback reports.

**Response:** We appreciate the commenter’s support for providing monthly confidential feedback reports.

**Comment:** Several commenters suggested that LTCHs be able to correct data during the 30-day preview period, and that CMS address any potential issues such as system errors and revise confirmed errors before the calculation results are made public. Commenters further suggested that the 30-day preview period was intended by Congress to enable correction of the data prior to public reporting. In addition, the commenters noted that CMS will be updating the NHSN system to permit changes to the CDC quality data. One commenter recommended that CMS conduct a “dry run” in which LTCHs receive confidential preview reports prior to publicly reporting measures so that LTCHs can become familiar with the methodology, understand the measure results, know how well they are performing, and have an opportunity to give CMS feedback on potential technical issues with the measures.

**Response:** We interpret the commenter to be referring to the preview reports that will be provided prior to public reporting and appreciate their concern about correcting data during the 30-day preview period and addressing any potential issues. Section 1886(m)(5)(E) of the Act requires the Secretary to establish procedures for making the LTCH QRP data available to the public and to ensure that LTCHs have the opportunity to review any such data with respect to the LTCH prior to its release to the public. In addition, section 1899B(g) of the Act, as added by the IMPACT Act, requires the Secretary to establish procedures for making information available to the public regarding the performance of individual PAC providers with respect to IMPACT Act measures beginning no later than two years after the applicable specified application date.

We implemented the 30-day preview period to be consistent with other public reporting programs such as the Hospital IQR Program. We provide opportunity for assessment-based data and NHSN data to be reviewed and corrected prior to their freeze dates, and LTCHs will have up until the run off period ends for ensuring their data used in the claims-based measures are accurate prior to the data file being used to calculate the measures. The 30-day preview period serves as the final opportunity for providers to review their data and alert CMS should they find an error in the measure calculation or any component thereof. While LTCHs will not have the opportunity to correct the underlying data during the 30-day preview period before public display, there will be a process by which LTCHs may request a review of their data should they disagree with quality measure calculations, or the components of such calculations (numerators and denominators), as
displayed on their preview reports. We will also consider suppressing quality reporting data if any systemic issues, such as on the part of the QIES ASAP system or the CDC’s NHSN is discovered. We refer readers to the LTCH QRP Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html, for further information on public reporting, such as the process of accessing reports, and where we will provide an email address should LTCHs have questions regarding any of the above-mentioned reports or processes.

With regard to the commenter’s suggestion that we provide a dry run, we wish to convey that we intend to offer providers information related to their measures so that they become familiar with the measure’s methodology and can utilize their confidential preview reports which they will receive prior to the public reporting of new LTCH QRP measures. LTCHs will also receive other confidential reports such as the LTCH facility and patient level QM Reports as well as an additional confidential facility-level report to incorporate the quarterly freeze dates, for example, the Review and Correct Report. We believe that these various reports will provide an indication on how well the LTCH is performing as well as opportunities to provide CMS feedback on technical issues with the measures. Therefore, no additional dry run period is warranted.

Finally, with regard to the commenter’s suggestion that we will be updating the NHSN system to permit changes to the CDC quality data, we interpret the commenter to be suggesting that we are working to update the CDC NHSN submission system, and we wish to clarify that at this time we are not doing so. That said, we also wish to clarify that providers have 4.5 months from the end of a reporting quarter until the freeze date to enter corrections into their CDC HAIS measure data prior to the file being transmitted from the CDC to CMS.

Comment: Several commenters recommended that CMS create an LTCH Compare Web site to separate LTCH and short-term acute care hospital performance data due to different patient populations and federal requirements. One commenter voiced their concern that LTCHs and short-term acute care hospitals are different venues. LTCHs treat sicker, more medically complex patients and therefore their quality metrics are different. The separate LTCH Compare Web page would allow patients, families, and providers to compare quality performance data with other LTCHs and not provide an incorrect impression of the care provided in LTCHs.

Response: We appreciate commenters’ suggestion on creating a separate LTCH Compare Web site. CMS is currently developing a separate Compare Web site for the reporting of LTCH quality measures similar to other PAC provider types. The LTCH Compare Web site is scheduled to be publicly available in late fall 2016.

Comment: One commenter suggested providing more frequent updates and requested patient-level data for the claims-based measures.

Response: The decision to update claims-based measures on an annual basis was to ensure that the amount of data received during the reporting period was sufficient to generate reliable measure rates. However, we will explore the feasibility of providing LTCHs with information more frequently. We believe that we are limited in our ability to provide patient-level information that stems from claims submitted by providers other than LTCHs, but we will explore the feasibility of providing patient-level data.

Comment: Several commenters noted that CMS will publish a list of LTCHs that comply with the LTCH QRP each year on its Web site.

Response: We intend to publish a list of LTCHs that comply with the LTCH QRP each year on our Web site, and it will be updated to reflect changes made as a result of appeals.

After consideration of the public comments we received, we are finalizing our proposals related to procedures to LTCHs on how to obtain and interpret these reports. For additional information on this and other training opportunities, please refer to the CMS LTCH Quality Reporting Training Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Training.html.

Section 1899B(f) of the Act requires the Secretary to provide confidential feedback reports to PAC providers on their performance to the measures specified under sections 1899B(c)(1) and (d)(1) of the Act, beginning 1 year after the specified application date that applies to such measures and PAC providers. As discussed earlier, the reports we proposed to provide for use by LTCHs to review their data and information will be confidential feedback reports that will enable LTCHs to review their performance on the measures required under the LTCH QRP. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25237 through 25258), we proposed that the confidential feedback reports will be available to each LTCH using the CASPER system. Data contained within these CASPER reports will be updated as previously described, on a monthly basis as the data become available except for our claims-based measures which are only updated on an annual basis.

We intend to provide detailed procedures to LTCHs on how to obtain their confidential feedback CASPER reports on the LTCH QRP Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/index.html.

We proposed to use the CMS QIES ASAP system to provide quality measure reports in a manner consistent with how providers obtain various reports to date. The QIES ASAP system is a confidential and secure system with access granted to providers, or their designees.

We sought public comment on this proposal to satisfy the requirement to provide confidential feedback reports to LTCHs.

Comment: One commenter encouraged CMS to provide instructions on how to obtain CASPER reports and suggestion training for LTCHs on how to improve their measures via these confidential feedback reports.

Response: We will provide LTCHs with detailed instructions and training regarding how to obtain and interpret these reports. For additional information on this and other training opportunities, please refer to the CMS LTCH Quality Reporting Training Web page at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/LTCH-Quality-Reporting/LTCH-Quality-Reporting-Training.html.

Section 1886(s)(4)(a) of the Act, as added and amended by sections 3401(f) and 10222(a) of the Affordable Care Act, requires the Secretary to implement a quality reporting program for inpatient psychiatric hospitals and psychiatric units.

Section 1886(s)(4)(A)(i) of the Act requires that, for FY 2014 and each subsequent year, the Secretary shall provide each inpatient psychiatric hospital and psychiatric unit that submits claims to the Secretary under section 1886(s)(4)(A)(ii) a measure report for the inpatient psychiatric hospital or psychiatric unit for each rate year.

333 The statute uses the term “rate year” (RY). However, beginning with the annual update of the inpatient psychiatric facility prospective payment system (IPPS) that took effect on July 1, 2011 (RY 2012), we aligned the IPPS update with the annual update of the ICD–9–CM codes, effective on October 1 of each year. This change allowed for
subsequent fiscal year, the Secretary must reduce any annual update to a standard federal rate for discharges occurring during the fiscal year by 2.0 percentage points for any inpatient psychiatric hospital or psychiatric unit that does not comply with quality data submission requirements with respect to an applicable fiscal year.

As provided in section 1886(s)(4)(A)(ii) of the Act, the application of the reduction for failure to report under section 1886(s)(4)(A)(i) of the Act may result in an annual update of less than 0.0 percent for a fiscal year, and may result in payment rates under section 1886(s)(1) of the Act being less than the payment rates for the preceding year. In addition, section 1886(s)(4)(B) of the Act requires that the application of the reduction to a standard Federal rate update be noncumulative across fiscal years. Thus, any reduction applied under section 1886(s)(4)(A) of the Act will apply only with respect to the fiscal year rate involved and the Secretary may not take into account in computing the payment amount under the system described in section 1886(s)(1) of the Act for subsequent years.

Section 1886(s)(4)(C) of the Act requires that, for FY 2014 (October 1, 2013 through September 30, 2014) and each subsequent year, each psychiatric hospital and psychiatric unit must submit to the Secretary data on quality measures as specified by the Secretary. The data must be submitted in a form and manner and at a time specified by the Secretary. Under section 1886(s)(4)(D)(i) of the Act, unless the exception of subclause (ii) applies, measures selected for the quality reporting program must have been endorsed by the entity with a contract under section 1890(a) of the Act. The National Quality Forum (NQF) currently holds this contract.

Section 1886(s)(4)(D)(ii) of the Act provides an exception to the requirement for NQF endorsement of measures: In the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization identified by the Secretary.

Section 1886(s)(4)(E) of the Act requires the Secretary to establish procedures for making public the data submitted by inpatient psychiatric hospitals and psychiatric units under the IPFQR Program. These procedures must ensure that a facility has the opportunity to review its data prior to the data being made public. The Secretary must report quality measures that relate to services furnished by the psychiatric hospitals and units on the CMS Web site.

b. Covered Entities

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53645), we established that the IPFQR Program’s quality reporting requirements cover those psychiatric hospitals and psychiatric units paid under Medicare’s IPF PPS (42 CFR 412.404(b)). Generally, psychiatric hospitals and psychiatric units within acute care and critical access hospitals that treat Medicare patients are paid under the IPF PPS. Consistent with prior rules, we continue to use the term “inpatient psychiatric facility” (IPF) to refer to both inpatient psychiatric hospitals and psychiatric units. This usage follows the terminology in our IPF PPS regulation at 42 CFR 412.402. For more information on covered entities, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53645).

c. Considerations in Selecting Quality Measures

Our objective in selecting quality measures is to balance the need for information on the full spectrum of care delivery and the need to minimize the burden of data collection and reporting. We have focused on measures that evaluate critical processes of care that have significant impact on patient outcomes and support CMS and HHS priorities for improved quality and efficiency of care provided by IPFs. We refer readers to section VIII.F.4.a. of the FY 2013 IPPS/LTCH PPS final rule (77 FR 53645 through 53646) for a detailed discussion of the considerations taken into account in selecting quality measures.

Before being proposed for inclusion in the IPFQR Program, measures are placed on a list of measures under consideration, which is published annually by December 1 on behalf of CMS by the NQF. In compliance with section 1890A(a)(2) of the Act, measures that we proposed for the IPFQR Program in the proposed rule were included in a publicly available document: “List of Measures under Consideration for December 1, 2015” (http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81172). The Measure Applications Partnership (MAP), a multi-stakeholder group convened by the NQF, reviews the measures under consideration for the IPFQR Program, among other Federal programs, and provides input on those measures to the Secretary. The MAP’s 2016 recommendations for quality measures under consideration are captured in the following document: “Process and Approach for MAP Pre-Rulemaking Deliberations 2015–2016—Final Report, February 2016” (http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81599). We considered the input and recommendations provided by the MAP in selecting all measures for the IPFQR Program, including those discussed below.

2. Retention of IPFQR Program Measures Adopted in Previous Payment Determinations

The current IPFQR Program includes 16 mandatory measures. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53646 through 53652), we adopted 6 measures for the FY 2014 payment determination and subsequent years. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50889 through 50895), we added 2 measures for the FY 2016 payment determination and subsequent years. In the FY 2015 IPPS final rule (79 FR 45963 through 45974), we adopted another 2 measures for the FY 2016 payment determination and subsequent years, and finalized 4 measures for the FY 2017 payment determination and subsequent years. In the FY 2016 IPPS final rule (80 FR 46694 through 46714), we removed 1 measure beginning with the FY 2017 payment determination; we also adopted 5 measures and removed 2 measures beginning with the FY 2018 payment determination. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25239), we indicated that we are retaining 15 of these previously adopted measures and proposed to update one measure, as discussed below.

Comment: Many commenters expressed concerns about implementation of the Screening for Metabolic Disorders Transition Record with the specifications elements received by Discharged Patients (Discharges from an Inpatient Facility to Home/Self Care or...
Any Other Site of Care) (NQF #0647), and Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0647). Commenters were primarily concerned with the increased burden of data collection associated with these measures. Some commenters were unsure of how to abstract the Transition Record measures and referred to having unanswered questions regarding the technical specifications of these measures, even following CMS Webinars.

Response: The Screening for Metabolic Disorders, Transition Record with Specified Elements Received by Discharged Patients (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0647), and Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0647) measures were updated in the FY 2016 IPPS final rule (80 FR 46706, 46709 and 46713) for the FY 2016 payment determination and subsequent years via an IPPQR Program listserv announcement sent on June 9, 2016. 339 These updated technical specifications are available in the IPPQR Program Manual at: http://www.qualityreportingcenter.com/wp-content/uploads/2016/06/IPF_CY2016_IPFQRManual_Guide_20160607_FINAL.pdf. In addition, CMS provided an updated tool for collection of all of these measures to assist facilities in data collection and submission.

Due to these updates, we postponed data collection and implementation of these three measures until January 1, 2017 for the FY 2017 payment determination and subsequent years. To summarize, we delayed data collection and are not requiring submission of Transition Record with Specified Elements Received by Discharged Patients (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0647), Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0648) and Screening for Metabolic Disorders for the FY 2018 payment determination. We refer readers to the chart in section VIII.D.5. of the preamble of this final rule for an updated list of measures for the FY 2018 payment determination.

Comment: Several commenters thanked CMS for delaying implementation of Screening for Metabolic Disorders, Transition Record with Specified Elements Received by Discharged Patients (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0647), and Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0648) until January 1, 2017.

Response: We thank the commenters for their support.

339 Slides from and a Q&A transcript from this Webinar are available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1229773668169.
length of stay equal to or greater than 365 days, or less than or equal to 3 days. As discussed above, we note that we have delayed measure implementation until January 1, 2017 for the FY 2019 payment determination and subsequent years.

4. New Quality Measures for the FY 2019 Payment Determination and Subsequent Years

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25239 through 25243), we proposed two new measures for the FY 2019 payment determination and subsequent years:

- **SUB–3 Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and the subset measure SUB–3a Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664) (SUB3 and SUB–3a); and**
- **30-day all-cause unplanned readmission following psychiatric hospitalization in an IPF.**

The sections below outline our rationale for proposing these measures.

a. **SUB–3 Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and the Subset Measure SUB–3a Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664) (SUB3 and SUB3a)**

Individuals with mental illness experience substance use disorders (SUDs) at a much higher rate than the general population. Nearly 18 percent of the 43.6 million adults aged 18 years and older who had a mental illness in 2013 met the criteria for a SUD. Of those who met the criteria for a SUD, 26.7 percent used illicit drugs. Illicit drug use is particularly high among adults with serious mental illnesses and abuse of prescription drugs among individuals with mental illnesses, in particular opioids, are also of growing concern.

Individuals with co-occurring mental disorders and SUDs, the combination of one or more mental disorders and one or more SUDs, experience far more physical illnesses and episodes of care than individuals with a single diagnosis. These co-occurring disorders tend to go undetected and untreated, especially among the elderly population, which experiences more adverse effects than the non-elderly population. Treatment of only one disorder for individuals who have two or more mental and SUDs often leads to poor functioning and poor treatment compliance that inhibits full recovery, increases the risk of relapse, and can lead to other high-risk illnesses, such as coronary heart disease, diabetes, infections, and respiratory disease. Furthermore, individuals with undetected, untreated or undertreated co-occurring disorders are more likely to experience homelessness, incarceration, additional medical illness, suicide, and early death.

Due to the prevalence of substance abuse among individuals with mental illness, and the negative effects therefrom, we believe it is imperative to assess IPsFs’ efforts to offer treatment options for patients who screen positive for drug and alcohol use. As described under the Measure Description section of the NQF Web page regarding this measure, the SUB–3 measure includes hospitalized patients age 18 years and older who are identified with an alcohol or drug use disorder who receive or refuse a referral for addictions treatment.345 The numerator of the SUB–3 measure includes patients who received a prescription at discharge for medications for alcohol or drug use disorder, OR who receive or refuse a referral for addiction treatment.346 The SUB–3a subset measure includes hospitalized patients age 18 years and older who receive a prescription for FDA-approved medications for alcohol or drug use disorder or a referral for addiction treatment. The numerator of the SUB–3a measure includes patients who received or refused a prescription at discharge for medication treatment for alcohol or drug use disorder OR a referral for addiction treatment. The denominator of the SUB–3 measure includes patients who received a prescription at discharge for medication treatment for alcohol or drug use disorder OR a referral for addiction treatment. The denominator of the SUB–3a measure includes patients who received or refused a prescription at discharge for medication treatment for alcohol or drug use disorder OR a referral for addiction treatment.


341 SAMHSA. Results from the 2014 National Survey on Drug Use and Health: Mental Health Findings.

342 Ibid.

343 SAMHSA. “Mental and Substance Use Disorders.”

344 Robert Drake. “Dual Diagnosis and Integrated Treatment of Mental Illness and Substance Abuse Disorder.”

345 SAMHSA. “Mental and Substance Use Disorders.”

346 Mental Health Foundation. “Physical Health and Mental Health.”

347 SAMHSA. “Mental and Substance Use Disorders.”

348 NQF SUB–3 and SUB–3a Measure Specifications. Available at: http://www.qualityforum.org/QPS/1664.

349 Ibid.

350 Ibid.

351 Ibid.

We previously adopted the SUB–1 measure (Alcohol Use Screening (NQF #1661)) (78 FR 50890 through 50892) and the SUB–2 (Alcohol Use Brief Intervention Provided or Offered) and the subset measure SUB–2a (Alcohol Use Brief Intervention (NQF #1663)) measure (80 FR 46699 through 46701). While the SUB–1 measure assesses “hospitalized patients 18 years of age and older who are screened during the hospital stay using a validated screening questionnaire for unhealthy alcohol use,”352 the SUB–2 and SUB–2a measure assesses “hospitalized patients who screened positive for unhealthy alcohol use who received or refused a brief intervention during the hospital stay”353 and “hospitalized patients 18 years and older who received the brief intervention during the hospital stay.”354 The numerator of the SUB–2 measure and the SUB–2a measure combined provide a greater understanding of the rate at which patients are screened for potential alcohol abuse and the rate at which those who screen positive accept the offered interventions.

Despite the value created by the inclusion of the SUB–1 measure and the SUB–2 and SUB–2a measure in the IPFQR Program measure set, neither fully captures hospitalized patients 18 years of age and older with other SUDs because these measures focus on alcohol use only. In the past, commenters have urged CMS to include measures related to illicit and opioid drugs in our measure set (80 FR 46701) stating that co-occurring substance use disorders are prevalent in many patients with psychiatric diagnoses and the SUB–3...
Actions to Address Opioid-Drug Related Overdoses

We recognize the high prevalence of substance use disorders, including disorders associated with alcohol and drug use disorders, including disorders associated with the misuse of prescription drugs. For these reasons, we included the SUB–3 and SUB–3a measure in our “List of Measures under Consideration for December 1, 2015” available at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81172. The MAP provided input on the measure and supported its inclusion in the IPFQR Program in its report “Process and Approach for MAP Pre-Rulemaking Deliberations 2015–2016—Final Report, February 2016.”

The SUB–3 and SUB–3a measure does not guarantee that patients will continue to receive treatment for substance use disorders after discharge, the addition of the SUB–3 and SUB–3a measure to the existing measure set would encourage IPFs to offer and provide FDA-approved medication OR a referral for addictions treatment to patients with co-occurring drug or alcohol use disorders at discharge. This measure would also provide information regarding the rate at which these treatment options are accepted by patients. The SUB–3 and SUB–3a measure also provides a fuller picture of the entire episode of care. In addition, aggregated data from the SUB–1 measure, SUB–2 and SUB–2a measure, and the SUB–3 and SUB–3a measure from each IPF would help provide patients with adequate consumer information to guide their decision-making process in selecting a treatment facility, specifically for patients that are diagnosed with a substance use disorder.

Furthermore, we believe that this measure set promotes the National Quality Strategy priority of Effective Prevention and Treatment for leading causes of mortality, starting with cardiovascular disease. It is notable that the high prevalence of SUDs among adults age 65 years and older contributes to serious medical conditions, including cardiovascular disease and liver disease. The proposed measure also supports HHS’ Opioid Abuse Reduction Initiative to reduce prescription opioid and heroin related overdose, death, and dependence. We also note that the addition of SUB–3 and SUB–3a in the measure set could encourage interventions and promote prevention of conditions that are associated with alcohol and drug use disorders, including disorders associated with the misuse of prescription drugs.

For these reasons, we included the SUB–3 and SUB–3a measure in our “List of Measures under Consideration for December 1, 2015” available at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81599. Moreover, this measure is NQF-endorsed for the IPF setting, in conformity with the statutory criteria for measure selection under section 1886(s)(4)(D)(i) of the Act.

Therefore, we proposed to adopt the SUB–3 and SUB–3a measure for the FY 2019 payment determination and subsequent years. We welcomed public comment on this proposal.

We note that the SUB–3 and SUB–3a measure in the IPFQR Program citing reasons including: Encouraging IPFs to offer and provide addiction treatment for patients with co-occurring drug or alcohol disorders; helping to ensure patients continue to receive treatment after discharge; and complementing the SUB–1, SUB–2/2a measure set. One commenter observed that the requirements for this measure, as outlined in the proposed rule, seem reasonable for IPFs.

Response: We thank the commenters for their support.

Comment: Several commenters recommended enhancing the SUB–3a measure. For example, commenters suggested referral to evidence-based behavioral therapies which complement Medication Assisted Therapy (MAT) or discharge to counties for assessment for care evaluation be included in the numerator of this measure.

Response: We thank these commenters for their suggestions. When feasible and practicable, we consider that it is important to implement measures as they are specified, especially after measures are NQF-endorsed. We encourage commenters to suggest changes to the measure’s steward, The Joint Commission, so that any changes to the measure can be properly specified, tested, and endorsed for these changes as part of the measure maintenance process.

Comment: Many commenters recommended that CMS not adopt SUB–3 and SUB–3a for the IPFQR Program, citing concerns that these measures are not specified for IPFs, they are not related to the primary reason patients seek IPF care, they evaluate patient compliance rather than quality of care, and they do not provide useful public information as they are not based on evidence-based practices.

Response: As we stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50891), although the SUB measures were developed using all hospitalizations in the general acute care, the SUB–3/3a measure is equally applicable to freestanding IPFs and psychiatric units within acute care hospitals because substance use disorders (SUDs) are a common comorbidity for populations hospitalized in these settings and offering SUD treatment at discharge when a comorbid SUD has been identified is a part of high quality care regardless of the treatment setting. In addition, we note that the NQF has endorsed this measure for both the Hospital/Acute Care Facility setting and the Behavioral Health/Psychiatric: Inpatient setting. Furthermore, we maintain that it is important that providers understand gaps in patient compliance so they can modify their discharge processes to influence and encourage compliance. We believe that this measure will provide information regarding the rate at which these treatment options are offered to and accepted by patients who screened positive for drug and alcohol use disorders and may present an opportunity to improve treatment rates. In addition, the aggregated data from the SUB–3 and SUB–3a measure, and the SUB–3 and SUB–3a measure from each IPF will provide patients with important consumer information to guide their decision-making process in selecting a treatment facility. Furthermore, we note that the MAP supported this measure for the IPFQR Program and refer readers to their final recommendations at: http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81593.

Comment: Several commenters recommended that CMS not adopt SUB–3 and SUB–3a for the IPFQR Program, citing concerns that these measures are not consistent with the screening and treatment provided by IPFs. These commenters observed that IPFs provide a more comprehensive screening than required by the SUB measures, and that treatment is more intensive than that required by the measure.

Response: We note that the SUB–3/3a measure is focused on a facility’s discharge procedures for patients who screened positive for an SUD during their stay in the IPF. This measure does not address inpatient treatment provided by the IPF during the patient’s stay. We believe that offering patients who have screened positive for SUD a prescription for medication for treatment of alcohol or drug use disorder or a referral for addictions treatment represents a minimum standard for discharge and we expect that IPFs which provide more intensive interventions than described in the measure will meet the criteria for this measure.
Comment: One commenter recommended that CMS not adopt SUB–3 and SUB–3a for the IPFQR Program, citing concerns that treatment for SUD is more appropriate for the non-acute setting. This commenter acknowledged that screening for these disorders is appropriate for the acute setting.

Response: We thank the commenter for the support of screening for SUD in the inpatient setting. We would like to clarify that the numerator for SUB–3 is “The number of patients who received or refused at discharge a prescription for medication for treatment of alcohol or drug use disorder OR received or refused a referral for addictions treatment;” and the numerator for SUB–3a is “The number of patients who received a prescription at discharge for medication for treatment of alcohol or drug use disorder OR a referral for addictions treatment.” We note that this measure is focused on inpatient facilities providing patients with the appropriate tools for continuing or beginning treatment for SUD after discharge in the non-acute setting. Furthermore, as stated above, we note that the MAP, composed of national stakeholders, identified readmissions as a key gap area in the IPFQR Program in a January 2015 report. A goal of the CMS Quality Strategy is to “promote effective communication and coordination of care” across different care settings and providers. In addition, readmission following discharge from IPFs is undesirable for patients because readmissions represent a deterioration in patients’ mental and/or physical health status. Furthermore, an analysis of Medicare claims data for calendar years 2012 and 2013 showed that among the 716,174 IPF admissions for Medicare beneficiaries, more than 20 percent resulted in readmission to an IPF or a short-stay acute care hospital within 30 days of discharge. Risk-standardized readmission rates ranged from 11 percent to 35 percent, indicating wide variation across IPFs and clear opportunity for improvement. Finally, MedPAC estimates of Medicare payments to IPFs in 2012 indicated that the average payment per discharge was nearly $10,000. Therefore, reducing readmissions would substantially reduce costs. For these reasons, we developed a facility-level outcome measure of all-cause, unplanned

Identification of alcohol and substance abuse disorders, IPF performance on the SUB–1 measure indicates that there is likely variation in performance across providers on the SUB–3/3a measure as well.

Comment: One commenter expressed concern that this measure may create an incentive for hospitals to refer patients to treatment for which the patients do not have coverage, such as Partial Hospitalization Programs and Intensive Outpatient Programs.

Response: We understand the commenter’s concern regarding affordability of treatment. We agree that IPFs should consider patient’s insurance coverage and cost of care when providing referrals.

Comment: One commenter expressed concern that addition of a chart-abstracted measure to the IPFQR Program is too burdensome for IPFs because they are already updating processes for other measures.

Response: We appreciate the commenter sharing its thoughts on the burden of data collection. We believe that the requirements associated with reporting on this measures strike a reasonable balance between IPF burden and providing useful information to IPFs, CMS, and the public on the quality of care provided in IPFs.

After consideration of the public comments we received, we are finalizing our proposal to adopt both SUB–3: Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and subset measure SUB–3a: Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664) for the FY 2019 payment determination and subsequent years as proposed.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53657 through 53658) and FY 2014 IPPS/LTCH PPS final rule (78 FR 50901 through 50902), we finalized policies for population, sampling, and minimum case thresholds. In the FY 2016 IPPS PPS final rule, we made one change to these requirements (80 FR 46717 through 46719) in finalizing a policy in which IPFs may take one global, sample for all measures for which sampling is permitted. This policy was adopted to decrease burden on IPFs and streamline policies and procedures. We also refer readers to section VIII.D.8.c. of the preamble of this final rule for additional information about population and sampling requirements.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25240), we proposed to allow sampling for the SUB–3 and SUB–3a measures and proposed to include the SUB–3 and SUB–3a measure in the list of measures covered by the global sample. We welcomed public comment on this proposal.

We did not receive any public comments on this proposal. Therefore, for the reasons discussed above, we are finalizing our proposal to include SUB–3: Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and subset measure SUB–3a: Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664) in the list of measures covered by the global sample for the FY 2019 payment determination and subsequent years as proposed.

b. 30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF

The MAP, composed of national stakeholders, identified readmissions as a key gap area in the IPFQR Program in a January 2015 report. A goal of the CMS Quality Strategy is to “promote effective communication and coordination of care” across different care settings and providers. In addition, readmission following discharge from IPFs is undesirable for patients because readmissions represent a deterioration in patients’ mental and/or physical health status. Furthermore, an analysis of Medicare claims data for calendar years 2012 and 2013 showed that among the 716,174 IPF admissions for Medicare beneficiaries, more than 20 percent resulted in readmission to an IPF or a short-stay acute care hospital within 30 days of discharge. Risk-standardized readmission rates ranged from 11 percent to 35 percent, indicating wide variation across IPFs and clear opportunity for improvement. Finally, MedPAC estimates of Medicare payments to IPFs in 2012 indicated that the average payment per discharge was nearly $10,000. Therefore, reducing readmissions would substantially reduce costs. For these reasons, we developed a facility-level outcome measure of all-cause, unplanned...
readmissions following discharge from a qualifying IPF admission. This measure would provide an important indicator of the quality of care patients receive in the IPF setting. Although not all readmissions are preventable, there is evidence that improvements in the quality of care for patients in the IPF setting can reduce readmission rates which, in turn, would reduce costs to Medicare and the burden to patients and their caregivers. For example, a study of 30-day behavioral health readmissions using a multisite Medicaid data found that connecting patients to services they will need post-discharge can help prevent readmissions. A 1-percent increase in the percentage of patients receiving follow-up care within 7 days of discharge was associated with a 5 percent reduction in the probability of being readmitted. Other studies have also found that transitional interventions such as pre- and post-discharge patient education, structured needs assessments, medication reconciliation, transition managers, and inpatient/outpatient provider communication have been effective in reducing early psychiatric readmissions. A systematic review of such interventions observed reductions of 13.6 percent to 37.0 percent of readmissions.

The proposed readmission measure would complement the portfolio of facility-level, risk-standardized readmission measures in the acute care setting that CMS quality reporting and pay-for-performance programs currently use. These programs include, among others, the Hospital IQR Program, which requires facilities to report on condition-specific risk-standardized readmission measures (including Acute Myocardial Infarction (AMI), Heart Failure (HF), Pneumonia, and elective Hip/Knee replacements, among others). In addition, the Hospital IQR Program requires reporting on a Hospital-Wide All-Cause Unplanned Readmissions measure (READM–30–HWR) as finalized in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53521 through 53528). The Hospital Readmissions Reduction Program, a pay-for-performance program for subsection (d) hospitals or hospitals paid under section 1814(b)(3) of the Act, also uses risk-standardized condition-specific readmission measures (including AMI, HF, and Pneumonia, among others).

The proposed IPF readmission measure, 30-day all-cause unplanned readmission following psychiatric hospitalization in an IPF, estimates a facility-level, risk-standardized readmission rate for unplanned, all-cause readmissions within 30 days of discharge from an IPF. Detailed information about the development of the measure as well as final measure specifications can be downloaded from the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html#17 on this page, the file is listed as “Inpatient Psychiatric Facility (IPF) Outcome and Process Measure Development and Maintenance” under “Downloads.” The denominator for this measure includes Medicare FFS beneficiaries aged 18 years and older who were admitted to and discharged alive from an IPF with a principal diagnosis of a psychiatric disorder. Admissions to IPFs for nonpsychiatric disorders, which account for only 1.1 percent of admissions, were not included in the measure cohort because IPFs are expected to admit patients who need inpatient care for psychiatric causes. Therefore, nonpsychiatric admissions could represent either admissions that were initiated for presumed or preliminary psychiatric diagnoses but later were changed to nonpsychiatric primary diagnoses during the admission or admissions with unreliable data. Eligible index admissions require enrollment in Medicare Parts A and B for 12 months prior to the index admission, the month of admission, and at least 30 days post-discharge. Admissions to IPFs are excluded from the denominator if any of the following apply:

- **Subsequent admission on day of discharge (Day 0) or within 2 days post-discharge (Day 1-Day 2) due to transfers to another inpatient facility on Day 0 or 1 or billing procedures for interrupted stays, which do not allow for identification of readmissions to the same IPF within 3 days:** Patient discharged against medical advice (AMA) because the provider would not have an opportunity to provide optimal care; and

- **Unreliable patient data (for example, has a death date but also admission afterwards).**

The numerator for the IPF readmission measure is defined as any admission to an IPF or acute care hospital that occurs on or between days 3 and 30 post-discharge, except those considered planned by the CMS Planned Readmission Algorithm, Version 3.0. The all-cause, unplanned, 30-day readmission rate is harmonized with other readmission measures that are endorsed by NQF and in use by CMS programs. For the timeframe for measurement, literature supports the connection between 30-day readmissions and the quality of care provided during the index admission. This timeframe also supports interventions that have been developed on a wide range of patient populations that focus on reducing 30-day readmission rates.


365 76 FR 51660 through 51676.


workgroup of relevant clinical experts agreed that the 30-day time period captures complications that may be attributable to the IPF.

An all-cause readmission rate was selected because it promotes a holistic approach to the treatment of patients with psychiatric disorders, who often have comorbid medical conditions. From the patient and caregiver perspective, these readmissions indicate a deterioration in the patient’s condition. In addition, the relationship between principal discharge diagnosis of the index admission and the principal discharge diagnosis of the readmission may be complex and difficult to determine based only on principal diagnosis codes. For example, a patient discharged with bipolar disorder may be readmitted because of a suicide attempt or self-harm due to poorly controlled symptoms of bipolar disorder. A measure that looks only for readmissions with principal discharge diagnoses of bipolar disorder would miss these readmissions.

The IPF readmission measure uses Medicare FFS claims and enrollment data over a 24-month measurement period to calculate the measure results. Twenty-four months was determined to provide an adequate number of cases and reliable results. Because this measure is not limited to a single diagnosis, a 24-month measurement period gives sufficient sample size. The IPF measure had 4.2 percent of IPFs with fewer than 25 cases in the 24-month measurement period from January 2012 to December 2013. For comparison, the HWR measure had 3.8 percent of hospitals with fewer than 25 cases in the 12-month measurement period from July 2013 to June 2014.

We recognize that the risk of readmission is influenced by patient factors, so the measure is risk-adjusted to account for differences in the patients served across IPFs. Hierarchical logistic regression is used to estimate a risk standardized readmission rate for each facility. Factors considered in the risk-adjustment model include patient demographics, principal discharge diagnoses of the index admission, comorbidities in claims during the 12 months prior to the index admission or during the index admission with the exception of complications of care, and several risk variables specific to the IPF patient population. Risk factors were selected for inclusion in the final risk model if they were positively selected at least 70 percent of the time in a stepwise backward elimination process. The final model includes age, gender, 13 principal discharge diagnosis categories, 38 comorbidity CMS Hierarchical Condition Categories (CC), history of discharge against medical advice, history of suicide or self-harm, history of aggression, and the hospital as a random effect. For more information about factors used in calculating the risk-standardized readmission rate, we refer readers to the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html#17. (On this page, the file is listed as “Inpatient Psychiatric Facility (IPF) Outcome and Process Measure Development and Maintenance” under “Downloads.”)

We understand the importance of the role that sociodemographic status plays in the care of patients. However, we continue to have concerns about holding hospitals to different standards for the outcomes of their patients of diverse sociodemographic status because we do not want to mask potential disparities or minimize incentives to improve the outcomes of disadvantaged populations. We routinely monitor the impact of sociodemographic status on hospitals’ results on our measures.

The NQF is currently undertaking a 2-year trial period in which new measures and measures undergoing maintenance review will be assessed to determine if risk-adjusting for sociodemographic factors is appropriate. This trial entails temporarily allowing inclusion of sociodemographic factors in the risk-adjustment approach for some performance measures. At the conclusion of the trial, NQF will issue recommendations on future permanent inclusion of sociodemographic factors. During the trial, measure developers are encouraged to submit information such as analyses and interpretations, as well as performance scores with and without sociodemographic factors in the risk adjustment model. Several measures developed by CMS have been brought to NQF since the beginning of the trial. CMS, in compliance with NQF’s guidance, has tested sociodemographic factors in the measures’ risk models and made recommendations about whether or not to include these factors in the endorsed measure. We intend to continue engaging in the NQF process as we consider the appropriateness of adjusting for sociodemographic factors in our outcome measures.

Furthermore, the Office of the Assistant Secretary for Planning and Evaluation support continued research to examine the effect of sociodemographic status on quality measures, resource use, and other measures under the Medicare program, as directed by the IMPACT Act. We will closely examine the findings of the ASPE reports and related Secretarial recommendations and consider how they apply to our quality programs at such time as they are available.

As part of the measure development process for this measure, we solicited public comments on the measure via the CMS Public Comment Web page. As part of our comment solicitation, we provided the Measure Information Form (MIF), Data Dictionary, and the Measure Technical Report to the public to inform their review of the measure. We accepted public comments from November 25, 2015 through December 11, 2015. The significant majority of stakeholders who provided comments on the measure design supported this measure because of the importance of measuring readmissions in this population. Commenters who provided input on the methodology agreed that it appears to be scientifically acceptable, and those who provided input on the feasibility agreed with our belief that the measure is feasible as designed. After review and evaluation of all the public comments received, we did not identify any areas in which the measure needed to be modified. For specific information regarding the comments we received, we refer readers to the CMS Web site at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/MMS/CallforPublicComment.html#17. (On this page, the file is listed as “Inpatient Psychiatric Facility (IPF) Outcome and Process Measure Development and Maintenance” under “Downloads.”)

While section 1886(e)(4)(D)(ii) of the Act authorizes the Secretary to specify a measure that is not endorsed by NQF, the proposed IPF readmission measure was submitted to NQF for endorsement on January 29, 2016, and we anticipate the measure will receive endorsement prior to the release of the final rule. However, the exception to the requirement to specify an endorsed measure states that in the case of a specified area or medical topic determined appropriate by the Secretary for which a feasible and practical measure has not been endorsed by the entity with a contract under section 1890(a) of the Act, the Secretary may specify a measure that is not so endorsed as long as due consideration is given to measures that have been endorsed or adopted by a consensus organization. We have reviewed NQF-endorsed and other non-endorsed measures related to all-cause unplanned readmissions and believe that none are
appropriate to the inpatient psychiatric setting. Therefore, no equivalent readmission measure that is endorsed by a consensus organization is available for use in the IPFQR Program.

For the reasons stated above, we proposed the IPF readmission measure described in this section for the FY 2019 payment determination and subsequent years. We welcomed public comment on this proposal.

Comment: A few commenters supported inclusion of the Thirty-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF measure in the IPFQR Program.

Response: We thank the commenters for their support.

Comment: Many commenters recommended that CMS postpone adoption of the 30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF measure until it has been NQF endorsed and risk-adjusted for sociodemographic factors. Some commenters observed that some IPFs treat a disproportionate share of disadvantaged patients, and that sociodemographic factors influence the IPF’s ability to manage chronic psychiatric conditions. Other commenters observed that this measure may reflect on community resources, such as availability of outpatient treatment, rather than IPF quality. One commenter asked that CMS provide additional detail on the variables included in the risk-adjustment algorithm for this measure.

Response: We appreciate the commenters’ concern for appropriate risk adjustment and NQF endorsement. We note that this measure (MUC15–1082) was included on the “List of Measures Under Consideration for December 1, 2015” (http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=81172) that is used by the MAP to consider measures for use in CMS programs. The MAP noted the importance of addressing readmissions for patients admitted for psychiatric disorders and conditionally supported this measure for use in the IPFQR Program, pending NQF review, including the examination of SDS risk factors, and endorsement. We refer readers to http://www.qualityforum.org/ProjectMaterials.aspx?projectID=75367 (on this site download “MAP 2015–2016 Preliminary Recommendations” or “MAP 2016 Considerations for Implementing Measures Draft Report”) for additional information on the MAP consideration and recommendations.

The 30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF measure was submitted to NQF for consideration on January 29, 2016. As part of the submission, we evaluated the impact and appropriateness of including sociodemographic status (SDS) factors in the risk model; as part of the NQF SDS 2-year trial described earlier. The domains of SDS risk factors that were considered for inclusion in the risk model were income, education, and access to care.

While most SDS risk factors had an association with readmission in the univariate models, it is worth noting that SDS risk factors indicating that a patient resides in a mental health or primary care shortage area were associated with lower risk of readmission, contrary to the commenters concern that readmissions would be increased in these settings. Another noteworthy finding was that the association between readmission and all of the SDS risk factors was attenuated once clinical variables were added to the risk model. Therefore, when we compared the results of a model with both SDS risk factors and clinical risk factors to one with only clinical risk factors we found that the inclusion of SDS risk factors did not improve model performance. Because of the negligible impact on model performance, the complexity of operationalizing variables that utilize census-level data, and concerns about the potential to partially mask a quality signal, these factors were not included in the final risk model for the measure as submitted to the NQF. For more detail about the SDS risk factors that were considered and the results of the analyses we refer readers to the NQF Supplemental Document for this measure, available at: http://www.qualityforum.org/ProjectTemplateDownload.aspx?SubmissionID=2860. The NQF Committee met on June 9, 2016 to consider the measure for endorsement. During this meeting, the committee reviewed the measure testing results, which included the SDS evaluation as discussed above, and final measure specifications with adjustment for clinical risk factors. Ninety-five percent of the committee members voted in support of the measure as specified in the final technical report without inclusion of SDS factors in the risk model.378 Review for a final NQF endorsement decision was anticipated in the fall of 2016. The complete NQF submission with the results of the SDS testing and final technical report is located at the following link: http://www.qualityforum.org/ProjectTemplateDownload.aspx?SubmissionID=2860.

Comment: A few commenters expressed concerns because the measure is not risk-adjusted for involuntary admissions. One commenter recommended that CMS evaluate stratification by IPFs that are designated for involuntary admissions and those that are not.

Response: We appreciate the commenters’ concerns relating to the impact of involuntary admissions on readmission rates and evaluated this as a risk factor during measure development. Patients admitted involuntarily, as assessed by an indication in the claims data, accounted for 3 percent of all IPF admissions and had a lower unadjusted readmission rate than the general IPF patient population (17 percent compared to 19 percent, respectively). Based on these findings, the measure development expert workgroup,379 convened by the measure development team, recommended that the “involuntary” admission indicator in the claims data does not capture all incidences of involuntary admissions and might, therefore, result in erroneous associations. However, we will take the suggestion to stratify the measure results by IPFs that are and are not designated for involuntary admission into consideration for the future.

Comment: Many commenters recommended that CMS not adopt the 30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF measure citing concerns that inclusion of all-cause readmissions in this measure may unfairly reflect on IPFs for unrelated readmissions and that the inclusion of these readmissions may impact the ability of IPFs to use the measure results for quality improvement. One commenter expressed concern that CMS has not appropriately studied the link between psychiatric admissions and acute care readmissions.

Response: We appreciate the commenters’ views. This measure evaluates an all-cause, unplanned readmission rate in order to capture adverse events experienced by patients following discharge from an IPF. There are several reasons to measure both psychiatric and nonpsychiatric readmissions following psychiatric admissions: (1) The measure will encourage improved integration of

378 The transcript from this discussion is available at: http://www.qualityforum.org/ProjectMaterials.aspx?projectID=80825. For information on this measure, see Day 2 of the transcript.
physical and behavioral health care, which is important for adults living with serious mental illness because they die on average 25 years earlier than the general population, largely due to preventable conditions, such as cardiovascular disease, diabetes, and infectious diseases; 380 (2) readmissions, regardless of cause, are disruptive to patients and their families or caregivers; 381 (3) readmission due to medical conditions may actually be related to the previous psychiatric index admission (for example, a patient may be readmitted for a hip fracture that was caused by adverse effects of psychotropic medications prescribed by the IPF); or a patient with poorly managed depression may neglect management of his/her comorbid diabetes); 382 and (4) the designation of the principal versus secondary diagnosis may be somewhat arbitrary making it difficult to determine if the readmission is related to the previous psychiatric treatment, especially if patients present with complex problems that involve both mental and physical issues (for example, using 2012–2013 Medicare fee-for-service claims data, 93 percent of readmissions to an acute care hospital with a non-psychiatric diagnosis following discharge from an IPF had a secondary diagnosis of mental illness).

Reporting an all-cause readmission rate will provide quality improvement teams within IPFs with a more complete picture of their patients’ recovery than if the readmission rate included a more limited set of post-discharge admission events (for example, only psychiatric readmissions). We believe this information would help IPFs improve quality at their facilities.

We also note that we have aligned and harmonized this measure with the Hospital-Wide Readmission measure previously adopted in the Hospital IQR Program to measure all-cause readmissions. 383 This will allow for easier interpretation of measure rates, especially among IPFs that are part of larger hospital systems.

Comment: Several commenters recommended against adoption of the 30-Day All-Cause Unplanned Readmissions Following Psychiatric Hospitalization in an IPF measure citing concerns with the validity of the evidence for this measure. Specifically, they expressed concern that the chronic nature of some psychiatric and substance use disorders may necessitate readmissions within 30 days in some instances. Furthermore, many of these commenters noted that not all strategies to reduce readmissions in Medicare patients are available to this disabled subset of Medicare patients.

Response: We appreciate the commenters’ concerns and recognize that some readmissions are unavoidable. However, we note that there have been improvements in all-cause readmission rates among patients admitted to the hospitalsetting for conditions evaluated by readmission measures adopted by CMS. 384

While not all interventions to reduce readmissions in the hospital setting may be applicable to this disabled patient population, the evidence supporting processes that can be adopted by IPFs to influence readmission rates in this population is robust and valid. Specifically, we noted several interventions cited in the technical report that were identified from clinical guidelines and systematic reviews of multiple studies involving patients with chronic psychiatric conditions (for example, administering evidence-based treatments to patients with bipolar disorder and discharge planning in mental health). Many of the interventions, such as connecting patients to intensive case management, are specifically targeted toward patients with severe mental disability.

Furthermore, the NQF committee that reviewed this measure in June 2016 agreed that the evidence sufficiently supported this measure with 95 percent of steering committee members in agreement that it passed the “importance” criterion, which includes a review of the validity of the evidence. 386

Comment: One commenter’s support for the adoption of the Thirty-Day All-Cause Unplanned Readmissions Following Psychiatric Hospitalization in an IPF measure was contingent on the measure having been tested for validity and reliability.

Response: We tested for validity and reliability as part of the measure development process. We refer readers to the technical report for this measure, which includes a detailed description of the validity and reliability testing. This report can be found at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/HospitalQualityInits/ Measure-Methodology.html. (The Technical Report can be downloaded from the “Inpatient Psychiatric Facility Readmission Measure” folder.)

Comment: Several commenters requested information about the sample size for the measure and recommended reducing the lag between claims being generated by facilities and public reporting.

Response: Public reporting of claims-based measures requires some lag time to ensure that the measure is calculated on final action claims and includes a long enough timeframe to ensure most facilities have enough cases to calculate reliable measure rates. The readmission measure for the IPFQR Program uses a measurement period of 24 months. Consistent with readmissions measures for other programs, the 30-Day All-Cause Readmission Following Psychiatric Hospitalization in an IPF will be publicly reported on Hospital Compare for IPFs that meet a case threshold of 25 cases per measurement period. With a 2-year measurement period, 96 percent of IPFs would have enough cases for public reporting. For comparison, the Hospital-Wide Readmission measure in the Hospital IQR Program, is able to report rates for 96 percent of hospitals with a one-year measurement period. 387

Comment: Many commenters requested that CMS address how the planned readmission algorithm was adapted for psychiatric patients.

Response: We carefully considered how to identify appropriate planned


381 Based on evidence provided by patients and caregivers during the measure development process.

382 Based on evidence provided by technical experts during the measure development process.

383 This measure was adopted in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53521 through 53528). Technical specifications for this measure are available at: http://altarum.org/sites/default/files/uploaded-publication-files/Readmsn_MsrUpdates_HWR_0714_0.pdf.


385 For more information on the clinical guidelines and studies, we refer readers to the technical report at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html (The Technical Report can be downloaded from the “Inpatient Psychiatric Facility Readmission Measure” folder).

386 The transcript from this discussion is available at: http://www.qualityforum.org/ProjectMaterials.aspx?projectID=80625. For information on this measure, see Day 2 of the transcript.

387 This measure was adopted in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53521 through 53528). Technical specifications for this measure are available at: http://altarum.org/sites/default/files/uploaded-publication-files/Readmsn_MsrUpdates_HWR_0714_0.pdf.
The new measures that we are finalizing for the IPFQR Program for the FY 2019 payment determination and subsequent years are set forth in the table below.

### Finalized Measures for FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>NQF #</th>
<th>Measure ID</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>0640</td>
<td>HBIPS-2</td>
<td>Hours of physical restraint use.</td>
</tr>
<tr>
<td>0641</td>
<td>HBIPS-3</td>
<td>Patients discharged on multiple antipsychotic medications with appropriate justification.</td>
</tr>
<tr>
<td>0560</td>
<td>HBIPS-5</td>
<td>Follow-Up After Hospitalization for Mental Illness.</td>
</tr>
<tr>
<td>0576</td>
<td>FUH</td>
<td>Alcohol Use Screening.</td>
</tr>
<tr>
<td>1661</td>
<td>SUB-1</td>
<td>Alcohol Use Brief Intervention Provided or Offered and the subset measure Alcohol Use Brief Intervention.</td>
</tr>
<tr>
<td>1663</td>
<td>SUB-2 and SUB-2a</td>
<td>Tobacco Use Screening.</td>
</tr>
<tr>
<td>1651</td>
<td>TOB-1</td>
<td>Tobacco Use Treatment Provided or Offered and the subset measure Tobacco Use Treatment.</td>
</tr>
<tr>
<td>1654</td>
<td>TOB-2 and TOB-2a</td>
<td>Tobacco Use Treatment Provided or Offered at Discharge and the subset measure Tobacco Use Treatment at Discharge.</td>
</tr>
<tr>
<td>1656</td>
<td>TOB-3 and TOB-3a</td>
<td>Influenza Immunization.</td>
</tr>
<tr>
<td>1659</td>
<td>IMM-2</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel.</td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Assessment of Patient Experience of Care.</td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Use of an Electronic Health Record.</td>
</tr>
</tbody>
</table>

The measures that we have previously finalized for the FY 2018 payment determination and subsequent years are set forth in the table below. We note that this table does not include Screening for Metabolic Disorders, Transition Record with Specified Elements Received by Discharged Patients (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0647), and Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care) (NQF #0648) because we have postponed these measures until the FY 2019 payment determination and subsequent years, as discussed in section VIII.D.2. of the preamble of this final rule.

### Finalized New IPFQR Program Measures for the FY 2019 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>National quality strategy priority</th>
<th>NQF #</th>
<th>Measure ID</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective Treatment and Prevention.</td>
<td>1664</td>
<td>SUB-3 and SUB-3a</td>
<td>SUB-3 Alcohol &amp; Other Drug Use Disorder Treatment Provided or Offered at Discharge and SUB-3a Alcohol &amp; Other Drug Use Disorder Treatment at Discharge.</td>
</tr>
<tr>
<td>Communication/Care Coordination.</td>
<td>N/A</td>
<td>(Under review for endorsement) N/A</td>
<td>30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF.</td>
</tr>
</tbody>
</table>

Footnotes:

388 Ibid.

389 Calculated from Medicare fee-for-service administrative claims data from 2012–2013.
For the IPFQR Program, the total number of measures for the FY 2019 payment determination and subsequent years is 18, as set forth in the table below.

### Finalized Measures for FY 2019 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>NQF #</th>
<th>Measure ID</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>0640</td>
<td>HBIPS–2</td>
<td>Hours of physical restraint use.</td>
</tr>
<tr>
<td>0641</td>
<td>HBIPS–3</td>
<td>Hours of seclusion use.</td>
</tr>
<tr>
<td>0560</td>
<td>HBIPS–5</td>
<td>Patients discharged on multiple antipsychotic medications with appropriate justification.</td>
</tr>
<tr>
<td>0576</td>
<td>FUH</td>
<td>Follow-Up After Hospitalization for Mental Illness.</td>
</tr>
<tr>
<td>1661</td>
<td>SUB–1</td>
<td>Alcohol Use Screening.</td>
</tr>
<tr>
<td>1663</td>
<td>SUB–2 and SUB–2a</td>
<td>Alcohol Use Brief Intervention Provided or Offered and the subset measure Alcohol Use Brief Intervention.</td>
</tr>
<tr>
<td>1651</td>
<td>TOB–1</td>
<td>Tobacco Use Screening.</td>
</tr>
<tr>
<td>1654</td>
<td>TOB–2 and TOB–2a</td>
<td>Tobacco Use Treatment Provided or Offered and the subset measure Tobacco Use Treatment.</td>
</tr>
<tr>
<td>1656</td>
<td>TOB–3 and TOB–3a</td>
<td>Tobacco Use Treatment Provided or Offered and the subset measure Tobacco Use Treatment.</td>
</tr>
<tr>
<td>1659</td>
<td>IMM–2</td>
<td>Influenza Immunization.</td>
</tr>
<tr>
<td>0647</td>
<td>N/A</td>
<td>Transition Record with Specified Elements Received by Discharged Patients (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care).**</td>
</tr>
<tr>
<td>0648</td>
<td>N/A</td>
<td>Timely Transmission of Transition Record (Discharges from an Inpatient Facility to Home/Self Care or Any Other Site of Care).**</td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Use of an Electronic Health Record.</td>
</tr>
<tr>
<td>0431</td>
<td>N/A</td>
<td>Influenza Vaccination Coverage Among Healthcare Personnel.</td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Assessment of Patient Experience of Care.</td>
</tr>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Alcohol &amp; Other Drug Use Disorder Treatment Provided or Offered at Discharge and the subset measure Alcohol &amp; Other Drug Use Disorder Treatment at Discharge.*</td>
</tr>
<tr>
<td>1664</td>
<td>SUB–3 and SUB–3a</td>
<td>30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an IPF.*</td>
</tr>
</tbody>
</table>

*New measures finalized for the FY 2019 payment determination and future years.

** Measures previously finalized for the FY 2018 payment determination and subsequent years, but postponed to FY 2019 payment determination and subsequent years through a subregulatory process described in section VIII.D.2. of the preamble of this final rule.

6. Possible IPFQR Program Measures and Topics for Future Consideration

As we have indicated in prior rulemaking (79 FR 45974 through 45975), we seek to develop a comprehensive set of quality measures to be available for widespread use for informed decision-making and quality improvement in the IPF setting. Therefore, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25243), we stated that through future rulemaking, we intend to propose new measures for adoption that will help further our goals of achieving better health care and improved health for Medicare beneficiaries who obtain inpatient psychiatric services through the widespread dissemination and use of quality information.

We welcomed public comments on possible new measures.

**Comment:** Several commenters recommended that CMS develop and adopt an additional measure for identifying individuals with substance use disorders. Some of these commenters specifically suggested that CMS evaluate HBIPS–1 for adoption in the IPFQR Program.

**Response:** We thank these commenters for their suggestions and will consider measures for identifying individuals with substance use disorders, such as the HBIPS–1 measure in the future.

**Comment:** Many commenters recommended that CMS focus on measures that are meaningful to patients. Some commenters recommended that CMS only adopt measures specifically associated with the primary reasons that patients seek care from an IPF.

**Response:** We agree with the commenters that the IPFQR Program should focus on measures that are meaningful to patients. However, we continue to believe that there also is value in including measures that are not directly tied to the reason that the patient seeks care from an IPF, such as those reflecting professional standards for quality care or evidence-based factors associated with better outcomes. We also believe that limiting the program to measures that specifically apply to psychiatric services creates a false demarcation between non-psychiatric and psychiatric care, and ignores the broader responsibility of the facility for the overall health of the patient.

**Response:** When proposing measures for the IPFQR Program, our objective is to balance the need for information on the full spectrum of care delivery with the need to minimize the burden of data collection and reporting. To that end, we focus on measures that evaluate critical processes of care that have significant impact on patient outcomes and support CMS and HHS priorities for improved quality and efficiency of care provided by IPFs. Because we are sensitive to the need to minimize the burden on IPFs, we address this issue during Technical Expert Panels (TEPs) as part of our measure development process. We also refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 45974, August 22, 2013).
37845 through 37846) for our considerations for the development and selection of measures for the IPFQR Program.

Comment: Several commenters requested that CMS pursue development of a patient and caregiver perception of care measure focused on the psychiatric patient population.

Response: We thank the commenters for their recommendations. We believe that patient and family engagement measures are important, and we will consider this suggestion as we develop future measures.

Comment: One commenter urged CMS to consider the use of psychiatric scales and instruments which are commonly used in IPF settings and specifically suggested the 24 item Behavior and Symptom Identification Scale (Basis 24).

Response: We thank the commenter for its suggestion and will consider measures related to the use of specific diagnostic or assessment tools, such as the Basis-24 tool. We also are required to establish procedures for making the data submitted under the IPFQR Program available to the public. Such procedures must ensure that an IPF has the opportunity to review its data that are to be made public prior to such data being made public. Section 1866(s)(4)(E) of the Act also provides for its facility, and to submit measure rate errors resulting from CMS calculations of IPF submitted patient-level claims and Web-based measure numerator and denominator data. It is not for the purpose of correcting an IPF’s possible submission errors. As finalized in the 2015 IPPS final rule (79 FR 45076), IPFs have the entire data submission period to review and correct claims data element and Web-based measure numerator and denominator count data that have been made public. In the FY 2015 IPPS/LTCH PPS final rule (78 FR 50897 through 50898), we stated that the preview period would be 30 days and would begin approximately 12 weeks prior to the public display of the data.

Because we proposed to make the data for the IPFQR Program available as soon as possible, and the timeframe for publication may change from year-to-year, we proposed to no longer specify the dates for review in rulemaking, nor to specify in rulemaking that the preview period will begin approximately 12 weeks prior to publicly displaying the data. Instead, we proposed to announce the exact timeframes through subregulatory guidance, including on a CMS Web site and/or on our applicable listservs. We also proposed to continue our policy that the time period for review will be approximately 30 days in length.

As noted earlier, we wish to publicly display data as early as possible. For the FY 2017 payment determination, it may be technically feasible for us to display the data as early as December 2016. We previously finalized that the preview period would be 30 days and would be approximately 12 weeks prior to the public date (in the FY 2014 IPPS/LTCH PPS final rule, 78 FR 50897 through 50898). However, in this case (for the FY 2017 payment determination), 12 weeks prior to December 1, 2016 is in mid-September 2016, which is 2 weeks before the usual effective date of the IPPS/LTCH PPS final rule. Therefore, for FY 2017 only, if it is technically feasible to display the data as early as December 2016, we proposed a 2-week preview period that would start on October 1, 2016.

However, as a courtesy, and to give IPFs 30 days for review if they so choose, we proposed to provide IPFs with their data as early as mid-September. The actual dates will be dependent on technical feasibility and will ensure that IPFs have 30 days to preview their data. We believe that this proposal complies with prior policies while still allowing us to display data as soon as possible for the FY 2017 payment determination.

We invited public comment on these proposals.

Comment: Many commenters supported the objective of publicly displaying the data as soon as possible to improve transparency, but requested that CMS clarify that IPFs will continue to have a 30-day preview period. These commenters further requested that CMS clarify how it will ensure there is sufficient time between the preview period and public display to correct any inaccuracies in the data since CMS is no longer providing the approximately 30 day preview period beginning 12 weeks prior to publicly posting the data.

Response: We thank the commenters for their support. As noted above, we are not changing the duration of the preview period from the previously finalized “approximately 30 days” and as such we will continue to ensure that IPFs have approximately 30 days to preview their data prior to publication on Hospital Compare. As we clarified in the proposed rule (81 FR 25244), the purpose of this preview period is to allow each IPF to see its facility level data prior to that data being made public, not to correct an IPF’s possible submission errors. In the event that an IPF identifies measure rate errors resulting from CMS calculations of IPF submitted data, we will ensure that these errors are corrected prior to making the data publicly available.

After consideration of the public comments we received, for the FY 2018 payment determination and subsequent years we are finalizing our proposals to: (1) No longer specify the dates of preview period or data publication in rulemaking; (2) make the data for the IPFQR Program available as soon as possible; (3) announce the exact timeframes through subregulatory guidance, including on a CMS Web site and/or on our applicable listservs; and (4) continue our policy that the time period for review will be approximately
the preamble of this final rule where we finalizes our proposal to include both 
SUB–3: Alcohol & Other Drug Use 
Disorder Treatment Provided or Offered 
at Discharge and subset measure SUB– 
3a: Alcohol & Other Drug Use 
Disorder Treatment at Discharge (NQF 
#1664) in the list of measures covered by 
the global sample for the FY 2019 payment 
determination and subsequent years as 
proposed.

d. Data Accuracy and Completeness 
Acknowledgement (DACA) 
Requirements

In the FY 2017 IPPS/LTCH PPS 
proposed rule (81 FR 25244), we did not 
propose any changes to the DACA 
requirements, and we refer readers to 
the FY 2013 IPPS/LTCH PPS final rule 
(77 FR 53658) for more information on 
these requirements.

9. Reconsideration and Appeals 
Procedures

In the FY 2013 IPPS/LTCH PPS final 
rule (77 FR 53658 through 53660), we 
adopted a reconsideration and appeals 
process, later codified at 42 CFR 
412.434, by which an IPF can request a 
reconsideration of its payment update 
reduction if an IPF believes that its 
annual payment update has been 
incorrectly reduced for failure to meet 
all IPFQR Program requirements and, if 
dissatisfied with a decision made by 
CMS on its reconsideration request, may 
file an appeal with the Provider 
Reimbursement Review Board. In the 
FY 2017 IPPS/LTCH PPS proposed rule 
(81 FR 25244), we did not propose any 
changes to the Reconsideration and 
Appeals Procedure and refer readers to 
the FY 2013 IPPS/LTCH PPS final rule 
(77 FR 53658 and 53660) for further 
information on the reconsideration process.

10. Exceptions to Quality Reporting 
Requirements

In the FY 2017 IPPS/LTCH PPS 
proposed rule (81 FR 25244), we did not 
propose any changes to the exceptions 
to quality reporting requirements. For 
more information, we refer readers to 
the FY 2013 IPPS/LTCH PPS final rule 
(77 FR 53658 through 53660), where we 
initially finalized the policy as “Waivers 
from Quality Reporting,” and the FY 
2015 IPPS PPS final rule (79 FR 45078), 
where we renamed the policy as “Exceptions to Quality Reporting 
Requirements.”

E. Clinical Quality Measurement for 
Eligible Hospitals and Critical Access 
Hospitals (CAHs) Participating in the 
EHR Incentive Programs in 2017

1. Background

The HITECH Act (Title IV of Division 
B of the ARRA, together with Title XIII 
of Division A of the ARRA) authorizes 
incentive payments under Medicare and 
Medicaid for the adoption and 
meaningful use of certified electronic 
health record (EHR) technology 
(CEHRT). Eligible hospitals and CAHs 
may qualify for these incentive 
payments under Medicare (as 
authorized under sections 1886(n) and 
1814(l) of the Act, respectively) if they 
successfully demonstrate meaningful 
use of CEHRT, which includes reporting 
on clinical quality measures (CQMs) 
using CEHRT.

Sections 1886(b)(3)(B) and 1814(l) of 
the Act also establish downward 
payment adjustments under Medicare, 
beginning with FY 2015, for eligible 
hospitals and CAHs that are not 
meaningful users of CEHRT for certain 
associated reporting periods. Section 
1903(a)(3)(F)(I) of the Act establishes 
100 percent Federal financial 
payment adjustments (FFP) to States for 
providing incentive payments to eligible 
Medicaid providers (described in 
section 1903(l)(2) of the Act) to adopt, 
implement, upgrade and meaningfully 
use CEHRT.

Under sections 1886(n)(3)(A) and 
1814(l)(3)(A) of the Act and the 
definition of “meaningful EHR user” 
under 42 CFR 495.4, eligible hospitals 
and CAHs must report on CQMs 
selected by CMS using CEHRT, as part 
of being a meaningful EHR user under 
the Medicare EHR Incentive Program. 
The set of CQMs from which eligible 
hospitals and CAHs will report under 
the EHR Incentive Program beginning in 
FY 2014 is listed in Table 10 of the EHR 
Incentive Program Stage 2 final rule (77 
FR 54083).

In order to further align CMS quality 
reporting programs for eligible hospitals 
and CAHs and avoid redundant or 
duplicative reporting among hospital 
programs, the Medicare and Medicaid 
Programs; Electronic Health Record 
Incentive Program—Stage 3 and 
Modifications to Meaningful Use in 
2015 Through 2017 (hereinafter referred 
to as the 2015 EHR Incentive Programs 
Final Rule)391 (80 FR 62890) indicated 
our intent to address CQM reporting 
requirements for the Medicare and 

391 Medicare and Medicaid Programs: Electronic 
Health Record Incentive Program—Stage 3 and 
Modifications to Meaningful Use in 2015 Through 
2017; final rule (80 FR 62761 through 62955) (“2015 
EHR Incentive Programs Final Rule”).
Medicaid EHR Incentive Programs for eligible hospitals and CAHs for 2016, 2017, and future years in the IPPS rulemaking. We believe that receiving and reviewing public comments for various CMS quality programs at one time while simultaneously finalizing the requirements for these programs would provide us with an opportunity to better align these programs for eligible hospitals and CAHs, allow more flexibility within the Medicare and Medicaid EHR Incentive Programs, and add overall value and consistency. To further achieve this goal, the 2015 Edition final rule (80 FR 62652) published by ONC indicated that it would address certification policy regarding the reporting of CQMs for eligible hospitals and CAHs in reporting periods in conjunction with the annual IPPS rulemaking to better align with the reporting goals of other CMS programs.

2. CQM Reporting for the Medicare and Medicaid EHR Incentive Programs in 2017

   a. Background

   In the EHR Incentive Program Stage 2 final rule, we outlined the CQMs available for use in the EHR Incentive Programs beginning in 2014 for eligible hospitals and CAHs in Table 10 at 77 FR 54083 through 54087. In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25245), we proposed to maintain the existing requirements established in earlier rulemaking for the reporting of CQMs under the EHR Incentive Programs in 2017, unless otherwise indicated in the proposed rule. These requirements include reporting on 16 CQMs covering at least 3 NQS domains for eligible hospitals and CAHs (77 FR 54079). We noted in the proposed rule (81 FR 25245) that the proposals would apply to both the Medicare and Medicaid EHR Incentive Programs, with the exception of the submission period proposed policy.

   As we expect to expand the current measures to align with the National Quality Strategy and the CMS Quality Strategy and incorporate updated standards and terminology in current CQMs, including updating the electronic specifications for these CQMs, and creating de novo CQMs, we plan to expand the set of CQMs available for reporting under the EHR Incentive Programs in future years. We will continue to engage stakeholders to provide input on future proposals for CQMs as well as request comment on future electronic specifications for new and updated CQMs.

   In addition, we are transitioning from the quality data model (QDM) expression language to the clinical quality language (CQL) specification, which defines a representation for the expression of clinical knowledge that can be used within both the clinical decision support (CDS) and CQM domains. The QDM logic expression is tightly coupled to the QDM logic model and based on capabilities of the health level 7 (HL7) reference information model (RIM), an object model which does not have significant ability to express mathematical logic such as addition, subtraction, division, and multiplication. The QDM logic expression requires multiple, often repetitious lines of logic to compare relationships among different activities, usually by indicating the time of one activity with the time of the other activity. Also, software cannot easily parse QDM logic directly from the Healthcare Quality Measures Format (HQMF), the HL7 standard for representing a clinical quality measure as an electronic document. Using QDM logic expression in HQMF often require significant human interaction and interpretation to program or configure software, such as EHRs, to calculate a measure. In general, the CQL is a mathematical expression language that can be parsed by software to calculate results, without needing human interpretation to implement the expressed logic. The CQL includes basic math and allows descriptions of relationship among activities in a simple, direct manner, which significantly reduces the lines of logic. With a modest effort, it represents a change that is straightforward to learn and interpret compared to the existing QDM logic statements.

   The CQL specification defines two components: CQL—author-friendly domain specific language; and expression logical model—computable extensible markup language (XML). The CQL leverages best practices and lessons learned from the quality data model, health e-decisions, and electronic CQM and clinical decision support (CDS) communities. The CQL is designed to work with any data model, more expressive and robust than the QDM logic, and is a HL7 draft standard for trial use (DSTU). The CQL includes: Datatypes; data retrieval and queries; timing phrases and operators; variable and function declaration; input parameters with default values; conditional logic; Boolean logic, and value comparison; simple arithmetic and aggregate functions; operations on value sets, lists, intervals, sets and dates/times; and shared libraries. We anticipate the incorporation of the CQL into the CQM electronic specifications as we support the development and testing of this standard. We anticipate starting this work effort in 2016 with the expectation that extensive development and testing will continue, at minimum, through the fall of 2017. We will not implement CQL until the development and testing phases show success for utilization with the CQMs. We are engaging the participation of hospitals and other providers, health IT developer, measure developer, and other stakeholder communities as we undertake this effort at all stages of development and testing. For further information, we refer readers to the eCQI Resource Center Web page (https://ecqi.healthit.gov/).

   b. CQM Reporting Period for the Medicare and Medicaid EHR Incentive Programs in CY 2017

   In the 2015 EHR Incentive Programs Final Rule (80 FR 62892 through 62893), beginning in CY 2017 and for subsequent years, we established a CQM reporting period of one full calendar year consisting of four quarterly data reporting periods) for CQM reporting for eligible hospitals and CAHs participating in the Medicare and Medicaid EHR Incentive Programs, with a limited exception for providers demonstrating meaningful use for the first time under the Medicare EHR Incentive Program, for whom the CQM reporting period is any continuous 90-day period within the calendar year. We believe that one full calendar year of data will result in more complete and accurate data. Providers will be able to submit one full calendar year of data for both the EHR Incentive Program and the Hospital IQR Program, thereby reducing the reporting burden. We continue to assess electronically submitted data for accuracy and reliability. If data are determined to be flawed, such data will be identified by CMS in order to preserve the integrity of data used for differentiating performance.

   We also established a reporting period for CQMs of any continuous 90-day period within CY 2017 for eligible hospitals and CAHs that are demonstrating meaningful use for the first time in either the Medicare or Medicaid EHR Incentive Programs (80 FR 62892 through 62893). In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25245 through 25246), we proposed the following submission periods for the Medicare EHR Incentive Program, as well as requirements for eligible...
hospitals and CAHs reporting CQMs electronically.

- Eligible hospitals and CAHs

Reporting CQMs by Attestation:

++ For eligible hospitals and CAHs demonstrating meaningful use for the first time in 2017, the reporting period is any continuous 90-day period within CY 2017. The submission period for attestation is the 2 months following the close of the calendar year, ending February 28, 2018.

++ For eligible hospitals and CAHs that demonstrated meaningful use in any year prior to 2017, the reporting period is the full CY 2017 (consisting of four quarterly data reporting periods). The submission period for attestation is the 2 months following the close of the calendar year, ending February 28, 2018.

- Eligible hospitals and CAHs Reporting CQMs Electronically: For eligible hospitals and CAHs demonstrating meaningful use for the first time in 2017 or that have demonstrated meaningful use in any year prior to 2017, the reporting period is the full CY 2017 (consisting of four quarterly data reporting periods). The submission period for reporting CQMs electronically is the 2 months following the close of the calendar year, ending February 28, 2018.

In regard to the Medicare EHR Incentive Program, we provide States with the flexibility to determine the submission periods for reporting CQMs. For the reporting period in CY 2017, we did not propose new CQMs. However, section 1886(n)(3)(B)(iii) of the Act requires that, in selecting measures for eligible hospitals and CAHs for the Medicare EHR Incentive Program, and establishing the form and manner for reporting measures, the Secretary shall seek to avoid redundant or duplicative reporting with reporting otherwise required, including reporting under section 1886(b)(3)(B)(viii) of the Act, the Hospital IQR Program. In the interest of avoiding redundant or duplicative reporting with the Hospital IQR Program, we proposed to remove 13 CQMs from the set of CQMs available for eligible hospitals and CAHs to report for the EHR Incentive Programs, beginning with the reporting periods in CY 2017. We proposed to remove such measures for both the Medicare and Medicaid EHR Incentive Programs.

We anticipate that this coordinated reduction in the overall number of CQMs reported electronically in both the Hospital IQR and the Medicare and Medicaid EHR Incentive Programs would reduce the burden associated with electronic reporting for hospitals and improve the quality of reported data by enabling hospitals to focus on a smaller, more specific subset of electronic CQMs. For the list of measures we proposed to remove from the Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs, as well as the rationale in support of our proposals to remove these measures, we refer readers to the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25175 through 25178). All of the remaining measures listed in Table 10 of the EHR Incentive Program Stage 2 final rule (77 FR 54083 through 54087) would be available for eligible hospitals and CAHs to report for the Medicare and Medicaid EHR Incentive Programs. From that available set of measures, we proposed the following reporting criteria for eligible hospitals and CAHs beginning with the reporting periods in CY 2017:

- For attestation: If only participating in the EHR Incentive Program, report on all 16 available CQMs.
- For electronic reporting—
  ++ If only participating in the EHR Incentive Program, report on 15 of the 16 available CQMs (among the 16 available CQMs, the Outpatient Quality Reporting (OQR) Program CQM (Emergency Department (ED)–3, NQF 0496) is not required to be reported on for electronic reporting, in which 15 of the 16 available CQMs can be selected to meet this reporting requirement); or
  ++ If participating in both the EHR Incentive Program and the Hospital IQR Program, report on all 15 available CQMs (the electronic reporting of the Outpatient Quality Reporting (OQR) Program CQM (ED–3, NQF 0496) is not applicable when reporting on CQMs for both programs, which results in the reporting of 15 available CQMs).

We also considered an alternative proposal to require eligible hospitals and CAHs to select and report electronically on 8 CQMs for the reporting periods in CY 2017 and all available CQMs beginning with the reporting periods in CY 2018, which was further outlined in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25195). We noted our intent is to align, to the extent possible, the EHR Incentive Program reporting requirements with the Hospital IQR Program reporting requirements established in this final rule. We believe that the alignment of these programs will serve to reduce hospital reporting burden and encourage the adoption and meaningful use of CEHRT by eligible hospitals and CAHs. We invited public comment on these proposals.

Commenters expressed concern that hospitals report a full year of CQM data because of the burden it would impose on hospitals. One commenter indicated that the increase would be four times greater than previous years and would cause increased difficulties for hospitals transitioning to a new EHR system. Some commenters expressed concern that the increase in the volume of information being reported might increase susceptibility to inaccurate data. Commenters noted that EHR vendors are still struggling to overcome the barriers encountered during the first year of CQM reporting because designing, building, reviewing, and testing that takes place between hospitals and vendors is extremely expensive and extensive. Commenters also expressed concern that this effort will take resources away from true quality improvement efforts. One commenter acknowledged that once a CQM is in place, it can continue to gather data beyond implementation, but expressed concern regarding the ability of EHR vendors and health care providers to have all CQMs in place by January 1, 2017. The commenter suggested that CMS continue the current reporting period of one of the two final quarters of the reporting year.

Several commenters specifically expressed concern that the time period between when the final rule is published and the beginning of the CY 2017 reporting period is too short to make the appropriate health IT and workflow adjustments to accommodate transmission of a full year of CQM data. One commenter noted that requiring hospitals to submit a full year of CQM data for the CY 2017 reporting period would require hospitals to begin data collection on a full year of data prior to completion of the first deadline to report only one quarter of data which is February 28, 2017. Another commenter questioned whether CMS has considered its ability to receive data submissions for hundreds of thousands of cases from hospitals within a two-month period (January 1 through the February 28).

A few commenters expressed concern with the proposals to align the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program because there are differences in the available and required number of CQMs for reporting between the Hospital IQR Program and the Medicare and Medicaid EHR Incentive Programs, particularly relating to the reporting of CQMs electronically (a full year) or by attestation (any continuous 90-day period) under the EHR Incentive Programs. One commenter encouraged CMS to change the CQM reporting period for both Hospital IQR Program and the Medicare
and Medicaid EHR Incentive Programs in CY 2017 to a 90-day period reflecting the proposed reporting period for attestation under the Medicare and Medicaid EHR Incentive Programs.

Response: We appreciate the commenters’ concerns that reporting a full year of CQM data may impose a greater burden on hospitals than reporting one quarter of CQM data, but in response to the commenter’s concern that the increase would be four times greater than previous years and would cause increased difficulties for hospitals transitioning to a new EHR system, we disagree. We believe that the burden associated with submitting a full year of CQM data will not be substantially greater than the burden associated with submitting a single quarter of data. Once CQMs are properly certified and mapped to successfully collect data for one quarter, collecting data for an additional 3 quarters should not require much additional burden. We believe that electronic reporting is an important step in the use of CEHRT, in which a full year reporting period that consists of data for four quarterly reporting periods is a critical component to making progress in electronic reporting.

In response to concerns about the challenges associated with submitting a full year of CQM data, we believe that accuracy will be improved over time by assessing an increased volume of CQM data. Through the assessment of more data, we are able to identify and address issues surrounding CQM data more quickly. We continue to assess electronically submitted data for accuracy and reliability. If data are determined to be flawed, such data will be identified by CMS in order to preserve the integrity of data used for differentiating performance. We believe that, with the advancement of technology and the use of electronic measures, even more precise, accurate, and reliable data will be captured for analysis.

We appreciate commenters sharing their concerns about the challenges associated with electronic reporting, including the significant expenditure of resources required to make necessary changes to health IT systems, documentation or utilization of EHRs, and workflow process changes. We encourage eligible hospitals and CAHs to continue refining their electronic reporting implementation activities to successfully achieve electronic data capture and reporting despite mapping and integration issues or to work with their vendors to do so. We acknowledge commenters’ concerns about the timing of the publication of the final rule in relation to the CY 2017 reporting period, and encourage early testing and the use of presubmission testing tools to reduce errors and inaccurate data submissions in CQM reporting. As time passes, we expect that hospitals will continue to build and refine their EHR systems and gain more familiarity with reporting CQM data, resulting in more accurate data submissions with fewer errors. We believe that the best way to encourage eligible hospitals and CAHs to invest in improving their EHR systems is by requiring reporting of additional CQMs.

In response to concerns regarding the ability of the our receiving systems to receive the significant volume of data submissions during the 2-month submission period, we have worked to continually develop and improve our CMS receiving system and are working to ensure that the infrastructure is in place to receive the full volume of CQM data submissions from eligible hospitals and CAHs by the February 28, 2018 deadline for the CY 2017 reporting period.

We disagree with commenters that a 90-day reporting period should apply for all eligible hospitals and CAHs, regardless of the reporting method (electronic reporting or attestation) or whether they have successfully demonstrated meaningful use in a prior year. While we are allowing a reporting period of any continuous 90-day period for eligible hospitals and CAHs that choose to report QRDA I files by attestation that demonstrate meaningful use for the first time in CY 2017, we believe a full-year reporting period (consisting of four quarterly data reporting periods) is appropriate for eligible hospitals and CAHs that have demonstrated meaningful use in a prior year, as well as for all eligible hospitals and CAHs that choose to report electronically regardless of whether they have previously demonstrated meaningful use.

Comment: As an alternative to the annual reporting of a full year of CQM data, a few commenters suggested that CMS require quarterly submission of the CQM data, with submission being required four-and-a-half months after the end of the reporting quarter to align the electronic submission requirements with the Hospital IQR Program chart-abstracted reporting requirements and with other quality reporting programs, such as the SNF Quality Reporting Program and meaningful use, to ensure sufficient time for providers to final-bill code all cases for a reporting quarter before being required to generate QRDA files for submission to CMS, and to alleviate pressure on providers, vendors, and the QualityNet team to put together and submit the required information for electronic CQM data submission. A few commenters noted that upgrading to a new edition of certified EHR technology during the same reporting period (CY 2017) that would require hospitals to report a full year of CQM data could pose additional implementation difficulties. One commenter expressed the opinion that quarterly reporting would reduce the volume of data that vendors and CMS must process at one time, give providers more frequent benchmarking of their performance on these measures, and make the timing of electronic reporting consistent with reporting of chart-abstracted measures.

Response: We thank commenters for their suggestions and acknowledge their concerns regarding a two-month timeframe allotted for submitting a full year of CQM data. We agree with commenters that there may be advantages with an extended submission period, therefore, in this final rule, we are finalizing a modification to the proposed submission period regarding the electronic reporting of CQMs. We anticipate that following the close of the CMS data receiving system for the CY 2016 reporting period, we will re-open the system in late spring 2017 to be able to receive both QRDA I test files and QRDA I production files for the CY 2017 reporting period (consisting of four quarterly reporting periods). We believe that a longer submission period will provide eligible hospitals and CAHs with the flexibility to submit a full year of CQM data quarterly, bi-annually, or annually. This greater flexibility will allow eligible hospitals, CAHs, and vendors to submit QRDA I files as soon as each calendar quarter ends, rather than waiting to submit all QRDA I files during the last two months of the submission period. We encourage all eligible hospitals, CAHs, and vendors to submit QRDA I files early, as well as to use one of the presubmission testing tools for electronic reporting, such as the CMS Pre-Submission Validation Application (PSVA), to allow additional time for testing and to make sure all required data files are successfully submitted by the deadline. The PSVA can be downloaded from the Secure File Transfer (SFT) section of the QualityNet Secure Portal at: https://cportal.qualitynet.org/QNet/pgm/select.jsp. We refer readers to section V.II.A.11.b.(4) of the preamble of this of the final rule for more information about the PSVA.
Comment: The majority of commenters supported the proposed removal of 13 CQMs from the EHR Incentive Programs beginning in CY 2017 in an effort to move quality measurement toward outcomes measures. Many commenters stated their belief that these measures were topped out, and that the measures’ complexity could not be captured in an electronic form. A number of commenters also stated their belief that the CQM measure specifications were not feasible to implement. Others noted removing these measures would decrease administrative burden, minimize confusion among providers and provide alignment among the Hospital IQR Program the EHR Incentive Programs.

Response: We thank the commenters for their support of our proposal to remove 13 CQMs in an effort to move quality measurement toward outcomes measures. Therefore, for the reasons stated in section VIII.A.3.b.(3) of the preamble of this final rule, we are finalizing our proposal to remove the 13 CQMs beginning with the reporting periods in CY 2017.

Comment: Several commenters supported CMS’ efforts to reduce reporting burden on hospitals, but expressed concern with the timeline of the proposal to remove 13 CQMs for CY 2017 because hospitals may need time to adjust workflows and work with health IT vendors to add support for measures not previously supported and ensure valid CQMs are submitted. Commenters encouraged CMS to consider the time, effort, and resources expended on reporting on these measures when deciding to remove them from the EHR Incentive Programs. One commenter noted that EHR vendors will phase out support for these measures and clinicians may become skeptical about benefits to workflow changes related to future measures if measures are continuously added and removed. Another commenter urged CMS to provide more lead time for the removal of measures that hospitals have dedicated so many resources to developing and implementing. Specifically, the commenter requested that for CY 2017, CMS maintain the current requirements of reporting four CQMs out of the current list of 28, in order to give hospitals more time to plan and prepare for implementation of additional CQMs in future years.

Response: We understand the commenters’ concern with removing CQMs that have been previously reported and implemented in an existing EHR workflow, and we acknowledge the time, effort, and resources that hospitals expend on reporting on these measures. However, our decision to remove measures from the EHR Incentive Program and the Hospital IQR Program is an extension of our programmatic goal to continually refine the measure set and ensure that it consists of quality performance standards. We believe that a reduction in the overall number of CQMs reduces certification burden on eligible hospitals and CAHs and improves the quality of reported data by enabling hospitals to focus on a smaller, more specific subset of CQMs.

We encourage eligible hospitals and CAHs that retain vendors to work closely together to ensure that a contract is in place which supports the hospital’s quality reporting requirements and the annual update of quality measures. Also, we encourage eligible hospitals and CAHs to continue refining their electronic reporting implementation activities to successfully achieve electronic data capture and reporting despite mapping and integration issues or to work with their vendors to do so. We encourage early testing and the use of presubmission testing tools to reduce errors and inaccurate data submissions in CQM reporting. We will work to provide hospitals with the education, tools, and resources necessary to enhance their workflows to more seamlessly account for the removal or addition of CQMs.

Comment: A few commenters suggested that topped-out measures should not be removed from the Medicare and Medicaid EHR Incentive Programs measure set. One commenter opposed the proposal to remove the CQMs that are topped out, stating that the measures should not be retired until the CQM reporting process has matured. The commenter further stated that allowing hospitals the option to electronically report topped-out measures would provide them with an opportunity to test the accuracy of their EHR reporting systems. Another commenter requested that any topped-out CQM that is removed from the EHR Incentive Programs be kept on reserve so that performance can be monitored as necessary to ensure that performance and/or adherence to best practices do not decline. In addition, the commenter suggested that an alternative use of topped-out measures is inclusion as components of composite measures. A commenter recommended that CMS implement a periodic auditing system of topped-out measures. Another commenter suggested that CMS maintain a library of measures that are not included in the program so that vendors and hospitals can still support monitoring and improving these removed measures.

Response: We disagree with commenters that the removal of these measures may hinder measurement and reduce performance improvement. Although eligible hospitals and CAHs are not reporting data for measures that have been removed from the Hospital IQR Program and EHR Incentive Programs, if the CQM specifications are maintained by the measure developer, eligible hospitals and CAHs are encouraged to continue to monitor data for their own efforts to improve quality. We appreciate the commenter’s suggestion to maintain a library of CQMs that have been removed and will take it into consideration.

Comment: Several commenters did not support the proposed requirement that hospitals report on all CQMs in the Medicare and Medicaid EHR Incentive Programs because of concerns about general feasibility, accuracy, validity, and reliability of electronically-submitted measures. Several commenters suggested that CMS consider amending the proposal to require an addition of 2 to 4 CQMs to the CY 2016 required number of CQMs, which would require the reporting a total of 6 to 8 CQMs for the CY 2017 reporting period. A few commenters suggested an incremental approach requiring only 8 CQMs for two quarters for the first increase. Other commenters requested that CMS retain the current requirement of 4 CQMs until hospitals...
have successfully operationalized reporting complete and accurate data on existing required CQMs before adding new measures. Commenters indicated that EHR vendors are not prepared for the functional and operational demands of an increase in CQM reporting. Further, commenters argued that requiring hospitals to collect electronic data for measures that still have flawed specifications and/or for services the hospitals do not provide is inefficient and burdensome. One commenter also noted that the CQM specifications have flaws that prove challenging with current clinical workflows, given how EHRs track orders and documentation and in some cases the measure specifications do not accurately measure the quality of care delivered, absent the development of manual workarounds that divert time and resources from patient care. These commenters recommended delaying any mandatory reporting of CQMs until these concerns are resolved.

Commenters also expressed concern that CQM data submission to CMS has not been fully tested at this point and recommended that expanding the required number of CQMs should be delayed until there has been successful transmission of data. Commenters noted that the infrastructure and reporting functionality for CQMs are not mature enough to facilitate mandatory electronic reporting for hospitals. Commenters recommended that CMS continue outreach to EHR vendors, hospital quality staff, and other affected stakeholders to identify and address structural problems prior to increasing the number of required CQMs.

Response: We believe that increasing the requirements for hospitals to report measures electronically is in line with our goals to make progress towards eventual electronic reporting on all CQMs in the Medicare and Medicaid EHR Incentive Programs. Retaining the reporting requirements from CY 2016 would not be in alignment with our goal to move toward the electronic reporting of all available CQMs. Eligible hospitals and CAHs have been engaged in the process of reporting CQM data electronically for the EHR Incentive Programs and Hospital IQR Program for several years (three years of pilot reporting and three years of voluntary reporting). However, we recognize the challenges associated with electronic reporting and encourage eligible hospitals and CAHs to continue refining their electronic reporting implementation activities and work with their vendors to achieve electronic capture and reporting despite mapping and integration issues. We encourage eligible hospitals and CAHs to work closely with their vendors to ensure that a contract is in place which supports the hospital’s quality reporting requirements and the annual update of those measures. Reliable, accurate data and the engagement of electronic reporting are critical to advancing our goal of increasing the electronic reporting of CQMs. We recognize the importance of having feasible and accurate measure data and in order to readily identify issues, we need to assess more data. We believe that, with the advancement of technology and the use of electronic measures, even more precise, accurate, and reliable data will be captured for analysis.

In response to the commenters’ concerns relating to vendors not being prepared for the functional and operational demands of an increase in CQM reporting, we note that CQM electronic specifications are posted at least 6 months prior to the start of the reporting period, and well in advance of the submission window. We believe this timeframe allows an adequate amount of time for vendors to make those updates while ensuring that the CQMs are still current and clinically valid once implemented.

We appreciate commenters sharing their concerns regarding flaws with measure specifications, the maturity of infrastructure and reporting functionality for CQMs, and CMS testing of CQM data submission. We note that measure specifications are updated regularly to account for changes, including, but not limited to, changes in billing and diagnosis codes and changes in medical practices. In order for CQMs to remain current and clinically valid, the specifications must be updated on a regular basis. We disagree with commenters that CQM reporting should be delayed until agreement is achieved regarding the maturity of CQM specifications. We believe that CQMs have matured since their inception, and any delay in the CQM reporting requirements would inhibit progress toward the eventual electronic reporting of all CQMs for the Medicare and Medicaid EHR Incentive Programs.

In this final rule, we are adopting a modification of our proposal and requiring the reporting of only 8 CQMs for eligible hospitals and CAHs that choose to report electronically, in response to commenters’ suggestion of incrementally increasing the reporting requirements. We believe that this modification balances the concerns raised by commenters while simultaneously advancing our goal of increased CQM electronic reporting. While the number of CQMs required to report increases from 4 CQMs (as established for the CY 2016 reporting period) to 8 CQMs for the CY 2017 reporting period, we believe that a coordinated reduction in the overall number of CQMs in both the Hospital IQR Program (from 28 to 15 available CQMs) and Medicare and Medicaid EHR Incentive Programs (from 29 to 16 available CQMs) will reduce certification burden on hospitals and improve the quality of reported data by enabling hospitals to focus on a smaller, more specific subset of CQMs. It is one of our goals to expand electronic reporting in the Medicare and Medicaid EHR Incentive Programs. We intend to introduce additional CQMs into the Medicare and Medicaid EHR Incentive Programs as CQMs that support the programs goals become available.

After consideration of the public comments we received, we are finalizing the following policies. We are finalizing a modification to our proposal regarding the number of CQMs required for eligible hospitals and CAHs that report electronically for the Medicare and Medicaid EHR Incentive Programs and will require reporting on 8 CQMs beginning with the CY 2017 reporting period, which eligible hospitals and CAHs may select from the set of available CQMs listed in the table below. We are finalizing as proposed the removal of 13 CQMs from the set of CQMs available for eligible hospitals and CAHs to report for the Medicare and Medicaid EHR Incentive Programs, beginning with the reporting periods in CY 2017. For the list of CQMs we are removing, we refer readers to section VIII.A.3.b.(3) of the preamble of this final rule. All 16 of the remaining measures listed in Table 10 of the EHR Incentive Program Stage 2 final rule (77 FR 54083 through 54087) are available for eligible hospitals and CAHs to report for the Medicare and Medicaid EHR Incentive Programs. The following table lists the remaining 16 CQMs available for eligible hospitals and CAHs to report for the Medicare and Medicaid EHR Incentive Programs beginning in CY 2017.
The CQM reporting periods in CY 2017 for the Medicare and Medicaid EHR Incentive Programs are set out below. For the Medicare EHR Incentive Program, we are finalizing the proposed submission periods for eligible hospitals and CAHs reporting CQMs by attestation and are finalizing with modification the proposed submission periods for eligible hospitals and CAHs electronically reporting CQMs. We are providing States with the flexibility to determine the submission periods for reporting CQMs for their Medicaid EHR Incentive Program.

- **Eligible hospitals and CAHs Reporting CQMs by Attestation:**
  - ++ For eligible hospitals and CAHs demonstrating meaningful use for the first time in 2017, the reporting period is any continuous 90-day period within CY 2017. The submission period for attestation is the 2 months following the close of the calendar year, ending February 28, 2018.
  - ++ For eligible hospitals and CAHs that demonstrated meaningful use in any year prior to 2017, the reporting period is the full CY 2017 (consisting of four quarterly data reporting periods). The submission period for attestation is the 2 months following the close of the calendar year, ending February 28, 2018.

- **Eligible hospitals and CAHs Reporting CQMs Electronically:**
  - For eligible hospitals and CAHs demonstrating meaningful use for the first time in 2017 or that have demonstrated meaningful use in any year prior to 2017, the reporting period is the full CY 2017 (consisting of four quarterly data reporting periods). The submission period for reporting CQMs electronically begins in late spring 2017 and continues through the 2 months following the close of the calendar year, ending February 28, 2018.

As we continue to align the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program, we are finalizing the same number of CQMs to be reported electronically for both programs. However, we are finalizing a policy under which eligible hospitals and CAHs reporting electronically will be required to report on 8 available CQMs. Thus, in this final rule, we are finalizing a modified version of our proposed reporting criteria regarding the number of CQMs eligible hospitals and CAHs are required to report electronically, starting with the reporting periods in CY 2017:

- **For attestation:** If only participating in the EHR Incentive Program, report on all 16 available CQMs.
  - For electronic reporting: If only participating in the EHR Incentive Program, or participating in both the EHR Incentive Program and the Hospital IQR Program, report on 8 of the available CQMs.

For CY 2018 and future calendar years, we plan to continue to align the CQM reporting requirements for the Medicare and Medicaid EHR Incentive Programs with the Hospital IQR Program reporting requirements established in this final rule and future rules.

### CQM Reporting Form and Method for the Medicare EHR Incentive Program in 2017

As finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49759 through 49760), we removed the QRDA–III as an option for reporting under the Medicare EHR Incentive Program for eligible hospitals and CAHs. For the reporting periods in 2016 and future years, we are requiring QRDA–I for CQM electronic submissions for the Medicare EHR Incentive Program. As noted in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49760), States would continue to have the option, subject to our prior approval, to allow or require QRDA–III for CQM reporting.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49578 through 49579), we established the following options for CQM submission for eligible hospitals and CAHs in the Medicare EHR Incentive Program for the reporting periods in 2017:

- Eligible hospital and CAH options for Medicare EHR Incentive Program participation (single program participation)—
  - ++ Option 1: Attest to CQMs through the EHR Registration & Attestation System; or
  - ++ Option 2: Electronically report CQMs through QualityNet Portal.
- Eligible hospital and CAH options for electronic reporting for multiple programs (for example, EHR Incentive Program plus Hospital IQR Program participation)—electronically report through QualityNet Portal.

As stated in the 2015 EHR Incentive Programs Final Rule (80 FR 62894), in 2017, eligible hospitals and CAHs have two options to report CQM data, either through attestation or use of established methods for electronic reporting where feasible. However, starting in 2018, eligible hospitals, and CAHs participating in the Medicare EHR Incentive Program must electronically report CQMs using CEHRT where feasible; and attestation to CQMs will no longer be an option except in certain

### Electronic Clinical Quality Measures (eCQMs)

<table>
<thead>
<tr>
<th>Short name</th>
<th>Measure name</th>
<th>NQF #</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI–8a</td>
<td>Primary PCI Received Within 90 Minutes of Hospital Arrival</td>
<td>0163</td>
</tr>
<tr>
<td>ED–3</td>
<td>Median Time from ED Arrival to ED Departure for Discharged ED Patients</td>
<td>0480</td>
</tr>
<tr>
<td>CAC–3</td>
<td>Home Management Plan of Care Document Given to Patient/Caregiver</td>
<td>1354</td>
</tr>
<tr>
<td>ED–1*</td>
<td>Median Time from ED Arrival to ED Departure for Admitted ED Patients</td>
<td>0495</td>
</tr>
<tr>
<td>ED–2*</td>
<td>Admit Decision Time to ED Departure Time for Admitted Patients</td>
<td>0497</td>
</tr>
<tr>
<td>EHD–1a</td>
<td>Hearing Screening Prior to Hospital Discharge</td>
<td>0469</td>
</tr>
<tr>
<td>PC–01</td>
<td>Elective Delivery (Collected in aggregate, submitted via Web-based tool or electronic clinical quality measure)</td>
<td>0439</td>
</tr>
<tr>
<td>PC–05</td>
<td>Exclusive Breast Milk Feeding</td>
<td>0438</td>
</tr>
<tr>
<td>STK–02</td>
<td>Discharged on Antithrombotic Therapy</td>
<td>0436</td>
</tr>
<tr>
<td>STK–03</td>
<td>Anticoagulation Therapy for Atrial Fibrillation/Flutter</td>
<td>0088</td>
</tr>
<tr>
<td>STK–05</td>
<td>Antithrombotic Therapy by the End of Hospital Day Two</td>
<td>0438</td>
</tr>
<tr>
<td>STK–06</td>
<td>Discharged on Statin Medication</td>
<td>0438</td>
</tr>
<tr>
<td>STK–08</td>
<td>Stroke Education</td>
<td>0441</td>
</tr>
<tr>
<td>STK–10</td>
<td>Assessed for Rehabilitation</td>
<td>0371</td>
</tr>
<tr>
<td>VTE–1a</td>
<td>Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
<tr>
<td>VTE–2</td>
<td>Intensive Care Unit Venous Thromboembolism Prophylaxis</td>
<td>0372</td>
</tr>
</tbody>
</table>

* NQF endorsement has been removed.
circumstances where electronic reporting is not feasible. Therefore, we encourage eligible hospitals and CAHs to begin electronically reporting CQMs as soon as feasible.

For the Medicaid EHR Incentive Program, States will continue to be responsible for determining whether and how electronic reporting of CQMs would occur, or if they wish to allow reporting through attestation. Any changes that States make to their CQM reporting methods must be submitted through the State Medicaid Health IT Plan (SMHIP) process for CMS review and approval prior to being implemented.

In the FY 2017 IPPS/LTC Program proposed rule (81 FR 25246 through 25247), we proposed to continue our policy that electronic submission of CQMs will require the use of the most recent version of the CQM electronic specification for each CQM to which the EHR is certified. In the event that an eligible hospital or CAH has certified EHR technology that is certified to the 2014 Edition and not certified to all 16 CQMs that would be available for reporting in 2017 under our proposals, we proposed to require that an eligible hospital or CAH would need to have its EHR technology certified to all such CQMs in order to meet the reporting requirements for 2017. For electronic reporting in 2017, this means eligible hospitals and CAHs would be required to use the Spring 2016 version of the CQM electronic specifications available on the eCQI Resource Center Web page (https://ecqi.healthit.gov/). We solicited public comment on this proposal.

Comment: One commenter expressed concern that the vendor community will not have adequate time to deliver the updated products to the market in time for all providers to meet the reporting requirements for CY 2107, which would require use of EHR technology certified to the 2015 Edition. The commenter explained that the proposed changes in CQM reporting necessitates sufficient time for vendors and providers to test and deploy CEHRT. The commenter acknowledged that measures need to evolve, but stated that a balance needs to be reached such that the churn around development and deployment is not endless. Therefore, the commenter urged CMS to make greater strides to enact a “predictable” cycle from measure development to provider data submission.

Response: We believe requiring use of the most recent version of the CQM electronic specification for each CQM is important in allowing us to collect relevant clinical and electronic data. We note that the commenter’s statement regarding the use of EHR technology certified to the 2015 Edition is not accurate and clarify that CMS proposed to accept the use of EHR technology certified to the 2014 or 2015 Edition for CQM reporting in 2017. We further note that, consistent with prior policy, a provider may continue to use their current certified health IT module for CQMs as an EHR certified for CQMs under the 2014 Edition certification criteria and it does not need to be recertified each time it is updated to a more recent version of the CQMs (80 FR 62889). With the continuing evolution of technology and clinical standards, as well as the need for a predictable cycle from measure development to provider data submission, on December 31, 2015, we published in the Federal Register (80 FR 81824 through 81828) a Request for Information: Certification Frequency and Requirements for the Reporting of Quality Measures Under CMS Programs. We requested comments on the establishment of an ongoing cycle for the introduction and certification of new measures, the testing of updated measures, and the testing and certification of submission capabilities in future rulemaking. We intend to address such policies in future rulemaking.

Comment: One commenter expressed concern that requiring electronic submission of CQM data using the most recent version of the CQM electronic specification for each CQM may create a disconnect in the timing cycle of the regulatory adoption of standards and the rapid evolution of electronic standards for CQM reporting. The commenter recommended that CMS and ONC collaborate to establish a regulatory framework that is more responsive to the speed at which standards are developed, maintained, upgraded and improved.

Response: We appreciate the commenter’s concerns about the quickly evolving electronic standards and the timing cycle for the regulatory adoption of standards; we will continue to collaborate with colleagues at ONC to ensure that our policies are responsive to evolving electronic standards to the greatest extent feasible.

Comment: Several commenters supported the proposals to align the CERHT requirements, measure set, and deadlines between the Medicare and Medicaid EHR Incentive Programs and the Hospital IQR Program because these proposals would decrease the burden on organizations who currently report for both programs.

Response: We thank the commenters for this support.

Comment: A few commenters supported the alignment of the reporting requirements for the EHR Incentive Programs and the Hospital IQR Program, which would reduce provider burden and minimize confusion about reporting criteria across various quality reporting programs. However, these commenters expressed concern about the expansion of CQMs with the current state of EHR technology. One commenter urged CMS, as part of its certification process, to seek stakeholder input and to define standards and structure for EHR vendors that allows documentation to fit into the clinical workflow and interact with providers at the point-of-contact to guide them to provide timely and appropriate care. One commenter urged CMS to utilize chart abstraction for quality reporting until the EHR transformation is made to allow clinicians to focus on delivering high quality patient focused care without the distraction of CQM reporting using an EHR structure that has yet to evolve to support true meaningful use.

Response: We thank the commenters for this support. We will continue to seek stakeholder input to define standards and structure for EHR vendors that allows documentation to fit into the clinical workflow and interact with providers at the point-of-contact to guide them to provide timely and appropriate care. We appreciate the commenter’s recommendation to utilize chart abstraction for quality reporting until EHR systems are more mature. However, when eligible hospitals and CAHs work with their vendors to ensure that EHRs are appropriately structured in a way that fits in with the clinical workflow to yield reliable data through electronic CQMs, we believe that electronic CQMs promote high quality outcomes, lower costs, and ultimately decrease reporting burden on hospitals as compared with chart-abstracted CQMs.

After consideration of the public comments we received, we are finalizing our proposal to continue the policy that electronic submission of CQMs will require the use of the most recent version of the CQM electronic specification for each CQM to which the EHR is certified. In the event that an eligible hospital or CAH has certified EHR technology that is certified to the 2014 Edition and not certified to the 16 available CQMs (as established in this final rule) that would be available for reporting in 2017 under our finalized policies, we are finalizing our proposal that requires an eligible hospital or CAH to have its EHR technology certified to such CQMs in order to meet the reporting requirements for 2017.
As noted in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49759), an EHR certified for CQMs under the 2014 Edition certification criteria does not need to be recertified each time it is updated to a more recent version of the CQMs. We proposed to accept the use of EHR technology certified to the 2014 or 2015 Edition for CQM reporting in 2017. Certification to the 2015 Edition is expected to be available beginning in 2016. (For further information on CQM reporting, we refer readers to the EHR Incentive Program Web site where guides and tip sheets are available for each reporting option (http://www.cms.gov/ehrincentiveprograms/).)

As noted in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49759), we encourage health IT developers to test any updates, including any updates to the CQMs and CMS reporting requirements based on the CMS Implementation Guide for Quality Reporting Document Architecture (QRDA) Category I and Category III (CMS Implementation Guide for QRDA) for Eligible Professional Programs and Hospital Quality Reporting (HQR), on an annual basis.

The form and method of electronic submission are further explained in subregulatory guidance and the certification process. For example, the following documents are updated annually to reflect the most recent CQM electronic specifications: The CMS Implementation Guide for QRDA; program specific performance calculation guidance; and CQM electronic specifications and guidance documents. These documents are located on the eCQI Resource Center Web page: (https://ecqi.healthit.gov/).

We invited public comments on these proposals. We did not receive comments on our proposed policy. Therefore, we are finalizing our proposal to accept the use of EHR technology certified to the 2014 or 2015 Edition for CQM reporting in 2017.

IX. MedPAC Recommendations

Under section 1886(e)[4][B] of the Act, the Secretary must consider MedPAC’s recommendations regarding hospital inpatient payments. Under section 1886(e)[5] of the Act, the Secretary must publish in the annual proposed and final IPPS rules the Secretary’s recommendations regarding MedPAC’s recommendations. We have reviewed MedPAC’s March 2016 “Report to the Congress: Medicare Payment Policy” and have given the recommendations in the report consideration in conjunction with the policies set forth in this final rule.

MedPAC recommendations for the IPPS for FY 2017 are addressed in Appendix B to this final rule.

For further information relating specifically to the MedPAC reports or to obtain a copy of the reports, contact MedPAC at (202) 653–7226, or visit MedPAC’s Web site at: http://www.medpac.gov.

X. Other Required Information

A. Requests for Data From the Public

In order to respond promptly to public requests for data related to the prospective payment system, we have established a process under which commenters can gain access to raw data on an expedited basis. Generally, the data are now available on compact disc (CD) format. However, many of the files are available on the Internet at: http://www.cms.hhs.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. We listed the data files and the cost for each file, if applicable, in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25247 through 25249).

Commenters interested in discussing any data files used in construction of this final rule should contact Michael Treitel at (410) 766–4552.

B. Collection of Information Requirements

1. Statutory Requirement for Solicitation of Comments

Under the Paperwork Reduction Act of 1995, we are required to provide 60-day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25249 through 25257), we solicited public comment on each of these issues for the following sections of this document that contain information collection requirements (ICRs) (except for the ICRs addressed under section X.B.5. of the preamble of this final rule).

2. ICRs for Add-On Payments for New Services and Technologies

Section II.H.1. of the preamble of the proposed rule (81 FR 25031 through 25033) and this final rule discuss add-on payments for new services and technologies. Specifically, this section states that applicants for add-on payments for new medical services or technologies for FY 2018 must submit a formal request. A formal request includes a full description of the clinical applications of the medical service or technology and the results of any clinical evaluations demonstrating that the new medical service or technology represents a substantial clinical improvement. In addition, the request must contain a significant sample of the data to demonstrate that the medical service or technology meets the high-cost threshold.

We believe the burden associated with this requirement is exempt from the PRA under 5 CFR 1320.3(c), which defines the agency collection of information subject to the requirements of the PRA as information collection imposed on 10 or more persons within any 12-month period. This information collection does not impact 10 or more entities in a 12-month period. For FYs 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, and 2017, we received 1, 4, 5, 3, 3, 5, 5, 7, 9, and 9 applications, respectively. (We note that 2 applications received for FY 2017 that were discussed in the proposed rule are not addressed in this final rule because the technology did not receive FDA approval by July 2016.)

We did not receive any public comments regarding this information collection.

3. ICRs for the Occupational Mix Adjustment to the FY 2017 Wage Index (Hospital Wage Index Occupational Mix Survey)

Section III.E. of the preamble of the proposed rule (81 FR 25064 through 25065) and this final rule discuss the occupational mix adjustment to the proposed and final FY 2017 wage index. While the preamble does not contain any new ICRs, we note that there is an OMB approved information collection request associated with the hospital wage index.

Section 304(c) of Public Law 106–554 amended section 1886(d)(3)(E) of the Act to require us to collect data at least once every 3 years on the occupational mix of employees for each short-term, acute care hospital participating in the Medicare program in order to construct
an occupational mix adjustment to the wage index. We collect the data via the occupational mix survey.

The burden associated with this information collection requirement is the time and effort required to collect and submit the data in the Hospital Wage Index Occupational Mix Survey to CMS. The aforementioned burden is subject to the PRA; it is currently approved under OMB control number 0938–0977.

We did not receive any public comments regarding this information collection.

4. Hospital Applications for Geographic Reclassifications by the MGCRB

Section III.J.3. of the preambles of the proposed rule (81 FR 25069) and this final rule discuss changes to the proposed and final wage index based on hospital reclassifications. As stated in that section, under section 1886(d)(10) of the Act, the MGCRB has the authority to accept short-term IPPS hospital applications requesting geographic reclassification for wage index and to issue decisions on these requests for hospitals for geographic reclassification for purposes of payment under the IPPS.

The burden associated with this application process is the time and effort necessary for an IPPS hospital to complete and submit an application for reclassification to the MGCRB. The burden associated with this requirement is subject to the PRA. It is currently approved under OMB control number 0938–0573.

We did not receive any public comments regarding this information collection.

5. ICRs for Application for GME Resident Slots

The information collection requirements associated with the preservation of resident cap positions from closed hospitals, addressed under section IV.J.3. of the preamble of this final rule, are not subject to the Paperwork Reduction Act, as stated in section 5506 of the Affordable Care Act.

6. ICRs for the Notice of Observation Treatment by Hospitals and CAHs

In section IV.L. of the preambles of the proposed rule (81 FR 25131 through 25134) and this final rule, we discuss our implementation of the NOTICE Act (Pub. L. 114–42), which amended section 1866(a)(1) of the Act to require hospitals and CAHs to provide written and oral notification to Medicare beneficiaries receiving observation services as outpatients for more than 24 hours. We have developed a standardized format for the notice (the MOON), which will be disseminated during the normal course of related business activities. The standardized notice discussed in this final rule is simultaneously being subject to public review and comment through the Office of Management and Budget (OMB) Paperwork Reduction Act process before implementation under OMB control number 0938–new.

In the proposed rule, we estimated that it would take hospitals and CAHs 5 minutes (0.0833 hour) to complete and deliver each notice. We estimated an annual cost burden of $5,461,430 or approximately $889.19 per hospital or CAH.

Comment: A number of commenters suggested that CMS had underestimated the burden. Some commenters believed that the estimates did not account fully for the costs that hospitals and CAHs will incur for business functions such as system programming, creating internal operating procedures, scanning, and translation. One commenter suggested that CMS break out the burden separately for CAHs and non-CAHs. One commenter was concerned that the burden on smaller, rural hospitals would be particularly large. One commenter recommended that the estimated delivery time should be increased.

Response: We believe the burden estimate in the proposed rule appropriately took into account the time to gather and enter the necessary data and information (including the information to be inserted into the free-text fields), review the instructions, complete and review necessary responses, and deliver the notice to the beneficiary. The burden estimates were not intended to include time spent on customary and usual business practices. We did not break out the impact on CAHs and non-CAHs separately, as we anticipate a general, comparable burden on CAHs and hospitals.

As discussed below, we have reassessed our proposed burden estimate and for this final rule and we have increased the estimated time for hospitals to prepare and deliver the MOON from 5 minutes to 15 minutes. This increase addresses the public comments received on the proposed rule related to the burden specific to the requirements for delivery of the MOON; for example, the population of a free text field on the MOON to indicate why a beneficiary is receiving outpatient observation services. We believe the increase from 5 minutes to 15 minutes adequately accounts for additional time spent complying with the MOON delivery requirements.

For this final rule, we estimate that it will take hospitals and CAHs 15 minutes (0.25 hour) to complete and deliver each notice. In 2014, there were approximately 1,399,999 claims for Medicare outpatient observation services lasting greater than 24 hours furnished by 6,142 hospitals and CAHs.393 The annual hour burden is estimated to be 350,000 (1,399,999 responses × 0.25 hour). To derive average cost, we used data from the U.S. Bureau of Labor Statistics’ May 2014 National Occupational Employment and Wage Estimates for all salary estimates (http://www.bls.gov/oes/current/oes_ nat.htm). In this regard, we used the mean hourly wage of $33.55 and the cost of fringe benefits, $33.55 (calculated at 100 percent of salary), to determine an adjusted hourly wage of $67.10. This is necessarily a rough adjustment because fringe benefits and overhead costs vary significantly from employer to employer, methods of estimating these costs vary widely from study to study, and hospitals vary widely both in terms of size and geographic location. Nonetheless, there is no practical alternative and we believe that doubling the hourly wage to estimate total cost is a reasonable accurate estimation method. The cost per response is approximately $16.78 based on an hourly salary rate of $67.10 and the 15-minute response estimate. By multiplying the annual responses by $16.78, the annual cost burden estimate is $23,491,983 (1,399,999 responses × $16.78) or approximately $3,824.81 per hospital or CAH ($23,491,983/6,142).

7. ICRs for the Hospital Inpatient Quality Reporting (IQR) Program

The Hospital IQR Program (formerly referred to as the Reporting Hospital Quality Data for Annual Payment (RHQDAPU) Program) was originally established to implement section 501(b) of the MMA, Public Law 108–173. This program expanded our voluntary Hospital Quality Initiative. The Hospital IQR Program originally consisted of a “starter set” of 10 quality measures. The collection of information associated with the original starter set of quality measures was previously approved under OMB control number 0938–0918. All of the information collection requirements previously approved under OMB control number 0938–0918 have been combined with the information collection request currently approved under OMB control number 0938–1022. We no longer use OMB control number 0938–0918.

393 Source: CMS Office of Enterprise and Data Analytics.
We added additional quality measures to the Hospital IQR Program and submitted the information collection request to OMB for approval. This expansion of the Hospital IQR Program measures was part of our implementation of section 5001(a) of the Deficit Reduction Act of 2005 (DRA). Section 1886(b)(3)(B)(viii)(III) of the Act, added by section 5001(a) of the DRA, requires that the Secretary expand the “starter set” of 10 quality measures that were established by the Secretary as of November 1, 2003, to include measures “that the Secretary determines to be appropriate for the measurement of the quality of care furnished by hospitals in inpatient settings.” The burden associated with these reporting requirements is currently approved under OMB control number 0938–1022.

In section VII.A.3.b. of the preamble of this final rule, we are finalizing our proposal to remove 13 eCQM versions of measures, 2 “topped-out” chart-abstracted measures, and 2 structural measures, beginning with the FY 2019 payment determination. However, we note that the total number of measures removed is 15 because the STK–4 and VTE–5 measures were removed twice—one in the chart-abstracted form and again in electronic form.

The 13 eCQM versions of measures we are removing are: (1) AMI–2: Aspirin Prescribed at Discharge for AMI (NQF #0142); (2) AMI–7a: Fibrinolytic Therapy Received Within 30 minutes of Hospital Arrival; (3) AMI–10: Statin Prescribed at Discharge; (4) HTN: Hypertension Control (NQF #0716); (5) PN–6: Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients (NQF #0147); (6) SCIP–Inf–1a: Prophylactic Antibiotic Received within 1 Hour Prior to Surgical Incision (NQF #0527); (7) SCIP–Inf–2a: Prophylactic Antibiotic Selection for Surgical Patients (NQF #0528); (8) SCIP–Inf–9: Urinary Catheter Removed on Postoperative Day 1 (POD1) or Postoperative Day 2 (POD2) with Day of Surgery Being Day Zero; (9) STK–4: Thrombolytic Therapy (NQF #0437); (10) VTE–3: Venous Thromboembolism Patients with Anticoagulation Overlap Therapy (NQF #0373); (11) VTE–4: Venous Thromboembolism Patients Receiving Unfractionated Heparin (UFH) with Dosages/Platelet Count Monitoring by Protocol (or Nomogram); (12) VTE–5: Venous Thromboembolism Discharge Instructions; and (13) VTE–6: Incidence of Potentially Preventable Venous Thromboembolism. The two chart-abstracted measures we are removing are: (1) STK–4: Thrombolytic Therapy (NQF #0437); and (2) VTE–5: Venous Thromboembolism Discharge Instructions. The two structural measures we are removing are: (1) Participation in a Systematic Clinical Database Registry for Nursing Sensitive Care; and (2) Participation in a Systematic Clinical Database Registry for General Surgery.

We believe that removing 13 eCQMS will reduce burden for hospitals, as they will have a smaller number of eCQMs from which to select. As finalized in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49698), hospitals are required to select 4 out of 28 available eCQMs on which to report data beginning with the FY 2018 payment determination. As discussed below, in this rule, we are not finalizing our proposal that hospitals must report on all of the available eCQMs in the Hospital IQR Program. Instead, we are finalizing a modified version of our proposal and requesting that, for the CY 2017 reporting period/FY 2019 payment determination and CY 2018 reporting period/FY 2020 payment determination, hospitals must report on 8 of the available eCQMs in the Hospital IQR Program. Because 13 eCQMs are being removed from a pool of 28 eCQMs, hospitals will then have a total pool of only 15 eCQMs to choose from, which will decrease the burden associated with selecting and reporting data. However, because we are now requiring hospitals to submit data on 8 of the available eCQMs included in the Hospital IQR Program measure set, the modest reduction in burden associated with the decreased number of eCQMs from which hospitals may choose, will be offset by the increased burden associated with submitting data on 8 eCQMs instead of 4 eCQMs. We discuss the burden associated with our finalized proposal to require the submission of 8 of the available eCQMs included in the Hospital IQR Program measure set below.

We also believe that there will be a reduction in burden for hospitals as a result of the removal of the two chart-abstracted measures listed above (STK–4 and VTE–5). Due to the burden associated with the collection of chart-abstracted data (based on updated measure record abstraction time estimates from the third quarter in 2014 through the second quarter in 2015, the number of reporting periods in a calendar year, and the number of IPPS hospitals reporting), we estimate that the removal of STK–4 will result in a burden reduction of approximately 303,534 hours and approximately $9.9 million across all 3,300 IPPS hospitals participating in the Hospital IQR Program for the FY 2019 payment determination. More specifically, for both the STK and VTE measure sets, we calculated the hours of burden by taking the difference in the burden estimates from this FY 2017 IPPS/LTCH PPS final rule and the burden estimates from the FY 2016 IPPS/LTCH PPS final rule. With regard to STK–4, because it is the only STK measure left in the Hospital IQR Program, and in this FY 2017 IPPS/LTCH PPS final rule, we are finalizing our proposal to remove it, we calculated the total burden hours as follows: 0 hours (time required to report in CY 2017) – 303,534 hours (time required to report in CY 2016) = −303,534 hours for the STK measure set. With regard to the VTE measure set, we used an updated estimate (based on data from the third quarter of 2014 through second quarter of 2015), that the time per record (that is, to report all 4 of the VTE measures in the Hospital IQR Program during the noted time period) is 28 minutes; thus, we estimate a burden reduction of 7 minutes for removing 1 VTE measure. Based on this estimate, we deducted 21 minutes from the 28-minute estimate to account for the removal of VTE–1, VTE–2, and VTE–3 in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49645) and subsequent removal of VTE–5 in this final rule, for a total of 7 minutes to report on the one remaining VTE chart-abstracted measure in the Hospital IQR Program. We then calculated the estimated total hours of burden per hospital for reporting the remaining VTE measure as follows: 7 minutes per record/60 minutes per hour × 4 reporting quarters per year × 198.05 records per hospital per quarter = 23,076 burden hours per hospital. Because there are 3,300 IPPS hospitals, we then multiplied 92 hours per hospital × 3,300 hospitals to get a total annual burden estimate of 304,997 hours to report the 1 remaining measure in the VTE measure set. The reduction in the total burden hours for VTE from this FY 2017 IPPS/LTCH PPS final rule and the FY 2016 IPPS/LTCH PPS final rule, is calculated as follows: 304,997 (FY 2017 total annual estimate) – 1,742,840 (FY 2016 total annual estimate) = −1,437,843 hours for the VTE measure set. We note that this burden estimate is revised based on the updated estimates mentioned above, and is different from what we stated in the proposed rule (81 FR 25251). In the FY
2017 IPPS/LTCI PPS proposed rule, we used the incorrect time estimate (3 minutes) associated with the removal of one VTE measure. We believe that there will be a negligible burden reduction due to the removal of two structural measures. Consistent with previous years (80 FR 49762), we estimate a burden of 15 minutes per hospital to report all four previously finalized structural measures and to complete other forms (such as the Extraordinary Circumstances Extension/Exemption Request Form). Therefore, our burden estimate of 15 minutes per hospital remains unchanged because we believe the reduction in burden associated with removing these two structural measures will be sufficiently minimal that it will not substantially impact this estimate.

In addition, in section VIII.A.6. of the preamble of this final rule, we discuss refinements to two previously adopted measures beginning with the FY 2018 payment determination: (1) Expanding the cohort for the Hospital-Level, Risk-standardized Payment Associated with a 30-Day Episode-of-Care for Pneumonia (NQF #2579); and (2) adopting the modified Patient Safety and Adverse Events Composite (NQF #0531). Because these claims-based measures can be calculated based on data that are already reported to the Medicare program for payment purposes, we believe no additional burden on hospitals will result from the refinements to these two claims-based measures.

Also, in section VIII.A.7. of the preamble of this final rule, we discuss our adoption of four claims-based measures to the Hospital IQR Program measure set beginning with the FY 2019 payment determination: (1) Aortic Aneurysm Procedure Clinical Episode-Based Payment Measure; (2) Cholecystectomy and Common Duct Exploration Clinical Episode-Based Payment Measure; (3) Spinal Fusion Clinical Episode-Based Payment Measure; and (4) Excess Days in Acute Care after Hospitalization for Pneumonia. Because these claims-based measures can be calculated based on data that are already reported to the Medicare program for payment purposes, we believe no additional burden on hospitals will result from the addition of these four claims-based measures.

For the FY 2019 payment determination and the FY 2020 payment determination, in section VIII.A.8. of the preamble of this final rule, we are requiring hospitals to submit data for 8 of the 16 eCQMs included in the Hospital IQR Program measure set in a manner that will permit eligible hospitals to align Hospital IQR Program requirements with some requirements under the Medicare and Medicaid EHR Incentive Programs. This is a modification from our proposal, which was to require all available eCQMs in the Hospital IQR Program measure set. Specifically, hospitals will be required to submit a full calendar year of data on 8 of the 15 eCQMs in the Hospital IQR Program measure set, on an annual basis, for the CY 2017 reporting period/FY 2018 payment determination and the CY 2018 reporting period/FY 2019 payment determination. We believe that the burden associated with submitting a full year of eCQM data will not be substantially greater than the burden associated with transmission of a single quarter of data. As described in section VII.A.10.d of the preamble of this final rule, the CMS data receiving system requires that each QRDA I file include data for one patient, per quarter, per reporting CCN. Once hospitals establish their protocols to ensure this is maintained, hospitals and vendors should not experience much added burden reporting an additional 3 quarters of data. However, in our conservative estimates here, we calculate as if burden is four times as much in an abundance of caution.

We believe that the total burden associated with the eCQM reporting policy will be similar to that previously outlined in the Medicare EHR Incentive Program Stage 2 final rule (77 FR 54126 through 54133). In that final rule, the burden estimate for a hospital to report all 16 eCQMs is 2 hours and 40 minutes (160 total minutes or 10 minutes per measure) per submission for a 3-month period (77 FR 54127). We believe that this estimate is accurate and appropriate to apply to the Hospital IQR Program because we are aligning the eCQM reporting requirements between both programs. Therefore, using the estimate of 10 minutes per measure, we anticipate that our finalized policies to require: (1) Reporting on 8 of the available eCQMs (8 eCQMs for the CY 2017 reporting period/FY 2018 payment determination); and (2) submission of one year of eCQM data (covering Q1, Q2, Q3, and Q4), will result in a burden of 80 minutes per quarter per hospital to report one medical record containing information on all the required eCQMs. In total, for the FY 2019 payment determination, we expect our policy to require hospitals to report data on 8 eCQMs for 4 quarters (as compared to our previously finalized requirement to report data on 4 eCQMs for 1 quarter) to represent a burden increase of 15,400 hours across all 3,300 IPPS hospitals participating in the Hospital IQR Program. This figure was derived by calculating the difference between the FY 2017 burden estimate of 17,600 hours (80 minutes per record/60 minutes per hour × 4 reporting quarters per year × 1 record per hospital per quarter × 3,300 hospitals) and the FY 2016 burden estimate of 2,200 hours (20 minutes per record/60 minutes per hour × 1 reporting quarter per year × 1 record per hospital per quarter × 3,300 hospitals) (80 FR 49763), for an incremental increase of 15,400 hours.

Furthermore, we estimate that reporting these eCQMs can be accomplished by staff with a mean hourly wage of $16.42 per hour.394 However, obtaining data on other overhead costs is challenging. Overhead costs vary greatly across industries and firm sizes. In addition, the precise cost elements assigned as “indirect” or “overhead” costs, as opposed to direct costs or employee wages, are subject to some interpretation at the firm level. Therefore, we have chosen to calculate the cost of overhead at 100 percent of the mean hourly wage. This is necessarily a rough adjustment, both because fringe benefits and overhead costs vary significantly from employer to employer and because methods of estimating these costs vary widely from study to study. Nonetheless, there is no practical alternative, and we believe that doubling the hourly wage to estimate total cost is a reasonably accurate estimation method. This is a change from how we have accounted for the cost of overhead in our previous rules regarding the Hospital IQR Program. In calculating labor cost, we estimate an hourly labor cost of $32.84 ($16.42 base salary + $16.42 fringe) and a cost increase of $505,736 (15,400 additional burden hours × $32.84 per hour) across approximately 3,300 hospitals participating in the Hospital IQR Program to report a full calendar year of data for 8 eCQMs, on an annual basis.

We did not propose any changes to our validation requirements related to chart-abstracted measures, but provided some background in our previous rules for our eCQM validation proposals. As noted in the FY 2016 IPPS/LTCI IPPS final rule (80 FR 49762 and 49763), for validation of chart-abstracted data for the FY 2018 payment determination and subsequent years, we require hospitals to provide 72 charts per hospital per year (with an average page length of 1,500), including 40 charts for HAI validation and 32 charts for clinical process of care validation, for a total of

This estimate excludes the burden associated with the NHSN and HCAHPS measures, both of which are submitted under separate information collection requests and are approved under OMB control numbers 0920–0666 and 0938–0981, respectively. The burden estimates in this final rule are the estimates for which we are requesting OMB approval.

We received the following public comments regarding our burden estimates.

*Comment: Some commenters expressed concern about the amount of change required for documenting new measures, which creates challenges in accurately reflecting patient severity of illness. As an example, one commenter noted that last year’s severe sepsis and septic shock measure (SEP–1) introduced requirements for documentation that have not been easily implemented. Therefore, this commenter indicated that the value of very specific documentation has to be weighed against the value for patient care that it brings. Likewise, other commenters expressed concern regarding the number of measures required by Medicare hospital performance and reporting programs.

<table>
<thead>
<tr>
<th>Activity</th>
<th>Estimated time per record (minutes) FY 2017</th>
<th>Number reporting quarters per year FY 2017</th>
<th>Number of hospitals reporting</th>
<th>Average number records per hospital per quarter</th>
<th>Annual burden (hours) per hospital</th>
<th>Annual burden (hours) across hospitals FY 2017</th>
<th>Net difference in annual burden hours (FY 2017–FY 2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Removal of Stroke (STK–4) measure.....</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removal of Venous thromboembolism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(VTE–5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reporting on 8 electronic Clinical Quality Measures</td>
<td>80</td>
<td>80</td>
<td>3,300</td>
<td>1</td>
<td>5.33</td>
<td>17,600</td>
<td>15,400</td>
</tr>
<tr>
<td>eCQM Validation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total Change in Burden Hours: \(-1,717,444\).

Total Cost Estimate: Hourly Wage (\$32.84) \times Change in Burden Hours (\(-1,717,444\)) = \(-56,400,861\).

---

and the burden associated with reporting, monitoring, and transmitting data for these quality measures. These commenters cited the Institute of Medicine (IOM)’s April 2015 Vital Signs report on Core Metrics for Health and Health Care Progress and recommended that CMS adopt the IOM 15 core measure areas, along with 39 additional priority measures, in which to provide benchmarks and improve overall health system performance, which, they argue, would reduce overall measure burden across all programs by creating a streamlined measure set that provides the most value for patients and providers.

Response: We understand that many of the requirements of the Hospital IQR Program increase the reporting burden on hospitals, and, before proposing any measure, we critically weigh this burden against the benefit we believe will be achieved in the improvement of quality of care. We also note that, this year, every new measure we propose is claims-based; claims-based measures do not require additional documentation from providers. Thus, there should be no increase in burden based on new measures in this final rule. As we move forward, we will continue to consider the number of measures in this and other programs and consider the aggregate effect of reporting.

8. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

As discussed in sections VIII.B. of the preambles of the proposed rule (81 FR 25205 through 25213) and this final rule, section 1866(k)(1) of the Act requires, for purposes of FY 2014 and each subsequent fiscal year, that a hospital described in section 1866(d)(1)(B)(v) of the Act (a PPS-exempt cancer hospital, or a PCH) submit data in accordance with section 1866(k)(2) of the Act with respect to such fiscal year.

We refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 28124), the FY 2014 IPPS/LTCH PPS final rule (78 FR 50957 through 50959), the FY 2015 IPPS/LTCH PPS final rule (79 FR 50347 through 50348), and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49764) for a detailed discussion of the burden for the program requirements that we have previously adopted. Below we discuss only any changes in burden that will result from the proposals we are finalizing in this final rule.

In section VIII.B.3.b. of the preamble of this final rule, we are finalizing our proposal that PCHs submit data on the Oncology: Radiation Dose Limits to Normal Tissues (NQF #0382) measure for an expanded cohort of patients. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 50285) we finalized a sampling methodology for Clinical Process/Oncology Care Measures, which includes the Oncology: Radiation Dose Limits to Normal Tissues measure. Because our previous burden estimates were based on the maximum sample of 25 patients for this measure, the expansion of the patient cohort will increase the pool of patients from which the sample can be drawn but will not raise the burden for this measure beyond that which we described in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50347 through 50348).

In section VIII.B.4.b. of the preamble of this final rule, we are finalizing our proposal to adopt the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure beginning with the FY 2019 program year. This is a claims-based measure, and therefore, does not require PCHs to submit any new data. Thus, this measure will not pose any new burden on PCHs.

In summary, as a result of our finalized policies, we do not anticipate any changes to previously finalized burden estimates.

9. ICRs for the Hospital Value-Based Purchasing (VBP) Program

In section IV.H. of the preambles of the proposed rule (81 FR 25099 through 25177) and this final rule, we discuss requirements for the Hospital VBP Program. Specifically, in this final rule, with respect to quality measures, we are finalizing our proposals to: include selected ward non-Intensive Care Unit (ICU) locations in certain NHSN measures beginning with the FY 2019 program year; adopt the Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Acute Myocardial Infarction (AMI) and the Hospital-Level, Risk-Standardized Payment Associated with a 30-Day Episode-of-Care for Heart Failure (HF) measures beginning with the FY 2021 program year; update the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Pneumonia (PN) Hospitalization (Updated Cohort) measure beginning with the FY 2021 program year; and adopt the Hospital 30-Day, All-Cause, Risk-Standardized Mortality Rate (RSMR) Following Coronary Artery Bypass Graft (CABG) Surgery measure beginning with the FY 2022 program year.

As required under section 1886(o)(2)(A) of the Act, the additional and updated measures are required for the Hospital IQR Program. Therefore, their inclusion in the Hospital VBP Program does not result in any additional burden because the Hospital VBP Program uses data that are required for the Hospital IQR Program. Therefore, the burden associated with these reporting requirements is currently approved under OMB control number 0938–1022.

10. ICRs for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP)

As discussed in section VIIIC.5 of the preambles of the proposed rule (81 FR 25214 through 25215) and this final rule, we are retaining the following 13 previously finalized quality measures for use in the LTCH QRP:

### LTCH QRP Quality Measures Previously Adopted for the FY 2014 Payment Determinations and Subsequent Years

<table>
<thead>
<tr>
<th>Measure title</th>
<th>IPPS/LTCH PPS Final rule</th>
<th>Annual payment determination: Initial and subsequent APU years</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (NQF #0138).</td>
<td>Adopted an application of the measure in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51745 through 51747); Adopted the NQF endorsed version and expanded measure (with standardized infection ratio [SIR]) in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53616 through 53619).</td>
<td>FY 2014 payment determination and subsequent years.</td>
</tr>
</tbody>
</table>
### LTCH QRP Quality Measures Previously Adopted for the FY 2014 Payment Determinations and Subsequent Years—Continued

<table>
<thead>
<tr>
<th>Measure title</th>
<th>IPPS/LTC PPS Final rule</th>
<th>Annual payment determination: Initial and subsequent APU years</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Healthcare Safety Network (NHSN) Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (NQF #0139).</td>
<td>Adopted an application of the measure in the FY 2012 IPPS/LTC PPS final rule (76 FR 51747 through 51748); Adopted the NQF endorsed and expanded measure (with SIR) in the FY 2013 IPPS/LTC PPS final rule (77 FR 53616 through 53619).</td>
<td>FY 2014 payment determination and subsequent years.</td>
</tr>
<tr>
<td>Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678).</td>
<td>Adopted an application of the measure in the FY 2012 IPPS/LTC PPS final rule (76 FR 51748 through 51750); Adopted the NQF endorsed version in the FY 2014 IPPS/LTC PPS final rule (78 FR 50861 through 50863); Adopted in the FY 2016 IPPS/LTC PPS final rule (80 FR 49731 through 49736) to fulfill IMPACT Act requirements.</td>
<td>FY 2016 payment determination and subsequent years.</td>
</tr>
<tr>
<td>Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680).</td>
<td>Adopted in the FY 2013 IPPS/LTC PPS final rule (77 FR 53624 through 53627); Revised data collection timeframe in the FY 2014 IPPS/LTC PPS final rule (78 FR 50858 through 50861); Revised data collection timeframe in the FY 2015 IPPS/LTC PPS final rule (79 FR 50289 through 50290).</td>
<td>FY 2016 payment determination and subsequent years.</td>
</tr>
<tr>
<td>Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431).</td>
<td>Adopted in the FY 2013 IPPS/LTC PPS final rule (77 FR 53630 through 53631); Revised data collection timeframe in the FY 2014 IPPS/LTC PPS final rule (78 FR 50857 through 50858).</td>
<td>FY 2016 payment determination and subsequent years.</td>
</tr>
<tr>
<td>All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from Long-Term Care Hospitals (NQF #2512).</td>
<td>Adopted in the FY 2014 IPPS/LTC PPS final rule (78 FR 50868 through 50874); Adopted the NQF endorsed version in the FY 2016 IPPS/LTC PPS final rule (80 FR 49730 through 49731).</td>
<td>FY 2017 payment determination and subsequent years.</td>
</tr>
<tr>
<td>Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674).</td>
<td>Adopted in the FY 2014 IPPS/LTC PPS final rule (78 FR 50291 through 50296).</td>
<td>FY 2018 payment determination and subsequent years.</td>
</tr>
<tr>
<td>Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631). Functional Outcome Measure: Change in Mobility among Long-Term Care Hospital Patients Requiring Ventilator Support (NQF #2632). Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631).</td>
<td>Adopted an application of the measure in the FY 2016 IPPS/LTC PPS final rule (80 FR 49739 through 49747) to fulfill IMPACT Act requirements.</td>
<td>FY 2018 payment determination and subsequent years.</td>
</tr>
</tbody>
</table>

As discussed in section VIII.C.6 and VIIIC.7 of the preamble of this final rule, we are finalizing the addition of the following four measures for use in the LTCH QRP:

### LTCH QRP Quality Measures Newly Finalized for the FY 2018 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Measure title</th>
<th>Annual payment determination: Initial and subsequent APU years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potentially Preventable 30-Day Post-Discharge Readmission Measure for LTCH QRP*</td>
<td>FY 2018 payment determination and subsequent years.</td>
</tr>
</tbody>
</table>

*Only applied to LTCH QRP for the FY 2018 payment determination.
Currently, LTCHs use two separate data collection mechanisms to report quality data to CMS. Six of the 13 measures being retained in this FY 2017 IPPS/LTCH PPS final rule are currently collected via the CDC’s NHSN. The NHSN is a secure, Internet-based HAI tracking system maintained and managed by the CDC. The NHSN enables health care facilities to collect and use data about HAI, adherence to clinical practices known to prevent HAI, and other adverse events within their organizations. NHSN data collection occurs via a Web-based tool hosted by the CDC and is provided free of charge to facilities. In the proposed rule, we did not propose any new quality measures that would be collected via the CDC’s NHSN. Therefore, at this time, there will be no additional burden related to this submission method. Any burden related to NHSN-based quality measures we have retained in this final rule has been previously discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50443 through 50445) and FY 2016 IPPS/LTCH PPS final rule (80 FR 49766) and has been previously approved under OMB control number 0920–0666, with an expiration date of November 31, 2016. In addition to the previously finalized All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge From LTCHs (NQF #2512), we are finalizing our proposals to add three Medicare FFS claims-based measures in this final rule: Potentially Preventable 30 Day Post-Discharge Readmission Measure for LTCH QRP; Discharge to Community-PAC LTCH QRP; and MSBP–PAC LTCH QRP. Because these claims-based measures will be calculated based on data that are already reported to the Medicare program for payment purposes, we believe no additional information collection will be required from the LTCHs. We did not propose new assessment-based quality measures in the LTCH QRP in the proposed rule for the FY 2018 payment determination and subsequent years. The remaining assessment-based quality measure data are reported to CMS by LTCHs using the LTCH CARE Data Set. In section VIII.C.9.d. of the preamble of this final rule, we discuss our proposal to expand the data collection timeframe for the measure Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) (77 FR 53624 through 53627), beginning with the FY 2019 payment determination. The data collection time frame and associated data submission deadlines are currently aligned with the Influenza Vaccination Season (IVS) (October 1 of a given year through March 31 of the subsequent year), and only require data collection during the 2 calendar year quarters that align with the IVS. We are finalizing our proposal to expand the data collection timeframe from just 2 quarters (covering the IVS) to a full four quarters or 12 months. We refer readers to section VIII.C.9.d. of the preamble of this final rule for further details on the expansion of data collection for the Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680), including data collection timeframes and associated submission deadlines. We originally finalized this measure for use in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53624 through 53627). Although we finalized data collection for this measure to coincide with the IVS, we originally proposed year-round data collection. The associated PRA package, which was approved under OMB control number 0938–1163, contains burden calculations that aligned with our original proposal for year-round data collection. All subsequent PRA packages, and the PRA package that is currently under review, included burden calculations reflecting year-round (12 month) data collection for this measure. Because of this, the change in the data collection timeframe for this measure, and any associated burden related to increased data collection, has already been accounted for in the total burden figures included in this section of the preamble of this final rule.

For the FY 2020 payment determination and subsequent years, we are finalizing our proposal to use one new assessment based quality measure in the LTCH QRP: Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP. This is a cross-setting measure that satisfies the required addition of a quality measure under the domain of medication reconciliation, as mandated by section 1899B of the Act, as added by the IMPACT Act. In addition to the newly finalized Drug Regimen Review Conducted with Follow-Up for Identified Issues-PAC LTCH QRP quality measure, the remaining six measures, outlined below, will continue to be collected utilizing the LTCH CARE Data Set.

The LTCH CARE Data Set Version 2.01 has been approved under OMB control number 0938–1163. The LTCH CARE Data Set Version 2.01 contains data elements related to patient demographic data, various voluntary questions, as well as data elements related to the following quality measures:

- Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678);
- Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680).

We have submitted a revision to the PRA package that addressed the changes from LTCH CARE Data Set Version 2.01 to Version 3.00. The LTCH CARE Data Set Version 3.00, which was implemented April 1, 2016, contains those data elements included in Version 2.01, as well as additional data elements in order to allow for the collection of data associated with the following quality measures:

- Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) (previously finalized in the FY 2016 IPPS/LTCH PPS final rule);
- Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631) (previously finalized in the FY 2015 IPPS/LTCH PPS final rule);
- Functional Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support (NQF #2632) (previously finalized in the FY 2015 IPPS/LTCH PPS final rule); and
- Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF # 2631) (previously finalized in the FY 2016 IPPS/LTCH PPS final rule).

The LTCH CARE Data Set Version 4.00, effective April 1, 2018, will contain those data elements included in Version 3.00, as well as additional data elements in order to allow for the collection of data associated with the newly finalized quality measure: Drug Regimen Review Conducted with Follow-Up for Identified Issues—PAC LTCH QRP.

Each time we add new data elements to the LTCH CARE Data Set related to newly proposed or finalized LTCH QRP quality measures, we are required by the PRA to submit the expanded data collection instrument to OMB for review and approval. Section 1899B(m) of the Act, as added by IMPACT Act, provides that the PRA requirements do not apply to section 1899B of the Act and the sections referenced in section 1899B(a)(2)(B) of the Act that require the Secretary to implement a quality reporting program for inpatient psychiatric hospitals and psychiatric units. We refer to this program as the Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program.

In section VII.D of the preamble of the proposed rule (81 FR 25238 through 25244) and this final rule, we are finalizing the following measure-related changes: To update a previously finalized measure (Screening for Metabolic Disorders); and to adopt two new measures beginning with the FY 2019 payment determination (SUB–3 Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and subset measure SUB–3a Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664), and Thirty-day all-cause unplanned readmission following psychiatric hospitalization in an IPF). In addition, we are finalizing our proposal to include SUB–3: Alcohol & Other Drug Use Disorder Treatment Provided or Offered at Discharge and subset measure SUB–3a: Alcohol & Other Drug Use Disorder Treatment at Discharge (NQF #1664) in the list of measures covered by the global sample for the FY 2019 payment determination and subsequent years as proposed. We also are finalizing that we will make the data for the IPFQR Program available as soon as possible and to no longer specify in rulemaking when measure data will be publicly available, when the approximately 30-day preview period will occur, or that the preview period will begin approximately 12 weeks before the public display date, but rather to announce these using subregulatory guidance. Lastly, for the FY 2017 payment determination only, we are also finalizing our proposal that, if it is technically feasible to display the data in December 2016, we will provide data to IPFs for a 2-week preview period that will start on October 1, 2016 as proposed. Moreover, we are finalizing as proposed that as a courtesy, for the FY 2017 payment determination only, if we are able to display the data in December 2016, we will ensure that IPFs have approximately 30 days for review if they so choose by providing IPFs with their data as early as mid-September.

We refer readers to the FY 2015 IPF PPS final rule (79 FR 45978 through 45980) and the FY 2016 IPF PPS final rule (80 FR 46720 through 46721) for a detailed discussion of the burden for the IPFQR Program requirements that we have previously adopted. Below we discuss only the changes in burden resulting from the newly finalized policies in this final rule. Although we are finalizing provisions that impact policies beginning in both the FY 2017 and FY 2019 payment determinations, IPFs must take steps to comply with all of these policies beginning in FY 2017. For example, data collection for the measures that affect FY 2019 payment determination begins in FY 2017, and the changes to the public display dates take effect beginning with the posting of data that informs the FY 2017 payment determination on Hospital Compare during FY 2017. For purposes of calculating burden, we will attribute the costs to the year in which these costs begin; for the purposes of all of the newly finalized policies in this final rule, that year is FY 2017.

We believe that approximately 1,684396 IPFs will participate in the IPFQR Program for requirements occurring in FY 2017 and subsequent years. Based on program data, we believe that each IPF will submit measure data on approximately 848397 cases per year. In prior rulemaking, we estimated that the time required to chart-abstract data for chart-abstracted measures is 12 minutes per case per measure.398 Based on the experience of other quality reporting programs, such as the Hospital QIP Program, we are updating this estimate to 15 minutes (that is, 0.25 hour) per case per measure. We are only finalizing one new chart-abstracted measure this year: SUB–3/ subset SUB–3a. The other measure that we are finalizing, Thirty-day all-cause unplanned readmission following psychiatric hospitalization in an IPF, is claims-based and, therefore, does not require IPFs to report any additional data.

We estimate that reporting data for the IPFQR Program measures can be

396 In the FY 2016 IPF PPS final rule, we estimated 1,617 IPFs and are adjusting that estimate by +47 to account for more recent data.
397 In the FY 2016 IPF PPS final rule, we estimated 431 cases per year and are adjusting that estimate by +417 to account for more recent data.
398 80 FR 46720.
accomplished by staff with a mean hourly wage of $16.42. However, obtaining data on other overhead costs is challenging. Overhead costs vary greatly across industries and firm sizes. In addition, the precise cost elements assigned as “indirect” or “overhead” costs, as opposed to direct costs or employee wages, are subject to some interpretation at the firm level. Therefore, we have chosen to calculate the cost of overhead at 100 percent of the mean hourly wage. This is necessarily a rough adjustment, both because fringe benefits and overhead costs vary significantly from employer to employer and because methods of estimating these costs vary widely from study to study. Nonetheless, there is no practical alternative, and we believe that doubling the hourly wage to estimate total cost is a reasonably accurate estimation method.

In section VIII.D.7 of the preamble of this final rule, we are finalizing our proposal to specify in subregulatory guidance, when measure data will be publicly available and when the preview period will occur. We do not believe this policy will result in any change in burden because it does not require IPFs to report any more or less data. Rather, the timeline for public display of that data is simply shifting.

In the table below, we set out a summary of annual burden estimates.

### ANNUAL RECORDKEEPING AND REPORTING REQUIREMENTS UNDER OMB CONTROL NUMBER 0938–1171 (CMS–10432)

<table>
<thead>
<tr>
<th>Finalized action [preamble section]</th>
<th>Respondents</th>
<th>Responses per respondent</th>
<th>Burden per response (hours)</th>
<th>Total annual burden (hours)</th>
<th>Labor cost ($/hr)</th>
<th>Total cost ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Add NQF #1664 [VIII.D.4.a.] ..........</td>
<td>1,684</td>
<td>848</td>
<td>0.25</td>
<td>357,008</td>
<td>32.84</td>
<td>11,724,143</td>
</tr>
<tr>
<td>Add Readmissions Measure [VIII.D.4.b.]</td>
<td>1,684</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>32.84</td>
<td>0</td>
</tr>
<tr>
<td>Training ........................................</td>
<td>1,684</td>
<td>1</td>
<td>2</td>
<td>3,368</td>
<td>32.84</td>
<td>110,605</td>
</tr>
<tr>
<td>Shift Public Display Timeline [VIII.D.7] ...</td>
<td>1,684</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>32.84</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>1,684</td>
<td></td>
<td></td>
<td>360,376</td>
<td>32.84</td>
<td>11,834,748</td>
</tr>
</tbody>
</table>

12. ICRs for the Electronic Health Record (EHR) Incentive Programs and Meaningful Use

In section VII.E. of the preambles of the proposed rule (81 FR 25244 through 25247) and this final rule, we discuss our proposals to align the Medicare and Medicaid EHR Incentive Programs reporting and submission timelines for electronically submitted clinical quality measures for eligible hospitals and CAHs with the Hospital IQR Program’s reporting and submission timelines for the FY 2019 payment determination. Because these newly finalized policies for data collection in this final rule will align with the reporting requirements in place for the Hospital IQR Program, and eligible hospitals and CAHs still have the option to submit their clinical quality measures via attestation for the Medicare and Medicaid EHR Incentive Programs for CY 2017 reporting, we do not believe there is any additional burden for this collection of information. However, starting with CY 2018 reporting, eligible hospitals and CAHs participating in the Medicare EHR Incentive Programs must electronically report CQMs using CEHRT where feasible; and attestation to CQMs will no longer be an option except in certain

circumstances where electronic reporting is not feasible (80 FR 62894).

We did not receive any public comments regarding this information collection. We refer readers to the table in section X.B.7. of the preamble of this final rule for burden estimates relating to the reporting of 8 CQMs.

List of Subjects
42 CFR Part 405
Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping, Rural areas, X-rays.

42 CFR Part 412
Administrative practice and procedure, Health facilities, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

42 CFR Part 413
Health facilities, Kidney diseases, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

42 CFR Part 489
Health facilities, Medicare, Reporting and recordkeeping requirements.

For the reasons set forth in the preamble of this final rule, the Centers for Medicare and Medicaid Services confirms, as final, the interim final rules and recordkeeping requirements.

42 CFR Part 412

Administrative practice and procedure, Health facilities, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

PART 412—PROSPECTIVE PAYMENT SYSTEMS FOR INPATIENT HOSPITAL SERVICES

3. The authority citation for Part 412 is revised to read as follows:


4. Section 412.104 is amended by adding paragraph (d)(1)(vii) and revising paragraphs (b)(4) introductory text and (h)(4)(vi) introductory text to read as follows:

§ 412.64 Federal rates for inpatient operating costs for Federal fiscal year 2005 and subsequent fiscal years.

(d) * * * * * * (1) * * * * * * (vii) For fiscal year 2017, the percentage increase in the market basket index (as defined in § 413.40(a)(3) of this chapter) for prospective payment hospitals, subject to the provisions of paragraphs (d)(2) and (3) of this section, less a multifactor productivity adjustment (as determined by CMS) and less 0.75 percentage point.

(h) * * *

(4) For discharges on or after October 1, 2004 and before October 1, 2011, CMS establishes a minimum wage index for each all-urban State, as defined in paragraph (h)(5) of this section. This minimum wage index value is computed using the following methodology:

(vi) For discharges on or after October 1, 2012 and before October 1, 2017, the minimum wage index value for the State is the higher of the value determined under paragraph (h)(4)(iv) of this section or the value computed using the following alternative methodology:

(b) * * * * * * (6) Lock-in date for the wage index calculation and budget neutrality. In order for a hospital to be treated as rural in the wage index and budget neutrality calculations under § 412.64(e)(1)(ii), (2), and (4) and (b) for the payment rates for the next Federal fiscal year, the hospital’s filing date must be no later than 70 days prior to the second Monday in June of the current Federal fiscal year and the application must be approved by the CMS Regional Office in accordance with the requirements of this section.

§ 412.106 Special treatment: Hospitals that serve a disproportionate share of low-income patients.

(g) * * * (1) * * * (iii) * * *(C)(j) For fiscal years 2014 and 2015, CMS will base its estimates of the amount of hospital uncompensated care on the most recent available data on utilization for Medicaid and Medicare SSI patients, as determined by CMS in accordance with paragraphs (b)(2)(i) and (4) of this section.

(2) For fiscal year 2016, CMS will base its estimates of the amount of hospital uncompensated care on utilization data for Medicaid and Medicare SSI patients, as determined by CMS in accordance with paragraphs (b)(2)(i) and (4) of this section, using data on Medicaid utilization from 2012 or 2011 cost reports from the most recent HCRIS database extract, the 2012 cost report data submitted to CMS by IHS hospitals, and the most recent available data on Medicaid SSI utilization.

(3) For fiscal year 2017, CMS will base its estimates of the amount of hospital uncompensated care on utilization data for Medicaid and Medicare SSI patients, as determined by CMS in accordance with paragraphs (b)(2)(i) and (4) of this section, using data on Medicaid utilization from 2011, 2012, and 2013 cost reports from the most recent HCRIS database extract, the 2011 and 2012 cost report data submitted to CMS by IHS hospitals, and the most recent available 3 years of data on Medicare SSI utilization (or, for Puerto Rico hospitals, a proxy for Medicare SSI utilization data).

§ 412.140 Participation, data submission, and validation requirements under the Hospital Inpatient Quality Reporting (IQR) Program.

(d) * * *

(2) A hospital meets the chart-abstracted validation requirement with respect to a fiscal year if it achieves a
8. Section 412.160 is amended by revising the definitions of “Achievement threshold (or achievement performance standard)”, “Benchmark”, and “Cited for deficiencies that pose immediate jeopardy” to read as follows:

§ 412.160 Definitions for the Hospital Value-Based Purchasing (VBP) Program.

(A) * * * *

Achievement threshold (or achievement performance standard) means the median (50th percentile) of hospital performance on a measure during a baseline period with respect to a fiscal year, for Hospital VBP Program measures other than the measures in the Efficiency and Cost Reduction domain, and the median (50th percentile) of hospital performance on a measure during the performance period with respect to a fiscal year, for the measures in the Efficiency and Cost Reduction domain.

(B) * * * *

Benchmark means the arithmetic mean of the top decile of hospital performance on a measure during the baseline period with respect to a fiscal year, for Hospital VBP Program measures other than the measures in the Efficiency and Cost Reduction domain, and the arithmetic mean of the top decile of hospital performance on a measure during the performance period with respect to a fiscal year, for the measures in the Efficiency and Cost Reduction domain.

(C) * * * *

Cited for deficiencies that pose immediate jeopardy means that, during the applicable performance period, the Secretary cited the hospital for immediate jeopardy on at least three surveys using the Form CMS–2567, Statement of Deficiencies and Plan of Correction. CMS assigns an immediate jeopardy citation to a performance period as follows: (1) If the Form CMS–2567 only contains one or more EMTALA-related immediate jeopardy citations, CMS uses the date that the Form CMS–2567 is issued to the hospital; (2) If the Form CMS–2567 only contains one or more Medicare conditions of participation immediate jeopardy citations, CMS uses the survey end date generated in ASPEN; and (3) If the Form CMS–2567 contains both one or more EMTALA-related immediate jeopardy citations and one or more Medicare conditions of participation immediate jeopardy citations, CMS uses the survey end date generated in ASPEN.

9. Section 412.170 is amended by revising the definition of “Applicable period” to read as follows:

§ 412.170 Definitions for the Hospital-Acquired Condition Reduction Program.

(A) * * * *

Applicable period is, unless otherwise specified by the Secretary, with respect to a fiscal year, the 2-year period (specified by the Secretary) from which data are collected in order to calculate the total hospital-acquired condition score under the Hospital-Acquired Condition Reduction Program.

(B) * * * *

10. Section 412.204 is amended by revising paragraph (d) introductory text and adding paragraph (e) to read as follows:

§ 412.204 Payment to hospitals located in Puerto Rico.

(A) * * * *

(d) FY 2005 through December 31, 2015. For discharges occurring on or after October 1, 2004 and before January 1, 2016, payments for inpatient operating costs to hospitals located in Puerto Rico that are paid under the prospective payment system are equal to the sum of—

(E) January 1, 2016 and thereafter. For discharges occurring on or after January 1, 2016, payments for inpatient operating costs to hospitals located in Puerto Rico that are paid under the prospective payment system are equal to 100 percent of a national prospective payment rate for inpatient operating costs, as determined under § 412.212.

11. Section 412.256 is amended by revising paragraph (a)(1) to read as follows:

§ 412.256 Application requirements.

(A) * * * 

(1) An application must be submitted to the MCCR in accordance with the method prescribed by the MCCR, with an electronic copy of the application sent to CMS.

(B) * * * *

12. Section 412.374 is amended by revising paragraph (b) introductory text and adding paragraph (e) to read as follows:

§ 412.374 Payments to hospitals located in Puerto Rico.

(A) * * * *

(b) FY 2005 through FY 2016. For discharges occurring on or after October 1, 2004 and on or before September 30, 2016, payments for capital-related costs to hospitals located in Puerto Rico that are paid under the prospective payment system are equal to the sum of the following:

(E) FY 2017 and subsequent fiscal years. For discharges occurring on or after October 1, 2016, payments for capital-related costs to hospitals located in Puerto Rico that are paid under the prospective payment system are based on 100 percent of the Federal rate, as determined under § 412.308.

13. Section 412.503 is amended by adding definitions of “MSA”, “MSA-dominant area”, and “MSA-dominant hospital” and revising the definitions of “Outlier payment” and “Subsection (d) hospital”, to read as follows:

§ 412.503 Definitions.

(A) * * * *

MSA means a Metropolitan Statistical Area, as defined by the Executive Office of Management and Budget.

(B) * * * *

MSA-dominant area means an MSA in which an MSA-dominant hospital is located.

(C) * * * *

MSA-dominant hospital means a hospital that has discharged more than 25 percent of the total subsection (d) hospital Medicare discharges in the MSA (not including discharges paid by a Medicare Advantage plan) in which the hospital is located.

(D) * * * *

Outlier payment means an additional payment beyond the long-term care hospital standard Federal payment rate or the site neutral payment rate (including, when applicable, the blended payment rate), as applicable, for cases with unusually high costs.

(E) * * * *

Subsection (d) hospital means, for purposes of § 412.522, a hospital defined in section 1886(d)(1)(B) of the Social Security Act and includes any hospital that is located in Puerto Rico and that would be a subsection (d) hospital as defined in section 1886(d)(1)(B) of the Social Security Act if it were located in one of the 50 States.

14. Section 412.507 is amended by revising paragraph (a) and adding paragraph (b)(3) to read as follows:

§ 412.507 Limitation on charges to beneficiaries.

(A) * * * *

Prohibited charges. Except as provided in paragraph (b) of this section, a long-term care hospital may not charge a beneficiary for any covered services for which payment is made by Medicare, even if the hospital’s costs of furnishing services to that beneficiary...
are greater than the amount the hospital is paid under the prospective payment system.

(1) If Medicare has paid at the full LTCH prospective payment system standard Federal payment rate, that payment applies to the hospital’s costs for services furnished until the high-cost outlier threshold is met.

(2) If Medicare pays less than the full LTCH prospective payment system standard Federal payment rate and payment was not made at the site neutral payment rate (including, when applicable, the blended payment rate), that payment only applies to the hospital’s costs for those costs or days used to calculate the Medicare payment.

(3) For cost reporting periods beginning on or after October 1, 2016, for Medicare payments to a long-term care hospital specified in §412.538, hospital admissions from referring hospitals.

(4) If Medicare has paid at the full site neutral payment rate, that payment applies to the hospital’s costs for services furnished until the high-cost outlier is met.

(b) * * *

(3) For cost reporting periods beginning on or after October 1, 2016, a long-term care hospital described in §412.23(e)(2)(ii) may only charge the Medicare beneficiary for the applicable deductible and coinsurance amounts under §§409.82, 409.83, and 409.87 of this chapter, for items and services as specified under §409.20(a) of this chapter, and for services provided during the stay for which benefit days were not available and that were not the basis for adjusted LTCH prospective payment system payment amount under §412.526.

(4) If Medicare has paid at the full site neutral payment rate, that payment applies to the hospital’s costs for services furnished until the high-cost outlier is met.

§ 412.522 Application of site neutral payment rate.

* * * * *

(c) * * *

(2) * * *

(v) The limitation on long-term care hospital admissions from referring hospitals specified in §412.538.

* * * * *

16. Section 412.523 is amended by adding paragraph (c)(3)(xiii) to read as follows:

§ 412.523 Methodology for calculating the Federal prospective payment rates.

* * * * *

(c) * * *

(3) * * *

(xiii) For long-term care hospital prospective payment system fiscal year beginning October 1, 2016, and ending September 30, 2017. The LTCH PPS standard Federal payment rate for the long-term care hospital prospective payment system beginning October 1, 2016, and ending September 30, 2017, is the standard Federal payment rate for the previous long-term care hospital prospective payment system fiscal year updated by 1.75 percent and further adjusted, as appropriate, as described in paragraph (d) of this section.

17. Section 412.525 is amended by adding paragraph (d)(6), to read as follows:

§ 412.525 Adjustments to the Federal prospective payment.

* * * * *

(d) * * *

(6) The limitation on long-term care hospital admissions from referring hospitals specified in §412.538.

18. The section heading of §412.534 is revised to read as follows:

§ 412.534 Special payment provisions for long-term care hospitals-within-hospitals and satellites of long-term care hospitals, effective for discharges occurring in cost reporting periods beginning on or before September 30, 2016.

* * * * *

19. The section heading of §412.536 is revised to read as follows:

§ 412.536 Special payment provisions for long-term care hospitals and satellites of long-term care hospitals that discharge Medicare patients admitted from a hospital not located in the same building or on the same campus as the long-term care hospital or satellite of the long-term care hospital, effective for discharges occurring on or before September 30, 2016 or in cost reporting periods beginning on or before June 30, 2016.

* * * * *

20. Section 412.538 is added to read as follows:

§ 412.538 Limitation on long-term care hospital admissions from referring hospitals.

(a) Scope. (1) The provisions of this section apply to all long-term care hospitals excluded from the hospital inpatient prospective payment system under §412.23(e), except as specified in paragraph (a)(2) of this section, effective for—

(i) Discharges occurring in cost reporting periods beginning on or after October 1, 2016 (for long-term care hospitals that formerly would have been subject to §412.534); or

(ii) Discharges occurring on or after October 1, 2016 in cost reporting periods beginning on or after July 1, 2016 (for long-term care hospitals that would not have been formerly subject to §412.534).

(2) Notwithstanding the preceding paragraphs of this section, the provisions of this section do not apply to—

(i) A long-term care hospital described in §412.23(e)(2)(ii); or

(ii) A long-term care hospital described in §412.23(e)(2)(ii) that meets the criteria in §412.23(f).

(3) For purposes of this section, all long-term care hospitals described in paragraph (a)(1) of this section and all referring hospitals are as identified by CCN.

(b) Discharges at or below the applicable percent threshold. For any long-term care hospital that is not exempted by paragraph (a)(2) of this section with discharges occurring as described in paragraph (a)(1) of this section, of which no more than the applicable percent threshold (as defined in paragraph (e) of this section) was admitted to the long-term care hospital from a single referring hospital, payments are the amount otherwise payable under this subpart without adjustment under this section.

(c) Discharges in excess of the applicable percent threshold. For any long-term care hospital that is not exempted by paragraph (a)(2) of this section with discharges occurring as described in paragraph (a)(1) of this section, of which more than the applicable percentage threshold (as defined in paragraph (e) of this section) was admitted to the long-term care hospital from a single referring hospital, payments for the Medicare discharges that caused the long-term care hospital to exceed or remain in excess of such threshold are paid at the lesser of the amount otherwise payable under this subpart without adjustment under this section or the amount equivalent to the hospital inpatient prospective payment system amount as defined in paragraph (f) of this section. Payments for discharges not in excess of the applicable percentage threshold (as defined in paragraph (e) of this section) are the amount otherwise payable under this subpart without adjustment under this section.

(d) Determination of exceeding the applicable percentage threshold.

(1) General. The determination of whether a long-term care hospital (as described in paragraph (a)(1)) of this section has exceeded its applicable percentage threshold (as defined in paragraph (e) of this section) is the amount otherwise payable under this subpart without adjustment under this section.

(2) Notwithstanding the preceding paragraphs of this section, the provisions of this section do not apply to—

(i) A long-term care hospital described in §412.23(e)(2)(ii); or

(ii) A long-term care hospital described in §412.23(e)(2)(ii) that meets the criteria in §412.23(f).
from a single referring hospital is made by comparing the long-term care hospital’s percentage of Medicare discharges occurring as described in paragraph (a)(1) of this section (as calculated under paragraph (d)(2) of this section) to the long-term care hospital’s applicable percentage threshold in paragraph (e) of this section.

(2) Percentage of Medicare discharges. For each referring hospital, the percentage of Medicare discharges admitted to the long-term care hospital is calculated by dividing the amount in paragraph (d)(2)(i) of this section by the amount in paragraph (d)(2)(ii) of this paragraph.

(i) The number of the long-term care hospital’s Medicare discharges in the cost reporting period that were admitted from a single referring hospital is made by determining the applicable fixed-loss amount established for the hospital inpatient prospective payment system operating standardized amount and capital Federal rate in effect (as set forth in section §412.529(d)(4)) at the time of the long-term care hospital discharge.

(ii) In addition to the payment amount under paragraph (f)(1) of this section, an additional payment for high-cost outlier cases is based on the applicable fixed-loss amount established for the hospital inpatient prospective payment system in effect at the time of the long-term care hospital discharge.

21. Section 412.560 is amended by revising paragraph (c)(1) to read as follows:

§412.560 Participation, data submission, and other requirements under the Long-Term Care Hospital Quality Reporting (LTCHQR) Program.

(c) * * *

(1) A long-term care hospital that wishes to request an exception or extension with respect to quality data reporting requirements must submit its request to CMS within 90 days of the date that the extraordinary circumstances occurred.

22. The authority for Part 413 is revised to read as follows:

Authority: Secs. 1102, 1812(d), 1814(b), 1815, 1833(a), (i), and (n), 1861(v), 1871, 1881, 1883 and 1886 of the Social Security Act (42 U.S.C. 1302, 1395d(i), 1395f(b), 1395g, 1395f(a), (i), and (n), 1395x(v), 1395hh, 1395rr, 1395tt, and 1395ww); and sec. 124 of Pub. L. 101–508 (115 Stat. 1501A–332), sec. 1201 of Pub. L. 112–152 (126 Stat. 156); sec. 632 of Pub. L. 112–240 (126 Stat. 2354), sec. 217 of Pub. L. 113–93 (129 Stat. 1040), and sec. 204 of Pub. L. 113–295 (128 Stat. 4010).

23. Section 413.17 is amended by revising paragraph (d)(1) introductory text to read as follows:

§413.17 Cost to related organizations.

(d) * * *

(1) An exception is provided to this general principle if the provider demonstrates by convincing evidence to the satisfaction of the contractor, that—

24. Section 413.24 is amended by revising paragraphs (f)(4)(i), (ii), and (iv) to read as follows:

§413.24 Adequate cost data and cost finding.

(f) * * *

(iv) Effective for cost reporting periods beginning on or after October 1, 1989 for hospitals, cost reporting periods ending on or after November 1, 1997 for skilled nursing facilities and home health agencies, cost reporting periods ending on or after December 31, 2004 for hospices, and end-stage renal disease facilities, and cost reporting periods ending on or after March 31, 2005 for organ procurement organizations, histocompatibility laboratories, rural health clinics, Federally qualified health centers, and community mental health centers, a provider is required to submit cost reports in a standardized electronic format. The provider’s electronic program must be capable of producing the CMS standardized output file in a format that can be read by the contractor’s automated system. This electronic file, which must contain the input data required to complete the cost report and to pass specified edits, must be forwarded to the contractor for processing through its system.
periods ending on or after March 31, 2005 for organ procurement organizations, histocompatibility laboratories, rural health clinics, Federally qualified health centers, and community mental health centers, a provider must submit a hard copy of a settlement summary, a statement of certain worksheet totals found within the electronic file, and a statement signed by its administrator or chief financial officer certifying the accuracy of the electronic file or the manually prepared cost report. During a transition period (first two cost-reporting periods on or after December 31, 2004 for hospices and end-stage renal disease facilities, and the first two cost-reporting periods on or after March 31, 2005 for organ procurement organizations, histocompatibility laboratories, rural health clinics, Federally qualified health centers, community mental health centers), providers must submit a hard copy of the completed cost report forms in addition to the electronic file. The following statement must immediately precede the dated signature of the provider’s administrator or chief financial officer:

I hereby certify that I have read the above certification statement and that I have examined the accompanying electronically filed or manually submitted cost report and the Balance Sheet and Statement of Revenue and Expenses prepared by (Provider Name(s) and Number(s)) for the cost reporting period beginning ___ and ending ___ and that to the best of my knowledge and belief, this report and statement are true, correct, complete and prepared from the books and records of the provider in accordance with applicable instructions, except as noted. I further certify that I am familiar with the laws and regulations regarding the provision of health care services, and that the services identified in this cost report were provided in compliance with such laws and regulations.

* * * * *

25. Section 413.79 is amended by revising paragraphs (k)(1)(i) and (ii) and (k)(2), (3), (4), and (7)(i) and (iii) to read as follows:

§ 413.79 Direct GME payments: Determination of the weighted number of FTE residents. * * * *

(k) * * *

(1) * * *

(i) For rural track programs started prior to October 1, 2012, for the first 3 years of the rural track’s existence, the rural track FTE limitation for each urban hospital will be the actual number of FTE residents, subject to the rolling average at paragraph (d)(7) of this section, training in the rural track at the urban hospital. For rural track programs started on or after October 1, 2012, prior to the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation for each urban hospital will be the actual number of FTE residents, subject to the rolling average at paragraph (d)(7) of this section, training in the rural track at the urban hospital.

(ii) For rural track programs started prior to October 1, 2012, beginning with the fourth year of the rural track’s existence, the rural track FTE limitation is equal to the product of the highest number of residents, in any program year, who during the third year of the rural track’s existence are training in the rural track at the urban hospital and are designated at the beginning of their training to be rotated to the rural hospital(s) for at least two-thirds of the duration of the program for cost reporting periods beginning on or after April 1, 2000, and before October 1, 2003, or for more than one-half of the duration of the program effective for cost reporting periods beginning on or after October 1, 2003, and the number of years those residents are training at the urban hospital. For rural track programs started on or after October 1, 2012, beginning with the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation is calculated in accordance with paragraph (o) of this section.

(B) For rural track programs started on or after October 1, 2012, beginning with the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation is calculated in accordance with paragraph (o)(1) of this section.

(2) If an urban hospital rotates residents to a separately accredited rural track program at a rural nonprovider site(s) for two-thirds of the duration of the program for cost reporting periods beginning on or after April 1, 2000, and before October 1, 2003, or for more than one-half of the duration of the program for cost reporting periods beginning on or after October 1, 2003, the urban hospital may include those residents in its FTE count, subject to the requirements under § 413.78(d) through (g). The urban hospital may include in its FTE count those residents in the rural track, not to exceed its rural track FTE limitation, determined as follows:

(i) For rural track programs started prior to October 1, 2012, for the first 3 years of the rural track’s existence, the rural track FTE limitation for each urban hospital will be the actual number of FTE residents, subject to the rolling average specified in paragraph (d)(7) of this section, training in the rural track at the urban hospital and the rural nonprovider site(s). For rural track programs started on or after October 1, 2012, prior to the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation for each urban hospital will be the actual number of FTE residents, subject to the rolling average specified in paragraph (d)(7) of this section, training in the rural track at the urban hospital and the rural nonprovider site(s).

(ii) For rural track programs started prior to October 1, 2012, beginning with the fourth year of the rural track’s existence, the rural track FTE limitation is equal to the product of—

(I) The highest number of residents in any program year who, during the third year of the rural track’s existence, are training in the rural track at—

1. The urban hospital and are designated at the beginning of their training to be rotated to a rural nonprovider site(s) for at least two-thirds of the duration of the program for cost reporting periods beginning on or after April 1, 2000, and before October 1, 2003, or for more than one-half of the duration of the program for cost reporting periods beginning on or after October 1, 2003; and

2. The number of years in which the residents are expected to complete each program based on the minimum accredited length for the type of program.

(B) For rural track programs started on or after October 1, 2012, beginning with the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation is calculated in accordance with paragraph (o)(1) of this section.

(3) For rural track programs started prior to October 1, 2012, if an urban hospital rotates residents in the rural track program to a rural hospital(s) for less than two-thirds of the duration of the program for cost reporting periods beginning on or after April 1, 2000, and before October 1, 2003, or for one-half or less than one-half of the duration of the program for cost reporting periods beginning on or after October 1, 2003, the rural hospital may not include those residents in its FTE count if the rural track is not a new program under paragraph (e)(3) of this section, or if the rural hospital’s FTE count exceeds that hospital’s FTE cap, nor may the urban hospital include those residents when calculating its rural track FTE limitation. For rural track programs started on or after October 1, 2012, if an urban hospital rotates residents in the rural track program to a rural hospital(s)
for one-half or less than one-half of the duration of the program, the rural hospital may not include those residents in its FTE count (if the rural track is not a new program under paragraph (e)(3) of this section, or if the rural hospital’s FTE count exceeds that hospital’s FTE cap), nor may the urban hospital include those residents when calculating its rural track FTE limitation.

(4)(i) For rural track programs started prior to October 1, 2012, if an urban hospital rotates residents in the rural track program to a rural nonprovider site(s) for less than two-thirds of the duration of the program for cost reporting periods beginning on or after April 1, 2000 and before October 1, 2003, or for one-half or less than one-half of the duration of the program for cost reporting periods beginning on or after October 1, 2003, the urban hospital may include those residents in its FTE count, subject to the requirements under §413.78(b) through (g), as applicable. The urban hospital may include in its FTE count those residents in the rural track, not to exceed its rural track FTE limitation, determined as follows:

(A) For the first 3 years of the rural track’s existence, the rural track FTE limitation for the urban hospital will be the actual number of FTE residents, subject to the requirements under §413.78(d) through (g), as applicable. The urban hospital may include in its FTE count those residents in the rural track, not to exceed its rural track FTE limitation, determined as follows:

(1) The highest number of residents in any program year who, during the fifth year of the rural track’s existence, are training in the rural track at the rural nonprovider site(s) or are designated at the beginning of their training to be rotated to the rural nonprovider site(s) for a period that is for one-half or less than one-half of the duration of the program; and

(2) The ratio of the length of time in which the residents are training at the rural nonprovider site(s) only to the total duration of the program.

(ii) For rural track programs started after October 1, 2012, the urban hospital may include in its FTE count those residents in the rural track, not to exceed its rural track FTE limitation, determined as follows:

(A) Prior to the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation for the urban hospital will be the actual number of FTE residents, subject to the rolling average specified in paragraph (d)(7) of this section, training in the rural track at the rural nonprovider site(s).

(B) Beginning with the start of the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural track’s existence, the rural track FTE limitation is equal to the product of—

(i) The highest number of residents in any program year who, during the fifth year of the rural track’s existence, are training in the rural track at the rural nonprovider site(s) or are designated at the beginning of their training to be rotated to the rural nonprovider site(s) for a period that is for one-half or less than one-half of the duration of the program; and

(ii) The ratio of the length of time in which the residents are training at the rural nonprovider site(s) only to the total duration of the program.

(7) * * * * *

(iii)(A) For rural track programs started prior to October 1, 2012, effective October 1, 2014, if an urban hospital started a rural track training program under the provisions of this paragraph (k) with a hospital located in a rural area and that rural area subsequently becomes an urban area due to the most recent OMB standards for delineating statistical areas adopted by CMS and the most recent Census Bureau data, the urban hospital may continue to adjust its FTE resident limit in accordance with this paragraph (k) based on the rural track programs started prior to the change in the hospital’s geographic designation. In order for the urban hospital to receive or use the adjustment to its FTE resident cap for training FTE residents in the rural track residency program that was started prior to the most recent OMB standards for delineating statistical areas adopted by CMS, one of the following two conditions must be met by the end of a period that begins when the most recent OMB standards for delineating statistical areas are adopted by CMS and continues through the end of the second residency training year following the date the most recent OMB delineations are adopted by CMS: The hospital that has been redesignated from rural to urban must reclassify as rural under §412.103 of this chapter, for purposes of IME only; or the urban hospital must find a new site that is geographically rural consistent with the most recent geographical location delineations adopted by CMS. In order to receive an adjustment to its FTE resident cap for an additional new rural track residency program, the urban hospital must participate in a rural track program with sites that are geographically rural based on the most recent geographical location delineations adopted by CMS.

(B) For rural track programs started on or after October 1, 2012, effective October 1, 2014, if an urban hospital started a rural track training program
under the provisions of this paragraph (k) with a hospital located in a rural area and that rural area subsequently becomes an urban area due to the most recent OMB standards for delineating statistical areas adopted by CMS and the most recent Census Bureau data, regardless of whether the redesignation of the rural hospital occurs during the 5-year period that is used to calculate the urban hospital’s rural track FTE limit, or after the 5-year period used to calculate the urban hospital’s rural track FTE limit, the urban hospital may continue to adjust its FTE resident limit in accordance with this paragraph (k) based on the rural track programs started prior to the change in the hospital’s geographic designation. In order for the urban hospital to receive or use the adjustment to its FTE resident cap for training FTE residents in the rural track residency program that was started prior to the most recent OMB standards for delineating statistical areas adopted by CMS, one of the following two conditions must be met by the end of a period that begins when the most recent OMB standards for delineating statistical areas are adopted by CMS and continues through the end of the second residency training year following the date the most recent OMB delineations are adopted by CMS: The hospital that has been redesignated from rural to urban must reclassify as rural under §412.103 of this chapter, for purposes of IME only; or the urban hospital must find a new site that is geographically rural consistent with the most recent geographical location delineations adopted by CMS. In order to receive an adjustment to its FTE resident cap for an additional new rural track residency program, the urban hospital must participate in a rural track program with sites that are geographically rural based on the most recent geographical location delineations adopted by CMS.

§489.20 Basic commitments.

(y) In the case of a hospital or critical access hospital, to provide notice, as specified in paragraphs (y)(1) and (2) of this section, to each individual entitled to Medicare benefits under Title XVIII of the Act when such individual receives observation services as an outpatient for more than 24 hours. Notice must be provided to the individual not later than 36 hours after observation services are initiated or sooner if the individual is transferred, discharged, or admitted. Notice may be provided before such individual receives 24 hours of observation services as an outpatient.

(1) Written notice. Hospitals and critical access hospitals must use a standardized written notice, as specified by the Secretary, which includes the following information:

(i) An explanation of the status of the individual as an outpatient receiving observation services and not as an inpatient of the hospital or critical access hospital and the reason for status as an outpatient receiving observation services; and

(ii) An explanation of the implications of such status as an outpatient on services furnished by the hospital or critical access hospital (including services furnished on an inpatient basis), such as Medicare cost-sharing requirements, and subsequent eligibility for Medicare coverage for skilled nursing facility services.

(2) Oral notice. The hospital must give an oral explanation of the written notification described in paragraph (y)(1) of this section.

(3) Signature requirements. The written notice specified in paragraph (y)(1) of this section must either—

(i) Be signed by the individual who receives observation services as an outpatient or a person acting on the individual’s behalf to acknowledge receipt of such notification; or

(ii) If the individual who receives observation services as an outpatient or the person acting on behalf of the individual refuses to provide the signature described in paragraph (y)(1) of this section, is signed by the staff member of the hospital or critical access hospital who presented the written notification and includes the name and title of the staff member, a certification that the notification was presented, and the date and time the notification was presented.

Dated: July 25, 2016.

Andrew M. Slavitt,
Administrator, Centers for Medicare & Medicaid Services.


Sylvia M. Burwell,
Secretary, Department of Health and Human Services.

Note: The following Addendum and Appendices will not appear in the Code of Federal Regulations.

Addendum—Schedule of Standardized Amounts, Update Factors, Rate-of-Increase Percentages Effective With Cost Reporting Periods Beginning On or After October 1, 2016, and Payment Rates for LTCHs Effective for Discharges Occurring On or After October 1, 2016

I. Summary and Background

In this Addendum, we are setting forth a description of the methods and data we used to determine the prospective payment rates for Medicare hospital inpatient operating costs and Medicare hospital inpatient capital-related costs for FY 2017 for acute care hospitals. We also are setting forth the rate-of-increase percentage for updating the target amounts for certain hospitals excluded from the IPPS for FY 2017. We note that, because certain hospitals excluded from the IPPS are paid on a reasonable cost basis subject to a rate-of-increase ceiling (and not by the IPPS), these hospitals are not affected by the figures for the standardized amounts, offsets, and budget neutrality factors. Therefore, in this final rule, we are setting forth the rate-of-increase percentage for updating the target amounts for certain hospitals excluded from the IPPS that will be effective for cost reporting periods beginning on or after October 1, 2016.

In addition, we are setting forth a description of the methods and data we used to determine the LTCH PPS standard Federal payment rate that will be applicable to Medicare LTCHs for FY 2017.

In general, except for SCHs and MDHs, for FY 2017, each hospital’s payment per discharge under the IPPS is based on 100 percent of the Federal national rate, also known as the national adjusted standardized amount. This amount reflects the national average hospital cost per case from a base year, updated for inflation. SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: The Federal national rate (including, as discussed in section IV.F. of the preamble of this final rule, uncompensated care payments under section 1886(r)(2) of the Act); the
updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge.

We note that section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114–10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

Under section 1886(d)(5)(G) of the Act, MDHs historically were paid based on the Federal national rate or, if higher, the Federal national rate plus 50 percent of the difference between the Federal national rate and the updated hospital-specific rate based on FY 1982 or FY 1987 costs per discharge, whichever was higher. However, section 5003(a)(1) of Pub. L. 109–171 extended and modified the MDH special payment provision that was previously set to expire on October 1, 2006, to include discharges occurring on or after October 1, 2006, but before October 1, 2011. Under section 5003(b) of Pub. L. 109–171, if the change results in an increase to an MDH’s target amount, we must rebase an MDH’s hospital-specific rates based on its FY 2002 cost report. Section 5003(c) of Pub. L. 109–171 further required that MDHs be paid based on the Federal national rate or, if higher, the Federal national rate plus 75 percent of the difference between the Federal national rate and the updated hospital-specific rate. Further, based on the provisions of section 5003(d) of Pub. L. 109–171, MDHs are no longer subject to the 12.5 percent cap on their DSH payment adjustment factor.

As discussed in section IV.A. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the Puerto Rico-specific standardized amount and 25 percent of the Puerto Rico-specific standardized amount. As a result, CMS calculated the Puerto Rico-specific standardized amount. Section 601 of the Consolidated Appropriations Act, 2016 (Pub. L. 114–113) amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016, shall use 100 percent of the national standardized amount. Because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount under the amendments to section 1886(d)(9)(E) of the Act, there is no longer a need for us to calculate a Puerto Rico-specific standardized amount. For operating costs for inpatient hospital discharges occurring in FY 2017 and subsequent fiscal years, consistent with the provisions of section 1886(d)(9)(E) of the Act as amended by section 601 of Pub. L. 114–113, subsection (d) Puerto Rico hospitals will continue to be paid based on 100 percent of the national standardized amount. Because Puerto Rico hospitals are now paid 100 percent of the national standardized amount and are subject to the same national standardized amount as subsection (d) hospitals that receive the full update, our discussion below does not include references to the Puerto Rico standardized amount or the Puerto Rico-specific wage index.

As discussed in section II. of this Addendum, we are making changes in the determination of the prospective payment rates for Medicare inpatient operating costs for acute care hospitals for FY 2017. In section III. of this Addendum, we discuss our policy changes for determining the prospective payment rates for Medicare inpatient capital-related costs for FY 2017. In section IV. of this Addendum, we set forth the rate-of-increase percentage for determining the rate-of-increase limits for certain hospitals excluded from the IPPS for FY 2017. In section V. of this Addendum, we discuss policy changes for determining the LTCH PPS standard Federal payment rate for LTCHs paid under the LTCH PPS for FY 2017. The tables to which we refer to in the preamble of this final rule are listed in section VI. of this Addendum and are available via the Internet on the CMS Web site.

II. Changes to Prospective Payment Rates for Hospital Inpatient Operating Costs for Acute Care Hospitals for FY 2017

The basic methodology for determining prospective payment rates for hospital inpatient operating costs for acute care hospitals for FY 2005 and subsequent fiscal years is set forth under § 412.64. The basic methodology for determining the prospective payment rates for hospital inpatient operating costs for hospitals located in Puerto Rico for FY 2005 and subsequent fiscal years is set forth under §§ 412.211 and 412.212. Below we discuss the factors we used for determining the prospective payment rates for FY 2017.

In summary, the standardized amounts set forth in Tables 1A, 1B, and 1C that are listed and published in section VI. of this Addendum (and available via the Internet on the CMS Web site) reflect—

- Equalization of the standardized amounts for urban and other areas at the level computed for large urban hospitals during FY 2004 and onward, as provided for under section 1886(d)(3)(A)(iv)(II) of the Act.
- The labor-related share that is applied to the standardized amounts to give the hospital the highest payment, as provided for under sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act. For FY 2017, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR user), there are four possible applicable percentage increases that can be applied to the national standardized amount. We refer readers to section IV.B. of the preamble of this final rule for a complete discussion on the FY 2017 inpatient hospital update. Below is a table with these four options:

<table>
<thead>
<tr>
<th>FY 2017</th>
<th>Hospital submitted quality data and is a meaningful EHR user</th>
<th>Hospital submitted quality data and is NOT a meaningful EHR user</th>
<th>Hospital did NOT submit quality data and is a meaningful EHR user</th>
<th>Hospital did NOT submit quality data and is NOT a meaningful EHR user</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>2.7</td>
<td>2.7</td>
<td>2.7</td>
<td>2.7</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0.0</td>
<td>0.0</td>
<td>−0.675</td>
<td>−0.675</td>
</tr>
</tbody>
</table>
We note that section 1886(b)(3)(B)(viii) of the Act, which specifies the adjustment to the applicable percentage increase for "subsection (d)" hospitals that do not submit quality data under the rules established by the Secretary, is not applicable to hospitals located in Puerto Rico.

In addition, section 602 of Public Law 114–113 amended section 1886(n)(6)(B) of the Act to specify that Puerto Rico hospitals are eligible for incentive payments for the meaningful use of certified EHR technology, effective beginning FY 2016, and also to apply the adjustments to the applicable percentage increase under section 1886(b)(3)(B)(ix) of the Act to Puerto Rico hospitals that are not meaningful EHR users, effective FY 2022.

Accordingly, because the provisions of section 1886(b)(3)(B)(ix) of the Act are not applicable to hospitals located in Puerto Rico until FY 2022, the adjustments under this provision are not applicable for FY 2017.

• An adjustment to the standardized amount to ensure budget neutrality for DRG recalibration and reclassification, as provided for under section 1886(d)(4)(C)(iii) of the Act.
• An adjustment to ensure the wage index changes are budget neutral, as provided for under section 1886(d)(3)(E)(i) of the Act. We note that section 1886(d)(3)(E)(i) of the Act requires that when we compute such budget neutrality, we assume that the provisions of section 1886(d)(3)(E)(iii) of the Act (requiring a 62-percent labor-related share in certain circumstances) had not been enacted.
• An adjustment to ensure the effects of geographic reclassification are budget neutral, as provided for under section 1886(d)(8)(D) of the Act, by removing the FY 2016 budget neutrality factor and applying a revised factor.
• As discussed below and in section III.G. of the preamble of this final rule, an adjustment to offset the cost of the 3-year hold harmless transitional wage index provisions provided by CMS as a result of the implementation of the new OMB labor market area delineations (beginning with FY 2015).
  • An adjustment to remove the FY 2016 outlier offset and apply an offset for FY 2017, as provided for under section 1886(d)(3)(B) of the Act.
  • As discussed below and in section II.D. of the preamble of this final rule, a recoupment to meet the requirements of section 631 of ATRA to adjust the standardized amount to offset the estimated amount of the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Public Law 110–90 until FY 2013.
  • As discussed below and in section IV.P. of the preamble of this final rule, we are applying a (1/0.998) adjustment to the FY 2017 payment rates using our authority under sections 1886(d)(5)(I)(i) and 1886(g) of the Act to permanently prospectively remove the 0.2 percent reduction to the rate put in place in FY 2014 to offset the estimated increase in IPPS expenditures associated with the projected increase in inpatient encounters that was expected to result from the new inpatient admission guidelines under the 2-midnight policy.
  • As discussed below and in section IV.P. of the preamble of this final rule, we are applying a temporary one-time prospective increase to the FY 2017 payment rates of 0.6 percent or a factor of 1.006 using our authority under sections 1886(d)(5)(I)(i) and 1886(g) of the Act to address the effects of the 0.2 percent reduction to the payment rate for the 2-midnight policy in effect for FY 2014, FY 2015, and FY 2016.

For FY 2017, consistent with current law, we applied the rural floor budget neutrality adjustment to hospital wage indexes. Also, consistent with section 3141 of the Affordable Care Act, instead of applying a State-level rural floor budget neutrality adjustment to the wage index, we applied a uniform, national budget neutrality adjustment to the FY 2017 wage index for the rural floor. We note that, in section III.H.2.h. of the preamble to this final rule, we are extending the imputed floor policy (both the original methodology and alternative methodology) for FY 2017. Therefore, for FY 2017, in this final rule, we are continuing to include the imputed floor (calculated under the original and alternative methodologies) in calculating the uniform, national rural floor budget neutrality adjustment, which will be reflected in the FY 2017 wage index.

In prior fiscal years, CMS made an adjustment to ensure the effects of the rural community hospital demonstration program required under section 410A of Public Law 108–173, as amended by sections 3123 and 10313 of Public Law 111–148, which extended the demonstration program for an additional 5 years, were budget neutral as required under section 410A(c)(2) of Public Law 108–173. As discussed in section IV.K.3. of the preamble to this final rule, given the small number of participating hospitals and the limited time of participation during FY 2017, as we proposed, we are foregoing the process of estimating the costs attributable to the demonstration for FY 2017 and instead analyzing the set of finalized cost reports for reporting periods beginning in FY 2016 when they become available. In addition, we discuss how we will reconcile the budget neutrality offset amounts identified in the IPPS final rules for FYs 2011 through 2016 with the actual costs of the demonstration for those years, considering the fact that the demonstration will end December 31, 2016. We stated that we believe it would be appropriate to conduct this analysis for FYs 2011 through 2016 at one time, when all of the finalized cost reports for cost reporting periods beginning in FYs 2011 through 2016 are available. Such an aggregate analysis encompassing the cost experience through the end of the period of performance of the demonstration represents an administratively streamlined method, allowing for the determination of any appropriate final adjustment to the IPPS rates and obviating the need for...
multiple fiscal-year-specific calculations and regulatory actions. Given the general lag of 3 years in finalizing cost reports, we expect any such analysis to be conducted in FY 2020. Therefore, for FY 2017, we are not making any adjustment to the standardized amounts for the rural community hospital demonstration program. We refer the reader to section IV.K. of the preamble of this final rule for a complete discussion on the rural community hospital demonstration program.

A. Calculation of the Adjusted Standardized Amount

1. Standardization of Base-Year Costs or Target Amounts

In general, the national standardized amount is based on per discharge averages of adjusted hospital costs from a base period (FY 1984). Section 1886(d)(2)(A) of the Act, updated and otherwise adjusted in accordance with the provisions of section 1886(d) of the Act. The September 1, 1983 interim final rule (48 FR 39763) contained a detailed explanation of how base-year cost data (from cost reporting periods ending during FY 1981) were established for urban and rural hospitals in the initial development of standardized amounts for the IPPS.

Sections 1886(d)(2)(B) and 1886(d)(2)(C) of the Act require us to update base-year per discharge costs for FY 1984 and then standardize the cost data in order to remove the effects of certain sources of cost variations among hospitals. These effects include case-mix, differences in area wage levels, cost-of-living adjustments for Alaska and Hawaii, IME costs, and costs to hospitals serving a disproportionate share of low-income patients.

For FY 2017, we are continuing to use the national labor-related and nonlabor-related shares (which are based on the FY 2010-based hospital market basket) that were used in FY 2016. Specifically, under section 1886(d)(3)(E) of the Act, the Secretary estimates, from time to time, the proportion of payments that are labor-related and adjusts the proportion (as estimated by the Secretary from time to time) of hospitals’ costs which are attributable to wages and wage-related costs of the DRG prospective payment rates. We refer to the proportion of hospitals’ costs that are attributable to wages and wage-related costs as the “labor-related share.” For FY 2017, as discussed in section III. of the preamble of this final rule, we are continuing to use a labor-related share of 62.6 percent for the national standardized amounts for all IPPS hospitals (including hospitals in Puerto Rico) that have a wage index value that is greater than 1.0000. Consistent with section 1886(d)(3)(E) of the Act, we applied the wage index to a labor-related share of 62 percent of the national standardized amount for all IPPS hospitals (including hospitals in Puerto Rico) whose wage index values are less than or equal to 1.0000.

The standardized amounts for operating costs appear in Tables 1A, 1B, and 1C that are listed and published in section VI. of the Addendum to this final rule and are available via the Internet on the CMS Web site.

2. Computing the National Average Standardized Amount

Section 1886(d)(3)(A)(vi)(II) of the Act requires that, beginning with FY 2004 and thereafter, an equal standardized amount be computed for all hospitals at the level computed for large urban hospitals during FY 2003, updated by the applicable percentage update. Accordingly, we calculated the FY 2017 national average standardized amount irrespective of whether a hospital is located in an urban or rural location.

3. Updating the National Average Standardized Amount

Section 1886(b)(3)(B) of the Act specifies the applicable percentage increase used to update the standardized amount for payment for inpatient hospital operating costs. We note that, in compliance with section 404 of the MMA, in this final rule, we are using the revised and rebased FY 2010-based IPPS operating and capital market baskets for FY 2017 (which replaced the FY 2006-based IPPS operating and capital market baskets in FY 2014). As discussed in section IV.B. of the preamble of this final rule, in accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, we reduced the FY 2017 applicable percentage increase (which is based on IHS Global Insight, Inc.’s (IGI’s) second quarter 2016 forecast of the FY 2010-based IPPS market basket) by the MFP adjustment (the 10-year moving average of MFP for the period ending FY 2017) of 0.3 percentage point, which is calculated based on IGI’s second quarter 2016 forecast.

In addition, in accordance with section 1886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are further updating the standardized amount for FY 2017 by the estimated market basket percentage increase less 0.75 percentage point for hospitals in all areas. Sections 1886(b)(3)(B)(xi) and (xii) of the Act, as added and amended by sections 3401(a) and 10319(a) of the Affordable Care Act, further state that these adjustments may result in the applicable percentage increase being less than zero. The percentage increase in the market basket reflects the average change in the price of goods and services comprising routine, ancillary, and special care unit hospital inpatient services.

Based on IGI’s 2016 second quarter forecast of the hospital market basket increase (as discussed in Appendix B of this final rule), the most recent forecast of the hospital market basket increase for FY 2017 is 2.7 percent. As discussed earlier, for FY 2017, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act, there are four possible applicable percentage increases that could be applied to the standardized amount. We refer readers to section IV.B. of the preamble of this final rule for a complete discussion on the FY 2017 inpatient hospital update to the standardized amount. We also refer readers to the table above for the four possible applicable percentage increases that will be applied to update the national standardized amount. The standardized amounts shown in Tables 1A through 1C that are published in section VI. of this Addendum and that are available via the Internet on the CMS Web site reflect these differential amounts.

Although the update factors for FY 2017 are set by law, we are required by section 1886(e)(4) of the Act to recommend, taking into account MedPAC’s recommendations, appropriate update factors for FY 2017 for both IPPS hospitals and hospitals and hospital units excluded from the IPPS. Section 1886(e)(5)(A) of the Act requires that we publish our recommendations in the Federal Register for public comment. Our recommendation on the update factors is set forth in Appendix B of this final rule.

4. Methodology for Calculation of the Average Standardized Amount

The methodology we used to calculate the FY 2017 standardized amount is as follows:

- To ensure we are only including hospitals paid under the IPPS in the calculation of the standardized amount, we applied the following inclusion and exclusion criteria: include hospitals whose last four digits fall between 0001 and 0879 (section 279A1 of Chapter 2 of the State Operations Manual on the
CMS Web site at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/som107c02.pdf; exclude critical access hospitals at the time of this final rule; exclude hospitals in Maryland (because these hospitals are paid under an all payer model under section 1115A of the Act); and remove PPS-excluded cancer hospitals that have a “V” in the fifth position of their provider number or a “E” or “F” in the sixth position.

- As in the past, we adjusted the FY 2017 standardized amount to remove the effects of the FY 2016 geographic reclassifications and outlier payments before applying the FY 2017 updates. We then applied budget neutrality offsets for outliers and geographic reclassifications to the standardized amount based on FY 2017 payment policies.

- We do not remove the prior year’s budget neutrality adjustments for reclassification and recalibration of the DRG relative weights and for updated wage index, in accordance with sections 1886(d)(4)(C)(iii) and 1886(d)(3)(E) of the Act, estimated aggregate payments after updates in the DRG relative weights and wage index should equal estimated aggregate payments prior to the changes. If we removed the prior year’s adjustment, we would not satisfy these conditions.

Budget neutrality is determined by comparing aggregate IPPS payments before and after making changes that are required to be budget neutral (for example, changes to MS–DRG classifications, recalibration of the MS–DRG relative weights, updates to the wage index, and different geographic reclassifications). We include outlier payments in the simulations because they may be affected by changes in these parameters.

- Consistent with our methodology established in the FY 2011 IPPS/LTCH PPS final rule (75 FR 50422 through 50423), we examine the MedPAR file and remove pharmacy charges for anti-hemophilic blood factor (which are paid separately under the IPPS) with an indicator of “E” in the record title with a revenue code of “0636” from the covered charge field for the budget neutrality adjustments. We also remove organ acquisition charges from the covered charge field for the budget neutrality adjustments because organ acquisition is a pass-through payment not paid under the IPPS.

- The Bundled Payments for Care Improvement (BPCI) initiative, developed under the authority of section 3021 of the Affordable Care Act (codified at section 1115A of the Act), is comprised of four broadly defined models of care, which link payments for multiple services beneficiaries receive during an episode of care. Under the BPCI initiative, organizations enter into payment arrangements that include financial and performance accountability for episodes of care. On January 31, 2013, CMS announced the first set of health care organizations selected to participate in the BPCI initiative. Additional organizations were selected in 2014. For additional information on the BPCI initiative, we refer readers to the CMS Center for Medicare and Medicaid Innovation’s Web site at: http://innovation.cms.gov/initiatives/Bundled-Payments/index.html.

In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53687 through 53688), for FY 2013 and subsequent fiscal years, we finalized a methodology to treat hospitals that participate in the BPCI initiative the same as prior fiscal years for the IPPS payment modeling and ratesetting process (which includes recalibration of the MS–DRG relative weights, ratesetting, calculation of the budget neutrality factors, and the impact analysis) without regard to a hospital’s participation within these bundled payment models (that is, as if they are not participating in those models under the BPCI initiative). For FY 2017, as we proposed, we are continuing to include all applicable data from subsection (d) hospitals participating in BPCI Models 1, 2, and 4 in our IPPS payment modeling and ratesetting calculations.

- Consistent with our methodology established in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53687 through 53688), we believe that it is appropriate to include adjustments for the Hospital Readmissions Reduction Program and the Hospital VBP Program (established under the Affordable Care Act) within our budget neutrality calculations. Both the hospital readmissions payment adjustment (reduction) and the hospital VBP payment adjustment (redistribution) are applied on a claim-by-claim basis by adjusting, as applicable, the base-operating DRG payment amount for individual hospital financial and performance accountability for episodes of care. On January 31, 2013, CMS announced the first set of health care organizations selected to participate in the BPCI initiative. Additional organizations were selected in 2014. For additional information on the BPCI initiative, we refer readers to the CMS Center for Medicare and Medicaid Innovation’s Web site at: http://innovation.cms.gov/initiatives/Bundled-Payments/index.html.

For the purpose of calculating the FY 2017 readmissions payment adjustment factors, we used excess readmission ratios and aggregate payments for excess readmissions based on admissions from the prior fiscal year’s applicable period because hospitals have had the opportunity to review and correct these data before the data were made public under the policy we adopted regarding the reporting of hospital-specific readmission rates, consistent with section 1886(q)(6) of the Act. For FY 2017, in this final rule, we calculated the readmissions payment adjustment factors using excess readmission ratios and aggregate payments for excess readmissions based on admissions from the finalizable applicable period for FY 2017 as hospitals have had the
opportunity to review and correct these data under our policy regarding the reporting of hospital-specific readmission rates consistent with section 1886(q)(6) of the Act. We discuss our policy regarding the reporting of hospital-specific readmission rates for FY 2017 in section IV.G.3.f. of the preamble of this final rule. (For additional information on our general policy for the reporting of hospital-specific readmission rates, consistent with section 1886(q)(6) of the Act, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53399 through 53400).)

In addition, for FY 2017, in this final rule, for the purpose of modeling aggregate payments when determining all budget neutrality factors, we used proxy hospital VBP payment adjustment factors for FY 2017 that are based on data from a historical period because hospitals have not yet had an opportunity to review and submit corrections for their data from the FY 2017 performance period. (For additional information on our policy regarding the review and correction of hospital-specific measure rates under the Hospital VBP Program, consistent with section 1886(o)(10)(A)(ii) of the Act, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53578 through 53581), the CY 2012 OPPS/ASC final rule with comment period (76 FR 74544 through 74547), and the Hospital Inpatient VBP final rule (76 FR 26534 through 26536).

• The Affordable Care Act also established section 1886(r) of the Act, which modifies the methodology for computing the Medicare DSH payment adjustment beginning in FY 2014. Beginning in FY 2014, IPPS hospitals receiving Medicare DSH payment adjustments will receive an empirically justified Medicare DSH payment equal to 25 percent of the amount that would previously have been received under the statutory formula set forth under section 1886(d)(5)(F) of the Act governing the Medicare DSH payment adjustment. In accordance with section 1886(r)(2) of the Act, the remaining amount, equal to an estimate of 75 percent of what otherwise would have been paid as Medicare DSH payments, reduced to reflect changes in the percentage of individuals under age 65 who are uninsured and an additional statutory adjustment, will be available to make additional payments to Medicare DSH hospitals based on their share of the total amount of uncompensated care reported by Medicare DSH hospitals for a given MS–DRG. In order to properly determine aggregate payments on each side of the comparison for budget neutrality, prior to FY 2014, we included estimated Medicare DSH payments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

To do this for FY 2017 (as we did for the last 3 fiscal years), we included estimated empirically justified Medicare DSH payments that will be paid in accordance with section 1886(e)(1) of the Act and estimates of the additional uncompensated care payments made to hospitals receiving Medicare DSH payment adjustments as described by section 1886(r)(2) of the Act. That is, we considered estimated empirically justified Medicare DSH payments at 25 percent of what would otherwise have been paid, and also the estimated additional uncompensated care payments for hospitals receiving Medicare DSH payment adjustments on both sides of our comparison of aggregate payments when determining all budget neutrality factors described in section II.A.4. of this Addendum.

• When calculating total payments for budget neutrality, to determine total payments for SCHs, we model total hospital-specific rate payments and total Federal rate payments and then include whichever one of the total payments is greater. As discussed in section IV.F. of the preamble to this final rule and below, we are continuing the FY 2014 finalized methodology under which we will take into consideration uncompensated care payments in the comparison of payments under the Federal rate and the hospital-specific rate for SCHs. Therefore, we included estimated uncompensated care payments in this comparison.

Similarly, for MDHs, as discussed in section IV. of the preamble to this final rule, when computing payments under the Federal national rate plus 75 percent of the difference between the payments under the Federal national rate and the payments under the updated hospital-specific rate, we are continuing to take into consideration uncompensated care payments in the computation of payments under the Federal rate and the hospital-specific rate for MDHs.

• We include an adjustment to the standardized amount for those hospitals that are not meaningful EHR users in our modeling of aggregate payments for budget neutrality for FY 2017. Similar to FY 2016, we are including this adjustment based on data on the prior year’s performance. Payments for hospitals will be estimated based on the applicable amount in Tables 1A and 1B for discharges occurring in FY 2017.

a. Recalibration of MS–DRG Relative Weights

Section 1886(d)(4)(C)(iii) of the Act specifies that, beginning in FY 1991, the annual DRG reclassification and recalibration of the relative weights must be made in a manner that ensures that aggregate payments to hospitals are not affected. As discussed in section II.G. of the preamble of this final rule, we normalized the recalibrated MS–DRG relative weights by an adjustment factor so that the average case relative weight after recalibration is equal to the average case relative weight prior to recalibration. However, equating the average case relative weight after recalibration to the average case relative weight before recalibration does not necessarily achieve budget neutrality with respect to aggregate payments to hospitals because payments to hospitals are affected by factors other than average case relative weight. Therefore, as we have done in past years, we are making a budget neutrality adjustment to ensure that the requirement of section 1886(d)(4)(C)(iii) of the Act is met.

For FY 2017, to comply with the requirement that MS–DRG reclassification and recalibration of the relative weights be budget neutral for the standardized amount and the hospital-specific rates, we used FY 2015 discharge data to simulate payments and compared the following:

• Aggregate payments using the FY 2016 labor-related share percentages, the FY 2016 relative weights, and the FY 2016 pre-reclassified wage data, and applied the FY 2017 hospital readmissions payment adjustments and estimated FY 2017 hospital VBP payment adjustments; and

• Aggregate payments using the FY 2016 labor-related share percentages, the FY 2017 relative weights, and the FY 2016 pre-reclassified wage data, and applied the same FY 2017 hospital readmissions payment adjustments and estimated FY 2017 hospital VBP payment adjustments applied above.

Based on this comparison, we computed a budget neutrality adjustment factor equal to 0.999079 and applied this factor to the standardized amount. As discussed in section IV. of this Addendum, we also applied the MS–DRG reclassification and recalibration budget neutrality factor of 0.999079 to the hospital-specific rates that are effective for cost reporting periods beginning on or after October 1, 2016.

b. Updated Wage Index—Budget Neutrality Adjustment

Section 1886(d)(3)(E)(ii) of the Act
index on an annual basis beginning October 1, 1993. This provision also requires us to make any updates or adjustments to the wage index in a manner that ensures that aggregate payments to hospitals are not affected by the change in the wage index. Section 1886(d)(3)(E)(i) of the Act requires that we implement the wage index adjustment in a budget neutral manner. However, section 1886(d)(3)(E)(ii) of the Act sets the labor-related share at 62 percent for hospitals with a wage index less than or equal to 1.0000, and section 1886(d)(3)(E)(i) of the Act provides that the Secretary shall calculate the budget neutrality adjustment for the adjustments or updates made under that provision as if section 1886(d)(3)(E)(ii) of the Act had not been enacted. In other words, this section of the statute requires that we implement the updates to the wage index in a budget neutral manner, but that our budget neutrality adjustment should not take into account the requirement that we set the labor-related share for hospitals with wage indexes less than or equal to 1.0000 at the more advantageous level of 62 percent. Therefore, for purposes of this budget neutrality adjustment, section 1886(d)(3)(E)(i) of the Act prohibits us from taking into account the fact that hospitals with a wage index less than or equal to 1.0000 are paid using a labor-related share of 62 percent. Consistent with current policy, for FY 2017, we are adjusting 100 percent of the wage index factor for occupational mix. We describe the occupational mix adjustment in section III.E. of the preamble of this final rule.

To compute a budget neutrality adjustment factor for wage index and labor-related share percentage changes, we used FY 2015 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2017 relative weights and the FY 2016 pre-reclassified wage indexes, applied the FY 2016 labor-related share of 69.6 percent to all hospitals (regardless of whether the hospital’s wage index was above or below 1.0000), and the FY 2017 hospital readmissions payment adjustment and the estimated FY 2017 hospital VBP payment adjustment; and
- Aggregate payments using the FY 2017 relative weights and the FY 2017 pre-reclassified wage indexes, applied the labor-related share for FY 2017 of 69.6 percent to all hospitals (regardless of whether the hospital’s wage index was above or below 1.0000), and the same FY 2017 hospital readmissions payment adjustments and estimated FY 2017 hospital VBP payment adjustments applied above.

In addition, we applied the MS–DRG reclassification and recalibration budget neutrality adjustment factor (derived in the first step) to the payment rates that were used to simulate payments for this comparison of aggregate payments from FY 2016 to FY 2017. By applying this methodology, we determined a budget neutrality adjustment factor of 1.000209 for changes to the wage index.

We note that, in prior fiscal years, we used a three-step process and combined the recalibration and wage index budget neutrality factors into one factor by multiplying the recalibration adjustment factor by the wage index adjustment factor. Because these two adjustments are required under two different sections of the Act (sections 1886(d)(4)(C)(iii) and 1886(d)(3)(E)(i) of the Act) and the law requires that the wage index budget neutrality adjustment not take into account the requirement that we set the labor-related share for hospitals with wage indexes less than or equal to 1.0000 at the more advantageous level of 62 percent for FY 2017, we separated these two adjustments and applied them individually to the standardized amount. Applying these factors individually rather than as a combined factor has no effect mathematically on adjusting the standardized amount.

C. Reclassified Hospitals—Budget Neutrality Adjustment

Section 1886(d)(8)(B) of the Act provides that certain rural hospitals are deemed urban. In addition, section 1886(d)(10) of the Act provides for the reclassification of hospitals based on determinations by the MGCRB. Under section 1886(d)(10) of the Act, a hospital may be reclassified for purposes of the wage index.

Under section 1886(d)(6)(D) of the Act, the Secretary is required to adjust the standardized amount to ensure that aggregate payments under the IPPS after implementation of the provisions of sections 1886(d)(6)(B) and (C) and 1886(d)(10) of the Act are equal to the aggregate prospective payments that would have been made absent these provisions. We note that the wage index adjustments provided for under section 1886(d)(13) of the Act are not budget neutral. Section 1886(d)(13)(H) of the Act provides that any increase in a wage index under section 1886(d)(13) shall not be taken into account in applying any budget neutrality adjustment with respect to such index under section 1886(d)(6)(D) of the Act. To calculate the budget neutrality adjustment factor for FY 2017, we used FY 2015 discharge data to simulate payments and compared the following:

- Aggregate payments using the FY 2017 labor-related share percentages, FY 2017 relative weights and FY 2017 wage data prior to any reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, and the applied the FY 2017 hospital readmissions payment adjustments and the estimated FY 2017 hospital VBP payment adjustments; and
- Aggregate payments using the FY 2017 labor-related share percentages, FY 2017 relative weights, and FY 2017 wage data after such reclassifications, and applied the same FY 2017 hospital readmissions payment adjustments and the estimated FY 2017 hospital VBP payment adjustments applied above.

We note that the reclassifications applied under the second simulation and comparison are those listed in Table 2 associated with this final rule, which is available via the Internet on the CMS Web site. This table reflects reclassification crosswalks for FY 2017, and applies the policies explained in section III. of the preamble to this final rule. Based on these simulations, we calculated a budget neutrality adjustment factor of 0.988224 to ensure that the effects of these provisions are budget neutral, consistent with the statute.

The FY 2017 budget neutrality adjustment factor was applied to the standardized amount after removing the effects of the FY 2016 budget neutrality adjustment factor. We note that the FY 2017 budget neutrality adjustment reflects FY 2017 wage index reclassifications approved by the MGCRB or the Administrator at the time of development of this final rule.

D. Rural Floor Budget Neutrality Adjustment

Under § 412.64(e)(4), we make an adjustment to the wage index to ensure that aggregate payments after implementation of the rural floor under section 4410 of the BBA (Pub. L. 105–33) and the imputed floor under § 412.64(b)(4) are equal to the aggregate prospective payments that would have been made in the absence of such provisions. Consistent with section 3141 of the Affordable Care Act and as discussed in section III.H. of the preamble of this final rule and codified at § 412.64(e)(4)(i), the budget neutrality adjustment for the rural floor and the imputed floor is a national adjustment to the wage index.

As noted above and as discussed in section III.H.2. of the preamble of this final rule, we are extending the imputed floor policy (both the original methodology and alternative
methodology) for FY 2017. Therefore, in order to ensure that aggregate payments to hospitals are not affected, similar to prior years, for FY 2017, we follow our policy of including the imputed floor (calculated under the original and alternative methodologies) in the national rural floor budget neutrality adjustment to the wage index.

Similar to our calculation in the FY 2015 IPPS/LTPP PPS final rule (79 FR 50369 through 50370), for FY 2017, we calculated a national rural Puerto Rico wage index. Because there are no rural Puerto Rico hospitals with established wage data, our calculation of the FY 2017 rural Puerto Rico wage index is based on the policy adopted in the FY 2008 IPPS final rule with comment period (72 FR 47323). That is, we used the unweighted average of the wage indexes from all CBSAs (urban areas) that are contiguous (share a border with) to the rural counties to compute the rural floor (72 FR 47323; 76 FR 51594).

Under the new OMB labor market area delineations, except for Arecibo, Puerto Rico (CBSA 11640), all other Puerto Rico urban areas are contiguous to a rural area. Therefore, based on our existing policy, the FY 2017 rural Puerto Rico wage index was calculated based on the average of the FY 2017 wage indexes for the following urban areas: Aguadilla-Isabela, PR (CBSA 10380); Guayama, PR (CBSA 25020); Mayaguez, PR (CBSA 32420); Ponce, PR (CBSA 38660), San German, PR (CBSA 41900) and San Juan-Carolina-Caguas, PR (CBSA 41980).

To calculate the national rural floor and imputed floor budget neutrality adjustment factor, we used FY 2015 discharge data to simulate payments and the post-reclassified national wage indexes and compared the following:
- National simulated payments without the national rural floor and imputed floor; and
- National simulated payments with the national rural floor and imputed floor.

Based on this comparison, we determined a national rural floor and imputed floor budget neutrality adjustment factor of 0.993200. The national adjustment was applied to the national wage indexes to produce a national rural floor and imputed floor budget neutral wage index.

e. Wage Index Transition Budget Neutrality

As discussed in section III.G. of the preamble of this final rule, in the past, we have provided for transition periods when adopting changes that have significant payment implications, particularly large negative impacts.

Similar to FY 2005, for FY 2015, we determined that the transition to using the new OMB labor market area delineations would have the largest impact on hospitals that were located in an urban county that became rural under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations. To alleviate the decreased payments associated with having a rural wage index, in calculating the area wage index, similar to the transition provided in the FY 2005 IPPS final rule, we finalized a policy to generally assign the hospitals in these counties the urban wage index value of the CBSA where they are physically located in FY 2014 for FYs 2015, 2016, and 2017. FY 2017 will be the final year of this 3-year transition policy. We note that the 1-year blended wage index transitional policy for all hospitals that experienced any decrease in their wage index value expired in FY 2015.

As discussed in the FY 2015 IPPS/LTPP PPS final rule (79 FR 50372 through 50373), in the past, CMS has budget neutralized transitional wage indexes. We stated that because we established a policy that allows for the application of a transitional wage index only when it benefits the hospital, we believe that it would be appropriate to ensure that such a transitional policy does not increase aggregate Medicare payments beyond the payments that would be made had we simply adopted the OMB delineations without any transitional provisions. Therefore, as we did for FYs 2015 and 2016, for FY 2017, we used our exceptions and adjustments authority under section 1886(d)(5)(I)(i) of the Act to make an adjustment to the national standardized amounts to ensure that total payments for the effect of the 3-year transitional wage index provisions will equal what payments would have been if we had fully adopted the new OMB delineations without providing these transitional provisions. To calculate the transitional wage index budget neutrality factor for FY 2017, we used FY 2015 discharge data to simulate payments and compared the following:
- Aggregate payments using the OMB delineations for FY 2017, the FY 2017 relative weights, FY 2017 wage data after such reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, application of the rural floor budget neutrality adjustment factor to the wage index, and application of the FY 2017 hospital readmissions payment adjustments and the estimated FY 2017 hospital VBP payment adjustments; and
- Aggregate payments using the OMB delineations for FY 2017, the FY 2017 relative weights, FY 2017 wage data after such reclassifications under sections 1886(d)(8)(B) and (C) and 1886(d)(10) of the Act, application of the rural floor budget neutrality adjustment factor to the wage index, application of the 3-year transitional wage indexes, and application of the same FY 2017 hospital readmissions payment adjustments and the estimated FY 2017 hospital VBP payment adjustments applied above.

Based on these simulations, we calculated a budget neutrality adjustment factor of 0.999994. Therefore, for FY 2017, we applied a transitional wage index budget neutrality adjustment factor of 0.999994 to the national average standardized amounts to ensure that the effects of these transitional wage indexes are budget neutral.

We note that the budget neutrality adjustment factor calculated above is based on the increase in payments in FY 2017 that will result from the final year of the 3-year transitional wage index policies. Therefore, we are applying this budget neutrality adjustment factor as a one-time adjustment to the FY 2017 national standardized amounts in order to offset the increase in payments in FY 2017 as a result of this final year of the 3-year transitional wage index. For FY 2017, we did not take into consideration the adjustment factor applied to the national standardized amounts in the previous fiscal year’s update when calculating the current fiscal year transitional wage index budget neutrality adjustment factor (that is, this adjustment is not applied cumulatively).

f. Case-Mix Budget Neutrality Adjustment

(1) Background

Below we summarize the recoupment adjustment to the FY 2017 payment rates, as required by section 631 of the ATRA, to account for the increase in aggregate payments as a result of not completing the prospective adjustment authorized under section 7(b)(1)(A) of Public Law 110–90 until FY 2013. We refer readers to section II.D. of the preamble of this final rule for a complete discussion regarding our policies for FY 2017 in this final rule and previously finalized policies (including our historical adjustments to the payment rates) relating to the effect of changes in documentation and coding that do not reflect real changes in case-mix.
(2) Recoupment or Repayment

Adjustment Authorized by Section 631 of the American Taxpayer Relief Act of 2012 (ATRA) to the National Standardized Amount

Section 631 of the ATRA amended section 7(b)(1)(B) of Public Law 110–90 to require the Secretary to make a recoupment adjustment totaling $11 billion by FY 2017. Our actuaries estimated that if CMS were to fully account for the $11 billion recoupment required by section 631 of the ATRA in FY 2014, a one-time – 0.3 percent adjustment to the standardized amount would be necessary. It is often our practice to delay or phase-in payment rate adjustments over more than 1 year, in order to moderate the effect on payment rates in any 1 year. Therefore, consistent with the policies that we have adopted in many similar cases, for FY 2014, FY 2015 and FY 2016, we applied a – 0.8 percent adjustment to the standardized amount. For FY 2017, as we proposed, we are applying a – 1.5 percent adjustment to the standardized amount. We refer the reader to section II. D. 6. of the preamble to this final rule for a complete discussion on this adjustment. We note that, as section 631 of the ATRA instructs the Secretary to make a recoupment adjustment only to the standardized amount, this adjustment does not apply to the hospital-specific payment rates.

g. Adjustment to IPPS Rates Resulting From 2-Midnight Policy

As discussed in section IV. P. of the preamble to this final rule, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50906 through 50954), we adopted the 2-midnight policy effective for dates of admission on or after October 1, 2013. We used our authority under section 1886(d)(3)(I)(i) of the Act to make a reduction of 0.2 percent to the standardized amount, the Puerto Rico standardized amount, and the hospital-specific payment rate, and we used our authority under section 1886(g) of the Act to make a reduction of 0.2 percent to the national capital Federal rate and the Puerto Rico-specific capital rate, in order to offset the estimated increase of $220 million in IPPS expenditures in FY 2014 as a result of the 2-midnight policy.

In Shands Jacksonville Medical Center, Inc. v. Burwell, No. 14–263 (D.D.C.) and related cases, hospitals challenged the 0.2 percent reduction in IPPS rates to account for the estimated $220 million in additional FY 2014 expenditures resulting from the 2- midnight policy. In its Memorandum Opinion, issued September 21, 2015, the Court found that the “Secretary’s interpretation of the exceptions and adjustments provision is a reasonable one” for this purpose. However, the Court also ordered the 0.2 percent reduction remanded back to the Secretary, without vacating the rule, to correct certain procedural deficiencies in the promulgation of the 0.2 percent reduction and reconsider the adjustment. In accordance with the Court’s order, we published a notice with comment period that appeared in the December 1, 2015 Federal Register (80 FR 75107), which discussed the basis for the 0.2 percent reduction and its underlying assumptions and invited comments on the same in order to facilitate our further consideration of the FY 2014 reduction.

We still believe that the assumptions underlying the 0.2 percent reduction to the rates put in place beginning in FY 2014 were reasonable at the time we made them in 2013. Nevertheless, taking all the factors discussed in section IV. P of the preamble to this final rule into account, we believe it is appropriate to use our authority under section 1886(d)(3)(I)(i) to prospectively remove, beginning in FY 2017, the 0.2 percent reduction to the standardized amount and hospital-specific rates put in place beginning in FY 2014. The 0.2 percent reduction was implemented by including a factor of 0.998 in the calculation of the FY 2014 standardized amount and hospital-specific rates, permanently reducing the standardized amount and hospital-specific rates for FY 2014 and future years until the 2.998 is removed. As we proposed, we are permanently removing the 0.998 reduction beginning in FY 2017 by including a factor of (1/0.998) in the calculation of the FY 2017 standardized amount and hospital-specific rate.

In addition, for the reasons discussed in section IV.P. of the preamble of this final rule, we believe that it is appropriate to use our authority under section 1886(d)(3)(I)(i) to temporarily increase the standardized amount and hospital-specific rates, only for FY 2017, to address the effect of the 0.2 percent reduction to the standardized amount and hospital-specific rates in effect for FY 2014, the 0.2 percent reduction to the standardized amount and hospital-specific rates in effect for FY 2015 (recall the 0.998 factor included in the calculation of the FY 2014 payment rates permanently reduced the payment rates for FY 2014 and future years until it is removed), and the 0.2 percent reduction to the standardized amount and hospital-specific rates in effect for FY 2016. We believe that the most transparent, expedient, and administratively feasible method to accomplish this is a temporary one-time prospective increase to the FY 2017 standardized amount and hospital-specific rates of 0.6 percent (= 0.2 percent + 0.2 percent + 0.2 percent). Specifically, we are including a factor of 1.006 in the calculation of the standardized amount and the hospital-specific rates in FY 2017 and then removing this temporary one-time prospective increase by including a factor of (1/1.006) in the calculation of the standardized amount and hospital-specific rates for FY 2018.

We refer the reader to section IV. P. of the preamble to this final rule for a complete discussion.

h. Outlier Payments

Section 1886(d)(5)(A) of the Act provides for payments in addition to the basic prospective payments for “outlier” cases involving extraordinarily high costs. To qualify for outlier payments, a case must have costs greater than the sum of the prospective payment rate for the MS–DRG, any IME and DSH payments, uncompensated care payments, any new technology add-on payments, and the “outlier threshold” or “fixed-loss” amount (a dollar amount by which the costs of a case must exceed payments in order to qualify for an outlier payment). We refer to the sum of the prospective payment rate for the MS–DRG, any IME and DSH payments, uncompensated care payments, any new technology add-on payments, and the outlier threshold as the outlier “fixed-loss cost threshold.” To determine whether the costs of a case exceed the fixed-loss cost threshold, a hospital’s CCR is applied to the total covered charges for the case to convert the charges to estimated costs. Payments for eligible cases are then made based on a marginal cost factor, which is a percentage of the estimated costs above the fixed-loss cost threshold. The marginal cost factor for FY 2017 is 80 percent, or 90 percent for burn MS–DRGs 927, 928, 929, 933, 934, and 935. We have used a marginal cost factor of 90 percent since FY 1989 (54 FR 36479 through 36480) for designated burn DRGs as well as a marginal cost factor of 80 percent for all other DRGs since FY 1995 (59 FR 45367).

In accordance with section 1886(d)(5)(A)(iv) of the Act, outlier payments for any year are projected to be not less than 5 percent nor more than 6 percent of total operating DRG payments (which does not include IME and DSH payments) plus outlier payments. When the outlier threshold, we compute the 5.1 percent target by dividing the total operating
outlier payments by the total operating DRG payments plus outlier payments. We do not include any other payments such as IME and DSH within the outlier target amount. Therefore, it is not necessary to include Medicare Advantage IME payments in the outlier threshold calculation. Section 1886(d)(3)(B) of the Act requires the Secretary to reduce the average standardized amount by a factor to account for the estimated proportion of total DRG payments made to outlier cases. More information on outlier payments may be found on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/outlier.html.

(1) FY 2017 Outlier Fixed-Loss Cost Threshold

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50977 through 50983), in response to public comments on the FY 2013 IPPS/LTCH PPS proposed rule, we made changes to our methodology for projecting the outlier fixed-loss cost threshold for FY 2014. We refer readers to the FY 2014 IPPS/LTCH PPS final rule for detailed discussion of the changes.

As we have done in the past, to calculate the FY 2017 outlier threshold, we inflated the charges on the MedPAR file by the total operating charge inflation factor; included hospitals in Maryland; and removed PPS excluded cancer hospitals who have a “V” in the fifth position of their provider number or a “F” or “F” in the sixth position.

• We excluded Medicare Advantage IME claims for the reasons described in section I.A.4. of this Addendum. We refer readers to the FY 2011 IPPS/LTCH PPS final rule for a complete discussion on our methodology of identifying and adding the total Medicare Advantage IME payment amount to the budget neutrality adjustments.

• In order to ensure that we captured only FFS claims, we included claims with a “Claim Type” of 60 (which is a field on the MedPAR file that indicates a claim is an FFS claim).

• In order to further ensure that we captured only FFS claims, we excluded claims with a “GHOPAID” indicator of 1 (which is a field on the MedPAR file that indicates a claim is not an FFS claim and is paid by a Group Health Organization).

• We examined the MedPAR file and removed pharmacy charges for anti-hemophilic blood factor (which are paid separately under the IPPS) with an indicator of “3” for blood clotting with a revenue code of “0636” from the covered charge field. We also removed organ acquisition charges from the covered charge field because organ acquisition is a pass-through payment not paid under the IPPS.

In the FY 2016 IPPS/LTCH final rule (80 FR 49779–49780), we stated that commenters were concerned that they were unable to replicate the calculation of the charge inflation factor that CMS used in the proposed rule. In response to those comments, we stated that we continue to believe that it is optimal to use the most recent period of charge data available to measure charge inflation. In addition, similar to FY 2016, for FY 2017 we grouped claims data by quarter in the table below. We have made available the CMS Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html (click on the link on the left titled “FY 2017 IPPS Proposed Rule Home Page” and then click the link “FY 2017 Proposed Rule Data Files”) a more detailed summary table by provider with the monthly charges that were used to compute the charge inflation factor. In the proposed rule we stated that we would continue to work with our systems teams and privacy office to explore expanding the information available in the current LDS structure, perhaps through the provision of a supplemental data file for future rulemaking.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$126,156,195,005</td>
<td>2,479,295</td>
<td>$134,250,323,661</td>
<td>2,546,078</td>
</tr>
<tr>
<td>2</td>
<td>122,171,248,575</td>
<td>2,445,370</td>
<td>126,880,227,174</td>
<td>2,416,569</td>
</tr>
<tr>
<td>3</td>
<td>119,364,629,662</td>
<td>2,364,553</td>
<td>122,165,668,615</td>
<td>2,308,537</td>
</tr>
<tr>
<td>4</td>
<td>124,733,843,923</td>
<td>2,436,787</td>
<td>90,677,073,204</td>
<td>1,696,180</td>
</tr>
<tr>
<td>Total</td>
<td>492,425,917,165</td>
<td>9,726,005</td>
<td>473,973,292,654</td>
<td>8,967,364</td>
</tr>
</tbody>
</table>

Under this methodology, to compute the 1-year average annualized rate-of-change in charges per case for FY 2017, as we proposed, we compared the average covered charge per case of $50,360 ($492,425,917,165/9,726,005) from the second quarter of FY 2014 through the first quarter of FY 2015 (January 1, 2014, through December 31, 2014) to the average covered charge per case of $52,855 ($473,973,292,654/8,967,364) from the second quarter of FY 2015 through the first quarter of FY 2016 (January 1, 2015, through December 31, 2015). This rate-of-change
was 4.4 percent (1.043957) or 9.8 percent (1.089846) over 2 years. The billed charges are obtained from the claim from the MedPAR file and inflated by the inflation factor specified above.

Comment: Many commenters were concerned with what they stated was a lack of transparency with respect to the charge inflation component of the fixed-loss threshold calculation. One commenter stated that it is unable to match the figures in the table from the proposed rule with publicly available data sources and that CMS did not disclose the source of the data. The commenter further stated that CMS has not made the necessary data available, or any guidance that describes whether and how CMS edited such data to arrive at the total of quarterly charges and charges per case used to measure charge inflation. Consequently, the commenter stated that the table provided in the proposed rule is not useful in assessing the accuracy of the charge inflation figure that CMS used in the proposed rule to calculate the outlier threshold. The commenter noted that CMS provided a detailed summary table by provider with the monthly charges that were used to compute the charge inflation factor. The commenters appreciated the additional data, but still believed that CMS has not provided enough specific information and data to allow the underlying numbers used in CMS’ calculation of the charge inflation factor to be replicated and/or tested for accuracy. The commenter concluded that in the absence of more specific data and information about how the data were edited by CMS to arrive at the totals used in the charge inflation calculation, CMS has not provided adequate notice to allow for meaningful comment.

Response: We responded to a similar comment in the FY 2015 IPPS/LTCH final rule (79 FR 50375) and FY 2016 IPPS/LTCH final rule (80 FR 49779 through 49780) and refer readers to those final rules for our complete response. While the charge data may not be immediately available after the issuance of this final rule, we believe the data and supporting files we have provided will provide the commenters with additional information that can be verified once the charge data are available. We have produced the actual figures we used and disclosed our formula. We intend to post the actual charge data as soon as possible so that the public can verify the raw data with the figures we used in the calculation. As stated above and in the proposed rule, the charge data used to calculate the charge inflation factor are sourced from our MedPAR database.

In addition, as stated in last year’s final rule, we continue to believe that it is optimal to use the most recent period of charge data available to measure charge inflation. Similar to last year, the commenters did not propose to use charge data from a different period to compute the charge inflation factor. If we computed the charge inflation factor using the latest data available to the public at the time of issuance of this final rule, we would need to compare charge data from FY 2014 (October 2013–September 2014) to FY 2015 (October 2014–September 2015), data which would be at least 10 months old compared to the charge data we currently use that are 4 months old.

Comment: One commenter requested that CMS add the claims data used to compute the charge inflation factor to the list of limited data set (LDS) files that can be ordered through the usual LDS data request process. Response: There are limitations on how expeditiously we can add the charge data to the LDS. After consulting with our systems teams and privacy office, we do not anticipate being able to provide the charge data we currently use to calculate the charge inflation factor within the commenter’s requested timeframe. We prefer using the latest data available at the time of the proposed and final rules to compute the charge inflation factor because we believe it leads to greater accuracy in the calculation of the fixed-loss cost outlier threshold. If the charge data are still not available for replication after the FY 2018 IPPS/LTCH PPS proposed rule, we would invite commenters to suggest alternative data sources that we could use to calculate the charge inflation factor (such as older data). As noted, we believe that using older data may not provide the same accuracy as the current data we use, and therefore the commenters should inform us which is more important to them, the need to have complete access to the data we use in our methodology or the greater accuracy provided by the use of more up-to-date data. As noted above, the data we currently use will eventually be publicly available for replication but not in the timeframe the commenter has requested. To summarize, we are confronted with a dilemma—either we use older data that commenters can access earlier, or we use the most up-to-date data which will be more accurate, but will not be available to the public until after publication of the proposed and final rules. We believe the latter approach, using the best available data to produce a more accurate charge inflation factor, is preferable.

As we have done in the past, in the FY 2017 IPPS/LTCH proposed rule, we proposed to establish the FY 2017 outlier threshold using hospital CCRs from the December 2015 update to the Provider-Specific File (PSF)—the most recent available data at the time of the development of the proposed rule. As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we apply the following edits to providers’ CCRs in the PSF. We believe that these edits are appropriate in order to accurately model the outlier threshold. We first search for Indian Health Service providers and those providers assigned the statewide average CCR from the current fiscal year. We then replace these CCRs with the statewide average CCR for the upcoming fiscal year. We also assign the statewide average CCR (for the upcoming fiscal year) to those providers that have no value in the CCR field in the PSF. We do not apply the adjustment factors described below to hospitals assigned the statewide average CCR.

For FY 2017, we proposed to continue to apply an adjustment factor to the CCRs to account for cost and charge inflation (as explained below). We proposed that, if more recent data become available, we would use those data to calculate the final FY 2017 outlier threshold.

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we adopted a new methodology to adjust the CCRs. Specifically, we finalized a policy to compare the national average case-weighted operating and capital CCR from the most recent update of the PSF to the national average case-weighted operating and capital CCR from the same period of the prior year.

Therefore, as we did for the last 3 fiscal years, we proposed to adjust the CCRs from the December 2015 update of the PSF by comparing the percentage change in the national average case-weighted operating CCR and capital CCR from the December 2014 update of the PSF to the national average case-weighted operating CCR and capital CCR from the December 2015 update of the PSF. We note that, in the proposed rule, we used total transfer-adjusted cases from FY 2015 to determine the national average case-weighted CCRs for both sides of the comparison. As stated in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50979), we believe that it is appropriate to use the same case count on both sides of the comparison because that will produce the true percentage change in the average case-weighted operating and capital CCR from 1 year.
to the next without any effect from a change in case count on different sides of the comparison.

Using the proposed methodology above, for the proposed rule, we calculated a December 2014 operating national average case-weighted CCR of 0.289007 and a December 2015 operating national average case-weighted CCR of 0.272363. We then calculated the percentage change between the two national operating case-weighted CCRs by subtracting the December 2014 operating national average case-weighted CCR from the December 2015 operating national average case-weighted CCR and then dividing the result by the December 2014 national operating average case-weighted CCR. This resulted in a proposed national operating CCR adjustment factor of 0.969695.

We used the same methodology proposed above to adjust the capital CCRs. Specifically, for the proposed rule, we calculated a December 2014 capital national average case-weighted CCR of 0.024615 and a December 2015 capital national average case-weighted CCR of 0.024008. We then calculated the percentage change between the two national capital case-weighted CCRs by subtracting the December 2014 capital national average case-weighted CCR from the December 2015 capital national average case-weighted CCR and then dividing the result by the December 2014 capital national average case-weighted CCR. This resulted in a proposed national capital CCR adjustment factor of 0.973495.

As discussed above, for FY 2017, we applied the final year of the 3-year transitional wage index because of the adoption of the new OMB labor market area delineations. Also, as discussed in section III.B.3. of the preamble to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50160 and 50161) and in section III.H.3. of the preamble of this final rule, sections 1886(q) and 1886(o) of the Act establish the Hospital Readmissions Reduction Program and the Hospital VBP Program, respectively. We do not believe that it is appropriate to include the hospital VBP payment adjustments and the hospital readmissions payment adjustments in the outlier threshold calculation or the outlier offset to the standardized amount. Specifically, consistent with our definition of the base operating DRG payment amount for the Hospital Readmissions Reduction Program under § 412.152 and the Hospital VBP Program under § 412.160, outlier payments under section 1886(d)(5)(A) of the Act are not affected by these payment adjustments. Therefore, outlier payments will continue to be calculated based on the unadjusted base DRG payment amount (as opposed to using the base-operating DRG payment amount adjusted by the hospital readmissions payment adjustment and the hospital VBP payment adjustment). Consequently, we proposed to exclude the hospital VBP payment adjustments and the hospital readmissions payment adjustments from the calculation of the outlier fixed-loss cost threshold.

We note that, to the extent section 1886(r) of the Act modifies the DSH payment methodology under section 1886(d)(5)(F) of the Act, the new uncompensated care payment under section 1886(r)(2) of the Act, like the empirically justified Medicare DSH payment under section 1886(r)(1) of the Act, may be considered an amount payable under section 1886(d)(5)(F) of the Act such that it would be reasonable to include the payment in the outlier determination under section 1886(d)(5)(A) of the Act. As we have done since the implementation of uncompensated care payments in FY 2014, for FY 2017 we proposed allocating an estimated per-discharge uncompensated care payment amount to all cases for the hospitals eligible to receive the uncompensated care payment amount in the calculation of the outlier fixed-loss cost threshold methodology. We continue to believe that allocating an eligible hospital’s estimated uncompensated care payment to all cases equally in the calculation of the outlier fixed-loss cost threshold will best approximate the amount we will pay in uncompensated care payments during the year because, when we make claim payments to a hospital eligible for such payments, we will be making estimated per-discharge uncompensated care payments to all cases equally. Furthermore, we continue to believe that using the estimated per-claim
The commenter stated that it was concerned that CMS believed the agency would reach the 5.1 percent target for FY 2015 (based on the estimate in the FY 2016 proposed rule) only to learn that the original estimate in the FY 2016 proposed rule was overestimated compared to the FY 2017 proposed rule. The commenter concluded it is critical that CMS not allow the use of incomplete data from prior years to affect its calculation of current period thresholds.

Another commenter noted that the final outlier threshold established by CMS is always significantly lower than the threshold set forth in the proposed rule. The commenter believed the decline is most likely due to the use of updated CCRs or other data in calculating the final threshold. The commenter stated this emphasizes that CMS must use the most recent data available when the agency calculates the outlier threshold. The commenter cited as an example that, in the proposed rule, CMS used data from the December 2015 PSF file, but at the time the proposed rule was issued, the March 2016 PSF file was available.

Response: We responded to similar comments in the FY 2015 IPPS/LTCH PPS final rule (78 FR 50379) and the FY 2016 IPPS/LTCH PPS final rule (80 FR 49783) and refer readers to those final rules for our complete responses.

Comment: One commenter was concerned that CMS constantly misestimates the 5.1 percent target. The commenter recommended that CMS conduct additional analysis to evaluate the methodology for incorporating uncompensated care and DSH payments into the outlier threshold calculation.

Response: As discussed above, we include updates to the uncompensated care payment calculation as part of the fixed-loss outlier threshold calculation. Without additional information or data analysis, we are unsure what exactly the commenter is referencing when the commenter stated that CMS should further evaluate the methodology for incorporating uncompensated care and DSH payments into the outlier threshold calculation. It would have been beneficial to us if the commenter had specifically identified the areas that CMS should review and suggested alternative approaches. We already conduct analysis of uncompensated care and DSH payments, but are open to other approaches. However, without more specificity, we cannot meaningfully respond to or adopt the commenter’s suggestion.

After consideration of the public comments we received, we are not making any changes to our methodology in this final rule for FY 2017. Therefore, we are using the same methodology we proposed to calculate the final outlier threshold.

Similar to the table provided in the proposed rule, for this final rule, we are providing the following table that displays covered charges and cases by quarter in the periods used to calculate the charge inflation factor based on the latest claims data from the MedPAR file.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$135,268,674,848</td>
<td>2,559,124</td>
<td>$100,321,539,956</td>
<td>1,825,635</td>
</tr>
<tr>
<td>2</td>
<td>122,466,434,387</td>
<td>2,450,512</td>
<td>127,944,664,075</td>
<td>2,432,402</td>
</tr>
<tr>
<td>3</td>
<td>119,706,545,046</td>
<td>2,370,067</td>
<td>124,301,570,497</td>
<td>2,340,555</td>
</tr>
</tbody>
</table>
Under our current methodology, to compute the 1-year average annualized rate-of-change in charges per case for FY 2017, we compared the average covered charge per case of $51,171 ($502,567,787,353/9,821,348) from the third quarter of FY 2014 through the second quarter of FY 2015 (April 1, 2014, through March 31, 2015) to the average covered charge per case of $56,361 ($479,546,875,755/8,941,661) from the third quarter of FY 2015 through the second quarter of FY 2016 (April 1, 2015, through March 31, 2016). This rate-of-change is 4.8 percent (1.048067) or 9.8 percent (1.098446) over 2 years.

As we have done in the past, we are establishing the FY 2017 outlier threshold using hospital CCRs from the March 2016 update to the Provider-Specific File (PSF)—the most recent available data at the time of development of this final rule. For FY 2017, we also are continuing to apply an adjustment factor to the CCRs to account for cost and charge inflation (as explained below).

Therefore, as we did for the last 3 fiscal years, we are adjusting the CCRs from the March 2016 update of the PSF by comparing the percentage change in the national average case-weighted operating CCR and capital CCR from the March 2015 update of the PSF to the national average case-weighted operating CCR and capital CCR from the March 2016 update of the PSF. We note that we used total transfer-adjusted cases from FY 2015 to determine the national average case-weighted CCRs for both sides of the comparison.

Using the methodology above, we calculated a March 2015 operating national average case-weighted CCR of 0.278734 and a March 2016 operating national average case-weighted CCR of 0.270034. We then calculated the percentage change between the two national operating case-weighted CCRs by subtracting the March 2015 operating national average case-weighted CCR from the March 2016 operating national average case-weighted CCR and then dividing the result by the March 2015 national operating average case-weighted CCR. This resulted in a national operating CCR adjustment factor of 0.96879.

We also used the same methodology above to adjust the capital CCRs. Specifically, we calculated a March 2015 capital national average case-weighted CCR of 0.024375 and a March 2016 capital national average case-weighted CCR of 0.023688. We then calculated the percentage change between the two national capital case-weighted CCRs by subtracting the March 2015 capital national average case-weighted CCR from the March 2016 capital national average case-weighted CCR and then dividing the result by the March 2015 capital national average case-weighted CCR. This resulted in a national capital CCR adjustment factor of 0.971819.

As discussed above, similar to the proposed rule, for FY 2017 we applied the following policies (see discussion above for more details):

- The final year of the 3-year transitional wage index because of the adoption of the new OMB labor market area delineations.
- In accordance with section 10324(a) of the Affordable Care Act, we created a wage index floor of 1.0000 for all hospitals located in States determined to be frontier States.
- As we did in establishing the FY 2009 outlier threshold (73 FR 57891), in our projection of FY 2017 outlier payments, we did not make any adjustments for the possibility that hospitals’ CCRs and outlier payments may be reconciled upon cost report settlement.
- We excluded the hospital VBP payment adjustments and the hospital readmissions payments adjustments from the calculation of the outlier fixed-loss cost threshold.
- We used the estimated per-discharge uncompensated care payments to hospitals eligible for the uncompensated care payment for all cases in the calculation of the outlier fixed-loss cost threshold methodology.

Using this methodology, we used the formula described in section I.C.1. of this Addendum to simulate and calculate the Federal payment rate and outlier payments for all claims. We calculated a threshold of $23,570 and calculated total operating Federal payments of $479,546,875,755 and total outlier payments of $4,479,256,519. We then divided total outlier payments by total operating Federal payments plus total outlier payments and determined that this threshold met the 5.1 percent target. As a result, we are finalizing an outlier fixed-loss cost threshold for FY 2017 equal to the prospective payment rate for the MS–DRG, plus any IME, empirically justified Medicare DSH payments, estimated uncompensated care payment, and any add-on payments for new technology, plus $23,570.

(2) Other Changes Concerning Outliers

As stated in the FY 1994 IPPS final rule (58 FR 46348), we establish an outlier threshold that is applicable to both hospital inpatient operating costs and hospital inpatient capital-related costs. When we modeled the combined operating and capital outlier payments, we found that using a common threshold resulted in a lower percentage of outlier payments for capital-related costs than for operating costs. We project that the thresholds for FY 2017 will result in outlier payments that will equal 5.1 percent of operating DRG payments and 6.14 percent of capital payments based on the Federal rate.

In accordance with section 1886(d)(3)(B) of the Act, we reduced the FY 2017 standardized amount by the same percentage to account for the projected proportion of payments paid as outliers.

The outlier adjustment factors that were applied to the standardized amount based on the FY 2017 outlier threshold are as follows:

<table>
<thead>
<tr>
<th>Operating standardized amounts</th>
<th>Capital federal rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>National .....</td>
<td>0.948999</td>
</tr>
</tbody>
</table>

We applied the outlier adjustment factors to the FY 2017 payment rates after removing the effects of the FY 2016 outlier adjustment factors on the standardized amount.

To determine whether a case qualifies for outlier payments, we apply hospital-specific CCRs to the total covered charges for the case. Estimated operating and capital costs for the case are calculated separately by applying separate operating and capital CCRs. These costs are then combined and compared with the outlier fixed-loss cost threshold.
Under our current policy at §412.84, we calculate operating and capital CCR ceilings and assign a statewide average CCR for hospitals whose CCRs exceed 3.0 standard deviations from the mean of the log distribution of CCRs for all hospitals. Based on this calculation, for hospitals for which the MAC computes operating CCRs greater than 1.183 or capital CCRs greater than 0.17, or hospitals for which the MAC is unable to calculate a CCR (as described under §412.84(i)(3) of our regulations), statewide average CCRs are used to determine whether a hospital qualifies for outlier payments. Table 8A listed in section VI of this Addendum (and available only via the Internet on the CMS Web site) contains the statewide average operating CCRs for urban hospitals and for rural hospitals for which the MAC is unable to compute a hospital-specific CCR within the above range. Effective for discharges occurring on or after October 1, 2016, these statewide average ratios will replace the ratios posted on our Web site at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcutelnpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Final-Rule-Tables.html. Table 8B listed in section VI of this Addendum (and available via the Internet on the CMS Web site) contains the comparable statewide average capital CCRs. As previously stated, the CCRs in Tables 8A and 8B will be used during FY 2017 when hospital-specific CCRs based on the latest settled cost report either are not available or are outside the range noted above. Table 8C listed in section VI of this Addendum (and available via the Internet on the CMS Web site) contains the statewide average total CCRs used under the LTCH PPS as discussed in section V. of this Addendum.

We finally note that we published a manual update (Change Request 3966) to our outlier policy on October 12, 2005, which updated Chapter 3, Section 20.1.2 of the Medicare Claims Processing Manual. The manual update covered an array of topics, including CCRs, reconciliation, and the time value of money. We encourage hospitals that are assigned the statewide average operating and/or capital CCRs to work with their MAC on a possible alternative operating and/or capital CCR as explained in Change Request 3966. Use of an alternative CCR developed by the hospital in conjunction with the MAC can avoid possible overpayments or underpayments at cost report settlement, thereby ensuring better accuracy when making outlier payments and negating the need for outlier reconciliation. We also note that a hospital may request an alternative operating or capital CCR ratio at any time as long as the guidelines of Change Request 3966 are followed. In addition, as mentioned above, we published an additional manual update (Change Request 7192) to our outlier policy on December 3, 2010, which also updated Chapter 3, Section 20.1.2 of the Medicare Claims Processing Manual. The manual update outlines the outlier reconciliation process for hospitals and Medicare contractors. To download and view the manual instructions on outlier reconciliation, we refer readers to the CMS Web site: http://www.cms.hhs.gov/manuals/downloads/clm104c03.pdf.

(3) FY 2015 Outlier Payments

Our current estimate, using available FY 2015 claims data, is that actual outlier payments for FY 2015 were approximately 4.68 percent of actual total MS–DRG payments. Therefore, the data indicate, for FY 2015, the percentage of actual outlier payments relative to actual total payments is lower than we projected for FY 2015. Consistent with the policy and statutory interpretation we have maintained since the inception of the IPPS, we do not make retroactive adjustments to outlier payments to ensure that total outlier payments for FY 2015 are equal to 5.1 percent of total MS–DRG payments. As explained in the FY 2003 Outlier Final Rule (68 FR 34502), if we were to make retroactive adjustments to all outlier payments to ensure total payments are 5.1 percent of MS–DRG payments (by retroactively adjusting outlier payments), we would be removing the important aspect of the prospective nature of the IPPS. Because such an across-the-board adjustment would either lead to more or less outlier payments for all hospitals, hospitals would no longer be able to reliably approximate their payment for a patient while the patient is still hospitalized. We believe that it would be neither necessary nor appropriate to make such an aggregate retroactive adjustment. Furthermore, we believe it is consistent with the intent of the language at section 1886(d)(5)(A)(iv) of the Act not to make retroactive adjustments to outlier payments. This section calls for the Secretary to ensure that outlier payments are equal to or greater than 5 percent and less than or equal to 6 percent of projected or estimated (not actual) MS–DRG payments. We believe this language reflects the intent of Congress to approximate the predictability of the IPPS. We believe that an important goal of a PPS is predictability.

Therefore, we believe that the fixed-loss outlier threshold should be projected based on the best available historical data and should not be adjusted retroactively. A retroactive change to the fixed-loss outlier threshold would affect all hospitals subject to the IPPS, thereby undercutting the predictability of the system as a whole.

We note that because the MedPAR claims data for the entire FY 2016 will not be available until after September 30, 2016, we are unable to provide an estimate of actual outlier payments for FY 2016 based on FY 2016 claims data in this final rule. We will provide an estimate of actual FY 2016 outlier payments in the FY 2018 IPPS/LTCH PPS proposed rule.

5. FY 2017 Standardized Amount

The adjusted standardized amount is divided into labor-related and nonlabor-related portions. Tables 1A and 1B listed and published in section VI. of this Addendum (and available via the Internet on the CMS Web site) contain the national standardized amounts that we are applying to all hospitals, except hospitals located in Puerto Rico, for FY 2017. The standardized amount for hospitals in Puerto Rico is shown in Table 1C listed and published in section VI. of this Addendum (and available via the Internet on the CMS Web site). The amounts shown in Tables 1A and 1B differ only in that the labor-related share applied to the standardized amounts in Table 1A is 69.6 percent, and the labor-related share applied to the standardized amounts in Table 1B is 62 percent. In accordance with sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act, we are applying a labor-related share of 62 percent, unless application of that percentage will result in lower payments to a hospital than would otherwise be made. In effect, the statutory provision means that we will apply a labor-related share of 62 percent for all hospitals whose wage indexes are less than or equal to 1.0000.

In addition, Tables 1A and 1B include the standardized amounts reflecting the applicable percentage increases for FY 2017.

The labor-related and nonlabor-related portions of the national average standardized amounts for Puerto Rico hospitals for FY 2017 are set forth in Table 1C listed and published in section VI. of this Addendum (and available via the Internet on the CMS Web site). Similar to above, section 1886(d)(9)(C)(iv) of the Act, as amended by section 403(b) of Public Law 108–173, provides that the labor-related share for hospitals located in Puerto Rico be 62 percent, unless the
application of that percentage would result in lower payments to the hospital.

The following table illustrates the changes from the FY 2016 national standardized amount to the FY 2017 national standardized amount. The second through fifth columns display the changes from the FY 2016 standardized amount to the FY 2017 standardized amount. The first row of the table shows the updated (through FY 2016) average standardized amount. The first row of the table shows the updated (through FY 2016) average standardized amount after restoring the FY 2016 offsets for outlier payments, demonstration budget neutrality, geographic reclassification budget neutrality, new labor market delineation wage index transition budget neutrality, retrospective documentation and coding adjustment under section 7(b)(1)(B) of Public Law 110–90 and an adjustment to the standardized amount using our authority under section 1886(d)(5)(I)(i) of the Act to permanently prospectively remove the 0.2 percent reduction to the payment rate established in FY 2014 to offset the estimated increase in IPPS expenditures as a result of the 2-midnight policy. The MS–DRG reclassification and recalibration and wage index budget neutrality adjustment factors are cumulative. Therefore, those FY 2016 adjustment factors were not removed from this table.

<table>
<thead>
<tr>
<th>FY 2016 Base Rate after removing:</th>
<th>Hospital submitted quality data and is a meaningful EHR user</th>
<th>Hospital submitted quality data and is NOT a meaningful EHR user</th>
<th>Hospital did NOT submit quality data and is a meaningful EHR user</th>
<th>Hospital did NOT submit quality data and is NOT a meaningful EHR user</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. FY 2016 Geographic Reclassification Budget Neutrality (0.988169)</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,420.31; Nonlabor (38 percent): $1,919.26.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,494.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,494.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,494.09; Nonlabor (38 percent): $2,399.07.</td>
</tr>
<tr>
<td>2. FY 2016 Rural Community Hospital Demonstration Program Budget Neutrality (0.999837)</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,839.57; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,914.28; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,914.28; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,914.28; Nonlabor (38 percent): $2,399.07.</td>
</tr>
<tr>
<td>3. Cumulative FY 2008, FY 2009, FY 2012, FY 2013, FY 2014, FY 2015 and FY 2016 Documentation and Coding Adjustments as Required under Sections 7(b)(1)(A) and 7(b)(1)(B) of Pub. L. 110–90 and Documentation and Coding Recoupment Adjustment as Required under Section 631 of the American Taxpayer Relief Act of 2012 (0.9255)</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $3,914.28; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
</tr>
<tr>
<td>4. FY 2016 Operating Outlier Offset (0.948998)</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
</tr>
<tr>
<td>5. FY 2016 New Labor Market Delineation Wage Index Transition Budget Neutrality Factor (0.999994)</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
</tr>
<tr>
<td>6. FY 2017 2-Midnight Rule Permanent Adjustment (1/0.998)</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
<td>If Wage Index is Greater Than 1.0000: Labor (69.6 percent): $4,394.09; Nonlabor (38 percent): $2,399.07.</td>
</tr>
<tr>
<td>Cumulative Factor: FY 2008, FY 2009, FY 2012, FY 2013, FY 2014, FY 2015, FY 2016 and FY 2017 Documentation and Coding Adjustment as Required under Sections 7(b)(1)(A) and 7(b)(1)(B) of Pub. L. 110–90 and Documentation and Coding Recoupment Adjustment as Required under Section 631 of the American Taxpayer Relief Act of 2012.</td>
<td>1.0165</td>
<td>0.99625</td>
<td>1.00075</td>
<td>0.9895</td>
</tr>
<tr>
<td>FY 2017 Update Factor</td>
<td>0.999079</td>
<td>0.999079</td>
<td>0.999079</td>
<td>0.999079</td>
</tr>
<tr>
<td>FY 2017 MS–DRG Recalibration Budget Neutrality Factor.</td>
<td>1.000090</td>
<td>1.000090</td>
<td>1.000090</td>
<td>1.000090</td>
</tr>
<tr>
<td>FY 2017 Wage Index Transition Budget Neutrality Factor.</td>
<td>0.999994</td>
<td>0.999994</td>
<td>0.999994</td>
<td>0.999994</td>
</tr>
<tr>
<td>FY 2017 Reclassification Budget Neutrality Factor.</td>
<td>0.988224</td>
<td>0.988224</td>
<td>0.988224</td>
<td>0.988224</td>
</tr>
<tr>
<td>FY 2017 Operating Outlier Factor</td>
<td>0.948999</td>
<td>0.948999</td>
<td>0.948999</td>
<td>0.948999</td>
</tr>
<tr>
<td>Cumulative Factor: FY 2008, FY 2009, FY 2012, FY 2013, FY 2014, FY 2015, FY 2016 and FY 2017 Documentation and Coding Adjustment as Required under Sections 7(b)(1)(A) and 7(b)(1)(B) of Pub. L. 110–90 and Documentation and Coding Recoupment Adjustment as Required under Section 631 of the American Taxpayer Relief Act of 2012.</td>
<td>0.9118</td>
<td>0.9118</td>
<td>0.9118</td>
<td>0.9118</td>
</tr>
<tr>
<td>FY 2017 New Labor Market Delineation Wage Index 3-Year Hold Harmless Transition Budget Neutrality Factor.</td>
<td>0.999994</td>
<td>0.999994</td>
<td>0.999994</td>
<td>0.999994</td>
</tr>
<tr>
<td>FY 2017 2–Midnight Rule One-Time Prospective Increase.</td>
<td>1.006</td>
<td>1.006</td>
<td>1.006</td>
<td>1.006</td>
</tr>
<tr>
<td>National Standardized Amount for FY 2017 if Wage Index is Greater Than 1.0000: LaborNon-Labor Share Percentage (69.6/30.4).</td>
<td>Labor: $3,839.57; Nonlabor: $1,677.06.</td>
<td>Labor: $3,914.28; Nonlabor: $2,096.32.</td>
<td>Labor: $3,914.28; Nonlabor: $2,096.32.</td>
<td>Labor: $3,914.28; Nonlabor: $2,096.32.</td>
</tr>
</tbody>
</table>
B. Adjustments for Area Wage Levels and Cost-of-Living

Tables 1A through 1C, as published in section VI. of this Addendum (and available via the Internet on the CMS Web site), contain the labor-related and nonlabor-related shares that we used to calculate the prospective payment rates for hospitals located in the 50 States, the District of Columbia, and Puerto Rico for FY 2017. This section addresses two types of adjustments to the standardized amounts that are made in determining the prospective payment rates as described in this Addendum.

1. Adjustment for Area Wage Levels

Sections 1886(d)(3)(E) and 1886(d)(9)(C)(iv) of the Act require that we make an adjustment to the labor-related portion of the national prospective payment rate to account for area differences in hospital wage levels. This adjustment is made by multiplying the labor-related portion of the adjusted standardized amounts by the appropriate wage index for the area in which the hospital is located. In section III. of the preamble of this final rule, we discuss the data and methodology for the FY 2017 wage index.

2. Adjustment for Cost-of-Living in Alaska and Hawaii

Section 1886(d)(5)(H) of the Act provides discretionary authority to the Secretary to make such adjustments as the Secretary deems appropriate to take into account the unique circumstances of hospitals located in Alaska and Hawaii. Higher labor-related costs for these two States are taken into account in the adjustment for area wages described above. To account for higher nonlabor-related costs for these two States, we multiply the nonlabor-related portion of the standardized amount for hospitals located in Alaska and Hawaii by an adjustment factor.

In the FY 2013 IPPS/LTCH PPS final rule, we established a methodology to update the COLA factors for Alaska and Hawaii that were published by the U.S. Office of Personnel Management (OPM) every 4 years (at the same time as the update to the labor-related share of the IPPS market basket), beginning in FY 2014. We refer readers to the FY 2013 IPPS/LTCH PPS proposed and final rules for additional background and a detailed description of this methodology (77 FR 28145 through 28146 and 77 FR 53700 through 53701, respectively).

For FY 2014, in the FY 2014 IPPS/LTCH PPS final rule (78 FR 50985 through 50987), we updated the COLA factors published by OPM for 2009 (as these are the last COLA factors OPM published prior to transitioning from COLAs to locality pay) using the methodology that we finalized in the FY 2013 IPPS/LTCH PPS final rule.

Based on the policy finalized in the FY 2013 IPPS/LTCH PPS final rule, we are continuing to use the same COLA factors in FY 2017 that were used in FY 2016 to adjust the nonlabor-related portion of the standardized amount for hospitals located in Alaska and Hawaii. Below is a table listing the COLA factors for FY 2017.

**FY 2017 COST-OF-LIVING ADJUSTMENT FACTORS: ALASKA AND HAWAII HOSPITALS**

<table>
<thead>
<tr>
<th>Area</th>
<th>Cost of living adjustment factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alaska:</td>
<td></td>
</tr>
<tr>
<td>City of Anchorage and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>City of Fairbanks and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>City of Juneau and 80-kilometer (50-mile) radius by road</td>
<td>1.23</td>
</tr>
<tr>
<td>Rest of Alaska</td>
<td>1.25</td>
</tr>
<tr>
<td>Hawaii:</td>
<td></td>
</tr>
<tr>
<td>City and County of Honolulu</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Hawaii</td>
<td>1.19</td>
</tr>
<tr>
<td>County of Kauai</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Maui and County of Kalawao</td>
<td>1.25</td>
</tr>
</tbody>
</table>

Based on the policy finalized in the FY 2013 IPPS/LTCH PPS final rule, the next update to the COLA factors for Alaska and Hawaii will occur in FY 2018.

C. Calculation of the Prospective Payment Rates

**General Formula for Calculation of the Prospective Payment Rates for FY 2017**

In general, the operating prospective payment rate for all hospitals (including hospitals in Puerto Rico) paid under the IPPS, except SCHs and MDHs, for FY 2017 equals the Federal rate (which includes uncompensated care payments); the updated hospital-specific rate based on FY 1982 costs per discharge; the updated hospital-specific rate based on FY 1987 costs per discharge; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge to determine the rate that yields the greatest aggregate payment.

The prospective payment rate for SCHs for FY 2017 equals the higher of the applicable Federal rate, or the hospital-specific rate as described below. The prospective payment rate for MDHs for FY 2017 equals the higher of the Federal rate, or the Federal rate plus 75 percent of the difference between the Federal rate and the hospital-specific rate as described below. For MDHs, the updated hospital-specific rate is based on FY 1982, FY 1987 or FY 2002 costs per discharge, whichever yields the greatest aggregate payment.

1. Operating and Capital Federal Payment Rate and Outlier Payment Calculation

**Note:** The formula below is used for actual claim payment and is also used by CMS to project the outlier threshold for the upcoming FY. The difference is the source of some of the variables in the formula. For example, operating and capital CCRs for actual claim payment are from the PSF while CMS uses an adjusted CCR (as described above) to project the threshold for the upcoming FY. In addition, charges for a claim payment are from the bill while charges to project the threshold are from the MedPAR data with an inflation factor applied to the charges (as described above).

Step 1—Determine the MS–DRG and MS–DRG relative weight for each claim based on the ICD–10–CM procedure and diagnosis codes on the claim.
Step 2—Select the applicable average standardized amount depending on whether the hospital submitted qualifying quality data and is a meaningful EHR user, as described above.

Step 3—Compute the operating and capital Federal payment rate:

<table>
<thead>
<tr>
<th>Operating Payment Rate</th>
<th>Capital Payment Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>MS–DRG Relative Weight</td>
<td>MS–DRG Relative Weight</td>
</tr>
<tr>
<td>(Labor-Related Applicable</td>
<td>(Capital Cost-to-Charge Ratio)</td>
</tr>
</tbody>
</table>
| Standardized Amount x Applicable | (Nonlabor-
| CBSA Wage Index) + (Nonlabor- | Related Applicable Standardized |
| -Related Applicable Standardized | Amount x Cost of Living Adjustment) |

Step 4—Determine operating and capital costs:

<table>
<thead>
<tr>
<th>Operating Costs</th>
<th>Capital Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Billed Charges x Operating Cost-to-Charge Ratio)</td>
<td>(Billed Charges x Capital Cost-to-Charge Ratio)</td>
</tr>
</tbody>
</table>

Step 5—Compute operating and capital outlier thresholds (CMS applies a geographic adjustment to the operating and capital outlier threshold to account for local cost variation):

<table>
<thead>
<tr>
<th>Operating Outlier Payment</th>
<th>Capital Outlier Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Operating Costs—Operating Outlier Threshold) x Marginal Cost Factor</td>
<td>(Capital Costs—Capital Outlier Threshold) x Marginal Cost Factor</td>
</tr>
</tbody>
</table>

Step 6: Compute operating and capital outlier payments:

- Marginal Cost Factor = 0.80 or 0.90 (depending on the MS–DRG)
- Operating Outlier Payment = (Operating Costs—Operating Outlier Threshold) x Marginal Cost Factor
- Capital Outlier Payment = (Capital Costs—Capital Outlier Threshold) x Marginal Cost Factor

The payment rate is further adjusted for hospitals that qualify for a low-volume payment adjustment under section 1886(d)(12) of the Act and 42 CFR 412.101(b). The base-operating DRG payment amount is further adjusted by the hospital readmissions payment adjustment and the hospital VBP payment adjustment as described under sections 1886(q) and 1886(e) of the Act, respectively. Payments also are reduced by the 1-percent adjustment under the HAC Reduction Program as described in section 1886(p) of the Act. We also make new technology add-on payments in accordance with section 1886(d)(5)(K) and (L) of the Act. Finally, we added the uncompensated care payment to the total claim payment amount. As noted in the formula above, we take uncompensated care payments and new technology add-on payments into consideration when calculating outlier payments.

2. Hospital-Specific Rate (Applicable Only to SCHs and MDHs)

a. Calculation of Hospital-Specific Rate

Section 1886(b)(3)(C) of the Act provides that SCHs are paid based on whichever of the following rates yields the greatest aggregate payment: The Federal rate; the updated hospital-specific rate based on FY 1996 costs per discharge; or the updated hospital-specific rate based on FY 2006 costs per discharge to determine the rate that yields the greatest aggregate payment.

As noted above, section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114–10) extended the MDH program through FY 2017 (that is, for discharges occurring on or before September 30, 2017). Currently MDHs are paid based on the Federal national rate or, if higher, the Federal national rate plus 75 percent of the difference between the Federal national rate and the greater of the updated hospital-specific rates based on either FY 1982, FY 1987 or FY 2002 costs per discharge.

For a more detailed discussion of the calculation of the hospital-specific rates, we refer readers to the FY 1984 IPPS interim final rule (48 FR 39772); the April 20, 1990 final rule with comment period (55 FR 15150); the FY 1991 IPPS final rule (55 FR 35994); and the FY 2001 IPPS final rule (65 FR 47082).

b. Updating the FY 1982, FY 1987, FY 1996, FY 2002 and FY 2006 Hospital-Specific Rate for FY 2017

Section 1886(b)(3)(B)(iv) of the Act provides that the applicable percentage increase applicable to the hospital-specific rates for SCHs and MDHs equals the applicable percentage increase set forth in section 1886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS). Because the Act sets the update factor for SCHs and MDHs equal to the update factor for all other IPPS hospitals, the update to the hospital-specific rates for SCHs and MDHs is subject to the amendments to section 1886(b)(3)(B)(i) of the Act made by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, the applicable percentage increases to the hospital-specific rates applicable to SCHs and MDHs are the following:

<table>
<thead>
<tr>
<th>FY 2017</th>
<th>Hospital submitted quality data and is a meaningful EHR user</th>
<th>Hospital submitted quality data and is NOT a meaningful EHR user</th>
<th>Hospital did NOT submit quality data and is a meaningful EHR user</th>
<th>Hospital did NOT submit quality data and is NOT a meaningful EHR user</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Basket Rate-of-Increase</td>
<td>2.7</td>
<td>2.7</td>
<td>2.7</td>
<td>2.7</td>
</tr>
<tr>
<td>Adjustment for Failure to Submit Quality Data Under Section 1886(b)(3)(B)(viii) of the Act</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.675</td>
<td>-0.675</td>
</tr>
<tr>
<td>Adjustment for Failure to be a Meaningful EHR User Under Section 1886(b)(3)(B)(ix) of the Act</td>
<td>0.0</td>
<td>-2.025</td>
<td>0.0</td>
<td>-2.025</td>
</tr>
<tr>
<td>MFP Adjustment Under Section 1886(b)(3)(B)(xii) of the Act</td>
<td>-0.3</td>
<td>-0.3</td>
<td>-0.3</td>
<td>-0.3</td>
</tr>
<tr>
<td>Statutory Adjustment Under Section 1886(b)(3)(B)(xii) of the Act</td>
<td>-0.75</td>
<td>-0.75</td>
<td>-0.75</td>
<td>-0.75</td>
</tr>
<tr>
<td>Applicable Percentage Increase Applied to Hospital-Specific Rate</td>
<td>1.65</td>
<td>-0.375</td>
<td>0.975</td>
<td>-1.05</td>
</tr>
</tbody>
</table>
For a complete discussion of the applicable percentage increase applied to the hospital-specific rates for SCHs and MDHs, we refer readers to section IV.B. of the preamble of this final rule.

In addition, because SCHs and MDHs use the same MS-DRGs as other hospitals when they are paid based in whole or in part on the hospital-specific rate, the hospital-specific rate is adjusted by a budget neutrality factor to ensure that changes to the MS-DRG classifications and the recalibration of the MS-DRG relative weights are made in a manner so that aggregate IPPS payments are unaffected. Therefore, the hospital-specific rate for an SCH or an MDH is adjusted by the MS-DRG reclassification and recalibration budget neutrality factor of 0.999079, as discussed in section III. of this Addendum. The resulting rate is used in determining the payment rate that an SCH or MDH will receive for its discharges beginning on or after October 1, 2016. We note that, in this final rule, for FY 2017, we are not making a documentation and coding adjustment to the hospital-specific rate. We refer readers to section II.D. of the preamble of this final rule for a complete discussion regarding our policies and previously finalized policies (including our historical adjustments to the payment rates) relating to the effect of changes in documentation and coding that do not reflect real changes in case-mix.

Also, as discussed above and in section IV.P. of the preamble of this final rule, we are making an adjustment to the hospital-specific rates using our authority under section 1886(d)(5)(I)(i) of the Act to permanently prospectively remove the 0.2 percent reduction to the payment rates established in FY 2014 to offset the estimated increase in IPPS expenditures as a result of the 2-midnight policy. In addition, as discussed above and in section IV.P. of the preamble of this final rule, we are applying a temporary one-time prospective increase to the FY 2017 hospital-specific rates of 0.6 percent by including an additional one-time factor of 1.006 in the calculation of the hospital-specific rates, using our authority under section 1886(d)(5)(I)(i) of the Act, to address the effects of the 0.2 percent reduction to the rates for the 2-midnight policy in effect for FY 2014, FY 2015, and FY 2016.

III. Changes to Payment Rates for Acute Care Hospital Inpatient Capital-Related Costs for FY 2017

The PPS for acute care hospital inpatient capital-related costs was implemented for cost reporting periods beginning on or after October 1, 1991. Effective with that cost reporting period, over a 10-year transition period (which extended through FY 2001) the payment methodology for Medicare acute care hospital inpatient capital-related costs changed from a reasonable cost-based methodology to a prospective methodology (based fully on the Federal rate).

The basic methodology for determining Federal capital prospective rates is set forth in the regulations at §§ 412.308 through 412.332. Below we discuss the factors that we used to determine the capital Federal rate for FY 2017, which is effective for discharges occurring on or after October 1, 2016.

The 10-year transition period ended with hospital cost reporting periods beginning on or after October 1, 2001 (FY 2002). Therefore, for cost reporting periods beginning in FY 2002, all hospitals (except “new” hospitals under § 412.304(c)(2)) are paid based on the capital Federal rate. For FY 1992, we computed the Federal payment rate for capital-related costs under the IPPS by updating the FY 1989 Medicare inpatient capital per case by an actuarial estimate of the increase in Medicare inpatient capital costs per case. Each year after FY 1992, we update the capital standard Federal rate, as provided at § 412.308(c)(1), to account for capital input price increases and other factors. The regulations at § 412.308(c)(2) also provide that the capital Federal rate be adjusted annually by a factor equal to the estimated proportion of outlier payments under the capital Federal rate to total capital payments under the capital Federal rate. In addition, § 412.308(c)(3) requires that the capital Federal rate be reduced by an adjustment factor equal to the estimated proportion of payments for exceptions under § 412.348. (We note that, as discussed in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53705), there is generally no longer a need for an exceptions payment adjustment factor.) However, in limited circumstances, an additional payment exception for extraordinary circumstances is provided for under § 412.348(f) for qualifying hospitals. Therefore, in accordance with § 412.308(c)(3), an exceptions payment adjustment factor may need to be applied if such payments are made. Section 412.308(c)(4)(ii) requires that the capital standard Federal rate be adjusted so that the effects of the annual DRG reclassification and the recalibration of DRG weights and changes in the geographic adjustment factor (GAF) and budget neutrality.

Section 412.374 provides for blended payments to hospitals located in Puerto Rico under the IPPS for acute care hospital inpatient capital-related costs. Accordingly, historically, under the capital PPS, we have computed a separate payment rate specific to hospitals located in Puerto Rico using the same methodology used to compute the national Federal rate for capital-related costs. Effective with discharges occurring on or after October 1, 2004, in conjunction with the change to the operating payment methodology, we adopted a methodology for computing capital payments made to hospitals located in Puerto Rico based on a blend of 25 percent of the Puerto Rico capital rate and 75 percent of the national capital Federal rate (69 FR 49185).

Effective with discharges on or after January 1, 2016, operating IPPS payments to hospitals located in Puerto Rico are now based on 100 percent of the Federal rate—the operating payment methodology is no longer a blend of 75 percent of the Federal rate and 25 percent of the Puerto Rico rate. Consistent with historical practice and under the authority of section 1886(g) of the Act, as discussed in section V.B.3. of the preamble of this final rule, we are making the capital IPPS payments to hospitals located in Puerto Rico based on 100 percent of the capital Federal rate, effective with discharges on or after October 1, 2016, and will no longer be based on the current 75/25 blended rate.

A. Determination of the Federal Hospital Inpatient Capital-Related Prospective Payment Rate Update

In the discussion that follows, we explain the factors that we used to determine the capital Federal rate for FY 2017. In particular, we explain why the FY 2017 capital Federal rate increases approximately 1.84 percent, compared to the FY 2016 capital Federal rate. As discussed in the impact analysis in Appendix A to this final rule, we estimate that capital payments per discharge will increase approximately 0.8 percent during that same period. Because capital payments constitute approximately 10 percent of hospital payments, a percent change in the capital Federal rate yields only approximately a 0.1 percent change in actual payments to hospitals.

1. Projected Capital Standard Federal Rate Update

a. Description of the Update Framework

Under § 412.308(c)(1), the capital standard Federal rate is updated on the basis of an analytical framework that takes into account changes in a capital input price index (CIPI) and several other policy adjustment factors.
Specifically, we adjust the projected CPl rate-of-increase as appropriate each year for case-mix index-related changes, for intensity, and for errors in previous CPl forecasts. The update factor for FY 2017 under that framework is 0.9 percent based on the best data available at this time. The update factor under that framework is based on a projected 1.2 percent increase in the FY 2010-based CPl, a 0.0 percentage point adjustment for intensity, a 0.0 percentage point adjustment for case-mix, a 0.0 percentage point adjustment for the DRG reclassification and recalibration, and a forecast error correction of −0.3 percentage point. As discussed in section II.C. of this Addendum, we continue to believe that the CPl is the most appropriate input price index for capital costs to measure capital price changes in a given year. We also explain the basis for the FY 2017 CPl projection in that same section of this Addendum. Below we describe the policy adjustments that we are applying in the update framework for FY 2017.

The case-mix index is the measure of the average DRG weight for cases paid under the IPPS. Because the DRG weight determines the prospective payment for each case, any percentage increase in the case-mix index corresponds to an equal percentage increase in hospital payments.

The case-mix index can change for any of several reasons:

- The average resource use of Medicare patient changes ("real" case-mix change);
- Changes in hospital documentation and coding of patient records result in higher-weighted DRG assignments ("coding effects"); and
- The annual DRG reclassification and recalibration changes may not be budget neutral ("reclassification effect").

We define real case-mix change as actual changes in the mix (and resource requirements) of Medicare patients as opposed to changes in documentation and coding behavior that result in assignment of cases to higher-weighted DRGs, but do not reflect higher resource requirements. The capital update framework includes the same case-mix index adjustment used in the former operating IPPS update framework (as discussed in the May 18, 2004 IPPS proposed rule for FY 2005 (69 FR 28816)). (We no longer use an update framework to make a recommendation for updating the operating IPPS standard, as the parameters discussed in section II. of Appendix B to the FY 2006 IPPS final rule (70 FR 47707).)

For FY 2017, we are projecting a 0.5 percent total increase in the case-mix index. We estimated that the real case-mix increase will equal 0.5 percent for FY 2017. The net adjustment for change in case-mix is the difference between the projected real increase in case-mix and the projected total increase in case-mix. Therefore, the net adjustment for case-mix change in FY 2017 is 0.0 percentage point.

The capital update framework also contains an adjustment for the effects of DRG reclassification and recalibration. This adjustment is intended to remove the effect on total payments of prior year’s changes to the DRG classifications and relative weights, in order to retain budget neutrality for all case-mix index-related changes other than those due to patient severity of illness. Due to the lag time in the availability of data, there is a 2-year lag in data used to determine the adjustment for the effects of DRG reclassification and recalibration. For example, we have data available to evaluate the effects of the FY 2015 DRG reclassification and recalibration as part of our update for FY 2017. We estimate that FY 2015 DRG reclassification and recalibration resulted in no change in the case-mix when compared with the case-mix index that would have resulted if we had not made the reclassification and recalibration changes to the DRGs. Therefore, we are making a 0.0 percentage point adjustment for reclassification and recalibration in the update framework for FY 2017.

The capital update framework also contains an adjustment for forecast error. The input price index forecast is based on historical trends and relationships ascertainable at the time the update factor is established for the upcoming year. In any given year, there may be unanticipated price fluctuations that may result in differences between the actual increase in prices and the forecast used in calculating the update factors. In setting a prospective payment rate under the framework, we make an adjustment for forecast error only if our estimate of the change in the capital input price index for any year is off by 0.25 percentage point or more. There is a 2-year lag between the forecast and the availability of data to develop a measurement of the forecast error. Historically, when a forecast error of the CPl is greater than 0.25 percentage point in absolute terms, it is reflected in the update recommended under this framework. A forecast error of −0.3 percentage point was calculated for the FY 2015 update, for which there are historical data. That is, the historical data indicate that the forecasted FY 2015 CPl (1.5 percent) used in calculating the FY 2015 update factor was 0.3 percentage points higher than actual realized price increases (1.2 percent). This over-prediction was primarily due to prices from municipal bond yields declining in 2015 whereas the forecast projected an increase. Therefore, we are making a −0.3 percentage point adjustment for forecast error in the update for FY 2017.

Under the capital IPPS update framework, we also make an adjustment for changes in intensity. Historically, we calculated this adjustment using the same methodology and data that were used in the past under the framework for operating IPPS. The intensity factor for the operating update framework reflected how hospital services are utilized to produce the final product, that is, the discharge. This component accounts for changes in the use of quality-enhancing services, for changes within DRG severity, and for expected modification of practice patterns to remove noncost-effective services. Our intensity measure is based on a 5-year average.

We calculate case-mix constant intensity as the change in total cost per discharge, adjusted for price level changes (the CPl for hospital and related services) and changes in real case-mix. Without reliable estimates of the proportions of the overall annual intensity increases that are due, respectively, to ineffective practice patterns and the combination of quality-enhancing new technologies and complexity within the DRG system, we assume that one-half of the annual increase is due to each of these factors. The capital update framework thus provides an add-on to the input price index rate of increase of one-half of the estimated annual increase in intensity, to allow for increases within DRG severity and the adoption of quality-enhancing technology.

In this final rule, we are continuing to use a Medicare-specific intensity measure that is based on a 5-year adjusted average of cost per discharge for FY 2017 (we refer readers to the FY 2011 IPPS/LTCH PPS final rule (75 FR 50436) for a full description of our Medicare-specific intensity measure). Specifically, for FY 2017, we are using an intensity measure that is based on an average of cost per discharge data from the 5-year period beginning with FY 2010 and extending through FY 2014. Based on these data, we estimated that case-mix constant intensity declined during FYs 2010 through 2014. In the past, when found intensity to be declining, we believed a negative (rather than a positive) intensity adjustment was appropriate. Consistent with this
approach, because we estimate that intensity declined during that 5-year period, we believe it is appropriate to continue to apply a zero intensity adjustment for FY 2017. Therefore, we are making a 0.9 percentage point adjustment for intensity in the update for FY 2017.

Above, we described the basis of the components used to develop the 0.9 percent capital update factor under the capital update framework for FY 2017 as shown in the following table.

**CMS FY 2017 Update Factor to the Capital Federal Rate**

<table>
<thead>
<tr>
<th>Component</th>
<th>Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital Input Price Index *</td>
<td>1.2</td>
</tr>
<tr>
<td>Intensity</td>
<td>0.0</td>
</tr>
<tr>
<td>Case-Mix Adjustment Factors:</td>
<td></td>
</tr>
<tr>
<td>Real Across DRG Change</td>
<td>0.5</td>
</tr>
<tr>
<td>Projected Case-Mix Change</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>1.2</strong></td>
</tr>
<tr>
<td>Effect of FY 2015 Reclassification and Recalibration</td>
<td>0.0</td>
</tr>
<tr>
<td>Forecast Error Correction</td>
<td>-0.3</td>
</tr>
<tr>
<td><strong>Total Update</strong></td>
<td><strong>0.9</strong></td>
</tr>
</tbody>
</table>

*The capital input price index represents the FY 2010-based CPI.*

b. Comparison of CMS and MedPAC Update Recommendation


2. Outlier Payment Adjustment Factor

Section 412.312(c) establishes a unified outlier payment methodology for inpatient operating and inpatient capital-related costs. A single set of thresholds is used to identify outlier cases for both inpatient operating and inpatient capital-related payments. Section 412.308(c)(2) provides that inpatient capital-related costs be reduced by an adjustment factor equal to the estimated proportion of capital-related outlier payments to total inpatient capital-related PPS payments. The outlier thresholds are set so that operating outlier payments are projected to be 5.1 percent of total operating IPPS DRG payments.

For FY 2016, we estimated that outlier payments for capital would equal 6.35 percent of inpatient capital-related payments based on the capital Federal rate in FY 2016. Based on the thresholds as set forth in section II.A. of this Addendum, we estimate that outlier payments for capital-related costs will equal 6.14 percent for inpatient capital-related payments based on the capital Federal rate in FY 2017. Therefore, we are applying an outlier adjustment factor of 0.9386 in determining the capital Federal rate for FY 2017. Thus, we estimate that the percentage of capital outlier payments to total capital Federal rate payments for FY 2017 will be lower than the percentage for FY 2016.

The outlier reduction factors are not built permanently into the capital rates; that is, they are not applied cumulatively in determining the capital Federal rate. The FY 2017 outlier adjustment of 0.9386 is a 0.22 percent change from the FY 2016 outlier adjustment of 0.9365. Therefore, the net change in the outlier adjustment to the capital Federal rate for FY 2017 is 1.0022 (0.9386/0.9365). Thus, the outlier adjustment will increase the FY 2017 capital Federal rate by 0.22 percent compared to the FY 2016 outlier adjustment.

3. Budget Neutrality Adjustment Factor for Changes in DRG Classifications and Weights and the GAF

Section 412.308(c)(4)(i) requires that the capital Federal rate be adjusted so that aggregate payments for the fiscal year based on the capital Federal rate after any changes resulting from the annual DRG reclassification and recalibration and changes in the GAF are projected to equal aggregate payments that would have been made on the basis of the capital Federal rate without such changes. Because we are determining capital IPPS payments to hospitals located in Puerto Rico based on 100 percent of the capital Federal rate beginning in FY 2017, we have not calculated a separate GAF for Puerto Rico, and therefore, we are not applying a separate budget neutrality adjustment for Puerto Rico GAF. Similarly, the budget neutrality factor for DRG reclassifications and recalibration nationally is applied in determining the capital IPPS Federal rate, and is applicable for all hospitals, including those hospitals located in Puerto Rico.

To determine the national capital rate factors for FY 2017, we compared estimated aggregate capital Federal rate payments based on the FY 2016 MS–DRG classifications and relative weights and the FY 2016 GAF to estimated aggregate capital Federal rate payments based on the FY 2016 MS–DRG classifications and relative weights and the FY 2017 GAFs. To achieve budget neutrality for the changes in the national GAFs, based on calculations using updated data, we are applying an incremental budget neutrality adjustment factor of 0.9995 for FY 2017 to the previous cumulative FY 2016 adjustment factor of 0.9860, yielding an adjustment factor of 0.9855 through FY 2017.

We then compared estimated aggregate capital Federal rate payments based on the FY 2016 MS–DRG relative weights and the FY 2017 GAFs to estimated aggregate capital Federal rate payments based on the cumulative effects of the FY 2017 MS–DRG classifications and relative weights and the FY 2017 GAFs. The incremental adjustment factor for DRG classifications and changes in relative weights is 0.9996. The cumulative adjustment factor for MS–DRG classifications and changes in relative weights and for changes in the GAFs through FY 2017 is 0.9851. (We note that all the values are calculated with unrounded numbers.)

The GAF/DRG budget neutrality adjustment factors are built permanently into the capital rates; that is, they are applied cumulatively in determining the capital Federal rate. This follows the requirement under § 412.308(c)(4)(ii) that estimated aggregate payments each year be no more or less than they would have been in the absence of the annual DRG reclassification and recalibration and changes in the GAFs.

The methodology used to determine the recalibration and geographic adjustment factor (GAF/DRG) budget neutrality adjustment is similar to the methodology used in establishing budget neutrality adjustments under the IPPS for operating costs. One difference is that, under the operating IPPS, the budget neutrality adjustments for the effect of geographic reclassifications are determined separately from the effects of other changes in the hospital wage index and the MS–DRG relative weights.

Under the capital IPPS, there is a single GAF/DRG budget neutrality adjustment factor for changes in the GAF (including geographic reclassification) and the MS–DRG relative weights. In addition, there is no adjustment for the effects that geographic reclassification has on the other payment parameters, such as the payments for DSH or IME.

The cumulative adjustment factor of 0.9991 (the product of the incremental national GAF budget neutrality adjustment factor of 0.9995 and the incremental DRG budget neutrality adjustment factor of 0.9996) accounts for the MS–DRG reclassifications and recalibration and for changes in the GAFs. It also incorporates the effects on the GAFs of FY 2017 geographic reclassification decreed by the MCCR in comparison to FY 2016 decisions. However, it does not account for
changes in payments due to changes in the DSH and IME adjustment factors.

As discussed in section V.C. of the preamble of this final rule, we are making an adjustment of (1/0.998) to the national capital Federal rate to remove the 0.2 percent reduction (an adjustment factor of 0.998) to the national capital Federal rate to offset the estimated increase in capital IPPS expenditures associated with the 2-midnight policy. This is consistent with the adjustment to the operating IPPS standardized amount and the hospital-specific payment rates. In addition, consistent with the approach for the operating IPPS standardized amount and hospital-specific payment rates and for the reasons discussed in sections IV.P. and V.C. of the preamble of this final rule, we are making a one-time prospective adjustment of 1.006 in FY 2017 to the national capital Federal rate to address the effect of the 0.2 percent reduction to the national capital Federal rates in effect for FY 2014, FY 2015, and FY 2016. We also are removing this one-time prospective adjustment through an adjustment of (1/1.006) to the national capital Federal rate in FY 2018, consistent with the approach for the operating IPPS standardized amount and hospital-specific payment rates (as discussed in section IV.P. of the preamble of this final rule). We refer readers to sections IV.P. and V.C. of the preamble of this final rule for a complete discussion of these issues.

4. Capital Federal Rate for FY 2017

For FY 2016, we established a capital Federal rate of $438.75 (as revised, in the FY 2016 IPPS/LTCH PPS correction notice CMS–1632–CN2 (80 FR 60060 and 60061)). We are establishing an update of 0.9 percent in determining the FY 2017 capital Federal rate for all hospitals. As a result of this update, the budget neutrality factors discussed earlier, and the adjustments to remove the 0.2 percent reductions (both the (1/0.998) adjustment to permanently remove the 0.2 percent reduction and the one-time 0.6 percent adjustment) resulting from the 2-midnight policy, we are establishing a national capital Federal rate of $446.81 for FY 2017. The national capital Federal rate for FY 2017 was calculated as follows:

- The FY 2017 update factor is 1.009, that is, the update is 0.9 percent.
- The FY 2017 budget neutrality adjustment factor is applied to the capital Federal rate for changes in the MS–DRG classifications and relative weights and changes in the GAFs is 0.9991.
- The FY 2017 outlier adjustment factor is 0.9386.
- The 2-midnight policy adjustment to permanently remove the 0.2 percent reduction is (1/0.998).
- The 2-midnight one-time policy adjustment is 1.006.

(We note that, as discussed in section V.C. of the preamble of this final rule, we are not making an additional MS–DRG documentation and coding adjustment to the capital IPPS Federal rate for FY 2017.)

Because the FY 2017 capital Federal rate has already been adjusted for differences in case-mix, wages, cost-of-living, indirect medical education costs, and payments to hospitals serving a disproportionate share of low-income patients, we are not making additional adjustments in the capital Federal rate for these factors, other than the budget neutrality factor for changes in the MS–DRG classifications and relative weights and for changes in the GAFs.

We are providing the following chart that shows how each of the factors and adjustments for FY 2017 affects the computation of the FY 2017 national capital Federal rate in comparison to the FY 2016 national capital Federal rate. The FY 2017 update factor has the effect of increasing the capital Federal rate by 0.9 percent compared to the FY 2016 capital Federal rate. The GAF/DRG budget neutrality adjustment factor has the effect of decreasing the capital Federal rate by 0.09 percent. The FY 2017 outlier adjustment factor has the effect of increasing the capital Federal rate by 0.22 percent compared to the FY 2016 capital Federal rate. The permanent 2-midnight policy adjustment has the effect of increasing the capital Federal rate by 0.2 percent and the temporary 2-midnight policy adjustment has the effect of increasing the capital Federal rate by 0.6 percent. The combined effect of all the changes would increase the national capital Federal rate by approximately 1.84 percent compared to the FY 2016 national capital Federal rate.

**COMPARISON OF FACTORS AND ADJUSTMENTS: FY 2016 CAPITAL FEDERAL RATE AND FY 2017 CAPITAL FEDERAL RATE**

<table>
<thead>
<tr>
<th>Factor</th>
<th>FY 2016</th>
<th>FY 2017</th>
<th>Change</th>
<th>Percent change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Update Factor</td>
<td>$1,0130</td>
<td>$1,009</td>
<td>1.009</td>
<td>0.9</td>
</tr>
<tr>
<td>GAF/DRG Adjustment Factor</td>
<td>0.9976</td>
<td>0.9991</td>
<td>0.0015</td>
<td>−0.09</td>
</tr>
<tr>
<td>Outlier Adjustment Factor</td>
<td>0.9365</td>
<td>0.9386</td>
<td>0.0021</td>
<td>0.22</td>
</tr>
<tr>
<td>Permanent 2-midnight Policy Adjustment Factor</td>
<td>N/A</td>
<td>1.002</td>
<td>1.002</td>
<td>0.2</td>
</tr>
<tr>
<td>One-Time 2-midnight Policy Adjustment Factor</td>
<td>N/A</td>
<td>1.006</td>
<td>1.006</td>
<td>0.6</td>
</tr>
<tr>
<td>Capital Federal Rate</td>
<td>438.75</td>
<td>446.81</td>
<td>1.0184</td>
<td>1.84</td>
</tr>
</tbody>
</table>

1. The update factor and the GAF/DRG budget neutrality adjustment factors are built permanently into the capital Federal rates. Thus, for example, the incremental change from FY 2016 to FY 2017 resulting from the application of the 0.9991 GAF/DRG budget neutrality adjustment factor for FY 2017 is a net change of 0.9991 (or −0.09 percent).

2. The outlier reduction factor is not built permanently into the capital Federal rate; that is, the factor is not applied cumulatively in determining the capital Federal rate. Thus, for example, the net change resulting from the application of the FY 2017 outlier adjustment factor is 0.9386/0.9365, or 1.0022 (or 0.22 percent).

In this final rule, we also are providing the following chart that shows how the final FY 2017 capital Federal rate differs from the proposed FY 2017 capital Federal rate as presented in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25280).
B. Calculation of the Inpatient Capital-Related Prospective Payments for FY 2017

For purposes of calculating payments for each discharge during FY 2017, the capital Federal rate is adjusted as follows: (Standard Federal Rate) × (DRG weight) × (GAF) × (COLA for hospitals located in Alaska and Hawaii) × (1 + DSH Adjustment Factor + IME Adjustment Factor, if applicable). The result is the adjusted capital Federal rate.

Hospitals also may receive outlier payments for those cases that qualify under the thresholds established for each fiscal year. Section 412.312(c) provides for a single set of thresholds to identify outlier cases for both inpatient operating and inpatient capital-related payments. The outlier thresholds for FY 2017 are in section II.A. of this Addendum. For FY 2017, a case would qualify as a cost outlier if the cost for the case plus the (operating) IME and DSH payments (including both the empirically justified Medicare DSH payment and the estimated uncompensated care payment, as discussed in section II.A.4.g.(1) of this Addendum) is greater than the prospective payment rate for the MS–DRG plus the fixed-loss amount of $23,570.

Currently, as provided under § 412.304(c)(2), we pay a new hospital 85 percent of its reasonable costs during the first 2 years of operation unless it elects to receive payment based on 100 percent of the capital Federal rate. Effective with the third year of operation, we pay the hospital based on 100 percent of the capital Federal rate (that is, the same methodology used to pay all other hospitals subject to the capital PPS).

C. Capital Input Price Index

1. Background

Like the operating input price index, the capital input price index (CIPI) is a fixed-weight price index that measures the price changes associated with capital costs during a given year. The CIPI differs from the operating input price index in one important aspect—the CIPI reflects the vintage nature of capital, which is the acquisition and use of capital over time. Capital expenses in any given year are determined by the stock of capital in that year (that is, capital that remains on hand from all current and prior capital acquisitions).

An index measuring capital price changes needs to reflect this vintage nature of capital. Therefore, the CIPI was developed to capture the vintage nature of capital by using a weighted-average of past capital purchase prices up to and including the current year.

We periodically update the base year for the operating and capital input price indexes to reflect the changing composition of inputs for operating and capital expenses. In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50603 through 50607), we rebased and revised the CIPI to a FY 2010 base year to reflect the more current structure of capital costs in hospitals. For a complete discussion of this rebasing, we refer readers to the FY 2014 IPPS/LTCH PPS final rule.

2. Forecast of the CIPI for FY 2017

Based on the latest forecast by IHS Global Insight, Inc. (second quarter of 2016), we are forecasting the FY 2010-based CIPI to increase 1.2 percent in FY 2017. This reflects a projected 1.6 percent increase in vintage-weighted depreciation prices (building and fixed equipment, and movable equipment), and a projected 2.7 percent increase in other capital expense prices in FY 2017, partially offset by a projected 1.6 percent decline in vintage-weighted interest expense prices in FY 2017. The weighted average of these three factors produces the forecasted 1.2 percent increase for the FY 2010-based CIPI as a whole in FY 2017.

IV. Changes to Payment Rates for Excluded Hospitals: Rate-of-Increase Percentages for FY 2017

Payments for services furnished in children’s hospitals, 11 cancer hospitals, and hospitals located outside the 50 States, the District of Columbia and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) that are excluded from the IPPS are made on the basis of reasonable costs based on the hospital’s own historical cost experience, subject to a rate-of-increase ceiling. A per discharge limit (the target amount as defined in § 413.40(a) of the regulations) is set for each hospital based on the hospital’s own cost experience in its base year, and updated annually by a rate-of-increase percentage. (We note that, in accordance with § 403.752(a), RNHCIs are also subject to the rate-of-increase limits established under § 413.40 of the regulations.)

As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25281), the FY 2017 rate-of-increase percentage for updating the target amounts for the 11 cancer hospitals, children’s hospitals, the short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNHCIs is the estimated percentage increase in the IPPS operating market basket for FY 2017, in accordance with applicable regulations at § 413.40. Based on IHS Global Insight, Inc.’s 2016 first quarter forecast, we estimated that the FY 2010-based IPPS operating market basket update for FY 2017 would be 2.8 percent (that is, the estimate of the market basket rate-of-increase).

However, we proposed that if more recent data became available for the final rule, we would use them to calculate the IPPS operating market basket update for FY 2017. Therefore, based on IHS Global Insight, Inc.’s 2016 second quarter forecast, with historical data through 2016 first quarter, we estimate that the FY 2010-based IPPS operating market basket update for FY 2017 is 2.7 percent (that is, the estimate of the market basket rate-of-increase).
care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa), and RNHCIs, the FY 2017 rate-of-increase percentage that will be applied to the FY 2016 target amounts in order to determine the final FY 2017 target amounts is 2.7 percent.

The IRF PPS, the IPF PPS, and the LTCH PPS are updated annually. We refer readers to section VII. of the preamble of this final rule and section V. of the Addendum to this final rule for the update changes to the Federal payment rates for LTCHs under the LTCH PPS for FY 2017. The annual updates for the IRF PPS and the IPF PPS are issued by the agency in separate Federal Register documents.

V. Changes to the Payment Rates for the LTCH PPS for FY 2017

A. LTCH PPS Standard Federal Payment Rate for FY 2017

1. Background

In section VII. of the preamble of this final rule, we discuss our annual updates to the payment rates, factors, and specific policies under the LTCH PPS for FY 2017.

Under § 412.523(c)(3)(ii) of the regulations, for LTCH PPS rate years beginning RY 2004 through RY 2006, we updated the standard Federal rate annually by a factor to adjust for the most recent estimate of the increases in prices of an appropriate market basket of goods and services for LTCHs. We established this policy of annually updating the standard Federal rate because, at that time, we believed that was the most appropriate method for updating the LTCH PPS standard Federal rate for years after the initial implementation of the LTCH PPS in FY 2003. Therefore, under § 412.523(c)(3)(ii), for RYs 2004 through 2006, the annual update to the LTCH PPS standard Federal rate was equal to the previous rate year’s Federal rate updated by the most recent estimate of increases in the appropriate market basket of goods and services included in covered inpatient LTCH services.

In determining the annual update to the standard Federal rate for RY 2007, based on our ongoing monitoring activity, we believed that, rather than solely using the most recent estimate of the LTCH PPS market basket update as the basis of the annual update factor, it was appropriate to adjust the standard Federal rate to account for the effect of documentation and coding in a prior period that was unrelated to patients’ severity of illness. According to the annual update factor, it was estimated that the annual update to the standard Federal rate for FY 2007 was zero percent based on the most recent estimate of the LTCH PPS market basket at that time, offset by an adjustment to account for changes in case-mix in prior periods due to the effect of documentation and coding that were unrelated to patients’ severity of illness. For RY 2008 through FY 2011, we also made an adjustment to account for the effect of documentation and coding that was unrelated to patients’ severity of illness in establishing the annual update to the standard Federal rate as set forth in the regulations at §§ 412.523(c)(3)(iv) through (c)(3)(vii).

For FYs 2012 through 2016, we updated the standard Federal rate by the most recent estimate of the LTCH PPS market basket at that time, including additional statutory adjustments required by sections 1886(m)(3)(A)(i) (citing sections 1886(b)(3)(B)(xi)(II), 1886(m)(3)(A)(ii), and 1886(m)(4) of the Act as set forth in the regulations at §§ 412.523(c)(3)(viii) through (c)(3)(xi)).

Section 1886(m)(3)(A) of the Act, as added by section 3401(c) of the Affordable Care Act, specifies that, for rate year 2010 and each subsequent rate year, any annual update to the standard Federal rate shall be reduced:

- For rate year 2010 through 2019, by the other adjustment specified in section 1886(m)(3)(A)(ii) and (m)(4) of the Act; and
- For rate year 2012 and each subsequent year, by the productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act (which we refer to as “the multifactor productivity (MFP) adjustment”) as discussed in section VII.E.2. of the preamble of this final rule.

Section 1886(m)(3)(B) of the Act provides that the application of paragraph (3) of section 1886(m) of the Act may result in the annual update being less than zero for a rate year, and may result in payment rates for a rate year being less than such payment rates for the preceding rate year. (As noted in section VII.E.2.a. of the preamble of this final rule, the annual update to the LTCH PPS occurs on October 1 and we have adopted the term “fiscal year” (FY) rather than “rate year” (RY) under the LTCH PPS beginning October 1, 2010. Therefore, for purposes of clarity, when discussing the annual update for the LTCH PPS, including the provisions of the Affordable Care Act, we use the term “fiscal year” rather than “rate year” for 2011 and subsequent years.)

For FY 2016, consistent with our historical practice, we established an update of the standard Federal payment rate based on the full estimated LTCH PPS market basket increase of 2.4 percent and the 0.7 percentage point reductions required by sections 1886(m)(3)(A)(i) and 1886(m)(3)(A)(ii) with 1886(m)(4)(E) of the Act. Accordingly, at § 412.523(c)(3)(xii) of the regulations, we established an annual update of 1.7 percent to the standard Federal payment rate for FY 2016 (80 FR 49636 through 49637). In addition, as discussed in that same final rule, the annual update for FY 2016 was further reduced by 2.0 percentage points for LTCHs that failed to submit quality reporting data in accordance with the requirements of the LTCH QRP under section 1886(m)(3) of the Act.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25281), based on the best available data at that time, we proposed an annual update to the LTCH PPS standard Federal payment rate of 1.45 percent for FY 2017, which was based on the full estimated increase in the LTCH PPS market basket of 2.7 percent (based on the proposed rebased and revised 2013-based LTCH market basket present in that same proposed rule), less the proposed MFP adjustment of 0.5 percentage point consistent with section 1886(m)(3)(A)(i) of the Act, and less the 0.75 percentage point required by sections 1886(m)(3)(A)(ii) and (m)(4)(F) of the Act. For LTCHs that fail to submit the required quality reporting data for FY 2017 in accordance with the LTCH QRP, the annual update is further reduced by 2.0 percentage points as required by section 1886(m)(5) of the Act. Accordingly, we proposed an annual update to the LTCH PPS standard Federal payment rate of −0.55 percent for LTCHs that fail to submit the required quality reporting data for FY 2017 (that is, the proposed full update of 1.45 percent and less 2.0 percentage points for failure to submit quality reporting data as required by section 1886(m)(5) of the Act). Consistent with our historical practice, we also proposed to use the best data available to determine the update for FY 2017 in the final rule.

For FY 2017, in this final rule, based on the best available data, as we proposed, we are establishing an annual update to the LTCH PPS standard Federal payment rate of 1.75 percent, which is based on the full estimated increase in the LTCH PPS market basket of 2.8 percent, less the MFP adjustment of 0.3 percentage point consistent with section 1886(m)(3)(A)(i) of the Act, and less the 0.75 percentage point required by sections 1886(m)(3)(A)(ii) and (m)(4)(F) of the Act. (As discussed in section VII.E.2.a. of the preamble of this final rule, as we proposed, we are rebasing and revising the 2009-based
LTCH-specific market basket to reflect a 2013 base year.) For LTCHs that fail to submit the required quality reporting data for FY 2017 in accordance with the LTCH QRP, the annual update is further reduced by 2.0 percentage points as required by section 1886(m)(5) of the Act (as discussed in greater detail in section VII.E.2.c. of the preamble of this final rule). Accordingly, as we proposed, we are establishing an annual update to the LTCH PPS standard Federal payment rate of −0.25 percent for LTCHs that fail to submit the required quality reporting data for FY 2017. This −0.25 percent update was calculated based on the full estimated increase in the LTCH PPS market basket of 2.8 percent, less a MFP adjustment of 0.3 percentage point, less an additional adjustment of 0.75 percentage point required by the statute, and less 2.0 percentage points for failure to submit quality reporting data as required by section 1886(m)(5) of the Act.

2. Development of the FY 2017 LTCH PPS Standard Federal Payment Rate

We continue to believe that the annual update to the LTCH PPS standard Federal payment rate should be based on the most recent estimate of the increase in the LTCH PPS market basket, including any statutory adjustments. Consistent with our historical practice, for FY 2017, as we proposed, we applied the annual update to the LTCH PPS standard Federal payment rate from the previous year. Furthermore, in determining the LTCH PPS standard Federal payment rate for FY 2017, we also made certain regulatory adjustments, consistent with past practices. Specifically, in determining the FY 2017 LTCH PPS standard Federal payment rate, as we proposed, we applied a budget neutrality adjustment factor for the changes related to the area wage adjustment (that is, changes to the wage data and labor-related share) in accordance with § 412.523(d)(4). We also used more recent data to determine the update to the LTCH PPS standard Federal payment rate for FY 2017 in this final rule.

For FY 2016, we established an annual update to the LTCH PPS standard Federal payment rate of 1.7 percent based on the full estimated LTCH PPS market basket increase of 2.4 percent, less the MFP adjustment of 0.5 percentage point consistent with section 1886(m)(3)(A)(i) of the Act and less the 0.2 percentage point required by sections 1886(m)(5)(A)(ii) and (m)(4)(E) of the Act. Accordingly, at § 412.523(c)(3)(xii), we established an annual update to the LTCH PPS standard Federal payment rate for FY 2015 of 1.7 percent. That is, we applied an update factor of 1.017 to the FY 2015 Federal rate of $41,043.71 to determine the FY 2016 LTCH PPS standard Federal payment rate. We also applied an area wage level budget neutrality factor for FY 2016 of 1.000513 to the LTCH PPS standard Federal payment rate to ensure that any changes to the area wage level adjustment would not result in any change in estimated aggregate LTCH PPS payments. Consequently, we established a LTCH PPS standard Federal payment rate for FY 2016 of $41,762.85 (calculated as $41,043.71 × 1.017 × 1.000513) (80 FR 49797).

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25281, based on the best available data at that time, we proposed an annual update to the LTCH PPS standard Federal payment rate of 1.45 percent (as described above). Accordingly, under § 412.523(c)(3)(xiii), we proposed to apply a factor of 1.0145 to the FY 2017 LTCH PPS standard Federal payment rate of $41,762.85 to determine the proposed FY 2017 LTCH PPS standard Federal payment rate.

Also, under proposed § 412.523(c)(3)(xiii), in conjunction with the provisions of § 412.523(c)(4), we proposed to apply an annual update to the LTCH PPS standard Federal payment rate of −0.55 percent (that is, a proposed update factor of 0.9945) for FY 2017 for LTCHs that fail to submit the required quality reporting data for FY 2017 as required under the LTCH QRP.

Consistent with § 412.523(d)(4), we also applied an area wage level budget neutrality factor to the FY 2017 LTCH PPS standard Federal payment rate of 0.999593, which was determined using the methodology described below in section V.B.4. of this Addendum. We are applying this area wage level budget neutrality factor to the FY 2017 LTCH PPS standard Federal payment rate to ensure that any changes to the area wage level adjustment (that is, the annual update of the wage index values and labor-related share) will not result in any change (increase or decrease) in estimated aggregate LTCH PPS standard Federal payment rate payments. Accordingly, consistent with our proposal, we are establishing a LTCH PPS standard Federal payment rate of $42,476.41 (calculated as $41,762.85 × 1.0175 × 0.999593) for FY 2017. For LTCHs that fail to submit quality reporting data for FY 2017 in accordance with the requirements of the LTCH QRP under section 1886(m)(5) of the Act, we are establishing a LTCH PPS standard Federal payment rate of $41,641.49 (calculated as $41,762.85 × 0.9975 × 0.999593) for FY 2017. We note, as discussed in section VII.B. of the preamble of this final rule, under our application of the site neutral payment rate required under section 1886(m)(6) of the Act, this LTCH PPS standard Federal payment rate will only be used to determine payments for LTCH PPS standard Federal payment rate cases (that is, those LTCH PPS cases that meet the statutory criteria to be
excluded from the site neutral payment rate).

B. Adjustment for Area Wage Levels under the LTCH PPS for FY 2017

1. Background

Under the authority of section 123 of the BBRA, as amended by section 307(b) of the BIPA, we established an adjustment to the LTCH PPS standard Federal payment rate to account for differences in LTCH area wage levels under § 412.525(c). The labor-related share of the LTCH PPS standard Federal payment rate is adjusted to account for geographic differences in area wage levels by applying the applicable LTCH PPS wage index. The applicable LTCH PPS wage index is computed using wage data from inpatient acute care hospitals without regard to reclassification under section 1886(d)(8) or section 1886(d)(10) of the Act.

When we implemented the LTCH PPS, we established a 5-year transition to the full area wage level adjustment. The area wage level adjustment was completed phased-in for cost reporting periods beginning in FY 2007. Therefore, for cost reporting periods beginning on or after October 1, 2006, the applicable LTCH area wage index values are the full LTCH PPS area wage index values calculated based on acute care hospital inpatient wage index data without taking into account geographic reclassification under section 1886(d)(8) and section 1886(d)(10) of the Act. For additional information on the phase-in of the area wage level adjustment under the LTCH PPS, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56015 through 56019) and the FY 2008 LTCH PPS final rule (72 FR 26891).

2. Geographic Classifications (Labor Market Areas) for the LTCH PPS Standard Federal Payment Rate

In adjusting for the differences in area wage levels under the LTCH PPS, the labor-related portion of an LTCH’s Federal prospective payment is adjusted by using an appropriate area wage index based on the geographic classification (labor market area) in which the LTCH is located. Specifically, the application of the LTCH PPS area wage level adjustment under existing § 412.525(c) is made based on the location of the LTCH—either in an “urban area,” or a “rural area,” as defined in § 412.503. Under § 412.503, an “urban area” is defined as a Metropolitan Statistical Area (MSA) (which includes a Metropolitan division, where applicable), as defined by the Executive OMB and a “rural area” is defined as any area outside of an urban area. (Information on OMB’s MSA delineations based on the 2010 standards can be found at: http://www.whitehouse.gov/sites/default/files/omb/assets/fedreg_2010/06282010_metro_standards-Complete.pdf.)

The CBSA-based geographic classifications (labor market area definitions) currently used under the LTCH PPS, effective for discharges occurring on or after October 1, 2014, are based on the OMB labor market area delineations based on the 2010 Decennial Census data. The current statistical areas (which were implemented beginning with FY 2015) are based on revised OMB delineations issued on February 28, 2013, in OMB Bulletin No. 13–01. We adopted these labor market area delineations because they are based on the best available data that reflect the local economies and area wage levels of the hospitals that are currently located in these geographic areas. We also believe that these OMB delineations will ensure that the LTCH PPS area wage level adjustment most appropriately accounts for and reflects the relative hospital wage levels in the geographic area of the hospital as compared to the national average hospital wage level. We noted that this policy was consistent with the IPPS policy adopted in FY 2015 under § 412.64(b)(1)(ii)(D) of the regulations (79 FR 49951 through 49963). (For additional information on the CBSA-based labor market area (geographic classification) definitions used under the LTCH PPS and the history of the labor market area definitions used under the LTCH PPS, we refer readers to the FY 2015 IPPS/LTCH PPS final rule (79 FR 50180 through 50185).)

In general, it is our historical practice to update the CBSA-based labor market area delineations annually based on the most recent updates issued by OMB. Generally, OMB issues major revisions to statistical areas every 10 years, based on the results of the decennial census. However, OMB occasionally issues minor updates and revisions to statistical areas in the years between the decennial censuses. As discussed in the FY 2017 IPPS/LTCH proposed rule (81 FR 25282 through 25283), on July 15, 2015, OMB issued OMB Bulletin No. 15–01, which provides updates to and supersedes OMB Bulletin No. 13–01 that was issued on February 28, 2013. The attachment to OMB Bulletin No. 15–01 provides detailed information on the updates to statistical areas since February 28, 2013. As discussed in section III.A.2. of the preamble of the proposed rule, the updates provided in OMB Bulletin No. 15–01 are based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2012 and July 1, 2013. A copy of this bulletin may be obtained on the Web site at: https://www.whitehouse.gov/omb/bulletins/.

OMB Bulletin No. 15–01 made the following changes that are relevant to the LTCH PPS CBSA-based labor market area (geographic classification) delineations:

- Garfield County, OK, with principal city Enid, OK, which was a Micropolitan (geographically rural) area, now qualifies as an urban area under new CBSA 21420 entitled Enid, OK.
- The county of Bedford City, VA, a component of the Lynchburg, VA CBSA 31340, changed to town status and is added to Bedford County. Therefore, the county of Bedford City is now part of the county of Bedford, VA. The CBSA remains Lynchburg, VA, 31340.
- The name of Macon, GA, CBSA 31420, as well as a principal city of the Macon-Warner Robins, GA combined statistical area, is now Macon-Bibb County, GA. The CBSA code remains as 31420.

We believe that these revisions to the CBSA-based labor market area delineations will ensure that the LTCH PPS area wage level adjustment most appropriately accounts for and reflects the relative hospital wage levels in the geographic area of the hospital as compared to the national average hospital wage level based on the best available data that reflect the local economies and area wage levels of the hospitals that are currently located in these geographic areas (81 FR 25282 through 25283). Therefore, as we proposed, we are adopting them under the LTCH PPS, effective October 1, 2016. Accordingly, the FY 2017 LTCH PPS wage index values in Tables 12A and 12B listed in section VI. of the Addendum of this final rule (which are available via the Internet on the CMS Web site) reflect the revisions to the CBSA-based labor market area delineations described above. We note that, as discussed in section III.C.2. of the preamble of this final rule, the revisions to the CBSA-based delineations also are being adopted under the IPPS, effective beginning October 1, 2016.

3. Labor-Related Share for the LTCH PPS Standard Federal Payment Rate

Under the payment adjustment for the differences in area wage levels under § 412.525(c), the labor-related share of the
an LTCH’s standard Federal payment rate payment is adjusted by the applicable wage index for the labor market area in which the LTCH is located. The LTCH PPS labor-related share currently represents the sum of the labor-related portion of operating costs (Wages and Salaries; Employee Benefits; Professional Fees Labor-Related, Administrative and Business Support Services; and All-Other: Labor-Related Services) and a labor-related portion of capital costs using the applicable LTCH PPS market basket. Additional background information on the historical development of the labor-related share under the LTCH PPS can be found in the FY 2007 LTCH PPS final rule (71 FR 27810 through 27817 and 27829 through 27830) and the FY 2012 IPPS/LTCH PPS final rule (76 FR 51766 through 51769 and 51808).

For FY 2013, we revised and rebased the market basket used under the LTCH PPS by adopting the newly created FY 2009-based LTCH-specific market basket. In addition, beginning in FY 2013, we determined the labor-related share annually as the sum of the relative importance of each labor-related cost category of the 2009-based LTCH-specific market basket for the respective fiscal year based on the best available data. (For more details, we refer readers to the FY 2013 IPPS/LTCH PPS final rule (77 FR 53477 through 53479).) As noted previously, as we proposed, we are rebasing and revising the 2009-based LTCH-specific market basket to reflect a 2013 base year. In conjunction with that policy, as discussed in section VII.D.4.e. of the preamble of this final rule, we are establishing that the LTCH PPS labor-related share for FY 2017 is the sum of the FY 2017 relative importance of each labor-related cost category in the 2013-based LTCH market basket using the most recent available data. Specifically, as we discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25283 through 25284), we are establishing that the labor-related share for FY 2017 will include the sum of the labor-related portion of operating costs from the 2013-based LTCH market basket (that is, the sum of the FY 2017 relative importance share of Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related, Administrative and Facilities Support Services; Installation, Maintenance, and Repair Services; All Other: Labor-Related Services) and a portion of the Capital-Related cost weight from the 2013-based LTCH PPS market basket. Based on IGI’s second quarter 2016 forecast of the 2013-based LTCH market basket, as we proposed, we are establishing a labor-related share under the LTCH PPS for FY 2017 of 66.5 percent. This labor-related share is determined using the same methodology as employed in calculating all previous LTCH PPS labor-related shares. Consistent with our historical practice, as we proposed, we used more recent data to determine the final FY 2017 labor-related share in this final rule.

Table VII–9 in section VII.D.4.e. of the preamble of this final rule shows the FY 2017 relative importance labor-related share using the 2013-based LTCH market basket and the FY 2016 relative importance labor-related share using the 2009-based LTCH-specific market basket. The labor-related share for FY 2017 is the sum of the FY 2017 relative importance of each labor-related cost category, and will reflect the different rates of price change for these cost categories between the base year (2013) and FY 2017. The sum of the relative importance for FY 2017 for operating costs (Wages and Salaries; Employee Benefits; Professional Fees: Labor-Related, Administrative and Facilities Support Services; Installation, Maintenance, and Repair Services; All Other: Labor-Related Services) is 62.2 percent. The portion of capital-related costs that is influenced by the local labor market is estimated to be 46 percent (the same percentage applied to the 2009-based LTCH-specific market basket). Because the relative importance for capital-related costs under our policies is 9.43 percent of the 2013-based LTCH market basket in FY 2017, as we proposed, we took 46 percent of 9.43 percent to determine the labor-related share of capital-related costs for FY 2017 (0.46 × 9.43). The result is 4.3 percent, which we added to 62.2 percent for the operating cost amount to determine the total labor-related share for FY 2017. Therefore, the labor-related share under the LTCH PPS for FY 2017 is 66.5 percent. We note that the FY 2017 labor-related share using the 2013-based LTCH market basket is 4.5 percentage points higher than the FY 2016 labor-related share using the 2009-based LTCH-specific market basket. This is primarily due to, as discussed in greater detail in section VII.D.4.e. of the preamble of this final rule, the change in the quantity of labor, particularly for professional services, outpacing the change in quantity of products (which are not included in the labor-related share) between 2009 and 2013, which more than offsets the faster relative growth in prices for products.

4. Wage Index for FY 2017 for the LTCH PPS Standard Federal Payment Rate

Historically, we have established LTCH PPS area wage index values calculated from acute care IPPS hospital wage data without taking into account geographic reclassification under sections 1886(d)(8) and 1886(d)(10) of the Act (67 FR 56019). The area wage level adjustment established under the LTCH PPS is based on an LTCH’s actual location without regard to the “urban” or “rural” designation of any related or affiliated provider.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49798 through 49799), we calculated the FY 2016 LTCH PPS area wage index values using the same data used for the FY 2016 acute care hospital IPPS (that is, data from cost reporting periods beginning during FY 2012), without taking into account geographic reclassification under sections 1886(d)(8) and 1886(d)(10) of the Act, as these were the most recent complete data available at that time. In that same final rule, we indicated that we computed the FY 2016 LTCH PPS area wage index values, consistent with the urban and rural geographic classifications (labor market areas) that were in place at that time and consistent with the pre-reclassified IPPS wage index policy (that is, our historical policy of not taking into account IPPS geographic reclassifications in determining payments under the LTCH PPS). As with the IPPS wage index, wage data for multcampus hospitals with campuses located in different labor market areas (CBSAs) are apportioned to each CBSA where the campus (or campuses) are located. We also continued to use our existing policy for determining area wage index values for areas where there are no IPPS wage data.

Consistent with our historical methodology, as discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25283 through 25284), to determine the applicable area wage index values for the FY 2017 LTCH PPS standard Federal payment rate, under the broad authority of section 123 of the BBRA, as amended by section 307(b) of the BIPA, as we proposed, we used wage data collected from cost reports submitted by IPPS hospitals for cost reporting periods beginning during FY 2013, without taking into account geographic reclassification under sections 1886(d)(8) and 1886(d)(10) of the Act, because these data are the most recent complete data available. We also note that these are the same data we are using to compute the FY 2017 acute care hospital inpatient wage index, as discussed in section III. of the preamble of this final rule. We computed the FY 2017 LTCH PPS Federal payment rate area wage index values consistent with the “urban” and “rural”
geographic classifications (that is, labor market area delineations, including the proposed updates, as previously discussed in section V.B.2. of this Addendum) and our historical policy of not taking into account IPPS geographic reclassifications under sections 1886(d)(8) and 1886(d)(10) of the Act in determining payments under the LTCH PPS. As we also proposed, we are continuing to apportion wage data for multicampus hospitals with campuses located in different labor market areas to each CBSA where the campus or campuses are located, consistent with the IPPS policy. Lastly, consistent with our existing methodology for determining the LTCH PPS wage index values, for FY 2017, as we proposed, we are continuing to use our existing policy for determining area wage index values for areas where there are no IPPS wage data. Under our existing methodology, the LTCH PPS wage index value for urban CBSAs with no IPPS wage data would be determined by using an average of all of the urban areas within the State and the LTCH PPS wage index value for rural areas with no IPPS wage data would be determined by using the unweighted average of the wage indices from all of the CBSAs that are contiguous to the rural counties of the State.

Based on the FY 2013 IPPS wage data that we used to determine the FY 2017 LTCH PPS standard Federal payment rate area wage index values in this final rule, there are no IPPS wage data for the urban area of Hinesville, GA (CBSA 25980). Consistent with the methodology discussed above, we calculated the FY 2017 wage index value for CBSA 25980 as the average of the wage index values for all of the other urban areas within the state of Georgia (that is, CBSAs 10500, 12020, 12060, 12260, 15260, 16680, 17980, 19140, 23580, 31420, 40660, 42340, 46660 and 47580), as shown in Table 12A, which is listed in section VI. of the Addendum to this final rule and available via the Internet on the CMS Web site. We note that, as IPPS wage data are dynamic, it is possible that urban areas without IPPS wage data will vary in the future.

Based on the FY 2013 IPPS wage data that we used to determine the FY 2017 LTCH PPS standard Federal payment rate area wage index values in this final rule, there are no rural areas without IPPS hospital wage data. Therefore, as was the case in the proposed rule, it is not necessary to use our established methodology to calculate a LTCH PPS standard Federal payment rate wage index value for rural areas with no IPPS wage data for FY 2017. We note that, as IPPS wage data are dynamic, it is possible that the number of rural areas without IPPS wage data will vary in the future. The FY 2017 LTCH PPS standard Federal payment rate wage index values that are applicable for LTCH PPS standard Federal payment rate discharges occurring on or after October 1, 2016, through September 30, 2017, are presented in Table 12A (for urban areas) and Table 12B (for rural areas), which are listed in section VI. of the Addendum of this final rule and available via the Internet on the CMS Web site.

5. Budget Neutrality Adjustment for Changes to the LTCH PPS Standard Federal Payment Rate Area Wage Level Adjustment

Historically, the LTCH PPS wage index and labor-related share are updated annually based on the latest available data. Under § 412.523(c)(2), any changes to the area wage index values or labor-related share are to be made in a budget neutral manner such that estimated aggregate LTCH PPS payments are unaffected; that is, will be neither greater than nor less than estimated aggregate LTCH PPS payments without such changes to the area wage level adjustment. Under this policy, we determine an area wage-level adjustment budget neutrality factor that will be applied to the standard Federal payment rate to ensure that any changes to the area wage level adjustments are budget neutral such that any changes to the area wage index values or labor-related share would not result in any change (increase or decrease) in estimated aggregate LTCH PPS payments. Accordingly, under § 412.523(d)(4), we apply an area wage level adjustment budget neutrality factor in determining the standard Federal payment rate, and we also established a methodology for calculating an area wage level adjustment budget neutrality factor. (For additional information on the establishment of our budget neutrality policy for changes to the area wage level adjustment, we refer readers to the FY 2012 IPPS/LTCH PPS final rule (76 FR 51771 through 51773 and 51809).)

In this final rule, for FY 2017 LTCH PPS standard Federal payment rate cases, in accordance with § 412.523(d)(4), as we proposed, we applied an area wage level adjustment budget neutrality factor to adjust the LTCH PPS standard Federal payment rate to account for the estimated effect of the adjustments or updates to the area wage index values under § 412.525(c)(1) on estimated aggregate LTCH PPS payments using a methodology that is consistent with the methodology we established in the FY 2012 IPPS/LTCH PPS final rule (76 FR 51773). Specifically, as we proposed in the FY 2017 IPPS/LTCH proposed rule (81 FR 25284), we determined an area wage level adjustment budget neutrality factor that was applied to the LTCH PPS standard Federal payment rate under § 412.523(d)(4) for FY 2017 using the following methodology:

Step 1—We simulated estimated aggregate LTCH PPS standard Federal payment rate payments using the FY 2016 wage index values and the FY 2016 labor-related share of 62.0 percent (as established in the FY 2016 IPPS/ LTCH PPS final rule (80 FR 49798 and 49799).

Step 2—We simulated estimated aggregate LTCH PPS standard Federal payment rate payments using the FY 2017 wage index values (as shown in Tables 12A and 12B listed in the Addendum to this rule and available via the Internet on the CMS Web site) and the FY 2017 labor-related share of 66.5 percent (based on the latest available data as previously discussed previously in this Addendum).

Step 3—We calculated the ratio of these estimated total LTCH PPS standard Federal payment rate payments by dividing the estimated total LTCH PPS standard Federal payment rate payments using the FY 2016 area wage level adjustments (calculated in Step 1) by the estimated total LTCH PPS standard Federal payment rate payments using the FY 2017 area wage level adjustments (calculated in Step 2) to determine the area wage level adjustment budget neutrality factor for FY 2017 LTCH PPS standard Federal payment rate payments.

Step 4—We then applied the FY 2017 area wage level adjustment budget neutrality factor from Step 3 to determine the FY 2017 LTCH PPS standard Federal payment rate after the application of the FY 2017 annual update (discussed previously in section V.A.2. of this Addendum).

We note that, with the exception of cases subject to the transitional blend payment rate provisions in the first 2 years, under the dual rate LTCH PPS payment structure, only LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) are paid based on the LTCH PPS standard Federal payment rate. Because the area wage level adjustment under § 412.525(c) is an adjustment to the LTCH PPS standard Federal payment rate, we only used data from claims that
would have qualified for payment at the LTCH PPS standard Federal payment rate if such rate were in effect at the time of discharge to calculate the FY 2017 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor described above.

For this final rule, using the steps in the methodology previously described, we determined a FY 2017 LTCH PPS standard Federal payment rate area wage level adjustment budget neutrality factor of 0.999593. Accordingly, in section V.A.2. of the Addendum to this final rule, to determine the FY 2017 LTCH PPS standard Federal payment rate, we applied an area wage level adjustment budget neutrality factor of 0.999593, in accordance with § 412.523(d)(4). The FY 2017 LTCH PPS standard Federal payment rate shown in Table 1E of the Addendum to this final rule reflects this adjustment factor.

C. Cost-of-Living Adjustment (COLA) for LTCHs Located in Alaska and Hawaii

Under § 412.525(b), a cost-of-living adjustment (COLA) is provided for LTCHs located in Alaska and Hawaii to account for the higher costs incurred in those States. Specifically, we apply a COLA to payments to LTCHs located in Alaska and Hawaii by multiplying the nonlabor-related portion of the standard Federal payment rate by the applicable COLA factors established annually by CMS. Higher labor-related costs for LTCHs located in Alaska and Hawaii are taken into account in the adjustment for area wage levels previously described.

Under our current methodology, we update the COLA factors for Alaska and Hawaii every 4 years (at the same time as the update to the labor-related share of the IPPS market basket) (77 FR 53712 through 53713). This methodology is based on a comparison of the growth in the Consumer Price Indexes (CPIs) for Anchorage, Alaska, and Honolulu, Hawaii, relative to the growth in the CPI for the average U.S. city as published by the Bureau of Labor Statistics (BLS). It also includes a 25-percent cap on the CPI-updated COLA factors. (For additional details on our current methodology for updating the COLA factors for Alaska and Hawaii, we refer readers to section VII.D.3. of the preamble of the FY 2013 IPPS/LTCH PPS final rule (77 FR 53481 through 53482).) As discussed in the FY 2017 IPPS/LTCH proposed rule (81 FR 25284 through 25285), we continue to believe that determining updated COLA factors using this methodology will appropriately adjust the nonlabor-related portion of the FY 2017 COLA factors for the average U.S. city as established in the FY 2014 IPPS/LTCH PPS final rule. (We refer readers to the FY 2014 IPPS/LTCH PPS final rule (79 FR 50594) for a discussion of the FY 2014 COLA factors.) Consistent with our historical practice, as we proposed, we are establishing that the COLA factors shown in the following table will be used to adjust the nonlabor-related portion of the LTCH PPS standard Federal payment rate for LTCHs located in Alaska and Hawaii under § 412.525(b).

#### COST-OF-LIVING ADJUSTMENT FACTORS FOR ALASKA AND HAWAII HOSPITALS UNDER THE LTCH PPS FOR FY 2017

<table>
<thead>
<tr>
<th>Area</th>
<th>Adjustment Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>City of Anchorage</td>
<td>1.10</td>
</tr>
<tr>
<td>City of Fairbanks</td>
<td>1.10</td>
</tr>
<tr>
<td>City of Juneau</td>
<td>1.10</td>
</tr>
<tr>
<td>All areas of Alaska</td>
<td>1.10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Area</th>
<th>Adjustment Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>City and County of Honolulu</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Hawaii</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Kauai</td>
<td>1.25</td>
</tr>
<tr>
<td>County of Maui and County of Kauawao</td>
<td>1.25</td>
</tr>
</tbody>
</table>

D. Adjustment for LTCH PPS High-Cost Outlier (HCO) Cases

1. HCO Background

From the beginning of the LTCH PPS, we have included an adjustment to account for cases in which there are extraordinarily high costs relative to the costs of most discharges. Under this policy, additional payments are made based on the degree to which the estimated cost of a case (which is calculated by multiplying the Medicare allowable covered charge by the hospital’s overall hospital CCR) exceeds a fixed-loss amount. This policy results in greater payment accuracy under the LTCH PPS and the Medicare program, and the LTCH sharing the financial risk for the treatment of extraordinarily high-cost cases.

We retained the basic tenets of our HCO policy in FY 2016 when we implemented the dual rate LTCH PPS payment structure under section 1206 of Public Law 113–67. LTCH discharges that meet the criteria for exclusion from site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) are paid at the LTCH PPS standard Federal payment rate, which includes, as applicable, HCO payments under § 412.523(e). LTCH discharges that do not meet the criteria for exclusion are paid at the site neutral payment rate, which includes, as applicable, HCO payments under § 412.522(c)(2)(I). In the same rule, we established separate fixed-loss amounts and targets for the two different LTCH PPS payment rates. Under this bifurcated policy, the historic 8 percent HCO target was retained for LTCH PPS standard Federal payment rate cases, with the fixed-loss amount calculated using only data from LTCH cases which would have been paid at the LTCH PPS standard Federal payment rate if that rate had been in effect at the time of those discharges. For site neutral payment rate cases, we adopted the operating IPPS HCO target (currently 5.1 percent) and set the fixed-loss amount for site neutral payment rate cases at the value of the IPPS fixed-loss amount.

Under the HCO policy for both payment rates, an LTCH receives 80 percent of the difference between the estimated cost of the case and the applicable HCO...
threshold, which is the sum of the LTCH PPS payment for the case and the applicable fixed-loss amount for such case.

In order to maintain budget neutrality, consistent with the budget neutrality requirement for HCO payments to LTCH PPS standard Federal rate payment cases, we also adopted a budget neutrality requirement for HCO payments to site neutral payment rate cases by applying a budget neutrality factor to the LTCH PPS payment for those site neutral payment rate cases. (We refer readers to § 412.522(c)(2)(i) of the regulation for further details). We note during the 2-year transitional period, the site neutral payment rate HCO budget neutrality factor does not apply to the LTCH PPS standard Federal payment rate portion of the blended rate at § 412.522(c)(3) payable to site neutral payment rate cases. (For additional details on the HCO policy adopted for site neutral payment rate cases under the dual rate LTCH PPS payment structure, including the budget neutrality adjustment for HCO payments to site neutral payment rate cases, we refer readers to the FY 2016 IPPS/LTCH PPS final rule (80 FR 49617 through 49629).)

2. Determining LTCH CCRs Under the LTCH PPS

a. Background

As noted above, CCRs are used to determine payments for HCO adjustments for both payment rates under the LTCH PPS, and are also used to determine payments for SSO cases under § 412.529 as well as payments for site neutral payment rate cases. (We note that the provisions of § 412.529 are only applicable to LTCH PPS standard Federal payment rate cases.) Therefore, this discussion is relevant to all HCO, SSO, and site neutral payment rate calculations.

As discussed earlier, in determining HCO, SSO, and the site neutral payment rate (regardless of whether the case is also an HCO) payments, we generally calculate the estimated cost of the case by multiplying the LTCH’s overall CCR by the Medicare allowable charges for the case. An overall CCR is used because the LTCH PPS uses a single prospective payment per discharge that covers both inpatient operating and capital-related costs. The LTCH’s overall CCR is generally computed based on the sum of LTCH operating and capital costs (as described in Section 150.24, Chapter 3, of the Medicare Claims Processing Manual (Pub. 100–4) as compared to total Medicare charges (that is, the sum of its operating and capital inpatient routine and ancillary charges), with those values determined from either the most recently settled cost report or the most recently tentatively settled cost report, whichever is from the latest cost reporting period. However, in certain instances, we use an alternative CCR, such as the statewide average CCR, a CCR that is specified by CMS, or one that is requested by the hospital. (We refer readers to § 412.525(a)(4)(iv) of the regulations for further details regarding HCO adjustments for either LTCH PPS payment rate, § 412.529(f)(4) for SSO adjustments, and § 412.522(c)(1)(ii) for the site neutral payment rate, respectively.)

The LTCH’s calculated CCR is then compared to the LTCH total CCR ceiling. Under our established policy, an LTCH with a calculated CCR in excess of the applicable maximum CCR threshold (that is, the LTCH total CCR ceiling, which is calculated as 3 standard deviations from the national geometric average CCR) is generally assigned the applicable statewide CCR. This policy is premised on a belief that calculated CCRs above the LTCH total CCR ceiling are most likely due to faulty data reporting or entry, and CCRs based on erroneous data should not be used to identify and make payments for outlier cases.

b. LTCH Total CCR Ceiling

Consistent with our historical practice, we used more recent data to determine the LTCH total CCR ceiling for this FY 2017 in this final rule. Specifically, in this final rule, using our established methodology for determining the LTCH total CCR ceiling based on IPPS total CCR data from the March 2016 update of the Provider Specific File (PSF), which is the most recent data available, we are establishing a LTCH total CCR ceiling of 1.297 under the LTCH PPS for FY 2017 in accordance with § 412.525(a)(4)(iv)(C)(2) for HCO cases under either payment rate, § 412.529(f)(4)(iii)(B) for SSOs, and § 412.522(c)(1)(ii) for the site neutral payment rate. For additional information on our methodology for determining the LTCH total CCR ceiling, we refer readers to the FY 2007 IPPS final rule (71 FR 48118 through 48119.))

c. LTCH Statewide Average CCRs

Our general methodology for determining the statewide average CCRs used under the LTCH PPS is similar to our established methodology for determining the LTCH total CCR ceiling because it is based on the IPPS CCR data. (For additional information on our methodology for determining statewide average CCRs under the LTCH PPS, we refer readers to the FY 2007 IPPS final rule (71 FR 48119 through 48120.) Under the LTCH PPS HCO policy for cases paid under either payment rate at § 412.525(a)(4)(iv)(C)(2), the SSO policy at § 412.529(f)(4)(iii)(B), and the site neutral payment rate at § 412.522(c)(1)(ii), the MAC may use a statewide average CCR, which is established annually by CMS, if it is unable to determine an accurate CCR for an LTCH in one of the following circumstances: (1) New LTCHs that have not yet submitted their first Medicare cost report (a new LTCH is defined as an entity that has not accepted assignment of an existing hospital’s provider agreement in accordance with § 489.18); (2) LTCHs whose calculated CCR is in excess of the LTCH total CCR ceiling; and (3) other LTCHs for whom data with which to calculate a CCR are not available (for example, missing or faulty data). (Other sources of data that the MAC may consider in determining an LTCH’s CCR include data from a different cost reporting period for the LTCH, data from the cost reporting period preceding the period in which the hospital began to be paid as an LTCH (that is, the period of at least 6 months that it was paid as a short-term, acute care hospital), or data from other comparable LTCHs, such as LTCHs in the same chain or in the same region.)

Consistent with our historical practice of using the best available data and as we proposed, in this final rule, using our established methodology for determining the LTCH statewide average CCRs, based on the most recent complete IPPS “total CCR” data from the March 2016 update of the PSF, we are establishing LTCH PPS statewide average total CCRs for urban and rural hospitals that will be effective for discharges occurring on or after October 1, 2016 through September 30, 2017, in Table 6C listed in section VI. of the Addendum to this final rule (and available via the Internet on the CMS Web site). Consistent with our historical practice, as we proposed, we used more recent data to determine the LTCH PPS statewide average total CCRs for FY 2017 in this final rule.

Under the current LTCH PPS labor market areas, all areas in Delaware, the District of Columbia, New Jersey, and Rhode Island are classified as urban. Therefore, there are no rural statewide average total CCRs listed for those jurisdictions in Table 6C. This policy is consistent with the policy that we established when we revised our methodology for determining the applicable LTCH statewide average CCRs in the FY 2007 IPPS final rule (71
FR 48119 through 48121) and is the same as the policy applied under the IPPS. In addition, although Connecticut has areas that are designated as rural, in our calculation of the LTCH statewide average CCRs, there was no data available from short-term, acute care IPPS hospitals to compute a rural statewide average CCR or there were no short-term, acute care IPPS hospitals or LTCHs located in that area as of March 2016. (We note that, based on the best available data at the time of the proposed rule, there were no data available from short-term acute care IPPS hospitals (or LTCHs) located in the rural areas of North Dakota. However, based on the more recent data available for this final rule, there is now data available from short-term acute care IPPS hospitals in the rural areas of North Dakota from which to compute a rural statewide average CCR. Therefore, it is no longer necessary to use the national average total CCR for rural IPPS hospitals for rural North Dakota in Table 8C associated with this final rule, which is available via the Internet on the CMS Web site.) Therefore, consistent with our existing methodology, as we proposed, we used the national average total CCR for rural IPPS hospitals and the national average total CCR for rural IPPS hospitals, respectively. We used this proxy because we believe that the CCR data in the PSF for Maryland hospitals may not be entirely accurate (as discussed in greater detail in the FY 2007 IPPS final rule (71 FR 48120)).

d. Reconciliation of HCO and SSO Payments

Under the HCO policy for cases paid under either payment rate at § 412.525(a)(4)(iv)(D) and the SSO policy at § 412.529(f)(4)(iv), the payments for HCO and SSO cases are subject to reconciliation. Specifically, any such payments are reconciled at settlement based on the CCR that is calculated based on the cost report coinciding with the discharge. (We note the existing reconciliation process for HCO payments is also applicable to LTCH PPS payments for site neutral payment rate cases (80 FR 49610).) For additional information on the reconciliation policy, we refer readers to Sections 150.26 through 150.28 of the Medicare Claims Processing Manual (Pub. 100–4) as added by Change Request 7192 (Transmittal 2111; December 3, 2010) and the FY 2009 LTCH PPS final rule (73 FR 26820 through 26821).

e. Technical Change to the Definition of “Outlier Payment”

The existing regulations at § 412.503 includes a definition of “outlier payment,” applied when the LTCH PPS was implemented (67 FR 56049). This definition does not account for the dual rate LTCH PPS payment structure that began in FY 2016. Therefore, in this final rule, to account for our HCO policy for LTCH cases paid under either payment rate, as we proposed, we are revising the definition of “outlier payment” at § 412.503 to mean an additional payment beyond the LTCH PPS standard Federal payment rate or the site neutral payment rate (including, when applicable, the transitional blended rate), as applicable, for cases with unusually high costs. We did not receive any public comments on our proposed technical revisions to the definition of “outlier payment” at § 412.503 to account for the dual rate LTCH PPS payment structure that began in FY 2016. Therefore, we are adopting this revision as final, without modification.

3. High-Cost Outlier Payments for LTCH PPS Standard Federal Payment Rate Cases

a. Establishment of the Fixed-Loss Amount for LTCH PPS Standard Federal Payment Rate Cases for FY 2017

When we implemented the LTCH PPS, we established a fixed-loss amount so that total estimated outlier payments are projected to equal 8 percent of total estimated payments under the LTCH PPS (67 FR 56022 through 56026). When we implemented the dual rate LTCH PPS payment structure beginning in FY 2016, we established that, in general, that the historical LTCH PPS HCO policy will continue to apply to LTCH PPS standard Federal payment rate cases. That is, the fixed-loss amount and target for LTCH PPS standard Federal payment rate cases is determined using the LTCH PPS HCO policy adopted when the LTCH PPS was first implemented, but we limited the data used under that policy to LTCH cases that would have been LTCH PPS standard Federal payment rate cases if the statutory changes had been in effect at the time of those discharges.

To determine the applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases, we estimate outlier payments and total LTCH PPS payments for each LTCH PPS standard Federal payment rate case (or for each case that would have been a LTCH PPS standard Federal payment rate case if the statutory changes had been in effect at the time of the discharge) using claims data from the MedPAR files. The applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases results in estimated total outlier payments being projected to be equal to 8 percent of projected total LTCH PPS payments for LTCH PPS standard Federal payment rate cases. We use MedPAR claims data and CCRs based on data from the most recent PSF (or from the applicable statewide average CCR if an LTCH’s CCR data are faulty or unavailable) to establish an applicable fixed-loss threshold amount for LTCH PPS standard Federal payment rate cases.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25286 through 25287), we proposed to continue to use our current methodology to calculate an applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017 using the best available data that would maintain estimated HCO payments at the projected 8 percent of total estimated LTCH PPS payments for LTCH PPS standard Federal payment rate cases (based on the payment rates and policies for these cases presented in that proposed rule). Specifically, based on the most recent complete LTCH data available (that is, LTCH claims data from the December 2015 update of the FY 2015 MedPAR file and CCRs from the December 2015 update of the PSF), we determined that a proposed fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017 of $22,728 would result in estimated outlier payments projected to be equal to 8 percent of estimated FY 2017 payments for such cases. Under this proposal, we would continue to make an additional HCO payment for the cost of an LTCH PPS standard Federal payment rate case that exceeds the HCO threshold amount that is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of the adjusted LTCH PPS standard Federal payment rate payment and the fixed-loss amount for LTCH PPS standard Federal payment cases of $22,728). We also noted that the proposed fixed-loss amount for HCO cases paid under the LTCH PPS standard Federal payment rate in FY 2017 of $22,728 is notably higher than the FY 2016 fixed-
loss amount for LTCH PPS standard Federal payment rate cases of $16,423, and explains that the increase is largely attributable to rate-of-change in the Medicare allowable charges on the claims data in the MedPAR file. Based on the most recent available data at the time of the proposed rule, we found that the current FY 2016 HCO threshold of $16,423 results in estimated HCO payments for LTCH PPS standard Federal payment rate cases of approximately 9.1 percent of the estimated total LTCH PPS payments in FY 2016, which exceeds the 8 percent target by 1.1 percentage points. We also noted that fluctuations in the fixed-loss amount occurred in the first few years after the implementation of the LTCH PPS, due, in part, to the changes in LTCH behavior (such as Medicare beneficiary treatment patterns) in response to the new payment system and the lack of data and information available to predict how those changes would affect the estimate costs of LTCH cases. As we gained more experience with the effects and implementation of the LTCH PPS, the annual changes on the fixed-loss amount generally stabilized relative to the fluctuations that occurred in the early years of the LTCH PPS. Therefore, we did not propose any changes to our method for the inflation factor applied to update the costs of each case (that is, an inflation factor based on the most recent estimate of the proposed 2013-based LTCH market basket as determined by the Office of the Actuary) in determining the proposed fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017. We stated our continued belief that it is appropriate to continue to use our historical approach until we gain experience with the effects and implementation of the dual rate LTCH PPS payment structure that began with discharges occurring in cost reporting periods beginning on or after October 1, 2015, and the types of cases paid at the LTCH PPS standard Federal payment rate under this dual rate payment structure. We stated that we may revisit this issue in the future if data demonstrate such a change is warranted, and would propose any changes in the future through the notice-and-comment rulemaking process. Furthermore, we invited public comments on potential improvements to the determination of the fixed-loss amount for LTCH PPS standard Federal payment rate cases, including the most appropriate method of determining an inflation factor for projecting the costs of each case when determining the fixed-loss threshold.

Comment: A few commenters expressed concern with the notable increase in the proposed FY 2017 fixed-loss amount for LTCH PPS standard Federal payment rate cases as compared to the current fixed-loss amount for such cases. Some of these commenters expressed general support for continuing to use a target amount of 8 percent for HCO payments for LTCH PPS standard Federal payment rate cases. Some commenters stated that they are concerned about the potential instability in the fixed-loss amount from year to year and requested that CMS continue to be transparent about the possible causes for such large year-to-year changes in the fixed-loss amount and how much of this variability may be attributable to the new dual rate LTCH PPS payment structure. Some commenters also expected that the fixed-loss amount would change in the final rule based on the use of more recent LTCH claims data from the MedPAR file and the latest CCRs from the PSF. In addition to using the most recent LTCH claims data and CCRs, some commenters suggested that CMS consider whether the new dual rate LTCH PPS payment structure warrants the use of other relevant data or a change in the inflation factor for projecting the costs of each case when determining the fixed-loss amount. One commenter stated that it is not reasonable for the HCO fixed-loss amount for LTCH PPS standard Federal payment rate cases to increase to such a high level, and suggested that the increase in the HCO fixed-loss amount be established at 7 percent, which would reflect the LTCH industry’s average increase in charges.

Response: We understand the commenters’ concern with the proposed increase to the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017, and we appreciate the commenters’ support for our proposed continued use of a HCO target amount of 8 percent for LTCH PPS standard Federal payment rate cases. (For information on the rationale for the existing 8 percent HCO “target” requirement, we refer readers to the August 30, 2002 LTCH PPS final rule (67 FR 56022 through 56024).) As we discussed in the proposed rule, based on the best available data at that time, we estimated that the current FY 2016 HCO fixed-loss amount of $16,423 results in estimated HCO payments for LTCH PPS standard Federal payment rate cases in excess of the 8 percent target by 1.1 percentage points. Similarly, based on the most recent available data for this final rule (discussed below), we found that the current FY 2016 HCO threshold of $16,423 results in estimated HCO payments for LTCH PPS standard Federal payment rate cases of approximately 9.0 percent of the estimated total LTCH PPS payments in FY 2016, which exceeds the 8 percent target by 1.0 percentage point. Maintaining the fixed-loss amount at the current level would result in HCO payments that are substantially more than the current regulatory 8 percent target that we apply to total payments for LTCH PPS standard Federal payment rate cases because a lower fixed-loss amount results in more cases qualifying as outlier cases, as well as higher HCO payments for qualifying cases because the maximum loss that an LTCH must incur before receiving an HCO payment (that is, the fixed-loss amount) would be smaller. For these reasons, we continue to believe it is necessary and appropriate to increase to the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017 to maintain estimated HCO payments equal to 8 percent of estimated total LTCH PPS payments for such cases as required under § 412.325(a). In addition, for these reasons, we are not adopting the commenter’s suggestion to only increase the fixed-loss amount for LTCH PPS standard Federal payment rate cases by the average increase in LTCHs’ charges because the resulting fixed-loss amount would not maintain estimated HCO payments to equal 8 percent of estimated total LTCH PPS payments for such cases, as required under current policy.

As discussed in the proposed rule, fluctuations in the fixed-loss amount have occurred previously under the LTCH PPS, due, in part, to the changes in LTCH behavior in response to the changes in Medicare payments and the lack of data and information available to predict how those changes affect the estimated costs of LTCH cases. As was the case when there were fluctuations in the fixed-loss amount in the early years of the LTCH PPS, we expect annual changes to the fixed-loss amount to generally stabilize as experience is gained under the new dual rate LTCH PPS payment structure. We intend to continue to monitor annual changes in the HCO fixed-loss amount, including factors that cause any such changes. We appreciate the commenters’ suggestions for potential improvements to the determination of the fixed-loss amount for LTCH PPS standard Federal payment rate cases, including the use of other relevant data or a change in the inflation factor for projecting the costs of each
case when determining the fixed-loss amount. As we indicated in the proposed rule, we may revisit this issue in the future if data demonstrate such a change is warranted, and would propose any changes in the future through the notice-and-comment rulemaking process. We note, as in greater detail discussed below, the fixed-loss amount for FY 2017 for LTCH PPS standard Federal payment rate cases we are establishing in this final rule, after consideration of public comments and based on the most recent LTCH claims data from the MedPAR file and the latest CCRs from the PSF, does result in a fixed-loss amount for such cases that is lower than the proposed fixed-loss amount, consistent with commenters’ expectations.

After consideration of the public comments we received, for the reasons discussed above, we are finalizing our proposal to continue to use the current LTCH PPS HCO payment methodology for LTCH PPS standard Federal payment rate cases for FY 2017 without modification. Therefore, in this final rule, for FY 2017, we determined an applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases using data from LTCH PPS standard Federal payment rate cases (or cases that would have been LTCH PPS standard Federal payment rate cases had the dual rate LTCH PPS payment structure been in effect at the time of those discharges). The fixed-loss amount for LTCH PPS standard Federal payment rate cases will continue to be determined so that estimated HCO payments will be projected to equal 8 percent of estimated total LTCH PPS standard Federal payment rate cases. Furthermore, in accordance with §412.523(d)(1), a budget neutrality factor will continue to be applied to LTCH PPS standard Federal payment rate cases to offset that 8 percent so that HCO payments for LTCH PPS standard Federal payment rate cases will be budget neutral. Below we present our policies for these cases presented in this final rule. Specifically, based on the data and policies for these cases presented in this final rule.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49803 through 49804), we presented our policies regarding the methodology and data we used to establish a fixed-loss amount of $16,423 for FY 2016 for LTCH PPS standard Federal payment rate cases, which was calculated based on the data and the rates and policies presented in that final rule in order to maintain estimated HCO payments at the projected 8 percent of total estimated LTCH PPS payments. Consistent with our historical practice of using the best data available, as we proposed, in determining the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017, we used the most recent available LTCH claims data and CCR data, that is, LTCH claims data from the March 2016 update of the FY 2015 MedPAR file and CCRs from the March 2016 update of the PSF, as these data were the most recent complete LTCH data available at that time.

For FY 2017, as we proposed, we are continuing to use our current methodology to calculate an applicable fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017 using the best available data that will maintain estimated HCO payments at the projected 8 percent of total estimated LTCH PPS payments for LTCH PPS standard Federal payment rate cases (based on the rates and policies for these cases presented in this final rule). Specifically, based on the most recent complete LTCH data available (that is, LTCH claims data from the March 2016 update of the FY 2015 MedPAR file and CCRs from the March 2016 update of the PSF), we determined a fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017 that will result in estimated outlier payments projected to be equal to 8 percent of estimated FY 2017 payments for such cases. Under the broad authority of section 123(a)(1) of the BBRA and section 307(b)(1) of the BIPA, we are establishing a fixed-loss amount of $21,943 for LTCH PPS standard Federal payment rate cases for FY 2017.

Under our policy, we will continue to make an additional HCO payment for the cost of an LTCH PPS standard Federal payment rate case that exceeds the HCO threshold amount that is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of the adjusted LTCH PPS standard Federal payment rate payment and the fixed-loss amount for LTCH PPS standard Federal payment rate cases of $21,943).

We note that the fixed-loss amount of $21,943 for FY 2017 for LTCH PPS standard Federal payment rate cases is somewhat lower than the proposed FY 2017 fixed-loss amount of $22,728 for FY 2017 for such cases, but notably higher than the FY 2016 fixed-loss amount for LTCH PPS standard Federal payment rate cases of $16,423. As discussed in the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25287), the fixed-loss amount for LTCH PPS standard Federal payment rate cases was determined using LTCH claims data from the March 2015 update of the FY 2014 MedPAR file and CCRs from the March 2015 update of the PSF. Based on that data, the estimated outlier payments were projected to be equal to 8 percent of estimated FY 2016 payments for such cases (80 FR 49803). Using the more recent LTCH claims data (that is, FY 2015 LTCH discharges from the March 2016 update of the MedPAR file and CCRs from the March 2016 update of the PSF), we currently estimate that the FY 2016 fixed-loss amount of $16,423 results in estimated HCO payments for LTCH PPS standard Federal payment rate cases of approximately 9.0 percent of total estimated FY 2016 LTCH PPS payments to those cases, which exceeds the 8 percent target. While many factors contribute to this increase, we found that the rate-of-change in the Medicare allowable charges on the claims data in the MedPAR is a significant contributing factor. In the payment modeling used to estimate LTCH PPS payments for the FY 2016 IPPS/LTCH PPS final rule, for SSO and HCO cases paid as LTCH PPS standard Federal payment rate cases, we applied an inflation factor of 4.6 percent (determined by the Office of the Actuary) to update the 2014 costs of each case to 2016 (80 FR 49833). Upon examining FY 2014 LTCH and FY 2015 LTCH discharge data, we found that Medicare allowable charges for LTCH PPS standard Federal payment rate cases (had the dual rate LTCH PPS payment structure been in effect at the time of the discharges) increased approximately 7 percent. This higher inflation factor results in higher estimated costs for outlier cases and, therefore, more estimated outlier payments. For the reasons discussed above, we believe that it is necessary and appropriate to apply an increase to the fixed-loss amount for LTCH PPS standard Federal payment rate cases for FY 2017 to ensure that, for LTCH PPS standard Federal payment rate cases, estimated HCO payments will equal 8 percent of estimated total LTCH PPS payments for those cases as required under §412.525(a).

b. Application of the High-Cost Outlier Policy to SSO Cases

Under our implementation of the dual rate LTCH PPS payment structure required by statute, LTCH PPS standard Federal payment rate cases (that is, LTCH discharges that meet the criteria for exclusion from the site neutral payment rate) will continue to be paid based on the LTCH PPS standard Federal payment rate, and will include all of the existing payment adjustments.
under § 412.525(d), such as the adjustments for SSO cases under § 412.529. Under some rare circumstances, an LTCH discharge can qualify as an SSO case (as defined in the regulations at § 412.529 in conjunction with § 412.503) and also as an HCO case, as discussed in the August 30, 2002 final rule (67 FR 56026). In this scenario, a patient could be hospitalized for less than five-sixths of the geometric average length of stay for the specific MS–LTC–DRG, and yet incur extraordinarily high treatment costs. If the estimated costs exceeded the HCO threshold (that is, the SSO payment plus the applicable fixed-loss amount), the discharge is eligible for payment as an HCO. Therefore, for an SSO case in FY 2017, as we proposed, we are establishing that the HCO payment will be 80 percent of the difference between the estimated cost of the case and the applicable HCO threshold (80 FR 49618 through 49629). In the FY 2016 IPPS/LTCH PPS final rule, in examining the appropriate fixed-loss amount for site neutral payment rate cases issue, we considered how LTCH discharges based on historical claims data would have been classified under the dual rate LTCH PPS payment structure and the CMS’ Office of the Actuary (OACT) projections regarding how LTCHs will likely respond to our implementation of policies resulting from the statutory payment changes. For FY 2016, at that time our actuaries projected that the proportion of cases that would qualify as LTCH PPS standard Federal payment rate cases versus site neutral payment rate cases under the statutory provisions would remain consistent with what is reflected in the historical LTCH PPS claims data. Although our actuaries did not project an immediate change in the proportions found in the historical data, they did project cost and resource use changes to account for the lower payment rates. Our actuaries also projected that the costs and resource use for cases paid at the site neutral payment rate would likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate and would likely mirror the costs and resource use for IPPS cases assigned to the same MS–DRG, regardless of whether the proportion of site neutral payment rate cases in the future remains similar to what is found based on the historical data. In light of these projections and expectations, we discussed that we believed that the use of a single fixed-loss amount and HCO target for all LTCH PPS cases would be problematic. In addition, we discussed that we did not believe that it would be appropriate for comparable LTCH PPS site neutral payment rate cases to receive dramatically different HCO payments from those cases that would be paid under the IPPS (80 FR 49618 through 49619). For those reasons, in the FY 2016 IPPS/LTCH PPS final rule (FR 80 49619), we stated that we believe that the most appropriate fixed-loss amount for site neutral payment rate cases for a given fiscal year, beginning with FY 2016, would be the IPPS fixed-loss amount for that fiscal year. Accordingly, we established that for FY 2016, a fixed-loss amount for site neutral payment rate cases of $22,544, which was the same as the FY 2016 IPPS fixed-loss amount. (We note that the FY 2016 fixed-loss amount under the IPPS was updated, applicable for discharges on or after January 1, 2016, as a conforming change to the implementation of section 601 of the Consolidated Appropriations Act, 2016, which modified the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016 (Change Request 9523, Transmittal 3449, dated February 4, 2016.) Consistent with this change, the FY 2016 fixed-loss amount for site neutral payment rate cases under the LTCH PPS was updated, applicable for discharges on or after January 1, 2016, to $22,538, which is the same as the updated IPPS outlier fixed-loss cost threshold for FY 2016. (We refer readers to Change Request 9527, Transmittal 3445, dated January 29, 2016, which also updated the IPPS comparable amount calculation, applicable to discharges occurring on or after January 1, 2016, consistent with the conforming changes made as a result of the new IPPS payment requirement.)

In developing a fixed-loss amount for site neutral payment rate cases for FY 2017, as discussed in the FY 2017 IPPS/LTCH proposed rule (81 FR 25288), we considered the same factors we did developing a fixed-loss amount for such cases for FY 2016. For FY 2017, our actuaries currently project that the proportion of cases that will qualify as LTCH PPS standard Federal payment rate cases versus site neutral payment rate cases under the dual rate LTCH PPS payment structure provisions will remain consistent with what is reflected in the historical LTCH PPS claims data. Based on FY 2014 LTCH claims data, LTCH claims data, we found that approximately 55 percent of LTCH cases would have been paid the LTCH PPS standard Federal payment rate and approximately 45 percent of LTCH cases would have been paid the site neutral payment rate if those rates had been in effect at that time.) At this time, our actuaries continue to project no immediate change in these proportions. However, they do continue to project that the costs and resource use for cases paid at the site neutral payment rate would likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate and will likely mirror the costs and resource use for IPPS cases assigned to the same MS–DRG, regardless of whether the proportion of site neutral payment rate cases in the future remains similar to what is found based on the historical data. As discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49619), this actuarial assumption is based on our expectation that site neutral payment rate cases would generally be paid based on an IPPS comparable per diem amount under the statutory LTCH PPS payment changes that began in FY 2016, which, in the majority of cases, is much lower than the payment that would have been paid if these statutory changes were not enacted. For these reasons, we continue to believe that the most appropriate fixed-loss amount for site neutral payment rate cases for FY 2017 is the IPPS fixed-loss amount for FY 2017.

Therefore, for FY 2017, we proposed that the applicable HCO threshold for site neutral payment rate cases is the sum of the site neutral payment rate for the case and the IPPS fixed-loss amount. That is, we proposed a fixed-loss amount for site neutral payment rate cases of $23,681, which is the same FY 2017 IPPS fixed-loss amount discussed in section II.A.4.g.(1) of the Addendum to that proposed rule. We stated that we continued to believe that this policy will reduce differences between HCO payments for similar cases under the IPPS and site neutral payment rate cases under the LTCH PPS and promote fairness between the two systems. Accordingly, for FY 2017, we proposed to calculate a HCO payment for site neutral payment rate cases with costs that exceed the HCO threshold amount,
which is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of site neutral payment rate payment and the fixed-loss amount for site neutral payment rate cases of $23,681).

**Comment:** Some commenters expressed support for our proposal to continue to use the FY 2017 IPPS fixed-loss amount and 5.1 percent HCO target for LTCH discharges paid at the site neutral payment rate in FY 2017. However, some commenters suggested that the IPPS fixed-loss amount and 5.1 percent HCO target not be used automatically for site neutral payment rate cases every year.

**Response:** We appreciate the commenters support for our proposal to continue to use the FY 2017 IPPS fixed-loss amount and 5.1 percent HCO target for LTCH discharges paid at the site neutral payment rate in FY 2017. Given the current expectation that cases paid at the site neutral payment rate would likely be similar to IPPS cases assigned to the same MS–DRG, we continue to believe the most appropriate fixed-loss amount for site neutral payment rate cases is the IPPS fixed-loss amount for that fiscal year. As we indicated in the FY 2016 IPPS/LTCH PS final rule (80 FR 49619), to the extent experience under the revised LTCH PPS indicates site neutral payment rate cases differ sufficiently from these expectations, we agree it would be appropriate to revisit in future rulemaking the most appropriate fixed-loss amount used to determine case payments for site neutral payment rate cases.

**Comment:** One commenter recommended that CMS apply geographic adjustments (that is, the wage index and COLA) to the fixed-loss amount when determining the HCO threshold for site neutral payment rate cases, consistent with the approach used under the IPPS.

**Response:** The LTCH PPS HCO policy does not include the application of geographic adjustments when determining the HCO threshold, and therefore, our current policy for determining the HCO threshold for site neutral payment rate cases, which we proposed to continue to use for FY 2017, is consistent with our longstanding LTCH PPS HCO policy. The LTCH PPS and IPPS HCO policies have historically differed with regard to this aspect of the HCO payment policy calculation. Moreover, the commenter offered little support to demonstrate that its recommended change, which we did not propose and are not accepting, would result in more appropriate HCO payments to site neutral payment rate cases paid under the LTCH PPS. We will keep this recommended change in mind as we consider potential refinements to the LTCH PPS HCO policy, including the HCO threshold for site neutral payment rate cases, in the future.

After consideration of the public comments we received, we are finalizing, without modification, our proposals to use the FY 2017 IPPS fixed-loss amount and 5.1 percent HCO target for LTCH discharges paid at the site neutral payment rate in FY 2017. Therefore, for FY 2017, as we proposed, we are establishing that the applicable HCO threshold for site neutral payment rate cases is the sum of the site neutral payment rate for the case and the IPPS fixed-loss amount. That is, we are establishing a fixed-loss amount for site neutral payment rate cases of $23,570, which is the same FY 2017 IPPS fixed-loss amount discussed in section II.A.4.g.(1) of the Addendum to this final rule. We continue to believe that this policy will reduce differences between HCO payments for similar cases under the IPPS and site neutral payment rate cases under the LTCH PPS and promote fairness between the two systems. Accordingly, under this policy, for FY 2017, we are calculating a HCO payment for site neutral payment rate cases with costs that exceed the HCO threshold amount, which is equal to 80 percent of the difference between the estimated cost of the case and the outlier threshold (the sum of site neutral payment rate payment and the fixed-loss amount for site neutral payment rate cases of $23,570). (We note that any site neutral payment rate case that is paid under the blended transitional rate.)

In establishing a HCO policy for site neutral payment rate cases, we established a budget neutrality requirement at § 412.522(c)(2)(i). We established this requirement because we believe that the HCO policy for site neutral payment rate cases should be budget neutral, just as the HCO policy for LTCH PPS standard Federal payment rate cases are budget neutral, meaning that estimated site neutral payment rate HCO payments should not result in any change in estimated aggregate LTCH PPS payments. Under § 412.522(c)(2)(i), we adjust all payments for site neutral payment rate cases by a budget neutrality factor so that the estimated HCO payments payable for site neutral payment rate cases do not result in any increase in aggregate LTCH PPS payments. Specifically, under § 412.522(c)(2)(i), we apply a budget neutrality factor to the site neutral payment rate portion of the transitional blended rate payment (that is applicable to site neutral payment rate cases during the 2-year transition period provided by the statute) that is established based on an estimated basis. (We refer readers to 80 FR 49621 through 49622 and 49805.)

Under the approach adopted for applying the budget neutrality adjustment to the site neutral payment rate portion of the transitional blended rate payment in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49805), we explained that there is no need to perform any calculation of the site neutral payment rate case HCO payment budget neutrality adjustment under our finalized policy. This is because, as discussed in the proposed rule (81 FR 25288), based on our actuarial assumptions we project that our proposal to use the IPPS fixed-loss threshold for the site neutral payment rate cases would result in HCO payments for those cases that are similar in proportion as is seen in IPPS cases assigned to the same MS–DRG; that is, 5.1 percent. In other words, we estimated that HCO payments for site neutral payment rate cases would be 5.1 percent of the site neutral payment rate payments. Under the statutory transition period, payments to site neutral payment rate cases in FY 2017 will be paid under the blended transitional rate. As such, we stated that estimated HCO payments for site neutral payment rate cases in the FY 2017 policy will be projected to be 5.1 percent of the portion of the blended rate payment that is based on the estimated site neutral payment rate payment amount (and will not include the LTCH PPS standard Federal payment rate payment amount as specified in § 412.522(c)(2)(i)). To ensure that estimated HCO payments payable to site neutral payment rate cases in FY 2017 will not result any increase in estimated aggregate FY 2017 LTCH PPS payments, under the budget neutrality requirement at § 412.522(c)(2)(i), we explained it is necessary to reduce the site neutral payment rate portion of the blended rate payment by 5.1 percent to account for the estimated additional HCO payments payable to those cases in FY 2017. In order to achieve this, for FY 2017, we proposed to continue to apply a budget neutrality factor to the site neutral payment rate portion of the blended rate payment by 5.1 percent reduction, determined as 1.0 − 5.1/100 =
neutral payment rate cases that are paid
adjustment should not be applied to site
neutrality adjustment is therefore unwarranted. These
Comment: As was the case in the FY
2016 rulemaking cycle, commenters
again objected to the proposed
application of a high-cost outlier (HCO)
budget neutrality adjustment to site
neutral payment rate cases, stating that
it results in savings to the Medicare
program instead of being budget neutral.
The commenters’ primary objection was
again based on their belief that, because
the IPPS base rates used in the IPPS
comparable per diem amount
calculation of the site neutral payment
rate include a budget neutrality
adjustment for IPPS HCO payments
(that is, a 5.1 percent adjustment on the
operating IPPS standardized amount), an
“additional” budget neutrality factor is not necessary and is, in fact,
duplicative. Some of these commenters
stated that, in addition to not applying a
HCO budget neutrality adjustment to site
neutral payment rate payments, its
application in FY 2016 should be
discontinued, and that a retroactive
adjustment to the FY 2016 site neutral
payment rate payments that have
already occurred should be made to
address this perceived error. In
addition, some commenters also
indicated that the HCO budget
neutrality payment adjustment is
inappropriate because it increases the
payment difference between the IPPS
payment amount for a case and the
“LTCH PPS payment amount” (which
we took to mean cases paid the IPPS
comparable per diem amount under the
site neutral payment rate) for similar
cases. Other commenters stated that
there is no statutory requirement for
budget neutrality for HCO payments,
and that any HCO budget neutrality
adjustment for site neutral payment rate
cases is therefore unwarranted. These
commenters stated that there was
nothing in their review of the
rulemaking record that they read to
mean that CMS would apply a HCO
budget neutrality adjustment on an
ongoing basis, and that they believed
that a budget neutrality adjustment was
only required for the first year of the
LTCH PPS. A few other commenters
stated that if CMS finalizes its proposal
to apply a HCO budget neutrality
adjustment for site neutral payment rate
cases, the per diem neutrality
adjustment should not be applied to site
neutral payment rate cases that are paid
at 100 percent of the estimated cost
because they believed that doing so
would violate the statute, which they
understood to require payment at “100
percent of the estimated cost for the
services involved,” without adjustment.
Response: We continue to disagree
with the commenters who assert that a
HCO budget neutrality adjustment for site
neutral payment rate cases is
inappropriate, unnecessary, or
duplicative. We have made a budget
neutrality adjustment for estimated HCO
payments under the LTCH PPS under
§ 412.525 every year since its inception
in FY 2003. Specifically, at
§ 412.523(d)(1), under the broad
authority provided by section 123 of
Public Law 106–113 and section 307 of
Public Law 106–554, which includes
the authority to establish adjustments,
we established that the standard Federalate (now termed the LTCH PPS
standard Federal payment rate under
the new dual rate system) would be
adjusted by a reduction factor of 8
percent, the estimated proportion
outlier payments under the LTCH PPS
(67 FR 56052). Thus, Congress was well
aware of how we had implemented our
HCO policy under the LTCH PPS under
§ 412.525 at the time of the enactment
Section 1206 of Public Law 113–67
defined the site neutral payment rate as
the lower of the estimated cost of the
case or the IPPS comparable per diem
amount determined under paragraph
d(4) of § 412.529, including any
applicable outlier payments under
§ 412.525. The term “IPPS comparable
per diem amount” was not new at the
time of enactment. That term had
already previously been defined under
§ 412.529(d)(4), which has been in effect
since July 1, 2006, and used as a
component of the payment adjustment
formula for LTCH PPS SSO cases. From
the July 1, 2006 inception of the IPPS
comparable component of the LTCH
PPS’ SSO payment formula, we have
budget neutralized the estimated HCO
payments that we expected to pay to
SSO cases involving those paid based on
the IPPS comparable per diem
amount. Congress was also well aware
of how we had implemented our “IPPS
comparable per diem amount” concept
in the SSO context at the time of the
enactment of section 1206 of Public Law
113–67. As such, we believe Congress
left us with the discretion to continue to
treat the “IPPS comparable per diem
amount” in the site neutral payment
rate context as we have historically
done with respect to LTCH PPS HCO
payments, as discussed charges paid using
the “IPPS comparable per diem
amount,” that is, to adopt a policy in the
site neutral context to budget neutralize
HCO payments made to LTCH PPS
discharges including those paid using the
“IPPS comparable per diem amount.”
In response to the commenters who
believe that budget neutrality was only
required in the first year of the LTCH
PPS, we suspect that they are
referencing the budget neutrality
adjustment that was made to the LTCH
PPS relative to the reasonable cost-based
TEFRA payment system that preceded
it. That initial budget neutrality
adjustment is unrelated to our ongoing
authority to make annual HCO budget
neutrality adjustments for payments
under the LTCH PPS, adjustments we
adopted through prior notice-and-
comment rulemaking using the broad
authority provided by section 123 of
Public Law 106–113 and section 307 of
Public Law 106–554.
In response to commenters who stated
that there is no statutory requirement to
apply a budget neutrality adjustment for HCO payments, as discussed
previously, the authorizing statutes grant the
Secretary broad authority to determine
appropriate adjustments under the
LTCH PPS, and that although the statute
did not “require” that a HCO policy be
implemented in a budget neutral
manner, we adopted such an approach
through notice-and-comment
rulemaking when we initially
implemented the LTCH PPS. As such,
we have made a budget neutrality
adjustment for estimated HCO payments
under the LTCH PPS every year since its
inception in FY 2003 under
§ 412.523(d)(1), where we established
that the standard Federal rate is
adjusted by a reduction factor of 8
percent, the estimated proportion
outlier payments under the LTCH PPS
(67 FR 56052).
In response to commenters who
indicated that the adjustment is
inappropriate because it increases the
payment difference between the IPPS
comparable component of the LTCH
PPS’ SSO payment formula, we have
budget neutralized the estimated HCO
payments that we expected to pay to
SSO cases involving those paid based on
the IPPS comparable per diem
amount. Congress was also well aware
of how we had implemented our “IPPS
comparable per diem amount” concept
in the SSO context at the time of the
enactment of section 1206 of Public Law
113–67. As such, we believe Congress
left us with the discretion to continue to
treat the “IPPS comparable per diem
amount” in the site neutral payment
rate context as we have historically
done with respect to LTCH PPS HCO
payments, as discussed charges paid using
the “IPPS comparable per diem
amount,” that is, to adopt a policy in the
payment rate payments that are paid at 100 percent of the estimated cost violates the statute. As noted above, CMS regularly uses its broad authorities under the authorizing statutes for the LTCH PPS to apply additional adjustments, where appropriate, to base payment amounts. For this reason, we are not adopting the commenter’s request, and for FY 2017 we will apply a HCO budget neutrality adjustment factor to all site neutral payment rate cases (or the site neutral payment rate portion of the blended payment rate for all such cases), as proposed.

In summary, we continue to disagree with commenters that a HCO budget neutrality adjustment for site neutral payment rate cases is inappropriate, unnecessary or duplicative. As such, we will continue to use the IPPS comparable per diem amount (calculated in accordance with our historical practices, which predates enactment of section 1206 of Pub. L. 113–67), and we will continue to apply a HCO budget neutrality adjustment to all site neutral payment rate payments (or portion thereof in the blended payment rate context). For these reasons, we are not adopting the commenter’s recommendation to discontinue the application of the HCO budget neutrality adjustment for site neutral payment rate cases in FY 2016, or their suggestion that we make a retroactive adjustment to the FY 2016 site neutral payment rate case payments that have already occurred.

Comment: One commenter noted that the HCO policy and itself is being reduced under our proposed application of a budget neutrality factor to the site neutral payment rate portion of the blended payment rate, which is inconsistent with high-cost outlier payments for other LTCH PPS and IPPS cases, and requested that we treat all cases in the same manner.

Response: On review, we agree that our proposed application would be inconsistent with our budget neutrality treatment of HCO payments for other LTCH PPS and IPPS cases, and we agree with the commenter that we should remove this variance. As such, we are adopting a policy of not applying the 0.949 budget neutrality adjustment factor to any applicable HCO payment for the site neutral payment rate (or, during the transition, the site neutral payment rate portion of the blended payment rate).

After consideration of the public comments we received, we are finalizing our proposal to apply a budget neutrality adjustment for HCO payments made to site neutral payment rate cases, with one modification. That is, we will not apply the HCO budget neutrality adjustment to the HCO portion of the payment amount. To ensure that estimated HCO payments payable to site neutral payment rate cases in FY 2017 will not result any increase in estimated aggregate FY 2017 LTCH PPS payments, under the budget neutrality requirement at §412.522(c)(2)(ii), it is necessary to reduce the site neutral payment rate (or portion thereof in the blended payment rate context) by 5.1 percent to account for the estimated additional HCO payments payable to those cases in FY 2017. To effectuate this policy, for FY 2017, in this final rule we have adopted a budget neutrality policy under which we will apply a budget neutrality factor of 0.949 (that is, the decimal equivalent of a 5.1 percent reduction, determined as 1.0 – 5.1/100 = 0.949) to the site neutral payment rate (or portion thereof in the blended payment rate context). This policy will be applied to cases paid at the IPPS comparable per diem amount and cases paid at 100 percent of the estimated cost.

E. Update to the IPPS Comparable/Equivalent Amounts to Reflect the Statutory Changes to the IPPS DSH Payment Adjustment Methodology

In the FY 2014 IPPS/LTCH PPS final rule (78 FR 50766), we established a policy for reflecting the changes to the Medicare IPPS DSH payment adjustment methodology provided for by section 3133 of the Affordable Care Act in the calculation of the “IPPS comparable amount” under the SSO policy at §412.529 and the “IPPS equivalent amount” under the 25-percent threshold payment adjustment policy at §412.534 and §412.536. Historically, the determination of both the “IPPS comparable amount” and the “IPPS equivalent amount” includes an amount for inpatient operating costs “for the costs of serving a disproportionate share of low-income patients.” Under the statutory changes to the Medicare DSH payment adjustment methodology that began in FY 2014, in general, eligible IPPS hospitals receive an empirically justified Medicare DSH payment equal to 25 percent of the amount they otherwise would have received under the statutory formula for Medicare DSH payments prior to the amendments made by the Affordable Care Act. The remaining amount, equal to an estimate of 75 percent of the amount that otherwise would have been paid as Medicare DSH payments, is made available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. The additional uncompensated care payments are based on the hospital’s amount of uncompensated care for a given time period relative to the total amount of uncompensated care for that same time period reported by all IPPS hospitals that receive Medicare DSH payments.

To reflect the statutory changes to the Medicare DSH payment adjustment methodology in the calculation of the “IPPS comparable amount” and the “IPPS equivalent amount” under the LTCH PPS, we stated that we will include a reduced Medicare DSH payment amount that reflects the projected percentage of the payment amount calculated based on the statutory Medicare DSH payment formula prior to the amendments made by the Affordable Care Act that will be paid to eligible IPPS hospitals as empirically justified Medicare DSH payments and uncompensated care payments in that year (that is, a percentage of the operating DSH payment amount that has historically been reflected in the LTCH PPS payments that is based on IPPS rates). We also stated that the projected percentage will be updated annually, consistent with the annual determination of the amount of uncompensated care payments that will be made to eligible IPPS hospitals. We believe that this approach results in appropriate payments under the LTCH PPS and is consistent with our intention that the “IPPS comparable amount” and the “IPPS equivalent amount” under the LTCH PPS closely resemble what an IPPS payment would have been for the same episode of care, while recognizing that some features of the IPPS cannot be translated directly into the LTCH PPS (79 FR 50766 through 50767).

For FY 2017, as discussed in greater detail in section IV.D.3.d.(2) of the preamble of this final rule, based on the most recent data available, our estimate of 75 percent of the amount that would otherwise have been paid as Medicare DSH payments (under the methodology outlined in section 1886(r)(2) of the Act) is adjusted to 55.36 percent of that amount to reflect the change in the percentage of individuals who are uninsured. The resulting amount was then used to determine the amount of uncompensated care payments that will be made to eligible IPPS hospitals in FY 2017. In other words, Medicare DSH payments prior to the amendments made by the Affordable Care Act will be adjusted to 41.52 percent (the product of 75 percent and 55.36 percent) and the
resulting amount will be used to calculate the uncompensated care payments to eligible hospitals. As a result, for FY 2017, we project that the reduction in the amount of Medicare DSH payments pursuant to section 1886(r)(1) of the Act, along with the payments for uncompensated care under section 1886(r)(2) of the Act, will result in overall Medicare DSH payments of 66.52 percent of the amount of Medicare DSH payments that would otherwise have been made in the absence of amendments made by the Affordable Care Act (that is, 25 percent + 41.52 percent = 66.52 percent). In this final rule, for FY 2017, as we proposed, we are establishing that the calculation of the “IPPS comparable amount” under § 412.529 and the “IPPS equivalent amount” under new § 412.538 will include an applicable operating Medicare DSH payment amount that is equal to 66.52 percent of the operating Medicare DSH payment amount that would have been paid based on the statutory Medicare DSH payment method for the amendments made by the Affordable Care Act. Furthermore, consistent with our historical practice, as we proposed, we used more recent data, to determine this factor in this final rule.

F. Computing the Adjusted LTCH PPS Federal Prospective Payments for FY 2017

Section 412.525 sets forth the adjustments to the LTCH PPS standard Federal payment rate. Under the dual rate LTCH PPS payment structure, only LTCH PPS cases that meet the statutory criteria to be excluded from the site neutral payment rate are paid based on the LTCH PPS standard Federal payment rate. Under § 412.525(c), the LTCH PPS standard Federal payment rate is adjusted to account for differences in area wages by multiplying the labor-related share of the LTCH PPS standard Federal payment for a case by the applicable LTCH PPS wage index (the FY 2017 values are shown in Tables 12A through 12B listed in section VI. of the Addendum of this final rule and are available via the Internet on the CMS Web site). The LTCH PPS standard Federal payment is also adjusted to account for the higher costs of LTCHs located in Alaska and Hawaii by the applicable COLA factors (the FY 2017 factors are shown in the chart in section V.D. of this Addendum) in accordance with § 412.525(b). In this final rule, as we proposed, we are establishing an LTCH PPS standard Federal payment rate for FY 2017 of $42,476.41, as discussed in section V.A.2. of the Addendum to this final rule. We illustrate the methodology to adjust the LTCH PPS standard Federal payment rate for FY 2017 in the following example:

Example

During FY 2017, a Medicare discharge that meets the criteria to be excluded from the site neutral payment rate, that is an LTCH PPS standard Federal payment rate case, is from an LTCH that is located in Chicago, Illinois (CBSA 16974). The FY 2017 LTCH PPS wage index value for CBSA 16974 is 1.0460 (obtained from Table 12A listed in section VI. of the Addendum of this final rule and available via the Internet on the CMS Web site). The Medicare patient case is classified into MS–LTC–DRG 189 (Pulmonary Edema & Respiratory Failure), which has a relative weight for FY 2017 of 0.9012 (obtained from Table 11 listed in section VI. of the Addendum of this final rule and available via the Internet on the CMS Web site). The LTCH submitted quality reporting data for FY 2017 in accordance with the LTCHQRP under section 1886(m)(5) of the Act.

To calculate the LTCH’s total adjusted Federal prospective payment for this Medicare patient case in FY 2017, we computed the wage-adjusted Federal prospective payment amount by multiplying the unadjusted FY 2017 LTCH PPS standard Federal payment rate ($42,476.41) by the labor-related share (66.5 percent) and the wage index value (1.0460). This wage-adjusted amount was then added to the nonlabor-related portion of the unadjusted LTCH PPS standard Federal payment rate (33.5 percent; adjusted for cost of living, if applicable) to determine the adjusted LTCH PPS standard Federal payment rate, which was then multiplied by the MS–LTC–DRG relative weight (0.9012) to calculate the total adjusted LTCH PPS standard Federal prospective payment for FY 2017 ($39,450.71). The table below illustrates the components of the calculations in this example.

<table>
<thead>
<tr>
<th>LTCH PPS Federal Prospective Payment Rate</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor-Related Share</td>
<td></td>
<td>$42,476.41</td>
</tr>
<tr>
<td>Labor-Related Portion of the LTCH PPS Standard Federal Payment Rate</td>
<td></td>
<td>$28,246.81</td>
</tr>
<tr>
<td>Wage Index (CBSA 16974)</td>
<td></td>
<td>× 0.665</td>
</tr>
<tr>
<td>Wage-Adjusted Labor Share of LTCH PPS Standard Federal Payment Rate</td>
<td></td>
<td>$29,546.16</td>
</tr>
<tr>
<td>Nonlabor-Related Portion of the LTCH PPS Standard Federal Payment Rate</td>
<td></td>
<td>$14,229.60</td>
</tr>
<tr>
<td>Adjusted LTCH PPS Standard Federal Payment Amount</td>
<td></td>
<td>+ $43,775.76</td>
</tr>
<tr>
<td>MS–LTC–DRG 189 Relative Weight</td>
<td></td>
<td>× 0.9012</td>
</tr>
<tr>
<td>Total Adjusted LTCH PPS Standard Federal Prospective Payment</td>
<td></td>
<td>$39,450.71</td>
</tr>
</tbody>
</table>

VI. Tables Referenced in This Final Rule and Available Only Through the Internet on the CMS Web Site

This section lists the tables referred to throughout the preamble of this final rule and in this Addendum. In the past, a majority of these tables were published in the Federal Register as part of the annual proposed and final rules. However, similar to FY’s 2012 through 2016, for the FY 2017 rulemaking cycle, the IPPS and LTCH tables will not be published in the Federal Register in the annual IPPS/LTCH PPS proposed and final rules and will be available only through the Internet. Specifically, all IPPS tables listed below, with the exception of IPPS Tables 1A, 1B, 1C, and 1D, and LTCH PPS Table 1E will be available only through the Internet. IPPS Tables 1A, 1B, 1C, and 1D, and LTCH PPS Table 1E are displayed at the end of this section and will continue to be published in the Federal Register as part of the annual proposed and final rules.

As discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49807), we streamlined and consolidated the wage index tables for FY 2016 and subsequent fiscal years.

As discussed in sections II.F.14., II.F.15.b., II.F.16., II.F.17.a., and II.F.19.a.1., a.3., and c.1. of the preamble of this final rule, we developed the following ICD–10–CM and ICD–10–PCS code tables for FY 2017: Table 6A—New Diagnosis Codes; Table 6B—New Procedure Codes; Table 6C—Invalid Diagnosis Codes; Table 6D—Invalid Procedure Codes; Table 6E—Revised Diagnosis Code Titles; Table 6F—Revised Procedure Code Titles; Table 6G.1—Secondary Diagnosis Order.
Additions to the CC Exclusion List:
Table 6G.2—Principal Diagnosis Order Additions to the CC Exclusion List
Table 6H.1—Secondary Diagnosis Order Deletions to the CC Exclusion List
Table 6H.2—Principal Diagnosis Order Deletions to the CC Exclusion List
Table 6I—Complete MCC List
Table 6I.1—Additions to the MCC List
Table 6I.2—Deletions to the MCC List
Table 6J—Complete CC List
Table 6J.1—Additions to the CC List
Table 6J.2—Deletions to the CC List
Table 6K—Complete List of CC Exclusions
Table 6L—Principal Diagnosis Is Its Own MCC List
Table 6M—Principal Diagnosis Is Its Own CC List
Table 6N.1—Additions to the Principal Diagnosis Is Its Own CC List
Table 6N.2—Deletions to the Principal Diagnosis Is Its Own CC List
Table 6O.1—Additions to the Principal Diagnosis Is Its Own MCC List
Table 6O.2—Deletions to the Principal Diagnosis Is Its Own MCC List
Table 6P—ICD–10–CM and ICD–10–PCS Codes for MCE and MS–DRG Changes
Table 6Q.1—ICD–10–CM and ICD–10–PCS Codes for MCE and MS–DRG Changes
Table 6Q.2—ICD–10–CM and ICD–10–PCS Codes for MCE and MS–DRG Changes

Crosswalk for FY 2017

Table 6A—New Diagnosis Codes—FY 2017
Table 6B—New Procedure Codes—FY 2017
Table 6C—Revised Procedure Code Titles—FY 2017
Table 6D—Invalid Procedure Codes—FY 2017
Table 6E—Revised Diagnosis Code Titles—FY 2017
Table 6F—Revised Diagnosis Code Titles—FY 2017
Table 6G.1—Secondary Diagnosis Order Additions to the CC Exclusions List—FY 2017
Table 6G.2—Principal Diagnosis Order Additions to the CC Exclusions List—FY 2017
Table 6H.1—Secondary Diagnosis Order Deletions to the CC Exclusions List—FY 2017
Table 6H.2—Principal Diagnosis Order Deletions to the CC Exclusions List—FY 2017
Table 6I—Complete Major Complication and Comorbidity (MCC) List—FY 2017
Table 6I.1—Additions to the MCC List—FY 2017
Table 6I.2—Deletions to the MCC List—FY 2017
Table 6J—Complete Complication and Comorbidity (CC) List—FY 2017
Table 6J.1—Additions to the CC List—FY 2017
Table 6J.2—Deletions to the CC List—FY 2017
Table 6K—Complete List of CC Exclusions—FY 2017
Table 6L—Principal Diagnosis Is Its Own MCC List—FY 2017
Table 6M—Principal Diagnosis Is Its Own CC List—FY 2017
Table 6N.1—Additions to the Principal Diagnosis Is Its Own CC List—FY 2017
Table 6N.2—Deletions to the Principal Diagnosis Is Its Own CC List—FY 2017
Table 6O.1—Additions to the Principal Diagnosis Is Its Own MCC List—FY 2017
Table 6O.2—Deletions to the Principal Diagnosis Is Its Own MCC List—FY 2017

Uncompensated care payment for uncompensated care for FY 2017.
Readers who experience any problems accessing any of the tables that are posted on the CMS Web sites identified below should contact Michael Treitel at (410) 786–4552.

The following IPPS tables for this FY 2017 final rule are available only through the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html. Click on the link on the left side of the screen titled, “FY 2017 IPPS Final Rule Home Page” or “Acute Inpatient—Files for Download”.

Table 2—Case-Mix Index and Wage Index Table by CCN—FY 2017
Table 3—Wage Index Table by CBSA—FY 2017
Table 5—List of Medicare Severity Diagnosis-Related Groups (MS–DRGs), Relative Weighting Factors, and Geometric and Arithmetic Mean Length of Stay—FY 2017
Table 6A—New Diagnosis Codes—FY 2017
Table 6B—New Procedure Codes—FY 2017
Table 6C—Revised Procedure Code Titles—FY 2017
Table 6D—Invalid Procedure Codes—FY 2017
Table 6E—Revised Diagnosis Code Titles—FY 2017
Table 6F—Revised Diagnosis Code Titles—FY 2017
Table 6G—Complete Major Complication and Comorbidity (MCC) List—FY 2017
Table 6H—Complete Major Complication and Comorbidity (MCC) List—FY 2017
Table 7A—Medicare Prospective Payment System Selected Percentile Lengths of Stay: FY 2015 MedPAR Update—March 2016 GROUPER V3.0—MS–DRGs
Table 7B—Medicare Prospective Payment System Selected Percentile Lengths of Stay: FY 2015 MedPAR Update—March 2016 GROUPER V34.0—MS–DRGs
Table 8A—FY 2017 Statewide Average Operating Cost-to-Charge Ratios (CCRs) for Acute Care Hospitals (Urban and Rural)
Table 8B—FY 2017 Statewide Average Capital Cost-to-Charge Ratios (CCRs) for Acute Care Hospitals
Table 9—New Technology Add-On Payment Thresholds for Applications for FY 2018
Table 10—List of Hospitals with Fewer Than 1,600 Medicare Discharges Based on the March 2016 Update of the FY 2015 MedPAR File and Potentially Eligible Hospitals for the FY 2017 Low Volume Hospital Payment Adjustment (eligibility for the low-volume hospital payment adjustment is also dependent upon meeting the mileage criteria specified at 42 CFR 412.101(b)[2][iii].)
Table 15—FY 2017 Readmissions Adjustment Factors
Table 16A—Updated Proxy Hospital Value-Based Purchasing (VBP) Program Adjustment Factors for FY 2017
Table 18—FY 2017 Uncompensated Care Payment Factor 3

The following LTCH PPS tables for this FY 2017 final rule are available only through the Internet on the CMS Web site at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/LongTermCareHospitalPPS/index.html under the list item for Regulation Number CMS–1655–F:
Table 8C—FY 2017 Statewide Average Total Cost-to-Charge Ratios (CCRs) for LTCHs (Urban and Rural)
Table 11—MS–LTC–DRGs, Relative Weights, Geometric Average Length of Stay, Short-Stay Outlier (SSO) Threshold, and “IPPS Comparable” Threshold for LTCH PPS Discharges Occurring from October 1, 2016 through September 30, 2017
Table 12A—LTCH PPS Wage Index for Urban Areas for Discharges Occurring from October 1, 2016 through September 30, 2017
Table 12B—LTCH PPS Wage Index for Rural Areas for Discharges Occurring from October 1, 2016 through September 30, 2017
Table 13A—Composition of Low Volume Quintiles for MS–LTC–DRGs—FY 2017
Table 13B—No Volume MS LTC–DRG Crosswalk for FY 2017
TABLE 1A—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR (69.6 PERCENT LABOR SHARE/30.4 PERCENT NONLABOR SHARE IF WAGE INDEX IS GREATER THAN 1)—FY 2017

<table>
<thead>
<tr>
<th>Hospital submitted quality data and is a meaningful EHR user (update = 1.65 percent)</th>
<th>Hospital submitted quality data and is NOT a meaningful EHR user (update = -0.375 percent)</th>
<th>Hospital did NOT submit quality data and is a meaningful EHR user (update = 0.975 percent)</th>
<th>Hospital did NOT submit quality data and is NOT a meaningful EHR user (update = -1.05 percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor</td>
<td>Nonlabor</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>$3,839.57</td>
<td>$1,677.06</td>
<td>$3,763.08</td>
<td>$1,643.65</td>
</tr>
</tbody>
</table>

TABLE 1B—NATIONAL ADJUSTED OPERATING STANDARDIZED AMOUNTS, LABOR/NONLABOR (62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE IF WAGE INDEX IS LESS THAN OR EQUAL TO 1)—FY 2017

<table>
<thead>
<tr>
<th>Hospital submitted quality data and is a meaningful EHR user (update = 1.65 percent)</th>
<th>Hospital submitted quality data and is NOT a meaningful EHR user (update = -0.375 percent)</th>
<th>Hospital did NOT submit quality data and is a meaningful EHR user (update = 0.975 percent)</th>
<th>Hospital did NOT submit quality data and is NOT a meaningful EHR user (update = -1.05 percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor</td>
<td>Nonlabor</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>$3,420.31</td>
<td>$2,096.32</td>
<td>$3,352.17</td>
<td>$2,054.56</td>
</tr>
</tbody>
</table>

TABLE 1C—ADJUSTED OPERATING STANDARDIZED AMOUNTS FOR HOSPITALS IN PUERTO RICO, LABOR/NONLABOR (NATIONAL: 62 PERCENT LABOR SHARE/38 PERCENT NONLABOR SHARE BECAUSE WAGE INDEX IS LESS THAN OR EQUAL TO 1)—FY 2017

<table>
<thead>
<tr>
<th>Standardized amount</th>
<th>Rates if wage index is greater than 1</th>
<th>Rates if wage index is less than or equal to 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
<td>Labor</td>
<td>Nonlabor</td>
</tr>
<tr>
<td>1</td>
<td>Not Applicable</td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>

1 For FY 2017, there are no CBSAs in Puerto Rico with a national wage index greater than 1.

TABLE 1D—CAPITAL STANDARD FEDERAL PAYMENT RATE—FY 2017

<table>
<thead>
<tr>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>National</td>
</tr>
</tbody>
</table>

TABLE 1E—LTCPPS STANDARD FEDERAL PAYMENT RATE—FY 2017

<table>
<thead>
<tr>
<th>Standard Federal Rate</th>
<th>Full Update (1.75 percent)</th>
<th>Reduced Update* (−0.25 percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$42,476.41</td>
<td>$41,641.49</td>
<td></td>
</tr>
</tbody>
</table>

*For LTCs that fail to submit quality reporting data for FY 2017 in accordance with the LTC Quality Reporting Program (LTC QRP), the annual update is reduced by 2.0 percentage points as required by section 1886(m)(5) of the Act.

Appendix A: Economic Analyses

I. Regulatory Impact Analysis

A. Introduction

We have examined the impacts of this final rule as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (February 2, 2011), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96–354), section 1102(b) of the Social Security Act, section 202 of the Unfunded Mandates Reform Act of 1995 (March 22, 1995, Pub. L. 104–4), Executive Order 13132 on Federalism (August 4, 1999), and the Congressional Review Act (5 U.S.C. 804(2)).

Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. A regulatory impact analysis (RIA) must be prepared for major rules with economically significant effects ($100 million or more in any 1 year).

We have determined that this final rule is a major rule as defined in 5 U.S.C. 804(2). We estimate that the final changes for FY 2017 acute care hospital operating and capital payments will redistribute amounts in excess of $100 million to acute care hospitals. The applicable percentage increase to the IPPS rates required by the statute, in conjunction with other payment changes in this final rule, will result in an estimated $987 million increase in FY 2017 operating payments (or 0.9 percent change) and an estimated $66 million increase in FY 2017 capital payments (or 0.8 percent change). These changes are relative to payments made in FY 2016. The impact analysis of the capital payments can be found in section I.F. of this Appendix. In addition, as described in section I.J. of this Appendix, LTCHs are expected to experience...
a decrease in payments by $363 million in FY 2017 relative to FY 2016. Our operating impact estimate includes the –1.5 percent documentation and coding adjustment applied to the IPPS standardized amount, as discussed in section I.D. of the preamble of this final rule, which represents part of the recoupment required under section 631 of the ATRA. In addition, our operating payment impact estimate includes the 1.65 percent hospital update to the standardized amount, which includes the estimated 2.7 percent market basket update less 0.3 percentage point for the multifactor productivity adjustment and less 0.75 percentage point required under the Affordable Care Act). Our operating payment impact estimate also includes an adjustment of (1/0.998) to permanently remove the –0.2 percent reduction and a 1.060 temporary adjustment to address the effects of the 0.2 percent reduction in effect for FYs 2014 through 2016 as a result of the 2-midnight policy (see to section IV.P. of the preamble of this final rule for an explanation of these adjustments). The estimates of IPPS operating payments to acute care hospitals do not reflect any changes in hospital admissions or real case-mix intensity, which will also affect operating changes.

The analysis in this Appendix, in conjunction with the remainder of this document, demonstrates that this final rule is consistent with the regulatory philosophy and principles identified in Executive Orders 12866 and 13563, the RFA, and section 1102(b) of the Act. This final rule will affect payments to a substantial number of small rural hospitals, as well as other classes of hospitals, and the effects on some hospitals may be significant. Finally, in accordance with the provisions of Executive Order 12866, the Executive Office of Management and Budget has reviewed this final rule.

B. Statement of Need

This final rule is necessary in order to make payment and policy changes under the Medicare IPPS for Medicare acute care hospital inpatient services for operating and capital-related costs as well as for certain hospitals and hospital units excluded from the IPPS. This final rule also is necessary to make payment and policy changes for Medicare hospitals under the LTCH PPS.

C. Objectives of the IPPS

The primary objective of the IPPS is to create incentives for hospitals to operate efficiently and minimize unnecessary costs while at the same time ensuring that payments are sufficient to adequately compensate hospitals for their legitimate costs attributable to Medicare beneficiaries. In addition, we share national goals of preserving the Medicare Hospital Insurance Trust Fund.

We believe that the changes in this final rule will further each of these goals while maintaining financial viability of the hospital industry and ensuring access to high quality health care for Medicare beneficiaries. We expect that these changes will ensure that the outcomes of the prospective payment systems are reasonable and equitable while avoiding or minimizing unintended adverse consequences.

D. Limitations of Our Analysis

The following quantitative analysis presents the predicted effects of our policy changes, as well as statutory changes effective for FY 2017, on various hospital groups. We estimate the effects of individual policy changes by estimating payments per case while holding all other payment policies constant. While general in available, but, generally, we do not attempt to make adjustments for future changes in such variables as admissions, lengths of stay, or case-mix.

E. Hospitals Included in and Excluded From the IPPS

The prospective payment systems for hospital inpatient operating and capital-related costs of acute care hospitals encompass most general short-term, acute care hospitals that participate in the Medicare program. There were 32 Indian Health Service hospitals in our database, which we excluded from the analysis due to the special characteristics of the prospective payment methodology for these hospitals. Among other short-term, acute care hospitals, hospitals in Maryland are paid in accordance with the Maryland All-Payer Model, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, 5 short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa) receive payment for inpatient hospital services they furnish on the basis of reasonable costs, subject to a rate-of-increase ceiling.

As of July 2016, there were 3,330 IPPS acute care hospitals included in our analysis. This represents approximately 55 percent of all Medicare-participating hospitals. The majority of this impact analysis focuses on this set of hospitals. There also are approximately 1,336 CAHs. These small, limited service hospitals are paid on the basis of reasonable costs rather than under the IPPS. IPPS-excluded hospitals and units, which are paid under separate payment systems, include IPFs, IRFs, LTCHs, RNHCIs, children’s hospitals, cancer hospitals, and 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa.

Changes in the prospective payment systems for IPPS-excluded hospitals and units are made through separate rulemaking. Payment impacts of changes to the prospective payment systems for these IPPS-excluded hospitals and units are not included in this final rule. The impact of the update and policy changes to the LTCH PPS for FY 2017 is discussed in section I.J. of this Appendix.

F. Effects on Hospitals and Hospital Units Excluded From the IPPS

As of July 2016, there were 98 children’s hospitals, 11 cancer hospitals, 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands and American Samoa, and 18 RNHCIs being paid on a reasonable cost basis subject to the rate-of-increase ceiling under §413.40. (In accordance with §403.752(a) of the regulation, RNHCIs are paid under §413.40.) Among the remaining providers, 263 rehabilitation hospitals and 870 rehabilitation units, and approximately 430 LTCHs, are paid the Federal prospective per discharge rate under the IRF PPS and the LTCH PPS, respectively, and 513 psychiatric hospitals and 1,113 psychiatric units are paid the Federal per diem amount under the IRF PPS. As stated previously, IRFs and IPFs are not affected by the rate updates discussed in this final rule. The impacts of the changes on LTCHs are discussed in section I.J. of this Appendix. For children’s hospitals, the 11 cancer hospitals, the 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNHCIs, the update of the rate-of-increase limit (or target amount) is the estimated FY 2017 percentage increase in the IPPS operating market basket, consistent with section 1886(b)(3)(B)(ii) of the Act, and §§403.752(a) and 413.40 of the regulations. As discussed in section IV. of the preamble of the FY 2014 IPPS/LTCH PPS final rule, we rebased the IPPS operating market basket to a FY 2010 base year. Therefore, we are using the percentage increase in the FY 2010-based IPPS operating market basket to update the target amounts for FY 2017 and subsequent fiscal years for children’s hospitals, the 11 cancer hospitals, the 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNHCIs that are paid based on reasonable costs subject to the rate-of-increase limits. Consistent with current law, based on EIS Global Insight, Inc.’s second quarter 2016 forecast of the FY 2010-based IPPS market basket increase, we are estimating the FY 2017 update to be 2.7 percent (that is, the current estimate of the market basket rate-of-increase). However, the Affordable Care Act requires an adjustment for multifactor productivity (currently estimated to be 0.3 percentage point for FY 2017) and a 0.75 percentage point reduction to the market basket update, resulting in a 1.65 percent applicable percentage increase for IPPS hospitals that submit quality data and are meaningful EHR users as discussed in section IV.B. of the preamble of this final rule. Children’s hospitals, the 11 cancer hospitals, the 5 short-term acute care hospitals located in the Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa, and RNHCIs that continue to be paid on reasonable costs subject to the rate-of-increase limits under §413.40 of the regulations are not subject to the reductions in the applicable percentage increase required under the Affordable Care Act. Therefore, for those hospitals paid under §413.40 of the regulations, the update is the percentage increase in the FY 2010-based IPPS operating market basket for FY 2017, estimated at 2.7 percent, without the reductions described previously under the Affordable Care Act.

The impact of the update in the rate-of-increase limit on those excluded hospitals depends on the cumulative cost increases experienced by each excluded hospital since its applicable base period. For excluded hospitals that have maintained their cost increases at a level below the rate-of-increase limits since their base period, the major effect
is on the level of incentive payments these excluded hospitals receive. Conversely, for excluded hospitals with cost increases above the cumulative update in their rate-of-increase limits, the major effect is the amount of excess costs that would not be paid.

We note that, under § 413.40(d)(3), an excluded hospital that continues to be paid under the TEFRA system and whose costs exceed 110 percent of its rate-of-increase limit receives its rate-of-increase limit plus the lesser of: (1) 50 percent of its reasonable costs in excess of 110 percent of the limit; or (2) 10 percent of its limit. In addition, under the various provisions set forth in § 413.40, hospitals can obtain payment adjustments for justifiable increases in operating costs that exceed the limit.

G. Quantitative Effects of the Policy Changes Under the IPPS for Operating Costs

1. Basis and Methodology of Estimates

In this final rule, we are announcing final policy changes and final payment rate updates for the IPPS for FY 2017 for operating acute care hospitals. The FY 2017 updates to the capital payments to acute care hospitals are discussed in section I.I. of this Appendix. Based on the overall percentage change in payments per case estimated using our payment simulation model, we estimate that total FY 2017 operating payments will increase by 0.9 percent compared to FY 2016. In addition to the applicable percentage increase, this amount reflects the FY 2017 recoupment adjustment for documentation and coding described in section I.I.D. of the preamble of this final rule of −1.5 percent to the IPPS national standardized amounts. This amount also reflects the adjustment of (1/0.998) to permanently remove the 0.2 percent reduction and the 1.006 temporary adjustment to address the effects of the 0.2 percent reduction in effect for FYs 2014 through 2016 related to the 2-midnight policy, which are discussed in section IV.P. of the preamble of this final rule. The impacts do not reflect changes in the number of hospital discharges or real case-mix intensity, which will also affect overall payment changes.

We have prepared separate impact analyses of the changes to each system. This section deals with the changes to the operating inpatient prospective payment system for acute care hospitals. Our payment simulation model relies on the most recent available data to enable us to estimate the impacts on payments per case of certain changes in this final rule. However, there are other changes for which we do not have data available that will allow us to estimate the payment impacts using this model. For those changes, we have attempted to predict the payment impacts based upon our experience and other more limited data.

The data used in developing the quantitative changes in payments per case presented in this section are taken from the FY 2015 MedPAR file and the most current Provider-Specific File (PSF) that is used for payment purposes. Although the analyses of the changes to the operating IPPS do not incorporate cost data, data from the most recently available hospital cost reports were used to categorize hospitals. Our analysis has several qualifications. First, in this analysis, we do not make adjustments for future changes in such variables as admissions, lengths of stay, or underlying growth in real case-mix. Second, due to the interdependent nature of the IPPS payment components, it is very difficult to precisely quantify the impact associated with each change. Third, we use various data sources to categorize hospitals in the tables. In some cases, particularly the number of beds, there is a fair degree of variation in the data from the different sources. We have attempted to construct these variables with the best available source overall. However, for individual hospitals, some misclassifications are possible.

Using cases from the FY 2015 MedPAR file, we simulate payments under the operating IPPS given various combinations of payment parameters. As described previously, Indian Health Service hospitals and hospitals in Maryland were excluded from the simulations. The impact of payments under the capital IPPS, or the impact of payments for costs other than inpatient operating costs, are not analyzed in this section. Estimated payment impacts for the capital IPPS for FY 2017 are discussed in section I.I. of this Appendix.

We discuss the following changes:

• The effects of the application of the documentation and coding adjustment and the applicable percentage increase (including the market basket update, the multifactor productivity adjustment, and the applicable percentage reduction in accordance with the Affordable Care Act) to the standardized amount and hospital-specific rates.
• The effects of the adjustment of (1/0.998) to permanently remove the 0.2 percent reduction and the 1.006 temporary adjustment to address the effects of the 0.2 percent reduction in effect for FYs 2014 through 2016 related to the 2-midnight policy, as discussed in section IV.P. of the preamble of this final rule.
• The effects of the changes to the relative weights and MS–DRG GROUPER.
• The effects of the changes in hospitals’ wage index values reflecting updated wage data from hospitals’ cost reporting periods beginning during FY 2014, compared to the FY 2012 wage data, to calculate the FY 2017 wage index.
• The effects of the geographic reclassifications by the MGCRB (as of publication of this final rule) that will be effective for FY 2017.
• The effects of the rural floor and imputed floor with the application of the national budget neutrality factor to the wage index.
• The effects of the last year of the 3-year transition for hospitals that were located in an urban county that became rural under the new OMB delineations or hospitals that were deemed urban where the urban area became rural under the new OMB delineations.
• The effects of the 1.65 percent (or 2.7 percent market basket update with a reduction of 0.3 percentage point for the multifactor productivity adjustment, and a 0.75 percent point reduction, as required under the Affordable Care Act).

To illustrate the impact of the FY 2017 changes, our analysis begins with a FY 2016 baseline simulation model using: The FY 2016 applicable percentage increase of 1.7 percent and the documentation and coding recoupment adjustment of −0.8 percent to the Federal standardized amount, the FY 2016 MS–DRG GROUPER, the last year of the 0.2 percent productivity adjustment, and the applicable percentage increase determined without regard to section 505 of Public Law 108–173, which provides for an increase in a hospital’s wage index if a threshold percentage of residents of the county where the hospital is located commute to work at hospitals in counties with higher wage indexes. This provision is non-budget neutral.

• The total estimated change in payments based on the FY 2017 policies relative to payments based on FY 2016 policies that include the applicable percentage increase of 1.65 percent (or 2.7 percent market basket update with a reduction of 0.3 percentage point for the multifactor productivity adjustment, and a 0.75 percent point reduction, as required under the Affordable Care Act).
applicable percentage increase of ~0.375 percent. At the time that this impact analysis was prepared, 154 hospitals are estimated to not receive the full market basket rate-of-increase for FY 2017 because they are identified as not meaningful EHR users that do not submit quality data under section 1886(b)(3)(B)(viii) of the Act. For purposes of the simulations shown in this section, we modeled the payment changes for FY 2017 using a reduced update for these 154 hospitals.

Hospitals that are identified as not meaningful EHR users under section 1886(b)(3)(B)(ix) of the Act and also do not submit quality data under section 1886(b)(3)(B)(viii) of the Act will receive an applicable percentage increase of ~1.05 percent, which reflects a one-quarter reduction of the market basket update for failure to submit quality data and a three-quarter reduction of the market basket update for being identified as not a meaningful EHR user. At the time that this impact was prepared, 31 hospitals are estimated to not receive the full market basket rate-of-increase for FY 2017 because they are identified as not meaningful EHR users that do not submit quality data under section 1886(b)(3)(B)(viii) of the Act.

Each policy change, statutory or otherwise, is then added incrementally to this baseline, finally arriving at an FY 2017 model incorporating all of the changes. This simulation allows us to isolate the effects of each change.

Our final comparison illustrates the percent change in payments per case from FY 2016 to FY 2017. Two factors not discussed separately have significant impacts here. The first factor is the update to the standardized amount. In accordance with section 1886(b)(3)(B)(i) of the Act, we are updating the standardized amounts for FY 2017 using an applicable percentage increase of 1.65 percent. This includes our forecasted IPPS operating hospital market basket increase of 2.7 percent with a 0.3 percentage point reduction for the multifactor productivity adjustment and a 0.75 percent point reduction as required under the Affordable Care Act. Hospitals that fail to comply with the quality data submission requirements and are meaningful EHR users will receive an update of 0.975 percent. This update includes a reduction of one-quarter of the market basket update for failure to submit these data. Hospitals that do comply with the quality data submission requirements but are not meaningful EHR users will receive an update of ~0.375 percent, which includes a reduction of three-quarters of the market basket update. Furthermore, hospitals that do not comply with the quality data submission requirements and also are not meaningful EHR users will receive an update of ~1.05 percent. Under section 1886(b)(3)(B)(iv) of the Act, the update to the hospital-specific amounts for SCHs and MDHs also is equal to the applicable percentage increase, or 1.65 percent if the hospital submits quality data and is a meaningful EHR user.

A second significant factor that affects the changes in hospitals’ payments per case from FY 2016 to FY 2017 is the change in hospitals’ geographic reclassification status from one year to the next. That is, payments may be reduced for hospitals reclassified in FY 2016 that are no longer reclassified in FY 2017. Conversely, payments may increase for hospitals not reclassified in FY 2016 that are reclassified in FY 2017.

Our final comparison illustrates the percent change in payments per case from FY 2016 to FY 2017. Two factors not discussed separately have significant impacts here. The first factor is the update to the standardized amount. In accordance with section 1886(b)(3)(B)(i) of the Act, we are updating the standardized amounts for FY 2017 using an applicable percentage increase of 1.65 percent. This includes our forecasted IPPS operating hospital market basket increase of 2.7 percent with a 0.3 percentage point reduction for the multifactor productivity adjustment and a 0.75 percent point reduction as required under the Affordable Care Act. Hospitals that fail to comply with the quality data submission requirements and are meaningful EHR users will receive an update of 0.975 percent. This update includes a reduction of one-quarter of the market basket update for failure to submit these data. Hospitals that do comply with the quality data submission requirements but are not meaningful EHR users will receive an update of ~0.375 percent, which includes a reduction of three-quarters of the market basket update. Furthermore, hospitals that do not comply with the quality data submission requirements and also are not meaningful EHR users will receive an update of ~1.05 percent. Under section 1886(b)(3)(B)(iv) of the Act, the update to the hospital-specific amounts for SCHs and MDHs also is equal to the applicable percentage increase, or 1.65 percent if the hospital submits quality data and is a meaningful EHR user.

A second significant factor that affects the changes in hospitals’ payments per case from FY 2016 to FY 2017 is the change in hospitals’ geographic reclassification status from one year to the next. That is, payments may be reduced for hospitals reclassified in FY 2016 that are no longer reclassified in FY 2017. Conversely, payments may increase for hospitals not reclassified in FY 2016 that are reclassified in FY 2017.

2. Analysis of Table I

Table I displays the results of our analysis of the changes for FY 2017. The table categorizes hospitals by various geographic and special payment consideration groups to illustrate the varying impacts on different types of hospitals. The top row of the table shows the overall impact on the 3,330 acute care hospitals included in the analysis. The next four rows of Table I contain hospitals categorized according to their geographic location: All urban, which is further divided into large urban and other urban; and rural. There are 2,515 hospitals located in urban areas included in our analysis. Among these, there are 1,380 hospitals located in large urban areas (populations over 1 million), and 1,135 hospitals in other urban areas (populations of 1 million or fewer). In addition, there are 815 hospitals in rural areas. The next two groupings are by bed-size categories, shown separately for urban and rural hospitals. The final groupings by geographic location are by census divisions, also shown separately for urban and rural hospitals.

The second part of Table I shows hospital groups based on hospitals’ FY 2017 payment classifications, including any reclassifications under section 1886(d)(10) of the Act. For example, the rows labeled urban, large urban, other urban, and rural show that the numbers of hospitals paid based on these categorizations after consideration of geographic reclassifications (including reclassifications under sections 1886(d)(8)(B) and 1886(d)(6)(E) of the Act that have implications for capital payments) are 2,522, 1,372, 1,150, and 808, respectively.

The next three groupings examine the impacts of the changes on hospitals grouped by whether or not they have GME residency programs (teaching hospitals that receive an IME adjustment) or receive Medicare DSH payments, or some combination of these two adjustments. There are 2,266 nonteaching hospitals in our analysis, 815 teaching hospitals with fewer than 100 residents, and 249 teaching hospitals with 100 or more residents.

In the DSH categories, hospitals are grouped according to their DSH payment status, and whether they are considered urban or rural for DSH purposes. The next category groups together hospitals considered urban or rural, in terms of whether they receive the IME adjustment, the DSH adjustment, both, or neither.

The next three rows examine the impacts of the changes on rural hospitals by special payment groups (SCHs, RRCs, and MDHs). There were 189 RRCs, 324 SCHs, 148 MDHs, 126 hospitals that are both SCHs and RRCs, and 12 hospitals that are both MDHs and RRCs.

The next series of groupings are based on the type of ownership and the hospital’s Medicare utilization expressed as a percent of total patient days. These data were taken from the FY 2013 or FY 2012 Medicare cost reports.

The next two groupings concern the geographic reclassification status of hospitals. The first grouping displays all urban hospitals that were reclassified by the MGCRB for FY 2017. The second grouping shows the MGCRB rural reclassifications.

<table>
<thead>
<tr>
<th>Number of hospitals 1</th>
<th>Hospital update and documentation and coding adjustment</th>
<th>FY 2017 weights and DRG changes with application recalibration budget neutrality</th>
<th>FY 2017 wage data under new CBSA designations with application of wage budget neutrality</th>
<th>FY 2017 MGCRB reclassifications</th>
<th>Rural and imputed floor with application of national and imputed floor budget neutrality</th>
<th>Application of the frontier wage index and out-migration adjustment</th>
<th>All FY 2017 changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,330</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.9</td>
</tr>
<tr>
<td>By Geographic Location:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,515</td>
<td>0.9</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,380</td>
<td>0.9</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,135</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>815</td>
<td>1.6</td>
<td>-0.4</td>
<td>0.1</td>
<td>1.4</td>
<td>-0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Bed Size (Urban):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–99 beds</td>
<td>659</td>
<td>0.9</td>
<td>-0.2</td>
<td>0.2</td>
<td>-0.5</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>100–199 beds</td>
<td>767</td>
<td>1.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>200–299 beds</td>
<td>446</td>
<td>1.0</td>
<td>-0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.0</td>
<td>0.1</td>
</tr>
</tbody>
</table>

1. Number of hospitals is estimated.
## Table I—Impact Analysis of Changes to the IPPS for Operating Costs for FY 2017—Continued

<table>
<thead>
<tr>
<th>Number of hospitals</th>
<th>Hospital rate update and documentation and coding adjustment</th>
<th>FY 2017 weights and DRG changes with application of recalibration budget neutrality</th>
<th>FY 2017 wage data under new CBSA designations with application of wage budget neutrality</th>
<th>FY 2017 MGCRB reclassifications</th>
<th>Rural and imputed floor with application of national rural and imputed floor budget neutrality</th>
<th>Application of the frontier wage index and out-migration adjustment</th>
<th>All FY 2017 changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>300–499 beds</td>
<td>431</td>
<td>1.0</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.2</td>
<td>0.0</td>
<td>0.2</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>212</td>
<td>0.9</td>
<td>0.2</td>
<td>0.0</td>
<td>-0.2</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Bed Size (Rural):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–49 beds</td>
<td>317</td>
<td>1.5</td>
<td>-0.5</td>
<td>0.1</td>
<td>0.2</td>
<td>-0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>50–99 beds</td>
<td>292</td>
<td>1.8</td>
<td>-0.6</td>
<td>0.1</td>
<td>0.8</td>
<td>-0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>100–149 beds</td>
<td>120</td>
<td>1.6</td>
<td>-0.4</td>
<td>0.0</td>
<td>1.5</td>
<td>-0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>150–199 beds</td>
<td>46</td>
<td>1.7</td>
<td>-0.2</td>
<td>0.2</td>
<td>1.7</td>
<td>-0.2</td>
<td>0.0</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>40</td>
<td>1.6</td>
<td>-0.1</td>
<td>0.2</td>
<td>2.5</td>
<td>-0.2</td>
<td>0.0</td>
</tr>
<tr>
<td>Rural by Region:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>116</td>
<td>0.8</td>
<td>0.0</td>
<td>-0.5</td>
<td>1.1</td>
<td>1.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>315</td>
<td>0.9</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.9</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>407</td>
<td>1.0</td>
<td>0.0</td>
<td>-0.2</td>
<td>-0.5</td>
<td>-0.2</td>
<td>0.0</td>
</tr>
<tr>
<td>East North Central</td>
<td>390</td>
<td>0.9</td>
<td>0.0</td>
<td>-0.1</td>
<td>-0.2</td>
<td>0.4</td>
<td>-0.4</td>
</tr>
<tr>
<td>East South Central</td>
<td>147</td>
<td>1.0</td>
<td>0.0</td>
<td>-0.1</td>
<td>-0.4</td>
<td>0.3</td>
<td>-0.3</td>
</tr>
<tr>
<td>West North Central</td>
<td>163</td>
<td>1.1</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.8</td>
<td>0.3</td>
<td>-0.3</td>
</tr>
<tr>
<td>West South Central</td>
<td>385</td>
<td>0.9</td>
<td>0.0</td>
<td>-0.2</td>
<td>-0.5</td>
<td>-0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Mountain</td>
<td>163</td>
<td>1.7</td>
<td>0.0</td>
<td>0.4</td>
<td>0.4</td>
<td>-0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Pacific</td>
<td>378</td>
<td>0.9</td>
<td>0.0</td>
<td>0.4</td>
<td>-0.4</td>
<td>1.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>0.9</td>
<td>0.1</td>
<td>-0.5</td>
<td>-1.0</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Rural by Region:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,522</td>
<td>0.9</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,372</td>
<td>0.9</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,150</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>Rural areas</td>
<td>808</td>
<td>1.6</td>
<td>-0.4</td>
<td>0.1</td>
<td>1.4</td>
<td>-0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Teaching Status:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonteaching</td>
<td>2,266</td>
<td>1.1</td>
<td>-0.2</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>815</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.2</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>249</td>
<td>0.9</td>
<td>0.2</td>
<td>0.0</td>
<td>-0.1</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Urban DSH:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-DSH</td>
<td>589</td>
<td>0.9</td>
<td>-0.1</td>
<td>-0.2</td>
<td>0.2</td>
<td>-0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>1,642</td>
<td>0.9</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.2</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Rural DSH:</td>
<td>363</td>
<td>1.0</td>
<td>-0.3</td>
<td>0.0</td>
<td>-0.5</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Urban teaching and DSH:</td>
<td>898</td>
<td>0.9</td>
<td>0.1</td>
<td>0.0</td>
<td>-0.2</td>
<td>-0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td>109</td>
<td>0.9</td>
<td>0.0</td>
<td>-0.1</td>
<td>1.1</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td>1,107</td>
<td>1.0</td>
<td>-0.1</td>
<td>0.1</td>
<td>-0.1</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td>408</td>
<td>1.0</td>
<td>-0.1</td>
<td>-0.2</td>
<td>-0.4</td>
<td>-0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Special Hospital Types:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RRC</td>
<td>189</td>
<td>0.8</td>
<td>-0.1</td>
<td>0.1</td>
<td>1.9</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>SCH</td>
<td>324</td>
<td>2.1</td>
<td>-0.3</td>
<td>-0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>MDH</td>
<td>148</td>
<td>1.7</td>
<td>-0.6</td>
<td>0.0</td>
<td>0.6</td>
<td>-0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>SCH and RRC</td>
<td>126</td>
<td>2.2</td>
<td>-0.3</td>
<td>0.1</td>
<td>0.4</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>MDH and RRC</td>
<td>12</td>
<td>2.1</td>
<td>-0.6</td>
<td>-0.1</td>
<td>1.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Type of Ownership:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,927</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Proprietary</td>
<td>881</td>
<td>1.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Government</td>
<td>522</td>
<td>1.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.2</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Medicare Utilization as a Percent of Inpatient Days:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–25</td>
<td>523</td>
<td>0.8</td>
<td>0.1</td>
<td>0.1</td>
<td>-0.4</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>25–60</td>
<td>2,122</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>60–95</td>
<td>545</td>
<td>1.2</td>
<td>-0.2</td>
<td>-0.1</td>
<td>0.6</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Over 65</td>
<td>89</td>
<td>1.3</td>
<td>-0.3</td>
<td>0.3</td>
<td>-0.4</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>FY 2017 Reclassifications by the Medicare Geographic Classification Review Board:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Reclassified Hospitals</td>
<td>792</td>
<td>1.1</td>
<td>-0.1</td>
<td>0.0</td>
<td>2.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
</tbody>
</table>
TABLE 1—IMPACT ANALYSIS OF CHANGES TO THE IPPS FOR OPERATING COSTS FOR FY 2017—Continued

<table>
<thead>
<tr>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
<th>Column 7</th>
<th>Column 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital rate update and documentation and coding adjustment</td>
<td>FY 2017 weights and changes with application of recalibration budget neutrality</td>
<td>FY 2017 wage data under new CBBSA designations with application of wage budget neutrality</td>
<td>FY 2017 MGCRB recalibration adjustments</td>
<td>Rural and imputed floor with application of national rural and imputed floor budget neutrality</td>
<td>Application of the frontier wage index and out-migration adjustment</td>
<td>All FY 2017 changes</td>
<td></td>
</tr>
<tr>
<td>Non-Reclassified Hospitals</td>
<td>2,538</td>
<td>1.0</td>
<td>0.0</td>
<td>0.0</td>
<td>-0.8</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Urban Hospitals Reclassified</td>
<td>533</td>
<td>1.0</td>
<td>0.0</td>
<td>-0.1</td>
<td>2.3</td>
<td>-0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Urban Nonreclassified Hospitals</td>
<td>1,938</td>
<td>0.9</td>
<td>0.0</td>
<td>0.0</td>
<td>2.9</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Rural Hospitals Reclassified Full Year</td>
<td>277</td>
<td>1.7</td>
<td>-0.3</td>
<td>0.1</td>
<td>2.2</td>
<td>-0.0</td>
<td>0.1</td>
</tr>
<tr>
<td>Rural Nonreclassified Hospitals Full Year</td>
<td>489</td>
<td>1.6</td>
<td>-0.4</td>
<td>0.2</td>
<td>-0.2</td>
<td>-0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>All Section 401 Reclassified Hospitals:</td>
<td>69</td>
<td>1.7</td>
<td>-0.2</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Other Reclassified Hospitals (Section 1886(d)(8)(B))</td>
<td>48</td>
<td>1.2</td>
<td>-0.4</td>
<td>0.1</td>
<td>3.1</td>
<td>-0.3</td>
<td>0.0</td>
</tr>
</tbody>
</table>

1 Because data necessary to classify some hospitals by category were missing, the total number of hospitals in each category may not equal the national total. Discharge data are from FY 2015, and hospital cost report data are from reporting periods beginning in FY 2012 and FY 2013.

2 This column displays the payment impact of the hospital rate update and other adjustments, including the 1.65 percent adjustment to the national standardized amount and the hospital-specific rate (the estimated 2.7 percent market basket update and the recalibration budget neutrality factor of 0.998879 in accordance with section 1886(d)(4)(C)(iii) of the Act. This column displays the payment impact of the application of the recalibration budget neutrality factor of 0.999079 in accordance with section 1886(d)(4)(C)(iii) of the Act.

3 This column displays the payment impact of the changes to the Version 34 GROUPER, the changes to the relative weights and the recalibration of the MS–DRG weights based on FY 2015 MedPAR data in accordance with section 1886(d)(4)(C)(iii) of the Act. This column displays the payment impact of the application of the recalibration budget neutrality factor of 0.999079 in accordance with section 1886(d)(4)(C)(iii) of the Act.

4 This column displays the payment impact of the update to wage index data using FY 2013 cost report data and the OMB labor market area delineations based on 2010 Decennial Census data. This column displays the payment impact of the application of the wage budget neutrality factor, which is calculated separately from the recalibration budget neutrality factor, and is calculated in accordance with section 1886(d)(4)(C)(i)(B) of the Act. The wage budget neutrality factor is 1.002309.

5 Shown here are the effects of geographic reclassifications by the Medicare Geographic Classification Review Board (MGCRB) along with the effects of the continued implementation of the new OMB labor market area delineations on these reclassifications. The effects demonstrate the FY 2017 payment impact of going from nonreclassifications to the reclassifications scheduled to be in effect for FY 2017. Reclassification for prior years has no bearing on the payment impacts shown here. This column reflects the geographic budget neutrality factor of 0.988224.

6 This column displays the effects of the rural and imputed floor based on the continued implementation of the new OMB labor market area delineations. The Affordable Care Act requires the rural floor budget neutrality adjustment to be 100 percent national level adjustment. The rural floor budget neutrality factor (which includes the imputed floor) applied to the wage index is 0.923. This column also reflects the effect of the 3-year transition for hospitals that were located in urban counties that became rural under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations, with a budget neutrality factor of 0.98997.

7 This column shows the combined impact of the policy required under section 10324 of the Affordable Care Act that hospitals located in frontier States have a wage index no less than 1.0 and of section 1886(d)(13) of the Act, as added by section 505 of Pub. L. 108–173, which provides for an increase in a hospital’s wage index if a threshold percentage of residents of the county where the hospital is located commute to work at hospitals in counties with higher wage indexes. These are not budget neutral policies.

8 This column shows the estimated change in payments from FY 2016 to FY 2017.

a. Effects of the Hospital Update, Documentation and Coding Adjustment, and Other Adjustments (Column 1)

As discussed in section IV.B of the preamble of this final rule, this column includes the 2.7 percent market basket update, the reduction of 0.3 percentage point for the multifactor productivity adjustment, and the 0.75 percentage point reduction in accordance with the Affordable Care Act. In addition, this column includes the adjustment to the hospital-specific rate (the estimated 2.7 percent market basket update and the recalibration budget neutrality factor of 0.998879) to permanently remove the -0.2 percent reduction and the 1.006 temporary adjustment to address the effects of the 0.2 percent reduction in effect for FYs 2014 through 2016 related to the 2-midnight policy to both the national standardized amount and the hospital-specific rate.

Overall, hospitals will experience a 1.0 percent increase in payments primarily due to the combined effects of the hospital update and the documentation and coding adjustment on the national standardized amount and the hospital update to the hospital-specific rate as well as the adjustment of (1/0.998) to permanently remove the -0.2 percent reduction and the 1.006 temporary adjustment to address the effects of the 0.2 percent reduction in effect for FYs 2014 through 2016 related to the 2-midnight policy to both the national standardized amount and the hospital-specific rate. Hospitals that are paid under the hospital-specific rate will experience a 2.45 percent increase in payments; therefore, hospital categories containing hospitals paid under the hospital-specific rate will experience higher than average increases in payments.

b. Effects of the Changes to the MS–DRG Reclassifications and Relative Cost-Based Weights With Recalibration Budget Neutrality (Column 2)

Column 2 shows the effects of the changes to the MS–DRGs and relative weights with the application of the recalibration budget neutrality factor to the standardized amounts. Section 1886(d)(4)(C)(ii) of the Act requires us annually to make appropriate classification changes in order to reflect changes in treatment patterns, technology, and any other factors that may change the relative use of hospital resources. Consistent with section 1886(d)(4)(C)(i)(B) of the Act, we are calculating a recalibration budget neutrality factor to account for the changes in MS–DRGs and relative weights with the application of the recalibration budget neutrality factor to the standardized amounts.
and relative weights will result in a 0.0 percent change in payments with the application of the recalibration budget neutrality factor of 0.999079 on to the standardized amount. Hospital categories that generally treat more surgical cases than medical cases will experience increases in their payments under the relative weights. Rural hospitals will experience a 0.4 percent decrease in payments because rural hospitals tend to treat fewer surgical cases than medical cases while teaching hospitals with more than 100 residents will experience an increase in payments by 0.2 percent as those hospitals treat more surgical cases than medical cases.

c. Effects of the Wage Index Changes (Column 3)

Column 3 shows the impact of updated wage data using FY 2013 cost report data, with the application of the wage budget neutrality factor. The wage index is calculated and assigned to hospitals on the basis of the labor market area in which the hospital is located. Under section 1886(d)(3)(E) of the Act, beginning with FY 2005, we delineate hospital labor market areas based on the Core Based Statistical Areas (CBSAs) established by OMB. The current statistical standards used in FY 2017 are based on OMB standards published on February 28, 2013 (75 FR 37246 and 37252), and 2010 Decennial Census data (OMB Bulletin No. 13–01), as updated in OMB Bulletin No. 15–01. (We refer readers to the FY 2015 IPPS/LTCCH PPS Final rule (79 FR 49951 through 49963) for a full discussion on our adoption of the OMB labor market area delineations based on the 2010 Decennial Census data, effective beginning with the FY 2015 IPPS wage index and to section III.A.2. of the preamble of this final rule for a discussion of OMB Bulletin No. 15–01.)

Section 1886(d)(3)(E) of the Act requires that, beginning October 1, 1993, we annually update the wage data used to calculate the wage index. In accordance with this requirement, the wage index for acute care hospitals for FY 2017 is based on data submitted for hospital cost reporting periods beginning after October 1, 2012 and before October 1, 2013. The estimated impact of the updated wage data using the FY 2013 cost report data and the OMB labor market area delineations on hospital payments is isolated in Column 3 by holding the other payment parameters constant in this simulation. That is, Column 3 shows the percentage change in payments when going from a model using the FY 2016 wage index, based on FY 2012 wage data, the labor-related share of 69.6 percent, under the OMB delineations and having a 100-percent occupational mix adjustment applied, to a model using the FY 2017 recalibration wage index based on FY 2013 wage data with the labor-related share of 69.6 percent, under the OMB delineations, also having a 100-percent occupational mix adjustment applied, while holding other payment parameters such as the Version 34 MS–DRG GROUPER constant. The FY 2017 occupational mix adjustment is based on the CY 2013 occupational mix survey.

In addition, the column shows the impact of the application of the wage budget neutrality to the national standardized amount. In FY 2010, we began calculating separate wage budget neutrality and recalibration budget neutrality factors, in accordance with section 1886(d)(3)(E) of the Act, which specifies that budget neutrality to account for wage index changes or updates made under that subparagraph must be made without regard to the 62 percent labor-related share guaranteed under section 1886(d)(3)(E)(ii) of the Act. Therefore, for FY 2017, we are calculating the wage budget neutrality factor to ensure that payments under updated wage data and the labor-related share of 69.6 percent are budget neutral without regard to the lower labor-related share of 62 percent applied to hospitals with a wage index less than or equal to 1.0. In other words, the wage budget neutrality is calculated under the assumption that all hospitals receive the higher labor-related share of the standardized amount. The FY 2017 wage budget neutrality factor is 1.000209, and the overall payment change is 0.0 percent.

Column 3 shows the impacts of updating the wage data using FY 2013 cost reports. Overall, the new wage data and the labor-related share, combined with the wage budget neutrality adjustment, will lead to no change for all hospitals as shown in Column 3.

In looking at the wage data itself, the national average hourly wage increased 1.02 percent compared to FY 2016. Therefore, the only manner in which to maintain or exceed the prior year’s wage index was to match or exceed the 1.02 percent increase in the national average hourly wage. Of the 3,309 hospitals with wage data for both FYs 2016 and 2017, 1,539 or 46.5 percent would experience an average hourly wage increase of 1.02 percent or more.

The following chart compares the shifts in wage index values for hospitals due to changes in the average hourly wage data for FY 2017 relative to FY 2016. Among urban hospitals, 4 will experience a decrease of 10 percent or more, and 14 urban hospitals will experience an increase of 10 percent or more. One hundred and nine urban hospitals will experience an increase of at least 5 percent but less than 10 percent. Among rural hospitals, 4 will experience an increase of at least 5 percent but less than 10 percent, but no rural hospitals will experience a decrease of greater than or equal to 5 percent but less than 10 percent. No rural hospital will experience increases of 10 percent or more, and no rural hospitals will experience decreases of 10 percent or more. However, 777 rural hospitals will experience increases or decreases of less than 5 percent, while 2,378 urban hospitals will experience increases or decreases of less than 5 percent. No urban hospitals but 23 rural hospitals will not experience any change to their wage index. These figures reflect changes in the “pre-reclassified, occupational mix-adjusted wage index,” that is, the wage index before the application of geographic reclassification, the rural and imputed floors, the out-migration adjustment, and other wage index exceptions and adjustments. (We refer readers to sections III.G. through III.L. of the preamble of this final rule for the complete discussion of the exceptions and adjustments to the wage index.) We note that the “post-reclassified wage index” or “payment wage index,” which is the wage index that includes all such exceptions and adjustments (as reflected in Tables 2 and 3 associated with this final rule, which are available via the Internet on the CMS Web site) is used to adjust the labor-related share of a hospital’s standardized amount, either 69.6 percent or 62 percent, depending upon whether a hospital’s wage index is greater than 1.0 or less than or equal to 1.0. Therefore, the pre-reclassified wage index figures in the following chart may illustrate a somewhat larger or smaller change than will occur in a hospital’s payment wage index and total payment.

The following chart shows the projected impact of changes in the area wage index values for urban and rural hospitals.

<table>
<thead>
<tr>
<th>Number of hospitals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FY 2017 percentage change in area wage index values</strong></td>
</tr>
<tr>
<td><strong>Urban</strong></td>
</tr>
<tr>
<td>Increase 10 percent or more</td>
</tr>
<tr>
<td>Increase greater than or equal to 5 percent and less than 10 percent</td>
</tr>
<tr>
<td>Increase or decrease less than 5 percent</td>
</tr>
<tr>
<td>Decrease greater than or equal to 5 percent and less than 10 percent</td>
</tr>
<tr>
<td>Decrease 10 percent or more</td>
</tr>
<tr>
<td>Unchanged</td>
</tr>
</tbody>
</table>

**d. Effects of MGCRB Reclassifications (Column 4)**

Our impact analysis to this point has assumed acute care hospitals are paid on the basis of their actual geographic location (with the exception of ongoing policies that provide that certain hospitals receive payments on bases other than where they are geographically located). The changes in Column 4 reflect the per case payment impact of moving from this baseline to a
simulation incorporating the MGCRB decisions for FY 2017.

By spring of each year, the MGCRB makes recategorization determinations that will be effective for the next fiscal year, which begins on October 1. The MGCRB may approve a hospital’s recategorization request for the purpose of using another area’s wage index value. Hospitals may appeal denials of MGCRB decisions to the CMS Administrator. Further, hospitals have 45 days from publication of the IPPS proposed rule in the Federal Register to decide whether to withdraw or terminate an approved geographic reclassification for the following year.

The overall effect of geographic reclassification is required by section 1886(d)(8)(D) of the Act to be budget neutral. Therefore, for purposes of this impact analysis, we are applying an adjustment of 0.988224 to ensure that the effects of the reclassifications under section 1886(d)(10) of the Act are budget neutral (section II.A. of the Addendum to this final rule). Geographic reclassification generally benefits hospitals in rural areas. We estimate that the geographic reclassification will increase payments to rural hospitals by an average of 1.4 percent. By region, all the rural hospital categories will experience increases in payments due to MGCRB reclassifications.

New Table 2 listed in section VI. of the Addendum to this final rule and available via the Internet on the CMS Web site reflects the reclassifications for FY 2017.

e. Effects of the Rural Floor and Imputed Floor

Incorporating Application of National Budget Neutrality (Column 5)

As discussed in section III.B. of the preamble of the FY 2009 IPPS final rule, the FY 2010 IPPS/RY 2010 LTCH PPS final rule, the FY’s 2011, 2012, 2013, 2014, 2015, 2016 IPPS/LTC PPS final rules, and this final rule, section 4410 of Public Law 105–33 established by requiring that the wage index for a hospital in any urban area cannot be less than the wage index received by rural hospitals in the same State. We apply a uniform budget neutrality adjustment to the wage index. The imputed floor, which is also included in the calculation of the budget neutrality adjustment to the wage index, was extended in FY 2012 for 2 additional years and in FY 2014 and FY 2015 for 1 additional year. Prior to FY 2013, only urban hospitals in New Jersey received the imputed floor. As discussed in the FY 2013 IPPS/LTC PPS final rule (77 FR 53369), we established an alternative temporary methodology for the imputed floor, which resulted in an imputed floor for Rhode Island for FY 2013. For FY 2014 and FY 2015, we extended the imputed rural floor, as calculated under the original methodology and the alternative methodology. Due to the adoption of the new OMB labor market area delineations in FY 2014, a State can also become an all-urban State and thus eligible for an imputed floor. For FY 2016, we extended the imputed floor for 1 year, as calculated under the original methodology and the alternative methodology, through September 30, 2016. For FY 2017, we are extending the imputed rural floor for 1 year, as calculated under the original methodology and the alternative methodology, through September 30, 2017. As a result, New Jersey, Rhode Island, and Delaware will be able to receive an imputed floor through September 30, 2017. In New Jersey, 18 out of 64 hospitals will receive the imputed floor, including the 10 out of 11 hospitals in Rhode Island, and 2 out of 6 hospitals in Delaware.

The Affordable Care Act requires that we apply one rural floor budget neutrality factor to the wage index nationally and the imputed floor is part of the rural floor budget neutrality factor applied to the wage index nationally. We have calculated a FY 2017 rural floor budget neutrality factor to be applied to the wage index of 0.9930, which will reduce wage indexes by 0.7 percent.

Column 5 shows the projected impact of the rural floor and imputed floor with the national rural floor budget neutrality factor applied to the wage index based on the OMB labor market area delineations. The column compares the post-reclassification FY 2017 wage index of providers before the rural floor and imputed floor adjustment and the post-reclassification FY 2017 wage index of providers with the rural floor and imputed floor adjustment based on the OMB labor market area delineations. Only urban hospitals can benefit from the rural and imputed floors. Because the provision is budget neutral, all other hospitals (that is, all rural hospitals and those urban hospitals to which the adjustment is not made) will experience a decrease in payments due to the budget neutrality adjustment that is applied nationally to their wage index.

We estimate that 397 hospitals will receive the rural and imputed floors in FY 2017. All IPPS hospitals in our model will have their wage index reduced by the rural floor budget neutrality adjustment of 0.9930 (or 0.7 percent). We project that, in aggregate, rural hospitals will experience a 0.2 percent decrease in payments as a result of the application of the budget neutrality because the rural hospitals do not benefit from the rural floor but have their wage indexes downwardly adjusted to ensure that the application of the rural floor is budget neutral overall. We project hospitals located in urban areas will experience no change in payments because increases in payments by hospitals benefitting from the rural floor offset decreases in payments by nonrural floor urban hospitals whose wage index is downwardly adjusted by the rural floor budget neutrality factor. Urban hospitals in the New England region will experience a 1.0 percent increase in payments primarily due to the application of the rural floor in Massachusetts and the impact of the rural floor in Rhode Island. Fifteen urban providers in Massachusetts are expected to receive the rural floor wage index value, including the rural floor budget neutrality adjustment, increasing payments overall to Massachusetts by an estimated $24 million. We estimate that Massachusetts hospitals will receive approximately a 0.7 percent increase in IPPS payments due to the application of the rural floor in FY 2017. Urban Puerto Rico hospitals are expected to experience a 0.1 percent increase in payments as a result of the application of the rural floor.

There are 18 hospitals out of the 64 hospitals in New Jersey that will benefit from the extension of the imputed floor and will receive the imputed floor wage index value under the OMB labor market area delineations. Overall, New Jersey will receive a net increase of $10 million in payments taking into account the 10 hospitals that will benefit from the imputed floor and the application of the national rural floor and imputed floor budget neutrality adjustment to all hospitals in the state. There are 10 hospitals out of the 11 hospitals in Rhode Island that will benefit from the extension of the imputed floor and will receive the imputed floor wage index value. Overall, Rhode Island will receive a net increase of $17 million in payments taking into account the 10 hospitals that will benefit from the imputed floor and the application of the national rural floor and imputed floor budget neutrality adjustment to all hospitals in the state. There are 2 hospitals out of the 6 hospitals in Delaware that will benefit from the application of the imputed floor and will receive the imputed floor wage index value. Overall, Delaware will see no net increase in payments (to the nearest million) taking into account the 2 hospitals that will benefit from the imputed floor and the application of the national rural floor and imputed floor budget neutrality adjustment to all hospitals in the state.

Column 5 also shows the projected effects of the last year of the 3-year hold harmless provision for hospitals that were located in an urban county that became rural under the new OMB delineations or hospitals deemed urban where the urban area became rural under the new OMB delineations. As discussed in section III.G.2. of the preamble of this final rule, under this transition, hospitals that were located in an urban county that became rural under the new OMB delineations were generally assigned the urban wage index value of the CBSA in which they were physically located in FY 2014 for a period of 3 fiscal years (that is, FY’s 2015, 2016, and 2017). In addition, as discussed in section III.G.2. of the preamble of this final rule, under this transition, hospitals that were deemed urban where the urban area became rural under the new OMB delineations were generally assigned the area wage index value of hospitals reclassified to the urban CBSA (that is, the attaching wage index, if applicable) to which they were designated in FY 2014. For FY 2017, we are applying the 3-year transition wage index adjustments in a budget neutral manner, with a budget neutrality factor of 0.999994.

In response to a public comment addressed in the FY 2012 IPPS/LTC PPS final rule (76 FR 51593), we are providing the payment impact of the rural floor and imputed floor with budget neutrality at the State level. Column 1 of the following table displays the number of IPPS hospitals located in each State. Column 2 displays the number of hospitals in each State that will receive the rural floor or imputed floor wage index for FY 2017. Column 3 displays the percentage of total payments each State will receive or contribute to fund the rural floor and imputed floor with national budget neutrality. The column compares the post-
reclassification FY 2017 wage index of providers before the rural floor and imputed floor adjustment and the post-reclassification FY 2017 wage index of providers with the rural floor and imputed floor adjustment. Column 4 displays the estimated payment amount that each State will gain or lose due to the application of the rural floor and imputed floor with national budget neutrality.

### FY 2017 IPPS estimated payments due to rural and imputed floor with national budget neutrality

<table>
<thead>
<tr>
<th>State</th>
<th>Number of hospitals</th>
<th>Number of hospitals that will receive the rural floor or imputed floor</th>
<th>Percent change in payments due to application of rural floor and imputed floor with budget neutrality</th>
<th>Difference (in $ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alabama</td>
<td>83</td>
<td>6</td>
<td>-0.3</td>
<td>-5</td>
</tr>
<tr>
<td>Alaska</td>
<td>6</td>
<td>4</td>
<td>2.1</td>
<td>4</td>
</tr>
<tr>
<td>Arizona</td>
<td>57</td>
<td>7</td>
<td>-0.1</td>
<td>-2</td>
</tr>
<tr>
<td>Arkansas</td>
<td>44</td>
<td>0</td>
<td>-0.3</td>
<td>-3</td>
</tr>
<tr>
<td>California</td>
<td>301</td>
<td>186</td>
<td>1.3</td>
<td>139</td>
</tr>
<tr>
<td>Colorado</td>
<td>48</td>
<td>3</td>
<td>0.3</td>
<td>3</td>
</tr>
<tr>
<td>Connecticut</td>
<td>31</td>
<td>8</td>
<td>0.3</td>
<td>5</td>
</tr>
<tr>
<td>Delaware</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Washington, DC</td>
<td>7</td>
<td>0</td>
<td>-0.4</td>
<td>-2</td>
</tr>
<tr>
<td>Florida</td>
<td>171</td>
<td>16</td>
<td>-0.2</td>
<td>-14</td>
</tr>
<tr>
<td>Georgia</td>
<td>105</td>
<td>0</td>
<td>-0.3</td>
<td>-8</td>
</tr>
<tr>
<td>Hawaii</td>
<td>12</td>
<td>0</td>
<td>-0.3</td>
<td>-1</td>
</tr>
<tr>
<td>Idaho</td>
<td>14</td>
<td>0</td>
<td>-0.2</td>
<td>-1</td>
</tr>
<tr>
<td>Illinois</td>
<td>126</td>
<td>3</td>
<td>-0.4</td>
<td>-16</td>
</tr>
<tr>
<td>Indiana</td>
<td>89</td>
<td>0</td>
<td>-0.4</td>
<td>-9</td>
</tr>
<tr>
<td>Iowa</td>
<td>35</td>
<td>0</td>
<td>-0.3</td>
<td>-3</td>
</tr>
<tr>
<td>Kansas</td>
<td>53</td>
<td>0</td>
<td>-0.3</td>
<td>-3</td>
</tr>
<tr>
<td>Kentucky</td>
<td>65</td>
<td>0</td>
<td>-0.3</td>
<td>-5</td>
</tr>
<tr>
<td>Louisiana</td>
<td>95</td>
<td>2</td>
<td>-0.3</td>
<td>-4</td>
</tr>
<tr>
<td>Maine</td>
<td>18</td>
<td>0</td>
<td>-0.3</td>
<td>-2</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>58</td>
<td>15</td>
<td>0.7</td>
<td>24</td>
</tr>
<tr>
<td>Michigan</td>
<td>95</td>
<td>0</td>
<td>-0.4</td>
<td>-15</td>
</tr>
<tr>
<td>Minnesota</td>
<td>49</td>
<td>0</td>
<td>-0.3</td>
<td>-5</td>
</tr>
<tr>
<td>Mississippi</td>
<td>62</td>
<td>0</td>
<td>-0.3</td>
<td>-3</td>
</tr>
<tr>
<td>Missouri</td>
<td>74</td>
<td>2</td>
<td>-0.3</td>
<td>-7</td>
</tr>
<tr>
<td>Montana</td>
<td>12</td>
<td>4</td>
<td>0.3</td>
<td>1</td>
</tr>
<tr>
<td>Nebraska</td>
<td>26</td>
<td>0</td>
<td>-0.4</td>
<td>-2</td>
</tr>
<tr>
<td>Nevada</td>
<td>24</td>
<td>3</td>
<td>-0.2</td>
<td>-1</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>13</td>
<td>9</td>
<td>2.3</td>
<td>12</td>
</tr>
<tr>
<td>New Jersey</td>
<td>64</td>
<td>18</td>
<td>0.3</td>
<td>10</td>
</tr>
<tr>
<td>New Mexico</td>
<td>25</td>
<td>0</td>
<td>-0.2</td>
<td>-1</td>
</tr>
<tr>
<td>New York</td>
<td>154</td>
<td>21</td>
<td>-0.2</td>
<td>-15</td>
</tr>
<tr>
<td>North Carolina</td>
<td>84</td>
<td>1</td>
<td>-0.3</td>
<td>-10</td>
</tr>
<tr>
<td>North Dakota</td>
<td>6</td>
<td>1</td>
<td>-0.2</td>
<td>-1</td>
</tr>
<tr>
<td>Ohio</td>
<td>130</td>
<td>10</td>
<td>-0.3</td>
<td>-11</td>
</tr>
<tr>
<td>Oklahoma</td>
<td>86</td>
<td>2</td>
<td>-0.3</td>
<td>-4</td>
</tr>
<tr>
<td>Oregon</td>
<td>34</td>
<td>2</td>
<td>-0.3</td>
<td>-3</td>
</tr>
<tr>
<td>Pennsylvania</td>
<td>151</td>
<td>5</td>
<td>-0.4</td>
<td>-17</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>12</td>
<td>0.1</td>
<td>0</td>
</tr>
<tr>
<td>Rhode Island</td>
<td>11</td>
<td>10</td>
<td>4.5</td>
<td>17</td>
</tr>
<tr>
<td>South Carolina</td>
<td>57</td>
<td>5</td>
<td>-0.1</td>
<td>-1</td>
</tr>
<tr>
<td>South Dakota</td>
<td>18</td>
<td>0</td>
<td>-0.2</td>
<td>-1</td>
</tr>
<tr>
<td>Tennessee</td>
<td>92</td>
<td>20</td>
<td>-0.2</td>
<td>-6</td>
</tr>
<tr>
<td>Texas</td>
<td>320</td>
<td>3</td>
<td>-0.3</td>
<td>-22</td>
</tr>
<tr>
<td>Utah</td>
<td>33</td>
<td>1</td>
<td>-0.3</td>
<td>-1</td>
</tr>
<tr>
<td>Vermont</td>
<td>6</td>
<td>0</td>
<td>-0.2</td>
<td>0</td>
</tr>
<tr>
<td>Virginia</td>
<td>76</td>
<td>1</td>
<td>-0.3</td>
<td>-7</td>
</tr>
<tr>
<td>Washington</td>
<td>49</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>West Virginia</td>
<td>29</td>
<td>3</td>
<td>-0.1</td>
<td>-1</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>65</td>
<td>6</td>
<td>-0.2</td>
<td>-4</td>
</tr>
<tr>
<td>Wyoming</td>
<td>10</td>
<td>0</td>
<td>-0.1</td>
<td>0</td>
</tr>
</tbody>
</table>
f. Effects of the Application of the Frontier State Wage Index and Out-Migration Adjustment (Column 6)

This column shows the combined effects of the application of section 10324(a) of the Affordable Care Act, which requires that we establish a minimum post-reclassified wage-index of 1.00 for all hospitals located in “Frontier States,” and the effects of section 1886(d)(13) of the Act, as added by section 505 of Public Law 108–173, which provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county, but work in a different area with a higher wage index. These two wage index provisions are not budget neutral and increase payments overall by 0.1 percent compared to the provisions not being in effect.

The term “Frontier States” is defined in the statute as States in which at least 50 percent of counties have a population density less than 6 persons per square mile. Based on these criteria, 5 States (Montana, Nevada, North Dakota, South Dakota, and Wyoming) are considered frontier States and 50 hospitals located in those States will receive a frontier wage index of 1.0000. Overall, this provision is not budget neutral and is estimated to increase IPPS operating payments by approximately $58 million. Rural and urban hospitals located in the West North Central region will experience an increase in payments by 0.3 and 0.7 percent, respectively, because many of the hospitals located in this region are frontier State hospitals.

In addition, section 1886(d)(13) of the Act, as added by section 505 of Public Law 108–173, provides for an increase in the wage index for hospitals located in certain counties that have a relatively high percentage of hospital employees who reside in the county, but work in a different area with a higher wage index. Hospitals located in counties that qualify for the payment adjustment are to receive an increase in the wage index that is equal to a weighted average of the difference between the wage index of the resident county, post-reclassification and the higher wage index work area(s), weighted by the overall percentage of workers who are employed in an area with a higher wage index. There are an estimated 277 providers that will receive the out-migration wage adjustment in FY 2017. Rural hospitals generally qualify for the adjustment, resulting in a 0.1 percent increase in payments. This provision appears to benefit section 401 hospitals and RRCs in that they will experience a 1.0 percent and 0.5 percent increase in payments, respectively. This out-migration wage adjustment also is not budget neutral, and we estimate the impact of these providers receiving the out-migration increase will be approximately $30 million.

g. Effects of All FY 2017 Changes (Column 7)

Column 7 shows our estimate of the changes in payments per discharge from FY 2016 and FY 2017, resulting from all changes reflected in this final rule for FY 2017. It includes combined effects of the year to year change of the previous columns in the table.

The average increase in payments under the IPPS for all hospitals is approximately 0.9 percent for FY 2017 relative to FY 2016 and for this row is primarily driven by the changes reflected in Column 1. Column 7 includes the annual hospital update of 1.65 percent to the national standardized amount. This annual hospital update includes the 2.7 percent market basket update, the reduction of 0.3 percent for the multifactor productivity adjustment, and the 0.75 percent point reduction under section 3401 of the Affordable Care Act. As discussed in section II.D. of the preamble of this final rule, this column also includes the FY 2017 documentation and coding recoupment adjustment of –1.5 percent on the national standardized amount as part of the recoupment required under section 631 of the ATRA. In addition, this column includes the adjustment of (1/0.998) to permanently remove the 0.2 percent reduction, and the 1.006 temporary adjustment to address the effects of the change reflected in Column 1. Column 7 includes the annual hospital update of 1.65 percent to the national standardized amount. This annual hospital update includes the 2.7 percent market basket update, the reduction of 0.3 percent for the multifactor productivity adjustment, and the 0.75 percent point reduction under section 3401 of the Affordable Care Act. As discussed in section II.D. of the preamble of this final rule, this column also includes the FY 2017 documentation and coding recoupment adjustment of –1.5 percent on the national standardized amount as part of the recoupment required under section 631 of the ATRA. In addition, this column includes the adjustment of (1/0.998) to permanently remove the 0.2 percent reduction, and the 1.006 temporary adjustment to address the effects of the change reflected in Column 1.

3. Impact Analysis of Table II

Table II presents the projected impact of the changes for FY 2017 for urban and rural hospitals and for the different categories of hospitals shown in Table I. It compares the estimated average payments per discharge for FY 2016 with the estimated average payments per discharge for FY 2017, as calculated under our models. Therefore, this table presents, in terms of the average dollar amounts paid per discharge, the combined effects of the changes presented in Table I.

The estimated percentage changes shown in the last column of Table II equal the estimated percentage changes in average payments per discharge from Column 7 of Table I.

<table>
<thead>
<tr>
<th>TABLE II—IMPACT ANALYSIS OF CHANGES FOR FY 2017 ACUTE CARE HOSPITAL OPERATING PROSPECTIVE PAYMENT SYSTEM</th>
<th>Number of hospitals</th>
<th>Estimated average FY 2016 payment per discharge</th>
<th>Estimated average FY 2017 payment per discharge</th>
<th>FY 2017 changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,330</td>
<td>11,542</td>
<td>11,648</td>
<td>0.9</td>
</tr>
<tr>
<td>By Geographic Location:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,515</td>
<td>11,890</td>
<td>11,996</td>
<td>0.9</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,380</td>
<td>12,698</td>
<td>12,805</td>
<td>0.8</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,135</td>
<td>10,922</td>
<td>11,028</td>
<td>1.0</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>815</td>
<td>8,602</td>
<td>8,709</td>
<td>1.2</td>
</tr>
<tr>
<td>Bed Size (Urban):</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–99 beds</td>
<td>659</td>
<td>9,392</td>
<td>9,476</td>
<td>0.9</td>
</tr>
</tbody>
</table>
TABLE II—IMPACT ANALYSIS OF CHANGES FOR FY 2017 ACUTE CARE HOSPITAL OPERATING PROSPECTIVE PAYMENT SYSTEM—Continued

[Payments per discharge]

<table>
<thead>
<tr>
<th>Type of Ownership:</th>
<th>Estimated average FY 2016 payment per discharge</th>
<th>Estimated average FY 2017 payment per discharge</th>
<th>FY 2017 changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special Hospital Types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban teaching and DSH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both teaching and DSH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teaching and no DSH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special Hospital Types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural DSH:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RRC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 or more beds</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban teaching and DSH:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No teaching and DSH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No teaching and no DSH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of Ownership:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proprietary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Number of hospitals | Estimated average FY 2016 payment per discharge | Estimated average FY 2017 payment per discharge | FY 2017 changes |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>100–199 beds</td>
<td>767</td>
<td>10,050</td>
<td>10,118</td>
</tr>
<tr>
<td>200–299 beds</td>
<td>446</td>
<td>10,757</td>
<td>10,836</td>
</tr>
<tr>
<td>300–499 beds</td>
<td>431</td>
<td>12,092</td>
<td>12,200</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>212</td>
<td>14,613</td>
<td>14,775</td>
</tr>
<tr>
<td>Bed Size (Rural):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–49 beds</td>
<td>317</td>
<td>7,208</td>
<td>7,281</td>
</tr>
<tr>
<td>50–99 beds</td>
<td>292</td>
<td>8,192</td>
<td>8,295</td>
</tr>
<tr>
<td>100–149 beds</td>
<td>120</td>
<td>8,434</td>
<td>8,518</td>
</tr>
<tr>
<td>150–199 beds</td>
<td>67</td>
<td>9,243</td>
<td>9,370</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>40</td>
<td>10,171</td>
<td>10,324</td>
</tr>
<tr>
<td>Urban by Region:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>116</td>
<td>12,957</td>
<td>12,909</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>315</td>
<td>13,471</td>
<td>13,604</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>407</td>
<td>10,498</td>
<td>10,602</td>
</tr>
<tr>
<td>East North Central</td>
<td>390</td>
<td>11,190</td>
<td>11,312</td>
</tr>
<tr>
<td>East South Central</td>
<td>147</td>
<td>10,042</td>
<td>10,167</td>
</tr>
<tr>
<td>West North Central</td>
<td>163</td>
<td>11,578</td>
<td>11,698</td>
</tr>
<tr>
<td>West South Central</td>
<td>385</td>
<td>10,693</td>
<td>10,827</td>
</tr>
<tr>
<td>Mountain</td>
<td>163</td>
<td>12,279</td>
<td>12,388</td>
</tr>
<tr>
<td>Pacific</td>
<td>378</td>
<td>15,372</td>
<td>15,464</td>
</tr>
<tr>
<td>Rural by Region:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>21</td>
<td>11,818</td>
<td>12,015</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>54</td>
<td>8,655</td>
<td>8,781</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>128</td>
<td>8,043</td>
<td>8,125</td>
</tr>
<tr>
<td>East North Central</td>
<td>115</td>
<td>8,918</td>
<td>9,025</td>
</tr>
<tr>
<td>East South Central</td>
<td>155</td>
<td>7,639</td>
<td>7,721</td>
</tr>
<tr>
<td>West North Central</td>
<td>88</td>
<td>9,420</td>
<td>9,561</td>
</tr>
<tr>
<td>West South Central</td>
<td>160</td>
<td>7,243</td>
<td>7,332</td>
</tr>
<tr>
<td>Mountain</td>
<td>60</td>
<td>10,100</td>
<td>10,229</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>12,045</td>
<td>12,200</td>
</tr>
<tr>
<td>By Payment Classification:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,522</td>
<td>11,886</td>
<td>11,993</td>
</tr>
<tr>
<td>Large urban areas</td>
<td>1,372</td>
<td>12,695</td>
<td>12,801</td>
</tr>
<tr>
<td>Other urban areas</td>
<td>1,150</td>
<td>10,928</td>
<td>11,035</td>
</tr>
<tr>
<td>Rural areas</td>
<td>808</td>
<td>8,602</td>
<td>8,708</td>
</tr>
<tr>
<td>Teaching Status:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonteaching</td>
<td>2,266</td>
<td>9,600</td>
<td>9,677</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>815</td>
<td>11,133</td>
<td>11,235</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>249</td>
<td>16,764</td>
<td>16,952</td>
</tr>
<tr>
<td>Urban DSH:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-DSH</td>
<td>589</td>
<td>10,055</td>
<td>10,132</td>
</tr>
<tr>
<td>100 or more beds</td>
<td>1,642</td>
<td>12,247</td>
<td>12,360</td>
</tr>
<tr>
<td>Less than 100 beds</td>
<td>363</td>
<td>8,853</td>
<td>8,916</td>
</tr>
</tbody>
</table>
### H. Effects of Other Policy Changes

In addition to those policy changes discussed previously that we are able to model using our IPPS payment simulation model, we are making various other changes in this final rule. Generally, we have limited or no specific data available with which to estimate the impacts of these changes. Our estimates of the likely impacts associated with these other changes are discussed in this section.

#### I. Effects of Policy Relating to New Medical Service and Technology Add-On Payments

In section II.I of the preamble to this final rule, we discuss seven applications (MAGEC® Spine, Iraducizumab, Defitelio®, GORE® EXCLUDER® IBE, and Vistogard™) for new technology add-on payments for FY 2017. As we proposed, in this final rule, we are continuing to make new technology add-on payments in FY 2017. For new technology add-on payments for FY 2017, we currently estimate that new technology add-on payments for LUTONIX® DCA PTA and IN.PACT™ Admiral™ Paclitaxel Coated PTA Balloon Catheter will increase overall FY 2017 payments by $36,120,735 (maximum add-on payment of $1,035.72 * 26,000 patients for IN.PACT™ Admiral™ Paclitaxel Coated PTA Balloon Catheter), based on the applicant’s estimate for FY 2017.

Based on the applicant’s estimate for FY 2017, we currently estimate that new technology add-on payments for MAGEC® Spine will increase overall FY 2017 payments by $267,750 (maximum add-on payment of $15,750 * 17 patients). Based on the applicant’s estimate for FY 2017, we currently estimate that new technology add-on payments for Defitelio® will increase overall FY 2017 payments by $5,161,200 (maximum add-on payment of $5,161,200 * 200 patients). Based on the applicant’s estimate for FY 2017, we currently estimate that new technology add-on payments for GORE® EXCLUDER® IBE will increase overall FY 2017 payments by $5,685,750 (maximum add-on payment of $5,685,750 * 85 patients). Based on the applicant’s estimate for FY 2017, we currently estimate that new technology add-on payments for Vistogard™ will increase overall FY 2017 payments by $2,812,500 (maximum add-on payment of $2,812,500 * 170 patients). Based on the weighted cost average for FY 2016 described in the FY 2016 IPPS/LTCH final rule (80 FR 49469 through 49470), we currently estimate that new technology add-on payments for LUTONIX® DCA PTA and IN.PACT™ Admiral™ Paclitaxel Coated PTA Balloon Catheter will increase overall FY 2017 payments by $36,120,735 (maximum add-on payment of $1,035.72 * 26,000 patients for IN.PACT™ Admiral™ Paclitaxel Coated PTA Balloon Catheter).

#### TABLE II—IMPACT ANALYSIS OF CHANGES FOR FY 2017 ACUTE CARE HOSPITAL OPERATING PROSPECTIVE PAYMENT SYSTEM—Continued

<table>
<thead>
<tr>
<th>Number of hospitals</th>
<th>Estimated average FY 2016 payment per discharge</th>
<th>Estimated average FY 2017 payment per discharge</th>
<th>FY 2017 changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Utilization as a Percent of Inpatient Days:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–25</td>
<td>523</td>
<td>14,996</td>
<td>15,135</td>
</tr>
<tr>
<td>25–50</td>
<td>2,122</td>
<td>11,460</td>
<td>11,565</td>
</tr>
<tr>
<td>50–65</td>
<td>545</td>
<td>9,133</td>
<td>9,353</td>
</tr>
<tr>
<td>Over 65</td>
<td>89</td>
<td>6,948</td>
<td>7,023</td>
</tr>
</tbody>
</table>

FY 2017 Reclassifications by the Medicare Geographic Classification Review Board:

- All Reclassified Hospitals
- Non-Reclassified Hospitals
- Urban Hospitals Reclassified
- Rural Hospitals Reclassified Full Year
- Rural Nonreclassified Hospitals Full Year
- All Section 401 Reclassified Hospitals
- Other Reclassified Hospitals (Section 1886(d)(8)(B))
2. Effects of the Changes to Medicare DSH Payments for FY 2017

As discussed in section IV.F. of the preamble of this final rule, under section 3133 of the Affordable Care Act, hospitals that are eligible to receive Medicare DSH payments will receive 25 percent of the amount they previously would have received under the former statutory formula for Medicare DSH payments. The remainder, equal to an estimate of 75 percent of what formerly would have been paid as Medicare DSH payments (Factor 1), reduced to reflect changes in the percentage of individuals under age 65 who are uninsured and additional statutory adjustments (Factor 2), is available to make additional payments to each hospital that qualifies for Medicare DSH payments and that has uncompensated care. Each hospital eligible for Medicare DSH payments will receive an additional payment based on its estimated share of the total amount of uncompensated care for all hospitals eligible for Medicare DSH payments. The uncompensated care payment methodology has redistributive effects based on the proportion of a hospital's uncompensated care relative to the uncompensated care for all hospitals eligible for Medicare DSH payments (Factor 3). For FY 2017, we are continuing to use low-income patient days as a proxy for uncompensated care, and the uncompensated care payment methodology has redistributive effects based on the proportion of a hospital's low-income insured patient days (sum of Medicaid patient days and Medicare SSI patient days) relative to the low-income insured patient days for all hospitals eligible for DSH payments. The reduction to Medicare DSH payments under section 3133 of the Affordable Care Act is not budget neutral.

In this FY 2017 IPPS/LTCH PPS final rule, we are establishing the amount to be distributed as uncompensated care payments to DSH eligible hospitals, which for FY 2017 is $5,977,483,146.86, or 75 percent of what otherwise would have been paid for Medicare DSH payment adjustments adjusted by a Factor 2 of 55.36 percent. For FY 2016, for each hospital, we calculated the sum of: (1) 25 percent of the estimated amount of what would have been paid as Medicare DSH in FY 2016 in the absence of section 3133 of the Affordable Care Act; and (2) 75 percent of the estimated amount of what would have been paid as Medicare DSH payments in the absence of section 3133 of the Affordable Care Act, adjusted by a Factor 2 of 63.69 percent and multiplied by a Factor 3 as stated in the FY 2016 IPPS/LTCH PPS final rule. For FY 2017, we calculated the sum of: (1) 25 percent of the estimated amount of what would be paid as Medicare DSH payments in FY 2017 absent section 3133 of the Affordable Care Act; and (2) 75 percent of the estimated amount of what would have been paid as Medicare DSH payments absent section 3133 of the Affordable Care Act, adjusted by a Factor 2 of 55.36 percent and multiplied by a Factor 3 as previously stated.

Our analysis included 2,426 hospitals that are projected to be eligible for DSH in FY 2017. It did not include hospitals that terminated their participation from the Medicare program as of July 1, 2016, Maryland hospitals, and SCHs that are expected to be paid based on their hospital-specific rates. In addition, low-income insured days from merged or acquired hospitals were combined into the surviving hospital’s CCN, and the nonsurviving CCN was excluded from the analysis. In contrast to FY 2016, hospitals participating in the Rural Community Hospital Demonstration program, which is scheduled to end in FY 2017, are included in the analysis if projected to be eligible for DSH payments during FY 2017. The estimated impact of the changes in Factors 1, 2, and 3 across all hospitals projected to be eligible for DSH payments in FY 2017, by hospital characteristic, is presented in the following table.

<table>
<thead>
<tr>
<th>MODELED DISPROPORTIONATE SHARE HOSPITAL PAYMENTS FOR ESTIMATED FY 2017 DSHs BY HOSPITAL TYPE: MODEL DSH $ (IN MILLIONS) FROM FY 2016 TO FY 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of estimated DSHs (FY 2017)</td>
</tr>
<tr>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>By Geographic Location:</td>
</tr>
<tr>
<td>Urban Hospitals</td>
</tr>
<tr>
<td>Large Urban Areas</td>
</tr>
<tr>
<td>Other Urban Areas</td>
</tr>
<tr>
<td>Rural Hospitals</td>
</tr>
<tr>
<td>Bed Size (Urban):</td>
</tr>
<tr>
<td>0 to 99 Beds</td>
</tr>
<tr>
<td>100 to 249 Beds</td>
</tr>
<tr>
<td>250+ Beds</td>
</tr>
<tr>
<td>Bed Size (Rural):</td>
</tr>
<tr>
<td>0 to 99 Beds</td>
</tr>
</tbody>
</table>
### MODELED DISPROPORTIONATE SHARE HOSPITAL PAYMENTS FOR ESTIMATED FY 2017 DSHs BY HOSPITAL TYPE: MODEL DSH $ (IN MILLIONS) FROM FY 2016 TO FY 2017—Continued

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>100 to 249 Beds</td>
<td>117</td>
<td>211</td>
<td>200</td>
<td>–11</td>
</tr>
<tr>
<td>250+ Beds</td>
<td>13</td>
<td>56</td>
<td>53</td>
<td>–3</td>
</tr>
<tr>
<td><strong>Urban by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>East North Central</td>
<td>322</td>
<td>1,273</td>
<td>1,252</td>
<td>–22</td>
</tr>
<tr>
<td>East South Central</td>
<td>130</td>
<td>574</td>
<td>566</td>
<td>–8</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>232</td>
<td>1,614</td>
<td>1,570</td>
<td>–4</td>
</tr>
<tr>
<td>Mountain</td>
<td>125</td>
<td>448</td>
<td>448</td>
<td>0</td>
</tr>
<tr>
<td>New England</td>
<td>90</td>
<td>394</td>
<td>385</td>
<td>–9</td>
</tr>
<tr>
<td>Pacific</td>
<td>314</td>
<td>1,459</td>
<td>1,448</td>
<td>–10</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>42</td>
<td>104</td>
<td>116</td>
<td>12</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>314</td>
<td>1,777</td>
<td>1,721</td>
<td>–55</td>
</tr>
<tr>
<td>West North Central</td>
<td>104</td>
<td>451</td>
<td>440</td>
<td>–1</td>
</tr>
<tr>
<td>West South Central</td>
<td>254</td>
<td>1,200</td>
<td>1,161</td>
<td>–39</td>
</tr>
<tr>
<td><strong>Rural by Region:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>East North Central</td>
<td>64</td>
<td>49</td>
<td>45</td>
<td>–4</td>
</tr>
<tr>
<td>East South Central</td>
<td>142</td>
<td>149</td>
<td>141</td>
<td>–8</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>27</td>
<td>34</td>
<td>32</td>
<td>–2</td>
</tr>
<tr>
<td>Mountain</td>
<td>21</td>
<td>16</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>New England</td>
<td>11</td>
<td>15</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>Pacific</td>
<td>7</td>
<td>9</td>
<td>7</td>
<td>–3</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>86</td>
<td>98</td>
<td>92</td>
<td>–6</td>
</tr>
<tr>
<td>West North Central</td>
<td>31</td>
<td>20</td>
<td>19</td>
<td>–1</td>
</tr>
<tr>
<td>West South Central</td>
<td>110</td>
<td>83</td>
<td>76</td>
<td>–7</td>
</tr>
<tr>
<td><strong>By Payment Classification:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban Hospitals</td>
<td>1,892</td>
<td>9,243</td>
<td>9,056</td>
<td>–187</td>
</tr>
<tr>
<td>Large Urban Areas</td>
<td>1,048</td>
<td>5,884</td>
<td>5,764</td>
<td>–120</td>
</tr>
<tr>
<td>Other Urban Areas</td>
<td>844</td>
<td>3,359</td>
<td>3,292</td>
<td>–68</td>
</tr>
<tr>
<td>Rural Hospitals</td>
<td>534</td>
<td>523</td>
<td>493</td>
<td>–30</td>
</tr>
<tr>
<td><strong>Teaching Status:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonteaching</td>
<td>1,550</td>
<td>3,117</td>
<td>3,050</td>
<td>–67</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>638</td>
<td>3,213</td>
<td>3,132</td>
<td>–80</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>238</td>
<td>3,437</td>
<td>3,367</td>
<td>–71</td>
</tr>
<tr>
<td><strong>Type of Ownership:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,404</td>
<td>6,044</td>
<td>5,909</td>
<td>–136</td>
</tr>
<tr>
<td>Proprietary</td>
<td>546</td>
<td>1,672</td>
<td>1,631</td>
<td>–41</td>
</tr>
<tr>
<td>Government</td>
<td>474</td>
<td>2,023</td>
<td>1,984</td>
<td>–39</td>
</tr>
<tr>
<td>Unknown</td>
<td>2</td>
<td>27</td>
<td>25</td>
<td>–2</td>
</tr>
<tr>
<td><strong>Medicare Utilization Percent:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 to 25</td>
<td>429</td>
<td>3,013</td>
<td>2,975</td>
<td>–38</td>
</tr>
<tr>
<td>25 to 50</td>
<td>1,617</td>
<td>6,356</td>
<td>6,189</td>
<td>–167</td>
</tr>
<tr>
<td>50 to 65</td>
<td>318</td>
<td>385</td>
<td>374</td>
<td>–11</td>
</tr>
<tr>
<td>Greater than 65</td>
<td>51</td>
<td>12</td>
<td>11</td>
<td>–1</td>
</tr>
</tbody>
</table>

Source: Dobson | DaVanzo analysis of 2011–2013 Hospital Cost Reports.

* Dollar DSH calculated by [0.25 * estimated section 1886(d)(5)(F) payments] + [0.75 * estimated section 1886(d)(5)(F) payments * Factor 2 * Factor 3]. When summed across all hospitals projected to receive DSH payments, DSH payments are estimated to be $9,767 million in FY 2016 and $9,549 million in FY 2017.

** Percentage change is determined as the difference between Medicare DSH payments modeled for the FY 2017 IPPS/LTCH PPS final rule (column 3) and Medicare DSH payments modeled for the FY 2016 IPPS/LTCH final rule (column 2) divided by Medicare DSH payments modeled for the FY 2016 final rule (column 2) 1 times 100 percent.

Changes in projected FY 2017 DSH payments from DSH payments in FY 2016 are primarily driven by three factors: (1) An increase in Factor 1 from $10.058 billion to $10.798 billion; (2) a reduction in the percent of uninsured (Factor 2) from 63.69 percent to 56.36 percent; and (3) a revised proxy methodology for calculating Factor 3 values. The impact analysis found that, across all projected DSH eligible hospitals, FY 2017 DSH payments are estimated at approximately $14.397 billion, or an increase of approximately 7.4 percent from FY 2016 DSH payments (approximately $13.411 billion). Although Factor 1 increased substantially, the reduction in Factor 2 offsets this and results in a net decrease in the amount available to be distributed in uncompensated care payments. As seen in the above table, percent reductions greater than 2.2 percent indicate that hospitals within the specified category are projected to experience a greater reduction in DSH payments, on average, compared to the universe of FY 2017 projected DSH hospitals. Conversely, percent reductions that are less than 2.2 percent indicate a hospital type is projected to have a smaller reduction than the overall average. The variation in the distribution of payments by hospital characteristic is largely dependent on the change in a given hospital’s number of Medicaid days and SSI days used in the Factor 3 computation. Rural hospitals, grouped by geographic location, payment classification, and bed size, are projected to experience a larger reduction in DSH payments than urban hospitals. Overall, urban hospitals are projected to receive a 2.0 percent decrease in DSH payments, and rural hospitals are projected to receive a 6.4 percent decrease in
DSH payments. The smaller the rural hospital, the larger the projected reduction in DSH payments, with rural hospitals that have 0–99 beds projected to experience a 7.8 percent payment reduction, and larger rural hospitals with 100–249 beds and greater than 250 beds projected to experience a 5.2 and 5.9 percent payment reductions respectively. In contrast, the smallest urban hospitals (0–99 beds) are projected to receive a decrease in DSH payments of 2.2 percent. Larger urban hospitals (100–250 beds and 250+ beds) are projected to receive reductions of 2.6 and 1.8 percent respectively.

By region, projected DSH payment reductions for urban hospitals are largest in the South Atlantic and West South Central, with New England, Middle Atlantic, and West North Central hospitals also projected to receive reductions in DSH payments greater than the overall average. Urban hospitals in the East North Central, East South Central, Mountain, and Pacific regions are projected to receive reductions less than the overall average. Puerto Rico hospitals are expected to receive an 11.4 percent increase in DSH payments.

Teaching hospitals with fewer than 100 residents are projected to receive relatively larger reductions than nonteaching hospitals or hospitals with 100 or more residents, although all are fairly consistent with the national average. Voluntary, proprietary, and government hospitals are projected to receive payment reductions generally consistent with the national average, where government hospitals are projected to receive slightly smaller reductions in DSH payments and proprietary hospitals are projected to receive slightly larger reductions than the overall average. Hospitals with over 65 percent Medicare utilization are projected to receive a significant reduction in DSH payments, while lower Medicare utilization percentiles show smaller reductions.

Puerto Rico hospitals are projected to receive an increase in overall DSH payments, including both empirically justified DSH payments and uncompensated care payments. With the finalized policy to create proxy values for SSI days for hospitals in Puerto Rico for purposes of calculating Factor 3 of the uncompensated care payment methodology. For FY 2017, Puerto Rico hospitals are projected to receive $116 million in overall DSH and uncompensated care payments, or an 11.4 percent increase from FY 2016 payments ($104 million). Of the estimated $116 million for FY 2017, we estimate that $78 million will be uncompensated care payments to Puerto Rico hospitals. This represents an increase of approximately 13.8 percent, or $9.5 million, in FY 2017 compared to the estimated $68 million in uncompensated care payments to Puerto Rico hospitals in FY 2016. Moreover, we estimate that uncompensated care payments to Puerto Rico hospitals for FY 2017 are 19.8 percent, or $12.9 million, higher with the finalized SSI proxy than they otherwise would have been without the finalized SSI proxy for FY 2017. In other words, without the finalized SSI proxy, we would have expected uncompensated care payments to Puerto Rico hospitals to decline by approximately $3.4 million between FY 2016 and FY 2017. With the change because the finalized SSI proxy for Puerto Rico hospitals increases the number of days in the denominator of Factor 3, this affects hospitals nationally. We estimate that uncompensated care payments to non-Puerto Rico hospitals for FY 2017 are approximately 0.15 percent lower with the finalized SSI proxy than they otherwise would have been without the finalized SSI proxy.

3. Effects of Reduction Under the Hospital Readmissions Reduction Program

In section IV.G. of the preamble of this final rule, we discuss our proposed and final policies for the FY 2017 Hospital Readmissions Reduction Program (established under section 3025 of the Affordable Care Act), which requires a reduction to a hospital’s base operating DRG payments for excess readmissions. For FY 2017, the reduction is based on a hospital’s risk-adjusted readmission rate during a 3-year period for acute myocardial infarction (AMI), heart failure (HF), pneumonia, chronic obstructive pulmonary disease (COPD), total hip arthroplasty/total knee arthroplasty (THA/TKA), and coronary artery bypass graft (CABG). This provision is not budget neutral. A hospital’s readmission adjustment is the higher of a ratio of the hospital’s aggregate payments for excess readmissions to their aggregate payments for all discharges, or a floor, which has been defined in the statute as 0.97 (or a 3.0 percent reduction). A hospital’s base operating DRG payment (that is, wage-adjusted DRG payment amount, as discussed in section IV.G. of the preamble of this final rule) is the portion of the IPPS payment subject to the readmissions payment (DSH, IME, outliers and low-volume add-on payments are not subject to the readmissions adjustment). In this final rule, we estimate that 2,588 hospitals will have their base operating DRG payments reduced by their base FY 2017 hospital-specific readmissions adjustment. As a result, we estimate that the Hospital Readmissions Reduction Program will save approximately $528 million in FY 2017, an increase of $108 million over the estimated FY 2016 savings.

4. Effects of Changes Under the FY 2017 Hospital Value-Based Purchasing (VBP) Program

In section IV.H. of the preamble of this final rule, we discuss the Hospital VBP Program under which the Secretary makes value-based incentive payments to hospitals based on their performance on measures during the performance period with respect to a fiscal year. These incentive payments will be funded for FY 2017 through a reduction to the FY 2017 base operating DRG payment amounts for all discharges for participating hospitals for such fiscal year, as required by section 1886(o)(7)(B) of the Act. The applicable percentage for FY 2017 and subsequent years is 2 percent. The total amount available for value-based incentive payments must be equal to the total amount of reduced payments for all hospitals for the fiscal year, as estimated by the Secretary.

In section IV.H. of the preamble of this final rule, we estimate the available pool of funds for value-based incentive payments in the FY 2017 program year, which, in accordance with section 1886(o)(7)(C)(v) of the Act, will be 2.00 percent of base operating DRG payments, or a total of approximately $1.8 billion. This estimated available pool for FY 2017 is based on the historical pool of hospitals that were eligible to participate in the FY 2016 program year and the payment information from the March 2016 update to the FY 2015 MedPAR file. The estimated impacts of the FY 2017 program year by hospital characteristic, found in the table below, are based on historical TPSs. We used the FY 2016 program year’s TPSs to calculate the proxy adjustment factors used for this impact analysis. These are the most recently available scores that hospitals were given an opportunity to review and correct. The proxy adjustment factors use estimated annual base operating DRG payment amounts derived from the March 2016 update to the FY 2015 MedPAR file. The proxy adjustment factors can be found in Table 16A associated with this final rule (available via the Internet on the CMS Web site).

The impact analysis shows that, for the FY 2017 program year, the number of hospitals that will receive an increase in their base operating DRG payment amounts is higher than the number of hospitals that will receive a decrease. Among urban hospitals, those in the New England, South Atlantic, East North Central, East South Central, West North Central, West South Central, Mountain, and Pacific regions will have an increase, on average, in their base operating DRG payment amounts. Urban hospitals in the Middle Atlantic region will receive an average decrease in their base operating DRG payment amounts. Among rural hospitals, those in all regions will have an increase, on average, in their base operating DRG payment amounts.

On average, hospitals that receive a higher (50–65) percent of DSH payments will receive decreases in base operating DRG payment amounts. With respect to hospitals’ Medicare utilization as a percent of inpatient days (MCR), those hospitals with an MCR above 65 percent will have the largest average increase in base operating DRG payment amounts. Nonteaching hospitals will have an average increase, and teaching hospitals will experience an average decrease in base operating DRG payment amounts.
IMPACT ANALYSIS OF BASE OPERATING DRG PAYMENT AMOUNT CHANGES RESULTING FROM THE FY 2017 HOSPITAL VBP PROGRAM

<table>
<thead>
<tr>
<th>By Geographic Location:</th>
<th>Number of hospitals</th>
<th>Average percentage change</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Hospitals</td>
<td>3,041</td>
<td>0.244</td>
</tr>
<tr>
<td>Large Urban</td>
<td>1,247</td>
<td>0.117</td>
</tr>
<tr>
<td>Other Urban</td>
<td>1,048</td>
<td>0.202</td>
</tr>
<tr>
<td>Rural Area</td>
<td>746</td>
<td>0.515</td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,295</td>
<td>0.156</td>
</tr>
<tr>
<td>0–99 beds</td>
<td>518</td>
<td>0.709</td>
</tr>
<tr>
<td>100–199 beds</td>
<td>716</td>
<td>0.141</td>
</tr>
<tr>
<td>200–299 beds</td>
<td>434</td>
<td>−0.031</td>
</tr>
<tr>
<td>300–499 beds</td>
<td>420</td>
<td>−0.147</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>207</td>
<td>−0.170</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>746</td>
<td>0.514</td>
</tr>
<tr>
<td>0–99 beds</td>
<td>267</td>
<td>0.692</td>
</tr>
<tr>
<td>50–99 beds</td>
<td>285</td>
<td>0.540</td>
</tr>
<tr>
<td>100–149 beds</td>
<td>113</td>
<td>0.308</td>
</tr>
<tr>
<td>150–199 beds</td>
<td>44</td>
<td>0.150</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>37</td>
<td>0.103</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By Region:</th>
<th>Number of hospitals</th>
<th>Average percentage change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban by Region</td>
<td>2,295</td>
<td>0.156</td>
</tr>
<tr>
<td>New England</td>
<td>110</td>
<td>0.152</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>297</td>
<td>−0.065</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>389</td>
<td>0.108</td>
</tr>
<tr>
<td>East North Central</td>
<td>368</td>
<td>0.205</td>
</tr>
<tr>
<td>East South Central</td>
<td>141</td>
<td>0.126</td>
</tr>
<tr>
<td>West North Central</td>
<td>155</td>
<td>0.370</td>
</tr>
<tr>
<td>West South Central</td>
<td>326</td>
<td>0.212</td>
</tr>
<tr>
<td>Mountain</td>
<td>159</td>
<td>0.128</td>
</tr>
<tr>
<td>Pacific</td>
<td>350</td>
<td>0.225</td>
</tr>
<tr>
<td>Rural by Region</td>
<td>746</td>
<td>0.515</td>
</tr>
<tr>
<td>New England</td>
<td>20</td>
<td>0.528</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>53</td>
<td>0.373</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>117</td>
<td>0.621</td>
</tr>
<tr>
<td>East North Central</td>
<td>112</td>
<td>0.515</td>
</tr>
<tr>
<td>East South Central</td>
<td>138</td>
<td>0.389</td>
</tr>
<tr>
<td>West North Central</td>
<td>94</td>
<td>0.623</td>
</tr>
<tr>
<td>West South Central</td>
<td>133</td>
<td>0.418</td>
</tr>
<tr>
<td>Mountain</td>
<td>55</td>
<td>0.714</td>
</tr>
<tr>
<td>Pacific</td>
<td>24</td>
<td>0.677</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By MCR Percent:</th>
<th>Number of hospitals</th>
<th>Average percentage change</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–25</td>
<td>372</td>
<td>0.116</td>
</tr>
<tr>
<td>25–50</td>
<td>2,036</td>
<td>0.208</td>
</tr>
<tr>
<td>50–65</td>
<td>501</td>
<td>0.405</td>
</tr>
<tr>
<td>Over 65</td>
<td>125</td>
<td>0.580</td>
</tr>
<tr>
<td>Missing</td>
<td>7</td>
<td>0.114</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By DSH Percent:</th>
<th>Number of hospitals</th>
<th>Average percentage change</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–25</td>
<td>1,307</td>
<td>0.393</td>
</tr>
<tr>
<td>25–50</td>
<td>1,412</td>
<td>0.162</td>
</tr>
<tr>
<td>50–65</td>
<td>169</td>
<td>−0.015</td>
</tr>
<tr>
<td>Over 65</td>
<td>153</td>
<td>0.012</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By Teaching Status:</th>
<th>Number of hospitals</th>
<th>Average percentage change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Teaching</td>
<td>2,022</td>
<td>0.388</td>
</tr>
<tr>
<td>Teaching</td>
<td>1,019</td>
<td>−0.041</td>
</tr>
</tbody>
</table>

Actual FY 2017 program year’s TPSs will not be reviewed and corrected by hospitals until after this FY 2017 IPPS/LTCH PPS final rule has been published. Therefore, the same historical universe of eligible hospitals and corresponding TPSs from the FY 2016 program year are used for the updated impact analysis in this final rule.

5. Effects of Changes to the HAC Reduction Program for FY 2017

In section IV.I. of the preamble of this final rule, we discuss the changes to the HAC Reduction Program for FY 2017. The table and analysis below show the estimated cumulative effect of the measures and scoring system for the HAC Reduction Program in this final rule. In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49575 through 49576), we finalized a Total HAC Score methodology that assigns, for FY 2017, weights for Domain 1 and Domain 2 at 15 percent and 85 percent, respectively. Based on this methodology, the table below presents data on the estimated proportion of hospitals in the worst-performing quartile of the Total HAC Scores by hospital characteristic. We note that because scores will undergo a 30-day review and correction period by the hospitals that will not conclude until after the publication of this FY 2017 IPPS/LTCH PPS final rule, we are not providing hospital-level data or a hospital-level payment impact in conjunction with this FY 2017 IPPS/LTCH PPS final rule. To estimate the impact of the FY 2017 HAC Reduction Program, we used, as previously finalized, AHRQ PSI 90 measure results based on Medicare FFS discharges from July 2013 through June 2015 and version 5.0.1 (recalibrated) of the AHRQ software. For the CLABSI, CAUTI, Colon and Abdominal Hysterectomy SSI, MRSA Bacteremia, and
CDI measure results, we used standardized infection ratios (SIRs) calculated with hospital surveillance data reported to the NHSN for infections occurring between January 1, 2013 and December 31, 2014. To analyze the results by hospital characteristic, we used the FY 2017 Proposed Rule Impact File. This table includes 3,215 non-Maryland hospitals with a Total HAC Score FY 2017. Of these, 3,200 hospitals had information for geographic location, region, bed size, DSH percent, and teaching status; 3,178 had information for ownership; and 3,176 had information for MCR percent. Maryland hospitals and hospitals without a Total HAC Score are not included in the table below.

## ESTIMATED PROPORTION OF HOSPITALS IN THE WORST-PERFORMING QUARTILE (≥75TH PERCENTILE) OF THE TOTAL HAC SCORE FOR THE FY 2017 HAC REDUCTION PROGRAM

<table>
<thead>
<tr>
<th>Hospital characteristic</th>
<th>Number of hospitals</th>
<th>Number of hospitals in the worst-performing quartile</th>
<th>Percent of hospitals in the worst-performing quartile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>3,215</td>
<td>771</td>
<td>24.0</td>
</tr>
<tr>
<td>By Geographic Location:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All hospitals:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>2,404</td>
<td>653</td>
<td>27.2</td>
</tr>
<tr>
<td>Rural</td>
<td>796</td>
<td>107</td>
<td>13.4</td>
</tr>
<tr>
<td>Urban hospitals:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–99 beds</td>
<td>592</td>
<td>91</td>
<td>15.4</td>
</tr>
<tr>
<td>100–199 beds</td>
<td>734</td>
<td>166</td>
<td>22.6</td>
</tr>
<tr>
<td>200–299 beds</td>
<td>440</td>
<td>134</td>
<td>30.5</td>
</tr>
<tr>
<td>300–399 beds</td>
<td>276</td>
<td>101</td>
<td>36.6</td>
</tr>
<tr>
<td>400–499 beds</td>
<td>150</td>
<td>61</td>
<td>40.7</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>212</td>
<td>100</td>
<td>47.2</td>
</tr>
<tr>
<td>Rural hospitals:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–49 beds</td>
<td>303</td>
<td>48</td>
<td>15.8</td>
</tr>
<tr>
<td>50–99 beds</td>
<td>289</td>
<td>29</td>
<td>10.0</td>
</tr>
<tr>
<td>100–149 beds</td>
<td>118</td>
<td>11</td>
<td>9.3</td>
</tr>
<tr>
<td>150–199 beds</td>
<td>45</td>
<td>9</td>
<td>20.0</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>41</td>
<td>10</td>
<td>24.4</td>
</tr>
<tr>
<td>By Region:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New England</td>
<td>134</td>
<td>42</td>
<td>31.3</td>
</tr>
<tr>
<td>Mid-Atlantic</td>
<td>365</td>
<td>131</td>
<td>35.9</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>519</td>
<td>133</td>
<td>25.6</td>
</tr>
<tr>
<td>East North Central</td>
<td>494</td>
<td>96</td>
<td>19.4</td>
</tr>
<tr>
<td>East South Central</td>
<td>295</td>
<td>45</td>
<td>15.3</td>
</tr>
<tr>
<td>West North Central</td>
<td>259</td>
<td>38</td>
<td>14.7</td>
</tr>
<tr>
<td>West South Central</td>
<td>511</td>
<td>104</td>
<td>20.4</td>
</tr>
<tr>
<td>Mountain</td>
<td>226</td>
<td>55</td>
<td>24.3</td>
</tr>
<tr>
<td>Pacific</td>
<td>397</td>
<td>116</td>
<td>29.2</td>
</tr>
<tr>
<td>By DSH Percent:*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–24</td>
<td>1,387</td>
<td>321</td>
<td>23.1</td>
</tr>
<tr>
<td>25–49</td>
<td>1,454</td>
<td>324</td>
<td>22.3</td>
</tr>
<tr>
<td>50–64</td>
<td>181</td>
<td>58</td>
<td>32.0</td>
</tr>
<tr>
<td>65 and over</td>
<td>178</td>
<td>57</td>
<td>32.0</td>
</tr>
<tr>
<td>By Teaching Status:*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-teaching</td>
<td>2,160</td>
<td>381</td>
<td>17.6</td>
</tr>
<tr>
<td>Fewer than 100 residents</td>
<td>790</td>
<td>237</td>
<td>30.0</td>
</tr>
<tr>
<td>100 or more residents</td>
<td>250</td>
<td>142</td>
<td>56.8</td>
</tr>
<tr>
<td>By Type of Ownership:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voluntary</td>
<td>1,868</td>
<td>478</td>
<td>25.6</td>
</tr>
<tr>
<td>Proprietary</td>
<td>825</td>
<td>154</td>
<td>18.7</td>
</tr>
<tr>
<td>Government</td>
<td>485</td>
<td>121</td>
<td>24.9</td>
</tr>
<tr>
<td>By MCR Percent:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–24</td>
<td>472</td>
<td>148</td>
<td>31.4</td>
</tr>
<tr>
<td>25–49</td>
<td>2,106</td>
<td>481</td>
<td>22.8</td>
</tr>
<tr>
<td>50–64</td>
<td>518</td>
<td>104</td>
<td>20.1</td>
</tr>
<tr>
<td>65 and over</td>
<td>80</td>
<td>18</td>
<td>22.5</td>
</tr>
</tbody>
</table>


*The total number of non-Maryland hospitals with a Total HAC Score with hospital characteristic data (3,200 for geographic location, bed size, and teaching status; 3,178 for type of ownership; and 3,176 for MCR) does not add up to the total number of non-Maryland hospitals with a Total HAC Score for the FY 2017 HAC Reduction Program (3,215) because 15 hospitals are not included in the FY 2017 Proposed Rule Impact File and not all hospitals have data for all characteristics.

*This column is the number of non-Maryland hospitals with a Total HAC Score within the corresponding characteristic that are estimated to be in the worst-performing quartile.

*This column is the percent of hospitals within each characteristic that are estimated to be in the worst-performing quartile. The percentages are calculated by dividing the number of non-Maryland hospitals with a Total HAC Score in the worst-performing quartile by the total number of non-Maryland hospitals with a Total HAC Score within that characteristic.

*Total excludes 47 Maryland hospitals and 64 non-Maryland hospitals without a Total HAC Score for FY 2017.

* A hospital is considered to be a DSH hospital if it has a DSH patient percentage greater than zero.

* A hospital is considered to be a teaching hospital if it has an IME adjustment factor for Operation PPS (TCHOP) greater than zero.
6. Effects of Policy Changes Relating to Direct GME and IME Payments for Rural Training Tracks at Urban Hospitals

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25308) and section IV.J. of the preamble of this final rule, we discuss our proposed and finalized policy to extend the period for establishing rural track FTE limitations from 3 years to 5 years for purposes of direct GME and IME payments to urban hospitals with rural track training programs. Specifically, we are revising the regulations to permit that, in the first 5 program years (rather than the first 3 program years) of the rural track’s existence, the rural track FTE limitation for each urban hospital would be the actual number of FTE residents training in the rural training track at the urban hospital, and beginning with the urban hospital’s cost reporting period that coincides with or follows the start of the sixth program year of the rural training track’s existence, the rural track FTE limitation will take effect. This change addresses concerns expressed by the hospital community that rural training tracks, like any program, should have a sufficient amount of time for a hospital to “grow” and to establish a rural track FTE limitation that reflects the number of FTE residents that it will actually train, once the program is fully grown. In the proposed rule (81 FR 25308) and in section IV.J. of the preamble of this final rule, we explain that because we inadvertently did not also amend the separate direct GME and IME regulations regarding the growth window and effective date of FTE limitations for rural track training programs when we amended the regulations regarding the 5-year growth window in the FY 2013 IPPS/LTCH PPS final rule and regarding the additional changes we made in the FY 2015 IPPS/LTCH PPS final rule, we are making the effective date regarding the change in the growth window also effective for rural track training programs after October 1, 2012. As stated in the proposed rule, mostly due to the relatively small size of rural track programs, we estimate that the proposal would cost approximately $1 million by the end of the 10-year period, a negligible cost. We amended as proposed, and therefore our estimate remains unchanged for the final rule.

7. Effects of Implementation of Rural Community Hospital Demonstration Program

In section IV.K. of the preamble of this final rule, for FY 2017, we discuss our implementation of section 410A of Public Law 108–173, as amended, which requires the Secretary to conduct a demonstration that would modify payments for inpatient services for up to 30 rural community hospitals. Section 410A(c)(2) requires that in conducting the demonstration program under this section, the Secretary shall ensure that the aggregate payments made by the Secretary for the amount which the Secretary would have paid if the demonstration program under this section was not implemented.

As discussed in section IV.K. of the preamble of this final rule, in the IPPS final rules for each of the previous 12 fiscal years, we have estimated the additional payments made by the program for each of the participating hospitals as a result of the demonstration. In order to achieve budget neutrality, we have adjusted the national IPPS rates by an amount sufficient to account for the added costs of this demonstration. In other words, we have offset budget neutrality across the payment system as a whole rather than across the participants of this demonstration. The language of the statutory budget neutrality requirement permits the agency to implement the budget neutrality provision demonstrated. The statutory language requires that aggregate payments made by the Secretary do not exceed the amount which the Secretary would have paid if the demonstration was not implemented but does not identify the range across which aggregate payments must be held equal.

In the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25130), we proposed a different methodology as compared to previous years for analyzing the costs attributable to the demonstration. The demonstration will have substantially phased out by the beginning of FY 2017. The 7 “originally participating hospitals”, that is, those hospitals that were selected for the demonstration in 2004 and 2008, ended their participation in the 5-year extension period authorized by the Affordable Care Act prior to the start of FY 2016. In addition, we stated in the proposed rule that the participation period for the 14 hospitals that entered the demonstration following the extension of the demonstration mandated by the Affordable Care Act and that were participating would end on a rolling basis according to the end dates of the hospitals’ cost report periods, respectively, from April 30, 2016 through December 31, 2016. Of these 14 hospitals, 10 hospitals will end participation on or before September 30, 2016, leaving 4 hospitals participating for the last 3 months of CY 2016 (that is, the first 3 months of FY 2017). Given the small number of participating hospitals and the limited time of participation, we proposed to forego the process of estimating this amount attributable to the demonstration for FY 2017 and to instead analyze the set of finalized cost reports for reporting periods beginning in FY 2016 when they become available.

In previous IPPS/LTCH PPS final rules, we have determined the amount by which the actual costs of the demonstration for an earlier, previous year differed from the estimated costs of the demonstration set forth in the corresponding final rule for the corresponding fiscal year, and we incorporated that amount into the budget neutrality offset amount for the upcoming fiscal year. We note that we have calculated this difference between the actual costs of the demonstration for FYs 2005 through 2010, as determined from finalized cost reports once available, and estimated costs of the demonstration as described in the applicable IPPS final rules for these years. In the proposed rule (81 FR 25130), we proposed to conduct this analysis for FYs 2011 through 2016 at one time, when all of the finalized cost reports for cost reporting periods beginning in FYs 2011 through 2016 are available. Given the general lag of 3 years in finalizing cost reports, we stated in the proposed rule that we expect any such analysis to be conducted in FY 2020.

Because, as discussed earlier, we proposed that we would not calculate and apply an estimated budget neutrality offset amount for FY 2017, but instead analyze the set of finalized cost reports for cost reporting periods beginning in FY 2016 when they become available, and proposed to reconcile the budget neutrality offset amounts for FYs 2011 through 2016 with the actual costs of the demonstration once the finalized cost reports for all of these years are available, we stated in the proposed rule that there would be no impact from the demonstration on the national IPPS rates for FY 2017 (81 FR 25308).

In this final rule, we are finalizing these proposals without modification. Thus, in this final rule, we are applying no budget neutrality offset amount to the national IPPS rates for FY 2017.

8. Effects of Implementation of the Notice of Observation Treatment and Implications for Care Eligibility Act (NOTICE Act)

In the proposed rule (81 FR 25131 through 25135) and in section IV.M. of the preamble of this final rule, we discuss implementation of section 1866(a)(1)(Y) of the Act as amended by the NOTICE Act (Pub. L. 114–42) and revisions to the basic commitments providers agree to as part of participating in Medicare under a provider agreement. These revisions specify a process for hospitals and CAHs to notify an individual, orally and in writing, regarding the individual’s receipt of observation services as an outpatient for more than 24 hours and the implications of receiving such services. The statute mandates the Secretary develop a plain language written notice for this purpose. The written notice must be delivered no later than 36 hours after observation services are initiated (or, if sooner, upon release).

We developed a standardized format for the notice, which is undergoing OMB approval. The notice will be disseminated during the normal course of related business activities. In 2014, there were approximately 1,399,999 claims for Medicare outpatient observation services lasting greater than 24 hours furnished by 6,142 hospitals and CAHs. We refer readers to section IX.B. of the preamble of this final rule for a discussion of the burden associated with this notice requirement.


In the FY 2017 IPPS/LTCH proposed rule (81 FR 25134 through 25135) and in section IV.M. of the preamble of this final rule, we discuss a number of technical changes or corrections of typographical errors in 42 CFR part 413 relating to costs to related organizations and Medicare cost reports that need to be made. We believe that the impact of these technical changes and corrections is negligible.

***Source: CMS Office of Enterprise and Data Analytics.***
In addition to the other adjustments, we have specified the payment adjustments in this final rule, we are finalizing this proposal, and the time an adjustment to account for forecast error, comparisons in the demonstration will produce savings from the demonstration will produce savings from the demonstration on its own terms (that is, the demonstration will produce savings from reduced transfers and admissions to other health care providers, thus offsetting any increase in payments resulting from the demonstration). However, because of the small size of this demonstration program and uncertainty associated with projected Medicare utilization and costs, we proposed a contingency plan (81 FR 25141) to ensure that the budget neutrality requirement in section 123 of Public Law 110–275 is met. Accordingly, if an analysis of claims data for the Medicare beneficiaries receiving services at each of the participating CAHs, as well as of other sources, shows that increases in Medicare payments under the demonstration during the 3-year period are not sufficiently offset by reductions elsewhere, we will recoup the additional expenditures attributable to the demonstration through a reduction in payments to all CAHs nationwide. The demonstration is projected to impact payments to participating CAHs under both Medicare Part A and Part B. Thus, in the event that we determine that aggregate payments under the demonstration exceed the payments that would otherwise have been made, we proposed that CMS would recoup payments through reductions of Medicare payments to all CAHs under both Medicare Part A and Part B. Because of the small scale of the demonstration, it would not be feasible to implement budget neutrality by reducing payments only to the participating CAH providers. We proposed to make the reduction to payments to all CAHs, not just those participating in the demonstration. The budget neutrality requirement in section 123 of the demonstration program is specifically designed to test innovations that affect delivery of services by this provider category. We believe that the language of the statutory budget neutrality requirement at section 123(g)(1)(B) of the Act permits the agency to implement the budget neutrality provision in this manner. The statutory language refers merely to ensuring that aggregate payments made by the Secretary do not exceed the amount which the Secretary estimates would have been paid if the demonstration project was not implemented, and does not identify the range across which aggregate payments may be held equal. Given the 3-year period of performance of the FCHIP demonstration and the time needed to conduct the budget neutrality analysis, we proposed that, in the event the demonstration is found not to have been budget neutral, any excess costs would be recouped over a period of three cost report periods, beginning in CY 2020. Therefore, in this final rule, we are finalizing this proposal, which has no impact for any national payment system for FY 2017.

1. Effects of Changes in the Capital IPPS

1. General Considerations

For the impact analysis presented below, we used data from the March 2016 update of the FY 2015 MedPAR file and the March 2016 update of the Provider-Specific File (PSF) that is used for payment purposes. Although the analyses of the changes to the capital prospective payment system do not incorporate cost data, we used the March 2016 update of the most recently available hospital cost report data (FYs 2013 and 2014) to categorize hospitals. Our analysis has several qualifications. We use the best data available and make assumptions about case-mix and beneficiary enrollment as described later in this section.

Due to the interdependent nature of the IPPS, it is very difficult to precisely quantify the impact associated with each change. In addition, we draw upon various sources for the data used to categorize hospitals in the tables. In some cases (for instance, the number of beds), there is a fair degree of variation in the data from different sources. We have attempted to construct these variables with the best available sources overall. However, it is possible that some individual hospitals are placed in the wrong category.

Using cases from the March 2016 update of the FY 2015 MedPAR file, we simulated payments under the capital IPPS for FY 2016 and FY 2017 for a comparison of total payments per case. Any short-term, acute care hospitals not paid under the general IPPS (for example, Indian Health Service hospitals and hospitals in Maryland) are excluded from the simulations.

The methodology for determining a capital IPPS payment is set forth at §412.312. The basic methodology for determining the capital IPPS payments in FY 2017 is as follows:

(Standard Federal Rate) × (DRG weight) × (GAF) × (COLA for hospitals located in Alaska and Hawaii) × (1 + DSH Adjustment Factor + IME adjustment factor, if applicable).

In addition to the other adjustments, hospital payments per case for those cases that qualify under the threshold established for each fiscal year. We modeled payments for each hospital by multiplying the capital Federal rate by the GAF and the hospital’s case-mix. We then added estimated payments for indirect medical education, disproportionate share, and outliers, if applicable. For purposes of this impact analysis, the model includes the following assumptions:

- We estimate that the Medicare case-mix index will increase by 0.5 percent in both FYs 2016 and 2017.
- We estimate that Medicare discharges will be approximately 11.0 million in FY 2016 and 11.1 million in FY 2017.
- The capital Federal rate was updated beginning in FY 1996 by an analytical framework that considers changes in the prices associated with capital-related costs and adjustments to account for forecast error, changes in the case-mix index, allowable changes in intensity, and other factors. As discussed in section III.A.1.a. of the Addendum rule, the update is 0.9 percent for FY 2017.
- In addition to the FY 2017 update factor, the FY 2017 capital Federal rate was calculated based on a GAF/DRG budget neutrality adjustment factor of 0.9991, a outlier adjustment factor of 0.9861, and an adjustment of (1/0.998) to permanently remove the 0.2 percent adjustment, as well as a temporary 2-midnight adjustment of 1.006. The 2-midnight adjustments are discussed in section V.C. of the preamble of this final rule and are consistent with adjustments on the operating Federal rate. As discussed in section V.C. of the preamble of this final rule, we are not making an additional MS–DRG documentation and coding adjustment to the capital IPPS Federal rates for FY 2017.

2. Results

We used the actuarial model previously described in section I.I of Appendix A of this final rule to estimate the potential impact of our changes for FY 2017 on total capital payments per case, using a universe of 3,330 hospitals. As previously described, the individual hospital payment parameters are taken from the best available data, including the March 2016 update of the FY 2015 MedPAR file, the March 2016 update to the PSF, and the most recent cost report data from the March 2016 update of HCRIS. In Table III, we present a comparison of estimated total payments per case for FY 2016 and estimated total payments per case for FY 2017 based on the FY 2017 payment policies. Column 2 shows estimates of payments per case under our model for FY 2016. Column 3 shows estimates of payments per case under our model for FY 2017. Column 4 shows the total percentage change in payments from FY 2016 to FY 2017. The change represented in Column 4 includes the 0.9 percent update to the capital Federal rate and other changes in the adjustments to the capital Federal rate. The comparisons are provided by: (1) Geographic location; (2) region; and (3) payment classification.

The simulation results show that, on average, capital payments per case in FY 2017 are expected to increase as compared to capital payments per case in FY 2016. This expected increase overall is due primarily to the approximately 1.84 percent increase in the capital Federal rate for FY 2017 as compared to the FY 2016 capital Federal rate.

(For a discussion of the determination of the capital Federal rate, we refer readers to section III.A. of the Addendum to this final...
rule.) Less than half of the hospitals in urban areas are expected to experience a slight increase in capital payments per case due to the effects of changes to the GAFs, while the remainder of these urban area hospitals would experience no change or a decrease in capital payments per case due to changes in the GAFs. For most hospitals in rural areas, changes in the GAFs are expected to increase capital payments, to a greater or lesser extent, except for two rural areas where changes in the GAFs are expected to decrease capital payments per case. These regional effects of the changes to the GAFs on capital payments are consistent with the projected changes in payments due to changes in the wage index (and policies affecting the wage index) as shown in Table I in section I.G. of this Appendix A.

The net impact of these changes is an estimated 0.8 percent change in capital payments per case from FY 2016 to FY 2017 for all hospitals (as shown in Table III).

The geographic comparison shows that, on average, most hospitals in all classifications (urban and rural) will experience an increase in capital IPPS payments per case in FY 2017 as compared to FY 2016. Capital IPPS payments per case for hospitals in “large urban areas” have an estimated increase of 0.7 percent, while hospitals in rural areas, on average, are expected to experience a 0.8 percent increase in capital payments per case from FY 2016 to FY 2017. Capital IPPS payments per case for “other urban hospitals” are estimated to increase 0.9 percent. The primary factor contributing to the small difference in the projected increase in capital IPPS payments per case for urban hospitals as compared to rural hospitals is the changes to the GAFs.

The comparisons by region show that the estimated increases in capital payments per case from FY 2016 to FY 2017 in urban areas range from a 4.2 percent increase for the Puerto Rico urban hospitals, and a 1.4 percent increase for the West South Central urban region to a 0.7 percent increase for the Mountain urban region. The New England urban region is expected to experience a 0.6 percent decrease in capital payments per case, largely due to changes in the GAFs as compared to the other urban hospitals. The 4.2 percent increase in capital payments per case for the Puerto Rico urban region is in part due to the change in the capital payment rate to 100 percent of the capital Federal rate rather than a blend of the capital Puerto Rico rate and the capital Federal rate, as discussed in section V.B.3. of the preamble of this final rule. For rural regions, the Middle Atlantic rural region is projected to experience the largest increase in capital IPPS payments per case of 1.6 percent, while the Mountain rural region is projected to experience a small decrease in capital IPPS payments per case of 0.4 percent. The change in the GAFs is the main factor for the projected decrease in the capital IPPS payments for the Mountain rural region compared to the other rural regions, as it is for the projected decrease in capital IPPS payments for the New England urban region.

Hospitals of all types of ownership (that is, voluntary hospitals, government hospitals, and proprietary hospitals) are expected to experience an increase in capital payments per case from FY 2016 to FY 2017. The increases in capital payments for voluntary and proprietary hospitals is estimated to be 0.8 percent and for government hospitals, the increase is estimated to be 0.7 percent.

Section 1886(d)(10) of the Act established the MGCRB. Hospitals may apply for reclassification for purposes of the wage index for FY 2017. Reclassification for wage index purposes also affects the GAFs because that factor is constructed from the hospital wage index. To present the effects of the hospitals being reclassified as of the publication of this rule for FY 2017, we show the average capital payments per case for hospitals for FY 2017. Urban reclassified hospitals are expected to experience an increase in capital payments of 1.0 percent; rural nonreclassified hospitals are expected to experience an increase in capital payments of 0.7 percent. The estimated percentage increase for rural reclassified hospitals is 1.0 percent, and for rural nonreclassified hospitals, the estimated percentage increase is 0.2 percent. Other reclassified hospitals (section 1886(d)(8)(B) of the Act) are expected to experience an increase in capital payments of 0.5 percent.

### Table III—Comparison of Total Payments per Case

<table>
<thead>
<tr>
<th>By Geographic Location:</th>
<th>Average FY 2016 payments/case</th>
<th>Average FY 2017 payments/case</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>All hospitals</td>
<td>3,330</td>
<td>912</td>
<td>920</td>
</tr>
<tr>
<td>Rural areas</td>
<td></td>
<td></td>
<td>815</td>
</tr>
<tr>
<td>Urban hospitals</td>
<td>2,515</td>
<td>870</td>
<td>878</td>
</tr>
<tr>
<td>0–99 beds</td>
<td>659</td>
<td>768</td>
<td>774</td>
</tr>
<tr>
<td>100–199 beds</td>
<td>576</td>
<td>824</td>
<td>829</td>
</tr>
<tr>
<td>200–299 beds</td>
<td>446</td>
<td>865</td>
<td>871</td>
</tr>
<tr>
<td>300–499 beds</td>
<td>431</td>
<td>958</td>
<td>967</td>
</tr>
<tr>
<td>500 or more beds</td>
<td>212</td>
<td>1,139</td>
<td>1,149</td>
</tr>
<tr>
<td>Rural hospitals</td>
<td>815</td>
<td>618</td>
<td>623</td>
</tr>
<tr>
<td>0–99 beds</td>
<td>317</td>
<td>520</td>
<td>524</td>
</tr>
<tr>
<td>100–199 beds</td>
<td>120</td>
<td>610</td>
<td>614</td>
</tr>
<tr>
<td>150–199 beds</td>
<td>46</td>
<td>669</td>
<td>673</td>
</tr>
<tr>
<td>200 or more beds</td>
<td>40</td>
<td>738</td>
<td>746</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>By Region:</th>
<th>Average FY 2016 payments/case</th>
<th>Average FY 2017 payments/case</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>New England</td>
<td>2,515</td>
<td>947</td>
<td>955</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>116</td>
<td>1,031</td>
<td>1,025</td>
</tr>
<tr>
<td>South Atlantic</td>
<td>315</td>
<td>1,056</td>
<td>1,065</td>
</tr>
<tr>
<td>East North Central</td>
<td>407</td>
<td>840</td>
<td>847</td>
</tr>
<tr>
<td>East South Central</td>
<td>390</td>
<td>908</td>
<td>916</td>
</tr>
<tr>
<td>West North Central</td>
<td>163</td>
<td>923</td>
<td>930</td>
</tr>
<tr>
<td>West South Central</td>
<td>163</td>
<td>977</td>
<td>984</td>
</tr>
<tr>
<td>Mountain</td>
<td>378</td>
<td>1,219</td>
<td>1,228</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>51</td>
<td>435</td>
<td>453</td>
</tr>
<tr>
<td>Rural by Region</td>
<td>815</td>
<td>618</td>
<td>623</td>
</tr>
<tr>
<td>New England</td>
<td>21</td>
<td>868</td>
<td>878</td>
</tr>
<tr>
<td>Middle Atlantic</td>
<td>54</td>
<td>588</td>
<td>586</td>
</tr>
</tbody>
</table>
1. Introduction and General Considerations

In section VII. of the preamble of this final rule and section V. of the Addendum to this final rule, we set forth the annual update to the payment rates for the LTCH PPS for FY 2017. In the preamble of this final rule, we specify the statutory authority for the provisions that are presented, identify the proposed and final policies, and present rationales for our decisions as well as alternatives that were considered. In this section of Appendix A to this final rule, we discuss the impact of the changes to the payment rate, factors, and other payment rate policies related to the LTCH PPS that are presented in the preamble of this final rule in terms of their estimated fiscal impact on the Medicare budget and on LTCHs.

There are 420 LTCHs included in this impacts analysis, which includes data for 78 nonprofit (voluntary ownership control) LTCHs, 325 proprietary LTCHs, and 17 LTCHs that govern- owned and operated. (We note that, although there are currently approximately 430 LTCHs, for purposes of this impact analysis, we excluded the data of all-inclusive rate
PPS market basket and the reductions required by sections 1886(m)(3) and (m)(4) of the Act, the update to the MS–LTC–DRG classifications and relative weights, the update to the wage index values and labor-related share, and the best available claims and cost data to estimate the change in payments for FY 2017.

Under the dual rate LTCH PPS payment structure, payment for LTCH discharges that meet the criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) is based on the LTCH PPS standard Federal payment rate. Consistent with the statute, the site neutral payment rate is the lower of the IPPS comparable per diem amount as determined under §412.529(d)(4), including any applicable outlier payments as specified in §412.525(a); or 100 percent of the estimated cost of the case as determined under existing §412.529(d)(2). In addition, there are two separate HCO targets—one for LTCH PPS standard Federal payment rate cases and one for site neutral payment rate cases. The statute also establishes a transitional payment method for cases that are paid the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 and FY 2017. The transitional payment amount for site neutral payment rate cases is a blended payment rate, which is calculated as 50 percent of the applicable site neutral payment rate amount for the discharge as determined under new §412.522(c)(1) and 50 percent of the applicable LTCH PPS standard Federal payment rate amount for the discharge determined under §412.523.

Based on the best available data for the 420 LTCHs in our database that were considered in the analyses used for this final rule, we estimate that overall LTCH PPS payments in FY 2017 will decrease by approximately 7.1 percent (or approximately $363 million). This projection takes into account estimated payments for LTCH cases in our database that would have met the patient-level criteria and been paid the LTCH PPS standard Federal payment rate, had the criteria been in effect at the time of the discharge, and estimated payments for LTCH cases that would not have met the patient-level criteria and been paid under the site neutral payment rate if that rate had been in effect at the time of the discharge, as described in the following paragraph.

The statutory transitional payment method for cases that are paid the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning during FY 2016 or FY 2017 uses a blended payment rate, which is determined as 50 percent of the site neutral payment rate amount for the discharge and 50 percent of the standard Federal prospective payment rate amount for the discharge (§412.522(c)(3)). The transitional blended payment rate uses the same 50 percent rate that is, 50 percent for both years of the 2-year transition period.

Therefore, when estimating FY 2017 LTCH PPS payments for site neutral payment rate cases for this impact analysis, the transitional blended payment rate was applied to all such cases because all discharges in FY 2017 will either be in the hospital’s cost reporting period that began during FY 2016 or in the hospital’s cost reporting period that will begin during FY 2017. However, when estimating FY 2016 LTCH PPS payments for site neutral payment rate cases for this impact analysis because the statute specifies that the site neutral payment rate when that rate is determined based on the date on which that LTCH’s cost reporting period begins during FY 2016, we included an adjustment to account for this rolling effective date, consistent with the approach used in the LTCH PPS impact analysis presented in the 2016 IPPS/LTCH PPS final rule (80 FR 49831). This approach accounts for the fact that LTCHs with discharges in FY 2016 that are in cost reporting periods that begin before October 1, 2015, continued to be paid for all discharges (including those that did not meet the patient-level criteria for exclusion from the site neutral payment rate) at the LTCH PPS standard Federal payment rate until the start of their first cost reporting period beginning after October 1, 2015.

For purposes of this impact analysis, to estimate total FY 2016 LTCH PPS payments for site neutral payment rate cases, we used the same approach as was used in the FY 2016 IPPS/LTCH PPS final rule. In summary, under this approach, we grouped LTCHs based on the quarter of FY 2016 their cost reporting periods began during FY 2016. For example, LTCHs with cost reporting periods that began during October through December 2015 began during the first quarter of FY 2016. For LTCHs grouped in each quarter of FY 2016, we estimated FY 2016 site neutral payment rate payments under the transitional blended payment rate based on the quarter in which the LTCHs in each group become subject to the site neutral payment rate. Then, we modeled for LTCHs grouped in each quarter of FY 2016, estimated FY 2016 payments under the LTCH PPS standard Federal payment rate based on the quarter in which the LTCHs in each group become subject to the site neutral payment rate. (For additional details on how we estimate these payments, see the FY 15 LTCH PPS final rule (80 FR 49603).)

As we explained in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49603), currently the publically available IPPS and LTCH PPS MedPAR files do not contain any specified direct patient identifiers consistent with CMS’ privacy and security standards and as outlined in the HIPAA Privacy Rule. (For additional information on CMS’ privacy and security standards under the HIPAA Privacy Rule, we refer readers to the CMS Web site at: https://www.cms.gov/Regulations-and-Guidance/Administrative-Simplification/ HIPAA-ACA/PrivacyandSecurityInformation.html, and for additional information on CMS’ publically available LDS files, we refer readers to the CMS Web site at: http://www.cms.hhs.gov/ Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/index.html.) It is for these reasons that, as noted by commenters, we added an identifier to the publically available FY 2014 LTCH MedPAR File to identify the historical LTCH discharges in that file as LTCH PPS standard Federal payment rate cases or site neutral.
payment rate cases (had the statutory dual rate LTCH PPS payment structure been in effect at the time of the discharge). These are the same payment rate identifiers we used to develop the FY 2017 proposed payment rates, factors, and payment estimates as described in the proposed rule. We believe that the addition of this payment rate identifier to the publically available LTCH MedPAR file provides sufficient information for commenters to replicate and evaluate the proposed payment rates, factors, and payment estimates in the proposed rule. We will continue to consider adding the encrypted information requested by commenters to the publically available IPPS and LTCH PPS MedPAR files. However, we are not able to do so at this time because to add such specific direct patient identifiers would need to be done in conformance with CMS’ privacy and security standards, including any requirements outlined in the HIPAA Privacy and Security Rules.

Based on the FY 2015 LTCH cases that were used for the analyses in this final rule, approximately 45 percent of those LTCH cases would have been classified as site neutral payment rate cases if the site neutral payment rate had been in effect in FY 2015 (that is, 45 percent of such LTCH cases would not have met the patient-level criteria for exclusion from the site neutral payment rate). Our Office of the Actuary estimates that the percent of LTCH PPS cases that will be paid at the site neutral payment rate in FY 2017 will not change significantly from the historical data. Taking into account the transformed payment rate and other changes that will apply to the site neutral payment rate cases in FY 2017, we estimate that aggregate LTCH PPS payments for these site neutral payment rate cases will decrease by approximately 23 percent (or approximately $388 million).

Approximately 55 percent of LTCH cases are expected to meet the patient-level criteria for exclusion from the site neutral payment rate in FY 2017, and will be paid based on the LTCH PPS standard Federal payment rate for the LTCH PPS standard Federal payment rate cases in FY 2017 is primarily due to the combined effects of the 1.75 percent annual update to the LTCH PPS standard Federal payment rate for FY 2017 (discussed in section V.A. of the Addendum to this final rule) and an estimated decrease in HCO payments for these cases (discussed in section V.D.3. of the Addendum to this final rule).

Based on the 420 LTCHs that were represented in the FY 2015 LTCH cases that were used for the analyses in this final rule, we estimate that aggregate FY 2017 LTCH PPS payments of approximately $4.771 billion, as compared to estimated aggregate FY 2016 LTCH PPS payments of approximately $5.134 billion, resulting in an estimated overall decrease in LTCH PPS payments of approximately $363 million. Because the combined distributional effects and estimated payment changes exceed $100 million, this final rule is a major economic rule. We note that this estimated $363 million decrease in LTCH PPS payments in FY 2017 (which includes estimated payments for LTCH PPS standard Federal payment rate cases and site neutral payment rate cases) does not result in a change in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases (had the statutory dual rate structure been in effect at the time of the discharge). Therefore, the projected increase in payments from FY 2016 to FY 2017 for LTCH PPS standard Federal payment rate cases does not result in a change in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases (had the statutory dual rate structure been in effect at the time of the discharge). Therefore, for all hospital categories, the projected increase in payments from FY 2016 to FY 2017 for LTCH PPS standard Federal payment rate cases is an option in the SSO payment formula (§412.5329). We estimate that these increased SSO payments in FY 2017 will increase total payments for LTCH PPS standard Federal payment rate cases by approximately 0.25 percent. (Payments for SSO cases represent approximately 14 percent of the estimated total FY 2017 payments for LTCH PPS standard Federal payment rate cases).

Table IV shows the estimated impact of the proposed payment rates, factors, and payment changes that will apply to the site neutral payment rate cases. The estimated change attributable solely to the annual update to the LTCH PPS standard Federal payment rate is projected to result in an increase of 1.5 percent in payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017 on average, for all LTCHs (Column 6). In addition to the annual update to the LTCH PPS standard Federal payment rate for FY 2017, the estimated increase of 1.5 percent represents an LTCH PPS standard Federal payment rate factor of 1.015 (Table IV also includes estimated payments for SSO cases that will be paid using special methodologies that are not affected by the annual update to the LTCH PPS standard Federal payment rate, as well as the reduction that is applied to the annual update of LTCHs that do not submit the required LTCH QRP data. Therefore, for all hospital categories, the projected increase in payments based on the LTCH PPS standard Federal payment rate to LTCH PPS standard Federal payment rate cases is somewhat less than the 1.75 percent annual update for FY 2017.

For FY 2017, we are updating the wage index values based on the most recent available data, and we are continuing to use labor market areas based on the OMB CBSA delineations (as discussed in section V.B. of the Addendum to this final rule). In addition, we are increasing the labor-related share from 62.0 percent to 66.5 percent under the LTCH PPS standard Federal payment rate (Column 6) and the effect of the estimated decrease in HCO payments for LTCH PPS standard Federal payment rate cases in the labor-related share of operating and capital costs of the 2015-based LTCH market basket (as discussed in section VII.D. of the preamble of this final rule). We also are applying an area wage level budget neutrality factor of 0.999593 to ensure that the changes to the wage data and labor-related share do not result in a change in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases (had the statutory dual rate structure been in effect at the time of the discharge). Therefore, for all hospital categories, the projected increase in payments from FY 2016 to FY 2017 for LTCH PPS standard Federal payment rate cases does not result in a change in estimated aggregate LTCH PPS payments to LTCH PPS standard Federal payment rate cases (had the statutory dual rate structure been in effect at the time of the discharge). Therefore, for all hospital categories, the projected increase in payments from FY 2016 to FY 2017 for LTCH PPS standard Federal payment rate cases is an option in the SSO payment formula (§412.5329). We estimate that these increased SSO payments in FY 2017 will increase total payments for LTCH PPS standard Federal payment rate cases by approximately 0.25 percent. (Payments for SSO cases represent approximately 14 percent of the estimated total FY 2017 payments for LTCH PPS standard Federal payment rate cases).
As discussed in section VII.B.7.h. of the preamble of this final rule, our actuaries project cost and resource changes for site neutral payment rate cases due to the site neutral payment rates required under the statute. Specifically, our actuaries project that the case neutral payment rate for cases paid at the site neutral payment rate will likely be lower, on average, than the costs and resource use for cases paid at the LTCH PPS standard Federal payment rate, and will likely mirror the costs and resource use for IPPS cases assigned to MS-LTC–DRG. While we are able to incorporate this projection at an aggregate level into our payment modeling, because the historical claims data that we are using in this final rule to project estimated FY 2017 LTCH PPS payments (that is, FY 2015 LTCH claims data) do not reflect this actuarial projection, we are unable to model the impact of the change in LTCH PPS payments for site neutral payment rate cases at the same level of detail with which we are able to model the impacts of the changes to LTCH PPS payments for LTCH PPS standard Federal payment rate cases. Therefore, Table IV only reflects changes in LTCH PPS payments for LTCH PPS standard Federal payment rate cases and, unless otherwise noted, the remaining discussion in section I.J.3. of this Appendix refers only to the impact on LTCH PPS payments for LTCH PPS standard Federal payment rate cases. In the following section, we present our provider impact analysis for LTCH PPS payments for LTCH PPS standard Federal payment rate cases.

b. Impact on Providers

Under the dual rate LTCH PPS payment structure, there are two distinct payment rates for LTCH discharges beginning in FY 2016. Under this statutory change, LTCH discharges that meet the patient-level criteria for exclusion from the site neutral payment rate (that is, LTCH PPS standard Federal payment rate cases) are paid based on the LTCH PPS standard Federal payment rate. LTCH discharges paid at the site neutral payment rate are generally paid the lower of the IPPS comparable per diem amount including any applicable HCO payments, or 100 percent of the estimated cost of the case. The statute also establishes a transitional payment method for cases that are paid at the site neutral payment rate for LTCH discharges occurring in cost reporting periods beginning on or after October 1, 2016. Under that statute, any discharges that occur on or after October 1, 2015, but prior to the LTCH’s, but not the 2016 cost reporting period, will be paid at the LTCH PPS standard Federal payment rate. On or after the start of an LTCH’s FY 2017 cost reporting period, discharges are paid based on the nature of the case. As described previously, LTCH PPS standard Federal payment rate cases are defined as LTCH discharges that meet the patient-level criteria to be excluded from the typically lower site neutral payment rate, and site neutral payment rate cases are defined as LTCH discharges that do not meet the patient-level criteria and generally will be paid the lower site neutral payment rate. However, for discharges occurring in cost reporting periods beginning in FY 2016 or 2017, the statute specifies that site neutral payment rate cases assigned to the same transitional payment method that is calculated as 50 percent of the applicable site neutral payment rate amount and 50 percent of the applicable LTCH PPS standard Federal payment rate.

As discussed in section I.J.1. of this Appendix, we project a decrease in aggregate LTCH PPS payments in FY 2017 of approximately $363 million. This estimated decrease reflects the projected increase in payments to LTCH PPS standard Federal payment rate cases of approximately $25 million and the projected decrease in payments to site neutral payment rate cases of approximately $388 million under the dual rate LTCH PPS payment rate structure required by the statute beginning in FY 2016.

For purposes of this impact analysis, to estimate the per discharge payment impacts of our policies on payments for LTCH PPS standard Federal payment rate cases, we simulated FYs 2016 and 2017 payments on a case-by-case basis using historical LTCH claims from the FY 2015 MedPAR files that would have met the criteria for exclusion from the LTCH PPS standard Federal payment rate if the statutory patient-level criteria had been in effect at the time of discharge for those cases. For modeling FY 2016 LTCH PPS payments, we used the FY 2016 standard Federal payment rate of $41,762.85, or $40,941.55 for LTCHs that failed to submit dual rate LTCH PPS payment rate structure, and the resulting LTCH PPS payment amounts will result in appropriate Medicare payments that are consistent with the statute.
quality data as required under the requirements of the LTCH QRP. Similarly, for modeling payments based on the FY 2017 LTCH PPS standard Federal payment rate, we used the FY 2017 standard Federal payment rate of $42,476.41, or $41,641.49 for LTCHs that failed to submit quality data as required under the requirements of the LTCH QRP. In each case, we applied the applicable adjustments for area wage levels and the COLA for LTCHs located in Alaska and Hawaii. Specifically, for modeling FY 2016 LTCH PPS payments, we used the current FY 2016 labor-related share (62.0 percent); the wage index values established in the Tables 12A through 12D listed in the Addendum to the FY 2016 IPPS/LTCHE final rule (which are available via the Internet on the CMS Web site); the FY 2016 HCO fixed-loss amount of LTCH PPS standard Federal payment rate cases of $16,423 (as discussed previously in section V.C. of the Addendum to that final rule) to adjust the FY 2016 nonlabor-related share (38.0 percent) for LTCHs located in Alaska and Hawaii. Similarly, for modeling payments for SSO and HCO cases for LTCH PPS standard Federal payment rate cases, we applied an inflation factor of 4.8 percent (determined by the Office of the Actuary) to update the 2015 costs of each case. The impacts that follow reflect the estimated “losses” or “gains” among the various classifications of LTCHs from FY 2016 to FY 2017 based on the payment rates and policy changes applicable to LTCH PPS standard Federal payment rate cases presented in this final rule. Table IV illustrates the estimated aggregate impact of the change in LTCH PPS payments for LTCH PPS standard Federal payment rate cases among various classifications of LTCHs. (As discussed previously, these impacts do not include LTCH PPS site neutral payment rate cases.)

- The first column, LTCH Classification, identifies the type of LTCH.
- The second column lists the number of LTCHs of each classification type.
- The third column identifies the number of LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria.
- The fourth column shows the estimated FY 2016 payment per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria (as described previously).
- The fifth column shows the estimated FY 2017 payment per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria (as described previously).
- The sixth column shows the percentage change in estimated payments per discharge for LTCH cases expected to meet the LTCH PPS standard Federal payment rate criteria from FY 2016 to FY 2017 due to the annual update to the standard Federal rate (as discussed in section V.A.2. of the Addendum to this final rule).
- The seventh column shows the percentage change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017 for changes to the area wage level adjustment (that is, the wage indexes and the labor-related share), including the application of the area wage level budget neutrality factor (as discussed in section V.B. of the Addendum to this final rule).
### TABLE IV—IMPACT OF PAYMENT RATE AND POLICY CHANGES TO LTCH PPS PAYMENTS FOR STANDARD PAYMENT RATE CASES FOR FY 2017—Continued

[Estimated FY 2016 payments compared to estimated FY 2017 payments]

<table>
<thead>
<tr>
<th>LTCH Classification</th>
<th>Number of LTCHS</th>
<th>Number of LTCH PPS standard Federal payment rate cases</th>
<th>Average FY 2016 LTCH PPS payment per standard payment rate</th>
<th>Average FY 2017 LTCH PPS payment per standard payment rate</th>
<th>Percent change due to increase in estimated payments per discharge for the area wage adjustment</th>
<th>Percent change due to budget neutrality</th>
<th>Percent change due to payment rate changes 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beds: 50–74</td>
<td>119</td>
<td>19,819</td>
<td>48,784</td>
<td>49,127</td>
<td>1.5</td>
<td>0.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Beds: 75–124</td>
<td>48</td>
<td>13,490</td>
<td>49,594</td>
<td>50,141</td>
<td>1.5</td>
<td>0.2</td>
<td>1.1</td>
</tr>
<tr>
<td>Beds: 125–199</td>
<td>23</td>
<td>8,100</td>
<td>47,771</td>
<td>47,179</td>
<td>1.5</td>
<td>0.1</td>
<td>0.9</td>
</tr>
<tr>
<td>Beds: 200+</td>
<td>10</td>
<td>5,162</td>
<td>47,952</td>
<td>48,474</td>
<td>1.5</td>
<td>0.3</td>
<td>1.1</td>
</tr>
</tbody>
</table>

1 Estimated FY 2017 LTCH PPS payments for LTCH PPS standard Federal payment rate criteria based on the payment rate and factor changes applicable to such cases presented in the preamble and the Addendum to this final rule.

2 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017 for the annual update to the LTCH PPS standard Federal payment rate. The temporary exclusion from the site neutral payment rate provided by section 231 of Public Law 114–113 is not reflected in these estimated FY 2017 LTCH PPS payments.

3 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017 for changes to the area wage level adjustment under §412.525(c) (as discussed in section V.B. of the Addendum to this final rule).

4 Percent change in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017 for changes to the area wage level adjustment with budget neutrality (Column 6) due to the effect of changes in both estimated payments to SSO cases that are based on estimated costs and aggregate HCO payments for LTCH PPS standard Federal payment rate cases (as discussed in this impact analysis), as well as other interactive effects that cannot be isolated.

### d. Results

Based on the FY 2015 LTCH cases (from 420 LTCHs) that were used for the analyses in this final rule, we have prepared the following summary of the impact (as shown in Table IV) of the LTCH PPS payment rate and policy changes for LTCH PPS standard Federal payment rate cases presented in this final rule. The impact analysis in Table IV shows that estimated payments per discharge for LTCH PPS standard Federal payment rate cases are expected to increase 0.7 percent, on average, for all LTCHs from FY 2016 to FY 2017 as a result of the payment rate and policy changes applicable to LTCH PPS standard Federal payment rate cases presented in this final rule. This estimated 0.7 percent increase in LTCH PPS payments per discharge was determined by comparing estimated FY 2017 LTCH PPS payments (using the payment rates and factors discussed in this final rule) to estimated FY 2016 LTCH PPS payments for LTCH discharges which will be LTCH PPS standard Federal payment rate cases if the dual rate LTCH PPS payment structure had been in effect at the time of the discharge (as described in section I.J.3. of this Appendix).

As stated previously, we are updating the LTCH PPS standard Federal payment rate for FY 2017 by 1.75 percent based on the estimate of the 2013-based LTCH PPS market basket increase (2.8 percent), the reduction of 0.3 percentage point for the MFP adjustment, and the 0.75 percentage point reduction consistent with sections 1886(m)(3) and (m)(4) of the Act. For LTCHs that fail to submit quality data under the requirements of the LTCH QRR, as required by section 1886(m)(5)(C) of the Act, a 2.0 percentage point reduction is applied to the annual update to the LTCH PPS standard Federal payment rate. As explained earlier in this section, for most categories of LTCHs (as shown in Table IV, Column 6), the estimated payment increase due to the 1.75 percent annual update to the LTCH PPS standard Federal payment rate is projected to result in approximately a 1.5 percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases for all LTCHs from FY 2016 to FY 2017. This is because our estimate of the changes in payments due to the LTCH PPS standard Federal payment rate also reflects estimated payments for SSO cases that are using special methodologies that are not affected by the update to the LTCH PPS standard Federal payment rate.

Consequently, for certain hospital categories, we estimate that payments to LTCH PPS standard Federal payment rate cases may increase by less than 1.75 percent due to the annual update to the LTCH PPS standard Federal payment rate for FY 2017.

(1) Location

Based on the most recent available data, the vast majority of LTCHs are located in urban areas. Only approximately 5 percent of the LTCHs are identified as being located in a rural area, and approximately 3 percent of all LTCH PPS standard Federal payment rate cases are expected to be treated in these rural hospitals. The impact analysis presented in Table IV shows that the overall average percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases is 0.7 percent. For rural LTCHs, the overall percent change for LTCH PPS standard Federal payment rate cases is estimated to be a 0.3 percent increase, while for urban LTCHs, we estimate the increase will be 0.7 percent. Large urban LTCHs are projected to experience an increase of 0.3 percent in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017, which is primarily due to a projected larger than average increase in payments due to the changes to the area wage adjustment. LTCHs that began participating in the Medicare program after October 1, 2002, which treat approximately 41 percent of all LTCH PPS standard Federal payment rate cases, are projected to experience a 0.7 percent increase in estimated payments from FY 2016 to FY 2017.

(2) Participation Date

LTCHs are grouped by participation date into four categories: (1) Before October 1983; (2) between October 1983 and September 1993; (3) between October 1993 and September 2002; and (4) October 2002 and after. Based on the most recent available data, the categories of LTCHs with the largest expected percentage of LTCH PPS standard Federal payment rate cases (approximately 44 percent) are in LTCHs that began participating in the Medicare program between October 1993 and September 2002, and they are projected to experience a 0.7 percent increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017, as shown in Table IV.

Approximately 2.9 percent of LTCHs began participating in the Medicare program before October 1983, and these LTCHs are projected to experience an average percent increase (0.8 percent) in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017, as shown in Table IV. Approximately 10 percent of LTCHs began participating in the Medicare program between October 1983 and September 1993. These LTCHs are projected to experience a larger than average increase (0.9 percent) in estimated payments for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017, which is primarily due to a projected larger than average increase in payments due to the changes to the area wage adjustment. LTCHs that began participating in the Medicare program after October 1, 2002, which treat approximately 41 percent of all LTCH PPS standard Federal payment rate cases, are projected to experience a 0.7 percent increase in estimated payments from FY 2016 to FY 2017.
(3) Ownership Control

LTCHs are grouped into three categories based on ownership control type: Voluntary, proprietary, and government. Based on the most recent available data, approximately 19 percent of LTCHs are identified as voluntary (Table IV). The majority (approximately 77 percent of LTCHs identified as proprietary, while government owned and operated LTCHs represent approximately 4 percent of LTCHs. Based on ownership type, voluntary LTCHs are expected to experience a lower than average increase in payments to LTCH PPS standard Federal payment rate cases of 0.3 percent. Proprietary LTCHs are expected to experience an average increase of 0.8 percent in payments to LTCH PPS standard Federal payment rate cases, while government owned and operated LTCHs are expected to experience a smaller than average increase of 0.5 percent in payments to LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017.

(4) Census Region

Estimated payments per discharge for LTCH PPS standard Federal payment rate cases for FY 2017 are projected to experience no change from FY 2016 for LTCHs located in the East South Central and West North Central regions. LTCHs located in all other regions are projected to experience an increase in estimated payments per discharge in comparison to FY 2016. Of the 9 census regions, we project that the increase in estimated payments per discharge to LTCH PPS standard Federal payment rate cases will have the largest positive impact on LTCHs in the Pacific and Middle Atlantic regions (2.2 percent and 1.4 percent, respectively, as shown in Table IV), which is largely attributable to the changes in the area wage level adjustment.

In contrast, LTCHs located in the South Atlantic and West South Central regions are projected to experience the smallest increase in estimated payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017. The lower than national average estimated increase in payments of 0.2 percent among LTCHs located in the South Atlantic region and 0.4 percent among LTCHs located in the West South Central region is primarily due to estimated decreases in payments associated with the changes to the area wage level adjustment.

(5) Bed Size

LTCHs are grouped into six categories based on bed size: 0–24 beds; 25–49 beds; 50–74 beds; 75–124 beds; 125–199 beds; and 200+ beds categories, will experience a larger than average increase in payments to LTCH PPS standard Federal payment rate cases of 1.1 percent. LTCHs with 25 or more beds but fewer than 50 beds (that is, LTCHs in the 25–49 beds category) are expected to experience a smaller than average increase in payments per discharge for LTCH PPS standard Federal payment rate cases from FY 2016 to FY 2017 (0.4 percent), mostly due to estimated decreases in payments from the area wage level adjustment.

4. Effect on the Medicare Program

As stated previously, we project that the provisions of this final rule will result in an increase in estimated aggregate LTCH PPS payments to LTCH PPS Federal payment rate cases in FY 2017 relative to FY 2016 of approximately $246 million (or approximately 23 percent) for the 420 LTCHs in our database. Although, as stated previously, the hospital-level impacts do not include LTCH PPS site neutral payment rate cases, we estimate that the provisions of this final rule will result in a decrease in estimated aggregate LTCH PPS payments to LTCH PPS site neutral payment rate cases in FY 2017 relative to FY 2016 of approximately $25 million (or approximately 0.7 percent) for the 420 LTCHs in our database. Therefore, we project that the provisions of this final rule will result in a decrease in estimated aggregate LTCH PPS payments to all LTCH cases in FY 2017 relative to FY 2016 of approximately $388 million (or approximately 7.1 percent) for the 420 LTCHs in our database.

5. Effect on Medicare Beneficiaries

Under the LTCH PPS, hospitals receive payment based on the average resources consumed by patients for each diagnosis. We do not expect any changes in the quality of care or access to services for Medicare beneficiaries as a result of this final rule, but we continue to expect that paying prospectively for LTCH services will enhance the efficiency of the Medicare program.  

K. Effects of Requirements for the Hospital Inpatient Quality Reporting (IQR) Program

In section VIII.A of the preamble of this final rule, we discuss our requirements for hospitals to report quality data under the Hospital IQR Program in order to receive the full annual percentage increase for the FY 2019 payment determination.

In section VIII.A.3.b. of the preamble of this final rule, we discuss finalizing our proposals to remove 15 measures: 13 eCQMs (2 of which we are also finalizing to remove in their chart-abstracted form) and 2 structural measures. Our proposal to remove 15 measures, including 13 eCQMs, is based on the modest reduction in burden associated with removing 13 eCQMs from which hospitals may choose to report will be offset by the increased burden associated with submitting data on 8 eCQMs, instead of 4 eCQMs as previously finalized. We also believe that there will be a negligible burden reduction due to the removal of the two structural measures.

Also, we are finalizing refinements to two previously adopted measures: (1) Expanding the population cohort for the Hospital-Level, Risk-Standardized 30-Day Episode-of-Care Payment Measure for Pneumonia; and (2) Patient Safety and Adverse Events Composite Measure. As further explained in section X.B.7. of the preamble of this final rule, we believe no additional burden on hospitals will result from the refinements to these two claims-based measures.

With the finalization of these refinements, we are finalizing our proposals to add four claims-based measures to the Hospital IQR Program measure set beginning with the FY 2019 payment determination: (1) Aortic Aneurysm Procedure Clinical Episode-Based Payment Measure; (2) Carcasscancerectomy and Colorectal Dilatation Procedure Clinical Episode-Based Payment Measure; (3) Spinal Fusion Clinical Episode-Based Payment Measure; and (4) Excess Days in Acute Care after Hospitalization for Pneumonia.
We are finalizing a modified version of our eCQM proposals; instead of requiring hospitals to submit data for all available eCQMs in the Hospital IQR Program measure set for the FY 2019 payment determination and subsequent years as proposed, we are finalizing a measure-based approach. For the FY 2019 payment determination and the FY 2020 payment determination, we are requiring hospitals to submit data for 8 of the available eCQMs included in the Hospital IQR Program measure set for a manner that will permit eligible hospitals to align Hospital IQR Program requirements with some requirements under the Medicare and Medicaid EHR Incentive Programs. Specifically, hospitals will be required to submit a full calendar year of data for 8 eCQMs, on an annual basis, for CY 2017 reporting for the FY 2019 payment determination and CY 2018 reporting for the FY 2020 payment determination, as further explained in section X.B.7. of the preamble of this final rule. We believe that the burden associated with submitting a full year of eCQM data will not be substantially greater than the burden associated with transmission of a single quarter of data. As described in section VII.D. of the preamble of this final rule, the CMS data receiving system requires that each QRDA I file include data for one patient, per quarter, per reporting CCN. Once hospitals establish their protocols to ensure this is maintained, hospitals and vendors should not experience much added burden reporting an additional 3 quarters of data. However, in our conservative estimates here, we calculate as if burden is four times as much in an abundance of caution. In total, we expect that this newly finalized proposal will increase burden by 15,400 hours across all hospitals participating in the Hospital IQR Program. This figure was derived by calculating the difference between the FY 2017 burden estimate of 17,600 hours (80 minutes per record/60 minutes per hour × 4 reporting quarters per year × 1 record per hospital per quarter × 3,300 hospitals) and the FY 2016 burden estimate of 2,200 hours (20 minutes per record/60 minutes per hour × 1 reporting quarter per year × 1 record per hospital per quarter × 3,300 hospitals) (80 FR 49763), for an incremental increase of 15,400 hours.

As we noted in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49763), for validation of chart-abstracted data, we require hospitals to provide 72 charts per hospital per year (with an average page length of 1,500), including 40 charts for HAI validation and 32 charts for clinical process of care validation, for a total of 108,000 pages per hospital per year. We reimburse hospitals at 12 cents per photocopied page for a total per hospital cost of $12,960. For hospitals providing charts digitally via a re-writable disc, such as encrypted CD–ROMs, DVDs, or flash drives, we will reimburse hospitals at a rate of 40 cents per disc, and additionally hospitals will be reimbursed at a rate of $3.00 per record. For hospitals providing charts via secure file transfer, we will reimburse hospitals at a rate of $3.00 per record. We will maintain these requirements for the FY 2019 payment determination and subsequent years.

In this final rule, we are expanding the existing validation process for Hospital IQR Program data to include a random sample of up to 200 hospitals for validation of eCQMs in the Hospital IQR Program. As further explained in section X.B.7. of the preamble of this final rule, we estimate that 43 hours of work for up to 200 hospitals reflects a total burden increase of 8,553 labor hours. We estimate an hourly labor cost of $32.84. Therefore, we estimate a cost increase of $280,224 ($5,333 additional burden hours × $32.84 per hour) across the up to 200 hospitals selected for eCQM validation, on an annual basis.

Finally, we are updating our Extraordinary Circumstances Extensions or Exemptions (ECE) policy. We believe the updates will have no effect on burden for hospitals.

Historically, 100 hospitals, on average, that participate in the Hospital IQR Program do not receive the full annual percentage increase in any fiscal year due to the requirements of this program. We anticipate that, because of the new requirements for reporting we are finalizing for the FY 2019 payment determination, the number of hospitals not receiving the full annual percentage increase may be higher than at average. At this time, information is not available to determine the precise number of hospitals that will not meet the requirements to receive the full annual percentage increase for the FY 2019 payment determination. If the number of hospitals failing to receive the full annual percentage increase does increase because of the new requirements, we anticipate that, over the long run, this number will decline as hospitals gain more experience with these requirements.

UnderOMB number 0938–1022, considering the newly finalized policies above, we estimate a total burden decrease of 1,717,444 hours, at a total cost decrease of approximately $56.4 million across approximately 3,300 hospitals participating in the Hospital IQR Program for the FY 2019 payment determination. In implementing the Hospital IQR Program and other quality reporting programs, we have focused on measures that have high impact and support CMS and HHS priorities for improved quality and efficiency of care for Medicare beneficiaries.

L. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality Reporting Program (PCHQR) Program

In section VIII.B. of the preamble of the proposed rule (81 FR 25213) and this final rule, we discuss our policies for the quality data reporting program for PPS-exempt cancer hospitals (PCHs), which we refer to as the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program. The PCHQR Program is authorized under section 1866(k) of the Act, which was added by section 3004(a) of the Affordable Care Act. Section 1886(m)(5) of the Act provides that, for rate year 2014 and each subsequent year, any LTCH that does not submit data to the Secretary in accordance with section 1886(m)(5)(C) and (F) of the Act shall receive a 2 percentage point reduction to the annual update to the standard Federal rate for discharges for the hospital during the applicable fiscal year.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49838 through 49839), we estimated that only a few LTCHs will not receive the full annual percentage increase in any fiscal year as a result of failure to submit data under the LTCH QRP. There are approximately 422 LTCHs currently reporting quality data to CMS. At the time that this analysis was prepared, 39, or approximately 9.5 percent, of 412 eligible LTCHs were determined to be noncompliant and therefore received a 2 percentage point reduction to their FY 2016 annual payment update.

The impact of the newly finalized requirements for the PCHQR Program is expected to be minimal overall since beginning with Q1 2016 events, PCHs have been reporting Clinical Process/Oncology Care Measures using a sampling methodology which requires reporting no more than 25 cases per facility (79 FR 28259). As the measure cohort expands, the Radiation Dose Limits to Normal Tissues (NQF #0382) does not expand the maximum required sample, we do not anticipate that this cohort expansion will significantly impact the operational burden for PCHs.

In the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure is a claims-based measure and, therefore, poses no additional burden for PCHs to submit data beyond that which they currently submit as part of the claims process.

One expected effect of the PCHQR Program is to keep the public informed of the quality of care provided by PCHs. We will display publicly the quality measures applicable to PCHs under the PCHQR Program as required under the Act. These data will be displayed on the Hospital Compare Web site. The goals of making these data available to the public in a user-friendly and relevant format include: (1) Allowing the public to compare PCHs in order to make informed health care decisions regarding care setting; and (2) providing information about current trends in health care. Furthermore, PCHs can use their own health care quality data for many purposes such as in risk management programs, healthcare associated infection prevention programs, and research and development activities, among others.

M. Effects of Requirements for the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) for the FY 2018 Payment Determination and Subsequent Years

In section VIII.C.1. of the preambles of the proposed rule (81 FR 25213) and this final rule, we discuss the implementation of section 1866(m)(5) of the Act, which was added by section 3004(a) of the Affordable Care Act. Section 1886(m)(5) of the Act provides that, for rate year 2014 and each subsequent year, any LTCH that does not submit data to the Secretary in accordance with section 1886(m)(5)(C) and (F) of the Act shall receive a 2 percentage point reduction to the annual update to the standard Federal rate for discharges for the hospital during the applicable fiscal year.

In the FY 2016 IPPS/LTCH PPS final rule (80 FR 49838 through 49839), we estimated that only a few LTCHs will not receive the full annual percentage increase in any fiscal year as a result of failure to submit data under the LTCH QRP. There are approximately 422 LTCHs currently reporting quality data to CMS. At the time that this analysis was prepared, 39, or approximately 9.5 percent, of 412 eligible LTCHs were determined to be noncompliant and therefore received a 2 percentage point reduction to their FY 2016 annual payment update.

The impact of the newly finalized requirements for the LTCH QR Program is expected to be minimal overall since beginning with Q1 2016 events, LTCHs have been reporting Clinical Process/Oncology Care Measures using a sampling methodology which requires reporting no more than 25 cases per facility (79 FR 28259). As the measure cohort expands, the Radiation Dose Limits to Normal Tissues (NQF #0382) does not expand the maximum required sample, we do not anticipate that this cohort expansion will significantly impact the operational burden for LTCHs.

In the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy measure is a claims-based measure and, therefore, poses no additional burden for LTCHs to submit data beyond that which they currently submit as part of the claims process. We believe the updates will have no effect on burden for LTCHs.

One expected effect of the LTCH QRP Program is to keep the public informed of the quality of care provided by LTCHs. We will display publicly the quality measures applicable to LTCHs under the LTCH QRP Program as required under the Act. These data will be displayed on the Hospital Compare Web site. The goals of making these data available to the public in a user-friendly and relevant format include: (1) Allowing the public to compare LTCHs in order to make informed health care decisions regarding care setting; and (2) providing information about current trends in health care. Furthermore, LTCHs can use their own health care quality data for many purposes such as in risk management programs, healthcare associated infection prevention programs, and research and development activities, among others.
Information is not available to determine the precise number of LTCHs that will not meet the requirements to receive the full annual percentage increase for the FY 2017 payment determination.

We believe that a majority of LTCHs will continue to submit data for the FY 2017 payment determination and subsequent years because they will continue to view the LTCH QRP as an important step in improving the quality of care patients receive in the LTCHs. We believe that the burden associated with the LTCH QRP is the time and effort associated with data collection.

Currently, LTCHs use two separate data collection mechanisms to report quality data to CMS: The CDC’s NHSN, which is used to report all Healthcare Associated Infections (HAI) (CAUTI, CLABSI, MRSA Bacteremia, CDI, VAE) and vaccination data, (Influenza Vaccination Coverage Among Healthcare Personnel measure); and the LTCH CARE Data Set, which is submitted to the QIES ASAP system.

The data collection burden associated with reporting quality measures via the CDC’s NHSN is discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49838 through 49839). These measures are stewarded by the CDC, and the reporting burden is approved under OMB control number 0920–0666.

The All-Cause Unplanned Readmission Measure for 30 Days Post-Discharge from Long-Term Care Hospitals (NQF #2512) measure is calculated based on Medicare FFS claims data, and therefore does not have any associated burden for LTCHs.

The remaining assessment-based quality measure data are reported to CMS by LTCHs using the LTCH CARE Data Set. As of April 1, 2016, LTCHs use the LTCH CARE Data Set Version 3.00 (approved under OMB control number 0920–0666) which includes data elements related to the following quality measures: Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (NQF #0078), Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680), Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674); Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631); Application of Percent of Long-Term Care Hospital Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631); and Functional Outcome Measure: Change in Mobility Among Long-Term Care Hospital Patients Requiring Ventilator Support (NQF #2632).

In this final rule, we are retaining 13 previously finalized quality measures and are adding 4 measures for use in the LTCH QRP.

In the preamble of this final rule, we are finalizing our proposals to add three measures for the FY 2018 payment determination and subsequent years: (1) MSPB–PAC LTCH QRP; (2) Discharge to Community–PAC LTCH QRP; and (3) Potentially Preventable 30-Day Post-Discharge Readmission Measure for the PAC LTCH QRP. These three measures are Medicare claims-based measures, and because claims-based measures can be calculated based on data that are already reported to the Medicare program for payment purposes, we believe there will be no additional burden for any of these newly finalized measures.

In section VIII.C.9.d. of the preamble of this final rule, we are finalizing our proposal to expand the data collection timeframe for the measure Percent of Residents or Patients Who Were Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) (77 FR 53624 through 53627), beginning with the FY 2019 payment determination. The data collection time frame and associated data submission deadlines are currently aligned with the Influenza Vaccination Season (IVS) (October 1 of a given year through March 31 of the subsequent year), and only require data collection during the two calendar year quarters that align with the IVS. We are finalizing this modification to the data collection timeframe from just two quarters (covering the IVS) to a full four quarters or 12 months.

We refer readers to section VII.C.9.d. of the preamble of this final rule for further details on the expansion of the data collection for this measure. Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) including data collection timeframes and associated submission deadlines. We originally finalized this measure for use in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53624 through 53627). Although we finalized data collection for this measure to coincide with the IVS, we originally proposed year-round data collection. The associated PRA package, which was approved under OMB control number 0920–0666, included burden calculations that aligned with our original proposal for year-round data collection. All subsequent PRA packages, and the PRA package that is currently under review by OMB, included burden calculations reflecting year-round data collection for this measure. Because of this, the newly finalized change in the data collection timeframe for this measure, and any associated burden related to increased data collection, has already been accounted for in the total burden figures included in this section of the preamble of this final rule.

In section VIII.C.7. of the preamble of this final rule, we are finalizing our proposal to adopt one measure for the FY 2020 payment determination and subsequent years: Drug Regimen Review Conducted with Follow-Up for Identified Issues- PAC LTCH QRP. In addition, we are finalizing our proposal that data for this measure will be collected and reported using the LTCH CARE Data Set Version 4.00 (effective April 1, 2018).

While reporting quality measure data involves costs associated with data collection, we believe that the burden associated with modifications to the LTCH CARE Data Set discussed in this final rule fall under the PRA exceptions provided in section 1899B(m) of the Act. Section 1899B(m) of the Act, which was added by the IMPACT Act, states that the PRA requirements do not apply to section 1899B of the Act and the sections referenced in section 1899B(a)(2)(B) of the Act that require modifications in order to achieve standardized patient assessment data. However, the PRA requirements and burden estimates will be submitted to OMB for review and approval when modifications to the LTCH CARE Data Set or other applicable PAC assessment instruments are not used to achieve standardized patient assessment data.

In the FY 2016 IPPS/LTCH PPS final rule (81 FR 49838 through 49840), we discussed burden estimates for the 13 previously finalized quality measures which we are retaining in this final rule using the LTCH CARE Data Set Version 2.01. Based on a revised PRA package for the LTCH CARE Data Set Version 3.00, we estimate the total cost for the previously finalized assessment-based measures was $13,929 per LTCH annually or $6,017,146 for all LTCHs annually. In addition, we estimate that the cost to report the previously finalized quality measures via the CDC’s NHSN was $4,190 per LTCH annually or $4,706,857 for all LTCHs annually. The revised total estimate for all 13 previously finalized measures was $24,825 per LTCH annually or $10,724,003 for all LTCHs annually. The two estimates discussed above, as well as the comprehensive estimate discussed below, include overhead; however, obtaining data on other overhead costs is challenging.

Overhead costs vary greatly across industries and firm sizes. In addition, the precise cost elements assigned as “indirect” or “overhead” costs, as well as direct costs or employee wages, are subject to some interpretation at the firm level. Therefore, we have chosen to calculate the cost of overhead at 100 percent of the mean hourly wage. This is necessarily a rough adjustment, both because fringe benefits and overhead costs vary significantly from employer to employer and because methods of estimating these costs vary widely from study to study. Nonetheless, there is no practical alternative, and we believe that doubling the hourly wage to estimate total costs is a reasonably accurate estimation method.

Because we are finalizing our proposal to add the Drug Regimen Review Conducted with Follow-Up for Identified Issues- PAC LTCH QRP measure in the LTCH CARE Data Set Version 4.00, the estimated burden and cost will increase. The additional data elements for this quality measure will take 6 minutes of nursing/clinical staff time to report data on admission and 4 minutes of nursing/clinical staff time to report data on discharge, for a total of 10 minutes. We believe that the additional LTCH CARE Data Set items we are newly finalizing will be completed by registered nurses and pharmacists. As a result, we estimate that the total cost related to the newly finalized Drug Regimen Review Conducted with Follow-Up for Identified Issues- PAC LTCH QRP measure will be $3,080 per LTCH annually, or $1,330,721 for all LTCHs annually. Because the three measures newly finalized in section VII.C.6. of the preamble of this final rule are claims-based and will be calculated based on data that are already reported to the Medicare program for payment purposes, we believe
that there will be no additional LTCH burden for any of these newly finalized measures.

Overall, we estimate the total cost for the 13 previously adopted measures and the 4 newly finalized measures will be $27,905 per LTCH annually or $12,054,724 for all LTCHs annually. This is an average increase of 14 percent to all LTCHs over the burden discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49838 through 49840), which included all quality measures that LTCHs are required to report under the LTCH QRP, with the exception of those 4 newly finalized measures in this final rule.

We intend to continue to closely monitor the effects of the LTCH QRP on LTCHs and help facilitate successful reporting outcomes through ongoing stakeholder education, national trainings, LTCH announcements, Web site postings, CMS Open Door Forums, and general and technical help desks.

We received comments about the effects of requirements for the LTCH QRP, which we summarize and respond to below.

Response: Burden on providers is always a consideration for CMS, and we take this into account when developing quality measures for inclusion into our quality reporting programs. When developing new measures, we try to leverage existing data items whenever possible, and only include new items in existing data sets, when necessary to inform the calculation of these metrics. We will continue to take these and future stakeholder inputs into consideration to inform our ongoing measure development and refinement efforts.

Comment: One commenter expressed concerns over the burden associated with the development of new measures, data-collection and operational and technical data extraction. The commenter suggested that any of the quality reporting or pay-for-performance programs weigh the value of the data generated in proportion to the intensity of the data-collection effort and that the data be the most clinically relevant and actionable to the facility and its patients.

Response: Burden on providers is always a consideration for CMS, and we take this into account when developing quality measures for inclusion into our quality reporting programs. When developing new measures, we try to leverage existing data items whenever possible, and only include new items in existing data sets, when necessary to inform the calculation of these metrics. We will continue to take these and future stakeholder inputs into consideration to inform our ongoing measure development and refinement efforts.

One commenter expressed concerns about the complexities of the LTCH CARE Data Set transmittal process and associated costs implementing the LTCH CARE Data Set Version 4.00, effective April 1, 2018 after implementation of LTCH CARE Data Set Version 3.00.

Response: We thank the commenter for its comment and consider the data transmittal process and associated cost burden as we develop the LTCH CARE Data Set Version 4.00. We have leveraged CMS claims as the data source, whenever possible and appropriate for newly introduced measures, in order to limit the burden on LTCHs. In addition, when possible, we leverage existing data elements, again in an attempt to limit burden. Beyond this, we offer free software for LTCHs (LASER), allowing LTCHs to record and transmit the required LTCH CARE Data Set assessment based data. This free software, including instructions for installing and using the software, is located at: https://www.nqso.com/laser.html.

N. Effects of Updates to the Inpatient Psychiatric Facility Quality Reporting (IPFQR) Program

As discussed in section VIII.D. of the preamble of the proposed rule (81 FR 25238 through 25244) and this final rule and in accordance with section 1866(s)(4)(A)(i) of the Act, we will implement a 2.0 percentage point reduction in the FY 2019 market basket update for IPFs that have failed to comply with the IPFQR Program requirements for FY 2019, including reporting on the required measures. In section VIII.D. of the preamble of this final rule, we discuss how the 2 percentage point reduction would be applied. For FY 2016, of the 1,684 IPFs eligible for the IPFQR Program, 51 did not receive the full market basket update because of the IPFQR Program; 24 of these IPFs chose not to participate and 27 did not meet the requirements of the program. We anticipate that even fewer IPFs will receive the reduction for FY 2017 as IPFs become more familiar with the requirements. Thus, we estimate that this policy will have a negligible impact on overall IPF payments for FY 2017.

Based on the proposals we are finalizing in this final rule, we estimate a total increase in burden due to the newly finalized addition of a chart-abstracted measure set of 212 hours per IPF or 357,008 hours across all IPFs, resulting in a total increase in financial burden of approximately $6,962 per IPF or $11,724,143 across all IPFs. We also are finalizing that we will make the data for the IPFQR Program available as soon as possible and to no longer specify in rulemaking when measure data will be functionally available, when the approximately 30-day preview period will occur, or that the preview period will begin approximately 12 weeks before the public display date, but rather to announce these using subregulatory guidance. Lastly, for the FY 2017 payment determination only, we also are finalizing our proposal that, if it is technically feasible to display the data in December 2016, we will provide data to IPFs for a 2-week preview period that will start on October 1, 2016. Moreover, we are finalizing that, for the proposed FY 2017 payment determination only, if we are able to display the data in December 2016, we will ensure that IPFs have approximately 30 days for review if they choose by providing IPFs with their data as early as mid-September. However, we do not expect this will change the burden on IPFs.

In addition, we are finalizing our proposal to update the denominator exclusions for Screening for Metabolic Disorders to align with other measures eligible for the global sample. As this will not alter the number of cases that facilities are required to report on, we do not anticipate a change in IPF burden. We also estimate a total increase in burden for training personnel on chart abstraction and data collection for the newly finalized measures of 2 hours per IPF or 3,368 hours across all IPFs, resulting in a total increase in financial burden of $65.68 per IPF or $11,605 across all IPFs. Our estimate of the total increase in burden, including the newly finalized chart-abstracted measure set and training, is $360,376 hours across all IPFs, which at $32.84 labor cost per hour, totals $11,834,748.

As discussed in section X.B.11. of the preamble of this final rule, we will attribute the costs associated with the newly finalized policies to the year in which these costs begin; for the purposes of all the changes made in this final rule, that year is FY 2017. Further information on these estimates can be found in section X.B.11. of the preamble of this final rule.

We intend to closely monitor the effects of this quality reporting program on IPFs and help facilitate successful reporting outcomes through ongoing stakeholder education, national trainings, and a technical help desk.

O. Effects of Requirements Regarding the Electronic Health Record (EHR) Incentive Programs and Meaningful Use

As discussed in section VIII.E. of the preamble of the proposed rule (81 FR 25244 through 25247) and this final rule, we discuss requirements for the Medicare and Medicaid EHR Incentive Programs. For CY 2017, we are finalizing the proposed CQM reporting period requirements pertaining to the Medicare and Medicaid EHR Incentive Programs; the number of CQMs eligible hospitals and CAHs are required to report by attestation; the removal of 13 CQMs from the set of CQMs available for eligible hospitals and CAHs to report; and the policy determining that the electronic submission of CQMs will require a new version of the CQM electronic specification for each CQM to which the EHR is certified. In addition, we are finalizing a modified version of our proposed submission period requirements and the number of CQMs eligible hospitals and CAHs are required to report electronically for CY 2017. We note that these requirements will only apply for eligible hospitals and CAHs submitting CQMs electronically in CY 2017. Because these requirements for data collection will align with the reporting requirements in place for the Hospital IQR Program and because eligible hospitals and CAHs will still have the option to submit their clinical quality measures via attestation for the Medicare and Medicaid EHR Incentive Programs, we do not believe these requirements will have a significant impact.

P. Alternatives Considered

This final rule contains a range of policies. It also provides descriptions of the statutory provisions that are addressed, identifies the finalized policies, and presents rationales for
our decisions and, where relevant, alternatives that were considered.

Q. Overall Conclusion
1. Acute Care Hospitals

Table 1 of section I.G. of this Appendix demonstrates the estimated distributional impact of the IPPS budget neutrality requirements for the MS-DRG and wage index changes, and for the wage index reclassifications under the MGCRB. Table I also shows a projected overall increase of 0.9 percent in operating payments. As discussed in section I.G. of this Appendix, we estimate that operating payments will increase by approximately $987 million in FY 2017 relative to FY 2016. However, when we account for the impact of the changes in Medicare DSH payments and the impact of the additional payments based on uncompensated care in accordance with section 3133 of the Affordable Care Act, based on estimates provided by the CMS Office of the Actuary, consistent with our policy discussed in section IV.F. of the preamble of this final rule, we estimate that operating payments will increase by approximately $809 million relative to FY 2016. We currently estimate that the changes in new technology add-on payments for FY 2017 will decrease spending by approximately $20 million. In addition, the changes to the Hospital Readmissions Reduction Program for FY 2017 are estimated to decrease spending by $108 million, as a result of the inclusion of the refinement to the pneumonia readmissions measure that expanded the measure to CABG, along with the addition of the CABG readmission measure, in the calculation of the FY 2017 payment adjustment factor. These estimates, combined with our estimated increase in FY 2017 operating payment of $809 million, will result in an estimated increase of approximately $680 million for FY 2017. We estimate that hospitals will experience a 0.8 percent increase in capital payments per case, as shown in Table III of section I.I. of this Appendix. We project that there will be a $66 million increase in capital payments in FY 2017 compared to FY 2016. The cumulative operating and capital payments will result in a net increase of approximately $746 million to IPPS providers. The discussions presented in the previous pages, in combination with the rest of this final rule, constitute a regulatory impact analysis.

2. LTCHs

Overall, LTCHs are projected to experience a decrease in estimated payments per discharge in FY 2017. In the impact analysis, we are using the rates, factors, and policies presented in this final rule, including updated wage index values and relative weights, and the best available claims and CCR data to estimate the change in payments under the LTCH PPS for FY 2017. Accordingly, based on the best available data for the 420 LTCHs in our database, we estimate that FY 2017 LTCH PPS payments will decrease approximately $363 million relative to FY 2016 as a result of the payment rates and factors presented in this final rule.

II. Accounting Statements and Tables

A. Acute Care Hospitals

As required by OMB Circular A–4 (available at http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf), in the following Table V, we have prepared an accounting statement showing the classification of the expenditures associated with the provisions of this final rule as they relate to acute care hospitals. This table provides our best estimate of the change in Medicare payments to providers as a result of the changes to the IPPS presented in this final rule. All expenditures are classified as transfers to Medicare providers. The costs to the Federal Government associated with the policies in this final rule are estimated at $746 million.

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>$746 million.</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to IPPS Medicare Providers.</td>
</tr>
</tbody>
</table>

B. LTCHs

As discussed in section I.J. of this Appendix, the impact analysis of the payment rates and factors presented in this final rule under the LTCH PPS is projected to result in a decrease in estimated aggregate LTCH PPS payments in FY 2017 relative to FY 2016 of approximately $363 million based on the data for 420 LTCHs in our database that are subject to payment under the LTCH PPS. Therefore, as required by OMB Circular A–4 (available at http://www.whitehouse.gov/omb/circulars/a004/a-4.pdf), in Table VI, we have prepared an accounting statement showing the classification of the expenditures associated with the provisions of this final rule as they relate to the changes to the LTCH PPS. Table VI provides our best estimate of the estimated change in Medicare payments under the LTCH PPS as a result of the payment rates and factors and other provisions presented in this final rule based on the data for the 420 LTCHs in our database. All expenditures are classified as transfers to Medicare providers (that is, LTCHs). The savings to the Federal Government associated with the policies for LTCHs in this final rule are estimated at $363 million.

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>$363 million.</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to LTCH Medicare Providers.</td>
</tr>
</tbody>
</table>

III. Regulatory Flexibility Act (RFA) Analysis

The RFA requires agencies to analyze options for regulatory relief of small entities. For purposes of the RFA, small entities include small businesses, nonprofit organizations, and small government jurisdictions. We estimate that most hospitals and most other providers and suppliers are small entities as that term is used in the RFA. The great majority of hospitals and most other health care providers and suppliers are small entities, either by being nonprofit organizations or by meeting the SBA definition of a small business (having revenues of less than $7.5 million to $38.5 million in any 1 year). (For details on the latest standards for health care providers, we refer readers to page 30 of the Table of Small Business Size Standards for NAIC 622 found on the SBA Web site at: http://www.sba.gov/sites/default/files/files/Size_Standards_Table.pdf.) For purposes of the RFA, all hospitals and other providers and suppliers are considered to be small entities. Individuals and States are not included in the definition of a small entity. We believe that the provisions of this final rule relating to acute care hospitals will have a significant impact on small entities as explained in this Appendix. Because we lack data on individual hospital receipts, we cannot determine the number of small proprietary LTCHs. Therefore, we are assuming that all LTCHs are considered small entities for the purpose of the analysis in section I.J. of this Appendix. MACs are not considered to be small entities. Because we acknowledge that many of the affected
entities are small entities, the analysis discussed throughout the preamble of this final rule constitutes our regulatory flexibility analysis. In the FY 2017 IPPS/LTCH PPS proposed rule, we solicited public comments on our estimates and analysis of the impact of our proposals on those small entities. Any public comments that we received and our responses are presented throughout this final rule.

IV. Impact on Small Rural Hospitals

Section 1102(b) of the Social Security Act requires us to prepare a regulatory impact analysis for any proposed or final rule that may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section 1102(b) of the Act, we define a small rural hospital as a hospital that is located outside of an urban area and has fewer than 100 beds. Section 603(g) of the Social Security Amendments of 1983 (Pub. L. 98–21) designated hospitals in certain New England counties as belonging to the adjacent urban area. Thus, for purposes of the IPPS and the LTCH PPS, we continue to classify these hospitals as urban hospitals. (We refer readers to Table I in section I.G. of this Appendix for the quantitative effects of the policy changes under the IPPS for operating costs.)

V. Unfunded Mandates Reform Act Analysis

Section 202 of the Unfunded Mandates Reform Act of 1995 (Pub. L. 104–4) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. In 2016, that threshold level is approximately $146 million. This final rule will not mandate any requirements for State, local, or tribal governments, nor will it affect private sector costs.

VI. Executive Order 12866

In accordance with the provisions of Executive Order 12866, the Executive Office of Management and Budget reviewed this final rule.

Appendix B: Recommendation of Update Factors for Operating Cost Rates of Payment for Inpatient Hospital Services

I. Background

Section 1886(e)(4)(A) of the Act requires that the Secretary, taking into consideration the recommendations of MedPAC, recommend update factors for inpatient hospital services for each fiscal year that take into account the amounts necessary for the efficient and effective delivery of medically appropriate and necessary care of high quality. Under section 1886(e)(5) of the Act, we are required to publish update factors recommended by the Secretary in the proposed and final IPPS rules, respectively. Accordingly, this Appendix provides the recommendations for the update factors for the IPPS national standardized amount, the hospital-specific rate for SCHs and MDHs, and the rate-of-increase limits for certain hospitals excluded from the IPPS, as well as LTCHs. In prior years, we have made a recommendation in the proposed rule and final rule for the update factors for the payment rates for IRFs and IPFs. However, for FY 2017 consistent with approach for FY 2016, we are including the Secretary’s recommendation for the update factors for IRFs and IPFs in separate Federal Register documents at the time that we announce the annual updates for IRFs and IPFs. We also discuss our response to MedPAC’s recommended update factors for inpatient hospital services.

II. Inpatient Hospital Update for FY 2017

A. FY 2017 Inpatient Hospital Update

As discussed in section IV.B. of the preamble to this final rule, for FY 2017, consistent with section 1886(b)(3)(B) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act, we are setting the applicable percentage increase by applying the following adjustments in the following sequence. Specifically, the applicable percentage increase under the IPPS is equal to the rate-of-increase in the hospital market basket for IPPS hospitals in all areas, subject to a reduction of one-quarter of the applicable percentage increase (prior to the application of other statutory adjustments; also referred to as the market basket update or rate-of-increase (with no adjustments)) for hospitals that fail to submit quality information under rules established by the Secretary in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that is not a meaningful EHR user). Under section 1886(b)(3)(B)(v) of the Act, as amended by section 3401(a) of the Affordable Care Act, as discussed in section IV.B. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25077), we proposed a multifactor productivity (MFP) adjustment (the 10-year moving average of MFP for the period ending FY 2017) of 0.5 percent. Therefore, based on IGI’s first quarter 2016 forecast of the FY 2010-based IPPS market basket rate-of-increase with historical data through first quarter 2016, which is estimated to be 2.7 percent.

In accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, in section IV.B. of the preamble of the FY 2017 IPPS/LTCH PPS proposed rule (81 FR 25077), we proposed a multifactor productivity (MFP) adjustment (the 10-year moving average of MFP for the period ending FY 2017) of 0.5 percent. Therefore, based on IGI’s first quarter 2016 forecast of the FY 2010-based IPPS market basket, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act (hereafter referred to as a hospital that submits quality data) and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act (hereafter referred to as a hospital that is a meaningful EHR user), we presented in the proposed rule four possible applicable percentage increases that could be applied to the standardized amount. Based on the most recent data available for this FY 2017 IPPS/LTCH PPS final rule, in accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, in section IV.B. of the preamble of this final rule, we are establishing a MFP adjustment (the 10-year moving average of MFP for the period ending FY 2017) of 0.3 percent.

In accordance with section 1886(b)(3)(B) of the Act, as amended by section 3401(a) of the Affordable Care Act, as discussed in section IV.B. of the preamble of this final rule, we are establishing the applicable percentage increases for the FY 2017 updates based on IGI’s second quarter 2016 forecast of the FY 2010-based IPPS market basket, depending on whether a hospital submits quality data under the rules established in accordance with section 1886(b)(3)(B)(viii) of the Act and is a meaningful EHR user under section 1886(b)(3)(B)(ix) of the Act, as outlined in the table below.
Section 886(b)(3)(B)(iv) of the Act provides that the FY 2017 applicable percentage increase in the hospital-specific rate for SCHs and MDHs equals the applicable percentage increase set forth in section 886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS).

As discussed in section IV.N. of the preamble of this final rule, section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114–10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

As previously mentioned, the update to the hospital-specific rate for SCHs and MDHs is subject to section 886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, depending on whether a hospital submits quality data and is a meaningful EHR user, we are establishing the same four possible applicable percentage increases in the table above for the hospital-specific rate applicable to SCHs and MDHs.

### B. Update for SCHs and MDHs for FY 2017

Section 886(b)(3)(B)(iv) of the Act provides that the FY 2017 applicable percentage increase in the hospital-specific rate for SCHs and MDHs equals the applicable percentage increase set forth in section 886(b)(3)(B)(i) of the Act (that is, the same update factor as for all other hospitals subject to the IPPS).

As discussed in section IV.N. of the preamble of this final rule, section 205 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) (Pub. L. 114–10, enacted on April 16, 2015) extended the MDH program (which, under previous law, was to be in effect for discharges on or before March 31, 2015 only) for discharges occurring on or after April 1, 2015, through FY 2017 (that is, for discharges occurring on or before September 30, 2017).

As previously mentioned, the update to the hospital-specific rate for SCHs and MDHs is subject to section 886(b)(3)(B)(i) of the Act, as amended by sections 3401(a) and 10319(a) of the Affordable Care Act. Accordingly, depending on whether a hospital submits quality data and is a meaningful EHR user, we are establishing the same four possible applicable percentage increases in the table above for the hospital-specific rate applicable to SCHs and MDHs.

### C. FY 2017 Puerto Rico Hospital Update

As discussed in section IV.A. of the preamble of this final rule, prior to January 1, 2016, Puerto Rico hospitals were paid based on 75 percent of the national standardized amount and 25 percent of the Puerto Rico-specific standardized amount. Section 601 of Public Law 114–113 amended section 1886(d)(9)(E) of the Act to specify that the payment calculation with respect to operating costs of inpatient hospital services of a subsection (d) Puerto Rico hospital for inpatient hospital discharges on or after January 1, 2016, shall use 100 percent of the national standardized amount. Because Puerto Rico hospitals are no longer paid with a Puerto Rico-specific standardized amount under the amendments to section 886(d)(9)(E) of the Act, there is no longer a need for us to make an update to the Puerto Rico standardized amount. Hospitals in Puerto Rico are now paid 100 percent of the national standardized amount and, therefore, are subject to the same update to the national standardized amount discussed under section IV.B.1. of the preamble of this final rule. Accordingly, for FY 2017, we are establishing an applicable percentage increase of 1.65 percent to the standardized amount for hospitals located in Puerto Rico.

### D. Update for Hospitals Excluded From the IPPS for FY 2017

Section 886(b)(3)(B)(ii) of the Act is used for purposes of determining the percentage increase in the rate-of-increase limits for children’s hospitals, cancer hospitals, and hospitals located outside the 50 States, the District of Columbia, and Puerto Rico (that is, short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and America Samoa). Section 886(b)(3)(B)(ii) of the Act sets the percentage increase in the rate-of-increase limits equal to the market basket percentage increase. In accordance with § 403.752(a) of the regulations, RNCIs are paid under the provisions of § 413.40, which also use section 886(b)(3)(B)(ii) of the Act to update the percentage increase in the rate-of-increase limits.

Currently, children’s hospitals, PPS-excluded cancer hospitals, RNCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa are among the remaining types of hospitals still paid under the reasonable cost methodology, subject to the rate-of-increase limits. As we finalized in the FY 2015 IPPS/LTCH PPS final rule (79 FR 50156 through 50157), we are applying the FY 2017 percentage increase in the IPPS operating market basket to the target amount for children’s hospitals, PPS-excluded cancer hospitals, RNCIs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa. For this final rule, the current FY 2017 estimate of the market basket rate-of-increase of 2.8 percent less an adjustment of 0.3 percentage point for MFP and less 0.75 percentage point, which is 0.75 percent point. Based on the most recent data available for this final rule, that is, IGIs second quarter 2016 forecast of the FY 2017 LTCH PPS market basket increase, we are establishing an annual update to the LTCH PPS Federal rate by 1.75 percent (that is, the current FY 2017 estimate of the market basket rate-of-increase of 2.8 percent less an adjustment of 0.3 percentage point for MFP and less 0.75 percentage point). Accordingly, we are applying an update factor of 1.0175 percent in determining the LTCH PPS standard Federal rate for FY 2017. For LTCHs that fail to submit quality data for FY 2017, we are applying an annual update to the LTCH PPS Federal rate by 0.25 percent (that is, the annual update for FY 2017 of 1.75 percent less an adjustment of 0.75 percentage points for failure to submit the required quality data in accordance with section 1886(m)(5) of the Act and our rules) by applying an update factor of 0.9975 percent in determining the LTCH PPS standard Federal rate for FY 2017.

### III. Secretary’s Recommendations

MedPAC is recommending an inpatient hospital update in the amount specified in current law for FY 2017. MedPAC’s rationale for this update recommendation is described in more detail below. As mentioned above, section 1886(e)(4)(A) of the Act requires that the Secretary, taking into consideration the recommendations of MedPAC, recommend update factors for inpatient hospital services for each fiscal year that the LTCH PPS market basket increase estimate subject to an adjustment based on changes in economy-wide productivity and an additional reduction required by sections 1886(m)(3)(A)(ii)(I), 1886(m)(3)(A)(ii)(I), and 1886(m)(4)(F) of the Act. In accordance with the LTCHQR Program under section 1886(m)(5) of the Act, we are reducing the annual update to the LTCH PPS standard Federal rate by 2.0 percentage points for failure of an LTCH to submit the required quality data. The MFP adjustment described in section 886(b)(3)(B)(xi)(i) of the Act is currently estimated to be 0.3 percent for FY 2017. In addition, sections 1886(m)(3)(A)(ii) and 1886(m)(4)(F) Act require that the annual update for FY 2017 be reduced by the “other adjustment,” which is 0.75 percent point. Based on the most recent data available for this final rule, that is, IGIs second quarter 2016 forecast of the FY 2017 LTCH PPS market basket increase, we are establishing an annual update to the LTCH PPS standard Federal rate by 1.75 percent (that is, the current FY 2017 estimate of the market basket rate-of-increase of 2.8 percent less an adjustment of 0.3 percentage point for MFP and less 0.75 percentage point). Accordingly, we are applying an update factor of 1.0175 percent in determining the LTCH PPS standard Federal rate for FY 2017. For LTCHs that fail to submit quality data for FY 2017, we are applying an annual update to the LTCH PPS Federal rate by 0.25 percent (that is, the annual update for FY 2017 of 1.75 percent less an adjustment of 0.75 percentage points for failure to submit the required quality data in accordance with section 1886(m)(5)(C) of the Act and our rules) by applying an update factor of 0.9975 percent in determining the LTCH PPS standard Federal rate for FY 2017.
the standardized amount listed in the table under section II. of this Appendix B. We are recommending that the same applicable percentage increases apply to SCHs and MDHs.

In addition to making a recommendation for IPPS hospitals, in accordance with section 1886(e)(4)(A) of the Act, we are recommending update factors for certain other types of hospitals excluded from the IPPS. Consistent with our policies for these facilities, we are recommending an update to the target amounts for children’s hospitals, cancer hospitals, RNHHCs, and short-term acute care hospitals located in the U.S. Virgin Islands, Guam, the Northern Mariana Islands, and American Samoa of 2.7 percent.

For FY 2017, consistent with policy set forth in section VII. of the preamble of this final rule, for LTCHs that submit quality data, we are recommending an update of 1.75 percent to the LTCH PPS standard Federal rate. For LTCHs that fail to submit quality data for FY 2017, we are recommending an annual update to the LTCH PPS standard Federal rate of −0.25 percent.

IV. MedPAC Recommendation for Assessing Payment Adequacy and Updating Payments in Traditional Medicare

In its March 2016 Report to Congress, MedPAC assessed the adequacy of current payments and costs, and the relationship between payments and an appropriate cost base. MedPAC recommended an update to the hospital inpatient rates in the amount specified in current law. We refer the reader to the March 2016 MedPAC report, which is available for download at www.medpac.gov for a complete discussion on this recommendation. MedPAC expects Medicare margins to remain low in 2016. At the same time, MedPAC’s analysis finds that efficient hospitals have been able to maintain positive Medicare margins while maintaining a relatively high quality of care.

Response: We agree with MedPAC and, consistent with current law, we are applying an applicable percentage increase for FY 2017 of 1.65 percent, provided the hospital submits quality data and is a meaningful EHR user, consistent with statutory requirements. We note that, because the operating and capital prospective payment systems remain separate, we are continuing to use separate updates for operating and capital payments. The update to the capital rate is discussed in section III. of the Addendum to this final rule.